PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lange, T; Guttmann-Raviv, N; Baruch, L; Machluf, M; Neufeld, G				Lange, T; Guttmann-Raviv, N; Baruch, L; Machluf, M; Neufeld, G			VEGF(162), a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VEGF; EXTRACELLULAR-MATRIX; TUMOR-CELLS; RECEPTORS; ISOFORMS; IDENTIFICATION; ANGIOGENESIS; MICE; NEUROPILIN-1; SEMAPHORIN	The splice forms of vascular endothelial growth factor (VEGF) differ in biological properties such as the receptor types that they recognize and their interaction with heparan sulfate proteoglycans. We have identified a new VEGF mRNA splice form encoding a VEGF species containing 162 amino acids (VEGF162) in human A431 ovarian carcinoma cells. This novel mRNA contains the peptides encoded by exons 1-5, 6A, 6B, and 8 of the VEGF gene. Recombinant VEGF162 is biologically active. It induces proliferation of endothelial cells in vitro and angiogenesis in vivo as determined by the alginate bead assay. VEGF162 binds less efficiently than VEGF145 but more efficiently than VEGF165 to a natural basement membrane produced by corneal endothelial cells. VEGF138, an artificial VEGF form that contains exon 6B but lacks exons 6A and 7, did not bind to this basement membrane at all, indicating that exon 6B probably interferes with the interaction of exon 6A with heparin and heparan sulfate proteoglycans.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Cell Biol & Anat, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Biotechnol & Food Engn, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Neufeld, G (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Cell Biol & Anat, POB 9697,1 Efron St, IL-31096 Haifa, Israel.		Neufeld, Gera/F-1524-2019					Ancelin M, 2002, P NATL ACAD SCI USA, V99, P6023, DOI 10.1073/pnas.082110999; Bates DO, 2002, CANCER RES, V62, P4123; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; CIUDAD CJ, 1988, J BIOL CHEM, V263, P16274; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Meiron M, 2001, BIOCHEM BIOPH RES CO, V282, P1053, DOI 10.1006/bbrc.2001.4684; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; TISCHER E, 1991, J BIOL CHEM, V266, P11947; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016	32	45	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17164	17169		10.1074/jbc.M212224200	http://dx.doi.org/10.1074/jbc.M212224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598527	hybrid			2022-12-25	WOS:000182818600096
J	Merienne, K; Helmlinger, D; Perkin, GR; Devys, D; Trottier, Y				Merienne, K; Helmlinger, D; Perkin, GR; Devys, D; Trottier, Y			Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEAT NEURODEGENERATIVE DISEASES; JUN ACTIVATION DOMAIN; SCA1 TRANSGENIC MICE; N-TERMINAL KINASE; HUNTINGTONS-DISEASE; MOLECULAR CHAPERONES; APAF-1 APOPTOSOME; CELL-DEATH; HSP70; PHOSPHATASE	Polyglutamine diseases, including Huntington's disease, designate a group of nine neurodegenerative disorders characterized by the presence of a toxic polyglutamine expansion in specific target proteins. Using cell and mouse models, we have shown that expanded polyglutamine led to activation of the stress kinase JNK and the transcription factor AP-1, which are implicated in neuronal death. Polyglutamine expansion-induced stress shared common features with protein-damaging stress such as heat shock, because activation of JNK involved inhibition of JNK phosphatase activities. Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6. Aggregation of M3/6 by polyglutamine expansion appeared to be indirect, because M3/6 was not recruited into polyglutamine inclusions. The heat shock protein HSP70, which is known to inhibit JNK during the heat shock response, suppressed polyglutamine-mediated aggregation of M3/6 and activation of JNK. Interestingly, levels of HSP70 were down-regulated by polyglutamine expansion. We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; UCL, Sch Med, Dept Immunol, London W1P 6DB, England	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of London; University College London; UCL Medical School	Merienne, K (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, CU De Strasbour, France.	merienne@igbmc.u-strasbg.fr; yvon@igbmc.u-strasbg.fr	Helmlinger, Dom/T-4419-2019; Trottier, Yvon/H-8852-2016	Helmlinger, Dom/0000-0003-1501-0423; Trottier, Yvon/0000-0001-7230-4810; Devys, Didier/0000-0001-9655-3512; Merienne, Karine/0000-0003-2549-2315				Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Helmlinger D, 2002, HUM MOL GENET, V11, P3351, DOI 10.1093/hmg/11.26.3351; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yvert G, 2000, HUM MOL GENET, V9, P2491, DOI 10.1093/hmg/9.17.2491; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	49	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16957	16967		10.1074/jbc.M212049200	http://dx.doi.org/10.1074/jbc.M212049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598532	Green Published, hybrid			2022-12-25	WOS:000182818600070
J	Moumen, A; Polomack, L; Unge, T; Veron, M; Buc, H; Negroni, M				Moumen, A; Polomack, L; Unge, T; Veron, M; Buc, H; Negroni, M			Evidence for a mechanism of recombination during reverse transcription dependent on the structure of the acceptor RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; STRAND TRANSFER; COPY-CHOICE; CHAPERONE ACTIVITY; IN-VITRO; FREQUENCY; GENOMES; REGION	Genetic recombination is a major force driving retroviral evolution. In retroviruses, recombination proceeds mostly through copy choice during reverse transcription. Using a reconstituted in vitro system, we have studied the mechanism of strand transfer on a major recombination hot spot we previously identified within the genome of HIV-1. We show that on this model sequence the frequency of copy choice is strongly influenced by the folding of the RNA template, namely by the presence of a stable hairpin. This structure must be specifically present on the acceptor template. We previously proposed that strand transfer follows a two-step process: docking of the nascent DNA onto the acceptor RNA and strand invasion. The frequency of recombination under copy choice conditions was not dependent on the concentration of the acceptor RNA, in contrast with strand transfer occurring at strong arrests of reverse transcription. During copy choice strand transfer, the docking step is not rate limiting. We propose that the hairpin present on the acceptor RNA could mediate strand transfer following a mechanism reminiscent of branch migration during DNA recombination.	Inst Pasteur, CNRS, Dept Biol Struct & Chim, FRE 2364,Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1960, F-75724 Paris 15, France; Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, SE-75124 Uppsala, Sweden	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Uppsala University	Buc, H (corresponding author), Inst Pasteur, CNRS, Dept Biol Struct & Chim, FRE 2364,Unite Regulat Enzymat Act Cellulaires, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.	matteo@pasteur.fr		Negroni, Matteo/0000-0003-3005-8871				Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Hiom K, 2001, CURR BIOL, V11, pR278, DOI 10.1016/S0960-9822(01)00138-5; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; Quinones-Mateu ME, 2002, J VIROL, V76, P9600, DOI 10.1128/JVI.76.19.9600-9613.2002; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sharp PM, 1999, BIOL BULL-US, V196, P338, DOI 10.2307/1542965; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; Vogt V.M., 1997, RETROVIRUSES; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Ye YJ, 2000, J VIROL, V74, P11955, DOI 10.1128/JVI.74.24.11955-11962.2000; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	34	59	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15973	15982		10.1074/jbc.M212306200	http://dx.doi.org/10.1074/jbc.M212306200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595540	hybrid			2022-12-25	WOS:000182680000067
J	Salim, S; Sinnarajah, S; Kehrl, JH; Dessauer, CW				Salim, S; Sinnarajah, S; Kehrl, JH; Dessauer, CW			Identification of RGS2 and type V adenylyl cyclase interaction sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; CYTOSOLIC DOMAINS; KINETIC-ANALYSIS; ALPHA-SUBUNITS; G(S ALPHA); EXPRESSION; REGULATOR; MECHANISM; BINDING; GAIP	The production of cAMP is controlled on many levels, notably at the level of cAMP synthesis by the enzyme adenylyl cyclase. We have recently identified a new regulator of adenylyl cyclase activity, RGS2, which decreases cAMP accumulation when overexpressed in HEK293 cells and inhibits the in vitro activity of types III, V, and VI adenylyl cyclase. In addition, RGS2 blocking antibodies lead to elevated cAMF levels in olfactory neurons. Here we examine the nature of the interaction between RGS2 and type V adenylyl cyclase. In HEK293 cells expressing type V adenylyl cyclase, RGS2 inhibited Galpha(s)-Q227L- or beta(2)-adrenergic receptor-stimulated cAMP accumulation. Deletion of the N-terminal 19 amino acids of RGS2 abolished its ability to inhibit cAMP accumulation and to bind adenylyl cyclase. Further mutational analysis indicated that neither the C terminus, RGS GAP activity, nor the RGS box domain is required for inhibition of adenylyl cyclase. Alanine scanning of the N-terminal amino acids of RGS2 identified three residues responsible for the inhibitory function of RGS2. Furthermore, we show that RGS2 interacts directly with the C, but not the C-2 domain of type V adenylyl cyclase and that the inhibition by RGS2 is independent of inhibition by Galpha(i). These results provide clear evidence for functional effects of RGS2 on adenylyl cyclase activity that adds a new dimension to an intricate signaling network.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; NIAID, Immunoregulat Lab, B Cell Mol Biol Sect, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dessauer, CW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	Carmen.W.Dessauer@uth.tmc.edu	Kehrl, John/AAE-6292-2019; Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280; Kehrl, John/0000-0002-6526-159X	NIGMS NIH HHS [GM 60419, R01 GM060419-03, R01 GM060419] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 2002, METHOD ENZYMOL, V345, P112; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Ingi T, 1998, J NEUROSCI, V18, P7178; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Smith MS, 1998, ANN EMERG MED, V32, P65, DOI 10.1016/S0196-0644(98)70101-5; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tseng CC, 1998, ENDOCRINOLOGY, V139, P4470, DOI 10.1210/en.139.11.4470; Wang CR, 1997, PROTEIN SCI, V6, P2264; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zmijewski JW, 2001, BBA-MOL CELL RES, V1541, P201, DOI 10.1016/S0167-4889(01)00144-6	42	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15842	15849		10.1074/jbc.M210663200	http://dx.doi.org/10.1074/jbc.M210663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604604	hybrid			2022-12-25	WOS:000182680000050
J	Umenishi, F; Schrier, RW				Umenishi, F; Schrier, RW			Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY CONCENTRATING ABILITY; N-TERMINAL KINASE; WATER CHANNELS; C-JUN; HYPEROSMOTIC STRESS; RAT-KIDNEY; MEMBRANE; CELLS; PROTEIN; TRANSCRIPTION	Aquaporin-1 (AQP1) is a water channel that is induced by hypertonicity. The present study was undertaken to clarify the osmoregulation mechanism of AQP1 in renal medullary cells. In cultured mouse medullary (mIMCD-3) cells, AQP1 expression was significantly induced by hypertonic treatment with impermeable solutes, whereas urea had no effect on AQP1 expression. This result indicates the requirement of a hypertonic gradient. Hypertonicity activated ERK, p38 kinase, and JNK in mIMCD-3 cells. Furthermore, all three MAPKs were phosphorylated by the upstream activation of MEK1/2, MKK3/6, and MKK4, respectively. The treatments with MEK inhibitor U0126, p38 kinase inhibitor SB203580, and JNK inhibitor SP600125 significantly attenuated hypertonicity-induced AQP1 expression in mIMCD-3 cells. In addition, hypertonicity-induced AQP1 expression was significantly reduced by both the dominant-negative mutants of JNK1- and JNK2-expressing mIMCD-3 cells. NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2. These data demonstrate that the activation of ERK, p38 kinase, and JNK pathways and the hypertonicity response element in the AQP1 promoter are involved in hypertonicity-induced AQP1 expression in mIMCD-3 cells.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Umenishi, F (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, 4200 E 9th Ave,Box C281, Denver, CO 80262 USA.	Fuminori.Umenishi@UCHSC.edu			NIDDK NIH HHS [DK 19928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Berl Tomas, 1997, P1; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; Jenq W, 1998, BIOCHEM BIOPH RES CO, V245, P804, DOI 10.1006/bbrc.1998.8518; Jenq WM, 1999, BIOCHEM BIOPH RES CO, V256, P240, DOI 10.1006/bbrc.1999.0306; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Nielsen S, 2001, DIS KIDNEY URINARY T, P109; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHRIER RW, 1979, AM J PHYSIOL, V236, pF321, DOI 10.1152/ajprenal.1979.236.4.F321; SMITH HW, 1951, FISH PHILOS STORY OU; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V293, P913, DOI 10.1016/S0006-291X(02)00316-9; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang XY, 1999, AM J PHYSIOL-RENAL, V277, pF176, DOI 10.1152/ajprenal.1999.277.2.F176; Zhang Z, 1996, AM J PHYSIOL-RENAL, V271, pF1234, DOI 10.1152/ajprenal.1996.271.6.F1234	43	144	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15765	15770		10.1074/jbc.M209980200	http://dx.doi.org/10.1074/jbc.M209980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600999	hybrid			2022-12-25	WOS:000182680000040
J	van Huizen, R; Martindale, JL; Gorospe, M; Holbrook, NJ				van Huizen, R; Martindale, JL; Gorospe, M; Holbrook, NJ			P58(IPK), a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2 alpha signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; EUKARYOTIC INITIATION FACTOR-2-ALPHA; TRANSLATIONAL CONTROL; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; MESSENGER-RNA; ER STRESS; CELLULAR INHIBITOR; GENE-EXPRESSION; KINASE PKR	The unfolded protein response, which is activated in response to the loss of endoplasmic reticulum (ER) Ca2+ homeostasis and/or the accumulation of misfolded, unassembled, or aggregated proteins in the ER lumen, involves both transcriptional and translational regulation. In the current studies we sought to identify novel ER stress-induced genes by conducting microarray analysis on tunicamycin-treated cells. We identified P58(IPK). an inhibitor of the interferon-induced double-stranded RNA-activated protein kinase, as induced during ER stress. Additional studies suggested that p58(IPK) induction was mediated via ATF6 and that P58(IPK) played a role in down-regulating the activity of the pancreatic eIF2 kinase/eukaryotic initiation factor 2alpha (eIF2alpha)-like ER kinase/activation transcription factor (ATF) 4 pathway. Modulation of P58(IPK) levels altered the phosphorylation status of eIF2alpha, and thereby affected expression of its downstream targets, ATF4 and Gadd153. Overexpression of p58(IPK) inhibited eIF2alpha phosphorylation and reduced ATF4 and Gadd153 protein accumulation, whereas silencing of P58(IPK) expression enhanced pancreatic eIF2alpha-like ER kinase and eIF2alpha phosphorylation and increased ATF4 and Gadd153 accumulation. These findings implicate P58(IPK) as an important component of a negative feedback loop used by the cell to inhibit eIF2alpha signaling, and thus attenuate the unfolded protein response.	NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06520 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Yale University	van Huizen, R (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Mayne M, 2001, J VIROL, V75, P11641, DOI 10.1128/JVI.75.23.11641-11650.2001; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Samuel CE, 1997, INT J HEMATOL, V65, P227; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sood R, 2000, GENETICS, V154, P787; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	45	197	207	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15558	15564		10.1074/jbc.M212074200	http://dx.doi.org/10.1074/jbc.M212074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601012	hybrid			2022-12-25	WOS:000182680000014
J	Vischer, HF; Granneman, JCM; Noordam, MJ; Mosselman, S; Bogerd, J				Vischer, HF; Granneman, JCM; Noordam, MJ; Mosselman, S; Bogerd, J			Ligand selectivity of gonadotropin receptors - Role of the beta-strands of extracellular leucine-rich repeats 3 and 6 of the human luteinizing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL REGION; CHORIONIC-GONADOTROPIN; BINDING; DOMAIN; PROTEIN; MUTAGENESIS; ACTIVATION; MUTATIONS; RESIDUES; CONTACTS	The difference in hormone selectivity between the human follicle-stimulating hormone receptor (hFSH-R) and human luteinizing hormone/chorionic gonadotropin receptor (hLH-R) is determined by their similar to350 amino acid-long N-terminal receptor exodomains that allow the mutually exclusive binding of human follicle-stimulating hormone (hFSH) and human luteinizing hormone (hLH) when these hormones are present in physiological concentrations. The exodomains of each of these receptors consist of a nine-leucine-rich repeat-containing subdomain (LRR subdomain) flanked by Nand C-terminal cysteine-rich subdomain). Chimeric receptors, in which the structural subdomains of the hFSH-R exodomain were substituted with those of the hLH-R, showed a similar high responsiveness to human chorionic gonadotropin (hCG) and hLH as long as they harbored the LRR subdomain of the hLH-R. In addition, these chimeric receptors showed no responsiveness to hFSH. The LRR subdomains of the gonadotropin receptor exodomains are predicted to adopt a horseshoe-like conformation, of which the hormone-binding concave surface is composed of nine parallel beta-strands. Receptors in which individual beta-strands of the hFSH-R were replaced with the corresponding hLH-R sequences revealed that hCG and hLH selectivity is predominantly determined by hLH-R beta-strands 3 and 6. A mutant receptor in which the hFSH-R beta-strands 3 and 6 were substituted simultaneously with their hLH-R counterparts displayed a responsiveness to hCG and hLH similar to that of the wild type hLH-R. Responsiveness to hFSH was not affected by most beta-strand substitutions, suggesting the involvement of multiple low-impact determinants for this hormone.	Univ Utrecht, Fac Biol, Dept Endocrinol, NL-3584 CH Utrecht, Netherlands; Organon Inc, Dept Pharmacol, NL-5342 CC Oss, Netherlands	Utrecht University	Bogerd, J (corresponding author), Univ Utrecht, Fac Biol, Dept Endocrinol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Bogerd, Jan/B-8858-2011	Bogerd, Jan/0000-0003-1120-7974				ALI SA, 1995, BIOTECHNIQUES, V18, P746; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Vischer HF, 2003, BIOL REPROD, V68, P262, DOI 10.1095/biolreprod.102.004515; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	21	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15505	15513		10.1074/jbc.M300634200	http://dx.doi.org/10.1074/jbc.M300634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598521	hybrid			2022-12-25	WOS:000182680000008
J	Horiba, N; Masuda, S; Takeuchi, A; Takeuchi, D; Okuda, M; Inui, K				Horiba, N; Masuda, S; Takeuchi, A; Takeuchi, D; Okuda, M; Inui, K			Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; MEDIATING BASOLATERAL UPTAKE; PLASMA-MEMBRANE VESICLES; GENE-EXPRESSION PROFILES; FUNCTIONAL-CHARACTERIZATION; NA+/GLUCOSE COTRANSPORTER; LOCALIZATION; TUBULES	To identify novel transporters in the kidney, we have constructed an mRNA data base composed of 1000 overall clones by random sequencing of a male rat kidney cDNA library. After a BLAST search, similar to40% of the clones were unknown and/or unannotated and were screened by measuring the uptake of various compounds using Xenopus oocytes. One clone stimulated the uptake of a-methyl-D-glucopyranoside and therefore was termed rat Na+-dependent glucose transporter 1 (rNaGLT1). The rNaGLT1 cDNA (2173 bp) has an open reading frame encoding a 484-amino acid protein, showing <22% homology to known SGLT and GLUT glucose transporters. a-Methyl-D-glucopyranoside uptake by rNaGLT1 cRNA-injected oocytes showed saturability, with an apparent K-m of 3.7 mm and a coupling ratio of 1:1 with Na+. rNa-GLT1 mRNA was expressed predominantly in the kidney upon Northern blot analysis and reverse transcription-PCR. Reverse transcription-PCR in microdissected nephron segments revealed that rNaGLT1 mRNA was primarily localized in the proximal tubules. A clear signal corresponding to rNaGLT1 protein was recognized in the brush-border (but not basolateral) membrane fraction by immunoblot analysis. The rNaGLT1 mRNA level in the kidney was significantly higher than rat SGLT1 and SGLT2 mRNA levels. These findings suggest that rNaGLT1 is a novel Na+-dependent glucose transporter with low substrate affinity that mediates tubular reabsorption of glucose.	Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Inui, K (corresponding author), Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 6068507, Japan.		Inui, Ken-ichi/AAH-8748-2020; Masuda, Satohiro/E-6691-2010	Masuda, Satohiro/0000-0002-3589-5989				ALLIKMETS R, 1995, MAMM GENOME, V6, P114, DOI 10.1007/BF00303254; CHEUNG PT, 1988, AM J PHYSIOL, V254, pF711, DOI 10.1152/ajprenal.1988.254.5.F711; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; INUI K, 1981, BIOCHIM BIOPHYS ACTA, V647, P150, DOI 10.1016/0005-2736(81)90303-5; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; KINNE R, 1975, J MEMBRANE BIOL, V21, P375, DOI 10.1007/BF01941077; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee WJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1552, DOI 10.1152/ajpcell.1997.272.5.C1552; Masuda S, 1997, FEBS LETT, V407, P127, DOI 10.1016/S0014-5793(97)00314-1; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Nakajima H, 2002, KIDNEY INT, V61, P1577, DOI 10.1046/j.1523-1755.2002.00300.x; OELBERG DG, 1994, BBA-BIOMEMBRANES, V1194, P92, DOI 10.1016/0005-2736(94)90206-2; Ogihara H, 1996, BIOCHEM BIOPH RES CO, V220, P848, DOI 10.1006/bbrc.1996.0493; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Phay JE, 2000, SURGERY, V128, P946, DOI 10.1067/msy.2000.109967; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; SRIDHAR R, 1979, IN VITRO CELL DEV B, V15, P685; Takahashi K, 1998, J PHARMACOL EXP THER, V286, P1037; Takahashi K, 2001, AM J PHYSIOL-RENAL, V281, pF1109, DOI 10.1152/ajprenal.0346.2000; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; Takenaka M, 2000, KIDNEY INT, V57, P19, DOI 10.1046/j.1523-1755.2000.00834.x; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; TURNER RJ, 1982, AM J PHYSIOL, V242, P406; Uwai Y, 1998, FEBS LETT, V438, P321, DOI 10.1016/S0014-5793(98)01328-3; Wright EM, 2001, AM J PHYSIOL-RENAL, V280, pF10, DOI 10.1152/ajprenal.2001.280.1.F10; YOU GF, 1995, J BIOL CHEM, V270, P29365, DOI 10.1074/jbc.270.49.29365	32	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14669	14676		10.1074/jbc.M212240200	http://dx.doi.org/10.1074/jbc.M212240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590146	hybrid			2022-12-25	WOS:000182516100013
J	Kametaka, S; Shibata, M; Moroe, K; Kanamori, S; Ohsawa, Y; Waguri, S; Sims, PJ; Emoto, K; Umeda, M; Uchiyama, Y				Kametaka, S; Shibata, M; Moroe, K; Kanamori, S; Ohsawa, Y; Waguri, S; Sims, PJ; Emoto, K; Umeda, M; Uchiyama, Y			Identification of phospholipid scramblase 1 as a novel interacting molecule with beta-secretase (beta-site amyloid precursor protein (APP) cleaving enzyme (BACE))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; HUMAN NEUROBLASTOMA-CELLS; TRANS-GOLGI NETWORK; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; LIPID RAFTS; CATHEPSIN-D; CLEAVAGE; NEURONS	beta-Site amyloid precursor protein (APP)-cleaving enzyme (BACE) is an integral membrane aspartic proteinase responsible for beta-site processing of APP, and its cytoplasmic region composed of 24 amino acid residues has been shown to be involved in the endosomal localization of BACE. With the yeast two-hybrid screening, we found that the cytoplasmic domain of phospholipid scramblase 1 (PLSCR1), a type II integral membrane protein, interacts with the cytoplasmic region of BACE. In cultured cells, BACE and PLSCR1 were colocalized in the Golgi area and in endosomal compartments, whereas they were co-redistributed in late endosome-derived multivesicular bodies when treated with U18666A, suggesting that both proteins share a common trafficking pathway in cells. Co-immunoprecipitation analysis showed that both proteins form a protein complex at an endogenous expression level in the human neuroblastoma SH-SY5Ycells, and the dileucine residue of the BACE tail is also revealed to be essential for the physical interaction with PLSCR1 in vitro and in vivo. Moreover, both BACE and PLSCR1 were localized in a low buoyant lipid microdomain in SH-SY5Y cells. The dileucine-defective BACE mutant was also fractionated into the lipid microdomain, but much less stably than wild-type BACE. Taken together, our current study suggests the functional involvement of PLSCR1 in the intracellular distribution of BACE and/or recruitment of BACE into the detergent-insoluble lipid raft.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci A1, Suita, Osaka 5650871, Japan; Scripps Res Inst, La Jolla, CA 92037 USA; Tokyo Metropolitan Inst Med Sci RINSHOKEN, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan	Osaka University; Scripps Research Institute; Tokyo Metropolitan Institute of Medical Science	Uchiyama, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci A1, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		EMOTO, KAZUO/G-4992-2014; Kametaka, Satoshi/GVT-6091-2022; Kametaka, Satoshi/AAA-7407-2020	Kametaka, Satoshi/0000-0003-0659-6426	NHLBI NIH HHS [HL63819, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063819, R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; BIEDLER JL, 1973, CANCER RES, V33, P2643; Boman AL, 2001, J CELL SCI, V114, P3413; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; GOLDE TE, 1993, ANN NY ACAD SCI, V695, P103, DOI 10.1111/j.1749-6632.1993.tb23036.x; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hooper NM, 2000, ADV EXP MED BIOL, V477, P379; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; James P, 1996, GENETICS, V144, P1425; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Waguri S, 2001, J HISTOCHEM CYTOCHEM, V49, P1397, DOI 10.1177/002215540104901108; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	49	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15239	15245		10.1074/jbc.M208611200	http://dx.doi.org/10.1074/jbc.M208611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586838	hybrid			2022-12-25	WOS:000182516100085
J	Lin, CY; Varma, MG; Joubel, A; Madabushi, S; Lichtarge, O; Barber, DL				Lin, CY; Varma, MG; Joubel, A; Madabushi, S; Lichtarge, O; Barber, DL			Conserved motifs in somatostatin, D-2-dopamine, and alpha(2B)-adrenergic receptors for inhibiting the Na-H exchanger, NHE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY; MUSCARINIC ACETYLCHOLINE-RECEPTOR; ACTIVATED CALCIUM CHANNELS; PROTEIN-COUPLED RECEPTORS; ARACHIDONIC-ACID RELEASE; HAMSTER OVARY CELLS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; NEUROTRANSMITTER RELEASE	Receptor subtypes within families of G protein-coupled receptors that are activated by similar ligands can regulate distinct intracellular effectors. We identified conserved motifs within intracellular domains 2 and 3 of selective subtypes of several G protein-coupled receptor families that confer coupling to the Na-H exchanger, NHE1 A T(s,p)V motif within intracellular domain 2 and a QQ(r) motif within intracellular domain 3 are shared by the somatostatin receptor subtypes SSTR1, -3, and -4, which couple to the inhibition of NHE1, but not by SSTR2 and -5, which do not signal to NHE1 Only the collective substitution of cognate SSTR2 residues with these two motifs conferred the ability of mutant SSTR2 to inhibit NHE1. Both motifs are present in D-2-dopamine receptors, which inhibit NHE1, and in alpha(2B)-adrenergic receptors, which couple to the inhibition of NHE1, but not in alpha(2A)-adrenergic receptors, which do not regulate NHE1. These findings indicate that motifs shared by different subfamilies of G protein-coupled receptors, but not necessarily by receptor subtypes within a subfamily, can confer coupling to a common effector.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Baylor Coll Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; Baylor College of Medicine	Barber, DL (corresponding author), Univ Calif San Francisco, Box 0512,513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040259, R01DK040259] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32DE07204] Funding Source: Medline; NIDDK NIH HHS [DK40259] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Audubert F, 1999, BBA-MOL CELL BIOL L, V1437, P265, DOI 10.1016/S1388-1981(99)00018-9; BARBER DL, 1989, J BIOL CHEM, V264, P21038; Beukers MW, 1999, TRENDS PHARMACOL SCI, V20, P475, DOI 10.1016/S0165-6147(99)01403-0; BITO H, 1994, J BIOL CHEM, V269, P12722; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Cai K, 1999, BIOCHEMISTRY-US, V38, P12893, DOI 10.1021/bi9912443; Chung DA, 2002, BIOCHEMISTRY-US, V41, P3596, DOI 10.1021/bi015811+; Cussac D, 2002, AM J PHYSIOL-RENAL, V282, pF943, DOI 10.1152/ajprenal.0108.2001; Cypess AM, 1999, J BIOL CHEM, V274, P19455, DOI 10.1074/jbc.274.27.19455; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; FLORIO T, 1992, J BIOL CHEM, V267, P24169; Florio T, 2000, J PHYSIOL-PARIS, V94, P239, DOI 10.1016/S0928-4257(00)00214-X; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; FUJII Y, 1994, FEBS LETT, V355, P117, DOI 10.1016/0014-5793(94)01159-1; GANZ MB, 1990, J BIOL CHEM, V265, P8989; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hofland LJ, 1999, ANN MED, V31, P23; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; HOU CF, 1994, J BIOL CHEM, V269, P10357; KANTERMAN RY, 1991, MOL PHARMACOL, V39, P364; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KOCHHAR N, 1992, FEBS LETT, V299, P19, DOI 10.1016/0014-5793(92)80090-4; Kreienkamp HJ, 1997, FEBS LETT, V419, P92, DOI 10.1016/S0014-5793(97)01437-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; Miettinen HM, 1999, J BIOL CHEM, V274, P27934, DOI 10.1074/jbc.274.39.27934; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MORO O, 1993, J BIOL CHEM, V268, P22273; NEVE KA, 1994, METHODS NEUROSCI, V25, P225; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1994, ENDOCRINOLOGY, V135, P2814, DOI 10.1210/en.135.6.2814; Reardon DB, 1996, BIOCHEM J, V314, P401, DOI 10.1042/bj3140401; Roosterman D, 1998, FEBS LETT, V425, P137, DOI 10.1016/S0014-5793(98)00221-X; Rufini S, 1999, AM J PHYSIOL-CELL PH, V277, pC814, DOI 10.1152/ajpcell.1999.277.4.C814; Schwartz DD, 1997, J PHARMACOL EXP THER, V282, P248; SENOGLES SE, 1994, ENDOCRINOLOGY, V134, P783, DOI 10.1210/en.134.2.783; Sharma K, 1999, MOL ENDOCRINOL, V13, P82, DOI 10.1210/me.13.1.82; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Viana F, 1996, J NEUROSCI, V16, P6000; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wade SM, 1999, MOL PHARMACOL, V56, P1005, DOI 10.1124/mol.56.5.1005; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; Ye WZ, 1999, CELL MOL BIOL, V45, P1183	75	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15128	15135		10.1074/jbc.M212315200	http://dx.doi.org/10.1074/jbc.M212315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566440	hybrid			2022-12-25	WOS:000182516100071
J	Xin, ZH; Tachibana, M; Guggiari, M; Heard, E; Shinkai, Y; Wagstaff, J				Xin, ZH; Tachibana, M; Guggiari, M; Heard, E; Shinkai, Y; Wagstaff, J			Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; H3 METHYLTRANSFERASE; GENES; ESTABLISHMENT; EXPRESSION; LYSINE-9; PATTERNS	Imprinted genes in mammals are often located in clusters whose imprinting is subject to long range regulation by cis-acting sequences known as imprinting centers (ICs). The mechanisms by which these ICs exert their effects is unknown. The Prader-Willi syndrome IC (PWS-IC) on human chromosome 15 and mouse chromosome 7 regulates imprinted gene expression bidirectionally within an similar to2-megabase region and shows CpG methylation and histone H3 Lys-9 methylation in somatic cells specific for the maternal chromosome. Here we show that histone H3 Lys-9 methylation of the PWS-IC is reduced in mouse embryonic stem (ES) cells lacking the G9a histone H3 Lys-9/Lys-27 methyltransferase and that maintenance of CpG methylation of the PWS-IC in mouse ES cells requires the function of G9a. We show by RNA fluorescence in situ hybridization (FISH) that expression of Snrpn, an imprinted gene regulated by the PWS-IC, is biallelic in G9a -/- ES cells, indicating loss of imprinting. By contrast, Dnmt1 -/- ES cells lack CpG methylation of the PWS-IC but have normal levels of H3 Lys-9 methylation of the PWS-IC and show normal monoallelic Snrpn expression. Our results demonstrate a role for histone methylation in the maintenance of parent-specific CpG methylation of imprinting regulatory regions and suggest a possible role of histone methylation in establishment of these CpG methylation patterns.	Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; Inst Curie, F-75248 Paris, France	University of Virginia; University of Virginia; Kyoto University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wagstaff, J (corresponding author), Univ Virginia Hlth Syst, Dept Pediat, Jordan Hall,Box 800733, Charlottesville, VA 22908 USA.	wagstaff@virginia.edu	Shinkai, Yoichi/N-3909-2014; Heard, Edith/D-7197-2017	Shinkai, Yoichi/0000-0002-6051-2484; Heard, Edith/0000-0001-8052-7117				Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Bressler J, 2001, NAT GENET, V28, P232, DOI 10.1038/90067; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; SZABO P, 1994, DEVELOPMENT, V120, P1651; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zwart R, 2001, GENE DEV, V15, P2361, DOI 10.1101/gad.206201	22	126	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14996	15000		10.1074/jbc.M211753200	http://dx.doi.org/10.1074/jbc.M211753200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586828	hybrid			2022-12-25	WOS:000182516100055
J	Yamaguchi, Y; Katoh, H; Negishi, M				Yamaguchi, Y; Katoh, H; Negishi, M			N-terminal short sequences of alpha subunits of the G(12) family determine selective coupling to receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; STRESS FIBER FORMATION; THROMBIN RECEPTOR; G-ALPHA(12); RHO; G(13); ACYLATION; PATHWAYS; MUTANT; KINASE	The Galpha subunits of the G(12) family of heterotrimeric G proteins, defined by Galpha(12) and Galpha(13), have many cellular functions in common, such as stress fiber formation and neurite retraction. However, a variety of G protein-coupled receptors appear to couple selectively to Galpha(12) and Galpha(13). For example, thrombin and lysophosphatidic acid (LPA) have been shown to induce stress fiber formation via Galpha(12) and Galpha(13), respectively. We recently showed that active forms of Galpha(12) and Galpha(13) interact with Ser/Thr phosphatase type 5 through its tetratricopeptide repeat domain. Here we developed a novel assay to measure the activities of Galpha(12) and Galpha(13), by using glutathione S-transferase-fused tetratricopeptide repeat domain of Ser/Thr phosphatase type 5, taking advantage of the property that tetratricopeptide repeat domain strongly interacts with active forms of Galpha(12) and Galpha(13). By using this assay, we identified that thrombin and LPA selectively activate Galpha(12) and Galpha(13), respectively. Galpha(12) and Galpha(13) show a high amino acid sequence homology except for their N-terminal short sequences. Then we generated chimeric G proteins Galpha(12N/13C) and Galpha(13N/12C), in which the N-terminal short sequences are replaced by each other, and showed that thrombin and LPA selectively activate Galpha(12N/13C) and Galpha(13N/12C), respectively. Moreover, thrombin and LPA stimulate RhoA activity through Galpha(12) and Galpha(13), respectively, in a Galpha(12) family N-terminal sequence-dependent manner. Thus, N-terminal short sequences of the G(12) family determine the selective couplings of thrombin and LPA receptors to the Galpha(12) family.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.		Yamaguchi, Yoshiaki/K-9418-2013	Yamaguchi, Yoshiaki/0000-0003-4126-542X; Katoh, Hironori/0000-0002-8191-8117				Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Ponimaskin E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Yamaguchi Y, 2000, J NEUROCHEM, V75, P708, DOI 10.1046/j.1471-4159.2000.0750708.x; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5	21	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14936	14939		10.1074/jbc.M301409200	http://dx.doi.org/10.1074/jbc.M301409200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594220	hybrid			2022-12-25	WOS:000182516100047
J	Li, JQ; Sheng, SH; Perry, CJ; Kleyman, TR				Li, JQ; Sheng, SH; Perry, CJ; Kleyman, TR			Asymmetric organization of the pore region of the epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; CYSTEINE MUTAGENESIS; SELECTIVITY FILTER; ION PERMEATION; MEMBRANE TOPOLOGY; LINING SEGMENTS; MOLECULAR-BASIS; CA2+ CHANNEL; ENAC; RESIDUES	Epithelial sodium channels (ENaCs) are composed of three homologous subunits that have regions preceding the second transmembrane domain (also referred as pre-M2) that form part of the channel pore. To identify residues within this region of the beta-subunit that line the pore, we systematically mutated residues Gln(523)-Ile(536). to cysteine. Wild type and mutant mouse ENaCs were expressed in Xenopus oocytes, and a two-electrode voltage clamp was used to examine the properties of mutant channels. Cysteine substitutions of 9 of 13 residues significantly altered Li+ to Na+ current ratios, whereas only cysteine replacement of betaGly(529) resulted in K+-permeable channels. Besides betaG525C, large increases in the inhibitory constant of amiloride were observed with mutations at betaGly(529) and betaSer(531) within the previously identified 3-residue tract that restricts K+ permeation. Cysteine substitution preceding (betaPhe(524) and betaGly(525)), within (betaGly(530)) or following (betaLeu(533)) this 3-residue tract, resulted in enhanced current inhibition by external MTSEA. External MTSET partially blocked channels with cysteine substitutions at betaGln(523), betaPhe(524), and betaTrp(527). MTSET did not inhibit alphabetaG525Cgamma, although previous studies showed that channels with cysteine substitutions at the corresponding sites within the alpha- and gamma-subunits were blocked by MTSET. Our results, placed in context with previous observations, suggest that pore regions from the three ENaC subunits have an asymmetric organization.	Univ Pittsburgh, Div Renal & Electrolyte, Dept Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania	Kleyman, TR (corresponding author), Univ Pittsburgh, Div Renal & Electrolyte, Dept Med, A919 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	kleyman@pitt.edu	Sheng, Shaohu/G-7052-2016	Sheng, Shaohu/0000-0002-7198-1702; Solvi, Cwyn/0000-0003-2517-6179	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Koch SE, 2000, J BIOL CHEM, V275, P34493, DOI 10.1074/jbc.M005569200; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Snyder PM, 2000, J GEN PHYSIOL, V116, P781, DOI 10.1085/jgp.116.6.781; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; Wu XS, 2000, J BIOL CHEM, V275, P31778, DOI 10.1074/jbc.M004829200	28	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13867	13874		10.1074/jbc.M300149200	http://dx.doi.org/10.1074/jbc.M300149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576470	hybrid			2022-12-25	WOS:000182405000040
J	Li, Y; Inoki, K; Vacratsis, P; Guan, KL				Li, Y; Inoki, K; Vacratsis, P; Guan, KL			The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; TSC2 GENE; CELL-GROWTH; MAP KINASE; 3-KINASE/AKT PATHWAY; PROTEIN; COMPLEX; ACTIVATION; HAMARTIN; AKT	Tuberous sclerosis complex (TSC) is a genetic disease caused by mutations in either TSC1 or TSC2 tumor suppressor genes. TSC1 and TSC2 (also known as hamartin and tuberin, respectively) form a functional complex and negatively regulate cell growth by inhibiting protein synthesis. 14-3-3 binds to TSC2 and may inhibit TSC2 function. We have reported previously that phosphorylation of serine 1210 (Ser(1210)) in TSC2 is essential for 14-3-3 binding. Here we show that serum and anisomycin enhance the interaction between TSC2 and 14-3-3 by stimulating phosphorylation of Ser(1210). Activation of p38 MAP kinase (p38) is essential for the stimulating effect of serum and anisomycin although p38 is not directly responsible for the phosphorylation of Ser(1210) in TSC2. Both in vitro and in vivo experiments demonstrate that the p38-activated kinase MK2 (also known as MAP-KAPK2) is directly responsible for the phosphorylation of Ser(1210). Our data show that anisomycin stimulates phosphorylation of Ser(1210) of TSC2 via the p38-MK2 kinase cascade. Phosphorylation of TSC2 by MK2 creates a 14-3-3 binding site and thus regulates the cellular function of the TSC2 tumor suppressor protein.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 E Catherine St, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	INOKI, KEN/A-1202-2007		NIDDK NIH HHS [R01 DK124709] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu MY, 2002, CANCER RES, V62, P6475; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; [No title captured]	45	135	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13663	13671		10.1074/jbc.M300862200	http://dx.doi.org/10.1074/jbc.M300862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582162	hybrid			2022-12-25	WOS:000182405000015
J	Sharypova, LA; Niehaus, K; Scheidle, H; Holst, O; Becker, A				Sharypova, LA; Niehaus, K; Scheidle, H; Holst, O; Becker, A			Sinorhizobium meliloti acpXL mutant lacks the C28 hydroxylated fatty acid moiety of lipid A and does not express a slow migrating form of lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-ETLI; MENINGOCOCCAL POLYSACCHARIDES; GENETIC-CHARACTERIZATION; POLYACRYLAMIDE GELS; CHEMICAL PROPERTIES; MOLECULAR-WEIGHT; WHITE CLOVER; K-ANTIGENS; NODULES	Lipid A is the hydrophobic anchor of lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria. Lipid A of all Rhizobiaceae is acylated with a long fatty acid chain, 27-hydroxyoctacosanoic acid. Biosynthesis of this long acyl substitution requires a special acyl carrier protein, AcpXL, which serves as a donor of C28 (omega-1)-hydroxylated fatty acid for acylation of rhizobial lipid A (Brozek, K.A., Carlson, R.W., and Raetz, C. R. (1996) J. BioL Chem 271,32126-32136). To determine the biological function of the C28 acylation of lipid A, we constructed an acpXL mutant of Sinorhizobium meliloti strain 1021. Gas-liquid chromatography and mass spectrometry analysis of the fatty acid composition showed that the acpXL mutation indeed blocked C28 acylation of lipid A. SDS-PAGE analysis of acpXL mutant LPS revealed only a fast migrating band, rough LPS, whereas the parental strain 1021 manifested both rough and smooth LPS. Regardless of this, the LPS of parental and mutant strains had a similar sugar composition and exposed the same antigenic epitopes, implying that different electrophoretic profiles might account for different aggregation properties of LPS molecules with and without a long acyl chain. The acpXL mutant of strain 1021 displayed sensitivity to deoxycholate, delayed nodulation of Medicago sativa, and a reduced competitive ability. However, nodules elicited by this mutant on roots of M. sativa and Medicago truncatula had a normal morphology and fixed nitrogen. Thus, the C28 fatty acid moiety of lipid A is not crucial, but it is beneficial for establishing an effective symbiosis with host plants. acpXL lies upstream from a cluster of five genes, including msbB (lpxXL), which might be also involved in biosynthesis and transfer of the C28 fatty acid to the lipid A precursor.	Univ Bielefeld, Fak Biol, Lehrstuhl Genet, Inst Genet, D-33501 Bielefeld, Germany; Res Ctr Borstel, Ctr Med & Biosci, Div Struct Biochem, D-23845 Borstel, Germany	University of Bielefeld; Forschungszentrum Borstel	Sharypova, LA (corresponding author), Univ Bielefeld, Fak Biol, Lehrstuhl Genet, Inst Genet, Postfach 100131, D-33501 Bielefeld, Germany.		Niehaus, Karsten/A-3966-2010					Albus U, 2001, NEW PHYTOL, V151, P597, DOI 10.1046/j.0028-646x.2001.00214.x; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BERINGER JE, 1974, J GEN MICROBIOL, V84, P188; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BREWIN NJ, 1991, ANNU REV CELL BIOL, V7, P191, DOI 10.1146/annurev.cb.07.110191.001203; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; Capela D, 2001, P NATL ACAD SCI USA, V98, P9877, DOI 10.1073/pnas.161294398; CASSE F, 1979, J GEN MICROBIOL, V113, P229, DOI 10.1099/00221287-113-2-229; Choma A, 2000, SYST APPL MICROBIOL, V23, P185, DOI 10.1016/S0723-2020(00)80003-X; Clementz T, 1997, J BIOL CHEM, V272, P10353; DAZZO FB, 1991, J BACTERIOL, V173, P5371, DOI 10.1128/jb.173.17.5371-5384.1991; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Geiger O, 2002, FEMS MICROBIOL LETT, V208, P153, DOI 10.1111/j.1574-6968.2002.tb11075.x; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Lagares A, 2001, J BACTERIOL, V183, P1248, DOI 10.1128/JB.183.4.1248-1258.2001; LAGARES A, 1992, J BACTERIOL, V174, P5941, DOI 10.1128/jb.174.18.5941-5952.1992; LIU TY, 1971, J BIOL CHEM, V246, P2849; LIU TY, 1971, J BIOL CHEM, V246, P4703; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; Niehaus K, 1998, Subcell Biochem, V29, P73; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PETROVICS G, 1993, MOL MICROBIOL, V8, P1083, DOI 10.1111/j.1365-2958.1993.tb01653.x; PITTMAN MARGARET, 1931, JOUR EXP MED, V53, P471, DOI 10.1084/jem.53.4.471; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 1999, APPL ENVIRON MICROB, V65, P5186; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; Ridley BL, 2000, GLYCOBIOLOGY, V10, P1013, DOI 10.1093/glycob/10.10.1013; ROLFE BG, 1980, PLANT SCI LETT, V19, P277, DOI 10.1016/0304-4211(80)90082-6; RUSSA R, 1995, ARCH MICROBIOL, V163, P345, DOI 10.1007/BF00404207; Russa R, 1996, ARCH MICROBIOL, V165, P26, DOI 10.1007/s002030050292; Sambrook J., 1989, MOL CLONING, pA1; SHANDS JW, 1980, J BIOL CHEM, V255, P1221; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Tauch A, 1998, PLASMID, V40, P126, DOI 10.1006/plas.1998.1362; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Urbanik-Sypniewska T, 2000, IMMUNOBIOLOGY, V202, P408, DOI 10.1016/S0171-2985(00)80043-1; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; Valverde C, 1997, BIOTECHNIQUES, V22, P230, DOI 10.2144/97222bm07; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WOLLENWEBER HW, 1990, J MICROBIOL METH, V11, P195, DOI 10.1016/0167-7012(90)90056-C; York GM, 1997, MOL MICROBIOL, V25, P117, DOI 10.1046/j.1365-2958.1997.4481804.x; ZEVENHUIZEN LPTM, 1980, ARCH MICROBIOL, V125, P1, DOI 10.1007/BF00403191	56	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12946	12954		10.1074/jbc.M209389200	http://dx.doi.org/10.1074/jbc.M209389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566460	hybrid			2022-12-25	WOS:000182189500046
J	Agirre, X; Vizmanos, JL; Calasanz, MJ; Garcia-Delgado, M; Larrayoz, MJ; Novo, FJ				Agirre, X; Vizmanos, JL; Calasanz, MJ; Garcia-Delgado, M; Larrayoz, MJ; Novo, FJ			Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients	ONCOGENE			English	Article						TP53; methylation analysis; promoter analysis; gene expression; ALL	TUMOR-SUPPRESSOR GENE; P53 GENE; DNA METHYLATION; IN-VIVO; CARCINOGENESIS; REGION; CELLS	It has been shown that methylation of CpG dinucleotides located in the promoter region of TP53 is associated with low expression levels of this gene. We have analysed the methylation status of one CpG dinucleotide and of three CCWGG motifs, also located in the promoter region of the gene, in bone marrow samples obtained from patients with acute lymphoblastic leukemia (ALL). Eight out of 25 samples analysed showed methylation of either the CpG dinucleotide, the CCWGG motifs or both. Relative to nonmethylated leukemia samples, TP53 expression levels were decreased in all methylated samples in which TP53 expression could be measured. Methylation of CpG and CCWGG motifs in the promoter of TP53 could represent a novel mechanism leading to functional impairment of this tumor suppressor gene in ALL.	Univ Navarra, Sch Sci, Dept Genet, E-31080 Pamplona, Navarra, Spain	University of Navarra	Vizmanos, JL (corresponding author), Univ Navarra, Sch Sci, Dept Genet, C Irunlarrea S-N, E-31080 Pamplona, Navarra, Spain.		Novo, Francisco/M-7596-2015; Vizmanos, José L./G-2833-2012; Calasanz, MJ/R-5813-2016; Agirre, Xabier/ABE-4110-2020	Novo, Francisco/0000-0003-4961-3097; Vizmanos, José L./0000-0001-7416-3679; Calasanz, MJ/0000-0002-0374-3008; 				Agirre X, 2002, BIOTECHNIQUES, V32, P1064, DOI 10.2144/02325rr01; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Davis CD, 2000, J NUTR, V130, P2903, DOI 10.1093/jn/130.12.2903; Herman JG, 1996, CANCER RES, V56, P722; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mass MJ, 1997, MUTAT RES-REV MUTAT, V386, P263, DOI 10.1016/S1383-5742(97)00008-2; Pogribny IP, 2000, CANCER RES, V60, P588; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Preudhomme C, 1997, BRIT J HAEMATOL, V98, P502, DOI 10.1046/j.1365-2141.1997.2403057.x; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Schutte M, 1997, CANCER RES, V57, P3126; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657	15	63	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1070	1072		10.1038/sj.onc.1206236	http://dx.doi.org/10.1038/sj.onc.1206236			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592393				2022-12-25	WOS:000180926100012
J	Pajer, P; Pecenka, V; Karafiat, V; Kralova, J; Horejsi, Z; Dvorak, M				Pajer, P; Pecenka, V; Karafiat, V; Kralova, J; Horejsi, Z; Dvorak, M			The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma	ONCOGENE			English	Article						Twist gene; MAV retrovirus; common viral integration site; nephroblastoma	MYELOBLASTOSIS-ASSOCIATED VIRUS; SAETHRE-CHOTZEN-SYNDROME; PROTEIN; MUTATIONS; ONCOGENE; CANCER; CELLS; BHLH; NOV	The genes involved in the transformation of kidney blastema cells were searched for in avian nephroblastomas induced by the MAV2 retrovirus. The twist gene was identified as a common site of provirus integration in tumor cells. Twist was rearranged by the MAV2 provirus in three out of 76 independent nephroblastoma samples. The MAV2 integration sites were localized within 40 nucleotides of the twist 5'UTR region, right upstream from the ATG initiation codon. The integrated proviruses were deleted at their 5'ends. As a consequence, twist transcription became controlled by the retroviral 3'LTR promoter and was strongly upregulated, more than 200 times. In addition, 2-100 times elevated twist transcription was also detected in the majority of other nephroblastoma samples not containing MAV2 in the twist locus. We propose that chicken nephroblastoma originates from a single blastemic cell in which the MAV retrovirus, through its integration, has deregulated specific combinations of genes controlling proliferation and differentiation. The activation of the twist gene expression appears to contribute to tumorigenesis, as there is an in vivo positive selection of tumor cell clones containing the twist gene hyperactivated by MAV2 sequences inserted within the twist promoter.	Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Dvorak, M (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Flemingovo 2, CR-16637 Prague 6, Czech Republic.		Kralova, Jarmila/G-3834-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014; Pajer, Petr/G-5869-2014	Kralova, Jarmila/0000-0002-4735-8857; Licenikova Horejsi, Zuzana/0000-0002-9943-1649				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; BONISCHNETZLER M, 1985, J VIROL, V55, P213; Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945; Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9; Coffin J, 1997, RETROVIRUSES; COLLART KL, 1990, J VIROL, V64, P3541, DOI 10.1128/JVI.64.7.3541-3544.1990; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; ElGhouzzi V, 1997, NAT GENET, V15, P42; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; Joliot V, 1996, J VIROL, V70, P2576, DOI 10.1128/JVI.70.4.2576-2580.1996; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P147; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P215; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Plachy J, 1997, FOLIA BIOL-PRAGUE, V43, P133; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	28	25	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					665	673		10.1038/sj.onc.1206105	http://dx.doi.org/10.1038/sj.onc.1206105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569359				2022-12-25	WOS:000180642100004
J	Routhier, EL; Donover, PS; Prendergast, GC				Routhier, EL; Donover, PS; Prendergast, GC			hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress	ONCOGENE			English	Article						amphiphysin; Rvs167; endocytosis; Myc; cell cycle; DNA damage	CYCLIN-DEPENDENT KINASE-5; MYC-INTERACTING PROTEIN; TUMOR-SUPPRESSOR BIN1; APOPTOTIC CELL-DEATH; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; AMPHIPHYSIN ISOFORM; ASTROCYTOMA-CELLS; SPLICE VARIANTS; GENE	BAR (Bin/Amphiphysin/Rvs) adapter proteins have been suggested to regulate endocytosis, actin organization, apoptosis, and transcription, but their precise roles are obscure. There are at least five mammalian genes that encode BAR adapter proteins, including the evolutionarily conserved and ubiquitously expressed Bin1/Amphiphysin-II and Bin3 genes. Bin1 holds special interest as certain splice isoforms localize to the nucleus, interact with the c-Ab1 and c-Myc oncoproteins, and display tumor suppressor properties. To obtain functional insights, we embarked upon a genetic analysis of the two BAR adapter proteins expressed in the fission yeast Schizosaccharomyces pombe. In a previous work, a role in actin organization and cytokinesis was identified for the Bin3 homolog hob3+. In this study, a role in stress signaling was defined for the Bin1 homolog, hob1 +. Notably, hoh1 + was dispensable for endocytosis, actin organization, or osmotic sensitivity. Instead, mutation of hob1 + led to slight cell elongation and faulty cell cycle arrest upon nutrient starvation. These defects were complemented by Bin1, but not by Amphiphyrsin-I, arguing that these genes have distinct functions despite their structural similarity. hob1 A mutant cells were also hypersensitive to genotoxic stress. This was not related to faulty checkpoint response, but mutation in the checkpoint gene rad3(+) further exacerbated the sensitivity of hob1Delta mutant cells. Interestingly, mutation of the cell cycle regulator wee1(+) partially relieved the sensitivity defect, suggesting that hob1 + may influence the efficiency of DNA repair or checkpoint release after DNA damage. Genetic and biochemical evidence indicated that hob3 + is epistatic to hob1 + in the response to genotoxic stress. Our findings indicate that the Bin1 homolog hob1 + participates in DNA damage signaling and they suggest a novel role for BAR adapter proteins in stress response processes.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA 19036 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org						Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Brazer SCW, 2000, YEAST, V16, P149, DOI 10.1002/(SICI)1097-0061(20000130)16:2<149::AID-YEA514>3.0.CO;2-C; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Colwill K, 1999, GENETICS, V152, P881; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; Galderisi U, 1999, J CELL BIOCHEM, V74, P313, DOI 10.1002/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.3.CO;2-Q; Gao C, 2001, J CELL SCI, V114, P1145; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P559, DOI 10.1002/1096-911X(20001201)35:6<559::AID-MPO14>3.3.CO;2-A; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Mao NC, 1999, GENOMICS, V56, P51, DOI 10.1006/geno.1998.5709; MARKS J, 1986, J CELL SCI, P229; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pelloquin L, 1999, FEBS LETT, V443, P71, DOI 10.1016/S0014-5793(98)01682-2; PRAMANIK A, 1995, CELL MOL BIOL, V41, pS73; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Routhier EL, 2001, J BIOL CHEM, V276, P21670, DOI 10.1074/jbc.M101096200; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SAZER S, 1990, J CELL SCI, V97, P509; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	51	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					637	648		10.1038/sj.onc.1206162	http://dx.doi.org/10.1038/sj.onc.1206162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569356				2022-12-25	WOS:000180642100001
J	Koike, H; Morishita, R; Iguchi, S; Aoki, M; Matsumoto, K; Nakamura, T; Yokoyama, C; Tanabe, T; Ogihara, T; Kaneda, Y				Koike, H; Morishita, R; Iguchi, S; Aoki, M; Matsumoto, K; Nakamura, T; Yokoyama, C; Tanabe, T; Ogihara, T; Kaneda, Y			Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene	FASEB JOURNAL			English	Article						peripheral arterial disease; vasodilation; angiogenesis; gene therapy; diabetes	PERIPHERAL ARTERIAL-DISEASE; NERVE-CONDUCTION-VELOCITY; HUMAN DIABETIC-NEUROPATHY; LIMB ISCHEMIA MODEL; BLOOD-FLOW; POTENTIAL ROLE; PHVEGF(165); EXPRESSION; RATS; HGF	The current therapeutic angiogenesis strategy to treat ischemic disease by using angiogenic growth factors has been limited to use of a single gene. However, as vasodilator substances such as prostacyclin are widely used for the treatment of peripheral arterial disease, it might be useful to combine angiogenesis with vasodilation of new vessels. In a mouse hind limb ischemia model, cotransfection of the hepatocyte growth factor (HGF) gene with the prostacyclin synthase gene demonstrated a further increase in blood flow and capillary density compared with a single gene. Even in the rabbit ischemia model, cotransfection of HGF plasmid with the prostacyclin synthase gene demonstrated a further increase in angiogenic activity compared with HGF alone. Because peripheral neuropathy due to diabetes is common for significant morbidity, we examined the hypothesis that experimental diabetic neuropathy can be reversed by HGF and prostacyclin synthase genes. Severe peripheral neuropathy, characterized by significant slowing of nerve conduction velocity compared with nondiabetic control animals, was ameliorated. Overall, cotransfection of the prostacyclin synthase and HGF genes is more effective than single-gene transfection to stimulate angiogenesis, and it significantly improved neuropathy. These data provide important information relating to the clinical application of therapeutic angiogenesis to treat peripheral arterial disease.	Osaka Univ, Sch Med, Div Gene Therapy Sci, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Suita, Osaka 565, Japan; Natl Cardiovasc Res Ctr, Dept Pharmacol, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University; National Cerebral & Cardiovascular Center - Japan	Morishita, R (corresponding author), Osaka Univ, Sch Med, Div Gene Therapy Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	morishit@geriat.med.osaka-u.ac.jp	Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				Aoki M, 2000, GENE THER, V7, P417, DOI 10.1038/sj.gt.3301104; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; CAMERON NE, 1991, AM J PHYSIOL, V261, pE1, DOI 10.1152/ajpendo.1991.261.1.E1; Davey F, 2000, MOL CELL NEUROSCI, V15, P79, DOI 10.1006/mcne.1999.0803; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; DYCK PJ, 1989, NEUROLOGY, V39, P111, DOI 10.1212/WNL.39.1.111; HARA S, 1995, BIOCHEM BIOPH RES CO, V216, P862, DOI 10.1006/bbrc.1995.2701; Hayashi S, 1999, CIRCULATION, V100, P301; HIRST DG, 1979, BRIT J CANCER, V39, P159, DOI 10.1038/bjc.1979.26; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; MALIK RA, 1989, DIABETOLOGIA, V32, P92, DOI 10.1007/BF00505180; Melian EB, 2002, DRUGS, V62, P107, DOI 10.2165/00003495-200262010-00005; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; Miyazawa T, 1998, J CEREBR BLOOD F MET, V18, P345, DOI 10.1097/00004647-199804000-00001; Morishita R, 1999, HYPERTENSION, V33, P1379, DOI 10.1161/01.HYP.33.6.1379; Morishita R, 1997, DIABETOLOGIA, V40, P1053, DOI 10.1007/s001250050787; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakano N, 1998, HYPERTENSION, V32, P444, DOI 10.1161/01.HYP.32.3.444; Rajagopalan S, 2001, CIRCULATION, V104, P753, DOI 10.1161/hc3201.095192; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; STANLEY EF, 1981, EXP NEUROL, V71, P497, DOI 10.1016/0014-4886(81)90027-3; STEVENS EJ, 1994, DIABETOLOGIA, V37, P43, DOI 10.1007/BF00428776; Szczeklik A, 1980, Adv Prostaglandin Thromboxane Res, V7, P687; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Taniyama Y, 2001, CIRCULATION, V104, P2344, DOI 10.1161/hc4401.098470; Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379; TESFAYE S, 1993, DIABETOLOGIA, V36, P1266, DOI 10.1007/BF00400804; TESFAYE S, 1992, DIABETOLOGIA, V35, P155, DOI 10.1007/BF00402548; Todaka T, 1999, STROKE, V30, P419, DOI 10.1161/01.STR.30.2.419; TUCK RR, 1984, BRAIN, V107, P935, DOI 10.1093/brain/107.3.935; Van Belle E, 1998, CIRCULATION, V97, P381; Vincent KA, 2000, CIRCULATION, V102, P2255; WHITELEY SJ, 1985, EXP NEUROL, V89, P314, DOI 10.1016/0014-4886(85)90092-5; YAMADA C, 1995, BIOMED RES-TOKYO, V16, P105; Yang XM, 1998, J NEUROSCI, V18, P8369; YOUNG MJ, 1995, DIABETOLOGIA, V38, P1051, DOI 10.1007/s001250050390	42	44	56	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					779	+		10.1096/fj.02-0754fje	http://dx.doi.org/10.1096/fj.02-0754fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586736				2022-12-25	WOS:000181456900026
J	Kuijpers, MJE; Schulte, V; Bergmeier, W; Lindhout, T; Brakebusch, C; Offermanns, S; Fassler, R; Heemskerk, JWM; Nieswandt, B				Kuijpers, MJE; Schulte, V; Bergmeier, W; Lindhout, T; Brakebusch, C; Offermanns, S; Fassler, R; Heemskerk, JWM; Nieswandt, B			Complementary roles of platelet glycoprotein VI and integrin alpha 2 beta 1 in collagen-induced thrombus formation in flowing whole blood ex vivo	FASEB JOURNAL			English	Article						collagen receptors; flow model; phosphatidylserine; platelet aggregation; whole blood perfusion	VON-WILLEBRAND-FACTOR; RECEPTOR GAMMA-CHAIN; COUPLED RECEPTORS; PHOSPHOLIPASE-C; IB INTERACTION; CA2+ ENTRY; ACTIVATION; ADHESION; MOUSE; KINASE	Platelets interact vigorously with subendothelial collagens that are exposed by injury or pathological damage of a vessel wall. The collagen-bound platelets trap other platelets to form aggregates, and they expose phosphatidylserine (PS) required for coagulation. Both processes are implicated in the formation of vaso-occlusive thrombi. We previously demonstrated that the immunoglobulin receptor glycoprotein VI (GPVI), but not integrin alpha2beta1, is essential in priming platelet-collagen interaction and subsequent aggregation. Here, we report that these receptors have yet a complementary function in ex vivo thrombus formation during perfusion of whole blood over collagen. With mice deficient in GPVI or blocking antibodies, we found that GPVI was indispensable for collagen-dependent Ca2+ mobilization, exposure of PS, and aggregation of platelets. Deficiency of integrin beta1 reduces the GPVI-evoked responses but still allows the formation of loose platelet aggregates. By using mice deficient in Galpha(q) or specific thromboxane A(2) and ADP antagonists, we show that these autocrine agents mediated aggregation but not collagen-induced Ca2+ mobilization or PS exposure. Collectively, these data indicate that integrin alpha2beta1 facilitates the central function of GPVI in the platelet activation processes that lead to thrombus formation, whereas the autocrine thromboxane A(2) and ADP serve mainly to trigger aggregate formation.	Univ Maastricht, CARIM, Dept Biochem & Human Biol, NL-6200 MD Maastricht, Netherlands; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Heidelberg Univ, Dept Pharmacol, D-69120 Heidelberg, Germany	Maastricht University; Maastricht University Medical Centre (MUMC); University of Wurzburg; Max Planck Society; Ruprecht Karls University Heidelberg	Heemskerk, JWM (corresponding author), Univ Maastricht, CARIM, Dept Biochem, POB 616, NL-6200 MD Maastricht, Netherlands.	jwm.heemskerk@bioch.unimaas.nl	Kuijpers, Marijke/AAN-9876-2021; Heemskerk, Johan/AAM-8323-2021; Offermanns, Stefan/L-3313-2017	Heemskerk, Johan/0000-0002-2848-5121; Offermanns, Stefan/0000-0001-8676-6805; Brakebusch, Cord/0000-0002-9342-1634				ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Briede JJ, 2001, THROMB HAEMOSTASIS, V85, P509, DOI 10.1055/s-0037-1615613; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; Furihata K, 2001, ARTERIOSCL THROM VAS, V21, P1857, DOI 10.1161/hq1001.096643; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Heemskerk JWM, 2001, J PHYSIOL-LONDON, V535, P625, DOI 10.1111/j.1469-7793.2001.00625.x; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; Jackson SP, 2000, TRENDS CARDIOVAS MED, V10, P192, DOI 10.1016/S1050-1738(00)00062-1; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Kehrel B, 1998, BLOOD, V91, P491; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Moroi M, 1997, BLOOD, V90, P4413; Moroz LL, 2000, NITR OXIDE BIO MED, V2, P1; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, BLOOD, V97, P3829, DOI 10.1182/blood.V97.12.3829; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Roest M, 2000, BLOOD, V96, P1433, DOI 10.1182/blood.V96.4.1433.h8001433_1433_1437; Ruggeri ZM, 2001, HEMOSTASIS THROMBOSI, P683; SAELMAN EUM, 1994, BLOOD, V83, P3240, DOI 10.1182/blood.V83.11.3240.bloodjournal83113240; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Storey RF, 2000, BRIT J HAEMATOL, V110, P925, DOI 10.1046/j.1365-2141.2000.02208.x; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Turner NA, 2001, BLOOD, V98, P3340, DOI 10.1182/blood.V98.12.3340; Verkleij MW, 1998, BLOOD, V91, P3808; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wu YP, 2000, ARTERIOSCL THROM VAS, V20, P1661, DOI 10.1161/01.ATV.20.6.1661; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	44	121	129	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					685	+		10.1096/fj.02-0381fje	http://dx.doi.org/10.1096/fj.02-0381fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586747				2022-12-25	WOS:000181456900019
J	Miller, G; Lahrs, S; DeMatteo, RP				Miller, G; Lahrs, S; DeMatteo, RP			Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity	FASEB JOURNAL			English	Article						immunity; cytokines; tumor	NATURAL-KILLER-CELLS; INTERFERON-GAMMA PRODUCTION; NF-KAPPA-B; IFN-GAMMA; ANTIMETASTATIC ACTIVITY; RECOMBINANT IL-12; TUMOR-REGRESSION; RECEPTOR; MACROPHAGE; EXPRESSION	Dendritic cells (DC) are initiators of T cell-mediated immunity. However, less is known about the relationship between DC and natural killer (NK) cells, and direct evidence of their interaction in vivo is scarce. Interleukin (IL)-12 is an activator of both DC and NK cells. We postulated that secretion of IL-12 by DC would enable them to activate NK cells. Bone marrow-derived DC propagated only in granulocyte macrophage colony-stimulating factor did not activate NK cells. In contrast, DC engineered to express IL-12 markedly stimulated NK cells as determined by coculture experiments in vitro, assays of NK cells isolated from treated animals, and survival experiments in a systemic tumor model. Activation depended on both DC-NK cellular interaction and secretion of IL-12. Adoptive transfer of DC expressing IL-12 to mice markedly increased NK cell interferon-gamma production and lytic activity in vivo. Treated mice were also protected against B16 melanoma hepatic metastases. The in vivo effects on NK cells were DC-specific. Administration of IL-12 protein alone or melanoma cells or fibroblasts engineered to secrete IL-12 were only weakly activating. Our findings demonstrate that IL-12 expression by DC enables them to activate NK cells and provide evidence for a substantial DC-NK relationship in vivo.	Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, 1275 York Ave, New York, NY 10021 USA.	dematter@mskcc.org						Ahuja SS, 1998, J IMMUNOL, V161, P868; Amakata Y, 2001, CLIN EXP IMMUNOL, V124, P214, DOI 10.1046/j.1365-2249.2001.01550.x; Atkins MB, 1997, CLIN CANCER RES, V3, P409; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; CHAN SH, 1992, J IMMUNOL, V148, P92; COHEN J, 1995, SCIENCE, V270, P908; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; DeMatteo RP, 1997, J VIROL, V71, P5330, DOI 10.1128/JVI.71.7.5330-5335.1997; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Furumoto K, 2000, INT J CANCER, V87, P665, DOI 10.1002/1097-0215(20000901)87:5<665::AID-IJC8>3.0.CO;2-F; GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; Hendrzak JA, 1996, CURR TOP MICROBIOL, V213, P65; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; Hirschowitz EA, 2000, GENE THER, V7, P1112, DOI 10.1038/sj.gt.3301210; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jenne L, 2000, CANCER RES, V60, P4446; Kelly JJ, 1998, FASEB J, V12, pA14; Kikuchi T, 2000, CANCER RES, V60, P6391; Kim KD, 1999, ARCH PHARM RES, V22, P340, DOI 10.1007/BF02979055; KLEIN E, 1993, CURR OPIN IMMUNOL, V5, P714, DOI 10.1016/0952-7915(93)90126-D; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Kodama T, 1999, EUR J IMMUNOL, V29, P1390, DOI 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.3.CO;2-3; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Maruo S, 1997, J LEUKOCYTE BIOL, V61, P346, DOI 10.1002/jlb.61.3.346; Melero I, 1999, GENE THER, V6, P1779, DOI 10.1038/sj.gt.3301010; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Nagayama H, 2000, J IMMUNOL, V165, P59, DOI 10.4049/jimmunol.165.1.59; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Ng P, 2000, HUM GENE THER, V11, P693; Nishioka Y, 2001, EUR J IMMUNOL, V31, P2633, DOI 10.1002/1521-4141(200109)31:9<2633::AID-IMMU2633>3.0.CO;2-2; Nouri-Shirazi M, 2000, J IMMUNOL, V165, P3797, DOI 10.4049/jimmunol.165.7.3797; OGarra A, 1995, RES IMMUNOL, V146, P466, DOI 10.1016/0923-2494(96)83017-3; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; TAHARA H, 1994, CANCER RES, V54, P182; Wilkinson VL, 1996, J IMMUNOL METHODS, V189, P15, DOI 10.1016/0022-1759(95)00223-5; Zitvogel L, 1995, RES IMMUNOL, V146, P628, DOI 10.1016/0923-2494(96)83041-0; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040; ZITVOGEL L, 1996, ANN NY ACAD SCI, V795, P84	44	38	43	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					728	+		10.1096/fj.02-0900fje	http://dx.doi.org/10.1096/fj.02-0900fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594171				2022-12-25	WOS:000181456900004
J	Gastaldelli, M; Canino, G; Croce, R; Bassi, R				Gastaldelli, M; Canino, G; Croce, R; Bassi, R			Xanthophyll binding sites of the CP29 (Lhcb4) subunit of higher plant photosystem II investigated by domain swapping and mutation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; ANTENNA COMPLEX; ENERGY-TRANSFER; PIGMENT-BINDING; ZEAXANTHIN FORMATION; PROTEINS; LHCII; DICYCLOHEXYLCARBODIIMIDE; RECONSTITUTION; STOICHIOMETRY	The binding sites for xanthophylls in the CP29 antenna protein of higher plant Photosystem II have been investigated using recombinant proteins refolded in vitro. Despite the presence of three xanthophyll species CP29 binds two carotenoids per polypeptide. The localization of neoxanthin was studied producing a chimeric protein constructed by swapping the C-helix domain from CP29 to LHCII. The resulting holoprotein did not bind neoxanthin, confirming that the N1 site is not present in CP29. Neoxanthin in CP29 was, instead, bound to the L2 site, which is thus shown to have a wider specificity with respect to the homologous site L2 in LHCII. Lutein was found in the L1 site of CP29. For each site the selectivity for individual xanthophyll species was studied as well as its role in protein stabilization, energy transfer, and photoprotection. Putative xanthophyll binding sequences, identified by primary structure analysis as a stretch of hydrophobic residues including an acidic term, were analyzed by site-directed mutagenesis or, in one case, by deleting the entire sequence. The mutant proteins were unaffected in their xanthophyll composition, thus suggesting that the target motifs had little influence in determining xanthophyll binding, whereas hydrophobic sequences in the membrane-spanning helices are important.	Univ Aix Marseille 2, Fac Sci Luminy, Dept Biol, LGBP, F-13288 Marseille 09, France; Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; CNR, Ist Biofis, I-20133 Milan, Italy	UDICE-French Research Universities; Aix-Marseille Universite; University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Bassi, R (corresponding author), Univ Aix Marseille 2, Fac Sci Luminy, Dept Biol, LGBP, Case 901-163,Ave Luminy, F-13288 Marseille 09, France.		Croce, Roberta/ABG-3595-2021; Croce, Roberta/F-1174-2014; Croce, Roberta/HGU-9554-2022; Croce, Roberta/N-4067-2014	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 2003, BIOPHYS J, V84, P2517, DOI 10.1016/S0006-3495(03)75057-7; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Croce R, 2000, PHOTOSYNTH RES, V64, P221, DOI 10.1023/A:1006455230379; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; Das SK, 2002, BIOCHEMISTRY-US, V41, P13087, DOI 10.1021/bi0204802; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; Dolan PM, 2001, J PHYS CHEM B, V105, P12134, DOI 10.1021/jp010271b; Faller P, 2001, BIOCHEMISTRY-US, V40, P6431, DOI 10.1021/bi0026021; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; Heinemann B, 1999, BIOCHEMISTRY-US, V38, P14088, DOI 10.1021/bi991439a; Jegerschold C, 2000, J BIOL CHEM, V275, P12781, DOI 10.1074/jbc.275.17.12781; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Pascal A, 1999, EUR J BIOCHEM, V262, P817, DOI 10.1046/j.1432-1327.1999.00457.x; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Prince SM, 1997, J MOL BIOL, V268, P412, DOI 10.1006/jmbi.1997.0966; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; Simonetto R, 1999, BIOCHEMISTRY-US, V38, P12974, DOI 10.1021/bi991140s; Tracewell CA, 2001, BIOCHEMISTRY-US, V40, P193, DOI 10.1021/bi001992o; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x	40	30	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19190	19198		10.1074/jbc.M212125200	http://dx.doi.org/10.1074/jbc.M212125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12601013	hybrid			2022-12-25	WOS:000182932200063
J	Gil-Henn, H; Elson, A				Gil-Henn, H; Elson, A			Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY KINASES; BREAST-CANCER; C-SRC; DOWN-REGULATION; PTP-EPSILON; RPTP-ALPHA; GROWTH; SIGNAL; PHOSPHORYLATION; EXPRESSION	Few tyrosine phosphatases support, rather than inhibit, survival of tumor cells. We present genetic evidence that receptor-type protein-tyrosine phosphatase (RPTP)-epsilon performs such a function, as cells from mammary epithelial tumors induced by activated Neu in mice genetically lacking RPTPLepsilon appeared morphologically less transformed and exhibited reduced proliferation. We show that at the molecular level, RPTPepsilon activates Src, a known collaborator of Neu in mammary tumorigenesis. Lack of RPTPepsilon reduced Src activity and altered Src phosphorylation in tumor cells; RPTPepsilon dephosphorylated and activated Src; and Src bound a substrate-trapping mutant of RPTPepsilon. The altered morphology of tumor cells lacking RPTPepsilon was corrected by exogenous Src and exogenous RPTPepsilon or RPTPalpha; exogenous activated Src corrected also the growth rate phenotype. Together, these results suggest that the altered morphology of RPTPepsilon-deficient tumor cells is caused by reduced Src activity, caused, in turn, by lack of RPTPepsilon. Unexpectedly, the phenotype of RPTPepsilon-deficient tumor cells occurs despite expression of the related RPTPalpha, indicating that endogenous RPTPalpha does not compensate for the absence of RPTPepsilon in this case. We conclude that RPTPepsilon is a physiological activator of Src in Neuinduced mammary tumors and suggest that pharmacological inhibition of phosphatases that activate Src may be useful to augment direct pharmacological inhibition of Src.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Herzl St, IL-76100 Rehovot, Israel.	ari.elson@weizmann.ac.il		Elson, Ari/0000-0001-9808-9135				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Andrechek ER, 2000, BREAST CANCER RES, V2, P211, DOI 10.1186/bcr56; Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sully V, 2001, BIOCHEM BIOPH RES CO, V286, P184, DOI 10.1006/bbrc.2001.5360; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tanuma N, 2001, BLOOD, V98, P3030, DOI 10.1182/blood.V98.10.3030; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Thompson LJ, 2001, AM J PHYSIOL-HEART C, V281, pH396, DOI 10.1152/ajpheart.2001.281.1.H396; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	53	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15579	15586		10.1074/jbc.M210273200	http://dx.doi.org/10.1074/jbc.M210273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598528	hybrid			2022-12-25	WOS:000182680000017
J	Wilsie, LC; Orlando, RA				Wilsie, LC; Orlando, RA			The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CHYLOMICRON REMNANT UPTAKE; APOLIPOPROTEIN-E; LDL RECEPTOR; BETA-VLDL; IN-VITRO; ALPHA(2)-MACROGLOBULIN RECEPTOR; HEYMANN NEPHRITIS; CULTURED-CELLS	It has been proposed that clearance of cholesterol-enriched very low density lipoprotein (VLDL) particles occurs through a multistep process beginning with their initial binding to cell-surface heparan sulfate proteoglycans (HSPG), followed by their uptake into cells by a receptor-mediated process that utilizes members of the low density lipoprotein receptor (LDLR) family, including the low density lipoprotein receptor-related protein (LRP). We have further explored the relationship between HSPG binding of VLDL and its subsequent internalization by focusing on the LRP pathway using a cell line deficient in LDLR. In this study, we show that LRP and HSPG are part of a co-immunoprecipitable complex at the cell surface demonstrating a novel association for these two cell surface receptors. Cell surface binding assays show that this complex can be disrupted by an LRP-specific ligand binding antagonist, which in turn leads to increased VLDL binding and degradation. The increase in VLDL binding results from an increase in the availability of HSPG sites as treatment with heparinase or competitors of glycosaminoglycan chain addition eliminated the augmented binding. From these results we propose a model whereby LRP regulates the availability of VLDL binding sites at the cell surface by complexing with HSPG. Once HSPG dissociates from LRP, it is then able to bind and internalize VLDL independent of LRP endocytic activity. We conclude that HSPG and LRP together participate in VLDL clearance by means of a synergistic relationship.	Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Orlando, RA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, MSC08-4670, Albuquerque, NM 87131 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063291] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63291] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1993, ARTERIOSCLER THROMB, V13, P618, DOI 10.1161/01.ATV.13.4.618; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BEMFIELD M, 1992, ANN REV CELL BIOL, V8, P365; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Bu GJ, 1997, J CELL SCI, V110, P65; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; Chappell DA, 1998, PROG LIPID RES, V37, P393, DOI 10.1016/S0163-7827(98)00017-4; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; CZEKAY RP, 1995, J CELL SCI, V108, P1433; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; de Beer F, 1999, ARTERIOSCL THROM VAS, V19, P633, DOI 10.1161/01.ATV.19.3.633; Field PA, 2000, METABOLISM, V49, P492, DOI 10.1016/S0026-0495(00)80014-1; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Havel Richard J., 1994, Current Opinion in Lipidology, V5, P102, DOI 10.1097/00041433-199404000-00006; HAVEL RJ, 1989, ARTERIOSCLEROSIS, V9, pI33; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huff MW, 1997, J LIPID RES, V38, P1318; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JAAKKOLA O, 1989, ATHEROSCLEROSIS, V79, P173, DOI 10.1016/0021-9150(89)90122-6; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; Karpe F, 1999, J INTERN MED, V246, P341, DOI 10.1046/j.1365-2796.1999.00548.x; Kerjaschki D, 1997, J CLIN INVEST, V100, P2303, DOI 10.1172/JCI119768; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; LUNDSTROM M, 1993, AM J PATHOL, V143, P1423; MacPhee CE, 2000, BIOCHEMISTRY-US, V39, P3433, DOI 10.1021/bi992523t; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKEONE BJ, 1988, BIOCHEMISTRY-US, V27, P4500, DOI 10.1021/bi00412a042; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Olivecrona G, 1997, ARTERIOSCL THROM VAS, V17, P1545, DOI 10.1161/01.ATV.17.8.1545; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Rinninger F, 1998, J LIPID RES, V39, P1335; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROSKAMS T, 1995, HEPATOLOGY, V21, P950, DOI 10.1016/0270-9139(95)90239-2; Seo T, 1997, J LIPID RES, V38, P765; SHAFI S, 1994, J LIPID RES, V35, P709; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Taylor WH, 1998, J BIOL CHEM, V273, P22260, DOI 10.1074/jbc.273.35.22260; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; van der Voort R, 2000, J EXP MED, V192, P1115, DOI 10.1084/jem.192.8.1115; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Weaver AM, 1997, J LIPID RES, V38, P1841; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Willnow TE, 1998, BIOL CHEM, V379, P1025; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Yu KCW, 2001, FRONT BIOSCI-LANDMRK, V6, pD332, DOI 10.2741/Yu; Zeng BJ, 1998, J LIPID RES, V39, P845; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	79	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15758	15764		10.1074/jbc.M208786200	http://dx.doi.org/10.1074/jbc.M208786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598530	hybrid			2022-12-25	WOS:000182680000039
J	Blencke, S; Ullrich, A; Daub, H				Blencke, S; Ullrich, A; Daub, H			Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLINICAL RESISTANCE; SIGNAL-TRANSDUCTION; PROTEIN; DRUG; EGF; PHOSPHORYLATION; FAMILY; TARGET; DOMAIN; STI571	Small molecule inhibitors of protein tyrosine kinases such as STI571 represent a major new class of therapeutics for target-selective treatment of human cancer. Clinical resistance formation to the BCR-ABL inhibitor STI571 has been observed in patients with advanced chronic myeloid leukemia and was frequently caused by a C to T single nucleotide change in the Abl kinase domain, which substituted Thr-315 with isoleucine and rendered BCR-ABL resistant to STI571 inhibition. The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilino-quinazoline inhibitors such as PD153035. Inhibitor-resistant EGFR exhibited the same signaling capacity as wild-type receptor in vivo and provides a useful tool for analyzing EGFR-mediated signal transduction. Our data identify Thr-766 of the EGFR as a structural determinant that bears the potential to become a relevant feature in resistance formation during cancer therapy with EGFR-specific 4-anilinoquinazoline inhibitors.	Axxima Pharmaceut AG, D-81377 Munich, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Daub, H (corresponding author), Axxima Pharmaceut AG, Max Lebsche Pl 32, D-81377 Munich, Germany.	daub@axxima.com						Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; McCormick F, 2001, NATURE, V412, P281, DOI 10.1038/35085665; NAPIER MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P296, DOI 10.1016/0003-9861(87)90496-6; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	28	100	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15435	15440		10.1074/jbc.M211158200	http://dx.doi.org/10.1074/jbc.M211158200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594213	hybrid			2022-12-25	WOS:000182516100110
J	Su, L; Hattori, M; Moriyama, M; Murata, N; Harazaki, M; Kaibuchi, K; Minato, N				Su, L; Hattori, M; Moriyama, M; Murata, N; Harazaki, M; Kaibuchi, K; Minato, N			AF-6 controls integrin-mediated cell adhesion by regulating Rap1 activation through the specific recruitment of Rap1GTP and SPA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAINS; PROTEIN; GTPASE; RAS; TARGET; DEGRADATION; DISTINCT; PARTNER; PATHWAY; COMPLEX	In the present study, we showed that SPA-1, a Rap1 GTPase-activating protein (GAP), was bound to a cytoskeleton-anchoring protein AF-6. SPA-1 and AF-6 were co-immunoprecipitated in the 293T cells transfected with both cDNAs as well as in normal thymocytes. In vitro binding studies using truncated fragments and their mutants suggested that SPA-1 was bound to the PDZ domain of AF-6 via probable internal PDZ ligand motif within the GAP-related domain. The motif was conserved among Rap1 GAPs, and it was shown that rapGAP I was bound to AF-6 comparably with SPA-1. RapV12 was also bound to AF-6 via the N-terminal domain, and SPA-1 and RapV12 were co-immunoprecipitated only in the presence of AF-6, indicating that they could be brought into close proximity via AF-6 in cells. Immunostaining analysis revealed that SPA-1 and RapV12 were co-localized with AF-6 at the cell attachment sites. In HeLa cells expressing SPA-1 in a tetracycline-regulatory manner, expression of AF-6 inhibited endogenous Rap1GTP and beta(1) integrin-mediated cell adhesion to fibronectin in SPA-1-induced conditions, whereas it affected neither of them in SPA-1-repressed conditions. These results suggested that AF-6 could control integrin-mediated cell adhesion by regulating Rap1 activation through the recruitment of both SPA-1 and Rap1GTP via distinct domains.	Kyoto Univ, Dept Immunol & Cell Biol, Grad Sch Med, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4668550, Japan	Kyoto University; Kyoto University; Nagoya University	Minato, N (corresponding author), Kyoto Univ, Dept Immunol & Cell Biol, Grad Sch Med, Kyoto 6068501, Japan.							Abbitt KB, 2000, J IMMUNOL METHODS, V239, P109, DOI 10.1016/S0022-1759(00)00189-7; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Flaishon L, 2001, J BIOL CHEM, V276, P46701, DOI 10.1074/jbc.M103484200; Gao QS, 2002, CANCER RES, V62, P3315; Gao QS, 1999, MOL CELL BIOL, V19, P733; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; PRASAD R, 1993, CANCER RES, V53, P5624; Roy BC, 2002, GENES CELLS, V7, P607; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	30	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15232	15238		10.1074/jbc.M211888200	http://dx.doi.org/10.1074/jbc.M211888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590145	hybrid, Green Submitted			2022-12-25	WOS:000182516100084
J	Taheri, M; Saragovi, HU; Stanners, CP				Taheri, M; Saragovi, HU; Stanners, CP			The adhesion and differentiation-inhibitory activities of the immunoglobulin superfamily member, carcinoembryonic antigen, can be independently blocked	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TUMOR-MARKER; IG SUPERFAMILY; CEA; IDENTIFICATION; FIBRONECTIN; SPECIFICITY; EXPRESSION; MOLECULES; PROTEINS; DOMAINS	The external domains of Ig superfamily members are involved in multiple binding interactions, both homophilic and heterophilic, that initiate molecular events leading to the execution of diverse cell functions. Human carcinoembryonic antigen (CEA), an Ig superfamily cell surface glycoprotein used widely as a clinical tumor marker, undergoes homophilic interactions that mediate intercellular adhesion. Recent evidence supports the view that deregulated overexpression of CEA has an instrumental role in tumorigenesis through the inhibition of cell differentiation and the disruption of tissue architecture. The CEA-mediated block of the myogenic differentiation of rat L6 myoblasts depends on homophilic binding of its external domains. We show here that L6 transfectant cells expressing CEA can "trans-block" the myogenesis of juxtaposed differentiation-competent L6 transfectant cells expressing a deletion mutant of CEA (DeltaNCEA). This result implies the efficacy of antiparallel CEA-CEA interactions between cells in the differentiation block. In addition, DeltaNCEA can acquire differentiation blocking activity by cross-linking with specific anti-CEA antibodies, thus implying the efficacy of parallel CEA-CEA interactions on the same cell surface. The myogenic differentiation blocking activity of CEA was demonstrated by site-directed mutations to involve three subdomains of the amino-terminal domain, shown previously to be critical for its intercellular adhesion function. Monovalent Fab fragments of monoclonal antibodies binding to the region bridging subdomains 1 and 2 could both inhibit intercellular adhesion and release the myogenic differentiation block. Amino acid substitutions Q80A, Q80R, and D82N in subdomain 3, QNDTG, however, were found to completely ablate the differentiation blocking activity of CEA but had no effect on intercellular adhesion activity. A cyclized peptide representing this subdomain was the most effective at releasing the differentiation block.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; McGill University	Stanners, CP (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	cliff.stanners@mcgill.ca						AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BEAUCHEMIN N, 1987, MOL CELL BIOL, V7, P3221, DOI 10.1128/MCB.7.9.3221; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOETTIGER D, 1995, DEV BIOL, V169, P261, DOI 10.1006/dbio.1995.1142; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; DEGIOVANNI C, 1993, BRIT J CANCER, V67, P674, DOI 10.1038/bjc.1993.125; Draber P, 1998, CELL ADHES COMMUN S, V5, P121; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GULLBERG D, 1995, EXP CELL RES, V220, P112, DOI 10.1006/excr.1995.1297; HAUCK W, 1991, CANCER RES, V51, P3526; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; Huang ZW, 1997, BIOPOLYMERS, V43, P367, DOI 10.1002/(SICI)1097-0282(1997)43:5<367::AID-BIP3>3.0.CO;2-T; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Ilantzis C, 1997, LAB INVEST, V76, P703; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; Ordonez C, 2000, CANCER RES, V60, P3419; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Sippel CJ, 1996, J BIOL CHEM, V271, P33095, DOI 10.1074/jbc.271.51.33095; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P141; Taheri M, 2000, J BIOL CHEM, V275, P26935; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; Tan KM, 2002, EMBO J, V21, P2076, DOI 10.1093/emboj/21.9.2076; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU H, 1993, CANCER RES, V53, P3817; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	38	30	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14632	14639		10.1074/jbc.M212500200	http://dx.doi.org/10.1074/jbc.M212500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12571231	hybrid			2022-12-25	WOS:000182516100009
J	Barbier, O; Villeneuve, L; Bocher, V; Fontaine, C; Torra, IP; Duhem, C; Kosykh, V; Fruchart, JC; Guillemette, C; Staels, B				Barbier, O; Villeneuve, L; Bocher, V; Fontaine, C; Torra, IP; Duhem, C; Kosykh, V; Fruchart, JC; Guillemette, C; Staels, B			The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER; PPAR-ALPHA; CLINICAL PHARMACOKINETICS; IN-VITRO; METABOLISM; EXPRESSION; GLUCURONIDATION; ACID; IDENTIFICATION; RAT	Peroxisome proliferator-activated receptor (PPAR) alpha and gamma are ligand-activated transcription factors belonging to the nuclear receptor family. PPARa mediates the hypolipidemic action of the fibrates, whereas PPARgamma is a receptor for the antidiabetic glitazones. In the present study, the UDP-glucuronosyltransferase (UGT) 1A9 enzyme is identified as a PPARalpha and PPARgamma target gene. UGTs catalyze the glucuronidation reaction, which is a major pathway in the catabolism and elimination of numerous endo- and xenobiotics. Among the UGT1A family enzymes, UGT1A9 metabolizes endogenous compounds, including catecholestrogens, and xenobiotics, such as fibrates and to a lesser extent troglitazone. Treatment of human hepatocytes and macrophages and murine adipocytes with activators of PPARalpha or PPARgamma resulted in an enhanced UGT1A9 expression and activity. In addition, disruption of the PPARalpha gene in mice completely abolished the PPARalpha agonist-induced UGT1A9 mRNA and activity levels. A PPAR response element was identified in the promoter of UGT1A9 at positions -719 to -706 bp by transient transfection and electromobility shift assays. Considering the role of UGT1A9 in catecholestrogen metabolism, PPARalpha and PPARgamma activation may contribute to the protection against genotoxic catecholestrogens by stimulating their inactivation in glucuronide derivatives. Furthermore, since UGT1A9 is involved in the catabolism of fibrates, these results suggest that PPARalpha and PPARgamma may control the intracellular level of active fibrates.	Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59019 Lille, France; CHUL, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Pharm, Quebec City, PQ G1V 4G2, Canada; Inst Expt Cardiol, Moscow 121552, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Laval University; Laval University; National Medical Research Center of Cardiology	Staels, B (corresponding author), Inst Pasteur, INSERM, U545, Dept Atherosclerose, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Guillemette, Chantal/J-6463-2012; Fontaine, Coralie/N-3814-2017; Guillemette, Chantal/AAT-6246-2020; Staels, Bart/N-9497-2016	Guillemette, Chantal/0000-0002-1113-1212; Staels, Bart/0000-0002-3784-1503; Pineda Torra, Ines/0000-0002-7349-2208; Barbier, Olivier/0000-0002-3067-1134; Duhem, Christian/0000-0003-0931-3815; Fontaine, Coralie/0000-0002-7253-922X				Albert C, 1999, ENDOCRINOLOGY, V140, P3292, DOI 10.1210/en.140.7.3292; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Bock KW, 1999, DRUG METAB REV, V31, P411, DOI 10.1081/DMR-100101927; BODE BP, 1995, HEPATOLOGY, V21, P511; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claudel T, 2002, J CLIN INVEST, V109, P961; Congiu M, 2002, DRUG METAB DISPOS, V30, P129, DOI 10.1124/dmd.30.2.129; Cox PJ, 2000, DRUG METAB DISPOS, V28, P772; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dutton G.F., 1980, GLUCURONIDATION DRUG; EBNER T, 1993, DRUG METAB DISPOS, V21, P50; Findlay KAB, 2000, J CLIN ENDOCR METAB, V85, P2879, DOI 10.1210/jc.85.8.2879; Goodman MT, 2001, CANCER EPIDEM BIOMAR, V10, P209; HAUTANEN A, 1992, J STEROID BIOCHEM, V42, P433, DOI 10.1016/0960-0760(92)90149-D; Hedrick CC, 1999, ADV EXP MED BIOL, V469, P455; Huang LY, 2001, DRUG METAB DISPOS, V29, P634; Jemnitz K, 2000, DRUG METAB DISPOS, V28, P34; Jude AR, 2001, DRUG METAB DISPOS, V29, P652; Khan MA, 2002, DIABETES CARE, V25, P708, DOI 10.2337/diacare.25.4.708; King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171; Kockx M, 1999, BLOOD, V93, P2991; Kok T, 2003, BIOCHEM J, V369, P539, DOI 10.1042/BJ20020981; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; KRIETER PA, 1994, DRUG METAB DISPOS, V22, P625; Lavigne JA, 1997, CANCER RES, V57, P5493; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Liehr JG, 1997, EUR J CANCER PREV, V6, P3, DOI 10.1097/00008469-199702000-00002; LIU HF, 1991, EUR J CLIN PHARMACOL, V41, P153; Loi CM, 1999, CLIN PHARMACOKINET, V37, P91, DOI 10.2165/00003088-199937020-00001; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Miller DB, 1998, CLIN PHARMACOKINET, V34, P155, DOI 10.2165/00003088-199834020-00003; MOUNIE J, 1988, FUND CLIN PHARMACOL, V2, P259, DOI 10.1111/j.1472-8206.1988.tb00637.x; Natarajan R, 2001, ARTERIOSCL THROM VAS, V21, P1408, DOI 10.1161/hq0901.095278; Owens IS, 1996, J PHARMACOKINET BIOP, V24, P491, DOI 10.1007/BF02353476; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Pless D, 1999, DRUG METAB DISPOS, V27, P588; Prueksaritanont T, 2002, J PHARMACOL EXP THER, V301, P1042, DOI 10.1124/jpet.301.3.1042; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P1280, DOI 10.1124/dmd.30.11.1280; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Rubin GL, 2002, ENDOCRINOLOGY, V143, P2863, DOI 10.1210/en.143.8.2863; Rubin GL, 2000, CANCER RES, V60, P1604; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Strassburg CP, 1999, GASTROENTEROLOGY, V116, P149, DOI 10.1016/S0016-5085(99)70239-8; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Torra IP, 2002, MOL ENDOCRINOL, V16, P1013; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Viita H, 1999, ANTIOXID REDOX SIGN, V1, P83, DOI 10.1089/ars.1999.1.1-83; Viollon-Abadie C, 2000, TOXICOL IN VITRO, V14, P505, DOI 10.1016/S0887-2333(00)00044-8; Watanabe Y, 2002, DRUG METAB DISPOS, V30, P1462, DOI 10.1124/dmd.30.12.1462; Wheelan P, 1999, J PHARMACOL EXP THER, V288, P326; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yoshigae Yasushi, 2000, Journal of Toxicological Sciences, V25, P433; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1	66	105	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13975	13983		10.1074/jbc.M300749200	http://dx.doi.org/10.1074/jbc.M300749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582161	hybrid			2022-12-25	WOS:000182405000054
J	Henrikson, CA; Xue, T; Dong, PH; Sang, DP; Marban, E; Li, RA				Henrikson, CA; Xue, T; Dong, PH; Sang, DP; Marban, E; Li, RA			Identification of a surface charged residue in the S3-S4 linker of the pacemaker (HCN) channel that influences activation gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; VOLTAGE-SENSING RESIDUES; CALF PURKINJE-FIBERS; PACE-MAKER CURRENT; POTASSIUM CHANNEL; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; ION CHANNELS; S4 REGION; SENSOR	it, encoded by the hyperpolarization-activated cyclic nucleotide-modulated (HCN) channel family, is a key player in cardiac and neuronal pacing. Although HCN channels structurally resemble voltage-gated K+ (Kv) channels, their structure-function correlation is much less clear. Here we probed the functional importance of the HCN1 S3-S4 linker by multiple substitutions of its residues. Neutralizing Glu(235), an acidic S3-S4 linker residue conserved in all hyperpolarization-activated channels, by Ala substitution produced a depolarizing activation shift (V-1/2 = -65.0 +/- 0.7 versus -70.6 +/- 0.7 mV for wild-type HCN1); the charge-reversed mutation E235R shifted activation even more positively (-56.2 +/- 0.5 mV). Increasing external Me, mimicked the progressive rightward shifts of E235A and E235R by gradually shifting activation (V-1/2 = 1 < 3 < 10 < 30 mM); DeltaV(1/2) induced by 30 mM me, was significantly attenuated for E235A (+7.9 +/- 1.2 versus +11.3 +/- 0.9 mV for wild-type HCN1) and E235R (+3.3 +/- 1.4 mV) channels, as if surface charges were already shielded. Consistent with an electrostatic role, the energetic changes associated with DeltaV(1/2) resulting from various Glu(235) substitutions (ie. Asp, Ala, Pro, His, Lys, and Arg) displayed a strong correlation with their charges (DeltaDeltaG = -2.1 +/- 0.3 kcal/mol/charge; r = 0.94). In contrast, D233E, D233A, D233G, and D233R did not alter activation gating. D233C (in C318S background) was also not externally accessible when probed with methanethiosulfonate ethylammonium (MTSEA). We conclude that the S3-S4 linker residue Glu(235) influences activation gating, probably by acting as a surface charge.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022; Li, Ronald/E-9833-2010; Xue, Tian/G-9009-2018		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007227, R01HL052768] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07227-26, R01 HL52768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; BROWN HF, 1977, J PHYSIOL-LONDON, V271, P783, DOI 10.1113/jphysiol.1977.sp012026; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; Chen SG, 2000, FACT RES INTERV GER, V1-2, P491; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Henrikson CA, 2002, CIRCULATION, V106, P226; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1993, NEURON, V10, P1121, DOI 10.1016/0896-6273(93)90060-5; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Mathur R, 1997, J GEN PHYSIOL, V109, P191, DOI 10.1085/jgp.109.2.191; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Xue T, 2002, J BIOL CHEM, V277, P46233, DOI 10.1074/jbc.M204915200; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V388, P255, DOI 10.1007/BF00658491	42	30	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13647	13654		10.1074/jbc.M211025200	http://dx.doi.org/10.1074/jbc.M211025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582169	hybrid			2022-12-25	WOS:000182405000013
J	Zhang, DL; Brodt, P				Zhang, DL; Brodt, P			Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling	ONCOGENE			English	Article						IGF-I; MT1-MMP; PI 3-kinase; Akt; PTEN; invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; ACTIVATED PROTEIN-KINASE; HEPATIC STELLATE CELLS; HUMAN GLIOMA-CELLS; FACTOR-I; CARCINOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; INHIBITS APOPTOSIS	The membrane type I matrix metalloproteinase (MT1-MMP) has been identified as a major activator of MMP-2 - a process involving the formation of a trimolecular complex with TIMP-2. We previously identified the IGF-I receptor as a positive regulator of MMP-2 synthesis. Here, we investigated the role of IGF-IR in the regulation of MT1-MMP. Highly invasive Lewis lung carcinoma subline H-59 cells express MT1-MMP and utilize it to activate their major extracellular matrix degrading proteinase-MMP-2. These cells were transiently transfected with a plasmid vector expressing a luciferase reporter gene downstream of the mouse MT1-MMP promoter. IGF-I treatment increased luciferase activity in the transfected cells by up to 10-fold and augmented endogenous MT1-MMP mRNA and protein synthesis by up to 2-3-fold, relative to controls. MT1-MMP induction and invasion were blocked by the PI 3-kinase inhibitors LY294002 and wortmannin and by rapamycin, but not by the MEK inhibitor PD98059. Overexpression of a dominant negative Akt mutant or of the tumor suppressor phosphatase and tensin homologue, PTEN, in these cells also caused a significant reduction in MT1-MMP expression and invasion. The results demonstrate that IGF-IR controls tumor cell invasion by coordinately regulating MMP-2 expression and its MT1-MMP-mediated activation and identify PI 3-kinase/Akt/mTOR signaling as critical to this regulation.	McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Brodt, P (corresponding author), McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Surg, Room H6-25,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	pnina.brodt@muhc.mcgill.ca						Allgayer H, 1998, ONCOLOGY-BASEL, V55, P152, DOI 10.1159/000011850; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Cha HJ, 2001, CLIN EXP METASTAS, V18, P675, DOI 10.1023/A:1013190118556; Davies MA, 1998, CANCER RES, V58, P5285; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanemaaijer R, 2000, INT J CANCER, V86, P204, DOI 10.1002/(SICI)1097-0215(20000415)86:2<204::AID-IJC9>3.0.CO;2-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Khatib AM, 1999, CANCER RES, V59, P1356; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Parrizas M, 1997, J BIOL CHEM, V272, P154; Penninger JM, 2001, SCIENCE, V294, P2116, DOI 10.1126/science.1067931; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Sato T, 1999, BRIT J CANCER, V80, P1137, DOI 10.1038/sj.bjc.6690477; Seddighzadeh M, 1999, CLIN EXP METASTAS, V17, P649, DOI 10.1023/A:1006741228402; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Skrtic S, 1999, ENDOCRINOLOGY, V140, P5729, DOI 10.1210/en.140.12.5729; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; Sugiyama H, 1998, KIDNEY INT, V54, P1188, DOI 10.1046/j.1523-1755.1998.00116.x; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; TRUMPER K, 2002, ANN NY ACAD SCI, V921, P242; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Weng LP, 1999, CANCER RES, V59, P5808; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0	60	138	153	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					974	982		10.1038/sj.onc.1206197	http://dx.doi.org/10.1038/sj.onc.1206197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592384	Bronze			2022-12-25	WOS:000180926100003
J	Nencioni, L; Iuvara, A; Aquilano, K; Ciriolo, MR; Cozzolino, F; Rotilio, G; Garaci, E; Palamara, AT				Nencioni, L; Iuvara, A; Aquilano, K; Ciriolo, MR; Cozzolino, F; Rotilio, G; Garaci, E; Palamara, AT			Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2	FASEB JOURNAL			English	Article						orthomyxovirus; redox state; glutathione; viral persistence	NF-KAPPA-B; OXIDATIVE STRESS; INDUCED APOPTOSIS; GLUTATHIONE DEFICIENCY; EPITHELIAL-CELLS; SENDAI-VIRUS; BCL-2-EXPRESSING CELLS; REDOX REGULATION; HIV REPLICATION; GENE-EXPRESSION	Growing evidence indicates that viral replication is regulated by the redox state of the host cell. We demonstrate that cells of different origins display differential permissivity for influenza A virus replication, depending on their intracellular redox power as reflected by Bcl-2 expression and glutathione (GSH) content. Bcl-2 expressing cells were found to have higher intracellular levels of GSH and to produce lower amounts of virus than Bcl-2 negative cells. Two different steps in the virus life-cycle were involved in Bcl-2/GSH mediated viral inhibition: 1) expression of late viral proteins (in particular hemagglutinin and matrix); and 2) nuclear-cytoplasmic translocation of viral ribonucleoproteins (vRNPs). Buthionine-sulfoximine-induced inhibition of GSH synthesis in Bcl-2 expressing cells caused an increase in the expression of late viral proteins but did not restore vRNP export to the cytoplasm. Collectively, our findings show that both Bcl-2 expression and GSH content contribute to the host cell's ability to down-regulate influenza virus replication, although their effects are exerted at different stages of the viral life-cycle. In certain cell populations, this form of down-regulation might conceivably favor the establishment of persistent viral infection.	Univ Roma La Sapienza, Fac Pharm, Inst Microbiol, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Roma Tor Vergata, Dept Biol, Rome, Italy; Univ G DAnnunzio, Inst Biomed Sci, Chieti, Italy; CNR, INeMM, Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR)	Palamara, AT (corresponding author), Univ Roma La Sapienza, Fac Pharm, Inst Microbiol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	annateresa.palamara@uniroma1.it	Ciriolo, Maria Rosa/K-6572-2016; AQUILANO, KATIA/K-8888-2016; Nencioni, Lucia/K-5988-2016; GARACI, ENRICO/AAB-3349-2021	AQUILANO, KATIA/0000-0002-5905-9870; Nencioni, Lucia/0000-0003-4427-4823; PALAMARA, ANNA TERESA/0000-0001-8330-4381; Cozzolino, Federico/0000-0002-2800-640X; Ciriolo, Maria Rosa/0000-0002-7863-9029				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; Barbaro G, 1996, AM J GASTROENTEROL, V91, P2569; Beck MA, 2000, ANN NY ACAD SCI, V917, P906; Boya P, 1999, J HEPATOL, V31, P808, DOI 10.1016/S0168-8278(99)80281-5; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BUHL R, 1989, LANCET, V2, P1294; Bui M, 2000, J VIROL, V74, P1781, DOI 10.1128/JVI.74.4.1781-1786.2000; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; Casola A, 2001, J BIOL CHEM, V276, P19715, DOI 10.1074/jbc.M101526200; Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; De Rosa SC, 2000, EUR J CLIN INVEST, V30, P915, DOI 10.1046/j.1365-2362.2000.00736.x; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; Elbim C, 1999, J VIROL, V73, P4561, DOI 10.1128/JVI.73.6.4561-4566.1999; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; GARACI E, 1992, BIOCHEM BIOPH RES CO, V188, P1090, DOI 10.1016/0006-291X(92)91343-O; Garaci E, 1997, J LEUKOCYTE BIOL, V62, P54, DOI 10.1002/jlb.62.1.54; Gaudernak E, 2002, J VIROL, V76, P6004, DOI 10.1128/JVI.76.12.6004-6015.2002; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gu Y, 2001, VIROLOGY, V286, P62, DOI 10.1006/viro.2001.0998; HENNET T, 1992, J GEN VIROL, V73, P39, DOI 10.1099/0022-1317-73-1-39; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; HIERHOLZER JC, 1993, J CLIN MICROBIOL, V31, P1504, DOI 10.1128/JCM.31.6.1504-1510.1993; HINSHAW VS, 1994, J VIROL, V68, P3667, DOI 10.1128/JVI.68.6.3667-3673.1994; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kaul P, 2000, J INFECT DIS, V181, P1885, DOI 10.1086/315504; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAMB RA, 2001, VIROLOGY, P1487; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Liao CL, 1997, J VIROL, V71, P5963, DOI 10.1128/JVI.71.8.5963-5971.1997; Liao CL, 1998, J VIROL, V72, P9844, DOI 10.1128/JVI.72.12.9844-9854.1998; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKACS N, 1985, J VIROL, V53, P166; Macchia I, 1999, INT J IMMUNOPHARMACO, V21, P185, DOI 10.1016/S0192-0561(98)00080-0; May B.V.J., 1991, VIROLOGY PRACTICAL A, P119; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; Mileva M, 2000, TOXICOL LETT, V114, P39, DOI 10.1016/S0378-4274(99)00265-9; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mori I, 1999, J NEUROVIROL, V5, P355, DOI 10.3109/13550289909029476; Nucci C, 2000, EXP EYE RES, V70, P215, DOI 10.1006/exer.1999.0782; O'Neill RE, 1998, EMBO J, V17, P288, DOI 10.1093/emboj/17.1.288; Olsen CW, 1996, J VIROL, V70, P663, DOI 10.1128/JVI.70.1.663-666.1996; Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1373, DOI 10.1089/aid.1996.12.1373; Palamara AT, 1996, BIOCHEM BIOPH RES CO, V228, P579, DOI 10.1006/bbrc.1996.1701; PALAMARA AT, 1995, ANTIVIR RES, V27, P237, DOI 10.1016/0166-3542(95)00008-A; Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1537, DOI 10.1089/aid.1996.12.1537; Pekosz A, 1996, J VIROL, V70, P5329, DOI 10.1128/JVI.70.8.5329-5335.1996; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; RAVENHOLT RT, 1982, LANCET, V2, P860; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; Scallan MF, 1997, J VIROL, V71, P1583, DOI 10.1128/JVI.71.2.1583-1590.1997; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Su HL, 2001, VIROLOGY, V282, P141, DOI 10.1006/viro.2000.0820; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; VOGEL U, 1994, VIROLOGY, V198, P227, DOI 10.1006/viro.1994.1025; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001	77	100	107	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					758	+		10.1096/fj.02-0508fje	http://dx.doi.org/10.1096/fj.02-0508fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594179				2022-12-25	WOS:000181456900013
J	Pestryakov, PE; Weisshart, K; Schlott, B; Khodyreva, SN; Kremmer, E; Grosse, F; Lavrik, OI; Nasheuer, HP				Pestryakov, PE; Weisshart, K; Schlott, B; Khodyreva, SN; Kremmer, E; Grosse, F; Lavrik, OI; Nasheuer, HP			Human replication protein A - The C-terminal RPA70 and the central RPA32 domains are involved in the interactions with the 3 '-end of a primer-template DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING DOMAIN; SUBUNIT; PURIFICATION; MECHANISM; POLARITY	Although the mechanical aspects of the single-stranded DNA (ssDNA) binding activity of human replication protein A (RPA) have been extensively studied, only limited information is available about its interaction with other physiologically relevant DNA structures. RPA interacts with partial DNA duplexes that resemble DNA intermediates found in the processes of DNA replication and DNA repair. Limited proteolysis of RPA showed that RPA associated with ssDNA is less protected against proteases than RPA bound to a partial duplex DNA containing a 5'-protruding tail that had the same length as the ssDNA. Modification of both the 70- and 32-kDa subunits, RPA70 and RPA32, respectively, by photoaffinity labeling indicates that RPA can bind the primer-template junction of partial duplex DNAs by interacting with the 3'-end of the primer. The identification of the protein domains modified by the photoreactive 3'-end of the primer showed that domains located in the central part of the RPA32 subunit (amino acids 39 180) and the C-terminal part of the RPA70 subunit (amino acids 432-616) are involved in these interactions.	Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany; Russian Acad Sci, Siberian Div, Novosibirsk Bioorgan Chem Inst, Novosibirsk 630090, Russia; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Galway, Ireland	Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Ollscoil na Gaillimhe-University of Galway	Nasheuer, HP (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Galway, Ireland.	h.nasheuer@nuigalway.ie	Khodyreva, Svetlana N/G-4659-2013; Nasheuer, Heinz P./B-9025-2008; Lavrik, Olga I/G-4641-2013; Pestryakov, Pavel/AAH-2022-2020	Pestryakov, Pavel/0000-0003-3277-5321; Nasheuer, Heinz Peter/0000-0002-9218-9079				Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; CARTY MP, 1992, MUTAT RES, V274, P29, DOI 10.1016/0921-8777(92)90041-Z; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; Harlow E., 1988, ANTIBODIES LAB MANUA; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; KENNY MK, 1990, J BIOL CHEM, V265, P769; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; Kolpashchikov DM, 2001, NUCLEIC ACIDS RES, V29, P373, DOI 10.1093/nar/29.2.373; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lavrik OI, 1998, FEBS LETT, V441, P186, DOI 10.1016/S0014-5793(98)01544-0; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Maga G, 2001, J BIOL CHEM, V276, P18235, DOI 10.1074/jbc.M009599200; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; Mass G, 2001, NUCLEIC ACIDS RES, V29, P3892, DOI 10.1093/nar/29.18.3892; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; SWAIN M, 1995, ELECTROPHORESIS, V16, P948, DOI 10.1002/elps.11501601159; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wong JMS, 2003, ONCOGENE, V22, P28, DOI 10.1038/sj.onc.1206071	39	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17515	17524		10.1074/jbc.M301265200	http://dx.doi.org/10.1074/jbc.M301265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600993	hybrid			2022-12-25	WOS:000182818600140
J	Borjigin, J; Deng, J; Sun, X; De Jesus, M; Liu, TC; Wang, MM				Borjigin, J; Deng, J; Sun, X; De Jesus, M; Liu, TC; Wang, MM			Diurnal pineal 3-O-sulphotransferase 2 expression controlled by beta-adrenergic repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GLAND; STIMULATION; MELATONIN; GENE	The 3-O-sulfotransferases (3OSTs) catalyze the addition of sulfate groups at the 3-OH site of glucosamine in heparan sulfate proteoglycans, which serve as critical mediators of various biological functions. We demonstrate that the 3OST2 isoform is expressed at high levels in the rat pineal specifically during the daylight hours. The dramatic diurnal rhythm of 3OST2 is regulated by central clock-controlled activities of the superior cervical ganglion, persists in constant darkness, and is inducible by light at nighttime. Importantly, 3OST2 transcription is blocked by beta-adrenergic agonists that activate the pineal melatonin formation and is induced by beta-adrenergic antagonists, which block melatonin production in vivo. Because of the inverse expression and regulation patterns of 3OST2 with serotortin N-acetyltransferase, the enzyme controlling the melatonin rhythm in the pineal, we tested the effects of forced expression of 3OST2 in the night pineals on N-acetyltransferase gene expression and melatonin production and found that, surprisingly, 3OST2 expression at night fails to interfere with melatonin synthesis. These data suggest 3OST2 may serve a unique function in the pineal that may be independent of melatonin formation.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Carnegie Institution for Science; University of Pennsylvania; Johns Hopkins University	Borjigin, J (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.		Borjigin, Jimo/GXA-3484-2022					Arendt J., 1995, MELATONIN MAMMALIAN; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; Borjigin J, 1999, ANNU REV PHARMACOL, V39, P53, DOI 10.1146/annurev.pharmtox.39.1.53; Borjigin J, 1999, J NEUROSCI, V19, P1018; Borjigin J, 1999, J BIOL CHEM, V274, P35012, DOI 10.1074/jbc.274.49.35012; DRIJFHOUT WJ, 1993, J NEUROCHEM, V61, P936, DOI 10.1111/j.1471-4159.1993.tb03605.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; ROSENBERG RD, 1997, J CLIN INVEST, V100, P67; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STEHLE JH, 1995, MOL ENDOCRINOL, V9, P706, DOI 10.1210/me.9.6.706; Sun X, 2002, P NATL ACAD SCI USA, V99, P4686, DOI 10.1073/pnas.062585499; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505	18	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16315	16319		10.1074/jbc.M300828200	http://dx.doi.org/10.1074/jbc.M300828200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601002	hybrid			2022-12-25	WOS:000182680000109
J	Bosserhoff, AK; Moser, M; Scholmerich, J; Buettner, R; Hellerbrand, C				Bosserhoff, AK; Moser, M; Scholmerich, J; Buettner, R; Hellerbrand, C			Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS IN-VIVO; MALIGNANT-MELANOMA; INTERLEUKIN-6-DEFICIENT MICE; TRANSCRIPTION FACTORS; RETINOIC ACID; LIVER-INJURY; TGF-BETA; PROTEIN; DIFFERENTIATION; ENDOTOXIN	The novel human gene MIA2 encoding a melanoma inhibitory activity (MIA) homologous protein was identified by a GenBank(TM) search. MIA2, together with MIA, OTOR, and TANGO, belongs to the novel MIA gene family sharing important structural features, significant homology at both the nucleotide and protein levels, and similar genomic organization. In situ hybridization, reverse transcriptase-PCR, and Northern blots presented a highly tissue-specific MIA2 expression pattern in the liver. Promoter studies analyzing transcriptional regulation of MIA2 revealed an HNF-1-binding site at position -236 controlling hepatocyte-specific expression. Mutation of the site led to a complete loss of promoter activity in HepG2 cell. Further sites detected in the MIA,2 promoter were consensus binding sites for SMAD and STAT3, Consistently, stimulation of MIA2 mRNA expression occurred by treatment with interleukin-6, transforming growth factor-beta, and conditioned medium from activated hepatic stellate cells. In accordance with these results, MIA2 mRNA was found to be increased in liver tissue of patients with chronic hepatitis C infection compared with controls. MIA2 mRNA levels were significantly higher in patients with severe fibrosis or inflammation than in patients with less severe fibrosis or inflammation. In summary our data indicate that MIA2 represents a potential novel acute phase protein and MIA2 expression responds to liver damage. The increased transcription in more severe chronic liver disease suggests that MIA2 may serve as a marker of hepatic disease activity and severity.	Univ Regensburg, Inst Pathol, D-93042 Regensburg, Germany; Univ Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; Univ Bonn, Inst Pathol, D-52127 Bonn, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany	University of Regensburg; University of Regensburg; University of Bonn; Max Planck Society	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.		Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				BLESCH A, 1994, CANCER RES, V54, P5695; BOGDAHN U, 1989, CANCER RES, V49, P5358; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; Burke PA, 1996, SURGERY, V120, P374, DOI 10.1016/S0039-6060(96)80312-6; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Cohen-Salmon M, 2000, J BIOL CHEM, V275, P40036, DOI 10.1074/jbc.M002876200; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; Koehler MR, 1996, GENOMICS, V35, P265, DOI 10.1006/geno.1996.0352; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414-424.2001; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; Memon RA, 1999, BBA-MOL CELL BIOL L, V1440, P118, DOI 10.1016/S1388-1981(99)00120-1; Navasa M, 1998, J LIPID RES, V39, P1220; Ninomiya T, 1996, J HEPATOL, V25, P445, DOI 10.1016/S0168-8278(96)80203-0; Rendtorff ND, 2001, GENOMICS, V71, P40, DOI 10.1006/geno.2000.6409; Robertson NG, 2000, GENOMICS, V66, P242, DOI 10.1006/geno.2000.6224; Schlott T, 2002, ANTICANCER RES, V22, P1545; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Wach F, 1998, SKIN PHARMACOL APPL, V11, P43, DOI 10.1159/000029807; Wheeler MD, 2001, J LEUKOCYTE BIOL, V69, P622; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X	33	40	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15225	15231		10.1074/jbc.M212639200	http://dx.doi.org/10.1074/jbc.M212639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586826	hybrid			2022-12-25	WOS:000182516100083
J	Kim, J; Ogata, Y; Feldman, RA				Kim, J; Ogata, Y; Feldman, RA			Fes tyrosine kinase promotes survival and terminal granulocyte differentiation of factor-dependent myeloid progenitors (32D) and activates lineage-specific transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; BINDING PROTEIN-ALPHA; SRC FAMILY KINASES; C/EBP-ALPHA; CELL-LINE; HEMATOPOIETIC-CELLS; MACROPHAGE DIFFERENTIATION; INTERLEUKIN-3 DEPENDENCE; SIGNALING PATHWAYS; GENE-EXPRESSION	The c-fps/fes proto-oncogene encodes a 92-kDa protein-tyrosine kinase that is involved in myeloid cell development and function. We have recently shown that expression of an activated allele of Fes (Fes(act)) in monocyte precursors resulted in their differentiation into functional macrophages through the activation of lineage-specific transcription factors. We now report that this kinase also plays a role in the survival and terminal differentiation of granulocyte progenitors. The expression of Fes(act) in factor-dependent 32D cells prevented their apoptotic death after interleukin-3 removal, but Fes(act)-expressing cells remained factor-dependent for proliferation. Removal of interleukin-3 from the Fes(act)-expressing cells was followed by granulocytic differentiation in the absence of granulocyte colony-stimulating factor within 4-8 days. The differentiated cells had distinctive granulocyte morphology and there was up-regulation of CD11b, Gr-1, and late differentiation markers such as lactoferrin, suggesting that this kinase induced terminal granulocytic differentiation. Concomitantly, Fes(act) down-regulated the macrophage marker F4/80, suggesting that the biological activity of Fes was coordinated in a lineage-specific manner. Further analysis showed that Fes(act) caused activation of CCAAT/enhancer-binding protein-alpha and STAT3, two transcription factors that are involved in granulocyte differentiation. Our results provide evidence that Fes may be a key component of the granulocyte differentiation machinery, and suggest a potential mechanism by which this kinase may regulate granulocyte-specific gene expression.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Feldman, RA (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.			Feldman, Ricardo A./0000-0001-6090-0439	NATIONAL CANCER INSTITUTE [R29CA055293, R01CA055293] Funding Source: NIH RePORTER; NCI NIH HHS [CA55293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FRIEDMAN AD, 1991, BLOOD, V78, P2426; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HACKEN MI, 2002, DEV BIOL, V245, P255; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Jucker M, 1997, J BIOL CHEM, V272, P2104; Kim J, 2002, MOL CELL BIOL, V22, P1903, DOI 10.1128/MCB.22.6.1903-1918.2002; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; KRUGER A, 1991, ONCOGENE, V6, P245; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Mocsai A, 1999, J IMMUNOL, V162, P1120; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pereira S, 2001, J IMMUNOL, V166, P4115, DOI 10.4049/jimmunol.166.6.4115; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; ROVERA G, 1987, ONCOGENE, V1, P29; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YU G, 1989, J BIOL CHEM, V264, P10276; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zirngibl RA, 2002, MOL CELL BIOL, V22, P2472, DOI 10.1128/MCB.22.8.2472-2486.2002	48	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14978	14984		10.1074/jbc.M212118200	http://dx.doi.org/10.1074/jbc.M212118200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584192	hybrid			2022-12-25	WOS:000182516100053
J	Milutinovic, S; Zhuang, QL; Niveleau, A; Szyf, M				Milutinovic, S; Zhuang, QL; Niveleau, A; Szyf, M			Epigenomic stress response - Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATION; TUMOR-ANTIGEN; LUNG-CANCER; METHYLATION; INHIBITION; EXPRESSION; COMPLEX; TRANSCRIPTION; FAMILY; DIFFERENTIATION	The DNA methylation pattern is an important component of the epigenome that regulates and maintains gene expression programs. In this paper, we test the hypothesis that vertebrate cells possess mechanisms protecting them from epigenomic stress similar to DNA damage checkpoints. We show that knockdown of DNMT1 (DNA methyltransferase 1) by an antisense oligonucleotide triggers an intra-S-phase arrest of DNA replication that is not observed with control oligonucleotide. The cells are arrested at different positions throughout the S-phase of the cell cycle, suggesting that this response is not specific to distinct classes of origins of replication. The intra-S-phase arrest of DNA replication is proposed to protect the genome from extensive DNA demethylation that could come about by replication in the absence of DNMT1. This protective mechanism is not induced by 5-aza-2'-deoxycytidine, a nucleoside analog that inhibits DNA methylation by trapping DNMT1 in the progressing replication fork, but does not reduce de novo synthesis of DNMT1. Our data therefore suggest that the intra-S-phase arrest is triggered by a reduction in DNMT1 and not by demethylation of DNA. DNMT1 knockdown also leads to an induction of a set of genes that are implicated in genotoxic stress response such as NF-kappaB, JunB, ATF-3, and GADD45beta (growth arrest DNA damage 45beta gene). Based on these data, we suggest that this stress response mechanism evolved to guard against buildup of DNA methylation errors and to coordinate inheritance of genomic and epigenomic information.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Grenoble 1, Fac Med & Pharm, Lab Virol Mol & Structurale, EA 2939, F-38706 La Tronche, France	McGill University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.							Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Barbot W, 2002, NUCLEIC ACIDS RES, V30, P2365, DOI 10.1093/nar/30.11.2365; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bender CM, 1998, CANCER RES, V58, P95; Bender J, 1998, TRENDS BIOCHEM SCI, V23, P252, DOI 10.1016/S0968-0004(98)01225-0; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cilensek ZM, 2002, CANCER BIOL THER, V1, P380; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Habib M, 1999, EXP CELL RES, V249, P46, DOI 10.1006/excr.1999.4434; HARPER JW, 1993, CELL, V75, P805; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; JONES PA, 1985, PHARMACOL THERAPEUT, V28, P17, DOI 10.1016/0163-7258(85)90080-4; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; MERIO A, 1995, NAT MED, V1, P686; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; ORMEROD EJ, 1986, CANCER RES, V46, P884; Palmisano WA, 2000, CANCER RES, V60, P5954; Piyathilake CJ, 2001, HUM PATHOL, V32, P856, DOI 10.1053/hupa.2001.26471; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; RUSSO V, 1995, INT J CANCER, V64, P216, DOI 10.1002/ijc.2910640313; Scanlan MJ, 2002, CANCER RES, V62, P4041; Serrano A, 1996, INT J CANCER, V68, P464, DOI 10.1002/(SICI)1097-0215(19961115)68:4<464::AID-IJC11>3.0.CO;2-5; Shichijo S, 1996, JPN J CANCER RES, V87, P751, DOI 10.1111/j.1349-7006.1996.tb00288.x; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SUZUKI H, 2001, MOL CANCER THER, V1, P95; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; VANDERLAAN M, 1985, CYTOMETRY, V6, P501, DOI 10.1002/cyto.990060603; Wang XM, 1998, ANN SURG, V227, P922, DOI 10.1097/00000658-199806000-00016; WEBER J, 1994, CANCER RES, V54, P1766	61	93	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14985	14995		10.1074/jbc.M213219200	http://dx.doi.org/10.1074/jbc.M213219200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576480	hybrid			2022-12-25	WOS:000182516100054
J	Shi, CS; Kehrl, JH				Shi, CS; Kehrl, JH			Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein-kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; KAPPA-B; TNF; APOPTOSIS; ASK1; JNK; INHIBITOR; INDUCTION; REQUIRES; PATHWAY	Tumor necrosis factor (TNF)-induced activation of apoptosis signal-regulating kinase 1 (ASK1.) and germinal center kinases (GCKs) and the subsequent activation of stress-activated protein kinases (SAPKs and c-Jun NH2-terminal kinases) requires TNF receptor-associated factor 2 (TRAF2). Although the TRAF2 TRAF domain binds ASK1, GCK, and the highly related kinase GCKR, the RING finger domain is needed for their activation. Here, we report that TNF activates GCKR and the SAPK pathway in a manner that depends upon TRAF2 and Ubc13, a member along with Uev1A of a dimeric ubiquitin-conjugating enzyme complex. Interference with LTbc13 function or expression inhibits both TNF- and TRAF2-mediated GCKR and SAPK activation, but has a minimal effect on ASK1. activation. TNF signaling leads to TRAF2 polyubiquitination and oligomerization and to the oligomerization, ubiquitination, and activation of GCKR, all of which are sensitive to the disruption of Ubc13 function. These results indicate that the assembly of a TRAF2 lysine 63-linked polyubiquitin chain by LTbc13/Uev1A is required for TNF-mediated GCKR and SAPK activation, but may not be required for ASK1 activation.	NIAID, Cell Immunol Sect B, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Cell Immunol Sect B, NIH, Bldg 10,RmB-08,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.	Jkehrl@niaid.nih.gov	Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739, ZIAAI000739] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 2000, FR MOLEC B, V29, P40; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	21	152	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15429	15434		10.1074/jbc.M211796200	http://dx.doi.org/10.1074/jbc.M211796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591926	hybrid			2022-12-25	WOS:000182516100109
J	Yabuta, Y; Subbian, E; Oiry, C; Shinde, U				Yabuta, Y; Subbian, E; Oiry, C; Shinde, U			Folding pathway mediated by an intramolecular chaperone - A functional peptide chaperone designed using sequence databases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; PRO-SEQUENCE; SUBTILISIN-E; PROPEPTIDE; ACTIVATION; NUCLEOTIDE; COMPLEX; RATES	Catalytic domains of several prokaryotic and eukaryotic protease families require dedicated N-terminal propeptide domains or "intramolecular chaperones" to facilitate correct folding. Amino acid sequence analysis of these families establishes three important characteristics: (i) propeptides are almost always less conserved than their cognate catalytic domains, (ii) they contain a large number of charged amino acids, and (iii) propeptides within different protease families display insignificant sequence similarity. The implications of these findings are, however, unclear. In this study, we have used subtilisin as our model to redesign a peptide chaperone using information databases. Our goal was to establish the minimum sequence requirements for a functional subtilisin propeptide, because such information could facilitate subsequent design of tailor-made chaperones. A decision-based computer algorithm that maintained conserved residues but varied all non-conserved residues from a multiple protein sequence alignment was developed and utilized to design a novel peptide sequence (ProD). Interestingly, despite a difference of 5 pH units between their isoelectric points and despite displaying only 16% sequence identity with the wildtype propeptide (ProWT), ProD chaperones folding and functions as a potent subtilisin inhibitor. The computed secondary structures and hydrophobic patterns within these two propeptides are similar. However, unlike ProWT, ProD adopts a well defined alpha-beta conformation as an isolated peptide and forms a stoichiometric complex with mature subtilisin. The CD spectra of this complex is similar to ProWT-subtilisin. Our results establish that despite low sequence identity and dramatically different charge distribution, both propeptides adopt similar structural scaffolds. Hence, conserved scaffolds and hydrophobic patterns, but not absolute charge, dictate propeptide function.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Shinde, U (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Baker D, 1998, NAT STRUCT BIOL, V5, P1021, DOI 10.1038/4130; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; BIGELOW CC, 1967, J THEOR BIOL, V16, P187, DOI 10.1016/0022-5193(67)90004-5; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Buevich AV, 2001, J BIOMOL NMR, V20, P233, DOI 10.1023/A:1011243116136; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; *GEN COMP GROUP, PROGR MAN WISC PACK; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; Jaswal SS, 2002, NATURE, V415, P343, DOI 10.1038/415343a; Li W. H., 1985, MOL EVOLUTIONARY GEN, P1; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; MIYATA T, 1980, J MOL EVOL, V16, P23, DOI 10.1007/BF01732067; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruan B, 1999, BIOCHEMISTRY-US, V38, P8562, DOI 10.1021/bi990362n; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P362; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; WONG SL, 1986, J BIOL CHEM, V261, P176; Yabuta Y, 2001, J BIOL CHEM, V276, P44427, DOI 10.1074/jbc.M107573200; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	34	26	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15246	15251		10.1074/jbc.M212003200	http://dx.doi.org/10.1074/jbc.M212003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582173	hybrid			2022-12-25	WOS:000182516100086
J	Srinivasan, P; Piano, F; Shatkin, AJ				Srinivasan, P; Piano, F; Shatkin, AJ			mRNA capping enzyme requirement for Caenorhabditis elegans viability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA GUANYLYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; GENETIC INTERFERENCE; YEAST; TRANSCRIPTION; MECHANISM; 5'-TRIPHOSPHATASE; EXPRESSION; APPARATUS; EVOLUTION	Capping of the initiated 5' ends of RNA polymerase II products is evolutionarily and functionally conserved from yeasts to humans. The m 7 GpppN cap promotes RNA stability, processing, transport, and translation. Deletion of capping enzymes in yeasts was shown to be lethal due to rapid exonucleolytic degradation of un-capped transcripts or failure of capped but unmethylated RNA to initiate protein synthesis. Using RNA interference and Caenorhabditis elegans we have found that RNA capping is also essential for metazoan viability. C. elegans bifunctional capping enzyme was cloned, and capping activity by the expressed protein as well as growth complementation of yeast deletion strains missing either RNA triphosphatase or guanylyltransferase required terminal sequences not present in the previously isolated cel-1 clone. By RNA interference analysis we show that cel-1 is required for embryogenesis. cel-1(RNAi) embryos formed cytoplasmic granules characteristic of a phenocluster of RNA processing genes and died early in development.	Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Grad Sch Biomed Sci, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Grad Program Biochem, Grad Sch Biomed Sci, Piscataway, NJ 08854 USA; NYU, Dept Biol, New York, NY 10012 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; New York University	Shatkin, AJ (corresponding author), Univ Med & Dent New Jersey, Ctr Adv Biotechnol & Med, Grad Sch Biomed Sci, 679 Hoes Lane, Piscataway, NJ 08854 USA.	shatkin@cabm.rutgers.edu						Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 2002, NAT STRUCT BIOL, V9, P790, DOI 10.1038/nsb1102-790; MAO XD, 1995, MOL CELL BIOL, V15, P4167; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; PIANO F, 2002, CURR BIO, V12, P1; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	30	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14168	14173		10.1074/jbc.M212102200	http://dx.doi.org/10.1074/jbc.M212102200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576475	hybrid			2022-12-25	WOS:000182405000078
J	Didierjean, C; Corbier, C; Fatih, M; Favier, F; Boschi-Muller, S; Branlant, G; Aubry, A				Didierjean, C; Corbier, C; Fatih, M; Favier, F; Boschi-Muller, S; Branlant, G; Aubry, A			Crystal structure of two ternary complexes of phosphorylating glyceraldehyde-3-phosphate dehydrogenase from Bacillus stearothermophilus with NAD and D-glyceraldehyde 3-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOBSTER D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; PHOSPHATE-BINDING SITES; HOLO-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ANGSTROM RESOLUTION; KINETIC MECHANISM; ESCHERICHIA-COLI; RABBIT MUSCLE; DESIGN	The crystal structure of the phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Bacillus stearothermophilus was solved in complex with its cofactor, NAD, and its physiological substrate, D-glyceraldehyde 3-phosphate (D-G3P). To isolate a stable ternary complex, the nucleophilic residue of the active site, Cys(149), was substituted with alanine or serine. The C149A and C149S GAPDH ternary complexes were obtained by soaking the crystals of the corresponding binary complexes (enzyme(.)NAD) in a solution containing G3P. The structures of the two binary and the two ternary complexes are presented. The D-G3P adopts the same conformation in the two ternary complexes. It is bound in a non-covalent way, in the free aldehyde form, its C-3 phosphate group being positioned in the P-s site and not in the P-i site. Its C-1 carbonyl oxygen points toward the essential His(176), which supports the role proposed for this residue along the two steps of the catalytic pathway. Arguments are provided that the structures reported here are representative of a productive enzyme(.)NAD(.)D-G3P complex in the ground state (Michaelis complex).	UHP, CNRS, Fac Sci, Maturat ARN & Enzymol Mol UMR 7567, F-54506 Vandoeuvre Les Nancy, France; Univ Henri Poincare, CNRS, Fac Sci,Grp Biocristallog,UMR 7036, Lab Cristallog & Modelisat Mat Mineraux & Biol, F-54506 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Universite de Lorraine	Branlant, G (corresponding author), UHP, CNRS, Fac Sci, Maturat ARN & Enzymol Mol UMR 7567, F-54506 Vandoeuvre Les Nancy, France.		Favier, Frederique/B-3090-2013; DIDIERJEAN, Claude/L-1493-2013	Favier, Frederique/0000-0003-3249-997X; DIDIERJEAN, Claude/0000-0002-3176-8974; Boschi, Sandrine/0000-0001-8962-4749				Boschi-Muller S, 1999, ARCH BIOCHEM BIOPHYS, V363, P259, DOI 10.1006/abbi.1998.1080; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUEHNER M, 1974, J MOL BIOL, V82, P563, DOI 10.1016/0022-2836(74)90249-6; BYERS LD, 1978, ARCH BIOCHEM BIOPHYS, V186, P335, DOI 10.1016/0003-9861(78)90443-5; CANELLAS PF, 1991, BIOCHEMISTRY-US, V30, P8871, DOI 10.1021/bi00100a021; CHAKRABARTI P, 1993, J MOL BIOL, V234, P463, DOI 10.1006/jmbi.1993.1599; COPLEY RR, 1994, J MOL BIOL, V242, P321; CORBIER C, 1994, BIOCHEMISTRY-US, V33, P3260, DOI 10.1021/bi00177a017; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; CROW VL, 1979, J BIOL CHEM, V254, P1134; DALZIEL K, 1981, PHILOS T ROY SOC B, V293, P105, DOI 10.1098/rstb.1981.0064; Duee E, 1996, J MOL BIOL, V257, P814, DOI 10.1006/jmbi.1996.0204; DUGGLEBY RG, 1974, J BIOL CHEM, V249, P167; GRIFFITH JP, 1983, J MOL BIOL, V169, P963, DOI 10.1016/S0022-2836(83)80145-4; HARRIGAN PJ, 1974, BIOCHEM J, V143, P353, DOI 10.1042/bj1430353; HARRIS JI, 1976, ENZYMES, V13, P1; KIM HD, 1995, BIOCHEMISTRY-US, V34, P14975, DOI 10.1021/bi00046a004; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU L, 1992, BIOCHEMISTRY-US, V31, P6898, DOI 10.1021/bi00145a005; MACPHERSON A, 1999, CRYSTALLIZATION BIOL, P165; MERCER WD, 1976, J MOL BIOL, V104, P277, DOI 10.1016/0022-2836(76)90013-9; MEUNIER JC, 1978, EUR J BIOCHEM, V82, P483, DOI 10.1111/j.1432-1033.1978.tb12042.x; Michels S, 1996, EUR J BIOCHEM, V235, P641, DOI 10.1111/j.1432-1033.1996.00641.x; MORAS D, 1975, J BIOL CHEM, V250, P9137; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORSI BA, 1972, BIOCHEMISTRY-US, V11, P102, DOI 10.1021/bi00751a018; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Roussel P. A., 1991, TURBO FRODO SILICON; SEGAL HL, 1953, J BIOL CHEM, V204, P265; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Song SY, 1998, ACTA CRYSTALLOGR D, V54, P558, DOI 10.1107/S090744499701620X; Souza DHF, 1998, FEBS LETT, V424, P131, DOI 10.1016/S0014-5793(98)00154-9; Talfournier F, 1998, EUR J BIOCHEM, V252, P447, DOI 10.1046/j.1432-1327.1998.2520447.x; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P2597, DOI 10.1021/bi951988q; TRENTHAM DR, 1971, BIOCHEM J, V122, P71, DOI 10.1042/bj1220071; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; Yun M, 2000, BIOCHEMISTRY-US, V39, P10702, DOI 10.1021/bi9927080	40	30	32	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12968	12976		10.1074/jbc.M211040200	http://dx.doi.org/10.1074/jbc.M211040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569100	hybrid, Green Published			2022-12-25	WOS:000182189500049
J	Lim, K; Tempczyk, A; Bonander, N; Toedt, J; Howard, A; Eisenstein, E; Herzberg, O				Lim, K; Tempczyk, A; Bonander, N; Toedt, J; Howard, A; Eisenstein, E; Herzberg, O			A catalytic mechanism for D-Tyr-tRNA(Tyr) deacylase based on the crystal structure of Hemophilus influenzae HI0670	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; PROTEIN; METABOLISM; ALIGNMENT	D-Tyr-tRNA(Tyr) deacylase is an editing enzyme that removes D-tyrosine and other D-amino acids from charged tRNAs, thereby preventing incorrect incorporation of D-amino acids into proteins. A model for the catalytic mechanism of this enzyme is proposed based on the crystal structure of the enzyme from Haemophilus influenzae determined at a 1.64-Angstrom resolution. Structural comparison of this dimeric enzyme with the very similar structure of the enzyme from Escherichia coli together with sequence analyses indicate that the active site is located in the dimer interface within a depression that includes an invariant threonine residue, Thr-80. The active site contains an oxyanion hole formed by the main chain nitrogen atoms of Thr-80 and Phe-79 and the side chain amide group of the invariant Gln-78. The Michaelis complex between the enzyme and D-Tyr-tRNA was modeled assuming a nucleophilic attack on the carbonyl carbon of D-Tyr by the Thr-80 O-gamma atom and a role for the oxyanion hole in stabilizing the negatively charged tetrahedral transition states. The model is consistent with all of the available data on substrate specificity. Based on this model, we propose a substrate-assisted acylation/deacylation-catalytic mechanism in which the amino group of the D-Tyr is deprotonated and serves as the general base.	Univ Maryland, Biotechnol Inst, Ctr Adv Res In Biotechnol, Rockville, MD 20850 USA; NIST, Gaithersburg, MD 20899 USA; Argonne Natl Lab, Argonne, IL 60439 USA; IIT, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	National Institute of Standards & Technology (NIST) - USA; United States Department of Energy (DOE); Argonne National Laboratory; Illinois Institute of Technology; University System of Maryland; University of Maryland Baltimore County	Herzberg, O (corresponding author), Univ Maryland, Biotechnol Inst, Ctr Adv Res In Biotechnol, Rockville, MD 20850 USA.	osnat@carb.nist.gov	ID, IMCACAT/D-5867-2014	Herzberg, Osnat/0000-0003-2823-7627	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57890, P01 GM057890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dall'Acqua W, 2000, PROTEIN SCI, V9, P1; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; ROUSSEL A, 1989, TURBO FRODO VERSION; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Soutourina J, 2000, J BIOL CHEM, V275, P32535, DOI 10.1074/jbc.M005166200; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)90795-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	26	19	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13496	13502		10.1074/jbc.M213150200	http://dx.doi.org/10.1074/jbc.M213150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571243	hybrid, Green Accepted			2022-12-25	WOS:000182189500113
J	Ray, RM; McCormack, SA; Covington, C; Viar, MJ; Zheng, Y; Johnson, LR				Ray, RM; McCormack, SA; Covington, C; Viar, MJ; Zheng, Y; Johnson, LR			The requirement for polyamines for intestinal epithelial cell migration is mediated through Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IEC-6 CELLS; FOCAL ADHESIONS; RHO-PROTEINS; F-ACTIN; DEPLETION; GROWTH; INHIBITORS; EXPRESSION; ACTIVATION; MECHANISM	The rapid migration of intestinal epithelial cells is important to the healing 4 mucosal ulcers and wounds. This cell migration requires the presence of polyamines and the activation of RhoA. RhoA activity, however, is not sufficient for migration because polyamine depletion inhibited the migration of IEC-6 cells expressing constitutively active RhoA. The current study examines the role of Rac1 and Cdc42 in cell migration and whether their activities are polyamine-dependent. Polyamine depletion with alpha-difluoromethylornithine inhibited the activities of RhoA, Rac1, and Cdc42. This inhibition was prevented by supplying exogenous putrescine in the presence of a-difluoromethylornithine. IEC-6 cells transfected with constitutively active Rac1 and Cdc42 migrated more rapidly than vector-transfected cells, whereas cells expressing dominant negative Rac1 and Cdc42 migrated more slowly. Polyamine depletion had no effect on the migration of cells expressing Rac1 and only partially inhibited the migration of those expressing Cdc42. Although polyamine depletion caused the disappearance of actin stress fibers in cells transfected with empty vector, it had no effect on cells expressing Rac1. Constitutively active Rac1 increased RhoA and Cdc42 activity in both normal and polyamine-depleted cells. These results demonstrate that Rac1, RhoA, and Cdc42 are required for optimal epithelial cell migration and that Rac1 activity is sufficient for cell migration in the absence of polyamines due to its ability to activate RhoA and Cdc42 as well as its own effects on the process of cell migration. These data imply that the involvement of polyamines in cell migration occurs either at Rac1 itself or upstream from Rac1.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Johnson, LR (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIDDK NIH HHS [DK 52784] Funding Source: Medline; NIGMS NIH HHS [GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham VC, 1999, BIOPHYS J, V77, P1721, DOI 10.1016/S0006-3495(99)77018-9; Bachrach U, 2001, NEWS PHYSIOL SCI, V16, P106, DOI 10.1152/physiologyonline.2001.16.3.106; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; EDELMAN GM, 1992, DEV DYNAM, V192, P2; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GOKE M, 1996, AM J PHYSIOL, V271, P729; GRANT NJ, 1983, EUR J CELL BIOL, V30, P67; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KAMINSKA B, 1992, FEBS LETT, V304, P198, DOI 10.1016/0014-5793(92)80618-Q; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MARQUET R, 1998, BIOCHEM PHARMACOL, V37, P1857; MCCORMACK SA, 1994, AM J PHYSIOL, V267, pC715, DOI 10.1152/ajpcell.1994.267.3.C715; McCormack SA, 1999, AM J PHYSIOL-CELL PH, V276, pC459, DOI 10.1152/ajpcell.1999.276.2.C459; MCCORMACK SA, 1992, AM J PHYSIOL-GASTR L, V263, P426; MCCORMACK SA, 1993, AM J PHYSIOL-GASTR L, V264, P367; MCLEAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V950, P243, DOI 10.1016/0167-4781(88)90120-0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOORE R, 1989, LAB INVEST, V60, P227; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Patel AR, 1998, AM J PHYSIOL-CELL PH, V275, pC590, DOI 10.1152/ajpcell.1998.275.2.C590; Pfeffer LM, 2001, J BIOL CHEM, V276, P45909, DOI 10.1074/jbc.M108097200; POHJANPELTO P, 1981, NATURE, V293, P475, DOI 10.1038/293475a0; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rao JN, 2001, AM J PHYSIOL-CELL PH, V280, pC993, DOI 10.1152/ajpcell.2001.280.4.C993; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAKAMAKI Y, 1989, BIOCHEM PHARMACOL, V38, P1083, DOI 10.1016/0006-2952(89)90252-9; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; SCHUBER F, 1989, BIOCHEM J, V260, P1; SHINDLER M, 1980, P NATL ACAD SCI USA, V77, P1457; SILEN W, 1985, ANNU REV PHYSIOL, V47, P217; WANG JY, 1991, GASTROENTEROLOGY, V100, P333, DOI 10.1016/0016-5085(91)90200-5; Wang JY, 1996, AM J PHYSIOL-GASTR L, V270, pG355, DOI 10.1152/ajpgi.1996.270.2.G355; Wang JY, 2000, AM J PHYSIOL-CELL PH, V278, pC303, DOI 10.1152/ajpcell.2000.278.2.C303; WANG JY, 1990, AM J PHYSIOL, V259, P584; Yuan Q, 2000, AM J PHYSIOL-GASTR L, V278, pG49, DOI 10.1152/ajpgi.2000.278.1.G49	42	66	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13039	13046		10.1074/jbc.M208741200	http://dx.doi.org/10.1074/jbc.M208741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574162	hybrid			2022-12-25	WOS:000182189500058
J	Tremblay, M; Herblot, S; Lecuyer, E; Hoang, T				Tremblay, M; Herblot, S; Lecuyer, E; Hoang, T			Regulation of pT alpha gene expression by a dosage of E2A, HEB, and SCL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL DEVELOPMENT; LOOP-HELIX PROTEINS; TRANSGENIC MICE; LYMPHOCYTE DEVELOPMENT; THYMOCYTE DEVELOPMENT; SIGNALING PATHWAY; B-LYMPHOCYTE; IN-VIVO; TRANSCRIPTION; ENHANCER	The expression of the pTalpha gene is required for effective selection, proliferation, and survival of beta T-cell receptor (betaTCR)-expressing immature thymocytes. Here, we have identified two phylogenetically conserved E-boxes within the pTalpha enhancer sequence that are required for optimal enhancer activity and for its stage-specific activity in immature T cells. We have shown that the transcription factors E2A and HEB associate with high affinity to these E-boxes. Moreover, we have identified pTalpha as a direct target of E2A-HEB heterodimers in immature thymocytes because they specifically occupy the enhancer in vivo. In these cells, pTalpha mRNA levels are determined by the presence of one or two functional E2A or HEB alleles. Furthermore, E2A/HEB transcriptional activity is repressed by heterodimerization with SCL, a transcription factor that is turned off in differentiating thymocytes exactly at a stage when pTalpha is up-regulated. Taken together, our observations suggest that the dosage of E2A, HEB, and SCL determines pTalpha gene expression in immature T cells.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Program Mol Biol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Hoang, T (corresponding author), Inst Rech Clin Montreal, 110 Ave Pins Oueset, Montreal, PQ H2W 1R7, Canada.							Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; Barndt R, 1999, J IMMUNOL, V163, P3331; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Blom B, 1999, EMBO J, V18, P2793, DOI 10.1093/emboj/18.10.2793; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Goardon N, 2002, BLOOD, V100, P491, DOI 10.1182/blood.V100.2.491; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gounari F, 2002, NAT IMMUNOL, V3, P489, DOI 10.1038/ni778; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Liu XD, 1999, J BIOL CHEM, V274, P3285, DOI 10.1074/jbc.274.6.3285; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pan LH, 2002, J IMMUNOL, V168, P3923, DOI 10.4049/jimmunol.168.8.3923; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Petersson K, 2002, EUR J IMMUNOL, V32, P911, DOI 10.1002/1521-4141(200203)32:3<911::AID-IMMU911>3.0.CO;2-H; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Rabbitts T. H., 1997, Leukemia (Basingstoke), V11, P271; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Takeuchi A, 2001, J IMMUNOL, V167, P2157, DOI 10.4049/jimmunol.167.4.2157; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang BP, 1997, IMMUNOL REV, V157, P53, DOI 10.1111/j.1600-065X.1997.tb00973.x; Wang NH, 1998, INT IMMUNOL, V10, P1777, DOI 10.1093/intimm/10.12.1777; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	52	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12680	12687		10.1074/jbc.M209870200	http://dx.doi.org/10.1074/jbc.M209870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566462	hybrid			2022-12-25	WOS:000182189500013
J	Plymate, SR; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Zhang, YP; Oberley, LW; Zhong, WX; Drivdahl, R; Oberley, TD				Plymate, SR; Haugk, KH; Sprenger, CC; Nelson, PS; Tennant, MK; Zhang, YP; Oberley, LW; Zhong, WX; Drivdahl, R; Oberley, TD			Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1	ONCOGENE			English	Article						SOD-2; Mac25; prostate; cancer; IGFBP-rP1	EPITHELIAL-CELLS; EXPRESSION; APOPTOSIS; P53; OVEREXPRESSION; FIBROBLASTS; INHIBITION; SENESCENCE; IGFBP-RP1; SUBLINES	Increased expression of mac25/insulin-like growth factor binding-protein related protein-1 (IGFBP-rP1) in human breast and prostate epithelial cell lines results in the suppression of tumor growth. CDNA expression array analysis revealed increased manganese superoxide dismutase (SOD-2) expression in the mac25/IGFBP-rP1-transfected M12 human prostate cancer cell line compared to M12 control cells. SOD-2 has been postulated to be a tumor suppressor. SOD-2 was also increased in LNCaP cells stably transfected with mac25/IGFBP-rP1, but not in mac25/IGFBP-rP1-transfected PC-3 cells. Mac25 LNCaP cells had a marked decrease in tumor growth in nude mice compared to controls, but there was no difference in tumor growth in mac25 PC-3 cells compared to control. Phosphorylated Erk and Akt were increased in the M12 and LNCaP transfected mac25/ IGFBP-rP1 cells but not PC-3 mac25. Inhibition of PI-3 kinase results in a marked decrease in viability of the M12-mac25 cells compared to M12 controls. Cells treated with H2O2 result, in an increase in phospho-ERK. Transfection of SOD-2 in M12 cells markedly decreased tumor growth, apoptosis, G1 delay in the cell cycle, and expression of senescence associated beta-galactosidase. These results suggest that one of the downstream mediators of the senescence-associated tumor suppression effect of mac25/IGFBP-rP1 is SOD-2.	Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Mol, Seattle, WA 98105 USA; Univ Washington, Sch Med, Cell Biol Program, Seattle, WA 98105 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98107 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA; William S Middleton Mem Vet Adm Med Ctr, Pathol Serv, Madison, WI 53705 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Iowa; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Plymate, SR (corresponding author), Univ Washington, Harborview Med Ctr, 325 9Th Ave,Box 359755, Seattle, WA 98104 USA.	splymate@u.washington.edu			NATIONAL CANCER INSTITUTE [P01CA085859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 85859] Funding Source: Medline; NIDDK NIH HHS [DK52683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE V, 1995, P AM ASS CANC RES CA, V642, P55; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Baker AM, 1997, PROSTATE, V32, P229, DOI 10.1002/(SICI)1097-0045(19970901)32:4<229::AID-PROS1>3.0.CO;2-E; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; BIRNBAUM RS, 1994, J ENDOCRINOL, V141, P535, DOI 10.1677/joe.0.1410535; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; Hawkins V, 1999, NUCLEIC ACIDS RES, V27, P204, DOI 10.1093/nar/27.1.204; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Hwa V, 1998, J CLIN ENDOCR METAB, V83, P4355, DOI 10.1210/jc.83.12.4355; HWA V, 1998, ACTA PAEDIATR SCAND, V428, P37; JacksonCook C, 1996, CANCER GENET CYTOGEN, V87, P14, DOI 10.1016/0165-4608(95)00232-4; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kim KH, 2001, ANTIOXID REDOX SIGN, V3, P361, DOI 10.1089/15230860152409013; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; RHEE SG, 2000, SCI STKE, P1; Sachdeva RM, 2001, AM J HUM GENET, V69, P261; Sprenger CC, 1999, CANCER RES, V59, P2370; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wilson EM, 2001, J CLIN ENDOCR METAB, V86, P4504, DOI 10.1210/jc.86.9.4504; Zhong WX, 2001, CANCER RES, V61, P7071	34	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1024	1034		10.1038/sj.onc.1206210	http://dx.doi.org/10.1038/sj.onc.1206210			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592389				2022-12-25	WOS:000180926100008
J	Chauhan, SD; Seggara, G; Vo, PA; MacAllister, RJ; Hobbs, AJ; Ahluwalia, A				Chauhan, SD; Seggara, G; Vo, PA; MacAllister, RJ; Hobbs, AJ; Ahluwalia, A			Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice	FASEB JOURNAL			English	Article						nitric oxide; resistance arteries; inflammation; vasorelaxation; sepsis	NITRIC-OXIDE SYNTHASE; L-ARGININE; ENDOTOXIN-SHOCK; SUPEROXIDE; RAT; HYPOREACTIVITY; EXPRESSION; REACTIVITY; PHYSIOLOGY; PULMONARY	Endothelial dysfunction is a characteristic of, and may be pathogenic in, inflammatory cardiovascular diseases, including sepsis. The mechanism underlying inflammation-induced endothelial dysfunction may be related to the expression and activity of inducible nitric oxide synthase (iNOS). This possibility was investigated in isolated resistance (mesenteric) and conduit (aorta) arteries taken from lipopolysaccharide (LPS)-treated (12.5 mg/kg i.v.) or saline-treated iNOS knockout (KO) and wild-type (WT) mice. LPS pretreatment (for 15 h, but not 4 h) profoundly suppressed responses to acetylcholine (ACh) and significantly reduced sensitivity to the NO donor spermine-NONOate (SPER-NO) in aorta and mesenteric arteries of WT mice. This effect was temporally associated with iNOS protein expression in both conduit and resistance arteries and with a 10-fold increase in plasma NOx levels. In contrast, no elevation of plasma NOx was observed in LPS-treated iNOS KO animals, and arteries dissected from these animals did not express iNOS or display hyporeactivity to ACh or SPER-NO. The mechanism underlying this phenomenon may be suppression of eNOS expression, as observed in arteries of WT animals, that was absent in arteries of iNOS KO animals. These results clearly demonstrate that iNOS induction plays an integral role in mediation of the endothelial dysfunction associated with sepsis in both resistance and conduit arteries.	Barts & London Queen Marys Sch Med & Dent, London EC1M 6BQ, England; UCL, Ctr Clin Pharmacol, London WC1E 6JJ, England; Univ Valencia, Dept Physiol, Valencia, Spain; UCL, Wolfson Inst Biomed Res, London WC1, England	University of London; Queen Mary University London; University of London; University College London; University of Valencia; University of London; University College London	Ahluwalia, A (corresponding author), Barts & London Queen Marys Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.	a.ahluwalia@qmul.ac.uk	Segarra, Gloria/L-2495-2017	Segarra, Gloria/0000-0003-3069-2717; Hobbs, Adrian/0000-0002-3589-7108; AHLUWALIA, Amrita/0000-0001-7626-6399				Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Boyle WA, 2000, CIRC RES, V87, pE18; Brandes RP, 1999, HYPERTENSION, V33, P1243, DOI 10.1161/01.HYP.33.5.1243; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; FLEMING I, 1991, BRIT J PHARMACOL, V103, P1047, DOI 10.1111/j.1476-5381.1991.tb12298.x; GRUNFELD S, 1995, HYPERTENSION, V26, P854, DOI 10.1161/01.HYP.26.6.854; HALES CA, 1981, J CLIN INVEST, V68, P497, DOI 10.1172/JCI110281; HALPERN W, 1977, J PHYSIOL-LONDON, V265, pP21; Hamilton CA, 1997, ATHEROSCLEROSIS, V133, P77, DOI 10.1016/S0021-9150(97)00114-7; Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994; Hoang L, 1998, BBA-BIOMEMBRANES, V1369, P335, DOI 10.1016/S0005-2736(97)00237-X; Hollenberg SM, 2000, CIRC RES, V86, P774, DOI 10.1161/01.RES.86.7.774; HOM GJ, 1995, J PHARMACOL EXP THER, V272, P452; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Hussain MB, 1999, BRIT J PHARMACOL, V128, P1082, DOI 10.1038/sj.bjp.0702874; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; O'Brien AJ, 2001, BRIT J PHARMACOL, V133, P351, DOI 10.1038/sj.bjp.0704079; PerezVizcaino F, 1996, J VASC RES, V33, P249, DOI 10.1159/000159152; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; WHITWORTH PW, 1989, CIRC SHOCK, V27, P111; Yamashita T, 2000, CIRCULATION, V101, P931, DOI 10.1161/01.CIR.101.8.931; Zhou MA, 1997, BBA-GEN SUBJECTS, V1335, P182, DOI 10.1016/S0304-4165(96)00139-0	31	111	112	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					773	+		10.1096/fj.02-0668fje	http://dx.doi.org/10.1096/fj.02-0668fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586741				2022-12-25	WOS:000181456900033
J	Kaasik, A; Veksler, V; Boehm, E; Novotova, M; Ventura-Clapier, R				Kaasik, A; Veksler, V; Boehm, E; Novotova, M; Ventura-Clapier, R			From energy store to energy flux: a study in creatine kinase deficient fast skeletal muscle	FASEB JOURNAL			English	Article						permeabilized fibers; energy cross talk; mitochondrial respiration; myofilaments; sarcoplasmic reticulum	SARCOPLASMIC-RETICULUM; OXIDATIVE-PHOSPHORYLATION; IN-SITU; MITOCHONDRIAL-FUNCTION; ADENYLATE KINASE; MICE DEFICIENT; CELLS; MYOFIBRILLAR; HEART; ADAPTATIONS	Fast-twitch skeletal muscle of mice deficient in cytosolic and mitochondrial creatine kinase isoforms (CK-/-) lack burst activity but can sustain prolonged contractile activity, suggesting that adaptive mechanisms can regulate local adenine nucleotide turnover. We investigated whether direct energy and signal channeling between mitochondria and sarcoplasmic reticulum (SR) or myofilaments may exist that compensate for the lack of CK isoenzymes. Oxidative capacity of fast-twitch muscle was increased twofold in CK-/- mice. Energy cross talk between organelles was studied in muscle fibers with permeabilized sarcolemma. Energy supply to SR was estimated by analyzing the tension transient induced by caffeine and energy supply to myofilaments was estimated by the relaxation of rigor tension, both under different conditions of energy supply. In normal mice, ATP directly produced by mitochondria was not able to sustain calcium uptake and to relax rigor tension as efficiently as ATP produced by bound CK. However, in CK-/- mice, mitochondria ability to provide ATP for calcium uptake and relaxation of rigor tension was dramatically enhanced, suggesting a direct ATP/ADP channeling between sites of energy production (mitochondria) and energy utilization in CK-/- mice. These results demonstrate two possible patterns of energy transport in muscle cells: energy store with phosphocreatine and energy flux through mitochondria.	Univ Paris Sud, INSERM, U446, F-92296 Chatenay Malabry, France; Slovak Acad Sci, Bratislava, Slovakia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Slovak Academy of Sciences	Ventura-Clapier, R (corresponding author), Univ Paris Sud, INSERM, U446, F-92296 Chatenay Malabry, France.	Renee.Ventura@cep.u-psud.fr	Kaasik, Allen/I-2738-2015; Novotova, Marta/D-2578-2009	Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594; Kaasik, Allen/0000-0002-4850-3198				Bigard AX, 1998, J MOL CELL CARDIOL, V30, P2391, DOI 10.1006/jmcc.1998.0798; Boehm E, 1998, J MOL CELL CARDIOL, V30, P901, DOI 10.1006/jmcc.1998.0692; Boehm E, 2000, J MOL CELL CARDIOL, V32, P891, DOI 10.1006/jmcc.2000.1130; Dahlstedt AJ, 2000, FASEB J, V14, P982, DOI 10.1096/fasebj.14.7.982; Dahlstedt AJ, 2001, J PHYSIOL-LONDON, V533, P639, DOI 10.1111/j.1469-7793.2001.00639.x; Dahlstedt AJ, 2001, J PHYSIOL-LONDON, V533, P379, DOI 10.1111/j.1469-7793.2001.0379a.x; de Groof AJC, 2002, J BIOL CHEM, V277, P5275, DOI 10.1074/jbc.M108157200; de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4; de Groof AJC, 2001, MUSCLE NERVE, V24, P1188, DOI 10.1002/mus.1131; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Gorselink M, 2001, AM J PHYSIOL-ENDOC M, V281, pE619, DOI 10.1152/ajpendo.2001.281.3.E619; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; KHUCHUA Z, 1994, BBA-BIOENERGETICS, V1188, P373, DOI 10.1016/0005-2728(94)90058-2; KORGE P, 1994, AM J PHYSIOL, V267, pC357, DOI 10.1152/ajpcell.1994.267.2.C357; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; LEVITSKII D O, 1977, Biokhimiya, V42, P1766; Mannella CA, 1998, BIOFACTORS, V8, P225, DOI 10.1002/biof.5520080309; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; Novotova M, 2002, EUR J CELL BIOL, V81, P101, DOI 10.1078/0171-9335-00230; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; Qin WN, 1999, HISTOCHEM J, V31, P357, DOI 10.1023/A:1003748108062; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; SAKS VA, 1980, J BIOL CHEM, V255, P755; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; VENTURACLAPIER R, 1994, MOL CELL BIOCHEM, V133, P125, DOI 10.1007/BF01267952; Wallimann T, 1985, Cell Muscle Motil, V6, P239; Watchko JF, 1996, PEDIATR RES, V40, P53, DOI 10.1203/00006450-199607000-00010; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88	41	39	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2								10.1096/fj.02-0684fje	http://dx.doi.org/10.1096/fj.02-0684fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586739				2022-12-25	WOS:000181456900031
J	Mayr, D; Amann, G; Siefert, C; Diebold, J; Anderegg, B				Mayr, D; Amann, G; Siefert, C; Diebold, J; Anderegg, B			Does endometriosis really have premalignant potential? A clonal analysis of laser-microdissected tissue	FASEB JOURNAL			English	Article						PGK-1; X-chromosome inactivation; methylation pattern; HUMARA	X-CHROMOSOME INACTIVATION; POLYMERASE CHAIN-REACTION; ANDROGEN-RECEPTOR GENE; CLEAR-CELL-CARCINOMA; ABERRANT CRYPT FOCI; DIFFERENTIAL METHYLATION; OVARIAN ENDOMETRIOSIS; LOCUS DXS255; CYSTS; HETEROZYGOSITY	Since 1925, epidemiological and histological evidence for an association between endometriosis and ovarian neoplasia has accumulated. Recently, publications assaying the clonality of a given cell population have implied endometriosis has premalignant properties. However, the human androgen receptor used as a marker in these studies is of highly questionable reliability due to the instability of its methylation pattern in nonmalignant cells and during the course of malignancy. Therefore, we decided to readdress the question of clonality of endometriotic foci by using an alternative assay based on a polymorphism of the phosphoglycerate kinase-1 gene. We overcame the limitation to using ovarian cysts (a problem encountered in other studies) by laser-microdissecting defined tissue fractions of interest. From the 13/29 informative patients, a total of 32 endometriotic samples from various sites was assayed. Only 2/32 samples from different patients bore monoclonal tissue. With one of those cases, we present the first direct evidence of the two morphological endometric compartments comprising a single biphasic developmental unit. Neither monoclonal patient was characterized by any outstanding clinical parameters, including neoplasia. Individual endometriotic foci from the only patient in this study with neoplasia was assayed as being polyclonal. Therefore, former studies stating endometriosis as premalignant have to be cautiously reinterpreted.	Univ Munich, Dept Pathol, D-80337 Munich, Germany	University of Munich	Anderegg, B (corresponding author), Arcturus GmbH, Waldecker Str 9, D-64546 Morfelden Walldorf, Germany.	banderegg@arctureurope.com						ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Bischoff FZ, 2000, HUM REPROD UPDATE, V6, P37, DOI 10.1093/humupd/6.1.37; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BRALY PS, 1993, CANCER-AM CANCER SOC, V71, P1621, DOI 10.1002/cncr.2820710429; BROWN RM, 1990, GENOMICS, V7, P215, DOI 10.1016/0888-7543(90)90543-4; Buller RE, 1999, JNCI-J NATL CANCER I, V91, P339, DOI 10.1093/jnci/91.4.339; CORNER GW, 1950, AM J OBSTET GYNECOL, V59, P760; Diaz-Cano SJ, 2001, DIAGN MOL PATHOL, V10, P24, DOI 10.1097/00019606-200103000-00005; DUMANOIR S, 1995, CYTOMETRY, V19, P27, DOI 10.1002/cyto.990190105; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; Fujimoto J, 1999, STEROIDS, V64, P526, DOI 10.1016/S0039-128X(99)00025-2; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; Henegariu O, 2001, CYTOMETRY, V43, P101, DOI 10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8; Jang SJ, 2000, CANCER RES, V60, P864; Jiang XX, 1998, CANCER RES, V58, P1707; Jiang XX, 1996, CANCER RES, V56, P3534; Jimbo H, 1997, AM J PATHOL, V150, P1173; Jimbo H, 1999, FERTIL STERIL, V72, P1142, DOI 10.1016/S0015-0282(99)00416-1; KURMAN RJ, 1972, CANCER-AM CANCER SOC, V29, P1653, DOI 10.1002/1097-0142(197206)29:6<1653::AID-CNCR2820290633>3.0.CO;2-E; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MAYR D, 2002, IN PRESS MOD PATHOL; MOSTOUFIZADEH M, 1980, Clinical Obstetrics and Gynecology, V23, P951; MUTTER GL, 1995, NUCLEIC ACIDS RES, V23, P1411; MUTTER GL, 1995, AM J PATHOL, V146, P501; Nishida M, 2000, GYNECOL OBSTET INVES, V50, P18, DOI 10.1159/000052874; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Sakurazawa N, 2000, CANCER RES, V60, P3165; Sampson JA, 1925, ARCH SURG-CHICAGO, V10, P1, DOI 10.1001/archsurg.1925.01120100007001; Sato N, 2000, CANCER RES, V60, P7052; SCULLY RE, 1967, CANCER-AM CANCER SOC, V20, P1405, DOI 10.1002/1097-0142(196709)20:9<1405::AID-CNCR2820200907>3.0.CO;2-B; SCULLY RE, 1966, CLIN OBSTET GYNECOL, V9, P381; SEROV SF, 1973, INT HISTOLOGICAL CLA, V9, P51; Siu IM, 1999, CANCER RES, V59, P63; SYMONDS DA, 1988, CANCER, V61, P2511, DOI 10.1002/1097-0142(19880615)61:12<2511::AID-CNCR2820611220>3.0.CO;2-Y; TANAKA N, 1998, ACTA OBSTET GYNAECOL, V50, P765; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; Yano T, 1999, GYNECOL OBSTET INVES, V47, P41, DOI 10.1159/000052858; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759	40	27	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					693	+		10.1096/fj.02-0562fje	http://dx.doi.org/10.1096/fj.02-0562fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594178				2022-12-25	WOS:000181456900015
J	Michaelis, UR; Fisslthaler, B; Medhora, M; Harder, D; Fleming, I; Busse, R				Michaelis, UR; Fisslthaler, B; Medhora, M; Harder, D; Fleming, I; Busse, R			Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor	FASEB JOURNAL			English	Article						AG 1478; Akt; cyclin D1; endothelial cell proliferation; endothelium-derived hyperpolarizing factor	ARTERIAL SMOOTH-MUSCLE; EGF-RECEPTOR; 11,12-EPOXYEICOSATRIENOIC ACID; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; BINDING PROTEIN; CELL-MIGRATION; EXPRESSION	Cytochrome P450 (CYP) epoxygenase products, such as 11,12-epoxyeicosatrienoic acid (EET), stimulate endothelial cell proliferation. We set out to identify the signal transduction cascade linking EET generation to enhanced proliferation and angiogenesis. In human endothelial cells overexpressing CYP 2C9, cell number was increased compared with control cells and was inhibited by the CYP 2C9 inhibitor, sulfaphenazole. CYP 2C9 overexpression was associated with the activation of Akt and an increase in cyclin D1 expression, effects that were abolished by the epidermal growth factor (EGF) receptor inhibitor, AG1478, which also prevented the CYP 2C9-induced increase in cell proliferation. Stimulation of EGF receptor overexpressing cells with 11,12-EET or transfection of these cells with CYP 2C9 enhanced the tyrosine phosphorylation of the EGF receptor. Endothelial tube formation in a fibrin gel was significantly enhanced (6-fold) in CYP 2C9 overexpressing cells and was comparable with the tube formation induced by EGF. In the chick chorioallantoic membrane, 11,12-EET stimulated vessel formation (3.5-fold) and induced vessel convergence, an effect that was abolished by cotreatment with either an EGF receptor-neutralizing antibody or AG1478. These results indicate that CYP 2C9-derived EETs stimulate angiogenesis by a mechanism involving the activation of the EGF receptor.	Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-60590 Frankfurt, Germany; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Medical College of Wisconsin	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovask Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	fleming@em.uni-frankfurt.de	Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635				Augustin HG, 2001, CIRC RES, V89, P645, DOI 10.1161/res.89.8.645; Bauersachs J, 2002, CARDIOVASC RES, V54, P669, DOI 10.1016/S0008-6363(02)00257-2; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Chen JR, 2000, J BIOL CHEM, V275, P13789, DOI 10.1074/jbc.275.18.13789; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Fisslthaler B, 2000, HYPERTENSION, V36, P270, DOI 10.1161/01.HYP.36.2.270; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fleming I, 2001, PFLUG ARCH EUR J PHY, V442, P511, DOI 10.1007/s004240100565; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gallo O, 2001, NEOPLASIA, V3, P53, DOI 10.1038/sj.neo.7900127; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoebel BG, 1998, EUR J PHARMACOL, V346, P115, DOI 10.1016/S0014-2999(98)00118-6; Imig JD, 1999, HYPERTENSION, V33, P408, DOI 10.1161/01.HYP.33.1.408; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Li PL, 1997, HYPERTENSION, V29, P262, DOI 10.1161/01.HYP.29.1.262; Li PL, 2002, AM J PHYSIOL-HEART C, V282, pH1229, DOI 10.1152/ajpheart.00736.2001; Li PL, 1999, CIRC RES, V85, P349, DOI 10.1161/01.RES.85.4.349; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LIN JHC, 1996, ENDOTHELIUM, V4, P219; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Munzenmaier DH, 2000, AM J PHYSIOL-HEART C, V278, pH1163, DOI 10.1152/ajpheart.2000.278.4.H1163; Muthalif MM, 2001, PROSTAG OTH LIPID M, V65, P33, DOI 10.1016/S0090-6980(01)00112-5; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Node K, 2001, J BIOL CHEM, V276, P15983, DOI 10.1074/jbc.M100439200; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qi XJ, 2002, UROL RES, V30, P48, DOI 10.1007/s00240-001-0223-4; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Vernia S, 2001, ADV EXP MED BIOL, V500, P209; Vernia S, 2001, FEBS LETT, V488, P59, DOI 10.1016/S0014-5793(00)02388-7; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; West DC, 2001, METH MOLEC MED, V46, P107, DOI 10.1385/1-59259-143-4:107; Wong PYK, 2000, PROSTAG OTH LIPID M, V62, P321, DOI 10.1016/S0090-6980(00)00079-4; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	54	146	148	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					770	+		10.1096/fj.02-0640fje	http://dx.doi.org/10.1096/fj.02-0640fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586744				2022-12-25	WOS:000181456900027
J	Zhang, PS; Chan, SL; Fu, WM; Mendoza, M; Mattson, MP				Zhang, PS; Chan, SL; Fu, WM; Mendoza, M; Mattson, MP			TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein binding ability	FASEB JOURNAL			English	Article						cancer; cytochrome c; etoposide; mitochondria; site-directed mutagenesis	TELOMERASE ACTIVITY; 14-3-3 PROTEINS; CELL-PROLIFERATION; CATALYTIC SUBUNIT; HELA-CELLS; LIFE-SPAN; NEURONS; INHIBITION; EXPRESSION; STAUROSPORINE	The catalytic subunit of telomerase (TERT) is a reverse transcriptase (RT) that adds a six-base DNA repeat onto chromosome ends and prevents their shortening during successive cell divisions. Telomerase is associated with cell immortality and cancer, which may by related to the ability of TERT to prevent apoptosis by stabilizing telomeres. However, fundamental information concerning the antiapoptotic function of TERT is lacking, including whether RT activity and/or nuclear localization are required and where telomerase acts to suppress the cell death process. Here, we show that overexpression of wild-type human TERT in HeLa cells, and in a cells lacking TERT but containing the telomerase RNA template, increases their resistance to apoptosis induced by the DNA damaging agent etoposide or the bacterial alkaloid staurosporine. In contrast, TERT mutants with disruptions of either the RT domain or a 14-3-3 binding domain fail to protect cells against apoptosis, and overexpression of TERT in cells lacking the telomerase RNA template is also ineffective in preventing apoptosis. Additional findings show that TERT suppresses apoptosis at an early step before release of cytochrome c and apoptosis-inducing factor from mitochondria. We conclude that both RT activity and 14-3-3 protein binding ability are required for the antiapoptotic function of TERT in tumor cells and that TERT can suppress a nuclear signal(s) that is an essential component of apoptotic cascades triggered by diverse stimuli.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000317, Z01AG000313, ZIAAG000317, ZIAAG000314, ZIAAG000313, Z01AG000314] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Bernard B, 2001, CELL DEATH DIFFER, V8, P234, DOI 10.1038/sj.cdd.4400796; BLASCO MA, 2001, ADV CELL AGING GERON, V8, P151; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Capranico G, 1999, Cancer Chemother Biol Response Modif, V18, P125; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073.abs; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Lee CC, 2001, PHARMACEUT RES, V18, P846, DOI 10.1023/A:1011048831698; Lock RB, 1997, CANCER CHEMOTH PHARM, V39, P399, DOI 10.1007/s002800050590; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; MacManus J P, 1996, Hum Cell, V9, P197; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Reddy VG, 2001, BIOCHEM BIOPH RES CO, V282, P409, DOI 10.1006/bbrc.2001.4593; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Rowley PT, 2000, ANTICANCER RES, V20, P4419; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Sachsinger J, 2001, CANCER RES, V61, P5580; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Tafani M, 2001, CANCER RES, V61, P2459; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yegorov YE, 1996, FEBS LETT, V389, P115, DOI 10.1016/0014-5793(96)00533-9; Zaugg K, 2001, CANCER RES, V61, P732; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	51	69	83	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					767	+		10.1096/fj.02-0603fje	http://dx.doi.org/10.1096/fj.02-0603fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594176				2022-12-25	WOS:000181456900009
J	Zhao, H; Miller, M; Pfeiffer, K; Buras, JA; Stahl, GL				Zhao, H; Miller, M; Pfeiffer, K; Buras, JA; Stahl, GL			Anoxia and reoxygenation of human endothelial cells decreases ceramide glucosyltransferase expression and activates caspases	FASEB JOURNAL			English	Article						HUVEC; caspase activity; ischemia/reperfusion; apoptosis; glucosylceramide synthase	CARDIAC MYOCYTES; ISCHEMIA/REPERFUSION INJURY; GENE-EXPRESSION; ROCK-I; APOPTOSIS; GLUCOSYLCERAMIDE; STRESS; REPERFUSION; SPHINGOSINE; CLEAVAGE	Endothelial oxidative stress induces cellular activation and sometimes death. Endothelial death can occur via necrosis or apoptosis. Understanding the mechanisms involved in cellular activation and death may lead to therapeutics designed to increase death or preserve cellular function. In the present study, brief periods of anoxia (3 h) followed by varying lengths of reoxygenation (0-5 h) lead to a time-dependent increase in human umbilical vein endothelial cell (HUVEC) caspase activity. Furthermore, ROCK-1 cleavage, which is dependent on caspase-3 activity, was also increased in cells undergoing oxidative stress compared with normoxic cells. Microarray data demonstrated that glucosylceramide synthase (GCS; glucosylceramide transferase), but not acid sphingomyelinase, was modulated by anoxia and reoxygenation. We confirmed that GCS mRNA and protein expression were significantly decreased in a time-dependent fashion following oxidative stress by real-time polymerase chain reaction and Western blot, respectively. Treatment of normoxic cells with the GCS-specific inhibitor, D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), increased caspase activity to the same degree as cells undergoing oxidative stress. Fumonisin B-1, the N-acyl-sphinganine dehydrogenase (e.g., ceramide synthase) inhibitor significantly attenuated caspase activity in HUVECs undergoing oxidative stress. These data suggest that alterations in GCS expression following brief periods of oxidative stress in human endothelial cells lead to increased caspase activity.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Hosp Med Ctr, Dept Emergency Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Stahl, GL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Thorn 705,75 Francis St, Boston, MA 02115 USA.	gstahl@zeus.bwh.harvard.edu		Stahl, Gregory/0000-0002-4805-8119				BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Collard CD, 1997, CIRCULATION, V96, P326; Cordis GA, 1998, J PHARMACEUT BIOMED, V16, P1189, DOI 10.1016/S0731-7085(97)00260-4; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hofmann K, 1999, TRENDS BIOCHEM SCI, V24, P227, DOI 10.1016/S0968-0004(99)01410-3; Huwiler A, 2001, BIOCHEM BIOPH RES CO, V284, P404, DOI 10.1006/bbrc.2001.4941; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Scarabelli T, 2001, CIRCULATION, V104, P253, DOI 10.1161/01.CIR.104.3.253; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang NP, 2001, CIRC RES, V88, P1223, DOI 10.1161/hh1201.093162; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085	34	17	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					723	+		10.1096/fj.02-0806fje	http://dx.doi.org/10.1096/fj.02-0806fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586734				2022-12-25	WOS:000181456900021
J	Erdtmann, L; Franck, N; Lerat, H; Le Seyec, J; Gilot, D; Cannie, I; Gripon, P; Hibner, U; Guguen-Guillouzo, C				Erdtmann, L; Franck, N; Lerat, H; Le Seyec, J; Gilot, D; Cannie, I; Gripon, P; Hibner, U; Guguen-Guillouzo, C			The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CASPASE-ACTIVATED DNASE; CORE PROTEIN; CYTOCHROME-C; KINASE PKR; HIV-1 NEF; PATHWAY; FRAGMENTATION; REPLICATION; INTERACTS	Chronic hepatitis C virus (HCV) infection frequently leads to liver cancer. To determine the viral factor(s) potentially involved in viral persistence, we focused our work on NS2, a viral protein of unknown function. To assign a role for NS2, we searched for cellular proteins that interact with NS2. Performing a two-hybrid screen on a human liver cDNA library, we found that NS2 interacted with the liver-specific pro-apoptotic CIDE-B protein. Binding specificity of NS2 for CIDE-B was confirmed by cell-free assays associated with colocalization studies and coprecipitation experiments on human endogenous CIDE-B. CIDE-B, a member of the novel CIDE family of apoptosis-inducing factors, has been reported to show strong cell death-inducing activity in its C-terminal domain. We show that this CIDE-B killing domain is involved in the NS2 interaction. NS2 binding was sufficient to inhibit CIDE-B-induced apoptosis because an NS2 deletion mutant unable to interact with CIDE-B in vitro lost its capacity to interfere with CIDE-B cell death activity. Although it has been reported that CIDE-B-induced apoptosis is characterized by mitochondrial localization, the precise apoptotic mechanism remained unknown. Here, we show that CIDE-B induced cell death in a caspase-dependent manner through cytochrome c release from mitochondria. Furthermore, we found that NS2 counteracted the cytochrome c release induced by CIDE-B. In vivo, the CIDE-B protein level was extremely low in adenovirus-infected transgenic mice expressing the HCV polyprotein compared with that in wild-type mice. We suggest that NS2 interferes with the CIDE-B-induced death pathway and participates in HCV strategies to subvert host cell defense.	Hop Pontchaillou, INSERM, U522, F-35033 Rennes, France; CNRS, Inst Genet Mol, UMR 5535, F-34293 Montpellier 5, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Erdtmann, L (corresponding author), Hop Pontchaillou, INSERM, U522, 2 Rue Henri Guilloux, F-35033 Rennes, France.	lars.erdtmann@univ-rennes1.fr	Le Seyec, Jacques/J-5680-2015; LERAT, Hervé/D-4331-2019; GRIPON, Philippe/J-6068-2015	LERAT, Hervé/0000-0002-8505-378X; Le Seyec, Jacques/0000-0002-1118-3311; Hibner, Urszula/0000-0002-5520-7311				Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chen ZM, 2000, J BIOL CHEM, V275, P22619, DOI 10.1074/jbc.C000207200; Dumoulin FL, 1999, EUR J CLIN INVEST, V29, P940; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Erdtmann L, 2000, TRAFFIC, V1, P871, DOI 10.1034/j.1600-0854.2000.011106.x; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Grakoui A, 2001, HEPATOLOGY, V33, P489, DOI 10.1053/jhep.2001.23041; Hahn CS, 2000, VIROLOGY, V276, P127, DOI 10.1006/viro.2000.0541; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; Honda A, 2000, J HEPATOL, V33, P440, DOI 10.1016/S0168-8278(00)80280-9; INCHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292, DOI 10.1073/pnas.88.22.10292; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kalkeri G, 2001, VIROLOGY, V282, P26, DOI 10.1006/viro.2000.0835; Kim JE, 1999, ARCH VIROL, V144, P329, DOI 10.1007/s007050050507; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Klonjkowski B, 1997, HUM GENE THER, V8, P2103, DOI 10.1089/hum.1997.8.17-2103; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1996, J HEPATOL, V24, P11; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Mak P, 2001, FEBS LETT, V503, P13, DOI 10.1016/S0014-5793(01)02678-3; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Pallaoro M, 2001, J VIROL, V75, P9939, DOI 10.1128/JVI.75.20.9939-9946.2001; Pavio N, 2002, J VIROL, V76, P1265, DOI 10.1128/JVI.76.3.1265-1272.2002; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Sakahira H, 2001, ARCH BIOCHEM BIOPHYS, V388, P91, DOI 10.1006/abbi.2000.2266; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Wang XD, 2001, GENE DEV, V15, P2922; Yamaga AK, 2002, J BIOL CHEM, V277, P33228, DOI 10.1074/jbc.M202304200; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	57	97	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18256	18264		10.1074/jbc.M209732200	http://dx.doi.org/10.1074/jbc.M209732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12595532	Green Published, hybrid			2022-12-25	WOS:000182838300088
J	Mongiat, M; Fu, J; Oldershaw, R; Greenhalgh, R; Gown, AM; Iozzo, RV				Mongiat, M; Fu, J; Oldershaw, R; Greenhalgh, R; Gown, AM; Iozzo, RV			Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; DENSITY-LIPOPROTEIN-RECEPTOR; TERMINAL GLOBULAR DOMAIN; SILVERMAN-HANDMAKER TYPE; CELL-ADHESION MOLECULES; BASEMENT-MEMBRANE; STRUCTURAL BASIS; DYSSEGMENTAL DYSPLASIA; CHONDROGENIC ACTIVITY	The goal of this study was to discover novel partners for perlecan, a major heparan sulfate proteoglycan of basement membranes, and to examine new interactions through which perlecan may influence cell behavior. We employed the yeast two-hybrid system and used perlecan domain V as bait to screen a human keratinocyte cDNA library. Among the strongest interacting clones, we isolated a similar to1.6-kb cDNA insert that encoded extracellular matrix protein 1 (ECM1), a secreted glycoprotein involved in bone formation and angiogenesis. The sequencing of the clone revealed the existence of a novel splice variant that we name ECM1c. The interaction was validated by co-immunoprecipitation studies, using both cell-free systems and mammalian cells, and the specific binding site within each molecule was identified employing various deletion mutants. The C terminus of ECM1 interacted specifically with the epidermal growth factor-like modules flanking the LG2 subdomain of perlecan domain V. Perlecan and ECM1 were also co-expressed by a variety of normal and transformed cells, and immunohistochemical studies showed a partial expression overlap, particularly around dermal blood vessels and adnexal epithelia. ECM1 has been shown to regulate endochondral bone formation, stimulate the proliferation of endothelial cells, and induce angiogenesis. Similarly, perlecan plays an important role in chondrogenesis and skeletal development, as well as harboring pro- and anti-angiogenic activities. Thus, a physiological interaction could also occur in vivo during development and in pathological events, including tissue remodeling and tumor progression.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Signaling Program, Philadelphia, PA 19107 USA; Phenopath Labs, Seattle, WA 98103 USA	Jefferson University; Jefferson University; PhenoPath Laboratories	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Mongiat, Maurizio/H-8297-2018; Iozzo, Renato/AAS-1980-2020	Mongiat, Maurizio/0000-0001-6509-0068; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Arikawa-Hirasawa E, 2001, AM J MED GENET, V106, P254, DOI 10.1002/ajmg.10229.abs; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; BHALERAO J, 1995, J BIOL CHEM, V270, P16385, DOI 10.1074/jbc.270.27.16385; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; BROWN JR, 1976, FED PROC, V35, P2141; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; COHEN IR, 1994, CANCER RES, V54, P5771; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; COUCHMAN JR, 1989, MATRIX, V9, P311, DOI 10.1016/S0934-8832(89)80007-1; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; Deckers MML, 2001, BONE, V28, P14, DOI 10.1016/S8756-3282(00)00428-2; Dhanabal M, 2002, CANCER RES, V62, P3834; DUNLEVY JR, 2000, PROTEOGLYCANS STRUCT, P275; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; French MM, 2002, J BONE MINER RES, V17, P48, DOI 10.1359/jbmr.2002.17.1.48; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; Friedrich MVK, 2000, EUR J BIOCHEM, V267, P3149, DOI 10.1046/j.1432-1327.2000.01337.x; Godin RE, 1996, DEV BIOL, V179, P148, DOI 10.1006/dbio.1996.0247; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Hamada T, 2002, HUM MOL GENET, V11, P833, DOI 10.1093/hmg/11.7.833; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Smits P, 1999, GENE, V226, P253, DOI 10.1016/S0378-1119(98)00558-7; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; Villar MJ, 1999, J CELL BIOCHEM, V75, P665, DOI 10.1002/(SICI)1097-4644(19991215)75:4<665::AID-JCB12>3.0.CO;2-S; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668	75	129	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17491	17499		10.1074/jbc.M210529200	http://dx.doi.org/10.1074/jbc.M210529200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604605	hybrid			2022-12-25	WOS:000182818600137
J	Bitard, J; Daburon, S; Duplomb, L; Blanchard, F; Vuisio, P; Jacques, Y; Godard, A; Heath, JK; Moreau, JF; Taupin, JL				Bitard, J; Daburon, S; Duplomb, L; Blanchard, F; Vuisio, P; Jacques, Y; Godard, A; Heath, JK; Moreau, JF; Taupin, JL			Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor, increase or decrease its affinity for LIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; CYTOKINE-BINDING DOMAINS; FACTOR-II RECEPTOR; ONCOSTATIN-M; SIGNAL-TRANSDUCTION; HUMAN INTERLEUKIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; GP130; COMPLEX	The leukemia inhibitory factor (LIF) receptor comprises the low affinity binding chain gp190 and the high affinity converter gp130. The ectodomain of gp190 is among the most complex in the hematopoietin receptor family, because it contains two typical cytokine receptor homology domains separated by an immunoglobulin-like (Ig-like) domain. Human and murine gp190 proteins share 76% homology, but murine gp190 binds human LIF with a much higher affinity, a property attributed to the Ig-like domain. Using alanine-scanning mutagenesis of the Ig-like domain, we mapped a LIF binding site at its carboxyl terminus, mainly involving residue Phe-328. Mutation of selected residues into their orthologs in the murine receptor (Q251E and N321D) significantly increased the affinity for human LIF. Interestingly, these residues, although localized at both the amino and carboxyl terminus, make a spatially unique LIF binding site in a structural model of the Ig-like module. These results demonstrate definitively the role of the Ig-like domain in LIF binding and the potential to modulate receptor affinity in this family with very limited amino acid changes.	Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France; IFR 66, F-33076 Bordeaux, France; INSERM, U463, F-44035 Nantes, France; IFR 26, F-44035 Nantes, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Birmingham	Taupin, JL (corresponding author), Univ Bordeaux 2, CNRS, UMR 5540, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Heath, John/0000-0003-4886-4070; BITARD, Juliette/0000-0001-6626-3522; Duplomb, Laurence/0000-0002-5715-3759				Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Cabibbo A, 1995, GENE, V167, P41, DOI 10.1016/0378-1119(95)00632-X; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Chow DC, 2001, BIOCHEMISTRY-US, V40, P7593, DOI 10.1021/bi010192q; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Deller MC, 2000, STRUCT FOLD DES, V8, P863, DOI 10.1016/S0969-2126(00)00176-3; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Huang X, 1991, ADV APPL MATH, V12, P373; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; Pitard V, 1998, EUR CYTOKINE NETW, V9, P599; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Staunton D, 1998, PROTEIN ENG, V11, P1093, DOI 10.1093/protein/11.11.1093; Taupin JL, 1999, J BIOL CHEM, V274, P14482, DOI 10.1074/jbc.274.20.14482; Taupin JL, 2001, J BIOL CHEM, V276, P47975, DOI 10.1074/jbc.M105476200; TAUPIN JL, 1993, SCAND J IMMUNOL, V38, P293, DOI 10.1111/j.1365-3083.1993.tb01728.x; Taupin JL, 1997, CYTOKINE, V9, P112, DOI 10.1006/cyto.1996.0144; Tomida M, 1996, J BIOCHEM-TOKYO, V120, P201; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; Voisin MB, 2002, J BIOL CHEM, V277, P13682, DOI 10.1074/jbc.M111624200; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	37	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16253	16261		10.1074/jbc.M207193200	http://dx.doi.org/10.1074/jbc.M207193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601009	hybrid			2022-12-25	WOS:000182680000101
J	Dhani, SU; Mohammad-Panah, R; Ahmed, N; Ackerley, C; Ramjeesingh, M; Bear, CE				Dhani, SU; Mohammad-Panah, R; Ahmed, N; Ackerley, C; Ramjeesingh, M; Bear, CE			Evidence for a functional interaction between the CIC-2 chloride channel and the retrograde motor dynein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CL CURRENT; CYTOPLASMIC DYNEIN; POTENTIAL MECHANISM; EPITHELIAL-CELLS; DYNACTIN COMPLEX; DENTS-DISEASE; CLC-2; SUBUNIT; PHOSPHORYLATION; ORGANIZATION	The ClC-2 chloride channel has been implicated in essential physiological functions. Analyses of ClC-2 knock-out mice suggest that ClC-2 expression in retinal pigment epithelia and Sertoli cells normally supports the viability of photoreceptor cells and male germ cells, respectively. Further, other studies suggest that ClC-2 expression in neurons may modify inhibitory synaptic transmission via the gamma-aminobutyric acid, type A receptor. However, complete understanding of the physiological functions of ClC-2 requires elucidation of the molecular basis for its regulation. Using cell imaging and biochemical and electrophysiological techniques, we show that expression of ClC-2 at the cell surface may be regulated via an interaction with the dynein motor complex. Mass spectrometry and Western blot analysis of eluate from a ClC-2 affinity matrix showed that heavy and intermediate chains of dynein bind ClC-2 in vitro. The dynein intermediate chain co-immunoprecipitates with ClC-2 from hippocampal membranes suggesting that they also interact in vivo. Disruption of dynein motor function perturbs ClC-2 localization and increases the functional expression of ClC-2 in the plasma membranes of COS7 cells. Thus, cell surface expression of ClC-2 may be regulated by dynein motor activity. This work is the first to demonstrate an in vivo interaction between an ion channel and the dynein motor complex.	Hosp Sick Children, Res Inst, Programme Struct Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Bear, CE (corresponding author), Hosp Sick Children, Res Inst, Programme Struct Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NIDDK NIH HHS [DK 49096] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049096] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bali MZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1588, DOI 10.1152/ajpcell.2001.280.6.C1588; Blaisdell CJ, 1999, AM J RESP CELL MOL, V20, P842, DOI 10.1165/ajrcmb.20.4.3431; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; DUNN WA, 1980, J BIOL CHEM, V255, P5971; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; EKSTROM P, 1984, J NEUROCHEM, V43, P1342, DOI 10.1111/j.1471-4159.1984.tb05392.x; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; JANEVSKI J, 1995, EXP CELL RES, V217, P227, DOI 10.1006/excr.1995.1082; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marples D, 1996, J PHYSIOL-LONDON, V490, P767, DOI 10.1113/jphysiol.1996.sp021184; Martou G, 2000, EXP CELL RES, V256, P131, DOI 10.1006/excr.1999.4793; Mohammad-Panah R, 2001, J BIOL CHEM, V276, P8306, DOI 10.1074/jbc.M006764200; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Murray CB, 1996, AM J PHYSIOL-LUNG C, V271, pL829, DOI 10.1152/ajplung.1996.271.5.L829; Nehrke K, 2002, J BIOL CHEM, V277, P23604, DOI 10.1074/jbc.M202900200; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ramjeesingh M, 2000, BIOCHEMISTRY-US, V39, P13838, DOI 10.1021/bi001282i; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; Sik A, 2000, NEUROSCIENCE, V101, P51, DOI 10.1016/S0306-4522(00)00360-2; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; VANDEURS B, 1987, EXP CELL RES, V171, P137, DOI 10.1016/0014-4827(87)90257-6; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wan Q, 1997, J NEUROSCI, V17, P5062; Zheng YJ, 2002, J BIOL CHEM, V277, P32268, DOI 10.1074/jbc.M202105200	45	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16262	16270		10.1074/jbc.M209828200	http://dx.doi.org/10.1074/jbc.M209828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601004	hybrid			2022-12-25	WOS:000182680000102
J	Koerner, C; Guan, T; Gerace, L; Cingolani, G				Koerner, C; Guan, T; Gerace, L; Cingolani, G			Synergy of silent and hot spot mutations in importin beta reveals a dynamic mechanism for recognition of a nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; ELECTRON-DENSITY MAPS; PROTEIN IMPORT; CRYSTALLOGRAPHIC ANALYSIS; KARYOPHERIN-ALPHA; PORE COMPLEX; TRANSPORT; RAN; RECEPTOR; BIOLOGY	Molecular recognition of the importin beta-binding (IBB) domain of importin a by importin 6 is critical for the nuclear import of protein cargoes containing a classical nuclear localization signal. We have studied the function of four conserved tryptophans of importin beta (Trp-342, Trp-430, Trp-472, and Trp-864) located at the binding interface with the IBB domain by systematic alanine substitution mutagenesis. We found that Trp-864 is a mutational hot spot that significantly affects IBB-binding and import activity, whereas residues Trp-342, Trp-430, and Trp-472 are mutationally silent when analyzed individually. Interestingly, the combination of the hot spot at residue Trp-864 with mutations in the other three tryptophans gives rise to a striking synergy that diminishes IBB domain binding by up to similar to 1000-fold and, in turn, abolishes import activity. We propose that importin beta uses the tryptophans to select and stabilize a helical conformation of the IBB domain, which, in turn, conveys specific, high affinity binding.	Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell & Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Körner, Carolin/AAT-7799-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41955] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; Cingolani G, 2000, FEBS LETT, V484, P291, DOI 10.1016/S0014-5793(00)02154-2; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frosst P, 2002, J CELL BIOL, V156, P617, DOI 10.1083/jcb.200106046; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kumar S, 2000, PROTEIN SCI, V9, P10; Lyman SK, 2002, J CELL BIOL, V159, P55, DOI 10.1083/jcb.200204163; Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Melchior F, 1998, METH MOL B, V88, P265; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Ye XM, 1999, CHEM BIOL, V6, P657, DOI 10.1016/S1074-5521(99)80117-3	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16216	16221		10.1074/jbc.M301137200	http://dx.doi.org/10.1074/jbc.M301137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594203	hybrid			2022-12-25	WOS:000182680000096
J	Kouklis, P; Konstantoulaki, M; Malik, AB				Kouklis, P; Konstantoulaki, M; Malik, AB			VE-cadherin-induced Cdc42 signaling regulates formation of membrane protrusions in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CADHERIN; MOLECULAR-ORGANIZATION; FUNCTIONAL-ROLE; ALPHA-CATENIN; BETA-CATENIN; ADHESION; JUNCTIONS; COMPLEX; DOMAIN; RHO	The cytoplasmic domain of cadherins and the associated catenins link the cytoskeleton with signal transduction pathways. To study the signaling function of non-junctional VE-cadherin, which can form during the loss VE-cadherin homotypic adhesion, wild type VE-cadherin or VE-cadherin cytoplasmic domain (DeltaEXD) was expressed in sub-confluent endothelial cells. We observed that Cdc42 was activated in transfected cells and that these cells also developed Cdc42-dependent >70-mum-long plasma membrane protrusions. The formation of these structures required actin polymerization, and they developed specifically in endothelial cells as compared with epithelial cells. Expression of the VE-cadherin cytoplasmic domain lacking the beta-catenin binding site also induced Cdc42 activation; thus, its activation cannot be ascribed to beta-catenin binding. However, these cells were not able to form the protrusions. These results suggest that the cytoplasmic domain of non-junctional VE-cadherin can serve as a scaffold involved in Cdc42 activation at the endothelial plasma membrane. beta-Catenin and the associated alpha-catenin may serve as support sites for actin polymerization, leading to formation of long plasma membrane protrusions. Thus, non-junctional VE-cadherin actively participates in inside-out signaling at the plasma membrane, leading to the development of endothelial membrane protrusions.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kouklis, P (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	pkouklis@uic.edu		Malik, Asrar/0000-0002-8205-7128; Kouklis, Panos/0000-0003-0378-5619				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Allport JR, 2000, J CELL BIOL, V148, P203, DOI 10.1083/jcb.148.1.203; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Ben-Ze'Ev A, 1999, ANN NY ACAD SCI, V886, P37, DOI 10.1111/j.1749-6632.1999.tb09398.x; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Dejana E, 2000, INT J DEV BIOL, V44, P743; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; DUFOUR S, 1994, J CELL BIOL, V127, P521, DOI 10.1083/jcb.127.2.521; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Gotsch U, 1997, J CELL SCI, V110, P583; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hertig CM, 1996, J CELL SCI, V109, P1; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Luscinskas FW, 2002, IMMUNOL REV, V186, P57, DOI 10.1034/j.1600-065X.2002.18606.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL SCI, V112, P1621; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Zhu AJ, 1996, J CELL SCI, V109, P3013	42	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16230	16236		10.1074/jbc.M212591200	http://dx.doi.org/10.1074/jbc.M212591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595527	hybrid			2022-12-25	WOS:000182680000098
J	Lusetti, SL; Shaw, JJ; Cox, MM				Lusetti, SL; Shaw, JJ; Cox, MM			Magnesium ion-dependent activation of the RecA protein involves the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-RECA; SINGLE-STRANDED-DNA; ATP-GAMMA-S; BINDING-PROTEIN; CONFORMATIONAL-CHANGES; STABLE COMPLEXES; INACTIVE FORMS; GENE-PRODUCT; SOS RESPONSE; SSB PROTEIN	Optimal conditions for RecA protein-mediated DNA strand exchange include 6-8 mm.Mg2+ in excess of that required to form complexes with ATP. We provide evidence that the free magnesium ion is required to mediate a conformational change in the RecA protein C terminus that activates RecA-mediated DNA strand exchange. In particular, a "closed" (low Mg2+) conformation of a RecA nucleoprotein filament restricts DNA pairing by incoming duplex DNA, although single-stranded overhangs at the ends of a duplex allow limited DNA pairing to occur. The addition of excess Mg2+ results in an "open" conformation, which can promote efficient DNA pairing and strand exchange regardless of DNA end structure. The removal of 17 amino acid residues at the Escherichia coli RecA C terminus eliminates a measurable requirement for excess Mg2+ and permits efficient DNA pairing and exchange similar to that seen with the wild-type protein at high Mg2+ levels. Thus, the RecA C terminus imposes the need for the high magnesium. ion concentrations requisite in RecA reactions in vitro. We propose that the C terminus acts as a regulatory switch, modulating the access of double-stranded DNA to the presynaptic filament and thereby inhibiting homologous DNA pairing and strand exchange at low magnesium ion concentrations.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Datta S, 2000, NUCLEIC ACIDS RES, V28, P4964, DOI 10.1093/nar/28.24.4964; DAVIS RW, 1980, ADV BACTERIAL GENET, P70; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; FLORY SS, 1984, COLD SPRING HARB SYM, V49, P513, DOI 10.1101/SQB.1984.049.01.058; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KUHN A, 1985, J BACTERIOL, V163, P906, DOI 10.1128/JB.163.3.906-912.1985; KUHN AHU, 1983, J VIROL, V47, P540, DOI 10.1128/JVI.47.3.540-552.1983; Kurumizaka H, 1999, ARCH BIOCHEM BIOPHYS, V365, P83, DOI 10.1006/abbi.1999.1166; Kurumizaka H, 2000, FEBS LETT, V477, P129, DOI 10.1016/S0014-5793(00)01781-6; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PHILLIPS RC, 1966, J AM CHEM SOC, V88, P2631, DOI 10.1021/ja00964a002; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; ROBERTS JW, 1978, P NATL ACAD SCI USA, V75, P4714, DOI 10.1073/pnas.75.10.4714; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; Saecker RM, 2002, CURR OPIN STRUC BIOL, V12, P311, DOI 10.1016/S0959-440X(02)00326-3; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; Shinagawa H, 1996, EXS, V77, P221; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; WEDEKIND JE, 1994, BIOCHEMISTRY-US, V33, P9333, DOI 10.1021/bi00197a038; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	54	65	78	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16381	16388		10.1074/jbc.M212916200	http://dx.doi.org/10.1074/jbc.M212916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595538	hybrid			2022-12-25	WOS:000182680000117
J	Qiao, DH; Meyer, K; Mundhenke, C; Drew, SA; Friedl, A				Qiao, DH; Meyer, K; Mundhenke, C; Drew, SA; Friedl, A			Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; MOLECULAR-CLONING; FACTOR RECEPTOR-1; CARCINOMA CELLS; FGF RECEPTORS; TUMOR-GROWTH; IN-SITU; BINDING; ANGIOGENESIS; EXPRESSION	Fibroblast growth factor-2 (FGF2) is a potent angiogenic factor in gliomas. Heparan sulfate promotes ligand binding to receptor tyrosine kinase and regulates signaling. The goal of this study was to examine the contribution of heparan sulfate proteoglycans (HSPGs) to glioma angiogenesis. Here we show that all brain endothelial cell HSPGs carry heparan sulfate chains similarly capable of forming a ternary complex with FGF2 and fibroblast growth factor receptor-1c and of promoting a mitogenic. signal. Immunohistochemical analysis revealed that glypican-1 was overexpressed in glioma vessel endothelial cells, whereas this cell-surface HSPG was consistently undetectable in normal brain vessels. To determine the effect of increased glypican-1 expression on FGF2 signaling, we transfected normal brain endothelial cells, which express low base-line levels of glypican-1, with this proteoglycan. Glypican-1 expression enhanced growth of brain endothelial cells and sensitized them to FGF2-induced mitogenesis despite the fact that glypican-1 remained a minor proteoglycan. In contrast, overexpression of syndecan-1 had no effect on growth or FGF2 sensitivity. We conclude that the glypican-1 core protein has a specific role in FGF2 signaling. Glypican-1 overexpression may contribute to angiogenesis and the radiation resistance characteristic of this malignancy.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53562 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Clin Sci Ctr K4-850, Madison, WI 53562 USA.		Mundhenke, Christoph/D-2593-2010	Mundhenke, Christoph/0000-0002-6989-6250				ALBY L, 1984, P NATL ACAD SCI-BIOL, V81, P5739, DOI 10.1073/pnas.81.18.5739; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Friedl A, 2001, Methods Mol Biol, V171, P535; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GOTO F, 1993, LAB INVEST, V69, P508; Gualandris A, 1997, MICROVASC RES, V53, P254, DOI 10.1006/mvre.1996.1998; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; KITADAI Y, 1995, AM J PATHOL, V147, P1238; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; Kohl R, 2002, J BIOL CHEM, V277, P32760, DOI 10.1074/jbc.M204661200; Kumar R, 1998, ONCOL RES, V10, P301; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; LORIES V, 1992, J BIOL CHEM, V267, P1116; LORIES V, 1989, J BIOL CHEM, V264, P7009; Matsuda K, 2001, CANCER RES, V61, P5562; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 2001, GENOME BIOL; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Wu XC, 2001, CANCER RES, V61, P5295; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	42	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16045	16053		10.1074/jbc.M211259200	http://dx.doi.org/10.1074/jbc.M211259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591930	hybrid			2022-12-25	WOS:000182680000076
J	Bakovic, M; Waite, K; Vance, DE				Bakovic, M; Waite, K; Vance, DE			Oncogenic Ha-Ras transformation modulates the transcription of the CTP : Phosphocholine cytidylyltransferase alpha gene via p42/44(MAPK) and transcription factor Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PRO-INFLAMMATORY CYTOKINES; MESSENGER-RNA STABILITY; MAP-KINASE CASCADE; PHOSPHATIDYLCHOLINE METABOLISM; PHOSPHORYLATION SITES; CELL-CYCLE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE-2; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE	We have shown previously that expression of the murine CTP:phosphocholine cytidylyltransferase (CT) a gene is regulated during cell proliferation (Golfman, L. S., Bakovic, M., and Vance, D. E. (2001) J. Biol. Chem. 276, 43688-43692). We have now characterized the role of Ha-Ras in the transcriptional regulation of the CTalpha gene. The expression of CTalpha and CTbeta2 proteins and mRNAs was stimulated in C3H10T1/2 murine fibroblasts expressing oncogenic Ha-Ras. Incubation of cells with the specific inhibitor (PD98059) of p42/44 (MAPK) decreased the expression of both CT isoforms. Transfection of fibroblasts with CTalpha promoter-luciferase constructs resulted in an similar to2-fold enhanced luciferase expression in Ha-Ras-transformed, compared with nontransformed, fibroblasts. Electromobility shift assays indicated enhanced binding of the Sp3 transcription factor to the CTalpha promoter in Ha-Ras-transformed cells. Expression of several forms of Sp3 was increased in nuclear extracts of Ha-Ras-transformed fibroblasts compared with nontransformed cells. Tyrosine phosphorylation of one Sp3 form was decreased, whereas phosphorylation of two other forms of Sp3 was increased in nuclear extracts of Ha-Ras-transformed cells. When control fibroblasts were transfected with a Sp3-expressing plasmid, an enhanced expression of CTa and CTP was observed. However, the expression of CTalpha or CTbeta was not increased in Ha-Ras-transformed cells transfected with a Sp3 plasmid presumably because expression was already maximally enhanced. The results suggest that Sp3 is a downstream effector of a Ras/p42/44(MAPK) signaling pathway which increases CTalpha gene transcription.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Choi SB, 1997, MOL CELLS, V7, P58; Clement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643, DOI 10.1006/bbrc.1999.0512; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dhawan P, 1999, J LIPID RES, V40, P1911; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Geilen CC, 1996, BBA-LIPID LIPID MET, V1299, P299, DOI 10.1016/0005-2760(95)00221-9; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kast HR, 2001, J LIPID RES, V42, P1266; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kotzka J, 2000, J LIPID RES, V41, P99; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nishida I, 1996, PLANT MOL BIOL, V31, P205, DOI 10.1007/BF00021784; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; PERSENGIEV SP, 1995, P NATL ACAD SCI USA, V92, P9107, DOI 10.1073/pnas.92.20.9107; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; Ryan AJ, 2000, J LIPID RES, V41, P1268; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; SUGUIRA N, 2000, BIOCHEM J, V347, P155; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trevisi L, 2002, BIOCHEM PHARMACOL, V64, P425, DOI 10.1016/S0006-2952(02)01066-3; Tseu I, 2002, AM J RESP CELL MOL, V26, P506, DOI 10.1165/ajrcmb.26.4.4702; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; van Rossum GSAT, 2001, J BIOL CHEM, V276, P28976, DOI 10.1074/jbc.M101361200; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VISCARDI RM, 1994, LIFE SCI, V54, P1411, DOI 10.1016/0024-3205(94)00596-6; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200	88	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14753	14761		10.1074/jbc.M300162200	http://dx.doi.org/10.1074/jbc.M300162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584202	hybrid			2022-12-25	WOS:000182516100023
J	Gardner, AM; Olah, ME				Gardner, AM; Olah, ME			Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A(2A) adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLIOMA-CELLS; IN-VITRO; PERMEABILITY FACTOR; DOWN-REGULATION; INDUCED DIFFERENTIATION; HUMAN KERATINOCYTES; NERVE-TERMINALS; GENE-EXPRESSION; PKC-ZETA; ANGIOGENESIS	Vascular endothelial growth factor (VEGF) stimulates angiogenesis during development and in disease. In pheochromocytoma. (PC12) cells, VEGF expression is regulated by A(2A) adenosine receptor (A(2A)AR) activation. The present work examines the underlying signaling pathway. The adenylyl cyclase-protein kinase A cascade has no role in the down-regulation of VEGF mRNA induced by the A(2)AAR agonist, 2-[4-[(2-carboxyethyl)phenyllethyl-amino]-5'-N-ethylcarboxamidoadenosine (CGS21680). Conversely, 6-h exposure of cells to either phorbol 12-myristate 13-acetate (PMA) or protein kinase C (PKC) inhibitors mimicked the CGS21680-induced down-regulation. PMA activated PKCalpha, PKCepsilon, and PKCzeta, and CGS21680 activated PKCepsilon and PKCzeta as assessed by cellular translocation. By 6 h, PMA but not CGS21680 decreased PKCalpha and PKCepsilon expression. Neither compound affected PKCzeta levels. Following prolonged PMA treatment to down-regulate susceptible PKC isoforms, CGS21680 but not PMA inhibited the cobalt chloride induction of VEGF. mRNA. The proteasome inhibitor, MG-132, abolished PMA- but not CGS21680-induced downregulation of VEGF mRNA. Phorbol 12,13-diacetate reduced VEGF mRNA levels while down-regulating PKCepsilon but not PKCalpha expression. In cells expressing a dominant negative PKCC construct, CGS21680 was unable to reduce VEGF mRNA. Together, the findings suggest that phorbol ester-induced down-regulation of VEGF mRNA occurs as a result of a reduction of PKCepsilon activity, whereas that mediated by the A(2)AAR occurs following deactivation of PKC.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Olah, ME (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA.				NCI NIH HHS [R01 CA79531] Funding Source: Medline; NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; Arslan G, 1999, N-S ARCH PHARMACOL, V359, P28, DOI 10.1007/PL00005319; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Cunha RA, 2000, NEUROSCI LETT, V289, P127, DOI 10.1016/S0304-3940(00)01295-7; Cunha RA, 2000, NEUROPHARMACOLOGY, V39, P1156, DOI 10.1016/S0028-3908(99)00237-3; Deindl E, 1998, MOL CELL BIOCHEM, V186, P43, DOI 10.1023/A:1006853432678; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gille J, 2001, J INVEST DERMATOL, V117, P1581, DOI 10.1046/j.0022-202x.2001.01573.x; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Grant MB, 1999, CIRC RES, V85, P699, DOI 10.1161/01.RES.85.8.699; Gubitz AK, 1996, J NEUROCHEM, V67, P374; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; Huang HM, 1999, J NEUROSCI RES, V56, P668, DOI 10.1002/(SICI)1097-4547(19990615)56:6<668::AID-JNR13>3.3.CO;2-I; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawata H, 2001, CIRC RES, V88, P696, DOI 10.1161/hh0701.088842; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Kobayashi S, 1999, J BIOL CHEM, V274, P20358, DOI 10.1074/jbc.274.29.20358; Kotsonis P, 2001, BRIT J PHARMACOL, V132, P489, DOI 10.1038/sj.bjp.0703813; Lee HW, 1997, MOL PHARMACOL, V51, P439; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lohrer P, 2001, NEUROENDOCRINOLOGY, V74, P95, DOI 10.1159/000054675; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Mentlein R, 2001, INT J CANCER, V92, P545, DOI 10.1002/ijc.1223; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; Nagashima M, 2000, RHEUMATOLOGY, V39, P1255, DOI 10.1093/rheumatology/39.11.1255; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; Olah ME, 2000, J PHARMACOL EXP THER, V293, P779; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Redondo P, 2000, ARCH DERMATOL RES, V292, P621, DOI 10.1007/s004030000187; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Smith SK, 2001, TRENDS ENDOCRIN MET, V12, P147, DOI 10.1016/S1043-2760(01)00379-4; Sowter HM, 1997, LAB INVEST, V77, P607; Sparatore B, 2000, BIOCHEM BIOPH RES CO, V275, P149, DOI 10.1006/bbrc.2000.3258; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Volm M, 1997, ANTICANCER RES, V17, P99; Wakai A, 2001, SHOCK, V15, P297, DOI 10.1097/00024382-200115040-00008; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wilkinson-Berka JL, 2001, J VASC RES, V38, P527, DOI 10.1159/000051088; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	70	15	18	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15421	15428		10.1074/jbc.M208366200	http://dx.doi.org/10.1074/jbc.M208366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590138	hybrid			2022-12-25	WOS:000182516100108
J	Miller, M; Shuman, JD; Sebastian, T; Dauter, Z; Johnson, PF				Miller, M; Shuman, JD; Sebastian, T; Dauter, Z; Johnson, PF			Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; C/EBP-ALPHA; CRYSTAL-STRUCTURE; COMPLEX; IDENTIFICATION; DOMAIN; GCN4; GENE; GRANULOPOIESIS; ADIPOGENESIS	CCAAT/enhancer-binding proteins (C/EBPs) are basic region leucine zipper (bZIP) transcription factors that regulate cell differentiation, growth, survival, and inflammation. To understand the molecular basis of DNA recognition by the C/EBP family we determined the x-ray structure of a C/EBPalpha bZIP polypeptide bound to its cognate DNA site (A(-5)T(-4)T(-3)G(-2)C(-1)G(1)A(3)T(5)) and characterized several basic region mutants. Binding specificity is provided by interactions of basic region residues Arg(289), Asn(292), Ala(295), Val(296), Ser(299), and Arg(300) with DNA bases. A striking feature of the C/EBPalpha protein-DNA interface that distinguishes it from known 89 bZIP-DNA complexes is the central role of Are, which is hydrogen-bonded to base A(3), phosphate, Asn(292) (invariant in bZlPs), and Asn(293). The conformation of Arg(289) is also restricted by Tyr(285). In accordance with the structural model, mutation of Arg(289) or a pair of its interacting partners (Tyr(285) and Asn(293)) abolished C/EBPalpha binding activity. Val(296) (Ala in most other bZlPs) contributes to C/EBPalpha specificity by discriminating against purines at position -3 and imposing steric restraints on the invariant Arg(300). Mutating Val(296) to Ala strongly enhanced C/EBPalpha binding to cAMP response element (CRE) sites while retaining affinity for C/EBP sites. Thus, Arg(289) is essential for formation of the complementary protein-DNA interface, whereas Val(296) functions primarily to restrict interactions with related sequences such as CRE sites rather than specifying binding to C/EBP sites. Our studies also help to explain the phenotypes of mice carrying targeted mutations in the C/EBPalpha bZIP region.	NCI, Macromol Crystallog Lab, Prot Struct Sect, Frederick, MD 21702 USA; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA; Natl Canc Inst, Macromol Crystallog Lab, Synchrotron Radiat Res Sect, Upton, NY 11973 USA; Brookhaven Natl Lab, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Brookhaven National Laboratory	Miller, M (corresponding author), NCI, Macromol Crystallog Lab, Prot Struct Sect, Frederick, MD 21702 USA.		Miller, Maria/I-1636-2013; Johnson, Peter/A-1940-2012	Miller, Maria/0000-0003-0252-5348; Johnson, Peter/0000-0002-4145-4725; Shuman, Jon/0000-0001-8412-9087	NATIONAL CANCER INSTITUTE [Z01BC010328, ZIABC010328, Z01BC010378, ZIABC010378] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Falvey E, 1996, BIOL CHEM, V377, P797; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Fujii Y, 2000, NAT STRUCT BIOL, V7, P889; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; Osada S, 1996, J BIOL CHEM, V271, P3891; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tenen DG, 2001, LEUKEMIA, V15, P688, DOI 10.1038/sj.leu.2402088; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	40	110	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15178	15184		10.1074/jbc.M300417200	http://dx.doi.org/10.1074/jbc.M300417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578822	hybrid			2022-12-25	WOS:000182516100077
J	Yu, SW; Girotto, S; Lee, C; Magliozzo, RS				Yu, SW; Girotto, S; Lee, C; Magliozzo, RS			Reduced afflinity for isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE-PEROXIDASE KATG; SITE-DIRECTED MUTAGENESIS; DRUG-RESISTANCE; HALOARCULA-MARISMORTUI; MOLECULAR MECHANISMS; PURIFICATION; MUTATIONS; GENE; KATG(S315T); ACTIVATION	Catalase-peroxidase (KatG) from Mycobacterium tuberculosis is responsible for the activation of the antitubercular drug isonicotinic acid hydrazide (INH) and is important for survival of M. tuberculosis in macrophages. Characterization of the structure and catalytic mechanism of KatG is being pursued to provide insights into drug (INH) resistance in M. tuberculosis. Site-directed mutagenesis was used to prepare the INH-resistant mutant KatG[S315T], and the overexpressed enzyme was characterized and compared with wild-type KatG. KatG[S315T] exhibits a reduced tendency to form six-coordinate heme, because of coordination of water to iron during purification and storage, and also forms a highly unstable Compound III (oxyferrous enzyme). Catalase activity and peroxidase activity measured using, t-butylhydroperoxide and o-dianisidine were moderately reduced in the mutant compared with wild-type KatG. Stopped-flow spectrophotometric experiments revealed a rate of Compound I formation similar to wildtype KatG using peroxyacetic acid to initiate the catalytic cycle, but no Compound I was detected when bulkier peroxides (chloroperoxybenzoic acid, t-butylhydroperoxide) were used. The affinity of resting (ferric) KatG[S315T] for INH, measured using isothermal titration calorimetry, was greatly reduced compared with wild-type KatG, as were rates of reaction of Compound I with the drug. These observations reveal that although KatG[S315T] maintains reasonably good steady state catalytic rates, poor binding of the drug to the enzyme limits drug activation and brings about INH resistance.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Brooklyn, NY 11210 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.		Girotto, Stefania/F-5997-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CENDRIN F, 1994, BBA-PROTEIN STRUCT M, V1209, P1, DOI 10.1016/0167-4838(94)90129-5; Chouchane S, 2003, J BIOL CHEM, V278, P8154, DOI 10.1074/jbc.M208256200; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; Fraaije MW, 1996, EUR J BIOCHEM, V235, P192, DOI 10.1111/j.1432-1033.1996.00192.x; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1992, RES MICROBIOL, V143, P721, DOI 10.1016/0923-2508(92)90067-X; HICKS DB, 1995, BBA-BIOENERGETICS, V1229, P347, DOI 10.1016/0005-2728(95)00016-C; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Marttila HJ, 1998, ANTIMICROB AGENTS CH, V42, P2443, DOI 10.1128/AAC.42.9.2443; Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187, DOI 10.1128/AAC.40.9.2187; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Pym AS, 2002, INFECT IMMUN, V70, P4955, DOI 10.1128/IAI.70.9.4955-4960.2002; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; ROBITZEK EH, 1952, AM REV TUBERC PULM, V65, P402; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x; ROUSE DA, 1995, INFECT IMMUN, V63, P1427, DOI 10.1128/IAI.63.4.1427-1433.1995; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Saint-Joanis B, 1999, BIOCHEM J, V338, P753, DOI 10.1042/0264-6021:3380753; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Todorovic S, 1999, J AM CHEM SOC, V121, P10962, DOI 10.1021/ja9918674; van Soolingen D, 2000, J INFECT DIS, V182, P1788, DOI 10.1086/317598; Victor TC, 1996, ANTIMICROB AGENTS CH, V40, P1572, DOI 10.1128/AAC.40.6.1572; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Wengenack NL, 1997, J INFECT DIS, V176, P722, DOI 10.1086/514096; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; *WHO, 2002, 104 WHO; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	47	71	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14769	14775		10.1074/jbc.M300326200	http://dx.doi.org/10.1074/jbc.M300326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586821	hybrid			2022-12-25	WOS:000182516100025
J	Kim, KH; Min, YK; Baik, JH; Lau, LF; Chaqour, B; Chung, KC				Kim, KH; Min, YK; Baik, JH; Lau, LF; Chaqour, B; Chung, KC			Expression of angiogenic factor cyr61 during neuronal cell death via the activation of c-Jun N-terminal kinase and serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; SIGNAL-TRANSDUCTION; CCN FAMILY; APOPTOSIS; PRODUCT; JNK; PROLIFERATION; DIFFERENTIATION; CHONDROGENESIS; SURVIVAL	The immediate early gene, cyr61, is transcriptionally activated within minutes by serum and serum growth factors. The encoded Cyr61 protein is secreted into the extracellular matrix and promotes cell adhesion and migration. In this study, we sought to examine the expression profile of cyr61 gene during neuronal cell death induced by various toxic stimuli and the mechanisms involved. Our data show that toxic stimuli, such as etoposide, significantly increased cyr61 mRNA levels in immortalized hippocampal progenitor (H19-7) cells. Cyr61 transcriptional activation was corroborated at the protein level as well. To identify the upstream signaling cascades involved in cyr61 gene induction, the blocking effect of either JNK or p38 kinase-signaling pathway on cyr61 induction in response to etoposide was tested. Transfection of the cells with a kinase-deficient mutant MEKK, an upstream activator of JNK, significantly decreased the cyr61 expression induced by etoposide. In contrast, cyr61 mRNA levels did not change after pretreatment with SB203580, the p38 kinase inhibitor. When the induction of cyr61 was tested by using several of its deleted promoters driving the expression of reporter gene, the promoter activation occurred primarily within the region containing an SRE-like CArG box. In addition, the SRF, which binds to the CArG site, was directly phosphorylated by active JNK. Furthermore, the blockade of cyr61 gene expression using an antisense encoding cyr61 sequence significantly inhibited the cell death induced by etoposide. Overall, these results suggest that the induction of the immediate early gene, cyr61, is important for neuronal cell death in the central nervous system hippocampal progenitor cells, and JNR activation, but not of p38, as well as the subsequent SRF phosphorylation are involved in cyr61 gene induction.	Yonsei Univ, Coll Sci, Dept Biol, Seodaemun Gu, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seodaemun Gu, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seodaemun Gu, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Mol Biol Lab, Med Res Ctr,Seodaemun Gu, Seoul 120749, South Korea; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pennsylvania	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Seodaemun Gu, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr	Chaqour, Brahim/AEH-1314-2022	Chaqour, Brahim/0000-0002-8516-4324; Lau, Lester/0000-0002-4364-2914	NIDDK NIH HHS [R01 DK060572-03, R01 DK060572, R01 DK-60572] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Chung KC, 1998, NEUROSCI LETT, V255, P155, DOI 10.1016/S0304-3940(98)00733-2; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Fluck M, 2000, BIOCHEM BIOPH RES CO, V270, P488, DOI 10.1006/bbrc.2000.2457; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LYONS AB, 1992, CYTOMETRY, V13, P809; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Tamura I, 2001, AM J PHYSIOL-CELL PH, V281, pC1524, DOI 10.1152/ajpcell.2001.281.5.C1524; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	45	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13847	13854		10.1074/jbc.M210128200	http://dx.doi.org/10.1074/jbc.M210128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576482	hybrid			2022-12-25	WOS:000182405000037
J	Yu, H; Stasinopoulos, S; Leedman, P; Medcalf, RL				Yu, H; Stasinopoulos, S; Leedman, P; Medcalf, RL			Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RNA-BINDING PROTEIN; CONTAINING MESSENGER-RNAS; ALPHA-INDUCED APOPTOSIS; 3' UNTRANSLATED REGION; YEAST 3-HYBRID SYSTEM; PHORBOL ESTER; GENE PROMOTER; TRANSCRIPTION FACTOR; RICH ELEMENTS	Plasminogen activator inhibitor type 2 (PAI-2) is a serine protease inhibitor that is subject to regulation at the post-transcriptional level. At least two mRNA instability elements reside within the PAI-2 transcript; one in the coding region and another within the 3'-untranslated region (UTR). For the latter, a functional AU-rich motif (ARE) has been identified that provides a binding site for a number of cellular proteins, including the mRNA stability protein, HuR. In this study, we used the yeast three-hybrid system to screen a human leukocyte cDNA library to identify other proteins that associate with the PAI-2 ARE. This screen identified tristetraprolin (TTP) as a PAI-2 mRNA ARE-binding protein. UV cross-linking and immunoprecipitation experiments showed that TTP expressed in HEK293 cells could associate with the PAI-2 ARE in vitro. Co-transfection of plasmids expressing TTP and PAI-2 in HEK293 cells resulted in an increase in the decay rate of PAI-2 mRNA and loss of PAI-2 protein in a process that was dependent upon the PAI-2 3'-UTR. The 29-nt PAI-2 AU-rich element alone was also capable of conferring TTP-dependent mRNA instability to a reporter transcript. The extent of PAI-2 mRNA stability was remarkably sensitive to TTP since TTP-dependent PAI-2 mRNA decay occurred at TTP levels that were below Western blot detection limits. This study identifies TTP as a functional PAI-2 ARE-binding protein that modulates the post-transcriptional regulation of the PAI-2 gene.	Monash Univ, Box Hill Hosp, Dept Med, Box Hill, Vic 3128, Australia; Univ Western Australia, Western Australian Inst Med Res, Sch Med & Pharmacol,Ctr Med Res, Royal Perth Hosp Unit,Lab Canc Med, Perth, WA 6000, Australia	Box Hill Hospital; Monash University; Royal Perth Hospital; University of Western Australia	Medcalf, RL (corresponding author), Monash Univ, Box Hill Hosp, Dept Med, Box Hill, Vic 3128, Australia.	Robert.Medcalf@med.monash.edu.au	Leedman, Peter J/O-4044-2014; Medcalf, Robert L/E-9632-2011					BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costa M, 1996, EUR J BIOCHEM, V237, P532, DOI 10.1111/j.1432-1033.1996.00532.x; Costa M, 1998, EUR J BIOCHEM, V258, P123, DOI 10.1046/j.1432-1327.1998.2580123.x; Dear AE, 1997, FEBS LETT, V402, P265, DOI 10.1016/S0014-5793(97)00002-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; Hibino T, 1999, J INVEST DERMATOL, V112, P85, DOI 10.1046/j.1523-1747.1999.00466.x; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; MA QF, 1991, ONCOGENE, V6, P1277; Mahony D, 1998, EUR J BIOCHEM, V256, P550, DOI 10.1046/j.1432-1327.1998.2560550.x; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; Maurer F, 1996, J BIOL CHEM, V271, P26074, DOI 10.1074/jbc.271.42.26074; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MEDCALF RL, 1988, J EXP MED, V168, P751, DOI 10.1084/jem.168.2.751; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; Park YW, 1999, BIOTECHNIQUES, V26, P1102, DOI 10.2144/99266st01; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SCHWARTZ BS, 1989, BLOOD, V73, P2188; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shafren DR, 1999, J VIROL, V73, P7193, DOI 10.1128/JVI.73.9.7193-7198.1999; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Snee M, 2002, J CELL SCI, V115, P4661, DOI 10.1242/jcs.00137; Tierney MJ, 2001, J BIOL CHEM, V276, P13675, DOI 10.1074/jbc.M010627200; VARNUM BC, 1989, ONCOGENE, V4, P119; Yu H, 2002, BLOOD, V99, P2810, DOI 10.1182/blood.V99.8.2810; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	49	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13912	13918		10.1074/jbc.M213027200	http://dx.doi.org/10.1074/jbc.M213027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578825	hybrid			2022-12-25	WOS:000182405000046
J	Condliffe, SB; Carattino, MD; Frizzell, RA; Zhang, H				Condliffe, SB; Carattino, MD; Frizzell, RA; Zhang, H			Syntaxin 1A regulates ENaC via domain-specific interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; SODIUM-CHANNEL; CRYSTAL-STRUCTURE; LIDDLES SYNDROME; COMPLEX; TRAFFICKING; MUTATIONS; INHIBITION; EXOCYTOSIS; EXPRESSION	The epithelial sodium channel (ENaC) is a heterotrimeric protein responsible for Na+ absorption across the apical membranes of several absorptive epithelia. The rate of Na+ absorption is governed in part by regulated membrane trafficking mechanisms that control the apical membrane ENaC density. Previous reports have implicated a role for the t-SNARE protein, syntaxin 1A (S1A), in the regulation of ENaC current (I-Na). In the present study, we examine the structure-function relations influencing S1A-ENaC interactions. In vitro pull-down assays demonstrated that S1A directly interacts with the C termini of the alpha-, beta-, and gamma-ENaC subunits but not with the N terminus of any ENaC subunit. The H3 domain of S1A is the critical motif mediating S1A-ENaC binding. Functional studies in ENaC expressing Xenopus oocytes revealed that deletion of the H3 domain of co-expressed S1A eliminated its inhibition of I-Na, and acute injection of a GST-H3 fusion protein into ENaC expressing oocytes inhibited I-Na to the same extent as S1A co-expression. In cell surface ENaC labeling experiments, reductions in plasma membrane ENaC accounted for the H3 domain inhibition Of I-Na. Individually substituting C terminus-truncated alpha-, beta-, or gamma-ENaC subunits for their wild-type counterparts reversed the S1A-induced inhibition of I-Na, and oocytes expressing ENaC comprised of three C terminus-truncated subunits showed no S1A inhibition Of I-Na. C terminus truncation or disruption of the C terminus beta-subunit PY motif increases I-Na by interfering with ENaC endocytosis. In contrast to subunit truncation, a beta-ENaC PY mutation did not relieve S1A inhibition of I-Na, suggesting that S1A does not perturb Nedd4 interactions that lead to ENaC endocytosis/degradation. This study provides support for the concept that S1A inhibits ENaC-mediated Na+ transport by decreasing cell surface channel number via direct protein-protein interactions at the ENaC C termini.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	frizzell@pitt.edu; Zhangh@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54814] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Betz A, 1997, J BIOL CHEM, V272, P2520; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rettig J, 1997, J NEUROSCI, V17, P6647; Rotin D, 2000, CURR OPIN NEPHROL HY, V9, P529, DOI 10.1097/00041552-200009000-00012; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang H, 2002, J BIOL CHEM, V277, P28948, DOI 10.1074/jbc.M111706200	40	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12796	12804		10.1074/jbc.M210772200	http://dx.doi.org/10.1074/jbc.M210772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562778	hybrid			2022-12-25	WOS:000182189500028
J	Afaq, F; Adhami, VM; Ahmad, N; Mukhtar, H				Afaq, F; Adhami, VM; Ahmad, N; Mukhtar, H			Inhibition of ultraviolet B-mediated activation of nuclear factor kappa B in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate	ONCOGENE			English	Article						photochemopreventive; EGCG; NF-kappa B; NHEK; UVB	HUMAN SKIN; MOUSE SKIN; TRANSCRIPTION FACTOR; PYRIMIDINE DIMERS; IN-VITRO; CANCER; RADIATION; LIGHT; PROTEIN; KINASE	Epigallocatechin-3-gallate (EGCG), the major constituent of green tea, possesses significant anti-inflammatory and cancer chemopreventive properties. Studies have shown the photochemopreventive effects of green tea and EGCG in cell culture, animal models, and human skin. The molecular mechanism(s) of photochemopreventive effects of EGCG are incompletely understood. We recently showed that EGCG treatment of the normal human epidermal keratinocytes (NHEK) inhibits ultraviolet (UV)B-mediated activation of the mitogen-activated protein kinase (MAPK) pathway. In this study, we evaluated the effect of EGCG on UVB-mediated modulation of the nuclear factor kappa B (NF-kappaB) pathway, which is known to play a critical role in a variety of physiological functions and is involved in inflammation and development of cancer. Immunoblot analysis demonstrated that the treatment of NHEK with EGCG (10-40 mum) for 24 h resulted in a significant inhibition of UVB (40mJ/cm(2))-mediated degradation and phosphorylation of IkappaBalpha and activation of IKKalpha, in a dose-dependent manner. UVB-mediated degradation and phosphorylation of IkappaBalpha and activation of IKKalpha was also observed in a time-dependent protocol (15 and 30min, 1, 2, 3, 6, 12h post-UVB exposure). Employing immunoblot analysis, enzyme-linked immunosorbent assay, and gel shift assay, we demonstrate that EGCG treatment of the cells resulted in a significant dose- and time-dependent inhibition of UVB-mediated activation and nuclear translocation of a NF-kappaB/p65. Our data suggest that EGCG protects against the adverse effects of UV radiation via modulations in NF-kappaB pathway, and provide a molecular basis for the photochemopreventive effect of EGCG.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Room B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Adhami, Vaqar/AAY-2837-2020	Adhami, Vaqar/0000-0002-2048-4570				Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; Afaq F, 2001, J PHOTOCH PHOTOBIO B, V63, P61, DOI 10.1016/S1011-1344(01)00217-2; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 2001, SKIN PHARMACOL APPL, V14, P69, DOI 10.1159/000056336; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLOCK G, 1993, J NATL CANCER I, V85, P846, DOI 10.1093/jnci/85.11.846; Breuer-McHam J, 2001, PHOTOCHEM PHOTOBIOL, V74, P805, DOI 10.1562/0031-8655(2001)074&lt;0805:AOHIHS&gt;2.0.CO;2; Burren R, 1998, INT J CANCER, V76, P201, DOI 10.1002/(SICI)1097-0215(19980413)76:2<201::AID-IJC6>3.0.CO;2-0; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GoihmanYahr M, 1996, CLIN DERMATOL, V14, P153, DOI 10.1016/0738-081X(95)00150-E; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Helenius M, 1999, EXP CELL RES, V248, P194, DOI 10.1006/excr.1999.4393; Hong JT, 2001, MOL CARCINOGEN, V31, P152, DOI 10.1002/mc.1050; Ikeda M, 2002, J DERMATOL SCI, V28, P159, DOI 10.1016/S0923-1811(01)00164-5; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Katiyar SK, 2000, CLIN CANCER RES, V6, P3864; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Katiyar SK, 1997, CARCINOGENESIS, V18, P497, DOI 10.1093/carcin/18.3.497; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kim J, 2001, SKIN PHARMACOL APPL, V14, P11, DOI 10.1159/000056329; KLIGMAN LH, 1980, J AM ACAD DERMATOL, V3, P30, DOI 10.1016/S0190-9622(80)80221-0; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIPKE ML, 1992, P NATL ACAD SCI USA, V89, P7516, DOI 10.1073/pnas.89.16.7516; Lefort K, 2001, ONCOGENE, V20, P7375, DOI 10.1038/sj.onc.1204923; Legrand-Poels S, 1998, J PHOTOCH PHOTOBIO B, V45, P1, DOI 10.1016/S1011-1344(98)00118-3; Lu YP, 2000, CANCER RES, V60, P4785; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Pfundt R, 2001, J PATHOL, V193, P248; Rice-Evans C, 1999, P SOC EXP BIOL MED, V220, P262, DOI 10.1046/j.1525-1373.1999.d01-45.x; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Saliou C, 1999, FREE RADICAL BIO MED, V26, P174, DOI 10.1016/S0891-5849(98)00212-3; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VILE GF, 1995, PHOTOCHEM PHOTOBIOL, V62, P463, DOI 10.1111/j.1751-1097.1995.tb02369.x; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334	64	179	193	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1035	1044		10.1038/sj.onc.1206206	http://dx.doi.org/10.1038/sj.onc.1206206			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592390				2022-12-25	WOS:000180926100009
J	Dong, S; Qiu, JH; Stenoien, DL; Brinkley, WR; Mancini, MA; Tweardy, DJ				Dong, S; Qiu, JH; Stenoien, DL; Brinkley, WR; Mancini, MA; Tweardy, DJ			Essential role for the dimerization domain of NuMA-RAR alpha in its oncogenic activities and localization to NuMA sites within the nucleus	ONCOGENE			English	Article						NuMA-RAR alpha; dimerization domain; coiled-coil domain; acute promyclocytic leukemia	ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTORS; FUSION; PROTEINS; TRANSLOCATION; HOMODIMERS; GENE	Nuclear mitotic apparatus protein-retinoic acid receptor alpha (NuMA-RARalpha) is the fourth of five fusion proteins identified in acute promyelocytic leukemia (APL) patients. The molecular basis for its oncogenic activity has not been delineated. In gel-shift assays, NuMA-RARalpha bound to retinoic acid response elements (RAREs) both as a homodimer and as a heterodimer with RXRalpha. The binding profile of NuMA-RARalpha to a panel of RAREs was very similar to PML-RARalpha and PLZF-RARalpha. In transient transfection assays using HepG2 cells, NuMA-RARalpha inhibited wild-type RARalpha transcriptional activity, while it augmented STAT3 transcriptional activity. In GST-pull down experiments, NuMA-RARalpha formed a complex with the corepressor SMRT, was released from the NuMA-RARalpha/SMRT complexes by all-trans retinoic acid (ATRA) at 10(-7)-10(-6) (M) and became associated with the coactivator TRAM-1 at 10(-8) (M) ATRA. Studies comparing NuMA-RARalpha with NuMA-RARalpha(DeltaCC) demonstrated that the dimerization or alpha-helical coiled-coil domain of NuMA was required for homodimer formation, transcriptional repression of wild-type RARalpha, transcriptional activation of STAT3, and stability of the NuMA-RARalpha/SMRT complex. Confocal fluorescent microscopy of HeLa cells was performed following transient expression of cyan fluorescent protein (CFP)-tagged proteins and incubation of cells with or without ATRA. Within the nucleus, CFP-NuMA-RARalpha exhibited a speckled pattern identical to that observed in cells transfected with CFP-NuMA. Furthermore, CFP-NuMA-RARalpha colocalized with yellow fluorescent protein-tagged (YFP)-NuMA. In contrast, CFP-NuMA-RARalpha(DeltaCC) exhibited a diffuse granular pattern within the nucleus, similar to RARalpha. These results indicate that the dimerization domain of NuMA-RARalpha is critical for each of the known oncogenic activities of NuMA fusion proteins as well as its sequestration to nuclear sites normally occupied by NuMA and is distinct from RARalpha.	Baylor Coll Med, Infect Dis Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Tweardy, DJ (corresponding author), Baylor Coll Med, Infect Dis Sect, Dept Med, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA.		Tweardy, David/L-3929-2019					Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Kawasaki A, 2000, BLOOD, V96, p684A; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Xia Z, 1998, CANCER RES, V58, P3173; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	20	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					858	868		10.1038/sj.onc.1206182	http://dx.doi.org/10.1038/sj.onc.1206182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584566				2022-12-25	WOS:000180864300009
J	Fayos, R; Melacini, G; Newlon, MG; Burns, L; Scott, JD; Jennings, PA				Fayos, R; Melacini, G; Newlon, MG; Burns, L; Scott, JD; Jennings, PA			Induction of flexibility through protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; GROUP HYDROGEN-EXCHANGE; REGULATORY SUBUNIT RII; AMIDE PROTON-EXCHANGE; BACKBONE DYNAMICS; A-KINASE; LIGAND-BINDING; ANCHORING PROTEINS; ROTATIONAL DIFFUSION; DOMAIN	The (d) under bar imerization/(d) under bar ocking (D/D) domain of the cyclic AMP-dependent protein kinase (PKA) holoenzyme mediates important protein-protein interactions that direct the subcellular localization of the enzyme. (A) under bar (k) under bar inase (a) under bar nchoring (p) under bar roteins (AKAPs) provide the molecular scaffold for the localization of PKA. The recent solution structures of two D/D AKAP complexes revealed that the AKAP binds to a surface-exposed, hydrophobic groove on the D/D. In the present study, we present an analysis of the changes in hydrogen/deuterium exchange protection and internal motions of the backbone of the D/D when free and bound to the prototype anchoring protein, Ht31(pep). We observe that formation of the complex results in significant, but small, increases in H/D exchange protection factors as well as increases in backbone flexibility, throughout the D/D, and in particular, in the hydrophobic binding groove. This unusual observation of increased backbone flexibility and marginal H/D exchange protection, despite high affinity protein-ligand interactions, may be a general effect observed for the stabilization of hydrophobic ligand/hydrophobic pocket interactions.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; Oregon Health & Science University	Jennings, PA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKKE M, 1993, BIOCHEMISTRY-US, V32, P9832, DOI 10.1021/bi00088a039; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Baxter NJ, 1998, J MOL BIOL, V284, P1625, DOI 10.1006/jmbi.1998.2265; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; Cavanagh J, 2000, NAT STRUCT BIOL, V7, P11, DOI 10.1038/71202; CLARKE J, 1993, P NATL ACAD SCI USA, V90, P9837, DOI 10.1073/pnas.90.21.9837; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Favier A, 2002, J MOL BIOL, V317, P131, DOI 10.1006/jmbi.2002.5397; Fischer MWF, 1998, PROG NUCL MAG RES SP, V33, P207, DOI 10.1016/S0079-6565(98)00023-5; Forman-Kay JD, 1999, NAT STRUCT BIOL, V6, P1086, DOI 10.1038/70008; Ghaemmaghami S, 2000, P NATL ACAD SCI USA, V97, P8296, DOI 10.1073/pnas.140111397; Glover KJ, 2001, BIOCHEMISTRY-US, V40, P13137, DOI 10.1021/bi011485m; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; Hilser VJ, 1998, P NATL ACAD SCI USA, V95, P9903, DOI 10.1073/pnas.95.17.9903; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huster D, 1999, J AM CHEM SOC, V121, P1992, DOI 10.1021/ja9838413; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Li F, 2002, J MOL BIOL, V315, P459, DOI 10.1006/jmbi.2001.5256; Lillemoen J, 1997, J MOL BIOL, V268, P482, DOI 10.1006/jmbi.1997.0982; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lu JY, 1999, J MOL BIOL, V286, P1179, DOI 10.1006/jmbi.1999.2544; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8576, DOI 10.1021/bi00027a007; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; OHKI S, 1991, J BIOCHEM-TOKYO, V109, P234; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Pan H, 2000, P NATL ACAD SCI USA, V97, P12020, DOI 10.1073/pnas.220240297; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Powell KD, 2002, J AM CHEM SOC, V124, P10256, DOI 10.1021/ja026574g; SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P16036, DOI 10.1021/bi961834q; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Vijayaraghavan S, 1999, MOL ENDOCRINOL, V13, P705, DOI 10.1210/me.13.5.705; Wang GS, 2000, J BIOL CHEM, V275, P16401, DOI 10.1074/jbc.C000167200; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Yu LP, 1996, BIOCHEMISTRY-US, V35, P9661, DOI 10.1021/bi960507f; Yun SG, 2001, BIOCHEMISTRY-US, V40, P3967, DOI 10.1021/bi0023192; Zidek L, 1999, NAT STRUCT BIOL, V6, P1118	59	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18581	18587		10.1074/jbc.M300866200	http://dx.doi.org/10.1074/jbc.M300866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604595	hybrid			2022-12-25	WOS:000182838300130
J	Reigstad, LJ; Sande, HM; Fluge, O; Bruland, O; Muga, A; Varhaug, JE; Martinez, A; Lillehaug, JR				Reigstad, LJ; Sande, HM; Fluge, O; Bruland, O; Muga, A; Varhaug, JE; Martinez, A; Lillehaug, JR			Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ELECTROPHORETIC TRANSFER; INFRARED-SPECTROSCOPY; POLYACRYLAMIDE GELS; DISULFIDE LINKAGES; RECEPTOR-BINDING; ALPHA-RECEPTOR; BETA-RECEPTOR; TUMOR-CELLS; FACTOR-BB	Platelet-derived growth factor (PDGF)-C is a novel member of the PDGF family that binds to PDGF alphaalpha and alphabeta receptors. The growth factor domain of PDGF-C (GFD-PDGF-C) was expressed in high yields in Escherichia coli and was purified and refolded from inclusion bodies obtaining a biologically active growth factor with dimeric structure. The GFD-PDGF-C contains 12 cysteine residues, and Ellman assay analysis indicates that it contains three intramonomeric disulfide bonds, which is in accordance with GFD-PDGF-C being a member of the cystine knot superfamily of growth factors. The recombinant GFD-PDGF-C was characterized by CD, fluorescence, NMR, and infrared spectroscopy. Together, our data indicate that GFD-PDGF-C is a highly thermostable protein that contains mostly beta-sheet secondary structure and some (6%) alpha-helix structure. The structural model of PDGF-C, obtained by homology-based molecular modeling using the structural representatives of this family of growth factors, shows that GFD-PDGF-C has a higher structural homology to the vascular endothelial growth factor than to PDGF-B. The modeled structure can give further insights into the function and specificity of this molecule.	Univ Bergen, Dept Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Dept Pediat, N-5009 Bergen, Norway; Univ Bergen, Dept Surg, N-5009 Bergen, Norway; Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Basque Country, CSIC UPV EHU, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain	University of Bergen; University of Bergen; University of Bergen; University of Bergen; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Lillehaug, JR (corresponding author), Univ Bergen, HIB, Dept Mol Biol, Thormohlensgate 55, N-5020 Bergen, Norway.	johan.lillehaug@mbi.uib.no	Muga, Arturo/N-1174-2014; Martinez, Aurora/M-3088-2019	Muga, Arturo/0000-0003-0345-6882; Martinez, Aurora/0000-0003-1643-6506				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chehin R, 1999, BIOCHEMISTRY-US, V38, P1525, DOI 10.1021/bi981567j; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; Dijkmans J, 2002, INT J BIOCHEM CELL B, V34, P414, DOI 10.1016/S1357-2725(01)00124-8; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLUGE O, 2000, P AM ASSOC CANC RES, V41, P862; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GOODMAN SL, 1985, EMBO J, V4, P2769, DOI 10.1002/j.1460-2075.1985.tb04002.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HANIU M, 1994, ARCH BIOCHEM BIOPHYS, V310, P433, DOI 10.1006/abbi.1994.1189; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Iyer S, 2002, TRENDS CARDIOVAS MED, V12, P128, DOI 10.1016/S1050-1738(01)00164-5; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Khurana R, 2000, BIOPHYS J, V78, P994, DOI 10.1016/S0006-3495(00)76657-4; KINI RM, 1995, BIOCHEM BIOPH RES CO, V212, P1115, DOI 10.1006/bbrc.1995.2084; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Larrivee B, 2000, INT J MOL MED, V5, P447; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; MALE R, 1985, CARCINOGENESIS, V6, P1367, DOI 10.1093/carcin/6.9.1367; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wiesmann C, 2000, J MOL MED, V78, P247, DOI 10.1007/s001090000082; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WOODY RW, 1996, CIRCULAR DICHROISM C, P112; Zwerner JP, 2002, ONCOGENE, V21, P3847, DOI 10.1038/sj.onc.1205486	48	27	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17114	17120		10.1074/jbc.M301728200	http://dx.doi.org/10.1074/jbc.M301728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598536	hybrid			2022-12-25	WOS:000182818600090
J	Anestal, K; Arner, ESJ				Anestal, K; Arner, ESJ			Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; GENE-EXPRESSION; GLUTATHIONE-REDUCTASE; INSERTION-SEQUENCE; REDOX REGULATION; HUMAN PLACENTA; CYTOCHROME-C; INTERFERON; APOPTOSIS; MECHANISM	Mammalian thioredoxin reductases are selenoproteins. For native catalytic activity, these enzymes utilize a C-terminal -Gly-Cys-Sec-Gly-COOH sequence (where Sec is selenocysteine) forming a redox active selenenyl-sulfide/selenolthiol motif. A range of cellular systems depend upon or are regulated by thioredoxin reductase and its major protein substrate thioredoxin, including apoptosis signal-regulating kinase 1, peroxiredoxins, methionine sulfoxide reductase, and several transcription factors. Cytosolic thioredoxin reductase 1 (TrxR1) is moreover inhibited by various electrophilic anticancer compounds. TrxR1 is hence generally considered to promote cell viability. However, several recent studies have suggested that TrxR1 may promote apoptosis, and the enzyme was identified as GRIM-12 (gene associated with retinoid interferon-induced mortality 12). Transient transfection with GRIM-12/TrxR1 was also shown to directly, induce cell death. To further analyze such effects, we have here employed lipid-mediated delivery of recombinant TrxR1 preparations into human A549 cells, thereby bypassing selenoprotein translation to facilitate assessment of the protein-related effects on cell viability. We found that selenium-deficient TrxR1, having a two-amino acid-truncated C-terminal -Gly-Cys-COOH motif, rapidly induced cell death (38 +/- 29% apoptotic cells after 4 h; p < 0.005 compared with controls). Cell death induction was also promoted by selenium-compromised TrxR1 derivatized with either cis-diam-minedichloroplatinum (H) (cisplatin) or dinitrophenyl moieties but not by the structurally related non-selenoprotein glutathione reductase. In contrast, TrxR1 with intact selenocysteine could not promote cell death. The direct cellular effects of selenium-compromised forms of TrxR1 may be important for the pathophysiology of selenium deficiency as well as for the efficacy of antipro-liferative drugs targeting the selenocysteine moiety of this enzyme.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Arner, ESJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.	Elias.Arner@mbb.ki.se	Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Berggren M, 1996, ANTICANCER RES, V16, P3459; BROT N, 1991, BIOFACTORS, V3, P91; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chang SH, 2000, AM J PATHOL, V156, P637, DOI 10.1016/S0002-9440(10)64768-2; Fujiwara N, 1999, BIOCHEM J, V340, P439, DOI 10.1042/0264-6021:3400439; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gilmore KJ, 2001, CELL DEATH DIFFER, V8, P631, DOI 10.1038/sj.cdd.4400858; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lindner DJ, 2002, CLIN CANCER RES, V8, P3210; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1613, DOI 10.1016/0006-2952(92)90220-D; MAU BL, 1992, BIOCHEM PHARMACOL, V43, P1621; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Yarimizu J, 2000, ANTIOXID REDOX SIGN, V2, P643, DOI 10.1089/ars.2000.2.4-643; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	48	133	141	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15966	15972		10.1074/jbc.M210733200	http://dx.doi.org/10.1074/jbc.M210733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12574159	hybrid			2022-12-25	WOS:000182680000066
J	Dunckley, T; Lukas, RJ				Dunckley, T; Lukas, RJ			Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PATHWAY INHIBITOR-2; PROTEIN-KINASE PATHWAY; ACETYLCHOLINE-RECEPTOR; INDUCED CONVULSIONS; CONTACTIN FORM; COMPLEX; IDENTIFICATION; INVASIVENESS; ACTIVATION; MOLECULES	Nicotine exposure can have long lasting effects on nervous system function, some of which must contribute to nicotine dependence. Up-regulation, an increase in numbers of radioligand-binding nicotinic acetylcholine receptors (nAChR), occurs on exposure to nicotine at high concentrations. To determine whether altered gene expression might account for long term changes and up-regulation following nicotine exposure, we assessed effects of 1 h of 1 mm nicotine exposure on alteration of gene expression in the neuron-like SH-SY5Y neuroblastoma clonal line. Repeat and cross-controlled microarray analyses yielded a list of 17 genes from the initially screened similar to5,000 whose expression was consistently altered following nicotine treatment. Subsequent quantitative, real time reverse transcriptase PCR analyses confirmed altered expression in 14 of 16 genes tested. Further, the general nAChR antagonist, d-tubocurarine, blocked all but two of the observed changes in gene expression, indicating that these changes are dependent on nAChR activation. Use of other antagonists revealed that nAChR subtypes can differentially affect gene expression. The genes affected code for proteins that may be broadly categorized into four groups: transcription factors, protein processing factors, RNA-binding proteins, and plasma membrane-associated proteins. Our results suggest that nicotinic activation of nAChR may have a broad role in affecting cellular physiology through modulating gene expression.	Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA	Barrow Neurological Institute	Lukas, RJ (corresponding author), Barrow Neurol Inst, Div Neurobiol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	rlukas@chw.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040417] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 40417] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER WW, 1967, P SOC EXP BIOL MED, V124, P607; BELESLIN DB, 1986, PHARMACOL BIOCHEM BE, V24, P1509, DOI 10.1016/0091-3057(86)90476-4; CARR LA, 1989, NEUROCHEM RES, V14, P511, DOI 10.1007/BF00964911; CAULFIELD MP, 1983, NEUROPHARMACOLOGY, V22, P347, DOI 10.1016/0028-3908(83)90251-4; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; Donnelly-Roberts DL, 1999, NEURONAL NICOTINIC R, P337; FONTANA A, 1978, BIOCH MYASTHENIA GRA; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Heidebrecht HJ, 2000, GENOMICS, V68, P348, DOI 10.1006/geno.2000.6301; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Ichino N, 2002, J NEURAL TRANSM, V109, P1015, DOI 10.1007/s007020200084; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Kane JK, 2000, ENDOCRINOLOGY, V141, P3623, DOI 10.1210/en.141.10.3623; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; Kleines M, 2001, GENE, V275, P157, DOI 10.1016/S0378-1119(01)00620-5; Konduri SD, 2001, INT J ONCOL, V18, P127; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; Levin ED, 1998, PSYCHOPHARMACOLOGY, V138, P217, DOI 10.1007/s002130050667; Li MD, 2000, BRAIN RES, V867, P157, DOI 10.1016/S0006-8993(00)02283-6; Liu CJ, 2001, J BIOL CHEM, V276, P46553, DOI 10.1074/jbc.M108699200; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; Meagher MJ, 2001, MOL CELL BIOL, V21, P2880, DOI 10.1128/MCB.21.8.2880-2890.2001; MINER LL, 1985, LIFE SCI, V37, P75, DOI 10.1016/0024-3205(85)90628-9; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Nisell M, 1997, NEUROPSYCHOPHARMACOL, V17, P151, DOI 10.1016/S0893-133X(97)00040-7; Papke RL, 2001, J PHARMACOL EXP THER, V297, P646; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PENG X, 1994, MOL PHARMACOL, V45, P546; Pich EM, 1997, SCIENCE, V275, P83; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rasmussen R., 1998, BIOCHIMICA, V2, P8; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; *ROCH BIOCH, 2000, LIGHTC OP MAN VERS 3; Schinzel A, 2001, AM J MED GENET, V106, P119, DOI 10.1002/ajmg.1576; Shim IS, 2000, J ETHNOPHARMACOL, V70, P161, DOI 10.1016/S0378-8741(99)00166-X; SILVETTE H, 1962, PHARMACOL REV, V14, P137; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; Torres G, 1999, PSYCHOSOM MED, V61, P630, DOI 10.1097/00006842-199909000-00007; Wang J, 2001, ACTA PHARMACOL SIN, V22, P685; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang SL, 2001, PHYSIOL GENOMICS, V5, P187, DOI 10.1152/physiolgenomics.2001.5.4.187; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4	51	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15633	15640		10.1074/jbc.M210389200	http://dx.doi.org/10.1074/jbc.M210389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12588870	hybrid			2022-12-25	WOS:000182680000024
J	Richardson, RM; Tokunaga, K; Marjoram, R; Sata, T; Snyderman, R				Richardson, RM; Tokunaga, K; Marjoram, R; Sata, T; Snyderman, R			Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity - Role of signal strength and receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTORS; PHOSPHORYLATION SITES; CROSS-REGULATION; T-LYMPHOCYTES; EXPRESSION; CCR5; BINDING; ENTRY; IDENTIFICATION; MONOCYTES	Human immunodeficiency virus type 1 (HIV-1) entry into CD4(+) cells requires the chemokine receptors CCR5 or CXCR4 as co-fusion receptors. We have previously demonstrated that chemokine receptors are capable of cross-regulating the functions of each other and, thus, affecting cellular responsiveness at the site of infection. To investigate the effects of chemokine receptor cross-regulation in HIV-1 infection, monocytes and MAGIC5 and rat basophilic leukemia (RBL-2H3) cell lines co-expressing the interleukin-8 (IL-8 or CXCLS) receptor CXCR1 and either CCR5 (ACCR5) or CXCR4 (ACXCR4) were generated. IL-8 activation of CXCR1, but not the IL-8 receptor CXCR2, cross-phosphorylated CCR5 and CXCR4 and cross-desensitized their responsiveness to RANTES (regulated on activation normal T cell expressed and secreted) (CCL5) and stromal derived factor (SDF-1 or CXCL12), respectively. CXCR1 activation internalized CCR5 but not CXCR4 despite cross-phosphorylation of both. IL-8 pretreatment also inhibited CCR5- but not CXCR4-mediated virus entry into MAGIC5 cells. A tail-deleted mutant of CXCR1, DeltaCXCR1, produced greater signals upon activation (Ca2+ mobilization and phosphoinositide hydrolysis) and cross-internalized CXCR4, inhibiting HIV-1 entry. The protein kinase C inhibitor staurosporine prevented phosphorylation and internalization of the receptors by CXCR1 activation. Taken together, these results indicate that chemokine receptor-mediated HIV-1 cell infection is blocked by receptor internalization but not desensitization alone. Thus, activation of chemokine receptors unrelated to CCR5 and CXCR4 may play a cross-regulatory role in the infection and propagation of HIV-1. Since DeltaCXCR1, but not CXCR1, cross-internalized and cross-inhibited HIV-1 infection to CXCR4, the data indicate the importance of the signal strength of a receptor and, as a consequence, protein kinase C activation in the suppression of HIV-1 infection by cross-receptor-mediated internalization.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Meharry Medical College; Vanderbilt University; National Institute of Infectious Diseases (NIID); Duke University	Richardson, RM (corresponding author), Meharry Med Coll, Dept Biochem, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.	mrrichardson@mmc.edu	Tokunaga, Kenzo/Q-9914-2018	Tokunaga, Kenzo/0000-0002-2625-5322	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038910, R01AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38910] Funding Source: Medline; NIDCR NIH HHS [DE 03738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BACON KB, 1995, J IMMUNOL, V154, P3654; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Deng XY, 1999, BLOOD, V94, P1165, DOI 10.1182/blood.V94.4.1165.416k23_1165_1173; Dimitrov DS, 1998, J MEMBRANE BIOL, V166, P75, DOI 10.1007/s002329900450; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mochizuki N, 1999, AIDS RES HUM RETROV, V15, P1321, DOI 10.1089/088922299310223; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; RICHARDSON RM, 2001, CHEMOKINE RECEPTORS, P31; Shen WP, 2000, BIOCHEM BIOPH RES CO, V272, P276, DOI 10.1006/bbrc.2000.2770; Tani K, 1998, EUR J IMMUNOL, V28, P502, DOI 10.1002/(SICI)1521-4141(199802)28:02<502::AID-IMMU502>3.0.CO;2-5; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; Utsunomiya I, 1997, EUR J IMMUNOL, V27, P1406, DOI 10.1002/eji.1830270617; Wang Ji Ming, 1996, Methods (Orlando), V10, P135, DOI 10.1006/meth.1996.0087; Wuyts Anja, 1998, P271; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	40	48	51	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15867	15873		10.1074/jbc.M211745200	http://dx.doi.org/10.1074/jbc.M211745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594210	hybrid			2022-12-25	WOS:000182680000053
J	Shogren-Knaak, MA; Fry, CJ; Peterson, CL				Shogren-Knaak, MA; Fry, CJ; Peterson, CL			A native peptide Ligation strategy for deciphering nucleosomal histone modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; PHOSPHORYLATION; ACETYLATION; ARRAYS; H3; ACETYLTRANSFERASE; PURIFICATION; MODEL; GCN5P	Post-translational modifications of histones influence both chromatin structure and the binding and function of chromatin-associated proteins. A major limitation to understanding these effects has been the inability to construct nucleosomes in vitro that harbor homogeneous and site-specific histone modifications. Here, we describe a native peptide ligation strategy for generating nucleosomal arrays that can harbor a wide range of desired histone modifications. As a first test of this method, we engineered model nucleosomal arrays in which each histone H3 contains a phosphorylated serine at position 10 and performed kinetic analyses of Gcn5-dependent histone acetyltransferase activities. Recombinant Gcn5 shows increased histone acetyltransferase activity on nucleosomal arrays harboring phosphorylated H3 serine 10 and is consistent with peptide studies. However, in contrast to analyses using peptide substrates, we find that the histone acetyltransferase activity of the Gcn5-containing SAGA complex is not stimulated by H3 phosphorylation in the context of nucleosomal arrays. This difference between peptide and array substrates suggests that the ability to generate specifically modified nucleosomal arrays should provide a powerful tool for understanding the effects of post-translational histone modifications.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Biotech 2,Suite 210, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [P01CA082834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049650, R37GM049650, R01GM054096] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82834] Funding Source: Medline; NIAID NIH HHS [F32 AI 10611] Funding Source: Medline; NIGMS NIH HHS [R01 GM054096, GM 49650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZ H, 1994, SYNTHESIS-STUTTGART, P337; Blaschke UK, 2000, METHOD ENZYMOL, V328, P478, DOI 10.1016/S0076-6879(00)28414-0; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Futaki S, 1997, TETRAHEDRON LETT, V38, P6237, DOI 10.1016/S0040-4039(97)01434-2; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Logie C, 1999, METHOD ENZYMOL, V304, P726; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; MUSZYNSKA G, 1992, J CHROMATOGR, V604, P19, DOI 10.1016/0021-9673(92)85524-W; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; Smith CL, 2003, NAT STRUCT BIOL, V10, P141, DOI 10.1038/nsb888; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	23	92	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15744	15748		10.1074/jbc.M301445200	http://dx.doi.org/10.1074/jbc.M301445200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595522	hybrid			2022-12-25	WOS:000182680000037
J	Tanahashi-Hori, T; Tanahashi, N; Tanaka, K; Chiba, T				Tanahashi-Hori, T; Tanahashi, N; Tanaka, K; Chiba, T			Conditional knockdown of proteasomes results in cell-cycle arrest and enhanced expression of molecular chaperones Hsp70 and Hsp40 in chicken DT40 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; SACCHAROMYCES-CEREVISIAE; PROTEINS; SUBUNIT; INHIBITORS; RESOLUTION; THREONINE; COMPLEXES; HOMOLOG; KINASE	The 26 S proteasome is an evolutionarily conserved ATP-dependent protease complex that degrades poly-ubiquitinated proteins' and plays essential roles in a critical part of cellular regulation. In vertebrates, the roles of the proteasome have been widely studied by use of specific inhibitors, but not genetically. Here, we generated a cell line Z(-/-/-)/Z-HA, in which the expression of the catalytic subunit of the proteasome, Z (beta2) could be manipulated. This cell line expresses exogenous Z protein under the control of a tetracycline-repressible promoter in a Z-nullizygous genetic background. Treatment of these cells with doxycycline inhibited Z expression and, hence, the function of the proteasome. The latter resulted in accumulation of poly-ubiquitinated proteins and concomitant induction of molecular chaperones Hsp70 and Hsp40. These results suggest a synergistic role for the proteasome with these molecular chaperones to eliminate misfolded or damaged proteins in vivo. Furthermore, knockdown of the proteasome induced apoptotic cell death following cell-cycle arrest at G(2)/M phase. Our Z(-/-/-)/Z-HA cell line would be useful for evaluating proteolytic processes catalyzed by the proteasome in many biological events in vertebrate cells.	Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Sumitomo Elect Ind Ltd, Osaka R&D Labs, EPM Project Grps, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; New Energy & Ind Technol Dev Org, Sakae Ku, Yokohama, Kanagawa 2448588, Japan	Tokyo Metropolitan Institute of Medical Science; Sumitomo Electric Industries	Chiba, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.							Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kim KB, 1999, BIOORG MED CHEM LETT, V9, P3335, DOI 10.1016/S0960-894X(99)00612-5; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	29	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16237	16243		10.1074/jbc.M301331200	http://dx.doi.org/10.1074/jbc.M301331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594202	hybrid			2022-12-25	WOS:000182680000099
J	Wang, J; Liu, XJ				Wang, J; Liu, XJ			A G protein-coupled receptor kinase induces Xenopus oocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; BETA-GAMMA-SUBUNITS; G(BETA-GAMMA) SUBUNITS; ADENYLATE-CYCLASE; LAEVIS OOCYTES; CELL-CYCLE; INHIBITION; ACTIVATION; INSULIN; STIMULATION	Several recent studies have suggested that resumption of oocyte meiosis, indicated by germinal vesicle breakdown or GVBD, involves inhibition of endogenous heterotrimeric G proteins in both frogs and mice. These studies imply that a heterotrimeric G protein(s), and hence its upstream activator (a G protein-coupled receptor or GpCR), is activated in prophase oocytes and is responsible for maintaining meiosis arrest. To test the existence and function of this putative GpCR, we utilized a mammalian G-protein-coupled receptor kinase (GRK3) and. beta-arrestin-2, which together are known to cause GpCR desensitization. Injection of mRNA for rat GRK3 caused hormone-independent GVBD. The kinase activity of GRK3 was essential for GVBD induction as its kinase-dead mutant (GRK3-K220R) was completely ineffective. Another GRK3 mutant (GRK3-DeltaC), which lacked the C-terminal G(betagamma)-binding domain and which was not associated with oocyte membranes, also failed to induce GVBD. Furthermore, injection of rat beta-arrestin-2 mRNA also induced hormone-independent GVBD. Several inhibitors of clathrin-mediated receptor endocytosis (the clathrin-binding domain of beta-arrestin-2, concanavalin A, and monodansyl cadaverine) significantly reduced the abilities of GRK3/beta-arrestin-2 to induce GVBD. These results support the central role of a yet-unidentified GpCR in maintaining prophase arrest in frog oocytes and provide a potential means for its molecular identification.	Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Obstet & Gynaecol, Ottawa, ON K1N 6N5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Liu, XJ (corresponding author), Ottawa Hlth Res Inst, 725 Parkdale Ave,Ottawa Hosp Civ Campus, Ottawa, ON K1Y 4E9, Canada.	jliu@ohri.ca		Liu, X. Johne/0000-0003-3381-5030; Wang, Jing/0000-0003-2410-4771				ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; Booth RA, 2002, J BIOL CHEM, V277, P6719, DOI 10.1074/jbc.M108033200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; GALLO CJ, 1995, J CELL BIOL, V130, P275, DOI 10.1083/jcb.130.2.275; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Lutz LB, 2000, J BIOL CHEM, V275, P41512, DOI 10.1074/jbc.M006757200; MASUI Y, 1967, J EXP ZOOL, V166, P365, DOI 10.1002/jez.1401660309; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Mehlmann LM, 2002, SCIENCE, V297, P1343, DOI 10.1126/science.1073978; NANDI PK, 1981, BIOCHEMISTRY-US, V20, P6706, DOI 10.1021/bi00526a028; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SADLER SE, 1984, MOL PHARMACOL, V26, P526; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SALISBURY JL, 1981, COLD SPRING HARB SYM, V46, P733; SCHORDERETSLATKINE S, 1982, ENDOCRINOLOGY, V111, P1385, DOI 10.1210/endo-111-4-1385; Sheng YL, 2001, CURR BIOL, V11, P405, DOI 10.1016/S0960-9822(01)00123-3; SMITH LD, 1989, DEVELOPMENT, V107, P685; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723	41	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15809	15814		10.1074/jbc.M300320200	http://dx.doi.org/10.1074/jbc.M300320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600992	hybrid			2022-12-25	WOS:000182680000046
J	Corvaisier, S; Bordeau, V; Felden, B				Corvaisier, S; Bordeau, V; Felden, B			Inhibition of transfer messenger RNA aminoacylation and trans-translation by aminoglycoside antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HAMMERHEAD RIBOZYME; RIBOSOME RESCUE; METAL-IONS; 10SA RNA; TMRNA; BINDING; PROTEIN; SMPB; MOLECULES	Transfer messenger RNA (tmRNA) directs the modification of proteins of which the biosynthesis has stalled or has been interrupted. Here, we report that aminoglycosides can interfere with this quality control system in bacteria, termed trans-translation. Neomycin B is the strongest inhibitor of tmRNA aminoacylation with alanine (K-i value of similar to35 muM), an essential step during transtranslation. The binding sites of neomycin B do not overlap with the identity determinants for alanylation, but the aminoglycoside perturbs the conformation of the acceptor stem that contains the aminoacylation signals. Aminoglycosides reduce the conformational freedom of the transfer RNA-like domain of tmRNA. Additional contacts between aminoglycosides and tmRNA are within the tag reading frame, probably also disturbing reprogramming of the stalled ribosomes prior protein tagging. Aminoglycosides impair tmRNA aminoacylation in the presence of all of the transfer RNAs from Escherichia coli, small protein B, and elongation factor Tu, but when both proteins are present, the inhibition constant is 1 order of magnitude higher. SmpB and elongation factor Tu have RNA chaperone activities, ensuring that tmRNA adopts an optimal conformation during aminoacylation.	Univ Rennes 2, UPRES, Fac Pharm, Lab Biochim Pharmaceut, F-35043 Rennes, France	Universite de Rennes; Universite Rennes 2	Felden, B (corresponding author), Univ Rennes 2, UPRES, Fac Pharm, Lab Biochim Pharmaceut, Jeuna Equipe 2311,2 Ave Prof Leon Bernard, F-35043 Rennes, France.		Bordeau, Valérie/L-1992-2015; felden, brice/L-4825-2015	BORDEAU, VALERIE/0000-0003-1137-1053				Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; Earnshaw DJ, 1998, NUCLEIC ACIDS RES, V26, P5551, DOI 10.1093/nar/26.24.5551; Felden B, 1997, RNA, V3, P89; FELDEN B, 2003, LANDES BIOSCIENCES; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; GALE EF, 1981, MOL BASIS ANTIBIOTIC, P419; Gillet R, 2001, MOL MICROBIOL, V42, P879, DOI 10.1046/j.1365-2958.2001.02701.x; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hermann T, 1998, J MOL BIOL, V276, P903, DOI 10.1006/jmbi.1997.1590; Hickerson RP, 1998, J MOL BIOL, V279, P577, DOI 10.1006/jmbi.1998.1813; Hoch I, 1998, J MOL BIOL, V282, P557, DOI 10.1006/jmbi.1998.2035; Huang CH, 2000, EMBO J, V19, P1098, DOI 10.1093/emboj/19.5.1098; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; Mikkelsen NE, 1999, P NATL ACAD SCI USA, V96, P6155, DOI 10.1073/pnas.96.11.6155; Mikkelsen NE, 2001, NAT STRUCT BIOL, V8, P510, DOI 10.1038/88569; Nameki N, 1999, J MOL BIOL, V289, P1, DOI 10.1006/jmbi.1999.2754; Rogers J, 1996, J MOL BIOL, V259, P916, DOI 10.1006/jmbi.1996.0369; RUDINGERTHIRION J, 1999, RNA, V5, P1; Ryu DH, 2001, BIOORGAN MED CHEM, V9, P2601; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; STAGE TK, 1995, RNA, V1, P95; Tok JBH, 1999, BIOCHEMISTRY-US, V38, P199, DOI 10.1021/bi9819428; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Vicens Q, 2001, STRUCTURE, V9, P647, DOI 10.1016/S0969-2126(01)00629-3; Walter F, 1999, CURR OPIN CHEM BIOL, V3, P694, DOI 10.1016/S1367-5931(99)00028-9; Walter F, 2002, EMBO J, V21, P760, DOI 10.1093/emboj/21.4.760; Williams KP, 2002, NUCLEIC ACIDS RES, V30, P179, DOI 10.1093/nar/30.1.179; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B; Zvereva MI, 2001, J BIOL CHEM, V276, P47702, DOI 10.1074/jbc.M106786200	36	26	28	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14788	14797		10.1074/jbc.M212830200	http://dx.doi.org/10.1074/jbc.M212830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588865	hybrid			2022-12-25	WOS:000182516100028
J	Kim, TY; Lee, KH; Chang, S; Chung, C; Lee, HW; Yim, J; Kim, TK				Kim, TY; Lee, KH; Chang, S; Chung, C; Lee, HW; Yim, J; Kim, TK			Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; VIRUS-INFECTION; TUMOR-ANTIGEN; TRANSCRIPTION; IRF-3; ACTIVATION; PROTEIN; RAS; TRANSFORMATION; APOPTOSIS	Interferon regulatory factor 3 (IRF3) is activated in response to various environmental stresses including viral infection and DNA-damaging agents. However, the biological function of IRF3 in cell growth is not well understood. We demonstrated that IRF3 markedly inhibited growth and colony formation of cells. IRF3 blocked DNA synthesis and induced apoptosis. Based on this negative control of cell growth by IRF3, we examined whether functional loss of IRF3 may contribute to oncogenic transformation. IRF3 activity was specifically inhibited by expression of its dominant negative mutant. This mutant lacks a portion of the DNA binding domain like IRF3a, an alternative splice form of IRF3 in the cells. This dominant negative inhibition blocked expression of specific IRF3 target genes. Mutant IRF3 efficiently transformed NIH3T3 cells, as demonstrated by anchorage-independent growth in soft agar and tumorigenicity in. nude mice. These results imply that IRF3 may function as a tumor suppressor and suggest a possible role for the relative levels of IRF3 and its dominant negative mutant in tumorigenesis.	Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea; Seoul Natl Univ, Dept Microbiol, Seoul 151742, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Suwon 440746, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Sungkyunkwan University (SKKU); Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea.	tkkim@mail.kaist.ac.kr						BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duguay D, 2002, CANCER RES, V62, P5148; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Karpova AY, 2000, GENE DEV, V14, P2813, DOI 10.1101/gad.813800; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kim TK, 2000, CANCER RES, V60, P1153; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; OIJEN M, 2000, CLIN CANCER RES, V6, P2138; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	36	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15272	15278		10.1074/jbc.M205792200	http://dx.doi.org/10.1074/jbc.M205792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582166	hybrid			2022-12-25	WOS:000182516100089
J	Saito, H; Dhanasekaran, P; Nguyen, D; Baldwin, F; Weisgraber, KH; Wehrli, S; Phillips, MC; Lund-Katz, S				Saito, H; Dhanasekaran, P; Nguyen, D; Baldwin, F; Weisgraber, KH; Wehrli, S; Phillips, MC; Lund-Katz, S			Characterization of the heparin binding sites in human apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; SULFATE PROTEOGLYCAN-BINDING; AMPHIPATHIC ALPHA-HELIX; N-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; III HYPERLIPOPROTEINEMIA; E ISOFORMS; EXTRACELLULAR-MATRIX; TRANSPORT PROTEIN; E FRAGMENTS	Apolipoprotein (apo) E mediates lipoprotein remnant clearance via interaction with cell-surface heparan sulfate proteoglycans. Both the 22-kDa N-terminal domain and 10-kDa C-terminal domain of apoE contain a heparin binding site; the N-terminal site overlaps with the low density lipoprotein receptor binding region and the G terminal site is undefined. To understand the molecular details of the apoE-heparin interaction, we defined the microenvironments of all 12 lysine residues in intact apoE3 and examined their relative contributions to heparin binding. Nuclear magnetic resonance measurements showed that, in apoE3-dimyristoyl phosphatidylcholine discs, Lys-143 and -146 in the N-terminal domain and Lys-233 in the C-terminal domain have unusually low pK(a) values, indicating high positive electrostatic potential around these residues. Binding experiments using heparin-Sepharose gel demonstrated that the lipid-free 10-kDa fragment interacted strongly with heparin and a point mutation K233Q largely abolished the binding, indicating that Lys-233 is involved in heparin binding and that an unusually basic lysine microenvironment is critical for the interaction with heparin. With lipidated apoE3, it is confirmed that the Lys-233 site is completely masked and the N-terminal site mediates heparin binding. In addition, mutations of the two heparin binding sites in intact apoE3 demonstrated the dominant role of the N-teriminal site in the heparin binding of apoE even in the lipid-free state. These results suggest that apoE interacts predominately with cell-surface heparan sulfate proteoglycans through the N-terminal binding site. However, Lys-233 may be involved in the binding of apoE to certain cell-surface sites, such as the protein core of biglycan.	Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Lund-Katz, S (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Sch Med, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	katzs@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL56083, HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, R01HL056083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Aizawa Y, 1997, BRAIN RES, V768, P208, DOI 10.1016/S0006-8993(97)00640-9; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Burgess JW, 1998, J BIOL CHEM, V273, P5645, DOI 10.1074/jbc.273.10.5645; Cardin A D, 1988, Adv Exp Med Biol, V243, P157; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CASTANO EM, 1995, J BIOL CHEM, V270, P17610, DOI 10.1074/jbc.270.29.17610; Cooper AD, 1997, J LIPID RES, V38, P2173; Dong J, 2000, J LIPID RES, V41, P1783; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; DYER CA, 1991, J BIOL CHEM, V266, P15009; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; FUNAHASHI T, 1989, J BIOCHEM-TOKYO, V105, P582, DOI 10.1093/oxfordjournals.jbchem.a122708; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Klezovitch O, 2000, J BIOL CHEM, V275, P18913, DOI 10.1074/jbc.M909644199; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Lin CY, 2001, J LIPID RES, V42, P1125; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Lund-Katz S, 2001, J LIPID RES, V42, P894; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANN WA, 1995, J LIPID RES, V36, P517; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Olin KL, 2001, ARTERIOSCL THROM VAS, V21, P129, DOI 10.1161/01.ATV.21.1.129; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; Shuvaev VV, 1999, FEBS LETT, V459, P353, DOI 10.1016/S0014-5793(99)01285-5; Shuvaev VV, 2000, NEUROSCI LETT, V280, P131, DOI 10.1016/S0304-3940(00)00764-3; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; Verrecchio A, 2000, J BIOL CHEM, V275, P7701, DOI 10.1074/jbc.275.11.7701; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Zaiou M, 2000, J LIPID RES, V41, P1087	54	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14782	14787		10.1074/jbc.M213207200	http://dx.doi.org/10.1074/jbc.M213207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588864	hybrid			2022-12-25	WOS:000182516100027
J	Szabadkai, G; Simoni, AM; Rizzuto, R				Szabadkai, G; Simoni, AM; Rizzuto, R			Mitochondrial Ca2+ uptake requires sustained Ca2+ release from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOPLASMIC CA2+; CALCIUM; ENTRY; CELL; OSCILLATIONS; HOMEOSTASIS; PHOSPHORYLATION; OVEREXPRESSION; MICRODOMAINS	We analyzed the role of inositol 1,4,5-trisphosphate-induced Ca2+ release from the endoplasmic reticulum (ER) (i) in powering mitochondrial Ca2+ uptake and (ii) in maintaining a sustained elevation of cytosolic Ca2+ concentration ([Ca2+](c)). For this purpose, we expressed in HeLa cells aequorin-based Ca2+-sensitive probes targeted to different intracellular compartments and studied the effect of two agonists: histamine, acting on endogenous H-1 receptors, and glutamate, acting on co-transfected metabotropic glutamate receptor (mGluR1a), which rapidly inactivates through protein kinase C-dependent phosphorylation and thus causes transient inositol 1,4,5-trisphosphate production. Glutamate induced a transient [Ca2+](c) rise and drop in ER luminal [Ca2+] ([Ca2+](er)), and then the ER refilled with [Ca2+](c) at resting values. With histamine, [Ca2+](c) after the initial peak stabilized at a sustained plateau, and [Ca2+](er) decreased to a low steady-state value. In mitochondria, histamine evoked a much larger mitochondrial Ca2+ response than glutamate (similar to15 versus similar to65 muM). Protein kinase C inhibition, partly relieving mGluR1a desensitization, reestablished both the [Ca2+](c) plateau and the sustained ER Ca2+ release and markedly increased the mitochondrial Ca2+ response. Conversely, mitochondrial Ca2+ uptake evoked by histamine was drastically reduced by very transient (similar to2-s) agonist applications. These data indicate that efficient mitochondrial Ca2+ uptake depends on the preservation of high Ca2+ microdomains at the mouth of ER Ca2+ release sites close to mitochondria. This in turn depends on continuous Ca2+ release balanced by Ca2+ reuptake into the ER and maintained by Ca2+ influx from the extracellular space.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	r.rizzuto@unife.it	Rizzuto, Rosario/B-6312-2008	Rizzuto, Rosario/0000-0001-7044-5097; Szabadkai, Gyorgy/0000-0002-3006-3577	Telethon [1285] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; Blaustein MR, 2001, TRENDS NEUROSCI, V24, P602, DOI 10.1016/S0166-2236(00)01891-9; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Daub B, 2000, CELL CALCIUM, V27, P3, DOI 10.1054/ceca.1999.0084; Drummond RM, 2000, J PHYSIOL-LONDON, V522, P375, DOI 10.1111/j.1469-7793.2000.t01-2-00375.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; GABELLINI N, 1993, NEUROREPORT, V4, P531, DOI 10.1097/00001756-199305000-00017; Gerencser AA, 2001, CELL CALCIUM, V30, P311, DOI 10.1054/ceca.2001.0238; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Janssen LJ, 1999, AM J PHYSIOL-LUNG C, V276, pL744, DOI 10.1152/ajplung.1999.276.5.L744; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Moccia F, 2002, BIOCHEM J, V364, P235, DOI 10.1042/bj3640235; Mogami H, 1999, J PHYSIOL-LONDON, V518, P463, DOI 10.1111/j.1469-7793.1999.0463p.x; Montero M, 2002, FASEB J, V16, P1955, DOI 10.1096/fj.02-0553fje; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; Petersen OH, 1999, EUR J CELL BIOL, V78, P221, DOI 10.1016/S0171-9335(99)80054-5; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; Putney JW, 2001, J CELL SCI, V114, P2223; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rohacs T, 1997, BIOCHEM J, V322, P785, DOI 10.1042/bj3220785; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; Szabadkai G, 2001, PFLUG ARCH EUR J PHY, V441, P678, DOI 10.1007/s004240000466; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; Vandecasteele G, 2001, IUBMB LIFE, V52, P213, DOI 10.1080/15216540152846028; Verkhratsky A, 2002, EUR J PHARMACOL, V447, P141, DOI 10.1016/S0014-2999(02)01838-1; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	50	72	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15153	15161		10.1074/jbc.M300180200	http://dx.doi.org/10.1074/jbc.M300180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586823	hybrid			2022-12-25	WOS:000182516100074
J	Carneiro, FA; Stauffer, F; Lima, CS; Juliano, MA; Juliano, L; Da Poian, AT				Carneiro, FA; Stauffer, F; Lima, CS; Juliano, MA; Juliano, L; Da Poian, AT			Membrane fusion induced by vesicular stomatitis virus depends on histidine protonation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL-CHANGES; N-TERMINAL PEPTIDES; ENVELOPE GLYCOPROTEIN; LOW-PH; HEPTAD-REPEAT; CELL-FUSION; PHOSPHOLIPID INTERACTIONS; SYNTHETIC PEPTIDES; PROTEIN; DOMAIN	Entry of enveloped animal viruses into their host cells always depends on a step of membrane fusion triggered by conformational changes in viral envelope glycoproteins. Vesicular stomatitis virus (VSV) infection is mediated by virus spike glycoprotein G, which induces membrane fusion at the acidic environment of the endosomal compartment. VSV-induced membrane fusion occurs at a very narrow pH range, between 6.2 and 5.8, suggesting that His protonation. is required for this process. To investigate the role of His in VSV fusion, we chemically modified these residues using diethylpyrocarbonate (DEPC). We found that DEPC treatment inhibited membrane fusion mediated by VSV in a concentration-dependent manner and that the complete inhibition of fusion was fully reversed by incubation of modified virus with hydroxylamine. Fluorescence measurements showed that VSV modification with DEPC abolished pH-induced conformational changes in G protein, suggesting that His protonation drives G protein interaction with the target membrane at acidic pH. Mass spectrometry analysis of tryptic fragments of modified G protein allowed the identification of the putative active His residues. Using synthetic peptides, we showed that the modification of His-148 and His-149 by DEPC, as well as the substitution of these residues by Ala, completely inhibited peptide-induced fusion, suggesting the direct participation of these His in VSV fusion.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP)	Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941 Rio De Janeiro, Brazil.	dapoian@bioqmed.ufrj.br	CARNEIRO, FABIANA A/S-4525-2018; Da Poian, Andrea T./V-1699-2019; Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822; Da Poian, Andrea/0000-0002-3969-704X; Carneiro, Fabiana/0000-0002-6584-4875				Ben-Efraim I, 1999, J MOL BIOL, V285, P609, DOI 10.1006/jmbi.1998.2370; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; Carneiro FA, 2002, J VIROL, V76, P3756, DOI 10.1128/JVI.76.8.3756-3764.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Coll JM, 1997, ARCH VIROL, V142, P2089, DOI 10.1007/s007050050227; COLL JM, 1995, VIRUS GENES, V10, P107, DOI 10.1007/BF01702591; Da Poian AT, 1998, J VIROL METHODS, V70, P45, DOI 10.1016/S0166-0934(97)00166-3; DaPoian AT, 1996, P NATL ACAD SCI USA, V93, P8268, DOI 10.1073/pnas.93.16.8268; Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Estepa A, 1996, J VIROL METHODS, V61, P37, DOI 10.1016/0166-0934(96)02067-8; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FREDERICKSEN BL, 1995, J VIROL, V69, P1435, DOI 10.1128/JVI.69.3.1435-1443.1995; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; Gaudin Y, 1999, MOL MEMBR BIOL, V16, P21, DOI 10.1080/096876899294724; GAUDIN Y, 1993, J VIROL, V67, P1365, DOI 10.1128/JVI.67.3.1365-1372.1993; Ghosh JK, 1998, J BIOL CHEM, V273, P27182, DOI 10.1074/jbc.273.42.27182; Ghosh JK, 1999, J MOL BIOL, V292, P531, DOI 10.1006/jmbi.1999.3097; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LI Y, 1993, J VIROL, V67, P4070, DOI 10.1128/JVI.67.7.4070-4077.1993; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; Martin I, 1999, ADV DRUG DELIVER REV, V38, P233, DOI 10.1016/S0169-409X(99)00031-9; Miles E W, 1977, Methods Enzymol, V47, P431; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; Nunez E, 1998, VIROLOGY, V243, P322, DOI 10.1006/viro.1998.9076; PAL R, 1988, BIOCHEMISTRY-US, V27, P30, DOI 10.1021/bi00401a006; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; Saez-Cirion A, 2002, BBA-BIOMEMBRANES, V1564, P57, DOI 10.1016/S0005-2736(02)00400-5; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6257, DOI 10.1021/bi00478a021; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283; ZHANG L, 1994, J VIROL, V68, P2186, DOI 10.1128/JVI.68.4.2186-2193.1994	40	67	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13789	13794		10.1074/jbc.M210615200	http://dx.doi.org/10.1074/jbc.M210615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571240	hybrid			2022-12-25	WOS:000182405000030
J	Marchesini, N; Luberto, C; Hannun, YA				Marchesini, N; Luberto, C; Hannun, YA			Biochemical properties of mammalian neutral sphingomyelinase2 and its role in sphingolipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INDUCED CELL-DEATH; P55 TNF RECEPTOR; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; LYSOSOMAL SPHINGOMYELINASE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL REQUIREMENTS; ACID SPHINGOMYELINASE	Neutral sphingomyelinase (N-SMase) is one of the key enzymes involved in the generation of ceramide; however, the gene(s) encoding for the mammalian N-SMase is still not well defined. Previous studies on the cloned nSMase1 had shown that the protein acts primarily as lyso-platelet-activating factor-phospholipase C. Recently the cloning of another putative N-SMase, nSMase2, was reported. In this study, biochemical characterization of the mouse nSMase2 was carried out using the overexpressed protein in yeast cells in which the inositol phosphosphingolipid phospholipase C (Isc1p) was deleted. N-SMase activity was dependent on Mg2+ and was activated by phosphatidylserine and inhibited by GW4869. The ability of nSMase2 to recognize endogenous sphingomyelin (SM) as substrate was investigated by overexpressing nSMase2 in MCF7 cells. Mass measurements showed a 40% decrease in the SM levels in the overexpressor cells, and labeling studies demonstrated that nSMase2 accelerated SM catabolism. Accordingly, ceramide measurement showed a 60 +/- 15% increase in nSMase2-overexpressing cells compared with the vector-transfected MCF7. The role of nSMase2 in cell growth was next investigated. Stable overexpression of nSMase2 resulted in a 30-40% decrease in the rate of growth at the late exponential phase. Moreover, tumor necrosis factor induced similar to50% activation of nSMase2 in MCF7 cells overexpressing the enzyme, demonstrating that nSMase2 is a tumor necrosis factor-responsive enzyme. In conclusion, these results 1) show that nSMase2 is a structural gene for nSMase, 2) suggest that nSMase2 acts as a bona fide N-SMase in cells, and 3) implicate nSMase2 in the regulation of cell growth and cell signaling.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Bezombes C, 2001, FASEB J, V15, P297; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Chatterjee S, 1999, CHEM PHYS LIPIDS, V102, P79, DOI 10.1016/S0009-3084(99)00077-8; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; Fensome AC, 2002, BIOCHEM J, V365, P69, DOI 10.1042/BJ20020120; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koppenhoefer U, 1997, FEBS LETT, V414, P444, DOI 10.1016/S0014-5793(97)01035-1; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Mizutani Y, 2000, BBA-MOL CELL BIOL L, V1485, P236, DOI 10.1016/S1388-1981(00)00059-7; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Perry DK, 2000, METHOD ENZYMOL, V312, P22; PETTUS B, 2003, BIOCHIM BIOPHYS ACTA, V1585, P114; RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; Sawai H, 1997, J BIOL CHEM, V272, P2452; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Tanaka M, 1999, J ANTIBIOT, V52, P670, DOI 10.7164/antibiotics.52.670; Tcherkasowa AE, 2002, J IMMUNOL, V169, P5161, DOI 10.4049/jimmunol.169.9.5161; Tepper AD, 2001, BIOCHEM BIOPH RES CO, V280, P634, DOI 10.1006/bbrc.2000.4166; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	51	155	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13775	13783		10.1074/jbc.M212262200	http://dx.doi.org/10.1074/jbc.M212262200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566438	hybrid			2022-12-25	WOS:000182405000028
J	Noorwez, SM; Kuksa, V; Imanishi, Y; Zhu, L; Filipek, S; Palczewski, K; Kaushal, S				Noorwez, SM; Kuksa, V; Imanishi, Y; Zhu, L; Filipek, S; Palczewski, K; Kaushal, S			Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CYSTIC-FIBROSIS; FRAMESHIFT MUTATION; MOLECULAR-GENETICS; RHODOPSIN MUTANTS; MOUSE MODEL; ACTIVATION; MECHANISM; RETINALS; DISEASE	Protein conformational disorders, which include certain types of retinitis pigmentosa, are a set of inherited human diseases in which mutant proteins are misfolded and often aggregated. Many opsin mutants associated with retinitis pigmentosa, the most common being P23H, are misfolded and retained within the cell. Here, we describe a pharmacological chaperone, 11-cis-7-ring retinal, that quantitatively induces the in vivo folding of P23H-opsin. The rescued protein forms pigment, acquires mature glycosylation, and is transported to the cell surface. Additionally, we determined the temperature stability of the rescued protein as well as the reactivity of the retinal-opsin Schiff base to hydroxylamine. Our study unveils novel properties of P23H-opsin and its interaction with the chromophore. These properties suggest that 11-cis-7-ring retinal may be a useful therapeutic agent for the rescue of P23H-opsin and the prevention of retinal degeneration.	Univ Florida, Dept Ophthalmol, Gainesville, FL USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Warsaw, Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Univ Warsaw, Dept Chem, PL-02109 Warsaw, Poland	State University System of Florida; University of Florida; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw	Kaushal, S (corresponding author), Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.	skaushal@eye.ufl.edu	Imanishi, Yoshikazu/E-8178-2010; Filipek, Slawomir/A-2985-2008	Imanishi, Yoshikazu/0000-0003-4696-4836; Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY013385, P30EY001730, R01EY009339] Funding Source: NIH RePORTER; NEI NIH HHS [EY09339, EY13385, R01 EY013385, P30 EY001730, R01 EY009339, EY01730] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; Bai CX, 1998, J PHARMACOL TOX MET, V40, P39, DOI 10.1016/S1056-8719(98)00034-3; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; Burrows JAJ, 2000, P NATL ACAD SCI USA, V97, P1796, DOI 10.1073/pnas.97.4.1796; CALDWELL CG, 1993, J ORG CHEM, V58, P3533, DOI 10.1021/jo00065a014; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Frederick J, 2000, METHOD ENZYMOL, V316, P515; Fujimoto Y, 2002, CHIRALITY, V14, P340, DOI 10.1002/chir.10076; GOVARDHAN CP, 1994, J BIOL CHEM, V269, P6524; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Kuksa V, 2002, J BIOL CHEM, V277, P42315, DOI 10.1074/jbc.M206014200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Lou JH, 2000, METHOD ENZYMOL, V315, P219; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Papermaster DS, 2002, INVEST OPHTH VIS SCI, V43, P1300; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Saliba RS, 2002, J CELL SCI, V115, P2907; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Seibert FS, 1997, J BIOENERG BIOMEMBR, V29, P429, DOI 10.1023/A:1022478822214; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Yang T, 1997, P NATL ACAD SCI USA, V94, P13559, DOI 10.1073/pnas.94.25.13559; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	45	167	193	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14442	14450		10.1074/jbc.M300087200	http://dx.doi.org/10.1074/jbc.M300087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566452	hybrid, Green Accepted			2022-12-25	WOS:000182405000111
J	Zhout, PC; Fernandes, N; Dodge, IL; Reddi, AL; Rao, N; Safran, H; Dipetrillo, TA; Wazer, DE; Band, V; Band, H				Zhout, PC; Fernandes, N; Dodge, IL; Reddi, AL; Rao, N; Safran, H; Dipetrillo, TA; Wazer, DE; Band, V; Band, H			ErbB2 degradation mediated by the co-chaperone protein CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; TYROSINE KINASES; RING FINGER; CBL; RECEPTOR; GELDANAMYCIN; IDENTIFICATION; TARGET; DOMAIN; UBIQUITYLATION	ErbB2 overexpression contributes to the evolution of a substantial group of human cancers and signifies a poor clinical prognosis. Thus, down-regulation of ErbB2 signaling has emerged as a new anti-cancer strategy. Ubiquitinylation, mediated by the Cbl family of ubiquitin ligases, has emerged as a physiological mechanism of ErbB receptor down-regulation, and this mechanism appears to contribute to ErbB2 down-regulation induced by therapeutic anti-ErbB2 antibodies. Hsp90 inhibitory ansamycin antibiotics such as geldanamycin (GA) induce rapid ubiquitinylation and down-regulation of ErbB2. However, the ubiquitin ligase(s) involved has not been identified. Here, we show that ErbB2 serves as an in vitro substrate for the Hsp70/Hsp90-associated U-box ubiquitin ligase CHIP. Overexpression of wild type CHIP, but not its U-box mutant H260Q, induced ubiquitinylation and reduction in both cell surface and total levels of ectopically expressed or endogenous ErbB2 in vivo, and this effect was additive with that of 17-allylamino-geldanamycin (17-AAG). The CHIP U-box mutant H260Q reduced 17-AAG-induced ErbB2 ubiquitinylation. Wild type ErbB2 and a mutant incapable of association with Cbl (ErbB2 Y1112F) were equally sensitive to CHIP and 17-AAG, implying that Cbl does not play a major role in geldanamycin-induced ErbB2 down-regulation. Both endogenous and ectopically expressed CHIP and ErbB2 coimmunoprecipitated with each other, and this association was enhanced by 17-AAG. Notably, CHIP H260Q induced a dramatic elevation of ErbB2 association with Hsp70 and prevented the 17-AAG-induced dissociation of Hsp90. Our results demonstrate that ErbB2 is a target of CHIP ubiquitin ligase activity and suggest a role for CHIP E3 activity in controlling both the association of Hsp70/Hsp90 chaperones with ErbB2 and the down-regulation of ErbB2 induced by inhibitors of Hsp90.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Brown Univ, Miriam Hosp, Oncol Grp, Providence, RI 02906 USA; Tufts Univ, New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Tufts Medical Center; Tufts University	Band, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 538C,1 Jimmy Fund Way, Boston, MA 02115 USA.	hband@rics.bwh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA081076, R01CA075075, R01CA076118, R01CA070195, R01CA087986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75075, CA 76118, CA70195, CA 87986, CA 81076] Funding Source: Medline; NIAMS NIH HHS [T32AR07530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kimmins S, 2000, CELL STRESS CHAPERON, V5, P76, DOI 10.1379/1466-1268(2000)005<0076:MOSRAE>2.0.CO;2; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 2000, CANCER RES, V60, P3384; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng FF, 2000, CANCER RES, V60, P2090	42	158	174	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13829	13837		10.1074/jbc.M209640200	http://dx.doi.org/10.1074/jbc.M209640200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574167	hybrid			2022-12-25	WOS:000182405000035
J	Androutsellis-Theotokis, A; Goldberg, NR; Ueda, K; Beppu, T; Beckman, ML; Das, S; Javitch, JA; Rudnick, G				Androutsellis-Theotokis, A; Goldberg, NR; Ueda, K; Beppu, T; Beckman, ML; Das, S; Javitch, JA; Rudnick, G			Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; TRANSMEMBRANE DOMAIN-I; OBLIGATELY SYMBIOTIC THERMOPHILE; HUMAN DOPAMINE TRANSPORTER; COMPLETE GENOME SEQUENCE; SEROTONIN TRANSPORTER; ESCHERICHIA-COLI; SYMBIOBACTERIUM-THERMOPHILUM; RAT-BRAIN; ORPHAN TRANSPORTERS	The tnaT gene of Symbiobacterium thermophilum encodes a protein homologous to sodium-dependent neurotransmitter transporters. Expression of the tnaT gene product in Escherichia coli conferred the ability to accumulate tryptophan from the medium and the ability to grow on tryptophan as a sole source of carbon. Transport was Na+-dependent and highly selective. The K-m for tryptophan was similar to145 nM, and tryptophan transport was unchanged in the presence of 100 muM concentrations of other amino acids. Tryptamine and serotonin were weak inhibitors with K-I values of 200 and 440 muM, respectively. By using a T7 promoter-based system, TnaT with an N-terminal His(6) tag was expressed at high levels in the membrane and was purified to near-homogeneity in high yield.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, Ctr Mol Recognit, New York, NY 10032 USA; Nihon Univ, Dept Appl Biol Sci, Kanagawa 2528510, Japan	Yale University; Columbia University; Columbia University; Nihon University	Rudnick, G (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,POB 3333, New Haven, CT 06510 USA.	gary.rudnick@yale.edu		Androutsellis-Theotokis, Andreas/0000-0002-1985-4589; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014942] Funding Source: NIH RePORTER; NIDA NIH HHS [DA014942] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; ASBERG M, 1993, CLIN NEUROPHARMACOL, V16, pS32; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARZU O, 1994, PROG NUCLEIC ACID RE, V49, P241; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Blumwald E, 2000, BBA-BIOMEMBRANES, V1465, P140, DOI 10.1016/S0005-2736(00)00135-8; BRILEY M, 1993, CLIN NEUROPHARMACOL, V16, P387, DOI 10.1097/00002826-199310000-00002; CAIRNEY J, 1984, J BACTERIOL, V160, P22, DOI 10.1128/JB.160.1.22-27.1984; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Charney DS, 1998, J CLIN PSYCHIAT, V59, P11; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; ELMESTIKAWY S, 1994, J NEUROCHEM, V62, P445; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Farmer MK, 2000, GENOMICS, V70, P241, DOI 10.1006/geno.2000.6387; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; HIRAHARA T, 1992, APPL ENVIRON MICROB, V58, P2633, DOI 10.1128/AEM.58.8.2633-2642.1992; HIRAHARA T, 1993, APPL MICROBIOL BIOT, V39, P341, DOI 10.1007/BF00192089; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HRDINA PD, 1990, J PHARMACOL EXP THER, V252, P410; Johnson K, 1999, DEV BIOL, V212, P440, DOI 10.1006/dbio.1999.9351; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Jones SR, 1998, J NEUROSCI, V18, P1979; KABACK HR, 1974, SCIENCE, V186, P882, DOI 10.1126/science.186.4167.882; Kanner Baruch I., 2002, P235; KUGENHOLTZ J, 1981, P NATL ACAD SCI USA, V78, P3446; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LIU QR, 1993, FEBS LETT, V315, P114, DOI 10.1016/0014-5793(93)81145-P; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; Martin K, 1998, J BACTERIOL, V180, P107, DOI 10.1128/JB.180.1.107-118.1998; Ni YG, 2001, J BIOL CHEM, V276, P30942, DOI 10.1074/jbc.M104653200; Ohno M, 2000, INT J SYST EVOL MICR, V50, P1829, DOI 10.1099/00207713-50-5-1829; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PADAN E, 1994, J EXP BIOL, V196, P443; Pifl C, 2000, PURE APPL CHEM, V72, P1045, DOI 10.1351/pac200072061045; Pifl C, 1999, NEUROPHARMACOLOGY, V38, P157, DOI 10.1016/S0028-3908(98)00155-5; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; Rudnick Gary, 2002, P25; Saier MH, 1999, J CELL BIOCHEM, P84; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Soehnge H, 1996, P NATL ACAD SCI USA, V93, P13262, DOI 10.1073/pnas.93.23.13262; SULZER D, 1995, J NEUROSCI, V15, P4102; SUZUKI S, 1988, J GEN MICROBIOL, V134, P2353; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Tate CG, 2001, FEBS LETT, V504, P94, DOI 10.1016/S0014-5793(01)02711-9; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; UHL GR, 1992, MOL BRAIN RES, V16, P353, DOI 10.1016/0169-328X(92)90246-8; VERSAW WK, 1995, P NATL ACAD SCI USA, V92, P3884, DOI 10.1073/pnas.92.9.3884; WALL SC, 1993, MOL PHARMACOL, V43, P264; WALL SC, 1995, MOL PHARMACOL, V47, P544; WANG JB, 1995, J NEUROCHEM, V64, P1416; YANOFSKY C, 1991, J BACTERIOL, V173, P6009, DOI 10.1128/jb.173.19.6009-6017.1991	73	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12703	12709		10.1074/jbc.M206563200	http://dx.doi.org/10.1074/jbc.M206563200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569103	hybrid			2022-12-25	WOS:000182189500016
J	Goyal, K; Tisi, L; Basran, A; Browne, J; Burnell, A; Zurdo, J; Tunnacliffe, A				Goyal, K; Tisi, L; Basran, A; Browne, J; Burnell, A; Zurdo, J; Tunnacliffe, A			Transition from natively unfolded to folded state induced by desiccation in an anhydrobiotic nematode protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT CRATEROSTIGMA-PLANTAGINEUM; EMBRYOGENESIS-ABUNDANT PROTEIN; SECONDARY STRUCTURE; WATER-DEFICIT; LEA PROTEINS; TOLERANCE; SURVIVAL; STRESS; PURIFICATION; CONFORMATION	Late embryogenesis abundant (LEA) proteins are associated with desiccation tolerance in resurrection plants and in plant seeds, and the recent discovery of a dehydration-induced Group 3 LEA-like gene in the nematode Aphelenchus avenae suggests a similar association in anhydrobiotic animals. Despite their importance, little is known about the structure of Group 3 LEA proteins, although computer modeling and secondary structure algorithms predict a largely a-helical monomer that forms coiled coil oligomers. We have therefore investigated the structure of the nematode protein, Aav-LEA1, in the first such analysis of a well characterized Group 3 LEA-like protein. Immunoblotting and subunit cross-linking experiments demonstrate limited oligomerization of AavLEA1, but analytical ultracentrifugation and gel filtration show that the vast majority of the protein is monomeric. Moreover, CD, fluorescence emission, and Fourier transform-infrared spectroscopy indicate an unstructured conformation for the nematode protein. Therefore, in solution, no evidence was found to support structure predictions; instead, AavLEA1 seems to be natively unfolded with a high degree of hydration and low compactness. Such proteins can, however, be induced to fold into more rigid structures by partner molecules or by altered physiological conditions. Because AavLEA1 is associated with desiccation stress, its Fourier transform-infrared spectrum in the dehydrated state was examined. A dramatic but reversible increase in a-helix and, possibly, coiled coil formation was observed on drying, indicating that computer predictions of secondary structure may be correct for the solid state. This unusual finding offers the possibility that structural shifts in Group 3 LEA proteins occur on dehydration, perhaps consistent with their role in anhydrobiosis.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Natl Univ Ireland Maynooth, Dept Biol, Inst Bioengn & Agroecol, Maynooth, Kildare, Ireland; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge; Maynooth University; University of Cambridge	Tunnacliffe, A (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.	at10004@biotech.cam.ac.uk	Zurdo, Jesús/C-3110-2015	Zurdo, Jesús/0000-0001-5186-8633; Tunnacliffe, Alan/0000-0001-8570-125X				BAKER J, 1988, PLANT MOL BIOL, V11, P277, DOI 10.1007/BF00027385; Bartels D, 2001, PLANT PHYSIOL, V127, P1346, DOI 10.1104/pp.010765; Battista JR, 2001, CRYOBIOLOGY, V43, P133, DOI 10.1006/cryo.2001.2357; BLACKMAN SA, 1995, PHYSIOL PLANTARUM, V93, P630, DOI 10.1111/j.1399-3054.1995.tb05110.x; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Boothe JG, 1997, PLANT PHYSIOL, V113, P367, DOI 10.1104/pp.113.2.367; BRAY EA, 1993, PLANT PHYSIOL, V103, P1035, DOI 10.1104/pp.103.4.1035; Browne J, 2002, NATURE, V416, P38, DOI 10.1038/416038a; BURGESS AW, 1974, ISRAEL J CHEM, V12, P239; Burke MJ., 1986, MEMBRANES METABOLISM, P358; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CECCARDI TL, 1994, PROTEIN EXPRES PURIF, V5, P266, DOI 10.1006/prep.1994.1040; Clegg JS, 2001, COMP BIOCHEM PHYS B, V128, P613, DOI 10.1016/S1096-4959(01)00300-1; COGGINS JR, 1977, BIOCHEMISTRY-US, V16, P1111, DOI 10.1021/bi00625a013; COLACO C, 1992, BIO-TECHNOL, V10, P1007, DOI 10.1038/nbt0992-1007; Cole J L, 1999, J Biomol Tech, V10, P163; CROWE JH, 1987, BIOCHEM J, V242, P1, DOI 10.1042/bj2420001; Crowe JH, 1998, ANNU REV PHYSIOL, V60, P73, DOI 10.1146/annurev.physiol.60.1.73; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; Crowe JH, 1997, CRYOBIOLOGY, V35, P20, DOI 10.1006/cryo.1997.2020; Cuming AC, 1999, SEED PROTEINS, P753; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; Denning DP, 2002, J BIOL CHEM, V277, P33447, DOI 10.1074/jbc.M203499200; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Dong CN, 2002, PLANT PHYSIOL, V129, P1368, DOI 10.1104/pp.001925; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; DURE L, 1981, BIOCHEMISTRY-US, V20, P4162, DOI 10.1021/bi00517a033; DURE L, 1993, PLANT J, V3, P363, DOI 10.1046/j.1365-313X.1993.t01-18-00999.x; Dure L, 2001, PROTEIN PEPTIDE LETT, V8, P115, DOI 10.2174/0929866013409643; EVANS AAF, 1970, J NEMATOL, V2, P99; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GALAU GA, 1986, PLANT MOL BIOL, V7, P155, DOI 10.1007/BF00021327; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARNIER J, 1996, METHOD ENZYMOL, V266, P97; GRZELCZAK ZF, 1982, CAN J BIOCHEM CELL B, V60, P389, DOI 10.1139/o82-046; Hara M, 2001, J PLANT PHYSIOL, V158, P1333, DOI 10.1078/0176-1617-00600; Heimburg T, 1999, BIOCHEMISTRY-US, V38, P12727, DOI 10.1021/bi983079h; HIGA LM, 1993, J EXP ZOOL, V267, P120, DOI 10.1002/jez.1402670205; Hoekstra FA, 2001, TRENDS PLANT SCI, V6, P431, DOI 10.1016/S1360-1385(01)02052-0; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; Honjoh K, 2000, BIOSCI BIOTECH BIOCH, V64, P1656, DOI 10.1271/bbb.64.1656; Honjoh KI, 1996, J PLANT PHYSL, V155, P509; Imai R, 1996, GENE, V170, P243, DOI 10.1016/0378-1119(95)00868-3; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Ismail AM, 1999, PLANT PHYSIOL, V120, P237, DOI 10.1104/pp.120.1.237; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; KING RD, 1990, J MOL BIOL, V216, P441, DOI 10.1016/S0022-2836(05)80333-X; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lisse T, 1996, BIOL CHEM, V377, P555, DOI 10.1515/bchm3.1996.377.9.555; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; MCCUBBIN WD, 1985, CAN J BIOCHEM CELL B, V63, P803, DOI 10.1139/o85-102; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; Oliver MJ, 2000, PLANT ECOL, V151, P85, DOI 10.1023/A:1026550808557; Perry RN, 1999, PARASITOLOGY, V119, pS19, DOI 10.1017/S0031182000084626; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; ROBERTS JK, 1993, PLANT CELL, V5, P769, DOI 10.1105/tpc.5.7.769; Rowe A. J., 1992, ANAL ULTRACENTRIFUGA, P394, DOI DOI 10.1007/S00249-009-0425-1; ROWE AJ, 1977, BIOPOLYMERS, V16, P2595, DOI 10.1002/bip.1977.360161202; Russouw PS, 1997, SEED SCI RES, V7, P117, DOI 10.1017/S0960258500003457; RUSSOUW PS, 1995, SEED SCI RES, V5, P137, DOI 10.1017/S0960258500002750; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sivamani E, 2000, PLANT SCI, V155, P1, DOI 10.1016/S0168-9452(99)00247-2; Solomon A, 2000, PARASITOLOGY, V121, P409, DOI 10.1017/S0031182099006563; Soulages JL, 2002, PLANT PHYSIOL, V128, P822, DOI 10.1104/pp.010521; STELLWAGEN E, 1972, J BIOL CHEM, V247, P8074; Stetefeld J, 2000, NAT STRUCT BIOL, V7, P772, DOI 10.1038/79006; Sun WQ, 1997, COMP BIOCHEM PHYS A, V117, P327, DOI 10.1016/S0300-9629(96)00271-X; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Swire-Clark GA, 1999, PLANT MOL BIOL, V39, P117, DOI 10.1023/A:1006106906345; TUNNACLIFFE A, 2003, IN PRESS PHILOS T B; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Walters C, 1997, SEED SCI RES, V7, P125, DOI 10.1017/S0960258500003469; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wolfe J, 1986, MEMBRANES METABOLISM, P286; Wolkers WF, 1998, BBA-GEN SUBJECTS, V1425, P127, DOI 10.1016/S0304-4165(98)00059-2; Wolkers WF, 2001, BBA-PROTEIN STRUCT M, V1544, P196, DOI 10.1016/S0167-4838(00)00220-X; Womersley CZ, 1998, NEMATOLOGICA, V44, P269, DOI 10.1163/005425998X00044; Xu DP, 1996, PLANT PHYSIOL, V110, P249, DOI 10.1104/pp.110.1.249; Zhang L, 2000, J BIOCHEM, V127, P611, DOI 10.1093/oxfordjournals.jbchem.a022648; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	83	166	182	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12977	12984		10.1074/jbc.M212007200	http://dx.doi.org/10.1074/jbc.M212007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569097	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000182189500050
J	Kraus, TA; Lau, JF; Parisien, JP; Horvath, CM				Kraus, TA; Lau, JF; Parisien, JP; Horvath, CM			A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; GAMMA(1)34.5 PROTEIN; ESTABLISHED TUMORS; ALPHA-INTERFERON; BINDING DOMAIN; STAT PROTEINS; THERAPY; TRANSCRIPTION; SIGNAL; TRANSACTIVATION	Type I interferon (IFN) signaling induces the heterotrimeric transcription complex, IFN-stimulated gene factor (ISGF) 3, which contains STAT1, STAT2, and the DNA binding subunit, interferon regulatory factor (IRF) 9. Because IRF9 is targeted to the nucleus in the absence of IFN stimulation, the potential of IRF9 protein for gene regulation was examined using a GAL4 DNA binding domain fusion system. GAL4-IRF9 was transcriptionally active in reporter gene assays but not in the absence of cellular STAT1 and STAT2. However, the inert IRF9 protein was readily converted to a constitutively active ISGF3-like activator by fusion with the C-terminal transcriptional activation domain of STAT2 or the acidic activation domain of herpesvirus VP16. The IRF9 hybrids are targeted to endogenous ISGF3 target loci and can activate their transcription. Moreover, expression of the IRF9-STAT2 fusion can recapitulate the type I IFN biological response, producing a cellular antiviral state that protects cells from virus-induced cytopathic effects and inhibits virus replication. The antiviral state generated by regulated IRF9-STAT2 hybrid protein expression is independent of autocrine IFN signaling and inhibits both RNA and DNA viruses.	Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Horvath, CM (corresponding author), Box 1630,E Bldg,Rm 12-20D,1 Gustave L Levy Pl, New York, NY 10029 USA.	curt.horvath@mssm.edu		Horvath, Curt/0000-0003-2449-225X	NIAID NIH HHS [AI48722] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI048722, R01AI048722] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albini A, 2000, AM J PATHOL, V156, P1381, DOI 10.1016/S0002-9440(10)65007-9; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Bluyssen HAR, 1997, J BIOL CHEM, V272, P4600, DOI 10.1074/jbc.272.7.4600; Brassard DL, 2002, J LEUKOCYTE BIOL, V71, P565; Cassady KA, 1998, J VIROL, V72, P7005; Cheng GF, 2001, VIROLOGY, V290, P115, DOI 10.1006/viro.2001.1148; Coleman M, 1998, HUM GENE THER, V9, P2223, DOI 10.1089/hum.1998.9.15-2223; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; Ferrantini M, 2000, SEMIN CANCER BIOL, V10, P145, DOI 10.1006/scbi.2000.0333; FRIEDMAN RM, 1981, INTERFERONS PRIMER; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Horton HM, 1999, P NATL ACAD SCI USA, V96, P1553, DOI 10.1073/pnas.96.4.1553; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levy DE, 2002, J EXP MED, V195, pF15, DOI 10.1084/jem.20020075; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Luker KE, 2001, CANCER RES, V61, P6540; Majumder S, 1998, J IMMUNOL, V161, P4736; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MartinezMoczygemba M, 1997, J BIOL CHEM, V272, P20070, DOI 10.1074/jbc.272.32.20070; Mendiratta SK, 2000, HUM GENE THER, V11, P1851, DOI 10.1089/10430340050129477; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Parisien JP, 2002, J VIROL, V76, P6435, DOI 10.1128/JVI.76.13.6435-6441.2002; Parisien JP, 2002, J VIROL, V76, P4190, DOI 10.1128/JVI.76.9.4190-4198.2002; Park C, 1999, NUCLEIC ACIDS RES, V27, P4191, DOI 10.1093/nar/27.21.4191; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Poppers J, 2000, J VIROL, V74, P11215, DOI 10.1128/JVI.74.23.11215-11221.2000; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Shen Y, 2001, J VIROL, V75, P2627, DOI 10.1128/JVI.75.6.2627-2633.2001; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	42	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13033	13038		10.1074/jbc.M212972200	http://dx.doi.org/10.1074/jbc.M212972200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574168	hybrid			2022-12-25	WOS:000182189500057
J	Luo, ZQ; Smyth, AJ; Gao, P; Qin, YP; Farrand, SK				Luo, ZQ; Smyth, AJ; Gao, P; Qin, YP; Farrand, SK			Mutational analysis of TraR - Correlating function with molecular structure of a quorum-sensing transcriptional activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISCHERI LUXR PROTEIN; GRAM-NEGATIVE BACTERIA; C-TERMINAL REGION; VIBRIO-FISCHERI; AGROBACTERIUM-TUMEFACIENS; AUTOINDUCER-BINDING; DNA-BINDING; RHIZOBIUM-LEGUMINOSARUM; SYSTEM; GENES	TraR, the quorum-sensing activator of the Agrobacterium tumefaciens Ti plasmid conjugation system, induces gene expression in response to its quormone, N-(3-oxooctanoyl)-L-homoserine lactone. Ligand binding results in dimerization of TraR and is required for its activity. Analysis of N- and C-terminal deletion mutants of TraR localized the quormone-binding domain to a region between residues 39 and 140 and the primary dimerization domain to a region between residues 119 and 156. The dominant-negative properties of these mutants predicted a second dimerization domain at the C terminus of the protein. Analysis of fusions of N-terminal fragments of TraR to lambdacI' confirmed the dimerization activity of these two domains. Fifteen single amino acid substitution mutants of TraR defective in dimerization were isolated. According to the analysis of these mutants, Asp-70 and Gly-113 are essential for quormone binding, whereas Ala-38 and Ala-105 are important, but not essential. Additional residues located within the N-terminal half of TraR, including three located in a-helix 9, contribute to dimerization, but are not required for ligand binding. These results and the recently reported crystal structure of TraR are consistent with and complement each other and together define some of the structural and functional relationships of this quorum-sensing activator.	Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Farrand, SK (corresponding author), Univ Illinois, Dept Crop Sci, 240 ERML,1201 W Gregory Dr, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052465] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cangelosi GA, 1991, METHOD ENZYMOL, V145, P177; Cha C, 1998, MOL PLANT MICROBE IN, V11, P1119, DOI 10.1094/MPMI.1998.11.11.1119; CHILTON MD, 1974, P NATL ACAD SCI USA, V71, P3672, DOI 10.1073/pnas.71.9.3672; CHOI SH, 1992, J BACTERIOL, V174, P4064, DOI 10.1128/jb.174.12.4064-4069.1992; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; COOK DM, 1992, J BACTERIOL, V174, P6238, DOI 10.1128/JB.174.19.6238-6246.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; Egland KA, 2001, J BACTERIOL, V183, P382, DOI 10.1128/JB.183.1.382-386.2001; Farrand S. K, 1998, RHIZOBIACEAE MOL BIO, P199, DOI DOI 10.1007/978-94-011-5060-6; Farrand SK, 1996, J BACTERIOL, V178, P4233, DOI 10.1128/jb.178.14.4233-4247.1996; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; FUQUA WC, 1994, J BACTERIOL, V176, P2796, DOI 10.1128/JB.176.10.2796-2806.1994; Gray KM, 1996, J BACTERIOL, V178, P372, DOI 10.1128/jb.178.2.372-376.1996; HANZELKA BL, 1995, J BACTERIOL, V177, P815, DOI 10.1128/jb.177.3.815-817.1995; HU JC, 1995, STRUCTURE, V3, P431, DOI 10.1016/S0969-2126(01)00176-9; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kiratisin P, 2002, J BACTERIOL, V184, P4912, DOI 10.1128/JB.184.17.4912-4919.2002; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Lithgow JK, 2000, MOL MICROBIOL, V37, P81, DOI 10.1046/j.1365-2958.2000.01960.x; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; Luo ZQ, 1999, P NATL ACAD SCI USA, V96, P9009, DOI 10.1073/pnas.96.16.9009; Luo ZQ, 2001, MOL PLANT MICROBE IN, V14, P98, DOI 10.1094/MPMI.2001.14.1.98; McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703; Miller JH., 1972, EXPT MOL GENETICS; Minogue TD, 2002, MOL MICROBIOL, V44, P1625, DOI 10.1046/j.1365-2958.2002.02987.x; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Reverchon S, 1998, MOL MICROBIOL, V29, P1407, DOI 10.1046/j.1365-2958.1998.01023.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schripsema J, 1996, J BACTERIOL, V178, P366, DOI 10.1128/jb.178.2.366-371.1996; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; Shaw PD, 1997, P NATL ACAD SCI USA, V94, P6036, DOI 10.1073/pnas.94.12.6036; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; SLOCK J, 1990, J BACTERIOL, V172, P3974, DOI 10.1128/jb.172.7.3974-3979.1990; Trott AE, 2001, J BACTERIOL, V183, P387, DOI 10.1128/JB.183.1.387-392.2001; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832; Zhu J, 1998, J BACTERIOL, V180, P5398, DOI 10.1128/JB.180.20.5398-5405.1998	44	39	43	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13173	13182		10.1074/jbc.M210035200	http://dx.doi.org/10.1074/jbc.M210035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569101	hybrid			2022-12-25	WOS:000182189500075
J	Yang, Y; Borset, M; Langford, JK; Sanderson, RD				Yang, Y; Borset, M; Langford, JK; Sanderson, RD			Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEOGLYCAN; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; EPITHELIAL-CELLS; FINE-STRUCTURE; MYELOMA CELLS; EXPRESSION; RECEPTOR; GLYPICAN; BINDING	In polarized B lymphoid cells, syndecan-1 is targeted specifically to a discrete membrane domain termed the uropod that is located at the cell's trailing edge. Within this functional domain, syndecan-1 promotes cell-cell adhesion and concentration of heparin binding growth factors. The present study reveals the surprising finding that targeting of syndecan-1 to uropods is mediated by its heparan sulfate chains and that targeting is regulated by cell surface events rather than solely by intracellular mechanisms. The addition of exogenous heparin or the treatment of polarized cells with heparitinase initiates a rapid and dramatic redistribution of uropod syndecan-1 over the entire cell surface, and a mutated syndecan-1 lacking heparan sulfate chains fails to concentrate within uropods. Interestingly, the heparan sulfate-bearing proteoglycans glypican-1 and betaglycan fail to concentrate in uropods, indicating that targeting may require heparan sulfate structural motifs unique to syndecan-1 or that the core protein of syndecan-1 participates in specific interactions that promote heparan sulfate-mediated targeting. These findings suggest functional specificity for syndecan-1 within uropods and, in addition, reveal a novel mechanism for the targeting of molecules to discrete membrane subcellular domains via heparan sulfate.	Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Anat & Neurobiol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Sanderson, RD (corresponding author), Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Dept Pathol, Slot 517,4301 W Markham, Little Rock, AR 72205 USA.		Borset, Magne/AAY-1713-2021	Borset, Magne/0000-0001-5179-2835	NATIONAL CANCER INSTITUTE [R01CA068494] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borset M, 2000, BLOOD, V96, P2528; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; delPozo MA, 1997, J CELL BIOL, V137, P493; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P18881; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; LITWACK ED, 1994, J NEUROSCI, V14, P3713; Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.3.CO;2-8; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; MIETTINEN HM, 1994, J CELL SCI, V107, P1571; Millan J, 2002, BLOOD, V99, P978, DOI 10.1182/blood.V99.3.978; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood-2002-04-1190; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Wijdenes J, 1996, BRIT J HAEMATOL, V94, P318, DOI 10.1046/j.1365-2141.1996.d01-1811.x; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	37	26	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12888	12893		10.1074/jbc.M209440200	http://dx.doi.org/10.1074/jbc.M209440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566461	hybrid			2022-12-25	WOS:000182189500039
J	Zako, M; Dong, JY; Goldberger, O; Bernfield, M; Gallagher, JT; Deakin, JA				Zako, M; Dong, JY; Goldberger, O; Bernfield, M; Gallagher, JT; Deakin, JA			Syndecan-1 and-4 synthesized simultaneously by mouse mammary gland epithelial cells bear heparan sulfate chains that are apparently structurally indistinguishable	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; FINE-STRUCTURE; SURFACE; PROTEOGLYCANS; ADHESION; DOMAIN; TETRASACCHARIDES; IDENTIFICATION; ECTODOMAINS; AFFINITY	Many of the biological functions attributed to cell surface heparan sulfate (HS) proteoglycans, including the Syndecan family, are elicited through the interaction of their HS chains with soluble extracellular molecules. Tightly controlled, cell-specific sulfation and epimerization of HS precursors endows these chains with highly sulfated, iduronate-rich regions, which are major determinants of cytokine and matrix-protein binding and which are interspersed by N-acetylated, poorly sulfated regions. Until this study, there have been no comprehensive structural comparisons made on HS chains decorating simultaneously expressed, but different, syndecan core proteins. In this paper we demonstrate that the HS chains on affinity-purified syndecan-1 and -4 from murine mammary gland cells are essentially identical by a number of parameters. Size determination, disaccharide analyses, enzymatic and chemical scission methods, and affinity co-electrophoresis all failed to reveal any significant differences in fine structure, domain organization, or ligand-binding properties of these HS species. These findings lead us to suggest that the imposition of the fine structure onto HS occurs independently of the core protein to which it is attached and that these core proteins, in addition to the HS chains, may play a pivotal role in the various biological functions ascribed to these macromolecules.	Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med, Boston, MA 02215 USA; Univ Manchester, Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England	Harvard University; Boston Children's Hospital; Harvard Medical School; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Zako, M (corresponding author), Aichi Med Univ, Dept Ophthalmol, Nagakute Cho, Aichi 4801195, Japan.	zako@aichi-med-u.ac.jp						Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; Carey DJ, 1997, BIOCHEM J, V327, P1; DAVID G, 1981, J NATL CANCER I, V67, P719; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; Fitzgerald M. L., 1999, SYNDECANS GUIDEBOOK, P306; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinnunen A, 1998, EUR J NEUROSCI, V10, P635, DOI 10.1046/j.1460-9568.1998.00082.x; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; McFall AJ, 1997, J BIOL CHEM, V272, P12901, DOI 10.1074/jbc.272.20.12901; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; MERTENS G, 1992, J BIOL CHEM, V269, P2270; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; STANLEY MJ, 1995, J BIOL CHEM, V270, P5077, DOI 10.1074/jbc.270.10.5077; Stringer SE, 1999, J BIOL CHEM, V274, P25455, DOI 10.1074/jbc.274.36.25455; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Tumova S, 2000, J BIOL CHEM, V275, P9410, DOI 10.1074/jbc.275.13.9410; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; Yamashita Y, 1999, J IMMUNOL, V162, P5940; Zimmermann P, 1999, FASEB J, V13, pS91	56	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13561	13569		10.1074/jbc.M209658200	http://dx.doi.org/10.1074/jbc.M209658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571251	hybrid			2022-12-25	WOS:000182189500121
J	Zhu, H; Takahashi, Y; Xu, WP; Kawajiri, H; Murakami, T; Yamamoto, M; Iseki, S; Iwasaki, T; Hattori, H; Yoshimoto, T				Zhu, H; Takahashi, Y; Xu, WP; Kawajiri, H; Murakami, T; Yamamoto, M; Iseki, S; Iwasaki, T; Hattori, H; Yoshimoto, T			Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR; MOLECULAR-BIOLOGY; 15-LIPOXYGENASE; EXPRESSION; 12-LIPOXYGENASE; DOMAIN; GENE; LDL; ATHEROSCLEROSIS; LIPOXYGENASES	Oxidation of low density lipoprotein (LDL) is the key step for the development of atherosclerosis. The 12/15-lipoxygenase expressed in macrophages is capable of oxygenating linoleic acid esterified to cholesterol in the LDL particle, and thus this enzyme is presumed to initiate LDL oxidation. We recently reported that LDL receptor-related protein (LRP) was required for the enzyme-mediated LDL oxidation by macrophages and suggested the selective uptake of cholesterol ester from LDL to the plasma membrane (Xu, W., Takahashi, Y., Sakashita, T., Iwasaki, T., Hattori, H., and Yoshimoto. T. (2001) J. Biol. Chem 276,36454-36459). To elucidate precise mechanisms of lipoxygenase-mediated LDL oxidation, we investigated the intracellular localization of 12/15-lipoxygenase. The 12/15-lipoxygenase was predominantly detected in cytosol of resting peritoneal macrophages and of macrophage-like J774A.1 cells permanently transfected with the cDNA for the enzyme. When the cells were treated with LDL and subjected to subcellular fractionation, the 12/15-lipoxygenase was detected in the membranes with a concomitant decrease in cytosol as shown by Western blot analysis. The levels of the enzyme associated with the membrane reached maximum in 15 min after LDL addition and then decreased. However, the enzymatic activity of 12/15-lipoxygenase in the membrane fraction was very weak even after LDL treatment. This fact supports the suicide inactivation of the enzyme by the oxygenation of cholesterol ester transferred from the LDL particle to the plasma membrane. Immunohistochemical analysis using an antibody against 12/15-lipoxygenase revealed that the plasma membrane was the major site of the enzyme translocation by the LDL treatment. LDL-dependent 12/15-lipoxygenase translocation was inhibited by a blocking antibody against LRP. Furthermore, an enzyme translocation inhibitor, L655238, inhibited the LDL oxidation caused by the 12/15-lipoxygenase. We propose that cholesterol ester selectively transferred from the LDL particle to the plasma membrane via LRP is oxygenated by 12/15-lipoxygenase translocated to this membrane.	Kanazawa Univ, Grad Sch Med Sci, Dept Mol Pharmacol, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Mol Funct Anal, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University; Kanazawa University	Yoshimoto, T (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Mol Pharmacol, Kanazawa, Ishikawa 9208640, Japan.	yoshimot@med.kanazawa-u.ac.jp						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; Belkner J, 1998, J BIOL CHEM, V273, P23225, DOI 10.1074/jbc.273.36.23225; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; EVANS JF, 1991, MOL PHARMACOL, V40, P22; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiltunen TP, 1998, ATHEROSCLEROSIS, V137, pS81, DOI 10.1016/S0021-9150(97)00307-9; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Kawajiri H, 1997, BIOCHEM BIOPH RES CO, V238, P229, DOI 10.1006/bbrc.1997.7213; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Miller YI, 2001, J BIOL CHEM, V276, P19431, DOI 10.1074/jbc.M011276200; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Ozeki Y, 1999, BRIT J PHARMACOL, V128, P1699, DOI 10.1038/sj.bjp.0702976; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sakashita T, 1999, EUR J BIOCHEM, V265, P825, DOI 10.1046/j.1432-1327.1999.00803.x; Shen JH, 1995, FASEB J, V9, P1623, DOI 10.1096/fasebj.9.15.8529842; Swarnakar S, 2001, J BIOL CHEM, V276, P21121, DOI 10.1074/jbc.M101691200; TAKAHASHI Y, 2002, RES ADV CANC, V2, P221; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Xu WP, 2001, J BIOL CHEM, V276, P36454, DOI 10.1074/jbc.M105093200; Yamamoto M, 2001, ANAT REC, V262, P213, DOI 10.1002/1097-0185(20010201)262:2<213::AID-AR1031>3.0.CO;2-W; YOSHIMOTO T, 1995, J LIPID MEDIAT CELL, V12, P195, DOI 10.1016/0929-7855(95)00019-M; Zhuang DM, 2000, J BIOCHEM, V127, P451, DOI 10.1093/oxfordjournals.jbchem.a022627	40	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13350	13355		10.1074/jbc.M212104200	http://dx.doi.org/10.1074/jbc.M212104200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566436	hybrid, Green Submitted			2022-12-25	WOS:000182189500096
J	Kotlo, KU; Yehiely, F; Efimova, E; Harasty, H; Hesabi, B; Shchors, K; Einat, P; Rozen, A; Berent, E; Deiss, LP				Kotlo, KU; Yehiely, F; Efimova, E; Harasty, H; Hesabi, B; Shchors, K; Einat, P; Rozen, A; Berent, E; Deiss, LP			Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cells	ONCOGENE			English	Article						apoptosis; function profiling; functional genomics; FaS; Nrf2; phase II detoxifying enzymes	ACTIVATED PROTEIN-KINASE; MEDIATED APOPTOSIS; DT-DIAPHORASE; INTERFERON-GAMMA; BINDING PROTEIN; DEATH; ELEMENT; TRANSCRIPTION; EXPRESSION; INDUCTION	Here we describe the Achilles' Heel Method (AHM), a new function-based approach for identification of inhibitors of signaling pathways, optimized for human cells. The principle of AHM is the identification of 'sensitizing' cDNAs based on their decreased abundance following selection. As a proof of principle, we have employed AHM for the identification of Fas/CD95/APO-1 pathway inhibitors. HeLa cells were transfected with an antisense cDNA expression library in an episomal vector followed by selection with a suboptimal dose of the apoptotic inducer. Antisense inactivation of Fas inhibitors rendered the cells more sensitive to apoptosis resulting in their preferential death and consequent loss of their sensitizing episomes that were identified by subtraction. We show that the resulting products were enriched for sensitizing cDNAs as seven out of eight candidates tested were confirmed as inhibitors of Fas-induced killing either by transfection or by pharmacological inhibition. Furthermore, we demonstrate by multiple approaches that one candidate, NF-E2 related factor 2 (Nrf2), is an inhibitor of Fas-induced apoptosis. Inactivation of Nrf2 by antisense or by a membrane permeable dominant-negative polypeptide sensitized cells while overexpression of Nrf2 protected cells from Fas-induced apoptosis. In addition, dicumarol, an inhibitor of the phase 11 detoxifying enzyme NQO1, a downstream target of Nrf2, sensitized cells. Nrf2 induces the production of Glutathione (GSH) and we demonstrated that N-acetyl L-cysteine (NAC), a precursor to GSH, protected cells from Fas-mediated killing. Taken together, AHM is a powerful approach for the identification of inhibitors of a signaling pathway with a low rate of false positives that opens new avenues for function profiling of human genes and discovery of new drug targets.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Quark Biotech Inc, Cleveland, OH 44106 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Deiss, LP (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	Ldeiss@uic.edu						Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Begleiter A, 1997, ONCOL RES, V9, P371; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; HOSODA S, 1974, J BIOL CHEM, V249, P6416; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; JOSEPH P, 1994, ONCOL RES, V6, P525; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Ohtsubo T, 1999, CELL DEATH DIFFER, V6, P865, DOI 10.1038/sj.cdd.4400566; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Salinas AE, 1999, CURR MED CHEM, V6, P279; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Siemankowski LM, 2000, CANCER RES, V60, P3638; Stark GR, 1999, HUM MOL GENET, V8, P1925, DOI 10.1093/hmg/8.10.1925; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	44	67	73	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					797	806		10.1038/sj.onc.1206077	http://dx.doi.org/10.1038/sj.onc.1206077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584558				2022-12-25	WOS:000180864300001
J	Shimizu, H; Seiki, T; Asada, M; Yoshimatsu, K; Koyama, N				Shimizu, H; Seiki, T; Asada, M; Yoshimatsu, K; Koyama, N			alpha 6 beta 1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells	ONCOGENE			English	Article						integrin; erbB2; proteasome; breast cancer	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; ALPHA(2)BETA(1) INTEGRIN; P185(HER2) ONCOPROTEIN; DIFFERENTIATION FACTOR; PROTOONCOGENE PRODUCT; EXTRACELLULAR DOMAIN; CARCINOMA; ACTIVATION; EXPRESSION	ErbB2 and alpha6 integrin have been implicated in malignancy of breast cancer cells. Here we have determined the influence of alpha6beta1 integrin on erbB2 signaling in anchorage-independent growth, using MDA-MB435 breast cancer cells. Firstly, we transfected the cells with erbB2 cDNA, and isolated cells with high or low levels of alpha6beta1 integrin by cell sorting (alpha6H-ErbB and alpha6L-ErbB). We found that an erbB ligand, heregulin beta1, enhanced growth activity of alpha6L-ErbB cells, but not alpha6H-ErbB cells. Secondly, we established cells expressing a beta4 integrin deletion mutant (beta4-Deltacyt), which selectively inhibited alpha6beta1 integrin expression and adhesion to laminin-1. Again, heregulin beta1 enhanced the growth of erbB2 cDNA-transfected beta4-Deltacyt cells, but not mock cells. Western blot analysis revealed that heregulin beta1 stimulated phosphorylation of Akt and its downstream molecules, GSK3beta and p70S6kinase, and that the extent of phosphorylation was greater in ErbB2/beta4-Deltacyt cells than ErbB2/mock cells. Furthermore, we found that the erbB2 cytoplasmic domain was truncated in ErbB2/mock cells, which was independent of ligand stimulation and adhesion, and was suppressed by proteasome inhibitors. These results suggest that alpha6beta1 integrin inhibits erbB2 signals by inducing proteasome-dependent proteolytic cleavage of the erbB2 cytoplasmic domain, and may thereby contribute to the regulation of tumor growth.	Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan	Eisai Co Ltd	Shimizu, H (corresponding author), Eisai & Co Ltd, Tsukuba Res Labs, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	h4-shimizu@hhc.eisai.co.jp		Koyama, Noriyuki/0000-0002-7509-6583				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CAMPIGLIO M, 1994, J CELL BIOCHEM, V55, P409, DOI 10.1002/jcb.240550402; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Christianson TA, 1998, CANCER RES, V58, P5123; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Codony-Servat J, 1999, CANCER RES, V59, P1196; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Krane IM, 1996, ONCOGENE, V12, P1781; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LICHTNER RB, 1995, ONCOGENE, V10, P1823; LIN YZJ, 1991, ONCOGENE, V6, P639; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Manenti S, 2002, BIOCHEM BIOPH RES CO, V294, P976, DOI 10.1016/S0006-291X(02)00594-6; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; PUPA SM, 1993, ONCOGENE, V8, P2917; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shimizu H, 2002, INT J ONCOL, V21, P1073; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun H, 1998, CANCER RES, V58, P2224; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tan M, 1997, CANCER RES, V57, P1199; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Vafa A, 1998, INT J ONCOL, V13, P1191; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wewer UM, 1997, AM J PATHOL, V151, P1191; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yu DH, 1996, ONCOGENE, V13, P1359; Yu X, 2000, J CELL SCI, V113, P2139; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	68	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					831	839		10.1038/sj.onc.1206203	http://dx.doi.org/10.1038/sj.onc.1206203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584562				2022-12-25	WOS:000180864300005
J	Reinehr, R; Schliess, F; Haussinger, D				Reinehr, R; Schliess, F; Haussinger, D			Hyperosmolarity and CD95L trigger CD95/EGFR association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation	FASEB JOURNAL			English	Article						apoptosis; osmosignaling; oxidative stress; c-Jun-N-terminal kinase; protein kinase C	CELL-VOLUME; GROWTH-FACTOR; RECEPTOR; INHIBITION; ACTIVATION; FAS; SHRINKAGE; PROLIFERATION; INDUCTION; MECHANISM	The mechanisms underlying CD95 ligand (CD95L)- and hyperosmolarity-induced activation of the CD95 system [Reinehr, R., Graf, D., Fischer, R., Schliess, F., and Haussinger, D. (2002) Hepatology 36, 602-614] as initial steps of apoptosis were studied. Hyperosmotic exposure (405 mosmol/l) of rat hepatocytes induced within 1 min oxidative stress and antioxidant-sensitive activation of the epidermal growth factor receptor (EGFR) and c-Jun-N-terminal-kinase (JNK). After 30 min of hyperosmotic exposure EGFR associated with CD95 and CD95 became tyrosine phosphorylated. Inhibition of JNK or protein kinase C (PKC) had no effect on EGFR phosphorylation but abolished CD95/EGFR association, CD95-tyrosine phosphorylation, membrane targeting, and Fas-associated death domain/caspase 8 recruitment to CD95 [death-inducing signaling complex (DISC) formation]. Inhibition of EGFR tyrosine kinase activity prevented CD95 tyrosine phosphorylation and DISC formation but not hyperosmolarity-induced EGFR phosphorylation and EGFR association with CD95. Tyrosine-phosphorylated CD95 was enriched in the plasma membrane. All maneuvers preventing CD95 tyrosine phosphorylation inhibited CD95 membrane trafficking and DISC formation. Stimulation of EGFR by EGF induced EGFR phosphorylation but no association with CD95 or CD95 phosphorylation. Addition of CD95L also induced EGFR and JNK activation, EGFR/CD95 association, CD95 tyrosine phosphorylation, DISC formation, and CD95 membrane targeting with an inhibitor sensitivity profile similar to that of hyperosmotic CD95 activation, except that inhibition of PKC was ineffective. The data suggest that moderate hyperosmolarity or CD95L trigger oxidative stress and EGFR activation followed by a JNK-dependent EGFR/CD95association and CD95 tyrosine phosphorylation, probably through EGFR tyrosine kinase activity. This provides a signal for CD95 membrane trafficking and DISC formation.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Klinikum Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BORNER CD, 1996, AM J PHYSIOL-CELL PH, V40, pC950; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; GORG B, 2002, IN PRESS HEPATOLOGY; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KOH YH, 2001, FASEB J, DOI DOI 10.1096/FJ.00-572FJE; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meves A, 2002, ARCH DERMATOL RES, V294, P243, DOI 10.1007/s00403-002-0315-1; Nobel CSI, 2000, APOPTOSIS, V5, P153, DOI 10.1023/A:1009684713784; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAHA N, 1992, EUR J BIOCHEM, V209, P437, DOI 10.1111/j.1432-1033.1992.tb17307.x; SAHA N, 1993, BIOCHEM J, V296, P701, DOI 10.1042/bj2960701; Schlehr F, 1999, ATHLET THER TODAY, V4, P13, DOI 10.1123/att.4.4.13; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Wettstein M, 1997, HEPATOLOGY, V26, P1560; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3	37	97	98	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					731	+		10.1096/fj.02-0915fje	http://dx.doi.org/10.1096/fj.02-0915fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586732				2022-12-25	WOS:000181456900035
J	Zhang, Y; Luo, Y; Zhai, QW; Ma, LY; Dorf, ME				Zhang, Y; Luo, Y; Zhai, QW; Ma, LY; Dorf, ME			Negative role of cAMP-dependent protein kinase A in RANTES-mediated transcription of proinflammatory mediators through Raf	FASEB JOURNAL			English	Article						astrocytes; chemokines; inflammation	SIGNAL-REGULATED KINASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MAP KINASE; REACTIVE ASTROCYTES; ALZHEIMERS-DISEASE; ADENYLYL CYCLASES; MURINE ASTROCYTES; A ACTIVITY; ACTIVATION; EXPRESSION	The chemokine RANTES (regulated on activation normal T cell expressed and secreted) is expressed in several inflammatory diseases of the central nervous system and is a powerful stimulus for astrocyte production of proinflammatory mediators. The mechanism of RANTES-mediated astrocyte activation was investigated. RANTES stimulation decreased both intracellular cyclic AMP (cAMP) levels and cAMP-dependent protein kinase A (PKA) activity in cultures of primary mouse astrocytes. H-89, a potent inhibitor of PKA, mimicked RANTES-mediated chemokine and cytokine transcription. RANTES treatments activated Raf-1 kinase activity, and conversely a dominant negative Raf and a Raf-1 inhibitor blocked RANTES-induced chemokine transcription. Transfection with a constitutively active Raf was sufficient to induce transcription of proinflammatory mediators. The combined data indicate that Raf-1 is required for RANTES-mediated astrocyte activation. Decreases of cAMP and PKA activity contributed to the transcription of proinflammatory mediators by cross-talk with the Raf1/mitogen-activated protein kinase pathway. The results identify an upstream signaling pathway for amplification of proinflammatory mediators in the central nervous system.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Dorf, ME (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Bldg D530,200 Longwood Ave, Boston, MA 02115 USA.	dorf@hms.harvard.edu	Zhang, Ye/D-5015-2011	Zhang, Ye/0000-0002-3494-7206; Zhai, Qiwei/0000-0002-9617-7403				Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Barnes DA, 1998, J NEUROIMMUNOL, V87, P17, DOI 10.1016/S0165-5728(98)00041-1; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dorf ME, 2000, J NEUROIMMUNOL, V111, P109, DOI 10.1016/S0165-5728(00)00371-4; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fischer FR, 2000, J NEUROIMMUNOL, V110, P195, DOI 10.1016/S0165-5728(00)00351-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimaldi M, 1997, BIOCHEM BIOPH RES CO, V235, P242, DOI 10.1006/bbrc.1997.6513; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Han YL, 2000, GLIA, V30, P1; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KREBS EG, 1989, JAMA-J AM MED ASSOC, V262, P1815, DOI 10.1001/jama.262.13.1815; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu F, 2001, AM J PHYSIOL-LUNG C, V280, pL1309, DOI 10.1152/ajplung.2001.280.6.L1309; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Luo Y, 2002, GLIA, V39, P19, DOI 10.1002/glia.10079; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Ransohoff RM, 1999, J NEUROIMMUNOL, V98, P57, DOI 10.1016/S0165-5728(99)00082-X; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schwaninger M, 2000, GLIA, V31, P51, DOI 10.1002/(SICI)1098-1136(200007)31:1<51::AID-GLIA50>3.0.CO;2-M; Streit WJ, 2001, NEUROBIOL AGING, V22, P909, DOI 10.1016/S0197-4580(01)00290-1; Sun DM, 1997, J NEUROSCI RES, V48, P192; Tanabe S, 1997, J IMMUNOL, V159, P5671; Tani M, 1996, AM J PATHOL, V148, P889; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wagner BL, 2000, J BIOL CHEM, V275, P8263, DOI 10.1074/jbc.275.12.8263; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xia MQ, 2000, J NEUROIMMUNOL, V108, P227, DOI 10.1016/S0165-5728(00)00285-X; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Zhang Y, 2002, J BIOL CHEM, V277, P19042, DOI 10.1074/jbc.M112442200; Zhao J, 1998, J CELL BIOCHEM, V71, P36, DOI 10.1002/(SICI)1097-4644(19981001)71:1<36::AID-JCB4>3.0.CO;2-2	56	11	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					734	+		10.1096/fj.02-0962fje	http://dx.doi.org/10.1096/fj.02-0962fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586731				2022-12-25	WOS:000181456900029
J	Scott, PG; Grossmann, JG; Dodd, CM; Sheehan, JK; Bishop, PN				Scott, PG; Grossmann, JG; Dodd, CM; Sheehan, JK; Bishop, PN			Light and X-ray scattering show decorin to be a dimer in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN PROTEODERMATAN SULFATE; LEUCINE-RICH REPEAT; GROWTH-FACTOR-BETA; DERMATAN SULFATE; SELF-ASSOCIATION; EXTRACELLULAR-MATRIX; PROTEOGLYCAN-II; CORE PROTEIN; COLLAGEN; ACID	Decorin is a widely distributed member of the extracellular matrix small leucine-rich repeat glycoprotein/proteoglycan family. For investigation of its physical properties, decorin from two sources (young steer skin and a recombinant adenovirus) was used. The first sample was extracted into 7 M urea and purified, while the second was isolated from medium conditioned by 293A cells infected with adenovirus and purified without chaotropes. The only chemical differences detected between these materials were a slightly shorter glycosaminoglycan chain and the retention of the propeptide on the latter. Circular dichroism spectra of the two samples were virtually identical, showing a high proportion of beta-sheet and beta-turn and little alpha-helix. The protein cores were completely denatured in 2.25 M guanidine HCl (GdnHCl) but recovered their secondary structure on removal of chaotrope. Light scattering of material eluted from gel-filtration columns in Tris-buffered saline, pH 7.0, gave molecular mass values of 165 +/- 1 kDa and 84.6 +/- 4 kDa for intact decorin and the glycoprotein core produced by digestion with chondroitin ABC lyase, respectively. Intact recombinant prodecorin had a mass of 148 +/- 18 kDa. These values, which are double those estimated from SDS gel electrophoresis or from the known sequences and compositions, were halved in 2.5 M GdnHCl. Data from solution x-ray scattering of intact decorin and its core in Tris-buffered saline are consistent with a dimeric particle whose protein component has a radius of gyration of 31.6 +/- 0.4 Angstrom, a maximum diameter of 98 +/- 5 Angstrom, and approximates two intertwined C shapes.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Res Councils Daresbury Lab, Cent Lab, Synchrotron Radiat Dept, Mol Biophys Grp, Warrington WA4 4AD, Cheshire, England; Univ Manchester, Sch Med, Res Grp Eye & Vis Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PL, Lancs, England	University of Alberta; STFC Daresbury Laboratory; University of Manchester; University of Manchester	Scott, PG (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.			Bishop, Paul/0000-0001-7937-7932				Blaschke UK, 1996, J BIOL CHEM, V271, P30347, DOI 10.1074/jbc.271.48.30347; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; COSTER L, 1981, BIOCHEM J, V197, P483; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Feigin L.A., 1987, STRUCTURE ANAL SMALL; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LIU J, 1994, J BIOL CHEM, V269, P28366; MECHANIC G, 1979, SKELETAL RES EXPT AP, P227; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1993, J BIOL CHEM, V268, P11558; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; Scott PG, 1997, BBA-GEN SUBJECTS, V1336, P254, DOI 10.1016/S0304-4165(97)00040-8; SCOTT PG, 1993, DERMATAN SULPHATE PR, P81; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZANGRANDO D, 1989, BIOPOLYMERS, V28, P1295, DOI 10.1002/bip.360280710	39	44	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18353	18359		10.1074/jbc.M211936200	http://dx.doi.org/10.1074/jbc.M211936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12601001	hybrid			2022-12-25	WOS:000182838300100
J	Williams, ME; Strickland, P; Watanabe, K; Hinck, L				Williams, ME; Strickland, P; Watanabe, K; Hinck, L			UNC5H1 induces apoptosis via its juxtamembrane region through an interaction with NRAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; CELL-CYCLE PROGRESSION; DEATH DOMAIN; C-ELEGANS; NETRIN RECEPTOR; TNF RECEPTOR; PROTEIN; GROWTH; UNC-5; DCC	The UNC5Hs are axon guidance receptors that mediate netrin-1-dependent chemorepulsion, and dependence receptors that mediate netrin-1-independent apoptosis. Here, we report an interaction between UNC5H1 and NRAGE. Our experiments show that this interaction is responsible for apoptosis induced by UNC5H1, and this level of apoptosis is greater than the amount induced by either UNC5H2 or UNC5H3. We mapped the NRAGE binding domain of UNC5H1 to its ZU-5 domain and show that this region, in addition to an adjacent PEST sequence, is required for UNC5H1-mediated apoptosis. Chimeric UNC5H2 and UNC5H3 receptors, containing the NRAGE binding domain and PEST sequence of UNC5H1, bind NRAGE and cause increased levels of apoptosis. UNC5H1 expression does not induce apoptosis in differentiated PC12 cells, which down-regulate NRAGE, but induces apoptosis in native PC12 cells that endogenously express high levels of NRAGE and in differentiated PC12 cells when NRAGE is overexpressed. Together, these results demonstrate a mechanism for UNC5H1-mediated apoptosis that requires an interaction with the MAGE protein NRAGE.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan	University of California System; University of California Santa Cruz	Hinck, L (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.		Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915; Williams, Megan/0000-0002-5461-4126; Hinck, Lindsay/0000-0002-4009-3913	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039572] Funding Source: NIH RePORTER; NIMH NIH HHS [MH12813-02] Funding Source: Medline; NINDS NIH HHS [NS39572-01, R01 NS039572] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Barrett C, 2001, MECH DEVELOP, V106, P163, DOI 10.1016/S0925-4773(01)00415-4; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Finger JH, 2002, J NEUROSCI, V22, P10346; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; Kendall SE, 2002, MECH DEVELOP, V117, P187, DOI 10.1016/S0925-4773(02)00204-6; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Przyborski SA, 1998, DEVELOPMENT, V125, P41; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shiras Anjali, 2001, Molecular Cell Biology Research Communications, V4, P313, DOI 10.1006/mcbr.2001.0298; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	35	88	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17483	17490		10.1074/jbc.M300415200	http://dx.doi.org/10.1074/jbc.M300415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598531	hybrid			2022-12-25	WOS:000182818600136
J	Chen, L; Esteve, E; Sabatier, JM; Ronjat, M; De Waard, M; Allen, PD; Pessah, IN				Chen, L; Esteve, E; Sabatier, JM; Ronjat, M; De Waard, M; Allen, PD; Pessah, IN			Maurocalcine and peptide A stabilize distinct subconductance states of ryanodine receptor type 1, revealing a proportional gating mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; CALCIUM-RELEASE CHANNEL; MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; IMPERATOXIN-A; CA2+ RELEASE; CARDIAC-MUSCLE; CONTRACTION; ACTIVATION	Maurocalcine (MCa) isolated from Scorpio maurus palmatus venom shares 82% sequence identity with imperatoxin A. Both scorpion toxins are putative mimics of the II-III loop peptide (termed peptide A (pA)) of alpha(1s)-dihydropyridine receptor and are thought to act at a common site on ryanodine receptor type 1 (RyR1) important for skeletal muscle EC coupling. The relationship between the actions of synthetic MCa (sMCa) and pA on RyR1 were examined. sMCa released Ca2+ from SR vesicles (EC50 = 17.5 nm) in a manner inhibited by micromolar ryanodine or ruthenium red. pA (0.5-40 mum) failed to induce SR Ca2+ release. Rather, pA enhanced Ca2+ loading into SR and fully inhibited Ca2+-, caffeine-, and sMCa-induced Ca2+ release. The two peptides modified single channel gating behavior in distinct ways. With Cs+-carrying current, 10 nm to 1 mum sMCa induced long lived subconductances having 48% of the characteristic full open state and occasional transitions to 29% at either positive or negative holding potentials. In contrast, pA stabilized long lived channel closures with occasional burst transitions to 65% (s1) and 86% (s2) of the full conductance. The actions of pA and sMCa were observed in tandem. sMCa stabilized additional subconductance states proportional to pA-induced subconductances (i.e. 43% of pA-modified s1 and s2 substates), revealing a proportional gating mechanism. [H-3]Ryanodine binding and surface plasmon resonance analyses indicated that the peptides did not interact by simple competition for a single class of mutually exclusive sites on RyR1 to produce proportional gating. The actions of sMCa were also observed with ryanodine-modified channels and channels deficient in immunophilin 12-kDa FK506-binding protein. These results provide evidence that sMCa and pA stabilize distinct RyR1 channel states through distinct mechanisms that allosterically stabilize gating states having proportional conductance.	Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Grad Program Neurosci, Davis, CA 95616 USA; UJF, CEA, INSERM, EMI 9931,Lab Canaux Ion & Signalisat, F-38054 Grenoble, France; Fac Med Nord, CNRS, UMR 6560, F-13916 Marseille 20, France; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.		De Waard, Michel/G-7406-2014; ESTEVE, Eric/M-7490-2014; Pessah, Isaac N/K-7985-2017	De Waard, Michel/0000-0002-2782-9615; Pessah, Isaac N/0000-0002-8149-588X; Ronjat, Michel/0000-0002-9728-6425; SABATIER, Jean-Marc/0000-0002-9040-5647; ESTEVE, Eric/0000-0002-4548-9140	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER; NIAMS NIH HHS [2P01 AR 17605] Funding Source: Medline; NIEHS NIH HHS [1P01 ES 11269] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEELER GW, 1970, J PHYSIOL-LONDON, V207, P211, DOI 10.1113/jphysiol.1970.sp009057; BUCK E, 1992, J BIOL CHEM, V267, P23560; Chen L, 1999, J BIOL CHEM, V274, P32603, DOI 10.1074/jbc.274.46.32603; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; HORACKOVA M, 1976, J PHYSIOL-LONDON, V259, P597, DOI 10.1113/jphysiol.1976.sp011485; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XY, 1994, J BIOL CHEM, V269, P6511; MACK MM, 1992, J PHARMACOL EXP THER, V262, P1028; Mead F, 2002, BIOPHYS J, V82, P1953, DOI 10.1016/S0006-3495(02)75544-6; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MOSBAH A, 1998, 6 REC TAX AUG 1 4 19; NABAUER M, 1989, AM J PHYSIOL, V256, pH916, DOI 10.1152/ajpheart.1989.256.3.H916; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nabhani T, 2002, BIOPHYS J, V82, P1319, DOI 10.1016/S0006-3495(02)75487-8; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PALADE P, 1987, J BIOL CHEM, V262, P6142; Pessah IN, 1997, AM J PHYSIOL-CELL PH, V272, pC601, DOI 10.1152/ajpcell.1997.272.2.C601; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; ROUSSEAU E, 1987, AM J PHYSIOL, V253, P364; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098	47	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16095	16106		10.1074/jbc.M209501200	http://dx.doi.org/10.1074/jbc.M209501200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586831	hybrid			2022-12-25	WOS:000182680000082
J	Jourd'heuil, D; Jourd'heuil, FL; Feelisch, M				Jourd'heuil, D; Jourd'heuil, FL; Feelisch, M			Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide - Evidence for a free radical mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROGLUTATHIONE; SERUM-ALBUMIN; PEROXYNITRITE; KINETICS; NO; GLUTATHIONE; FATE; NITROSOTHIOLS; NITROSYLATION	Although the nitric oxide ((NO)-N-.)-mediated nitrosation of thiol-containing molecules is increasingly recognized as an important post-translational modification in cell signaling and pathology, little is known about the factors that govern this process in vivo. In the present study, we examined the chemical pathways of nitrosothiol (RSNO) production at low micromolar concentrations of (NO)-N-.. Our results indicate that, in addition to nitrosation by the (NO)-N-. derivative dinitrogen trioxide (N2O3), RSNOs may be formed via intermediate one-electron oxidation of thiols, possibly mediated by nitrogen dioxide ((NO2)-N-.), and the subsequent reaction of thiyl radicals with (NO)-N-.. In vitro, the formation of S-nitrosoglutathione (GSNO) from (NO)-N-. and excess glutathione (GSH) was accompanied by the formation of glutathione disulfide, which could not be ascribed to the secondary reaction of GSH with GSNO. Superoxide dismutase significantly increased GSNO yields and the thiyl radical trap, 5,5-dimethyl-1-pyrroline N-oxide (DMPO), inhibited by 45 and 98% the formation of GSNO and GSSG, respectively. Maximum nitrosation yields were obtained at an oxygen concentration of 3%, whereas higher oxygen tensions decreased GSNO and increased GSSG formation. When murine fibroblasts were exposed to exogenous WO, RSNO formation was sensitive to DMPO and oxygen tension in a manner similar to that observed with GSH alone. Our data indicate that RSNO formation is favored at oxygen concentrations that typically occur in tissues. Nitrosothiol formation in vivo depends not only on the availability of (NO)-N-. and O-2 but also on the degree of oxidative stress by affecting the steady-state concentration of thiyl radicals.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Albany Medical College; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Jourd'heuil, D (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave MC8, Albany, NY 12208 USA.	jourdhd@mail.ame.edu	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158; Jourd'heuil, David/0000-0002-6555-5061	NCI NIH HHS [CA 89366] Funding Source: Medline; NHLBI NIH HHS [HL 69029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089366] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Archer Stephen L., 1995, Methods (Orlando), V7, P21, DOI 10.1006/meth.1995.1004; Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; Ford E, 2002, FREE RADICAL BIO MED, V32, P1314, DOI 10.1016/S0891-5849(02)00850-X; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Pou S, 1998, J CHEM SOC PERK T 2, P1507, DOI 10.1039/a707662b; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stubauer G, 1999, J BIOL CHEM, V274, P28128, DOI 10.1074/jbc.274.40.28128; Tsikas D, 2001, J CHROMATOGR A, V915, P107, DOI 10.1016/S0021-9673(01)00634-3; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003	28	158	161	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15720	15726		10.1074/jbc.M300203200	http://dx.doi.org/10.1074/jbc.M300203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595536	hybrid			2022-12-25	WOS:000182680000034
J	Wojnar, P; Lechner, M; Redl, B				Wojnar, P; Lechner, M; Redl, B			Antisense down-regulation of lipocalin-interacting membrane receptor expression inhibits cellular internalization of lipocalin-1 in human NT2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; HUMAN TEAR LIPOCALIN; GENE FAMILY; LIPOPROTEIN; MEGALIN; CLONING; MOUSE; IDENTIFICATION; SUPERFAMILY; SCAVENGER	There is increasing experimental evidence demonstrating that many lipocalins bind to specific cell surface receptors. However, whereas the binding of lipocalins to their lipophilic ligands has now been characterized in much detail, there is a lack of knowledge about the nature of lipocalin receptors, the physiological role of receptor binding, and the molecular mechanism of ligand delivery. We previously identified a novel human membrane protein (lipocalin-l-interacting membrane receptor (LIMR)),which interacts with lipocalin-1 (Wojnar, P., Lechner, M., Merschak, P., and Redl, B. (2001) J. Biol. Chem. 276, 20206-20212). In the present study, we investigated the physiological role of LIMR and found this protein to be essential for mediating internalization of lipocalin-1 (Lcn-1) in NT2 cells, leading to its degradation. Whereas control NT2 cells rapidly internalized (125)I-Lcn-1 or fluorescein isothiocyanate-labeled Lcn-1, NT2 cells that were made LIMR deficient by cDNA antisense expression greatly accumulated Lcn-1 in the culture medium but did not internalize it. Because sequence and structure analysis indicated that proteins similar to LIMR are present in several organisms and at least two closely related orthologues are found in human and mouse, we suggest LIMR to be the prototype of a new family of endocytic receptors, which are topographically characterized by nine putative transmembrane domains and a characteristic large central cytoplasmic loop.	Univ Innsbruck, Dept Biol Mol, A-6020 Innsbruck, Austria	University of Innsbruck	Redl, B (corresponding author), Univ Innsbruck, Dept Biol Mol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	bernhard.redl@uibk.ac.at						Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersen UO, 1996, J MOL RECOGNIT, V9, P364, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<364::AID-JMR266>3.0.CO;2-6; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BISHOP RE, 1995, J BIOL CHEM, V270, P23097, DOI 10.1074/jbc.270.39.23097; Boudjelal M, 1996, BIOCHEM J, V317, P23, DOI 10.1042/bj3170023; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Bugos RC, 1998, J BIOL CHEM, V273, P15321, DOI 10.1074/jbc.273.25.15321; Cavaggioni A, 2000, BBA-PROTEIN STRUCT M, V1482, P218, DOI 10.1016/S0167-4838(00)00149-7; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHEN CC, 1977, J BIOL CHEM, V252, P5216; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Clark RM, 2000, GENOMICS, V67, P19, DOI 10.1006/geno.2000.6225; Clark RM, 2001, GENETICS, V159, P715; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; FERNANDEZLUNA JL, 1988, FEBS LETT, V236, P471, DOI 10.1016/0014-5793(88)80079-6; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Flower DR, 1996, BIOCHEM J, V318, P1; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; GLASGOW BJ, 1995, CURR EYE RES, V14, P363, DOI 10.3109/02713689508999934; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kang Y, 1997, BBA-BIOMEMBRANES, V1324, P285, DOI 10.1016/S0005-2736(96)00235-0; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lacazette E, 2000, HUM MOL GENET, V9, P289, DOI 10.1093/hmg/9.2.289; Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Logdberg L, 2000, BBA-PROTEIN STRUCT M, V1482, P284, DOI 10.1016/S0167-4838(00)00164-3; MALABA L, 1995, J BIOL CHEM, V270, P15686, DOI 10.1074/jbc.270.26.15686; Mansouri A, 1997, BBA-MOL CELL RES, V1357, P107, DOI 10.1016/S0167-4889(97)00018-9; Mansouri A, 1998, BIOFACTORS, V7, P287, DOI 10.1002/biof.5520070401; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; MU JZ, 1994, BBA-MOL CELL RES, V1222, P483, DOI 10.1016/0167-4889(94)90058-2; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; REDL B, 1992, J BIOL CHEM, V267, P20282; Redl B, 2000, BBA-PROTEIN STRUCT M, V1482, P241, DOI 10.1016/S0167-4838(00)00142-4; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SENOO H, 1990, J LIPID RES, V31, P1229; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; Wester L, 1998, SCAND J IMMUNOL, V48, P1; Wojnar P, 2001, J BIOL CHEM, V276, P20206, DOI 10.1074/jbc.M101762200	48	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16209	16215		10.1074/jbc.M210922200	http://dx.doi.org/10.1074/jbc.M210922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591932	hybrid			2022-12-25	WOS:000182680000095
J	Krell, T; Renauld-Mongenie, G; Nicolai, MC; Fraysse, S; Chevalier, M; Berard, Y; Oakhill, J; Evans, RW; Gorringe, A; Lissolo, L				Krell, T; Renauld-Mongenie, G; Nicolai, MC; Fraysse, S; Chevalier, M; Berard, Y; Oakhill, J; Evans, RW; Gorringe, A; Lissolo, L			Insight into the structure and function of the transferrin receptor from Neisseria meningitidis using microcalorimetric techniques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-B; DIFFERENTIAL SCANNING CALORIMETRY; ISOTHERMAL TITRATION CALORIMETRY; ESCHERICHIA-COLI; BACTERICIDAL ANTIBODIES; DOMAIN INTERACTIONS; IDENTIFICATION; VACCINE; GENES; TBPB	The transferrin receptor of Neisseria meningitidis is composed of the transmembrane protein TbpA and the outer membrane protein TbpB. Both receptor proteins have the capacity to independently bind their ligand human transferrin (htf). To elucidate the specific role of these proteins in receptor function, isothermal titration calorimetry was used to study the interaction between purified TbpA, TbpB or the entire receptor (TbpA + TbpB) with holo- and apo-htf. The entire receptor was shown to contain a single high affinity htf-binding site on TbpA and approximately two lower affinity binding sites on TbpB. The binding sites appear to be independent. Purified ThpA was shown to have strong ligand preference for apo-htf, whereas TbpA in the receptor complex with TbpB preferentially binds the holo form of htf. The orientation of the ligand specificity of TbpA toward holo-htf is proposed to be the physiological function of TbpB. Furthermore, the thermodynamic mode of htf binding by TbpB of isotypes I and II was shown to be different. A protocol for the generation of active, histidine-tagged TbpB as well as its individual N- and C-terminal domains is presented. Both domains are shown to strongly interact with each other, and isothermal titration calorimetry and circular dichroism experiments provide clear evidence for this interaction causing conformational changes. The N-terminal domain of TbpB was shown to be the site of htf binding, whereas the C-terminal domain is not involved in binding. Furthermore, the interactions between ThpA and the different domains of TbpB have been demonstrated.	Aventis Pasteur, F-69280 Marcy Letoile, France; Kings Coll London, Randall Ctr Mol Mechanisms Cell Funct, Metalloprot Res Grp, London SE1 1UL, England; Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England	Sanofi-Aventis; Sanofi France; University of London; King's College London	Krell, T (corresponding author), Aventis Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.	tino.krell@aventis.com	Gorringe, Andrew R/L-6022-2017; Oakhill, Jonathan S/F-5724-2011; Krell, Tino/G-7296-2015	Gorringe, Andrew R/0000-0003-2193-7954; Oakhill, Jonathan S/0000-0002-9475-1440; Krell, Tino/0000-0002-9040-3166				ALAALDEEN DAA, 1994, INFECT IMMUN, V62, P2984, DOI 10.1128/IAI.62.7.2984-2990.1994; ANDERSON JE, 1994, J BACTERIOL, V176, P3162, DOI 10.1128/jb.176.11.3162-3170.1994; Begg N, 1999, J INFECTION, V39, P1, DOI 10.1016/S0163-4453(99)90095-6; Boulton IC, 1997, FEBS LETT, V414, P409, DOI 10.1016/S0014-5793(97)01025-9; Boulton IC, 1998, BIOCHEM J, V334, P269, DOI 10.1042/bj3340269; Boulton IC, 1999, J THEOR BIOL, V198, P497, DOI 10.1006/jtbi.1999.0928; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; CHANG BS, 1993, PHARMACEUT RES, V10, P1478, DOI 10.1023/A:1018979410338; Cooper A., 1999, PROTEIN C T, P217; Cornelissen CN, 1997, INFECT IMMUN, V65, P822, DOI 10.1128/IAI.65.2.822-828.1997; Cornelissen CN, 1996, J BACTERIOL, V178, P1437, DOI 10.1128/jb.178.5.1437-1444.1996; Cornelissen CN, 1997, MOL MICROBIOL, V26, P25, DOI 10.1046/j.1365-2958.1997.5381914.x; CORNELISSEN CN, 1994, MOL MICROBIOL, V14, P843, DOI 10.1111/j.1365-2958.1994.tb01320.x; DANVE B, 1993, VACCINE, V11, P1214, DOI 10.1016/0264-410X(93)90045-Y; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Freire Ernesto, 1995, V40, P191; Fuller CA, 1998, MICROB PATHOGENESIS, V24, P75, DOI 10.1006/mpat.1997.0174; GORRINGE AR, 1995, VACCINE, V13, P1207, DOI 10.1016/0264-410X(95)00055-6; GRAYOWEN SD, 1995, INFECT IMMUN, V63, P1201, DOI 10.1128/IAI.63.4.1201-1210.1995; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; IRWIN SW, 1993, MOL MICROBIOL, V8, P1125, DOI 10.1111/j.1365-2958.1993.tb01657.x; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; Krell T, 2002, PROTEIN EXPRES PURIF, V24, P323, DOI 10.1006/prep.2001.1593; LEGRAIN M, 1993, GENE, V130, P73, DOI 10.1016/0378-1119(93)90348-7; LEGRAIN M, 1995, PROTEIN EXPRES PURIF, V6, P570, DOI 10.1006/prep.1995.1075; LISSOLO L, 1995, INFECT IMMUN, V63, P884, DOI 10.1128/IAI.63.3.884-890.1995; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Luke NR, 1999, INFECT IMMUN, V67, P5815, DOI 10.1128/IAI.67.11.5815-5819.1999; MAZARIN V, 1995, GENE, V158, P145, DOI 10.1016/0378-1119(95)00151-U; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; Myers LE, 1998, INFECT IMMUN, V66, P4183; OAKHILL JS, 2002, PROTEIN EXPRES PURIF, V364, P613; Pintor M, 1998, J MED MICROBIOL, V47, P757, DOI 10.1099/00222615-47-9-757; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Powell NBL, 1998, J MED MICROBIOL, V47, P257, DOI 10.1099/00222615-47-3-257; Remmele RL, 1999, BIOCHEMISTRY-US, V38, P5241, DOI 10.1021/bi982881g; Renauld-Mongenie G, 1998, FEMS MICROBIOL LETT, V169, P171; RenauldMongenie G, 1997, J BACTERIOL, V179, P6400, DOI 10.1128/jb.179.20.6400-6407.1997; Retzer MD, 1999, MOL MICROBIOL, V32, P111, DOI 10.1046/j.1365-2958.1999.01331.x; Rokbi B, 2000, INFECT IMMUN, V68, P4938, DOI 10.1128/IAI.68.9.4938-4947.2000; ROKBI B, 1993, FEMS MICROBIOL LETT, V110, P51, DOI 10.1016/0378-1097(93)90241-S; Ronpirin C, 2001, INFECT IMMUN, V69, P6336, DOI 10.1128/IAI.69.10.6336-6347.2001; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; VONDERHAAR RA, 1994, J BACTERIOL, V176, P6207, DOI 10.1128/jb.176.20.6207-6213.1994; WARD JH, 1987, INVEST RADIOL, V22, P74, DOI 10.1097/00004424-198701000-00017; West D, 2001, INFECT IMMUN, V69, P1561, DOI 10.1128/IAI.69.3.1561-1567.2001; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	55	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14712	14722		10.1074/jbc.M204461200	http://dx.doi.org/10.1074/jbc.M204461200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12571247	hybrid			2022-12-25	WOS:000182516100018
J	Yueh, MF; Huang, YH; Hiller, A; Chen, SJ; Nguyen, N; Tukey, RH				Yueh, MF; Huang, YH; Hiller, A; Chen, SJ; Nguyen, N; Tukey, RH			Involvement of the xenobiotic response element (XRE) in ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; CACO-2 CELLS; HUMAN BILIRUBIN; GASTROINTESTINAL-TRACT; METABOLIZING-ENZYMES; FLAVONOID CHRYSIN; NUCLEAR RECEPTOR; COMPLEX LOCUS; CYP1A1 GENE; EXPRESSION	UDP-glucuronosyltransferase 1A1 (UGT1A1) plays an important physiological role by contributing to the metabolism of endogenous substances such as bilirubin in addition to xenobiotics and drugs. The UGT1A1 gene has been shown to be inducible by nuclear receptors steroid xenobiotic receptor (SXR) and the constitutive active receptor, CAR. In this report, we show that in human hepatoma HepG2 cells the UGT1A1 gene is also inducible with aryl hydrocarbon receptor (Ah receptor) ligands such as 2,3,7,8-tetrachlodibenzo-p-dioxin (TCDD), beta-naphthoflavone, and benzo[a]pyrene metabolites. Induction was monitored by increases in protein and catalytic activity as well as UGT1A1 mRNA. To examine the molecular interactions that control UGT1A1 expression, the gene was characterized and induction by Ah receptor ligands was regionalized to bases -3338 to -3287. Nucleotide sequence analysis of this UGT1A1 enhancer region revealed a xenobiotic response element (XRE) at -3381/-3299. The dependence of the XRE on UGT1A1-luciferase activity was demonstrated by a loss of Ah receptor ligand inducibility when the XRE core region (CACGCA) was deleted or mutated. Gel mobility shift analysis confirmed that TCDD induction of nuclear proteins specifically bound to the UGT1A1-XRE, and competition experiments with Ah receptor and Arnt antibodies demonstrated that the nuclear protein was the Ah receptor. These observations reveal that the Ah receptor is involved in human UGT1A1 induction.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Lab Environm Toxicol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen SW, 2001, DRUG METAB DISPOS, V29, P1074; Anderson JW, 1999, MAR ENVIRON RES, V48, P389, DOI 10.1016/S0141-1136(99)00054-9; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bock KW, 2000, BIOCHEM PHARMACOL, V59, P467, DOI 10.1016/S0006-2952(99)00366-4; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; Dutton G.F., 1980, GLUCURONIDATION DRUG; Galijatovic A, 2000, PHARMACEUT RES, V17, P21, DOI 10.1023/A:1007506222436; Galijatovic A, 2001, PHARMACEUT RES, V18, P374, DOI 10.1023/A:1011019417236; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grams B, 2000, ARCH BIOCHEM BIOPHYS, V377, P255, DOI 10.1006/abbi.2000.1777; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kashfi K, 1995, CLIN PHARMACOL THER, V58, P625, DOI 10.1016/0009-9236(95)90018-7; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MERCHANT M, 1992, ARCH BIOCHEM BIOPHYS, V292, P250, DOI 10.1016/0003-9861(92)90076-9; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; Munzel PA, 1999, DRUG METAB DISPOS, V27, P569; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; PETERS WHM, 1987, GASTROENTEROLOGY, V93, P162, DOI 10.1016/0016-5085(87)90329-5; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; RITTER JK, 1992, J BIOL CHEM, V267, P3257; Soucek P, 1995, BIOCHEMISTRY-US, V34, P16013, DOI 10.1021/bi00049a015; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Walle T, 2000, DRUG METAB DISPOS, V28, P1077; Walle UK, 2002, DRUG METAB DISPOS, V30, P564, DOI 10.1124/dmd.30.5.564; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245; XIE W, 2003, IN PRESS P NATL ACAD; Ziccardi MH, 2002, ENVIRON TOXICOL CHEM, V21, P2027, DOI 10.1897/1551-5028(2002)021<2027:AOTLRC>2.0.CO;2	38	139	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15001	15006		10.1074/jbc.M300645200	http://dx.doi.org/10.1074/jbc.M300645200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566446	hybrid			2022-12-25	WOS:000182516100056
J	van der Wijk, T; Blanchetot, C; Overvoorde, J; den Hertog, J				van der Wijk, T; Blanchetot, C; Overvoorde, J; den Hertog, J			Redox-regulated rotational coupling of receptor protein-tyrosine phosphatase alpha dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSIBLE INACTIVATION; NEGATIVE REGULATION; LIGAND; DIMERIZATION; DOMAINS; CD45; PHOSPHORYLATION; ASSOCIATION; SPECIFICITY; INHIBITION	Receptor protein-tyrosine phosphatase a (RPTPalpha) constitutively forms dimers in the membrane, and activity studies with forced dimer mutants of RPTPalpha revealed that rotational coupling of the dimer defines its activity. The hemagglutinin (HA) tag of wild type RPTPalpha and of constitutively dimeric, active RPTPalpha-F135C with a disulfide bond in the extracellular domain was not accessible for antibody, whereas the HA tag of constitutively dimeric, inactive RPTPalpha-P137C was. All three proteins were expressed on the plasma membrane to a similar extent, and the accessibility of their extracellular domains did not differ as determined by biotinylation studies. Dimerization was required for masking the RA tag, and we identified a region in the N terminus of RPTPalpha that was essential for the effect. Oxidative stress has been shown to induce a conformational change of the membrane distal PTP domain (RPTPalpha-D2). Here we report that H2O2 treatment of cells induced a change in rotational coupling in RPTPa dimers as detected using accessibility of an HA tag in the extracellular domain as a read-out. The catalytic site Cys(723) in RPTPalpha-D2, which was required for the conformational change of RPTPalpha-D2 upon H2O2 treatment, was essential for the H2O2-induced increase in accessibility. These results show for the first time that a conformational change in the intracellular domain of RPTPalpha led to a change in conformation of the extracellular domains, indicating that RPTPs have the capacity for inside-out signaling.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl						Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, FEBS LETT, V484, P235, DOI 10.1016/S0014-5793(00)02165-7; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Dornan S, 2002, J BIOL CHEM, V277, P1912, DOI 10.1074/jbc.M108386200; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707	39	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13968	13974		10.1074/jbc.M300632200	http://dx.doi.org/10.1074/jbc.M300632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582170	hybrid			2022-12-25	WOS:000182405000053
J	Schlegel, BP; Starita, LM; Parvin, JD				Schlegel, BP; Starita, LM; Parvin, JD			Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells	ONCOGENE			English	Article						BRCA1; RNA helicase A; aneuploidy; centrosome; PARP-1	POLYMERASE-II HOLOENZYME; TRANSCRIPTION IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; BREAST-CANCER; EXPRESSION; CYCLE; ACTIVATION	The breast- and ovarian-specific tumor suppressor, BRCA1, has been implicated to function in many nuclear processes, including DNA damage repair, recombination, transcription, ubiquitination, cell cycle checkpoint enforcement, and centrosome regulation. Utilizing a previously described interaction between BRCA1 and RNA helicase A (RHA), we have developed a dominant-negative approach to block BRCA1 function in human breast epithelial cells. Overexpression of a truncated RHA peptide that can bind to the BRCA1 carboxy-terminus prevents normal BRCA1 function, such as BRCA1 association with nuclear foci following DNA damage. Overexpression of this dominant-negative protein induces pleomorphic nuclei, aberrant mitoses with extra centrosomes, and tetraploidy. This model system allows us to observe changes to mammary epithelial cells that occur acutely following loss of BRCA1 function. Furthermore, inhibition of BRCA1 via overexpressing the RHA fragment coincides with a reduction in PARP-1 protein expression, suggesting a possible mechanism for BRCA1 in the maintenance of genomic integrity.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parvin, JD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BENJAMIN RC, 1980, J BIOL CHEM, V255, P1502; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Larson JS, 1997, CANCER RES, V57, P3351; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; OHGUSHI H, 1980, J BIOL CHEM, V255, P6205; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TANIGUCHI T, 1982, J BIOL CHEM, V257, P4027; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	39	86	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					983	991		10.1038/sj.onc.1206195	http://dx.doi.org/10.1038/sj.onc.1206195			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592385				2022-12-25	WOS:000180926100004
J	Bundy, LM; Sealy, L				Bundy, LM; Sealy, L			CCAAT/enhancer binding protein beta (C/EBP beta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture	ONCOGENE			English	Article						C/EBP transcription factor; anchorage independence; EMT; invasion; mammary gland; retroviral vector	HUMAN BREAST-CANCER; C/EBP-BETA; CYCLIN D1; TRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 GENE; INHIBITORY PROTEIN; GLAND DEVELOPMENT; TRANSGENIC MICE; MESSENGER-RNA; EXPRESSION	The transcription factor CCAAT/enhancer binding protein (C/EBP)p is critical for normal growth and differentiation of the mammary gland. The intronless C/EBPbeta gene encodes a single mRNA that produces three protein isoforms, C/EBPbeta-1, -2, and -3, which share a common basic-leucine zipper domain at their C-terminus, but are distinguished at their N-termini by the in-frame methionine codon used to initiate translation. Although C/EBPbeta-1 and -2 are both transactivators, they likely perform distinct functions in mammary epithelial cells. C/EBPbeta-1 is the only isoform detected in normal human mammary tissue. In breast cancer cell lines, C/EBPbeta-1 is absent, and the C/EBPbeta-2 transactivator is expressed. Moreover, our data suggest that C/EBPbeta-2 is upregulated in human primary breast tumors. To assess C/EBPbeta-2's ability to participate in the transformation process, we generated recombinant retrovirus selectively encoding epitope-tagged C/EBPbeta-2. Strikingly, 10 days after infecting a normal human mammary epithelial cell line (MCF10A) with C/EBPbeta-2 virus, transformed subcultures were readily generated. Specifically, C/EBPbeta-2-overexpressing MCF10A cells form foci, gain anchorage independence, express markers associated with having undergone an epithelial-to-mesenchymal transition, and acquire an invasive phenotype. These studies, and our previous observations, provide supportive evidence that deregulated expression of C/EBPbeta-2 contributes to malignant conversion of the human breast.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Calkhoven CF, 2000, GENE DEV, V14, P1920; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; GILLES C, 1996, BREAST J, V2, P83; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Grignani F, 1998, CANCER RES, V58, P14; Half E, 2002, CANCER RES, V62, P1676; Hanlon M, 2000, BMC Cell Biol, V1, P2, DOI 10.1186/1471-2121-1-2; Hay ED, 1995, ACTA ANAT, V154, P8; Hirai Y, 2001, J CELL BIOL, V153, P785, DOI 10.1083/jcb.153.4.785; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Montell DJ, 2001, MECH DEVELOP, V105, P19, DOI 10.1016/S0925-4773(01)00393-8; Raught B, 1996, CANCER RES, V56, P4382; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; SOULE HD, 1990, CANCER RES, V50, P6075; TAIT L, 1990, CANCER RES, V50, P6087; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Xiong W, 2001, NUCLEIC ACIDS RES, V29, P3087, DOI 10.1093/nar/29.14.3087; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yuan CJ, 2000, CANCER RES, V60, P1084; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887; Zahnow CA, 2001, CANCER RES, V61, P261; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	49	101	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					869	883		10.1038/sj.onc.1206216	http://dx.doi.org/10.1038/sj.onc.1206216			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584567				2022-12-25	WOS:000180864300010
J	Zermati, Y; De Sepulveda, P; Feger, F; Letard, S; Kersual, J; Casteran, N; Gorochov, G; Dy, M; Dumas, AR; Dorgham, K; Parizot, C; Bieche, Y; Vidaud, M; Lortholary, O; Arock, M; Hermine, O; Dubreuil, P				Zermati, Y; De Sepulveda, P; Feger, F; Letard, S; Kersual, J; Casteran, N; Gorochov, G; Dy, M; Dumas, AR; Dorgham, K; Parizot, C; Bieche, Y; Vidaud, M; Lortholary, O; Arock, M; Hermine, O; Dubreuil, P			Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms	ONCOGENE			English	Article						mastocytosis; c-kit; STI571; kinase inhibitor	GASTROINTESTINAL STROMAL TUMOR; ACTIVATING MUTATION; MYELOID-LEUKEMIA; CATALYTIC DOMAIN; ABL PROTEIN; BONE-MARROW; LINE UT-7; MASTOCYTOSIS; DIFFERENTIATION; ERYTHROPOIETIN	Systemic mastocytosis (SM) is a rare disease caused by an abnormal mast cell accumulation in various tissues. Two classes of constitutive activating e-kit mutations are found in SM. The most frequent class occurs in the catalytic pocket coding region with substitutions at codon 816 and the other in the intracellular juxtamembrane coding region. Therefore, kinase inhibitors that block mutated c-kit activity might be used as therapeutic agents in SM. Here, we show that STI571 inhibits both wild-type and juxtamembrane mutant c-kit kinase activity, but has no effect an the activity of the D816 V mutant. Accordingly, STI571 selectively decreases the survival of normal mast cell and of mast cell lines either with juxtamembrane c-kit mutations, but not that of tumoral mast cell from patient with SM or of mast cell lines with the D816 V mutation. Therefore, STI571 is not a good candidate to treat SM and specific kinase inhibitors should be designed to inhibit constitutive activating mutations at codon 816.	Hop Necker Enfants Malad, Dept Adult Hematol, F-75743 Paris 15, France; Univ Paris 05, Hop Necker Enfants Malad, CNRS UMR 8603, Paris, France; INSERM, U119, F-13258 Marseille, France; GHPS, Inserm U584, Lab Immunol Cellulaire & Tissulaire, Paris, France; Univ Paris 05, Fac Pharm, UPRES JE 2195, Genet Mol Lab, Paris, France; Hop Avicenne, Dept Internal Med & Infect Dis, F-93009 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Dubreuil, P (corresponding author), Hop Necker Enfants Malad, Dept Adult Hematol, 149-161 Rue Sevres, F-75743 Paris 15, France.		Dorgham, karim/A-2241-2016; Gorochov, Guy/P-2911-2017; dubreuil, patrice/F-5346-2011; Vidaud, Michel/O-7346-2017; Dubreuil, Patrice/V-4816-2019; Hermine, Olivier/Q-7072-2018; De sepulveda, paulo/K-6043-2015	Dorgham, karim/0000-0001-9539-3203; dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; PARIZOT, Christophe/0000-0001-5723-4471; LETARD, Sebastien/0000-0002-6508-7376; Hermine, Olivier/0000-0003-2574-3874; Gorochov, Guy/0000-0003-2097-9677				Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hashimoto K, 1996, AM J PATHOL, V148, P189; HERMINE O, 1992, BLOOD, V80, P3060; Hongyo T, 2000, CANCER RES, V60, P2345; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; KITAMURA Y, 1978, BLOOD, V52, P447; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Longley BJ, 2000, HEMATOL ONCOL CLIN N, V14, P697, DOI 10.1016/S0889-8588(05)70303-8; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; Marone G, 2001, LEUKEMIA RES, V25, P583, DOI 10.1016/S0145-2126(01)00039-X; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Tsujimura T, 1996, BLOOD, V87, P273; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; Worobec AS, 2000, HEMATOL ONCOL CLIN N, V14, P659, DOI 10.1016/S0889-8588(05)70301-4; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Zermati Y, 2000, EXP HEMATOL, V28, P256, DOI 10.1016/S0301-472X(99)00155-1	25	152	162	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					660	664		10.1038/sj.onc.1206120	http://dx.doi.org/10.1038/sj.onc.1206120			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569358				2022-12-25	WOS:000180642100003
J	Luciano, F; Herrant, M; Jacquel, A; Ricci, JE; Auberger, P				Luciano, F; Herrant, M; Jacquel, A; Ricci, JE; Auberger, P			The P54-cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis	FASEB JOURNAL			English	Article						BCR-induced apoptosis; c-DNA array; c-Myc	MYC-INDUCED APOPTOSIS; RECEPTOR-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; ANTIGEN RECEPTOR; C-MYC; SIGNAL-TRANSDUCTION; DOWN-MODULATION; PROTEIN-KINASE; T-LYMPHOCYTES; MITOCHONDRIA	Engagement of the B cell receptor antigen (BCR) triggers apoptosis on immature B cell lines. We report here that BCR triggering leads to caspase activation followed by Lyn cleavage and induction of apoptosis. The cleavage process is mitochondrion-dependent and involves caspases 9 and 7. Stable expression of the cleaved form of Lyn (Lyn-Delta-N) in Ramos B cells impairs BCR-mediated apoptosis as judged by loss of Deltapsim, caspase activation and PARP cleavage. Activation of the main survival pathways upon BCR-triggering was unaltered in both cell variants. However, the PI3-K inhibitor Ly294002 resensitizes Lyn-Delta-N cells to apoptosis. Selected cDNA expression arrays revealed that anti-IgM modulates the expression of similar to20 genes in both cell variants. Among them, only c-Myc was found to be differentially regulated, which suggests a role for c-Myc in the B cell apoptotic response. Interestingly, c-Myc expression decreased more rapidly in Lyn-Delta-N compared with Lyn-WT cells during the first hours of anti-IgM stimulation. Nevertheless, rapid down-regulation of c-Myc following BCR engagement seems to correlate with the resistance of B cells to apoptosis. Thus, the soluble form of Lyn generated by caspases following BCR triggering acts as an inhibitor of B lymphocyte death likely through the modulation of c-Myc expression.	Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice 2, France; La Jolla Inst Allergy & Immunol, San Diego, CA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; La Jolla Institute for Immunology	Auberger, P (corresponding author), Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Contre Canc, UFR50,Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	AUBERGER, Patrick/G-1491-2013; RICCI, Jean Ehrland/AAS-4379-2020; luciano, frederic/P-6264-2016; Jacquel, Arnaud/O-1928-2017; Jacquel, Arnaud/AAJ-4760-2021; Ricci, Jean Ehrland/I-7117-2016	AUBERGER, Patrick/0000-0002-2481-8275; RICCI, Jean Ehrland/0000-0003-1585-8117; luciano, frederic/0000-0001-9253-4998; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Ricci, Jean Ehrland/0000-0003-1585-8117				Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Berard R, 1999, J IMMUNOL, V163, P4655; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; Bras A, 1999, FASEB J, V13, P931, DOI 10.1096/fasebj.13.8.931; Carey GB, 2000, IMMUNOL REV, V176, P105; Dang CV, 1999, MOL CELL BIOL, V19, P1; Doi T, 1999, INT IMMUNOL, V11, P933, DOI 10.1093/intimm/11.6.933; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; Gold MR, 2000, IMMUNOL REV, V176, P47; GRAVES JD, 1998, J EXP MED, V188, P651; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herold MJ, 2002, J IMMUNOL, V168, P3902, DOI 10.4049/jimmunol.168.8.3902; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; King LB, 2000, IMMUNOL REV, V176, P86; Koncz G, 2002, IMMUNOL LETT, V82, P41, DOI 10.1016/S0165-2478(02)00017-2; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Nagata S, 1998, J HUM GENET, V43, P2, DOI 10.1007/s100380050029; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nikiforov MA, 2000, ONCOGENE, V19, P4828, DOI 10.1038/sj.onc.1203880; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oberg F, 2001, LEUKEMIA, V15, P217, DOI 10.1038/sj.leu.2402025; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rolink AG, 2001, CURR OPIN IMMUNOL, V13, P202, DOI 10.1016/S0952-7915(00)00205-3; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tiberio L, 2001, CELL DEATH DIFFER, V8, P967, DOI 10.1038/sj.cdd.4400909; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wu M, 1996, MOL CELL BIOL, V16, P5015; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	45	18	19	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					711	+		10.1096/fj.02-0716fje	http://dx.doi.org/10.1096/fj.02-0716fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586738				2022-12-25	WOS:000181456900032
J	Veitonmaki, N; Fuxe, J; Hultdin, M; Roos, G; Pattersson, RF; Cao, Y				Veitonmaki, N; Fuxe, J; Hultdin, M; Roos, G; Pattersson, RF; Cao, Y			Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16(INK4A)/pRb	FASEB JOURNAL			English	Article						telomere; telomerase; p16(INK4A)	TELOMERASE REVERSE-TRANSCRIPTASE; HUMAN EPITHELIAL-CELLS; HUMAN FIBROBLASTS; LIFE-SPAN; REPLICATIVE SENESCENCE; DNA METHYLATION; IN-VIVO; EXPRESSION; GROWTH; CANCER	Recent studies show that stable expression of the human telomerase catalytic subunit, hTERT, alone can lead several types of normal human somatic cells to bypass replicative senescence and become immortal. The molecular mechanisms by which telomerase immortalizes cells are not fully understood, although a key function of telomerase is to maintain a critical length of telomeres in order to preserve the stability and integrity of the genome. Here we report that stable transfection of hTERT alone was sufficient to allow bovine capillary endothelial (BCE) cells to bypass senescence and acquire immortality. Surprisingly, telomere lengths in these stable transfectants were progressively shortened during an increasing number of population doublings (PDLs), despite high telomerase activity. The expression of the cyclin-dependent kinase inhibitors (CDKIs) p16(INK4A) and p21(CIP1/WAF1) was concomitantly repressed, and the retinoblastoma protein (pRb) was maintained in a hyperphosphorylated state in the telomerase-expressing cells. Re-expression of p16(INK4A) in these cells by either treatment with a demethylating agent or by adenovirus-mediated expression reinduced a senescence-like phenotype, suggesting that the inactivation of p16(INK4A) was due to DNA methylation and was crucial for the immortalization process. In agreement with this finding, the expression levels of the prototypic DNA methyltransferase DNMT1 were elevated in the hTERT-positive cells.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Umea University	Cao, Y (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	yihai.cao@mtc.ki.se	Fuxe, Jonas/T-4433-2017	Fuxe, Jonas/0000-0003-4576-9377				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Andersson AM, 1998, J VIROL, V72, P9585, DOI 10.1128/JVI.72.12.9585-9596.1998; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BICNELL R, 1996, ENDOTHELIAL CELL CUL; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; FOLKMAN J, 1980, T OPHTHAL SOC UK, V100, P346; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P17; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Fuxe J, 2000, ONCOGENE, V19, P1724, DOI 10.1038/sj.onc.1203496; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Loughran O, 1996, ONCOGENE, V13, P561; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; MEHLE C, 1994, CANCER RES, V54, P236; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Norrback KF, 1998, BLOOD, V92, P567, DOI 10.1182/blood.V92.2.567.414a18_567_573; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	54	37	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					764	+		10.1096/fj.02-0599-fje	http://dx.doi.org/10.1096/fj.02-0599-fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586745				2022-12-25	WOS:000181456900025
J	Kim, SJ; Ding, W; Albrecht, B; Green, PL; Lairmore, MD				Kim, SJ; Ding, W; Albrecht, B; Green, PL; Lairmore, MD			A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p12(I) functions to modulate nuclear factor of activated T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							READING FRAME-I; HTLV TYPE-I; ENDOPLASMIC-RETICULUM; NF-AT; PHOSPHATASE CALCINEURIN; INHIBITS CALCINEURIN; CYCLOPHILIN LIGAND; VIRAL INFECTIVITY; MESSENGER-RNAS; PX REGION	The PXIXIT calcineurin binding motif or highly related sequences are found in a variety of calcineurin-binding proteins in yeast, mammalian cells, and viruses. The accessory protein p12(I) encoded in the HTLV-1 pX ORF I promotes T cell activation during the early stages of HTLV-1 infection by activating nuclear factor of activated T cells (NFAT) through calcium release from the endoplasmic reticulum. We identified in p12(I), a conserved motif, which is highly homologous with the PXIXIT calcineurin-binding motif of NFAT. Both immunoprecipitation and calmodulin agarose bead pull-down assays indicated that wild type p12(I) and mutants of p12(I) that contained the motif-bound calcineurin. In addition, an alanine substitution p12(I) mutant (p12(I) AXAXAA) had greatly reduced binding affinity for calcineurin. We then tested whether p12(I) binding to calcineurin affected NFAT activity. p12(I) competed with NFAT for calcineurin binding in calmodulin bead pull-down experiments. Furthermore, the p12(I) AXAXAA mutant enhanced NFAT nuclear translocation compared with wild type p12(I) and increased NFAT transcriptional activity 2-fold greater than wild type p12(I). Similar to NFAT, endogenous calcineurin phosphatase activity was increased in Jurkat T cells expressing p12(I) independent of its calcineurin binding property. Thus, the reduced binding of p12(I) to calcineurin allows enhanced nuclear translocation and transcription mediated by NFAT. Herein, we are the first to identify a retroviral protein that binds calcineurin. Our data suggest that HTLV-1 p12(I) modulates NFAT activation to promote early virus infection of T lymphocytes, providing a novel mechanism for retrovirus-mediated cell activation.	Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lairmore, MD (corresponding author), Ohio State Univ, Ctr Retrovirus Res, 1925 Coffey Rd, Columbus, OH 43210 USA.				NCI NIH HHS [CA 92009, CA 70529] Funding Source: Medline; NCRR NIH HHS [RR 14324] Funding Source: Medline; NIAID NIH HHS [AI 01474] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Collins ND, 1996, J VIROL, V70, P7241, DOI 10.1128/JVI.70.10.7241-7246.1996; Dekaban GA, 2000, VIROLOGY, V274, P86, DOI 10.1006/viro.2000.0406; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Ding W, 2001, J VIROL, V75, P7672, DOI 10.1128/JVI.75.16.7672-7682.2001; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FURUKAWA K, 1991, FEBS LETT, V295, P141, DOI 10.1016/0014-5793(91)81404-V; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Holloway MP, 1998, J BIOL CHEM, V273, P16346, DOI 10.1074/jbc.273.26.16346; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; KORALNIK IJ, 1995, J GEN VIROL, V76, P1909, DOI 10.1099/0022-1317-76-8-1909; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lairmore MD, 2000, AIDS RES HUM RETROV, V16, P1757, DOI 10.1089/08892220050193272; Lefebvre L, 2002, J VIROL, V76, P7843, DOI 10.1128/JVI.76.15.7843-7854.2002; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Saksena NK, 1997, AIDS RES HUM RETROV, V13, P425, DOI 10.1089/aid.1997.13.425; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Trovato R, 1999, J VIROL, V73, P6460, DOI 10.1128/JVI.73.8.6460-6467.1999; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	50	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15550	15557		10.1074/jbc.M210210200	http://dx.doi.org/10.1074/jbc.M210210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601010	hybrid			2022-12-25	WOS:000182680000013
J	D'Angelo, G; Duplan, E; Vigne, P; Frelin, C				D'Angelo, G; Duplan, E; Vigne, P; Frelin, C			Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1 alpha Pro-564 hydroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; GROWTH-FACTOR; HIF-ALPHA; PROTEIN; ERYTHROPOIETIN; INHIBITION; EXPRESSION; 4-HYDROXYLASE	The mechanism by which hypoxia induces gene transcription involves the inhibition of hypoxia-inducible factor (HIF)-1alpha prolyl hydroxylase activity, which prevents von Hippel-Lindau (vHL)-dependent targeting of HIF-1alpha to the ubiquitin-proteasome pathway. HIF-1alpha is stabilized, translocates to the nucleus, interacts with hypoxia-responsive elements, and promotes the activation of target genes. This report shows that cyclosporin A (CsA) interferes with the hypoxic signaling cascade in C6 glioma cells. CsA inhibits hypoxia-dependent gene transcription in a reporter gene assay and prevents the hypoxic accumulation of HIF-1alpha. Addition of the 530603 C-terminal oxygen-dependent degradation (ODD) domain of HIF-1alpha to the green fluorescent protein (GFP) destabilized the protein in an oxygen-dependent manner. CsA prevented the hypoxic stabilization of an ODD.GFP fusion protein. An assay for 2-oxoglutarate-dependent dioxygenases was developed using a light mitochondrial kidney fraction as a source of enzyme. It uses the capacity of specific peptides to stimulate the degradation of [C-14]2-oxoglutarate. CsA stimulated the enzymatic activity in the presence of a peptide that mimicked the 557-576 sequence of HIF-1alpha. The enzyme promoted [S-35]vHL binding to glutathione S-transferase (GST)-ODD fusion protein. This association increased in the presence of CsA. CsA effects were not observed when the proline residue corresponding to Pro-564 in the HIF-1a sequence was replaced by a hydroxyproline or an alanine residue. Finally, CsA increased vHL-ODD interaction during hypoxia. We conclude that CsA destabilizes HIF-1alpha by promoting hydroxylation of Pro-564 in the ODD domain. Such a mechanism may prevent bypoxic adaptation during CsA-induced nephrotoxicity and contribute to the adverse effects of this drug.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	D'Angelo, G (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.		Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507; D'ANGELO, Gisela/0000-0003-3150-2241				BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; BLACKBURN MEC, 1992, INT J CARDIOL, V36, P263, DOI 10.1016/0167-5273(92)90294-D; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kang DH, 2001, AM J PHYSIOL-RENAL, V280, pF727, DOI 10.1152/ajprenal.2001.280.4.F727; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; MARUYAMA K, 1992, NEPHRON, V62, P27, DOI 10.1159/000186990; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; VANNUCCHI AM, 1991, BLOOD, V78, P1615; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	26	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15406	15411		10.1074/jbc.M211293200	http://dx.doi.org/10.1074/jbc.M211293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586829	hybrid, Green Published			2022-12-25	WOS:000182516100106
J	Gooding, C; Kemp, P; Smith, CWJ				Gooding, C; Kemp, P; Smith, CWJ			A novel polypyrimidine tract-binding protein paralog expressed in smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING; EXON; SELECTION; GENE; PTB; ANTAGONIZES; INVOLVEMENT; REPRESSION; DIVERSITY; UPSTREAM	Polypyrimidine tract-binding protein (PTB) is an abundant widespread RNA-binding protein with roles in regulation of pre-mRNA alternative splicing and 3'-end processing, internal ribosomal entry site-driven translation, and mRNA localization. Tissue-restricted paralogs of PTB have previously been reported in neuronal and hematopoietic cells. These proteins are thought to replace many general functions of PTB, but to have some distinct activities, e.g. in the tissue-specific regulation of some alternative splicing events. We report the identification and characterization of a fourth rodent PTB paralog (smPTB) that is expressed at high levels in a number of smooth muscle tissues. Recombinant smPTB localized to the nucleus, bound to RNA, and was able to regulate alternative splicing. We suggest that replacement of PTB by smPTB might be important in controlling some pre-mRNA alternative splicing events.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Smith, CWJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	cwjs1@mole.bio.cam.ac.uk		Kemp, Paul/0000-0001-8975-7293				Ashiya M, 1997, RNA, V3, P996; Back SH, 2002, J BIOL CHEM, V277, P27200, DOI 10.1074/jbc.M203887200; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; Goldberg, 1995, Fold Des, V1, P21; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Gooding C, 1998, RNA, V4, P85; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Hamilton BJ, 2003, MOL CELL BIOL, V23, P510, DOI 10.1128/MCB.23.2.510-525.2003; Jin W, 2000, CANCER RES, V60, P1221; Kaminski A, 1995, RNA, V1, P924; KEMP PR, 1991, BIOCHEM J, V277, P285, DOI 10.1042/bj2770285; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LIN CH, 1995, RNA, V1, P234; Lou H, 1999, MOL CELL BIOL, V19, P78; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Moreira A, 1998, GENE DEV, V12, P2522, DOI 10.1101/gad.12.16.2522; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; Perez I, 1997, RNA, V3, P764; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Roberts GC, 2002, CURR OPIN CHEM BIOL, V6, P375, DOI 10.1016/S1367-5931(02)00320-4; Sambrook J, 2001, MOL CLONING LAB MANU; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Southby J, 1999, MOL CELL BIOL, V19, P2699; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; WAITES GT, 1992, J BIOL CHEM, V267, P6263; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214; Yamamoto H, 1999, MOL CELL BIOL, V19, P3829; Zhang L, 1999, RNA, V5, P117, DOI 10.1017/S1355838299981530	49	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15201	15207		10.1074/jbc.M210131200	http://dx.doi.org/10.1074/jbc.M210131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578833	hybrid			2022-12-25	WOS:000182516100080
J	Kitano, J; Yamazaki, Y; Kimura, K; Masukado, T; Nakajima, Y; Nakanishi, S				Kitano, J; Yamazaki, Y; Kimura, K; Masukado, T; Nakajima, Y; Nakanishi, S			Tamalin is a scaffold protein that interacts with multiple neuronal proteins in distinct modes of protein-protein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; NUCLEOTIDE-EXCHANGE FACTORS; ELEGANS VULVAR INDUCTION; NMDA RECEPTOR SUBUNITS; EPITHELIAL-CELLS; POSTSYNAPTIC DENSITY; PDZ DOMAINS; FAMILY; LOCALIZATION; COMPLEX	Tamalin is a scaffold protein that comprises multiple protein-interacting domains, including a 95-kDa postsynaptic density protein (PSD-95)/discs-large/ZO-1 (PDZ) domain, a leucine-zipper region, and a carboxyl-terminal PDZ binding motif. Tamalin forms a complex with metabotropic glutamate receptors and guanine nucleotide exchange factor cytohesins and promotes intracellular trafficking and cell surface expression of group 1 metabotropic glutamate receptors. In the present study, using several different approaches we have shown that tamalin interacts with multiple neuronal proteins through its distinct protein-binding domains. The PDZ domain of tamalin binds to the PDZ binding motifs of SAP90/PSD-95-associated protein and tamalin itself, whereas the PDZ binding motif of tamalin is capable of interacting with the PDZ domain of S-SCAM. In addition, tamalin forms a complex with PSD-95 and Mint2/X11beta/X11L by mechanisms different from the PDZ-mediated interaction. Tamalin has the ability to assemble with these proteins in vivo; their protein complex with tamalin was verified by coimmunoprecipitation of rat brain lysates. Interestingly, the distinct protein-interacting domains of tamalin are evolutionarily conserved, and mRNA expression is developmentally up-regulated at the postnatal period. The results indicate that tamalin exists as a key element that forms a protein complex with multiple postsynaptic and protein-trafficking scaffold proteins.	Kyoto Univ, Dept Biol Sci, Fac Med, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Nakanishi, S (corresponding author), Kyoto Univ, Dept Biol Sci, Fac Med, Kyoto 6068501, Japan.		Kimura, Kouji/C-1847-2015					BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DULCOS F, 1993, P NATL ACAD SCI USA, V90, P109; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kawashima N, 1997, FEBS LETT, V418, P301, DOI 10.1016/S0014-5793(97)01399-9; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Liu XB, 1998, J COMP NEUROL, V395, P450, DOI 10.1002/(SICI)1096-9861(19980615)395:4<450::AID-CNE3>3.0.CO;2-0; Maximov A, 2002, J NEUROSCI, V22, P6939; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Niethammer M, 1996, J NEUROSCI, V16, P2157; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rowe J, 2001, J CELL SCI, V114, P3323; Sambrook J, 1995, MOL CLONING LAB MANU; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087	41	59	60	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14762	14768		10.1074/jbc.M300184200	http://dx.doi.org/10.1074/jbc.M300184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586822	hybrid			2022-12-25	WOS:000182516100024
J	Shimizu, K; Okada, M; Nagai, K; Fukada, Y				Shimizu, K; Okada, M; Nagai, K; Fukada, Y			Suprachiasmatic nucleus circadian oscillatory protein, a novel binding partner of K-Ras in the membrane rafts, negatively regulates MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; LEUCINE-RICH REPEATS; N-RAS; ADENYLATE-CYCLASE; KINASE ACTIVATION; PLASMA-MEMBRANE; LIPID RAFTS; H-RAS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION	Suprachiasmatic nucleus circadian oscillatory protein (SCOP) is a member of the leucine-rich repeat (LRR)-containing protein family. In addition to circathan expression in the rat hypothalamic suprachiasmatic nucleus, SCOP is constitutively expressed in neurons throughout the rat brain. Here we found that a substantial amount of SCOP was localized in the brain membrane rafts, in which only K-Ras was abundant among Ras isoforms. SCOP interacted directly through its LRR domain with a subset of K-Ras in the guanine nucleotide-free form that was present in the raft fraction. This interaction interfered with the binding of added guanine nucleotide to K-Ras in vitro. A negative regulatory role of SCOP for K-Ras function was examined in PC12 cell lines stably overexpressing SCOP or its deletion mutants. Overexpression of full-length SCOP markedly down-regulated ERK1/ERK2 activation induced by depolarization or phorbol ester stimulation, and this inhibitory effect of overexpressed SCOP was dependent on its LRR domain. These results strongly suggest that SCOP negatively regulates K-Ras signaling in the membrane rafts, identifying a novel mechanism for regulation of the Ras-MAPK pathway.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Osaka University	Fukada, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Bldg 3,Rm 218A,Yayoi 2-11-16, Tokyo 1130032, Japan.		Kimiko, Shimizu/ACS-9013-2022; 吉孝, 深田/G-5090-2014; Shimizu, Kimiko/G-4956-2014	Kimiko, Shimizu/0000-0003-4943-2552; Shimizu, Kimiko/0000-0003-4943-2552				BOS JL, 1989, CANCER RES, V49, P4682; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Hayashi Y, 2001, FEBS LETT, V491, P71, DOI 10.1016/S0014-5793(01)02153-6; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Li WQ, 2000, GENE DEV, V14, P895; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shimizu K, 1999, FEBS LETT, V458, P363, DOI 10.1016/S0014-5793(99)01190-4; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	41	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14920	14925		10.1074/jbc.M213214200	http://dx.doi.org/10.1074/jbc.M213214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594205	hybrid			2022-12-25	WOS:000182516100045
J	Shin, D; Cho, N; Heu, S; Ryu, S				Shin, D; Cho, N; Heu, S; Ryu, S			Selective regulation of ptsG expression by Fis - Formation of either activating or repressing nucleoprotein complex in response to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; MAJOR GLUCOSE; PHOSPHOTRANSFERASE SYSTEM; TRANSCRIPTION ACTIVATION; TRANSPORTER GENE; MLC; PROMOTER; INDUCTION; REGULON	Transcription of ptsG encoding glucose-specific permease, enzyme IICBGlc, in Escherichia coli is initiated from two promoters, P1 and P2. ptsG transcription is repressed by Mlc, a glucose-inducible regulator of carbohydrate metabolism. The regulation of ptsG P1 transcription is also under positive control by cyclic AMP receptor protein and cyclic AMP complex (CRP-cAMP) as observed in other Mlc regulon. We report here that Fis, one of the nucleoid-associated proteins, plays a key role in glucose induction of Mlc regulon. ptsG transcription was induced when wild-type cells were grown in the presence of glucose. However, in a fts mutant, the basal level of ptsG transcription was higher but decreased when cells were grown in the presence of glucose, which implies the possibility of regulatory interactions among Fis, Mlc, and CRP-cAMP. Footprinting experiments with various probes and transcription assays revealed that Fis assists both Mlc repression and CRP-cAMP activation of ptsG P1 through the formation of Fis-CRP-Mlc or Fis-CRP nucleoprotein complexes at ptsG P1 promoter depending on the availability of glucose in the growth medium. ptsG P2 transcription was inhibited by Fis and Mlc. Tighter Mlc repression and enhanced CRP-cAMP activation of ptsG P1 by Fis enable cells to regulate Mlc regulon efficiently by selectively controlling the concentration of enzyme IICBGlc that modulates Mlc activity.	Seoul Natl Univ, Dept Food Sci & Technol, Sch Agr Biotechnol, Suwon 441744, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Suwon 441744, South Korea; Natl Inst Agr Sci & Technol, Plant Pathol Div, Suwon 441707, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Ryu, S (corresponding author), Seoul Natl Univ, Dept Food Sci & Technol, Sch Agr Biotechnol, Suwon 441744, South Korea.	sangryu@snu.ac.kr						Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BUHR A, 1994, J BIOL CHEM, V269, P23437; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; DUMITRU I, 1994, NUCLEIC ACIDS RES, V22, P1450; ERNI B, 1986, J BIOL CHEM, V261, P6398; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; Gonzalez-Gil G, 1998, EMBO J, V17, P2877, DOI 10.1093/emboj/17.10.2877; GonzalezGil G, 1996, MOL MICROBIOL, V22, P21, DOI 10.1111/j.1365-2958.1996.tb02652.x; Hengen PN, 1997, NUCLEIC ACIDS RES, V25, P4994, DOI 10.1093/nar/25.24.4994; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; KONBERG HL, 1972, BIOCHEM J, V128, P1339; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; McLeod SM, 2000, J BACTERIOL, V182, P4180, DOI 10.1128/JB.182.15.4180-4187.2000; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Nasser W, 2001, J BIOL CHEM, V276, P17878, DOI 10.1074/jbc.M100632200; Pettijohn D.E., 1996, ESCHERICHIA COLI SAL, P158; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; RYU S, 1994, J BIOL CHEM, V269, P4767; SAIER MH, 1976, J BIOL CHEM, V251, P883; Sambrook J, 2001, MOL CLONING LAB MANU; Shin D, 2001, J BIOL CHEM, V276, P25871, DOI 10.1074/jbc.M101757200; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Weinstein-Fischer D, 2000, MOL MICROBIOL, V35, P1413, DOI 10.1046/j.1365-2958.2000.01805.x	36	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14776	14781		10.1074/jbc.M213248200	http://dx.doi.org/10.1074/jbc.M213248200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588863	hybrid			2022-12-25	WOS:000182516100026
J	Reddy, KV; Serio, KJ; Hodulik, CR; Bigby, TD				Reddy, KV; Serio, KJ; Hodulik, CR; Bigby, TD			5-lipoxygenase-activating protein gene expression - Key role of CCAAT/enhancer-binding proteins (C/EBP) in constitutive and tumor necrosis factor (TNF) alpha-induced expression in THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTIONAL ACTIVATOR PROTEIN; LEUCINE-ZIPPER; MESSENGER-RNA; DEVELOPMENTAL REGULATION; SYNTHASE GENE; FAMILY; ISOFORMS; DELTA; BETA	We examined expression of the 5-lipoxygenase activating protein (FLAP), which is critical for inflammatory cell leukotriene synthesis. A 3.4-kb segment of the FLAP gene 5'-untranslated region accounted for a 22-fold increase in promoter activity when transfected into the monocyte-like cell line, THP-1, and demonstrated no activity in non-inflammatory cells. Virtually all of the promoter activity was mediated by the first 134 bp upstream of the transcription start site, a region that contains CCAAT/enhancer-binding proteins (C/EBP) consensus binding sites, at -36 to -28 bp (distal) and -25 to -12 bp (proximal). DNase I footprint analyses demonstrated THP-1 nuclear extract proteins bind to the proximal site. Electrophoretic mobility shift assay analyses revealed that C/EBPalpha, delta, and epsilon bind to the proximal site and C/EBPalpha and epsilon bind to the distal site, constitutively. Transfection studies indicated that mutation of both the proximal and distal sites decreased constitutive FLAP promoter activity. Overexpression of C/EBPalpha, delta, and epsilon transactivated promoter activity and increased native FLAP mRNA accumulation. Mutation of both C/EBP sites essentially abolished promoter induction by C/EBP overexpression. Tumor necrosis factor (TNF) alpha induced FLAP mRNA expression, FLAP promoter activity, and C/EBPalpha, delta, and epsilon binding to the proximal and distal promoter consensus sites. Chromatin immunoprecipitation assays demonstrated that C/EBPalpha, delta, and epsilon bound to this region of the 5'-untranslated region, whereas C/EBPbeta does not bind even under conditions of overexpression and stimulation. We conclude that the FLAP gene is transactivated by members of the C/EBP family of transcription factors in inflammatory cells and that these factors play an important role in FLAP gene induction by TNFalpha.	Vet Affairs San Diego Healthcare Syst, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, San Diego, CA 92161 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego	Bigby, TD (corresponding author), Vet Affairs San Diego Healthcare Syst, Dept Med, Mail Code 111-J,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	tbigby@UCSD.edu						ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; Antonson P, 1996, GENOMICS, V35, P30, DOI 10.1006/geno.1996.0319; AVITAHL N, 1994, J BIOL CHEM, V269, P23553; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; CLEUTJENS CBJM, 1993, GENOMICS, V16, P520, DOI 10.1006/geno.1993.1220; Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORDHUTCHINSON AW, 1989, ADV PROSTAG THROMB L, V19, P507; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HOUGLUM K, 1994, J CLIN INVEST, V94, P808, DOI 10.1172/JCI117400; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KENNEDY BP, 1991, J BIOL CHEM, V266, P8511; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Koshino T, 1999, Mol Cell Biol Res Commun, V2, P32, DOI 10.1006/mcbr.1999.0147; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PALMANTIER R, 1994, LAB INVEST, V70, P696; Pan Z, 1999, J BIOL CHEM, V274, P23242, DOI 10.1074/jbc.274.33.23242; PAUWELS RA, 1995, ALLERGY, V50, P615, DOI 10.1111/j.1398-9995.1995.tb02578.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pope RM, 1999, CLIN IMMUNOL, V91, P271, DOI 10.1006/clim.1999.4723; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; RIFAI A, 1993, KIDNEY INT, V43, pS95; Ring WL, 1996, J CLIN INVEST, V97, P1293, DOI 10.1172/JCI118545; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCOTT LM, 1992, BLOOD, V80, P1725; Serio KJ, 2000, AM J RESP CELL MOL, V23, P234, DOI 10.1165/ajrcmb.23.2.4042; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEINHILBER D, 1993, BIOCHEM BIOPH RES CO, V193, P1083, DOI 10.1006/bbrc.1993.1736; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	56	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13810	13818		10.1074/jbc.M211102200	http://dx.doi.org/10.1074/jbc.M211102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571239	hybrid			2022-12-25	WOS:000182405000033
J	Rudolph, MJ; Wuebbens, MM; Turque, O; Rajagopalan, KV; Schindelin, H				Rudolph, MJ; Wuebbens, MM; Turque, O; Rajagopalan, KV; Schindelin, H			Structural studies of molybdopterin synthase provide insights into its catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; MOLECULAR REPLACEMENT; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; UBIQUITIN ACTIVATION; MAXIMUM-LIKELIHOOD; BIOSYNTHESIS; PROGRAM	Molybdenum cofactor biosynthesis is an evolutionarily conserved pathway present in eubacteria, archaea, and eukaryotes, including humans. Genetic deficiencies of enzymes involved in cofactor biosynthesis in humans lead to a severe and usually fatal disease. The molybdenum cofactor contains a tricyclic pyranopterin, termed molybdopterin, that bears the cis-dithiolene group responsible for molybdenum ligation. The dithiolene group of molybdopterin is generated by molybdopterin synthase, which consists of a large (MoaE) and small (MoaD) subunit. The crystal structure of molybdopterin synthase revealed a heterotetrameric enzyme in which the C terminus of each MoaD subunit is deeply inserted into a MoaE subunit to form the active site. In the activated form of the enzyme, the MoaD C terminus is present as a thiocarboxylate. The present study identified the position of the thiocarboxylate sulfur by exploiting the anomalous signal originating from the sulfur atom. The structure of molybdopterin synthase in a novel crystal form revealed a binding pocket for the terminal phosphate of molybdopterin, the product of the enzyme, and suggested a binding site for the pterin moiety present in precursor Z and molybdopterin. Finally, the crystal structure of the MoaE homodimer provides insights into the conformational changes accompanying bindin of the MoaD subunit.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Duke University	Schindelin, H (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	hermann.schindelin@sunysb.edu	Schindelin, Hermann/Q-2697-2019	Turque, Oliver/0000-0001-8987-8546	NIDDK NIH HHS [DK54835] Funding Source: Medline; NIGMS NIH HHS [GM00091] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Li HK, 2000, J AM CHEM SOC, V122, P7673, DOI 10.1021/ja000643e; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Rao-Naik C, 1998, J BIOL CHEM, V273, P34976, DOI 10.1074/jbc.273.52.34976; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Rizzi M, 2002, CURR OPIN STRUC BIOL, V12, P709, DOI 10.1016/S0959-440X(02)00385-8; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schindelin H, 2001, ADV PROTEIN CHEM, V58, P47; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Wuebbens MM, 2003, J BIOL CHEM, V278, P14523, DOI 10.1074/jbc.M300453200; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698	37	44	48	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14514	14522		10.1074/jbc.M300449200	http://dx.doi.org/10.1074/jbc.M300449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571227	hybrid			2022-12-25	WOS:000182405000119
J	Bondarava, N; De Pascalis, L; Al-Babili, S; Goussias, C; Golecki, JR; Beyer, P; Bock, R; Krieger-Liszkay, A				Bondarava, N; De Pascalis, L; Al-Babili, S; Goussias, C; Golecki, JR; Beyer, P; Bock, R; Krieger-Liszkay, A			Evidence that cytochrome b(559) mediates the oxidation of reduced plastoquinone in the dark	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; II REACTION-CENTER; PHOTOSYSTEM-II; THYLAKOID MEMBRANE; AXIAL LIGANDS; FLUORESCENCE; CHLOROPLASTS; B-559; CHLOROPHYLL; COMPLEX	The function of cytochrome b(559) in photosystem II (PSII) was investigated using a mutant created in tobacco in which the conserved phenylalanine at position 26 in the beta-subunit (PsbF) was changed to serine (Bock, R., Kossel, H., and Maliga, P. (1994) EMBO J. 13, 4623-4628). The mutant grew photoautotrophically, but the amount of PSII was reduced and the ultrastructure of the chloroplast was dramatically altered. Very few grana stacks were formed in the mutant. Although isolated PSII-enriched membrane fragments showed low PSII activity, electron paramagnetic resonance indicated the presence of functional PSII Difference absorption spectra showed that the cytochrome b(559) contained heme. The plastoquinone pool was largely reduced in dark-adapted leaves of the mutant, based on chlorophyll fluorescence and thermoluminescence measurements. We therefore propose that cytochrome b(559) plays an important role in PSII by keeping the plastoquinone pool and thereby the acceptor side of PSII oxidized in the dark. Structural alterations as induced by the single Phe --> Ser point mutation in the transmembrane domain of PsbF evidently inhibit this function.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Freiburg, Inst Biochem Pflanzen, D-79104 Freiburg, Germany; Univ Freiburg, Inst Zellbiol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Mikrobiol, D-79104 Freiburg, Germany; CNRS, URA 2096, Serv Bioenerget, Commissariat Energie Atom Saclay, F-91191 Gif Sur Yvette, France; Univ Munster, Inst Biochem & Biotechnol, D-48143 Munster, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Munster	Krieger-Liszkay, A (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.		Bock, Ralph/B-4352-2009	Bock, Ralph/0000-0001-7502-6940; Al-Babili, Salim/0000-0003-4823-2882; Krieger-Liszkay, Anja/0000-0001-7141-4129				ALBERTSSON PA, 1990, FEBS LETT, V273, P36, DOI 10.1016/0014-5793(90)81045-P; Allen JF, 2001, TRENDS PLANT SCI, V6, P317, DOI 10.1016/S1360-1385(01)02010-6; ANANYEV G, 1994, PHOTOSYNTH RES, V41, P327, DOI 10.1007/BF00019410; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BERGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V682, P452, DOI 10.1016/0005-2728(82)90060-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; BUTLER WL, 1973, BIOCHIM BIOPHYS ACTA, V292, P140, DOI 10.1016/0005-2728(73)90258-2; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; DUCRUET JM, 1992, PHOTOSYNTH RES, V33, P15, DOI 10.1007/BF00032979; Fiege R, 1996, FEBS LETT, V387, P33, DOI 10.1016/0014-5793(96)00458-9; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; Joet T, 2002, J BIOL CHEM, V277, P31623, DOI 10.1074/jbc.M203538200; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; Krieger A, 1998, PLANTA, V205, P587, DOI 10.1007/s004250050360; Kruk J, 2001, J BIOL CHEM, V276, P86, DOI 10.1074/jbc.M003602200; Kruk J, 1999, PHOTOSYNTH RES, V62, P273, DOI 10.1023/A:1006374319191; LAASCH H, 1987, PLANTA, V171, P220, DOI 10.1007/BF00391097; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Morais F, 2001, J BIOL CHEM, V276, P31986, DOI 10.1074/jbc.M103935200; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NEWMAN GR, 1983, HISTOCHEM J, V15, P543, DOI 10.1007/BF01954145; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; TAE GS, 1994, BIOCHEMISTRY-US, V33, P10060, DOI 10.1021/bi00199a033; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; VANDORSSEN RJ, 1987, BIOCHIM BIOPHYS ACTA, V890, P134, DOI 10.1016/0005-2728(87)90014-4; VASS I, 1992, PHOTOSYSTEMS STRUCTU, P259; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475; WHITMARSH J, 1978, BIOCHIM BIOPHYS ACTA, V501, P83, DOI 10.1016/0005-2728(78)90097-X; ZIMMERMANN JL, 1986, BIOCHIM BIOPHYS ACTA, V851, P416, DOI 10.1016/0005-2728(86)90078-2; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	41	70	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13554	13560		10.1074/jbc.M212842200	http://dx.doi.org/10.1074/jbc.M212842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571242	hybrid			2022-12-25	WOS:000182189500120
J	Darst, RP; Dasgupta, A; Zhu, CM; Hsu, JY; Vroom, A; Muldrow, T; Auble, DT				Darst, RP; Dasgupta, A; Zhu, CM; Hsu, JY; Vroom, A; Muldrow, T; Auble, DT			Mot1 regulates the DNA binding activity of free TATA-binding protein in an ATP-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; POLYMERASE-II TRANSCRIPTION; GENE-EXPRESSION; BOX-BINDING; IN-VIVO; TBP BINDING; CRYSTAL-STRUCTURE; NUCLEAR IMPORT; FAMILY MEMBER; COMPLEX	Mot1 is an essential Snf2/Swi2-related Saccharomyces cerevisiae protein that binds the TATA-binding protein (TBP) and removes TBP from DNA using ATP hydrolysis. Mot1 functions in vivo both as a repressor and as an activator of transcription. Mot1 catalysis of TBP-DNA disruption is consistent with its function as a repressor, but the Mot1 mechanism of activation is unknown. To better understand the physiologic role of Mot1 and its enzymatic mechanism, MOT1 mutants were generated and tested for activity in vitro and in vivo. The results demonstrate a close correlation between the TBP(.)DNA disruption activity of Mot1 and its essential in vivo function. Previous results demonstrated a large overlap in the gene sets controlled by Mot1 and NC2. Mot1 and NC2 can co-occupy TBP-DNA in vitro, and NC2 binding does not impair Mot1-catalyzed disruption of the complex. Residues on the DNA-binding surface of TBP are important for Mot1 binding and the Mot1(.)TBP binary complex binds very poorly to DNA and does not dissociate in the presence of ATP. However, the binary complex binds DNA well in the presence of the transition state analog ADP-AlF4. A model for Mot1 action is proposed in which ATP hydrolysis causes the Mot1 N terminus to displace the TATA box, leading to ejection of Mot1 and TBP from DNA.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Auble, DT (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055763] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55763, R01 GM055763] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamkewicz JI, 2000, J BIOL CHEM, V275, P21158, DOI 10.1074/jbc.M002639200; Adamkewicz JI, 2001, J BIOL CHEM, V276, P11883, DOI 10.1074/jbc.M010665200; Andrade MA, 2000, J MOL BIOL, V298, P521, DOI 10.1006/jmbi.2000.3684; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Andrau JC, 2002, EMBO J, V21, P5173, DOI 10.1093/emboj/cdf485; Auble DT, 1999, MOL CELL BIOL, V19, P412; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Auble DT, 1997, MOL CELL BIOL, V17, P4842, DOI 10.1128/MCB.17.8.4842; Banik U, 2001, J BIOL CHEM, V276, P49100, DOI 10.1074/jbc.M109246200; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Chicca JJ, 1998, MOL CELL BIOL, V18, P1701, DOI 10.1128/MCB.18.3.1701; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Darst RP, 2001, EMBO J, V20, P2028, DOI 10.1093/emboj/20.8.2028; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; GoldmanLevi R, 1996, NUCLEIC ACIDS RES, V24, P3121, DOI 10.1093/nar/24.16.3121; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guthrie C., 1991, GUIDE YEAST GENETICS, P194; Guyon JR, 2001, MOL CELL BIOL, V21, P1132, DOI 10.1128/MCB.21.4.1132-1144.2001; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; KARNITZ L, 1992, GENETICS, V132, P351; Kim TK, 1997, J BIOL CHEM, V272, P7540, DOI 10.1074/jbc.272.11.7540; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lemaire M, 2000, MOL MICROBIOL, V36, P163, DOI 10.1046/j.1365-2958.2000.01839.x; Leung DW, 1989, TECHNIQUE, V1, P11; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MARUTA S, 1993, J BIOL CHEM, V268, P7093; Morehouse H, 1999, P NATL ACAD SCI USA, V96, P12542, DOI 10.1073/pnas.96.22.12542; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Pereira LA, 2001, MOL CELL BIOL, V21, P7523, DOI 10.1128/MCB.21.21.7523-7534.2001; PIATTI S, 1992, CHROMOSOMA, V102, P107; POON D, 1994, J BIOL CHEM, V269, P23135; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIKORSKI RS, 1989, GENETICS, V122, P19; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7	56	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13216	13226		10.1074/jbc.M211445200	http://dx.doi.org/10.1074/jbc.M211445200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571241	hybrid			2022-12-25	WOS:000182189500080
J	Hesson, L; Dallol, A; Minna, JD; Maher, ER; Latif, F				Hesson, L; Dallol, A; Minna, JD; Maher, ER; Latif, F			NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers	ONCOGENE			English	Article						RASSF1A; NORE1; methylation	FREQUENT EPIGENETIC INACTIVATION; HUMAN-CHROMOSOME 3P21.3; PROMOTER HYPERMETHYLATION; CPG ISLAND; LUNG; CARCINOMA; REGION; IDENTIFICATION; EFFECTOR; BREAST	We recently demonstrated that RASSF1A, a new tumour-suppressor gene located at 3p21.3 is frequently inactivated by promoter region hypermethylation in a variety of human cancers including lung, breast, kidney and neuroblastoma. We have identified another member of the RASSF1 gene family by in silico sequence analysis using BLAST searches. NORE1 located at 1q32.1 exists in three isoforms (NORE1Aalpha, NORE1Abeta and NORE1B). Both NORE1A and NORE1B isoforms have separate CpG islands spanning their first exons. NORE1Aalpha Produces a 418 aa protein containing a Ras-association (RA) domain and a diacylglycerol (DAG) binding domain. NORE1Abeta produces a C-terminal truncation of the RA domain. NORE1B also contains the RA domain but not the DAG domain. NORE1 is the human homologue of the mouse Ras effector Nore1. No inactivating somatic mutations were found in lung tumour lines; however, NORE1A promoter region CpG island was hypermethylated in primary tumours and tumour cell lines. NORE1A promoter was methylated in 10/25 breast, 4/40 SCLC, 3/17 NSCLC, 1/6 colorectal and 3/9 kidney tumour cell lines, while NORE1B promoter was unmethylated in the same tumour cell lines. While 24% (6/25) of primary NSCLC underwent NORE1A methylation, methylation in SCLC was a rare event (0/22); (P = 0.0234). NORE1A expression in tumour cell lines was reactivated after treatment with a demethylating agent. There was no correlation between NORE1A and RASSF1A methylation status in NSCLC. Our results demonstrate that NOREIA is inactivated in a subset of human cancers by CpG island promoter hypermethylation, and in lung cancer this hypermethylation may be histological type specific.	Univ Birmingham, Sect Med & Mol Genet, Dept Paediat & Child Hlth, Sch Med, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Birmingham, Canc Res UK, Renal Mol Oncol Res Grp, Sch Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Dept Paediat & Child Hlth, Sch Med, Edgbaston, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022; Dallol, Ashraf/H-8661-2012	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X	NCI NIH HHS [P50CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Morrissey C, 2001, CANCER RES, V61, P7277; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200	22	105	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					947	954		10.1038/sj.onc.1206191	http://dx.doi.org/10.1038/sj.onc.1206191			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584574				2022-12-25	WOS:000180864300017
J	Berg, CP; Rothbart, A; Lauber, K; Stein, GM; Engels, IH; Belka, C; Janicke, RU; Schulze-Osthoff, K; Wesselborg, S				Berg, CP; Rothbart, A; Lauber, K; Stein, GM; Engels, IH; Belka, C; Janicke, RU; Schulze-Osthoff, K; Wesselborg, S			Tributyltin (TBT) induces ultra-rapid caspase activation independent of apoptosome formation in human platelets	ONCOGENE			English	Article						organotin; tributyltin; platelets; caspase-9; apoptosome; apoptosis	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NONSPECIFIC RESISTANCE; DISTINCT PATHWAYS; TERM EXPOSURE; CELL-DEATH; RAT; BIS(TRI-NORMAL-BUTYLTIN)OXIDE; PHOSPHORYLATION; STAUROSPORINE	Activation of caspases has been demonstrated to be involved in thrombocytopenia and prolonged storage of platelet concentrates. Platelets represent enucleate cells that comprise all elements of the mitochondrial apoptosis pathway. However, no apoptotic stimuli capable of activating the endogenous caspase cascade have been identified so far. Using tributyltin (TBT) we could identify a compound that is capable of activating caspase-9 and -3 in platelets. Recent studies implicate that TBT induces apoptosis via the mitochondrial signaling pathway that is characterized by the formation of a high-molecular-weight complex (apoptosome) containing the adapter protein Apaf-1 and active caspase-9. Interestingly, addition of TBT induced the activation of caspase-9 in an ultra-rapid kinetic within the first 2 min. In addition, size exclusion chromatography revealed that TBT-mediated processing of caspase-9 occurs in the absence of the apoptosome. Thus, these data implicate that TBT induces the activation of caspase-9 by a mechanism not involving the formation of the apoptosome.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Div Cell Biol & Immunol, D-4400 Munster, Germany; Univ Tubingen, Dept Radiat & Oncol, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Munster; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				AW TY, 1990, ARCH BIOCHEM BIOPHYS, V283, P46, DOI 10.1016/0003-9861(90)90610-B; Bantel H, 1999, CANCER RES, V59, P2083; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; CAIN K, 1977, FEBS LETT, V82, P23, DOI 10.1016/0014-5793(77)80877-6; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHOW SC, 1992, ARCH BIOCHEM BIOPHYS, V298, P143, DOI 10.1016/0003-9861(92)90105-6; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; HARRIS EJ, 1973, FEBS LETT, V29, P339, DOI 10.1016/0014-5793(73)80054-7; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Li JZ, 2000, TRANSFUSION, V40, P1320, DOI 10.1046/j.1537-2995.2000.40111320.x; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishikimi A, 2001, BIOCHEM J, V356, P621, DOI 10.1042/0264-6021:3560621; Nopp A, 2002, CLIN EXP IMMUNOL, V128, P267, DOI 10.1046/j.1365-2249.2002.01824.x; Piguet PF, 2002, APOPTOSIS, V7, P91, DOI 10.1023/A:1014341611412; Plenchette S, 2001, LEUKEMIA, V15, P1572, DOI 10.1038/sj.leu.2402231; POWERS MF, 1991, J BIOL CHEM, V266, P17250; RAFFRAY M, 1993, ARCH TOXICOL, V67, P231, DOI 10.1007/BF01974341; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SEINEN W, 1977, TOXICOL APPL PHARM, V42, P213, DOI 10.1016/0041-008X(77)90211-3; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; SNOEIJ NJ, 1988, INT J IMMUNOPHARMACO, V10, P891, DOI 10.1016/0192-0561(88)90014-8; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Stridh H, 1999, CHEM RES TOXICOL, V12, P874, DOI 10.1021/tx990041c; Vanags DM, 1997, BRIT J HAEMATOL, V99, P824, DOI 10.1046/j.1365-2141.1997.4813284.x; VOS JG, 1990, TOXICOL APPL PHARM, V105, P144, DOI 10.1016/0041-008X(90)90366-3; VOS JG, 1984, TOXICOL APPL PHARM, V75, P387, DOI 10.1016/0041-008X(84)90177-7; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692	41	12	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					775	780		10.1038/sj.onc.1206221	http://dx.doi.org/10.1038/sj.onc.1206221			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569371				2022-12-25	WOS:000180642100016
J	Srisailam, S; Krishnaswamy, T; Kumar, TKS; Rajalingam, D; Kathir, KM; Sheu, HS; Jan, FJ; Chao, PC; Yu, C				Srisailam, S; Krishnaswamy, T; Kumar, TKS; Rajalingam, D; Kathir, KM; Sheu, HS; Jan, FJ; Chao, PC; Yu, C			Amyloid-like fibril formation in an all beta-barrel protein - Partially structured intermediate state(s) is a precursor for fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ALPHA-SYNUCLEIN; GLOBULAR-PROTEIN; HUMAN LYSOZYME; AGGREGATION; PRION; INSULIN; BETA(2)-MICROGLOBULIN; CONFORMATION; INCLUSION	Acidic fibroblast growth factor from newt (Notopthalmus viridescens) is a similar to15-kDa, all beta-sheet protein devoid of disulfide bonds. In the present study, we investigate the effects of 2,2,2-trifluoroethanol (TFE) on the structure of newt acidic fibroblast growth factor (nFGF-1). The protein aggregates maximally in 10% (v/v) TFE. Congo red and thioflavin T binding experiments suggest that the aggregates induced by TFE have properties resembling the amyloid fibrils. Transmission electron microscopy and x-ray fiber diffraction data show that the fibrils (induced by TFE) are straight, unbranched, and have a cross-beta structure with an average diameter of 10-15 Angstrom. Preformed fibrils (induced by TFE) of nFGF-1 are observed to seed amyloid-like fibril formation in solutions containing the protein (nFGF-1) in the native beta-barrel conformation. Fluorescence, far-UV CD, anilino-8-napthalene sulfonate binding, multidimensional NMR, and Fourier transformed infrared spectroscopy data reveal that formation of a partially structured intermediate state(s) precedes the onset of the fibrillation process. The native beta-barrel structure of nFGF-1 appears to be disrupted in the partially structured intermediate state(s). The protein in the partially structured intermediate state(s) is found to be "sticky" with a solvent-exposed non-polar surface(s). Amyloid fibril formation appears to occur due to coalescence of the protein in the partially structured intermediate state(s) through solvent-exposed non-polar surfaces and intermolecular beta-sheet formation among the extended, linear beta-strands in the protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Synchrotron Radiat Res Ctr, Hsinchu 300, Taiwan; Natl Chung Hsing Univ, Reg Instrumentat Ctr, Taichung 40277, Taiwan	National Tsing Hua University; National Synchrotron Radiation Research Center; National Chung Hsing University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020; Jan, Fuh-Jyh/Y-1781-2019; Kumar, Dr Suresh/HHZ-2615-2022	Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553				Arunkumar AI, 2000, J BIOMOL NMR, V17, P279, DOI 10.1023/A:1008339701691; Arunkumar AI, 2002, PROTEIN SCI, V11, P1050, DOI 10.1110/ps.2270102; ARUNKUMAR AI, 1997, BIOCHIM BIOPHYS ACTA, V1138, P69; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2001, PHILOS T ROY SOC B, V356, P197, DOI 10.1098/rstb.2000.0765; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Chan W, 1996, FOLD DES, V1, P77, DOI 10.1016/S1359-0278(96)00017-X; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; COHBERG JA, 2002, BIOCHEMISTRY-US, V41, P1502; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DABORA JM, 1991, J BIOL CHEM, V266, P23637; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Finke JM, 2000, BIOCHEMISTRY-US, V39, P15633, DOI 10.1021/bi001307d; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; Hamada D, 2002, PROTEIN SCI, V11, P2417, DOI 10.1110/ps.0217702; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; JIANG X, 2001, P NATL ACAD SCI USA, V277, P1310; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; KLEIN J, 1995, APPL ENVIRON MICROB, V61, P1220, DOI 10.1128/AEM.61.4.1220-1225.1995; Krebs MRH, 2000, J MOL BIOL, V300, P541, DOI 10.1006/jmbi.2000.3862; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; MacPhee CE, 2000, J AM CHEM SOC, V122, P12707, DOI 10.1021/ja0029580; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; MULLINS J, 1993, CRYSTALLIZATION; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Padrick SB, 2001, J MOL BIOL, V308, P783, DOI 10.1006/jmbi.2001.4608; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; Rajan R, 1996, INT J PEPT PROT RES, V48, P328; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Srisailam S, 2002, J AM CHEM SOC, V124, P1884, DOI 10.1021/ja012070r; Srisailam S, 2002, J BIOL CHEM, V277, P19027, DOI 10.1074/jbc.M110762200; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 2001, J BIOL CHEM, V276, P37149, DOI 10.1074/jbc.M105720200; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; Tito P, 2000, J MOL BIOL, V303, P267, DOI 10.1006/jmbi.2000.4142; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858	53	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17701	17709		10.1074/jbc.M300336200	http://dx.doi.org/10.1074/jbc.M300336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12584201	Green Submitted, hybrid			2022-12-25	WOS:000182838300016
J	Lu, Q; Hutchins, AE; Doyle, CM; Lundblad, JR; Kwok, RPS				Lu, Q; Hutchins, AE; Doyle, CM; Lundblad, JR; Kwok, RPS			Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-binding protein enhances CREB-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; CYCLIC-AMP; IN-VIVO; PHOSPHORYLATED CREB; DNA-BINDING; COACTIVATOR CBP; GENE; ACTIVATION; DOMAIN; P300	The coactivator function of cAMP-responsive element-binding protein (CREB)-binding protein (CBP) is partly caused by its histone acetyltransferase activity. However, it has become increasingly clear that CBP acetylates both histones and non-histone proteins, many of which are transcription factors. Here we investigate the role of CBP acetylase activity in CREB-mediated gene expression. We show that CREB is acetylated within the cell and that in vitro, CREB is acetylated by CBP, but not by another acetylase, p300/CBP-associated factor. The acetylation sites within. CREB were mapped to three lysines within the CREB activation domain. Although inhibition of histone deacetylase activity results in an increase of CREB- or CBP-mediated gene expression, mutation of all three putative acetylation sites in the CREB activation domain markedly enhances the ability of CREB to activate a cAMP-responsive element-dependent reporter gene. Furthermore, these CREB lysine mutations do not increase interaction with the CRE or CBP. These data suggest that the transactivation potential of CREB may be modulated through acetylation by CBP. We propose that in addition to its functions as a bridging molecule and histone acetyltransferase, the ability of CBP to acetylate CREB may play a key role in modulating CREB-mediated gene expression.	Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Oregon Health & Science University; Oregon Health & Science University	Kwok, RPS (corresponding author), Univ Michigan, Dept Obstet & Gynecol, 6428 Med Sci Bldg 1,1301 E Catherine St, Ann Arbor, MI 48109 USA.	rkwok@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK060133, R29DK051732] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 051732, DK 060133, 5P60 DK 20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Candau R, 1996, MOL CELL BIOL, V16, P593; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ludlam WH, 2002, MOL CELL BIOL, V22, P3832, DOI 10.1128/MCB.22.11.3832-3841.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	55	85	88	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15727	15734		10.1074/jbc.M300546200	http://dx.doi.org/10.1074/jbc.M300546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595525	hybrid			2022-12-25	WOS:000182680000035
J	Takemae, H; Ueda, R; Okubo, R; Nakato, H; Izumi, S; Saigo, K; Nishihara, S				Takemae, H; Ueda, R; Okubo, R; Nakato, H; Izumi, S; Saigo, K; Nishihara, S			Proteoglyean UDP-galactose :beta-xylose beta 1,4-galactosyltransferase I is essential for viability in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN LINKAGE REGION; CAENORHABDITIS-ELEGANS; RNA-INTERFERENCE; D-XYLOSYLTRANSFERASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GENE; EXPRESSION; IDENTIFICATION	Heparan and chondroitin sulfates play essential roles in growth factor signaling during development and share a common linkage tetrasaccharide structure, GlcAbeta1,3Galbeta1,3Galbeta1,4Xylbeta1-O-Ser. In the present study, we identified the Drosophila proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I (dbeta4GalTI), and determined its substrate specificity. The enzyme transferred a Gal to the -beta-xylose (XyI) residue, confirming it to be the Drosophila ortholog of human proteoglycan UDP-galactose:beta-xylose 01,4-galactosyltransferase I. Then we established UAS-dbeta4GalTI-IR fly lines containing an inverted repeat of dbeta4GalTI ligated to the upstream activating sequence (UAS) promoter, a target of GAL4, and observed the Fi(1) generation of the cross between the UAS-dbeta4GalTI-IR fly and the Act5C-GAL4 fly. In the F, double-stranded RNA of dbeta4GalTI is expressed ubiquitously under the control of a cytoplasmic actin promoter to induce the silencing of the dbeta4GalTI gene. The expression of the target gene was disrupted specifically, and the degree of interference was correlated with phenotype. The lethality among the progeny proved that beta4GalTI is essential for viability. This study is the first to use reverse genetics, RNA interference, to study the Drosophila glycosyltransferase systematically.	Soka Univ, Div Cell Biol, Tokyo 1928577, Japan; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan; Natl Inst Genet, Invertebrate Genet Lab, Shizuoka 4418540, Japan; Mitsubishi Kagaku Inst Life Sci, Genet Networks Res Grp, Tokyo 1948511, Japan; Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Arizona, Div Neurobiol, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	Soka University; Tokyo Metropolitan University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Japan Science & Technology Agency (JST); University of Arizona; University of Arizona; University of Tokyo	Nishihara, S (corresponding author), Soka Univ, Div Cell Biol, Tokyo 1928577, Japan.		Takemae, Hitoshi/AEP-5503-2022	Nishihara, Shoko/0000-0002-1668-2603	NICHD NIH HHS [R01 HD042769] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042769] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Giordano E, 2002, GENETICS, V160, P637; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nakamura Y, 2002, J BIOL CHEM, V277, P46280, DOI 10.1074/jbc.M203873200; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Pace KE, 2002, J BIOL CHEM, V277, P13091, DOI 10.1074/jbc.M112105200; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Ueda R, 2001, J NEUROGENET, V15, P193, DOI 10.3109/01677060109167376; Vadaie N, 2002, GLYCOBIOLOGY, V12, P589, DOI 10.1093/glycob/cwf074; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200	36	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15571	15578		10.1074/jbc.M301123200	http://dx.doi.org/10.1074/jbc.M301123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590131	hybrid			2022-12-25	WOS:000182680000016
J	Vidricaire, G; Tardif, MR; Tremblay, MJ				Vidricaire, G; Tardif, MR; Tremblay, MJ			The low viral production in trophoblastic cells is due to a high endocytic internalization of the human immunodeficiency virus type 1 and can be overcome by the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NF-KAPPA-B; HUMAN PLACENTA; HIV TYPE-1; IMMUNOHISTOCHEMICAL LOCALIZATION; HUMAN ENDOMETRIUM; PROVIRAL DNA; BREAST-MILK; TNF-ALPHA; INFECTION	Maternal-infant transmission of human immunodeficiency virus type-1 (HIV-1) is the primary cause of this retrovirus infection in neonates. Trophoblasts have been proposed to play a critical role in modulating virus spread to the fetus. This paper addresses the mechanism of HIV-1 biology in trophoblastic cells. The trophoblastic cell lines BeWo, JAR, and JEG-3 were infected with reporter HIV-1 particles pseudotyped with envelope glycoproteins from the vesicular stomatitis virus or various strains of HIV-1. We demonstrate that despite a high internalization process of HIV-1 and no block in viral production, HIV-1 established a limited infection of trophoblasts with the production of very few progeny viruses. The factor responsible for this restriction to virus replication in such a cellular microenvironment is that the intracellular p24 is concentrated predominantly in endosomal vesicles following HIV-1 entry. HIV-1 transcription and virus production of infectious particles were both augmented upon treatment of trophoblasts with tumor necrosis factor-alpha and interleukin-1. However, the amount of progeny virions released by trophoblasts infected with native HIV-1 virions was so low even in the presence of pro-inflammatory cytokines that a co-culture step with indicator cells was necessary to detect virus production. Collectively these data illustrate for the first time that the natural low permissiveness of trophoblasts to productive HIV-1 infection is because of a restriction in the mode of entry, and such a limitation can be overcome with physiologic doses of tumor necrosis factor-a and interleukin-1, which are both expressed by the placenta, in conjunction with cell-cell contact. Considering that there is a linear correlation between viral load and HIV-1 vertical transmission, the environment may thus contribute to the propagation of HIV-1 across the placenta.	CHU Quebec, Hop CHUL, Lab Immunoretrovirol Humaine, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Med Biol, Fac Med, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), CHU Quebec, Hop CHUL, Lab Immunoretrovirol Humaine, Ctr Rech Infectiol, RC709,2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.							Al-Harthi L, 2002, AIDS RES HUM RETROV, V18, P13, DOI 10.1089/088922202753394673; AZOCAR J, 1979, CANCER RES, V39, P3388; BACKE E, 1992, J CLIN PATHOL, V45, P871, DOI 10.1136/jcp.45.10.871; Bacsi A, 2001, J INTERF CYTOK RES, V21, P1079, DOI 10.1089/107999001317205213; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; CHANDWANI S, 1991, J INFECT DIS, V163, P1134, DOI 10.1093/infdis/163.5.1134; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN HL, 1991, AM J PATHOL, V139, P327; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DABS F, 1993, AIDS, V7, P1139; DAVID FJE, 1992, CLIN EXP IMMUNOL, V88, P10; DAVID FJE, 1995, VIROLOGY, V208, P784, DOI 10.1006/viro.1995.1212; DeAndreis C, 1996, AIDS, V10, P711, DOI 10.1097/00002030-199606001-00004; DOUGLAS GC, 1994, J REPROD IMMUNOL, V27, P49, DOI 10.1016/0165-0378(94)90014-0; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HU XL, 1992, J REPROD IMMUNOL, V22, P257, DOI 10.1016/0165-0378(92)90047-8; HUNT JS, 1992, BIOL REPROD, V47, P141, DOI 10.1095/biolreprod47.1.141; JAATTELA M, 1988, LAB INVEST, V58, P48; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; Knofler M, 2000, PLACENTA, V21, P525, DOI 10.1053/plac.1999.0501; Lagaye S, 2001, J VIROL, V75, P4780, DOI 10.1128/JVI.75.10.4780-4791.2001; LAHM HW, 1985, J CHROMATOGR, V326, P357, DOI 10.1016/S0021-9673(01)87461-6; Lee BN, 1997, J VIROL, V71, P3628, DOI 10.1128/JVI.71.5.3628-3635.1997; LEPAGE P, 1987, LANCET, V2, P400; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; MANO H, 1991, AIDS RES HUM RETROV, V7, P83, DOI 10.1089/aid.1991.7.83; Marechal V, 1998, J VIROL, V72, P2208; MARTIN AW, 1992, HUM PATHOL, V23, P411, DOI 10.1016/0046-8177(92)90088-K; Menu E, 1999, J INFECT DIS, V179, P44, DOI 10.1086/314542; Miller SC, 1997, EXP CELL RES, V230, P9, DOI 10.1006/excr.1996.3397; Mognetti B, 2000, CLIN EXP IMMUNOL, V119, P486, DOI 10.1046/j.1365-2249.2000.01149.x; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; OPSJON SL, 1993, AM J OBSTET GYNECOL, V169, P397, DOI 10.1016/0002-9378(93)90096-2; PAULESU L, 1991, LYMPHOKINE CYTOK RES, V10, P443; Phillips TA, 2001, PLACENTA, V22, P663, DOI 10.1053/plac.2001.0703; Pijnenborg R, 1998, PLACENTA, V19, P231, DOI 10.1016/S0143-4004(98)90054-6; Plaud-Valentin M, 1999, CELL MOL BIOL, V45, P423; Poli G, 1995, HUMAN CYTOKINES THEI, P421; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; ROBERTSON SA, 1994, CRIT REV IMMUNOL, V14, P239, DOI 10.1615/CritRevImmunol.v14.i3-4.30; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Saito S, 2000, J REPROD IMMUNOL, V47, P87, DOI 10.1016/S0165-0378(00)00060-7; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; SOEIRO R, 1992, J INFECT DIS, V166, P699, DOI 10.1093/infdis/166.4.699; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TABIBZADEH S, 1991, AM J REPROD IMMUNOL, V26, P1; THIRY L, 1985, LANCET, V2, P891; Tscherning-Casper C, 1999, J VIROL, V73, P9673, DOI 10.1128/JVI.73.11.9673-9678.1999; VIDRICAIRE G, 2003, IN PRESS MED SCI; VIDRICAIRE G, 2003, 10 C RETR OPP INF BO, P370; Willumsen JF, 2001, AIDS, V15, P1896, DOI 10.1097/00002030-200109280-00026; YANG YP, 1993, J IMMUNOL, V150, P5614; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yui J, 1996, BIOL REPROD, V55, P400, DOI 10.1095/biolreprod55.2.400; YUI J, 1994, PLACENTA, V15, P819, DOI 10.1016/S0143-4004(05)80184-5; ZACHAR V, 1991, J VIROL, V65, P2102, DOI 10.1128/JVI.65.4.2102-2107.1991; Zachar V, 2002, AIDS RES HUM RETROV, V18, P839, DOI 10.1089/08892220260190317; Zachar V, 1999, AIDS RES HUM RETROV, V15, P1673, DOI 10.1089/088922299309711; ZACHAR V, 1994, AIDS, V8, P129, DOI 10.1097/00002030-199401000-00020	67	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15832	15841		10.1074/jbc.M210470200	http://dx.doi.org/10.1074/jbc.M210470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604606	hybrid			2022-12-25	WOS:000182680000049
J	Yu, LQ; York, J; von Bergmann, K; Lutjohann, D; Cohen, JC; Hobbs, HH				Yu, LQ; York, J; von Bergmann, K; Lutjohann, D; Cohen, JC; Hobbs, HH			Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; DIETARY-CHOLESTEROL; ACID SYNTHESIS; MICE LACKING; LXR-ALPHA; GENE; SITOSTEROLEMIA; XANTHOMATOSIS; ABSORPTION; MUTATIONS	Liver X receptor (LXR) is a nuclear receptor that plays a crucial role in orchestrating the trafficking of sterols between tissues. Treatment of mice with a potent and specific LXR agonist, T0901317, is associated with increased biliary cholesterol secretion, decreased fractional cholesterol absorption, and increased fecal neutral sterol excretion. Here we show that expression of two target genes of LXRalpha, the ATP-binding cassette (ABC) transporters Abcg5 and Abcg8, is required for both the increase in sterol excretion and the decrease in fractional cholesterol absorption associated with LXR agonist treatment. Mice expressing no ABCG5 and ABCG8 (G5G8(-/-) mice) and their littermate controls were treated for 7 days with T0901317. In wild type animals, treatment with the LXR agonist resulted in a 3-fold increase in biliary cholesterol concentrations, a 25% reduction in fractional cholesterol absorption, and a 4-fold elevation in fecal neutral sterol excretion. In contrast, the LXR agonist did not significantly affect biliary cholesterol levels, fractional cholesterol absorption, or neutral fecal sterol excretion in the G5G8(-/-) mice. Thus Abcg5 and Abcg8 are required for LXR agonist-associated changes in dietary and biliary sterol trafficking. These results establish a central role for ABCG5 and AECG8 in promoting cholesterol excretion in vivo.	Univ Texas, SW Med Ctr, Dept Mol Genet, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Bonn	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, McDermott Ctr Human Growth & Dev, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL 20948, HL 72304] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072304, P01HL020948, R37HL072304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chen JY, 2002, J BIOL CHEM, V277, P42588, DOI 10.1074/jbc.M205117200; Costet P, 2000, J BIOL CHEM, V275, P28240; GOULD RG, 1969, METABOLIS, V18, P652, DOI 10.1016/0026-0495(69)90078-X; GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; Mulligan JD, 2003, J BIOL CHEM, V278, P13356, DOI 10.1074/jbc.M212377200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1970, J CLIN INVEST, V49, P952, DOI 10.1172/JCI106315; SALEN G, 1985, J LIPID RES, V26, P1126; Schoenheimer R, 1931, SCIENCE, V74, P579, DOI 10.1126/science.74.1928.579; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwarz M, 1998, J LIPID RES, V39, P1833; TURLEY SD, 1991, METABOLISM, V40, P1063, DOI 10.1016/0026-0495(91)90131-F; TURLEY SD, 1994, J LIPID RES, V35, P328; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	36	231	240	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15565	15570		10.1074/jbc.M301311200	http://dx.doi.org/10.1074/jbc.M301311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601003	hybrid			2022-12-25	WOS:000182680000015
J	Chen, NF; Yu, JZ; Skiba, NP; Hamm, HE; Rasenick, MM				Chen, NF; Yu, JZ; Skiba, NP; Hamm, HE; Rasenick, MM			A specific domain of G(i)alpha required for the transactivation of G(i)alpha by tubulin is implicated in the organization of cellular microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL SIGNAL-TRANSDUCTION; GTP-BINDING PROTEINS; CYTOSKELETAL ELEMENTS; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; ACTIVATION; CELLS; MEMBRANE; PARTICIPATION; ASSOCIATION	G(s)x, G(i)alpha(1), and G(q)x subunits bind tubulin with high affinity, whereas transducin (Gtalpha) does not. The interaction between tubulin and Galpha, which also involves the direct transfer of GTP from tubulin to Got (transactivation), is not yet fully understood. This study, using chimeras of G(i)alpha and G(t)alpha, showed that the G(i)alpha (215-295) segment converted G(i)alpha to bind to tubulin and this chimera (chimera 1) could be transactivated by tubulin. Insertion of G(t)alpha (237-270) into chimera 1 to form chimera 2 resulted in a protein that, like G(t)alpha, did not bind tubulin. Thus, it was thought that the G(i)alpha (237-270) domain was essential to modulate the binding of G(i)alpha(1) to tubulin. Surprisingly, when domain (237-270) of G(i)alpha was replaced by G(t)alpha (237-270) to form chimera 3, the chimera bound to tubulin with a similar affinity (K-D congruent to120 nM) as wild-type G(i)alpha(1). However, even though chimera 3 displayed normal GTP binding, it was not transactivated by GTP-tubulin. Furthermore, when these chimeras were expressed in COS-1 cells, cellular processes in cells overexpressing G(i)alpha(1) or chimera 1 were more abundant and longer than those in native cells. Galpha was seen throughout the length of the process. Morphology of cells expressing chimera 2 was identical to controls. Consistent with the role of Chimera 3 as a "dominant negative" Galpha, cells transfected with chimera 3 had only few truncated processes. This study demonstrates that although G(i)alpha (237-270) is not obligatory for the binding of Galpha to tubulin, it is crucial for the transactivation of Galpha by tubulin. These results also suggest that the transactivation of Galpha by tubulin may play an important role in modulating microtubule organization and cell morphology.	Univ Illinois, Dept Physiol & Biophys, Coll Med, Chicago, IL 60612 USA; Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Vanderbilt University	Rasenick, MM (corresponding author), Univ Illinois, Dept Physiol & Biophys, Coll Med, M-C 901,835 Wolcott Ave, Chicago, IL 60612 USA.	raz@uic.edu	Hamm, Heidi E/G-2374-2014		NEI NIH HHS [EY 10291, EY06062] Funding Source: Medline; NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595, MH 57391] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595, R01MH057391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; Crouch MF, 2000, CELL SIGNAL, V12, P153, DOI 10.1016/S0898-6568(99)00080-7; HAGMANN J, 1980, J BIOL CHEM, V255, P2659; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Panagiotou S, 1999, J CELL BIOCHEM, V73, P204, DOI 10.1002/(SICI)1097-4644(19990501)73:2<204::AID-JCB6>3.0.CO;2-V; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; RASENICK MM, 1988, J NEUROCHEM, V51, P300, DOI 10.1111/j.1471-4159.1988.tb04870.x; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; RASENICK MM, 1990, ADV SEC MESS PHOSPH, V24, P381; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Thiyagarajan MM, 2002, BIOCHEMISTRY-US, V41, P9470, DOI 10.1021/bi025533u; WANG N, 1990, J BIOL CHEM, V265, P1239; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; Yan K, 2001, J NEUROCHEM, V76, P182, DOI 10.1046/j.1471-4159.2001.00013.x; Yan K, 1996, J NEUROCHEM, V66, P1489; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352	32	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15285	15290		10.1074/jbc.M300841200	http://dx.doi.org/10.1074/jbc.M300841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582171	hybrid			2022-12-25	WOS:000182516100091
J	Guo, FK; Gao, Y; Wang, L; Zheng, Y				Guo, FK; Gao, Y; Wang, L; Zheng, Y			P19(Arf)-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Rac1 GTPase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; WILD-TYPE P53; RHO-GTPASES; GENE-EXPRESSION; ACTIVATION; GROWTH; BINDING; RAS; FIBROBLASTS; APOPTOSIS	The p19(Arf)-p53 tumor suppressor pathway plays a critical role in cell-cycle checkpoint control and apoptosis, whereas Rho family small GTPases are key regulators of actin structure and cell motility. By using primary mouse embryonic fibroblasts that lack Arf, p53, or both, we studied the involvement of the p19(Arf)-p53 pathway in the regulation of cell motility and its relationship with Rho GTPases. Deletion of Arf and/or p53 led to actin cytoskeleton reorganization and a significant increase in cell motility. The endogenous phosphoinositide (PI) 3-kinase and Rac1 activities were elevated in Arf(-/-) and p53(-/-) cells, and these activities are required for p19(Arf)- and p53-regulated migration. Reintroduction of the wild type Arf or p53 genes into Arf(-/-) or p53(-/-) cells reversed the PI 3-kinase and Rho GTPase activities as well as the migration phenotype. These results suggest a functional relationship between an established tumor suppressor pathway and a signaling module that controls actin structure and cell motility and show that p19(Arf) and p53 negatively regulate cell migration by suppression of PI 3-kinase and Rac1 activities.	Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH 45229 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM53943] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li R, 1999, J BIOL CHEM, V274, P29648, DOI 10.1074/jbc.274.42.29648; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Williams DA, 2000, BLOOD, V96, P1646; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	36	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14414	14419		10.1074/jbc.M300341200	http://dx.doi.org/10.1074/jbc.M300341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578823	hybrid			2022-12-25	WOS:000182405000108
J	Cao, C; Leng, YM; Li, CF; Kufe, D				Cao, C; Leng, YM; Li, CF; Kufe, D			Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; APOPTOTIC RESPONSE; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; DROSOPHILA-ABL; ACTIVATION; NUCLEAR; BINDING; GENE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE	The AbI family of mammalian nonreceptor tyrosine kinases consists of c-Abl and Arg. Recent work has shown that c-Abl and Arg are activated in the cellular response to oxidative stress. The present studies demonstrate that reactive oxygen species (ROS) induce the formation of c-Abl and Arg heterodimers. The results show that the c-Abl SH3 domain binds directly to a proline-rich site (amino acids 567-576) in the Arg C-terminal region. Formation of c-Abl(.)Arg heterodimers also involves direct binding of the Arg Src homology 3 domain to the C-terminal region of c-Abl. The results further demonstrate that the interaction between c-Abl and Arg involves c-Abl-mediated phosphorylation of Arg. The functional significance of the c-Abl-Arg interaction is supported by the demonstration that both c-Abl and Arg are required for ROS-induced apoptosis. These findings indicate that ROS induce c-Abl(.)Arg heterodinters and that both c-Abl and Arg are necessary as effectors in the apoptotic response to oxidative stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Beijing Inst Biotechnol, Beijing 100850, Peoples R China	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.							Agami R, 1999, NATURE, V399, P809; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cao C, 2001, J BIOL CHEM, V276, P11465, DOI 10.1074/jbc.C100050200; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; Gong JG, 1999, NATURE, V399, P806; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Klohn PC, 1997, CHEM-BIOL INTERACT, V106, P15, DOI 10.1016/S0009-2797(97)00052-5; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; MATTIONI T, 1995, ONCOGENE, V10, P1325; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Walkenhorst J, 1996, ONCOGENE, V12, P1513; Wang BL, 1996, ONCOGENE, V13, P193; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	48	33	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12961	12967		10.1074/jbc.M300058200	http://dx.doi.org/10.1074/jbc.M300058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569093	hybrid			2022-12-25	WOS:000182189500048
J	Llamazares, M; Cal, S; Quesada, V; Lopez-Otin, C				Llamazares, M; Cal, S; Quesada, V; Lopez-Otin, C			Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-CLEAVING PROTEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; GENE FAMILY; CLONING; MATRIX; MEMBER; ADAM; AGGRECANASE-1; MUTATIONS; PROTEINS	We have cloned a mouse brain cDNA encoding a new protein of the ADAMTS family (A disintegrin and metalloproteinase domain, with thrombospondin type-1 repeats), which has been called ADAMTS-20. This protein shows a domain organization similar to that described for other ADAMTSs including signal sequence, propeptide, metalloproteinase domain, disintegrin domain, central TS-1 motif, cysteine-rich region, and C-terminal TS module. However, this last module is more complex than that of other ADAMTSs, being composed of a total of 14 repeats. The structural complexity of ADAMTS-20 is further increased by the presence of an additional domain 200 residues long and located immediately adjacent to the TS module. This domain has been tentatively called GON domain and can also be recognized in some ADAMTSs such as gon-1 from Caenorhabditis elegans and human and mouse ADAMTS-9. The presence of this domain is a hallmark of a novel subfamily of structurally and evolutionarily related ADAMTSs, called GON-ADAMTSs. Expression analysis demonstrated that ADAMTS-20 transcripts can be detected at low levels in several human and mouse tissues, especially in testis. This gene is also overexpressed in some human malignant tumors, including brain, colon, and breast carcinomas. Western blot analysis using polyclonal antibodies raised against recombinant ADAMTS-20 produced in Escherichia coli showed the presence of a 70-kDa band in mouse brain and testis extracts. This recombinant ADAMTS-20 hydrolyzed a synthetic peptide used for assaying matrix metalloproteinases. These data suggest that this novel enzyme may play a role in the tissue remodeling process occurring in both normal and pathological conditions.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, Inst Oncol, E-33006 Oviedo, Spain	University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, Inst Oncol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	López-Otín, Carlos/AAB-2106-2020; Quesada, Víctor/B-6557-2014	López-Otín, Carlos/0000-0001-6964-1904; Quesada, Víctor/0000-0002-8398-3457; Llamazares Prada, Maria/0000-0001-6559-9374				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Cin PD, 1999, GENE CHROMOSOME CANC, V24, P94, DOI 10.1002/(SICI)1098-2264(199901)24:1<94::AID-GCC14>3.0.CO;2-2; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; El-Rifai W, 2001, NEOPLASIA, V3, P173, DOI 10.1038/sj.neo.7900158; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gerritsen HE, 2001, BLOOD, V98, P1654, DOI 10.1182/blood.V98.6.1654; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Hough RE, 2001, BRIT J CANCER, V84, P499, DOI 10.1054/bjoc.2000.1638; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Kokame K, 2002, P NATL ACAD SCI USA, V99, P11902, DOI 10.1073/pnas.172277399; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Llano E, 1999, CANCER RES, V59, P2570; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Nakamura H, 2000, J BIOL CHEM, V275, P38885, DOI 10.1074/jbc.M003875200; Northrop DB, 1999, ADV ENZYMOL RAMB, V73, P25, DOI 10.1002/9780470123195.ch2; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEDEUTOUR F, 1994, GENOMICS, V22, P512, DOI 10.1006/geno.1994.1424; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	41	71	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13382	13389		10.1074/jbc.M211900200	http://dx.doi.org/10.1074/jbc.M211900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562771	hybrid, Green Published			2022-12-25	WOS:000182189500100
J	Moriuchi, M; Moriuchi, H				Moriuchi, M; Moriuchi, H			YY1 transcription factor down-regulates expression of CCR5, a major coreceptor for HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROMOTER ACTIVITY; T-LYMPHOCYTES; ENTRY; INFECTION; PROTEIN; REPLICATION; INCREASES; CXCR4; CELLS	Expression of CCR5, a major coreceptor for human immunodeficiency virus type 1 (HIV-1), is regulated by a number of transcription factors. Here we report that the YY1 transcription factor down-regulates CCR5 promoter activity and that overexpression of YY1 reduces cell surface CCR5 expression and infectibility by R5-HIV-1. Because YY1 also down-regulates promoter activities of CXCR4, another major coreceptor for HIV-1 and HIV-1 long terminal repeat, this transcription factor may play a critical role in the pathogenesis of HIV-1 disease.	Nagasaki Univ Hosp, Dept Pediat, Nagasaki 8528501, Japan; Nagasaki Univ, Sch Biomed Sci, Div Med Virol, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University	Moriuchi, H (corresponding author), Nagasaki Univ Hosp, Dept Pediat, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; Lusso P, 2000, VIROLOGY, V273, P228, DOI 10.1006/viro.2000.0443; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MORIUCHI H, 1995, J VIROL, V69, P4693, DOI 10.1128/JVI.69.8.4693-4701.1995; Moriuchi H, 1998, J EXP MED, V187, P1689, DOI 10.1084/jem.187.10.1689; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Moriuchi M, 2001, J BIOL CHEM, V276, P8639, DOI 10.1074/jbc.M008391200; Moriuchi M, 1999, BLOOD, V93, P1433, DOI 10.1182/blood.V93.4.1433.404a36c_1433_1435; Reynes J, 2001, AIDS, V15, P1627, DOI 10.1097/00002030-200109070-00004; Rosati M, 2001, J IMMUNOL, V167, P1654, DOI 10.4049/jimmunol.167.3.1654; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439; Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45; Tuttle DL, 1998, J VIROL, V72, P4962, DOI 10.1128/JVI.72.6.4962-4969.1998; Wang JH, 1998, J VIROL, V72, P7642, DOI 10.1128/JVI.72.9.7642-7647.1998; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187	22	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13003	13007		10.1074/jbc.M204980200	http://dx.doi.org/10.1074/jbc.M204980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571248	hybrid			2022-12-25	WOS:000182189500053
J	Nishigaki, K; Thompson, D; Yugawa, T; Rulli, K; Hanson, C; Cmarik, J; Gutkind, JS; Teramoto, H; Ruscetti, S				Nishigaki, K; Thompson, D; Yugawa, T; Rulli, K; Hanson, C; Cmarik, J; Gutkind, JS; Teramoto, H; Ruscetti, S			Identification and characterization of a novel Ste20/germinal center kinase-related kinase, polyploidy-associated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; ANCHORAGE-INDEPENDENT GROWTH; HUMAN STE20-LIKE KINASE; C-JUN; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; MOLECULAR-CLONING; PATHWAY	A novel protein kinase, polyploidy-associated protein kinase (PAPK), was isolated using a subtraction cDNA library approach from a mouse erythroleukemia cell line that had been induced to polyploidy after serum withdrawal. PAPK shares homology with members of the Ste20/germinal center kinase family of protein kinases and is ubiquitously expressed as two spliced forms, PAPK-A and PAPK-B, that encode for proteins of 418 and 189 amino acids, respectively. The expression of endogenous PAPK-A protein increased after growth factor withdrawal in murine hematopoietic and fibroblast cells. When tested in an in vitro kinase assay, PAPK-A was activated in response to the stress-inducing agent hydrogen peroxide and slightly by fetal calf serum. Biochemical characterization of the PAPK-A-initiated pathway revealed that this novel kinase does not affect MAP kinase activity but can stimulate both c-Jun N-terminal kinase 1 (JNK1) and ERK6/p38gamma. The kinase activity of PAPK appears to be required for the activation of ERK6/p38gamma but not JNK1. When an inducible construct of PAPK-A was expressed in stably transfected NIH3T3 cells, the cells exhibited distinct cytoskeletal changes and became resistant to apoptotic cell death induced by serum withdrawal, effects of PAPK that require its kinase activity. These data suggest that PAPK is a new member of the Ste20/germinal center kinase family that modulates cytoskeletal organization and cell survival.	NCI Frederick, Basic Res Lab, NIH, Ft Detrick, MD 21702 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Nishigaki, K (corresponding author), NCI Frederick, Basic Res Lab, NIH, Bldg 469,Rm 205, Ft Detrick, MD 21702 USA.	nishigakik@mail.ncifcrf.gov; ruscetti@ncifcrf.gov	Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Court NW, 2002, J MOL CELL CARDIOL, V34, P413, DOI 10.1006/jmcc.2001.1523; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kanai-Azuma M, 1999, MECH DEVELOP, V89, P155, DOI 10.1016/S0925-4773(99)00193-8; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Schrick K, 1997, GENETICS, V147, P19; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; Vannucchi AM, 2000, BLOOD, V95, P2559; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang WP, 2000, BIOCHEM BIOPH RES CO, V274, P872, DOI 10.1006/bbrc.2000.3244; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	73	13	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13520	13530		10.1074/jbc.M208601200	http://dx.doi.org/10.1074/jbc.M208601200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574163	hybrid			2022-12-25	WOS:000182189500116
J	Shimizu, Y; Yamamichi, N; Saitoh, K; Watanabe, A; Ito, T; Yamamichi-Nishina, M; Mizutani, M; Yahagi, N; Suzuki, T; Sasakawa, C; Yasugi, S; Ichinose, M; Iba, H				Shimizu, Y; Yamamichi, N; Saitoh, K; Watanabe, A; Ito, T; Yamamichi-Nishina, M; Mizutani, M; Yahagi, N; Suzuki, T; Sasakawa, C; Yasugi, S; Ichinose, M; Iba, H			Kinetics of v-src-induced epithelial-mesenchymal transition in developing glandular stomach	ONCOGENE			English	Article						RSV; epithelial-mesenchymal transition; MAP kinase; apoptosis; v-src	HIGH-LEVEL EXPRESSION; CHICKEN-EMBRYO FIBROBLASTS; RETROVIRUS VECTORS; CELLULAR-TRANSFORMATION; PHOSPHORYLATION SITES; PROTEIN CAUSES; DEVELOPING GUT; GENE-TRANSFER; FOS GENE; C-JUN	The oncogene function in primary epithelial cells is largely unclear. Recombination organ cultures in combination with the stable and transient gene transfer techniques by retrovirus and electroporation, respectively, enable us to transfer oncogenes specifically into primary epithelial cells of the developing avian glandular stomach (proventriculns). In this system, the epithelium and mesenchyme are mutually dependent on each other for their growth and differentiation. We report here that either stable or transient expression of v-src in the epithelium causes budding and migration of epithelial cells into mesenchyme. In response to the transient expression of v-Src or a constitutive active mutant of MEK, we observed immediate downregulation of the Sonic hedgehog gene and subsequent elimination of E-cadherine expression in migrating cells, suggesting the involvement of MAP kinase signaling pathway in these processes. v-src-expressing cells that were retained in the epithelium underwent apoptosis (anoikis) and detached from the culture. Continuous expression of v-src by, for example, Rous sarcoma virus (RSV) was required for the epithetial cells to acquire the ability to express type I collagen and fihronectin genes (mesenchymal markers), and finally to establish the epithelial-mesenchymal transition. These observations would partly explain why RSV does not apparently cause carcinoma formation, but induces sarcomas exclusively.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Bacterial Infect, Dept Microbiol & Immunol,Minato Ku, Tokyo 1088639, Japan; Nippon Inst Biol Sci, Lab Anim Res Stn, Yamanashi 4080041, Japan; Univ Tokyo, Dept Gastroenterol, Fac Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Metropolitan Univ, Fac Sci, Dept Biol, Hachioji, Tokyo 1920397, Japan; Wakayama Med Coll, Dept Internal Med 2, Wakayama 6400012, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Metropolitan University; Wakayama Medical University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Daigo Y, 1999, CANCER RES, V59, P4222; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; Fukuda K, 2000, DEV GROWTH DIFFER, V42, P207; Gailani MR, 1997, JNCI-J NATL CANCER I, V89, P1103, DOI 10.1093/jnci/89.15.1103; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; IBA H, 1988, ONCOGENE RES, V2, P121; Iba H, 2000, DEV GROWTH DIFFER, V42, P213; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Koike T, 1999, DIFFERENTIATION, V65, P13, DOI 10.1046/j.1432-0436.1999.6510013.x; Matsumoto K, 1998, ONCOGENE, V16, P1611, DOI 10.1038/sj.onc.1201675; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, GENE, V202, P23, DOI 10.1016/S0378-1119(97)00468-X; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Narita T, 2000, DEVELOPMENT, V127, P981; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; Rosenberg N., 1997, P475; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217; Sukegawa A, 2000, DEVELOPMENT, V127, P1971; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Tabata H, 1998, DEV GROWTH DIFFER, V40, P519; TAKIGUCHI K, 1988, DEV GROWTH DIFFER, V30, P241; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P3994, DOI 10.1073/pnas.94.8.3994; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; YASUGI S, 1993, DEV GROWTH DIFFER, V35, P1; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	40	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					884	893		10.1038/sj.onc.1206174	http://dx.doi.org/10.1038/sj.onc.1206174			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584568				2022-12-25	WOS:000180864300011
J	Wang, HY; Maechler, P; Antinozzi, PA; Herrero, L; Hagenfeldt-Johansson, KA; Bjorklund, A; Wollheim, CB				Wang, HY; Maechler, P; Antinozzi, PA; Herrero, L; Hagenfeldt-Johansson, KA; Bjorklund, A; Wollheim, CB			The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; DIABETIC FATTY RATS; INSULIN-SECRETION; GENE-EXPRESSION; MITOCHONDRIAL ACTIVATION; UNCOUPLING PROTEIN-2; PANCREATIC-ISLETS; TRANSGENIC MICE; ACID SYNTHESIS; MESSENGER-RNA	Accumulation of lipids in non-adipose tissues is often associated with Type 2 diabetes and its complications. Elevated expression of the lipogenic transcription factor, sterol regulatory element binding protein-1c (SREBP-1c), has been demonstrated in islets and liver of diabetic animals. To elucidate the molecular mechanisms underlying SREBP-1c-induced beta-cell dysfunction, we employed the Tet-On inducible system to achieve tightly controlled and conditional expression of the nuclear active form of SREBP-1c (naSREBP-1c) in INS-1 cells. Controlled expression of naSREBP-1c induced massive accumulation of lipid droplets and blunted nutrient-stimulated insulin secretion in INS-1 cells. K+-evoked insulin exocytosis was unaltered. Quantification of the gene expression profile in this INS-1 stable clone revealed that naSREBP-1c induced beta-cell dysfunction by targeting multiple genes dedicated to carbohydrate metabolism, lipid biosynthesis, cell growth, and apoptosis. naSREBP-1c elicits cell growth-arrest and eventually apoptosis. We also found that the SREBP-1c processing in beta-cells was irresponsive to acute stimulation of glucose and insulin, which was distinct from that in lipogenic tissues. However, 2-day exposure to these agents promoted SREBP-1c processing. Therefore, the SREBP-1c maturation could be implicated in the pathogenesis of beta-cell glucolipotoxicity.	Ctr Med Univ Geneva, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Wang, HY (corresponding author), Ctr Med Univ Geneva, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.	Haiyan.Wang@medicine.unige.ch	Herrero, Laura/D-4011-2014; Björklund, Anders/ABA-1326-2020	Herrero, Laura/0000-0003-4244-4673; Maechler, Pierre/0000-0002-2005-1433				Andreolas C, 2002, DIABETES, V51, P2536, DOI 10.2337/diabetes.51.8.2536; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cavaghan MK, 2000, J CLIN INVEST, V106, P329, DOI 10.1172/JCI10761; Diomede L, 2001, EUR CYTOKINE NETW, V12, P625; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Friedman J, 2002, NATURE, V415, P268, DOI 10.1038/415268a; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greenberg AS, 2002, EUR J CLIN INVEST, V32, P24, DOI 10.1046/j.1365-2362.32.s3.4.x; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harmon JS, 2001, DIABETES, V50, P2481, DOI 10.2337/diabetes.50.11.2481; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Lin HZ, 2000, NAT MED, V6, P998, DOI 10.1038/79697; Liu Y, 2002, ARTERIOSCL THROM VAS, V22, P76, DOI 10.1161/hq0102.101822; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Muller-Wieland D, 2002, ANN NY ACAD SCI, V967, P19; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Rubi B, 2001, J BIOL CHEM, V276, P36391, DOI 10.1074/jbc.M104999200; Saltiel AR, 2000, J CLIN INVEST, V106, P163, DOI 10.1172/JCI10533; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang MY, 1998, P NATL ACAD SCI USA, V95, P11921, DOI 10.1073/pnas.95.20.11921; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; WEIR GC, 1982, AM J MED, V73, P461, DOI 10.1016/0002-9343(82)90321-7; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zhou YT, 1998, DIABETES, V47, P1904, DOI 10.2337/diabetes.47.12.1904; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	73	78	82	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16622	16629		10.1074/jbc.M212488200	http://dx.doi.org/10.1074/jbc.M212488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600983	hybrid			2022-12-25	WOS:000182818600025
J	Dubbs, JM; Tabita, FR				Dubbs, JM; Tabita, FR			Interactions of the cbb(II) promoter-operator region with CbbR and RegA (PrrA) regulators indicate distinct mechanisms to control expression of the two cbb operons of Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; CO2 FIXATION OPERON; PHOTOSYNTHESIS GENE-EXPRESSION; SIGNAL-TRANSDUCTION SYSTEM; CLONING VECTORS; NUCLEOTIDE-SEQUENCE; IN-VITRO; FORM-I; CAPSULATUS; OXYGENASE	In a previous study (Dubbs, J. M., Bird, T. H., Bauer, C. E., and Tabita, F. R. (2000) J. Biol. Chem 275,1922419230), it was demonstrated that the regulators CbbR and RegA (PrrA) interacted with both promoter proximal and promoter distal regions of the form I (ebb,) promoter operon specifying genes of the Calvin-Benson-Bassham cycle of Rhodobacter sphaeroides. To determine how these regulators interact with the form II (ebb,,) promoter, three cbbF(II:):lacZ translational fusion plasmids were constructed containing various lengths of sequence 5' to the cbb(II) operon of R. sphaeroides CAC. Expression of beta-galactosidase was monitored under a variety of growth conditions in both the parental strain and knock-out strains that contain mutations that affect synthesis of CbbR and RegA. The binding sites for both CbbR and RegA were determined by DNase I footprinting. A region of the cbb(II) promoter from +38 to -227 bp contained a CbbR binding site and conferred low level regulated cbb(II) expression. The region from -227 to -1025 bp contained six RegA binding sites and conferred enhanced cbb(II) expression under all growth conditions. Unlike the cbb(I) operon, the region between -227 and -545 bp that contains one RegA binding site, was responsible for the majority of the observed enhancement. Both RegA and CbbR were required for maximal cbb(II) expression. Two potentially novel and specific cbb(II) promoter-binding proteins that did not interact with the cbb(I) promoter region were detected in crude extracts of R. sphaeroides. These results, combined with the observation that chemoautotrophic expression of the cbb(I) operon is RegA independent, indicated that the mechanisms controlling cbb(I) and cbb(II) operon expression during chemoautotrophic growth are quite different.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Plant Mol Biol Biotechnol Program, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.				PHS HHS [G, 45404] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Barber RD, 1998, J MOL BIOL, V280, P775, DOI 10.1006/jmbi.1998.1900; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; CHEN JH, 1991, J BIOL CHEM, V266, P20447; Du SY, 1998, J BIOL CHEM, V273, P18509, DOI 10.1074/jbc.273.29.18509; Dubbs JM, 2000, J BIOL CHEM, V275, P19224, DOI 10.1074/jbc.M002125200; Dubbs JM, 1998, J BACTERIOL, V180, P4903, DOI 10.1128/JB.180.18.4903-4911.1998; Elsen S, 2000, J BACTERIOL, V182, P2831, DOI 10.1128/JB.182.10.2831-2837.2000; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; FALCONE DL, 1991, J BACTERIOL, V173, P2099, DOI 10.1128/jb.173.6.2099-2108.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GIBSON JL, 1993, J BACTERIOL, V175, P5778, DOI 10.1128/JB.175.18.5778-5784.1993; GIBSON JL, 1987, J BACTERIOL, V169, P3685, DOI 10.1128/jb.169.8.3685-3690.1987; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; Gibson JL, 1996, ARCH MICROBIOL, V166, P141, DOI 10.1007/s002030050369; Gibson JL, 2002, J BACTERIOL, V184, P6654, DOI 10.1128/JB.184.23.6654-6664.2002; GIBSON JL, 1977, J BACTERIOL, V132, P818, DOI 10.1128/JB.132.3.818-823.1977; GIBSON JL, 1995, ANOXYGENIC PHOTOSYNT, P1107; HALLENBECK PL, 1990, J BACTERIOL, V172, P1749, DOI 10.1128/jb.172.4.1749-1761.1990; HALLENBECK PL, 1990, J BACTERIOL, V172, P1736, DOI 10.1128/jb.172.4.1736-1748.1990; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; O'Gara JP, 1998, J BACTERIOL, V180, P4044; OMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449; Paoli GC, 1998, ARCH MICROBIOL, V170, P8, DOI 10.1007/s002030050609; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; QIAN Y, 1997, THESIS OHIO STATE U; Qian YL, 1998, J BACTERIOL, V180, P4644, DOI 10.1128/JB.180.17.4644-4649.1998; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; Swem LR, 2001, J MOL BIOL, V309, P121, DOI 10.1006/jmbi.2001.4652; Vichivanives P, 2000, J MOL BIOL, V300, P1079, DOI 10.1006/jmbi.2000.3914; XU HH, 1994, J BACTERIOL, V176, P7299, DOI 10.1128/JB.176.23.7299-7308.1994; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	37	37	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16443	16450		10.1074/jbc.M211267200	http://dx.doi.org/10.1074/jbc.M211267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601011	hybrid			2022-12-25	WOS:000182680000124
J	Espert, L; Degols, G; Gongora, C; Blondel, D; Williams, BR; Silverman, RH; Mechti, N				Espert, L; Degols, G; Gongora, C; Blondel, D; Williams, BR; Silverman, RH; Mechti, N			ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; VESICULAR STOMATITIS-VIRUS; BODY-ASSOCIATED PROTEIN; MOLECULAR-CLONING; TRANSGENIC MICE; MESSENGER-RNA; MX PROTEINS; 2-5A SYSTEM; CELLS; PKR	Interferons (IFNs) encode a family of secreted proteins that provide the front-line defense against viral infections. Their diverse biological actions are thought to be mediated by the products of specific but usually overlapping sets of cellular genes induced in the target cells. We have recently isolated a new human IFN-induced gene that we have termed ISG20, which codes for a 3' to 5' exonuclease with specificity for single-stranded RNA and, to a lesser extent, for DNA. In this report, we demonstrate that ISG20 is involved in the antiviral functions of IFN. In the absence of IFN treatment, ISG20-overexpressing HeLa cells showed resistance to infections by vesicular stomatitis vir-us (VSV), influenza virus, and encephalomyocarditis virus (three RNA genomic viruses) but not to the DNA genomic adenovirus. ISG20 specifically interfered with VSV mRNA synthesis and protein production while leaving the expression of cellular control genes unaffected. No antiviral effect was observed in cells overexpressing a mutated ISG20 protein defective in exonuclease activity, demonstrating that the antiviral effects were due to the exonuclease activity of ISG20. In addition, the inactive mutant ISG20 protein, which is able to inhibit ISG20 exonuclease activity in vitro, significantly reduced the ability of IFN to block VSV development. Taken together, these data suggested that the antiviral activity of IFN against VSV is partly mediated by ISG20. We thus show that, besides RNase L, ISG20 has an antiviral activity, supporting the idea that it might represent a novel antiviral pathway in the mechanism of IFN action.	CNRS, EFS, UMR 5094, F-34094 Montpellier 5, France; CNRS, UMR 2472, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France; Lerner Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Mechti, N (corresponding author), CNRS, EFS, UMR 5094, 240 Ave Emile Jeanbrau, F-34094 Montpellier 5, France.		Espert, Lucile/ABF-5614-2021; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151; GONGORA, Celine/0000-0001-9034-4031				Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Arnheiter H, 1996, CURR TOP MICROBIOL, V206, P119; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BLONDEL D, 1990, J VIROL, V64, P1716, DOI 10.1128/JVI.64.4.1716-1725.1990; BLONDEL D, 1988, J VIROL, V62, P277, DOI 10.1128/JVI.62.1.277-284.1988; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DACQUISTO F, 2001, SCI STKE; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Khabar KSA, 2000, J INTERF CYTOK RES, V20, P653, DOI 10.1089/107999000414835; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; Mattei MG, 1997, CYTOGENET CELL GENET, V79, P286, DOI 10.1159/000134745; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5804; MILLHAUD PG, 1983, ANN VIROL E, V134, P405; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PAVLOVIC J, 1993, CIBA F SYMP, V176, P233; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Scadden ADJ, 1997, EMBO J, V16, P2140, DOI 10.1093/emboj/16.8.2140; Scadden ADJ, 2001, EMBO J, V20, P4243, DOI 10.1093/emboj/20.15.4243; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Staege H, 2001, IMMUNOGENETICS, V53, P105, DOI 10.1007/s002510100306; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; Vasandani VM, 1999, J INTERF CYTOK RES, V19, P447, DOI 10.1089/107999099313884; Williams B.R., 2001, SCI STKE, V2001, pre2; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	53	164	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16151	16158		10.1074/jbc.M209628200	http://dx.doi.org/10.1074/jbc.M209628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594219	hybrid, Green Published			2022-12-25	WOS:000182680000088
J	Cobucci-Ponzano, B; Trincone, A; Giordano, A; Rossi, M; Moracci, M				Cobucci-Ponzano, B; Trincone, A; Giordano, A; Rossi, M; Moracci, M			Identification of an archaeal alpha-L-fucosidase encoded by an interrupted gene - Production of a functional enzyme by mutations mimicking programmed-1 frameshifting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-SOLFATARICUS; FUCOSYL-TRANSFERASE; BETA-GLYCOSIDASE; N-GLYCANS; SEQUENCE; PROTEIN; GLUCOSIDASE; PREDICTION; BACTERIA; GENOME	The analysis of the complete genome of the thermoacidophilic Archaeon Sulfolobus solfataricus revealed two open reading frames (ORF), named SSO11867 and SSO3060, interrupted by a -1 frameshift and encoding for the N- and the C-terminal fragments, respectively, of an alpha-L-fucosidase. We report here that these ORFs are actively transcribed in vivo, and we confirm the presence of the -1 frameshift between them at the cDNA level, explaining why we could not find a-fucosidase activity in S. solfataricus extracts. Detailed analysis of the region of overlap between the two ORFs revealed the presence of the consensus sequence for a programmed -1 frameshifting. Two specific mutations, mimicking this regulative frameshifting event, allow the expression, in Escherichia coli, of a fully active thermophilic and thermostable alpha-L-fucosidase (EC 3.2.1.51) with micromolar substrate specificity and showing transfucosylating activity. The analysis of the fucosylated products of this enzyme allows, for the first time, assigning a retaining reaction mechanism to family 29 of glycosyl hydrolases. The presence of an alpha-fucosidase putatively regulated by programmed -1 frameshifting is intriguing both with respect to the regulation of gene expression and, in post-genomic era, for the definition of gene function in Archaea.	CNR, Inst Prot Biochem, I-80131 Naples, Italy; CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Dipartimento Chim Biol, I-80134 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Naples Federico II	Moracci, M (corresponding author), CNR, Inst Prot Biochem, Via P Castellino 111, I-80131 Naples, Italy.	moracci@dafne.ibpe.na.cnr.it	Trincone, Antonio/B-4323-2010; Cobucci Ponzano, Beatrice/G-8536-2013; giordano, assunta/E-3574-2012; Moracci, Marco/B-8444-2015; Cobucci-Ponzano, Beatrice/B-7654-2015; Cobucci-Ponzano, Beatrice/AAX-7630-2020	Trincone, Antonio/0000-0003-4191-7280; Moracci, Marco/0000-0002-9846-2531; Cobucci-Ponzano, Beatrice/0000-0002-8211-2297; GIORDANO, ASSUNTA/0000-0001-8139-407X				AbdelAleem H, 1996, INT J GYNECOL OBSTET, V55, P273, DOI 10.1016/S0020-7292(96)02770-1; Baranov PV, 2001, NUCLEIC ACIDS RES, V29, P264, DOI 10.1093/nar/29.1.264; Cobucci-Ponzano B, 2002, PROTEINS, V48, P98, DOI 10.1002/prot.10128; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Crombie HJ, 1998, PLANT J, V15, P27, DOI 10.1046/j.1365-313X.1998.00182.x; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; de la Torre F, 2002, PLANT PHYSIOL, V128, P247, DOI 10.1104/pp.010508; DEROSA M, 1975, J GEN MICROBIOL, V86, P156, DOI 10.1099/00221287-86-1-156; Eneyskaya EV, 2001, GLYCOCONJUGATE J, V18, P827, DOI 10.1023/A:1021163720282; Farabaugh PJ, 1996, ANNU REV GENET, V30, P507, DOI 10.1146/annurev.genet.30.1.507; Farkas E, 2000, CARBOHYD RES, V328, P293, DOI 10.1016/S0008-6215(00)00113-0; Fernandez-Rodriguez J, 2000, CANCER DETECT PREV, V24, P143; Fischer L, 1996, BIO-TECHNOL, V14, P88, DOI 10.1038/nbt0196-88; Hammell AB, 1999, GENOME RES, V9, P417; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Ishizuka H, 1999, INTERNAL MED, V38, P927, DOI 10.2169/internalmedicine.38.927; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Listinsky JJ, 1998, AM J CLIN PATHOL, V110, P425; Lower BH, 2002, J BACTERIOL, V184, P2614, DOI 10.1128/JB.184.10.2614-2619.2002; Michalski JC, 1999, BBA-MOL BASIS DIS, V1455, P69, DOI 10.1016/S0925-4439(99)00077-0; Moracci M, 2000, J BIOL CHEM, V275, P22082, DOI 10.1074/jbc.M910392199; Mori E, 1998, GLYCOCONJUGATE J, V15, P447, DOI 10.1023/A:1006926801717; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Noda K, 1998, INT J CANCER, V75, P444; PRISCO A, 1995, J BACTERIOL, V177, P1614, DOI 10.1128/jb.177.6.1614-1619.1995; Rapoport E, 1999, GLYCOBIOLOGY, V9, P1337, DOI 10.1093/glycob/9.12.1337; Russell L, 1998, BIOCHEM BIOPH RES CO, V250, P449, DOI 10.1006/bbrc.1998.9337; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Stahl B, 2001, ADV EXP MED BIOL, V501, P299; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; Tolstrup N, 2000, EXTREMOPHILES, V4, P175, DOI 10.1007/s007920070032; Trincone A, 2000, BIOORG MED CHEM LETT, V10, P365, DOI 10.1016/S0960-894X(99)00700-3; WANG LX, 1991, CARBOHYD RES, V219, P133, DOI 10.1016/0008-6215(91)89048-K; Wiese TJ, 1997, BBA-GEN SUBJECTS, V1335, P61, DOI 10.1016/S0304-4165(96)00123-7; XIANG JM, 1992, BIOCHEM BIOPH RES CO, V189, P27, DOI 10.1016/0006-291X(92)91520-Z	38	40	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14622	14631		10.1074/jbc.M211834200	http://dx.doi.org/10.1074/jbc.M211834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12569098	hybrid			2022-12-25	WOS:000182516100008
J	Fukuda, M				Fukuda, M			Distinct Rab binding specificity of Rim1, Rim2, rabphilin, and Noc2 - Identification of a critical determinant of Rab3A/Rab27A recognition by Rim2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-VESICLE FUSION; SLP HOMOLOGY DOMAIN; PC12 CELLS; C2 DOMAINS; MYOSIN-VA; MELANOSOME TRANSPORT; PHOSPHOLIPID-BINDING; SYNAPTOTAGMIN FAMILY; REGULATED SECRETION; PROTEIN	Rabphilin, Rim, and Noc2 have generally been believed to be the Rab3 isoform (Rab3A/B/C/D)-specific effectors that regulate secretory vesicle exocytosis in neurons and in some endocrine cells. The results of recent genetic analysis of rabphilin knock-out animals, however, strongly refute this notion, because there are no obvious genetic interactions between Rab3 and rabphilin in nematoda (Staunton, J., Ganetzky, B., and Nonet, M. L. (2001) J. Neurosci. 21, 9255-9264), suggesting that Rab3 is not a major ligand of rabphilin in vivo. In this study, I tested the interaction of rabphilin, Rim1, Rim2, and Noc2 with 42 different Rab proteins by cotransfection assay and found differences in rabphilin, Rim1, Rim2, and Noc2 binding to several Rab proteins that belong to the Rab functional group III (Rab3A/B/C/D, Rab26, Rab27A/B, and Rab37) and/or VIII (Rab8A and Rab10). Riml interacts with Rab3A/B/C/D, Rab10, Rab26, and Rab37; Rim2 interacts with Rab3A/B/C/D and Rab8A, and rabphilin and Noc2 interact with Rab3A/B/ C/D, Rab8A, and Rab27A/B. By contrast, the synaptotagmin-like protein homology domain of Slp homologue lacking C2 domains-a (Slac2-a)/melanophilin specifically recognizes Rab27A/B but not other Rabs. I also found that alternative splicing events in the first alpha-helical region (alpha(1)) of the Rab binding domain of Rim1 alter the Rab binding specificity of Rim1. Site-directed mutagenesis and chimeric analyses of Rim2 and Slac2-a indicate that the acidic cluster (Glu-50, Glu-51, and Glu-52) in the a, region of the Rab binding domain of Rim2, which is not conserved in the synaptotagmin-like pro tein homology domain of Slac2-a, is a critical determinant of Rab3A recognition. Based on these results, I propose that Rim, rabphilin, and Noc2 function differently in concert with functional group III and/or VIII Rab proteins, including Rab3 isoforms.	RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Chen S, 2001, J BIOL CHEM, V276, P13209, DOI 10.1074/jbc.M010798200; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Joberty G, 1999, J CELL SCI, V112, P3579; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Masuda ES, 2000, FEBS LETT, V470, P61, DOI 10.1016/S0014-5793(00)01288-6; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Yoshie S, 2000, HISTOCHEM CELL BIOL, V113, P259, DOI 10.1007/s004180000130; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	49	149	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15373	15380		10.1074/jbc.M212341200	http://dx.doi.org/10.1074/jbc.M212341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578829	hybrid			2022-12-25	WOS:000182516100102
J	Gatei, M; Sloper, K; Sorensen, C; Syljuasen, R; Falck, J; Hobson, K; Savage, K; Lukas, J; Zhou, BB; Bartek, J; Khanna, KK				Gatei, M; Sloper, K; Sorensen, C; Syljuasen, R; Falck, J; Hobson, K; Savage, K; Lukas, J; Zhou, BB; Bartek, J; Khanna, KK			Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; S-PHASE; CHECKPOINT; DNA; DISRUPTION; MUTATIONS; PATHWAYS; LEADS; UV	In mammals, the ATM (ataxia-telangiectasia-mutated) and ATR (ATM and Rad3-related) protein kinases function as critical regulators of the cellular DNA damage response. The checkpoint functions of ATR and ATM are mediated, in part, by a pair of checkpoint effector kinases termed Chk1 and Chk2. In mammalian cells, evidence has been presented that Chk1 is devoted to the ATR signaling pathway and is modified by ATR in response to replication inhibition and UV-induced damage, whereas Chk2 functions primarily through ATM in response to ionizing radiation (IR), suggesting that Chk2 and Chk1 might have evolved to channel the DNA damage signal from ATM and ATR, respectively. We demonstrate here that the ATR-Chk1 and ATM-Chk2 pathways are not parallel branches of the DNA damage response pathway but instead show a high degree of cross-talk and connectivity. ATM does in fact signal to Chk1 in response to IR. Phosphorylation of Chk1 on Ser-317 in response to IR is ATM-dependent. We also show that functional NBS1 is required for phosphorylation of Chk1, indicating that NES1 might facilitate the access of Chk1 to ATM at the sites of DNA damage. Abrogation of Chk1 expression by RNA interference resulted in defects in IR-induced S and G2/M phase checkpoints; however, the overexpression of phosphorylation site mutant (S317A, S345A or S317A/S345A double mutant) Chk1 failed to interfere with these checkpoints. Surprisingly, the kinase-dead Chk1 (D130A) also failed to abrogate the S and G2 checkpoint through any obvious dominant negative effect toward endogenous Chk1. Therefore, further studies will be required to assess the contribution made by phosphorylation events to Chk1 regulation. Overall, the data presented in the study challenge the model in which Chk1 only functions downstream from ATR and indicate that ATM does signal to Chk1. In addition, this study also demonstrates that Chk1 is essential for IR-induced inhibition of DNA synthesis and the G2/M checkpoint.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Incyte Genom, Newark, DE 19714 USA	QIMR Berghofer Medical Research Institute; Danish Cancer Society; Incyte	Khanna, KK (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Khanna, Kum Kum/I-1747-2013; Hobson, Keith/Q-9306-2019; Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Sorensen, Claus/0000-0001-6022-9710; Khanna, Kum Kum/0000-0001-8650-5381; Savage, Kienan/0000-0002-4898-899X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Brown EJ, 2000, GENE DEV, V14, P397; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Jackson JR, 2000, CANCER RES, V60, P566; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Liu QH, 2000, GENE DEV, V14, P1448; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Takai H, 2000, GENE DEV, V14, P1439; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	29	237	245	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14806	14811		10.1074/jbc.M210862200	http://dx.doi.org/10.1074/jbc.M210862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588868	hybrid			2022-12-25	WOS:000182516100030
J	Koike, H; Okuda, D; Morita, T				Koike, H; Okuda, D; Morita, T			Mutations in autolytic loop-2 and at Asp(554) of human prothrombin that enhance protein C activation by meizothrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECHIS-CARINATUS VENOM; HUMAN ALPHA-THROMBIN; BOVINE PROTHROMBIN; BLOOD-COAGULATION; ANTITHROMBIN-III; MOLECULAR MECHANISMS; BINDING-SITE; FACTOR-X; THROMBOMODULIN; INTERMEDIATE	Thrombin acts on many protein substrates during the hemostatic process. Its specificity for these substrates is modulated through interactions at regions remote from the active site of the thrombin molecule, designated exosites. Exosite interactions can be with the substrate, cofactors such as thrombomodulin, or fragments from prothrombin. The relative activity of alpha-thrombin for fibrinogen is 10 times greater than that for protein C. However, the relative activity of meizothrombin for protein C is 14 times greater than that for fibrinogen. Modulation of thrombin specificity is linked to its Na+-binding site and residues in autolytic loop-2 that interact with the Na+-binding site. Recombinant prothrombins that yield recombinant meizothrombin (rMT) and rMT des-fragment 1 (rMT(desF1)) enable comparisons of the effects of mutations at the Na+-binding residue (Asp(554)) and deletion of loop-2 (Glu(466)-Thr(469)) on the relative activity of meizothrombin for several substrates. Hydrolysis of t-butoxycarbonyl-VPR-p-nitroanilide by alpha-thrombin, recombinant alpha-thrombin, or rMT(desF1) was almost identical, but that by rMT was only 40% of that by alpha-thrombin. Clotting of fibrinogen by rMT and rMT(desF1) was 12-16% of that by alpha-thrombin, as already known. Strikingly, however, although meizothrombins modified by substitution of Asp(554) with either Ala or Leu or by deletion of loop-2 had 6-8 and <1%, respectively, of the clotting activity of alpha-thrombin, the activity of these meizothrombins for protein C was increased to >10 times that of alpha-thrombin. It is proposed that interactions within thrombin that involve autolytic loop-2 and the Na+-binding site primarily enhance thrombin action on fibrinogen, but impair thrombin action on protein C.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	Meiji Pharmaceutical University	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.							BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; DOULE MG, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KANE WH, 1988, BLOOD, V71, P539; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; MORITA T, 1981, METHOD ENZYMOL, V80, P303; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; Shi F, 1998, BIOPHYS CHEM, V75, P187, DOI 10.1016/S0301-4622(98)00205-1; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TANS G, 1991, J BIOL CHEM, V266, P21864; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER RK, 1994, J BIOL CHEM, V269, P27441; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Yamada D, 1996, J BIOL CHEM, V271, P5200, DOI 10.1074/jbc.271.9.5200	40	2	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15015	15022		10.1074/jbc.M208220200	http://dx.doi.org/10.1074/jbc.M208220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588872				2022-12-25	WOS:000182516100058
J	Yang, TY; McNally, BA; Ferrone, S; Liu, Y; Zheng, P				Yang, TY; McNally, BA; Ferrone, S; Liu, Y; Zheng, P			A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSENSE-MEDIATED DECAY; DOWN-REGULATION; GENES; EXPRESSION; STABILITY; MOLECULES; MACHINERY; MECHANISM; CODONS; LMP2	Both viruses and tumors evade cytotoxic T lymphocyte-mediated host immunity by down-regulation of antigen presentation machineries. This can be achieved by either down-regulation of transcription of antigen presentation genes or posttranslational inactivation of proteins involved in antigen presentation. In this study, a major histocompatibility complex (MHC) class I-deficient melanoma cell line, SK-MEL-19, was found deficient in the expression of the transporter associated with antigen processing (TAP)-1 mRNA even after IFN-gamma stimulation, despite its active transcription of the TAP-1 gene. This abnormality was caused by a single-nucleotide deletion at position +1489 of the TAP-1 gene and was corrected by cycloheximide, which inhibits RNA degradation. Using an inducible Tet-Off system, we demonstrated that deletion of the nucleotide resulted in a >2-fold decrease in the half-life of TAP-1 mRNA. However, the decrease of the half-life of TAP-1 mRNA is not mediated by nonsense-mediated mRNA decay because deletions of two additional nucleotides in the region, which corrected the nonsense mutation, did not restore TAP-1 mRNA stability. To our knowledge, this is the first evidence that the degradation of mRNA of an antigen presentation gene is involved in HLA class I down-regulation in malignant cells.	Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University; Roswell Park Cancer Institute	Zheng, P (corresponding author), Ohio State Univ, Med Ctr, Dept Pathol, 129 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	zheng-1@medctr.osu.edu	Zheng, Pan/E-8691-2011	Zheng, Pan/0000-0003-2598-3544	NCI NIH HHS [CA82355, CA69091, CA58033] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082355, R01CA069091, R01CA058033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Brocke KS, 2002, HUM MOL GENET, V11, P331, DOI 10.1093/hmg/11.3.331; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Dovhey SE, 2000, CANCER RES, V60, P5789; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hicklin DJ, 1996, TISSUE ANTIGENS, V48, P38, DOI 10.1111/j.1399-0039.1996.tb02603.x; Kallfelz M, 1999, INT J CANCER, V81, P125, DOI 10.1002/(SICI)1097-0215(19990331)81:1<125::AID-IJC21>3.0.CO;2-2; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; MCCUTCHEON JA, 1995, J EXP MED, V181, P2085, DOI 10.1084/jem.181.6.2085; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Rajavel KS, 2001, MOL CELL BIOL, V21, P5512, DOI 10.1128/MCB.21.16.5512-5519.2001; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; ROTEMYEHUDAR R, 1994, GENE, V144, P265, DOI 10.1016/0378-1119(94)90388-3; SalazarOnfray F, 1997, J IMMUNOL, V159, P3195; Seliger B, 1998, EUR J IMMUNOL, V28, P122, DOI 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F; Seliger B, 2001, CANCER RES, V61, P8647; Singal DP, 1998, INT J CANCER, V75, P112, DOI 10.1002/(SICI)1097-0215(19980105)75:1<112::AID-IJC17>3.3.CO;2-I; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zheng P, 1999, CANCER RES, V59, P3461; Zhou QM, 1998, MOL CELL BIOL, V18, P815, DOI 10.1128/MCB.18.2.815	34	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15291	15296		10.1074/jbc.M300954200	http://dx.doi.org/10.1074/jbc.M300954200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582163	hybrid			2022-12-25	WOS:000182516100092
J	Boucrot, E; Beuzon, CR; Holden, DW; Gorvel, JP; Meresse, S				Boucrot, E; Beuzon, CR; Holden, DW; Gorvel, JP; Meresse, S			Salmonella typhimurium SifA effector protein requires its membrane-anchoring C-terminal hexapeptide for its biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III SECRETION SYSTEM; PATHOGENICITY ISLAND 2; EPITHELIAL-CELLS; IN-VIVO; FILAMENTOUS STRUCTURES; CONTAINING VACUOLES; MURINE MACROPHAGES; RAB GTPASES; VIRULENCE; GENES	SifA is a Salmonella typhimurium effector protein that is translocated across the membrane of the Salmonella-containing vacuole by the Salmonella pathogenicity island 2-encoded type III secretion system. SifA is necessary for the formation of Salmonella-induced filaments and for the maintenance of the vacuolar membrane enclosing the pathogen. We have investigated the role of the C-terminal hexapeptide of SifA as a potential site for membrane anchoring. An S. typhimurium strain carrying a deletion of the sequence encoding this hexapeptide (sifADelta6) was found to be attenuated for systemic virulence in mice. In mouse macrophages, sifADelta6 mutant bacteria displayed a reduced association with vacuolar markers, similar to that of sifA null mutant bacteria, and exhibited a dramatic replication defect. Expression of SifA in epithelial cells results in the mobilization of lysosomal glycoproteins in large vesicular structures and Sif-like tubules. This process requires the presence of the C-terminal hexapeptide domain of SifA. Ectopic expression of truncated or mutated versions of SifA affecting the C-terminal hexapeptide revealed a strong correlation between the membrane binding capability and the biological activity of the protein. Finally, the eleven C-terminal residues of SifA are shown to be sufficient to target the Aequorea green fluorescent protein to membranes. Altogether, our results indicate that membrane anchoring of SifA requires its C-terminal hexapeptide domain, which is important for the biological function of this bacterial effector.	Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, F-13288 Marseille 9, France; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ctr Mol Microbiol & Infect, Dept Infect Dis, London SW7 2AZ, England	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Imperial College London	Meresse, S (corresponding author), Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, Case 906, F-13288 Marseille 9, France.		Meresse, Stephane/E-2192-2012; Beuzon, Carmen/G-7302-2011; Gorvel, Jean-Pierre/O-1332-2018	Meresse, Stephane/0000-0001-6578-5177; Beuzon, Carmen/0000-0002-6888-3845; Gorvel, Jean-Pierre/0000-0002-2829-9804				Beuzon CR, 1999, MOL MICROBIOL, V33, P806, DOI 10.1046/j.1365-2958.1999.01527.x; Beuzon CR, 2002, MICROBIOL-SGM, V148, P2705, DOI 10.1099/00221287-148-9-2705; Beuzon CR, 2001, MICROBES INFECT, V3, P1345, DOI 10.1016/S1286-4579(01)01496-4; Beuzon CR, 2001, INFECT IMMUN, V69, P7254, DOI 10.1128/IAI.69.12.7254-7261.2001; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Brumell JH, 2002, TRAFFIC, V3, P407, DOI 10.1034/j.1600-0854.2002.30604.x; Brumell JH, 2001, TRAFFIC, V2, P643, DOI 10.1034/j.1600-0854.2001.20907.x; Brumell JH, 2001, CELL MICROBIOL, V3, P75, DOI 10.1046/j.1462-5822.2001.00087.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Freeman JA, 2003, INFECT IMMUN, V71, P418, DOI 10.1128/IAI.71.1.418-427.2003; FRETER R, 1981, INFECT IMMUN, V34, P234, DOI 10.1128/IAI.34.1.234-240.1981; GARCIADELPORTILLO F, 1993, P NATL ACAD SCI USA, V90, P10544, DOI 10.1073/pnas.90.22.10544; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779; Guy RL, 2000, MOL MICROBIOL, V37, P1417, DOI 10.1046/j.1365-2958.2000.02092.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hansen-Wester I, 2002, INFECT IMMUN, V70, P1403, DOI 10.1128/IAI.70.3.1403-1409.2002; Hensel M, 1998, MOL MICROBIOL, V30, P163, DOI 10.1046/j.1365-2958.1998.01047.x; Jensen FB, 1998, AM J PHYSIOL-REG I, V274, pR661, DOI 10.1152/ajpregu.1998.274.3.R661; Knodler LA, 2002, MOL MICROBIOL, V43, P1089, DOI 10.1046/j.1365-2958.2002.02820.x; LEUNG KY, 1991, P NATL ACAD SCI USA, V88, P11470, DOI 10.1073/pnas.88.24.11470; LEVINE WC, 1991, J INFECT DIS, V164, P81, DOI 10.1093/infdis/164.1.81; Meresse S, 1997, ELECTROPHORESIS, V18, P2682, DOI 10.1002/elps.1150181425; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; Ruiz-Albert J, 2002, MOL MICROBIOL, V44, P645, DOI 10.1046/j.1365-2958.2002.02912.x; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Valdivia RH, 1997, SCIENCE, V277, P2007, DOI 10.1126/science.277.5334.2007; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	38	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14196	14202		10.1074/jbc.M207901200	http://dx.doi.org/10.1074/jbc.M207901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574170	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000182405000081
J	Duchesne, C; Charland, S; Asselin, C; Nahmias, C; Rivard, N				Duchesne, C; Charland, S; Asselin, C; Nahmias, C; Rivard, N			Negative regulation of beta-catenin signaling by tyrosine phosphatase SHP-1 in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; PROTEIN-KINASE; CYCLIN D1; GROWTH-REGULATION; BINDING PROTEIN; COLON-CARCINOMA; GENE-EXPRESSION; CACO-2 CELLS; MOTH-EATEN; DNA-DAMAGE	Protein-tyrosine phosphatase SHP-1 is expressed at high levels in hematopoietic cells and at moderate levels in many other cell types including epithelial cells. Although SHP-1 has been shown to be a negative regulator of multiple signaling pathways in hematopoietic cells, very little is known about the biological role of SHP-1 in epithelial cells. In order to elucidate the mechanism(s) responsible for the loss of proliferative potential once committed intestinal epithelial cells begin to differentiate, the role and regulation of SHP-1 were analyzed in both intact epithelium as well as in well established intestinal cell models recapitulating the crypt-villus axis in vitro. Results show that SHP-1 was expressed in the nuclei of all intestinal epithelial cell models as well as in epithelial cells of intact human fetal jejunum and colon. Expression and phosphatase activity levels of SHP-1 were much more elevated in confluent growth-arrested intestinal epithelial cells and in differentiated enterocytes as well. Overexpression of SHP-1 in intestinal epithelial crypt cells significantly inhibited dhfr, c-myc, and cyclin D1 gene expression but did not interfere with c-fos gene expression. In contrast, a mutated inactive form of SHP-1 had no effect on these genes. SHP-1 expression significantly decreased beta-catenin/TCF-dependent transcription in intestinal epithelial crypt cells. Immunoprecipitation experiments revealed that beta-catenin is one of the main binding partners and a substrate for SHP-1. Taken together, our results indicate that SHP-1 may be involved in the regulation of beta-catenin transcriptional function and in the negative control of intestinal epithelial cell proliferation.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada; Inst Cochin, Dept Cell Biol, F-75014 Paris, France	University of Sherbrooke; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1H 5N4, Canada.							Adachi M, 1996, CELL, V85, P15; Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1920, CONTRIBUTIONS EMBRYO; BABYATSKY MW, 1999, GROWTH DEV GASTROINT, P547; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chiang GG, 2001, J BIOL CHEM, V276, P23173, DOI 10.1074/jbc.M101219200; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Gallet A, 1999, EMBO J, V18, P2208, DOI 10.1093/emboj/18.8.2208; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hiscox S, 1999, ANTICANCER RES, V19, P509; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Ilan N, 1999, J CELL SCI, V112, P3005; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; Kim K, 2001, CELL BIOL INT, V25, P421, DOI 10.1006/cbir.2000.0650; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mariadason JM, 2001, CANCER RES, V61, P3465; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Qu CK, 2000, CELL RES, V10, P279, DOI 10.1038/sj.cr.7290055; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Treisman R, 1990, Semin Cancer Biol, V1, P47; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UMBAS R, 1992, CANCER RES, V52, P5104; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; VACHON PH, 1995, AM J PHYSIOL, V268, P857; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	75	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14274	14283		10.1074/jbc.M300425200	http://dx.doi.org/10.1074/jbc.M300425200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571228	hybrid			2022-12-25	WOS:000182405000090
J	Kihara, A; Ikeda, M; Kariya, Y; Lee, EY; Lee, YM; Igarashi, Y				Kihara, A; Ikeda, M; Kariya, Y; Lee, EY; Lee, YM; Igarashi, Y			Sphingosine-1-phosphate lyase is involved in the differentiation of F9 embryonal carcinoma cells to primitive endoderm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; SPHINGOSINE KINASE; RETINOIC ACID; FUNCTIONAL EXPRESSION; CALCIUM MOBILIZATION; MOLECULAR-CLONING; PARIETAL ENDODERM; 2ND MESSENGER; 1-PHOSPHATE; GROWTH	Sphingosine I-phosphate (SIP) is a bioactive lipid molecule that acts both extracellularly and intracellularly. The SPL gene encodes a mammalian SIP lyase that degrades SIP. Here, we have disrupted the SPL gene in mouse F9 embryonal carcinoma cells by gene targeting. This is the first report of gene disruption of mammalian SIP lyase. The SPL-null cells exhibited no SIP lyase activity, and intracellular SIP was increased similar to2-fold, compared with wild-type cells. Treatment of F9 embryonal carcinoma cells with retinoic acid induces differentiation to primitive endoderm (PrE). An acceleration in this PrE differentiation was observed in the SPL-null cells. This effect was apparently caused by the accumulated S1P, since N,N-dimethylsphingosine, a S1P synthesis inhibitor, had an inhibitory effect on the PrE differentiation. Moreover, F9 cells stably expressing sphingosine kinase also exhibited an acceleration in the differentiation. Exogenous S1P had no effect on differentiation, indicating that intracellular but not extracellular S1P is involved. Moreover, we determined that expression of the SPL protein is up-regulated during the progression to PrE. We also showed that sphingosine kinase activity is increased in PrE-differentiated cells. These results suggest that intracellular S1P has a role in the PrE differentiation and that SPL may be involved in the regulation of intracellular S1P levels during this differentiation.	Hokkaido Univ, Dept Biomembrane & Biofunct Chem, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Chungbuk Natl Univ, Coll Pharm, Chonju 361763, South Korea	Hokkaido University; Chungbuk National University	Igarashi, Y (corresponding author), Hokkaido Univ, Dept Biomembrane & Biofunct Chem, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Bjersing JL, 1997, J CELL BIOCHEM, V67, P378; Cho SY, 1999, MOL CELLS, V9, P179; Cho SY, 2000, BIOCHEM J, V352, P645, DOI 10.1042/0264-6021:3520645; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; Edsall LC, 1997, J NEUROSCI, V17, P6952; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Li GC, 2000, MICROBIOL-SGM, V146, P2219, DOI 10.1099/00221287-146-9-2219; Li GC, 2001, DEVELOPMENT, V128, P3473; Li Y, 1998, EXP CELL RES, V239, P320, DOI 10.1006/excr.1997.3904; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Murate T, 2001, J HISTOCHEM CYTOCHEM, V49, P845, DOI 10.1177/002215540104900705; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	45	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14578	14585		10.1074/jbc.M211416200	http://dx.doi.org/10.1074/jbc.M211416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584204	hybrid			2022-12-25	WOS:000182405000126
J	Lim, ST; Longley, RL; Couchman, JR; Woods, A				Lim, ST; Longley, RL; Couchman, JR; Woods, A			Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; PHOSPHORYLATION; CASK/LIN-2; ACTIVATION; CONTACTS; PICK1	Syndecan-4 is a transmembrane heparan sulfate proteoglycan that, acts as a coreceptor with integrins in focal adhesion formation. The central region of syndecan-4 cytoplasmic domain (4V, LGKKPIYKK) binds phosphatidylinositol 4,5-bisphosphate, and together they regulate protein kinase Calpha (PKCalpha) activity. Syndecan 4V peptide directly potentiates PKCalpha activity, leading to "superactivation" of the enzyme, apparently through an interaction with its catalytic domain. We now have performed yeast two-hybrid and in vitro binding assays to determine the interaction sites between 4V and PKCalpha. Full-length PKCa weakly interacted with 4V by yeast two-hybrid assays, but PKCalpha constructs that lack the pseudosubstrate region or constructs of the whole catalytic domain interacted more strongly. A mu tated 4V sequence (4V(YF): LGKKPIFKK) did not interact with PKCalpha, indicating that tyrosine 192 in the syndecan-4 cytoplasmic domain might be critical for this interaction. Further assays identified a novel interaction site in the C terminus of the catalytic domain of PKCalpha (amino acid sequence 513-672). This encompasses the autophosphorylation sites, which are implicated in activation and stability. Yeast two-hybrid data were confirmed by in vitro binding and coimmunoprecipitation assays. The interaction of syndecan-4 with PKCa appears unique since PKCS and E did not interact with 4V in yeast two-hybrid assays or coimmunoprecipitate with syndecan-4. Finally, overexpression of syndecan-4 in rat embryo fibroblast cells, but not expression of the YF mutant, increased PKCalpha localization to focal adhesions. The data support a mechanism where syndecan-4 binds PKCalpha and localizes it to focal adhesions, whose assembly may be regulated by the kinase.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Schering Plough Res Inst, Union, NJ 07083 USA; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England	University of Alabama System; University of Alabama Birmingham; Merck & Company; Schering-Plough Research Institute; Imperial College London	Woods, A (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, THT 946,1530 3rd Ave S, Birmingham, AL 35294 USA.	anwoods@ab.edu		Lim, Steve/0000-0003-0323-8607	NIGMS NIH HHS [GM50194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, P1503; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Carey DJ, 1997, BIOCHEM J, V327, P1; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Haller H, 1998, CIRC RES, V82, P157; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; Longley RL, 1999, J CELL SCI, V112, P3421; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Shin J, 2001, BIOCHEMISTRY-US, V40, P8471, DOI 10.1021/bi002750r; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1992, J CELL SCI, V101, P277; Zimmermann P, 1999, FASEB J, V13, pS91	37	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13795	13802		10.1074/jbc.M208300200	http://dx.doi.org/10.1074/jbc.M208300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571249	hybrid			2022-12-25	WOS:000182405000031
J	Raja, SM; Chhablani, N; Swanson, R; Thompson, E; Laffan, M; Lane, DA; Olson, ST				Raja, SM; Chhablani, N; Swanson, R; Thompson, E; Laffan, M; Lane, DA; Olson, ST			Deletion of P1 arginine in a novel antithrombin variant (antithrombin london) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-SITE; FACTOR-XA; CONFORMATIONAL-CHANGE; KINETIC CHARACTERIZATION; BINDING; ACTIVATION; DEFICIENCY; SEQUENCE; PENTASACCHARIDE; SUBSTITUTION	A novel variant of antithrombin, the major serpin inhibitor of coagulation proteases, has been identified in a patient with early onset thrombosis and abnormal plasma antithrombin activity. Sequencing of the antithrombin genes of the patient revealed that one of the two alleles was abnormal due to an in-frame deletion of the codon for the P1 arginine residue. The abnormal antithrombin was separated from the normal inhibitor by complexing the latter with thrombin followed by heparin-agarose affinity chromatography. The purified variant, antithrombin London, was completely inactive as a thrombin or factor Xa inhibitor even after heparin activation. Surprisingly, the variant bound heparin with a K-D reflecting an similar to10-fold greater affinity than the normal inhibitor. Stopped-flow kinetic analysis showed that this was almost entirely due to a more favorable conformational activation of the variant than the normal inhibitor, as reflected by a decreased rate constant for reversal of the activation. Consistent with its higher than normal heparin affinity, the inactive antithrombin variant was a potent competitive antagonist of the heparin-catalyzed reaction of normal antithrombin with thrombin but did not affect the uncatalyzed reaction. These results suggest that deletion of the antithrombin P1 residue partially activates the serpin by inducing strain in the reactive center loop, which destabilizes the native loop-buried state and favors the activated loop-exposed state with high heparin affinity. The unusually severe thrombosis associated with the heterozygous mutation may be explained by the ability of antithrombin London to bind endogenous heparan sulfate or heparin molecules with high affinity and to thereby block activation of the normal inhibitor.	Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA; Univ London Imperial Coll Sci Technol & Med, Dept Hematol, Fac Med, London W12 0NN, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Imperial College London	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Rm 530E Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.			Laffan, Michael/0000-0002-8268-3268	NHLBI NIH HHS [R01-HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjork I, 1997, ADV EXP MED BIOL, V425, P17; BJORK I, 1982, J BIOL CHEM, V257, P2406; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOWDHURY V, 1993, BRIT J HAEMATOL, V84, P656, DOI 10.1111/j.1365-2141.1993.tb03142.x; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1992, J CLIN INVEST, V90, P2422, DOI 10.1172/JCI116133; LANE DA, 1989, J BIOL CHEM, V264, P10200; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MILETICH JP, 1981, METHOD ENZYMOL, V80, P221; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Rezaie AR, 2002, J BIOL CHEM, V277, P1235, DOI 10.1074/jbc.M108544200; SAS G, 1975, THROMB RES, V6, P87, DOI 10.1016/0049-3848(75)90153-X; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; van Boven HH, 1999, BLOOD, V94, P2590, DOI 10.1182/blood.V94.8.2590.420k40_2590_2594; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13688	13695		10.1074/jbc.M300062200	http://dx.doi.org/10.1074/jbc.M300062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12591924	hybrid			2022-12-25	WOS:000182405000018
J	Boehr, DD; Jenkins, SI; Wright, GD				Boehr, DD; Jenkins, SI; Wright, GD			The molecular basis of the expansive substrate specificity of the antibiotic resistance enzyme aminoglycoside acetyltransferase-6 '-aminoglycoside phosphotransferase-2 '' - The role of Asp-99 as an active site base important for acetyl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; MAGNETIC-RESONANCE SPECTROSCOPY; SACCHAROMYCES-CEREVISIAE GNA1; CATALYTIC MECHANISM; KINASE APH(3')-IIIA; ANGSTROM RESOLUTION; MODIFYING ENZYMES; KINETIC MECHANISM; CRYSTAL-STRUCTURE; COENZYME-A	The most frequent determinant of aminoglycoside antibiotic resistance in Gram-positive bacterial pathogens is a bifunctional enzyme, aminoglycoside acetyltransferase-6'-aminoglycoside phosphotransferase-2" (AAC(6')-aminoglycoside phosphotransferase-2", capable of modifying a wide selection of clinically relevant antibiotics through its acetyltransferase and kinase activities. The aminoglycoside acetyltransferase domain of the enzyme, AAC(6')-Ie, is the only member of the large AAC(6') subclass known to modify fortimicin A and catalyze O-acetylation. We have demonstrated through solvent isotope, pH, and site-directed mutagenesis effects that Asp-99 is responsible for the distinct abilities of AAC(6')le. Moreover, we have demonstrated that small planar molecules such as 1-(bromomethyl)phenanthrene can inactivate the enzyme through covalent modification of this residue. Thus, Asp-99 acts as an active site base in the molecular mechanism of AAC(6')-Ie. The prominent role of this residue in aminoglycoside modification can be exploited as an anchoring site for the development of compounds capable of reversing antibiotic resistance in vivo.	McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University	Wright, GD (corresponding author), McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada.		Boehr, David/A-2068-2010; Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				Azucena E, 2001, DRUG RESIST UPDATE, V4, P106, DOI 10.1054/drup.2001.0197; Azucena E, 1997, J AM CHEM SOC, V119, P2317, DOI 10.1021/ja964278w; Boehr DD, 2001, CHEM BIOL, V8, P791, DOI 10.1016/S1074-5521(01)00051-5; Boehr DD, 2001, J BIOL CHEM, V276, P23929, DOI 10.1074/jbc.M100540200; BOTTO RE, 1983, J AM CHEM SOC, V105, P1021, DOI 10.1021/ja00342a062; Burk DL, 2001, BIOCHEMISTRY-US, V40, P8756, DOI 10.1021/bi010504p; Culebras Esther, 1999, Frontiers in Bioscience, V4, pD1, DOI 10.2741/culebras; Daigle DM, 1999, CHEM BIOL, V6, P99, DOI 10.1016/S1074-5521(99)80006-4; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DORMAN DE, 1976, J AM CHEM SOC, V98, P6885, DOI 10.1021/ja00438a020; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; LEATHERBARROW RJ, 2000, GRAFIT VERSION 4 0; Llano-Sotelo B, 2002, CHEM BIOL, V9, P455, DOI 10.1016/S1074-5521(02)00125-4; Magnet S, 2001, BIOCHEMISTRY-US, V40, P3700, DOI 10.1021/bi002736e; MARTEL A, 1983, EUR J BIOCHEM, V133, P515, DOI 10.1111/j.1432-1033.1983.tb07494.x; MILLER GH, 1997, CLIN INFECT DIS, V24, P46; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Peneff C, 2001, J BIOL CHEM, V276, P16328, DOI 10.1074/jbc.M009988200; RADIKA K, 1984, J BIOL CHEM, V259, P2543; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Shmara A, 2001, ANTIMICROB AGENTS CH, V45, P3287, DOI 10.1128/AAC.45.12.3287-3292.2001; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thompson PR, 2002, BIOCHEMISTRY-US, V41, P7001, DOI 10.1021/bi0256680; Vetting MW, 2002, NAT STRUCT BIOL, V9, P653, DOI 10.1038/nsb830; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; WRIGHT GD, 1990, BIOCHIM BIOPHYS ACTA, V1040, P95, DOI 10.1016/0167-4838(90)90151-5; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Wright Gerard D., 1999, Frontiers in Bioscience, V4, pD9, DOI 10.2741/Wright; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5	40	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12873	12880		10.1074/jbc.M211680200	http://dx.doi.org/10.1074/jbc.M211680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566434	hybrid			2022-12-25	WOS:000182189500037
J	Krohn, NM; Stemmer, C; Fojan, P; Grimm, R; Grasser, KD				Krohn, NM; Stemmer, C; Fojan, P; Grimm, R; Grasser, KD			Protein kinase CK2 phosphorylates the high mobility group domain protein SSRP1, inducing the recognition of UV-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; GROUP BOX PROTEIN; SACCHAROMYCES-CEREVISIAE; HMG DOMAIN; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME-BINDING; POLYMERASE-ALPHA; CHROMATIN; MAIZE; POB3	The structure-specific recognition protein SSRP1 plays a role in transcription and replication in the chromatin context. Mediated by its C-terminal high mobility group (HMG) box domain, SSRP1 binds DNA non-sequence specifically but recognizes certain DNA structures. Using acetic acid urea polyacrylamide gel electrophoresis and mass spectrometry, we have examined the phosphorylation of maize SSRP1 by protein kinase CK2alpha. The kinase phosphorylated several amino acid residues in the C-terminal part of the SSRP1 protein. Two phosphorylation sites were mapped in the very C-terminal region next to the HMG box domain, and about seven sites are localized within the acidic domain. Circular dichroism showed that the phosphorylation of the two C-terminal sites by CK2alpha resulted in a structural change in the region of HMG box domain, because the negative peak of the CD spectrum at 222 nm was decreased by similar to10%. In parallel, the phosphorylation induced the recognition of UV-damaged DNA, whereas the non-phosphorylated protein does not discriminate between UV-damaged DNA and control DNA. The affinity of CK2alpha-phosphorylated SSRP1 for the DNA correlates with the degree of UV-induced DNA damage. Moreover, maize SSRP1 can restore the increased UV-sensitivity of a yeast strain lacking the NHP6A/B HMG domain proteins to levels of the control strain. Collectively, these findings indicate a role for SSRP1 in the UV response of eukaryotic cells.	Aalborg Univ, Inst Life Sci, DK-9000 Aalborg, Denmark; Agilent Technol, D-76337 Waldbronn, Germany	Aalborg University; Agilent Technologies	Grasser, KD (corresponding author), Aalborg Univ, Inst Life Sci, Sohngaardsholmsvej 49, DK-9000 Aalborg, Denmark.	kdg@bio.auc.dk		Fojan, Peter/0000-0002-0626-4766				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398; Brenneisen P, 2002, BIOCHEM J, V365, P31, DOI 10.1042/BJ20020110; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; DOBROWOLSKA G, 1992, EUR J BIOCHEM, V204, P299, DOI 10.1111/j.1432-1033.1992.tb16637.x; Dyer MA, 1998, MOL CELL BIOL, V18, P2617, DOI 10.1128/MCB.18.5.2617; Espunya MC, 1997, PLANT SCI, V124, P131, DOI 10.1016/S0168-9452(96)04599-2; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Gariglio M, 1997, EXP CELL RES, V236, P472, DOI 10.1006/excr.1997.3742; Grasser KD, 1996, J BIOL CHEM, V271, P32900, DOI 10.1074/jbc.271.51.32900; Grasser KD, 2000, PHYSIOL PLANTARUM, V110, P427, DOI 10.1111/j.1399-3054.2000.1100401.x; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; LENNOX RW, 1989, METHOD ENZYMOL, V170, P532; Lichota J, 2001, BIOCHEMISTRY-US, V40, P7860, DOI 10.1021/bi010548y; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lysetska M, 2002, NUCLEIC ACIDS RES, V30, P2686, DOI 10.1093/nar/gkf378; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Riera M, 2001, MOL CELL BIOCHEM, V227, P119, DOI 10.1023/A:1013141713277; Rottgers K, 2000, PLANT J, V23, P395, DOI 10.1046/j.1365-313x.2000.00801.x; Schlesinger MB, 2000, GENETICS, V155, P1593; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Spencer JA, 1999, J BIOL CHEM, V274, P15686, DOI 10.1074/jbc.274.22.15686; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200	47	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12710	12715		10.1074/jbc.M300250200	http://dx.doi.org/10.1074/jbc.M300250200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571244	hybrid			2022-12-25	WOS:000182189500017
J	Hoyt, MA; Zhang, MS; Coffino, P				Hoyt, MA; Zhang, MS; Coffino, P			Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DOA4 DEUBIQUITINATING ENZYME; IN-VIVO DEGRADATION; SACCHAROMYCES-CEREVISIAE; 26S PROTEASOME; INTRACELLULAR DEGRADATION; REGULATED DEGRADATION; ACTIVATING ENZYME; ANTIZYME; GENE	The polyamine biosynthetic enzyme ornithine decarboxylase (ODC) is degraded by the 26 S proteasome via a ubiquitin-independent pathway in mammalian cells. Its degradation is greatly accelerated by association with the polyamine-induced regulatory protein antizyme I (AZ1). Mouse ODC (mODC) that is expressed in the yeast Saccharomyces cerevisiae is also rapidly degraded by the proteasome of that organism. We have now carried out in vivo and in vitro studies to determine whether S. cerevisiae proteasomes recognize mODC degradation signals. Mutations of mODC that stabilized the protein in animal cells also did so in the fungus. Moreover, the mODC degradation signal was able to destabilize a GFP or Ura3 reporter in GFP-mODC and Ura3-mODC fusion proteins. Co-expression of AZ1 accelerated mODC degradation 2-3-fold in yeast cells. The degradation of both mODC and the endogenous yeast ODC (yODC) was unaffected in S. cerevisiae mutants with various defects in ubiquitin metabolism, and ubiquitinylated forms of mODC were not detected in yeast cells. In addition, recombinant mODC was degraded in an ATP-dependent manner by affinity-purified yeast 26 S proteasomes in the absence of ubiquitin. Degradation by purified yeast proteasomes was sensitive to mutations that stabilized mODC in vivo, but was not accelerated by recombinant AZ1. These studies demonstrate that cell constituents required for mODC degradation are conserved between animals and fungi, and that both mammalian and fungal ODC are subject to proteasome-mediated proteolysis by ubiquitin-independent mechanisms.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Coffino, Philip/0000-0003-0344-5083	NIGMS NIH HHS [GM45335, GM20527] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Brachmann CB, 1998, YEAST, V14, P115; Chattopadhyay MK, 2001, J BIOL CHEM, V276, P21235, DOI 10.1074/jbc.M010643200; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; DAVIS RH, 1992, MICROBIOL REV, V56, P280, DOI 10.1128/MMBR.56.2.280-290.1992; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FONZI WA, 1989, J BIOL CHEM, V264, P18110; Gandre S, 2002, BIOCHEM BIOPH RES CO, V293, P139, DOI 10.1016/S0006-291X(02)00194-8; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLASS JR, 1986, BIOCHEM J, V236, P351, DOI 10.1042/bj2360351; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GUPTA M, 1985, J BIOL CHEM, V260, P2941; Gupta R, 2001, P NATL ACAD SCI USA, V98, P10620, DOI 10.1073/pnas.181341298; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Ivanov IP, 1998, MOL CELL BIOL, V18, P1553, DOI 10.1128/MCB.18.3.1553; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; MAMROUDKIDRON E, 1994, FEBS LETT, V356, P162, DOI 10.1016/0014-5793(94)01260-1; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MIYAZAKI Y, 1993, EUR J BIOCHEM, V214, P837, DOI 10.1111/j.1432-1033.1993.tb17987.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Swanson R, 2000, FEBS LETT, V477, P193, DOI 10.1016/S0014-5793(00)01802-0; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Toth C, 1999, J BIOL CHEM, V274, P25921, DOI 10.1074/jbc.274.36.25921; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Zhu C, 2000, BIOINFORMATICS, V16, P478, DOI 10.1093/bioinformatics/16.5.478	59	60	61	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12135	12143		10.1074/jbc.M211802200	http://dx.doi.org/10.1074/jbc.M211802200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12562772	hybrid			2022-12-25	WOS:000182015700055
J	Clarke, ID; Dirks, PB				Clarke, ID; Dirks, PB			Human brain tumor-derived PDGFR-alpha deletion mutant is transforming	ONCOGENE			English	Article						PDGFR-alpha; extracellular deletion; brain tumor; transformation	GROWTH-FACTOR RECEPTOR; SIMIAN SARCOMA-VIRUS; GLIOMA CELL-LINES; BETA-RECEPTOR; IN-VIVO; C-JUN; SIGNAL-TRANSDUCTION; HUMAN GLIOBLASTOMAS; V-SIS; MICE	Aberrant receptor tyrosine kinase signaling plays an important role in the molecular pathogenesis of brain tumors. We have been studying a previously identified human glioblastoma-derived PDGFR-alpha mutant that has an in-frame deletion in the extracellular domain, causing loss of exons 8 and 9 (PDGFR-alpha(Delta8,9)). In the primary tumor, this deletion mutant receptor was shown to be amplified and overexpressed. The purpose of this study was to determine the expression, activity, localization, and transformation properties of this deletion mutant. In the absence of serum, or PDGF-AA, PDGFR-alpha(Delta8,9) was phosphorylated on tyrosine residues, indicating ligand-independent autoactivation. Localization by staining and cell surface biotinylation studies revealed expression of the deletion mutant predominantly in the cytoplasm, with very little present on the cell surface. To determine if PDGFR-alpha(Delta8,9) was oncogenic, we transfected wild-type and mutant receptors into Rat1 cells and performed analyses of cell growth, in vitro transformation, and subcutaneous growth in the nude mouse. PDGFR-alpha(Delta8,9)-expressing cells displayed enhanced cell growth and survival in low serum, and formed foci in monolayer cultures. PDGFR-alpha(Delta8,9)-expressing Rat1 cells were also tumorigenic when injected subcutaneously into nude mice. Expression of PDGFR-alpha(Delta8,9) was also associated with increased c-Jun phosphorylation in the absence of PDGF ligand, demonstrating also that the mutant receptor is associated with altered intracellular signaling. These data demonstrate that PDGFR-alpha(Delta8,9) is transforming, and it is the first demonstration of a naturally occurring tumor-derived mutant PDGFR-alpha with oncogenic properties.	Univ Toronto, Div Neurosurg, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Program Dev Biol, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Lab, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Dirks, PB (corresponding author), Univ Toronto, Div Neurosurg, Hosp Sick Children, 555 Univ Ave,Suite 1504, Toronto, ON M5G 1X8, Canada.							Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BEJECK BE, 1989, SCIENCE, V245, P1496; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034; FLEMING TP, 1992, CANCER RES, V52, P4550; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KIM HRC, 1994, J BIOL CHEM, V269, P30604; Kirsch M, 1997, J NEURO-ONCOL, V35, P289, DOI 10.1023/A:1005872718547; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; KUMABE T, 1992, ONCOGENE, V7, P627; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1991, J BIOL CHEM, V266, P16755; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Uhrbom L, 1998, CANCER RES, V58, P5275; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YU JC, 1994, J BIOL CHEM, V269, P10668; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	55	78	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					722	733		10.1038/sj.onc.1206160	http://dx.doi.org/10.1038/sj.onc.1206160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569364				2022-12-25	WOS:000180642100009
J	Tomas, A; Moss, SE				Tomas, A; Moss, SE			Calcium- and cell cycle-dependent association of annexin 11 with the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CA2+-DEPENDENT MANNER; TERMINAL DOMAIN; ALG-2 INTERACTS; BINDING-SITE; XI; CALCYCLIN; MEMBRANE; CAP-50; S100C	Annexin 11 is a widely expressed calcium- and phospholipid-binding protein that resides in the nucleoplasm in many cultured cell lines. This is in contrast to its most extensively characterized in vitro ligand, the small calcium- binding protein S100A6 ( calcyclin), which is concentrated in the nuclear envelope. Here we have examined the significance of the association of annexin 11 and S100A6 by asking whether circumstances exist in which the two proteins occupy the same subcellular localization. First, we show that in both A431 and vascular smooth muscle cells, elevation of intracellular Ca2+ leads to translocation of annexin 11 from the nucleus to the nuclear envelope where it co-localizes with S100A6. We also demonstrate, using fusions of annexin 11 with green fluorescent protein, that whereas the C-terminal core domain of annexin 11 is essential for Ca2+ sensitivity, the N-terminal domain is required for targeting to the nuclear envelope. Second, we show that annexin 11 relocalizes to the nuclear envelope as A431 cells transit from early to mid-prophase. In late prophase, at the time of nuclear envelope breakdown, annexin 11 and S100A6 become intensely localized with lamina-associated polypeptide 2 to folds in the nuclear envelope. From metaphase to telophase S100A6 is degraded, but in late telophase annexin 11 associates with the reforming nuclear envelope before resuming a nucleoplasmic location in interphase. These results show that co-localization of annexin 11 and S100A6 at the nuclear envelope may be regulated either by elevation of intracellular Ca2+ or by cell cycle progression and provide the first evidence that these proteins may associate in vivo.	Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England	University of London; University College London	Moss, SE (corresponding author), Inst Ophthalmol, Div Cell Biol, 11-43 Bath St, London EC1V 9EL, England.			Tomas, Alejandra/0000-0002-2290-8453				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Badminton MN, 1998, CELL CALCIUM, V23, P79, DOI 10.1016/S0143-4160(98)90105-1; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DORING V, 1995, J CELL SCI, V108, P2065; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Furge LL, 1999, J BIOL CHEM, V274, P33504, DOI 10.1074/jbc.274.47.33504; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; Kubista H, 1999, CURR BIOL, V9, P1403, DOI 10.1016/S0960-9822(00)80085-8; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; MINAMI H, 1992, FEBS LETT, V305, P217, DOI 10.1016/0014-5793(92)80671-3; MIZUTANI A, 1993, J BIOL CHEM, V268, P15517; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; NEAMATI N, 1995, J IMMUNOL, V154, P3788; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Satoh H, 2002, BIOCHEM BIOPH RES CO, V291, P1166, DOI 10.1006/bbrc.2002.6600; Seemann J, 1997, FEBS LETT, V413, P185, DOI 10.1016/S0014-5793(97)00911-3; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Sudo T, 1999, FEBS LETT, V444, P11, DOI 10.1016/S0014-5793(99)00014-9; TOKUMITSU H, 1993, ARCH BIOCHEM BIOPHYS, V303, P302, DOI 10.1006/abbi.1993.1287; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191	33	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20210	20216		10.1074/jbc.M212669200	http://dx.doi.org/10.1074/jbc.M212669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12601007	hybrid, Green Published			2022-12-25	WOS:000183078000082
J	Fukuda, A; Tokonabe, S; Hamada, M; Matsumoto, M; Tsukui, T; Nogi, Y; Hisatake, K				Fukuda, A; Tokonabe, S; Hamada, M; Matsumoto, M; Tsukui, T; Nogi, Y; Hisatake, K			Alleviation of PC4-mediated transcriptional repression by the ERCC3 helicase activity of general transcription factor TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; COACTIVATOR PC4; MULTISUBUNIT COMPLEX; TERMINAL DOMAIN; BINDING PROTEIN; YEAST; DNA; ACTIVATION; PURIFICATION; COFACTORS	Positive cofactor 4 (PC4), originally identified as a transcriptional coactivator, possesses the ability to suppress promoter-driven as well as nonspecific transcription via its DNA binding activity. Previous studies showed that the repressive activity of PC4 on promoter-driven transcription is alleviated by transcription factor TFIIH, possibly through one of its enzymatic activities. Using recombinant TFIIH, we have analyzed the role of TFIIH for alleviating PC4-mediated transcriptional repression and determined that the excision repair cross complementing (ERCC3) helicase activity of TFIIH is the enzymatic activity that alleviates PC4-mediated repression via beta-gamma bond hydrolysis of ATP. In addition, the alleviation does not require either ERCC2 helicase or cyclin-dependent kinase 7 kinase activity. We also show that, as complexed within TFIIH, the cyclin-dependent kinase 7 kinase does not possess the activity to phosphorylate PC4. Thus, TFIIH appears to protect promoters from PC4-mediated repression by relieving the topological constraint imposed by PC4 through the ERCC3 helicase activity rather than by reducing the repressive activity of PC4 via its phosphorylation.	Saitama Med Sch, Dept Biol Mol, Moroyama, Saitama 3500495, Japan	Saitama Medical University	Hisatake, K (corresponding author), Saitama Med Sch, Dept Biol Mol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	kojihisa@saitama-med.ac.jp		Hisatake, Koji/0000-0002-5795-3115				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Bohm M, 1997, INT J CANCER, V74, P291; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Fukuda A, 2001, GENES CELLS, V6, P707, DOI 10.1046/j.1365-2443.2001.00456.x; FUKUDA A, 1999, P NATL ACAD SCI USA, V99, P1206; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; Holloway AF, 2000, J BIOL CHEM, V275, P21668, DOI 10.1074/jbc.M909058199; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; Kimura M, 2001, EUR J BIOCHEM, V268, P612, DOI 10.1046/j.1432-1327.2001.01911.x; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LILLEY DMJ, 1988, TRENDS GENET, V4, P111, DOI 10.1016/0168-9525(88)90099-6; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; LOU Y, 1998, MOL CELL BIOL, V18, P3803; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Werten S, 1999, J BIOL CHEM, V274, P3693, DOI 10.1074/jbc.274.6.3693; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Wieland I, 1996, ONCOGENE, V12, P97	36	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14827	14831		10.1074/jbc.M213172200	http://dx.doi.org/10.1074/jbc.M213172200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590132	hybrid			2022-12-25	WOS:000182516100033
J	Locke, D; Liu, CD; Peng, XH; Chen, H; Kahn, ML				Locke, D; Liu, CD; Peng, XH; Chen, H; Kahn, ML			Fc R gamma-independent signaling by the platelet collagen receptor glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; PHOSPHOLIPASE C-GAMMA-2; EPSILON-RI; CHAIN; ACTIVATION; SYK; ASSOCIATION; CALMODULIN	The platelet collagen receptor glycoprotein VI (GPVI) is structurally homologous to multisubunit immune receptors and signals through the immune receptor adaptor Fc Rgamma. Multisubunit receptors are composed of specialized subunits thought to be dedicated exclusively to ligand binding or signal transduction. However, recent studies of the intracellular region of GPVI, a ligand-binding subunit, have suggested the existence of protein-protein interactions that could regulate receptor signaling. In the present study we have investigated the signaling role of the GPVI intracellular domain by stably expressing GPVI mutants in RBL-2H3 cells, a model system that accurately reproduces the GPVI signaling events observed in platelets. Studies of mutant GPVI receptor protein-protein interaction and calcium signaling reveal the existence of discrete domains within the receptor's intracellular tail that mediate interaction with Fc Rgamma, calmodulin, and Src family tyrosine kinases. These receptor interactions are modular and mediated by non-overlapping regions of the receptor transmembrane and intracellular domains. GPVI signaling requires all three of these domains as receptor mutants able to couple to only two interacting proteins exhibited severe signaling defects despite normal surface expression. Our results demonstrate that the ligand-binding subunit of the GPVI-Fc Rgamma receptor participates directly in receptor signaling by interacting with downstream signaling molecules other than Fc Rgamma through an adaptor-like mechanism.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Kahn, ML (corresponding author), Univ Penn, Dept Med, 421 Cuie Blvd,BRB 2-3,Room 952, Philadelphia, PA 19104 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Berlanga O, 2002, EUR J BIOCHEM, V269, P2951, DOI 10.1046/j.1432-1033.2002.02969.x; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Edberg JC, 1999, J BIOL CHEM, V274, P30328, DOI 10.1074/jbc.274.42.30328; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Ichinohe T, 1997, J BIOL CHEM, V272, P63; Klaerke DA, 1997, BBA-PROTEIN STRUCT M, V1339, P203, DOI 10.1016/S0167-4838(96)00233-6; LANIER LL, 1991, J IMMUNOL, V146, P1571; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SUGIYAMA T, 1987, BLOOD, V69, P1712; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	26	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15441	15448		10.1074/jbc.M212338200	http://dx.doi.org/10.1074/jbc.M212338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594225	hybrid			2022-12-25	WOS:000182516100111
J	Nagamori, S; Vazquez-Ibar, JL; Weinglass, AB; Kaback, HR				Nagamori, S; Vazquez-Ibar, JL; Weinglass, AB; Kaback, HR			In vitro synthesis of lactose permease to probe the mechanism of membrane insertion and folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; LAC CARRIER PROTEIN; THIOL CROSS-LINKING; ESCHERICHIA-COLI; PROJECTION STRUCTURE; ANGSTROM RESOLUTION; TRANSPORT PROTEINS; SUBSTRATE-BINDING; HELIX PACKING; TRANSLOCATION	Insertion and folding of polytopic membrane proteins is an important unsolved biological problem. To study this issue, lactose permease, a membrane transport protein from Escherichia coli, is transcribed, translated, and inserted into inside-out membrane vesicles in vitro. The protein is in a native conformation as judged by sensitivity to protease, binding of a monoclonal antibody directed against a conformational epitope, and importantly, by functional assays. By exploiting this system it is possible to express the N-terminal six helices of the permease (N-6) and probe changes in conformation during insertion into the membrane. Specifically, when N-6 remains attached to the ribosome it is readily extracted from the membrane with urea, whereas after release from the ribosome or translation of additional helices, those polypeptides are not urea extractable. Furthermore, the accessibility of an engineered Factor Xa site to Xa protease is reduced significantly when N-6 is released from the ribosome or more helices are translated. Finally, spontaneous disulfide formation between Cys residues at positions 126 (Helix IV) and 144 (Helix V) is observed when N-6 is released from the ribosome and inserted into the membrane. Moreover, in contrast to full-length permease, N-6 is degraded by FtsH protease in vivo, and N-6 with a single Cys residue at position 148 does not react with N-ethylmaleimide. Taken together, the findings indicate that N-6 remains in a hydrophilic environment until it is released from the ribosome or additional helices are translated and continues to fold into a quasi-native conformation after insertion into the bilayer. Furthermore, there is synergism between N-6 and the C-terminal half of permease during assembly, as opposed to assembly of the two halves as independent domains.	Univ Calif Los Angeles, HHMI, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Physiol & Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Genet, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kaback, HR (corresponding author), Univ Calif Los Angeles, HHMI, 5-748 Macdonald Res Labs,Box 951662, Los Angeles, CA 90095 USA.		Vazquez-Ibar, Jose-Luis/AAD-8827-2021; Nagamori, Shushi/P-4530-2018	Vazquez-Ibar, Jose-Luis/0000-0002-8314-3378; Nagamori, Shushi/0000-0003-0203-2754	NIDDK NIH HHS [DK51131:08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; Dalbey RE, 2000, CURR OPIN CELL BIOL, V12, P435, DOI 10.1016/S0955-0674(00)00113-7; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; Guan L, 2002, P NATL ACAD SCI USA, V99, P3475, DOI 10.1073/pnas.052703699; Guan L, 2002, P NATL ACAD SCI USA, V99, P6613, DOI 10.1073/pnas.102178299; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; Herskovits AA, 2002, J CELL BIOL, V159, P403, DOI 10.1083/jcb.200204144; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KONINGS WN, 1996, HDB BIOL PHYSICS TRA; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Nagamori S, 2000, J BIOCHEM-TOKYO, V128, P129, DOI 10.1093/oxfordjournals.jbchem.a022723; Nishiyama K, 2000, BIOSCI BIOTECH BIOCH, V64, P2121, DOI 10.1271/bbb.64.2121; Nouwen N, 2002, MOL MICROBIOL, V44, P1397, DOI 10.1046/j.1365-2958.2002.02972.x; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Prinz WA, 1998, J BIOL CHEM, V273, P8419, DOI 10.1074/jbc.273.14.8419; Sahin-Toth M, 2002, BIOCHEMISTRY-US, V41, P13039, DOI 10.1021/bi0203076; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SahinToth M, 1996, BIOCHEMISTRY-US, V35, P2016, DOI 10.1021/bi952496g; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHULDINER S, 1975, J BIOL CHEM, V250, P1361; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Seluanov A, 1997, J BIOL CHEM, V272, P2053; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P1461, DOI 10.1073/pnas.71.4.1461; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P274, DOI 10.1021/bi962292f; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; Vazquez-Ibar JL, 2002, P NATL ACAD SCI USA, V99, P3487, DOI 10.1073/pnas.052703599; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Weinglass AB, 2000, P NATL ACAD SCI USA, V97, P8938, DOI 10.1073/pnas.140224497; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; WILLIAMS RW, 1986, METHOD ENZYMOL, V130, P311; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; YAMADA H, 1989, J BIOL CHEM, V264, P1723; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	79	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14820	14826		10.1074/jbc.M300332200	http://dx.doi.org/10.1074/jbc.M300332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590141	hybrid			2022-12-25	WOS:000182516100032
J	Nishizuka, M; Arimoto, E; Tsuchiya, T; Nishihara, T; Imagawa, M				Nishizuka, M; Arimoto, E; Tsuchiya, T; Nishihara, T; Imagawa, M			Crucial role of TCL/TC10 beta L, a subfamily of Rho GTPase, in adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; INSULIN-RESISTANCE; GENE-EXPRESSION; BINDING-PROTEIN; ADIPOSE-TISSUE; 3T3-L1 CELLS; EARLY-STAGE; ADIPOGENESIS; OBESITY	The events at the beginning of adipocyte differentiation are not well known. We previously cloned the genes expressed early in the differentiation of mouse 3T3-L1 preadipocyte cells. One of them, similar in sequence to human TC10, was identified as TC10-like/TC10betaLong (TCL/TC10betaL), a new Rho GTPase by the cloning of full-length cDNA. The expression of TCL/TC10betaL increased rapidly right after the addition of inducers for differentiation, whereas the levels of other Rho family genes were unchanged at this stage. The antisense TCL/TC10betaL-expressing experiment revealed that the differentiation of 3T3-L1 cells into adipocytes was inhibited. Moreover, the sense TCL/TC10betaL-expressing experiment using NIH-3T3 cells, which do not usually differentiate into adipocytes, clearly showed the accumulation of oil droplets as well as the elevated expression of various adipogenic marker genes in the presence of the ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). These results strongly indicated that TCL/TC10betaL has a crucial role in the early stage of adipocyte differentiation, probably linked to the PPARgamma pathway. Using a subtraction protocol, the genes specifically regulated by TCL/TC10betaL were also isolated. The expression pattern of some of them was similar to TCL/TC10betaL expression in adipogenesis, suggesting that the expression of these genes would be regulated by TCL/TC10betaL.	Nagoya City Univ, Dept Mol Biol, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Environm Biochem, Suita, Osaka 5650871, Japan	Nagoya City University; Osaka University	Imagawa, M (corresponding author), Nagoya City Univ, Dept Mol Biol, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.							Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Imagawa M, 1999, BIOCHEM BIOPH RES CO, V254, P299, DOI 10.1006/bbrc.1998.9937; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lee YH, 1996, BIOCHEM BIOPH RES CO, V222, P839, DOI 10.1006/bbrc.1996.0831; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nishizuka M, 2002, BIOCHEM J, V361, P629, DOI 10.1042/0264-6021:3610629; Nishizuka M, 2001, J BIOL CHEM, V276, P29625, DOI 10.1074/jbc.C100272200; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Sakaue H, 2002, GENE DEV, V16, P908, DOI 10.1101/gad.983202; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VAN AL, 1997, GENE DEV, V11, P2295; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; WARDEN CH, 1994, GENOMICS, V24, P14, DOI 10.1006/geno.1994.1576; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8	33	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15279	15284		10.1074/jbc.M211479200	http://dx.doi.org/10.1074/jbc.M211479200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578843	hybrid			2022-12-25	WOS:000182516100090
J	Qi, HY; Li, TK; Kuo, D; Nur-E-Kamal, A; Liu, LF				Qi, HY; Li, TK; Kuo, D; Nur-E-Kamal, A; Liu, LF			Inactivation of Cdc13p triggers MEC1-dependent apoptotic signals in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; TELOMERE MAINTENANCE; OXIDATIVE STRESS; BINDING PROTEIN; CASPASE ACTIVATION; CHECKPOINT GENES; BUDDING YEAST; CELLS	Inactivation of the budding yeast telomere binding protein Cdc13 results in abnormal telomeres (exposed long G-strands) and activation of the DNA damage checkpoint. In the current study, we show that inactivation of Cdc13p induces apoptotic signals in yeast, as evidenced by caspase activation, increased reactive oxygen species production, and flipping of phosphatidylserine in the cytoplasmic membrane. These apoptotic signals were suppressed in a mitochondrial (rho(0)) mutant. Moreover, mitochondrial proteins (e.g. MTCO3) were identified as multicopy suppressors of edc13-1, suggesting the involvement of mitochondrial functions in telomere-initiated apoptotic signaling. These telomere-initiated apoptotic signals were also shown to depend on MEC1, but not TELL, and were antagonized by MRE11. Our results are consistent with a model in which single-stranded G-tails in the cdc13-1 mutant trigger MEC1-dependent apoptotic signaling in yeast.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Qi, HY (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.			LI, TSAI-KUN/0000-0003-0393-2340; Liu, Leroy/0000-0001-9396-763X	NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM27731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Bhattacharya R, 1997, TOXICOLOGY, V123, P207, DOI 10.1016/S0300-483X(97)00130-3; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CERBON J, 1991, BIOCHIM BIOPHYS ACTA, V1067, P139, DOI 10.1016/0005-2736(91)90035-7; Craven RJ, 2000, MOL CELL BIOL, V20, P2378, DOI 10.1128/MCB.20.7.2378-2384.2000; Diede SJ, 2001, CURR BIOL, V11, P1336, DOI 10.1016/S0960-9822(01)00400-6; Enomoto S, 2002, MOL BIOL CELL, V13, P2626, DOI 10.1091/mbc.02-02-0012; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 2001, EMBO J, V20, P6127, DOI 10.1093/emboj/20.21.6127; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green-Willms NS, 1998, MOL CELL BIOL, V18, P1826, DOI 10.1128/MCB.18.4.1826; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; GUTHRIE G, 1991, METHOD ENZYMOL, V194, P150; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Laun P, 2001, MOL MICROBIOL, V39, P1166, DOI 10.1046/j.1365-2958.2001.02317.x; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIU HP, 1992, GENETICS, V132, P665; Longhese MP, 2000, GENETICS, V155, P1577; Lydall D, 1997, METHOD ENZYMOL, V283, P410; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Manon S, 2001, BIOCHEM BIOPH RES CO, V289, P1314, DOI 10.1006/bbrc.2001.6120; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mills EM, 1996, J NEUROCHEM, V67, P1039; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Qi HY, 2000, GENE DEV, V14, P1777; Ritchie KB, 2000, GENETICS, V155, P475; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; WRIGHT RM, 1990, MOL CELL BIOL, V10, P1297, DOI 10.1128/MCB.10.3.1297; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	46	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15136	15141		10.1074/jbc.M212808200	http://dx.doi.org/10.1074/jbc.M212808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12569108	hybrid			2022-12-25	WOS:000182516100072
J	Takebayashi, T; Higashi, H; Sudo, H; Ozawa, H; Suzuki, E; Shirado, O; Katoh, H; Hatakeyama, M				Takebayashi, T; Higashi, H; Sudo, H; Ozawa, H; Suzuki, E; Shirado, O; Katoh, H; Hatakeyama, M			NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A PROTEINS; CELL-CYCLE; GENE-PRODUCT; BREAST-CANCER; FUNCTIONAL INTERACTIONS; TRANSCRIPTION FACTOR; ECTOPIC EXPRESSION; SUPPRESSOR PROTEIN; CDK COMPLEXES; RB PROTEIN	The retinoblastoma protein (pRB) and its homologues, p107 and p130, prevent cell cycle progression from G(0)/G(1) to S phase by forming complexes with E2F transcription factors. Upon phosphorylation by G, cyclin-cyclin-dependent kinase (Cdk) complexes such as cyclin D1-Cdk4/6 and cyclin E-Cdk2, they lose the ability to bind E2F, and cells are thereby allowed to progress into S phase. Functional loss of one or more of the pRB family members, as a result of genetic mutation or deregulated phosphorylation, is considered to be an essential prerequisite for cellular transformation. In this study, we found that pRB family proteins have the ability to stimulate cyclin D1 transcription by activation of the NF-kappaB transcription factor. The cyclin D1-inducing activity of pRB is abolished by adenovirus E1A oncoprotein but not by the deletion of the A-box, the B-box, or the C-terminal region of the pocket, indicating that multiple pocket sequences are independently involved in cyclin D1 activation. Intriguingly, tumor-derived pRB pocket mutants retain the cyclin D1-inducing activity. Our results reveal a novel role of pRB family proteins as potential activators of NF-kappaB and inducers of G(1) cyclin. Certain pRB pocket mutants may give rise to a cellular situation in which deregulated E2F and cyclin D1 cooperatively promote abnormal cell proliferation.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Fac Med, Dept Internal Med, Div Nephrol & Endocrinol, Tokyo 1138655, Japan; Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Orthoped Surg, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; University of Tokyo; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Sudo, Hideki/G-2748-2012; Higashi, Hideaki/F-6872-2012					ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Coupland SE, 1998, BRIT J OPHTHALMOL, V82, P961, DOI 10.1136/bjo.82.8.961; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELMER A, 1995, LEUKEMIA, V9, P1240; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fortunato EA, 1997, J VIROL, V71, P8176, DOI 10.1128/JVI.71.11.8176-8185.1997; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Ibarra-Sanchez MD, 2001, ONCOGENE, V20, P4728, DOI 10.1038/sj.onc.1204648; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kondo T, 2001, J BIOL CHEM, V276, P17559, DOI 10.1074/jbc.M009911200; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Marhin WW, 1996, ONCOGENE, V12, P43; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; NEVINS JR, 1992, SCIENCE, V258, P424; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SuzukiTakahashi I, 1997, BIOCHEM BIOPH RES CO, V234, P386, DOI 10.1006/bbrc.1997.6654; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAM SW, 1994, ONCOGENE, V9, P2663; Tamami M, 1996, J BIOL CHEM, V271, P24551, DOI 10.1074/jbc.271.40.24551; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805	76	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14897	14905		10.1074/jbc.M210849200	http://dx.doi.org/10.1074/jbc.M210849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594215	hybrid			2022-12-25	WOS:000182516100042
J	Vanden Abeele, F; Roudbaraki, M; Shuba, Y; Skryma, R; Prevarskaya, N				Vanden Abeele, F; Roudbaraki, M; Shuba, Y; Skryma, R; Prevarskaya, N			Store-operated Ca2+ current in prostate cancer epithelial cells - Role of endogenous Ca2+ transporter type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; BASOPHILIC LEUKEMIA-CELLS; HUMAN EMBRYONIC KIDNEY; CURRENT I-CRAC; MAST-CELLS; ANTISENSE OLIGONUCLEOTIDES; PORE PROPERTIES; MIC CHANNELS; RELEASE; DEPLETION	Ca2+ influx via store-operated channels (SOCs) following stimulation of the plasma membrane receptors is the key event controlling numerous processes in nonexcitable cells. The human transient receptor potential vanilloid type 6 channel, originally termed Ca2+ transporter type 1 (CaT1) protein, is one of the promising candidates for the role of endogenous SOC, although investigations of its functions have generated considerable controversy. In order to assess the role of CaT1 in generating endogenous store-operated Ca2+ current (Is,c) in the lymph node carcinoma of the prostate (LN-CaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of Isoc. Antisense hybrid depletion of CaT1 decreased Isoc in LNCaP cells by similar to50%, whereas enhancement of CaT1 levels by 60% in response to Casodex treatment potentiated Isoc by 30%. The functional characteristics of Isoc in LNCaP cells were similar in many respects to those reported for heterologously expressed CaT1, although 2-aminoethoxydiphenyl borate sensitivity and lack of constitutive current highlighted notable departures. Our results suggest that CaT1 is definitely involved in Isoc, but it may constitute only a part of the endogenous SOC, which in general may be a heteromultimeric channel composed of homologous CaT1 and other transient receptor potential subunits.	Univ Sci & Tech Lille Flandres Artois, INSERM, EMI 0228, Lab Physiol Cellulaire, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), Univ Sci & Tech Lille Flandres Artois, INSERM, EMI 0228, Lab Physiol Cellulaire, Batiment SN3, F-59655 Villeneuve Dascq, France.		Vanden Abeele, Fabien/O-6012-2017; Shuba, Yaroslav/AAT-6758-2021	Vanden Abeele, Fabien/0000-0001-7111-7220; Prevarskaya, natacha/0000-0003-0316-197X; Morad, Roudbaraki/0000-0001-5751-3323				BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; CHOMCZYNSKY P, 1987, ANAL BIOCHEM, V172, P156; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Fierro L, 1999, J PHYSIOL-LONDON, V520, P407, DOI 10.1111/j.1469-7793.1999.00407.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Leung YM, 1999, JPN J PHARMACOL, V81, P253, DOI 10.1254/jjp.81.253; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; SKRYMA RN, 2000, J PHYSL, V527, P73; Tsavaler L, 2001, CANCER RES, V61, P3760; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	42	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15381	15389		10.1074/jbc.M212106200	http://dx.doi.org/10.1074/jbc.M212106200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584203	hybrid			2022-12-25	WOS:000182516100103
J	Venema, R; Tjalsma, H; van Dijl, JM; de Jong, A; Leenhouts, K; Buist, G; Venema, G				Venema, R; Tjalsma, H; van Dijl, JM; de Jong, A; Leenhouts, K; Buist, G; Venema, G			Active lipoprotein precursors in the gram-positive eubacterium Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; EXTRACELLULAR SERINE PROTEINASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; MYCOPLASMA-FERMENTANS; LIPID MODIFICATION; TRANSPORT-SYSTEM; CELL-ENVELOPE; ALPHA-AMYLASE; GENE	Lipid-modified proteins play important roles at the interface between eubacterial cells and their environment. The importance of lipoprotein processing by signal peptidase II (SPase II) is underscored by the fact that this enzyme is essential for viability of the Gram-negative eubacterium Escherichia coli. In contrast, SPase II is not essential for growth and viability of the Gram-positive eubacterium Bacillus subtilis. This could be due to alternative amino-terminal lipoprotein processing, which was shown previously to occur in SPase II mutants of B. subtilis. Alternatively, uncleaved lipoprotein precursors might be functional. To explore further the importance of lipoprotein processing in Gram-positive eubacteria, an SPase II mutant strain of Lactococcus lactis was constructed. Although some of the 39 (predicted) lactococcal lipoproteins, such as PrtM and OppA, are essential for growth in milk, the growth of SPase II mutant, L. lactis cells in this medium was not affected. Furthermore, the activity of the strictly PrtM-dependent extracellular protease PrtP, which is required for casein degradation, was not impaired in the absence of SPase II. Importantly, no alternative processing of pre-PrtM and pre-OppA was observed in cells lacking SPase II. Taken together, these findings show for the first time that authentic lipoprotein precursors retain biological activity.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Buist, G (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013					Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Beermann C, 2000, BIOCHEM BIOPH RES CO, V267, P897, DOI 10.1006/bbrc.1999.2057; Bengtsson J, 1999, J BACTERIOL, V181, P685, DOI 10.1128/JB.181.2.685-688.1999; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Calcutt MJ, 1999, INFECT IMMUN, V67, P760, DOI 10.1128/IAI.67.2.760-771.1999; Carlos J. L., 2001, ENZYMES, V22, P27; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; DEVOS WM, 1989, GENE, V85, P169, DOI 10.1016/0378-1119(89)90477-0; GASSON MJ, 1983, J BACTERIOL, V154, P1; HAANDRIKMAN AJ, 1989, J BACTERIOL, V171, P2789, DOI 10.1128/jb.171.5.2789-2794.1989; HAANDRIKMAN AJ, 1991, J BACTERIOL, V173, P4517, DOI 10.1128/JB.173.14.4517-4525.1991; HAANDRIKMAN AJ, 1991, APPL ENVIRON MICROB, V57, P1899, DOI 10.1128/AEM.57.7.1899-1904.1991; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; Kempf B, 1997, J BACTERIOL, V179, P6213, DOI 10.1128/jb.179.20.6213-6220.1997; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Leenhouts Kees, 1998, Methods in Cell Science, V20, P35, DOI 10.1023/A:1009862119114; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Mierau I, 1996, J BACTERIOL, V178, P2794, DOI 10.1128/jb.178.10.2794-2803.1996; MIERAU I, 1994, J BACTERIOL, V176, P2854, DOI 10.1128/JB.176.10.2854-2861.1994; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rawadi G, 1999, J BIOL CHEM, V274, P30794, DOI 10.1074/jbc.274.43.30794; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SANKARAN K, 1994, SIGNAL PEPTIDASES, P17; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scragg IG, 2000, J BIOL CHEM, V275, P937, DOI 10.1074/jbc.275.2.937; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Siezen RJ, 1999, ANTON LEEUW INT J G, V76, P139, DOI 10.1023/A:1002036906922; Simon MM, 1999, ZBL BAKT-INT J MED M, V289, P690; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; TJALSMA H, 2001, ENZYMES, V22, P3; TOKUNAGA M, 1982, J BIOL CHEM, V257, P9922; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; van Roosmalen ML, 2001, J BIOL CHEM, V276, P25230, DOI 10.1074/jbc.M102099200; VANDEGUCHTE M, 1990, APPL ENVIRON MICROB, V56, P2606, DOI 10.1128/AEM.56.9.2606-2611.1990; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1988, MOL GEN GENET, V214, P55; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; YAMAGATA H, 1982, J BACTERIOL, V152, P1163; [No title captured]	58	31	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14739	14746		10.1074/jbc.M209857200	http://dx.doi.org/10.1074/jbc.M209857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584195	Green Published, hybrid			2022-12-25	WOS:000182516100021
J	Wu, LY; Wu, YL; Gathings, B; Wan, M; Li, XL; Grizzle, W; Liu, ZY; Lu, CY; Mao, ZK; Cao, X				Wu, LY; Wu, YL; Gathings, B; Wan, M; Li, XL; Grizzle, W; Liu, ZY; Lu, CY; Mao, ZK; Cao, X			Smad4 as a transcription corepressor for estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; ACTIVATION FUNCTION AF-2; BREAST-CANCER; NUCLEAR RECEPTORS; POSTMENOPAUSAL WOMEN; MOLECULAR-CLONING; BINDING DOMAINS; CROSS-TALK; EXPRESSION; COACTIVATOR	Antiestrogen compounds exhibit a variety of different effects in different tissues and are widely used for the treatment of osteoporosis, breast cancer, and other diseases. Upon examining the molecular mechanisms, we found that Smad4, a common signal transducer in the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-beta) signaling pathway, functions as a transcription corepressor for human estrogen receptor alpha (ERalpha). Endogenous ERalpha was co-immunoprecipitated with Smad4, and the interaction was induced by antiestrogen ligands such as tamoxifen, raloxifene, and droloxifen, which was confirmed in chromatin immunoprecipitation assays. Smad4 and ERalpha form a complex when ERalpha binds to the estrogen-responsive element within the estrogen target gene promoter. Importantly, the expression of Smad4 inhibits both antiestrogen-induced luciferase activity and estrogen downstream target gene transcription in breast cancer cells. Mapping of the interaction domains indicates that the activation function 1 (AF1) domain of ERalpha is essential for its interaction with Smad4, while the MH1 domain and linker region of Smad4 are essential for the interaction. Our findings represent a novel mechanism that TGF-beta may regulate cell fate through Smad4-mediated crosstalk with estrogen.	Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA; Univ Alabama, Consortium Mat Dev Space, Huntsville, AL 35899 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Huntsville	Cao, X (corresponding author), Univ Alabama Birmingham, Dept Pathol, Sch Med, Birmingham, AL 35294 USA.	cao@path.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060913] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60913, DK57501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; Brattain MG, 1996, J MAMMARY GLAND BIOL, V1, P365, DOI 10.1007/BF02017392; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fuqua SAW, 1999, CANCER RES, V59, P5425; Goggins M, 1998, CANCER RES, V58, P5329; Grady WM, 1998, CANCER RES, V58, P3101; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; He W, 2001, ONCOGENE, V20, P471, DOI 10.1038/sj.onc.1204117; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; JORDAN VC, 1992, CANCER, V70, P977; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang HY, 2002, J BIOL CHEM, V277, P43749, DOI 10.1074/jbc.M205603200; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LHorset F, 1996, MOL CELL BIOL, V16, P6029; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; MUSS HB, 1992, BREAST CANCER RES TR, V21, P15, DOI 10.1007/BF01811960; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; ONATE SA, 1995, SCIENCE, V270, P1354; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; Pouliot F, 1999, INT J CANCER, V81, P98, DOI 10.1002/(SICI)1097-0215(19990331)81:1<98::AID-IJC17>3.0.CO;2-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Speirs V, 1999, CANCER RES, V59, P5421; Speirs V, 2000, BRIT J SURG, V87, P405, DOI 10.1046/j.1365-2168.2000.01402.x; Stoica A, 1997, ENDOCRINOLOGY, V138, P1498, DOI 10.1210/en.138.4.1498; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tsuchiya F, 2001, BIOCHEM BIOPH RES CO, V284, P2, DOI 10.1006/bbrc.2001.4892; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	71	86	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15192	15200		10.1074/jbc.M212332200	http://dx.doi.org/10.1074/jbc.M212332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576474	hybrid			2022-12-25	WOS:000182516100079
J	Dugan, TA; Yang, VWC; McQuillan, DJ; Hook, M				Dugan, TA; Yang, VWC; McQuillan, DJ; Hook, M			Decorin binds fibrinogen in a Zn2+-dependent interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; DERMATAN SULFATE PROTEOGLYCAN; COLLAGEN FIBRILLOGENESIS; CRYSTAL-STRUCTURE; MATRIX PROTEIN; SKIN FRAGILITY; CELL-MIGRATION; FRAGMENT-D; BIGLYCAN; EXPRESSION	We have previously shown that decorin, a member of the small leucine-rich proteoglycan family of extracellular matrix proteoglycans/glycoproteins is a Zn2+ metalloprotein at physiological Zn2+ concentrations (Yang, V. W-C., LaBrenz, S. R., Rosenberg, L. C., McQuillan, D., and Hook, M. (1999) J. Biol. Chem. 274,12454-12460). We now report that the decorin proteoglycan binds fibrinogen in the presence of Zn2+. The fibrinogen-binding site is located in the N-terminal domain of the decorin core protein and a 45-amino acid peptide representing this domain binds to the fibrinogen D fragment with an apparent K-D of 1.7 x 10(-6) m, as determined from fluorescence polarization data. Furthermore, we show that Zn2+ promotes the self-association of decorin. The N-terminal domain of the core protein also mediates this activity. The results of solid-phase binding assays and gel filtration chromatography suggest that the N-terminal domain of decorin, when present at low micromolar concentrations, forms an oligomer in a Zn2+-dependent manner. Thus, Zn2+ appears to play a pivotal role in the interactions and biological function of decorin.	Texas Med Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Tapei Med Univ, Grad Inst Biomed Mat, Taipei 110, Taiwan; LifeCell Corp, Somerville, NJ 08876 USA	Baylor College of Medicine; Taipei Municipal WanFang Hospital	Hook, M (corresponding author), Texas Med Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.	mhook@ibt.tamu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; COLLEN D, 1975, J BIOL CHEM, V250, P5808; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; LIU J, 1994, J BIOL CHEM, V269, P28366; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Merle B, 1999, J CELL BIOCHEM, V75, P538; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; Takanosu M, 2001, INVEST OPHTH VIS SCI, V42, P2202; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; YANG VWC, 1999, THESIS U TEXAS HLTH	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13655	13662		10.1074/jbc.M300171200	http://dx.doi.org/10.1074/jbc.M300171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582160	hybrid			2022-12-25	WOS:000182405000014
J	Yamazaki, K; Sakamoto, M; Ohta, T; Kanai, Y; Ohki, M; Hirohashi, S				Yamazaki, K; Sakamoto, M; Ohta, T; Kanai, Y; Ohki, M; Hirohashi, S			Overexpression of KIT in chromophobe renal cell carcinoma	ONCOGENE			English	Article						gene-expression profiling; KIT; renal cell carcinoma	GASTROINTESTINAL STROMAL TUMORS; GROWTH-FACTOR RECEPTOR; C-KIT; TYROSINE KINASE; LUNG-CANCER; SUPPRESSOR PROTEIN; MET PROTOONCOGENE; CLASSIFICATION; MUTATIONS; GENE	We analysed gene-expression profiles in 15 surgical specimens of conventional, papillary, and chromophobe renal cell carcinomas (RCCs) using high-density oligonucleotide arrays. From about 12 000 genes targeted by the array, 67 were upregulated specifically in each histological type of RCC. The oncogene KIT was one of the genes whose expression was upregulated specifically in chromophobe RCCs. Immunohistochemical analysis demonstrated the KIT gene product on the cell membrane of chromophobe RCC in all cases, although it was not detected in conventional RCCs or non-neoplastic kidneys except for weak staining in the cytoplasm of renal tubules. These results suggest that each histological subtype of RCC has a unique gene-expression profile, and in particular indicates for the first time that KIT could be a useful marker for chromophobe RCC. As overexpression of KIT might be involved in tumor growth, KIT could be a new therapeutic target in this special type of RCC.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuou Ku, Tokyo 1040045, Japan; Org Pharmaceut Safety & Res, Chiyoda Ku, Tokyo 1000013, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuou Ku, Tokyo 1040045, Japan	Keio University; National Cancer Center - Japan; National Cancer Center - Japan	Sakamoto, M (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinaimachi, Tokyo 1600016, Japan.		Kanai, Yae/AAE-6987-2019; Sakamoto, Michiie/N-2917-2015	Yamazaki, Ken/0000-0002-7220-7479				Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dijkhuizen T, 1996, INT J CANCER, V68, P47, DOI 10.1002/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X; FREEMAN MR, 1989, CANCER RES, V49, P6221; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GNERRA JR, 1994, NAT GENET, V7, P85; HIBI K, 1991, ONCOGENE, V6, P2291; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; ISHIKAWA J, 1990, INT J CANCER, V45, P1018, DOI 10.1002/ijc.2910450606; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kenck C, 1996, J PATHOL, V179, P157, DOI 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Nakopoulou L, 1997, PATHOL RES PRACT, V193, P299; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Rubin BP, 2001, CANCER RES, V61, P8118; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SPEICHER MR, 1994, AM J PATHOL, V145, P356; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	29	131	139	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					847	852		10.1038/sj.onc.1206153	http://dx.doi.org/10.1038/sj.onc.1206153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584564				2022-12-25	WOS:000180864300007
J	Igbavboa, U; Pidcock, JM; Johnson, LNA; Malo, TM; Studniski, AE; Yu, S; Sun, GY; Wood, WG				Igbavboa, U; Pidcock, JM; Johnson, LNA; Malo, TM; Studniski, AE; Yu, S; Sun, GY; Wood, WG			Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid beta-peptide-(1-42)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; APOLIPOPROTEIN-E; BETA-PEPTIDE; PRECURSOR PROTEIN; PHOSPHOLIPASE-D; SYNAPTOSOMAL MEMBRANES; BRAIN; DISEASE; DOMAINS; LOCALIZATION	The Golgi complex plays an important role in cholesterol trafficking in cells, and amyloid beta-peptides (Abetas) alter cholesterol trafficking. The hypothesis was tested that fresh and aged Abeta-(1-42) would differentially modify Golgi cholesterol content in DINTC1 astrocytes and that the effects of Abeta-(1-42) would be associated with the region of the Golgi complex. Two different methods were used to determine the effects of Abeta-(1-42) on Golgi complex cholesterol. Confocal microscopy showed that fresh Abeta-(1-42) significantly increased cholesterol and that aged Abeta-(1-42) significantly reduced cholesterol content in the Golgi complex. Isolation of the Golgi complex into two fractions using density gradient centrifugation showed effects of aged Abeta-(1-42) similar to those observed with confocal microscopy but revealed the novel finding that fresh Abeta-(1-42) had opposite effects on the two Golgi fractions suggesting a specificity of Abeta-(1-42) perturbation of the Golgi complex. Phosphatidylcholine-phospholipase D activity, cell membrane cholesterol, and apolipoprotein E levels were associated with effects of fresh Abeta-(1-42) on cholesterol distribution but not with effects of aged Abeta-(1-42), arguing against a common mechanism. Extracellular Abeta-(1-42) targets the Golgi complex and disrupts cell cholesterol homeostasis, and this action of Abeta-(1-42) could alter cell functions requiring optimal levels of cholesterol.	Univ Minnesota, Sch Med, Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55417 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	Geriatric Research Education & Clinical Center; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Missouri System; University of Missouri Columbia	Wood, WG (corresponding author), Univ Minnesota, Sch Med, Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, 11G,1 Vet Dr, Minneapolis, MN 55417 USA.	Woodx002@umn.edu			NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010806] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-10806] Funding Source: Medline; NIA NIH HHS [1P0AG-18357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRES J, 1996, EXP PARASITOL, V83, P174; ATSHAVES BP, 2000, J BIOL CHEM, V275, P36582; AUERBACH BJ, 1990, J LIPID RES, V31, P738; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Beffert U, 1998, J NEUROCHEM, V70, P1458; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chochina SV, 2001, J LIPID RES, V42, P1292; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Eckert GP, 2000, DEMENT GERIATR COGN, V11, P181, DOI 10.1159/000017234; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Hayashi H, 2000, BBA-MOL CELL BIOL L, V1483, P81, DOI 10.1016/S1388-1981(99)00174-2; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kirsch C, 2002, AMYLOID, V9, P149, DOI 10.3109/13506120209114816; Koudinov AR, 2001, FASEB J, V15, P1858, DOI 10.1096/fj.00-0815fje; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Liu YB, 1999, PROG NEURO-PSYCHOPH, V23, P377, DOI 10.1016/S0278-5846(99)00003-2; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; Maekawa S, 1999, J BIOL CHEM, V274, P21369, DOI 10.1074/jbc.274.30.21369; Marsh BJ, 2002, NAT REV MOL CELL BIO, V3, P789, DOI 10.1038/nrm933; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; Oshima N, 2001, AM J PATHOL, V158, P2209, DOI 10.1016/S0002-9440(10)64693-7; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Pappolla MA, 2002, FREE RADICAL BIO MED, V33, P173, DOI 10.1016/S0891-5849(02)00841-9; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; RAO AM, 1993, NEUROCHEM INT, V23, P45; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schroeder F, 2001, EXP BIOL MED, V226, P873, DOI 10.1177/153537020122601002; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Singh IN, 1998, NEUROCHEM RES, V23, P1225, DOI 10.1023/A:1020731813973; Singh IN, 1998, BRAIN RES, V800, P275, DOI 10.1016/S0006-8993(98)00532-0; Sparks DL, 1997, ANN NY ACAD SCI, V826, P128, DOI 10.1111/j.1749-6632.1997.tb48466.x; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; WOOD WG, 1995, BRAIN RES, V683, P36; Wood WG, 2003, BBA-BIOMEMBRANES, V1610, P281, DOI 10.1016/S0005-2736(03)00025-7; Wood WG, 2002, NEUROBIOL AGING, V23, P685, DOI 10.1016/S0197-4580(02)00018-0; WOOD WG, 1993, ALCOHOL CLIN EXP RES, V17, P345, DOI 10.1111/j.1530-0277.1993.tb00773.x; Yanagisawa K, 2002, J NEUROSCI RES, V70, P361, DOI 10.1002/jnr.10348; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	61	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17150	17157		10.1074/jbc.M301150200	http://dx.doi.org/10.1074/jbc.M301150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12584199	hybrid			2022-12-25	WOS:000182818600094
J	Yang, E; Lerner, L; Besser, D; Darnell, JE				Yang, E; Lerner, L; Besser, D; Darnell, JE			Independent and cooperative activation of chromosomal c-fos promoter by STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TERNARY COMPLEX-FORMATION; SERUM RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; PROTEIN-KINASES; 3T3 CELLS; STIMULATION	The c-fos gene was one of the earliest vertebrate genes shown to be transcriptionally induced by growth factors. Intensive study of the promoter of c-fos (-325 to -80) by transient or permanent transfections of synthetic DNA constructs has repeatedly shown the importance of several sequence elements and the resident nuclear proteins that bind them (e.g. ternary complex factor/ELK1; serum response factor, cAMP response element-binding protein/amino-terminal fragment/AP-1). However these studies have left unanswered numerous questions about the role of these proteins in the regulation of the native chromosomal gene. In particular, the role of a site in this enhancer that binds STATs has been controversial. We present evidence here that STAT3 and not STAT1 accumulates on the chromosomal c-fos promoter and provides a boost to transcription without the activation of resident nuclear proteins through serine kinases. Also, when resident nuclear proteins such as ELK1 are activated to varying extents by mitogen-activated protein kinase pathways, STAT3 activation provides a 2-fold boost regardless of the final level of activated transcription. Thus the several proteins that interact with the c-fos enhancer apparently can act either in a cooperative or independent manner to achieve very different levels of transcription.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.		Yang, Edward/Q-8175-2019; Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624	NCI NIH HHS [CA 09673] Funding Source: Medline; NIAID NIH HHS [AI 32489, AI 34420] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034420, R37AI034420, R01AI032489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; COFFER P, 1995, ONCOGENE, V10, P985; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirano Toshio, 1998, P197; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Yang E, 1999, MOL CELL BIOL, V19, P5106; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15794	15799		10.1074/jbc.M213073200	http://dx.doi.org/10.1074/jbc.M213073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600988	hybrid			2022-12-25	WOS:000182680000044
J	Yang, HM; Lin, CH; Ma, G; Baffi, MO; Wathelet, MG				Yang, HM; Lin, CH; Ma, G; Baffi, MO; Wathelet, MG			Interferon regulatory factor-7 synergizes with other transcription factors through multiple interactions with p300/CBP coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INFECTION; POSITIVE FEEDBACK; GENE INDUCTION; ALPHA GENES; ACTIVATION; DISTINCT; IRF-3; BINDING; CBP/P300; DOMAINS	Interferon regulatory factor (IRF)-7 is activated in response to virus infection and stimulates the transcription of a set of cellular genes involved in host antiviral defense. The mechanism by which IRF-7 is activated and cooperates with other transcription factors is not fully elucidated. Activation of IRF-7 results from a conformational change triggered by the virus-dependent phosphorylation of its C terminus. This conformational change leads to dimerization, nuclear accumulation, DNA-binding, and transcriptional transactivation. Here we show that activation of IRF-7, like that of IRF-3, is dependent on modifications of two distinct sets of Ser/ Thr residues. Moreover, we show that different virus-inducible cis-acting elements display requirements for specific IRFs. In particular, the virus-responsive element of the ISG15 gene promoter can be activated by either IRF-3 or IRF-7 alone, whereas the P31 element of the interferon-beta gene is robustly activated only when IRF-3, IRF-7, and the p300/CBP coactivators are all present. Furthermore, we find that IRF-7 interacts with four distinct regions of p300/CBP. These interactions not only stimulate the intrinsic transcriptional activity of IRF-7, but they are also indispensable for its ability to strongly synergize with other transcription factors, including c-Jun and IRF-3.	Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University System of Ohio; University of Cincinnati; Harvard University	Wathelet, MG (corresponding author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NIAID NIH HHS [AI 20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P419, DOI 10.1016/S0952-7915(00)00111-4; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Harlow E., 1988, ANTIBODIES LAB MANUA; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stewart W, 1979, INTERFERON SYSTEM; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	25	50	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15495	15504		10.1074/jbc.M212940200	http://dx.doi.org/10.1074/jbc.M212940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604599	hybrid			2022-12-25	WOS:000182680000007
J	Berdiev, BK; Xia, JZ; McLean, LA; Markert, JM; Gillespie, GY; Mapstone, TB; Naren, AP; Jovov, B; Bubien, JK; Ji, HL; Fuller, CM; Kirk, KL; Benos, DJ				Berdiev, BK; Xia, JZ; McLean, LA; Markert, JM; Gillespie, GY; Mapstone, TB; Naren, AP; Jovov, B; Bubien, JK; Ji, HL; Fuller, CM; Kirk, KL; Benos, DJ			Acid-sensing ion channels in malignant gliomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS CAUSING NEURODEGENERATION; EPITHELIAL SODIUM-CHANNELS; MAMMALIAN DEGENERIN MDEG; CFTR CHLORIDE CHANNELS; PLANAR LIPID BILAYERS; SENSITIVE NA+ CHANNEL; GATED CATION CHANNELS; CAENORHABDITIS-ELEGANS; CALCIUM CHANNELS; XENOPUS OOCYTES	High grade glioma cells derived from patient biopsies express an amiloride-sensitive sodium conductance that has properties attributed to the human brain sodium, channel family, also known as acid-sensing ion channels (ASICs). This amiloride-sensitive conductance was not detected in cells obtained from normal brain tissue or low grade or benign tumors. Differential gene profiling data showed that ASIC1 and ASIC2 mRNA were present in normal and low grade tumor cells. Although ASIC 1 was present in all of the high grade glial cells examined, ASIC2 mRNA was detected in less than half. The main purpose of our work was to ekamine the molecular mechanisms that may underlie the constitutively activated sodium currents present in high grade glioma cells. Our results show that 1) gain-of-function mutations of ASIC1 were not present in a number of freshly resected and cultured high grade,gliomas, 2) syntaxin 1A inhibited ASIC currents only when ASIC1 and ASIC2 were co-expressed, and 3) the inhibition of ASIC currents by syntaxin 1A had an absolute requirement for either gamma- or delta-hENaC. Transfection of cultured cells originally derived from high grade gliomas (U87-MG and SK-MG1) with ASIC2 abolished basal amiloride-sensitive sodium conductance; this inhibition was reversed by dialysis of the cell interior with Munc-18, a syntaxin-binding protein that typically blocks the interaction of syntaxin with other proteins. Thus, syntaxin 1A cannot inhibit Na+ permeability in the absence of adequate plasma membrane ASIC2 expression, accounting for the observed functional expression of amiloride-sensitive currents in high grade glioma cells.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.		JI, HONGLONG/N-7822-2014; Fuller, Cathy/B-4046-2011	JI, HONGLONG/0000-0002-3228-7144; Gillespie, George/0000-0001-6436-9542	NCI NIH HHS [CA71933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Berdiev BK, 2002, J BIOL CHEM, V277, P45734, DOI 10.1074/jbc.M208995200; Berdiev BK, 2001, J BIOL CHEM, V276, P38755, DOI 10.1074/jbc.M107266200; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; BRISMAR T, 1989, BRAIN RES, V480, P259, DOI 10.1016/0006-8993(89)90191-1; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 2001, EUR J HUM GENET, V9, P672, DOI 10.1038/sj.ejhg.5200699; Horimoto M, 2000, CANCER GENE THER, V7, P1341, DOI 10.1038/sj.cgt.0239; Ismailov II, 1997, J PHYSIOL-LONDON, V504, P287, DOI 10.1111/j.1469-7793.1997.287be.x; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Rettig J, 1997, J NEUROSCI, V17, P6647; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Ullrich N, 1996, AM J PHYSIOL-CELL PH, V270, pC1511; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Zhang P, 2001, J GEN PHYSIOL, V117, P563, DOI 10.1085/jgp.117.6.563; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721	39	108	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15023	15034		10.1074/jbc.M300991200	http://dx.doi.org/10.1074/jbc.M300991200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584187	hybrid			2022-12-25	WOS:000182516100059
J	Seabold, GK; Burette, A; Lim, IA; Weinberg, RJ; Hell, JW				Seabold, GK; Burette, A; Lim, IA; Weinberg, RJ; Hell, JW			Interaction of the tyrosine kinase Pyk2 with the N-methyl-D-aspartate receptor complex via the Src homology 3 domains of PSD-95 and SAP102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; FOCAL ADHESION KINASE; SYNAPSE-ASSOCIATED PROTEIN-97; CENTRAL NERVOUS-SYSTEM; AMINO-ACID RECEPTORS; NMDA-RECEPTOR; POSTSYNAPTIC DENSITY; INTRAMOLECULAR INTERACTION; GLUTAMATE RECEPTORS	The protein-tyrosine kinase Pyk2/CAKbeta/CADTK is a key activator of Src in many cells. At hippocampal synapses, induction of long term potentiation requires the Pyk2/Src signaling pathway, which up-regulates the activity of N-methyl-D-aspartate-type glutamate receptors. Because localization of protein kinases close to their substrates is crucial for effective phosphorylation, we investigated how Pyk2 might be recruited to the N-methyl-D-aspartate receptor complex. This interaction is mediated by PSD-95 and its homolog SAP102. Both proteins colocalize with Pyk2 at postsynaptic dendritic spines in the cerebral cortex. The proline-rich regions in the C-terminal half of Pyk2 bind to the SH3 domain of PSD-95 and SAP102. The SH3 and guanylate kinase homology (GK) domain of PSD-95 and SAP102 interact intramolecularly, but the physiological significance of this interaction has been unclear. We show that Pyk2 effectively binds to the Src homology 3 (SH3) domain of SAP102 only when the GK domain is removed from the SH3 domain. Characterization of PSD-95 and SAP102 as adaptor proteins for Pyk2 fills a critical gap in the understanding of the spatial organization of the Pyk2-Src signaling pathway at the postsynaptic site and reveals a physiological function of the intramolecular SH3-GK domain interaction in SAP102.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Hell, JW (corresponding author), Univ Iowa, Dept Pharmacol, 51 Newton Rd, Iowa City, IA 52242 USA.		Hell, Johannes W./P-5085-2019; Weinberg, Richard/AAC-1898-2020	Weinberg, Richard/0000-0001-9689-7278	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563, R01NS039444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017502, R56AG017502] Funding Source: NIH RePORTER; NIA NIH HHS [AG17502] Funding Source: Medline; NINDS NIH HHS [NS35563, NS39444] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Burette A, 1999, J COMP NEUROL, V411, P601; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; Cheung HH, 2001, J NEUROCHEM, V78, P524, DOI 10.1046/j.1471-4159.2001.00433.x; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Derkinderen P, 1998, EUR J NEUROSCI, V10, P1667, DOI 10.1046/j.1460-9568.1998.00174.x; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, J BIOL CHEM, V270, P28440; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Heidinger V, 2002, J NEUROSCI, V22, P5452; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Hunyady B, 1996, J HISTOCHEM CYTOCHEM, V44, P1353, DOI 10.1177/44.12.8985127; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KINGSTON R, 1997, CURRENT PROTOCOLS MO, V1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lan JY, 2001, J NEUROSCI, V21, P6058, DOI 10.1523/JNEUROSCI.21-16-06058.2001; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Logan SM, 1999, J NEUROSCI, V19, P974; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; Paarmann I, 2002, J BIOL CHEM, V277, P40832, DOI 10.1074/jbc.M205618200; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raja S, 1997, J BIOL CHEM, V272, P10941; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Xiong WC, 1998, J CELL SCI, V111, P1981; Xiong ZG, 1998, MOL PHARMACOL, V54, P1055, DOI 10.1124/mol.54.6.1055; Xiong ZG, 1999, J NEUROSCI, V19; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zheng F, 1998, NAT NEUROSCI, V1, P185, DOI 10.1038/634; Zheng X, 1999, P NATL ACAD SCI USA, V96, P15262, DOI 10.1073/pnas.96.26.15262	101	61	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15040	15048		10.1074/jbc.M212825200	http://dx.doi.org/10.1074/jbc.M212825200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576483	Green Published, hybrid			2022-12-25	WOS:000182516100061
J	Hill, KE; Zhou, JD; McMahan, WJ; Motley, AK; Atkins, JF; Gesteland, RF; Burk, RF				Hill, KE; Zhou, JD; McMahan, WJ; Motley, AK; Atkins, JF; Gesteland, RF; Burk, RF			Deletion of selenoprotein P alters distribution of selenium in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE-ACTIVITY; DEFICIENT RAT-LIVER; MESSENGER-RNA; SELENOCYSTEINE; PLASMA; PROTEIN; CELLS; EXPRESSION; RESIDUES; TISSUES	Selenoprotein P (Se-P) contains most of the selenium in plasma. Its function is not known. Mice with the Se-P gene deleted (Sepp(-/-)) were generated. Two phenotypes were observed: 1) Sepp(-/-) mice lost weight and developed poor motor coordination when fed diets with selenium below 0.1 mg/kg, and 2) male Sepp(-/-) mice had sharply reduced fertility. Weanling male Sepp(+/+), Sepp(+/-), and Sepp(-/-) mice were fed diets for 8 weeks containing <0.02-2 mg selenium/kg. Sepp(+/+) and Sepp(+/-) mice had similar selenium concentrations in all tissues except plasma where a gene-dose effect on Se-P was observed. Liver selenium was unaffected by Se-P deletion except that it increased when dietary selenium was below 0.1 mg/kg. Selenium in other tissues exhibited a continuum of responses to Se-P deletion. Testis selenium was depressed to 19% in mice fed an 0.1 mg selenium/kg diet and did not rise to Sepp(+/+) levels even with a dietary selenium of 2 mg/kg. Brain selenium was depressed to 43%, but feeding 2 mg selenium/kg diet raised it to Sepp(+/+) levels. Kidney was depressed to 76% and reached Sepp(+/+) levels on an 0.25 mg selenium/kg diet. Heart selenium was not affected. These results suggest that the Sepp(-/-) phenotypes were caused by low selenium in testis and brain. They strongly suggest that Se-P from liver provides selenium to several tissues, especially testis and brain. Further, they indicate that transport forms of selenium other than Se-P exist because selenium levels of all tissues except testis responded to increases of dietary selenium in Sepp(-/-) mice.	Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA	Vanderbilt University; Utah System of Higher Education; University of Utah	Burk, RF (corresponding author), Vanderbilt Univ Sch Med, N Med Ctr, C-2104, Nashville, TN 37232 USA.			Atkins, John/0000-0001-7933-0165	NIEHS NIH HHS [R01 ES02497, P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM48152, GM61200] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061200, R01GM048152] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson JB, 2001, LAB INVEST, V81, P193, DOI 10.1038/labinvest.3780227; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BURK RF, 1972, J NUTR, V102, P1049, DOI 10.1093/jn/102.8.1049; BURK RF, 1991, AM J PHYSIOL, V261, pE26, DOI 10.1152/ajpendo.1991.261.1.E26; Burk RF, 1997, HISTOCHEM CELL BIOL, V108, P11, DOI 10.1007/s004180050141; BURK RF, 1995, HEPATOLOGY, V21, P561; BURK RF, 1987, METHOD ENZYMOL, V143, P307; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; ESAKI N, 1981, BIOCHEMISTRY-US, V20, P4492, DOI 10.1021/bi00518a039; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hill KE, 1996, J NUTR, V126, P138, DOI 10.1093/jn/126.1.138; Hill KE, 1996, BBA-MOL CELL RES, V1313, P29, DOI 10.1016/0167-4889(96)00047-X; HILL KE, 1991, J BIOL CHEM, V266, P10050; Hondal RJ, 2001, J BIOL CHEM, V276, P15823, DOI 10.1074/jbc.M010405200; KATO T, 1992, AM J PHYSIOL, V262, pG854, DOI 10.1152/ajpgi.1992.262.5.G854; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kryukov GV, 2000, GENES CELLS, V5, P1049, DOI 10.1046/j.1365-2443.2000.00392.x; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; MOTSENBOCKER MA, 1982, BIOCHIM BIOPHYS ACTA, V719, P147, DOI 10.1016/0304-4165(82)90318-X; PROHASKA JR, 1993, COMP BIOCHEM PHYS B, V105, P111, DOI 10.1016/0305-0491(93)90176-6; READ R, 1990, J BIOL CHEM, V265, P17899; Saito Y, 2002, EUR J BIOCHEM, V269, P5746, DOI 10.1046/j.1432-1033.2002.03298.x; Schomburg L, 2003, BIOCHEM J, V370, P397, DOI 10.1042/BJ20021853; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Steinert P, 1998, BIOL CHEM, V379, P683, DOI 10.1515/bchm.1998.379.6.683; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Weiss SL, 1996, J NUTR, V126, P2260, DOI 10.1093/jn/126.9.2260; Yan J, 1998, J NEUROSCI, V18, P8682	34	356	369	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13640	13646		10.1074/jbc.M300755200	http://dx.doi.org/10.1074/jbc.M300755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574155	hybrid			2022-12-25	WOS:000182405000012
J	Mazin, AV; Alexeev, AA; Kowalczykowski, SC				Mazin, AV; Alexeev, AA; Kowalczykowski, SC			A novel function of Rad54 protein - Stabilization of the Rad51 nucleoprotein filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE RAD51; PRESYNAPTIC COMPLEX-FORMATION; MATING-TYPE HETEROZYGOSITY; RECA PROTEIN; YEAST RAD51; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; ATP HYDROLYSIS; REPAIR PROTEIN	Homologous recombination is important for the repair of double-stranded DNA breaks in all organisms. Rad51. and Rad54 proteins are two key components of the homologous recombination machinery in eukaryotes. In vitro, Rad51. protein assembles with single-stranded DNA to form the helical nucleoprotein filament that promotes DNA strand exchange, a basic step of homologous recombination. Rad54 protein interacts with this Rad51. nucleoprotein filament and stimulates its DNA pairing activity, suggesting that Rad54 protein is a component of the nucleoprotein complex involved in the DNA homology search. Here, using physical criteria, we demonstrate directly the formation of Rad54-Rad51-DNA nucleoprotein co-complexes that contain equimolar amounts of each protein. The binding of Rad54 protein significantly stabilizes the Rad51 nucleoprotein filament formed on either single-stranded DNA or double-stranded DNA. The Rad54-stabilized nucleoprotein filament is more competent in DNA strand exchange and acts over a broader range of solution conditions. Thus, the co-assembly of an interacting partner with the Rad51. nucleoprotein filament represents a novel means of stabilizing the biochemical entity central to homologous recombination, and reveals a new function of Rad54 protein.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, Briggs Hall, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062653, R01GM062653] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexeev A, 2003, NAT STRUCT BIOL, V10, P182, DOI 10.1038/nsb901; Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Clever B, 1999, YEAST, V15, P721, DOI 10.1002/(SICI)1097-0061(19990630)15:9<721::AID-YEA414>3.0.CO;2-W; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Essers J, 2002, DNA REPAIR, V1, P779, DOI 10.1016/S1568-7864(02)00110-6; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Game JC, 2000, MUTAT RES-FUND MOL M, V451, P277, DOI 10.1016/S0027-5107(00)00055-5; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kiianitsa K, 2002, J BIOL CHEM, V277, P46205, DOI 10.1074/jbc.M207967200; Kim PM, 2002, NUCLEIC ACIDS RES, V30, P2727, DOI 10.1093/nar/gkf413; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LAUDER SD, 1993, J MOL BIOL, V234, P72, DOI 10.1006/jmbi.1993.1564; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Mazin AV, 1996, P NATL ACAD SCI USA, V93, P10673, DOI 10.1073/pnas.93.20.10673; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Morgan EA, 2002, MOL CELL BIOL, V22, P6336, DOI 10.1128/MCB.22.18.6336-6343.2002; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RATTRAY AJ, 1995, GENETICS, V139, P45; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SCHILD D, 1995, GENETICS, V140, P115; Seitz EM, 2001, ADV APPL MICROBIOL, V50, P101, DOI 10.1016/S0065-2164(01)50005-2; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	57	132	135	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14029	14036		10.1074/jbc.M212779200	http://dx.doi.org/10.1074/jbc.M212779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566442	hybrid, Green Published			2022-12-25	WOS:000182405000061
J	Wang, HB; Faucette, S; Sueyoshi, T; Moore, R; Ferguson, S; Negishi, M; LeCluyse, EL				Wang, HB; Faucette, S; Sueyoshi, T; Moore, R; Ferguson, S; Negishi, M; LeCluyse, EL			A novel distal enhancer module regulated by pregnane x receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME P4502B6; HUMAN HEPATOCYTES; TRANSCRIPTIONAL REGULATION; NUCLEAR TRANSLOCATION; CATALYTIC-ACTIVITY; CAR; LIVER; METABOLISM; ACTIVATION; HYDROXYLATION	CYP2B6 plays an important role in the metabolism of a variety of structurally unrelated xenobiotics, including the anticancer drugs cyclophosphamide and ifosfamide. Previous studies have shown that the nuclear receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are involved in the transcriptional regulation of CYP2B genes through the phenobarbital-responsive enhancer module (PBREM). However, for human CYP2B6 the relatively weak response of the PBREM to PXR and CAR activation in transfection assays fails to describe the potent induction observed in primary human hepatocyte cultures. In this report, a novel nuclear receptor response module located -8.5 kilobases upstream from the CYP2B6 encoding region is described. Several potential PXR/CAR binding motifs were identified within the distal regulatory cluster. In electrophoretic mobility shift assays, one DR4 motif showed the strongest binding to both PXR and CAR. Transient transfection assays in HepG2 cells demonstrated that the novel distal response cluster could be activated by PXR and CAR. In primary human hepatocytes, both PBREM and the distal responsive element were activated individually by endogenous nuclear receptors upon exposure to prototypical inducers. However, in both HepG2 cells and primary human hepatocytes maximal reporter activation was observed in a construct containing both PBREM and the distal responsive element. In mouse tail-vein injection experiments, a construct containing both the distal responsive element and the proximal PBREM exhibited a strong synergistic expression in phenobarbital-treated mice. These results show that a novel xenobiotic-responsive enhancer module in the distal region of the CYP2B6 promoter (CYP2B6-XREM) together with the PBREM mediates optimal drug-induced expression of CYP2B6.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	LeCluyse, EL (corresponding author), Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA.	ed_lecluyse@une.edu	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; LeCluyse, Edward/0000-0002-2149-8990	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, P30ES010126, Z01ES071005, Z01ES021024] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987] Funding Source: Medline; NIEHS NIH HHS [P30 ES10126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Code EL, 1997, DRUG METAB DISPOS, V25, P985; Court MH, 2001, ANESTHESIOLOGY, V94, P110, DOI 10.1097/00000542-200101000-00021; Ekins S, 1998, J PHARMACOL EXP THER, V286, P1253; Erickson DA, 1999, DRUG METAB DISPOS, V27, P1488; Ferguson SS, 2002, MOL PHARMACOL, V62, P737, DOI 10.1124/mol.62.3.737; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Gervot L, 1999, PHARMACOGENETICS, V9, P295, DOI 10.1097/00008571-199906000-00004; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Hamilton GA, 2001, CELL TISSUE RES, V306, P85; Hanna IH, 2000, ARCH BIOCHEM BIOPHYS, V376, P206, DOI 10.1006/abbi.2000.1708; Hesse LM, 2000, DRUG METAB DISPOS, V28, P1176; Hidestrand M, 2001, DRUG METAB DISPOS, V29, P1480; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 1998, J BIOCHEM MOL TOXIC, V12, P3; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kobayashi K, 1999, DRUG METAB DISPOS, V27, P1429; LeCluyse EL, 2001, EUR J PHARM SCI, V13, P343, DOI 10.1016/S0928-0987(01)00135-X; Li AP, 1997, CHEM-BIOL INTERACT, V107, P5, DOI 10.1016/S0009-2797(97)00070-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maurel P, 1996, ADV DRUG DELIVER REV, V22, P105, DOI 10.1016/S0169-409X(96)00417-6; Oda Y, 2001, BRIT J CLIN PHARMACO, V51, P281, DOI 10.1046/j.1365-2125.2001.00344.x; PARKINSON A, 2001, BASIC SCI POISONS, V5, P113; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Roy P, 1999, DRUG METAB DISPOS, V27, P655; Sahi J, 2000, XENOBIOTICA, V30, P273, DOI 10.1080/004982500237668; Sridar C, 2002, J PHARMACOL EXP THER, V301, P945, DOI 10.1124/jpet.301.3.945; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; van Heeswijk RPG, 2001, ANTIVIR THER, V6, P201; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001	38	131	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14146	14152		10.1074/jbc.M212482200	http://dx.doi.org/10.1074/jbc.M212482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571232	hybrid			2022-12-25	WOS:000182405000075
J	Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE				Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE			F1F0-ATP synthase - Binding of delta subunit to a 22-residue peptide mimicking the N-terminal region of alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; F-1-ATPASE; STATOR; STALK; F1	The stator in F1F0-ATP synthase resists strain generated by rotor torque. In Escherichia coli the b(2)delta subunit complex comprises the stator, bound to subunit a in F-0 and to alpha(3)beta(3) hexagon of F-1. Proteolysis and cross-linking had suggested that N-terminal residues of a subunit are involved in binding delta. Here we demonstrate that a synthetic peptide consisting of the first 22 residues of a ("alphaN1-22") binds specifically to isolated wild-type delta subunit with high affinity (K-d = 130 nM), accounting for a major portion of the binding energy when delta-depleted F-1 and isolated delta bind together (K-d = 1.4 nM). Stoichiometry of binding of alphaN1-22 to delta at saturation was 1/1, showing that in intact F1F0-ATP synthase only one of the three a subunits is involved in delta binding. When alphaN1-22 was incubated with delta subunits containing mutations in helices I or 5 on the F-1-binding face of delta, peptide binding was impaired as was binding of delta-depleted F-2. Residues alpha6-18 are predicted to be helical, and a potential helix capping box occurs at residues alpha3-8. Circular dichroism measurements showed that alphaN1-22 had significant helical content. Hypothetically a helical region of residues alphaN1-22 packs with helices 1 and 5 on the F-1-binding face of delta, forming the alpha/delta interface.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews MJI, 1999, TETRAHEDRON, V55, P11711, DOI 10.1016/S0040-4020(99)00678-X; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Beck-Sickinger A G, 1995, Pharm Acta Helv, V70, P33, DOI 10.1016/0031-6865(94)00049-2; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; WEBER J, 2003, IN PRESS FEBS LETT; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381	20	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13623	13626		10.1074/jbc.C300061200	http://dx.doi.org/10.1074/jbc.C300061200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12595534	hybrid			2022-12-25	WOS:000182405000009
J	Gille, A; Seifert, R				Gille, A; Seifert, R			2 '(3 ')-O-(N-methylanthraniloyl)-substituted GTP analogs: A novel class of potent competitive adenylyl cyclase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; GUANINE-NUCLEOTIDE ANALOGS; SITE-MEDIATED INHIBITION; RETINAL G-PROTEIN; CRYSTAL-STRUCTURE; SF9 CELLS; CYTOSOLIC DOMAINS; LYMPHOMA-CELLS; RECEPTOR; TRANSDUCIN	2'(3')-O-(N-Methylanthraniloyl)-(MANT)-substituted nucleotides are fluorescent and widely used for the kinetic analysis of enzymes and signaling proteins. We studied the effects of MANT-guanosine 5'-[gamma-thio]triphosphate (MANT-GTPgammaS) and MANT-guanosine 5'-[beta,gamma-imido]triphosphate (MANT-GppNHp) on Galpha(s)- and Galpha(i)-protein-mediated signaling. MANT-GTPgammaS/MANT-GppNHp had lower affinities for Galpha(s) and Galpha(i) than GTPgammaS/GppNHp as assessed by inhibition of GTP hydrolysis of receptor-Galpha fusion proteins. MANT-GTPgammaS was much less effective than GTPgammaS at disrupting the ternary complex between the formyl peptide receptor and Galpha(12). MANT-GTPgammaS/MANT-GppNHp non-competitively inhibited GTPgammaS/GppNHp-, AlF4--, beta(2)-adrenoceptor plus GTP-, cholera toxin plus GTP-, and forskolin-stimulated adenylyl cyclase (AC) in Galpha(s)-expressing Sf9 insect cell membranes and S49 wild-type lymphoma cell membranes. AC inhibition by MANT-GTPgammaS/MANT-GppNHp was not due to Galpha(s) inhibition because it was also observed in Galpha(s)-deficient S49 cyc(-) lymphoma cell membranes. Mn2+ blocked AC inhibition by GTPgammaS/ GppNHp in S49 cyc(-) membranes but enhanced the potency of MANT-GTPgammaS/MANT-GppNHp at inhibiting AC by similar to4-8-fold. MANT-GTPgammaS and MANT-GppNHp competitively inhibited forskolin/Mn2+-stimulated AC in S49 cyc(-) membranes with K-i values of 53 and 160 lam, respectively. The K-i value for MANT-GppNHp at insect cell AC was 155 nm. Collectively, MANT-GTPgammaS/MANT-GppNHp bind to Galpha(s)- and Galpha(i)-proteins with low affinity and are ineffective at activating Galpha. Instead, MANT-GTPgammaS/MANT-GppNHp constitute a novel class of potent competitive AC inhibitors.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	University of Kansas	Seifert, R (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 1251 Wescoe Hall Dr,Malott Hall,Rm 5064, Lawrence, KS 66045 USA.		Seifert, Roland/G-3189-2013; Gille, Andreas/E-1531-2011	Gille, Andreas/0000-0001-5235-8897				ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CASSEL D, 1979, J BIOL CHEM, V254, P9835; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Dessauer CW, 1999, TRENDS PHARMACOL SCI, V20, P205, DOI 10.1016/S0165-6147(99)01310-3; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GETHER U, 1995, J BIOL CHEM, V270, P28268; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; Gille A, 2002, J BIOL CHEM, V277, P34434, DOI 10.1074/jbc.M204259200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; Houston C, 2002, J NEUROCHEM, V80, P678, DOI 10.1046/j.0022-3042.2001.00746.x; JAKOBS KH, 1983, EUR J BIOCHEM, V130, P605, DOI 10.1111/j.1432-1033.1983.tb07192.x; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Kawabe J, 1996, J BIOL CHEM, V271, P20132, DOI 10.1074/jbc.271.33.20132; Klinker JF, 1997, BIOCHEM PHARMACOL, V54, P551, DOI 10.1016/S0006-2952(97)00205-0; Klinker JF, 1999, BIOCHEM BIOPH RES CO, V262, P341, DOI 10.1006/bbrc.1999.1203; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; LONDOS C, 1977, J BIOL CHEM, V252, P5951; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Remmers AE, 1996, J BIOL CHEM, V271, P4791; Remmers AE, 1998, ANAL BIOCHEM, V257, P89, DOI 10.1006/abio.1997.2533; SARFATI RS, 1990, J BIOL CHEM, V265, P18902; SCHEIDIG AJ, 1995, J MOL BIOL, V253, P132, DOI 10.1006/jmbi.1995.0541; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SVOBODA M, 1980, FEBS LETT, V109, P275, DOI 10.1016/0014-5793(80)81104-5; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAO M, 1970, ARCH BIOCHEM BIOPHYS, V141, P236, DOI 10.1016/0003-9861(70)90127-X; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WATSON PA, 1994, J BIOL CHEM, V269, P28893; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; WENZELSEIFERT K, 1998, J BIOL CHEM, V273; Zera EM, 1996, J BIOL CHEM, V271, P12925, DOI 10.1074/jbc.271.22.12925	51	39	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12672	12679		10.1074/jbc.M211292200	http://dx.doi.org/10.1074/jbc.M211292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566433	hybrid			2022-12-25	WOS:000182189500012
J	Taylor, WA; Hatch, GM				Taylor, WA; Hatch, GM			Purification and characterization of monolysocardiolipin acyltransferase from pig liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; HEART MITOCHONDRIA; ACYL-COA; CARDIOLIPIN; ACID; PHOSPHATIDYLGLYCEROL; BIOSYNTHESIS; LIPIDS; QUANTITATION; REQUIREMENT	In mammalian tissues cardiolipin is rapidly remodeled by monolysocardiolipin acyltransferase subsequent to its de novo biosynthesis (Ma, B. J., Taylor, W. A, Dolinsky, V. W., and Hatch, G. M. (1999) J. Lipid Res. 40, 1837-1845). We report here the purification and characterization of a monolysocardiolipin acyltransferase activity from pig liver mitochondria. Monolysocardiolipin acyltransferase activity was purified over 1000-fold by butanol extraction, hydroxyapatite chromatography, and preparative SDS-PAGE. The purified 74-kDa protein catalyzed acylation of monolysocardiolipin to cardiolipin with [C-14]linoleoyl coenzyme A. Photoaffinity labeling of the protein with 12-[(4-[I-125]azidosalicyl)amino]dodecanoyl coenzyme A indicated coenzyme A was bound at its active site and photoaffinity cross-linking of 12-[(4-azidosalicyl)amino]dodecanoyl coenzyme A to the enzyme inhibited enzyme activity. Enzyme activity was optimum at pH 7.0, and the enzyme did not utilize other lysophospholipids as substrate. The purified enzyme was heat-labile and exhibited an isoelectric point of pH 5.4. To determine the enzymes kinetic mechanism the effect of varying concentrations of linoleoyl coenzyme A and monolysocardiolipin on initial velocity were determined. Double-reciprocal plots revealed parallel lines consistent with a ping pong kinetic mechanism. When the enzyme was incubated in the absence of monolysocardiolipin, coenzyme A was produced from linoleoyl coenzyme A at a rate consistent with the formation of an enzyme-linoleate intermediate. The true K-m value for linoleoyl coenzyme A and true K-m value for monolysocardiolipin were 100 and 44 muM, respectively. The calculated V-max was 6802 pmol/min.mg of protein. A polyclonal antibody, raised in rabbits to the purified protein, cross-reacted with the protein in crude pig liver mitochondrial fractions. In liver mitochondria prepared from thyroxine-treated rats, the level of the protein was elevated compared with euthyroid controls indicating that expression of monolysocardiolipin acyltransferase is regulated by thyroid hormone. The study represents the first purification and characterization of a monolysocardiolipin acyltransferase activity from any organism.	Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Ctr Aging, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Ctr Aging, Dept Internal Med Biochem & Med Genet, Winnipeg, MB R3E 0T6, Canada	University of Manitoba; University of Manitoba	Hatch, GM (corresponding author), Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Ctr Aging, Dept Pharmacol & Therapeut, A307 Chown Bldg,753 McDermot Ave, Winnipeg, MB R3E 0T6, Canada.	hatchgm@ms.umanitoba.ca						ADDANKI S, 1968, J BIOL CHEM, V243, P2337; BELEZNAI Z, 1989, BIOCHEM BIOPH RES CO, V159, P132, DOI 10.1016/0006-291X(89)92414-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; EBLE KS, 1990, J BIOL CHEM, V265, P19434; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Esposti MD, 2002, CELL DEATH DIFFER, V9, P234, DOI 10.1038/sj.cdd.4400997; FIOL CJ, 1984, J BIOL CHEM, V259, P3084; HATCH GM, 1994, BIOCHEM J, V297, P201, DOI 10.1042/bj2970201; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; HUTSON SM, 1990, P NATL ACAD SCI USA, V87, P1028, DOI 10.1073/pnas.87.3.1028; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Ma BJ, 1999, J LIPID RES, V40, P1837; MULLER M, 1985, J BIOL CHEM, V260, P3839; Mutter T, 2000, BIOCHEM J, V346, P403, DOI 10.1042/0264-6021:3460403; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Pangborn MC, 1942, J BIOL CHEM, V143, P247; POORTHUIS BJHM, 1976, J LIPID RES, V17, P433; RAJASEKHARAN R, 1993, BIOCHEMISTRY-US, V32, P12386, DOI 10.1021/bi00097a016; RUSTOW B, 1989, BIOCHIM BIOPHYS ACTA, V1002, P261, DOI 10.1016/0005-2760(89)90296-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; TARDI PG, 1992, LIPIDS, V27, P65, DOI 10.1007/BF02537062; Taylor WA, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-9; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; YAMAOKA S, 1990, J NUTR, V120, P415, DOI 10.1093/jn/120.5.415; YAMAOKAKOSEKI S, 1991, J NUTR, V121, P956, DOI 10.1093/jn/121.7.956	39	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12716	12721		10.1074/jbc.M210329200	http://dx.doi.org/10.1074/jbc.M210329200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569106	hybrid			2022-12-25	WOS:000182189500018
J	Arguello, M; Sgarbanti, M; Hernandez, E; Mamane, Y; Sharma, S; Servant, M; Lin, RT; Hiscott, J				Arguello, M; Sgarbanti, M; Hernandez, E; Mamane, Y; Sharma, S; Servant, M; Lin, RT; Hiscott, J			Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines	ONCOGENE			English	Article						primary effusion lymphoma (PEL); IRF-4; PU.1; Oct-2; HHV-8	CLASSICAL HODGKINS-DISEASE; CAVITY-BASED LYMPHOMAS; REED-STERNBERG CELLS; CHAIN GENE ENHANCER; KAPOSIS-SARCOMA; FACTOR PU.1; NUCLEAR FACTOR; DNA-SEQUENCES; EXPRESSION; OCT-2	Primary effusion lymphoma (PEL) is a lymphoproliferative disease of B-cell origin that is associated with HHV-8 infection. PEL cells harbor a non-B, non-T phenotype and lack significant surface immunoglobulin (Ig) expression, a characteristic that has not been fully explained. In the present study, we demonstrate that PEL cells constitutively express interferon regulatory factor (IRF)-4, a transcription factor that regulates the activity of the immunoglobulin light-chain enhancer elements 13 and KEY through binding to a composite Ets-IRF site. IRF-4 activity requires its physical interaction with PU.1, an Ets family member involved in the activation of genes essential for B-cell development. However, in PEL-derived B-cell lines, PU.1 expression was completely abrogated; expression of the B cell specific transcription factor Oct-2, which is known to regulate PU.1 expression, was also abolished. Moreover, the B-cell-specific coactivator of octamer factors, BOB-1/OcaB, was expressed at very decreased levels in PEL cells. Ectopic expression of Oct-2 was able to fully restore PU.1 promoter activity in the PEL cell line BCBL-1, while PU.1 expression also reconstituted the activity of the lambdaB Ets-IRF site. In addition, protein levels of BSAP/Pax-5 and IRF-8/ICSBP were undetectable in PEL cells. The pattern of transcription factor ablation observed in PEL was found to be comparable to that observed in classical Hodgkin's disease-derived cell lines, which also lack B-cell-specific surface markers. These observations indicate that disruption of the B-cell-specific transcriptional program is likely to contribute to the incomplete B-cell phenotype characteristic of PEL cells.	Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		SGARBANTI, MARCO/C-2962-2016; Lin, Rongtuan/A-1442-2008	SGARBANTI, MARCO/0000-0002-0433-5110; Lin, Rongtuan/0000-0002-2238-3503				Brass AL, 1999, EMBO J, V18, P977, DOI 10.1093/emboj/18.4.977; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chan WC, 2001, HEMATOL ONCOL, V19, P1; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dolcetti R, 2001, EUR J CANCER, V37, P1276, DOI 10.1016/S0959-8049(01)00105-8; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; Gaidano G, 1997, BLOOD, V89, P3755; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; Hertel CB, 2002, ONCOGENE, V21, P4908, DOI 10.1038/sj.onc.1205629; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; LIEBERMAN SA, 1993, J IMMUNOL, V151, P2588; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Mamane Y, 2002, ONCOGENE, V21, P6751, DOI 10.1038/sj.onc.1205843; Marecki S, 2002, J INTERF CYTOK RES, V22, P121, DOI 10.1089/107999002753452737; Matolcsy A, 1998, AM J PATHOL, V153, P1609, DOI 10.1016/S0002-9440(10)65749-5; Muller S, 1996, ONCOGENE, V13, P1955; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pernis AB, 2002, J INTERF CYTOK RES, V22, P111, DOI 10.1089/107999002753452728; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Re D, 2001, CANCER RES, V61, P2080; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Sharif MN, 2001, J IMMUNOL, V167, P4421, DOI 10.4049/jimmunol.167.8.4421; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SINGH H, 1994, IMMUNOL RES, V13, P280, DOI 10.1007/BF02935619; Stein H, 2001, BLOOD, V97, P496, DOI 10.1182/blood.V97.2.496; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Torlakovic E, 2001, AM J PATHOL, V159, P1807, DOI 10.1016/S0002-9440(10)63027-1	51	44	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					964	973		10.1038/sj.onc.1206270	http://dx.doi.org/10.1038/sj.onc.1206270			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592383				2022-12-25	WOS:000180926100002
J	Roccato, E; Pagliardini, S; Cleris, L; Canevari, S; Formelli, F; Pierotti, MA; Greco, A				Roccato, E; Pagliardini, S; Cleris, L; Canevari, S; Formelli, F; Pierotti, MA; Greco, A			Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation	ONCOGENE			English	Article						TRK-T3; coiled-coil domain; TFG; NTRK1; oncogenic activation	NERVE GROWTH-FACTOR; TYROSINE KINASE; OLIGOMERIZATION DOMAIN; PROMOTER REGION; PC MOTIF; PROTEIN; DIMERIZATION; RECEPTOR; TERMINUS; MEMBRANE	The TRK-T3 oncoprotein, isolated from a human papillary thyroid tumor, arises from the fusion between the N-terminal domain of the TFG gene and the tyrosine kinase domain of the NTRK1 receptor. The 68 kDa TRKT3 oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform NIH3T3 cells. The TFG portion of TRK-T3 contains a coiled-coil domain, which mediates protein oligomerization essential for the oncogene constitutive activation, and several consensus sites for protein interaction. In this study, we investigate the role of TFG sequences outside the coiled-coil domain on TRK-T3 activation, We constructed four mutants carrying different deletions of TFG sequences and expressed them in mammalian cells. By performing biochemical and biological assays we demonstrated that all the deleted regions are required for TRK-T3 activation, as they are involved in different mechanisms such as protein processing, formation of stable and/or functional complexes, and possible interaction with other proteins. By constructing site-specific mutants, we demonstrated a crucial role for a PB1 domain and a considerable contribution of an SH2-binding motif in TRK-T3 oncogenic activation. This work establishes an important role for TFG sequences outside the coiled-coil domain in the activation of the thyroid TRK-T3 oncogene.	Ist Nazl Tumori, Operat Unit 3, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Operat Unit 13, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Operat Unit 11, Dept Expt Oncol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Operat Unit 3, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017; Cleris, Loredana/T-3144-2018	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Cleris, Loredana/0000-0001-8778-7931				BORRELLO MG, 1994, ONCOGENE, V9, P1661; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Canu N, 1997, J NEUROCHEM, V68, P1390; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Mathews JM, 2000, J VIROL, V74, P5911, DOI 10.1128/JVI.74.13.5911-5920.2000; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Mencinger M, 1999, BIOCHEM BIOPH RES CO, V257, P67, DOI 10.1006/bbrc.1999.0417; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Miranda C, 2001, J CELL PHYSIOL, V186, P35; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, CURR OPIN GENE DEV, V13, P6711; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Tong Q, 1997, J BIOL CHEM, V272, P9043	28	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					807	818		10.1038/sj.onc.1206189	http://dx.doi.org/10.1038/sj.onc.1206189			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584559				2022-12-25	WOS:000180864300002
J	Karnauskas, R; Niu, Q; Talapatra, S; Plas, DR; Greene, ME; Crispino, JD; Rudin, CM				Karnauskas, R; Niu, Q; Talapatra, S; Plas, DR; Greene, ME; Crispino, JD; Rudin, CM			Bcl-X-L and Akt cooperate to promote leukemogenesis in vivo	ONCOGENE			English	Article						leukemia; Akt; Bcl-X-L; p53; interleukin-3	CHROMOSOMAL TRANSLOCATIONS; SURVIVAL; BCL-X(L); EXPRESSION; LYMPHOMA; GROWTH; CANCER; CELLS; GENE; HAPLOINSUFFICIENCY	To analyse individual factors that may contribute to leukemic transformation in vivo, we have developed a murine model of leukemogenesis based on the early hematopoietic precursor cell FL5.12. FL5.12 cells are interleukin-3 (IL-3) dependent for growth, proliferation, and survival. Relative resistance to cell death following IL-3 withdrawal can be conferred by either overexpression of the Bcl-x(L) apoptotic inhibitor, or constitutive activation of the serine/threonine kinase Akt. The ability of Bcl-x(L) or a constitutively active myristylated Akt to promote leukemic transformation of FL5.12 cells was compared in athymic nu(+)/nu(+) mice. Bcl-x(L) alone could not promote leukemic transformation, but mice injected with FL5.12 cells overexpressing Bcl-x(L), and a dominant-negative p53 construct developed leukocytosis and blastic infiltration of lymph nodes, spleen, and liver with features of a high-grade lymphoid malignancy. In contrast to the cells injected into these animals, cell lines derived from the mice were able to proliferate in the absence of IL-3, and were found to have constitutively activated Akt. This constitutive activation was associated with a variety of alterations of the signaling pathway regulating Akt activity, including alterations of PTEN mRNA and protein expression. In addition, some of these leukemic clones demonstrated concurrent constitutive upregulation of ERK activity. A constitutively active Akt construct introduced into FL5.12 cells promoted similar clonal expansion in vivo, with emergence of clonal IL-3-independent proliferation. Bcl-x(L) and Akt appeared to function cooperatively in this model, enhancing rapid clonal outgrowth in vivo relative to Akt alone. These results implicate activated Akt and growth-factor independence in leukemogenic transformation, and demonstrate the potential for in vivo analysis of genetic determinants of leukemogenesis.	Univ Chicago, Med Ctr, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Chicago	Rudin, CM (corresponding author), Univ Chicago, Med Ctr, Hematol Oncol Sect, Dept Med, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	crudin@medicine.bsd.uchicago.edu	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Crispino, John/0000-0002-8182-8306	NCI NIH HHS [CA81138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K23CA081138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BELLACOSA A, 1993, ONCOGENE, V8, P745; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DellaRagione F, 1995, HAEMATOLOGICA, V80, P557; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DREXLER HG, 1995, LEUKEMIA, V9, P480; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; ISSA JP, 1997, LEUKEMIA S1, V11, P7; Klein G, 2000, BIOESSAYS, V22, P414, DOI 10.1002/(SICI)1521-1878(200005)22:5<414::AID-BIES3>3.0.CO;2-5; Komuro Hiroaki, 1999, Neoplasia (New York), V1, P253, DOI 10.1038/sj.neo.7900033; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Rowley JD, 2000, SEMIN HEMATOL, V37, P315; RUDIN CM, 2001, METABOLIC MOL BASES, P631; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Xerri L, 1998, LEUKEMIA LYMPHOMA, V28, P451, DOI 10.3109/10428199809058352	37	30	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					688	698		10.1038/sj.onc.1206159	http://dx.doi.org/10.1038/sj.onc.1206159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569361				2022-12-25	WOS:000180642100006
J	Pompl, PN; Ho, L; Bianchi, M; McManus, T; Qin, W; Pasinetti, GM				Pompl, PN; Ho, L; Bianchi, M; McManus, T; Qin, W; Pasinetti, GM			A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						inflammation; COX-2; ALS; nimesulide	SPINAL-CORD; MICE; ALS; EXCITOTOXICITY; DISEASE; DEATH	Recent studies indicate that the proinflammatory enzyme cyclooxygenase (COX)-2, an enzyme involved in inflammatory cascades but also normal neuronal activities, is elevated in the brain and spinal cord of amyotrophic lateral sclerosis (ALS) patients and ALS mouse model systems. On the basis of this evidence, we explored the impact of COX-2 inhibition on the onset and progression of ALS-like disease in the G93A human superoxide dismutase (SOD)1 mouse model of ALS. We found that prophylactic administration of nimesulide, a preferential COX-2 inhibitor, in the feed resulted in a significant delay in the onset of ALS type motor impairment. This delay of ALS symptomatology temporally overlapped with the inhibition of prostaglandin E-2 elevation in the spinal cord of SOD1-G93A transgenic mice relative to untreated SOD1-G93A controls. This study strongly supports a role for COX-2 in the pathophysiology of ALS and provides the first experimental evidence that prophylactic treatment with COX-2 inhibitors can significantly delay the onset of motor dysfunction in the SOD1-G93A transgenic mouse model of ALS.	CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196				Aisen PS, 2002, NEUROLOGY, V58, P1050, DOI 10.1212/WNL.58.7.1050; Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.3.CO;2-O; Barneoud P, 1999, EXP NEUROL, V155, P243, DOI 10.1006/exnr.1998.6984; Bennett A, 2000, Expert Opin Pharmacother, V1, P277, DOI 10.1517/14656566.1.2.277; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Drachman DB, 2000, ANN NEUROL, V48, P792, DOI 10.1002/1531-8249(200011)48:5<792::AID-ANA14>3.3.CO;2-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; KIMURA H, 1985, BRAIN RES, V330, P235, DOI 10.1016/0006-8993(85)90682-1; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Miller RG, 1996, NEUROLOGY, V47, pS86, DOI 10.1212/WNL.47.4_Suppl_2.86S; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Olsen MK, 2001, ANN NEUROL, V50, P730, DOI 10.1002/ana.1252; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; Vane J. R., 1998, AM J MED, V104, p2S, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yasojima K, 2001, NEUROLOGY, V57, P952, DOI 10.1212/WNL.57.6.952	19	113	119	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					725	+		10.1096/fj.02-0876fje	http://dx.doi.org/10.1096/fj.02-0876fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586733				2022-12-25	WOS:000181456900003
J	Neal, JW; Clipstone, NA				Neal, JW; Clipstone, NA			A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; GLYCOGEN-SYNTHASE KINASE-3; T-CELL-ACTIVATION; NUCLEAR FACTOR; GROWTH-FACTOR; NF-ATC; CYCLOSPORINE-A; ADIPOCYTE DIFFERENTIATION; MOLECULAR REGULATION; GENE-EXPRESSION	The calcineurin/nuclear factor of activated T cells (NFAT) signaling pathway is best known for its role in T lymphocyte activation. However, it has become increasingly apparent that this signaling pathway is also involved in the regulation of cell growth and development in a wide variety of different tissues and cell types. Here we have investigated the effects of sustained NFATc1 signaling on the growth and differentiation of the murine 3T3-L1 preadipocyte cell line. Remarkably, we find that expression of a constitutively active NFATc1 mutant (caNFATc1) in these immortalized cells inhibits their differentiation into mature adipocytes and causes them to adopt a transformed cell phenotype, including loss of contact-mediated growth inhibition, reduced serum growth requirements, protection from growth factor withdrawal-induced apoptosis, and formation of colonies in semisolid media. Furthermore, we find that caNFATc1-expressing cells acquire growth factor autonomy and are able to proliferate even in the complete absence of serum. We provide evidence that this growth factor independence is caused by the NFATc1-dependent production of a soluble heat-labile autocrine factor that is capable of promoting the growth and survival of wild type 3T3-L1 cells as well as potently inhibiting their differentiation into mature adipocytes. Finally, we demonstrate that cells expressing caNFATc1 form tumors in nude mice. Taken together, these results indicate that deregulated NFATc1 activity is able to induce the immortalized 3T3-L1 preadipocyte cell line to acquire the well established hallmarks of cellular transformation and thereby provide direct evidence for the oncogenic potential of the NFATc1 transcription factor.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Clipstone, NA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	nclipstone@northwestern.edu			NIGMS NIH HHS [R29 GM55292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Calvo S, 1999, MOL CELL BIOL, V19, P515; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; JANIK P, 1975, CANCER RES, V35, P3698; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Neal JW, 2002, J BIOL CHEM, V277, P49776, DOI 10.1074/jbc.M207913200; Polakis P, 2000, GENE DEV, V14, P1837; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Schuh K, 1998, J EXP MED, V188, P1369, DOI 10.1084/jem.188.7.1369; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRICOLI JV, 1986, CANCER RES, V46, P6169; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VASSAUX G, 1994, J CELL PHYSIOL, V161, P249, DOI 10.1002/jcp.1041610209; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	57	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17246	17254		10.1074/jbc.M300528200	http://dx.doi.org/10.1074/jbc.M300528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598522	hybrid			2022-12-25	WOS:000182818600107
J	Watada, H; Scheel, DW; Leung, J; German, MS				Watada, H; Scheel, DW; Leung, J; German, MS			Distinct gene expression programs function in progenitor and mature islet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTOR; PANCREATIC BETA-CELLS; NUCLEAR FACTOR 3-BETA; MICE LACKING; ALPHA-CELLS; PDX-1 GENE; DIFFERENTIATION; PROTEIN; NKX2.2; NEUROGENIN3	Homeodomain transcription factor Nkx2.2 is required for the final differentiation of the beta-cells in the pancreas and for the production of insulin. Nkx2.2 is expressed in islet cell precursors during pancreatic development and persists in a subset of mature islet cells including all beta-cells. To understand the mechanisms regulating the expression of Nkx2.2 in these different cell populations, we outlined the structure of the mouse nkx2.2 gene and identified regions that direct cell type-specific expression. The nkx2.2 gene has two noncoding alternative first exons (exons 1a and 1b). In transgenic mice, sequences upstream from exon 1a directed expression predominantly in mature islet cells. Within this exon 1a promoter, cooperative interactions between HNF3 and basic helix-loop-helix factors neurogenin-3 or NeuroD1 binding to adjacent sites played key roles in its islet cell-specific expression. In contrast, sequences upstream from exon 1b restricted expression specifically to islet cell precursors. These studies reveal distinct mechanisms for directing the expression of a key differentiation factor in precursors versus mature islet cells.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave,HSW Rm 1090, San Francisco, CA 94143 USA.			Watada, Hirotaka/0000-0001-5961-1816	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021344, R56DK021344, R37DK021344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21344, DK553401, R01 DK021344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Furuta H, 1998, DIABETES, V47, P1356, DOI 10.2337/diabetes.47.8.1356; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Li H, 1999, NAT GENET, V23, P67; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SMITH RL, 1995, J VIROL, V69, P4593, DOI 10.1128/JVI.69.8.4593-4599.1995; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wilson ME, 2002, MECH DEVELOP, V115, P171, DOI 10.1016/S0925-4773(02)00118-1; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	42	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17130	17140		10.1074/jbc.M213196200	http://dx.doi.org/10.1074/jbc.M213196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604598	hybrid			2022-12-25	WOS:000182818600092
J	Bhullar, B; Zhang, Y; Junco, A; Oko, R; van der Hoorn, FA				Bhullar, B; Zhang, Y; Junco, A; Oko, R; van der Hoorn, FA			Association of kinesin light chain with outer dense fibers in a microtubule-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN SUPERFAMILY PROTEINS; DEVELOPMENTAL EXPRESSION; CYTOPLASMIC DYNEIN; MOLECULAR-CLONING; CANDIDATE MOTORS; SPERM PROTEIN; SEA-URCHIN; RAT; TESTIS; LOCALIZES	Conventional kinesin I motor molecules are heterotetramers consisting of two kinesin light chains (KLCs) and two kinesin heavy chains. The interaction between the heavy and light chains is mediated by the KLC heptad repeat (HR), a leucine zipper-like motif. Kinesins bind to microtubules and are involved in various cellular functions, including transport and cell division. We recently isolated a novel KLC gene, klc3. klc3 is the only known KLC expressed in post-meiotic male germ cells. A monoclonal anti-KLC3 antibody was developed that, in immunoelectron microscopy, detects KLC3 protein associated with outer dense fibers (ODFs), unique structural components of sperm tails. No significant binding of KLC3 with microtubules was observed with this monoclonal antibody. In vitro experiments showed that KLC3-ODF binding occurred in the absence of kinesin heavy chains or microtubules and required the KLC3 HR. ODF1, a major ODF protein, was identified as the KLC3 binding partner. The ODF1 leucine zipper and the KLC3 HR mediated the interaction. These results identify and characterize a novel interaction between a KLC and a non-microtubule macromolecular structure and suggest that KLC3 could play a microtubule-independent role during formation of sperm tails.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Queens Univ, Dept Cell Biol & Anat, Kingston, ON K7L 3N6, Canada	University of Calgary; Queens University - Canada	van der Hoorn, FA (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	fvdhoorn@ucalgary.ca			Canadian Institutes of Health Research [11361, 13680] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BEUSHAUSEN S, 1993, DNA CELL BIOL, V12, P901, DOI 10.1089/dna.1993.12.901; Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1; Block SM, 1998, J CELL BIOL, V140, P1281, DOI 10.1083/jcb.140.6.1281; BRYAN JHD, 1977, CELL TISSUE RES, V180, P187, DOI 10.1007/BF00231951; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Diez S, 2002, CURR BIOL, V12, pR203, DOI 10.1016/S0960-9822(02)00750-9; FAN J, 1994, J MOL BIOL, V240, P507, DOI 10.1006/jmbi.1994.1465; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Gindhart JG, 1996, TRENDS BIOCHEM SCI, V21, P52, DOI 10.1016/0968-0004(96)80865-6; Goldstein LSB, 2001, TRENDS CELL BIOL, V11, P477, DOI 10.1016/S0962-8924(01)02143-2; Gyoeva FK, 2000, J CELL SCI, V113, P2047; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; HALL ES, 1992, BIOL REPROD, V46, P817, DOI 10.1095/biolreprod46.5.817; Henson JH, 1997, CELL MOTIL CYTOSKEL, V38, P29, DOI 10.1002/(SICI)1097-0169(1997)38:1<29::AID-CM4>3.0.CO;2-C; HERMO L, 1991, ANAT REC, V229, P31, DOI 10.1002/ar.1092290106; HIGGY NA, 1994, BIOL REPROD, V50, P1357, DOI 10.1095/biolreprod50.6.1357; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Johnson KJ, 1996, EUR J CELL BIOL, V69, P276; Junco A, 2001, BIOL REPROD, V64, P1320, DOI 10.1095/biolreprod64.5.1320; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; Kierszenbaum AL, 2001, MOL REPROD DEV, V59, P347, DOI 10.1002/mrd.1040; Kierszenbaum AL, 2002, MOL REPROD DEV, V61, P1, DOI 10.1002/mrd.1124; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Miller MG, 1999, BIOL REPROD, V60, P1047, DOI 10.1095/biolreprod60.4.1047; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORALES CR, 1994, MOL REPROD DEV, V37, P229, DOI 10.1002/mrd.1080370215; Nakajima T, 1997, ZOOL SCI, V14, P917, DOI 10.2108/zsj.14.917; Oko R, 1998, ANDROLOGIA, V30, P193; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; Schalles U, 1998, DEV BIOL, V199, P250, DOI 10.1006/dbio.1998.8931; Shao XP, 1999, DEV BIOL, V211, P109, DOI 10.1006/dbio.1999.9297; Shao XP, 2001, MOL REPROD DEV, V59, P410, DOI 10.1002/mrd.1047; Shao XP, 1996, BIOL REPROD, V55, P1343, DOI 10.1095/biolreprod55.6.1343; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Sperry AO, 1996, MOL BIOL CELL, V7, P289, DOI 10.1091/mbc.7.2.289; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Xue JP, 2002, MOL CELL BIOL, V22, P1993, DOI 10.1128/MCB.22.7.1993-1997.2002; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Yang ZH, 2001, MOL CELL BIOL, V21, P5306, DOI 10.1128/MCB.21.16.5306-5311.2001; YU H, 1992, J BIOL CHEM, V267, P20457; Zarsky HA, 2003, BIOL REPROD, V68, P543, DOI [10.1095/BIOLREPROD.102.009076, 10.1095/biolreprod.102.009076]; Zou Y, 2002, BIOL REPROD, V66, P843, DOI 10.1095/biolreprod66.3.843	60	27	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16159	16168		10.1074/jbc.M213126200	http://dx.doi.org/10.1074/jbc.M213126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594206	Green Accepted, hybrid			2022-12-25	WOS:000182680000089
J	Gil-Parrado, S; Popp, O; Knoch, TA; Zahler, S; Bestvater, F; Felgentrager, M; Holloschi, A; Fernandez-Montalvan, A; Auerswald, EA; Fritz, H; Fuentes-Prior, P; Machleidt, W; Spiess, E				Gil-Parrado, S; Popp, O; Knoch, TA; Zahler, S; Bestvater, F; Felgentrager, M; Holloschi, A; Fernandez-Montalvan, A; Auerswald, EA; Fritz, H; Fuentes-Prior, P; Machleidt, W; Spiess, E			Subcellular localization and in vivo subunit interactions of ubiquitous mu-calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOFIBRILLAR PROTEIN-TURNOVER; CALCIUM-DEPENDENT PROTEASE; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; NEUTRAL PROTEASE; THIOL PROTEASE; RAT CALPAIN; IN-VITRO; C-JUN; ACTIVATION	Ubiquitously expressed calpains are Ca2+-dependent, intracellular cysteine proteases comprising a large catalytic subunit (domains DI-DIV) and a noncovalently bound small regulatory subunit (domains DV and DVI). It is unclear whether Ca2+-induced calpain activation is followed by subunit dissociation or not. Here, we have applied advanced fluorescence microscopy techniques to study calpain subunit interactions in living cells using recombinant calpain subunits or domains fused to enhanced cyan and enhanced yellow fluorescent reporter proteins. All of the overexpressed variants of the catalytic subunit (DI-IV, DI-III, and DI-IIb) were active and Ca2+-dependent. The intact large subunit, but not its truncated variants, associates with the small subunit under resting and ionomycin-activated conditions. All of the variants were localized in cytoplasm and nuclei, except DI-IIb, which accumulates in the nucleus and in nucleoli as shown by microscopy and cell fractionation. Localization studies with mutated and chimeric variants indicate that nuclear targeting of the DI-IIb variant is conferred by the two N-terminal helices of DI. Only those variants that contain DIII migrated to membranes upon the addition of ionomycin, suggesting that DIII is essential for membrane targeting. We propose that intracellular localization and in particular membrane targeting of activated calpain, but not dissociation of its intact subunits, contribute to regulate its proteolytic activity in vivo.	Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Munich, Inst Physiol, D-80336 Munich, Germany; Fachhsch Mannheim, Inst Mol Biol & Zellkulturtechn, D-68163 Mannheim, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Max Planck Society	Gil-Parrado, S (corresponding author), Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	shirgilpa@web.de		Fuentes-Prior, Pablo/0000-0002-6618-3204; Zahler, Stefan/0000-0002-5140-7287; Fernandez-Montalvan, Amaury/0000-0001-9156-0000				Averna M, 1999, FEBS LETT, V450, P13, DOI 10.1016/S0014-5793(99)00461-5; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bestvater F, 2002, BIOTECHNIQUES, V32, P844; Blanchard H, 1996, PROTEIN SCI, V5, P535; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Chen MZ, 1999, J VIROL, V73, P3236, DOI 10.1128/JVI.73.4.3236-3245.1999; Ciruela A, 2000, BIOCHEM J, V346, P587, DOI 10.1042/0264-6021:3460587; Cong M, 1998, J BIOL CHEM, V273, P660, DOI 10.1074/jbc.273.1.660; DAYTON WR, 1981, BIOCHIM BIOPHYS ACTA, V659, P48, DOI 10.1016/0005-2744(81)90270-9; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; Dutt P, 1998, FEBS LETT, V436, P367, DOI 10.1016/S0014-5793(98)01167-3; Elce JS, 1997, BIOCHEM J, V326, P31, DOI 10.1042/bj3260031; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; MURAKAMI T, 1981, J BIOCHEM-TOKYO, V90, P1809, DOI 10.1093/oxfordjournals.jbchem.a133659; MURAMATSU M, 1974, EXP CELL RES, V88, P345, DOI 10.1016/0014-4827(74)90250-X; Nakagawa K, 2001, J BIOCHEM-TOKYO, V130, P605, DOI 10.1093/oxfordjournals.jbchem.a003025; Norris FA, 1997, J BIOL CHEM, V272, P10987; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Piechaczyk M, 2000, METH MOL B, V144, P297; REVILLE WJ, 1976, J CELL BIOL, V70, P1, DOI 10.1083/jcb.70.1.1; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; YAMATO S, 1983, BIOCHEM BIOPH RES CO, V115, P715, DOI 10.1016/S0006-291X(83)80203-4; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; Zhang WL, 1996, BIOCHEM BIOPH RES CO, V227, P890, DOI 10.1006/bbrc.1996.1601; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	63	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16336	16346		10.1074/jbc.M208657200	http://dx.doi.org/10.1074/jbc.M208657200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591934	Green Published, hybrid			2022-12-25	WOS:000182680000112
J	Gutman, N; Steiner-Mordoch, S; Schuldiner, S				Gutman, N; Steiner-Mordoch, S; Schuldiner, S			An amino acid cluster around the essential Glu-14 is part of the substrate- and proton-binding domain of EmrE, a multidrug transporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; SCANNING MUTAGENESIS; MEMBRANE-PROTEINS; H+; EFFLUX; SITE; MODEL; REVEALS; GENE	EmrE is a small multidrug transporter (110 amino acids long) from Escherichia coli that extrudes various drugs in exchange with protons, thereby rendering bacteria resistant to these compounds. Glu-14 is the only charged membrane-embedded residue in EmrE and is evolutionarily highly conserved. This residue has an unusually high pK and is an essential part of the binding domain, shared by substrates and protons. The occupancy of the binding domain is mutually exclusive, and, as such, this provides the molecular basis for the coupling between substrate and proton fluxes. Systematic cysteine-scanning mutagenesis of the residues in the transmembrane segment (TM1), where Glu-14 is located, reveals an amino acid cluster on the same face of TM1 as Glu-14 that is part of the substrate- and proton-binding domain. Substitutions at most of these positions yielded either inactive mutants or mutants with modified affinity to substrates. Substitutions at the Ala-10 position, one helix turn away from Glu-14, yielded mutants with modified affinity to protons and thereby impaired in the coupling of substrate and proton fluxes. Taken as a whole, the results strongly support the concept of a common binding site for substrate and protons and stress the importance of one face of TM1 in substrate recognition, binding, and H+-coupled transport.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NINDS NIH HHS [NS 16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chung Y J, 2001, Curr Opin Drug Discov Devel, V4, P237; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Godsey MH, 2002, J BIOL CHEM, V277, P40169, DOI 10.1074/jbc.R200018200; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Neyfakh AA, 2002, MOL MICROBIOL, V44, P1123, DOI 10.1046/j.1365-2958.2002.02965.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; NINIO S, 2003, IN PRESS J BIOL CHEM, V278; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Torres J, 2000, EUR J BIOCHEM, V267, P3422, DOI 10.1046/j.1432-1327.2000.01324.x; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	30	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16082	16087		10.1074/jbc.M213120200	http://dx.doi.org/10.1074/jbc.M213120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590142	hybrid			2022-12-25	WOS:000182680000080
J	Koike, T; Yamagishi, H; Hatanaka, Y; Fukushima, A; Chang, JW; Xia, Y; Fields, M; Chandler, P; Iwashima, M				Koike, T; Yamagishi, H; Hatanaka, Y; Fukushima, A; Chang, JW; Xia, Y; Fields, M; Chandler, P; Iwashima, M			A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; MIGRATION INHIBITORY FACTOR; ANTIGEN RECEPTOR; LYMPHOCYTE-PROLIFERATION; SH2 DOMAINS; IL-2 GENE; REL; THETA; TCR	Engagement of the T cell antigen receptor (TCR) rapidly induces multiple signal transduction pathways, including ERR activation. Here, we report a critical role for ERK at a late stage of T cell activation. Inhibition of the ERK pathway 2-6 h after the start of TCR stimulation significantly impaired interleukin-2 (IL-2) production, whereas the same treatment during the first 2 h had no effect. ERK inhibition significantly impaired nuclear translocation of c-Rel with a minimum reduction of NF-AT activity. Requirement for sustained ERK activation was also confirmed using primary T cells. To induce sustained activation of ERK, T cells required continuous engagement of TCR. Stimulation of T cells with soluble anti-TCR antibody resulted in activation of ERK lasting for 60 min, but failed to induce IL-2 production. In contrast, plate-bound anti-TCR antibody activated ERK over 4 h and induced IL-2. Furthermore, T cells treated with soluble anti-TCR antibody produced IL-2 when phorbol 12-myristate 13-acetate, which activates ERK, was present in the culture medium 2-6 h after the start of stimulation. Together, the data demonstrate the presence of a novel activation process following TCR stimulation that requires ERK-dependent regulation of c-Rel, a member of the NF-kappaB family.	Med Coll Georgia, Program Mol Immunol, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Iwashima, M (corresponding author), Med Coll Georgia, Program Mol Immunol, Inst Mol Med & Genet, CA2004,1120 15th St, Augusta, GA 30912 USA.				NIAID NIH HHS [5R01 AI 47266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1994, EUR J IMMUNOL, V24, P2462, DOI 10.1002/eji.1830241031; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lanzavecchia A, 1997, J EXP MED, V185, P1717, DOI 10.1084/jem.185.10.1717; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MEUER SC, 1986, J IMMUNOL, V136, P4106; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; MISHELL B, 1980, SELECTED METHODS CEL, P227; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Roose J, 2000, NAT IMMUNOL, V1, P275, DOI 10.1038/79713; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Venkataraman L, 1996, J IMMUNOL, V157, P1149; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Zelenika D, 1998, J IMMUNOL, V161, P1868; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200	40	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15685	15692		10.1074/jbc.M210829200	http://dx.doi.org/10.1074/jbc.M210829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595531	hybrid			2022-12-25	WOS:000182680000030
J	Ning, Q; Lakatoo, S; Liu, MF; Yang, WM; Wang, ZM; Phillips, MJ; Levy, GA				Ning, Q; Lakatoo, S; Liu, MF; Yang, WM; Wang, ZM; Phillips, MJ; Levy, GA			Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; CORE PROTEIN; DNA-BINDING; C VIRUS; TRANSCRIPTION FACTORS; STRUCTURAL PROTEIN; GENE-EXPRESSION; RECEPTOR HNF-4; PROMOTER; PHOSPHORYLATION	Fibrinogen-like protein 2/fibroleukin (Fgl2) plays a pivotal role in the pathogenesis of both experimental and human fulminant hepatic failure. We have reported recently that the nucleocapsid (N) protein from strains of murine hepatitis virus (MHV-3, NLRV-A59), which cause massive hepatocellular necrosis but not from strains (MHV-JHM, MHV-2) which do not produce serious liver disease, induces transcription of fgl2. The purpose of the present study was to characterize both viral and host factor(s) necessary for viral induced transcription of fgl2. Mutation of residues Gly-12, Pro-38, Asn-40, Gln-41, and Asn-42 within domain 1 of the N protein of MHV-A59 to their corresponding residues found in MHV-2 abrogated. fgl2 transcription, whereas mutation of other N protein domains, including a protein expressed from an internal reading frame (1 protein), did not affect fgl2 gene transcription. We then examined the -372 to -306 sequence within the 1.3-kb fgl2 promoter region upstream from the transcription start site that was previously identified as necessary for N protein-induced gene transcription. We demonstrated that the -331/-325 HNF4 cis-element and its cognate transcription factor, HNF4alpha, are necessary for virus-induced fgl2 gene transcription. In uninfected macrophages and macrophages infected with MHV-2, an unidentified protein occupies the HNF4 cis-element. Following stimulation with AHW-A59, it was shown by electrophoretic mobility shift assay that HNF4alpha binds the HNF4 cis-element in the fgl2 promoter. We further report the unprecedented presence of HNF4alpha in peritoneal macrophages. Collectively, the results of this study define both viral and host factors necessary for induction of fgl2 prothrombinase gene transcription in MHV infection and may provide an explanation for the hepatotrophic nature of MHV-induced fulminant hepatic failure.	Univ Toronto, Toronto Gen Hosp, Multi Organ Transplant Program, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Dept Pathol & Med, Toronto, ON M5G 2C4, Canada; Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Immunol, Tongji Hosp,Dept Infect Dis, Wuhan 430030, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Huazhong University of Science & Technology	Levy, GA (corresponding author), Univ Toronto, Toronto Gen Hosp, Multi Organ Transplant Program, 621 Univ Ave,NU 10-116, Toronto, ON M5G 2C4, Canada.	glfg12@attglobal.net						Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DECIMO D, 1993, ARCH VIROL, V130, P279, DOI 10.1007/BF01309660; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; Farsetti A, 1998, ENDOCRINOLOGY, V139, P4581, DOI 10.1210/en.139.11.4581; FernandezRachubinski FA, 1996, J BIOL CHEM, V271, P29502, DOI 10.1074/jbc.271.46.29502; Fischer F, 1997, J VIROL, V71, P996, DOI 10.1128/JVI.71.2.996-1003.1997; Fukai K, 1997, VIROLOGY, V236, P279, DOI 10.1006/viro.1997.8750; HU CH, 1995, J BIOL CHEM, V270, P28342; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KUNITA S, 1993, VIROLOGY, V193, P520, DOI 10.1006/viro.1993.1158; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6; Large MK, 1999, J IMMUNOL, V162, P931; LAVI E, 1990, LAB INVEST, V62, P570; LEVY GA, 1984, SEMIN LIVER DIS, V4, P59, DOI 10.1055/s-2008-1040646; LEVY GA, 1983, HEPATOLOGY, V3, P964; Levy GA, 2000, AM J PATHOL, V156, P1217, DOI 10.1016/S0002-9440(10)64992-9; LI C, 1992, J EXP MED, V176, P689, DOI 10.1084/jem.176.3.689; MASTERS PS, 1990, ADV EXP MED BIOL, V276, P239; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; MIAO CH, 1992, J BIOL CHEM, V267, P7395; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; Naka H, 1996, BRIT J HAEMATOL, V92, P231, DOI 10.1046/j.1365-2141.1995.269804.x; NELSON GW, 1993, J GEN VIROL, V74, P1975, DOI 10.1099/0022-1317-74-9-1975; Ning Q, 1998, J IMMUNOL, V160, P3487; Ning Q, 1999, J BIOL CHEM, V274, P9930, DOI 10.1074/jbc.274.15.9930; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J; PENG D, 1995, J VIROL, V69, P3449, DOI 10.1128/JVI.69.6.3449-3457.1995; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; Rasul I, 1999, HEPATOLOGY, V30, p594A; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Rouet P, 1998, BIOCHEM J, V334, P577, DOI 10.1042/bj3340577; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Simpson KJ, 1997, J HEPATOL, V27, P1120, DOI 10.1016/S0168-8278(97)80160-2; SLADEK FM, 1993, RECEPTOR, V3, P223; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988; Tahara SM, 1998, ADV EXP MED BIOL, V440, P313; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Webster G, 2000, BEST PRACT RES CL GA, V14, P229, DOI 10.1053/bega.1999.0072; Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	56	38	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15541	15549		10.1074/jbc.M212806200	http://dx.doi.org/10.1074/jbc.M212806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594208	hybrid			2022-12-25	WOS:000182680000012
J	Fukuda, M				Fukuda, M			Slp4-a/granuphilin-a inhibits dense-core vesicle exocytosis through interaction with the GDP-bound form of Rab27A in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT OLIGOMERIZATION; SLP HOMOLOGY DOMAIN; TANDEM C2 DOMAINS; MYOSIN-VA; MELANOSOME TRANSPORT; SYNAPTOTAGMIN FAMILY; REGULATED SECRETION; GRISCELLI-SYNDROME; BINDING DOMAIN; ASHEN MICE	Slp4-a (synaptotagmin-like protein 4-a)/granuphilin-a is specifically localized on dense-core vesicles in PC12 cells and negatively controls dense-core vesicle exocytosis through specific interaction with Rab27A via the N-terminal Slp homology domain (SHD) (Fukuda, M., Kanno, E., Saegusa, C., Ogata, Y., and Kuroda, T. S. (2002) J. Biol. Chem. 277, 39673-39678). However, the mechanism of the inhibition by Slp4-a has never been elucidated at the molecular level and is still a matter of controversy. In this study, I discovered an unexpected biochemical property of Slp4-a, that Slp4-a, but not other Rab27 effectors reported thus far, is capable of interacting with both Rab27A(T23N), a dominant negative form that mimics the GDP-bound form, and Rab27A(Q78L), a dominant active form that mimics the GTP-bound form, whereas Slp4-a specifically recognizes the GTP-bound form of Rab3A and Rab8A and does not recognize their GDP-bound form. I show by deletion and mutation analyses that the TGDWFY sequence in SHD2 is essential for Rab27A(T23N) binding, whereas SHD1 is involved in Rab27A(Q78L) binding. I further show by immunoprecipitation and cotransfection assays that Aluncl.8-1, but not syntaxin IA, directly interacts with the C-terminal domain of Slp4-a in a Rab27A-independent manner. Expression of Slp4-a mutants that lack Rab27A(T23N) binding activity (i.e. specific binding to Rab27A(Q78L)) completely reverses the inhibitory effect of the wild-type Slp4-a on high KCl-dependent neuropeptide Y secretion in PC 12 cells. The results strongly indicate that interaction of Slp4-a with the GDP-bound form of Rab27A, not with syntaxin IA or Munc18-1, is the primary reason that Slp4-a expression inhibits dense core vesicle exocytosis in PC12 cells.	RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2002, J BIOL CHEM, V277, P30351, DOI 10.1074/jbc.M204056200; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	40	56	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15390	15396		10.1074/jbc.M213090200	http://dx.doi.org/10.1074/jbc.M213090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590134	hybrid			2022-12-25	WOS:000182516100104
J	Goto, E; Ishido, S; Sato, Y; Ohgimoto, S; Ohgimoto, K; Nagano-Fujii, M; Hotta, H				Goto, E; Ishido, S; Sato, Y; Ohgimoto, S; Ohgimoto, K; Nagano-Fujii, M; Hotta, H			C-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; MHC CLASS-I; T-CELLS; IMMUNOLOGICAL SYNAPSE; DOWN-REGULATION; IMMUNE EVASION; VIRAL PROTEIN; PHD DOMAIN; K5 PROTEIN; NK CELLS	Kaposi's sarcoma associated-herpes virus encodes two proteins, MIR (modulator of immune recognition) 1 and 2, which are involved in the evasion of host immunity. MIR1 and 2 have been shown to function as an E3 ubiquitin ligase for immune recognition-related molecules (e.g. major histocompatibility complex class 1, B7-2, and ICAM-1) through the BKS (bovine herpesvirus 4, Kaposi's sarcoma associated-herpes virus, and Swinepox virus) subclass of plant homeodomain (PHD) domain, termed the BKS-PHD domain. Here we show that the human genome also encodes a novel BKS-PHD domain-containing protein that functions as an E3 ubiquitin ligase and whose putative substrate is the B7-2 co-stimulatory molecule. This novel E3 ubiquitin ligase was designated as c-MIR (cellular MIR) based on its functional and structural similarity to MIR1 and 2. Forced expression of c-MIR induced specific down-regulation of B7-2 surface expression through ubiquitination, rapid endocytosis, and lysosomal degradation of the target molecule. This specific targeting was dependent upon the binding of c-MIR to B7-2. Replacing the BKS-PHD domain of MIR1 with the corresponding domain of cMIR did not alter MIR1 function. The discovery of cMIR, a novel E3 ubiquitin ligase, highlights the possibility that viral immune regulatory proteins originated in the host genome and presents unique functions of BKS-PHD domain-containing proteins in mammals.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Microbiol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Ishido, S (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Microbiol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.							Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Choi JK, 2001, CYTOKINE GROWTH F R, V12, P245, DOI 10.1016/S1359-6101(00)00029-0; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Coscoy L, 2000, P NATL ACAD SCI USA, V97, P8051, DOI 10.1073/pnas.140129797; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Coscoy L, 2001, J CLIN INVEST, V107, P1599, DOI 10.1172/JCI12432; Davis DM, 2002, TRENDS IMMUNOL, V23, P356, DOI 10.1016/S1471-4906(02)02243-3; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gao JX, 2002, J EXP MED, V195, P959, DOI 10.1084/jem.20011948; Haque M, 2001, J GEN VIROL, V82, P1175, DOI 10.1099/0022-1317-82-5-1175; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Ishido S, 2000, IMMUNITY, V13, P365, DOI 10.1016/S1074-7613(00)00036-4; Ishido S, 2000, J VIROL, V74, P5300, DOI 10.1128/JVI.74.11.5300-5309.2000; ITOH, 2002, J IMMUNOL, V168, P541; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Luhder F, 2000, P NATL ACAD SCI USA, V97, P12204, DOI 10.1073/pnas.200348397; Means RE, 2002, EMBO J, V21, P1638, DOI 10.1093/emboj/21.7.1638; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Sanchez DJ, 2002, J BIOL CHEM, V277, P6124, DOI 10.1074/jbc.M110265200; Stevenson PG, 2000, P NATL ACAD SCI USA, V97, P8455, DOI 10.1073/pnas.150240097; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	34	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14657	14668		10.1074/jbc.M211285200	http://dx.doi.org/10.1074/jbc.M211285200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582153	hybrid			2022-12-25	WOS:000182516100012
J	Kuai, J; Nickbarg, E; Wooters, J; Qiu, YC; Wang, J; Lin, LL				Kuai, J; Nickbarg, E; Wooters, J; Qiu, YC; Wang, J; Lin, LL			Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NONOBESE DIABETIC MICE; CELL-DEATH; SIGNALING COMPLEX; LYMPHOID-TISSUES; DEFICIENT MICE; CYTOCHROME-C; ABNORMAL-DEVELOPMENT; SMAC/DIABLO RELEASE	Lymphotoxin-beta receptor (LTbetaR) is a member of tumor necrosis factor receptor family and plays essential roles in the embryonic development and organization of secondary lymphoid tissues. It binds two types of tumor necrosis factor family cytokines, heterotrimer LTalpha1beta2 and homotrimer LIGHT, and activates multiple signaling pathways including transcriptional factor NFkappaB, c-Jun N-terminal kinase, and cell death. However, the molecular mechanism of the activation of these signaling pathways by LTbetaR is not clear. Because there is no enzymatic activity associated with the receptor itself, the signal transduction of LTbetaR is mediated by cytoplasmic proteins recruited to receptors. To identify these proteins, we took a proteomic approach. The endogenous LIGHT-LTbetaR complex was affinity-purified from U937 cells, and proteins associated with the complex were identified by mass spectrometry. Four of five proteins identified, TRAF2, TRAF3, cIAP1, and Smac, are reported here. Their association with LTbetaR was further confirmed by coimmunoprecipitation in U937 cells and HEK293 cells. The presence of cIAP1 and Smac in LIGHT-LTbetaR complex revealed a novel mechanism of LIGHT-LTbetaR-induced apoptosis.	Wyeth Ayerst Res, Musculoskeletal Sci, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Prot Chem & Proteom, Cambridge, MA 02140 USA	Pfizer; Pfizer	Lin, LL (corresponding author), Wyeth Ayerst Res, Musculoskeletal Sci, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	llin@wyeth.com						Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; BANKS TA, 1995, J IMMUNOL, V155, P1685; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Ettinger R, 2001, J EXP MED, V193, P1333, DOI 10.1084/jem.193.11.1333; FAVA R, 1998, J INTERFERON CYTOKIN, V18, P95; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Houthaeve T, 1997, J PROTEIN CHEM, V16, P343, DOI 10.1023/A:1026372302560; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Krajewska M, 1998, AM J PATHOL, V152, P1549; Kuprash DV, 1999, J IMMUNOL, V163, P6575; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mackay F, 1996, J BIOL CHEM, V271, P24934, DOI 10.1074/jbc.271.40.24934; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Murphy M, 1998, CELL DEATH DIFFER, V5, P497, DOI 10.1038/sj.cdd.4400374; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Rennert PD, 1998, IMMUNITY, V9, P71, DOI 10.1016/S1074-7613(00)80589-0; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Wu Q, 2001, J EXP MED, V193, P1327, DOI 10.1084/jem.193.11.1327; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoshikawa H, 2001, J IMMUNOL, V167, P2487, DOI 10.4049/jimmunol.167.5.2487; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492; Zhang XD, 2001, CANCER RES, V61, P7339	50	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14363	14369		10.1074/jbc.M208672200	http://dx.doi.org/10.1074/jbc.M208672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571250	hybrid			2022-12-25	WOS:000182405000101
J	Park, B; Ahn, K				Park, B; Ahn, K			An essential function of tapasin in quality control of HLA-G molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; NATURAL-KILLER-CELLS; ANTIGEN PRESENTATION; ENDOPLASMIC-RETICULUM; PEPTIDE REPERTOIRE; SURFACE EXPRESSION; RECYCLING PATHWAY; COMPLEX; TAP; PROTEINS	Tapasin plays an important role in the quality control of major histocompatibility complex (MHC) class I assembly, but its precise function in this process remains controversial. Whether tapasin participates in the assembly of HILA-G has not been studied. HIA-G, an MHC class Ib molecule that binds a more restricted set of peptides than class la molecules, is a particularly interesting molecule, because during assembly, it recycles between the endoplasmic reticulum (ER) and the cis-Golgi until it is loaded with a high affinity peptide. We have taken advantage of this unusual trafficking property of HILA-G and its requirement for high affinity peptides to demonstrate that a critical function of tapasin is to transform class I molecules into a high affinity, peptide-receptive form. In the absence of tapasin, HIA-G molecules cannot bind high affinity peptides, and an abundant supply of peptides cannot overcome the tapasin requirement for high affinity peptide loading. The addition of tapasin renders HILA-G molecules capable of loading high affinity peptides and of transporting to the surface, suggesting that tapasin is a prerequisite for the binding of high-affinity ligands. Interestingly, the "tapasin-dependent" HILA-G molecules are not empty in the absence of tapasin but are in fact associated with suboptimal peptides and continue to recycle between the ER and the cis-Golgi. Together with the finding that empty HIA-G heterodimers are strictly retained in the ER and degraded, our data suggest that MHC class I molecules bind any available peptides to avoid ER-mediated degradation and that the peptides are in turn replaced by higher affinity peptides with the aid of tapasin.	Korea Univ, Grad Sch Biotechnol, Sungbuk Gu, Seoul 136701, South Korea	Korea University	Park, B (corresponding author), Korea Univ, Grad Sch Biotechnol, Sungbuk Gu, 1,5-Ka,Anam Dong, Seoul 136701, South Korea.							Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; CARRENO BM, 1995, J IMMUNOL, V155, P4726; Chun T, 2001, J IMMUNOL, V167, P1507, DOI 10.4049/jimmunol.167.3.1507; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Diehl M, 1996, CURR BIOL, V6, P305, DOI 10.1016/S0960-9822(02)00481-5; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HOWELL DN, 1986, HUM IMMUNOL, V17, P443, DOI 10.1016/0198-8859(86)90303-4; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jun Y, 2000, J IMMUNOL, V164, P805, DOI 10.4049/jimmunol.164.2.805; Kropshofer H, 1999, IMMUNOL REV, V172, P267, DOI 10.1111/j.1600-065X.1999.tb01371.x; Kropshofer H, 1997, IMMUNOL TODAY, V18, P77, DOI 10.1016/S0167-5699(97)01006-2; LEE N, 1995, IMMUNITY, V3, P591, DOI 10.1016/1074-7613(95)90130-2; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Munz C, 1997, J EXP MED, V185, P385, DOI 10.1084/jem.185.3.385; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; Sijts AJAM, 1997, J EXP MED, V185, P1403, DOI 10.1084/jem.185.8.1403; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yu YYL, 1999, J IMMUNOL, V163, P4427	45	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14337	14345		10.1074/jbc.M212882200	http://dx.doi.org/10.1074/jbc.M212882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582157	hybrid			2022-12-25	WOS:000182405000098
J	Ridyard, MS; Robbins, SM				Ridyard, MS; Robbins, SM			Fibroblast growth factor-2-induced signaling through lipid raft-associated fibroblast growth factor receptor substrate 2 (FRS2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOCKING-PROTEIN FRS2-ALPHA; TYROSINE KINASE-ACTIVITY; PC12 CELLS; EARLY EMBRYOGENESIS; ADAPTER PROTEINS; FGF RECEPTORS; SH2 DOMAIN; CAVEOLAE; MEMBRANE; ACTIVATION	The plasma membrane is not homogenous but contains specific subcompartments characterized by their unique lipid and protein composition. Based on their enrichment in various signaling molecules, these membrane microdomains are recognized to be sites of localized signal transduction for a number of extracellular stimuli. We have previously shown that fibroblast growth factor-2 (FGF2) induced a specific signaling response within a lipid raft membrane microdomain in human neuroblastoma cells characterized by the tyrosine phosphorylation of a p,80 phosphoprotein. Herein, we show that this protein is the signaling adaptor FRS2 and that it is localized exclusively to lipid rafts in vitro and in vivo. We have examined how the tyrosine phosphorylation and serine-threonine phosphorylation of FRS2 within lipid rafts affect the response of cells to FGF2 signaling. Our data suggest that activation of protein kinase C, Src family kinases, and MEK1/2 are involved in regulating serine-threonine phosphorylation of FRS2, which can indirectly affect FRS2 phosphotyrosine levels. We also show that Grb2 is recruited to lipid rafts during signaling events and that activation of MEK1/2 by different mechanisms within lipid rafts may lead to different cellular responses. This work suggests that compartmentalized signaling within lipid rafts may provide a level of specificity for growth factor signaling.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr,NW, Calgary, AB T2N 4N1, Canada.							ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Bansal R, 1996, MOL CELL NEUROSCI, V7, P263, DOI 10.1006/mcne.1996.0020; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Davy A, 2000, J NEUROCHEM, V74, P676, DOI 10.1046/j.1471-4159.2000.740676.x; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Gritti A, 1996, J NEUROSCI, V16, P1091; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hama J, 2002, J BIOL CHEM, V277, P19806, DOI 10.1074/jbc.M110637200; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kusakabe M, 2001, EMBO REP, V2, P727, DOI 10.1093/embo-reports/kve152; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Llosas MD, 1996, BIOCHEM J, V315, P1049; McDougall K, 2001, MECH DEVELOP, V103, P145, DOI 10.1016/S0925-4773(01)00337-9; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; ORNITZ DM, 1996, J BIOL CHEM, V271, P1592; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang JK, 1996, ONCOGENE, V13, P721; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	51	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13803	13809		10.1074/jbc.M210245200	http://dx.doi.org/10.1074/jbc.M210245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571252	hybrid			2022-12-25	WOS:000182405000032
J	Wang, XD; Rosales, JL; Magliocco, A; Gnanakumar, R; Lee, KY				Wang, XD; Rosales, JL; Magliocco, A; Gnanakumar, R; Lee, KY			Cyclin E in breast tumors is cleaved into its low molecular weight forms by calpain	ONCOGENE			English	Article						cyclin E; calpain; breast cancer	CANCER; OVEREXPRESSION; CELLS; AMPLIFICATION; EXPRESSION; SYSTEM	Abundant levels of the hyperactive low molecular weight (LMW) forms of cyclin E contribute to deregulation of Cdk2 in breast tumors, but the mechanism through which they arise is not fully understood. Here, we explored the hypothesis that post-translational processing by a protease generates the LMW forms of cyclin E in breast tumors. In ZR75 tumor cell lysates, calcium-induced cyclin E truncation into peptides corresponding in size with LMW forms of cyclin E in tumor tissues. Calpeptin inhibited calcium-stimulated cyclin E truncation, indicating that cleavage resulted from activity of the calcium-dependent protease, calpain. Consistently, calcium + calpain caused truncation of cyclin E immunoprecipitated from tumor cells and tissues. Calcium also caused truncation of the calpain regulatory subunit in tumor cell lysates, indicating that elevated calpain activity accompanies cyclin E truncation. Increased levels of the calpain small subunit were also observed in breast tumors, and significant amounts of its proteolyzed forms indicated increased calpain activity. While elastase also caused cyclin E truncation, the cleavage pattern was distinct from that generated by calpain, suggesting discrete mechanisms in regulating the formation of LMW cyclin E in breast tumors. Treatment of ZR75 cultures with calcium + A23187 recapitulated the formation of the calcium/calpain/induced LMW forms of cyclin E. Altered calcium homeostasis and/or inability of the endogenous calpain inhibitor to control the activity of high levels of the calpain small subunit may contribute to increased calpain activity in breast tumors, causing abundant levels of LMW cyclin E.	Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Lee, KY (corresponding author), Univ Calgary, Fac Med, Dept Cell Biol & Anat, Canc Biol & Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Magliocco, Anthony M/E-5723-2010	Rosales, Jesusa/0000-0002-2543-3801				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Harwell RM, 2000, CANCER RES, V60, P481; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SEWING A, 1994, J CELL SCI, V107, P581; Shiba, 1996, Breast Cancer, V3, P13, DOI 10.1007/BF02966957; Steeg PS, 1998, BREAST CANCER RES TR, V52, P17, DOI 10.1023/A:1006102916060	21	44	53	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					769	774		10.1038/sj.onc.1206166	http://dx.doi.org/10.1038/sj.onc.1206166			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569370	Bronze			2022-12-25	WOS:000180642100015
J	Forster, MJ; Morris, P; Sohal, RS				Forster, MJ; Morris, P; Sohal, RS			Genotype and age influence the effect of caloric intake on mortality in mice	FASEB JOURNAL			English	Article						caloric restriction; aging; C57BL/6; DBA/2; B6D2F(1)	FOOD RESTRICTION; SURVIVAL	Long-term caloric restriction (CR) has been repeatedly shown to increase life span and delay the onset of age-associated pathologies in laboratory mice and rats. The purpose of the current study was to determine whether the CR-associated increase in life span occurs in all strains of mice or only in some genotypes and whether the effects of CR and ad libitum (AL) feeding on mortality accrue gradually or are rapidly inducible and reversible. In one experiment, groups of male C57BL/6, DBA/2, and B6D2F(1) mice were fed AL or CR (60% of AL) diets beginning at 4 months of age until death. In the companion study, separate groups of mice were maintained chronically on AL or CR regimens until 7, 17, or 22-24 months of age, after which, half of each AL and CR group was switched to the opposite regimen for 11 wk. This procedure yielded four experimental groups for each genotype, namely AL-->AL, AL-->CR, CR-->CR, and CR-->AL, designated according to long-term and short-term caloric regimen, respectively. Long-term CR resulted in increased median and maximum life span in C57BL/6 and B6D2F(1) mice but failed to affect either parameter in the DBA/2 mice. The shift from AL-->CR increased mortality in 17- and 24-month-old mice, whereas the shift from CR-->AL did not significantly affect mortality of any age group. Such increased risk of mortality following implementation of CR at older ages was evident in all three strains but was most dramatic in DBA/2 mice. Results of this study indicate that CR does not have beneficial effects in all strains of mice, and it increases rather than decreases mortality if initiated in advanced age.	Univ N Texas, Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	University of North Texas System; University of North Texas Health Science Center; University of Southern California	Forster, MJ (corresponding author), Univ N Texas, Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA.	forsterm@hsc.unt.edu			NIA NIH HHS [R01 AG013563-13, R01 AG013563] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; Fishbein L., 1991, BIOL EFFECTS DIETARY; FORSTER M J, 1991, Biomedical and Environmental Sciences, V4, P144; Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; HARRISON DE, 1987, J NUTR, V117, P376, DOI 10.1093/jn/117.2.376; Ingram D K, 1987, Basic Life Sci, V42, P247; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 1998, EXP GERONTOL, V33, P61, DOI 10.1016/S0531-5565(97)00071-5; MCCARTER RJM, 1995, CLIN GERIATR MED, V11, P553, DOI 10.1016/S0749-0690(18)30256-8; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Weindruch R., 1988, RETARDATION AGING DI	15	172	175	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					690	+		10.1096/fj.02-0533fje	http://dx.doi.org/10.1096/fj.02-0533fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586746	Green Accepted			2022-12-25	WOS:000181456900022
J	Linden, T; Katschinski, DM; Eckhardt, K; Scheid, A; Pagel, H; Wenger, RH				Linden, T; Katschinski, DM; Eckhardt, K; Scheid, A; Pagel, H; Wenger, RH			The antimycotic ciclopirox olamine induces HIF-1 alpha stability, VEGF expression, and angiogenesis	FASEB JOURNAL			English	Article						erythropoietin; hypoxia; iron; oxygen sensor; vascular endothelial growth factor	INDUCIBLE FACTOR-I; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; IRON CHELATORS; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CHELATABLE IRON; DNA-BINDING; HIF-ALPHA	The heterodimeric hypoxia-inducible factor (HIF)-1 is a master regulator of oxygen homeostasis. Protein stability and transactivation function of the subunit are controlled by iron- and oxygen-dependent hydroxylation of proline and asparagine residues. The anti-mycotic ciclopirox olamine (CPX) is a lipophilic bidentate iron chelator that stabilizes HIF-1alpha under normoxic conditions at lower concentrations than other iron chelators, probably by inhibiting HIF-1alpha hydroxylation. As shown by the inhibition of iron-dependent quenching of FITC-labeled deferoxamine (DFX) fluorescence, CPX appears to have an even higher affinity for iron than DFX. Initial observations that treatment with 1% CPX, but not with placebo, occasionally caused reddening of wound margins in a mouse skin wound model prompted us to investigate the capability of CPX to induce angiogenesis. CPX-induced HIF-1-mediated reporter gene activity and endogenous HIF-1 target gene expression, including elevation of transcription, mRNA, and protein levels of the vascular endothelial growth factor (VEGF). In the chick chorioallantoic membrane assay, inert polymer disks containing CPX but not the solvent alone induced angiogenesis. In summary, these results suggest that CPX induces angiogenesis in vivo via HIF-1 and VEGF induction. Therefore, CPX might serve as an alternative to recombinant VEGF treatment or to VEGF gene therapy for therapeutic angiogenesis.	Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Zurich Irchel, Inst Physiol, CH-8000 Zurich, Switzerland; Univ Childrens Hosp Zurich, Dept Surg, CH-8000 Zurich, Switzerland	Leipzig University; University of Lubeck; University of Zurich; University Children's Hospital Zurich	Wenger, RH (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.	wenr@medizin.uni-leipzig.de	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				ALPERMANN HG, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1328; Ash JD, 2000, DEV BIOL, V223, P383, DOI 10.1006/dbio.2000.9755; Bohn M, 2000, J AM ACAD DERMATOL, V43, pS57, DOI 10.1067/mjd.2000.109072; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuer W, 2001, BLOOD, V97, P792, DOI 10.1182/blood.V97.3.792; Chilov D, 1999, J CELL SCI, V112, P1203; COPPI G, 1992, FARMACO, V47, P779; Corral CJ, 1999, ARCH SURG-CHICAGO, V134, P200, DOI 10.1001/archsurg.134.2.200; Deodato B, 2002, GENE THER, V9, P777, DOI 10.1038/sj.gt.3301697; Di Peppe SR, 2002, GENE THER, V9, P1271, DOI 10.1038/sj.gt.3301798; DITTMAR W, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1317; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hanel H, 1991, Mycoses, V34 Suppl 1, P91; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HOCKEL M, 1993, ARCH SURG-CHICAGO, V128, P423; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HOYES KP, 1992, CANCER RES, V52, P4591; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; IWATA K, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1323; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; JUE SG, 1985, DRUGS, V29, P330, DOI 10.2165/00003495-198529040-00002; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KELLNER HM, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1337; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; LEDERMAN HM, 1984, BLOOD, V64, P748; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morishita R, 2001, PHARMACOL THERAPEUT, V91, P105, DOI 10.1016/S0163-7258(01)00150-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLIVO M, 1992, ANAT RECORD, V234, P105, DOI 10.1002/ar.1092340112; PAGEL H, 1991, ENDOCRINOLOGY, V128, P2633, DOI 10.1210/endo-128-5-2633; PAGEL H, 1998, J ONCOL PHARM PRACT, V4, P218; Rauen U, 2000, FASEB J, V14, P1953, DOI 10.1096/fj.00-0071com; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rosen T, 1997, INT J DERMATOL, V36, P788, DOI 10.1046/j.1365-4362.1997.00309.x; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; Szabo S, 2001, J PHYSIOL-PARIS, V95, P325, DOI 10.1016/S0928-4257(01)00045-6; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenk J, 2001, J INVEST DERMATOL, V116, P833, DOI 10.1046/j.1523-1747.2001.01345.x; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zaman K, 1999, J NEUROSCI, V19, P9821	60	85	95	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					761	+		10.1096/fj.02-0586fje	http://dx.doi.org/10.1096/fj.02-0586fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594177				2022-12-25	WOS:000181456900017
J	Berry, GT; Wu, S; Buccafusca, R; Ren, J; Gonzales, LW; Ballard, PL; Golden, JA; Stevens, MJ; Greer, JJ				Berry, GT; Wu, S; Buccafusca, R; Ren, J; Gonzales, LW; Ballard, PL; Golden, JA; Stevens, MJ; Greer, JJ			Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL UPTAKE; PHOSPHOINOSITIDE METABOLISM; MAMMALIAN BRAIN; RABBIT LUNG; SLC5A3 GENE; RAT; HOMEOSTASIS; PROTEIN; CELLS; PHOSPHATIDYLGLYCEROL	myo-Inositol (Ins) and its polyphosphoinositide derivatives that are important in membrane signaling have long been held to play a special role in brain metabolism. As polyphosphoinositides turn over rapidly and are exceptionally abundant in nervous tissue, high Ins levels in the range of 2-15 mM that have been observed in brain may be necessary to maintain the rates of phosphoinositide synthesis in diverse membrane locations within neurons. Cellular concentration gradients of this magnitude indicate a dependence on active Ins transport, especially at the time of growth and differentiation. The Na+/myo-inositol cotransporter (SMIT1 or SLC5A3) gene is highly expressed prenatally in the central nervous system and placenta. To gain more insight into brain Ins metabolism, while ascertaining the importance of SMIT1 as a transporter, we generated mice with a homozygous targeted deletion of this gene. Newborn SMIT1(-/-) animals have no evidence of SMIT1 mRNA, a 92% reduction in the level of brain Ins, an 84% reduction in whole body Ins, and expire shortly after birth due to hypoventilation. Gross pathologic and light microscopic examinations of each organ, as well as the placenta, of embryonic day 18.5 fetuses at near term gestation were normal. Based on [H-3] acetate incorporation into phospholipids of lung tissue explants, immunostaining of lung tissue for surfactant protein A, B, and C, and electron microscopic examination of alveolar cells, there was no evidence of abnormal pulmonary surfactant production by type 2 pneumocytes in lung. Although no histologic lesions were detected in the nervous system, electrophysiological studies of the brainstem pre-Botzinger respiratory control center demonstrated an abnormal rhythm discharge with periods of central apnea. The cause of death can be explained by the regulatory defect in brainstem control of ventilation. This model demonstrates the critical importance of SMIT1 in the developing nervous system. The high affinity SMIT1 transporter is responsible for the Ins concentration gradient in the murine fetal-placental unit.	Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Childrens Hosp, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Childrens Hosp, Div Neonatol Res, Philadelphia, PA 19104 USA; Univ Alberta, Div Neurosci, Dept Physiol, Edmonton, AB T6G 2S2, Canada; Univ Michigan, Sch Med, Dept Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Alberta; University of Michigan System; University of Michigan	Berry, GT (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, 1025 Walnut St,Suite 102, Philadelphia, PA 19107 USA.			Berry, Gerard/0000-0001-5299-3313; Golden, Jeffrey/0000-0001-9933-5502				BATTAGLIA F, 1961, Q J EXP PHYSIOL CMS, V46, P188, DOI 10.1113/expphysiol.1961.sp001532; Beers MF, 1998, AM J PHYSIOL-LUNG C, V275, pL950, DOI 10.1152/ajplung.1998.275.5.L950; BENJAMINS JA, 1969, J NEUROCHEM, V16, P513, DOI 10.1111/j.1471-4159.1969.tb06850.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BERRY GT, 1995, GENOMICS, V25, P507, DOI 10.1016/0888-7543(95)80052-N; BERRY GT, 1993, BIOCHEM J, V295, P863, DOI 10.1042/bj2950863; BERSUDSKY Y, 1994, EUR NEUROPSYCHOPHARM, V4, P463, DOI 10.1016/0924-977X(94)90294-1; BLEASDALE JE, 1983, BIOCHEM J, V212, P811, DOI 10.1042/bj2120811; BLEASDALE JE, 1979, BIOCHIM BIOPHYS ACTA, V575, P135, DOI 10.1016/0005-2760(79)90139-5; BLEASDALE JE, 1982, BIOCHEM J, V206, P43, DOI 10.1042/bj2060043; CAMPLING JD, 1954, J PHYSIOL-LONDON, V126, P71, DOI 10.1113/jphysiol.1954.sp005192; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; CHEN CP, 1979, J PHARM SCI, V68, P1022, DOI 10.1002/jps.2600680827; Coady MJ, 2002, J BIOL CHEM, V277, P35219, DOI 10.1074/jbc.M204321200; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; DAWSON RM, 1961, BIOCHEM J, V78, P606, DOI 10.1042/bj0780606; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; GODFREY DA, 1982, J NEUROCHEM, V38, P939, DOI 10.1111/j.1471-4159.1982.tb05333.x; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P678, DOI 10.1210/jcem-62-4-678; GREER JJ, 1991, J PHYSIOL-LONDON, V437, P727, DOI 10.1113/jphysiol.1991.sp018622; Guo W, 1997, MOL BRAIN RES, V51, P91, DOI 10.1016/S0169-328X(97)00220-9; HALLMAN M, 1986, PEDIATR RES, V20, P179, DOI 10.1203/00006450-198602000-00018; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOLUB BJ, 1986, ANNU REV NUTR, V6, P563, DOI 10.1146/annurev.nu.06.070186.003023; KWON HM, 1992, J BIOL CHEM, V267, P6297; LEWIN LM, 1978, PEDIATR RES, V12, P3, DOI 10.1203/00006450-197801000-00002; LOW MG, 2000, BIOL PHOSPHOINOSITIE; Lykidis A, 1997, J BIOL CHEM, V272, P33402, DOI 10.1074/jbc.272.52.33402; Mallee JJ, 1997, GENOMICS, V46, P459, DOI 10.1006/geno.1997.5055; McVeigh KE, 2000, CYTOGENET CELL GENET, V88, P153, DOI 10.1159/000015509; MOLITORIS BA, 1980, J CLIN INVEST, V65, P783, DOI 10.1172/JCI109728; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Novak JE, 1999, J NEUROCHEM, V72, P1431, DOI 10.1046/j.1471-4159.1999.721431.x; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; PAULUS H, 1960, J BIOL CHEM, V235, P1303; Porcellati F, 1998, AM J PHYSIOL-CELL PH, V274, pC1215, DOI 10.1152/ajpcell.1998.274.5.C1215; PRPIC V, 1982, J BIOL CHEM, V257, P1315; QUIRK JG, 1983, OBSTET GYNECOL, V62, P41; SHERMAN WR, 1981, J NEUROCHEM, V36, P1947, DOI 10.1111/j.1471-4159.1981.tb10819.x; SIGAL SH, 1993, METABOLISM, V42, P395, DOI 10.1016/0026-0495(93)90093-4; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; STOKES CE, 1983, BIOCHIM BIOPHYS ACTA, V753, P136, DOI 10.1016/0005-2760(83)90108-X; THURSTON JH, 1989, PEDIATR RES, V26, P482, DOI 10.1203/00006450-198911000-00024; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WOOTTON JA, 1977, INT J BIOCHEM, V8, P449, DOI 10.1016/0020-711X(77)90045-3; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129	51	72	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18297	18302		10.1074/jbc.M213176200	http://dx.doi.org/10.1074/jbc.M213176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12582158	hybrid			2022-12-25	WOS:000182838300093
J	Whitlow, RD; Sacher, A; Loo, DDF; Nelson, N; Eskandari, S				Whitlow, RD; Sacher, A; Loo, DDF; Nelson, N; Eskandari, S			The anticonvulsant valproate increases the turnover rate of gamma-aminobutyric acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA UPTAKE INHIBITORS; NA+CL COTRANSPORT FUNCTION; OOCYTE MEMBRANE PATCHES; XENOPUS-LAEVIS OOCYTES; SODIUM VALPROATE; SUBSTANTIA-NIGRA; EXTRACELLULAR GABA; STEADY-STATE; NA+/GLUCOSE COTRANSPORTER; AMINOOXYACETIC ACID	Valproate is an important anticonvulsant currently in clinical use for the treatment of seizures. We used electrophysiological and tracer uptake methods to examine the effect of valproate on a gamma-aminobutyric acid (GABA) transporter (mouse GAT3) expressed in Xenopus laevis oocytes. In the absence of GABA, valproate (up to 50 mM) had no noticeable effect on the steady-state electrogenic properties of mGAT3. In the presence of GABA, however, valproate enhanced the GABA-evoked steady-state inward current in a dose-dependent manner with a half-maximal concentration of 4.6 +/- 0.5 mM. Maximal enhancement of the GABA-evoked current was 275 +/- 10%. Qualitatively similar observations were obtained for human GAT1 and mouse GAT4. The valproate enhancement did not alter the Na+ or Cl- dependence of the steady-state GABA-evoked currents. Uptake experiments under voltage clamp suggested that the valproate enhancement of the GABA-evoked current was matched by an enhancement in GABA uptake. Thus, despite the increase in GABA-evoked current, ion/GABA co-transport remained tightly coupled. Uptake experiments indicated that valproate is not transported by mouse GAT3 in the absence or presence of GABA. Valproate also enhanced the rate of the partial steps involved in transporter presteady-state charge movements. We propose that valproate increases the turnover rate of GABA transporters by an allosteric mechanism. The data suggest that at its therapeutic concentration, valproate may enhance the activity of neuronal and glial GABA transporters by up to 10%.	Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	California State University System; California State Polytechnic University Pomona; Tel Aviv University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Eskandari, S (corresponding author), Calif State Polytech Univ Pomona, Dept Biol Sci, 3801 W Temple Ave, Pomona, CA 91768 USA.				NIGMS NIH HHS [S06 GM53933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM053933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGS CS, 1992, BRAIN RES, V594, P138, DOI 10.1016/0006-8993(92)91038-G; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; CLARK JA, 1994, MOL PHARMACOL, V46, P550; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dalby NO, 1997, EPILEPSY RES, V28, P51, DOI 10.1016/S0920-1211(97)00033-8; Dalby NO, 2000, NEUROPHARMACOLOGY, V39, P2399, DOI 10.1016/S0028-3908(00)00075-7; Eckstein-Ludwig U, 1999, BRIT J PHARMACOL, V128, P92, DOI 10.1038/sj.bjp.0702794; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FARRANT M, 1989, BRAIN RES, V504, P49, DOI 10.1016/0006-8993(89)91596-5; FINKJENSEN A, 1992, EUR J PHARMACOL, V220, P197, DOI 10.1016/0014-2999(92)90748-S; Fraser CM, 1999, EPILEPTIC DISORD, V1, P153; GODIN Y, 1969, J NEUROCHEM, V16, P869, DOI 10.1111/j.1471-4159.1969.tb08975.x; GRAM L, 1988, EPILEPSY RES, V2, P87, DOI 10.1016/0920-1211(88)90024-1; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; HACKMAN JC, 1981, BRAIN RES, V220, P269, DOI 10.1016/0006-8993(81)91217-8; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; HYDEN H, 1984, NEUROPHARMACOLOGY, V23, P319, DOI 10.1016/0028-3908(84)90193-X; IADAROLA MJ, 1979, J NEUROCHEM, V33, P1119, DOI 10.1111/j.1471-4159.1979.tb05250.x; IADAROLA MJ, 1979, EUR J PHARMACOL, V59, P125, DOI 10.1016/0014-2999(79)90034-7; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Kwan P, 2001, PHARMACOL THERAPEUT, V90, P21, DOI 10.1016/S0163-7258(01)00122-X; LARSSON OM, 1986, NEUROPHARMACOLOGY, V25, P617, DOI 10.1016/0028-3908(86)90214-5; Li M, 2000, J GEN PHYSIOL, V115, P491, DOI 10.1085/jgp.115.4.491; LIU QR, 1993, J BIOL CHEM, V268, P2106; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; LOSCHER W, 1980, J NEUROCHEM, V34, P1603, DOI 10.1111/j.1471-4159.1980.tb11250.x; LOSCHER W, 1984, LANCET, V2, P225; LOSCHER W, 1985, BIOCHEM PHARMACOL, V34, P1747, DOI 10.1016/0006-2952(85)90645-8; LOSCHER W, 1989, BRAIN RES, V501, P198, DOI 10.1016/0006-8993(89)91044-5; LOSCHER W, 1985, EPILEPSIA, V26, P314, DOI 10.1111/j.1528-1157.1985.tb05656.x; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Matskevitch I, 1999, J BIOL CHEM, V274, P16709, DOI 10.1074/jbc.274.24.16709; Morimoto K, 1997, EPILEPSIA, V38, P966, DOI 10.1111/j.1528-1157.1997.tb01478.x; Nelson N, 1998, J NEUROCHEM, V71, P1785; NIELSEN EB, 1991, EUR J PHARMACOL, V196, P257, DOI 10.1016/0014-2999(91)90438-V; NILSSON M, 1992, NEUROCHEM RES, V17, P327, DOI 10.1007/BF00974573; Richards DA, 1996, NEUROCHEM RES, V21, P135, DOI 10.1007/BF02529130; Roettger V R, 1999, Adv Neurol, V79, P551; ROSS SM, 1981, J NEUROCHEM, V36, P1006, DOI 10.1111/j.1471-4159.1981.tb01693.x; Rowley HL, 1995, EUR J PHARMACOL, V294, P541, DOI 10.1016/0014-2999(95)00589-7; Sacher A, 2002, J MEMBRANE BIOL, V190, P57, DOI 10.1007/s00232-002-1024-6; SAYIN U, 1995, BRAIN RES, V669, P67, DOI 10.1016/0006-8993(94)01240-I; SUZDAK PD, 1992, EUR J PHARMACOL, V224, P189, DOI 10.1016/0014-2999(92)90804-D; SWINYARD EA, 1991, EPILEPSIA, V32, P569, DOI 10.1111/j.1528-1157.1991.tb04694.x; TAYLOR CP, 1992, EPILEPSY RES, V11, P103, DOI 10.1016/0920-1211(92)90044-T; VANDERLAAN JW, 1979, J NEUROCHEM, V32, P1769, DOI 10.1111/j.1471-4159.1979.tb02290.x; WOLF R, 1994, EPILEPSIA, V35, P226, DOI 10.1111/j.1528-1157.1994.tb02938.x; YUNGER LM, 1984, J PHARMACOL EXP THER, V228, P109; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	57	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17716	17726		10.1074/jbc.M207582200	http://dx.doi.org/10.1074/jbc.M207582200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12595533	hybrid			2022-12-25	WOS:000182838300018
J	Jiang, TY; Qiu, Y				Jiang, TY; Qiu, Y			Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTORS; PH-DOMAIN; MECHANISM; TARGET; CELLS; ETK	Activation of Akt by growth factors is a multistep process. Here, we provide evidence that tyrosine kinase Src is directly associated with Akt through the interaction between its SH3 domain and a conserved proline-rich motif (PXXP) in the C-terminal regulatory region of Akt. Substitution of the proline residues Pro-424 and Pro-427 by alanines results in loss of Akt activity and phosphorylation induced by the epidermal growth factor (EGF), possibly because these mutations disrupt the interaction between Akt and the SH3 domain of Src. This possibility is corroborated by our observation that the Akt mutant lacking these two prolines fails to bind to Src both in vivo and in vitro. We also showed that phosphorylation of Tyr-315 in Akt induced by Src or EGF is dependent on the integrity of this proline-rich motif. Furthermore, the Akt mutant lacking this proline motif fails to block the transcription activity of Forkhead in 293 cells and poorly stimulates the proliferation of Madin-Darby canine kidney cells. Taken together, our data suggest that the interaction between the SH3 domain of Src family kinases and the proline-rich motif in the C-terminal regulatory region of Akt is required for tyrosine phosphorylation of Akt and its subsequent activation. It is noteworthy that this PXXP motif is conserved throughout several members of AGC kinase family, implying that association of this motif with the SH3 domain of an upstream regulator may represent a general mechanism applicable to these kinases as well.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; CHAN TO, 2001, SCI STKE, pPE1; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DATTA K, 1995, MOL CELL BIOL, V15, P2304; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; MARMYCONUS N, 2002, J BIOL CHEM; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	19	142	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15789	15793		10.1074/jbc.M212525200	http://dx.doi.org/10.1074/jbc.M212525200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600984	hybrid			2022-12-25	WOS:000182680000043
J	Eblen, ST; Kumar, NV; Shah, K; Henderson, MJ; Watts, CKW; Shokat, KM; Weber, MJ				Eblen, ST; Kumar, NV; Shah, K; Henderson, MJ; Watts, CKW; Shokat, KM; Weber, MJ			Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; UNNATURAL NUCLEOTIDE SPECIFICITY; NUCLEAR-PORE COMPLEX; MAP KINASE; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; PLASMA-MEMBRANE; FAMILY PROTEIN; V-SRC; DOMAIN	The mitogen-activated protein kinases are key regulators of cellular organization and function. To understand the mechanisms(s) by which these ubiquitous kinases affect specific cellular changes, it is necessary to identify their diverse and numerous substrates in different cell contexts and compartments. As a first step in achieving this goal, we engineered a mutant ERK2 in which a bulky amino acid residue in the ATP binding site (glutamine 103) is changed to glycine, allowing this mutant to utilize an analog of ATP (cyclopentyl ATP) that cannot be used by wild-type ERK2 or other cellular kinases. The mutation did not inhibit ERK2 kinase activity or substrate specificity in vitro or in vivo. This method allowed us to detect only ERK2-specific phosphorylations within a mixture of proteins. Using this ERK2 mutant/analog pair to phosphorylate ERK2-associated proteins in COS-1 cells, we identified the ubiquitin ligase EDD (E3 identified by differential display) and the nucleoporin Tpr (translocated promoter region) as two novel substrates of ERK2, in addition to the known ERK2 substrate Rsk1. To further validate the method, we present data that confirm that ERK2 phosphorylates EDD in vitro and in vivo. These results not only identify two novel ERK2 substrates but also provide a framework for the future identification of numerous cellular targets of this important signaling cascade.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University of Virginia; University of Virginia; University of California System; University of California San Francisco; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Weber, MJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.	mjw@virginia.edu	henderson, Michelle/G-6657-2012	Nandicoori, Vinay/0000-0002-5682-4178	NCI NIH HHS [CA40042, CA39076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chaudhary A, 2002, BIOCHEM BIOPH RES CO, V294, P293, DOI 10.1016/S0006-291X(02)00475-8; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frosst P, 2002, J CELL BIOL, V156, P617, DOI 10.1083/jcb.200106046; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; MANNING BD, 2002, SCI STKE; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIRANDA C, 1994, GENOMICS, V23, P714, DOI 10.1006/geno.1994.1566; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEBER MJ, 1971, J BIOL CHEM, V246, P1828; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	38	96	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14926	14935		10.1074/jbc.M300485200	http://dx.doi.org/10.1074/jbc.M300485200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594221	hybrid			2022-12-25	WOS:000182516100046
J	Bidasee, KR; Xu, L; Meissner, G; Besch, HR				Bidasee, KR; Xu, L; Meissner, G; Besch, HR			Diketopyridylryanodine has three concentration-dependent effects on the cardiac calcium-release channel/ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; CHANNEL; SKELETAL; DERIVATIVES; ACTIVATION; COMPLEX; PHARMACOLOGY; INHIBITION; SPARKS	By interacting with more than one site, ryanoids induce multiple effects on calcium-release channels. To date, the kinetics of interaction of only one of these sites has been characterized. Using C-4,C-12-diketopyridylryanodine in both [H-3]ryanodine binding and single channel experiments we characterized another site on the cardiac ryanodine receptor (RyR2) with which ryanoids interact. Competitive binding of this ryanoid to RyR2 implied a minimal two-site binding model. At the single channel level, C-4,C-12-diketopyridylryanodine induced three distinct effects. At nanomolar concentrations, it increased channel open probability several fold without inducing a subconductance. This effect was independent of membrane holding potential. As for other ryanoids, low micromolar concentrations of C-4,C-12-diketopyridylryanodine readily induced a subconductance state. The major subconductance had a current amplitude of 52% of fully open, it was reversible, and its time to induction and duration were voltage- and concentration-dependent, affording Hill slopes of >2. At higher micromolar concentrations C-4,C-12-diketopyridylryanodine induced long lasting, yet reversible shut states. Using a pharmacological strategy we have discerned an additional ryanoid-binding site on RyR2 that triggers an increase in channel activity. This site likely resides outside the strict confines of the transmembrane conducting pathway.	Univ Nebraska, Med Ctr, Dept Pharmacol, Nebraska Med Ctr 986260, Omaha, NE 68198 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Indiana Univ, Sch Med, Dept Pharmacol, Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Krannert Inst Cardiol, Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA	University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Bidasee, KR (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmacol, Nebraska Med Ctr 986260, Omaha, NE 68198 USA.	kbidasee@unmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430, R01HL066898] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66898, HL27430] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Bidasee KR, 1998, J BIOL CHEM, V273, P12176, DOI 10.1074/jbc.273.20.12176; BIDASEE KR, 1994, J LABELLED COMPD RAD, V34, P33, DOI 10.1002/jlcr.2580340106; Bidasee KR, 2000, J PHARMACOL EXP THER, V293, P1074; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Fessenden JD, 2001, P NATL ACAD SCI USA, V98, P2865, DOI 10.1073/pnas.041608898; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Hui CS, 2001, J PHYSIOL-LONDON, V534, P327, DOI 10.1111/j.1469-7793.2001.00327.x; HUMERICKHOUSE RA, 1994, J BIOL CHEM, V269, P30243; HUMERICKHOUSE RA, 1993, MOL PHARMACOL, V44, P412; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; JEFFERIES PR, 1993, J MED CHEM, V36, P1128, DOI 10.1021/jm00061a003; KELLY RB, 1951, CAN J CHEM, V29, P905, DOI 10.1139/v51-105; LAI FA, 1989, J BIOL CHEM, V264, P16776; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LEE HB, 1994, J BIOL CHEM, V269, P13305; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; MEISSNER G, 1991, ADV EXP MED BIOL, V304, P241; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Motulsky H., 1999, ANAL DATA GRAPHPAD P; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; Ozawa T, 2001, INT J MOL MED, V7, P21; Schleifer KJ, 2000, J COMPUT AID MOL DES, V14, P467, DOI 10.1023/A:1008141819487; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; SORRENTINO V, 1996, RYANODINE RECEPTOR; Sutko JL, 1997, PHARMACOL REV, V49, P53; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Tanna B, 2000, J GEN PHYSIOL, V116, P1, DOI 10.1085/jgp.116.1.1; Tinker A, 1996, BIOPHYS J, V70, P2110, DOI 10.1016/S0006-3495(96)79777-1; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; Xu L, 1998, ANN NY ACAD SCI, V853, P130; Xu XH, 2000, BIOPHYS J, V78, P1270, DOI 10.1016/S0006-3495(00)76683-5; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971	41	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14237	14248		10.1074/jbc.M208372200	http://dx.doi.org/10.1074/jbc.M208372200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566457	hybrid			2022-12-25	WOS:000182405000086
J	Neumar, RW; Xu, YA; Gada, H; Guttmann, RP; Siman, R				Neumar, RW; Xu, YA; Gada, H; Guttmann, RP; Siman, R			Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR PROTEIN CALPASTATIN; TRANSIENT FOREBRAIN ISCHEMIA; DRUG-INDUCED APOPTOSIS; CELL-DEATH; DNA FRAGMENTATION; HYPOXIA-ISCHEMIA; NEUROBLASTOMA-CELLS; TRIGGERS APOPTOSIS; T-CELLS; ACTIVATION	Cross-talk between calpain and caspase proteolytic systems has complicated efforts to determine their distinct roles in apoptotic cell death. This study examined the effect of overexpressing calpastatin, the specific endogenous calpain inhibitor, on the activity of the two proteolytic systems following an apoptotic stimulus. Human SH-SY5Y neuroblastoma cells were stably transfected with full-length human calpastatin eDNA resulting in 20-fold overexpression based on Western blot and 5-fold greater calpain inhibitory activity in cell extracts. Wild type and calpastatin overexpressing (CST1) cells were neuronally differentiated and apoptosis-induced with staurosporine (0.1-1.0 muM). Calpastatin overexpression decreased calpain activation, increased caspase-3-like activity, and accelerated the appearance of apoptotic nuclear morphology. Following 0.1-0.2 muM staurosporine, plasma membrane integrity based on calcein-acetoxymethyl fluorescence was significantly greater at 24 h in differentiated CST1 compared with differentiated wild type cells. However, this protective effect was lost at higher staurosporine doses (0.5-1.0 muM), which resulted in pronounced caspase-mediated degradation of the overexpressed calpastatin. These results suggest a dual role for calpains during neuronal apoptosis. In the early execution phase, calpain down-regulates caspase-3-like activity and slows progression of apoptotic nuclear morphology. Subsequent calpain activity, facilitated by caspase-mediated degradation of calpastatin, contributes to plasma membrane disruption and secondary necrosis.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Kentucky, Ctr Aging, Lexington, KY 40536 USA	University of Pennsylvania; University of Kentucky	Neumar, RW (corresponding author), Hosp Univ Penn, Dept Emergency Med, Ground Floor,Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	rneumar@mail.med.upenn.edu	guttmann, rodney/AAN-8880-2021	guttmann, rodney/0000-0001-5553-3099				Atencio IA, 2000, CELL GROWTH DIFFER, V11, P247; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Blomgren K, 1999, ANN NY ACAD SCI, V890, P270, DOI 10.1111/j.1749-6632.1999.tb08002.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Chen SJ, 1998, MOL CELL BIOCHEM, V178, P141, DOI 10.1023/A:1006893528428; Cheng AG, 1999, BRAIN RES, V850, P234, DOI 10.1016/S0006-8993(99)01983-6; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Colbourne F, 1999, J NEUROSCI, V19, P4200; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006; Gobbel GT, 2001, J NEUROCHEM, V76, P520, DOI 10.1046/j.1471-4159.2001.00070.x; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu Q, 1996, ARCH BIOCHEM BIOPHYS, V334, P175, DOI 10.1006/abbi.1996.0443; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakatsuka H, 2000, NEUROSCI LETT, V285, P127, DOI 10.1016/S0304-3940(00)01044-2; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; O'Donovan CN, 2001, J BIOL CHEM, V276, P43516, DOI 10.1074/jbc.M103894200; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509, DOI 10.1152/ajprenal.2000.279.3.F509; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Witkowski JM, 2002, BLOOD, V100, P1802, DOI 10.1182/blood-2001-11-0073; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhu DM, 2000, CLIN CANCER RES, V6, P2456; ZHU W, 1995, BIOCHEM BIOPH RES CO, V214, P1130, DOI 10.1006/bbrc.1995.2403	57	214	224	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14162	14167		10.1074/jbc.M212255200	http://dx.doi.org/10.1074/jbc.M212255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576481	hybrid			2022-12-25	WOS:000182405000077
J	Ohishi, K; Nagamune, K; Maeda, Y; Kinoshita, T				Ohishi, K; Nagamune, K; Maeda, Y; Kinoshita, T			Two Subunits of glycosylphosphatidylinositol transamidase, GPI8 and PIG-T, form a functionally important intermolecular disulfide bridge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; ENDOPLASMIC-RETICULUM PROTEINS; ANCHORED MEMBRANE-PROTEINS; CELL-FREE SYSTEM; TRYPANOSOMA-BRUCEI; IN-VITRO; A GENE; ATTACHMENT; BIOSYNTHESIS; PHOSPHATIDYLINOSITOL	Many eukaryotic proteins are tethered to the plasma membrane via glycosylphosphatidylinositol (GPI). GPI transamidase is localized in the endoplasmic reticulum and mediates post-translational transfer of preformed GPI to proteins bearing a carboxyl-terminal GPI attachment signal. Mammalian GPI transamidase is a multimeric complex consisting of at least five subunits. Here we report that two subunits of mammalian GPI transamidase, GP18 and PIG-T, form a functionally important disulfide bond between conserved cysteine residues. GP18 and PIG-T mutants in which relevant cysteines were replaced with serines were unable to fully restore the surface expression of GPI-anchored proteins upon transfection into their respective mutant cells. Microsomal membranes of these transfectants had markedly decreased activities in an in vitro transamidase assay. The formation of this disulfide bond is not essential but required for full transamidase activity. Antibodies against GPI8 and PIG-T revealed that endogenous as well as exogenous proteins formed a disulfide bond. Furthermore trypanosome GP18 forms a similar intermolecular disulfide bond via its conserved cysteine residue, suggesting that the trypanosome GPI transamidase is also a multimeric complex likely containing the orthologue of PIG-T. We also demonstrate that an inactive human GPI transamidase complex that consists of nonfunctional GP18 and four other components was co-purified with the proform of substrate proteins, indicating that these five components are sufficient to hold the substrate proteins.	Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Kinoshita, Taroh/C-7353-2009					ABE Y, 1993, J BIOL CHEM, V268, P3525; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(09)00098-3; Eisenhaber B, 2001, PROTEIN ENG, V14, P17, DOI 10.1093/protein/14.1.17; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; HONG Y, 2003, MOL BIOL CELL; Kang XD, 2002, J CELL SCI, V115, P2529; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LILLICO S, 2003, MOL BIOL CELL; Locker JK, 1999, J CELL BIOL, V144, P267, DOI 10.1083/jcb.144.2.267; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nozaki M, 1999, LAB INVEST, V79, P293; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; PATNAIK PK, 1994, NUCLEIC ACIDS RES, V22, P4111, DOI 10.1093/nar/22.20.4111; Sharma DK, 2000, BIOCHEM J, V351, P717, DOI 10.1042/0264-6021:3510717; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	34	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13959	13967		10.1074/jbc.M300586200	http://dx.doi.org/10.1074/jbc.M300586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582175	hybrid			2022-12-25	WOS:000182405000052
J	Sawaoka, H; Dixon, DA; Oates, JA; Boutaud, O				Sawaoka, H; Dixon, DA; Oates, JA; Boutaud, O			Tristetraprolin binds to the 3 '-untranslated region of cyclooxygenase-2 mRNA - A polyadenylation variant in a cancer cell line lacks the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA STABILITY; INTESTINAL EPITHELIAL-CELLS; GROWTH-FACTOR-ALPHA; COLON-CANCER; POSTTRANSCRIPTIONAL REGULATION; TNF-ALPHA; PROSTAGLANDIN H-2; GENE-EXPRESSION; CARCINOMA CELLS	In human colorectal adenocarcinoma cell lines, we found two major transcripts of cyclooxygenase-2, the full-length mRNA and a short polyadenylation variant (2577 kb) lacking the distal segment of the 3'-untranslated region. Tristetraprolin, an mRNA-binding protein that promotes message instability, was shown to bind the cyclooxygenase-2 mRNA in the region of the W-untranslated region between nucleotides 3125 and 3432 and to reduce levels of the full-length mRNA. During cell growth and confluence, the expression of tristetraprolin mRNA was inversely correlated with that of the full-length cyclooxygenase-2 transcript, and transfection of tristetraprolin into HCA-7 cells reduced the level of full-length cyclooxygenase-2 mRNA. However, the truncated transcript escaped tristetraprolin binding and downregulation.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Boutaud, O (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 514 RRB,23rd Ave S Pierce, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P01CA077839, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839, CA68485] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGHIB DF, 1990, ONCOGENE, V5, P707; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUBOIS RN, 1994, AM J PHYSIOL, V266, P822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KIRKLAND SC, 1985, CANCER RES, V45, P3790; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Martinez J, 1997, AM J PHYSIOL-CELL PH, V273, pC1466, DOI 10.1152/ajpcell.1997.273.5.C1466; Masferrer JL, 2000, CANCER RES, V60, P1306; Molina MA, 1999, CANCER RES, V59, P4356; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; RAYMOND V, 1989, ONCOGENE RES, V5, P1; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ristimaki A, 1997, CANCER RES, V57, P1276; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; Sawaoka H, 1999, PROSTAG LEUKOTR ESS, V61, P315, DOI 10.1054/plef.1999.0106; Sawaoka H, 1997, J CLIN GASTROENTEROL, V25, pS105, DOI 10.1097/00004836-199700001-00018; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VARNUM BC, 1989, ONCOGENE, V4, P119; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; Wolff H, 1998, CANCER RES, V58, P4997; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; Zimmermann KC, 1999, CANCER RES, V59, P198	62	118	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13928	13935		10.1074/jbc.M300016200	http://dx.doi.org/10.1074/jbc.M300016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578839	hybrid			2022-12-25	WOS:000182405000048
J	Lyu, J; Costantini, F; Jho, EH; Joo, CK				Lyu, J; Costantini, F; Jho, EH; Joo, CK			Ectopic expression of axin blocks neuronal differentiation of embryonic carcinoma P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; F-BOX PROTEIN; TRANSCRIPTION FACTOR LEF-1; MOUSE FUSED LOCUS; BETA-CATENIN; NEGATIVE REGULATOR; NEURAL CREST; COMPLEX; DOMAINS; PHOSPHORYLATION	Axin regulates Wnt signaling through down-regulation of beta-catenin. To test the role of Wnt signaling in neuronal differentiation, embryonal carcinoma P19 cells (P19 EC, which can be stimulated to differentiate into a neuron-like phenotype in response to retinoic acid (RA), were used. Reverse transcription-PCR and Western blot analysis showed that Axin is expressed in undifferentiated cells, whereas the level is clearly reduced during RA-induced neuronal differentiation. Interestingly, Axin levels were not reduced during endodermal differentiation of P19 EC cells and F9 EC cells by RA, suggesting that the reduction of the Axin level is a specific property of neuronal differentiation. Western analysis showed that the cytoplasmic level of beta-catenin increased during neuronal differentiation of P19 EC cells. Indirect immunofluorescence with beta-catenin antibody showed that the localization of beta-catenin was changed from membrane in undifferentiated cells to nuclei in neuronal P19 EC cells. Induced expression of Axin during endodermal and early neuronal differentiation, using the Tet-On system, did not block normal differentiation. However, maintenance of the Axin level blocked neuronal differentiation and inhibited expression of a neuron-specific marker protein, betaIII-tubulin. Also, ectopic induction of a beta-catenin signaling inhibitor, ICAT, inhibited expression of betaIII-tubulin. In contrast, addition of Wnt-3A-conditioned medium during the neuronal differentiation period enhanced the expression of betaIII-tubulin. Overall, our data show that Wnt-3a/canonical beta-catenin signaling through the down-regulation of Axin may play an important role in neuronal differentiation.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Catholic Univ Korea, Dept Ophthalmol, Seoul 137040, South Korea	University of Seoul; Columbia University; Catholic University of Korea	Jho, EH (corresponding author), Univ Seoul, Dept Life Sci, Seoul 130743, South Korea.			Jho, Eek-hoon/0000-0003-2414-6234				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dunn KJ, 2000, P NATL ACAD SCI USA, V97, P10050, DOI 10.1073/pnas.97.18.10050; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Gao X, 2001, BIOCHEM BIOPH RES CO, V284, P1098, DOI 10.1006/bbrc.2001.5089; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Julius MA, 2000, BIOCHEM BIOPH RES CO, V276, P1162, DOI 10.1006/bbrc.2000.3607; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kusek JC, 2001, BRAIN RES BULL, V54, P187, DOI 10.1016/S0361-9230(00)00447-0; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Muroyama Y, 2002, GENE DEV, V16, P548, DOI 10.1101/gad.937102; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1993, DEVELOPMENT, V119, P247; PERRY WL, 1995, GENETICS, V141, P321; Petropoulos H, 2002, J BIOL CHEM, V277, P15393, DOI 10.1074/jbc.M112141200; Polakis P, 2000, GENE DEV, V14, P1837; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; Tago K, 2000, GENE DEV, V14, P1741; Tang K, 2002, BIOCHEM BIOPH RES CO, V293, P167, DOI 10.1016/S0006-291X(02)00215-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Willert K, 1999, DEVELOPMENT, V126, P4165; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	63	44	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13487	13495		10.1074/jbc.M300591200	http://dx.doi.org/10.1074/jbc.M300591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569091	hybrid			2022-12-25	WOS:000182189500112
J	Batetta, B; Mulas, MF; Sanna, F; Putzolu, M; Bonatesta, RR; Gasperi-Campani, A; Roncuzzi, L; Baiocchi, D; Dessi, S				Batetta, B; Mulas, MF; Sanna, F; Putzolu, M; Bonatesta, RR; Gasperi-Campani, A; Roncuzzi, L; Baiocchi, D; Dessi, S			Role of cholesterol ester pathway in the control of cell cycle in human aortic smooth muscle cells	FASEB JOURNAL			English	Article						acyl-CoA : cholesterol acyltransferase multidrug resistance-1; caveolin-1; cyclin D1; mitogen-activated protein kinase; extracellular related kinase 1/2	DENSITY-LIPOPROTEIN CHOLESTEROL; RESISTANCE P-GLYCOPROTEINS; GENE-EXPRESSION; MDR1; ESTERIFICATION; ACYLTRANSFERASE; METABOLISM; CAVEOLIN; GROWTH; PROLIFERATION	Cholesterol esterification by acyl-CoA:cholesterol acyltransferase (ACAT) and proliferation of vascular smooth muscle cells (VSMC) are key events in vascular proliferative diseases. Here we performed experiments to ascertain the role of cholesterol ester pathway in the control of human aortic VSMC cycle progression. Results showed that serum-induced VSMC proliferation was preceded by an increased ability of the cells to esterify cholesterol as well as by an increased expression of ACAT and multidrug resistance (MDR1) mRNAs and extracellular related kinases 1/2 (ERK1/2), whereas caveolin-1 levels were markedly decreased. Cell cycle analyses performed in the presence of two inhibitors of cholesterol esterification, directly inhibiting ACAT (Sandoz 58-035) or the transport of cholesterol substrate from plasma membrane to endoplasmic reticulum (progesterone), indicate that each inhibitor suppressed the serum-induced DNA synthesis by accumulation of VSMCs in the G(1) phase. The effect was associated with a rapid inhibition of ERK1/2 mitogenic signaling pathway; a down-regulation of cyclin D1, ACAT, and MDR1 mRNA; and an up-regulation of caveolin-1. These data provide a plausible link between cholesterol esterification and control of cell cycle G(1)/S transition, supporting the hypothesis that cholesterol esterification may accelerate the progression of human vascular proliferative diseases by modulating the rate of the VSMC proliferation.	Univ Cagliari, Dept Biomed Sci & Biotechnol, I-09124 Cagliari, Italy; Univ Bologna, Interdepartmental Ctr Res Canc, Bologna, Italy; Univ Bologna, Dept Expt Pathol, Natl Inst Canc Res, Genova Biotechnol Unit, I-40126 Bologna, Italy	University of Cagliari; University of Bologna; University of Bologna; University of Genoa; IRCCS AOU San Martino IST	Dessi, S (corresponding author), Univ Cagliari, Dept Biomed Sci & Biotechnol, Italy Via Porcell 4, I-09124 Cagliari, Italy.	sdessi@vaxca1.unica.it	Roncuzzi, laura/C-7449-2019	Roncuzzi, laura/0000-0002-5437-6543; Batetta, Barbara/0000-0001-6932-778X				Batetta B, 1999, CELL PROLIFERAT, V32, P49, DOI 10.1046/j.1365-2184.1999.00132.x; Batetta B, 2001, CELL MOL LIFE SCI, V58, P1113, DOI 10.1007/PL00000925; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; DESSI S, 1984, CHEM-BIOL INTERACT, V48, P271, DOI 10.1016/0009-2797(84)90140-6; DESSI S, 1992, ONCOLOGY, V49, P436; Dessi S, 1997, BIOCHEM J, V321, P603, DOI 10.1042/bj3210603; DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F; DESSI S, 1991, INT J HEMATOL, V54, P483; DESSI S, 1992, BRIT J CANCER, V66, P787, DOI 10.1038/bjc.1992.361; DESSI S, 1995, CLIN SCI, V89, P505, DOI 10.1042/cs0890505; DESSI S, 1989, EXP MOL PATHOL, V51, P97, DOI 10.1016/0014-4800(89)90010-5; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Field FJ, 1998, J LIPID RES, V39, P1938; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2001, CURR OPIN LIPIDOL, V12, P281, DOI 10.1097/00041433-200106000-00007; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1994, J BIOL CHEM, V269, P29371; Lee WS, 1997, NAT MED, V3, P1005, DOI 10.1038/nm0997-1005; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; MATSUDA K, 1994, MED RES REV, V14, P271, DOI 10.1002/med.2610140302; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Pani A, 2000, CELL MOL LIFE SCI, V57, P1094, DOI 10.1007/PL00000745; PAPE ME, 1995, J LIPID RES, V36, P823; RAO KN, 1986, BRIT J CANCER, V54, P305, DOI 10.1038/bjc.1986.177; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rodriguez A, 1999, ARTERIOSCL THROM VAS, V19, P2199, DOI 10.1161/01.ATV.19.9.2199; Rosano GMC, 2001, INT J FERTIL WOMEN M, V46, P248; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPYRIDOPOULOS I, 1998, FRONT BIOSCI, V3, P269; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; Ward MR, 1998, ATHEROSCLEROSIS, V137, P267, DOI 10.1016/S0021-9150(97)00275-X; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200	45	28	34	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					746	+		10.1096/fj.02-0396fje	http://dx.doi.org/10.1096/fj.02-0396fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594184				2022-12-25	WOS:000181456900007
J	Hosogane, N; Shinki, T; Kasuga, H; Taketomi, S; Toyama, Y; Suda, T				Hosogane, N; Shinki, T; Kasuga, H; Taketomi, S; Toyama, Y; Suda, T			Mechanisms for the reduction of 24,25-dihydroxyvitamin D-3 levels and bone mass in 24-hydroxylase transgenic rats	FASEB JOURNAL			English	Article						CYP24; megalin; vitamin D binding protein; renal osteodystrophy; albuminuria	D-BINDING-PROTEIN; RENAL OSTEODYSTROPHY; NEPHROTIC SYNDROME; ESCHERICHIA-COLI; EPITHELIAL-CELLS; MESSENGER-RNA; COMPLEMENT C3; VITAMIN; EXPRESSION; IDENTIFICATION	24-Hydroxylase (CYP24) is an enzyme distributed in the target tissues of 1alpha,25-dihydroxyvitamin D-3 [1alpha,25(OH)(2)D-3]. Two functions for this enzyme have been reported: One is production of 24,25-dihydroxyvitamin D-3 [24,25(OH)(2)D-3] and the other is inactivation of 1alpha,25(OH)(2)D-3. To elucidate other physiologic roles of CYP24 in vivo, we previously generated rats that constitutively express the CYP24 gene. These transgenic (Tg) rats developed unexpected phenotypes, such as low plasma levels of 24,25(OH)(2)D-3, lipidemia, and albuminuria. In this study, we elucidated the mechanisms for inducing low plasma 24,25(OH)(2)D-3 levels and bone loss. Tg rats excreted massive amounts of vitamin D binding protein (DBP), which coincided with the loss of albumin. In Tg rats, the renal expression pattern of megalin, which serves as an endocytotic receptor responsible for the reuptake of urinary proteins such as DBP and albumin, was identical to that of the wild-type rats. Excreted albumin appeared to compete for the binding and reabsorption of the DBP-25-hydroxyvitamin D-3 [25(OH)D-3] complex with megalin, resulting in a loss of 25(OH)D-3 into the urine and subsequent reduction of plasma 24,25(OH)(2)D-3. In this prominent rat model of nephritis, supplementation of 25(OH)D-3 was effective in preventing bone loss in an early stage of renal insufficiency.	Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608582, Japan; Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Yodogawa Ku, Osaka 532, Japan; Saitama Med Sch, Res Ctr Genom Med, Div Pathophysiol, Hidaka, Saitama, Japan	Keio University; Showa University; Takeda Chemical Industries; Saitama Medical University	Hosogane, N (corresponding author), Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	shinki@dent.showa-u.ac.jp	Toyama, Yoshiaki/K-5743-2013					Abe K, 1998, KIDNEY INT, V54, P120, DOI 10.1046/j.1523-1755.1998.00961.x; AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; BERL T, 1978, ANN INTERN MED, V88, P774, DOI 10.7326/0003-4819-88-6-774; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boyan BD, 2001, STEROIDS, V66, P363, DOI 10.1016/S0039-128X(00)00162-8; BRICKMAN AS, 1974, ARCH INTERN MED, V134, P883; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; Christensen EI, 1999, J AM SOC NEPHROL, V10, P2224; Coburn J W, 1998, J Am Soc Nephrol, V9, pS71; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; Ghazali A, 1999, KIDNEY INT, V55, P2169, DOI 10.1046/j.1523-1755.1999.00480.x; HADDAD JG, 1981, J CLIN INVEST, V67, P1550, DOI 10.1172/JCI110186; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307; Kasuga H, 2002, BIOCHEM BIOPH RES CO, V297, P1332, DOI 10.1016/S0006-291X(02)02254-4; LAWSON DEM, 1971, NATURE, V230, P228, DOI 10.1038/230228a0; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; MALLUCHE HH, 1979, J CLIN INVEST, V63, P494, DOI 10.1172/JCI109327; MASSRY SG, 1980, KIDNEY INT, V18, P409, DOI 10.1038/ki.1980.154; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; Mittal SK, 1999, KIDNEY INT, V55, P1912, DOI 10.1046/j.1523-1755.1999.00413.x; Morita Y, 1997, J AM SOC NEPHROL, V8, P1363; MOUTABARRIK A, 1995, NEPHRON, V70, P55, DOI 10.1159/000188544; NAKAMURA T, 1992, CALCIFIED TISSUE INT, V50, P221, DOI 10.1007/BF00296286; NAKAMURA T, 1988, CALCIFIED TISSUE INT, V43, P235, DOI 10.1007/BF02555140; NAKAMURA T, 1992, BONE, V13, P229, DOI 10.1016/8756-3282(92)90202-8; NORMAN AW, 1971, SCIENCE, V173, P51, DOI 10.1126/science.173.3991.51; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; Oren R, 1995, IMMUNOLOGY, V86, P575; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Sakaki T, 1999, EUR J BIOCHEM, V262, P43, DOI 10.1046/j.1432-1327.1999.00375.x; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; Suda T, 1994, Curr Opin Nephrol Hypertens, V3, P59, DOI 10.1097/00041552-199401000-00008; Tang S, 1999, J AM SOC NEPHROL, V10, P69; WELCH TR, 1993, J CLIN INVEST, V92, P1451, DOI 10.1172/JCI116722; Welch TR, 2000, PEDIATR RES, V48, P200, DOI 10.1203/00006450-200008000-00013; YAMATO H, 1989, ENDOCRINOLOGY, V124, P511, DOI 10.1210/endo-124-1-511	46	12	12	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					737	+		10.1096/fj.02-0965fje	http://dx.doi.org/10.1096/fj.02-0965fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594170				2022-12-25	WOS:000181456900008
J	Capote, KR; McCormack, FX; Possmayer, F				Capote, KR; McCormack, FX; Possmayer, F			Pulmonary surfactant protein-A (SP-A) restores the surface properties of surfactant after oxidation by a mechanism that requires the Cys(6) interchain disulfide bond and the phospholipid binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE REGION; IN-VITRO; AGGREGATION; INHIBITION; DIPALMITOYLPHOSPHATIDYLCHOLINE; CHOLESTEROL; MONOLAYERS; DEFICIENT; SECRETION; EXPOSURE	Reactive oxygen species produced by activated leukocytes in the alveolar epithelial lining fluid have been implicated in the inactivation of pulmonary surfactant and the impairment of lung function. Oxidation of bovine lipid extract surfactant (BLES), a therapeutic surfactant, with hypochlorous acid (H-BLES) or the Fenton reaction (F-BLES) led to temporary increases in conjugated dienes and formation of malondialdehyde and 4-hydroxy-2-nonenal. Electrospray ionization mass spectrometry revealed the appearance of lipid hydroperoxides, peroxides, lysophospholipids, and free fatty acids. Captive bubble tensiometer studies of H-BLES demonstrated prolonged adsorption times, film instability at low surface tensions during film compression, and reduced respreadability during film expansion. F-BLES exhibited prolonged adsorption times, a marked effect on increasing compressibility during compression, and a lesser effect on reducing respreadability on expansion. Addition of native bovine or rat surfactant-associated protein A (SP-A) reversed the effects of oxidation on surfactant biophysical properties. Studies using mutant recombinant rat SP-As indicated that an intact carbohydrate recognition domain and disulfide-dependent oligomeric assembly are critical for these effects, but the collagen-like region is not required. We conclude that SP-A can reverse the detrimental effects of surfactant oxidation on the biophysical properties of surfactant, by a mechanism that is dependent on interchain disulfide bond formation and the C-terminal domains of the protein.	Univ Western Ontario, London Hlth Sci Ctr, Dept Obstet & Gynecol, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 5A5, Canada; Univ Western Ontario, Dept Biochem, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 5A5, Canada; Inst Ciencias Basicas & Preclin Victoria Giron, Inst Super Ciencias Med Habana, Dept Bioquim, Havana, Cuba; Univ Cincinnati, Div Pulm & Crit Care Med, Dept Med, Cincinnati, OH 45267 USA	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); University System of Ohio; University of Cincinnati	Possmayer, F (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Obstet & Gynecol, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, 339 Windermere Rd, London, ON N6A 5A5, Canada.	fpossmay@uwo.ca	McCormack, Francis X./ABE-8398-2020; Rodriguez Capote, Karina/H-7400-2019	McCormack, Francis X./0000-0001-7168-9464; Rodriguez Capote, Karina/0000-0003-1766-4527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amirkhanian JD, 1998, LUNG, V176, P63, DOI 10.1007/PL00007592; Andersson S, 1999, LUNG, V177, P179, DOI 10.1007/PL00007639; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Eberhardt M. K., 2000, REACTIVE OXYGEN META; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; Hawkins CL, 1999, BIOCHEM J, V340, P539, DOI 10.1042/0264-6021:3400539; Hohlfeld J, 1997, EUR RESPIR J, V10, P482, DOI 10.1183/09031936.97.10020482; HOLM BA, 1990, CHEM PHYS LIPIDS, V52, P243, DOI 10.1016/0009-3084(90)90120-G; Ikegami M, 2001, J BIOL CHEM, V276, P38542, DOI 10.1074/jbc.M102054200; KEOUGH KMW, 1998, MED INTELL UNIT, V5, P1; Lewis JE, 2003, ANNU REV PHYSIOL, V65, P613, DOI 10.1146/annurev.physiol.65.092101.142434; Mark L, 1999, AM J PHYSIOL-LUNG C, V276, pL491, DOI 10.1152/ajplung.1999.276.3.L491; Matthay MA, 1999, CRIT CARE MED, V27, P2028, DOI 10.1097/00003246-199909000-00055; McCormack F, 1997, CHEST, V111, pS114, DOI 10.1378/chest.111.6_Supplement.114S; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; McCormack FX, 1998, BBA-MOL BASIS DIS, V1408, P109, DOI 10.1016/S0925-4439(98)00062-3; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; McCormack FX, 2001, PEDIATR PATHOL MOL M, V20, P293, DOI 10.1080/15513810109168823; MERRITT TA, 1993, BIOCHEM J, V295, P19, DOI 10.1042/bj2950019; Palaniyar N, 2001, COMP BIOCHEM PHYS A, V129, P109, DOI 10.1016/S1095-6433(01)00309-9; Palaniyar N, 1999, AM J PHYSIOL-LUNG C, V276, pL642, DOI 10.1152/ajplung.1999.276.4.L642; Possmayer F, 2001, COMP BIOCHEM PHYS A, V129, P209, DOI 10.1016/S1095-6433(01)00317-8; POSSMAYER F, 2003, IN PRESS FETAL NEONA; Postle AD, 2000, CLIN EXP ALLERGY, V30, P1201; Postle AD, 2001, COMP BIOCHEM PHYS A, V129, P65, DOI 10.1016/S1095-6433(01)00306-3; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Putman E, 1997, LUNG, V175, P75, DOI 10.1007/PL00007561; Rodriguez-Capote K, 2001, AM J PHYSIOL-LUNG C, V281, pL231, DOI 10.1152/ajplung.2001.281.1.L231; RUSTOW B, 1994, BIOCHEM J, V302, P665; Schiller J, 2001, CHEM PHYS LIPIDS, V112, P67, DOI 10.1016/S0009-3084(01)00163-3; Schlame M, 1996, J LIPID RES, V37, P2608; SCHURCH S, 1989, J APPL PHYSIOL, V67, P2389, DOI 10.1152/jappl.1989.67.6.2389; Schurch S, 1998, BBA-MOL BASIS DIS, V1408, P180, DOI 10.1016/S0925-4439(98)00067-2; Schurch S, 2001, COMP BIOCHEM PHYS A, V129, P195, DOI 10.1016/S1095-6433(01)00316-6; SCHURCH S, 1995, BIOL NEONATE, V67, P61; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Taneva SG, 2000, BIOPHYS J, V79, P2010, DOI 10.1016/S0006-3495(00)76449-6; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VENKITARAMAN AR, 1990, CHEM PHYS LIPIDS, V56, P185, DOI 10.1016/0009-3084(90)90101-V; WARBURTON D, 1989, AM J PHYSIOL, V257, pL217, DOI 10.1152/ajplung.1989.257.4.L217; WATSON AD, 1937, J BIOL CHEM, V272, P13579; Wright SM, 2000, J APPL PHYSIOL, V89, P1283, DOI 10.1152/jappl.2000.89.4.1283; YU S, 1983, LIPIDS, V18, P522, DOI 10.1007/BF02535391; Yu SH, 1998, J LIPID RES, V39, P555; Yu SH, 1999, J LIPID RES, V40, P920	56	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20461	20474		10.1074/jbc.M212697200	http://dx.doi.org/10.1074/jbc.M212697200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12600986	hybrid			2022-12-25	WOS:000183230500005
J	Menendez, S; Khan, Z; Coomber, DW; Lane, DP; Higgins, M; Koufali, MM; Lain, S				Menendez, S; Khan, Z; Coomber, DW; Lane, DP; Higgins, M; Koufali, MM; Lain, S			Oligomerization of the human ARF tumor suppressor and its response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR-LOCALIZATION; UBIQUITIN LIGASE; NUCLEAR EXPORT; STABILIZES P53; IN-VIVO; MDM2; P19(ARF); P14(ARF); PROTEIN; INHIBITION	The tumor suppressor ARF plays an important role as an inhibitor of the Mdm2-mediated degradation of p53. Here we demonstrate that human ARF (p14ARF) can form homo-oligomers. The stability of the oligomers is favored by oxidizing agents in a reversible fashion and involves all three cysteine residues in p14ARF. Furthermore, the effect of p14ARF in clonogenic assays is moderately but reproducibly increased by the mutation of its cysteine residues. We also observed that altering the amino terminus of p14ARF resulted in the appearance of remarkably stable oligomers. This indicates that the amino terminus of p14ARF interferes with the ability of the protein to form multimeric complexes. These observations suggest that p14ARF activity may be linked to its oligomerization status and sensitive to the redox status of the cell.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Lain, S (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	s.lain@dundee.ac.uk	Lane, David P/C-4920-2008; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; Menendez, Sergio/0000-0002-7929-8641				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; DiGiammarino EL, 2001, BIOCHEMISTRY-US, V40, P2379, DOI 10.1021/bi0024005; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Nasir L, 2000, CANCER LETT, V152, P9, DOI 10.1016/S0304-3835(99)00427-9; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	35	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18720	18729		10.1074/jbc.M211007200	http://dx.doi.org/10.1074/jbc.M211007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12582152	hybrid			2022-12-25	WOS:000182932200004
J	Chen, EI; Li, WZ; Godzik, A; Howard, EW; Smith, JW				Chen, EI; Li, WZ; Godzik, A; Howard, EW; Smith, JW			A residue in the S-2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE; INHIBITOR MARIMASTAT; CATALYTIC DOMAIN; CYSTEINE SWITCH; MATRIX-METALLOPROTEINASE-9; MECHANISM; SPECIFICITY; ACTIVATION; CLEAVAGE	Matrix metalloproteinase (MMP)-2 and MMP-9 are closely related metalloproteinases that are implicated in angiogenesis. The two proteins have a similar domain structure and highly homologous catalytic domains, making them an excellent comparative model for understanding the structural basis of substrate recognition by the MMP family. Although the two MMPs exhibit some overlap in substrate recognition, our recent work showed that MMP-2 can cleave a set of peptide substrates that are only poorly recognized by MMP-9 (Chen, E.I., Kridel, S.J., Howard, E.W., Li, W., Godzik, A., and Smith, J.W. (2002) J. Biol. Chem. 277, 4485-4491). Mutations at the P-2 position of these peptide substrates dramatically reduced their selectivity for MMP-2. Inspection of the corresponding S-2 pocket of the substrate-binding cleft of the protease reveals that MMP-9 contains an Asp, whereas MMP-2 contains Glu. Here, we test the hypothesis that this conservative substitution has a role in substrate selectivity. Mutation of Glu(412) in MMP-2 to Asp significantly reduced the hydrolysis of selective substrates, with only a minor effect on hydrolysis of non-selective substrates. The predominant effect of the mutation is at the level of k(cat), or turnover rate, with reductions reaching as high as 37-fold. The residues that occupy this position in other MMPs are highly variable, providing a potential structural basis for substrate recognition across the MMP family.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA; Dept Pathol, Oklahoma City, OK 73104 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA.		Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020; Li, Weizhong/A-9735-2008	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Li, Weizhong/0000-0003-1804-9403	NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199, P01CA082713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060049] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA82713, CA69306] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline; NIGMS NIH HHS [GM60049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1730, DOI 10.1055/s-0037-1614906; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GREENWALD RA, 1999, ANN NEW YORK ACAD SC; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Millar AW, 1998, BRIT J CLIN PHARMACO, V45, P21, DOI 10.1046/j.1365-2125.1998.00639.x; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; Parsons SL, 1997, EUR J SURG ONCOL, V23, P526, DOI 10.1016/S0748-7983(97)93077-8; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOCKER W, 1995, PROTEIN SCI, V4, P823; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Yu Q, 2000, GENE DEV, V14, P163	28	43	45	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17158	17163		10.1074/jbc.M210324200	http://dx.doi.org/10.1074/jbc.M210324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12591933	hybrid			2022-12-25	WOS:000182818600095
J	El Yazidi-Belkoura, I; Adriaenssens, E; Dolle, L; Descamps, S; Hondermarck, H				El Yazidi-Belkoura, I; Adriaenssens, E; Dolle, L; Descamps, S; Hondermarck, H			Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; P75 RECEPTOR; APOPTOSIS; DIFFERENTIATION; PROLIFERATION; EXPRESSION; ACTIVATION; P75(NTR); NUCLEAR; FAMILY	The common neurotrophin receptor p75(NTR) has been shown to initiate intracellular signaling that leads either to cell survival or to apoptosis depending on the cell type examined; however, the mechanism by which p75(NTR) initiates its intracellular transduction remains unclear. We show here that the tumor necrosis factor receptor-associated death domain protein (TRADD) interacts with p75(NTR) upon nerve growth factor (NGF) stimulation. TRADD could be immunodetected after p75(NTR) immunoprecipitation from MCF-7 breast cancer cells stimulated by nerve growth factor. In addition, confocal microscopy indicated that NGF stimulation induced the plasma membrane localization of TRADD. Using a dominant negative form of TRADD, we also show that interactions between p75(NTR) and TRADD are dependent on the death domain of TRADD, thus demonstrating its requirement for binding. Furthermore, the p75(NTR)-mediated activation of NF-kappaB was inhibited by transfection with a dominant negative TRADD, resulting in an inhibition of NGF antiapoptotic activity. These results thus demonstrate that TRADD is involved in the p75(NTR)-mediated antiapoptotic activity of NGF in breast cancer cells.	Univ Sci & Technol Lille, IFR 118, UPRES EA 1033, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, IFR 118, UPRES EA 1033, Batiment SN3, F-59655 Villeneuve Dascq, France.		Dollé, Laurent/H-4612-2014; El Yazidi-Belkoura, Ikram/AAE-8805-2022; Malwad, Govind V/F-4682-2010	EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Chiarenza A, 2001, CANCER RES, V61, P3002; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; DJAKIEW D, 1991, CANCER RES, V51, P3304; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Jones EY, 2000, CURR OPIN STRUC BIOL, V10, P644, DOI 10.1016/S0959-440X(00)00149-4; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; RABIZADEH S, 1993, SCIENCE, V261, P346; Sukits SF, 2001, J MOL BIOL, V310, P895, DOI 10.1006/jmbi.2001.4790; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	28	59	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16952	16956		10.1074/jbc.M300631200	http://dx.doi.org/10.1074/jbc.M300631200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604596	Green Published, hybrid			2022-12-25	WOS:000182818600069
J	Wu, ZLL; Zhang, LJ; Yabe, T; Kuberan, B; Beeler, DL; Love, A; Rosenberg, RD				Wu, ZLL; Zhang, LJ; Yabe, T; Kuberan, B; Beeler, DL; Love, A; Rosenberg, RD			The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FGF RECEPTOR DIMERIZATION; MITOGENIC ACTIVITY; FACTOR-BINDING; CELL-SURFACE; HEPARIN/HEPARAN SULFATE; CRYSTAL-STRUCTURE; BASIC FGF; PROTEOGLYCANS; OLIGOSACCHARIDES	Fibroblast growth factor (FGF) signaling begins with the formation of a ternary complex of FGF, FGF receptor (FGFR), and heparan sulfate (HS). Multiple models have been proposed for the ternary complex. However, major discrepancies exist among those models, and none of these models have evaluated the functional importance of the interacting regions on the HS chains. To resolve the discrepancies, we measured the size and molar ratio of HS in the complex and showed that both FGF1 and FGFR1 simultaneously interact with HS; therefore, a model of 2:2:2 FGF1.HS.FGFR1 was shown to fit the data. Using genetic and biochemical methods, we generated HSs that were defective in FGF1 and/or FGFR1 binding but could form the signaling ternary complex. Both genetically and chemically modified HSs were subsequently assessed in a BaF3 cell mitogenic activity assay. The ability of HS to support the ternary complex formation was found to be required for FGF1-stimulated cell proliferation. Our data also proved that specific critical groups and sites on HS support complex formation. Furthermore, the molar ratio of HS, FGF1, and FGFR1 in the ternary complex was found to be independent of the size of HS, which indicates that the selected model can take place on the cell surface proteoglycans. Finally, a mechanism for the FGF.FGFR signaling complex formation on cell membrane was proposed, where FGF and FGFR have their own binding sites on HS and a distinct ternary complex formation site is directly responsible for mitogenic activity.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 31 Ames St,MIT Bldg 68-488, Cambridge, MA 02139 USA.		Yabe, Tomio/B-5900-2013	Yabe, Tomio/0000-0002-9295-8560; Wu, Zhengliang/0000-0002-0700-0906				Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berry D, 2001, FASEB J, V15, P1422, DOI 10.1096/fj.00-0661fje; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; DELEHEDDE M, 2002, BIOCHEM J, V9, P235; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200; Zhou FY, 1997, EUR J CELL BIOL, V73, P71	56	126	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17121	17129		10.1074/jbc.M212590200	http://dx.doi.org/10.1074/jbc.M212590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604602	hybrid			2022-12-25	WOS:000182818600091
J	Chen, MC; Hwang, MJ; Chou, YC; Chen, WH; Cheng, GH; Nakano, H; Luh, TY; Mai, SC; Hsieh, SL				Chen, MC; Hwang, MJ; Chou, YC; Chen, WH; Cheng, GH; Nakano, H; Luh, TY; Mai, SC; Hsieh, SL			The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CYTOPLASMIC DOMAIN; ACTIVATION; ASK1; LIGHT; INHIBITOR; PATHWAYS; BINDING; DISSOCIATION	LIGHT (homologous to lymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes) is a member of the tumor necrosis factor superfamily that can interact with lym-photoxin-beta receptor (LTbetaR), herpes virus entry mediator, and decoy receptor (DcR3). In our previous study, we showed that LIGHT is able to induce cell death via the non-death domain containing receptor LTbetaR to activate both caspase-dependent and caspase-independent pathway. In this study, a LIGHT mutein, LIGHT-R228E, was shown to exhibit similar binding specificity as wild type LIGHT to LTbetaR, but lose the ability to interact with herpes virus entry mediator. By using both LIGHT-R228E and agonistic anti-LTbetaR monoclonal antibody, we found that signaling triggered by LTbetaR alone is sufficient to activate both caspase-dependent and caspase-independent pathways. Cross-linking of LTbetaR is able to recruit TRAF3 and TRAF5 to activate ASK1, whereas its activity is inhibited by free radical scavenger carboxyfullerenes. The activation of ASK1 is independent of caspase-3 activation, and kinase-inactive ASK1-KE mutant can inhibit LTbetaR-mediated cell death. This suggests that ASK1 is one of the factors involved in the caspase-independent pathway of LTbetaR-induced cell death.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan; Natl Yang Ming Univ, Dept Microbiol & Immunol, Taipei 11221, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Yang Ming Univ, Immunol Res Ctr, Taipei 11221, Taiwan; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Taiwan University; Juntendo University	Hsieh, SL (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 11221, Taiwan.		Hwang, Ming-jing/E-9210-2012; Hsieh, Shie-Liang Edmond/ABA-9184-2021	Hwang, Ming-jing/0000-0002-9657-5663; Luh, Tien-Yau/0000-0002-0415-6454; Nakano, Hiroyasu/0000-0003-4843-1427				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chang YH, 2002, EXP CELL RES, V278, P166, DOI 10.1006/excr.2002.5573; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Dohi T, 2001, J IMMUNOL, V167, P2781, DOI 10.4049/jimmunol.167.5.2781; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; FORCE WR, 1995, J IMMUNOL, V155, P5280; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Koni PA, 1998, J EXP MED, V187, P1977, DOI 10.1084/jem.187.12.1977; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Mackay F, 1997, EUR J IMMUNOL, V27, P2033, DOI 10.1002/eji.1830270830; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Puglielli MT, 1999, NAT MED, V5, P1370; Rennert PD, 1997, INT IMMUNOL, V9, P1627, DOI 10.1093/intimm/9.11.1627; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Wu MY, 1997, J BIOL CHEM, V272, P17154, DOI 10.1074/jbc.272.27.17154; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	47	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16073	16081		10.1074/jbc.M208661200	http://dx.doi.org/10.1074/jbc.M208661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12566458	hybrid			2022-12-25	WOS:000182680000079
J	Malcolm, KC; Worthen, GS				Malcolm, KC; Worthen, GS			Lipopolysaccharide stimulates p38-dependent induction of antiviral genes in neutrophils independently of paracrine factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TOLL-LIKE RECEPTOR-4; DOUBLE-STRANDED-RNA; INTERFERON REGULATORY FACTOR-3; CELL-WALL COMPONENTS; N-TERMINAL KINASE; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; HIV-1 INFECTION	Lipopolysaccharide (LPS) induces neutrophils to synthesize and secrete pro-inflammatory cytokines and chemokines, which are regulated at both the transcriptional and translational level. We reported previously that neutrophils stimulated with LPS induce expression of genes typically expressed in response to stimulation with antiviral type I interferons (IFN), such as myxovirus resistance-1 (MX1). However, we present evidence that this response of neutrophils to lipopolysaccharide occurs in the absence of interferon-dependent signaling. Lipopolysaccharide-stimulated neutrophils do not phosphorylate the interferon-associated transcription factors signal transducer and activator of transcription-1 and -3, and medium from lipopolysaccharide-stimulated cells was unable to induce MX1 gene expression, suggesting a soluble factor is not involved. Furthermore, LPS did not alter expression of IFNA and IFNB genes. In contrast to neutrophils, LPS-stimulated human monocyte-derived macrophages induced the expression of MX1, but IFNB was induced, and medium from LPS-stimulated monocyte-derived macrophages supported MX1 induction. An inhibitor of p38 kinase blocked induction of MX1 by lipopolysaccharide, but not IFNalpha, in neutrophils, and induction of MX1 was dependent on protein synthesis. LPS, but not IFNa, substantially activated p38. In contrast, the induction of MX1 by LPS in monocyte-derived macrophages was insensitive to p38 inhibition, although p38 is phosphorylated in LPS-stimulated but not IFNalpha-stimulated monocyte-derived macrophages. The expression of MX1 in neutrophils and monocyte-derived macrophages is mediated by TLR4 but not TLR2. The data presented here indicate that lipopolysaccharide activates novel interferon-independent signaling pathways in neutrophils and that induction of antiviral genes is a consequence of exposure of neutrophils to bacterial products.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Malcolm, KC (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; AU WC, 1993, J BIOL CHEM, V268, P24032; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Cassatella MA, 1997, ANN NY ACAD SCI, V832, P233, DOI 10.1111/j.1749-6632.1997.tb46251.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Detmers PA, 1998, J IMMUNOL, V161, P1921; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; Franchin G, 2000, J IMMUNOL, V164, P2592, DOI 10.4049/jimmunol.164.5.2592; Gao JJ, 1998, J IMMUNOL, V161, P4803; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; GOETSCHY JF, 1989, J VIROL, V63, P2616, DOI 10.1128/JVI.63.6.2616-2622.1989; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HASLETT C, 1985, AM J PATHOL, V119, P101; HAYES MP, 1991, J LEUKOCYTE BIOL, V50, P176, DOI 10.1002/jlb.50.2.176; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Liverton NJ, 1999, J MED CHEM, V42, P2180, DOI 10.1021/jm9805236; MAEHARA N, 1977, INFECT IMMUN, V15, P78, DOI 10.1128/IAI.15.1.78-83.1977; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mellado M, 2001, CELL MOL BIOL, V47, P575; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Nick JA, 2002, J IMMUNOL, V169, P5260, DOI 10.4049/jimmunol.169.9.5260; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Scherle PA, 1998, J IMMUNOL, V161, P5681; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Tumpey TM, 1996, J VIROL, V70, P898, DOI 10.1128/JVI.70.2.898-904.1996; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Wang S Z, 2000, Respirology, V5, P1, DOI 10.1046/j.1440-1843.2000.00219.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985; Zu YL, 1998, J IMMUNOL, V160, P1982; Zybarth G, 1999, J IMMUNOL, V162, P400	83	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15693	15701		10.1074/jbc.M212033200	http://dx.doi.org/10.1074/jbc.M212033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595530	hybrid			2022-12-25	WOS:000182680000031
J	Rybkin, II; Markham, DW; Yan, Z; Bassel-Duby, R; Williams, RS; Olson, EN				Rybkin, II; Markham, DW; Yan, Z; Bassel-Duby, R; Williams, RS; Olson, EN			Conditional expression of SV40 T-antigen in mouse cardiomyocytes facilitates an inducible switch from proliferation to differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL-LINE; IN-VITRO; VENTRICULAR MYOCYTES; CARDIAC-HYPERTROPHY; ADENOVIRAL VECTORS; TRANSGENIC MOUSE; MODEL SYSTEM; HEART; TRANSFORMATION; RECOMBINATION	Studies of cardiac muscle gene expression and signaling have been hampered by the lack of immortalized cardiomyocyte cell lines capable of proliferation and irreversible withdrawal from the cell cycle. With the goal of creating such cell lines, we generated transgenic mice using cardiac-specific cis-regulatory elements from the mouse Nkx2.5 gene to drive the expression of a simian virus 40 large T-antigen (TAg) gene flanked by sites for recombination by Cre recombinase. These transgenic mice developed tumors within the ventricular myocardium. Cells isolated from these tumors expressed cardiac markers and proliferated rapidly during serial passage in culture, without apparent senescence. However, they were unable to exit the cell cycle and failed to exhibit morphological features of terminal differentiation. Introduction of Cre recombinase to these cardiac cell lines by adenoviral delivery resulted in the elimination of TAg expression, accompanied by rapid cessation of cell division, and increase in cell size without an apparent induction of cellular differentiation. Incubation of cells lacking TAg in serum-deficient media with various pharmacological agents (norepinephrine, phenylephrine, or bone morphogenetic protein-2/4) or constitutively active calcium/calmodulin-dependent protein kinase I and/or calcineurin led to the formation of sarcomeres and up-regulation of cardiac genes involved in excitation-contraction coupling. The combination of TAg expression under the control of an early cardiac promoter and Cre-mediated recombination allowed us to derive an immortal cell line from the ventricular myocardium. that could be controllably withdrawn from the cell cycle. The conditional expression of TAg in this manner permits propagation and regulated growth termination of cell types that are otherwise unable to be maintained in cell culture and may have applications for cardiac repair technologies.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Duke Univ, Sch Med, Durham, NC 27710 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Eric.Olson@utsouthwestern.edu		Yan, Zhen/0000-0002-4826-9813; Rybkin, Igor/0000-0002-8434-1093				ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Brunskill EW, 2001, DEV BIOL, V235, P507, DOI 10.1006/dbio.2001.0313; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CYRAN SE, 1992, J MOL CELL CARDIOL, V24, P1167, DOI 10.1016/0022-2828(92)93180-R; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; Eisenberg CA, 1996, CIRC RES, V78, P205, DOI 10.1161/01.RES.78.2.205; ENGELMANN GL, 1993, J MOL CELL CARDIOL, V25, P197, DOI 10.1006/jmcc.1993.1022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jahn L, 1996, J CELL SCI, V109, P397; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KLINE RP, 1993, J CARDIOVASC ELECTR, V4, P642, DOI 10.1111/j.1540-8167.1993.tb01251.x; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Lien CL, 1999, DEVELOPMENT, V126, P75; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MILLER C, 1994, MOL CELL BIOCHEM, V136, P29, DOI 10.1007/BF00931601; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Mouly V, 1996, EXP CELL RES, V225, P268, DOI 10.1006/excr.1996.0176; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Ng P, 1999, HUM GENE THER, V10, P2667, DOI 10.1089/10430349950016708; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; Soonpaa MH, 1997, AM J PHYSIOL-HEART C, V272, pH220, DOI 10.1152/ajpheart.1997.272.1.H220; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995	35	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15927	15934		10.1074/jbc.M213102200	http://dx.doi.org/10.1074/jbc.M213102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590133	hybrid			2022-12-25	WOS:000182680000061
J	Wu, KJ; Jiang, SW; Couch, FJ				Wu, KJ; Jiang, SW; Couch, FJ			p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE BRCA2; TATA-BINDING PROTEIN; BREAST-CANCER CELLS; FACTOR-KAPPA-B; RADIATION HYPERSENSITIVITY; TRANSCRIPTION FACTOR; RAD51; REPAIR; EXPRESSION; IDENTIFICATION	Adriamycin and other DNA-damaging agents have been shown to reduce BRCA2 mRNA levels in breast cancer cell lines, but the mechanism by which this occurs is unknown. In this study, we show that adriamycin and mitomycin C, but not other DNA-damaging agents, repress BRCA2 promoter activity in a dose- and time-dependent manner. We demonstrate that the effect is dependent on wild type p53 and that adriamycin and p53 mediate repression of the BRCA2 promoter by inhibiting binding of an upstream stimulatory factor protein complex to the promoter. In addition, we present evidence indicating that adriamycin and other DNA-damaging agents reduce BRCA2 mRNA and protein levels by altering both BRCA2 mRNA stability and protein stability. Thus, BRCA2 levels in the cell are regulated by three independent mechanisms in a p53-dependent manner.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Couch, FJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,1001 Guggenheim Bldg, Rochester, MN 55905 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bertwistle D, 1997, CANCER RES, V57, P5485; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blagosklonny MV, 1998, J CLIN ENDOCR METAB, V83, P2516, DOI 10.1210/jc.83.7.2516; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Galibert MD, 1997, J IMMUNOL, V159, P6176; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Le Page F, 2000, CANCER RES, V60, P5548; LIU X, 1995, MOL CELL BIOL, V15, P6474; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Vaughn JP, 1996, CANCER RES, V56, P4590; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang SC, 2001, CANCER RES, V61, P2838; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	36	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15652	15660		10.1074/jbc.M211297200	http://dx.doi.org/10.1074/jbc.M211297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591928	hybrid			2022-12-25	WOS:000182680000026
J	Warke, VG; Nambiar, MP; Krishnan, S; Tenbrock, K; Geller, DA; Koritschoner, NP; Atkins, JL; Farber, DL; Tsokos, GC				Warke, VG; Nambiar, MP; Krishnan, S; Tenbrock, K; Geller, DA; Koritschoner, NP; Atkins, JL; Farber, DL; Tsokos, GC			Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RAT MESANGIAL CELLS; ZINC-FINGER PROTEIN; GENE-EXPRESSION; INOS GENE; BINDING PROTEIN; MURINE MELANOMA; PHOSPHORYLATION; SUPPRESSION; TUMORIGENICITY	Nitric oxide is a ubiquitous free radical that plays a key role in a broad spectrum of signaling pathways in physiological and pathophysiological processes. We have explored the transcriptional regulation of inducible nitric-oxide synthase (iNOS) by Kruppel-like factor 6 (KLF6), an Sp1-like zinc finger transcription factor. Study of serial deletion constructs of the iNOS promoter revealed that the proximal 0.63-kb region can support a 3-6-fold reporter activity similar to that of the full-length 16-kb promoter. Within the 0.63-kb region, we identified two CACCC sites (-164 to -168 and -261 to -265) that bound KLF6 in both electrophoretic mobility shift and chromatin immunoprecipitation assays. Mutation of both these sites abrogated the KLF6-induced enhancement of the 0.63-kb iNOS promoter activity. The binding of KLF6 to the iNOS promoter was significantly increased in Jurkat cells, primary T lymphocytes, and COS-7 cells subjected to NaCN-induced hypoxia, heat shock, serum. starvation, and phorbol 12-myristate 13-acetate/A23187 ionophore stimulation. Furthermore, in KLF6-transfected and NaCN-treated COS-7 cells, there was a 3-4-fold increase in the expression of the endogenous iNOS mRNA and protein that correlated with increased production of nitric oxide. These findings indicate that KLF6 is a potential transactivator of the human iNOS promoter in diverse pathophysiological conditions.	Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD 20910 USA; Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, RA-5000 Cordoba, Argentina	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University System of Maryland; University of Maryland College Park; Uniformed Services University of the Health Sciences - USA; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National University of Cordoba	Tsokos, GC (corresponding author), Walter Reed Army Inst Res, Dept Cellular Injury, Bldg 503,Rm 1A32,Robert Grant Ave, Silver Spring, MD 20910 USA.	gtsokos@usa.net	tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360; Farber, Donna/0000-0001-8236-9183	PHS HHS [R01 49954] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Blanchon L, 2001, MECH DEVELOP, V105, P185, DOI 10.1016/S0925-4773(01)00391-4; Bouchie JL, 1998, ARTERIOSCL THROM VAS, V18, P1771, DOI 10.1161/01.ATV.18.11.1771; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Eberhardt W, 2002, KIDNEY INT, V61, P20, DOI 10.1046/j.1523-1755.2002.00087.x; Efron D T, 2000, Curr Opin Clin Nutr Metab Care, V3, P197, DOI 10.1097/00075197-200005000-00006; Efron DT, 1999, J GASTROINTEST SURG, V3, P592, DOI 10.1016/S1091-255X(99)80080-8; Fischer EA, 2001, J AM SOC NEPHROL, V12, P726, DOI 10.1681/ASN.V124726; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Grisham MB, 2000, ALIMENT PHARM THERAP, V14, P3, DOI 10.1046/j.1365-2036.2000.014s1003.x; Hur GM, 1999, BIOCHEM BIOPH RES CO, V261, P917, DOI 10.1006/bbrc.1999.1143; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Jensen MS, 2000, TOXICOL SCI, V58, P127, DOI 10.1093/toxsci/58.1.127; Juang SH, 1998, HUM GENE THER, V9, P845, DOI 10.1089/hum.1998.9.6-845; Juang SH, 1997, CANCER BIOTHER RADIO, V12, P167, DOI 10.1089/cbr.1997.12.167; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Liossis SNC, 1998, J CLIN INVEST, V101, P1448, DOI 10.1172/JCI1457; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Ouyang L, 1998, J BIOL CHEM, V273, P23019, DOI 10.1074/jbc.273.36.23019; Paulsen Stephen M., 1998, Wound Repair and Regeneration, V6, P142, DOI 10.1046/j.1524-475X.1998.60208.x; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Ralston SH, 1996, BONE, V19, P29, DOI 10.1016/8756-3282(96)00101-9; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Slavin D, 1999, BIOL REPROD, V61, P1586, DOI 10.1095/biolreprod61.6.1586; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; Wang IJ, 2002, MOL VIS, V8, P94; Wang YN, 2002, ANN NY ACAD SCI, V962, P415, DOI 10.1111/j.1749-6632.2002.tb04085.x; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu WM, 2001, FASEB J, V15, P213, DOI 10.1096/fj.01-0590fje; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067; Yang C W, 1996, J Biochem Toxicol, V11, P251, DOI 10.1002/(SICI)1522-7146(1996)11:5<251::AID-JBT6>3.0.CO;2-J; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	51	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14812	14819		10.1074/jbc.M300787200	http://dx.doi.org/10.1074/jbc.M300787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590140	hybrid			2022-12-25	WOS:000182516100031
J	Zhao, YG; Xiao, AZ; Newcomer, RG; Park, HI; Kang, TB; Chung, LWK; Swanson, MG; Zhau, HE; Kurhanewicz, J; Sang, QXA				Zhao, YG; Xiao, AZ; Newcomer, RG; Park, HI; Kang, TB; Chung, LWK; Swanson, MG; Zhau, HE; Kurhanewicz, J; Sang, QXA			Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; MATRIX-METALLOPROTEINASE; TISSUE INHIBITOR; CYSTEINE-SWITCH; IV COLLAGENASE; MATRIX-METALLOPROTEINASE-9; PROGELATINASE; PROCOLLAGENASE; OVEREXPRESSION; FIBROBLASTS	This work has explored a putative biochemical mechanism by which endometase/matrilysin-2/matrix metalloproteinase-26 (MMP-26) may promote human prostate cancer cell invasion. Here, we showed that the levels of MMP-26 protein in human prostate carcinomas from multiple patients were significantly higher than those in prostatitis, benign prostate hyperplasia, and normal prostate glandular tissues. The role of MMP-26 in prostate cancer progression is unknown. MMP-26 was capable of activating pro-MMP-9 by cleavage at the Ala(93)-Met(94) site of the prepro-enzyme. This activation proceeded in a time- and dose-dependent manner, facilitating the efficient cleavage of fibronectin by MMP-9. The activated MMP-9 products generated by MMP-26 appeared more stable than those cleaved by MMP-7 under the conditions tested. To investigate the contribution of MMP-26 to cancer cell invasion via the activation of MMP-9, highly invasive and metastatic human prostate carcinoma cells, androgen-repressed prostate cancer (ARCaP) cells were selected as a working model. ARCaP cells express both MMP-26 and MMP-9. Specific anti-MMP-26 and anti-MMP-9 functional blocking antibodies both reduced the invasiveness of ARCaP cells across fibronectin or type IV collagen. Furthermore, the introduction of MMP-26 antisense cDNA into ARCaP cells significantly reduced the MMP-26 protein level in these cells and strongly suppressed the invasiveness of ARCaP cells. Double immunofluorescence staining and confocal laser scanning microscopic images revealed that MMP-26 and MMP-9 were co-localized in parental and MMP-26 sense-transfected ARCaP cells. Moreover, MMP-26 and MMP-9 proteins were both expressed in the same human prostate carcinoma tissue samples examined. These results indicate that MMP-26 may be a physiological and pathological activator of pro-MMP-9.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Emory Univ, Winship Canc Inst, Mol Urol & Therapeut Program, Atlanta, GA 30322 USA; Univ Calif San Francisco, Magnet Resonance Sci Ctr, San Francisco, CA 94143 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; Emory University; University of California System; University of California San Francisco	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, Chem Res Bldg,Rm 203,203 DLC, Tallahassee, FL 32306 USA.	sang@chem.fsu.edu			NCI NIH HHS [CA76620, CA82739, CA78646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078646, R01CA082739, R01CA076620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt M, 2002, CANCER RES, V62, P5543; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; GOLDFARB RH, 1986, SEMIN THROMB HEMOST, V12, P294, DOI 10.1055/s-2007-1003570; Hrabec E, 2001, RESP MED, V95, P1, DOI 10.1053/rmed.2000.0923; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Li H, 1998, MOL CARCINOGEN, V22, P84; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Marchenko ND, 2002, J BIOL CHEM, V277, P18967, DOI 10.1074/jbc.M201197200; Mase K, 2002, LUNG CANCER-J IASLC, V36, P271, DOI 10.1016/S0169-5002(02)00004-1; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsubara S, 2001, CANCER RES, V61, P6012; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Nemeth JA, 2002, J NATL CANCER I, V94, P17; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; Sakamoto Y, 2000, INT J ONCOL, V17, P237; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 2000, BIOCHEM BIOPH RES CO, V274, P780, DOI 10.1006/bbrc.2000.3212; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Seftor REB, 2001, CANCER RES, V61, P6322; Shen KH, 2000, ANTICANCER RES, V20, P1307; Singer CF, 2002, BREAST CANCER RES TR, V72, P69, DOI 10.1023/A:1014918512569; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; Tschesche H, 2001, EUR J BIOCHEM, V268, P1918, DOI 10.1046/j.1432-1327.2001.02066.x; Uria JA, 2000, CANCER RES, V60, P4745; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Zhang J, 2002, MOL HUM REPROD, V8, P659, DOI 10.1093/molehr/8.7.659; Zhao YG, 2002, MOL REPROD DEV, V62, P149, DOI 10.1002/mrd.10123; Zhao YG, 2001, BIOCHEM BIOPH RES CO, V289, P288, DOI 10.1006/bbrc.2001.5958; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152	40	105	119	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15056	15064		10.1074/jbc.M210975200	http://dx.doi.org/10.1074/jbc.M210975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586837	hybrid			2022-12-25	WOS:000182516100063
J	Janknecht, R				Janknecht, R			Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1)	ONCOGENE			English	Article						CBP; ER81; MSK1; p300; phosphorylation; transcription	RUBINSTEIN-TAYBI-SYNDROME; PROTEIN-KINASE; MAP KINASE; HISTONE H3; INDUCED PHOSPHORYLATION; EXPRESSION PATTERNS; BINDING PROTEIN; ETS-DOMAIN; PEA3 GROUP; GENE	The transcription factor ER81 has been shown to be involved in ontogenesis and breast tumor formation. ER81 is activated by many signals through phosphorylation directly mediated by mitogen-activated protein kinases (MAPKs), but also by an unknown protein kinase(s). Here, mitogen- and stress-activated protein kinase I (MSK1), which itself is directly activated by distinct classes of MAPKs, is identified to regulate ER81 function. MSK1 expression enhances ER81-dependent transcription upon stimulation of especially the p38-MAPK pathway. Two serine residues in ER81 are phosphorylated by MSK1, and mutating these serine residues to alanines dramatically diminishes the ability of MSK1 to stimulate ER81. However, mutation of the MSK1 phosphorylation sites in ER81 does not completely abrogate the ability of MSK1 to activate ER81 function, suggesting that MSK1 may also target cofactors of ER81. Consistently, MSK1 interacts with two homologous coactivators of ER81, CBP and p300, and stimulates the transactivation domains of CBP. Thus, MSK1 may regulate ER81-dependent transcription via direct phosphorylation of ER81 as well as via stimulation of CBP/p300, which might be important for ER81's normal function and during mammary tumor formation.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER; NCI NIH HHS [CA085257, R01 CA085257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blough RI, 2000, AM J MED GENET, V90, P29, DOI 10.1002/(SICI)1096-8628(20000103)90:1<29::AID-AJMG6>3.0.CO;2-Z; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goodman RH, 2000, GENE DEV, V14, P1553; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hung MC, 1999, SEMIN ONCOL, V26, P51; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 2001, J BIOL CHEM, V276, P41856, DOI 10.1074/jbc.M106630200; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JEON IS, 1995, ONCOGENE, V10, P1229; Kucera J, 2002, DEV DYNAM, V223, P389, DOI 10.1002/dvdy.10066; Kung AL, 2000, GENE DEV, V14, P272; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MONTE D, 1995, ONCOGENE, V11, P771; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Smits PHM, 1996, ONCOGENE, V12, P1529; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Strelkov IS, 2002, CANCER RES, V62, P75; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tomas-Zuber M, 2001, J BIOL CHEM, V276, P5892, DOI 10.1074/jbc.M005822200; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	54	81	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					746	755		10.1038/sj.onc.1206185	http://dx.doi.org/10.1038/sj.onc.1206185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569367				2022-12-25	WOS:000180642100012
J	Cortajarena, AL; Goni, FM; Ostolaza, H				Cortajarena, AL; Goni, FM; Ostolaza, H			A receptor-binding region in Escherichia coli alpha-haemolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; HUMAN TARGET-CELLS; PHOSPHOLIPID-VESICLES; LIPID-BILAYERS; RTX TOXINS; LEUKOTOXIN; INSERTION; MEMBRANE; PROTEIN; IDENTIFICATION	Escherichia coli alpha-hemolysin (HlyA) is a 107-kDa protein toxin with a wide range of mammalian target cells. Previous work has shown that glycophorin is a specific receptor for HlyA in red blood cells (Cortajarena, A. L., Goni, F. M., and Ostolaza, H. (2001) J. Biol. Chem. 276, 12513-12519). The present study was aimed at identifying the glycophorin-binding region in the toxin. Data in the literature pointed to a short amino acid sequence near the C terminus as a putative receptor-binding domain. Previous sequence analyses of several homologous toxins that belong, like HlyA, to the so-called RTX toxin family revealed a conserved region that corresponded to residues 914-936 of HlyA. We therefore prepared a deletion mutant lacking these residues (HlyADelta914-936) and found that its hemolytic activity was decreased by 10,000-fold with respect to the wild type. This deletion mutant was virtually unable to bind human and horse red blood cells or to bind pure glycophorin in an affinity column. The peptide Trp(914)-Arg(936) had no lytic activity of its own, but it could bind glycophorin reconstituted in lipid vesicles. Moreover, the peptide Trp(914)-Arg(936) protected red blood cells from hemolysis induced by wild type HlyA. It was concluded that amino acid residues 914-936 constitute a major receptor-binding region in alpha-hemolysin.	Univ Basque Country Euskal Herriko Unibertsitatea, CSIC, Unidad Biofis, Bilbao 48080, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Ostolaza, H (corresponding author), Univ Basque Country Euskal Herriko Unibertsitatea, CSIC, Unidad Biofis, Aptdo 644, Bilbao 48080, Spain.	gbzoseth@lg.ehu.es	Goni, Felix M/M-5425-2015; Cortajarena, Aitziber L/J-6202-2012	Goni, Felix M/0000-0001-6270-9216; Cortajarena, Aitziber L/0000-0002-5331-114X; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Bakas L, 1998, BBA-BIOMEMBRANES, V1368, P225, DOI 10.1016/S0005-2736(97)00181-8; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Bauer ME, 1996, INFECT IMMUN, V64, P4665, DOI 10.1128/IAI.64.11.4665-4672.1996; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Bejerano M, 1999, MOL MICROBIOL, V31, P381, DOI 10.1046/j.1365-2958.1999.01183.x; Chervaux C, 1996, J BACTERIOL, V178, P1232, DOI 10.1128/jb.178.4.1232-1236.1996; COOTE JG, 1996, REV MED MICROBIOL, V7, P53, DOI [10.1097/00013542-199601000-00006, DOI 10.1097/00013542-199601000-00006]; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; CRUZ WT, 1990, MOL MICROBIOL, V4, P1933, DOI 10.1111/j.1365-2958.1990.tb02042.x; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Lainson FA, 1996, MICROBIOL-UK, V142, P2499, DOI 10.1099/00221287-142-9-2499; LALLY ET, 1994, J BIOL CHEM, V269, P31289; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lim KB, 2000, J BIOL CHEM, V275, P36698, DOI 10.1074/jbc.C000544200; MACDONALD RI, 1975, J BIOL CHEM, V250, P9206; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; PEREIRA FB, 1995, FEBS LETT, V362, P243, DOI 10.1016/0014-5793(95)00257-A; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Soloaga A, 1999, MOL MICROBIOL, V31, P1013, DOI 10.1046/j.1365-2958.1999.01225.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Sun YD, 1999, INFECT IMMUN, V67, P6264; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3	28	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19159	19163		10.1074/jbc.M208552200	http://dx.doi.org/10.1074/jbc.M208552200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12582172	hybrid			2022-12-25	WOS:000182932200058
J	Koo, IC; Stephens, RS				Koo, IC; Stephens, RS			A developmentally regulated two-component signal transduction system in Chlamydia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; COMPLETE GENOME SEQUENCE; RNA-POLYMERASE; ACTIVATE TRANSCRIPTION; SIGMA(54) SIGMA(N); MYXOCOCCUS-XANTHUS; CENTRAL DOMAIN; TRACHOMATIS; NTRC; GENE	Two-component systems allow bacteria to adapt to changing environmental conditions and may induce developmental changes necessary for survival. Chlamydia trachomatis alternates between two distinct developmental forms, each optimized for survival in a separate niche. Transcriptional regulation of development is not understood. The C. trachomatis genome sequence revealed a single pair of genes (ctcB-ctcC) predicted to encode proteins with sequence conservation to bacterial two-component systems. Sequence analysis revealed that the sensor kinase, CtcB, possessed an energy-sensing PAS domain and phosphorylation site. The response regulator, CtcC, had homology to sigma(54) activators, possessing conserved receiver and ATPase domains and phosphorylation site, but lacked the C-terminal DNA-binding domain. ctcB and ctcC were expressed late in the developmental cycle, and both proteins were detected in EB lysates. Recombinant CtcB and CtcC were purified from denatured Escherichia coli inclusion bodies and refolded. CtcC was found to aggregate as dimers and tetramers in solution. In vitro phosphorylation assays showed that CtcB autophosphorylated in the presence of Mg2+, Mn2+, and Fe2+ and transferred the phosphoryl group in the presence of CtcC. Collectively, these results show that CtcB and CtcC function as a two-component system and are likely responsible for transcriptional regulation by sigma(54) holoenzyme during late-stage chlamydial development.	Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco	Stephens, RS (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, 140 Warren Hall, Berkeley, CA 94720 USA.				PHS HHS [AY42156] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAVOIL P, 1984, INFECT IMMUN, V44, P479, DOI 10.1128/IAI.44.2.479-485.1984; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; CONTRERAS A, 1988, NUCLEIC ACIDS RES, V16, P4025, DOI 10.1093/nar/16.9.4025; Cullen PJ, 1996, J BIOL CHEM, V271, P6530, DOI 10.1074/jbc.271.11.6530; Fehlner-Gardiner C, 2002, J BIOL CHEM, V277, P26893, DOI 10.1074/jbc.M203937200; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; HACKSTADT T, 1985, J BACTERIOL, V161, P25, DOI 10.1128/JB.161.1.25-31.1985; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HUALA E, 1989, J BACTERIOL, V171, P3354, DOI 10.1128/jb.171.6.3354-3365.1989; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; KAUL R, 1986, J BACTERIOL, V168, P722, DOI 10.1128/jb.168.2.722-727.1986; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOSHIYAMA KY, 1998, P 9 INT S HUM CHLAM, P535; Kroos L, 1999, MOL MICROBIOL, V31, P1285, DOI 10.1046/j.1365-2958.1999.01214.x; Laskos L, 1998, GENE, V208, P95, DOI 10.1016/S0378-1119(97)00664-1; Li YH, 1996, J BACTERIOL, V178, P289, DOI 10.1128/jb.178.1.289-292.1996; Marques MDV, 1997, J BACTERIOL, V179, P5502, DOI 10.1128/jb.179.17.5502-5510.1997; Mathews SA, 2000, J BACTERIOL, V182, P6239, DOI 10.1128/JB.182.21.6239-6242.2000; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; MORETT E, 1988, NUCLEIC ACIDS RES, V16, P11469, DOI 10.1093/nar/16.24.11469; Neuwald AF, 1999, GENOME RES, V9, P27; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Shaw EI, 2000, MOL MICROBIOL, V37, P913, DOI 10.1046/j.1365-2958.2000.02057.x; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; STEPHENS RS, 2001, P 10 INT S HUM CHLAM, P3; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Studholme DJ, 2000, FEMS MICROBIOL LETT, V186, P1; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Ward ME, 1988, MICOBIOLOGY CHLAMYDI, P71; WICHLAN DG, 1993, J BACTERIOL, V175, P2936, DOI 10.1128/JB.175.10.2936-2942.1993; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	41	42	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17314	17319		10.1074/jbc.M212170200	http://dx.doi.org/10.1074/jbc.M212170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600998	hybrid			2022-12-25	WOS:000182818600116
J	Stock, M; Schafer, H; Stricker, S; Gross, G; Mundlos, S; Otto, F				Stock, M; Schafer, H; Stricker, S; Gross, G; Mundlos, S; Otto, F			Expression of galectin-3 in skeletal tissues is controlled by Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE-BINDING-FACTOR; OSTEOBLAST DIFFERENTIATION; BONE-FORMATION; CELL LINEAGES; GENE; PROTEIN; LECTINS; CBFA1; AML1; SECRETION	The beta-galatoside-specific lectin galectin-3 is expressed in vivo in osteoblasts as well as in epiphyseal cartilage. Here we show that in vitro, galectin-3 expression is upregulated in the preosteoblastic cell line MC3T3-E1 during the matrix maturation stage of the osteoblast developmental sequence. Expression persists into late differentiation stages when the mature osteoblastic phenotype is established. The skeletal expression pattern of galectin-3 overlaps at many sites with that of the transcription factor Runx2. Runx2 is a key regulator of osteoblast development and necessary for chondrocyte differentiation in the growth plate. Both human and mouse galectin-3 promoters contain putative Runx-binding sites. The constitutive or inducible forced expression of Runx2 is sufficient for the onset of galectin-3 transcription in the mesenchymal precursor cell line C3H10T1/2. Moreover, Runx2 is able to bind to at least two sites in the galectin-3 promoter region. The crucial role of Runx2 was confirmed in Runx2-deficient mice, which are devoid of galectin-3 expression in skeletal cells. The overlapping expression pattern of galectin-3 with the other two members of the Runt family of transcription factors (Runx1 and Runx3) points to a potential regulation of the galectin-3 gene (LGALS3) by these factors in hematopoietic, skin, and dorsal root ganglial cells.	Univ Freiburg, Med Ctr, Div Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Inst Biol 1, D-79106 Freiburg, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany	University of Freiburg; University of Freiburg; Max Planck Society; Gesellschaft fur Biotechnologische Forschung mbH	Otto, F (corresponding author), Univ Freiburg, Med Ctr, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.		Stock, Michael/B-9829-2009; Stricker, Sigmar/B-9169-2009; Mundlos, Stefan/ABH-9585-2020	Stricker, Sigmar/0000-0002-7174-5363; Mundlos, Stefan/0000-0002-9788-3166; Stock, Michael/0000-0002-3322-0961				AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Aubin JE, 1996, J CELL PHYSIOL, V169, P468, DOI 10.1002/(SICI)1097-4652(199612)169:3<468::AID-JCP7>3.0.CO;2-M; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Colnot C, 1999, CELL MOL BIOL, V45, P1191; Colnot C, 2001, DEV BIOL, V229, P203, DOI 10.1006/dbio.2000.9933; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; GESSNER A, 1994, INFECT IMMUN, V62, P4112, DOI 10.1128/IAI.62.10.4112-4117.1994; Gotz W, 1997, DIFFERENTIATION, V62, P149, DOI 10.1046/j.1432-0436.1997.6230149.x; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Heilmann S, 2000, HISTOCHEM CELL BIOL, V113, P241, DOI 10.1007/s004180050444; HO MK, 1982, J IMMUNOL, V128, P1221; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LIU FT, 1993, IMMUNOPHARMACOLOGY, V26, P187, DOI 10.1016/0162-3109(93)90034-N; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; Maniatis T., 1982, MOL CLONING LAB MANU; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nishiyama J, 2000, AM J PATHOL, V157, P815, DOI 10.1016/S0002-9440(10)64595-6; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Pesheva P, 2000, NEUROSCI LETT, V293, P37, DOI 10.1016/S0304-3940(00)01499-3; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	52	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17360	17367		10.1074/jbc.M207631200	http://dx.doi.org/10.1074/jbc.M207631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604608	hybrid			2022-12-25	WOS:000182818600122
J	Atcha, FA; Munguia, JE; Li, TWH; Hovanes, K; Waterman, ML				Atcha, FA; Munguia, JE; Li, TWH; Hovanes, K; Waterman, ML			A new beta-catenin-dependent activation domain in T cell factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; COLORECTAL-CANCER; TRANSCRIPTIONAL REPRESSION; NUCLEAR-LOCALIZATION; SIGNALING PATHWAY; GENE-EXPRESSION; PROMOTER; PROTEIN; ISOFORMS; TCF-1	Transcription of the lymphoid enhancer factor-1 (LEF1) gene is aberrantly activated in sporadic colon cancer, whereas this gene is not expressed in the normal adult colon. We have shown previously that promoter I of the LEF1 gene is activated by T cell factor (TCF)-beta-catenin complexes in transient transfection assays, suggesting that LEF1 is a target of the Wnt pathway in colon cancer. To further explore the link between LEF1 expression and the Wnt pathway, we studied two response elements in the promoter. Surprisingly we found that the LEF1 promoter is selectively activated by specific isoforms of the LEF/TCF transcription factor family that contain an alternative C-terminal "E" tail. These isoforms, TCF-1E and TCF-4E, activate the promoter in a beta-catenin-dependent manner. We show that a complete E-tail domain is necessary for fall activity and delimits residues within two highly conserved peptide motifs within the tail that are required (KKCRARFG; WCXX-CRRKKKC). These peptide motifs are not only conserved among the TCF family members but are also found in two newly identified DNA-binding proteins named papillomavirus binding factor and GLUT4 enhancer factor. This study thus identifies a new and unique set of motifs used by the Wnt pathway for target gene regulation.	Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Waterman, ML (corresponding author), Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NCI NIH HHS [CA 83982, CA 09054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083982, T32CA009054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker N, 2000, BIOESSAYS, V22, P961; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boeckle S, 2002, VIROLOGY, V293, P103, DOI 10.1006/viro.2001.1231; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Duval A, 2000, CANCER RES, V60, P3872; EISENBERG SP, 1985, MOL CELL BIOL, V5, P1940, DOI 10.1128/MCB.5.8.1940; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Mayer K, 1997, INT J CANCER, V72, P625, DOI 10.1002/(SICI)1097-0215(19970807)72:4<625::AID-IJC13>3.0.CO;2-A; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	37	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16169	16175		10.1074/jbc.M213218200	http://dx.doi.org/10.1074/jbc.M213218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12582159	hybrid			2022-12-25	WOS:000182680000090
J	Kargul, J; Nield, J; Barber, J				Kargul, J; Nield, J; Barber, J			Three-dimensional reconstruction of a light-harvesting complex I-photosystem I (LHCI-PSI) supercomplex from the green alga Chlamydomonas reinhardtii - Insights into light harvesting for PSI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-PARTICLE ANALYSIS; SYNECHOCOCCUS-ELONGATUS; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; STATE TRANSITIONS; MEMBRANE-PROTEIN; ANTENNA RING; SUBUNIT; CYANOBACTERIA; ORGANIZATION	A supercomplex containing the photosystem I (PSI) and chlorophyll a/b light-harvesting complex I (LHCI) has been isolated using a His-tagged mutant of Chlamydomonas reinhardtii. This LHCI-PSI supercomplex contained similar to215 chlorophyll molecules of which 175 were estimated to be chlorophyll a and 40 to be chlorophyll b, based on P700 oxidation and chlorophyll a/b ratio measurements. Its room temperature long wavelength absorption peak was at 680 nm, and it emitted chlorophyll fluorescence maximally at 715 nm (77 K). The LHCI was composed of four or more different types of Lhca polypeptides including Lhca3. No LHCII proteins or other phosphoproteins were detected in the LHCI-PSI supercomplexes suggesting that the cells from which they were isolated were in State 1. Electron microscopy of negatively stained samples followed by image analysis revealed the LHCI-PSI supercomplex to have maximal dimensions of 220 Angstrom by 180 Angstrom and to be similar to 105 Angstrom thick. An averaged top view was used to model in x-ray and electron crystallographic data for PSI and Lhca proteins respectively. We conclude that the supercomplex consists of a PSI reaction center monomer with 11 Lhca proteins arranged along the side where the PSI proteins, PsaK, PsaJ, PsaF, and PsaG are located. The estimated molecular mass for the complex is 700 kDa including the bound chlorophyll molecules. The assignment of 11 Lhca proteins is consistent with a total chlorophyll level of 215 assuming that the PSI reaction center core binds similar to100 chlorophylls and that each Lhca subunit binds 10 chlorophylls. There was no evidence for oligomerization of Chlamydomonas PSI in contrast to the trimerization of PSI in cyanobacteria.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AZ, England	Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, S Kensington Campus, London SW7 2AZ, England.	j.barber@ic.ac.uk	Nield, Jon/C-5892-2013; Kargul, Joanna/AAN-4227-2021; Kargul, Joanna/AGD-9163-2022	Nield, Jon/0000-0001-9983-0239; Kargul, Joanna/0000-0003-1410-1905				Barber J, 2002, CURR OPIN STRUC BIOL, V12, P523, DOI 10.1016/S0959-440X(02)00357-3; BASSI R, 1992, J BIOL CHEM, V267, P25714; Bibby TS, 2001, NATURE, V413, P590, DOI 10.1038/35098153; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Bibby TS, 2001, J BIOL CHEM, V276, P43246, DOI 10.1074/jbc.M106541200; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Buchel C, 2001, J MOL BIOL, V312, P371, DOI 10.1006/jmbi.2001.4951; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; Fischer N, 1997, BIOCHEMISTRY-US, V36, P93, DOI 10.1021/bi962244v; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; GLAZER AN, 1994, PHOTOSYNTH RES, V40, P167, DOI 10.1007/BF00019333; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2002, J BIOL CHEM, V277, P2798, DOI 10.1074/jbc.M110448200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KEREN N, 1998, MOL BIOL CHLOROPLAST, V7, P569; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; MARSHO TV, 1971, METHOD ENZYMOL, V23, P515; Moseley JL, 2002, EMBO J, V21, P6709, DOI 10.1093/emboj/cdf666; Nield J, 2000, J BIOL CHEM, V275, P27940; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Ruprecht J, 2001, PROG BIOPHYS MOL BIO, V75, P121, DOI 10.1016/S0079-6107(01)00004-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ M, 1990, ULTRAMICROSCOPY, V32, P255, DOI 10.1016/0304-3991(90)90003-5; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Sugiura M, 1998, FEBS LETT, V426, P140, DOI 10.1016/S0014-5793(98)00328-7; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; Zheleva D, 1996, BIOCHEMISTRY-US, V35, P15074, DOI 10.1021/bi961382h; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	44	101	107	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16135	16141		10.1074/jbc.M300262200	http://dx.doi.org/10.1074/jbc.M300262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12588873	hybrid			2022-12-25	WOS:000182680000086
J	VanLeeuwen, D; Steffey, ME; Donahue, C; Ho, GY; MacKenzie, RG				VanLeeuwen, D; Steffey, ME; Donahue, C; Ho, GY; MacKenzie, RG			Cell surface expression of the melanocortin-4 receptor is dependent on a C-terminal di-isoleucine sequence at codons 316/317	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOPRESSIN V-2 RECEPTOR; EARLY-ONSET OBESITY; FRAMESHIFT MUTATION; DILEUCINE SEQUENCE; MORBID-OBESITY; GENE; AGONIST; HUMANS; MICE; DEFICIENCY	Loss-of-function mutations in the human melanocortin-4 receptor (MC4R) are associated with obesity. Previous work has implicated a C-terminal di-isoleucine motif at residues 316/317 in MC4R cell surface targeting. It was therefore of interest to examine function and cell surface expression of an MC4R mutation found in an obese proband in which one of these isoleucines was substituted by threonine (I317T). Single mutant (I316T or I317T) and double mutant (I316T,I317T) forms of MC4R were constructed by oligonucleotide-directed mutagenesis and tested for function and cell surface expression in transfected cells. Function was assessed using assays for agonist, [Nle(4)-D-Phe(7)]alpha-melanocyte-stimulating hormone (NDP-alpha-MSH) or forskolin-stimulated cAMP accumulation. Cell surface expression was determined by whole-cell binding of [I-125]NDP-alpha-MSH, fluorescence immunocytochemistry and fluorescence-activated cell sorting. Maximal cAMP generation of the single mutants was reduced by 40% of wild-type receptor; the double mutant further reduced function to 40% of control, effects that were mirrored by decreases in cell-surface expression. Quantitative RT-PCR showed that, relative to wild-type receptor, transcript levels for the mutated receptors were not reduced. The results further implicate the C-terminal di-isoleucines in cell surface expression of MC4R and suggest that mutations of residues 316 or 317 would predict MC4R hypofunction.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA	Wayne State University; Pfizer	MacKenzie, RG (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 510 E Canfield, Detroit, MI 48201 USA.							Alewijnse AE, 1997, FEBS LETT, V419, P171, DOI 10.1016/S0014-5793(97)01440-3; Benoit SC, 2000, J NEUROSCI, V20, P3442, DOI 10.1523/JNEUROSCI.20-09-03442.2000; Boutin P, 2001, BEST PRACT RES CL EN, V15, P391, DOI 10.1053/beem.2001.0153; Clement K, 2000, ANN ENDOCRINOL-PARIS, V61, P39; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cody JD, 1999, HUM GENET, V105, P424, DOI 10.1007/s004390051125; Cone RD, 2000, J CLIN INVEST, V106, P185, DOI 10.1172/JCI10628; Cone RD, 2001, INT J OBESITY, V25, pS63, DOI 10.1038/sj.ijo.0801913; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Ho GY, 1999, J BIOL CHEM, V274, P35816, DOI 10.1074/jbc.274.50.35816; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Krause G, 2000, MOL PHARMACOL, V57, P232; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Yeo GSH, 2000, QJM-INT J MED, V93, P7, DOI 10.1093/qjmed/93.1.7; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	25	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15935	15940		10.1074/jbc.M211546200	http://dx.doi.org/10.1074/jbc.M211546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594226	hybrid			2022-12-25	WOS:000182680000062
J	Katoh, S; Hong, C; Tsunoda, Y; Murata, K; Takai, R; Minami, E; Yamazaki, T; Katoh, E				Katoh, S; Hong, C; Tsunoda, Y; Murata, K; Takai, R; Minami, E; Yamazaki, T; Katoh, E			High precision NMR structure and function of the RING-H2 finger domain of EL5, a rice protein whose expression is increased upon exposure to pathogen-derived oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLCHITOOLIGOSACCHARIDE ELICITOR; UBIQUITIN-CONJUGATING ENZYME; ARABIDOPSIS-THALIANA; REPRESSOR COMPLEX; LARGER PROTEINS; C-CBL; LIGASE; FAMILY; ZINC; IDENTIFICATION	EL5, a RING-H2 finger protein, is rapidly induced by N-acetylchitooligosaccharides in rice cell. We expressed the EL5 RING-H2 finger domain in Escherichia coli and determined its structure in solution by NAIR spectroscopy. The EL5 RING-H2 finger domain consists of two-stranded beta-sheets (beta1, Ala(147)-Phe(149); beta2, Gly(156)-HiS(158)), one a-helix (Cys(161)-Leu(166)), and two large N- and C-terminal loops. It is stabilized by two tetrahedrally coordinated zinc ions. This structure is similar to that of other RING finger domains of proteins of known function. From structural analogies, we inferred that the EL5 RING-H2 finger is a binding domain for ubiquitin-conjugating enzyme (E2). The binding site is probably formed by solvent-exposed hydrophobic residues of the N- and C-terminal loops and the a-helix. We demonstrated that the fusion protein with EL5-(96-181) and maltose-binding protein (AMP) was polyubiquitinated by incubation with ubiquitin, ubiquitin-activating enzyme (E1), and a rice E2 protein, OsUBC5b. This supported the idea that the EL5 RING finger domain is essential for ubiquitin-ligase activity of EL5. By NAIR titration experiments, we identified residues that are critical for the interaction between the EL5 RING-H2 finger and OsUBC5b. We conclude that the RING-H2 finger domain of EL5 is the E2 binding site of EL5.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300192, Japan	National Institute of Agrobiological Sciences - Japan; Nara Institute of Science & Technology	Katoh, E (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan.							Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Brunger A. T, 1993, XPLOR MANUAL VERSION; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOSAREV P, 2002, GENOME BIOL, V3; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIVE DH, 1984, J AM CHEM SOC, V106, P1934; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MartinezGarcia M, 1996, MOL GEN GENET, V252, P587, DOI 10.1007/s004380050266; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Salinas-Mondragon RE, 1999, PLANT MOL BIOL, V40, P579, DOI 10.1023/A:1006267201855; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shibuya N, 2001, PHYSIOL MOL PLANT P, V59, P223, DOI 10.1006/pmpp.2001.0364; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SPERA S, 1991, J AM CHEM SOC, V111, P8317; Takai R, 2002, PLANT J, V30, P447, DOI 10.1046/j.1365-313X.2002.01299.x; Takai R, 2001, PLANT SCI, V160, P577, DOI 10.1016/S0168-9452(00)00390-3; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	40	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15341	15348		10.1074/jbc.M210531200	http://dx.doi.org/10.1074/jbc.M210531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588869	hybrid			2022-12-25	WOS:000182516100099
J	Morales, JC; Xia, ZF; Lu, T; Aldrich, MB; Wang, B; Rosales, C; Kellems, RE; Hittelman, WN; Elledge, SJ; Carpenter, PB				Morales, JC; Xia, ZF; Lu, T; Aldrich, MB; Wang, B; Rosales, C; Kellems, RE; Hittelman, WN; Elledge, SJ; Carpenter, PB			Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; PHOSPHORYLATION; REPAIR; CHECKPOINTS; INSTABILITY; COMPONENT; COMPLEX; GENES; ATM	p53-binding protein-1 (53BP1) is phosphorylated in response to DNA damage and rapidly relocalizes to presumptive sites of DNA damage along with Mrell and the phosphorylated histone 2A variant, gamma-H2AX. 53BP1 associates with the BRCA1 tumor suppressor, and knockdown experiments with small interfering RNA have revealed a role for the protein in the checkpoint response to DNA damage. By generating mice defective in m53BP1 (m53BP1(tr/tr)), we have created an animal model to further explore its biochemical and genetic roles in vivo. We find that m53BP1(tr/tr) animals are growth-retarded and show various immune deficiencies including a specific reduction in thymus size and T cell count. Consistent with a role in responding to DNA damage, we find that m53BP1(tr/tr) mice are sensitive to ionizing radiation (gamma-IR), and cells from these animals exhibit chromosomal abnormalities consistent with defects in DNA repair. Thus, 53BP1 is a critical element in the DNA damage response and plays an integral role in maintaining genomic stability.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Verna & Mars Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Carpenter, PB (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	Phillip.B.Carpenter@uth.tmc.edu		Morales, Julio/0000-0002-0854-7866	NCI NIH HHS [5P30 CA16672] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM65812-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM065812, R01GM065812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Jullien D, 2002, J CELL SCI, V115, P71; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang Y, 2000, GENE DEV, V14, P927; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	30	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14971	14977		10.1074/jbc.M212484200	http://dx.doi.org/10.1074/jbc.M212484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578828	hybrid			2022-12-25	WOS:000182516100052
J	Wojtanik, KM; Liscum, L				Wojtanik, KM; Liscum, L			The transport of low density lipoprotein-derived cholesterol to the plasma membrane is defective in NPC1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICK TYPE-C; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; PROTEIN; CYCLODEXTRINS; FIBROBLASTS; LYSOSOMES; TRAFFICKING; METABOLISM; MUTATIONS	Niemann-Pick disease type C (NPC) is characterized by lysosomal storage of cholesterol and gangliosides, which results from defects in intracellular lipid trafficking. Most studies of NPC1 have focused on its role in intracellular cholesterol movement. Our hypothesis is that NPC1 facilitates the egress of cholesterol from late endosomes, which are where active NPC1 is located. When NPC1 is defective, cholesterol does not exit late endosomes; instead, it is carried along to lysosomal storage bodies, where it accumulates. In this study, we addressed whether cholesterol is transported from endosomes to the plasma membrane before reaching NPC1-containing late endosomes. Our study was conducted in Chinese hamster ovary cell lines that display the classical NPC biochemical phenotype and belong to the NPC1 complementation group. We used three approaches to test whether low density lipoprotein (LDL)derived cholesterol en route to NPC1-containing organelles passes through the plasma membrane. First, we used cyclodextrins to measure the arrival of LDL cholesterol at the plasma membrane and found that the arrival of LDL cholesterol in a cyclodextrin-accessible pool was significantly delayed in NPC1 cells. Second, the movement of LDL cholesterol to NPC1-containing late endosomes was assessed and found to be normal in Chinese hamster ovary mutant 3-6, which exhibits defective movement of plasma membrane cholesterol to intracellular membranes. Third, we examined the movement of plasma membrane cholesterol to the endoplasmic reticulum and found that this pathway is intact in NPC1 cells, i.e. it does not pass through N-PC1-containing late endosomes. Our data suggest that in N-PC1 cells LDL cholesterol traffics directly through endosomes to lysosomes, bypassing the plasma membrane, and is trapped there because of dysfunctional NPC1.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Liscum, L (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.		Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK049564, T32DK007704] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07704, DK49564, P30 DK34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Christian AE, 1997, J LIPID RES, V38, P2264; Christian AE, 1999, J LIPID RES, V40, P1475; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; FAUST JR, 1977, J BIOL CHEM, V252, P4861; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Jacobs NL, 1997, J LIPID RES, V38, P1973; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 2002, J LIPID RES, V43, P198; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Xie CL, 2000, J LIPID RES, V41, P1278; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	32	120	122	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14850	14856		10.1074/jbc.M300488200	http://dx.doi.org/10.1074/jbc.M300488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591922	hybrid			2022-12-25	WOS:000182516100036
J	Chilkova, O; Jonsson, BH; Johansson, E				Chilkova, O; Jonsson, BH; Johansson, E			The quaternary structure of DNA polymerase epsilon from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK; CHROMOSOMAL DNA; POL-EPSILON; S-PHASE; DELTA; YEAST; SUBUNIT; PURIFICATION; REPLISOME; STRANDS	DNA polymerase epsilon (Pol epsilon) from Saccharomyces cerevisiae consists of four subunits (Pol2, Dpb2, Dpb3, and Dpb4) and is essential for chromosomal DNA replication. Biochemical characterizations of Pol E have been cumbersome due to protease sensitivity and the limited amounts of Pol E in cells. We have developed a protocol for overexpression and purification of Pol E from S. cerevisiae. The native four-subunit complex was purified to homogeneity by conventional chromatography. Pol E was characterized biochemically by sedimentation velocity experiments and gel filtration experiments. The stoichiometry of the four subunits was estimated to be 1:1:1:1 from colloidal Coomassie-stained gels. Based on the sedimentation coefficient (11.9 S) and the Stokes radius (74.5 Angstrom), a molecular mass for Pol epsilon of 371 kDa was calculated, in good agreement with the calculated molecular mass of 379 kDa for a heterotetramer. Furthermore, analytical equilibrium ultracentrifugation experiments support the proposed heterotetrameric structure of Pol epsilon. Thus, both DNA polymerase 5 and Pol E are purified as monomeric complexes, in agreement with accumulating evidence that Pol delta and Pol epsilon are located on opposite strands of the eukaryotic replication fork.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden; Linkoping Univ, Dept Phys & Measurement Technol Mol Biotechnol, SE-58183 Linkoping, Sweden	Umea University; Linkoping University	Johansson, E (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	erik.johansson@medchem.umu.se		Johansson, Erik/0000-0002-8526-6224; Shilkova, Olga/0000-0001-8607-4008				Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Bermudez VP, 2002, J BIOL CHEM, V277, P36853, DOI 10.1074/jbc.M202897200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; Burgers PMJ, 1995, METHOD ENZYMOL, V262, P49; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CHANCE B, 1950, BIOCHEM J, V46, P402, DOI 10.1042/bj0460402; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Dua R, 2002, J BIOL CHEM, V277, P7889, DOI 10.1074/jbc.M108546200; Falaschi A, 2000, TRENDS GENET, V16, P88, DOI 10.1016/S0168-9525(99)01917-4; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kawasaki Y, 2001, MOL CELLS, V12, P277; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Liu W, 2000, NUCLEIC ACIDS RES, V28, P4180, DOI 10.1093/nar/28.21.4180; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Shcherbakova PV, 1996, GENETICS, V142, P717; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	31	53	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14082	14086		10.1074/jbc.M211818200	http://dx.doi.org/10.1074/jbc.M211818200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571237	hybrid			2022-12-25	WOS:000182405000068
J	Tincu, JA; Menzel, LP; Azimov, R; Sands, J; Hong, T; Waring, AJ; Taylor, SW; Lehrer, RI				Tincu, JA; Menzel, LP; Azimov, R; Sands, J; Hong, T; Waring, AJ; Taylor, SW; Lehrer, RI			Plicatamide, an antimicrobial octapeptide from Styela plicata Hemocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL 3,4-DIHYDROXYPHENYLALANINE; ERYTHROCYTE-MEMBRANES; AEROMONAS-HYDROPHILA; TYROSINE KINASE; BACTERIA; PHOSPHORYLATION; PHENOLOXIDASE; POLYPEPTIDES; DERIVATIVES; NEUTROPHILS	Plicatamide (Phe-Phe-His-Leu-His-Phe-His-dcDeltaDOPA), where dcDeltaDOPA represents decarboxy-(E)-alpha,beta-dehydro-3,4-dihydroxyphenylalanine, is a potently antimicrobial octapeptide from the blood cells of the solitary tunicate, Styela plicata. Wild type and methicillin-resistant Staphylococcus aureus (MRSA) responded to plicatamide exposure with a massive potassium efflux that began within seconds. Soon thereafter, treated bacteria largely ceased consuming oxygen, and most became nonviable. Native plicatamide also formed cation-selective channels in model lipid bilayers composed of bacterial lipids. Methicillin-resistant S. aureus treated with plicatamide for 5 min contained prominent mesosomes as well as multiple, small dome-shaped surface protrusions that suggested the involvement of osmotic forces in its antimicrobial effects. To ascertain the contribution of the C-terminal dcDeltaDOPA residue to antimicrobial activity, we synthesized several analogues of plicatamide that lacked it. One of these peptides, PL-101 (Phe-Phe-His-Leu-His-Phe-His-Tyr-amide), closely resembled native plicatamide in its antimicrobial activity and its ability to induce potassium efflux. Plicatamide was potently hemolytic for human red blood cells but did not lyse ovine erythrocytes. The small size, rapid action, and potent anti-staphylococcal activity of plicatamide and PL-101 make them intriguing subjects for future antimicrobial peptide design.	Univ Calif Los Angeles, Ctr Hlth Sci, Dept Med, Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Pediat, Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biotechnol & Biomed, La Jolla, CA 92093 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego; Scripps Institution of Oceanography	Lehrer, RI (corresponding author), Univ Calif Los Angeles, Ctr Hlth Sci, Dept Med, Mol Biol Inst, 10833 LeConte Ave, Los Angeles, CA 90095 USA.		Menzel, Lorenzo/C-4179-2013	Menzel, Lorenzo/0000-0001-6974-5375				AZUMI K, 1990, EXPERIENTIA, V46, P1066, DOI 10.1007/BF01940675; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BAGELLA L, 1995, FEBS LETT, V376, P225, DOI 10.1016/0014-5793(95)01285-3; Ballarin L, 1998, DEV COMP IMMUNOL, V22, P479, DOI 10.1016/S0145-305X(98)00035-4; Bellm L, 2000, EXPERT OPIN INV DRUG, V9, P1731, DOI 10.1517/13543784.9.8.1731; BETTICHER DC, 1989, COMP BIOCHEM PHYS A, V93, P429, DOI 10.1016/0300-9629(89)90061-3; Craig AG, 2001, J AM SOC MASS SPECTR, V12, P470, DOI 10.1016/S1044-0305(01)00229-X; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Ganz T, 1997, Curr Opin Hematol, V4, P53; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hata S, 1998, COMP BIOCHEM PHYS B, V119, P769, DOI 10.1016/S0305-0491(98)00054-6; Hijikata M, 1999, FEBS LETT, V457, P405, DOI 10.1016/S0014-5793(99)01077-7; Karupiah G, 2000, Rev Immunogenet, V2, P387; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; Leem JY, 1996, J BIOL CHEM, V271, P13573, DOI 10.1074/jbc.271.23.13573; Leem JY, 1998, BIOL PHARM BULL, V21, P784, DOI 10.1248/bpb.21.784; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Malabarba A, 2001, CURR MED CHEM, V8, P1759, DOI 10.2174/0929867013371716; Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5; Mirzabekov T A, 1999, Methods Enzymol, V294, P661; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; National Committee for Clinical Laboratory Standards, 1993, METH DIL ANT SUSC TE; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; NouriSorkhabi MH, 1996, LIPIDS, V31, P765, DOI 10.1007/BF02522893; NouriSorkhabi MH, 1996, COMP BIOCHEM PHYS B, V113, P221, DOI 10.1016/0305-0491(95)02011-X; Orlov D., 2001, Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, V41, P99; Orlov DS, 2002, J MICROBIOL METH, V49, P325, DOI 10.1016/S0167-7012(01)00383-9; ROMEO D, 1988, J BIOL CHEM, V263, P9573; RZEPECKI LM, 1991, ARCH BIOCHEM BIOPHYS, V285, P17, DOI 10.1016/0003-9861(91)90323-B; Sai KP, 2001, J BIOL CHEM, V276, P2701, DOI 10.1074/jbc.M006615200; Saiman L, 2001, ANTIMICROB AGENTS CH, V45, P2838, DOI 10.1128/AAC.45.10.2838-2844.2001; SALVIOLI G, 1993, LIPIDS, V28, P999, DOI 10.1007/BF02537121; Schibli DJ, 1999, BIOCHEMISTRY-US, V38, P16749, DOI 10.1021/bi990701c; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Taylor SW, 2002, ANAL BIOCHEM, V302, P70, DOI 10.1006/abio.2001.5522; TAYLOR SW, 1991, J NAT PROD, V54, P918, DOI 10.1021/np50075a034; Tincu JA, 2000, BIOCHEM BIOPH RES CO, V270, P421, DOI 10.1006/bbrc.2000.2449; Tossi A, 2000, BIOPOLYMERS, V55, P4; VALET G, 1978, J CELL PHYSIOL, V94, P215, DOI 10.1002/jcp.1040940211; Waite JH, 1999, ANN NY ACAD SCI, V875, P301, DOI 10.1111/j.1749-6632.1999.tb08513.x; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1991, MOL MICROBIOL, V5, P2745, DOI 10.1111/j.1365-2958.1991.tb01983.x; Zheng ZB, 1999, CHEM PHARM BULL, V47, P136	48	62	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13546	13553		10.1074/jbc.M211332200	http://dx.doi.org/10.1074/jbc.M211332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569105	hybrid			2022-12-25	WOS:000182189500119
J	Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M				Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M			Mutations of Arg(440) and Gly(455)/Gly(456) oppositely change pH sensing of Na+/H+ exchanger 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCINEURIN HOMOLOGOUS PROTEIN; NA-H EXCHANGE; ESCHERICHIA-COLI; GROWTH-FACTOR; TRANSMEMBRANE HELIX; RANDOM MUTAGENESIS; ANTIPORTER NHAA; POINT MUTATION; NHE1; MEMBRANE	To identify important amino acid residues involved in intracellular pH (pH(i)) sensing of Na+/H+ exchanger 1, we produced single-residue substitution mutants in the region of the exchanger encompassing the putative 11 th transmembrane segment (TM11) and its adjacent intracellular (intracellular loop (IL) 5) and extracellular loops (extracellular loop 6). Substitution of Arg(440) in IL5 with other residues except positively charged Lys caused a large shift in pHi dependence of Na-22(+) uptake to an acidic side, whereas substitution of Gly(455) or Gly(456) within the highly conserved glycine-rich sequence of TM11 shifted pHi dependence to an alkaline side. The observed alkaline shift was larger with substitution of Gly(455) with residues with increasing sizes, suggesting the involvement of the steric effect. Interestingly, mutation of Arg440 (114401)) abolished the ATP depletion-induced acidic shift in pHi dependence of Na-22(+) uptake as well as the cytoplasmic alkalinization induced by various extracellular stimuli, whereas with that of Gly455 (G455Q) these functions were preserved. These mutant exchangers did not alter apparent affinities for extracellular transport substrates Na+ and H+ and the inhibitor 5-(N-ethyl-N-isopropyl)amiloride. These results suggest that positive charge at Arg440 is required for normal pHi sensing, whereas mutation-induced perturbation of the TM11 structure may be involved in the effects of Gly mutations. Thus, both Arg(440) in IL5 and Gly residues in the conserved segment of TM11 appear to constitute important elements for proper functioning of the putative "pH(i) sensor" of Na+/H+ exchanger 1.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishirodai 5-7-1, Suita, Osaka 5658565, Japan.	wak@ri.ncvc.go.jp						Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; CASSEL D, 1986, J BIOL CHEM, V261, P5460; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Counillon L, 1997, BIOCHEMISTRY-US, V36, P2951, DOI 10.1021/bi9615405; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Khadilkar A, 2001, J BIOL CHEM, V276, P43792, DOI 10.1074/jbc.M106659200; Kobayashi Y, 2000, PFLUG ARCH EUR J PHY, V439, P455, DOI 10.1007/s004240050963; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Miyazaki E, 2001, J BIOL CHEM, V276, P49221, DOI 10.1074/jbc.M106267200; NAKAMURA T, 1995, BBA-BIOENERGETICS, V1230, P170, DOI 10.1016/0005-2728(95)00053-L; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 2000, FEBS LETT, V487, P257, DOI 10.1016/S0014-5793(00)02348-6; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; Yan WH, 2001, J BIOL CHEM, V276, P31349, DOI 10.1074/jbc.M102679200; YUN CHC, 1995, P NATL ACAD SCI USA, V92, P10723, DOI 10.1073/pnas.92.23.10723; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	44	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11828	11835		10.1074/jbc.M213243200	http://dx.doi.org/10.1074/jbc.M213243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12562776	hybrid			2022-12-25	WOS:000182015700015
J	Kroger, A; Dallugge, A; Kirchhoff, S; Hauser, H				Kroger, A; Dallugge, A; Kirchhoff, S; Hauser, H			IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo	ONCOGENE			English	Article						interferon regulatory factor-1 (IRF-1); cell proliferation; reversion of tumorigenicity; interferon	REGULATORY FACTOR-I; TRANSCRIPTION FACTOR IRF-1; HIGHER EUKARYOTIC CELLS; NATURAL-KILLER-CELLS; GROWTH INHIBITION; PROTEIN-KINASE; LYSYL OXIDASE; DNA-DAMAGE; INTERFERON; GENE	The expression of the transcriptional activator and tumor suppressor IRF-1 induces multiple effects that counteract the growth of tumor cells in vitro and in vivo. These include the inhibition of cell proliferation, the secretion of interferon-beta (IFN-beta), the induction of apoptosis specifically in certain cell types and the induction of a strong T-cell response. Here, we show that apart from its immune-activating properties, IRF-1 expression leads to a reversion of the tumorigenic phenotype of NIH3T3 cells transformed by different oncogenes. This was analysed in detail in a cell line in which the expression of c-Ha-ras and c-myc is under the control of a doxycycline-regulated promoter allowing to switch between the normal and oncogenic cell status. In the same cells, a beta-estradiol activatable IRF-1 fusion protein is expressed. After IRF-1 activation the oncogene-mediated acceleration of the cell cycle is reverted. Further, a complete IRF-1-mediated reversion of the oncogenic phenotype is observed in soft-agar growth assays. IRF-1 activation induces IFN-beta secretion; however, the observed effects are not mediated by IFN-beta. Inhibition of tumor growth is observed in nude mice as long as IRF-1 is active, indicating that neither B-nor T-cells must become activated for tumor growth suppression.	GBF, German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Hauser, H (corresponding author), GBF, German Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, Mascheroder Weg 1, D-38124 Braunschweig, Germany.							Andoh A, 2002, J IMMUNOL, V169, P1683, DOI 10.4049/jimmunol.169.4.1683; Baasner S, 1996, ONCOGENE, V13, P901; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DINTER H, 1987, EUR J BIOCHEM, V166, P103, DOI 10.1111/j.1432-1033.1987.tb13488.x; Futaki M, 1996, LEUKEMIA RES, V20, P601, DOI 10.1016/0145-2126(96)00013-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRESSER I, 1989, ACTA ONCOL, V28, P347, DOI 10.3109/02841868909111205; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; Hobart M, 1996, TRANSPLANTATION, V62, P1895, DOI 10.1097/00007890-199612270-00037; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIRCHHOFF S, 1995, TRENDS GENET, V11, P219, DOI 10.1016/S0168-9525(00)89053-8; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kirchhoff S, 1999, EUR J BIOCHEM, V261, P546, DOI 10.1046/j.1432-1327.1999.00308.x; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Kroger A, 2001, CANCER RES, V61, P2609; Kwissa M, 2000, J MOL MED-JMM, V78, P495, DOI 10.1007/s001090000135; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Qin XQ, 2001, MOL THER, V4, P356, DOI 10.1006/mthe.2001.0464; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Sambrook J., 2002, MOL CLONING LAB MANU; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Unsinger J, 2001, MOL THER, V4, P484, DOI 10.1006/mthe.2001.0480; Yim JH, 1997, J IMMUNOL, V158, P1284	50	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1045	1056		10.1038/sj.onc.1206260	http://dx.doi.org/10.1038/sj.onc.1206260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592391				2022-12-25	WOS:000180926100010
J	Tsai, MS; Shamon-Taylor, LA; Mehmi, I; Tang, CK; Lupu, R				Tsai, MS; Shamon-Taylor, LA; Mehmi, I; Tang, CK; Lupu, R			Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer	ONCOGENE			English	Article						HRG antisense; tumorigenicity; metastasis; breast cancer	MATRIX-METALLOPROTEINASE-9 EXPRESSION; SIGNAL-TRANSDUCTION; ONCOGENE PRODUCT; GROWTH-FACTOR; RECEPTOR; ERBB-2; DIFFERENTIATION; ACTIVATION; PATHWAYS; LIGAND	The growth factor heregulin (HRG), expressed in about 30% of breast cancer tumors, activates the erbB-2 receptor via induction of heterodimeric complexes of erbB-2 with erbB-3 or erB-4. HRG induces tumorigenicity and metastasis of breast cancer cells. Our investigation into whether HRG is a factor likely to promote tumor formation independently of erbB-2 overexpression concludes that blockage of HRG expression suppresses the aggressive phenotype of MDA-MB-231 breast cancer cells by inhibiting cell proliferation, preventing anchorage-independent growth, and suppressing the invasive potential of the cells in vitro. More importantly, we observed a marked reduction in tumor formation, tumor size, and a lack of metastasis in vivo. These studies were achieved by blocking HRG expression in MDA-MB-231 cells using an HRG antisense cDNA. In the search for the mechanism by which blockage of HRG reverts this aggressive phenotype, we discovered that the cells in which HRG is blocked exhibit a marked decrease in erbB activation and a significant reduction in MMP-9 activity, demonstrating a direct causal role in HRG induction of tumorigenicity. Our study is the first report and serves as a proof of the concept that HRG is a key promoter of breast cancer tumorigenicity and metastasis independently of erbB-2 overexpression and should be deemed a potential target in developing therapies for breast cancer.	Northwestern Univ, Evanston NW Healthcare Res Inst, Sch Med, Evanston, IL 60201 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Georgetown University	Lupu, R (corresponding author), Northwestern Univ, Evanston NW Healthcare Res Inst, Sch Med, 1001 Univ Pl, Evanston, IL 60201 USA.	rlupu@enh.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49049] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; ATLAS E, 2003, IN PRESS MOL CANC RE; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; CARDILLO M, 1995, HEREGULIN INDUCES ME; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Hijazi MM, 2000, INT J ONCOL, V17, P629; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hua J, 1996, CANCER RES, V56, P5279; Lee KS, 1996, CLIN EXP METASTAS, V14, P512; Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014; Liu WM, 1999, CANCER RES, V59, P5695; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; LUPU R, 1992, BIOCHEMISTRY-US, V31, P7330, DOI 10.1021/bi00147a018; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Tang CK, 1996, CANCER RES, V56, P3350; Tripathy D, 1992, Cancer Treat Res, V63, P15; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; Tsang KJ, 2001, INT J ONCOL, V18, P369; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944	33	105	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					761	768		10.1038/sj.onc.1206130	http://dx.doi.org/10.1038/sj.onc.1206130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569369				2022-12-25	WOS:000180642100014
J	Kenchappa, RS; Ravindranath, V				Kenchappa, RS; Ravindranath, V			Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP	FASEB JOURNAL			English	Article						brain; mitochondria; thioltransferase; oxidative stress; thiol oxidation	ELECTRON-TRANSPORT CHAIN; OXIDATIVE STRESS; PARKINSONS-DISEASE; THIOLTRANSFERASE GLUTAREDOXIN; GLUTATHIONE DEPLETION; SITU HYBRIDIZATION; MIXED DISULFIDES; S-THIOLATION; RAT-BRAIN; EXPRESSION	Mitochondrial complex I dysfunction is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. Identification of factors involved in maintenance and restoration of complex I function could potentially help to develop prophylactic and therapeutic strategies for treatment of this class of disorders. Down-regulation of glutaredoxin (thioltransferase, a thiol disulfide oxido-reductase) using antisense oligonucleotides results in the loss of mitochondrial complex I activity in mouse brain. 1-Methyl-4-phenyl-1,2,3,6,tetrahydropyridine (MPTP), the neurotoxin that causes Parkinson's disease-like symptoms in primates and dopaminergic cell loss in mice, acts through the inhibition of complex I. Regeneration of complex I activity in the striatum occurs concurrently with increase in glutaredoxin activity, 4 h after the neurotoxic insult, and is mediated through activation of activating protein-1. Downregulation of glutaredoxin using anti-sense oligonucleotides prevents recovery of complex I in the striatum after MPTP treatment, providing support for the critical role for glutaredoxin in recovery of mitochondrial function in brain. Maintenance and restoration of protein thiol homeostasis by glutaredoxin may be important factors in preventing complex I dysfunction.	Natl Brain Res Ctr, Gurgaon 122001, India; Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore 560029, Karnataka, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); National Institute of Mental Health & Neurosciences - India	Ravindranath, V (corresponding author), Natl Brain Res Ctr, SCO 5,6&7,Sector 15 2, Gurgaon 122001, India.	vijir@nbrc.ac.in						Annepu J, 2000, NEUROSCI LETT, V289, P209, DOI 10.1016/S0304-3940(00)01300-8; Balijepalli S, 2000, MOL BRAIN RES, V85, P123, DOI 10.1016/S0169-328X(00)00206-0; Balijepalli S, 1999, J NEUROCHEM, V72, P1170, DOI 10.1046/j.1471-4159.1999.0721170.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; DUPUIS A, 1991, BIOCHEM J, V227, P11; GAN ZR, 1986, J BIOL CHEM, V261, P996; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MANNERVIK B, 1975, BIOCHEM J, V149, P785, DOI 10.1042/bj1490785; Mayfield RD, 2002, J NEUROCHEM, V81, P802, DOI 10.1046/j.1471-4159.2002.00860.x; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1995, GLUTATHIONYL SPECIFI, P305; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Park JB, 1997, GENE, V197, P189, DOI 10.1016/S0378-1119(97)00262-X; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V135, P269, DOI 10.1016/0006-291X(86)90972-1; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1992, BRAIN RES, V595, P256, DOI 10.1016/0006-8993(92)91058-M; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; VAZQUEZ EJ, 2001, J INVEST MED, V49, pA285; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	37	65	66	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					717	+		10.1096/fj.02-0771fje	http://dx.doi.org/10.1096/fj.02-0771fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594173				2022-12-25	WOS:000181456900005
J	Kupatt, C; Hinkel, R; Vachenauer, R; Horstkotte, J; Raake, P; Sandner, T; Kreuzpointner, R; Muller, F; Dimmeler, S; Feron, O; Boekstegers, P				Kupatt, C; Hinkel, R; Vachenauer, R; Horstkotte, J; Raake, P; Sandner, T; Kreuzpointner, R; Muller, F; Dimmeler, S; Feron, O; Boekstegers, P			VEGF(165) transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation	FASEB JOURNAL			English	Article						nitric oxide; VEGF; PMN; myocardial infarction	NITRIC-OXIDE SYNTHASE; PRESSURE-REGULATED RETROINFUSION; ADHESION MOLECULE-1 ICAM-1; GROWTH-FACTOR EXPRESSION; VEGF GENE-TRANSFER; ENDOTHELIAL-CELLS; ISCHEMIA-REPERFUSION; TNF-ALPHA; TUMOR ANGIOGENESIS; LEUKOCYTE ADHESION	Endothelial nitric oxide synthase (eNOS) phosphorylation increases nitric oxide formation, for example, after VEGF stimulation. We investigated whether nitric oxide formed after overexpression of VEGF or of phosphomimetic eNOS (S1177D) affects PMN-induced myocardial detriment after ischemia and reperfusion. Pigs (n=8 per group) were subjected to percutaneous liposome-based gene transfer by retroinfusion of the anterior interventricular vein 48 h before LAD occlusion (60 min) and reperfusion (24 h). Thereafter, regional myocardial function was assessed as subendocardial segment shortening (SES), and infarct size was determined. Tissue from the infarct region, the noninfarcted area at risk, and a control region was analyzed for NF-kappaB activation (EMSA), tumor necrosis factor (TNF)-alpha, and E-selectin mRNA and infiltration of polymorphonuclear neutrophils (PMN). L-NAME was applied in one group of VEGF-transfected animals. NF-kappaB activition, PMN infiltration in the infarct region, and AAR were reduced after transfection of VEGF or eNOS S1177D, but not after VEGF+L-NAME coapplication. Infarct size decreased, whereas SES improved after either VEGF or eNOS S1177D transfection, an effect inhibited by L-NAME coapplication. Retroinfusion of liposomal VEGF cDNA reduces NF-kappaB-dependent postischemic inflammation and subsequent myocardial reperfusion injury, an effect mediated at least in part by enhanced eNOS phosphorylation.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; Goethe Univ Frankfurt, Dept Med 4, D-6000 Frankfurt, Germany; Univ Louvain, Sch Med, Pharmacol & Therapeut Unit, Brussels, Belgium	University of Munich; Goethe University Frankfurt; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Kupatt, C (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	c.kupatt@lrz.uni-muenchen.de	FERON, Olivier/AAM-6395-2020; Hinkel, Rabea/I-9165-2014	FERON, Olivier/0000-0001-5360-0286; Hinkel, Rabea/0000-0002-2936-0400; Dimmeler, Stefanie/0000-0002-1045-2436; Kupatt, Christian/0000-0002-3611-1218				Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; BOEKSTEGERS P, 1994, J AM COLL CARDIOL, V23, P459, DOI 10.1016/0735-1097(94)90434-0; Boekstegers P, 2000, GENE THER, V7, P232, DOI 10.1038/sj.gt.3301079; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Chen YX, 1999, ARTERIOSCL THROM VAS, V19, P131, DOI 10.1161/01.ATV.19.1.131; DE CR, 1995, J CLIN INVEST, V96, P60; Di Napoli P, 2001, CARDIOVASC RES, V51, P283, DOI 10.1016/S0008-6363(01)00306-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duilio C, 2001, AM J PHYSIOL-HEART C, V280, pH2649, DOI 10.1152/ajpheart.2001.280.6.H2649; Flogel U, 1999, J MOL CELL CARDIOL, V31, P827, DOI 10.1006/jmcc.1998.0921; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Hashimoto Etsuo, 1994, American Journal of Physiology, V267, pH1948; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Ichikawa H, 1997, CIRC RES, V81, P922; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Iwata A, 2001, CIRCULATION, V103, P2753; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kalra D, 2000, CIRCULATION, V102, P1302, DOI 10.1161/01.CIR.102.11.1302; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kinugawa K, 1997, CIRC RES, V81, P911; Kupatt C, 1997, CARDIOVASC RES, V36, P386, DOI 10.1016/S0008-6363(97)00191-0; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Kupatt C, 2002, GENE THER, V9, P518, DOI 10.1038/sj.gt.3301673; Kupatt C, 1997, J MOL CELL CARDIOL, V29, P2599, DOI 10.1006/jmcc.1997.0439; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; Ma XL, 2000, J PHARMACOL EXP THER, V292, P912; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; Mehta JL, 2002, CIRCULATION, V105, P2206, DOI 10.1161/01.CIR.0000015602.94990.3D; NAKANISHI K, 1992, AM J PHYSIOL, V263, pH1650, DOI 10.1152/ajpheart.1992.263.6.H1650; Nossuli TO, 2001, AM J PHYSIOL-HEART C, V281, pH2549, DOI 10.1152/ajpheart.2001.281.6.H2549; Pabla R, 1996, CIRC RES, V78, P65, DOI 10.1161/01.RES.78.1.65; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Sato K, 2001, J AM COLL CARDIOL, V37, P616, DOI 10.1016/S0735-1097(00)01144-X; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; Schluter KD, 2000, CIRC RES, V86, P946, DOI 10.1161/01.RES.86.9.946; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shimpo M, 2002, CARDIOVASC RES, V53, P993, DOI 10.1016/S0008-6363(01)00546-6; SIEGFRIED MR, 1992, AM J PHYSIOL, V263, pH771, DOI 10.1152/ajpheart.1992.263.3.H771; Torry RJ, 2001, J MOL CELL CARDIOL, V33, P175, DOI 10.1006/jmcc.2000.1292; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; Tsao PS, 1997, CIRCULATION, V96, P934; vonDegenfeld G, 1997, CARDIOVASC RES, V35, P233, DOI 10.1016/S0008-6363(97)00126-0; Wang WJ, 2002, CARDIOVASC RES, V53, P165, DOI 10.1016/S0008-6363(01)00445-X; Zahler S, 1997, J MOL CELL CARDIOL, V29, P2953, DOI 10.1006/jmcc.1997.0530; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	55	43	44	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					705	+		10.1096/fj.02-0673fje	http://dx.doi.org/10.1096/fj.02-0673fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586740	Green Submitted			2022-12-25	WOS:000181456900030
J	Park, Y; Kim, YJ; Dupriez, V; Adams, ME				Park, Y; Kim, YJ; Dupriez, V; Adams, ME			Two subtypes of ecdysis-triggering hormone receptor in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRUSTACEAN CARDIOACTIVE PEPTIDE; IDENTIFICATION; SEQUENCE; NEURONS	Insect ecdysis is a hormonally programmed physiological sequence that enables insects to escape their old cuticle at the end of each developmental stage. The immediate events leading to ecdysis, which are initiated upon release of ecdysis-triggering hormones (ETH) into the bloodstream, include respiratory inflation and sequential stereotypic behaviors that facilitate shedding of the cuticle. Here we report that the Drosophila gene CG5911 encodes two functionally distinct subtypes of G protein-coupled receptors through alternative splicing (CG5911a and CG5911b) that respond preferentially to ecdysis-triggering hormones of flies and moths. These subtypes show differences in ligand sensitivity and specificity, suggesting that they may play separate roles in ETH signaling. At significantly higher concentrations (> 100-fold), certain insect and vertebrate peptides also activate these receptors, providing evidence that CG5911 is evolutionarily related to the thyrotropin-releasing hormone and neuromedin U receptors. The ETH signaling system in insects is a vital system that provides opportunities for the construction of models for the molecular basis of stereotypic animal behavior as well as a target for the design of more sophisticated insect-selective pest control strategies.	Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Euroscreen SA, B-6041 Gosselies, Belgium	University of California System; University of California Riverside; University of California System; University of California Riverside	Adams, ME (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, 5429 Boyce Hall, Riverside, CA 92521 USA.	adams@mail.ucr.edu	Adams, Michael/ABF-6728-2020; Park, Yoonseong/J-5861-2013	Adams, Michael/0000-0003-0519-6113; Kim, Young-Joon/0000-0002-7990-754X; Park, Yoonseong/0000-0003-1191-7335	NIAID NIH HHS [AI-40555] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040555, R21AI040555] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adams ME, 1997, BIOCHEM BIOPH RES CO, V230, P188, DOI 10.1006/bbrc.1996.5915; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Ewer J, 1996, J COMP NEUROL, V370, P330; Gammie SC, 1999, J EXP BIOL, V202, P343; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; HUESMANN GR, 1995, FEBS LETT, V371, P311, DOI 10.1016/0014-5793(95)00929-4; Iversen A, 2002, BIOCHEM BIOPH RES CO, V299, P924, DOI 10.1016/S0006-291X(02)02798-5; Jespersen T, 2002, BIOTECHNIQUES, V32, P536, DOI 10.2144/02323st05; Le Poul E, 2002, J BIOMOL SCREEN, V7, P57, DOI 10.1089/108705702753520341; MATSUMOTO S, 1990, J INSECT PHYSIOL, V36, P427, DOI 10.1016/0022-1910(90)90060-S; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; Meng XJ, 2002, MECH DEVELOP, V117, P5, DOI 10.1016/S0925-4773(02)00175-2; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; O'Brien MA, 1998, J EXP BIOL, V201, P193; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Park Y, 1999, FEBS LETT, V463, P133, DOI 10.1016/S0014-5793(99)01622-1; Park Y, 2002, DEVELOPMENT, V129, P493; Park Y, 2002, P NATL ACAD SCI USA, V99, P11423, DOI 10.1073/pnas.162276199; RAINA AK, 1989, SCIENCE, V244, P796, DOI 10.1126/science.244.4906.796; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Truman JW, 1996, J EXP BIOL, V199, P749; Zitnan D, 2000, J EXP BIOL, V203, P1329; Zitnan D, 1999, NEURON, V23, P523, DOI 10.1016/S0896-6273(00)80805-3; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88	25	67	71	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17710	17715		10.1074/jbc.M301119200	http://dx.doi.org/10.1074/jbc.M301119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12586820	hybrid			2022-12-25	WOS:000182838300017
J	Barnes, BJ; Field, AE; Pitha-Rowe, PM				Barnes, BJ; Field, AE; Pitha-Rowe, PM			Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-7; SEQUENCE-BINDING-PROTEIN; STIMULATED RESPONSE ELEMENT; ALPHA PROMOTER REGION; HISTONE H4 GENE; CELL-CYCLE; DIFFERENTIAL EXPRESSION; POSITIVE FEEDBACK; DNA-BINDING; INDUCTION	Transcription factors of the interferon regulatory factor (IRF) family have been identified as critical mediators of early inflammatory gene transcription in infected cells. We have shown previously that IRF-5, like IRF-3 and IRF-7, is a direct transducer of virus-mediated signaling and plays a role in the expression of multiple cytokines/chemokines. The present study is focused on the molecular mechanisms underlying the formation and function of IRF-5/IRF-7 heterodimers in infected cells. The interaction between IRF-5 and IRF-7 is not cooperative and results in a repression rather than enhancement of IFNA gene transcription. The formation of the IRF-5/IRF-7 heterodimer is dependent on IRF-7 phosphorylation, as shown by the glutathione S-transferase pull-down and immunoprecipitation assays. Mapping of the interaction domain revealed that formation of IRF-5/IRF-7 heterodimers occurs through the amino terminus resulting in a masking of the DNA binding domain, the consequent alteration of the composition of the enhanceosome complex binding to IFNA promoters in vivo, and modulation of the expression profile of IFNA subtypes. Thus, these results indicate that IRF-5 can act as both an activator and a repressor of IFN gene induction dependent on the IRF-interacting partner, and IRF-5 may be a part of the regulatory network that ensures timely expression of the immediate early inflammatory genes.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Barnes, BJ (corresponding author), Johns Hopkins Univ, Ctr Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.				NIAID NIH HHS [R01AI/CA19737-19A1, R21AI19737-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; CHEUNG SC, 1991, J IMMUNOL, V146, P121; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; Escalante CR, 1997, FEBS LETT, V414, P219, DOI 10.1016/S0014-5793(97)00996-4; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; Island ML, 2002, MOL CELL BIOL, V22, P7120, DOI 10.1128/MCB.22.20.7120-7133.2002; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; Kim YM, 1999, J IMMUNOL, V163, P2000; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Kuwata T, 2002, MOL CELL BIOL, V22, P7439, DOI 10.1128/MCB.22.21.7439-7448.2002; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LUBYOVA B, 2002, J INTERFERON CYTOKIN, V22, P121; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; MARIE I, 2002, J INTERFERON CYTOKIN, V22, P56; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; SUHARA W, 2002, J INTERFERON CYTOKIN, V22, P131; TANIGUCHI T, 2002, J INTERFERON CYTOKIN, V22, P37; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	67	98	100	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16630	16641		10.1074/jbc.M212609200	http://dx.doi.org/10.1074/jbc.M212609200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600985	hybrid			2022-12-25	WOS:000182818600026
J	Lilley, RMC; Wang, XQ; Krausz, E; Andrews, TJ				Lilley, RMC; Wang, XQ; Krausz, E; Andrews, TJ			Complete spectra of the far-red chemiluminescence of the oxygenase reaction of Mn2+-activated ribulose-bisphosphate carboxylase/oxygenase establish excited Mn2+ as the source	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSEBISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; KINETIC-PROPERTIES; CRYSTAL-STRUCTURE; RUBISCO; TRANSITIONS; GENERATION; MUTATION; SUBUNIT; ENZYME	Chemiluminescence emitted by Mn(2+)activated ribulose-,5-bisphosphate carboxylase/oxygenase (rubisco) while catalyzing oxygenation was analyzed to clarify the source of the emission. Using dual detectors capturing radiation over a wide range of visible and infrared wavelengths, we tested for radiation from singlet O-2 decay and found it to be essentially absent (less than 0.1% of the total luminescence intensity). Spectra were determined between 647 and 885 nm with a very sensitive, charge-coupled detector-based spectrograph to detect differences in the emission spectra between rubiscos from bacterial and higher plant sources. All Mn2+-activated rubiscos emitted a broad, smooth spectrum of chemiluminescence, unchanging as the reaction progressed. The spectra from higher plant rubiscos (spinach and both the wild type and an L335V mutant from tobacco), all exhibited maxima at about 800 nm. However, Mn2+-activated rubisco from the bacterium, Rhodospirillum rubrum, emitted at shorter wavelengths (760 nm peak), demonstrating host ligand-field influences arising from aminoacyl residue differences and/or conformational changes caused by the absence of small subunits. The findings provide strong evidence that the chemiluminescence arises from an excited state of the active-site Mn2+ that is produced during oxygenation. We propose that the Mn2+ becomes excited by a one-electron exchange mechanism of oxygenation that is not available to Mg2+-activated rubisco.	Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	University of Wollongong; Australian National University; Australian National University	Lilley, RMC (corresponding author), Univ Wollongong, Dept Biol Sci, Northfields Ave, Wollongong, NSW 2522, Australia.	rossl@uow.edu.au	Krausz, Elmars R/I-2885-2014; Lilley, Ross/B-8127-2008	Krausz, Elmars R/0000-0002-8536-6890; Lilley, Ross/0000-0002-4292-4629				Barnett NW, 2002, ANAL CHIM ACTA, V451, P181, DOI 10.1016/S0003-2670(01)01414-3; Blasse G., 1994, LUMINESCENT MAT, P1, DOI DOI 10.1007/978-3-642-79017-1_1; BUTZ ND, 1989, PLANT PHYSIOL, V89, P735, DOI 10.1104/pp.89.3.735; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; CHRISTELLER JT, 1979, BIOCHEM J, V183, P747, DOI 10.1042/bj1830747; Cox SD, 1999, AUST J PLANT PHYSIOL, V26, P475, DOI 10.1071/PP99032; DURNER J, 1994, FEBS LETT, V354, P71, DOI 10.1016/0014-5793(94)01097-8; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Frank J, 2000, PHYS CHEM CHEM PHYS, V2, P1301, DOI 10.1039/b000018n; GUTTERIDGE S, 1984, EMBO J, V3, P2737, DOI 10.1002/j.1460-2075.1984.tb02204.x; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JORDAN DB, 1983, ARCH BIOCHEM BIOPHYS, V227, P425, DOI 10.1016/0003-9861(83)90472-1; Kane HJ, 1998, PLANT PHYSIOL, V117, P1059, DOI 10.1104/pp.117.3.1059; Kanofsky JR, 2000, METHOD ENZYMOL, V319, P59; KANOFSKY JR, 1983, J BIOL CHEM, V258, P5991; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; KHAN AU, 1984, J PHOTOCHEM, V25, P327, DOI 10.1016/0047-2670(84)87035-5; LILLEY RM, 1993, J BIOL CHEM, V268, P13877; LORIMER GH, 1973, BIOCHEMISTRY-US, V12, P18, DOI 10.1021/bi00725a004; MARTIN MN, 1981, FEBS LETT, V129, P39, DOI 10.1016/0014-5793(81)80750-8; Matsumoto M, 1999, LUMINESCENCE, V14, P345, DOI 10.1002/(SICI)1522-7243(199911/12)14:6<345::AID-BIO559>3.0.CO;2-T; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; MIZIORKO HM, 1984, BIOCHEMISTRY-US, V23, P479, DOI 10.1021/bi00298a012; MOGEL SN, 1990, BIOCHEMISTRY-US, V29, P8333, DOI 10.1021/bi00488a019; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; Oelckers S, 1999, J PHOTOCH PHOTOBIO B, V53, P121, DOI 10.1016/S1011-1344(99)00137-2; PAUL K, 1993, PLANT PHYSIOL, V102, P1129, DOI 10.1104/pp.102.4.1129; Ruuska S, 1998, AUST J PLANT PHYSIOL, V25, P859, DOI 10.1071/PP98079; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; SERVAITES JC, 1985, ARCH BIOCHEM BIOPHYS, V238, P154, DOI 10.1016/0003-9861(85)90151-1; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Watanabe T, 2001, EUR J BIOCHEM, V268, P6114, DOI 10.1046/j.0014-2956.2001.02557.x; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579	34	14	14	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16488	16493		10.1074/jbc.M212402200	http://dx.doi.org/10.1074/jbc.M212402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604603	hybrid			2022-12-25	WOS:000182818600008
J	Yano, T; Sklar, J; Nakamaru-Ogiso, E; Takahashi, Y; Yagi, T; Ohnishi, T				Yano, T; Sklar, J; Nakamaru-Ogiso, E; Takahashi, Y; Yagi, T; Ohnishi, T			Characterization of cluster N5 as a fast-relaxing [4Fe-4S] cluster in the Nqo3 subunit of the proton-translocating NADH-ubiquinone oxidoreductase from Paracoccus denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; DEHYDROGENASE COMPLEX-I; IRON-SULFUR CLUSTERS; QUINONE OXIDOREDUCTASE; MITOCHONDRIAL NADH; CLOSTRIDIUM-PASTEURIANUM; 3-DIMENSIONAL STRUCTURE; EPR CHARACTERIZATION; YARROWIA-LIPOLYTICA; RESPIRATORY-CHAIN	The NADH-quinone oxidoreductase from Paracoccus denitrificans consists of 14 subunits (Nqol-14) and contains one FMN and eight iron-sulfur clusters. The Nqo3 subunit possesses fully conserved 11 Cys and 1 His in its N-terminal region and is considered to harbor three iron-sulfur clusters; however, only one binuclear (N1b) and one tetranuclear (N4) were previously identified. In this study, the Nqo3 subunit containing 1 x [2Fe-2S] and 2x[4Fe-4S] clusters was expressed in Escherichia coli. The second [4Fe-4S](1+) cluster is detected by EPR spectroscopy below 6 K, exhibiting very fast spin relaxation. The resolved EPR spectrum of this cluster is broad and nearly axial. The subunit exhibits an absorption-type EPR signal around g similar to 5 region below 6 K, most likely arising from an S = 3/2 ground state of the fast-relaxing [4Fe-4S](1+) species. The substitution of the conserved His(106) with Cys specifically affected the fast-relaxing [4Fe-4S](1+) cluster, suggesting that this cluster is coordinated by His(106). In the cholate-treated NDH-1-enriched P. denitrificans membranes, we observed EPR signals arising from a [4Fe-4S] cluster below 6 K exhibiting properties similar to those of cluster N5 detected in other complex I/NDH-1 and of the fast-relaxing [4Fe-4S](1+) cluster in the expressed Nqo3 subunit. Hence, we propose that the His-coordinated [4Fe-4S] cluster corresponds to cluster N5.	Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA; Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Osaka Univ, Dept Biol, Grad Sch Sci, Osaka 5600043, Japan	University of Pennsylvania; Scripps Research Institute; Osaka University	Yano, T (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.		/AAD-2249-2020; Takahashi, Yasuhiro/F-1119-2011	Takahashi, Yasuhiro/0000-0002-0588-6045	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM030736] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 33712, R01 GM 30736] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADAMS MWW, 1987, J BIOL CHEM, V262, P15054; Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; Beinert H, 1978, Methods Enzymol, V54, P435; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dutton P L, 1978, Methods Enzymol, V54, P411; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Gutierrez-Correa J, 2001, FREE RADICAL RES, V34, P363, DOI 10.1080/10715760100300311; KERSCHER S, 2003, BIOCHIM BIOPHYS ACTA, V155, P83; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; MEINHARDT SW, 1987, J BIOL CHEM, V262, P9147; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OHNISHI T, 1975, BIOCHIM BIOPHYS ACTA, V387, P475, DOI 10.1016/0005-2728(75)90087-0; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PILKINGTON SJ, 1991, BIOCHEMISTRY-US, V30, P2166, DOI 10.1021/bi00222a021; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; RUNSWICK MJ, 1989, BIOCHEMISTRY-US, V28, P9452, DOI 10.1021/bi00450a031; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; Yano T, 2001, J BIOENERG BIOMEMBR, V33, P213, DOI 10.1023/A:1010782903144; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; Yano T, 2000, BBA-BIOENERGETICS, V1459, P299, DOI 10.1016/S0005-2728(00)00164-X; Yano T, 2002, MOL ASPECTS MED, V23, P345, DOI 10.1016/S0098-2997(02)00011-0; ZAMBRANO IC, 1989, J BIOL CHEM, V264, P20974; Zu YB, 2002, BIOCHEMISTRY-US, V41, P10056, DOI 10.1021/bi026026f	53	39	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15514	15522		10.1074/jbc.M212275200	http://dx.doi.org/10.1074/jbc.M212275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600982	hybrid			2022-12-25	WOS:000182680000009
J	Dauphin, Y				Dauphin, Y			Soluble organic matrices of the calcitic prismatic shell layers of two pteriomorphid bivalves - Pinna nobilis and Pinctada margaritifera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSK SHELLS; PROTEINS; GLYCOPROTEINS; LOCALIZATION; PURIFICATION; ORGANIZATION; CARBONATE; SULFUR; GROWTH	The calcitic prisms of the shells of two bivalves, Pinna and Pinctada, are considered simple prisms according to some morphological and mineralogical characteristics. Scanning electron microscopic and atomic force microscopic studies show that the microstructures and nanostructures of these two shells are different. Pinna prisms are monocrystalline, whereas Pinctada prisms are not. Moreover, intraprismatic membranes are present only in the Pinctada prisms. The soluble organic matrices extracted from these prisms are acidic, but their bulk compositions differ. Ultraviolet and infrared spectrometries, fluorescence, high pressure liquid chromatography, and electrophoresis show that the sugar-protein ratios and the molecular weights are different. Sulfur is mainly associated with acidic sulfated sugars, not with amino acids, and the role of acidic sulfated sugars is still underestimated. Thus, the simple prism concept is not a relevant model for the biomineralization processes in the calcitic prismatic layer of mollusk shells.	Univ Paris 11, Lab Paleontol, FRE 2566, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Dauphin, Y (corresponding author), Univ Paris 11, Lab Paleontol, FRE 2566, Bat 504, F-91405 Orsay, France.	dauphin@geol.u-psud.fr						Addadi L., 1991, P29; Aizenberg J, 2002, J AM CHEM SOC, V124, P32, DOI 10.1021/ja016990l; Albeck S, 1996, CHEM-EUR J, V2, P278, DOI 10.1002/chem.19960020308; Boggild O. B., 1930, Kongelige Danske Videnskabernes Selskabs Skrifter, Vix 2, P231; CAEL JJ, 1978, J MOL BIOL, V125, P21, DOI 10.1016/0022-2836(78)90252-8; Crenshaw MA., 1976, MECHANISMS MINERALIZ, P355; Cuif J.P., 1983, Haliotis, V13, P131; CUIF JP, 1988, CR ACAD SCI II, V307, P1943; CUIF JP, 1986, CR ACAD SCI II, V303, P251; CUIF JP, 1987, CR ACAD SCI II, V304, P475; CUIF JP, 1989, B SOC GEOL FR, V5, P569; Dauphin Y, 1999, ANN SCI NAT ZOOL, V20, P73, DOI 10.1016/S0003-4339(99)80010-0; Dauphin Y, 2002, COMP BIOCHEM PHYS A, V132, P577, DOI 10.1016/S1095-6433(02)00099-5; Dauphin Y, 2001, INT J BIOL MACROMOL, V28, P293, DOI 10.1016/S0141-8130(01)00124-6; Dauphin Y, 1997, ELECTROPHORESIS, V18, P1180, DOI 10.1002/elps.1150180726; delaPorte PL, 1996, J HEPATOL, V25, P339, DOI 10.1016/S0168-8278(96)80121-8; DEVILLEPOIX RM, 1877, J PHYSIOL-PARIS, P461; Fernandez MS, 2001, MATRIX BIOL, V19, P793, DOI 10.1016/S0945-053X(00)00128-1; FREMY E, 1855, ANN CHIM PARIS, V43, P47; Gregoire C., 1961, Bull Inst sci nat Belg, V37, P1; Hattan SJ, 2001, J BIOL CHEM, V276, P4461, DOI 10.1074/jbc.M006803200; Killian CE, 1996, J BIOL CHEM, V271, P9150, DOI 10.1074/jbc.271.15.9150; Krampitz G., 1976, MECHANISMS MINERALIZ, P155; Lowenstam HA, 1989, BIOMINERALIZATION; MARIN F, 1994, CR ACAD SCI II, V318, P1653; Marxen JC, 1997, COMP BIOCHEM PHYS B, V118, P23, DOI 10.1016/S0305-0491(97)00010-2; Masuda F., 1980, Science Reports of the Institute of Geoscience University of Tsukuba Section B Geological Sciences, V1, P163; Nakahara H., 1980, JPN J MALACOL, V39, P167; NATHUSIUSKONIGS.W, 1877, RES NONCELLULAR ORGA, P144; Prange A, 1999, BBA-GEN SUBJECTS, V1428, P446, DOI 10.1016/S0304-4165(99)00095-1; PREAZANT RS, 1990, HONOUR CM YONGE, P83; Rose K, 1998, J AM CHEM SOC, V120, P10743, DOI 10.1021/ja981350c; Samata T, 1999, FEBS LETT, V462, P225, DOI 10.1016/S0014-5793(99)01387-3; SAMATA T, 1990, VELIGER, V33, P190; Samata T., 1980, P37; SUZUKI S, 1981, J FAC SCI HOKKAIDO U, V1, P7; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; TAYLOR JD, 1969, B BRIT MUSEUM NATU S, V3, P1; TERMINE JD, 1981, J BIOL CHEM, V256, P403; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Wada K., 1980, P79; Wada K., 1964, Bulletin of the Japanese Society of Scientific Fisheries, V30, P993; Wada K., 1956, B NATL PEARL RES LAB, V1, P1; Wada K., 1961, B NATN PEARL RES LAB, V7, P703; WATABE N, 1956, J FAC FISH PREFECT U, P227; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WEINER S, 1975, SCIENCE, V190, P987, DOI 10.1126/science.1188379; Weiss IM, 2000, BIOCHEM BIOPH RES CO, V267, P17, DOI 10.1006/bbrc.1999.1907; WISE SW, 1969, SCANNING ELECTRON MI, P205; WORMS D, 1986, J EXP ZOOL, V237, P11, DOI 10.1002/jez.1402370104	50	110	113	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15168	15177		10.1074/jbc.M204375200	http://dx.doi.org/10.1074/jbc.M204375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576478	hybrid			2022-12-25	WOS:000182516100076
J	Jin, C; Barrientos, A; Tzagoloff, A				Jin, C; Barrientos, A; Tzagoloff, A			Yeast dihydroxybutanone phosphate synthase, an enzyme of the riboflavin biosynthetic pathway, has a second unrelated function in expression of mitochondrial respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MEMBRANE SYSTEM; PROTEIN; VECTORS; CLONING; GENE; DNA; SITES	aE280/U1 is a pet mutant of Saccharomyces cerevisiae partially deficient in cytochromes a, a3, and cytochrome b. The ability of this mutant to respire is restored by RIB3, a gene previously shown to code for 3,4-dihydroxy2-butanone-4-phosphate synthase (DHBP synthase), an enzyme of the riboflavin biosynthetic pathway. The sequences of RIB3 from wild type and aE280/U1 indicated a single base change resulting in an A137T substitution. The alanine 137 is a conserved residue located in a cavity on the surface of the protein distant from the active site and from the subunit interaction domain involved in homodimer formation. The respiratory defect elicited by this mutation cannot be explained by a flavin insufficiency based on the following evidence: 1) growth of the aE280/U1 on respiratory substrates is not rescued by exogenous riboflavin; 2) the levels of flavin nucleotides are not significantly different in the mutant and wild type. We proposed that in addition to its known function in riboflavin synthesis, RIB3 also functions in expression of mitochondrial respiration. Restoration by riboflavin of growth of a rib3 deletion mutant on glucose but not glycerol/ethanol also supported this conclusion. An antibody against the N-terminal half of DHBP synthase was used to study its subcellular distribution. Most of the protein was localized in the cytosolic fraction, but a small fraction was detected in the mitochondrial intermembrane space.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Jin, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL022174, HL2274] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIARAMIREZ JJ, 1995, J BIOL CHEM, V270, P23801, DOI 10.1074/jbc.270.40.23801; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 2002, BIOCHEMISTRY-US, V41, P51806; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1972, J BIOL CHEM, V247, P594; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	26	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14698	14703		10.1074/jbc.M300593200	http://dx.doi.org/10.1074/jbc.M300593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12595523	hybrid			2022-12-25	WOS:000182516100016
J	Liu, M; Ramos-Castaneda, J; Arvan, P				Liu, M; Ramos-Castaneda, J; Arvan, P			Role of the connecting peptide in insulin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; ER STRESS; DISULFIDE BONDS; TRANSCRIPTION FACTOR; BIOLOGICAL-ACTIVITY; QUALITY-CONTROL; MESSENGER-RNA; ATF6; PROINSULIN	In single-chain insulins (SCIs), the C terminus of the insulin B-chain is contiguous with the N terminus of the A-chain, connected by a short bioengineered linker sequence. SCIs have been proposed to offer potential benefit for gene therapy of diabetes (Lee, H. C., Kim, S. J., Kim, K. S., Shin, H. C., and Yoon, J. W. (2000) Nature 408, 483-488) yet relatively little is known about their folding, intracellular transport, or secretion from mammalian cells. Because SCIs can be considered as mutant proinsulin (with selective shortening of the 35-amino acid connecting peptide that normally includes two sets of flanking dibasic residues), they offer insights into understanding the role of the connecting peptide in insulin biosynthesis. Herein we have explored the relationship of the linker sequence to SCI biosynthesis, folding, and intracellular transport in transiently transfected HEK293 or Chinese hamster ovary cells or in stably transfected AtT20 cells. Despite previous reports that direct linkage of B- and A-chains produces a structure isomorphous with authentic two-chain insulin, we find that constructs with short linkers tend to be synthesized at lower levels, with a significant fraction of molecules exhibiting improper disulfide bonding. Nevertheless, disulfide-mispaired isoforms from a number of different SCI constructs are secreted. While this suggests that a novel folded state goes unrecognized by secretory pathway quality control, we find that misfolded SCIs are detected at higher levels in Chinese hamster ovary cells with artificially activated unfolded protein response mediated by inducible overexpression of active ATF-6. Such a maneuver allows analysis of more seriously misfolded mutants with further foreshortening of the linker sequence or loss (by mutation) of the insulin interchain disulfide bonds.	Albert Einstein Coll Med, Div Endocrinol, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Albert Einstein Coll Med, Div Endocrinol, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Ramos-Castañeda, jose/V-6678-2019	Liu, Ming/0000-0003-2665-4072	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Chou KC, 2000, ANAL BIOCHEM, V286, P1, DOI 10.1006/abio.2000.4757; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10585, DOI 10.1021/bi020165f; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HANG BY, 2002, J BIOL CHEM, V278, P3687; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lucocq J, 2001, EUR J CELL BIOL, V80, P508, DOI 10.1078/0171-9335-00186; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; PERMUTT MA, 1981, ISLETS LANGERHANS BI, P75; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SIEBER P, 1978, H-S Z PHYSIOL CHEM, V359, P113; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Steiner DF, 1997, SCIENCE, V277, P531, DOI 10.1126/science.277.5325.531; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; STEINER DF, 1972, HDB PHYSL 7, P175; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	42	41	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14798	14805		10.1074/jbc.M212070200	http://dx.doi.org/10.1074/jbc.M212070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590147	hybrid			2022-12-25	WOS:000182516100029
J	Grabowska, D; Chelstowska, A				Grabowska, D; Chelstowska, A			The ALD6 gene product is indispensable for providing NADPH in yeast cells lacking glucose-6-phosphate dehydrogenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; ISOCITRATE DEHYDROGENASE; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; STRUCTURAL GENE; SHUTTLE VECTORS; FATTY-ACIDS; DISRUPTION; EXPRESSION; STRESS	Reducing equivalents in the form of NADPH are essential for many enzymatic steps involved in the biosynthesis of cellular macromolecules. An adequate level of NADPH is also required to protect cells against oxidative stress. The major enzymatic source of NADPH in the cell is the reaction catalyzed by glucose-6-phosphate dehydrogenase, the first enzyme in the pentose phosphate pathway. Disruption of the ZWF1 gene, encoding glucose-6-phosphate dehydrogenase in the yeast Saccharomyces cerevisiae, results in methionine auxotrophy and increased sensitivity to oxidizing agents. It is assumed that both phenotypes are due to an NADPH deficiency in the zwf1Delta strain. We used a Met(-) phenotype displayed by the zwf1Delta strain to look for multicopy suppressors of this deletion. We found that overexpression of the ALD6 gene coding for cytosolic acetaldehyde dehydrogenase, which utilizes NADP(+) as its cofactor, restores the Met(+) phenotype of the zwf1Delta strain. Another multicopy suppressor identified in our screen, the ZMS1 gene encoding a putative transcription factor, regulates the level of ALD6 expression. A strain bearing a double ZWF1 ALD6 gene disruption is not viable. Thus, our results indicate the reaction catalyzed by Ald6p as an important source of reducing equivalents in the yeast cells.	Polish Acad Sci, Inst Biochem & Biophys, Dept Genet, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Chelstowska, A (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Dept Genet, Pawinskiego 5A, PL-02106 Warsaw, Poland.			Chelstowska, Anna/0000-0002-2431-7921				Adams A, 1997, METHODS YEAST GENETI; BEUTLER E, 1990, METABOLIC BASIS INHE; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Boubekeur S, 2001, EUR J BIOCHEM, V268, P5057, DOI 10.1046/j.1432-1327.2001.02418.x; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; FRAENKEL DG, 1968, J BACTERIOL, V95, P1267, DOI 10.1128/JB.95.4.1267-1271.1968; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Kucharczyk R, 1999, YEAST, V15, P987, DOI 10.1002/(SICI)1097-0061(199907)15:10B<987::AID-YEA403>3.0.CO;2-5; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; Meaden PG, 1997, YEAST, V13, P1319, DOI 10.1002/(SICI)1097-0061(199711)13:14<1319::AID-YEA183>3.0.CO;2-T; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; RACKI W, 2002, THESIS CTR GENETIQUE; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Stryer L., 1989, BIOCHEMISTRY; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; Wang XP, 1998, J BACTERIOL, V180, P822, DOI 10.1128/JB.180.4.822-830.1998	32	95	101	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13984	13988		10.1074/jbc.M210076200	http://dx.doi.org/10.1074/jbc.M210076200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584194	hybrid			2022-12-25	WOS:000182405000055
J	Higashi, S; Miyazaki, K				Higashi, S; Miyazaki, K			Identification of a region of beta-amyloid precursor protein essential for its gelatinase a inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING METALLOPROTEINASE; 1.8-ANGSTROM CRYSTAL-STRUCTURE; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; ALZHEIMERS-DISEASE; IV COLLAGENASE; ACTIVATION; PURIFICATION; ANGIOGENESIS; ASSOCIATION	Because beta-amyloid precursor protein (APP) has the abilities both to interact with extracellular matrix and to inhibit gelatinase A activity, this molecule is assumed to play a regulatory role in the gelatinase A-catalyzed degradation of extracellular matrix. To determine a region of APP essential for the inhibitory activity, we prepared various derivatives of APP. Functional analyses of proteolytic fragments of soluble APP (sAPP) and glutathione S-transferase fusion proteins, which contain various COOH-terminal parts of sAPP, showed that a site containing residues 579-601 of APP(770) is essential for the inhibitory activity. Moreover, a synthetic decapeptide containing the 579-601 sequence corresponding to residues 586-595 of APP(770) had a gelatinase A inhibitory activity slightly higher than that of sAPP. Studies of deletion of the NH2- and COOH-terminal residues and alanine replacement of internal residues of the decapeptide further revealed that Tyr(588), Asp(591), and Leu(593) of APP mainly stabilize the interaction between gelatinase A and the inhibitor. We also found that the residues of Ile(586), Met(594), and Pro(595) modestly contribute to the inhibitory activity. The APP-derived decapeptide efficiently inhibited the activity of gelatinase A (IC50 = 30 nm), whereas its inhibitory activity toward membrane type 1 matrix metalloproteinase was much weaker (IC50 = 2 muM). The decapeptide had poor inhibitory activity toward gelatinase B, matrilysin, and stromelysin (IC50 > 10 muM). The APP-derived inhibitor formed a complex with active gelatinase A but not with progelatinase A, and the complex formation was prevented completely by a hydroxamate-based synthetic inhibitor. Therefore, the decapeptide region of APP is likely an active site-directed inhibitor that has high selectivity toward gelatinase A.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Higashi, S (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 2440813, Japan.	shigashi@yokohama-cu.ac.jp						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Caceres J, 1997, J CELL BIOCHEM, V65, P145, DOI 10.1002/(SICI)1097-4644(199705)65:2<145::AID-JCB2>3.0.CO;2-U; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KIBBEY MC, 1993, P NATL ACAD SCI USA, V90, P10150, DOI 10.1073/pnas.90.21.10150; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohsawa I, 2001, J NEUROCHEM, V76, P1411, DOI 10.1046/j.1471-4159.2001.00144.x; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; RICE A, 1995, BIOCHEMISTRY-US, V34, P9249, DOI 10.1021/bi00028a038; Sambrook J., 1989, MOL CLONING, V2.9, P14; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Segel I. H., 1975, ENZYME KINETICS, P320; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1992, J NEUROSCI, V12, P4143; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Zheng H, 1996, ANN NY ACAD SCI, V777, P421, DOI 10.1111/j.1749-6632.1996.tb34456.x	47	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14020	14028		10.1074/jbc.M212264200	http://dx.doi.org/10.1074/jbc.M212264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12586836	hybrid			2022-12-25	WOS:000182405000060
J	Kim, JW; Lee, JE; Kim, MJ; Cho, EG; Cho, SG; Choi, EJ				Kim, JW; Lee, JE; Kim, MJ; Cho, EG; Cho, SG; Choi, EJ			Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; CELL-DEATH; INDUCED APOPTOSIS; BETA-CATENIN; MAP KINASES; AKT; PATHWAY; TRANSDUCTION; AXIN; JNK	Glycogen synthase kinase 3beta (GSK3beta) is implicated in many biological events, including embryonic development, cell differentiation, apoptosis, and insulin response. GSK3beta has now been shown to induce activation of the mitogen-activated protein kinase kinase kinase MEKK1 and thereby to promote signaling by the stress-activated protein kinase pathway. GSK3beta-binding protein blocked the activation of MEKK1 by GSK3beta in human embryonic kidney 293 (HEK293) cells. Furthermore, co-immunoprecipitation analysis revealed a physical association between endogenous GSK3beta and MEKK1 in HEK293 cells. Overexpression of axin1, a GSK3beta-regulated scaffolding protein, did not affect the physical interaction between GSK3beta and MEKK1 in transfected HEK293 cells. Exposure of cells to insulin inhibited the activation of MEKK1 by GSK3beta, and this inhibitory effect of insulin was abolished by the phosphatidylinositol 3-kinase inhibitor wortmannin. Furthermore, MEKK1 activity under either basal or UV- or tumor necrosis factor alpha-stimulated conditions was reduced in embryonic fibroblasts derived from GSK3beta knockout mice compared with that in such cells from wild-type mice. Ectopic expression of GSK3beta increased both basal and tumor necrosis factor alpha-stimulated activities of HEKK1. in GSK3beta(-/-) cells. Together, these observations suggest that GSK3beta functions as a natural activator of MEKK1.	Korea Univ, Grad Sch Life Sci & Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea; Konkuk Univ, Dept Anim Sci, Seoul 143702, South Korea	Korea University; Konkuk University	Choi, EJ (corresponding author), Korea Univ, Grad Sch Life Sci & Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea.		KIM, JIN WOO/C-1655-2011	KIM, JIN WOO/0000-0003-0767-1918; Cho, Ssang-Goo/0000-0002-0968-7932				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hartigan JA, 2001, BIOCHEM BIOPH RES CO, V284, P485, DOI 10.1006/bbrc.2001.4986; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hetman M, 2000, J NEUROSCI, V20, P2567; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Kim JW, 2001, J CELL BIOL, V153, P457, DOI 10.1083/jcb.153.3.457; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Levresse V, 2000, J NEUROSCI RES, V62, P799; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schlesinger TK, 1998, FRONT BIOSCI, V3, P1181; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WOODGETT JR, 2001, SCI STKE; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	51	75	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13995	14001		10.1074/jbc.M300253200	http://dx.doi.org/10.1074/jbc.M300253200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584189	hybrid			2022-12-25	WOS:000182405000057
J	Rybin, VO; Sabri, A; Short, J; Braz, JC; Molkentin, JD; Steinberg, SF				Rybin, VO; Sabri, A; Short, J; Braz, JC; Molkentin, JD; Steinberg, SF			Cross-regulation of novel protein kinase C (PKC) isoform function in cardiomyocytes - Role of PKC epsilon in activation loop phosphorylations and PKC delta in hydrophobic motif phosphorylations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE-1; PDK-1; AUTOPHOSPHORYLATION; EXPRESSION; ISOZYMES; APOPTOSIS; ISOTYPES; MYOCYTES; 3-KINASE; PATHWAY	Recent studies identify conventional protein kinase C (PKC) isoform phosphorylations at conserved residues in the activation loop and C terminus as maturational events that influence enzyme activity and targeting but are not dynamically regulated by second messengers. In contrast, this, study identifies phorbol 12-myristoyl 13-acetate (PMA)- and norepinephrine-induced phosphorylations of PKCepsilon (at the C-terminal hydrophobic motif) and PKCdelta (at the activation loop) as events that accompany endogenous novel PKC (nPKC) isoform activation in neonatal rat cardiomyocytes. Agonist-induced nPKC phosphorylations are prevented (and the kinetics of PMA-dependent PKC down-regulation are slowed) by pharmacologic inhibitors of nPKC kinase activity. PKCdelta is recovered from PMA-treated cultures with increased in vitro lipid-independent kinase activity (and altered substrate specificity); the PMA-dependent increase in PKCdelta kinase activity is attenuated when PKCdelta activation loop phosphorylation is prevented. To distinguish roles of individual nPKC isoforms in nPKC phosphorylations, wild-type (WT) and dominant negative (DN) PKCdelta and PKCepsilon mutants were introduced into cardiomyocyte cultures using adenovirus-mediated gene transfer. WT-PKCdelta and WT-PKCepsilon are highly phosphorylated at activation loop and hydrophobic motif sites, even in the absence of allosteric activators. DN-PKCdelta is phosphorylated at the activation loop but not the hydrophobic motif, DN-PKCepsilon is phosphorylated at the hydrophobic motif but not the activation loop. Collectively, these results identify a role for PKCepsilon in nPKC activation loop phosphorylations and PKCdelta in nPKC hydrophobic motif phosphorylations. Agonist-induced nPKC isoform phosphorylations that accompany activation/translocation of the enzyme contribute to the regulation of PKCdelta kinase activity, may influence nPKC isoform trafficking/down-regulation, and introduce functionally important cross-talk for nPKC signaling pathways in cardiomyocytes.	Columbia Univ, Dept Pharmacol, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; Univ Cincinnati, Childrens Hosp, Dept Pediat, Cincinnati, OH 45229 USA	Columbia University; Columbia University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Steinberg, SF (corresponding author), Columbia Univ, Dept Pharmacol, Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.			Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [HL-64639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; Korichneva I, 2002, J BIOL CHEM, V277, P44327, DOI 10.1074/jbc.M205634200; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; NEWTON AC, 1995, J BIOL CHEM, V270, P28496; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 1999, PHARMACOL THERAPEUT, V82, P263, DOI 10.1016/S0163-7258(98)00047-3; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Rybin V, 1996, CIRC RES, V79, P388, DOI 10.1161/01.RES.79.3.388; Rybin VO, 1997, AM J PHYSIOL-HEART C, V272, pH1636, DOI 10.1152/ajpheart.1997.272.4.H1636; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0	31	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14555	14564		10.1074/jbc.M212644200	http://dx.doi.org/10.1074/jbc.M212644200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566450	hybrid			2022-12-25	WOS:000182405000124
J	Stiewe, T; Stanelle, J; Theseling, CC; Pollmeier, B; Beitzinger, M; Putzer, BM				Stiewe, T; Stanelle, J; Theseling, CC; Pollmeier, B; Beitzinger, M; Putzer, BM			Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER TISSUES; EXPRESSION; GENE; DELTA-NP73; PROTEIN; OVEREXPRESSION; NEUROBLASTOMA; TRANSCRIPTION; HOMOLOG; BINDING	The p53 family includes three members that share significant sequence homology, yet exhibit fundamentally different functions in tumorigenesis. Whereas p53 displays all characteristics of a classical tumor suppressor, its homologues p63 and p73 do not. We have previously shown, that NH2-terminally truncated isoforms of p73 (DeltaTA-p73), which act as dominant-negative inhibitors of p53 are frequently overexpressed in cancer cells. Here we provide evidence that DeltaTA-p73 isoforms also affect the retinoblastoma protein (RB) tumor suppressor pathway independent of p53. DeltaTA-p73 isoforms inactivate RB by increased phosphorylation, resulting in enhanced E2F activity and proliferation of fibroblasts. By inactivating the two major tumor suppressor pathways in human cells they act functionally analogous to several viral oncoproteins. These findings provide an explanation for the fundamentally different functions of p53 and p73 in tumorigenesis.	Univ Essen Gesamthsch, Ctr Canc Res & Canc Therapy, Inst Mol Biol, D-45122 Essen, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany	University of Duisburg Essen; University of Wurzburg	Putzer, BM (corresponding author), Univ Essen Gesamthsch, Ctr Canc Res & Canc Therapy, Inst Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.	brigitte.puetzer@uni-essen.de		Stiewe, Thorsten/0000-0003-0134-7826				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Senoo M, 2001, BIOCHEM BIOPH RES CO, V286, P628, DOI 10.1006/bbrc.2001.5429; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; STIEWE T, 2002, CANCER RES, V277, P14177; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Thompson JB, 2000, PETROLOGY+, V8, P303; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	54	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14230	14236		10.1074/jbc.M300357200	http://dx.doi.org/10.1074/jbc.M300357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584188	hybrid			2022-12-25	WOS:000182405000085
J	Usui, I; Imamura, T; Huang, J; Satoh, H; Olefsky, JM				Usui, I; Imamura, T; Huang, J; Satoh, H; Olefsky, JM			Cdc42 is a rho GTPase family member that can mediate insulin signaling to glucose transport in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; ACTIVATION; PATHWAY; PROTEIN; RESISTANCE; KINASE; OVEREXPRESSION; INHIBITION	We investigated the role of cdc42, a Rho GTPase family member, in insulin-induced glucose transport in 3T3-L1 adipocytes. Microinjection of anti-cdc42 antibody or cdc42 siRNA led to decreased insulin-induced and constitutively active G. (CA-G(q); Q209L)-induced GLUT4 translocation. Adenovirus-mediated expression of constitutively active cdc42 (CA-cdc42; V12) stimulated 2-deoxyglucose uptake to 56% of the maximal insulin response, and this was blocked by treatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin, or LY294002. Both insulin and CA-G(q) expression caused an increase in cdc42 activity, showing that cdc42 is activated by insulin and is downstream of Galpha(q/11) in this activation pathway. Immunoprecipitation experiments showed that insulin enhanced a direct association of cdc42 and p85, and both insulin treatment and CA-cdc42 expression stimulated PI3-kinase activity in immunoprecipitates with anti-cdc42 antibody. Furthermore, the effects of insulin, CA-G(q), and CA-cdc42 on GLUT4 translocation or 2-deoxyglucose uptake were inhibited by microinjection of anti-protein kinase CA (PKClambda) antibody or overexpression of a kinase-deficient PKClambda construct. In summary, activated cdc42 can mediate 1) insulin-stimulated GLUT4 translocation and 2) glucose transport in a PI3-kinase-dependent manner. 3) Insulin treatment and constitutively active G(q) expression can enhance the cdc42 activity state as well as the association of cdc42 with activated PI3-kinase. 4) PKClambda inhibition blocks CA-cdc42, CA-G(q), and insulin-stimulated GLUT4 translocation. Taken together, these data indicate that cdc42 can mediate insulin signaling to GLUT4 translocation and lies downstream of Galpha(q/11) and upstream of PI3-kinase and PKClambda in this stimulatory pathway.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA; San Diego Vet Adm Med Res Serv, La Jolla, CA 92037 USA; Whittier Inst Diabet & Endocrinol, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Satoh, Hiroaki/E-9096-2017	Satoh, Hiroaki/0000-0002-0353-5807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; JAMES DE, 1993, J CELL SCI, V104, P607; Janez A, 2000, J BIOL CHEM, V275, P26870; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Kanoh Y, 2001, ENDOCRINOLOGY, V142, P1595, DOI 10.1210/en.142.4.1595; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	69	77	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13765	13774		10.1074/jbc.M208904200	http://dx.doi.org/10.1074/jbc.M208904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566459	hybrid			2022-12-25	WOS:000182405000027
J	Santos, M; Perez, P; Segrelles, C; Ruiz, S; Jorcano, JL; Paramio, JM				Santos, M; Perez, P; Segrelles, C; Ruiz, S; Jorcano, JL; Paramio, JM			Impaired NF-kappa B activation and increased production of tumor necrosis factor alpha in Transgenic mice expressing keratin K10 in the basal layer of the epidermis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; GENE-EXPRESSION; INTERMEDIATE-FILAMENTS; RELA/P65 SUBUNIT; IKK ACTIVATION; SKIN; PROTEIN; KINASE; AKT; GROWTH	Both the diversity and the precisely regulated tissue-and differentiation-specific expression patterns of keratins suggest that these proteins have specific functions in epithelia besides their well known maintenance of cell integrity. In the search for these specific functions, our previous results have demonstrated that the expression of K10, a keratin expressed in postmitotic suprabasal cells of the epidermis, prevents cell proliferation through the inhibition of Akt kinase activity. Given the roles of Alit in NF-kappaB signaling and the importance of these processes in the epidermis, a study was made into the possible alterations of the NF-kappaB pathway in transgenic mice expressing K10 in the proliferative basal layer. It was found that the inhibition of Akt, mediated by K10 expression, leads to impaired NF-kappaB activity. This appears to occur through the decreased expression of IKKbeta and IKKgamma. Remarkably, increased production of tumor necrosis factor a and concomitant JNK activation was observed in the epidermis of these transgenic mice. These results confirm that keratin K10 functions in vivo include the control of many aspects of epithelial physiology, which affect the cells not only in a cell autonomous manner but also influence tissue homeostasis.	CIEMAT, Dept Cell & Mol Biol, E-28040 Madrid, Spain; Inst Biomed Valencia, Valencia 46010, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Paramio, JM (corresponding author), CIEMAT, Dept Cell & Mol Biol, Ave Complutense 22, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Santos, Mirentxu/AAA-1727-2020; Segrelles, Carmen/E-3655-2016; Paramio, Jesus M/M-8482-2014; Perez, Paloma/K-8841-2017; Ruiz, Sergio/G-1561-2016	Segrelles, Carmen/0000-0001-9340-2102; Paramio, Jesus M/0000-0001-7520-3177; Perez, Paloma/0000-0002-7166-2824; Ruiz, Sergio/0000-0002-0177-6965				Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS EV, 1997, MOL BIOL CELL, V69, P899; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Relchelt J, 2002, J CELL SCI, V115, P2639; ROOP DR, 1988, CANCER RES, V48, P3245; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TOFTGARD R, 1985, CANCER RES, V45, P5845; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	64	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13422	13430		10.1074/jbc.M208170200	http://dx.doi.org/10.1074/jbc.M208170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566451	hybrid			2022-12-25	WOS:000182189500105
J	Kieffer, AE; Goumon, Y; Ruh, O; Chasserot-Golaz, S; Nullans, G; Gasnier, C; Aunis, D; Metz-Boutigue, MH				Kieffer, AE; Goumon, Y; Ruh, O; Chasserot-Golaz, S; Nullans, G; Gasnier, C; Aunis, D; Metz-Boutigue, MH			The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities	FASEB JOURNAL			English	Article						chromaffin cells; calmodulin; calcineurin activity	MEDULLARY CHROMAFFIN GRANULES; FLIGHT MASS-SPECTROMETRY; BOVINE ADRENAL-MEDULLA; CHROMOGRANIN-A; INNATE IMMUNITY; ANTIBACTERIAL ACTIVITY; PROTEIN-DEGRADATION; NEUROSPORA-CRASSA; SUBSTRATE-SPECIFICITY; POSSIBLE INVOLVEMENT	Secretory granules of chromaffin cells contain catecholamines and several antimicrobial peptides derived from chromogranins and proenkephalin-A. These peptides are secreted in the extracellular medium following exocytosis. Here, we show that ubiquitin is stored in secretory chromaffin granules and released into the circulation upon stimulation of chromaffin cells. We also show that the C-terminal fragment (residues 65-76) of ubiquitin displays, at the micromolar range, a lytic antifungal activity. Using confocal laser scan microscopy and rhodamine-labeled synthetic peptides, we could demonstrate that the C-terminal peptide (residues 65-76) is able to cross the cell wall and the plasma membrane of fungi and to accumulate in fungi, whereas the N-terminal peptide (residues 1-34) is stopped at the fungal wall level. Furthermore, these two peptides act synergistically to kill filamentous fungi. Because of the interaction of the C-terminal sequence of ubiquitin with calmodulin, the synthetic peptide (residues 65-76) was tested in vitro against calmodulin-dependent calcineurin, an enzyme crucial for fungal growth. This peptide was found to inhibit the phosphatase activity of calcineurin. Our data show a new property of ubiquitin C-terminal-derived peptide (65-76) that could be used with N-terminal peptide (1-34) as a new potent antifungal agent.	INSERM, U575, IFR 37, F-67084 Strasbourg, France; CNRS, UPR 2356, IFR 37, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Metz-Boutigue, MH (corresponding author), INSERM, U575, IFR 37, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Chasserot-Golaz, Sylvette/K-7625-2017; Dominique, Aunis/W-1419-2019	Goumon, Yannick/0000-0003-4336-3437; Chasserot-Golaz, Sylvette/0000-0002-7437-2558				AGELL N, 1988, BIOCHEM J, V250, P883, DOI 10.1042/bj2500883; Ali MF, 2001, BBA-PROTEIN STRUCT M, V1550, P81, DOI 10.1016/S0167-4838(01)00272-2; ALIZADEHKHIAVI K, 1992, VIRCHOWS ARCH A, V420, P139, DOI 10.1007/BF02358805; ASKANAS V, 1991, NEUROSCI LETT, V130, P73, DOI 10.1016/0304-3940(91)90230-Q; ASSEMAN C, 1994, J IMMUNOL METHODS, V173, P93, DOI 10.1016/0022-1759(94)90286-0; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOND U, 1988, J BIOL CHEM, V263, P2384; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BULET P, 1993, J BIOL CHEM, V268, P14893; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; Daino H, 1996, BIOCHEM BIOPH RES CO, V223, P226, DOI 10.1006/bbrc.1996.0875; de Lucca AJ, 1999, ANTIMICROB AGENTS CH, V43, P1, DOI 10.1093/jac/43.1.1; Doskeland AP, 2002, EUR J BIOCHEM, V269, P1561, DOI 10.1046/j.1432-1033.2002.02808.x; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Fox DS, 2001, MOL MICROBIOL, V39, P835, DOI 10.1046/j.1365-2958.2001.02295.x; GALINDO E, 1991, J NEUROENDOCRINOL, V3, P669, DOI 10.1111/j.1365-2826.1991.tb00332.x; Glick BS, 2000, CURR OPIN CELL BIOL, V12, P450, DOI 10.1016/S0955-0674(00)00116-2; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; HAYASHI T, 1993, BRAIN RES, V620, P171, DOI 10.1016/0006-8993(93)90288-X; HELLE KB, 1971, BIOCHIM BIOPHYS ACTA, V245, P80, DOI 10.1016/0005-2728(71)90010-7; HENSOLD JO, 1988, BLOOD, V71, P1153; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; HORTNAGL H, 1974, J NEUROCHEM, V22, P197, DOI 10.1111/j.1471-4159.1974.tb12201.x; ISHIBASHI Y, 1991, BRIT J CANCER, V63, P320, DOI 10.1038/bjc.1991.75; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; JENNISSEN HP, 1992, FEBS LETT, V296, P51, DOI 10.1016/0014-5793(92)80401-2; Kano R, 1999, CURR MICROBIOL, V39, P302, DOI 10.1007/s002849900463; Kawakami T, 1999, J BIOCHEM, V126, P612, DOI 10.1093/oxfordjournals.jbchem.a022493; KELNER KL, 1985, J NEUROSCI, V5, P2161; KENT C, 1989, J ANAT, V166, P213; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laub M, 1998, EUR J BIOCHEM, V255, P422, DOI 10.1046/j.1432-1327.1998.2550422.x; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; MANAKA H, 1992, NEUROSCI LETT, V139, P47, DOI 10.1016/0304-3940(92)90854-Z; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MOR A, 1994, J BIOL CHEM, V269, P31635; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; Nabika T, 1999, BBA-MOL CELL RES, V1450, P25, DOI 10.1016/S0167-4889(99)00024-5; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; OKADA M, 1993, CLIN CHIM ACTA, V220, P135, DOI 10.1016/0009-8981(93)90042-3; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; Prokisch H, 1997, MOL GEN GENET, V256, P104, DOI 10.1007/s004380050551; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; SCHLESINGER DH, 1975, BIOCHEMISTRY-US, V14, P2214, DOI 10.1021/bi00681a026; SCHLESINGER DH, 1975, NATURE, V255, P42304; Sepulveda P, 1996, J MED VET MYCOL, V34, P315; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Suresh K, 1997, FEMS MICROBIOL LETT, V150, P95, DOI 10.1016/S0378-1097(97)00103-1; TACCIOLI GE, 1989, NUCLEIC ACIDS RES, V17, P6153, DOI 10.1093/nar/17.15.6153; Takada K, 1997, CLIN CHEM, V43, P1188; Towbin H, 1992, Biotechnology, V24, P145; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wang B, 1993, Hua Xi Yi Ke Da Xue Xue Bao, V24, P127; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; ZIEGENHAGEN R, 1990, FEBS LETT, V273, P253, DOI 10.1016/0014-5793(90)81097-8	81	78	78	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					776	+		10.1096/fj.02-0699fje	http://dx.doi.org/10.1096/fj.02-0699fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594174				2022-12-25	WOS:000181456900010
J	Im, H; Park, C; Feng, Q; Johnson, KD; Kiekhaefer, CM; Choi, K; Zhang, Y; Bresnick, EH				Im, H; Park, C; Feng, Q; Johnson, KD; Kiekhaefer, CM; Choi, K; Zhang, Y; Bresnick, EH			Dynamic regulation of histone H3 methylated at lysine 79 within a tissue-specific chromatin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; LOCUS-CONTROL REGION; RNA-POLYMERASE-II; BETA-GLOBIN LOCUS; NUCLEOSOMAL DNA; ACTIVE GENES; IN-VITRO; HP1; ACETYLATION; EXPRESSION	Post-translational modifications of individual lysine residues of core histones can exert unique functional consequences. For example, methylation of histone H3 at lysine 79 (H3-meK79) has been implicated recently in gene silencing in Saccharomyces cerevisiae. However, the distribution and function of H3-meK79 in mammalian chromatin are not known. We found that H3-meK79 has a variable distribution within the murine beta-globin locus in adult erythroid cells, being preferentially enriched at the active betamajor gene. By contrast, acetylated H3 and H4 and H3 methylated at lysine 4 were enriched both at betamajor and at the upstream locus control region. H3-meK79 was also enriched at the active cad gene, whereas the transcriptionally inactive loci necdin and MyoD1 contained very little H3-meK79. As the pattern of H3-meK79 at the beta-globin locus differed between adult and embryonic erythroid cells, establishment and/or maintenance of H3-meK79 was developmentally dynamic. Genetic complementation analysis in null cells lacking the erythroid and megakaryocyte-specific transcription factor p45/NF-E2 showed that p45/NF-E2 preferentially establishes H3-meK79 at the betamajor promoter. These results support a model in which H3-meK79 is strongly enriched in mammalian chromatin at active genes but not uniformly throughout active chromatin domains. As H3-meK79 is highly regulated at the beta-globin locus, we propose that the murine ortholog of Disruptor of Telomeric Silencing-1-like (mDOT1L) methyltransferase, which synthesizes H3-meK79, regulates beta-globin transcription.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dev Biol Program, St Louis, MO 63110 USA; Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave,383 Med Sci Ctr, Madison, WI 53706 USA.			Zhang, Yi/0000-0002-2789-0811	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050107, R01DK055700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063067] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07936] Funding Source: Medline; NIDDK NIH HHS [DK50107, DK55700] Funding Source: Medline; NIGMS NIH HHS [GM63067] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; BRESNICK EH, 1991, BIOCHEMISTRY-US, V30, P3490, DOI 10.1021/bi00228a020; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Im H, 2002, BIOCHEMISTRY-US, V41, P15152, DOI 10.1021/bi026786q; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; NUDEL U, 1977, P NATL ACAD SCI USA, V74, P1100, DOI 10.1073/pnas.74.3.1100; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Singer MS, 1998, GENETICS, V150, P613; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	45	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18346	18352		10.1074/jbc.M300890200	http://dx.doi.org/10.1074/jbc.M300890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604594	Green Published, hybrid			2022-12-25	WOS:000182838300099
J	Laursen, BS; Mortensen, KK; Sperling-Petersen, HU; Hoffman, DW				Laursen, BS; Mortensen, KK; Sperling-Petersen, HU; Hoffman, DW			A conserved structural motif at the N terminus of bacterial translation initiation factor IF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; GLUTAMINYL-TRANSFER-RNA; ESCHERICHIA-COLI; RIBOSOMAL-SUBUNITS; BACKBONE DYNAMICS; NMR RELAXATION; INFB GENE; PROTEIN; MODEL; SYNTHETASE	The 18-kDa Domain I from the N-terminal region of translation initiation factor IF2 from Escherichia coli was expressed, purified, and structurally characterized using multidimensional NMR methods. Residues 2-50 were found to form a compact subdomain containing three short beta-strands and three a-helices, folded to form a betaalphabetabetaalpha motif with the three helices packed on the same side of a small twisted beta-sheet. The hydrophobic amino acids in the core of the subdomain are conserved in a wide range of species, indicating that a similarly structured motif is present at the N terminus of IF2 in many of the bacteria. External to the compact 50-amino acid subdomain, residues 51-97 are less conserved and do not appear to form a regular structure, whereas residues 98-157 form a helix containing a repetitive sequence of mostly hydrophilic amino acids. Nitrogen-15 relaxation rate measurements provide evidence that the first 50 residues form a well ordered subdomain, whereas other regions of Domain I are significantly more mobile. The compact subdomain at the N terminus of IF2 shows structural homology to the tRNA anticodon stem contact fold domains of the methionyl-tRNA and glutaminyl-tRNA synthetases, and a similar fold is also found in the B5 domain of the phenylalanine-tRNA synthetase. The results of the present work will provide guidance for the design of future experiments directed toward understanding the functional roles of this widely conserved structural domain within IF2.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark; Univ Texas, Inst Cellular & Mol Biol, Dept Biochem & Chem, Austin, TX 78712 USA	Aarhus University; University of Texas System; University of Texas Austin	Sperling-Petersen, HU (corresponding author), Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boelens R, 2002, CURR PROTEIN PEPT SC, V3, P107, DOI 10.2174/1389203023380765; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FOLKERS PJM, 1993, J AM CHEM SOC, V115, P3798, DOI 10.1021/ja00062a065; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWE JG, 1983, J BIOL CHEM, V258, P1954; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Laursen BS, 2002, GENES CELLS, V7, P901, DOI 10.1046/j.1365-2443.2002.00571.x; Lillemoen J, 1998, J MOL BIOL, V281, P539, DOI 10.1006/jmbi.1998.1946; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Mechulam Y, 1999, J MOL BIOL, V294, P1287, DOI 10.1006/jmbi.1999.3339; Meunier S, 2000, EMBO J, V19, P1918, DOI 10.1093/emboj/19.8.1918; Moreno JMP, 1998, BIOCHEM BIOPH RES CO, V252, P465, DOI 10.1006/bbrc.1998.9664; Moreno JMP, 2000, IUBMB LIFE, V50, P347, DOI 10.1080/713803743; Moreno JMP, 1999, FEBS LETT, V455, P130, DOI 10.1016/S0014-5793(99)00858-3; MORTENSEN KK, 1995, BIOCHEM BIOPH RES CO, V214, P1254, DOI 10.1006/bbrc.1995.2421; Mortensen KK, 1998, BIOCHEM MOL BIOL INT, V46, P1027; NYENGAARD NR, 1991, BIOCHEM BIOPH RES CO, V181, P1572, DOI 10.1016/0006-291X(91)92118-4; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; PETERSEN HU, 1981, FEBS LETT, V128, P161, DOI 10.1016/0014-5793(81)81105-2; PETERSEN HU, 1984, BIOCHIMIE, V66, P625, DOI 10.1016/0300-9084(84)90116-0; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; SACERDOT C, 1992, J MOL BIOL, V225, P67, DOI 10.1016/0022-2836(92)91026-L; Sherman JM, 1996, J MOL BIOL, V256, P818, DOI 10.1006/jmbi.1996.0128; Sorensen HP, 2001, IUBMB LIFE, V51, P321; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Steffensen SAD, 1997, FEBS LETT, V419, P281; Sugiura I, 2000, STRUCTURE, V8, P197, DOI 10.1016/S0969-2126(00)00095-2; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yusupova G, 1996, BIOCHEMISTRY-US, V35, P2978, DOI 10.1021/bi9519415	40	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16320	16328		10.1074/jbc.M212960200	http://dx.doi.org/10.1074/jbc.M212960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600987	hybrid			2022-12-25	WOS:000182680000110
J	Loris, R; Imberty, A; Beeckmans, S; Van Driessche, E; Read, JS; Bouckaertt, J; De Greve, H; Buts, L; Wyns, L				Loris, R; Imberty, A; Beeckmans, S; Van Driessche, E; Read, JS; Bouckaertt, J; De Greve, H; Buts, L; Wyns, L			Crystal structure of Pterocarpus angolensis lectin in complex with glucose, sucrose, and turanose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; X-RAY; CARBOHYDRATE-RECOGNITION; BINDING-SITE; GRIFFONIA-SIMPLICIFOLIA; MOLECULAR-DYNAMICS; PLANT-LECTINS; LENTIL LECTIN; ISOLECTIN-I; CONCANAVALIN	The crystal structure of the Man/Glc-specific seed lectin from Pterocarpus angolensis was determined in complex with methyl-alpha-D-glucose, sucrose, and turanose. The carbohydrate binding site contains a classic Man/Glc type specificity loop. Its metal binding loop on the other hand is of the long type, different from what is observed in other Man/Glc-specific legume lectins. Glucose binding in the primary binding site is reminiscent of the glucose complexes of concanavalin A and lentil lectin. Sucrose is found to be bound in a conformation similar as seen in the binding site of lentil lectin. A direct hydrogen bond between Ser-137(OG) to Fru(02) in Pterocarpus angolensis lectin replaces a water-mediated interaction in the equivalent complex of lentil lectin. In the turanose complex, the binding site of the first molecule in the asymmetric unit contains the alphaGlc1-3betaFruf form of furanose while the second molecule contains the alphaGlc1-3betaFrup form in its binding site.	Free Univ Brussels, ULTR, Inst Mol Biol, Lab Ultrastructuur, B-1050 Brussels, Belgium; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France; Free Univ Brussels, Lab Scheikunde Prot, Inst Mol Biol, B-1050 Brussels, Belgium; Univ Zimbabwe, Dept Biochem, Harare, Zimbabwe	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Zimbabwe	Loris, R (corresponding author), Free Univ Brussels, ULTR, Inst Mol Biol, Lab Ultrastructuur, Pleinlaan 2, B-1050 Brussels, Belgium.	reloris@vub.ac.be	Loris, Remy/GPG-0894-2022; Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527; Bouckaert, Julie/0000-0001-8112-1442; Loris, Remy/0000-0002-8862-3338				ALLINGER NL, 1990, J AM CHEM SOC, V112, P8293, DOI 10.1021/ja00179a012; Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; ANGYAL SJ, 1984, ADV CARBOHYD CHEM BI, V42, P15, DOI 10.1016/S0065-2318(08)60122-5; Audette GF, 2000, J MOL BIOL, V304, P423, DOI 10.1006/jmbi.2000.4214; AVELEL D, 1976, ACTA CRYSTALLOGR B, V32, P2598; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; BECQUART J, 1982, CARBOHYD RES, V111, P9, DOI 10.1016/0008-6215(82)85002-7; Bouckaert J, 1999, CURR OPIN STRUC BIOL, V9, P572, DOI 10.1016/S0959-440X(99)00007-X; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; Bradbrook GM, 1998, J CHEM SOC FARADAY T, V94, P1603, DOI 10.1039/a800429c; BROWN GM, 1973, ACTA CRYSTALLOGR B, VB 29, P790, DOI 10.1107/S0567740873003353; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; Buts L, 2001, J MOL BIOL, V309, P193, DOI 10.1006/jmbi.2001.4639; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; Cebo C, 2002, BBA-GEN SUBJECTS, V1572, P422, DOI 10.1016/S0304-4165(02)00323-9; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DODDRELL D, 1971, J AM CHEM SOC, V93, P2779; DOWD MK, 1993, J CARBOHYD CHEM, V12, P449, DOI 10.1080/07328309308019400; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DUPENHOAT CH, 1991, J AM CHEM SOC, V113, P3720; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; Engelsen SB, 1997, J MOL GRAPH MODEL, V15, P122; ENGELSEN SB, 1995, J PHYS CHEM-US, V99, P13334, DOI 10.1021/j100036a005; FRENCH AD, 1990, BIOPOLYMERS, V29, P1599, DOI 10.1002/bip.360291210; Hamelryck TW, 2000, J MOL BIOL, V299, P875, DOI 10.1006/jmbi.2000.3785; HANSON JC, 1973, ACTA CRYSTALLOGR B, V29, P797, DOI 10.1107/S0567740873003365; Harrop SJ, 1996, ACTA CRYSTALLOGR D, V52, P143, DOI 10.1107/S0907444995008742; Imberty A, 2000, CHEM REV, V100, P4567, DOI 10.1021/cr990343j; Imberty A, 2000, J BIOL CHEM, V275, P17541, DOI 10.1074/jbc.M000560200; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Kawabata S, 2002, BBA-GEN SUBJECTS, V1572, P414, DOI 10.1016/S0304-4165(02)00322-7; Klemm P, 2000, INT J MED MICROBIOL, V290, P27; Lescar J, 2002, J BIOL CHEM, V277, P6608, DOI 10.1074/jbc.M109867200; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; LORIS R, 1994, GLYCOCONJUGATE J, V11, P507, DOI 10.1007/BF00731301; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; Loris R, 2000, J MOL BIOL, V301, P987, DOI 10.1006/jmbi.2000.4016; Manoj N, 2000, J MOL BIOL, V302, P1129, DOI 10.1006/jmbi.2000.4111; Moothoo DN, 1999, GLYCOBIOLOGY, V9, P539, DOI 10.1093/glycob/9.6.539; Mouricout M, 1997, ADV EXP MED BIOL, V412, P109; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEUMAN A, 1978, ACTA CRYSTALLOGR B, V34, P242, DOI 10.1107/S056774087801451X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez S., 2000, OLIGOSACCHARIDES CHE, P969; POPPE L, 1992, J AM CHEM SOC, V114, P1092, DOI 10.1021/ja00029a051; Prabu MM, 1998, J MOL BIOL, V276, P787, DOI 10.1006/jmbi.1997.1568; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SanzAparicio J, 1997, FEBS LETT, V405, P114, DOI 10.1016/S0014-5793(97)00137-3; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Tempel W, 2002, J BIOL CHEM, V277, P6615, DOI 10.1074/jbc.M109919200; TRAN VH, 1990, BIOPOLYMERS, V29, P961, DOI 10.1002/bip.360290609; VANDRIESSCHE E, 2000, LECTINS PATHOLOGY, P133; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; Wah DA, 2001, J MOL BIOL, V310, P885, DOI 10.1006/jmbi.2001.4814	63	33	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16297	16303		10.1074/jbc.M211148200	http://dx.doi.org/10.1074/jbc.M211148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595543	hybrid			2022-12-25	WOS:000182680000106
J	Meyer, RD; Latz, C; Rahimi, N				Meyer, RD; Latz, C; Rahimi, N			Recruitment and activation of phospholipase C gamma 1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; POINT MUTATION; EGF RECEPTOR; SH2 DOMAINS; PLC-GAMMA; NEUROPILIN-1; MITOGENESIS; SIGNAL	Vascular endothelial growth factor-mediated angiogenic signal transduction relay is achieved by coordinated induction of endothelial cell proliferation, migration, and differentiation. These complex cellular processes are most likely controlled by activation of both cooperative and antagonistic signals by vascular endothelial growth factor receptors (VEGFRs). Here, we investigated the contribution of tyrosine-phosphorylated residues of VEGFR-2/fetal liver kinase-1 to endothelial cell proliferation and differentiation and activation of signaling proteins. Mutation of tyrosine 1006 of VEGFR-2 to phenylalanine severely impaired the ability of this receptor to stimulate endothelial cell differentiation and tubulogenesis. Paradoxically, the mutant receptor stimulated endothelial cell proliferation far better than the wild-type receptor. Further analysis showed that tyrosine 1006 is responsible for phospholipase Cgamma1 (PLCgamma1) activation and intracellular calcium release in endothelial cells. Activation of PLCgamma1 was selectively mediated by tyrosine 1006. Mutation of tyrosines 799, 820, 949, 994, 1080, 1173, and 1221 had no measurable effect on the ability of VEGFR-2 to stimulate PLCgamma1 activation. Association of VEGFR-2 with PLCgamma1 was mainly established between tyrosine 1006 and the C-terminal SH2 domain of PLCgamma1 in vitro and in vivo. Taken together, the results indicate that phosphorylation of tyrosine 1006 is essential for VEGFR-2-mediated PLCgamma1 activation, calcium flux, and cell differentiation. More importantly, VEGFR-2-mediated endothelial cell proliferation is inversely correlated with the ability of VEGFR-2 to associate with and activate PLCgamma1.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, Rm L921,715 Albany St, Boston, MA 02118 USA.	nrahimi@bu.edu	Latz, Catharina/AAM-9079-2020	Rahimi, Nader/0000-0002-6745-1725	NEI NIH HHS [R03 EY013706, EY 012997, R01 EY012997] Funding Source: Medline; NATIONAL EYE INSTITUTE [R03EY013706, R01EY012997] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cross MJ, 2000, J CELL SCI, V113, P643; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Derman MP, 1996, J BIOL CHEM, V271, P4251; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Klepeis VE, 2001, J CELL SCI, V114, P4185; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Poulin B, 2000, J BIOL CHEM, V275, P6411, DOI 10.1074/jbc.275.9.6411; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421	33	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16347	16355		10.1074/jbc.M300259200	http://dx.doi.org/10.1074/jbc.M300259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598525	Green Accepted, hybrid			2022-12-25	WOS:000182680000113
J	Qian, Y; Luo, J; Leonard, SS; Harris, GK; Millecchia, L; Flynn, DC; Shi, XL				Qian, Y; Luo, J; Leonard, SS; Harris, GK; Millecchia, L; Flynn, DC; Shi, XL			Hydrogen peroxide formation and actin filament reorganization by Cdc42 are essential for ethanol-induced in vitro angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CELL-MIGRATION; GASTRIC-MUCOSA; GROWTH; ALCOHOL; CANCER; SRC; CYTOSKELETON; ACTIVATION; EXPRESSION	This report focuses on the identification of the molecular mechanisms of ethanol-induced in vitro angiogenesis. The manipulation of angiogenesis is an important therapeutic approach for the treatment of cancer, cardiovascular diseases, and chronic inflammation. Our results showed that ethanol stimulation altered the integrity of actin filaments and increased the formation of lamellipodia and filopodia in SVEC4-10 cells. Further experiments demonstrated that ethanol stimulation increased cell migration and invasion and induced in vitro angiogenesis in SVEC4-10 cells. Mechanistically, ethanol stimulation activated Cdc42 and produced H2O2 a reactive oxygen species intermediate in SVEC4-10 cells. Measuring the time course of Cdc42 activation and H2O2 production upon ethanol stimulation revealed that the Cdc42 activation and the increase of H2O2 lasted more than 3 h, which indicates the mechanisms of the long duration effects of ethanol on the cells. Furthermore, either overexpression. of a constitutive dominant negative Cdc42 or inhibition of H2O2 production abrogated the effects of ethanol on SVEC4-10 cells, indicating that both the activation of Cdc42 and the production of H2O2 are essential for the actions of ethanol. Interestingly, we also found that overexpression. of a constitutive dominant positive Cdc42 itself was sufficient to produce H2O2 and to induce in vitro angiogenesis. Taken together, our results suggest that ethanol stimulation can induce H2O2 production through the activation of Cdc42, which results in reorganizing actin filaments and increasing cell motility and in vitro angiogenesis.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; W Virginia Univ, Mary Bobb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; West Virginia University	Qian, Y (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA.	yaq2@cdc.gov	Shi, Xianglin/B-8588-2012; Luo, Jia/E-4674-2012	Luo, Jia/0000-0002-6968-3618				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BLOT WJ, 1992, CANCER RES, V52, pS2119; Brown MD, 2000, J NEUROBIOL, V43, P352, DOI 10.1002/1097-4695(20000615)43:4<352::AID-NEU4>3.0.CO;2-T; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHURCH MW, 1988, PEDIATRICS, V82, P147; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Gu JW, 2001, AM J PHYSIOL-REG I, V281, pR365, DOI 10.1152/ajpregu.2001.281.1.R365; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jones MK, 1999, AM J PHYSIOL-GASTR L, V276, pG1345, DOI 10.1152/ajpgi.1999.276.6.G1345; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Khayat ZA, 2000, J CELL SCI, V113, P279; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Li SJ, 2000, CANCER RES, V60, P3927; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1186, DOI 10.1111/j.1530-0277.1997.tb04436.x; Luo J, 1996, J NEUROCHEM, V67, P1448; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Maeda M, 1998, CANCER, V83, P1483, DOI 10.1002/(SICI)1097-0142(19981015)83:8&lt;1483::AID-CNCR2&gt;3.0.CO;2-Z; Mantle D., 1999, Adverse Drug Reactions and Toxicological Reviews, V18, P235; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; MILLER MW, 1991, ALCOHOL CLIN EXP RES, V15, P229, DOI 10.1111/j.1530-0277.1991.tb01861.x; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Redmond EM, 2000, ACTA PHARMACOL SIN, V21, P385; Roberts TM, 2000, J CELL BIOL, V149, P7, DOI 10.1083/jcb.149.1.7; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Szabo IL, 2001, LIFE SCI, V69, P3035, DOI 10.1016/S0024-3205(01)01410-2; Tang SQ, 1999, J CELL BIOL, V147, P1073, DOI 10.1083/jcb.147.5.1073; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Zhu YF, 2001, BREAST CANCER RES TR, V69, P29, DOI 10.1023/A:1012293507534	40	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16189	16197		10.1074/jbc.M207517200	http://dx.doi.org/10.1074/jbc.M207517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598535	hybrid, Green Submitted			2022-12-25	WOS:000182680000093
J	Ghosh, P; Kornfeld, S				Ghosh, P; Kornfeld, S			Phosphorylation-induced conformational changes regulate GGAs 1 and 3, function at the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; KINASE-II PHOSPHORYLATION; EAR HOMOLOGY DOMAIN; GAMMA-ADAPTIN; VHS DOMAINS; CYTOPLASMIC DOMAINS; PROTEINS INTERACT; STRUCTURAL BASIS; BINDING; AP-1	The GGAs ((G) under bar olgi-localizing, (&gamma;) under bar -adaptin ear homology domain, (A) under bar RF-binding) are a family of multidomain proteins implicated in protein trafficking between the Golgi and the endosomes. All three GGAs (1, 2, and 3). bind to the mannose. 6-phosphate receptor tail via their VHS domains, as well as to the adaptor protein complex-1 via their hinge domains. The latter interaction has been proposed to be important for cooperative packaging of cargo into forming clathrin-coated carriers at the trans-Golgi network. Here we present evidence that GGA1 function is highly regulated by cycles of phosphorylation and dephosphorylation. Cell fractionation showed that the phosphorylated pool of GGA1 resided predominantly in the cytosol and that recruitment onto membranes was associated with dephosphorylation. Okadaic acid inhibition studies and in vitro dephosphorylation assays indicated that dephosphorylation is mediated by a protein phosphatase 2A-like phosphatase. Dephosphorylation of GGA1 induced a change in the conformation to an "open" form as measured by gel filtration and sucrose gradient analyses. This was associated with enhanced binding to ligands because of release of autoinhibition and increased binding to the adaptor protein complex-1 gamma-appendage. A model is proposed for the regulation of GGA1 function at the trans-Golgi network.	Washington Univ, Sch Med, Div Hematol, Dept Internal Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.				NCI NIH HHS [CA08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERTRAND F, 1997, J BIOL CHEM, V272, P13856; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Doray B, 2002, J BIOL CHEM, V277, P18477, DOI 10.1074/jbc.M201879200; Ghosh P, 2003, J CELL BIOL, V160, P699, DOI 10.1083/jcb.200211080; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Kato Y, 2002, NAT STRUCT BIOL, V9, P532, DOI 10.1038/nsb807; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; PUERTOLLANO R, 2003, IN PRESS MOL BIOL CE; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Varlamov O, 2001, J CELL SCI, V114, P311; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	29	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14543	14549		10.1074/jbc.M212543200	http://dx.doi.org/10.1074/jbc.M212543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578827	hybrid			2022-12-25	WOS:000182405000122
J	Lauer-Fields, JL; Malkar, NB; Richet, G; Drauz, K; Fields, GB				Lauer-Fields, JL; Malkar, NB; Richet, G; Drauz, K; Fields, GB			Melanoma cell CD44 interaction with the alpha 1(IV)1263-1277 region from basement membrane collagen is modulated by ligand glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; AMINO-ACID-SEQUENCE; IV COLLAGEN; TRIPLE-HELIX; MOLECULAR ARCHITECTURE; ALPHA(3)BETA(1) INTEGRIN; SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; DISACCHARIDE UNIT	Invasion of the basement membrane is believed to be a critical step in the metastatic process. Melanoma cells have been shown previously to bind distinct triple-helical regions within basement membrane (type IV) collagen. Additionally, tumor cell binding sites within type IV collagen contain glycosylated hydroxylysine residues. In the present study, we have utilized triple-helical models of the type IV collagen alpha1(IV)1263-1277 sequence to (a) determine the melanoma cell receptor for this ligand and (b) analyze the results of single-site glycosylation on melanoma cell recognition. Receptor identification was achieved by a combination of methods, including (a) cell adhesion and spreading assays using triple-helical alpha1(IV)1263-1277 and an Asp(1266)Abu variant, W inhibition of cell adhesion and spreading assays, and (c) triple-helical al(IV)1263-1277 affinity chromatography with whole cell lysates and glycosaminoglycans. Triple-helical alpha1(IV)1263-1277 was bound by melanoma cell CD44/chondroitin sulfate proteoglycan receptors and not by the collagen-binding integrins or melanoma-associated proteoglycan. Melanoma cell adhesion to and spreading on the triple-helical al. (M 12631277 sequence was then compared for glycosylated (replacement of Lys(1265) with Hyl(O-beta-(D)-galactopyranosyl)) versus non-glycosylated ligand. Glycosylation was found to strongly modulate both activities, as adhesion and spreading were dramatically decreased due to the presence of galactose. CD44/chondroitin sulfate proteoglycan did not bind to glycosylated alpha1(IV)1263-1277. Overall, this study (a) is the first demonstration of the prophylactic effects of glycosylation on tumor cell interaction with the basement membrane, (b) provides a rare example of an apparent unfavorable interaction between carbohydrates, and (c) suggests that sugars may mask "cryptic sites" accessible to tumor cells with cell surface or secreted glycosidase activities.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Degussa Rexim SA, F-80400 Ham, France; Degussa AG, D-63457 Hanau, Germany	State University System of Florida; Florida Atlantic University; Evonik Industries; Evonik Industries	Lauer-Fields, JL (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu			NCI NIH HHS [CA 77402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BABIARZ B, 1992, EXP CELL RES, V203, P276, DOI 10.1016/0014-4827(92)90065-G; Bann JG, 2000, J BIOL CHEM, V275, P24466, DOI 10.1074/jbc.M003336200; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; Bella J, 2000, STRUCTURE, V8, pR121, DOI 10.1016/S0969-2126(00)00153-2; BERMAN A, 1993, BIOCHEM BIOPH RES CO, V194, P351, DOI 10.1006/bbrc.1993.1827; Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820; BORGIA JA, 2001, J BIOMOLECULAR TECHN, V12, P4; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; Broddefalk J, 1998, J AM CHEM SOC, V120, P7676, DOI 10.1021/ja980489k; BUTLER WT, 1966, J BIOL CHEM, V241, P3882; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHRUMS SC, 1982, CRC HDB CHROMATOGRAP, V1, P190; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Dome B, 2001, VIRCHOWS ARCH, V439, P628; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FIELDS CG, 1993, PEPTIDE RES, V6, P39; Fields CG, 1996, LETT PEPT SCI, V3, P3, DOI 10.1007/BF00131080; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, TETRAHEDRON LETT, V34, P6661, DOI 10.1016/S0040-4039(00)61669-6; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; Fields GB, 1995, CONNECT TISSUE RES, V31, P235, DOI 10.3109/03008209509010815; Fields GB, 1998, BIOPOLYMERS, V47, P143, DOI 10.1002/(SICI)1097-0282(1998)47:2<143::AID-BIP3>3.0.CO;2-U; FIELDS GB, 2001, SYNTHETIC PEPTIDES U, P93; Forns P, 2000, BIOPOLYMERS, V54, P531, DOI 10.1002/1097-0282(200012)54:7<531::AID-BIP60>3.0.CO;2-X; Fujisaki T, 1999, CANCER RES, V59, P4427; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; Goldbrunner RH, 1999, ACTA NEUROCHIR, V141, P295, DOI 10.1007/s007010050301; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAMAZAKI H, 1980, EUR J BIOCHEM, V111, P587, DOI 10.1111/j.1432-1033.1980.tb04975.x; HAMILTON PB, 1955, J BIOL CHEM, V213, P249; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; Herbold KW, 1996, J INVEST DERMATOL, V106, P1230, DOI 10.1111/1523-1747.ep12348871; ISHII I, 1987, COMP BIOCHEM PHYS B, V88, P313, DOI 10.1016/0305-0491(87)90121-0; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; KNUTZ T, 1995, SEA TECHNOL, V36, P68; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Leigh CJ, 1996, HUM PATHOL, V27, P1288, DOI 10.1016/S0046-8177(96)90339-1; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; Li CF, 1997, BIOCHEMISTRY-US, V36, P15404, DOI 10.1021/bi971817g; Mahal LK, 2001, SCIENCE, V294, P380, DOI 10.1126/science.1062192; Malkar NB, 2002, BIOCHEMISTRY-US, V41, P6054, DOI 10.1021/bi012071w; Malkar NB, 2000, TETRAHEDRON LETT, V41, P1137, DOI 10.1016/S0040-4039(99)02281-9; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; McCarthy JB, 1996, BIOPOLYMERS, V40, P371, DOI 10.1002/(SICI)1097-0282(1996)40:4<371::AID-BIP3>3.3.CO;2-2; MCCARTHY JB, 1993, PEPTIDES 1992, P109; MICKELSON D J, 1991, Journal of Cell Biology, V115, p287A; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; NAYAK BR, 1991, J BIOL CHEM, V266, P13978; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; PAULSEN H, 1985, LIEBIGS ANN CHEM, P2028; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PILI R, 1995, CANCER RES, V55, P2920; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Sacca B, 2002, CHEMBIOCHEM, V3, P904, DOI 10.1002/1439-7633(20020902)3:9<904::AID-CBIC904>3.0.CO;2-I; Spillmann D, 1996, J CELL BIOCHEM, V61, P562, DOI 10.1002/(SICI)1097-4644(19960616)61:4<562::AID-JCB9>3.0.CO;2-M; SPIRO MJ, 1971, J BIOL CHEM, V246, P4910; SPIRO RG, 1969, J BIOL CHEM, V244, P602; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; YAMAMOTO M, 1995, EXP CELL RES, V219, P249, DOI 10.1006/excr.1995.1225; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1999, BIOCHEMISTRY-US, V38, P1659, DOI 10.1021/bi982315l; Yu YC, 1997, METHOD ENZYMOL, V289, P571; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656	88	54	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14321	14330		10.1074/jbc.M212246200	http://dx.doi.org/10.1074/jbc.M212246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574156	hybrid			2022-12-25	WOS:000182405000096
J	Brahmbhatt, AA; Klemke, RL				Brahmbhatt, AA; Klemke, RL			ERK and RhoA differentially regulate pseudopodia growth and retraction during chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; ACTIVATED PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; BREAST-CANCER CELLS; LYSOPHOSPHATIDIC ACID; MAP KINASE; MYOSIN-II; FOCAL ADHESIONS; P21-ACTIVATED KINASE; MLC PHOSPHORYLATION	Nonmotile cells extend and retract pseudopodia-like structures in a random manner, whereas motile cells establish a single dominant pseudopodium in the direction of movement. This is a critical step necessary for cell migration and occurs prior to cell body translocation, yet little is known about how this process is regulated. Here we show that myosin II light chain (MLC) phosphorylation at its regulatory serine 19 is elevated in growing and retracting pseudopodia. MLC phosphorylation in the extending pseudopodium was associated with strong and persistent amplification of extracellular-regulated signal kinase (ERK) and MLC kinase activity, which specifically localized to the leading pseudopodium. Interestingly, inhibition of ERK or MLC kinase activity prevented MLC phosphorylation and pseudopodia extension but not retraction. In contrast, inhibition of RhoA activity specifically decreased pseudopodia retraction but not extension. Importantly, inhibition of RhoA activity specifically blocked MLC phosphorylation associated with retracting pseudopodia. Inhibition of either ERK or RhoA signals prevents chemotaxis, indicating that both pathways contribute to the establishment of cell polarity and migration. Together, these findings demonstrate that ERK and RhoA are distinct pathways that control pseudopodia extension and retraction, respectively, through differential modulation of MLC phosphorylation and contractile processes.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, SP-231,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R29CA078493, T32CA075924] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA75924, 5 R29 CA78493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; BENNETT H, 1986, J CELL SCI, V83, P61; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Buist A, 1998, BIOCHEM BIOPH RES CO, V251, P6, DOI 10.1006/bbrc.1998.9405; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Chew TL, 2002, J CELL BIOL, V156, P543, DOI 10.1083/jcb.200110161; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; CHRZANOWSKAWODNICKA M, 1992, BIOESSAYS, V14, P777, DOI 10.1002/bies.950141110; CONTI MA, 1981, J BIOL CHEM, V256, P3178; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Filardo EJ, 1996, J CELL SCI, V109, P1615; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Goetzl EJ, 1999, CANCER RES, V59, P4732; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; Gustafson T, 1999, EXP CELL RES, V253, P288, DOI 10.1006/excr.1999.4744; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HONER B, 1988, EUR J CELL BIOL, V47, P14; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HU YL, 2001, J NATL CANCER I, V93, P734; Imamura F, 1999, CLIN EXP METASTAS, V17, P141, DOI 10.1023/A:1006598531238; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JAY PY, 1995, J CELL SCI, V108, P387; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Jin Z, 1997, J NEUROSCI, V17, P6256; Joshi SA, 1998, FEBS LETT, V441, P67, DOI 10.1016/S0014-5793(98)01527-0; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Machesky LM, 1997, CURR BIOL, V7, pR164, DOI 10.1016/S0960-9822(97)70079-4; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; MILLER JR, 1983, MOL PHARMACOL, V24, P235; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Raj GV, 2002, J UROLOGY, V167, P1458, DOI 10.1016/S0022-5347(05)65345-1; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sliva D, 2000, BIOCHEM BIOPH RES CO, V268, P471, DOI 10.1006/bbrc.2000.2111; Smith JL, 1996, P NATL ACAD SCI USA, V93, P12321, DOI 10.1073/pnas.93.22.12321; STULL JT, 1990, J BIOL CHEM, V265, P16683; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takenawa T, 2001, J CELL SCI, V114, P1801; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; UEDA M, 1994, J CELL SCI, V107, P2071; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; Wittmann T, 2001, J CELL SCI, V114, P3795; Word R. A., 1997, CELLULAR ASPECTS SMO, P209; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yamamura S, 1997, BIOCHEMISTRY-US, V36, P10751, DOI 10.1021/bi970926s; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200	81	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13016	13025		10.1074/jbc.M211873200	http://dx.doi.org/10.1074/jbc.M211873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571246	hybrid			2022-12-25	WOS:000182189500055
J	Leask, A; Holmes, A; Black, CM; Abraham, DJ				Leask, A; Holmes, A; Black, CM; Abraham, DJ			Connective tissue growth factor gene regulation - Requirements for its induction by transforming growth factor-beta 2 in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; FACTOR-BETA; TGF-BETA; TRANSCRIPTION FACTORS; MAP KINASE; SELECTIVE INHIBITOR; MESANGIAL CELLS; EXPRESSION; ACTIVATION; BINDING	In skin, the profibrotic protein connective tissue growth factor (CTGF) is not normally expressed. However, when skin cells are exposed to transforming growth factor-beta (TGF-beta), CTGF is induced in fibroblasts but not in epithelial cells. We have begun to investigate the requirements for the fibroblast-selective induction of CTGF by TGF-beta. Previously we found that this response was Smad-dependent. Now we show that protein kinase C and Ras/MIEK/ERK are necessary for the TGF-beta induction of the CTGF promoter but not of a generic Smad-responsive promoter (SBE-lux). Induction of the CTGF promoter is antagonized by c-Jun or by MEKK1, suggesting that a proper balance between the Ras/MEK/ ERK and JNK MAPK cascades is necessary for TGF-beta induction of CTGF. We identify the minimal CTGF promoter element necessary and sufficient to confer TGF-beta responsiveness to a heterologous promoter and show that a tandem repeat of a consensus transcription enhancer factor binding element, 5'-GAGGAATGG-3', is necessary for this induction. This element has not been previously shown to play a role in TGF-beta induction of gene expression in fibroblasts. Get shift analysis shows that this sequence binds nuclear factors that are greatly enriched in fibroblasts relative to epithelial cells. Thus Smads, Ras/MEK/ERK, protein kinase C, and fibroblast-enriched factors that bind GAGGAATGG act together to drive the TGF-beta-mediated induction of CTGF in fibroblasts.	Fibrogen Inc, San Francisco, CA 94080 USA; UCL Royal Free & Univ Coll, Sch Med, Ctr Rheumatol, London NW3 2PF, England	FibroGen; University of London; University College London; UCL Medical School	Leask, A (corresponding author), Fibrogen Inc, 225 Gateway Blvd, San Francisco, CA 94080 USA.		Leask, Andrew/G-5217-2015; Leask, Andy/ABH-9433-2020		NIAMS NIH HHS [AR45879] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045879] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen YJ, 2001, EXP CELL RES, V271, P109, DOI 10.1006/excr.2001.5364; Chen YJ, 2002, KIDNEY INT, V62, P1149, DOI 10.1111/j.1523-1755.2002.kid567.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Goldberg HJ, 2002, CELL BIOL INT, V26, P165, DOI 10.1006/cbir.2001.0832; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hsu DKW, 1996, J BIOL CHEM, V271, P13786, DOI 10.1074/jbc.271.23.13786; IVKOVIC S, 2001, MOL PATHOL, V53, P118; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jiang SW, 2000, DNA CELL BIOL, V19, P507, DOI 10.1089/10445490050128430; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; Kaneko KJ, 1998, DEV GENET, V22, P43, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;43::AID-DVG5&gt;3.0.CO;2-7; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kutz SM, 2001, J CELL SCI, V114, P3905; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; Rousse S, 2001, J BIOL CHEM, V276, P46961, DOI 10.1074/jbc.M104440200; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; Simmonds AJ, 1998, GENE DEV, V12, P3815, DOI 10.1101/gad.12.24.3815; SMITH EA, 1990, J INVEST DERMATOL, V95, pS125, DOI 10.1111/1523-1747.ep12874998; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wong C, 1999, MOL CELL BIOL, V19, P1821; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V228, P365, DOI 10.1006/bbrc.1996.1667; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zuzarte PC, 2000, BBA-GENE STRUCT EXPR, V1517, P82, DOI 10.1016/S0167-4781(00)00261-X	61	257	279	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13008	13015		10.1074/jbc.M210366200	http://dx.doi.org/10.1074/jbc.M210366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571253	hybrid			2022-12-25	WOS:000182189500054
J	Cariati, R; Zancai, P; Righetti, E; Rizzo, S; De Rossi, A; Boiocchi, M; Dolcetti, R				Cariati, R; Zancai, P; Righetti, E; Rizzo, S; De Rossi, A; Boiocchi, M; Dolcetti, R			Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells	ONCOGENE			English	Article						Burkitt's lymphoma; retinoids; Ro 40-8757; Epstein-Barr virus; reactive oxygen species; oxidative phosphorylation	COMPLEX I; AROTINOID RO-40-8757; APOPTOSIS; CANCER; BIOLOGY; BCL-2; EXPRESSION; INDUCTION; THERAPY; VITRO	In the search for retinoids active against Burkitt's lymphoma (BL), we found that the arotinoid mofarotene (Ro 40-8757) induced strong antiproliferative and apoptotic responses in most established BL cell lines as well as in primary BL cells. Ro 40-8757-induced apoptosis is associated with mitochondrial membrane depolarization, activation of caspase-3 and -9, and enhanced production of reactive oxygen species. These effects were related to a transient drop in intracellular ATP content, probably favored by a downregulation of NADH dehydrogenase subunit-1, a component of the mitochondrial respiratory chain (MRC) Complex I. Inhibition of MRC with thenoyltrifluoroacetone suppressed both the ATP recovery and apoptosis, confirming that the effects of Ro 40-8757 are mediated by changes in mitochondrial function. Compared to EBV-negative lines, EBV-carrying BLs were more resistant to Ro 40-8757-induced apoptosis. EBV infection and ectopic LMP-1 expression increased the resistance of BL cells to Ro 40-8757-induced apoptosis, probably through bcl-2 upregulation. Finally, we also show that 2-methoxyoestradiol, an inhibitor of the scavenger enzymes superoxide dismutases, enhanced Ro 40-8757-mediated apoptosis. These findings provide the rationale for evaluating the clinical efficacy of Ro 40-8757 in BL patients and suggest that the combination of Ro 40-8757 with inhibitors of scavenger enzymes may be a promising therapeutic approach for this aggressive lymphoma.	Ctr Riferimento Oncol, Div Expt Oncol 1, IRCCS, Natl Canc Inst,Dept Pre Clin & Epidemiol Res, I-33081 Aviano, PN, Italy; AIDS Reference Ctr, Dept Oncol & Surg Sci, Padua, Italy	IRCCS Aviano (CRO); IRCCS Istituto Oncologico Veneto (IOV)	Boiocchi, M (corresponding author), Ctr Riferimento Oncol, Div Expt Oncol 1, IRCCS, Natl Canc Inst,Dept Pre Clin & Epidemiol Res, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	mboiocchi@cro.it	Rizzo, Silvana/AAW-1132-2020; Dolcetti, Riccardo/O-3832-2015; De Rossi, Anita/Q-4845-2019; De Rossi, A./L-3128-2015	Rizzo, Silvana/0000-0002-7156-1783; Dolcetti, Riccardo/0000-0003-1625-9853; De Rossi, Anita/0000-0001-6435-7509; De Rossi, A./0000-0001-6435-7509				Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cariati R, 2000, INT J CANCER, V86, P375, DOI 10.1002/(SICI)1097-0215(20000501)86:3<375::AID-IJC12>3.0.CO;2-Z; CASTLEBERRY RP, 1994, NEW ENGL J MED, V331, P1680, DOI 10.1056/NEJM199412223312503; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELIASON JF, 1993, BRIT J CANCER, V67, P1293, DOI 10.1038/bjc.1993.240; ELIASON JF, 1995, BLOOD, V86, P4516, DOI 10.1182/blood.V86.12.4516.bloodjournal86124516; ELIASON JF, 1994, INT J CANCER, V57, P192, DOI 10.1002/ijc.2910570211; FalK MH, 1998, INT J CANCER, V75, P620, DOI 10.1002/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO;2-B; Fenaux P, 1997, SEMIN ONCOL, V24, P92; FRENCH LE, 1994, LANCET, V344, P686, DOI 10.1016/S0140-6736(94)92122-9; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; HARTMANN D, 1993, RETINOIDS PROGR RES, P491; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Louvet C, 1996, BRIT J CANCER, V74, P394, DOI 10.1038/bjc.1996.371; Marton A, 1997, EUR J BIOCHEM, V250, P467, DOI 10.1111/j.1432-1033.1997.0467a.x; Morrison VA, 1999, SEMIN ONCOL, V26, P84; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OHNO R, 1994, LEUKEMIA LYMPHOMA, V14, P401, DOI 10.3109/10428199409049696; Pettus EH, 2000, J NEUROCHEM, V75, P383, DOI 10.1046/j.1471-4159.2000.0750383.x; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Pomponi F, 1996, BLOOD, V88, P3147, DOI 10.1182/blood.V88.8.3147.bloodjournal8883147; PRYOR WA, 1982, ANN NY ACAD SCI, V393, P1, DOI 10.1111/j.1749-6632.1982.tb31228.x; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; TEELMANN K, 1993, CANCER RES, V53, P2319; UCHIDA T, 1994, INT J CANCER, V58, P891, DOI 10.1002/ijc.2910580624; WHITE L, 1992, CRIT REV ONCOL HEMAT, V13, P55, DOI 10.1016/1040-8428(92)90016-J; Xu JW, 2000, J IMMUNOL, V164, P2815, DOI 10.4049/jimmunol.164.5.2815	40	5	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					906	918		10.1038/sj.onc.1206060	http://dx.doi.org/10.1038/sj.onc.1206060			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584570				2022-12-25	WOS:000180864300013
J	Funakoshi, T; Tachibana, I; Hoshida, Y; Kimura, H; Takeda, Y; Kijima, T; Nishino, K; Goto, H; Yoneda, T; Kumagai, T; Osaki, T; Hayashi, S; Aozasa, K; Kawase, I				Funakoshi, T; Tachibana, I; Hoshida, Y; Kimura, H; Takeda, Y; Kijima, T; Nishino, K; Goto, H; Yoneda, T; Kumagai, T; Osaki, T; Hayashi, S; Aozasa, K; Kawase, I			Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer	ONCOGENE			English	Article						small cell lung cancer (SCLC); tetraspanin; CD9; motility	KAI1/CD82 GENE-EXPRESSION; TRANSMEMBRANE-4 SUPERFAMILY; BREAST-CANCER; MONOCLONAL-ANTIBODY; TM4SF PROTEINS; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA-3-BETA-1; MOLECULAR-CLONING; PANCREATIC-CANCER; TUMOR PROGRESSION	Small cell lung cancer (SCLC) invades locally and metastasizes distantly extremely early when compared with nonsmall cell lung cancer (NSCLC). The underlying molecular mechanisms, however, have not been elucidated. Accumulating evidence suggests that downregulation of several members of tetraspanins is associated with progression of solid tumors, thus indicating poor prognosis. Here we screened 30 lung cancer cell lines for expression of tetraspanins, CD9, CD63, CD81, CD82, CD151, and NAG-2. Flow cytometry revealed that, among these proteins, CD9 is broadly expressed in NSCLC lines, but is absent or highly reduced in most SCLC lines (P < 0.0001). Using the Boyden chamber and videomicroscopic cell motility assays, we showed that stable transfection of CD9 into an SCLC line, OS3-R5, reduced cell motility on fibronectin. Furthermore, by transient transfection of green fluorescent protein (GFP)-tagged CD9 into three other SCLC lines, we observed that SCLC cells expressing GFP-CD9 were uniformly less motile than untransfected cells. CD9 or GFP-CD9 was associated with beta1 integrins and distributed at the tumor cell periphery and cell-cell contacts, suggesting that CD9 modifies beta1 integrin function to reduce motility. These findings suggest that low expression of CD9 may contribute to the highly invasive and metastatic phenotype of SCLC.	Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Thorac & Adult Oncol, Boston, MA 02115 USA	Osaka University; Osaka University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Tachibana, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Hoshida, Yujin/R-7513-2019	Hoshida, Yoshihiko/0000-0003-3166-9754				Adachi M, 1996, CANCER RES, V56, P1751; Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; BOUCHEIX C, 1985, ANN GENET-PARIS, V28, P19; Bredin CG, 1998, EUR RESPIR J, V11, P400, DOI 10.1183/09031936.98.11020400; Cajot JF, 1997, CANCER RES, V57, P2593; CARNEY DN, 1985, CANCER RES, V45, P2913; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; FELDMAN LE, 1991, CANCER RES, V51, P1065; FITTER S, 1995, BLOOD, V86, P1348, DOI 10.1182/blood.V86.4.1348.bloodjournal8641348; Guo XZ, 1996, CANCER RES, V56, P4876; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HOTTA H, 1988, CANCER RES, V48, P2955; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Inoue G, 2001, INT J MOL MED, V7, P67; KAPRIELIAN Z, 1995, J NEUROSCI, V15, P562; KASHII T, 1992, ANTICANCER RES, V12, P621; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; Lantuejoul S, 1998, AM J SURG PATHOL, V22, P1267, DOI 10.1097/00000478-199810000-00012; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Li J, 1996, ONCOGENE, V13, P2379; Lombardi DP, 1999, CANCER RES, V59, P5724; MABRY M, 1991, CANCER CELL-MON REV, V3, P53; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mashimo T, 2000, BIOCHEM BIOPH RES CO, V274, P370, DOI 10.1006/bbrc.2000.3139; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1995, CANCER RES, V55, P4127; Miyake M, 1996, CANCER RES, V56, P1244; MOUNTAIN CF, 1978, SEMIN ONCOL, V5, P272; NAGIRA M, 1994, CELL IMMUNOL, V157, P144, DOI 10.1006/cimm.1994.1212; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Oritani K, 1996, BLOOD, V87, P2252, DOI 10.1182/blood.V87.6.2252.bloodjournal8762252; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SAITO S, 1994, LUNG CANCER-J IASLC, V10, P307, DOI 10.1016/0169-5002(94)90660-2; SAITO S, 1991, CANCER IMMUNOL IMMUN, V33, P165, DOI 10.1007/BF01756137; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; SOUHAMI RL, 1987, LANCET, V2, P325; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tachibana I, 1996, EXP CELL RES, V227, P230, DOI 10.1006/excr.1996.0272; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TANIO Y, 1992, JPN J CANCER RES, V83, P736, DOI 10.1111/j.1349-7006.1992.tb01974.x; Testa JE, 1999, CANCER RES, V59, P3812; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yang XH, 2000, CLIN CANCER RES, V6, P3424; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	59	69	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					674	687		10.1038/sj.onc.1206106	http://dx.doi.org/10.1038/sj.onc.1206106			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569360				2022-12-25	WOS:000180642100005
J	Petrosillo, G; Ruggiero, FM; Di Venosa, N; Paradies, G				Petrosillo, G; Ruggiero, FM; Di Venosa, N; Paradies, G			Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin	FASEB JOURNAL			English	Article						ROS; mitochondrion; heart ischemia-reperfusion	C-OXIDASE ACTIVITY; CYTOCHROME-OXIDASE; MYOCARDIAL-ISCHEMIA; DEPENDENT DECREASE; LIPID-PEROXIDATION; RADICAL GENERATION; METABOLISM; CHAIN; DEHYDROGENASE; PROTEIN	Reactive oxygen species (ROS) are considered an important factor in ischemia-reperfusion injury to cardiac myocites. We have examined the effects of ischemia (30 min) and ischemia followed by reperfusion (15 min) of rat hearts on the activity of complex III and on the cardiolipin content in isolated mitochondria. Mitochondrial production of H2O2 and lipid peroxidation was also measured. The capacity of mitochondria to produce both H2O2 and lipid peroxidation increased upon reperfusion. The activity of complex III was 22% and 46% lower in ischemic and reperfused rat heart mitochondria, respectively, than that of controls. These changes in complex III activity were associated to parallel changes in state 3 respiration. The mitochondrial content of cardiolipin, which is required for optimal activity of complex III, decreased by 28% and by 50% as a function of ischemia and reperfusion, respectively. The lower complex III activity in mitochondria from reperfused rat hearts could be completely restored to the level of normal hearts by exogenously added cardiolipin. It is proposed that the loss of complex III activity in reperfused rat hearts can be mainly ascribed to a loss of cardiolipin content, due to oxidative attack by oxygen free radicals.	Univ Bari, Dept Biochem & Mol Biol, I-70126 Bari, Italy; Univ Bari, CNR, Unit Study Mitochondria & Bioenerget, I-70126 Bari, Italy; Univ Bari, Dept Emergency & Transplantat, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Via E Orabona 4, I-70126 Bari, Italy.	g.paradies@biologia.uniba.it						AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLLI R, 1991, CARDIOVASC DRUG THER, V82, P723; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Buege J A, 1978, Methods Enzymol, V52, P302; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; HACKENBROCK CR, 1986, METHOD ENZYMOL, V125, P35; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Hatch GM, 1996, MOL CELL BIOCHEM, V159, P139, DOI 10.1007/BF00420916; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; PARADIES G, 1993, ARCH GERONTOL GERIAT, V16, P263, DOI 10.1016/0167-4943(93)90037-I; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; PARADIES G, 1984, BIOCHIM BIOPHYS ACTA, V766, P446, DOI 10.1016/0005-2728(84)90260-3; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PARADIES G, 1994, BBA-MOL BASIS DIS, V1225, P165, DOI 10.1016/0925-4439(94)90074-4; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P207, DOI 10.1016/S0005-2760(97)00119-7; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	48	9	15	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					714	+		10.1096/fj.02-0729fje	http://dx.doi.org/10.1096/fj.02-0729fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586737				2022-12-25	WOS:000181456900020
J	Ritch, PA; Carroll, SL; Sontheimer, H				Ritch, PA; Carroll, SL; Sontheimer, H			Neuregulin-1 enhances motility and migration of human astrocytic glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; ERBB SIGNALING NETWORK; SRC FAMILY KINASES; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; CANCER CELLS; PROGENITOR CELLS; SURVIVAL FACTOR; TUMOR INVASION	Gliomas are the most frequently diagnosed adult primary brain malignancy. These tumors have a tendency to invade diffusely into the surrounding healthy brain tissue, thereby precluding their successful surgical removal. In this report, we examine the potential for the neuregulin-1/erbB receptor signaling network to contribute to this process by modulating glioma cell motility. Neuregulin-1 is expressed throughout the immature and adult central nervous system and has been demonstrated to influence the migration of a variety of cell types in the developing brain. In addition, erbB2, an integral member of the heterodimeric neuregulin-1 receptor, has been shown to be overexpressed in human glioma biopsies. Using antibodies specific for erbB2 and erbB3, we show that these receptors localize preferentially in regions of the plasma membrane which are involved in facilitating cellular movement. Here, erbB2 colocalizes and coimmunoprecipitates with members of the focal complex including beta(1)-integrin and focal adhesion kinase. Further, erbB receptor activation by neuregulin-1 enhances cell motility in two-dimensional scratch motility assays and stimulates cell invasion in three-dimensional Transwell migration assays. These effects of neuregulin-1 appear to involve the activation of focal adhesion kinase, which occurs downstream from erbB2 receptor stimulation. Taken together these data suggest that neuregulin-1 plays an important modulatory role in glioma cell invasion.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Civitan Int Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sontheimer, H (corresponding author), Univ Alabama, Dept Neurobiol, 1719 6th Ave S,CIRC 589, Birmingham, AL 35294 USA.			Sontheimer, Harald/0000-0002-5843-9871; Carroll, Steven/0000-0001-6714-4373				Anton ES, 1997, DEVELOPMENT, V124, P3501; Bannerman PG, 2000, DEV BRAIN RES, V124, P93, DOI 10.1016/S0165-3806(00)00090-0; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Bolteus A J, 2001, Curr Neurol Neurosci Rep, V1, P225, DOI 10.1007/s11910-001-0022-x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CHEN WT, 1990, CELL DIFFER DEV, V32, P329, DOI 10.1016/0922-3371(90)90047-Z; Dirks PB, 2001, J NEURO-ONCOL, V53, P203, DOI 10.1023/A:1012273922478; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; ENGELHARD HH, 1995, J NEURO-ONCOL, V23, P31, DOI 10.1007/BF01058457; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Hwang Shiuh-Lin, 1997, Kaohsiung Journal of Medical Sciences, V13, P417; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KLEIHUES P, 2002, WHO CLASSIFICATION T, P2; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KRISTT DA, 1993, NEUROSURGERY, V33, P106; Liu SC, 2000, J CELL SCI, V113, P3563; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Mahanthappa NK, 1996, J NEUROSCI, V16, P4673; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Mazumdar A, 2001, CANCER RES, V61, P400; Meintanis S, 2001, GLIA, V34, P39, DOI 10.1002/glia.1038; Murillo H, 2001, CANCER RES, V61, P7408; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; NOBLE M, 1995, GLIA, V15, P222, DOI 10.1002/glia.440150304; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; Pollock GS, 1999, EUR J NEUROSCI, V11, P769, DOI 10.1046/j.1460-9568.1999.00484.x; Raabe TD, 1997, J NEUROCHEM, V69, P1859; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; RITCH PS, 2001, SOC NEUR ABSTR; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; ROZENGURT E, 1995, CANCER SURV, V24, P81; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHWECHHEIMER K, 1994, HUM PATHOL, V25, P772, DOI 10.1016/0046-8177(94)90246-1; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Tsai CM, 1996, CANCER RES, V56, P1068; Tysnes BB, 1996, INT J CANCER, V67, P777, DOI 10.1002/(SICI)1097-0215(19960917)67:6<777::AID-IJC5>3.0.CO;2-O; Uhm J. H., 1999, FRONT BIOSCI, V4, P188; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Vartanian T, 2000, BIOCHEM BIOPH RES CO, V271, P414, DOI 10.1006/bbrc.2000.2624; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wells A, 2000, ADV CANCER RES, V78, P31; Westphal M, 1997, J NEURO-ONCOL, V35, P335, DOI 10.1023/A:1005837122181; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	60	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20971	20978		10.1074/jbc.M213074200	http://dx.doi.org/10.1074/jbc.M213074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12600989	hybrid			2022-12-25	WOS:000183230500069
J	Suhre, K; Claverie, JM				Suhre, K; Claverie, JM			Genomic correlates of hyperthermostability, an update	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								It has been shown (Cambillau, C., and Claverie, J.M. (2000) J. Biol. Chem. 275, 32383-32386) that a large difference between the proportions of charged versus polar (non-charged) amino acids (CvP-bias) was an adequate, if empirical, signature of the proteome of hyperthermophilic organisms (T-growth>80degreesC). Since that study, the number of available microbial genomes has more than doubled, raising the possibility that the simple CvP-bias rule might no longer hold. Taking advantage of the new sequence data, we re-analyzed the genomes of 9 fully sequenced thermophiles, 9 hyperthermophiles, and 53 mesothermophile microorganisms to identify the genomic correlates of hyperthermostability on a wider data set. Our new results confirm that the CvP-bias previously identified on a much smaller data set still holds. Moreover, we show that it is an optimal criterion, in the sense that it corresponds to the most discriminating factor between hyperthermophilic and mesothermophilic microorganisms in a principal component analysis. In parallel, we evaluated two other recently proposed correlates of hyperthermostability, the proteome average pI and the dinucleotide statistical index (Kawashima, T., Amano, N., Koike, H., Makino, S., Higuchi, S., Kawashima-Ohya, Y., Watanabe, K., Yamazaki, M., Kanehori, K., Kawamoto, T., Nunoshiba, T., Yamamoto, Y., Aramaki, H., Makino, K., and Suzuki, M. (2000) Proc. Natl. Acad. Sci. 97, 14257-14262). We show that the CvP-bias is the sole criterion that is able to clearly discriminate hyperthermophile from mesothermophile microorganisms on a global genomic basis.	CNRS, UPR 2589, Inst Struct Biol & Microbiol, Struct & Genom Informat Lab, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Claverie, JM (corresponding author), CNRS, UPR 2589, Inst Struct Biol & Microbiol, Struct & Genom Informat Lab, Marseille, France.		Suhre, Karsten/AAF-1778-2020; Claverie, Jean Michel/Z-2183-2019; Claverie, Jean-Michel/AAG-4889-2019	Suhre, Karsten/0000-0001-9638-3912; Claverie, Jean-Michel/0000-0003-1424-0315				Brochier C, 2002, NATURE, V417, P244, DOI 10.1038/417244a; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Kawashima T, 2000, P NATL ACAD SCI USA, V97, P14257, DOI 10.1073/pnas.97.26.14257; Kreil DP, 2001, NUCLEIC ACIDS RES, V29, P1608, DOI 10.1093/nar/29.7.1608; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Vieille C, 2001, EUR J BIOCHEM, V268, P6291, DOI 10.1046/j.0014-2956.2001.02587.x	7	136	138	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17198	17202		10.1074/jbc.M301327200	http://dx.doi.org/10.1074/jbc.M301327200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600994	hybrid			2022-12-25	WOS:000182818600101
J	Balog, EM; Norton, LE; Bloomquist, RA; Cornea, RL; Black, DJ; Louis, CF; Thomas, DD; Fruen, BR				Balog, EM; Norton, LE; Bloomquist, RA; Cornea, RL; Black, DJ; Louis, CF; Thomas, DD; Fruen, BR			Calmodulin oxidation and methionine to glutamine substitutions reveal methionine residues critical for functional interaction with ryanodine receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNELS; SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; ALPHA-HELICES; PROTEIN; INHIBITION; RECOGNITION; ACTIVATION; TROPONIN; DOMAIN	Calmodulin (CaM) binds to the skeletal muscle ryanodine receptor Ca2+ release channel (RyR1) with high affinity, and it may act as a Ca2+-sensing subunit of the channel. Apo-CaM increases RyR1 channel activity, but Ca2+-CaM is inhibitory. Here we examine the functional effects of CaM oxidation on RyR1 regulation by both apo-CaM and Ca2+-CaM, as assessed via determinations of [H-3]ryanodine and [S-35]CaM binding to skeletal muscle sarcoplasmic reticulum vesicles. Oxidation of all nine CaM Met residues abolished functional interactions of CaM with RyR1. Incomplete CaM oxidation, affecting 5-8 Met residues, increased the CaM concentration required to modulate RyR1, having a greater effect on the apo-CaM species. Mutating individual CaM Met residues to Gln demonstrated that Met-109 was required for apo-CaM activation of RyR1 but not for Ca2+-CaM inhibition of the channel. Furthermore, substitution of Gln for Met-124 increased the apo- and Ca2+-CaM concentrations required to regulate RyR1. These results thus identify Met residues critical for the productive association of CaM with RyR1 channels and suggest that oxidation of CaM may contribute to altered regulation of sarcoplasmic reticulum Ca2+ release during oxidative stress.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Ohio State Univ, Dept Mol & Cellular Biol, Columbus, OH 43210 USA; Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University of Minnesota System; University of Minnesota Twin Cities; Ohio State University; University System of Georgia; Georgia State University	Balog, EM (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Thomas, David D/B-4257-2012	Thomas, David D./0000-0002-8822-2040; Cornea, Razvan/0000-0001-5739-0992	NIGMS NIH HHS [GM 31382] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Hamilton SL, 2000, NEWS PHYSIOL SCI, V15, P281; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; Kranz JK, 2002, BIOCHEMISTRY-US, V41, P2599, DOI 10.1021/bi011818f; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P10676, DOI 10.1021/bi00033a044; Rodney GG, 2001, BIOCHEMISTRY-US, V40, P12430, DOI 10.1021/bi011078a; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Wang ST, 1998, BIOCHEMISTRY-US, V37, P14539, DOI 10.1021/bi9814641; Xin HB, 1999, J BIOL CHEM, V274, P15315, DOI 10.1074/jbc.274.22.15315; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Yin D, 1999, BIOCHEMISTRY-US, V38, P13654, DOI 10.1021/bi991152d; Yuan T, 1999, J BIOL CHEM, V274, P8411, DOI 10.1074/jbc.274.13.8411; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	34	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15615	15621		10.1074/jbc.M209180200	http://dx.doi.org/10.1074/jbc.M209180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586832	hybrid			2022-12-25	WOS:000182680000022
J	Braganca, J; Eloranta, JJ; Bamforth, SD; Ibbitt, JC; Hurst, HC; Bhattacharya, S				Braganca, J; Eloranta, JJ; Bamforth, SD; Ibbitt, JC; Hurst, HC; Bhattacharya, S			Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-SPECIFIC GENE; CAUSE CHAR-SYNDROME; MICE LACKING; DNA-BINDING; MOLECULAR-CLONING; CBP; COACTIVATOR; P300; DEFECTS; FAMILY	The transcriptional co-activators and histone acetyl-transferases p300/CREB-binding protein (CBP) interact with CITED2, a transcription factor AP-2 (TFAP2) coactivator. p300/CBP, CITED2, and TFAP2A are essential for normal neural tube and cardiac development. Here we show that p300 and CBP co-activate TFAP2A in the presence of CITED2. TFAP2A transcriptional activity was modestly impaired in p300(+/-) and CBP+/- mouse embryonic fibroblasts; this was rescued by ectopic expression of p300/CBP. p300, TFAP2A, and endogenous CITED2 could be co-immunoprecipitated from transfected U2-OS cells indicating that they can interact physically in vivo. CITED2 interacted with the dimerization domain of TFAP2C, which is highly conserved in TFAP2A/B. In mammalian two-hybrid experiments, full-length p300 and TFAP2A interacted only when CITED2 was co-transfected. N-terminal residues of TFAP2A, containing the transactivation domain, are both necessary and sufficient for interaction with p300, and this interaction was independent of CITED2. Consistent with this, N-terminal residues of TFAP2A were required for p300-and CITED2-dependent co-activation. A histone acetyltransferase-deficient p300 mutant (D1399Y) did not co-activate TFAP2A and did not affect the expression or cellular localization of TFAP2A or CITED2. In mammalian two-hybrid experiments p300D1399Y failed to interact with TFAP2A, explaining, at least in part, its failure to function as a co-activator. Our results suggest a model wherein interactions among TFAP2A, CITED2, and p300/CBP are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.	Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England; Hammersmith Hosp, Mol Oncol Unit, Canc Res UK, London W12 0HS, England	University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Imperial College London		sbhattac@well.ox.ac.uk	Braganca, Jose/F-4410-2012; Bhattacharya, Shoumo/F-4127-2010; Bamforth, Simon David/I-1277-2019	Braganca, Jose/0000-0001-9566-400X; Bhattacharya, Shoumo/0000-0002-5571-0478; Bamforth, Simon David/0000-0002-5666-4485				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Brewer S, 2002, MECH DEVELOP, V110, P139, DOI 10.1016/S0925-4773(01)00579-2; Chan HM, 2001, J CELL SCI, V114, P2363; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; LOO DT, 1989, CELL GROWTH CELL DIV, P17; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; Oike Y, 1999, BLOOD, V93, P2771; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; SKINNER A, 1993, ONCOGENE, V8, P3393; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2002, GENOMICS, V80, P601, DOI 10.1006/geno.2002.7005; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, AM J HUM GENET, V69, P695, DOI 10.1086/323410; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	42	127	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16021	16029		10.1074/jbc.M208144200	http://dx.doi.org/10.1074/jbc.M208144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586840	hybrid			2022-12-25	WOS:000182680000073
J	Kanipes, MI; Kalb, SR; Cotter, RJ; Hozbor, DF; Lagares, A; Raetz, CRH				Kanipes, MI; Kalb, SR; Cotter, RJ; Hozbor, DF; Lagares, A; Raetz, CRH			Relaxed sugar donor selectivity of a Sinorhizobium meliloti ortholog of the Rhizobium leguminosarum mannosyl transferase LpcC - Role of the lipopolysaccharide core in symbiosis of Rhizobiaceae with plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CHARACTERIZATION; ESCHERICHIA-COLI; BIOSYNTHESIS; IDENTIFICATION; PURIFICATION; EXPRESSION; MUTANTS; NODULES; ALFALFA; CLONING	The lpcC gene of Rhizobium leguminosarum and the lpsB gene of Sinorhizobium meliloti encode protein orthologs that are 58% identical over their entire lengths of about 350 amino acid residues. LpcC and LpsB are required for symbiosis with pea and Medicago plants, respectively. S. meliloti lpsB complements a mutant of R. leguminosarum defective in lpcC, but the converse does not occur. LpcC encodes a highly selective mannosyl transferase that utilizes GDP-mannose to glycosylate the inner 3-deoxy-D-manno-octulosonic acid (Kdo) residue of the lipopolysaccharide precursor Kdo(2)-lipid IVA. We now demonstrate that LpsB can also efficiently man-nosylate the same acceptor substrate as does LpcC. Unexpectedly, however, the sugar nucleotide selectivity of LpsB is greatly relaxed compared with that of LpcC. Membranes of the wild-type S. metiloti strain 2011 catalyze the glycosylation of Kdo(2)-[4-P-32] lipid IVA at comparable rates using a diverse set of sugar nucleotides, including GDP-mannose, ADP-mannose, UDP-glucose, and ADP-glucose. This complex pattern of glycosylation is due entirely to LpsB, since membranes of the S. meliloti lpsB mutant 6963 do not glycosylate Kdo(2)-[4-P-32]lipid IVA in the presence of any of these sugar nucleotides. Expression of lpsB in E. coli using a T7lac promoter-driven construct results in the appearance of similar multiple glycosyl transferase activities seen in S. meliloti 2011 membranes. Constructs expressing lpcC display only mannosyl transferase activity. We conclude that LpsB, despite its high degree of similarity to LpcC, is a much more versatile glycosyltransferase, probably accounting for the inability of lpcC to complement S. meliloti lpsB mutants. Our findings have important implications for the regulation of core glycosylation in S. meliloti and other bacteria containing LpcC orthologs.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Natl Univ La Plata, Fac Ciencias Exactas, Inst Bioquim & Biol Mol, RA-1900 La Plata, Argentina	Duke University; Johns Hopkins University; National University of La Plata	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X; Hozbor, Daniela/0000-0001-6379-0482	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 51796, GM 54882, R37 GM051796, R37 GM051796-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; Blatny JM, 1997, APPL ENVIRON MICROB, V63, P370, DOI 10.1128/AEM.63.2.370-379.1997; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CASSE F, 1979, J GEN MICROBIOL, V113, P229, DOI 10.1099/00221287-113-2-229; DANKERT M, 1964, BIOCHEM BIOPH RES CO, V14, P358, DOI 10.1016/S0006-291X(64)80010-3; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kanipes MI, 2003, J BIOL CHEM, V278, P16356, DOI 10.1074/jbc.M301255200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lagares A, 2001, J BACTERIOL, V183, P1248, DOI 10.1128/JB.183.4.1248-1258.2001; LAGARES A, 1992, J BACTERIOL, V174, P5941, DOI 10.1128/jb.174.18.5941-5952.1992; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; PASSERON S, 1964, BIOCHIM BIOPHYS ACTA, V89, P372, DOI 10.1016/0926-6569(64)90233-0; POOLE PS, 1994, MICROBIOL-SGM, V140, P2797, DOI 10.1099/00221287-140-10-2797; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7	28	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16365	16371		10.1074/jbc.M301256200	http://dx.doi.org/10.1074/jbc.M301256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591936	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000182680000115
J	Lusetti, SL; Wood, EA; Fleming, CD; Modica, MJ; Korth, J; Abbott, L; Dwyer, DW; Roca, AI; Inman, RB; Cox, MM				Lusetti, SL; Wood, EA; Fleming, CD; Modica, MJ; Korth, J; Abbott, L; Dwyer, DW; Roca, AI; Inman, RB; Cox, MM			C-terminal deletions of the Escherichia coli RecA protein - Characterization of in vivo and in vitro effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; INTERSTRAND CROSS-LINKS; BINDING-PROTEIN; ATP HYDROLYSIS; GENETIC-RECOMBINATION; MECHANISM; PURIFICATION; REPAIR; REMOVAL; SITE	A set of C-terminal deletion mutants of the RecA protein of Escherichia coli, progressively removing 6, 13, 17, and 25 amino acid residues, has been generated, expressed, and purified. In vivo, the deletion of 13 to 17 C-terminal residues results in increased sensitivity to mitomycin C. In vitro, the deletions enhance binding to duplex DNA as previously observed. We demonstrate that much of this enhancement involves the deletion of residues between positions 339 and 346. In addition, the C-terminal deletions cause a substantial upward shift in the pH-reaction profile of DNA strand exchange reactions. The C-terminal deletions of more than 13 amino acid residues result in strong inhibition of DNA strand exchange below pH 7, where the wild-type protein promotes a proficient reaction. However, at the same time, the deletion of 13-17 C-terminal residues eliminates the reduction in DNA strand exchange seen with the wild-type protein at pH values between 7.5 and 9. The results suggest the existence of extensive interactions, possibly involving multiple salt bridges, between the C terminus and other parts of the protein. These interactions affect the pK(a) of key groups involved in DNA strand exchange as well as the direct binding of RecA protein to duplex DNA.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu		Roca, Alberto I./0000-0002-7072-5301	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DAVIS RW, 1980, ADV BACTERIAL GENET, P70; Egelman EH, 1998, J STRUCT BIOL, V124, P123, DOI 10.1006/jsbi.1998.4050; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; HORII T, 1992, J MOL BIOL, V223, P105, DOI 10.1016/0022-2836(92)90719-Z; Huang LC, 1997, J BACTERIOL, V179, P6076, DOI 10.1128/jb.179.19.6076-6083.1997; Ishimori K, 1996, J MOL BIOL, V264, P696, DOI 10.1006/jmbi.1996.0670; IYER VN, 1963, P NATL ACAD SCI USA, V50, P355, DOI 10.1073/pnas.50.2.355; KARLIN S, 1995, J BACTERIOL, V177, P6881, DOI 10.1128/jb.177.23.6881-6893.1995; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Saecker RM, 2002, CURR OPIN STRUC BIOL, V12, P311, DOI 10.1016/S0959-440X(02)00326-3; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1998, MOL CELL, V1, P309, DOI 10.1016/S1097-2765(00)80031-3; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; Thompson TB, 1998, BIOCHEMISTRY-US, V37, P7686, DOI 10.1021/bi973178f; WEISEMANN JM, 1985, J BACTERIOL, V163, P748, DOI 10.1128/JB.163.2.748-755.1985; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7	51	91	91	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16372	16380		10.1074/jbc.M212917200	http://dx.doi.org/10.1074/jbc.M212917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598539	hybrid			2022-12-25	WOS:000182680000116
J	Rott, R; Zipor, G; Portnoy, V; Liveanu, V; Schuster, G				Rott, R; Zipor, G; Portnoy, V; Liveanu, V; Schuster, G			RNA polyadenylation and degradation in cyanobacteria are similar to the chloroplast but different from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCA-ADDING ENZYME; POLYNUCLEOTIDE PHOSPHORYLASE FUNCTIONS; MESSENGER-RNA; POLY(A) POLYMERASE; COMPLEX; NUCLEOTIDYLTRANSFERASE; SUPERFAMILY; EXONUCLEASE; MATURATION; PATHWAY	The mechanism of RNA degradation in Escherichia coli involves endonucleolytic cleavage, polyadenylation of the cleavage product by poly(A) polymerase, and exonucleolytic degradation by the exoribonucleases, polynucleotide phosphorylase (PNPase) and RNase II. The poly(A) tails are homogenous, containing only adenosines in most of the growth conditions. In the chloroplast, however, the same enzyme, PNPase, polyadenylates and degrades the RNA molecule; there is no equivalent for the E. coli poly(A) polymerase enzyme. Because cyanobacteria is a prokaryote believed to be related to the evolutionary ancestor of the chloroplast, we asked whether the molecular mechanism of RNA polyadenylation in the Synechoeystis PCC6803 cyanobacteria is similar to that in E. coli or the chloroplast. We found that RNA polyadenylation in Synechocystis is similar to that in the chloroplast but different from E. coli. No poly(A) polymerase enzyme exists, and polyadenylation is performed by PNPase, resulting in heterogeneous poly(A)-rich tails. These heterogeneous tails were found in the amino acid coding region, the 5' and 3' untranslated regions of mRNAs, as well as in rRNA and the single intron located at the tRNA(fmet). Furthermore, unlike E. coli, the inactivation of PNPase or RNase II genes caused lethality. Together, our results show that the RNA polyadenylation and degradation mechanisms in cyanobacteria and chloroplast are very similar to each other but different from E. coli.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Schuster, G (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	gadis@tx.technion.ac.il	Schuster, Gadi/AAE-2010-2019					Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Baginsky S, 2001, RNA, V7, P1464; Bonocora RP, 2001, MOL MICROBIOL, V39, P1299, DOI 10.1111/j.1365-2958.2001.02318.x; Bralley P, 2002, MICROBIOL-SGM, V148, P1421, DOI 10.1099/00221287-148-5-1421; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; Garcia-Dominguez M, 2000, J BACTERIOL, V182, P38, DOI 10.1128/JB.182.1.38-44.2000; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Jager S, 2001, NUCLEIC ACIDS RES, V29, P4581, DOI 10.1093/nar/29.22.4581; Jansson C, 1998, METHOD ENZYMOL, V297, P166; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; Komine Y, 2000, RNA, V6, P598, DOI 10.1017/S1355838200992252; Kujat SL, 2000, PLANT PHYSIOL, V124, P703, DOI 10.1104/pp.124.2.703; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Kusov YY, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e57; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Lilly JW, 2002, PLANT CELL, V14, P2681, DOI 10.1105/tpc.005595; Lisitsky I, 1997, PLANT J, V12, P1173, DOI 10.1046/j.1365-313X.1997.12051173.x; Lisitsky I, 1997, J BIOL CHEM, V272, P17648, DOI 10.1074/jbc.272.28.17648; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Raynal LC, 1998, J BACTERIOL, V180, P6276; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; Rott R, 1998, MOL CELL BIOL, V18, P4605, DOI 10.1128/MCB.18.8.4605; SACHS A, 1993, J BIOL CHEM, V268, P22955; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; Schwarz R, 1998, P NATL ACAD SCI USA, V95, P11008, DOI 10.1073/pnas.95.18.11008; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; TOMITA K, 2002, J BIOL CHEM, V277, P48912; Vogel J, 2002, EMBO J, V21, P3794, DOI 10.1093/emboj/cdf359; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001; Yue DX, 1996, RNA, V2, P895	42	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15771	15777		10.1074/jbc.M211571200	http://dx.doi.org/10.1074/jbc.M211571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601000	hybrid			2022-12-25	WOS:000182680000041
J	Wiederkehr-Adam, M; Ernst, P; Muller, K; Bieck, E; Gombert, FO; Ottl, J; Graff, P; Grossmuller, F; Heim, MH				Wiederkehr-Adam, M; Ernst, P; Muller, K; Bieck, E; Gombert, FO; Ottl, J; Graff, P; Grossmuller, F; Heim, MH			Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE RESPONSE FACTOR/STAT3; I INTERFERON RECEPTOR; SH2 DOMAINS; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; DIFFERENTIAL ACTIVATION; PATHWAY; PEPTIDE; GP130	Signal transducers and activators of transcription (STAT) 1 and STAT3 are activated by overlapping but distinct sets of cytokines. STATs are recruited to the different cytokine receptors through their Src homology (SH) 2 domains that make highly specific interactions with phosphotyrosine-docking sites on the receptors. We used a degenerate phosphopeptide library synthesized on 35-mum TentaGel beads and fluorescence-activated bead sorting to determine the sequence specificity of the peptide-binding sites of the SH2 domains of STAT1 and STAT3. The large bead library allowed not only peptide sequencing of pools of beads but also of single beads. The method was validated through surface plasmon resonance measurements of the affinities of different peptides to the STAT SH2 domains. Furthermore, when selected peptides were attached to a truncated erythropoietin receptor and stably expressed in DA3 cells, activation of STAT1 or STAT3 could be achieved by stimulation with erythropoietin. The combined analysis of pool sequencing, the individual peptide sequences, and plasmon resonance measurements allowed the definition of SH2 domain binding motifs. STAT1 preferentially binds peptides with the motif phosphotyrosine-(aspartic acid/glutamic acid)-(proline/ arginine)-(arginine/proline/glutamine), whereby a negatively charged amino acid at +1 excludes a proline at +2 and vice versa. STAT3 preferentially binds peptides with the motif phosphotyrosine-(basic or hydrophobic)(proline or basic)- glutamine. For both STAT1 and STAT3, specific high affinity phosphopeptides were identified that can be used for the design of inhibitory molecules.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Novartis Pharma AG, CH-4002 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Novartis Res Inst, A-1235 Vienna, Austria	University of Basel; Novartis; Max Planck Society; Novartis	Heim, MH (corresponding author), Kantonsspital, Zentrum Lehre & Forsch, Hebelstr 20, CH-4031 Basel, Switzerland.	Markus.Heim@unibas.ch	Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894; GOMBERT, Frank Otto/0000-0002-7507-697X				Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Kessels HWHG, 2002, P NATL ACAD SCI USA, V99, P8524, DOI 10.1073/pnas.142224499; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Muller K, 1996, J BIOL CHEM, V271, P16500; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Novak U, 1996, ONCOGENE, V13, P2607; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	52	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16117	16128		10.1074/jbc.M300261200	http://dx.doi.org/10.1074/jbc.M300261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591923	hybrid			2022-12-25	WOS:000182680000084
J	Hong, S; Gronert, K; Devchand, PR; Moussignac, RL; Serhan, CN				Hong, S; Gronert, K; Devchand, PR; Moussignac, RL; Serhan, CN			Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells - Autacoids in anti-inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; FISH-OIL; HUMAN-PLATELETS; LEUKOTRIENE; METABOLISM; EXPRESSION; PRODUCTS; N-3; TRANSFORMATION; BIOSYNTHESIS	Docosahexaenoic acid (DHA, C22:6) is highly enriched in brain, synapses, and retina and is a major w-3 fatty acid. Deficiencies in this essential fatty acid are reportedly associated with neuronal function, cancer, and inflammation. Here, using new lipidomic analyses employing high performance liquid chromatography coupled with a photodiode-array detector and a tandem mass spectrometer, a novel series of endogenous mediators was identified in blood, leukocytes, brain, and glial cells as 17S-hydroxy-containing docosanoids denoted as docosatrienes (the main bioactive member of the series was 10,17S-docosatriene) and 17S series resolvins. These novel mediators were biosynthesized via epoxide-containing intermediates and proved potent (pico- to nanomolar range) regulators of both leukocytes reducing infiltration in vivo and glial cells blocking their cytokine production. These results indicate that DHA is the precursor to potent protective mediators generated via enzymatic oxygenations to novel docosatrienes and 17S series resolvins that each regulate events of interest in inflammation and resolution.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Thorn Med Res Bldg,7th Floor, Boston, MA 02115 USA.	enserhan@zeus.bwh.harvard.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01-DE13499] Funding Source: Medline; NIDDK NIH HHS [K01 DK060583-03, DK60583] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazan N. G., 1990, NUTR BRAIN, V8, P1; BAZAN NG, 1992, NESTLE NUTR WORKS SE, V28, P121; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1984, BIOCHEM BIOPH RES CO, V125, P741, DOI 10.1016/0006-291X(84)90601-6; BAZAN NG, 2001, NEUROPROTECTION, P195; BERGSTROM S, 1982, PRIX NOBEL NOBEL PRI, P129; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Burr GO, 1929, J BIOL CHEM, V82, P345; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Chanez P, 2002, AM J RESP CELL MOL, V27, P655, DOI 10.1165/rcmb.F253; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; COREY EJ, 1986, TETRAHEDRON LETT, V27, P5173, DOI 10.1016/S0040-4039(00)85161-8; DeCaterina R, 1993, CURR TOP CARDIOV DIS, P105; FISCHER S, 1984, BIOCHEM BIOPH RES CO, V120, P907, DOI 10.1016/S0006-291X(84)80193-X; Gallin J.I., 1999, INFLAMMATION BASIC P; Garcia MC, 1997, BRAIN RES, V768, P43, DOI 10.1016/S0006-8993(97)00583-0; George HJ, 1996, PROTEIN EXPRES PURIF, V7, P19, DOI 10.1006/prep.1996.0003; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; Gronert K, 1999, METH MOL B, V120, P119; Gronert K, 1998, J PHARMACOL EXP THER, V285, P252; Gunstone FD, 1994, LIPID HDB; Hibbeln JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6; KHAIRELDIN TA, 1995, J IMMUNOL, V154, P1296; KIM HY, 1990, PROSTAG OTH LIPID M, V40, P473, DOI 10.1016/0090-6980(90)90110-H; LANDS WEM, 1993, ANN NY ACAD SCI, V676, P46; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; McLennan P, 1996, EUR J PHARMACOL, V300, P83, DOI 10.1016/0014-2999(95)00861-6; MILLER CC, 1991, J INVEST DERMATOL, V96, P98, DOI 10.1111/1523-1747.ep12515911; Moore MAS, 1999, NEW ENGL J MED, V341, P605, DOI 10.1056/NEJM199908193410811; RAPP JH, 1991, ARTERIOSCLER THROMB, V11, P903, DOI 10.1161/01.ATV.11.4.903; ROWLEY AF, 1994, BIOCHEMISTRY-US, V33, P856, DOI 10.1021/bi00170a002; Rudberg PC, 2002, P NATL ACAD SCI USA, V99, P4215, DOI 10.1073/pnas.072090099; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Salem N, 1996, P NATL ACAD SCI USA, V93, P49, DOI 10.1073/pnas.93.1.49; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; SAWAZAKI S, 1994, J NEUROCHEM, V62, P2437; Serhan Charles N., 2002, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V1, P177, DOI 10.2174/1568014023355881; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SOK DE, 1983, BIOCHEM BIOPH RES CO, V110, P273, DOI 10.1016/0006-291X(83)91291-3; TOU J, 1986, LIPIDS, V21, P324, DOI 10.1007/BF02535694; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Vane JR, 2001, THERAPEUTIC ROLES SE; Wallace JL, 1999, BRIT J PHARMACOL, V126, P1200, DOI 10.1038/sj.bjp.0702420; WHELAN J, 1990, BIOL OXIDATION SYSTE, V2, P765; YERGEY JA, 1986, ANAL CHEM, V58, P1344, DOI 10.1021/ac00298a016; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844	58	757	800	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14677	14687		10.1074/jbc.M300218200	http://dx.doi.org/10.1074/jbc.M300218200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590139	hybrid, Green Published			2022-12-25	WOS:000182516100014
J	Liu, GZ; Wang, H; Wang, ZX				Liu, GZ; Wang, H; Wang, ZX			Identification of a highly conserved domain in the androgen receptor that suppresses the DNA-binding domain-DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL EXTENSION; GLUCOCORTICOID RECEPTORS; PROSTATE-CANCER; GENE-MUTATIONS; TRANSCRIPTION; TRANSACTIVATION; INSENSITIVITY; COREGULATORS; COACTIVATOR; PROGRESSION	The androgen receptor (AR) is a ligand-regulated and sequence-specific transcription factor that activates or represses expression of target genes. Here, we show that the N terminus of AR contains an inhibitory domain located in an 81-amino acid segment lying upstream of the DNA-binding domain (DBD). The inhibitory domain interacted directly with DBD and repressed DBD binding to the androgen response element. Mutations of the conserved amino acid residues (K520E and R538E) within the inhibitory domain decreased its inhibiting ability in vitro and increased AR trans-activation in vivo. These data demonstrate the existence of a novel inhibitory domain in the N-terminal part of AR, which might play important roles in the regulation of AR trans-activation.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wang, ZX (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Unit 173, Houston, TX 77030 USA.	zhenwang@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed SF, 2000, J CLIN ENDOCR METAB, V85, P658, DOI 10.1210/jc.85.2.658; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRINKMANN AO, 1995, J STEROID BIOCHEM, V53, P443, DOI 10.1016/0960-0760(95)00090-M; Buchanan G, 2001, MOL ENDOCRINOL, V15, P46, DOI 10.1210/me.15.1.46; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Csaszar A, 2001, EUR J PHARMACOL, V414, P9, DOI 10.1016/S0014-2999(01)00755-5; Culig Z, 1997, DRUG AGING, V10, P50, DOI 10.2165/00002512-199710010-00005; Culig Z, 2001, Am J Pharmacogenomics, V1, P241, DOI 10.2165/00129785-200101040-00001; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2001, ENDOCRINE, V14, P143, DOI 10.1385/ENDO:14:2:143; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Kantoff P, 1998, BBA-REV CANCER, V1378, pC1; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lobaccaro JM, 1999, ENDOCRINOLOGY, V140, P350, DOI 10.1210/en.140.1.350; McEwan IJ, 2001, BIOCHEM SOC T, V29, P222; Melvin VS, 2002, J BIOL CHEM, V277, P25115, DOI 10.1074/jbc.M110400200; Nelson KA, 2002, AM J EPIDEMIOL, V155, P883, DOI 10.1093/aje/155.10.883; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sutherland RW, 1996, J UROLOGY, V156, P828, DOI 10.1016/S0022-5347(01)65830-0; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001	39	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14956	14960		10.1074/jbc.M212229200	http://dx.doi.org/10.1074/jbc.M212229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591938	hybrid			2022-12-25	WOS:000182516100050
J	Sato, S; Tomomori-Sato, C; Banks, CAS; Sorokina, I; Parmely, TJ; Kong, SE; Jin, JJ; Cai, Y; Lane, WS; Brower, CS; Conaway, RC; Conaway, JW				Sato, S; Tomomori-Sato, C; Banks, CAS; Sorokina, I; Parmely, TJ; Kong, SE; Jin, JJ; Cai, Y; Lane, WS; Brower, CS; Conaway, RC; Conaway, JW			Identification of mammalian mediator subunits with similarities to yeast mediator subunits Srb5, Srb6, Med11, and Rox3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; NUCLEAR RECEPTORS; COFACTOR COMPLEX; ACTIVATION; PATHWAYS; PROTEIN; SMCC	The Mediator is a multiprotein coactivator required for activation of RNA polymerase II transcription by DNA binding transactivators. We recently identified a mammalian homologue of yeast Mediator subunit Med8 and partially purified a Med8-containing Mediator complex from rat liver nuclei (Brower, C. S., Sato, S., Tomomori-Sato, C., Kamura, T., Pause, A., Stearman, R., Klausner, R. D., Malik, S., Lane, W. S., Sorokina, I., Roeder, R. G., Conaway, J. W., and Conaway, R. C. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10353-10358). Analysis of proteins present in the most highly purified Med8-containing fractions by tandem mass spectrometry led to the identification of many known mammalian Mediator subunits, as well as four potential Mediator subunits exhibiting sequence similarity to yeast Mediator subunits Srb5, Srb6, Med11, and Rox3. Here we present direct biochemical evidence that these four proteins are bona fide mammalian Mediator subunits. In addition, we identify direct pairwise binding partners of these proteins among the known mammalian Mediator subunits. Taken together, our findings identify a collection of novel mammalian Mediator subunits and shed new light on the underlying architecture of the mammalian Mediator complex.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Harvard Univ, Harvard Microchem & Prote Anal Facil, Cambridge, MA 02138 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; Harvard University; California Institute of Technology; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.			Conaway, Joan/0000-0002-2786-0663; Tomomori-Sato, Chieri/0000-0002-2543-293X; Banks, Charles/0000-0002-0404-2940; Sorokina, Irina/0000-0003-1531-1832	NIGMS NIH HHS [R37 GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gu JY, 2002, J BIOL CHEM, V277, P27154, DOI 10.1074/jbc.M204144200; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141	12	42	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15123	15127		10.1074/jbc.C300054200	http://dx.doi.org/10.1074/jbc.C300054200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584197	hybrid, Green Accepted			2022-12-25	WOS:000182516100070
J	Fitzsimmons, TJ; Zhao, XL; Wank, SA				Fitzsimmons, TJ; Zhao, XL; Wank, SA			The extracellular domain of receptor activity-modifying protein 1 is sufficient for calcitonin receptor-like receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; PARATHYROID-HORMONE; BINDING; ADRENOMEDULLIN; SELECTIVITY; EXPRESSION	A functional calcitonin gene-related peptide (CGRP) receptor requires dimerization of calcitonin receptor-like receptor (CRLR) with receptor activity-modifying protein 1 (RAMP 1). To determine the function of the three domains (extracellular, ECD; transmembrane, TM; and tail domains) of human RAMP 1, three mutants were constructed: RAMP 1 without the cytoplasmic tail, a chimera consisting of the ECD of PUMP I and the TM and tail of the platelet-derived growth factor receptor, and the ECD of RAMP 1 alone. These RAMP I mutants were examined for their ability to associate with CRLR to effect CGRP-stimulated cAMP accumulation, CGRP binding, CRLR trafficking, and cell surface expression. All RAMP 1 mutants were able to associate with CRLR with full efficacy for CGRP-stimulated cAMP accumulation. However, the RAMP 1/platelet-derived growth factor receptor chimera demonstrated a 10-fold decrease in potency for CGRP signaling and binding, and the RAMP 1-ECD mutant had a 4000-fold decrease in potency. In conclusion, the ECD of RAMP 1 is sufficient for normal CRLR association and efficacy. The presence of a TM domain and the specific sequence of the RAMP 1 TM domain contribute to CGRP affinity and potency. The C-terminal tail of RAMP 1 is unnecessary for CRLR function.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wank, SA (corresponding author), NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK069083, Z01DK053209] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; Carter PH, 1999, J BIOL CHEM, V274, P31955, DOI 10.1074/jbc.274.45.31955; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Flahaut M, 2002, J BIOL CHEM, V277, P14731, DOI 10.1074/jbc.M112084200; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40	14	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14313	14320		10.1074/jbc.M211946200	http://dx.doi.org/10.1074/jbc.M211946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574158	hybrid			2022-12-25	WOS:000182405000095
J	Putilina, T; Skouri-Panet, F; Prat, K; Lubsen, NH; Tardieu, A				Putilina, T; Skouri-Panet, F; Prat, K; Lubsen, NH; Tardieu, A			Subunit exchange demonstrates a differential chaperone activity of calf alpha-crystallin toward beta(LOW)- and individual gamma-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; RESONANCE ENERGY-TRANSFER; A-CRYSTALLIN; B-CRYSTALLIN; MOLECULAR CHAPERONE; PHASE-SEPARATION; EYE LENS; BETA-CRYSTALLIN; METHANOCOCCUS-JANNASCHII; OSMOTIC-PRESSURE	The chaperone activity of native alpha-crystallins toward beta(LOW)- and various gamma-crystallins at the onset of their denaturation, 60 and 66 degreesC, respectively, was studied at high and low crystallin concentrations using small angle x-ray scattering (SAXS) and fluorescence energy transfer (FRET). The crystallins were from calf lenses except for one recombinant human gammaS. SAXS data demonstrated an irreversible doubling in molecular weight and a corresponding increase in size of alpha-crystallins at temperatures above 60 degreesC. Further increase is observed at 66 degreesC. More subtle conformational changes accompanied the increase in size as shown by changes in environments around tryptophan and cysteine residues. These alpha-crystallin temperature-induced modifications were found necessary to allow for the association with beta(LOW)- and gamma-crystallins to occur. FRET experiments using IAEDANS (iodoacetylaminoethylaminonaphthalene sulfonic acid)- and IAF (iodoacetamidofluorescein)-labeled subunits showed that the heat-modified alpha-crystallins retained their ability to exchange subunits and that, at 37 degreesC, the rate of exchange was increased depending upon the temperature of incubation, 60 or 66 degreesC. Association with beta(LOW)- (60 degreesC) or various gamma-crystallins (66 degreesC) resulted at 37 degreesC in decreased subunit exchange in proportion to bound ligands. Therefore, beta(LOW)- and gamma-crystallins were compared for their capacity to associate with alpha-crystallins and inhibit subunit exchange. Quite unexpectedly for a highly conserved protein family, differences were observed between the individual gamma-crystallin family members. The strongest effect was observed for gammaS, followed by hgammaSrec, gammaE, gammaA-F, gammaD, gammaB. Moreover, fluorescence properties of alpha-crystallins in the presence of bound beta(LOW)-and gamma-crystallins indicated that the formation Of beta(LOW)/alpha- or gamma/alpha-crystallin complexes involved various binding sites. The changes in subunit exchange associated with the chaperone properties of alpha-crystallins toward the other lens crystallins demonstrate the dynamic character of the heat-activated alpha-crystallin structure.	CNRS, Lab Mineral Cristallog, F-75252 Paris 05, France; Univ Nijmegen, Dept Biochem 161, NL-6500 HB Nijmegen, Netherlands; Univ Paris 06, F-75252 Paris 05, France; Univ Paris 07, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Radboud University Nijmegen; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Tardieu, A (corresponding author), CNRS, Lab Mineral Cristallog, P6-P7 Univ,Case 115,4 Pl Jussieu, F-75252 Paris 05, France.		Lubsen, Nicolette H./B-8426-2011	Skouri-Panet, Feriel/0000-0002-2623-9058				Abgar S, 2000, BIOCHEM BIOPH RES CO, V276, P619, DOI 10.1006/bbrc.2000.3518; Abgar S, 2001, BIOPHYS J, V80, P1986, DOI 10.1016/S0006-3495(01)76168-1; Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; Arai H, 1997, CELL STRUCT FUNCT, V22, P539, DOI 10.1247/csf.22.539; Augusteyn Robert C, 2002, Clin Exp Optom, V85, P83; Bera S, 2002, BIOCHEMISTRY-US, V41, P297, DOI 10.1021/bi011010v; Bhattacharyya J, 2002, J PROTEIN CHEM, V21, P65, DOI 10.1023/A:1014187300930; Blakytny R, 1997, EXP EYE RES, V64, P1051, DOI 10.1006/exer.1997.0299; Borkman RF, 1996, EXP EYE RES, V62, P141, DOI 10.1006/exer.1996.0018; Bours J, 1996, OPHTHALMIC RES, V28, P23, DOI 10.1159/000267939; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; BROIDE ML, 1991, P NATL ACAD SCI USA, V88, P5660, DOI 10.1073/pnas.88.13.5660; Burgio MR, 2000, BIOCHEM BIOPH RES CO, V268, P426, DOI 10.1006/bbrc.1999.2036; Burgio MR, 2001, MOL VIS, V7, P228; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; Datta SA, 2000, J BIOL CHEM, V275, P41004, DOI 10.1074/jbc.M007686200; Derham BK, 2001, EUR J BIOCHEM, V268, P713, DOI 10.1046/j.1432-1327.2001.01929.x; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; Guinier A., 1955, SMALL ANGLE SCATTERI; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Liang JJN, 2000, FEBS LETT, V484, P98, DOI 10.1016/S0014-5793(00)02136-0; Liang JJN, 2000, MOL VIS, V6, P10; Lindner RA, 1997, J BIOL CHEM, V272, P27722, DOI 10.1074/jbc.272.44.27722; Lindner RA, 2001, BIOCHEM J, V354, P79, DOI 10.1042/0264-6021:3540079; Liu CW, 1996, P NATL ACAD SCI USA, V93, P377, DOI 10.1073/pnas.93.1.377; Lomakin A, 1996, J CHEM PHYS, V104, P1646, DOI 10.1063/1.470751; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Malfois M, 1996, J CHEM PHYS, V105, P3290, DOI 10.1063/1.471843; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; Pasta SY, 2002, J BIOL CHEM, V277, P45821, DOI 10.1074/jbc.M206499200; Rajaraman K, 1998, BIOCHEM BIOPH RES CO, V249, P917, DOI 10.1006/bbrc.1998.9242; Rajaraman K, 2001, FEBS LETT, V497, P118, DOI 10.1016/S0014-5793(01)02451-6; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Reddy GB, 2002, FEBS LETT, V522, P59, DOI 10.1016/S0014-5793(02)02884-3; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Sinha D, 2001, J BIOL CHEM, V276, P9308, DOI 10.1074/jbc.M010583200; Skouri-Panet F, 2001, BIOPHYS CHEM, V89, P65, DOI 10.1016/S0301-4622(00)00216-7; Sreelakshmi Y, 2001, J PROTEIN CHEM, V20, P123, DOI 10.1023/A:1011077307262; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VERETOUT F, 1989, J MOL BIOL, V205, P713, DOI 10.1016/0022-2836(89)90316-1; VERETOUT F, 1989, EUR BIOPHYS J BIOPHY, V17, P61, DOI 10.1007/BF00257103; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311; WANG KY, 1994, J BIOL CHEM, V269, P13601; Wang KY, 2000, EUR J BIOCHEM, V267, P4705, DOI 10.1046/j.1432-1327.2000.01521.x; Weinreb O, 2000, INVEST OPHTH VIS SCI, V41, P3893; Wenk M, 2000, BIOPHYS CHEM, V86, P95, DOI 10.1016/S0301-4622(00)00161-7; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	69	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13747	13756		10.1074/jbc.M208157200	http://dx.doi.org/10.1074/jbc.M208157200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562766	hybrid			2022-12-25	WOS:000182405000025
J	Zhang, XJ; Kurnasov, OV; Karthikeyan, S; Grishin, NV; Osterman, AL; Zhang, H				Zhang, XJ; Kurnasov, OV; Karthikeyan, S; Grishin, NV; Osterman, AL; Zhang, H			Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; NMN ADENYLYLTRANSFERASE; CRYSTAL-STRUCTURE; WALLERIAN DEGENERATION; ADENINE-DINUCLEOTIDE; NUCLEAR ENZYME; DNA-REPAIR; PROTEIN; CHROMATIN; IDENTIFICATION	Pyridine dinucleotides (NAD and NADP) are ubiquitous cofactors involved in hundreds of redox reactions essential for the energy transduction and metabolism in all living cells. In addition, NAD also serves as a substrate for ADP-ribosylation of a number of nuclear proteins, for silent information regulator 2 (Sir2)-like histone deacetylase that is involved in gene silencing regulation, and for cyclic ADP ribose (cADPR)-dependent Ca2+ signaling. Pyridine nucleotide adenylyltransferase (PNAT) is an indispensable central enzyme in the NAD biosynthesis pathways catalyzing the condensation of pyridine mononucleotide (NMN or NaMN) with the AMP moiety of ATP to form NAD (or NaAD). Here we report the identification and structural characterization of a novel human PNAT (hsPNAT-3) that is located in the cytoplasm and mitochondria. Its subcellular localization and tissue distribution are distinct from the previously identified human nuclear PNAT-1 and PNAT-2. Detailed structural analysis of PNAT-3 in its apo form and in complex with its substrate(s) or product revealed the catalytic mechanism of the enzyme. The characterization of the cytosolic human PNAT-3 provided compelling evidence that the final steps of NAD biosynthesis pathways may exist in mammalian cytoplasm and mitochondria, potentially contributing to their NAD/NADP` pool.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Integrated Genom Inc, Chicago, IL 60612 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zhang, H (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	zhang@chop.swmed.edu	Karthikeyan, Subramanian/F-8808-2010		NIGMS NIH HHS [GM65243] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065243] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALDUCCI E, 1995, ANAL BIOCHEM, V228, P64, DOI 10.1006/abio.1995.1315; BALDUCCI E, 1995, BIOCHEM J, V310, P395, DOI 10.1042/bj3100395; BALDUCCI E, 1992, BIOCHEM BIOPH RES CO, V189, P1275, DOI 10.1016/0006-291X(92)90211-3; Barile M, 1996, BIOCHEM MOL BIOL INT, V38, P297; Begley TP, 2001, VITAM HORM, V61, P103; BERGER SJ, 1982, J NEUROCHEM, V38, P821, DOI 10.1111/j.1471-4159.1982.tb08704.x; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; BRANSTER MV, 1956, BIOCHEM J, V63, P640, DOI 10.1042/bj0630640; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkle A, 2001, CANCER LETT, V163, P1, DOI 10.1016/S0304-3835(00)00694-7; CANTAROW W, 1977, ARCH BIOCHEM BIOPHYS, V180, P26, DOI 10.1016/0003-9861(77)90004-2; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; COONEY DA, 1983, ADV ENZYME REGUL, V21, P271, DOI 10.1016/0065-2571(83)90019-5; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Emanuelli M, 2001, J BIOL CHEM, V276, P406, DOI 10.1074/jbc.M008700200; EMANUELLI M, 1992, ARCH BIOCHEM BIOPHYS, V298, P29, DOI 10.1016/0003-9861(92)90089-F; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Garavaglia S, 2002, J BIOL CHEM, V277, P8524, DOI 10.1074/jbc.M111589200; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; Guarente L, 2000, GENE DEV, V14, P1021; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Izard T, 2002, J MOL BIOL, V315, P487, DOI 10.1006/jmbi.2001.5272; JAYARAM HN, 1986, BIOCHEM PHARMACOL, V35, P587, DOI 10.1016/0006-2952(86)90352-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurnasov OV, 2002, J BACTERIOL, V184, P6906, DOI 10.1128/JB.184.24.6906-6917.2002; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Lerner F, 2001, BIOCHEM BIOPH RES CO, V288, P69, DOI 10.1006/bbrc.2001.5735; LOWE G, 1983, EUR J BIOCHEM, V132, P117, DOI 10.1111/j.1432-1033.1983.tb07334.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MOAT AG, 1987, PYRIDINE NUCL COEN B, V2, P1; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; MORTON RK, 1958, NATURE, V181, P540, DOI 10.1038/181540a0; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PENFOUND T, 1996, ESCHERICHIA COLI SAL, V1, P721; Raffaelli N, 2002, BIOCHEM BIOPH RES CO, V297, P835, DOI 10.1016/S0006-291X(02)02285-4; RUGGIERI S, 1990, BIOCHEMISTRY-US, V29, P2501, DOI 10.1021/bi00462a010; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Schweiger M, 2001, FEBS LETT, V492, P95, DOI 10.1016/S0014-5793(01)02180-9; Sestini S, 2000, ARCH BIOCHEM BIOPHYS, V379, P277, DOI 10.1006/abbi.2000.1888; Singh SK, 2002, J BIOL CHEM, V277, P33291, DOI 10.1074/jbc.M204368200; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; UHR ML, 1982, EUR J BIOCHEM, V128, P435; Werner E, 2002, FEBS LETT, V516, P239, DOI 10.1016/S0014-5793(02)02556-5; Zhang QH, 2000, CHEMOECOLOGY, V10, P69, DOI 10.1007/s000490050010; Zhou TJ, 2002, J BIOL CHEM, V277, P13148, DOI 10.1074/jbc.M111469200; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	54	105	113	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13503	13511		10.1074/jbc.M300073200	http://dx.doi.org/10.1074/jbc.M300073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574164	hybrid			2022-12-25	WOS:000182189500114
J	Moorehead, RA; Sanchez, OH; Baldwin, RM; Khokha, R				Moorehead, RA; Sanchez, OH; Baldwin, RM; Khokha, R			Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma	ONCOGENE			English	Article						IGF-II; lung cancer; CREB; transgenic model	GROWTH-FACTOR-I; CANCER CELL-LINES; ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-I; NF-KAPPA-B; PULMONARY ADENOCARCINOMA; GENE-EXPRESSION; MOUSE; PROLIFERATION; ENDOTOXEMIA	Elevated levels of insulin-like growth factor (IGF)-II are associated with a poor prognosis in human pulmonary adenocarcinoma; however, a causal role for IGF-II in pulmonary adenocarcinoma has not been demonstrated. Here, we show that transgenic overexpression of IGF-II in lung epithelium induces lung tumors in 69% of mice older than 18 months of age. These tumors displayed morphological characteristics of human pulmonary adenocarcinoma such as their epithelial origin, tubulo-acinar architecture and expression of TTF-1, SP-B and proSP-C. Examination of signaling molecules downstream of the IGF-IR showed the activation of either the Erk1/Erk2 or p38 MAPK pathways, but not both, within the lung tumors. Notably, all lung tumors contained high levels of phosphorylated CREB, suggesting that both the Erk1/ Erk2 and p38 MAPK pathways converged on this transcription factor. Moreover, IGF-II induced proliferation and CREB phosphorylation in human lung cancer cell lines, suggesting that IGF-II and CREB also contribute to the growth of human lung tumors. Thus, IGF-II is an important genetic factor in the development of lung tumorigenesis, in which activation of CREB is a ubiquitous event. The MMTV-IGF-II transgenic mice provide a critical model for elucidating the role of IGF-II in this fatal human disease.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Khokha, R (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@oci.utoronto.ca		, Roger/0000-0001-9539-6295; Khokha, Rama/0000-0002-6028-1524				Abraham E, 2001, J IMMUNOL, V166, P522, DOI 10.4049/jimmunol.166.1.522; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chailley-Heu B, 2001, J PATHOL, V195, P482, DOI 10.1002/path.960; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DiLoreto C, 1997, J CLIN PATHOL, V50, P30, DOI 10.1136/jcp.50.1.30; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; George CLS, 1999, AM J PHYSIOL-LUNG C, V276, pL776, DOI 10.1152/ajplung.1999.276.5.L776; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; Inderdeo DS, 1996, BIOL REPROD, V55, P498, DOI 10.1095/biolreprod55.3.498; JAQUES G, 1988, EXP CELL RES, V176, P336, DOI 10.1016/0014-4827(88)90335-7; KAISER U, 1993, J CANCER RES CLIN, V119, P665, DOI 10.1007/BF01215985; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P8; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lee CT, 1996, CANCER RES, V56, P3038; London SJ, 2002, JNCI-J NATL CANCER I, V94, P749, DOI 10.1093/jnci/94.10.749; Lukanova A, 2001, INT J CANCER, V92, P888, DOI 10.1002/ijc.1265; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; MINUTO F, 1988, CANCER RES, V48, P3716; MINUTO F, 1986, CANCER RES, V46, P985; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; Nguyen LQ, 2000, MOL ENDOCRINOL, V14, P1448, DOI 10.1210/me.14.9.1448; Ordonez NG, 2000, AM J SURG PATHOL, V24, P1217, DOI 10.1097/00000478-200009000-00004; REHM S, 1994, TUMOURS MOUSE, V2, P325; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SCHARDT C, 1993, EXP CELL RES, V204, P22, DOI 10.1006/excr.1993.1004; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schneider MR, 2000, FASEB J, V14, P629, DOI 10.1096/fasebj.14.5.629; Shenkar R, 1999, J IMMUNOL, V163, P954; Shenkar R, 2001, AM J PHYSIOL-LUNG C, V281, pL418, DOI 10.1152/ajplung.2001.281.2.L418; Takanami I, 1996, J SURG ONCOL, V61, P205, DOI 10.1002/(SICI)1096-9098(199603)61:3<205::AID-JSO8>3.0.CO;2-F; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zia F, 1996, J CELL BIOCHEM, P269	40	69	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					853	857		10.1038/sj.onc.1206188	http://dx.doi.org/10.1038/sj.onc.1206188			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584565				2022-12-25	WOS:000180864300008
J	Lu, BS; Bishop, CE				Lu, BS; Bishop, CE			Mouse GGN1 and GGN3, two germ cell-specific proteins from the single gene Ggn, interact with mouse POG and play a role in spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; PROTO-ONCOGENE; W-LOCUS; MICE; PROLIFERATION; GENERATION; MIGRATION; MUTATION; ENCODES; EMBRYO	The germ cell-deficient (gcd) mutation is a recessive transgenic insertional mutation leading to a deficiency of primordial germ cells (PGCs). We have recently shown that the gene underlying this mutation is Pog, which is necessary for normal proliferation of PGCs. Here we show that Pog is also involved in spermatogenesis in that meiosis is impaired in Pog-deficient mice. Yeast two-hybrid screening revealed that POG interacted with GGN1 and GGN3, two proteins formed by alternate splicing of the same gene, gametogenetin (Ggn). Ggn had more than 10 different splice variants giving rise to three proteins, GGN1, GGN2, and GGN3. The three proteins had different subcellular localizations, with GGN1, GGN2, and GGN3 localized along the nuclear membrane, in the cytoplasm, and in the nucleus/nucleoli respectively. The expression of Ggn was confined to late pachytene spermatocytes and round spermatids, a time window concomitant with the occurrence of meiosis. Mouse Ggn and Pog were both expressed in primary spermatocytes. Co-expression of POG with GGN1 or GGN3 in HeLa cells changed the localization of POG to the perinuclear localization or the nucleoli, respectively. Our data showed that in addition to functioning in proliferation of primordial germ cells, POG also functioned in spermatogenesis. Two spatial and temporal regulated proteins, GGN1 and GGN3, interacted with POG, regulated the localization of POG, and played a role in spermatogenesis.	Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Bishop, CE (corresponding author), Baylor Coll Med, Dept Obstet & Gynecol, 6550 Fannin St 880, Houston, TX 77030 USA.		Lu, Baisong/B-5837-2013	Lu, Baisong/0000-0001-9240-558X	NICHD NIH HHS [HD 36289] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD036289] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Agoulnik AI, 2002, HUM MOL GENET, V11, P3047, DOI 10.1093/hmg/11.24.3047; ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; Anderson R, 1999, DEVELOPMENT, V126, P1655; Beck ARP, 1998, P NATL ACAD SCI USA, V95, P2331, DOI 10.1073/pnas.95.5.2331; Bendel-Stenzel MR, 2000, MECH DEVELOP, V91, P143, DOI 10.1016/S0925-4773(99)00287-7; BRADY G, 1993, METHOD ENZYMOL, V225, P611; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; BYSKOV AG, 1986, PHYSIOL REV, V66, P71, DOI 10.1152/physrev.1986.66.1.71; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Cobb J, 1998, SEMIN CELL DEV BIOL, V9, P445, DOI 10.1006/scdb.1998.0202; DUNCAN MK, 1995, MAMM GENOME, V6, P697, DOI 10.1007/BF00354290; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GINSBURG M, 1990, DEVELOPMENT, V110, P521; HATANAKA M, 1990, BIOESSAYS, V12, P143, DOI 10.1002/bies.950120310; HEYTING C, 1988, CHROMOSOMA, V96, P325, DOI 10.1007/BF00286921; KREMER EJ, 1991, EXP CELL RES, V197, P330, DOI 10.1016/0014-4827(91)90442-W; Krishnamurthy H, 1998, J ANDROL, V19, P710; LAWSON KA, 1994, CIBA F SYMP, V182, P68; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; LU B, 2003, IN PRESS BIOL REPROD; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; MOSS SB, 1993, MOL REPROD DEV, V34, P164, DOI 10.1002/mrd.1080340208; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; Russell L. D., 1990, HISTOLOGICAL HISTOPA; TAM PPL, 1981, J EMBRYOL EXP MORPH, V64, P133; Venables JP, 2002, CURR OPIN GENET DEV, V12, P615, DOI 10.1016/S0959-437X(02)00347-7; Ying Y, 2000, MOL ENDOCRINOL, V14, P1053, DOI 10.1210/me.14.7.1053; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	30	32	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16289	16296		10.1074/jbc.M211023200	http://dx.doi.org/10.1074/jbc.M211023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12574169	hybrid			2022-12-25	WOS:000182680000105
J	Morita, T; El-Kazzaz, W; Tanaka, Y; Inada, T; Aiba, H				Morita, T; El-Kazzaz, W; Tanaka, Y; Inada, T; Aiba, H			Accumulation of glucose 6-phosphate or fructose 6-phosphate is responsible for destabilization of glucose transporter mRNA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; MAJOR GLUCOSE; GENE-EXPRESSION; LACTOSE DIAUXIE; HFQ; DEGRADATION; PTSG; DECAY; INACTIVATION; REPRESSION	Previously we found that a mutation in either pgi or pfkA, encoding phosphoglucose isomerase or phosphofructokinase X respectively, facilitates degradation of the ptsG mRNA in an RNase E-dependent manner in Escherichia coli (1). In this study, we examined the effects of a series of glycolytic genes on the degradation of ptsG mRNA and how the mutations destabilize the ptsG mRNA. The conditional lethal mutation ts8 in fda, encoding fructose-1,6-P-2 aldolase just downstream of pthA in the glycolytic pathway, caused the destabilization of ptsG mRNA at the nonpermissive temperature. Mutations in any other gene did not destabilize the ptsG mRNA, rather, they reduced the ptsG transcription mainly by affecting the cAMP level. The rapid degradation of ptsG mRNA in mutant strains was completely dependent upon the presence of glucose or any one of its compounds, which enter the Embden-Meyerhof glycolytic pathway before the block points. A significant increase in the intracellular glucose-6-P level was observed in the presence of glucose in the pgi strain. An overexpression of glucose-6-phosphate dehydrogenase eliminated both the accumulation and the degradation of ptsG mRNA in the pgi strain. In addition, accumulation of fructose-6-P led to the rapid degradation of ptsG mRNA in a pgi,pfkA mutant strain lacking glucose-6-P. We conclude that the RNase E-dependent destabilization of ptsG mRNA occurs in response to accumulation of glucose-6-P or fructose-6-P.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Nagoya University	Aiba, H (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.	i45346a@nucc.cc.nagoya-u.ac.jp	kazzaz, waleed el/ABE-2805-2020; Inada, Toshifumi/AAE-1517-2019					AIBA H, 1981, J BIOL CHEM, V256, P1905; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; [Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; BRAND IA, 1986, J BIOL CHEM, V261, P5892; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; Hogema BM, 1999, MOL MICROBIOL, V31, P1825, DOI 10.1046/j.1365-2958.1999.01319.x; Inada T, 1996, GENES CELLS, V1, P293, DOI 10.1046/j.1365-2443.1996.24025.x; Inada T, 1996, MOL GEN GENET, V253, P198, DOI 10.1007/s004380050313; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; JOSEPH E, 1982, MOL GEN GENET, V185, P262, DOI 10.1007/BF00330796; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LEE AT, 1987, P NATL ACAD SCI USA, V84, P8311, DOI 10.1073/pnas.84.23.8311; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; Levi B, 2001, J NUTR BIOCHEM, V12, P235, DOI 10.1016/S0955-2863(00)00158-3; LIN ECC, 1996, ESCHERICHIA COLI SAL, P307; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Miller J. H., 1972, EXPT MOL GENETICS, P433; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Ow MC, 2000, MOL MICROBIOL, V38, P854, DOI 10.1046/j.1365-2958.2000.02186.x; PERLMAN RL, 1969, NATURE, V223, P810, DOI 10.1038/223810a0; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Regnier P, 2000, BIOESSAYS, V22, P235; Sambrook J, 1989, MOL CLONING LAB MANU, P202; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; SINGER M, 1991, J BACTERIOL, V173, P6249, DOI 10.1128/jb.173.19.6249-6257.1991; SINGER M, 1991, J BACTERIOL, V173, P6242, DOI 10.1128/jb.173.19.6242-6248.1991; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tsui HCT, 1997, J BACTERIOL, V179, P7476, DOI 10.1128/jb.179.23.7476-7487.1997; Vytvytska O, 2000, GENE DEV, V14, P1109; Vytvytska O, 1998, P NATL ACAD SCI USA, V95, P14118, DOI 10.1073/pnas.95.24.14118; Wachi M, 1997, MOL GEN GENET, V253, P515, DOI 10.1007/s004380050352; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	48	108	112	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15608	15614		10.1074/jbc.M300177200	http://dx.doi.org/10.1074/jbc.M300177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12578824	hybrid			2022-12-25	WOS:000182680000021
J	Worhunsky, DJ; Godek, K; Litsch, S; Schlax, PJ				Worhunsky, DJ; Godek, K; Litsch, S; Schlax, PJ			Interactions of the non-coding RNA DsrA and RpoS mRNA with the 30 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN HF-I; ESCHERICHIA-COLI; SIGMA(S) SUBUNIT; HOST FACTOR; TRANSLATION; EXPRESSION; GENE; POLYMERASE; RIBOREGULATION; ANTISILENCER	Expression of e, the gene product of rpoS, is controlled translationally in response to many environmental stresses. DsrA, a small 87-nucleotide non-coding RNA molecule, acts to increase translational efficiency of RpoS mRNA under some growth conditions. In this work, we demonstrate that DsrA binds directly to the 30 S ribosomal subunit with an observed equilibrium affinity of 2.8 x 10(7) m(-1). DsrA does not compete with RpoS mRNA or tRNA(f)(Met) for binding to the 30 S subunit. The 5' end of DsrA binds to 30 S subunits with an observed equilibrium association constant of 2.0 x 10(6) m(-1), indicating that the full affinity of the interaction requires the entire DsrA sequence. In order to investigate translational efficiency of RpoS mRNA, we examined both ribosome-binding site accessibility and the binding of RpoS mRNA to 30 S ribosomal subunits. We find that that ribosome-binding site accessibility is modulated as a function of divalent cation concentration during mRNA renaturation and by the presence of an antisense sequence that binds to nucleotides 1-16 of the RpoS mRNA fragment. The ribosome-binding site accessibility correlates with the amount of RpoS mRNA participating in 30 S-mRNA "pre-initiation" translational complex formation and provides evidence that regulation follows a competitive model of regulation.	Bates Coll, Dept Chem, Lewiston, ME 04240 USA; Bates Coll, Program Biol Chem, Lewiston, ME 04240 USA		Schlax, PJ (corresponding author), Bates Coll, Dept Chem, Lewiston, ME 04240 USA.	pschlax@bates.edu		Godek, Kristina/0000-0002-2512-9295				Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; Brescia CC, 2003, RNA, V9, P33, DOI 10.1261/rna.2570803; Brown L, 1997, J BACTERIOL, V179, P656, DOI 10.1128/jb.179.3.656-662.1997; Brown L, 1996, J BACTERIOL, V178, P3763, DOI 10.1128/jb.178.13.3763-3770.1996; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; CARMICHAEL GG, 1975, J BIOL CHEM, V250, P3607; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; Cunning C, 1998, J BACTERIOL, V180, P4564, DOI 10.1128/JB.180.17.4564-4570.1998; de Smit MH, 1998, COLD SPRING HARBOR M, P495; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; Donahue WF, 2002, MOL CELL, V9, P7, DOI 10.1016/S1097-2765(02)00429-X; Draper DE, 1998, COLD SPRING HARBOR M, P415; Gluick TC, 1997, J MOL BIOL, V270, P451, DOI 10.1006/jmbi.1997.1119; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lease RA, 2000, P NATL ACAD SCI USA, V97, P9919, DOI 10.1073/pnas.170281497; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; Lease RA, 2000, MOL MICROBIOL, V38, P667, DOI 10.1046/j.1365-2958.2000.02162.x; Loewen PC, 1998, CAN J MICROBIOL, V44, P707, DOI 10.1139/cjm-44-8-707; Majdalani N, 1998, P NATL ACAD SCI USA, V95, P12462, DOI 10.1073/pnas.95.21.12462; Majdalani N, 2001, MOL MICROBIOL, V39, P1382, DOI 10.1111/j.1365-2958.2001.02329.x; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Muffler A, 1996, GENE DEV, V10, P1143, DOI 10.1101/gad.10.9.1143; Muffler A, 1997, J BACTERIOL, V179, P445; Muffler A, 1996, J BACTERIOL, V178, P1607, DOI 10.1128/jb.178.6.1607-1613.1996; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RECORD MT, 1996, ESCHERICHIA COLI SAL, V1, P792; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Schlax PJ, 2001, J BIOL CHEM, V276, P38494, DOI 10.1074/jbc.M106934200; SCHLAX PJ, 2003, IN PRESS MOL MICROBI; Shiman R, 2000, J MOL BIOL, V302, P79, DOI 10.1006/jmbi.2000.4031; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; Sledjeski DD, 2001, J BACTERIOL, V183, P1997, DOI 10.1128/JB.183.6.1997-2005.2001; Takada A, 1997, BIOCHEM BIOPH RES CO, V236, P576, DOI 10.1006/bbrc.1997.7013; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; Vytvytska O, 2000, GENE DEV, V14, P1109; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3; Zhang AX, 1998, EMBO J, V17, P6061, DOI 10.1093/emboj/17.20.6061; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	44	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15815	15824		10.1074/jbc.M301684200	http://dx.doi.org/10.1074/jbc.M301684200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600997	hybrid			2022-12-25	WOS:000182680000047
J	Boccuni, P; MacGrogan, D; Scandura, JM; Nimer, SD				Boccuni, P; MacGrogan, D; Scandura, JM; Nimer, SD			The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA SEX COMB; TUMOR-SUPPRESSOR; GENE-EXPRESSION; MIDLEG SCM; MYELOPROLIFERATIVE DISORDERS; BINDING PROTEIN; CANDIDATE GENES; FUSION PROTEIN; HUMAN LEUKEMIA; HUMAN HOMOLOG	H-L(3)MIBT, the human homolog of the Drosophila lethal(3)malignant brain tumor protein, is a member of the polycomb group (PcG) of proteins, which function as transcriptional regulators in large protein complexes. Homozygous mutations in the l(3)mbt gene cause brain tumors in Drosophila, identifying l(3)mbt as a tumor suppressor gene. The h-l(3)mbt gene maps to chromo. some 20q12, within a common deleted region associated with myeloid hematopoietic malignancies. H-L(3)MBT contains three repeats of 100 residues called NMT repeats, whose function is unknown, and a C-terminal alpha-helical structure, the SPM (SCM, PH, MBT domain, which is structurally similar to the SAM (sterile btlpha motif) protein-protein interaction domain, found in several ETS transcription factors, including TEL (translocation Ets leukemia). We report that H-L(3)MBT is a transcriptional repressor and that its activity is largely dependent on the presence of a region containing the three MBT repeats. H-L(3)MBT acts as a histone deacetylase-independent transcriptional repressor, based on its lack of sensitivity to trichostatin A. We found that H-LMMET binds in vivo to TEL, and we have mapped the region of interaction to their respective SPWSAM domains. We show that the ability of TEL to repress TEL-responsive promoters is enhanced by the presence of H-L(3)MBT, an effect dependent on the H-L(3)MIBT and the TEL interacting domains. These experiments suggest that histone deacetylase-independent transcriptional repression by TEL depends on the recruitment of PcG proteins. We speculate that the interaction of TEL with H-L(3)AMT can direct a PcG complex to genes repressed by TEL, stabilizing their repressed state.	Sloan Kettering Inst Canc Res, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave,Box 575, New York, NY 10021 USA.		MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Scandura, Joseph/0000-0002-9525-143X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52208] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6; Bantignies F, 2000, MOL CELL BIOL, V20, P9317, DOI 10.1128/MCB.20.24.9317-9330.2000; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; Bench AJ, 2001, BEST PRACT RES CL HA, V14, P531, DOI 10.1053/beha.2001.0153; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; Berger J, 1999, GENE, V237, P185, DOI 10.1016/S0378-1119(99)00285-1; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Bornemann D, 1998, GENETICS, V150, P675; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BUIJS A, 1995, ONCOGENE, V10, P1511; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Knezevich SR, 1998, CANCER RES, V58, P5046; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kurtin PJ, 1996, AM J CLIN PATHOL, V106, P680; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; Montini E, 1999, GENOMICS, V58, P65, DOI 10.1006/geno.1999.5755; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; Poux S, 2001, DEVELOPMENT, V128, P75; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Schultz J, 1997, PROTEIN SCI, V6, P249; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang PW, 2000, GENOMICS, V67, P28, DOI 10.1006/geno.2000.6215; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Wismar J, 2001, FEBS LETT, V507, P119, DOI 10.1016/S0014-5793(01)02959-3; WLODARSKA I, 1995, BLOOD, V85, P2848, DOI 10.1182/blood.V85.10.2848.bloodjournal85102848; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	67	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15412	15420		10.1074/jbc.M300592200	http://dx.doi.org/10.1074/jbc.M300592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588862	hybrid			2022-12-25	WOS:000182516100107
J	Chandra, S; Chen, XC; Rizo, J; Jahn, R; Sudhof, TC				Chandra, S; Chen, XC; Rizo, J; Jahn, R; Sudhof, TC			A broken alpha-helix in folded alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; MEMBRANE; BINDING; PROTEIN; FAMILY; BRAIN; LOCALIZATION; SENSITIVITY; VESICLES; STATES	alpha-Synuclein is a small cytosolic protein of presynaptic nerve terminals composed of seven 11-residue repeats and a hydrophilic tail. alpha-Synuclein misfolding and dysfunction may contribute to the pathogenesis of Parkinson's disease and neurodegenerative dementias, but its normal folding and function are unknown. In solution, alpha-synuclein is natively unstructured but assumes an alpha-helical conformation upon binding to phospholipid membranes. We now show that this conformation of alpha-synuclein consists of two alpha-helical regions that are interrupted by a short break. The structural organization of the alpha-helices of alpha-synuclein was not anticipated by sequence analyses and may be important for its pathogenic role.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem & Pharmacol, Dallas, TX 75390 USA; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society	Chandra, S (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Jahn, Reinhard/0000-0003-1542-3498	NINDS NIH HHS [1-R01-NS40057] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040057] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BUDAVARI S, 1996, MERCK INDEX ENCY CHE, P8782; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Ji HJ, 1997, CANCER RES, V57, P759; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	21	408	414	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15313	15318		10.1074/jbc.M213128200	http://dx.doi.org/10.1074/jbc.M213128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586824	hybrid			2022-12-25	WOS:000182516100095
J	Goel, A; Mathupala, SP; Pedersen, PL				Goel, A; Mathupala, SP; Pedersen, PL			Glucose metabolism in cancer - Evidence that demethylation events play a role in activating type II hexokinase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BOUND HEXOKINASE; DNA METHYLATION PATTERNS; TUMOR-CELLS; OVARIAN CANCERS; CPG-ISLANDS; CATABOLISM; PROMOTER; PROTEIN; HYPOMETHYLATION; BINDING	One of the "signature" phenotypes of highly malignant, poorly differentiated tumors, including hepatomas, is their remarkable propensity to utilize glucose at a much higher rate than normal cells, a property frequently dependent on the marked overexpression of type II hexokinase (HKII). As the expression of the gene for this enzyme is nearly silent in liver tissue, we tested the possibility that DNA methylation/demethylation events may be involved in its regulation. Initial studies employing methylation restriction endonuclease analysis provided evidence for differential methylation patterns for the HKII gene in normal hepatocytes and hepatoma cells, the latter represented by a highly glycolytic model cell line (AS-30D). Subsequently, sequencing following sodium bisulfite treatment revealed 18 methylated CpG sites within a CpG island (- 350 to + 781 bp) in the hepatocyte gene but none in that of the hepatoma. In addition, treatment of a hepatocyte cell line with the DNA methyltransferase inhibitors, 5'-azacytidine and 5'-aza-2'-deoxycytidine, activated basal expression levels of HKII mRNA and protein. Finally, stably transfecting the hepatocyte cell line with DNA demethylase also resulted in activating the basal expression levels of HKII mRNA and protein. These novel observations indicate that one of the initial events in activating the HKII gene during either transformation or tumor progression may reside at the epigenetic level.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NCI NIH HHS [T32 CA 67751, CA 80118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067751, R01CA080118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aisenberg AC, 1961, GLYCOLYSIS RESP TUMO; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; CAMPAIN JA, 1993, MOL ENDOCRINOL, V7, P1331, DOI 10.1210/me.7.10.1331; CHANG JP, 1967, CANCER RES, V27, P2065; Freshney RI., 1987, CULTURE ANIMAL CELLS; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; HANADA M, 1993, BLOOD, V82, P1820; Hattori M, 2001, J INT MED RES, V29, P204, DOI 10.1177/147323000102900308; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Leonhardt H, 2000, J CELL BIOCHEM, P78; Lichtenstein AV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P235, DOI 10.1023/A:1010249510906; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Nabi Hani A, 2002, J Nucl Med Technol, V30, P3; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; NAKASHIMA RA, 1988, CANCER RES, V48, P913; PAGGI MG, 1991, BIOCHEM BIOPH RES CO, V178, P648, DOI 10.1016/0006-291X(91)90157-3; PARRY DM, 1983, J BIOL CHEM, V258, P904; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Rempel A, 1996, CANCER RES, V56, P2468; Rempel A, 1996, FEBS LETT, V385, P233, DOI 10.1016/0014-5793(96)00399-7; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; ROSE IA, 1982, ARCH BIOCHEM BIOPHYS, V213, P625, DOI 10.1016/0003-9861(82)90592-6; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SHARRARD RM, 1992, BRIT J CANCER, V65, P667, DOI 10.1038/bjc.1992.142; SMITH DF, 1970, CANCER RES, V30, P2306; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; WARBURG O, 1930, METABOLISM TUMORS; WEINSTEIN IB, 1975, CANCER RES, V35, P253; ZRIHANLICHT S, 1995, INT J CANCER, V62, P245, DOI 10.1002/ijc.2910620303	41	111	121	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15333	15340		10.1074/jbc.M300608200	http://dx.doi.org/10.1074/jbc.M300608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12566445	hybrid			2022-12-25	WOS:000182516100098
J	Priest, JW; Hajduk, SL				Priest, JW; Hajduk, SL			Trypanosoma brucei cytochrome c(1) is imported into mitochondria along an unusual pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C HEME LYASE; ADP ATP CARRIER; INTERMEMBRANE SPACE; PROTEIN IMPORT; APOCYTOCHROME-C; INNER MEMBRANE; BLOOD-STREAM; CRITHIDIA-FASCICULATA; PRECURSOR PROTEINS; ADP/ATP CARRIER	In most eukaryotic organisms, cytochrome c(1) is encoded in the nucleus, translated on cytosolic ribosomes, and directed to its final destination in the mitochondrial inner membrane by a bipartite, cleaved, amino-terminal presequence. However, in the kinetoplastids and euglenoids, the cytochrome c(1) protein has been shown to lack a cleaved presequence; a single methionine is removed from the amino terminus upon maturation, and the sequence upstream of the heme-binding site is generally shorter than that of the other eukaryotic homologs. We have used a newly developed mitochondrial protein import assay system from Trypanosoma brucei to demonstrate that the T. brucei cytochrome c(1) protein is imported along a non-conservative pathway similar to that described for the inner membrane carrier proteins of other organisms. This pathway requires external ATP and an external protein receptor but is not absolutely dependent on a membrane potential or on ATP hydrolysis in the mitochondrial matrix. We propose the cytochrome c(1) import in T. brucei is a two-step process first involving a membrane potential independent translocation across the outer mitochondrial membrane followed by heme attachment and a membrane potential-dependent insertion into the inner membrane.	Univ Alabama, Sch Med, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Dept Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Dept Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Univ Alabama, Sch Med, Dept Biochem, Birmingham, AL 35294 USA.				NIAID NIH HHS [AI08259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allemann N, 2000, MOL BIOCHEM PARASIT, V111, P87, DOI 10.1016/S0166-6851(00)00303-0; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Bertrand KI, 2000, MOL BIOCHEM PARASIT, V106, P249, DOI 10.1016/S0166-6851(99)00218-2; CUNARRO J, 1975, BIOCHIM BIOPHYS ACTA, V387, P234, DOI 10.1016/0005-2728(75)90106-1; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HARTL FU, 1987, CYTOCHROME SYSTEMS M, P189; Hausler T, 1997, EUR J CELL BIOL, V73, P240; JENSEN RE, 1992, MOL CELL BIOL, V12, P4677, DOI 10.1128/MCB.12.10.4677; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MUKAI K, 1989, J BIOCHEM-TOKYO, V106, P479, DOI 10.1093/oxfordjournals.jbchem.a122877; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P29, DOI 10.1111/j.1432-1033.1977.tb11567.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PRIEST JW, 1992, J BIOL CHEM, V267, P20188; PRIEST JW, 1994, MOL BIOCHEM PARASIT, V65, P291, DOI 10.1016/0166-6851(94)90080-9; Priest JW, 1996, J BIOL CHEM, V271, P20060, DOI 10.1074/jbc.271.33.20060; PRIEST JW, 1995, BBA-MOL CELL RES, V1269, P201, DOI 10.1016/0167-4889(95)00154-6; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WILLIAMS N, 1990, MOL BIOCHEM PARASIT, V43, P125, DOI 10.1016/0166-6851(90)90137-B; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	55	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15084	15094		10.1074/jbc.M212956200	http://dx.doi.org/10.1074/jbc.M212956200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578826	hybrid			2022-12-25	WOS:000182516100066
J	Suzuki, M; Kobayashi, H; Tanaka, Y; Hirashima, Y; Kanayama, N; Takei, Y; Saga, Y; Suzuki, M; Itoh, H; Terao, T				Suzuki, M; Kobayashi, H; Tanaka, Y; Hirashima, Y; Kanayama, N; Takei, Y; Saga, Y; Suzuki, M; Itoh, H; Terao, T			Bikunin target genes in ovarian cancer cells identified by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; MEMBRANE SERINE-PROTEASE; HEPATOCYTE GROWTH-FACTOR; TRANSCRIPTION FACTOR; BINDING PROTEINS; CDNA CLONING; EXPRESSION; LOCALIZATION; FAMILY; MATRIPTASE	Bikunin, a Kunitz-type protease inhibitor, could potentially suppress tumor cell invasion and metastasis. Our previous study revealed that overexpression of bikunin in a human ovarian cancer cell line, HRA, resulted in a down-regulation in uPA and uPAR gene expression. For identifying the full repertoire of bikunin-regulated genes, a cDNA microarray hybridization screening was conducted using mRNA from bikunin-treated or bikunin-transfected HRA cells. A number of bikunin-regulated genes were identified, and their regulation was confirmed by Northern blot analysis. Our screen identified 11 bikunin-stimulated genes and 29 bikunin-repressed genes. The identified genes can indeed be classified into distinct subsets. These include transcriptional regulators, oncogenes/tumor suppressor genes, signaling molecules, growth/cell cycle, invasion/metastasis, cytokines, apoptosis, ion channels, extracellular matrix proteins, as well as some proteases. This screen identified suppression of several genes such as CDC-like kinase, LIM domain binding, Ets domain transcription factor, Rho GTPase-activating protein, tyrosine phosphorylation-regulated kinase, hyaluronan-binding protein, matriptase, and pregnancy-associated plasma protein-A (PAPP-A), which have previously been implicated in enhancing tumor promotion. Northern blot analysis confirmed that several genes including matriptase and PAPP-A were down-regulated by bikunin by similar to9-fold. Further, genetic inhibition of matriptase or PAPP-A could lead to diminished invasion. These results show that bikunin alters the pattern of gene expression in HRA cells leading to a block in cell invasion.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan; Jichi Med Sch, Dept Obstet & Gynecol, Tochigi 3290498, Japan; Miyazaki Univ, Sch Med, Dept Pathol 2, Miyazaki 8891692, Japan	Hamamatsu University School of Medicine; Jichi Medical University; University of Miyazaki	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Hamamatsu, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp	Takei, Yuji/ABD-2485-2020					Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Cho EG, 2001, J BIOL CHEM, V276, P44581, DOI 10.1074/jbc.M107059200; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DRIVAS GT, 1991, ONCOGENE, V6, P3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fowlkes JL, 1999, ANN NY ACAD SCI, V878, P696, DOI 10.1111/j.1749-6632.1999.tb07765.x; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; Futamura Y, 1999, OBSTET GYNECOL, V93, P100, DOI 10.1016/S0029-7844(98)00396-2; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; KANAYAMA N, 1995, AM J OBSTET GYNECOL, V173, P192, DOI 10.1016/0002-9378(95)90189-2; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; KOBAYASHI H, 2002, J BIOL CHEM; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lee SMY, 1998, SOMAT CELL MOLEC GEN, V24, P197, DOI 10.1023/B:SCAM.0000007122.03392.4b; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; Nakamura H, 1997, INT ARCH ALLERGY IMM, V112, P157, DOI 10.1159/000237448; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Okumura K, 1997, NUCLEIC ACIDS RES, V25, P5025, DOI 10.1093/nar/25.24.5025; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Retaux S, 1999, J NEUROSCI, V19, P783; Soukas A, 2000, GENE DEV, V14, P963; SPENER F, 1990, MOL CELL BIOCHEM, V98, P57; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2001, BBA-PROTEIN STRUCT M, V1547, P26, DOI 10.1016/S0167-4838(01)00167-4; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Urabe M, 1997, GENE, V200, P157, DOI 10.1016/S0378-1119(97)00412-5; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wiksten JP, 2000, ANTICANCER RES, V20, P4905	46	42	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14640	14646		10.1074/jbc.M300239200	http://dx.doi.org/10.1074/jbc.M300239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12571229	hybrid			2022-12-25	WOS:000182516100010
J	Burhenne, K; Kristensen, BK; Rasmussen, SK				Burhenne, K; Kristensen, BK; Rasmussen, SK			A new class of N-hydroxycinnamoyltransferases - Purification, cloning, and expression of a barley agmatine coumaroyltransferase (Ec 2.3.1.64)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-TYRAMINE N-(HYDROXYCINNAMOYL)TRANSFERASE; CELL-SUSPENSION CULTURES; SOLANUM-TUBEROSUM; ACID-AMIDES; ACCUMULATION; TOBACCO; RESISTANCE; COENZYME; PROTEINS; LOCALIZATION	Agmatine coumaroyltransferase (ACT), which catalyzes the first step in the biosynthesis of antifungal hydroxycinnamoylagmatine derivatives, was purified to apparent homogeneity from 3-day-old etiolated barley (Hordeum vulgare L.) seedlings. The enzyme was highly specific for agmatine as acyl acceptor and had the highest specificity for p-coumaroyl-CoA among various acyl donors with a specific activity of 29.7 nanokatal x mg(-1) protein. Barley ACT was found to be a single polypeptide chain of 48 kDa with a pI of 5.20 as determined by isoelectric focusing. The 15 N-terminal amino acid residues were identified by micro-sequencing of the native protein and were used to clone a full-length barley ACT cDNA that predicted a protein of 439 amino acid residues. The sequence was devoid of N-terminal signal peptide, suggesting a cytosolic localization of barley ACT. Recombinant ACT produced and affinity-purified from Escherichia coli had a specific activity of 189 nanokatal X mg(-1) protein, thus confirming the identity of the purified native protein. A partial cDNA sequence for ACT was obtained from wheat that predicted a protein of 353 amino acid residues and had 95% sequence identity to barley ACT. Two motifs in the amino acid sequence reveal that barley ACT represents a new class of N-hydroxycinnamoyltransferases belonging to the transferase superfamily. The barley ACT is unique in producing the precursor of hordatine, a proven antifungal factor that may be directed toward Blumeria graminis.	Riso Natl Lab, Plant Res Dept, DK-4000 Roskilde, Denmark	Technical University of Denmark	Rasmussen, SK (corresponding author), Riso Natl Lab, Plant Res Dept, PRD-301, DK-4000 Roskilde, Denmark.		Rasmussen, Soren K./F-6728-2014	Rasmussen, Soren K./0000-0001-6169-2504				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Back K, 2001, PLANT CELL PHYSIOL, V42, P475, DOI 10.1093/pcp/pce060; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bernards MA, 2002, CAN J BOT, V80, P227, DOI [10.1139/B02-017, 10.1139/b02-017]; Bernards MA, 1998, PHYTOCHEMISTRY, V47, P915, DOI 10.1016/S0031-9422(98)80052-6; BIRD CR, 1983, PHYTOCHEMISTRY, V22, P2401, DOI 10.1016/0031-9422(83)80127-7; BIRD CR, 1984, ANN BOT-LONDON, V53, P483, DOI 10.1093/oxfordjournals.aob.a086712; BIRD CR, 1981, PHYTOCHEMISTRY, V20, P2345, DOI 10.1016/S0031-9422(00)82662-X; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Farmer MJ, 1999, EUR J BIOCHEM, V263, P686, DOI 10.1046/j.1432-1327.1999.00538.x; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; GRANDMAISON J, 1993, MYCORRHIZA, V3, P155, DOI 10.1007/BF00203609; Hoffmann L, 2003, J BIOL CHEM, V278, P95, DOI 10.1074/jbc.M209362200; Hohlfeld H, 1996, PLANTA, V199, P166, DOI 10.1007/BF00196893; HOHLFELD H, 1995, PLANT PHYSIOL, V107, P545, DOI 10.1104/pp.107.2.545; Jin S, 2000, BIOSCI BIOTECH BIOCH, V64, P1614, DOI 10.1271/bbb.64.1614; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; Lee J, 1997, PHYTOCHEMISTRY, V44, P589, DOI 10.1016/S0031-9422(96)00562-6; McLusky SR, 1999, PLANT J, V17, P523, DOI 10.1046/j.1365-313X.1999.00403.x; Meng HB, 1997, PHYTOCHEMISTRY, V44, P605, DOI 10.1016/S0031-9422(96)00594-8; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Negrel J, 1996, PHYTOCHEMISTRY, V43, P1195, DOI 10.1016/S0031-9422(96)00500-6; Negrel J, 1997, EUR J BIOCHEM, V247, P1127, DOI 10.1111/j.1432-1033.1997.01127.x; NEGREL J, 1992, PLANT PHYSIOL, V98, P1264, DOI 10.1104/pp.98.4.1264; NIEMANN GJ, 1993, PHYTOCHEMISTRY, V34, P319, DOI 10.1016/0031-9422(93)80003-B; Ogura Y, 2001, Z NATURFORSCH C, V56, P193; Pearce G, 1998, PHYTOCHEMISTRY, V47, P659, DOI 10.1016/S0031-9422(97)00620-1; Peipp H, 1997, PHYTOCHEMISTRY, V44, P581, DOI 10.1016/S0031-9422(96)00561-4; Schmidt A, 1999, J BIOL CHEM, V274, P4273, DOI 10.1074/jbc.274.7.4273; SMITH TA, 1978, PHYTOCHEMISTRY, V17, P1093, DOI 10.1016/S0031-9422(00)94295-X; SMITH TA, 1983, ADV POLYAMINE RES, V4, P347; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STOESSL A, 1967, CAN J CHEMISTRY, V45, P1745, DOI 10.1139/v67-283; STOESSL A, 1970, CAN J BOTANY, V48, P465, DOI 10.1139/b70-066; STOESSL A, 1966, TETRAHEDRON LETT, V7, P2849; STOESSL A, 1970, RECENT ADV PHYTOCHEM, V3, P143; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; WEI YD, 1994, PHYSIOL MOL PLANT P, V45, P469, DOI 10.1016/S0885-5765(05)80043-8; Yu M, 1999, PLANTA, V209, P33, DOI 10.1007/s004250050604	41	92	95	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13919	13927		10.1074/jbc.M213041200	http://dx.doi.org/10.1074/jbc.M213041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582168	hybrid			2022-12-25	WOS:000182405000047
J	Hermant, B; Bibert, S; Concord, E; Dublet, B; Weidenhaupt, M; Vernet, T; Gulino-Debrac, D				Hermant, B; Bibert, S; Concord, E; Dublet, B; Weidenhaupt, M; Vernet, T; Gulino-Debrac, D			Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ADHESION MOLECULE-1; RECRUITMENT IN-VIVO; VE-CADHERIN; TRANSENDOTHELIAL MIGRATION; LEUKOCYTE TRANSMIGRATION; CATALYTIC ACTIVITY; POLYMORPHONUCLEAR LEUKOCYTES; CATHEPSIN-G; ELASTASE; SURFACE	Transmigration of neutrophils across the endothelium occurs at the cell-cell junctions where the vascular endothelium cadherin WE cadherin) is expressed. This adhesive receptor was previously demonstrated to be involved in the maintenance of endothelium integrity. We propose that neutrophil transmigration across the vascular endothelium goes in parallel with cleavage of VE cadherin by elastase and cathepsin G present on the surface of neutrophils. This hypothesis is supported by the following lines of evidence. 1) Proteolytic fragments of VE cadherin are released into the culture medium upon adhesion of neutrophils to endothelial cell monolayers; 2) conditioned culture medium, obtained after neutrophil adhesion to endothelial monolayers, cleaves the recombinantly expressed VE cadherin extracellular domain; 3) these cleavages are inhibited by inhibitors of elastase; 4) VE cadherin fragments produced by conditioned culture medium or by exogenously added elastase are identical as shown by N-terminal sequencing and mass spectrometry analysis; 5) both elastase- and cathepsin G-specific VE cadherin cleavage patterns are produced upon incubation with tumor necrosis factor a-stimulated and fixed neutrophils; 6) transendothelial permeability increases in vitro upon addition of either elastase or cathepsin G; and 7) neutrophil transmigration is reduced in vitro in the presence of elastase and cathepsin G inhibitors. Our results suggest that cleavage of VE cadherin by neutrophil surface-bound proteases induces formation of gaps through which neutrophils transmigrate.	Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct Jean Pierre Ebel,Lab Ingn Macrom, F-38027 Grenoble, France; Univ Grenoble 1, CNRS, Inst Biol Struct Jean Pierre Ebel, Commissariat Energie Atom,Lab Spectrometrie Masse, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Gulino-Debrac, D (corresponding author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct Jean Pierre Ebel,Lab Ingn Macrom, 41 Rue Jules Horowitz, F-38027 Grenoble, France.		Vernet, Thierry/G-1118-2012	Bibert, Stephanie/0000-0001-5170-7506				Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Bibert S, 2002, J BIOL CHEM, V277, P12790, DOI 10.1074/jbc.M111597200; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; Carden D, 1998, AM J PHYSIOL-HEART C, V275, pH385, DOI 10.1152/ajpheart.1998.275.2.H385; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cepinskas G, 1999, J CELL SCI, V112, P1937; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Ferber A, 2002, EXP CELL RES, V274, P35, DOI 10.1006/excr.2001.5436; Gotsch U, 1997, J CELL SCI, V110, P583; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hordijk PL, 1999, J CELL SCI, V112, P1915; Johnson-Leger C, 2000, J CELL SCI, V113, P921; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Legrand P, 2001, J BIOL CHEM, V276, P3581, DOI 10.1074/jbc.M002667200; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; OWEN CA, 1997, AM J PHYSIOL, V272, P385; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rival Y, 1996, J IMMUNOL, V157, P1233; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Stockley RA, 2001, NOVART FDN SYMP, V234, P189; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Ukropec JA, 2002, EXP CELL RES, V273, P240, DOI 10.1006/excr.2001.5453; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; WEISS J, 1985, J CLIN INVEST, V76, P206, DOI 10.1172/JCI111947; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2	44	124	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14002	14012		10.1074/jbc.M300351200	http://dx.doi.org/10.1074/jbc.M300351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584200	hybrid			2022-12-25	WOS:000182405000058
J	Pedersen, LC; Dong, J; Taniguchi, F; Kitagawa, H; Krahn, JM; Pedersen, LG; Sugahara, K; Negishi, M				Pedersen, LC; Dong, J; Taniguchi, F; Kitagawa, H; Krahn, JM; Pedersen, LG; Sugahara, K; Negishi, M			Crystal structure of an alpha 1,4-N-acetylhexosaminyltransferase (EXTL2), a member of the exostosin gene family involved in heparan sulfate biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSORS; DONOR; ALPHA-1,3-GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; ALIGNMENT; SEQUENCE; COMPLEX	EXTL2, an alpha1,4-N-acetylhexosaminyltransferase, catalyzes the transfer reaction of N-acetylglucosamine and N-acetylgalactosamine from the respective UDP-sugars to the non-reducing end of [glucuronic acid]beta1-3[galactose]/beta1-O-naphthalenemethanol, an acceptor substrate analog of the natural common linker of various glycosylaminoglycans. We have solved the x-ray crystal structure of the catalytic domain of mouse EXTL2 in the apo-form and with donor substrates UDP-N-acetylglucosamine and UDP-N-acetylgalactosamine. In addition, a structure of the ternary complex with UDP and the acceptor substrate analog [glucuronic acid]beta1-3[galactose]beta1-O-naphthalenemethanol has been determined. These structures reveal three highly conserve residues, Asn-243, Asp-246, and Arg-293, located at the active site. Mutation of these residues greatly decreases the activity. In the ternary complex, an interaction exists between the P-phosphate of the UDP leaving group and the acceptor hydroxyl of the substrate that may play a functional role in catalysis. These structures represent the first structures from the exostosin gene family and provide important insight into the mechanisms of alpha1,4N-acetylhexosaminyl transfer in heparan biosynthesis.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6858858, Japan; NIH, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA; NIH, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	Kobe Pharmaceutical University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6858858, Japan.		Pedersen, Lee G/E-3405-2013; Kitagawa, Hiroshi/AAJ-1344-2020; Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Pedersen, Lee G/0000-0003-1262-9861; Kitagawa, Hiroshi/0000-0002-9307-7079; Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, ZIAES080040, Z01ES080040] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boix E, 2002, J BIOL CHEM, V277, P28310, DOI 10.1074/jbc.M202631200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Toth G, 2001, PROTEIN ENG, V14, P543, DOI 10.1093/protein/14.8.543; Wuyts W, 2000, HUM MUTAT, V15, P220, DOI 10.1002/(SICI)1098-1004(200003)15:3<220::AID-HUMU2>3.0.CO;2-K	27	86	89	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14420	14428		10.1074/jbc.M210532200	http://dx.doi.org/10.1074/jbc.M210532200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562774	hybrid			2022-12-25	WOS:000182405000109
J	Pendleton, A; Pope, B; Weeds, A; Koffer, A				Pendleton, A; Pope, B; Weeds, A; Koffer, A			Latrunculin B or ATP depletion induces cofilin-dependent translocation of actin into nuclei of mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL F-ACTIN; DEPOLYMERIZING FACTOR; CYTOPLASMIC ACTIN; FILAMENT TURNOVER; BINDING PROTEIN; LOCALIZATION; SECRETION; DYNAMICS; REQUIREMENTS; CYTOSKELETON	Increasing cellular G-actin, using latrunculin B, in either intact or permeabilized rat peritoneal mast cells, caused translocation of both actin and an actin regulatory protein, cofilin, into the nuclei. The effect was not associated with an increase in the proportion of apoptotic cells. The major part of the nuclear actin was not stained by rhodamine-phalloidin but could be visualized with an actin antibody, indicating its monomeric or a conformationally distinct state, e.g. cofilin-decorated filaments. Introduction of anti-cofilin into permeabilized cells inhibited nuclear actin accumulation, implying that an active, cofilin-dependent, import exists in this system. Nuclear actin was localized outside the ethidium bromide-stained region, in the extrachromosomal nuclear domain. In permeabilized cells, the appearance of nuclear actin and cofilin was not significantly affected by increasing [Ca2+] and/or adding guanosine 5'-O-(3-thiotriphosphate), but was greatly promoted when ATP was withdrawn. Similarly, ATP depletion in intact cells also induced nuclear actin accumulation. In contrast to the effects of latrunculin B, ATP depletion was associated with an increase in cortical F-actin. Our results suggest that the presence of actin in the nucleus may be required for certain stress-induced responses and that cofilin is essential for the nuclear import of actin.	UCL, Dept Physiol, London WC1E 6JJ, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of London; University College London; MRC Laboratory Molecular Biology	Koffer, A (corresponding author), UCL, Dept Physiol, Univ St, London WC1E 6JJ, England.	a.koffer@ucl.ac.uk						ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Baluska F, 2001, DEV BIOL, V231, P113, DOI 10.1006/dbio.2000.0115; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; Belmont LD, 1999, J CELL SCI, V112, P1325; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; BLIKSTAD I, 1978, CELL, V15, P935, DOI 10.1016/0092-8674(78)90277-5; CAO LG, 1993, J CELL BIOL, V123, P173, DOI 10.1083/jcb.123.1.173; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; Gachet Y, 2001, NATURE, V412, P352, DOI 10.1038/35085604; Gonsior SM, 1999, J CELL SCI, V112, P797; Holt MR, 2000, METHOD ENZYMOL, V325, P356; HOWELL TW, 1987, BIOCHIM BIOPHYS ACTA, V927, P177, DOI 10.1016/0167-4889(87)90132-7; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; Jahraus A, 2001, MOL BIOL CELL, V12, P155, DOI 10.1091/mbc.12.1.155; Kellerman PS, 1996, AM J KIDNEY DIS, V27, P709, DOI 10.1016/S0272-6386(96)90107-9; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P222, DOI 10.1016/0167-4889(93)90048-T; Koffer A, 2002, CELL BIOL INT, V26, P885, DOI 10.1006/cbir.2002.0940; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Meijerman I, 1999, TOXICOL APPL PHARM, V156, P46, DOI 10.1006/taap.1998.8616; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; Minamide LS, 1997, J BIOL CHEM, V272, P8303, DOI 10.1074/jbc.272.13.8303; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Nosworthy NJ, 2001, PROTEOMICS, V1, P1513, DOI 10.1002/1615-9861(200111)1:12<1513::AID-PROT1513>3.0.CO;2-K; Pendleton A, 2001, CELL MOTIL CYTOSKEL, V48, P37; Pope BJ, 2000, J MOL BIOL, V298, P649, DOI 10.1006/jmbi.2000.3688; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.0032i.x; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stanyon CA, 1999, INT J BIOCHEM CELL B, V31, P389, DOI 10.1016/S1357-2725(98)00116-2; Sullivan R, 1999, J BIOL CHEM, V274, P38140, DOI 10.1074/jbc.274.53.38140; Sullivan R, 2000, CELL CALCIUM, V28, P33, DOI 10.1054/ceca.2000.0127; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; White P, 2000, AM J PHYSIOL-RENAL, V278, pF886, DOI 10.1152/ajprenal.2000.278.6.F886; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; Yeoh S, 2002, J MOL BIOL, V315, P911, DOI 10.1006/jmbi.2001.5280	50	125	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14394	14400		10.1074/jbc.M206393200	http://dx.doi.org/10.1074/jbc.M206393200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566455	hybrid			2022-12-25	WOS:000182405000105
J	Zhang, J; Liu, Z; Masumiya, H; Wang, RW; Jiang, DW; Li, F; Wagenknecht, T; Chen, SRW				Zhang, J; Liu, Z; Masumiya, H; Wang, RW; Jiang, DW; Li, F; Wagenknecht, T; Chen, SRW			Three-dimensional localization of divergent region 3 of the ryanodine receptor to the clamp-shaped structures adjacent to the FKBP binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNELS; SKELETAL-MUSCLE; CRYOELECTRON MICROSCOPY; FK506-BINDING PROTEIN; RECONSTRUCTION; IDENTIFICATION; INACTIVATION; RESOLUTION; ISOFORMS; RIBOSOME	Of the three divergent regions of ryanodine receptors (RyRs), divergent region 3 (DR3) is the best studied and is believed to be involved in excitation-contraction coupling as well as in channel regulation by Ca2+ and Mg2+. To gain insight into the structural basis of DR3 function, we have determined the location of DR3 in the three-dimensional structure of RyR2. We inserted green fluorescent protein (GFP) into the middle of the DR3 region after Thr-1874 in the sequence. HEK293 cells expressing this GFP-RyR2 fusion protein, RyR2(T1874-GFP), were readily detected by their green fluorescence, indicating proper folding of the inserted GFP. RyR2(T1874-GFP) was further characterized functionally by assays of Ca2+ release and [H-3]ryanodine binding. These analyses revealed that RyR2(T1874-GFP) functions as a caffeine- and ryanodine-sensitive Ca2+ release channel and displays Ca2+ dependence and [H-3]ryanodine binding properties similar to those of the wild type RyR2. RyR2T1874-GFP was purified from cell lysates in a single step by affinity chromatography using GST-FKBP12.6 as the affinity ligand. The three-dimensional structure of the purified RYR2(T1874-GFP) was then reconstructed using cryoelectron microscopy and single particle image analysis. Comparison of the three-dimensional reconstructions of wild type RyR2 and RyR2T(1874-GFP) revealed the location of the inserted GFP, and hence the DR3 region, in one of the characteristic domains of RyR, domain 9, in the clamp-shaped structure adjacent to the FKBP12 and FKBP12.6 binding sites. COOH-terminal truncation analysis demonstrated that a region between 1815 and 1855 near DR3 is essential for GST-FKBP12.6 binding. These results provide a structural basis for the role of the DR3 region in excitation-contraction coupling and in channel regulation.	Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	University of Calgary; University of Calgary; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Chen, SRW (corresponding author), Univ Calgary, Cardiovasc Res Grp, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada.	swchen@ucalgary.ca		Liu, Zheng/0000-0001-6952-3406	NIAMS NIH HHS [AR40615] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bhat MB, 1997, BIOPHYS J, V73, P1320, DOI 10.1016/S0006-3495(97)78165-7; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Doi Nobuhide, 2002, Methods Mol Biol, V183, P49; Du GC, 2000, J BIOL CHEM, V275, P11778, DOI 10.1074/jbc.275.16.11778; Du GG, 1999, J BIOL CHEM, V274, P26120, DOI 10.1074/jbc.274.37.26120; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Frank J., 1996, 3 DIMENSIONAL ELECT, P54; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Hayek SM, 2000, BIOCHEM J, V351, P57, DOI 10.1042/0264-6021:3510057; Hayek SM, 1999, FEBS LETT, V461, P157, DOI 10.1016/S0014-5793(99)01464-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; Lamb GD, 2000, CLIN EXP PHARMACOL P, V27, P216, DOI 10.1046/j.1440-1681.2000.03224.x; Lamb GD, 2002, FRONT BIOSCI-LANDMRK, V7, pD834, DOI 10.2741/lamb; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Liu Z, 2002, J BIOL CHEM, V277, P46712, DOI 10.1074/jbc.M208124200; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Lohn M, 2001, CIRC RES, V89, P1051, DOI 10.1161/hh2301.100250; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nakai J, 1999, FEBS LETT, V459, P154, DOI 10.1016/S0014-5793(99)01232-6; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Ogawa Y, 1999, ADV BIOPHYS, V36, P27, DOI 10.1016/S0065-227X(99)80004-5; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; Proenza C, 2002, J BIOL CHEM, V277, P6530, DOI 10.1074/jbc.M106471200; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sambrook J, 1989, J SAMBROOK MOL CLONI; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Serysheva II, 2002, P NATL ACAD SCI USA, V99, P10370, DOI 10.1073/pnas.162363499; Sharma MR, 2000, J BIOL CHEM, V275, P9485, DOI 10.1074/jbc.275.13.9485; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wagenknecht T, 2002, FRONT BIOSCI, V7, pD1464, DOI 10.2741/wagen; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Yang DM, 2001, J BIOL CHEM, V276, P40210, DOI 10.1074/jbc.M106944200; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	54	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14211	14218		10.1074/jbc.M213164200	http://dx.doi.org/10.1074/jbc.M213164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576471	hybrid			2022-12-25	WOS:000182405000083
J	Martin, NI; Hu, HJ; Moake, MM; Churey, JJ; Whittal, R; Worobo, RW; Vederas, JC				Martin, NI; Hu, HJ; Moake, MM; Churey, JJ; Whittal, R; Worobo, RW; Vederas, JC			Isolation, structural characterization, and properties of mattacin (Polymyxin M), a cyclic peptide antibiotic produced by Paenibacillus kobensis M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; LISTERIA-MONOCYTOGENES; H-1-NMR ANALYSIS; BIOSYNTHESIS; IDENTIFICATION; PROTEIN; CLONING; GENES; LANTIBIOTICS; CONFORMATION	antibiotic produced by Paenibacillus kobensis M. The producing strain was isolated from a soil/manure sample and identified using 16 S rRNA sequence homology along with chemical and morphological characterization. An efficient production and isolation procedure was developed to afford pure mattacin. Structure elucidation using a combination of chemical degradation, multidimensional NMR studies (COSY, HMBC, HMQC, ROESY), and mass spectrometric (MALDI MS/MS) analyses showed that mattacin is identical to polymyxin M, an uncommon antibiotic reported previously in certain Bacillus species by Russian investigators. Mattacin (polymyxin M) is cyclic and possesses an amide linkage between the C-terminal threonine and the side chain amino group of the diaminobutyric acid residue at position 4. It contains an (S)-6-methyloctanoic acid moiety attached as an amide at the N-terminal amino group, one D-leucine, Six L-alpha,gamma-diaminobutyric acid, and three L-threonine residues. Transfer NOE experiments on the conformational preferences of mattacin when bound to lipid A and microcalorimetry studies on binding to lipopolysaccharide showed that its behavior was very similar to that observed in previous studies of polymyxin B (a commercial antibiotic), suggesting an identical mechanism of action. It was capable of inhibiting the growth of a wide variety of Gram-positive and Gram-negative bacteria, including several human and plant pathogens with activity comparable with purified polymyxin B. The biosynthesis of mattacin was also examined briefly using transpositional mutagenesis by which 10 production mutants were obtained, revealing a set of genes involved in production.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Cornell Univ, New York State Agr Expt Stn, Dept Food Sci & Technol, Geneva, NY 14456 USA	University of Alberta; Cornell University	Vederas, JC (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.	john.vederas@ualberta.ca	Worobo, Randy/D-8779-2014	Worobo, Randy/0000-0002-5211-3125; Vederas, John/0000-0002-2996-0326; Whittal, Randy/0000-0003-1174-8172				AHN C, 1990, J APPL BACTERIOL, V69, P302, DOI 10.1111/j.1365-2672.1990.tb01520.x; AINSWORTH GC, 1947, NATURE, V160, P263, DOI 10.1038/160263a0; Baldwin MA, 2001, ANAL CHEM, V73, P1707, DOI 10.1021/ac0011080; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CAMILLI A, 1990, J BACTERIOL, V172, P3738, DOI 10.1128/jb.172.7.3738-3744.1990; CHEN CL, 1995, MOL GEN GENET, V248, P121, DOI 10.1007/BF02190792; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Doekel S, 2001, METAB ENG, V3, P64, DOI 10.1006/mben.2000.0170; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Du LC, 1999, CHEM BIOL, V6, P507, DOI 10.1016/S1074-5521(99)80083-0; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Garneau S, 2002, BIOCHIMIE, V84, P577, DOI 10.1016/S0300-9084(02)01414-1; GRONENBORN AM, 1982, J MOL BIOL, V157, P155, DOI 10.1016/0022-2836(82)90518-6; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KLAENHAMMER TR, 1988, BIOCHIMIE, V70, P337, DOI 10.1016/0300-9084(88)90206-4; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KLEINKAUF H, 1988, CRIT REV BIOTECHNOL, V8, P1, DOI 10.3109/07388558809150536; Koch PJ, 1999, J COLLOID INTERF SCI, V213, P557, DOI 10.1006/jcis.1999.6137; KOMURA S, 1985, J BIOCHEM-TOKYO, V97, P1409, DOI 10.1093/oxfordjournals.jbchem.a135195; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; NissenMeyer J, 1997, ARCH MICROBIOL, V167, P67, DOI 10.1007/s002030050418; OKHANOV VV, 1991, BIOORG KHIM+, V17, P1689; OKHANOV VV, 1987, ANTIBIOT MED BIOTEK, V32, P738; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Reva ON, 2001, INT J SYST EVOL MICR, V51, P1361, DOI 10.1099/00207713-51-4-1361; RIETSCHEL ET, 1990, INT CONGR SER, V923, P15; Riley MA, 2002, ANNU REV MICROBIOL, V56, P117, DOI 10.1146/annurev.micro.56.012302.161024; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shida O, 1997, INT J SYST BACTERIOL, V47, P289, DOI 10.1099/00207713-47-2-289; SILAEV AB, 1975, ZH OBSHCH KHIM+, V45, P2331; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; TRAKHANOVA MN, 1989, ANTIBIOT KHIMIOTERAP, V34, P20; Tsubery H, 2000, J MED CHEM, V43, P3085, DOI 10.1021/jm0000057; Tsuge K, 2001, J BACTERIOL, V183, P6265, DOI 10.1128/JB.183.21.6265-6273.2001; Twomey D, 2002, ANTON LEEUW INT J G, V82, P165, DOI 10.1023/A:1020660321724; van Belkum MJ, 2000, NAT PROD REP, V17, P323, DOI 10.1039/a801347k; vanBelkum MJ, 1997, MOL MICROBIOL, V23, P1293, DOI 10.1046/j.1365-2958.1997.3111677.x; Wang YJ, 1999, BIOCHEMISTRY-US, V38, P15438, DOI 10.1021/bi991351x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zheng GL, 1999, J BACTERIOL, V181, P7346, DOI 10.1128/JB.181.23.7346-7355.1999	45	83	95	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13124	13132		10.1074/jbc.M212364200	http://dx.doi.org/10.1074/jbc.M212364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569104	hybrid			2022-12-25	WOS:000182189500069
J	Worthylake, RA; Burridge, K				Worthylake, RA; Burridge, K			RhoA and ROCK promote migration by limiting membrane protrusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; TRANSENDOTHELIAL MIGRATION; TYROSINE PHOSPHORYLATION; ACTIN CYTOSKELETON; INTEGRIN LFA-1; FAMILY GTPASES; SMOOTH-MUSCLE; ALPHA-ACTININ; MYOSIN-II; KINASE	Previously, we and others have shown that RhoA and ROCK signaling are required for negatively regulating integrin-mediated adhesion and for tail retraction of migrating leukocytes. This study continues our investigation into the molecular mechanisms underlying RhoA/ROCK-regulated integrin adhesion. We show that inhibition of ROCK up-regulates integrin-mediated adhesion, which is accompanied by both increased phosphotyrosine signaling through Pyk-2 and paxillin and inappropriate membrane protrusions. We provide evidence that inhibition of ROCK induces integrin adhesion by promoting remodeling of the actin cytoskeleton. Furthermore, we find that ROCK regulates membrane activity through a pathway involving cofilin. Inhibition of RhoA signaling allows the formation of multiple competing lamellipodia that disrupt productive migration of monocytes. Together, our results show that RhoA/ROCK signaling promotes migration by restricting integrin activity and membrane protrusions to the leading edge.	Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Worthylake, RA (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.				NIDCR NIH HHS [DE13079] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Allen WE, 1997, J CELL SCI, V110, P707; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brown EJ, 1997, TRENDS CELL BIOL, V7, P289, DOI 10.1016/S0962-8924(97)01076-3; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Dharmawardhane S, 1997, Curr Opin Hematol, V4, P12; Dunty JM, 2002, J BIOL CHEM, V277, P45644, DOI 10.1074/jbc.M201779200; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Eddy RJ, 2000, J CELL SCI, V113, P1287; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Johnson-Leger C, 2000, J CELL SCI, V113, P921; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Palecek SP, 1998, J CELL SCI, V111, P929; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rodriguez-Fernandez JL, 2001, J BIOL CHEM, V276, P40518, DOI 10.1074/jbc.M102896200; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; VAN AL, 1997, GENE DEV, V11, P2295; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; Watson JM, 2001, J BIOL CHEM, V276, P3536, DOI 10.1074/jbc.M006916200; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	57	234	250	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13578	13584		10.1074/jbc.M211584200	http://dx.doi.org/10.1074/jbc.M211584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12574166	Green Published, hybrid			2022-12-25	WOS:000182189500123
J	Masuda, Y; Nishida, A; Hori, K; Hirabayashi, T; Kajimoto, S; Nakajo, S; Kondo, T; Asaka, M; Nakaya, K				Masuda, Y; Nishida, A; Hori, K; Hirabayashi, T; Kajimoto, S; Nakajo, S; Kondo, T; Asaka, M; Nakaya, K			beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1)	ONCOGENE			English	Article						beta-hydroxyisovalerylshikonin; apoptosis; DNA fragmentation; PLK1	CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; PROTEIN-KINASE; POTENT INDUCER; ANTICANCER DRUGS; DNA-DAMAGE; ACTIVATION; GENE; EXPRESSION; INDUCTION	beta-Hydroxyisovalerylshikonin (beta-HIVS), which was isolated from the plant, Lithospermum radix, induces apoptosis in various lines of human tumor cells. To identify genes involved in beta-HIVS-induced apoptotic process, we performed cDNA array analysis and found that beta-HIVS suppresses the expression of the gene for a polo-like kinase 1 (PLK1) that is involved in control of the cell cycle. When U937 and HL60 cells were treated with 10(-6) m beta-HIVS for 0.5 h, both the amount of PLK1 itself and the kinase activity of this enzyme were decreased. By contrast, Bcr-Abl-positive K562 cells were resistant to the induction of apoptosis by beta-HIVS and this compound did not suppress the kinase activity of PLK1 in these cells. However, simultaneous treatment of K562 cells with both beta-HIVS and STI571, which selectively inhibits the protein tyrosine kinase (PTK) activity of Bcr-Abl, strongly induced apoptosis. Moreover, beta-HIVS increased the inhibitory effect of STI571 on PTK activity. Treatment of K562 cells with antisense oligodeoxynucleotides (ODNs) specific for PLK1 sensitized these cells to the beta-HIVS-induced fragmentation of DNA. These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by beta-HIVS might play a critical role in the induction of apoptosis.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 1428555, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido 0600815, Japan	Showa University; Hokkaido University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	nakaya@pharm.showa-u.ac.jp	Asaka, Masahiro/A-5948-2012; 堀, 孝一/AAU-8506-2021; Kondo, Takeshi/G-2103-2012; 堀, 孝一/K-5102-2019	堀, 孝一/0000-0002-0530-181X; Kondo, Takeshi/0000-0001-7455-5824; 堀, 孝一/0000-0002-0530-181X				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BHALLA K, 1993, LEUKEMIA, V7, P563; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHALIFOUR LE, 1994, ANAL BIOCHEM, V216, P299, DOI 10.1006/abio.1994.1045; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Conn CW, 2000, CANCER RES, V60, P6826; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p697A; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; EVANS DL, 1993, CANCER RES, V53, P2133; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Hamdane M, 1997, ONCOGENE, V15, P2267, DOI 10.1038/sj.onc.1201411; Hashimoto S, 1999, J BIOCHEM-TOKYO, V125, P17, DOI 10.1093/oxfordjournals.jbchem.a022255; Hashimoto S, 2002, JPN J CANCER RES, V93, P944, DOI 10.1111/j.1349-7006.2002.tb01341.x; HURLE JM, 1981, EXP CELL RES, V133, P465, DOI 10.1016/0014-4827(81)90343-8; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; MASUDA Y, 1995, LEUKEMIA RES, V19, P549, DOI 10.1016/0145-2126(95)00031-I; Masuda Y, 1997, INT J CANCER, V71, P691, DOI 10.1002/(SICI)1097-0215(19970516)71:4<691::AID-IJC29>3.0.CO;2-D; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; Perkins C, 1998, CANCER RES, V58, P4561; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SAKAI I, 1993, BIOCHEM BIOPH RES CO, V191, P873, DOI 10.1006/bbrc.1993.1298; SAKAI I, 1994, BIOCHEM BIOPH RES CO, V205, P1305, DOI 10.1006/bbrc.1994.2807; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; SUNKEL CE, 1988, J CELL SCI, V89, P25; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1997, CANCER RES, V57, P3097; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	50	74	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					1012	1023		10.1038/sj.onc.1206200	http://dx.doi.org/10.1038/sj.onc.1206200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592388				2022-12-25	WOS:000180926100007
J	Petrich, BG; Molkentin, JD; Wang, YB				Petrich, BG; Molkentin, JD; Wang, YB			Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination	FASEB JOURNAL			English	Article						heart failure; tamoxifen; JNK activation	PROTEIN-KINASES; CARDIAC-HYPERTROPHY; IN-VIVO; EXPRESSION; CARDIOMYOPATHY; STRESSES; DISEASES	Using a cre-loxP-mediated gene-switch approach, we achieved targeted JNK activation in adult hearts. A transgenic model is established carrying a floxed gene-switch construct that directs GFP marker gene expression in the absence of DNA recombination between two loxP sites. A tamoxifen-inducible Cre recombinase was introduced in the transgenic heart by breeding with previously established Mer-Cre-Mer transgenic mice. Upon tamoxifen administration in double transgenic adult animals, cre-loxP-mediated DNA recombination efficiently switches "off" the loxP-flanked GFP expression unit in cardiomyocytes and switches "on" the expression of the target gene, MKK7D, a constitutively activated upstream activator of c-Jun N-terminal kinases (JNK). Expression of MKK7D in adult hearts resulted in significant activation of JNK activities and causes progressive cardiomyopathy in transgenic animals. This unique animal model of cardiac-specific and temporally regulated JNK activation will provide a powerful tool to investigate the functional role of the JNK pathway in the development of heart failure. Our data also demonstrated that the inducible gene-switch approach reported here may also be applicable in other studies to achieve efficient, tissue-specific, and temporally regulated genetic manipulation in intact animals.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University System of Maryland; University of Maryland Baltimore; Cincinnati Children's Hospital Medical Center	Wang, YB (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.	ywang001@umaryland.edu		Molkentin, Jeffery/0000-0002-3558-6529; Wang, Yibin/0000-0003-0852-0767				BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Chen J, 1998, DEVELOPMENT, V125, P1943; Chien KR, 2001, CIRC RES, V88, P546, DOI 10.1161/01.RES.88.6.546; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Fishman GI, 1998, CIRC RES, V82, P837; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Huang Y, 1999, INT J FRACTURE, V100, P1, DOI 10.1023/A:1018313421855; Izumo S, 1998, J Card Fail, V4, P263, DOI 10.1016/S1071-9164(98)90231-7; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Verrou C, 1999, BIOL CHEM, V380, P1435, DOI 10.1515/BC.1999.184; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	22	55	59	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					749	+		10.1096/fj.02-0438fje	http://dx.doi.org/10.1096/fj.02-0438fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594183				2022-12-25	WOS:000181456900011
J	Levy, M; Faas, GC; Saggau, P; Craigen, WJ; Sweatt, JD				Levy, M; Faas, GC; Saggau, P; Craigen, WJ; Sweatt, JD			Mitochondrial regulation of synaptic plasticity in the hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; CYCLOSPORINE-A; AREA CA1; CALCIUM; TRANSMISSION; INVOLVEMENT; INHIBITION; RELEASE	Synaptic mechanisms of plasticity are calcium-dependent processes that are affected by dysfunction of mitochondrial calcium buffering. Recently, we observed that mice deficient in mitochondrial voltage-dependent anion channels, the outer component of the mitochondrial permeability transition pore, have impairments in learning and hippocampal synaptic plasticity, suggesting that the mitochondrial permeability transition pore is involved in hippocampal synaptic plasticity. In this study, we examined the effect on synaptic transmission and plasticity of blocking the permeability transition pore with low doses of cyclosporin A and found a deficit in synaptic plasticity and an increase in base-line synaptic transmission. Calcium imaging of presynaptic terminals revealed a transient increase in the resting calcium concentration immediately upon incubation with cyclosporin A that correlated with the changes in synaptic transmission and plasticity. The effect of cyclosporin A on presynaptic calcium was abolished when mitochondria were depolarized prior to cyclosporin A exposure, and the effects of cyclosporin A and mitochondrial depolarization on presynaptic resting calcium were similar, suggesting a mitochondrial locus of action of cyclosporin A. To further characterize the calcium dynamics of the mitochondrial permeability transition pore, we used an in vitro assay of calcium handling by isolated brain mitochondria. Cyclosporin A-exposed mitochondria buffered calcium more rapidly and subsequently triggered a more rapid mitochondrial depolarization. Similarly, mitochondria lacking the voltage-dependent anion channel 1 isoform depolarized more readily than littermate controls. The data suggest a role for the mitochondrial permeability transition pore and voltage-dependent anion channels in mitochondrial synaptic calcium buffering and in hippocampal synaptic plasticity.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Levy, M (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.			Faas, Guido/0000-0002-1339-7698; Sweatt, J. David/0000-0003-3567-485X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042488] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24064] Funding Source: Medline; NIMH NIH HHS [MH57014] Funding Source: Medline; NINDS NIH HHS [F31NS42488] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Billups B, 2002, J NEUROSCI, V22, P5840; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cavus I, 1996, J NEUROPHYSIOL, V76, P3038, DOI 10.1152/jn.1996.76.5.3038; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Jovanovic JN, 2001, J NEUROSCI, V21, P7944, DOI 10.1523/JNEUROSCI.21-20-07944.2001; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Miro O, 1998, BRIT J RHEUMATOL, V37, P1047; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pfeiffer DR, 2001, IUBMB LIFE, V52, P205, DOI 10.1080/15216540152846019; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; WU LG, 1994, J NEUROSCI, V14, P645	27	130	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17727	17734		10.1074/jbc.M212878200	http://dx.doi.org/10.1074/jbc.M212878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604600	hybrid			2022-12-25	WOS:000182838300019
J	Luo, BH; Springer, TA; Takagi, J				Luo, BH; Springer, TA; Takagi, J			High affinity ligand binding by Integrins does not involve head separation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; MURINE MONOCLONAL-ANTIBODY; INSIDE-OUT ACTIVATION; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; I-DOMAIN; FIBRINOGEN; CONFORMATIONS; REVEALS	Conformational change in the integrin extracellular domain is required for high affinity ligand binding and is also involved in post-ligand binding cellular signaling. Although there is evidence to the contrary, electron microscopic studies showing that ligand binding triggers alpha- and beta-subunit dissociation in the integrin headpiece have gained popularity and support the hypothesis that head separation activates integrins. To test directly the head separation hypothesis, we enforced head association by introducing disulfide bonds across the interface between the alpha-subunit beta-propeller domain and the beta-subunit I-like domain. Basal and activation-dependent ligand binding by alpha(IIb)beta(3) and alpha(V)beta(3) was unaffected. The covalent linkage prevented dissociation of alpha(IIb)beta(3) into its subunits on EDTA-treated cells. Whereas EDTA dissociated wild type alpha(IIb)beta(3) on the cell surface, a ligand-mimetic Arg-Gly-Asp peptide did not, as judged by binding of complex-specific antibodies. Finally, a high affinity ligand-mimetic compound stabilized noncovalent association between alpha(IIb) and beta(3) headpiece fragments in the presence of SDS, indicating that ligand binding actually stabilized subunit association at the head, as opposed to the suggested subunit separation. The mechanisms of conformational regulation of integrin function should therefore be considered in the context of the associated alphabeta headpiece.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Takagi, J (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave,Rm 238, Boston, MA 02115 USA.	takagi@cbr.med.harvard.edu			NHLBI NIH HHS [HL48675] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Billheimer JT, 2002, BLOOD, V99, P3540, DOI 10.1182/blood.V99.10.3540; BRASS LF, 1985, J BIOL CHEM, V260, P7875; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COLLER BS, 1986, J LAB CLIN MED, V107, P384; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DU XP, 1993, J BIOL CHEM, V268, P23087; Erb EM, 1997, BIOCHEMISTRY-US, V36, P7395, DOI 10.1021/bi9702187; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; Hantgan RR, 2001, PROTEIN SCI, V10, P1614, DOI 10.1110/ps.3001; Honda S, 1998, J CLIN INVEST, V102, P1183, DOI 10.1172/JCI3206; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liddington RC, 2002, STRUCTURE, V10, P605, DOI 10.1016/S0969-2126(02)00766-9; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETRUZZELLI L, 1995, LEUCOCYTE TYPING, V5, P1581; PIDARD D, 1983, J BIOL CHEM, V258, P2582; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Prueksaritanont T, 1997, DRUG METAB DISPOS, V25, P355; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Thibault G, 2001, J PHARMACOL EXP THER, V296, P690; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200; Zolotarjova NI, 2001, J BIOL CHEM, V276, P17063, DOI 10.1074/jbc.M009627200	44	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17185	17189		10.1074/jbc.M301516200	http://dx.doi.org/10.1074/jbc.M301516200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600996	Green Published, hybrid			2022-12-25	WOS:000182818600099
J	Wiley, JS; Dao-Ung, LP; Li, CP; Shemon, AN; Gu, BJ; Smart, ML; Fuller, SJ; Barden, JA; Petrou, S; Sluyter, R				Wiley, JS; Dao-Ung, LP; Li, CP; Shemon, AN; Gu, BJ; Smart, ML; Fuller, SJ; Barden, JA; Petrou, S; Sluyter, R			An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X(7) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LYMPHOCYTES; HUMAN MACROPHAGES; PURINERGIC RECEPTORS; CHANNEL MUTATION; CUTTING EDGE; L-SELECTIN; ATP; ACTIVATION; EXPRESSION; CELLS	The P2X(7) receptor is a ligand-gated channel that is highly expressed on mononuclear cells and that mediates ATP-induced apoptosis of these cells. Wide variations in the function of the P2X(7) receptor have been observed, in part because of a loss-of-function polymorphism that changes Glu-496 to Ala without affecting the surface expression of the receptor on lymphocytes. In this study a second polymorphism (Ile-568 to Asn) has been found in heterozygous dosage in three of 85 normal subjects and in three of 45 patients with chronic lymphocytic leukemia. P2X(7) function was measured by ATP-induced fluxes of Rb+, Ba2+, and ethidium(+) into various lymphocyte subsets and was decreased to values of similar to25% of normal. The expression of the P2X(7) receptor on lymphocytes was approximately half that of normal values as measured by the binding of fluorescein-conjugated monoclonal antibody. Transfection experiments showed that P2X(7) carrying the Ile-568 to Asn mutation was non-functional because of the failure of cell surface expression. The differentiation of monocytes to macrophages with interferon-gamma up-regulated P2X(7) function in cells heterozygous for the Ile-568 to Asn mutation to a value around 50% of normal. These data identify a second loss-of-function polymorphism within the P2X(7) receptor and show that Ile-568 is critical to the trafficking domain, which we have shown to lie between residues 551 and 581.	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2750, Australia; Univ Melbourne, Dept Physiol, Parkville, Vic 3050, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia	Nepean Hospital; University of Sydney; University of Melbourne; University of Sydney	Wiley, JS (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Level 5,S Block, Penrith, NSW 2750, Australia.	wileyj@medicine.usyd.edu.au	Petrou, Steven/M-8332-2013; Fuller, Stephen/W-6646-2019; Sluyter, Ronald/B-5798-2009	Fuller, Stephen/0000-0003-4637-7391; Sluyter, Ronald/0000-0003-4909-686X; Petrou, Steven/0000-0002-4960-6375; Wiley, James/0000-0001-9421-4154; Gu, Ben/0000-0001-5500-4453				Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; HICKMAN SE, 1994, BLOOD, V84, P2452; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jamieson GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3; JURKATROTT K, 1994, HUM MOL GENET, V3, P1415, DOI 10.1093/hmg/3.8.1415; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Li CM, 2002, FEBS LETT, V531, P127, DOI 10.1016/S0014-5793(02)03424-5; Moore KH, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-18-j0002.2001; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Slater M, 2002, CELL CALCIUM, V31, P201, DOI 10.1016/S0143-4160(02)00033-7; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Sluyter R, 2001, CELL TISSUE RES, V304, P231, DOI 10.1007/s004410100372; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wiley JS, 2002, LANCET, V359, P1114, DOI 10.1016/S0140-6736(02)08156-4; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T	41	135	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17108	17113		10.1074/jbc.M212759200	http://dx.doi.org/10.1074/jbc.M212759200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12586825	hybrid			2022-12-25	WOS:000182818600089
J	Choe, JY; Iancu, CV; Fromm, HJ; Honzatko, RB				Choe, JY; Iancu, CV; Fromm, HJ; Honzatko, RB			Metaphosphate in the active site of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; LIVER FRUCTOSE BISPHOSPHATASE; PHOSPHORYL-TRANSFER-REACTIONS; TRANSITION-STATE; MECHANISM; HYDROLYSIS; 1,6-BISPHOSPHATASE; CATALYSIS; PHOSPHATE; INHIBITION	The hydrolysis of a phosphate ester can proceed through an intermediate of metaphosphate (dissociative mechanism) or through a trigonal bipryamidal transition state (associative mechanism). Model systems in solution support the dissociative pathway, whereas most enzymologists favor an associative mechanism for enzyme-catalyzed reactions. Crystals of fiructose-1,6-bisphosphatase grow from an equilibrium mixture of substrates and products at near atomic resolution (1.3 Angstrom). At neutral pH, products of the reaction (orthophosphate and fructose 6-phosphate) bind to the active site in a manner consistent with an associative reaction pathway; however, in the presence of inhibitory concentrations of K+ (200 mm), or at pH 9.6, metaphosphate and water (or OH-) are in equilibrium with orthophosphate. Furthermore, one of the magnesium cations in the pH 9.6 complex resides in an alternative position, and suggests the possibility of metal cation migration as the 1-phosphoryl group of the substrate undergoes hydrolysis. To the best of our knowledge, the crystal structures reported here represent the first direct observation of metaphosphate in a condensed phase and may provide the structural basis for fundamental changes in the catalytic mechanism of fiructose-1,6-bisphosphatase in response to pH and different metal cation activators.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; BARNARD DWC, 1955, CHEM IND-LONDON, P760; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BUTCHER WW, 1955, J AM CHEM SOC, V77, P2420, DOI 10.1021/ja01614a018; CALVO KC, 1984, J AM CHEM SOC, V106, P4202, DOI 10.1021/ja00327a023; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P16008, DOI 10.1074/jbc.M212394200; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; DOMANICO PL, 1985, BIOCHEMISTRY-US, V24, P1623, DOI 10.1021/bi00328a009; Du XL, 2000, J BIOL CHEM, V275, P8492, DOI 10.1074/jbc.275.12.8492; FREY WA, 1977, BIOCHEMISTRY-US, V16, P2479, DOI 10.1021/bi00630a025; GUTHRIE JP, 1977, J AM CHEM SOC, V99, P3991, DOI 10.1021/ja00454a018; HENCHMAN M, 1985, J AM CHEM SOC, V107, P1453, DOI 10.1021/ja00291a081; HENGGE AC, 1994, J AM CHEM SOC, V116, P5045, DOI 10.1021/ja00091a003; HENGGE AC, 1998, COMPREHENSIVE BIOL C, V1, P517; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; JANKOWSKI S, 1994, J AM CHEM SOC, V116, P11675, DOI 10.1021/ja00105a008; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799; STONE SR, 1986, BIOCHEMISTRY-US, V25, P620; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Wright SW, 2002, J MED CHEM, V45, P3865, DOI 10.1021/jm010496a; WU YD, 1993, J AM CHEM SOC, V115, P11997, DOI 10.1021/ja00078a042; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	39	31	33	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16015	16020		10.1074/jbc.M212395200	http://dx.doi.org/10.1074/jbc.M212395200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595528	hybrid			2022-12-25	WOS:000182680000072
J	Kanipes, MI; Ribeiro, AA; Lin, SH; Cotter, RJ; Raetz, CRH				Kanipes, MI; Ribeiro, AA; Lin, SH; Cotter, RJ; Raetz, CRH			A mannosyl transferase required for lipopolysaccharide inner core assembly in Rhizobium leguminosarum - Purification, substrate specificity, and expression in Salmonella waaC mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-TUMEFACIENS C58; LIPID-A BIOSYNTHESIS; ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; POLYSACCHARIDE SYNTHESIS; SINORHIZOBIUM-MELILOTI; BACTERIAL-ENDOTOXINS; NMR-SPECTROSCOPY; GENOME SEQUENCE	The lipopolysaccharide (LPS) core domain of Gram-negative bacteria plays an important role in outer membrane stability and host interactions. Little is known about the biochemical properties of the glycosyltransferases that assemble the LPS core. We now report the purification and characterization of the Rhizobium leguminosarum mannosyI transferase LpcC, which adds a mannose unit to the inner 3-deoxy-D-manno-octulosonic acid (Kdo) moiety of the LPS precursor, Kdo(2)-lipid IVA. LpcC containing an N-terminal His, tag was assayed using GDP-mannose as the donor and Kdo(2)-[4'-P-32]lipid IVA as the acceptor and was purified to near homogeneity. Sequencing of the N terminus confirmed that the purified enzyme is the lpcC gene product. Mild acid hydrolysis of the glycolipid generated in vitro by pure LpcC showed that the mannosylation occurs on the inner Kdo residue Of Kdo(2)-[4'-P-32]lipid IVA. A lipid acceptor substrate containing two Kdo moieties is required by LpcC, since no activity is seen with lipid IVA or Kdo-lipid IVA. The purified enzyme can use GDP-mannose or, to a lesser extent, ADP-mannose (both of which have the alpha-anomeric configuration) for the glycosylation of Kdo2-[4'-P-32]lipid IVA. Little or no activity is seen with ADP-glucose, UDP-glucose, UDP-GlcNAc, or UDP-galactose. A Salmonella typhimurium waaC mutant, which lacks the enzyme for incorporating the inner L-glycero-D-manno-heptose moiety of LPS, regains LPS with O-antigen when complemented with lpcC. An Escherichia coli heptose-less waaC-waaF deletion mutant expressing the R. leguminosarum lpcC gene likewise generates a hybrid LPS species consisting of Kdo(2)-lipid A plus a single mannose residue. Our results demonstrate that heterologous lpcC expression can be used to modify the structure of the Salmonella and E. coli LPS cores in living cells.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Duke University; Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.				NCI NIH HHS [P30 CA014236, P30 CA 14236] Funding Source: Medline; NIGMS NIH HHS [R37 GM051796, R37 GM051796-07, R37 GM 51796, GM 54882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Carlson R W, 1995, Prog Clin Biol Res, V392, P25; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DANKERT M, 1964, BIOCHEM BIOPH RES CO, V14, P358, DOI 10.1016/S0006-291X(64)80010-3; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Elling L, 1996, GLYCOBIOLOGY, V6, P591, DOI 10.1093/glycob/6.6.591; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; Gronow S, 2001, J ENDOTOXIN RES, V7, P263, DOI 10.1177/09680519010070040701; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; KOCSIS B, 1984, J BIOL CHEM, V259, P1858; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; Lagares A, 2001, J BACTERIOL, V183, P1248, DOI 10.1128/JB.183.4.1248-1258.2001; Miller J.H., 1972, EXPT MOL GENETICS; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; PASSERON S, 1964, BIOCHIM BIOPHYS ACTA, V89, P372, DOI 10.1016/0926-6569(64)90233-0; PERLIN AS, 1969, TETRAHEDRON LETT, P2921; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; UBRINOVA S, 1991, MAGN RESON CHEM, V29, P912; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Zamyatina A, 2000, ANGEW CHEM INT EDIT, V39, P4150, DOI 10.1002/1521-3773(20001117)39:22<4150::AID-ANIE4150>3.0.CO;2-A	57	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16356	16364		10.1074/jbc.M301255200	http://dx.doi.org/10.1074/jbc.M301255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591937	Green Accepted, hybrid			2022-12-25	WOS:000182680000114
J	Petrini, EM; Zacchi, P; Barberis, A; Mozrzymas, JW; Cherubini, E				Petrini, EM; Zacchi, P; Barberis, A; Mozrzymas, JW; Cherubini, E			Declusterization of GABA(A) receptors affects the kinetic properties of GABAergic currents in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTOR; MICROTUBULE DEPOLYMERIZATION; MOLECULAR-CLONING; GLYCINE RECEPTORS; PROTEIN GABARAP; GEPHYRIN; CYTOSKELETON; CHANNELS; DESENSITIZATION; SYNAPSES	Speed and reliability of synaptic transmission are essential for information coding in neuronal networks and require the presence of clustered neurotransmitter receptors at the plasma membrane in precise apposition to presynaptic terminals. Receptor clusterization is the result of highly regulated processes involving functional and structural proteins. Among the structural elements, microtubules are known to play a crucial role in anchoring of gamma-aminobutyric acid, type A (GABA(A)) receptors. Here we show that microtubule depolymerization with nocodazole induces the declusterization of GABA(A) receptors and modifies the kinetic properties of GABAergic currents in cultured hippocampal neurons. In particular, this drug, applied either in the bath or via the patch pipette, induced the acceleration of the onset kinetics of miniature inhibitory postsynaptic currents (mIPSCs) without significantly affecting their frequency, thus suggesting a main postsynaptic site of action. After nocodazole treatment, current responses to ultrafast applications of GABA exhibited a faster rise time and an accelerated onset of desensitization. A quantitative analysis of GABA-evoked currents and model simulations suggest that declusterization affects the gating properties of GABA(A) receptors. In particular, a faster entry into the desensitized state of declustered GABA(A) receptors may account for the changes in the kinetic properties of mIPSCs after nocodazole treatment. Hence it appears that the clustered condition of GABA(A) receptors contributes in shaping GABAergic currents.	Sch Adv Int Studies, Neurosci Program, I-34014 Trieste, Italy; Scuola Int Super Studi Avanzati, Ist Nazl Fis Mat Unit, I-34014 Trieste, Italy; Wroclaw Med Univ, Dept Biophys, PL-50368 Wroclaw, Poland	International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); International School for Advanced Studies (SISSA); Wroclaw Medical University	Cherubini, E (corresponding author), Sch Adv Int Studies, Neurosci Program, Via Beirut 2-4, I-34014 Trieste, Italy.		Barberis, Andrea/AAB-8806-2019	Mozrzymas, Jerzy/0000-0003-1674-1818; Barberis, Andrea/0000-0002-5054-6517				Andjus PR, 1997, J PHYSIOL-LONDON, V504, P103, DOI 10.1111/j.1469-7793.1997.103bf.x; BAAS PW, 1991, J NEUROSCI RES, V30, P134, DOI 10.1002/jnr.490300115; Barberis A, 2000, J NEUROSCI, V20, P8618; Barnes EM, 2000, LIFE SCI, V66, P1063, DOI 10.1016/S0024-3205(99)00469-5; Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Bianchi MT, 2002, NEUROPHARMACOLOGY, V43, P492, DOI 10.1016/S0028-3908(02)00163-6; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; Birnir B, 2000, J MEMBRANE BIOL, V174, P21, DOI 10.1007/s002320001028; Birnir B, 2001, J MEMBRANE BIOL, V181, P171, DOI 10.1007/s00232-001-0021-5; Bueno OF, 1998, NEUROPHARMACOLOGY, V37, P383, DOI 10.1016/S0028-3908(98)00020-3; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Christie SB, 2002, PROG BRAIN RES, V136, P157; Christie SB, 2002, J NEUROSCI, V22, P684, DOI 10.1523/JNEUROSCI.22-03-00684.2002; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Ho WH, 2001, J CELL BIOCHEM, V83, P291, DOI 10.1002/jcb.1232; Jonas Peter, 1995, P231; Jones MV, 2001, BIOPHYS J, V81, P2660, DOI 10.1016/S0006-3495(01)75909-7; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Jones MV, 1998, J NEUROSCI, V18, P8590; Kannenberg K, 1999, EUR J NEUROSCI, V11, P1256, DOI 10.1046/j.1460-9568.1999.00533.x; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Koulen P, 1996, J NEUROSCI, V16, P2127; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legendre P, 2002, MOL PHARMACOL, V62, P817, DOI 10.1124/mol.62.4.817; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; Meyer DK, 2000, J NEUROSCI, V20, P6743, DOI 10.1523/JNEUROSCI.20-18-06743.2000; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Mozrzymas JW, 2003, J NEUROPHYSIOL, V89, P871, DOI 10.1152/jn.00951.2002; Mozrzymas JW, 1999, J NEUROSCI, V19, P2474; Overstreet LS, 2000, J NEUROSCI, V20, P7914; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SASSOEPOGNETTO M, 1995, J COMP NEUROL, V357, P1, DOI 10.1002/cne.903570102; Scotti AL, 2001, P NATL ACAD SCI USA, V98, P3489, DOI 10.1073/pnas.061028798; van Zundert B, 2002, J NEUROPHYSIOL, V87, P640, DOI 10.1152/jn.00455.2001; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Weiner JL, 1998, J PHARMACOL EXP THER, V284, P95; WHATLEY VJ, 1994, J BIOL CHEM, V269, P19546; Yeung JYT, 2003, MOL PHARMACOL, V63, P2, DOI 10.1124/mol.63.1.2	48	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16271	16279		10.1074/jbc.M213081200	http://dx.doi.org/10.1074/jbc.M213081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600990	hybrid			2022-12-25	WOS:000182680000103
J	Bailey, S; Sedelnikova, SE; Mesa, P; Ayora, S; Waltho, JP; Ashcroft, AE; Baron, AJ; Alonso, JC; Rafferty, JB				Bailey, S; Sedelnikova, SE; Mesa, P; Ayora, S; Waltho, JP; Ashcroft, AE; Baron, AJ; Alonso, JC; Rafferty, JB			Structural analysis of Bacillus subtilis SPP1 phage helicase loader protein G39P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; DNA-REPLICATION; BINDING; G40P; REPLISOME; INTERACTS; MOLSCRIPT; DISORDER; FLGM	The Bacillus subtilis SPP1 phage-encoded protein G39P is a loader and inhibitor of the phage G40P replicative helicase involved in the initiation of DNA replication. We have carried out a full x-ray crystallographic and preliminary NMR analysis of G39P and functional studies of the protein, including assays for helicase binding by a number of truncated mutant forms, in an effort to improve our understanding of how it both interacts with the helicase and with the phage replisome organizer, G38P. Our structural analyses reveal that G39P has a completely unexpected bipartite structure comprising a folded N-terminal domain and an essentially unfolded C-terminal domain. Although G39P has been shown to bind its G40P target with a 6:6 stoichiometry, our crystal structure and other biophysical characterization data reveal that the protein probably exists predominantly as a monomer in solution. The G39P protein is proteolytically sensitive, and our binding assays show that the C-terminal domain is essential for helicase interaction and that removal of just the 14 C-terminal residues abolishes interaction with the helicase in vitro. We propose a number of possible scenarios in which the flexibility of the C-terminal domain of G39P and its proteolytic sensitivity may have important roles for the function of G39P in vivo that are consistent with other data on SPP1 phage DNA replication.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Autonoma Madrid, Dept Mol Biol, Madrid 28049, Spain; CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, E-28049 Madrid, Spain; Univ Leeds, Sch Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Sheffield; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Leeds	Rafferty, JB (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	j.rafferty@sheffield.ac.uk	Alonso, Juan Carlos/D-2595-2009; Ayora, Silvia/D-2552-2009	Alonso, Juan Carlos/0000-0002-5178-7179; Ayora, Silvia/0000-0003-3121-1786; Mesa, Pablo/0000-0002-9218-3144; Rafferty, John/0000-0003-1183-7474; Waltho, Jonathan/0000-0002-7402-5492				Ayora S, 1998, FEBS LETT, V439, P59, DOI 10.1016/S0014-5793(98)01337-4; Ayora S, 1999, J MOL BIOL, V288, P71, DOI 10.1006/jmbi.1999.2662; Ayora S, 2002, NUCLEIC ACIDS RES, V30, P2280, DOI 10.1093/nar/30.11.2280; Ayora S, 2002, J BIOL CHEM, V277, P35969, DOI 10.1074/jbc.M204467200; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Barcena M, 1998, J MOL BIOL, V283, P809, DOI 10.1006/jmbi.1998.2128; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; CHAI S, 1993, GENE, V129, P41, DOI 10.1016/0378-1119(93)90694-X; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTIN JR, 1994, EUR J BIOCHEM, V225, P1181, DOI 10.1111/j.1432-1033.1994.1181b.x; Martinez-Jimenez MI, 2002, NUCLEIC ACIDS RES, V30, P5056, DOI 10.1093/nar/gkf650; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missich R, 1997, J MOL BIOL, V270, P50, DOI 10.1006/jmbi.1997.1060; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PEDRE X, 1994, J MOL BIOL, V236, P1324, DOI 10.1016/0022-2836(94)90061-2; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; WEISE F, 1997, THESIS FREIE U BERLI; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	40	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15304	15312		10.1074/jbc.M209300200	http://dx.doi.org/10.1074/jbc.M209300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588876	hybrid			2022-12-25	WOS:000182516100094
J	Brautaset, T; Borgos, SEF; Sletta, H; Ellingsen, TE; Zotchev, SB				Brautaset, T; Borgos, SEF; Sletta, H; Ellingsen, TE; Zotchev, SB			Site-specific mutagenesis and domain substitutions in the loading module of the nystatin polyketide synthase, and their effects on nystatin biosynthesis in Streptomyces noursei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-KETOACYL SYNTHASE; SUBSTRATE-SPECIFICITY; CHAIN INITIATION; ESCHERICHIA-COLI; GENE-CLUSTER; ATCC-11455	The loading module for the nystatin polyketide synthase (PKS) in Streptomyces noursei is represented by the NysA protein composed of a ketosynthase (KSS), acyltransferase, dehydratase, and an acyl carrier protein. The absolute requirement of this protein for initiation of nystatin biosynthesis was demonstrated by the in-frame deletion of the nysA gene in S. noursei. The role of the NysA KSS domain, however, remained unclear, since no data on the significance of the "active site" serine (Ser-170) residue in the loading modules of type I PKSs were available. Site-specific mutagenesis of Ser-170 both in the wild-type NysA and in the hybrid loading module containing malonyl-specific acyltransferase domain from the extender module had no effect on nystatin biosynthesis. A second mutation (S413N) of the NysA KSS domain was discovered that completely abolished the ability of the hybrids to restore nystatin biosynthesis, presumably by affecting the ability of the resulting proteins to catalyze the required substrate decarboxylation. In contrast, NysA and its Ser-170 mutants bearing the same S413N mutation were able to restore nystatin production to significant levels, probably by using acetyl-CoA as a starter unit. Together, these data suggest that the KSS domain of NysA differs from the KSQ domains found in the loading modules of several PKS type I systems in that the active site residue is not significant for its activity.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; SINTEF, N-7034 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); SINTEF	Brautaset, T (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.			Borgos, Sven Even/0000-0002-6222-9252; Zotchev, Sergey/0000-0002-9324-245X				Aparicio JF, 2000, CHEM BIOL, V7, P895, DOI 10.1016/S1074-5521(00)00038-7; Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; Brautaset T, 2000, CHEM BIOL, V7, P395, DOI 10.1016/S1074-5521(00)00120-4; Brautaset T, 2002, CHEM BIOL, V9, P367, DOI 10.1016/S1074-5521(02)00108-4; Caffrey P, 2001, CHEM BIOL, V8, P713, DOI 10.1016/S1074-5521(01)00046-1; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Flett F, 1997, FEMS MICROBIOL LETT, V155, P223, DOI 10.1111/j.1574-6968.1997.tb13882.x; HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014-5793(95)01119-Y; Jacobsen JR, 1998, BIOCHEMISTRY-US, V37, P4928, DOI 10.1021/bi9729920; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Liou GF, 2003, BIOCHEMISTRY-US, V42, P200, DOI 10.1021/bi0268100; Long PF, 2002, MOL MICROBIOL, V43, P1215, DOI 10.1046/j.1365-2958.2002.02815.x; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; Pereda A, 1998, MICROBIOL-UK, V144, P543, DOI 10.1099/00221287-144-2-543; Reeves CD, 2001, BIOCHEMISTRY-US, V40, P15464, DOI 10.1021/bi015864r; Sambrook J., 2002, MOL CLONING LAB MANU; Sekurova O, 1999, FEMS MICROBIOL LETT, V177, P297, DOI 10.1111/j.1574-6968.1999.tb13746.x; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Wilkinson CJ, 2001, CHEM BIOL, V8, P1197, DOI 10.1016/S1074-5521(01)00087-4; Witkowski A, 1999, BIOCHEMISTRY-US, V38, P11643, DOI 10.1021/bi990993h; YANISCHPERRON C, 1985, METHOD ENZYMOL, V113, P83; Zotchev S, 2000, MICROBIOL-UK, V146, P611, DOI 10.1099/00221287-146-3-611	25	25	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14913	14919		10.1074/jbc.M212611200	http://dx.doi.org/10.1074/jbc.M212611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594224	hybrid			2022-12-25	WOS:000182516100044
J	Ohdate, H; Lim, CR; Kokubo, T; Matsubara, K; Kimata, Y; Kohno, K				Ohdate, H; Lim, CR; Kokubo, T; Matsubara, K; Kimata, Y; Kohno, K			Impairment of the DNA binding activity of the TATA-binding protein renders the transcriptional function of Rvb2p/Tih2p, the yeast RuvB-like protein, essential for cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN REMODELING COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; C-MYC; ONCOGENIC TRANSFORMATION; BETA-CATENIN; BOX C/D; NUCLEOSOME; MUTANTS; IDENTIFICATION	In Saccharomyces cerevisiae, two highly conserved proteins, Rvb1p/Tih1p and Rvb2p/Tih2p, have been demonstrated to be major components of the chromatin-remodeling INO80 complex. The mammalian orthologues of these two proteins have been shown to physically associate with the TATA-binding protein (TBP) in vitro but not clearly in vivo. Here we show that yeast proteins interact with TBP under both conditions. To assess the functional importance of these interactions, we examined the effect of mutating both TIH2/RVB2 and SPT15, which encodes TBP, on yeast cell growth. Intriguingly, only those spt15 mutations that affected the ability of TBP to bind to the TATA box caused synthetic growth defects in a tih2-ts160 background. This suggests that Tih2p might be important in recruiting TBP to the promoter. A DNA microarray technique was used to identify genes differentially expressed in the tih2-ts160 strain grown at the restrictive temperature. Only 34 genes were significantly and reproducibly affected; some up-regulated and others down-regulated. We compared the transcription of several of these Tih2p target genes in both wild type and various mutant backgrounds. We found that the transcription of some genes depends on functions possessed by both Tih2p and TBP and that these functions are substantially impaired in the spt15/tih2-ts160 double mutants that confer synthetic growth defects.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan; DNA Chip Res Inc, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Div Mol & Cellular Biol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Nara Institute of Science & Technology; DNA Chip Research Inc.; Yokohama City University	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.							ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Cairns BR, 1999, MOL CELL, V4, P715, DOI 10.1016/S1097-2765(00)80382-2; Chao DM, 1996, NATURE, V383, P119, DOI 10.1038/383119a0; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Holzmann K, 1998, BIOCHEM BIOPH RES CO, V252, P39, DOI 10.1006/bbrc.1998.9604; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; John S, 2000, GENE DEV, V14, P1196; Jonsson ZO, 2001, J BIOL CHEM, V276, P16279, DOI 10.1074/jbc.M011523200; Kanemaki M, 1997, BIOCHEM BIOPH RES CO, V235, P64, DOI 10.1006/bbrc.1997.6729; Kikuchi N, 1999, J BIOCHEM, V125, P487, DOI 10.1093/oxfordjournals.jbchem.a022312; KIMATA Y, 1994, J BIOL CHEM, V269, P13497; King TH, 2001, MOL CELL BIOL, V21, P7731, DOI 10.1128/MCB.21.22.7731-7746.2001; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kobayashi A, 2001, J BIOL CHEM, V276, P395, DOI 10.1074/jbc.M008208200; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; LEE M, 1995, MOL CELL BIOL, V15, P5461; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lim CR, 2000, J BIOL CHEM, V275, P22409, DOI 10.1074/jbc.M001031200; Morales V, 2001, BIOCHIMIE, V83, P1029, DOI 10.1016/S0300-9084(01)01347-5; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neuwald AF, 1999, GENOME RES, V9, P27; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Salzer U, 1999, BBA-GENE STRUCT EXPR, V1446, P365, DOI 10.1016/S0167-4781(99)00104-9; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	59	28	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14647	14656		10.1074/jbc.M213220200	http://dx.doi.org/10.1074/jbc.M213220200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576485	hybrid			2022-12-25	WOS:000182516100011
J	Romijn, RA; Westein, E; Bouma, B; Schiphorst, ME; Sixma, JJ; Lenting, PJ; Huizinga, EG				Romijn, RA; Westein, E; Bouma, B; Schiphorst, ME; Sixma, JJ; Lenting, PJ; Huizinga, EG			Mapping the collagen-binding site in the von Willebrand factor-A3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBUS FORMATION; A3 DOMAIN; VONWILLEBRAND-FACTOR; I-DOMAIN; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; GLYCOPROTEIN-VI; ADHESION; VWF; RECEPTOR	The multimeric glycoprotein von Willebrand factor (VVVF) mediates platelet adhesion to collagen at sites of vascular damage. The binding site for collagen types I and III is located in the VWF-A3 domain. Recently, we showed that His(1023), located near the edge between the "front" and "bottom" faces of A3, is critical for collagen binding (Romijn, R. A., Bouma, B., Wuyster, W., Gros, P., Kroon, J., Sixma, J. J., and Huizinga, E. G. (2001) J. Biol. Chem. 276,9985-9991). To map the binding site in detail, we introduced 22 point mutations in the front and bottom faces of A3. The mutants were expressed as multimeric VWF, and binding to collagen type III was evaluated in a solid-state binding assay and by surface plasmon resonance. Mutation of residues Asp(979), Ser(1020), and His(1023) nearly abolished collagen binding, whereas mutation of residues Ile(975), Thr(977), Val(997), and Glu(1001) reduced binding affinity about 10-fold. Together, these residues define a flat and rather hydrophobic collagen-binding site located at the front face of the A3 domain. The collagen-binding site of VWF-A3 is distinctly different from that of the homologous integrin alpha(2) I domain, which has a hydrophilic binding site located at the top face of the domain. Based on the surface characteristics of the collagen-binding site of A3, we propose that it interacts with collagen sequences containing positively charged and hydrophobic residues. Docking of a collagen triple helix on the binding site suggests a range of possible engagements and predicts that at most eight consecutive residues in a collagen triple helix interact with A3.	Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Crystal & Struct Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Huizinga, EG (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, HP GO3-647,POB 85500, NL-3508 GA Utrecht, Netherlands.	E.G.Huizinga@chem.uu.nl	Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fischer BE, 1996, THROMB RES, V84, P55, DOI 10.1016/0049-3848(96)00161-2; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Goto SY, 2002, CIRCULATION, V106, P266, DOI 10.1161/01.CIR.0000021427.87256.7E; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kehrel B, 1998, BLOOD, V91, P491; KRAULIS P, 1991, J APPL CRYSTALLOGR, V25, P649; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; LAWRIE AS, 1990, THROMB RES, V59, P369, DOI 10.1016/0049-3848(90)90139-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; PIETU G, 1987, J LAB CLIN MED, V109, P637; Ribba AS, 2001, THROMB HAEMOSTASIS, V86, P848; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Saenko E, 2002, ANAL BIOCHEM, V302, P252, DOI 10.1006/abio.2001.5555; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Schneppenheim R, 2001, BLOOD, V98, p41A; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623	38	78	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15035	15039		10.1074/jbc.M208977200	http://dx.doi.org/10.1074/jbc.M208977200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582178	hybrid, Green Published			2022-12-25	WOS:000182516100060
J	Zhou, AW; Stein, PE; Huntington, JA; Carrell, RW				Zhou, AW; Stein, PE; Huntington, JA; Carrell, RW			Serpin polymerization is prevented by a hydrogen bond network that is centered on His-334 and stabilized by glycerol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; PLASMINOGEN-ACTIVATOR INHIBITOR-1; ELECTRON-DENSITY MAPS; BETA-SHEET-A; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL DISEASES; CRYSTAL-STRUCTURE; IN-VIVO; ANTITHROMBIN; MECHANISM	Polymerization of serpins commonly results from mutations in the shutter region underlying the bifurcation of strands 3 and 5 of the A-sheet, with entry beyond this point being barred by a H-bond network centered on His-334. Exposure of this histidine in antithrombin, which has a partially opened sheet, allows polymerization and peptide insertion to occur at pH 6 or less when His-334 will be predictably protonated with disruption of the H-bond network. Similarly, thermal stability of antithrombin is pH-dependent with a single unfolding transition at pH 6, but there is no such transition when His-334 is buried by a fully closed A-sheet in heparin-complexed antithrombin or in alpha(1)-antitrypsin. Replacement of His-334 in alpha(1)-antitrypsin by a serine or alanine at pH 7.4 results in the same polymerization and loop-peptide acceptance observed with antithrombin at low pH. The critical role of His-334 and the re-formation of its H-bond network by the conserved P8 threonine, on the full insertion of strand 4, are relevant for the design of therapeutic blocking agents. This is highlighted here by the crystallographic demonstration that glycerol, which at high concentrations blocks polymerization, can replace the P8 threonine and re-form the disrupted H-bond network with His-334.	Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge	Zhou, AW (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 2XY, England.	awz20@cus.cam.ac.uk		ZHOU, Aiwu/0000-0002-2555-5091				Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Carrell RW, 2001, THROMB HAEMOSTASIS, V86, P14; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; EVANS PR, 1993, P CCP4 STUD WEEK DAT, V114; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Hansen M, 2001, EUR J BIOCHEM, V268, P6274, DOI 10.1046/j.0014-2956.2001.02582.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 2002, J BIOL CHEM, V277, P46347, DOI 10.1074/jbc.M207682200; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P197; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Petitou M, 1992, Fortschr Chem Org Naturst, V60, P143; POLLER W, 1993, GENOMICS, V17, P740, DOI 10.1006/geno.1993.1396; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	50	62	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15116	15122		10.1074/jbc.M211663200	http://dx.doi.org/10.1074/jbc.M211663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578831	hybrid			2022-12-25	WOS:000182516100069
J	Kim, YM; Watanabe, T; Allen, PB; Kim, YM; Lee, SJ; Greengard, P; Nairn, AC; Kwon, YG				Kim, YM; Watanabe, T; Allen, PB; Kim, YM; Lee, SJ; Greengard, P; Nairn, AC; Kwon, YG			PNUTS, a protein phosphatase 1 (PP1) nuclear targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SPLICING FACTORS; MESSENGER-RNA; RETINOBLASTOMA PROTEIN; CATALYTIC SUBUNIT; BINDING-PROTEINS; MAMMALIAN-CELLS; PHOSPHORYLATION; TYPE-1; GENE; KINASE	PNUTS, Phosphatase 1 NUclear Targeting Subunit, is a recently described protein that targets protein phosphatase 1 (PP1) to the nucleus. In the present study, we characterized the biochemical properties of PNUTS. A variety of truncation and site-directed mutants of PNUTS was prepared and expressed either as glutathione S-transferase fusion proteins in Escherichia coli or as FLAG-tagged proteins in 293T cells. A 50-amino acid domain in the center of PNUTS mediated both high affinity PP1 binding and inhibition of PP1 activity. The PP1-binding domain is related to a motif found in several other PP1-binding proteins but is distinct in that Trp replaces Phe. Mutation of the Trp residue essentially abolished the ability of PNUTS to bind to and inhibit PP1. The central PP1-binding domain of PNUTS was an effective substrate for protein kinase A in vitro, and phosphorylation substantially reduced the ability of PNUTS to bind to PP1 in vitro and following stimulation of protein kinase A in intact cells. In vitro RNA binding experiments showed that a C-terminal region including several RGG motifs and a novel repeat domain rich in His and Gly interacted with mRNA and single-stranded DNA. PNUTS exhibited selective binding for poly(A) and poly(G) compared with poly(U) or poly(C) ribonucleotide homopolymers, with specificity being mediated by distinct regions within the domain rich in His and Gly and the domain containing the RGG motifs. Finally, a PNUTS-PP1 complex was isolated from mammalian cell lysates using RNA-conjugated beads. Together, these studies support a role for PNUTS in protein kinase A-regulated targeting of PP1 to specific RNA-associated complexes in the nucleus.	Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Kangwon National University; Kangwon National University; Rockefeller University	Kwon, YG (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea.	ygkwon@kangwon.ac.kr		Nairn, Angus/0000-0002-7075-0195	NIDA NIH HHS [P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Beullens M, 2002, J BIOL CHEM, V277, P19855, DOI 10.1074/jbc.M200847200; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Das A, 1996, J BIOL CHEM, V271, P15675, DOI 10.1074/jbc.271.26.15675; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KILEDJIAN M, 1992, EMBO J, V11, P2644; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACKINTOSH C, 1988, FEBS LETT, V234, P189, DOI 10.1016/0014-5793(88)81331-0; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 2000, J CELL SCI, V113, P1841; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Peggie MW, 2002, J CELL SCI, V115, P195; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Trinkle-Mulcahy L, 2001, J CELL SCI, V114, P4219; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	63	58	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13819	13828		10.1074/jbc.M209621200	http://dx.doi.org/10.1074/jbc.M209621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574161	hybrid			2022-12-25	WOS:000182405000034
J	Nekrasov, MP; Ivshina, MP; Chernov, KG; Kovrigina, EA; Evdokimova, VM; Thomas, AAM; Hershey, JWB; Ovchinnikov, LP				Nekrasov, MP; Ivshina, MP; Chernov, KG; Kovrigina, EA; Evdokimova, VM; Thomas, AAM; Hershey, JWB; Ovchinnikov, LP			The mRNA-binding protein YB-1 (p50) prevents association of the eukaryotic initiation factor eIF4G with mRNA and inhibits protein synthesis at the initiation stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YB-1; S RIBOSOMAL-SUBUNITS; MAJOR CORE PROTEIN; COLD-SHOCK DOMAIN; RIBONUCLEOPROTEIN PARTICLES; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; TRANSLATION; POLY(A); CELLS	The cytoplasmic messenger ribonucleoprotein particles of mammalian somatic cells contain the protein YB-1, also called p50, as a major core component. YB-1 is multifunctional and involved in regulation of mRNA transcription and translation. Our previous studies demonstrated that YB-1 stimulates initiation of translation in vitro at a low YB-1/mRNA ratio, whereas an increase of YB-1 bound to mRNA resulted in inhibition of protein synthesis in vitro and in vivo. Here we show that YB-1-mediated translation inhibition in a rabbit reticulocyte cell-free system is followed by a decay of polysomes, which is not a result of mRNA degradation or its functional inactivation. The inhibition does not change the ribosome transit time, and therefore, it affects neither elongation nor termination of polypeptide chains and only occurs at the stage of initiation. YB-1 induces accumulation of mRNA in the form of free messenger ribonucleoprotein particles, i.e. it blocks mRNA association with the small ribosomal subunit. The accumulation is accompanied by eukaryotic initiation factor eIF4G dissociation from mRNA. The C-terminal domain of YB-1 is responsible for inhibition of translation as well as the disruption of mRNA interaction with eIF4G.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Russian Academy of Sciences; Utrecht University; University of California System; University of California Davis	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	ovchinn@vega.protres.ru	Ovchinnikov, Lev/L-2397-2015	Ivshina, Maria/0000-0002-0999-3470				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BLOBEL G, 1972, BIOCHEM BIOPH RES CO, V47, P88, DOI 10.1016/S0006-291X(72)80014-7; Borman AM, 2002, J BIOL CHEM, V277, P36818, DOI 10.1074/jbc.M205065200; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JAIN SK, 1979, MOL BIOL REP, V5, P79, DOI 10.1007/BF00777492; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KOZAK M, 1978, J BIOL CHEM, V253, P6568; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Pisarev AV, 2002, J BIOL CHEM, V277, P15445, DOI 10.1074/jbc.M111954200; Preobrazhensky A A, 1978, Prog Nucleic Acid Res Mol Biol, V21, P1, DOI 10.1016/S0079-6603(08)60265-2; Ruzanov PV, 1999, J CELL SCI, V112, P3487; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Shibao K, 1999, INT J CANCER, V83, P732; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; SPIRIN A. S., 1964, ZH OBSHCH BIOL, V25, P321; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; VANVENROOIJ WJ, 1977, NATURE, V270, P189, DOI 10.1038/270189a0; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; Zasedateleva OA, 2002, J MOL BIOL, V324, P73, DOI 10.1016/S0022-2836(02)00937-3	50	106	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13936	13943		10.1074/jbc.M209145200	http://dx.doi.org/10.1074/jbc.M209145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582179	hybrid			2022-12-25	WOS:000182405000049
J	Wuebbens, MM; Rajagopalan, KV				Wuebbens, MM; Rajagopalan, KV			Mechanistic and mutational studies of Escherichia coli molybdopterin synthase clarify the final step of molybdopterin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; STRUCTURAL CHARACTERIZATION; THIAMIN BIOSYNTHESIS; UBIQUITIN ACTIVATION; CONVERTING FACTOR; PRECURSOR-Z; IDENTIFICATION; SULFUR; THIOCARBOXYLATE; INVOLVEMENT	Biosynthesis of the molybdenum cofactor, a chelate of molybdenum or tungsten with a novel pterin, occurs in virtually all organisms including humans. In the cofactor, the metal is complexed to the unique cis-dithiolene moiety located on the pyran ring of molybdopterin. Escherichia coli molybdopterin synthase, the protein responsible for adding the, dithiolene to a desulfo precursor termed precursor Z, is a dimer of dimers containing the MoaD and MoaE proteins. The sulfur used for dithiolene formation is carried in the form of a thiocarboxylate at the MoaD C terminus. Using an intein expression system for preparation of thiocarboxylated MoaD, the mechanism of the molybdopterin synthase reaction was examined. A stoichiometry of 2 molecules of thiocarboxylated MoaD per conversion of a single precursor Z molecule to molybdopterin was observed. Examination of several synthase variants bearing mutations in the MoaE subunit identified Lys-119 as a residue essential for activity and Arg-39 and Lys-126 as other residues critical for the reaction. An intermediate of the synthase reaction was identified and characterized. This intermediate remains tightly associated with the protein and is the predominant product formed by synthase containing the K126A variant of MoaE. Mass spectral data obtained from protein-bound intermediate are consistent with a monosulfurated structure that contains a terminal phosphate group similar to that present in molybdopterin.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu			NIGMS NIH HHS [GM00091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Hanzelmann P, 2002, J BIOL CHEM, V277, P18303, DOI 10.1074/jbc.M200947200; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; Johnson JL., 2001, METABOLIC MOL BASES, P3163; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kinsland C, 1998, PROTEIN SCI, V7, P1839, DOI 10.1002/pro.5560070821; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Mendel RR, 2002, MET IONS BIOL SYST, V39, P317; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Reiss J, 1999, AM J HUM GENET, V64, P706, DOI 10.1086/302296; Remko M, 1997, J MOL STRUC-THEOCHEM, V418, P179, DOI 10.1016/S0166-1280(96)05025-7; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Rudolph MJ, 2003, J BIOL CHEM, V278, P14514, DOI 10.1074/jbc.M300449200; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698	35	83	89	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14523	14532		10.1074/jbc.M300453200	http://dx.doi.org/10.1074/jbc.M300453200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571226	hybrid			2022-12-25	WOS:000182405000120
J	Yang, IY; Miller, H; Wang, ZG; Frank, EG; Ohmori, H; Hanaoka, F; Moriya, M				Yang, IY; Miller, H; Wang, ZG; Frank, EG; Ohmori, H; Hanaoka, F; Moriya, M			Mammalian translesion DNA synthesis across an acrolein-derived deoxyguanosine adduct - Participation of DNA polymerase eta in error-prone synthesis in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM VARIANT; ESCHERICHIA-COLI; LOW FIDELITY; Y-FAMILY; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; LESION-BYPASS; HUMAN HOMOLOG; HUMAN REV1; POL-KAPPA; UV-LIGHT	alpha-OH-PdG, an acrolein-derived deoxyguanosine adduct, inhibits DNA synthesis and miscodes significantly in human cells. To probe the cellular mechanism underlying the error-free and error-prone translesion DNA syntheses, in vitro primer extension experiments using purified DNA polymerases and site-specific alpha-OH-PdG were conducted. The results suggest the involvement of pol eta in the cellular error-prone translesion synthesis. Experiments with xeroderma pigmentosum variant cells, which lack pol eta, confirmed this hypothesis. The in vitro results also suggested the involvement of pol iota and/or REV1 in inserting correct dCMP opposite alpha-OH-PdG during error-free synthesis. However, none of translesion-specialized DNA polymerases catalyzed significant extension from a dC terminus when paired opposite alpha-OH-PdG. Thus, our results indicate the following. (i) Multiple DNA polymerases are involved in the bypass of alpha-OH-PdG in human cells. (ii) The accurate and inaccurate syntheses are catalyzed by different polymerases. (iii) A modification of the current eukaryotic bypass model is necessary to account for the accurate bypass synthesis in human cells.	SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; NICHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Lab Genet Informat Anal, Kyoto 6068507, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Kentucky; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kyoto University; Osaka University	Moriya, M (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA.	maki@pharm.sunysb.edu	Miller, Holly/I-6942-2015	Miller, Holly/0000-0002-9076-5335	NCI NIH HHS [CA76163, CA47995, CA92528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047995, R01CA076163, R56CA076163, R01CA092528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; CHUNG FL, 1984, CANCER RES, V44, P990; Cleaver JE, 1999, CANCER RES, V59, P1102; COHEN SM, 1992, CANCER RES, V52, P3577; CURREN RD, 1988, MUTAT RES, V209, P17, DOI 10.1016/0165-7992(88)90104-2; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG Y, 2003, IN PRESS BIOORG CHEM; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kawanishi M, 1998, MUTAT RES-GEN TOX EN, V417, P65, DOI 10.1016/S1383-5718(98)00093-X; KING SA, 1995, EXP CELL RES, V217, P100, DOI 10.1006/excr.1995.1068; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; MARNETT LJ, 1985, MUTAT RES, V148, P25; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Minko IG, 2003, J BIOL CHEM, V278, P784, DOI 10.1074/jbc.M207774200; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; NG L, 1991, J BIOL CHEM, V266, P11699; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; Pandya GA, 2000, J BACTERIOL, V182, P6598, DOI 10.1128/JB.182.23.6598-6604.2000; Parent RA, 1996, J APPL TOXICOL, V16, P103, DOI 10.1002/(SICI)1099-1263(199603)16:2<103::AID-JAT318>3.0.CO;2-Q; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; SMITH RA, 1990, CARCINOGENESIS, V11, P497, DOI 10.1093/carcin/11.3.497; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; Wang Z, 2001, Mol Interv, V1, P269; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; Yang IY, 2002, CHEM RES TOXICOL, V15, P160, DOI 10.1021/tx010123c; Yang IY, 2002, BIOCHEMISTRY-US, V41, P13826, DOI 10.1021/bi0264723; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630	60	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13989	13994		10.1074/jbc.M212535200	http://dx.doi.org/10.1074/jbc.M212535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584190	hybrid			2022-12-25	WOS:000182405000056
J	Zhang, F; Li, C; Halfter, H; Liu, JW				Zhang, F; Li, C; Halfter, H; Liu, JW			Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells	ONCOGENE			English	Article						oncostatin M; STAT3; cell growth; cell migration; extracellular matrix	C-MYC-GENE; INDUCED GROWTH-INHIBITION; P53 TUMOR-SUPPRESSOR; BREAST-CANCER CELLS; INTERFERON-GAMMA; TRANSDUCER; INDUCTION; TRANSCRIPTION; BINDING; DIFFERENTIATION	A number of studies have demonstrated that the STAT pathway is an important signaling cascade utilized by the IL-6 cytokine family to regulate a variety of cell functions. However, the downstream target genes of STAT activation that mediate the cytokine-induced cellular responses are largely uncharacterized. The aims of the current study are to determine whether the STAT signaling pathway is critically involved in the oncostatin M (OM)-induced growth inhibition and morphological changes of MCF-7 cells and to identify STAT3-target genes that are utilized by OM to regulate cell growth and morphology. We show that expression of a dominant negative (DN) mutant of STAT3 in MCF-7 cells completely eliminated the antiproliferative activity of OM, whereas expression of DN STAT1 had no effect. The growth inhibition of breast cancer cells was achieved through a concerted action of OM on cell cycle components. We have identified four cell cycle regulators including c-myc, cyclin D1, c/EBPdelta, and p53 as downstream effectors of the OM-activated STAT3 signaling cascade. The expression of these genes is differentially regulated by OM in MCF-7 cells, but is unaffected by OM in MCF-7-dnStat3 stable clones. We also demonstrate that the OM-induced morphological changes are correlated with increased cell motility in a STAT3-dependent manner. Expression analysis of extracellular matrix (ECM) proteins leads to the identification of fibronectin as a novel OM-regulated ECM component. Our studies further reveal that STAT3 plays a key role in the robust induction of fibronectin expression by OM in MCF-7 and T47D cells. These new findings provide a molecular basis for the mechanistic understanding of the effects of OM on cell growth and migration.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Univ Munster, Dept Neurol & Internal Med A Oncol, D-4400 Munster, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Munster	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 154P,3801 Miranda Ave, Palo Alto, CA 94304 USA.	jingwen.liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badache A, 2001, CANCER RES, V61, P383; Bamber B, 1998, J MOL MED-JMM, V76, P61, DOI 10.1007/s109-1998-8105-3; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Carroll JS, 2002, CANCER RES, V62, P3126; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Chang TLY, 2000, J BIOL CHEM, V275, P10212, DOI 10.1074/jbc.275.14.10212; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P128, DOI 10.1111/1523-1747.ep12613623; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GROVE RI, 1991, J LIPID RES, V32, P1889; Halfter H, 2000, J NEUROCHEM, V75, P973, DOI 10.1046/j.1471-4159.2000.0750973.x; Halfter H, 1998, GROWTH FACTORS, V15, P135, DOI 10.3109/08977199809117189; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Hutt JA, 2000, J BIOL CHEM, V275, P29123, DOI 10.1074/jbc.M004476200; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kerr C, 1999, J INTERF CYTOK RES, V19, P1195, DOI 10.1089/107999099313145; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Li C, 2001, BREAST CANCER RES TR, V66, P111, DOI 10.1023/A:1010614724664; Li C, 2001, ONCOGENE, V20, P8193, DOI 10.1038/sj.onc.1205046; LI W, 2002, J BIOL CHEM, V1, P1; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; Lin JY, 2002, CANCER RES, V62, P376; Liu HF, 1999, WORLD J GASTROENTERO, V5, P15; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Mahboubi K, 2002, J BIOL CHEM, V277, P8012, DOI 10.1074/jbc.M107542200; Makogonenko E, 2002, BIOCHEMISTRY-US, V41, P7907, DOI 10.1021/bi025770x; MARSTERS P, 2002, BIOCHEM J, V1, P1; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sauter ER, 2002, CANCER RES, V62, P3200; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spence MJ, 1997, CANCER RES, V57, P2223; Strand K, 2000, J CELL BIOCHEM, V79, P239, DOI 10.1002/1097-4644(20001101)79:2<239::AID-JCB70>3.0.CO;2-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wahl AF, 2001, ANN RHEUM DIS, V60, pIII75; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	53	97	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					894	905		10.1038/sj.onc.1206158	http://dx.doi.org/10.1038/sj.onc.1206158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584569				2022-12-25	WOS:000180864300012
J	Crowder, C; Kopantzev, E; Williams, K; Lengel, C; Miki, T; Rudikoff, S				Crowder, C; Kopantzev, E; Williams, K; Lengel, C; Miki, T; Rudikoff, S			An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth	ONCOGENE			English	Article						Ras; mutation; transformation; growth factor independence	GUANINE-NUCLEOTIDE-BINDING; N-RAS; K-RAS; ACTIVATING MUTATIONS; STRUCTURAL DIFFERENCES; TRANSDUCTION PATHWAY; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR-3; LIVER-TUMORS; PRODUCT P21	Multiple myeloma (MM) is an incurable plasma cell malignancy. To investigate biochemical lesions associated,with MM, we constructed an expression cDNA library from the OPM-2 human myeloma line. A highly transforming H-Ras mutant was identified by transfection analysis using NIH 3T3 cells. DNA sequencing demonstrated a single-point mutation at position 117 located in the guanine nucleotide-binding site resulting in a lysine-to-glutamic acid substitution. This mutant, H-Ras (K117E), was found to be constitutively activated in terms of GTP binding. We compared the biological effects of H-Ras (K117E) and H-Ras (G12V) in 32D murine hematopoietic progenitor cells. Whereas both Ras proteins are constitutively activated, 32D cells expressing H-Ras (G12V) are still dependent on IL-3 for survival and proliferation while cells carrying H-Ras (K117E) become IL-3 independent. Similar experiments conducted with the B9 line, an IL-6-dependent hybridoma, also demonstrated that B9/H-Ras (KI17E) became IL-6-independent. Expression of H-Ras (K117E) in the human IL-6-dependent ANBL-6 myeloma line resulted in enhanced proliferation at suboptimal concentrations of IL-6. These observations suggest that H-Ras mutations at the binding site for the GTP nucleotide ring structure may also represent activating lesions and have additional biological effects when compared to previously described Ras mutants.	NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA; NCI, Mol Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA.	rudikoff@helix.nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNA CH, 1994, CARCINOGENESIS, V15, P2255, DOI 10.1093/carcin/15.10.2255; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; BOS JL, 1987, BLOOD, V69, P1237; Chesi M, 2000, ANN ONCOL, V11, P131, DOI 10.1023/A:1008300325610; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; Cool RH, 1999, MOL CELL BIOL, V19, P6297; CORRADINI P, 1994, LEUKEMIA LYMPHOMA, V15, P17, DOI 10.3109/10428199409051673; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DIAMANT M, 1994, J IMMUNOL METHODS, V173, P229, DOI 10.1016/0022-1759(94)90301-8; Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; Ge NL, 2000, BLOOD, V96, P2856; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; Ho PJ, 2001, BLOOD, V97, P490, DOI 10.1182/blood.V97.2.490; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kalakonda N, 2001, BLOOD, V98, P1555, DOI 10.1182/blood.V98.5.1555; Kastrinakis NG, 2000, ANN ONCOL, V11, P1217, DOI 10.1023/A:1008331714186; KATAGIRI S, 1985, INT J CANCER, V36, P241, DOI 10.1002/ijc.2910360217; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lattanzio G, 1997, AM J PATHOL, V151, P689; LIDA S, 1997, NAT GENET, V17, P226; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; Liu Q, 2001, EXP HEMATOL, V29, P962, DOI 10.1016/S0301-472X(01)00677-4; MATOZAKI S, 1991, Kobe Journal of Medical Sciences, V37, P35; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rawat R, 2000, BLOOD, V96, P3514; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; STANLEY LA, 1994, CARCINOGENESIS, V15, P1125, DOI 10.1093/carcin/15.6.1125; TAKAHASHI M, 1994, HEMATOL ONCOL, V12, P53, DOI 10.1002/hon.2900120202; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TSUCHIYA H, 1988, BLOOD, V72, P796; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832	56	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					649	659		10.1038/sj.onc.1206180	http://dx.doi.org/10.1038/sj.onc.1206180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569357				2022-12-25	WOS:000180642100002
J	Wiegand, V; Chang, TY; Strauss, JF; Fahrenholz, F; Gimpl, G				Wiegand, V; Chang, TY; Strauss, JF; Fahrenholz, F; Gimpl, G			Transport of plasma membrane-derived cholesterol and the function of Niemann-Pick C1 protein	FASEB JOURNAL			English	Article						lipid droplets; esterification; progesterone; NPC	LIPID DROPLETS; INTRACELLULAR TRAFFICKING; STORAGE DISEASES; CELLS; RICH; ACCUMULATION; COMPARTMENTS; LOCALIZATION; MICRODOMAINS; MOBILIZATION	To visualize the intracellular transport of plasma membrane-derived cholesterol under physiological and pathophysiological conditions, a novel fluorescent cholesterol analog, 6-dansyl cholestanol (DChol), has been synthesized. We present several lines of evidence that DChol mimics cholesterol. The cholesterol probe could be efficiently incorporated into the plasma membrane via cyclodextrin-donor complexes. The itinerary of DChol from the plasma membrane to the cell was studied to determine its dependence on the function of Niemann-Pick C1 (NPC) protein. In all cells, DChol moved from the plasma membrane to the endoplasmic reticulum. Its further transport to the Golgi complex was observed but with marked differences among various cell lines. DChol was finally transported to small (similar to0.5 mum diameter) lipid droplets, a process that required functional acyl-CoA:cholesterol acyltransferase. In human NPC fibroblasts, NPC-like cells, or in cells mimicking the NPC phenotype, DChol was found in enlarged (>1 mum diameter) droplets. When the NPC-phenotype was corrected by transfection with NPC1, DChol was again found in small-sized droplets. Our data show that NPC1 has an essential role in the distribution of plasma membrane-derived cholesterol by maintaining the small size of cholesterol-containing lipid droplets in the cell.	Univ Mainz, Inst Biochem, D-55099 Mainz, Germany; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Penn, Ctr Res Reprod Womens Hlth, Philadelphia, PA 19104 USA	Johannes Gutenberg University of Mainz; Dartmouth College; University of Pennsylvania; Pennsylvania Medicine	Gimpl, G (corresponding author), Univ Mainz, Inst Biochem, Becherweg 30, D-55099 Mainz, Germany.	gimpl@mail.uni-mainz.de	Gimpl, Gerald/R-3722-2019	Chang, Ta-Yuan/0000-0002-3249-0468; Gimpl, Gerald/0000-0002-5703-1989				Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURGER K, 2000, THESIS MAINZ; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; COXEY RA, 1993, J LIPID RES, V34, P1165; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Garver WS, 2000, J LIPID RES, V41, P673; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; HIGGINS CM, 1999, CURRENT TOP VIROL, V1, P1; KAWASAKI T, 1982, J CHROMATOGR, V233, P61, DOI 10.1016/S0378-4347(00)81731-4; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Mintzer EA, 2002, FEBS LETT, V510, P181, DOI 10.1016/S0014-5793(01)03271-9; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; PELLETIER RM, 1994, J HISTOCHEM CYTOCHEM, V42, P1539, DOI 10.1177/42.12.7983355; Prattes S, 2000, J CELL SCI, V113, P2977; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; STEER CJ, 1984, J CELL BIOL, V99, P315, DOI 10.1083/jcb.99.1.315; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WUSTNER D, 2002, J BIOL CHEM; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	47	42	44	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					782	+		10.1096/fj.02-0818fje	http://dx.doi.org/10.1096/fj.02-0818fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594172				2022-12-25	WOS:000181456900012
J	Holtz, WA; O'Malley, KL				Holtz, WA; O'Malley, KL			Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; RECESSIVE JUVENILE PARKINSONISM; DISTINCT MECHANISMS; ALPHA-SYNUCLEIN; MESSENGER-RNA; ER STRESS; DISEASE; GENE; APOPTOSIS	Genes associated with Parkinson's disease (PD) have suggested a role for ubiquitin-proteasome dysfunction and aberrant protein degradation in this disorder. Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line. Microarray analysis of RNA isolated from toxin treated samples revealed that the stress-induced transcription factor CHOP/Gadd153 was dramatically up-regulated by both 6-OHDA and MPP+. Treatment with 6-OHDA also induced a large number of genes involved in endoplasmic reticulum stress and unfolded protein response (UPR) such as ER chaperones and elements of the ubiquitin-proteasome system. Reverse transcription-PCR, Western blotting, and immunocytochemical approaches were used to quantify and temporally order the UPR pathways involved in neurotoxin-induced cell death. 6-OHDA, but not MPP+, significantly increased hallmarks of UPR such as BiP, c-Jun, and processed Xbp1 mRNA. Both toxins increased the phosphorylation of UPR proteins, PERK and eIF2alpha, but only 6-OHDA increased phosphorylation of c-Jun. Thus, 6-OHDA is capable of triggering multiple pathways associated with UPR, whereas MPP+ exhibits a more restricted response. The involvement of UPR in these widely used neurotoxin models supports the role of ubiquitin-proteasome pathway dysfunction in PD.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	O'Malley, KL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.	omalleyk@pcg.wustl.edu	Longo, Kenneth A/A-5631-2010		NCI NIH HHS [P30 CA91842] Funding Source: Medline; NINDS NIH HHS [NS39084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS039084, R01NS039084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Castro-Obregon S, 2002, CELL DEATH DIFFER, V9, P807, DOI 10.1038/sj.cdd.4401035; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Choi WS, 1999, EXP NEUROL, V159, P274, DOI 10.1006/exnr.1999.7133; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Conn KJ, 2002, J NEUROSCI RES, V68, P755, DOI 10.1002/jnr.10252; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1983, NEW ENGL J MED, V309, P310; Lansbury PT, 2002, CURR OPIN CELL BIOL, V14, P653, DOI 10.1016/S0955-0674(02)00377-0; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu CY, 2003, BLOOD, V101, P295, DOI 10.1182/blood-2001-12-0266; Lotharius J, 1999, J NEUROSCI, V19, P1284; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; Mengesdorf T, 2002, MOL BRAIN RES, V104, P227, DOI 10.1016/S0169-328X(02)00384-4; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Nicotra A, 2002, NEUROTOXICOL TERATOL, V24, P599, DOI 10.1016/S0892-0362(02)00213-1; Oh YJ, 1995, NEUROBIOL DIS, V2, P157, DOI 10.1006/nbdi.1995.0017; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; OMALLEY KL, 2003, IN PRESS NEUROBIOL D; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Speciale SG, 2002, NEUROTOXICOL TERATOL, V24, P607, DOI 10.1016/S0892-0362(02)00222-2; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Williams B.R., 2001, SCI STKE, V2001, pre2; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	61	307	324	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19367	19377		10.1074/jbc.M211821200	http://dx.doi.org/10.1074/jbc.M211821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12598533	hybrid			2022-12-25	WOS:000182932200085
J	Cordes, FS; Komoriya, K; Larquet, E; Yang, SX; Egelman, EH; Blocker, A; Lea, SM				Cordes, FS; Komoriya, K; Larquet, E; Yang, SX; Egelman, EH; Blocker, A; Lea, SM			Helical structure of the needle of the type III secretion system of Shigella flexneri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL FLAGELLAR FILAMENTS; PROTEIN SECONDARY STRUCTURE; RAY FIBER DIFFRACTION; SUPRAMOLECULAR STRUCTURE; ELECTRON CRYOMICROSCOPY; NEURAL NETWORKS; SALMONELLA; RECONSTRUCTION; PREDICTION; COMPLEX	Gram-negative bacteria commonly interact with animal and plant hosts using type III secretion systems (TTSSs) for translocation of proteins into eukaryotic cells during infection. 10 of the 25 TTSS-encoding genes are homologous to components of the bacterial flagellar basal body, which the TTSS needle complex morphologically resembles. This indicates a common ancestry, although no TTSS sequence homologues for the genes encoding the flagellum are found. We here present an similar to16-Angstrom structure of the central component, the needle, of the TTSS. Although the needle subunit is significantly smaller and shares no sequence homology with the flagellar hook and filament, it shares a common helical architecture (similar to5.6 subunits/turn, 24-Angstrom helical pitch). This common architecture implies that there will be further mechanistic analogies in the functioning of these two bacterial systems.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Inst Pasteur, F-75724 Paris, France; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Oxford; University of Oxford; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Virginia	Lea, SM (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Parks Rd, Oxford OX1 3QU, England.		larquet, eric/ABB-3063-2021; Lea, Susan M/B-7678-2009; Egelman, Edward H/A-2488-2009; yang, shixin/B-4015-2010; Blocker, Ariel/Q-6617-2016	larquet, eric/0000-0002-9994-6845; Lea, Susan M/0000-0001-9287-8053; yang, shixin/0000-0002-3639-7818; Egelman, Edward/0000-0003-4844-5212	NIGMS NIH HHS [GM66771] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; BLOCKER A, 2003, IN PRESS P NATL ACAD; CALLADINE CR, 1975, NATURE, V255, P121, DOI 10.1038/255121a0; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DEROSIER DJ, 1968, NATURE, V217, P130, DOI 10.1038/217130a0; DIXON MF, 2000, GEN SYSTEMATIC PATHO, P383; Donnenberg MS, 2000, NATURE, V406, P768, DOI 10.1038/35021212; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; MIMORI Y, 1995, J MOL BIOL, V249, P69, DOI 10.1006/jmbi.1995.0281; MORGAN DG, 1993, J MOL BIOL, V229, P79, DOI 10.1006/jmbi.1993.1009; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Samatey FA, 2001, NATURE, V410, P331, DOI 10.1038/35066504; Szewzyk U, 2000, ANNU REV MICROBIOL, V54, P81, DOI 10.1146/annurev.micro.54.1.81; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Thomas D, 2001, J BACTERIOL, V183, P6404, DOI 10.1128/JB.183.21.6404-6412.2001; YAMASHITA I, 1991, J MOL BIOL, V217, P293, DOI 10.1016/0022-2836(91)90543-F; Yamashita I, 1998, J MOL BIOL, V278, P609, DOI 10.1006/jmbi.1998.1710; Yamashita I, 1998, NAT STRUCT BIOL, V5, P125; Yonekura K, 2001, J STRUCT BIOL, V133, P246, DOI 10.1006/jsbi.2000.4345; 2000, MERCK MANUAL DIAGNOS, P1164	28	154	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17103	17107		10.1074/jbc.M300091200	http://dx.doi.org/10.1074/jbc.M300091200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12571230	hybrid			2022-12-25	WOS:000182818600088
J	Li, T; Southall, MD; Yi, QF; Pei, Y; Lewis, D; Al-Hassani, M; Spandau, D; Travers, JB				Li, T; Southall, MD; Yi, QF; Pei, Y; Lewis, D; Al-Hassani, M; Spandau, D; Travers, JB			The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; HUMAN KERATINOCYTES; RAT STRIATUM; NECROSIS; BIOSYNTHESIS; DAMAGE; LIGAND	Most chemotherapeutic agents exert their cytotoxic effects in part through the induction of apoptosis. In addition, many chemotherapeutic agents are potent pro-oxidative stressors. Although the lipid mediator platelet-activating factor (PAF) is synthesized in response to oxidative stress, and many epidermal carcinomas express PAF receptors, it is not known whether PAF is involved in chemotherapeutic agent-induced apoptosis. These studies examined the role of the PAF system in chemotherapy-mediated cytotoxicity using model systems created by retroviral mediated transduction of the PAF receptor-negative human epidermal carcinoma cell line KB with the human PAF receptor (PAF-R) and ablation of the endogenous PAF-R in the carcinoma cell line HaCaT with a retroviral mediated inducible antisense PAF-R vector. The presence of the PAF-R in these models resulted in an augmentation of apoptosis induced by chemotherapeutic agents etoposide and mitomycin C but not by tumor necrosis factor-related apoptosis-inducing ligand or by C-2 ceramide. Oxidative stress and the transcription factor nuclear factor kappaB (NF-kappaB) are found to be involved in this augmentative effect because it was blocked by antioxidants and inhibition of the NF-kappaB pathway using a super-repressor form of inhibitor B. These studies provide evidence for a novel pathway whereby the epidermal PAF-R can augment chemotherapy-induced apoptotic effects through an NF-kappaB-dependent process.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Travers, JB (corresponding author), Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, HB Wells Ctr Pediat Res, Rm 2659,702 Barnhill Dr, Indianapolis, IN 46202 USA.		LI, TAO/AAL-5932-2020	LI, TAO/0000-0001-7343-9688; Travers, Jeffrey/0000-0001-7232-1039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62996] Funding Source: Medline; NIAMS NIH HHS [AR01993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Countryman NB, 2000, J INVEST DERMATOL, V115, P267, DOI 10.1046/j.1523-1747.2000.00058.x; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; Foo SY, 1999, TRENDS GENET, V15, P229; Goldman R, 1999, BBA-MOL CELL BIOL L, V1438, P349, DOI 10.1016/S1388-1981(99)00066-9; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kagan VE, 2001, CANCER RES, V61, P7777; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; McInnis J, 2002, J PHARMACOL EXP THER, V301, P478, DOI 10.1124/jpet.301.2.478; MICHEL L, 1990, J INVEST DERMATOL, V95, P576, DOI 10.1111/1523-1747.ep12505563; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Pei Y, 1998, J IMMUNOL, V161, P1954; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Southall MD, 2001, J BIOL CHEM, V276, P45548, DOI 10.1074/jbc.M105978200; Travers JB, 1999, J INVEST DERMATOL, V112, P279, DOI 10.1046/j.1523-1747.1999.00521.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Wang Y, 1999, NEUROSCIENCE, V94, P1153, DOI 10.1016/S0306-4522(99)00264-X; Williams DA, 2000, BLOOD, V96, P1646; XU BH, 1992, CANCER LETT, V66, P49, DOI 10.1016/0304-3835(92)90279-5	29	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16614	16621		10.1074/jbc.M211287200	http://dx.doi.org/10.1074/jbc.M211287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12601006	hybrid			2022-12-25	WOS:000182818600024
J	Petrie, K; Guidez, F; Howell, L; Healy, L; Waxman, S; Greaves, M; Zelent, A				Petrie, K; Guidez, F; Howell, L; Healy, L; Waxman, S; Greaves, M; Zelent, A			The histone deacetylase 9 gene encodes multiple protein isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SAETHRE-CHOTZEN-SYNDROME; COMPARATIVE GENOMIC HYBRIDIZATION; COREPRESSOR N-COR; TRANSCRIPTIONAL REPRESSION; MEDIATED REPRESSION; CLASS-I; FAMILY; TWIST; EXPRESSION	Histone deacetylases (HDACs) perform an important function in transcriptional regulation by modifying the core histones of the nucleosome. We have now fully characterized a new member of the Class II HDAC family, HDAC9. The enzyme contains a conserved deacetylase domain, represses reporter activity when recruited to a promoter, and utilizes histones H3 and H4 as substrates in vitro and in vivo. HDAC9 is expressed in a tissue-specific pattern that partially overlaps that of HDAC4. Within the human hematopoietic system, expression of HDAC9 is biased toward cells of monocytic and lymphoid lineages. The HDAC9 gene encodes multiple protein isoforms, some of which display distinct cellular localization patterns. For example, full-length HDAC9 is localized in the nucleus, but the isoform lacking the region encoded by exon 7 is in the cytoplasm. HDAC9 interacts and co-localizes in vivo with a number of transcriptional repressors and co-repressors, including TEL and N-CoR, whose functions have been implicated in the pathogenesis of hematological malignancies. These results suggest that HDAC9 plays a role in hematopoiesis; its deregulated expression may be associated with some human cancers.	Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai	Zelent, A (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.		Guidez, Fabien/P-4220-2019; Zelent, Arthur/B-3532-2009; Petrie, Kevin/I-7115-2015; Guidez, Fabien/B-3750-2009	Guidez, Fabien/0000-0003-1380-4473; Petrie, Kevin/0000-0002-9805-9152; Zelent, Arthur/0000-0002-7968-9888; Healy, Lyn/0000-0002-7044-8789				Agape P, 1997, BRIT J HAEMATOL, V98, P234, DOI 10.1046/j.1365-2141.1997.1973014.x; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Aragane H, 2001, INT J CANCER, V94, P623, DOI 10.1002/ijc.1522; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Capello D, 2000, BLOOD, V95, P651; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DAVID G, 2002, J BIOL CHEM, V17, P17; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; ElGhouzzi V, 1997, NAT GENET, V15, P42; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; ENVER T, 1985, NATURE, V318, P680, DOI 10.1038/318680a0; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; FURLEY AJ, 1986, BLOOD, V68, P1101; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 2001, CURR TOP MICROBIOL, V254, P165; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jarosova M, 2000, CANCER GENET CYTOGEN, V123, P114, DOI 10.1016/S0165-4608(00)00310-1; Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Krebs I, 1997, HUM MOL GENET, V6, P1079, DOI 10.1093/hmg/6.7.1079; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEWANDA AF, 1994, AM J HUM GENET, V55, P1195; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahlknecht U, 2000, BBA-GENE STRUCT EXPR, V1493, P342, DOI 10.1016/S0167-4781(00)00191-3; Mahlknecht U, 1999, GENOMICS, V56, P197, DOI 10.1006/geno.1998.5645; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Powlesland RM, 2000, BRIT J CANCER, V82, P323, DOI 10.1054/bjoc.1999.0922; RIO DC, 1985, SCIENCE, V227, P23, DOI 10.1126/science.2981116; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Schmidt H, 2002, GENE CHROMOSOME CANC, V34, P69, DOI 10.1002/gcc.10036; Schmidt H, 1999, GENE CHROMOSOME CANC, V25, P205, DOI 10.1002/(SICI)1098-2264(199907)25:3<205::AID-GCC2>3.0.CO;2-B; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Stankiewicz P, 2001, AM J MED GENET, V103, P56, DOI 10.1002/ajmg.1512; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; TSUJI K, 1994, AM J MED GENET, V49, P98, DOI 10.1002/ajmg.1320490119; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	85	119	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16059	16072		10.1074/jbc.M212935200	http://dx.doi.org/10.1074/jbc.M212935200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590135	hybrid			2022-12-25	WOS:000182680000078
J	Tjalsma, H; Bron, S; van Dijl, JM				Tjalsma, H; Bron, S; van Dijl, JM			Complementary impact of paralogous Oxa1-like proteins of Bacillus subtilis on post-translocational stages in protein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-II; ESCHERICHIA-COLI; MEMBRANE-PROTEIN; EFFICIENT SECRETION; FUNCTIONAL-ANALYSIS; THYLAKOID MEMBRANE; INNER MEMBRANE; ALPHA-AMYLASE; SPOIIIJ GENE; N-TERMINI	In mitochondria, chloroplasts, and Gram-negative eubacteria, Oxa1p(-like) proteins are critical for the biogenesis of membrane proteins. Here we show that the Gram-positive eubacterium Bacillus subtilis contains two functional Oxalp orthologues, denoted SpoIIIJ and YqjG. The presence of either SpoIIIJ or YqjG is required for cell viability. Whereas SpoIIIJ is required for sporulation, YqjG is dispensable for this developmental process. The stability of two membrane proteins was found to be mildly affected upon SpoIIIJ limitation in the absence of YqjG. Surprisingly, the topology and stability of other membrane proteins remained unaffected under these conditions. In contrast, SpoIIIJ- and YqjG-limiting conditions resulted in a strong post-translocational defect in the stability of secretory proteins. Together, these data indicate that SpoIIIJ and YqjG of B. subtilis are involved in both membrane protein hiogenesis and protein secretion. However, the reduced stability of secretory proteins seems to be the most prominent phenotype of SpoIIIJ/YqjG-depleted B. subtilis cells. In conclusion, our observations show that SpoIIIJ and YqjG have different, but overlapping, functions in R subtilis. Most importantly, it seems that different members of the Oxalp protein family have acquired at least partly distinct, species-specific, functions that are essential for life.	Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9750 AA Haren, Netherlands; Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen	Bron, S (corresponding author), Groningen Biomol Sci & Biotechnol Inst, Dept Genet, POB 14, NL-9750 AA Haren, Netherlands.		Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013					ALTEMURA N, 1996, FEBS LETT, V382, P111; Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Asai K, 1997, J BACTERIOL, V179, P544, DOI 10.1128/jb.179.2.544-547.1997; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; Bengtsson J, 1999, J BACTERIOL, V181, P685, DOI 10.1128/JB.181.2.685-688.1999; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; Bolhuis A, 1999, J BIOL CHEM, V274, P24585, DOI 10.1074/jbc.274.35.24585; Bolhuis A, 1999, J BIOL CHEM, V274, P24531, DOI 10.1074/jbc.274.35.24531; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; Bonnefoy N, 2000, MOL MICROBIOL, V35, P1135, DOI 10.1046/j.1365-2958.2000.01781.x; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DARTOIS V, 1994, APPL ENVIRON MICROB, V60, P1670, DOI 10.1128/AEM.60.5.1670-1673.1994; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Deuerling E, 1997, MOL MICROBIOL, V23, P921, DOI 10.1046/j.1365-2958.1997.2721636.x; ERRINGTON J, 1992, J GEN MICROBIOL, V138, P2609, DOI 10.1099/00221287-138-12-2609; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; Jiang M, 2000, J BACTERIOL, V182, P303, DOI 10.1128/JB.182.2.303-310.2000; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Miller J. H., 1982, EXPT MOL GENETICS; Murakami T, 2002, J BACTERIOL, V184, P1998, DOI 10.1128/JB.184.7.1998-2004.2002; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; POGLIANO KJ, 1993, GENETICS, V133, P763; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Pragai Z, 2000, J BACTERIOL, V182, P6819, DOI 10.1128/JB.182.23.6819-6823.2000; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Sambrook J., 2002, MOL CLONING LAB MANU; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stuart RA, 2000, NATURE, V406, P575, DOI 10.1038/35020668; Tjalsma H, 2000, J BIOL CHEM, V275, P25102, DOI 10.1074/jbc.M002676200; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van Wely KHM, 2000, MICROBIOL-SGM, V146, P2573, DOI 10.1099/00221287-146-10-2573; van Wely KHM, 1999, J BACTERIOL, V181, P1786, DOI 10.1128/JB.181.6.1786-1792.1999; VanDijl J. M., 2001, BACILLUS SUBTILIS IT, P337; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VIERA J, 1991, GENE, V100, P189; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6	61	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15622	15632		10.1074/jbc.M301205200	http://dx.doi.org/10.1074/jbc.M301205200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586834	hybrid, Green Published			2022-12-25	WOS:000182680000023
J	Wang, CC; Bozdech, Z; Liu, CI; Shipway, A; Backes, BJ; Harris, JL; Bogyo, M				Wang, CC; Bozdech, Z; Liu, CI; Shipway, A; Backes, BJ; Harris, JL; Bogyo, M			Biochemical analysis of the 20 S proteasome of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ORNITHINE DECARBOXYLASE; ACTIVE-SITE FORMATION; MULTICATALYTIC PROTEINASE; SUBSTRATE-SPECIFICITY; REGULATORY PARTICLE; SUBUNIT; DEGRADATION; COMPLEX; YEAST; IDENTIFICATION	We describe here biochemical characterization of the 20 S proteasome from the parasitic protozoan Trypanosoma brucei. Similar to the mammalian proteasome, the T. brucei proteasome is made up of seven alpha- and seven beta-subunits. Of the seven beta-type subunits, five contain pro-sequences that are proteolytically removed during assembly, and three of them are predicted to be catalytic based on primary sequence. Affinity labeling studies revealed that, unlike the mammalian proteasome where three beta-subunits were labeled by the affinity reagents, only two beta-subunits of the T. brucei proteasome were labeled in the complex. These two subunits corresponded to beta2 and 135 subunits responsible for the trypsin-like and chymotrypsin-like proteolytic activities, respectively. Screening of a library of 137,180 tetrapeptide fluorogenic substrates against the T. brucei 20 S proteasome confirmed the nominal beta1-subunit (caspase-like or PGPH) activity and identified an overall substrate preference for hydrophobic residues at the P1 to P4 positions in a substrate. This overall stringency is relaxed in the 11 S regulator (PA26)-20 S proteasome complex, which shows both appreciable activities for cleavage after acidic amino acids and a broadened activity for cleavage after basic amino acids. The 20 S proteasome from T. brucei also shows appreciable activity for cleavage after P1-Gln that is minimally observed in the human counterpart. These results demonstrate the importance of substrate sequence specificity of the T. brucei proteasome and highlight its biochemical divergence from the human enzyme.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Novartis Res Fdn, Dept Chem, Genom Inst, San Diego, CA 92121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.		Bozdech, Zbynek/A-2205-2011	Bozdech, Zbynek/0000-0002-9830-8446; Bogyo, Matthew/0000-0003-3753-4412	NIAID NIH HHS [AI 21786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786, R56AI021786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BASS KE, 1992, J BIOL CHEM, V267, P11034; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Groll M, 2002, CHEM BIOL, V9, P655, DOI 10.1016/S1074-5521(02)00144-8; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUA SB, 1995, J BIOL CHEM, V270, P10264, DOI 10.1074/jbc.270.17.10264; Hua SB, 1996, MOL BIOCHEM PARASIT, V78, P33, DOI 10.1016/S0166-6851(96)02599-6; Huang L, 1999, MOL BIOCHEM PARASIT, V102, P211, DOI 10.1016/S0166-6851(99)00096-1; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Yao Y, 1999, J BIOL CHEM, V274, P33921, DOI 10.1074/jbc.274.48.33921; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	41	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15800	15808		10.1074/jbc.M300195200	http://dx.doi.org/10.1074/jbc.M300195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600991	hybrid			2022-12-25	WOS:000182680000045
J	Yoon, JB; Kim, SJ; Hwang, SG; Chang, S; Kang, SS; Chun, JS				Yoon, JB; Kim, SJ; Hwang, SG; Chang, S; Kang, SS; Chun, JS			Non-steroidal anti-inflammatory drugs inhibit nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes independent of cyclooxygenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; COLON-CANCER CELLS; SODIUM-SALICYLATE; SULINDAC SULFIDE; OSTEOARTHRITIS CHONDROCYTES; PROSTAGLANDIN E-2; TNF-ALPHA; IN-VIVO; CARTILAGE	Nitric oxide (NO) causes apoptosis and dedifferentiation of articular chondrocytes by the modulation of extracellular signal-regulated kinase (ERK), p38 kinase, and protein kinase C (PKC) alpha and zeta. In this study, we investigated the effects and mechanisms of non-steroidal anti-inflammatory drugs (NSAIDs), such as indo-methacin, ketoprofen, ibuprofen, sulindac sulfide, and flurbiprofen, in NO-induced apoptosis and dedifferentiation of articular chondrocytes. We found that all of the examined NSAIDs inhibited apoptosis and dedifferentiation. NO production in chondrocytes caused activation of ERK-1/2 and p38 kinase, which oppositely regulate apoptosis and dedifferentiation. NO production also caused inhibition of PKCalpha and -zeta independent of and dependent on, respectively, p38 kinase, which is required for apoptosis and dedifferentiation. Among the signaling molecules modulated by NO, NSAIDs blocked NO-induced activation of p38 kinase, potentiated ERK activation, and blocked inhibition of PKCalpha and -zeta. NSAIDs also inhibited some of the apoptotic signaling that is downstream of p38 kinase and PKC, such as NFkappaB activation, p53 accumulation, and caspase-3 activation. The inhibitory effects of NSAIDs on apoptosis and dedifferentiation were independent of the inhibition of cyclooxygenase (COX)-2 and prostaglandin E-2 (PGE(2)) production, as evidenced by the observation that specific inhibition of COX-2 activity and PGE2 production or exogenous PGE2 did not affect NO-induced apoptosis and dedifferentiation. Taken together, our results indicate that NSAIDs block NO-induced apoptosis and dedifferentiation of articular chondrocytes by the modulation of ERK, p38 kinase, and PKCalpha and -zeta in a manner independent of their ability to inhibit COX-2 and PGE2 production.	Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea; Kyungpook Natl Univ, Dept Biol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea.	jschun@kjist.ac.kr	Chang, Sunghoe/J-2784-2012	chang, sunghoe/0000-0002-3446-7288				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Barnes CJ, 1998, BRIT J CANCER, V77, P573, DOI 10.1038/bjc.1998.93; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Cao M, 1997, BIOCHEM J, V324, P305, DOI 10.1042/bj3240305; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; Ding CH, 2002, INFLAMMATION, V26, P139, DOI 10.1023/A:1015504632021; Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; Frazer A, 1994, Osteoarthritis Cartilage, V2, P235; Giardina C, 1999, BBA-MOL CELL RES, V1448, P425, DOI 10.1016/S0167-4889(98)00156-6; Goldberg Y, 1996, ONCOGENE, V12, P893; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; HORTON WE, 1987, DEV BIOL, V123, P508, DOI 10.1016/0012-1606(87)90409-X; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Jones MK, 1999, NAT MED, V5, P1418; Jouzeau JY, 2002, BIORHEOLOGY, V39, P201; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; Mukherjee P, 2001, CLIN EXP RHEUMATOL, V19, pS7; Notoya K, 2000, J IMMUNOL, V165, P3402, DOI 10.4049/jimmunol.165.6.3402; Pelletier JP, 1998, ARTHRITIS RHEUM-US, V41, P1275, DOI 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Tamura T, 1996, ENDOCRINOLOGY, V137, P3729, DOI 10.1210/en.137.9.3729; TASKIRAN D, 1994, BIOCHEM BIOPH RES CO, V200, P142, DOI 10.1006/bbrc.1994.1426; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; VonKnethen A, 1997, FASEB J, V11, P887; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	48	56	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15319	15325		10.1074/jbc.M212520200	http://dx.doi.org/10.1074/jbc.M212520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588866	hybrid			2022-12-25	WOS:000182516100096
J	Adessi, C; Frossard, MJ; Boissard, C; Fraga, S; Bieler, S; Ruckle, T; Vilbois, F; Robinson, SM; Mutter, M; Banks, WA; Soto, C				Adessi, C; Frossard, MJ; Boissard, C; Fraga, S; Bieler, S; Ruckle, T; Vilbois, F; Robinson, SM; Mutter, M; Banks, WA; Soto, C			Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PEPTIDES; IN-VIVO; FIBRIL FORMATION; PSEUDO-PROLINES; AMINO-ACIDS; RAT-BRAIN; METABOLISM; AMYLOIDOGENICITY; FIBRILLOGENESIS; CONFORMATION	Amyloid plaques in brain, composed of aggregates of amyloid-beta peptide, play a central role in the pathogenesis of Alzheimer's disease and represent a good target for treatment. We have shown previously that a 5-amino acid beta-sheet breaker peptide (iAbeta5p), end-protected, has the ability to induce a dramatic reduction in amyloid deposition in two different transgenic Alzheimer's models (Permanne, B., Adessi, C., Saborio, G. P., Fraga, S., Frossard, M.-J., Dewachter, I., Van Dorpe, J., Banks, W. A., Van Leuven, F., and Soto, C. (2002) FASEB J. 16, 860 - 862). The aim of this study was to evaluate the effect of chemical modifications of the peptide bonds at the metabolite cleavage sites on the pharmacological properties of iAbeta5p derivatives. Using a rational approach, peptide analogs were designed and tested for in vitro activity and enzymatic stability. One peptide analog containing a methyl group introduced at the nitrogen atom of one amide bond showed increased stability in vitro, a 10-fold higher in vivo half-life, and good brain uptake compared with iAbeta5p while maintaining a similar activity in vitro. Our results suggest that the pharmacological profile of beta-sheet breaker peptides can be improved to produce compounds with drug-like properties that might offer a new promise in the treatment of Alzheimer's disease.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland; St Louis Univ, Sch Med, Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, St Louis, MO 63106 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Geriatric Research Education & Clinical Center; Saint Louis University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Soto, C (corresponding author), Serono Pharmaceut Res Inst, Chemin Aulx,14 Plan Ouates, CH-1228 Geneva, Switzerland.	Claudio.Soto@serono.com	Banks, William A/K-1330-2017	Banks, William A/0000-0002-0496-3619				Adessi C, 2002, CURR MED CHEM, V9, P963, DOI 10.2174/0929867024606731; Al-Obeidi E, 1998, MOL BIOTECHNOL, V9, P205, DOI 10.1007/BF02915794; Banks W A, 1993, Rev Neurosci, V4, P365; Banks WA, 1996, LIFE SCI, V59, P1923, DOI 10.1016/S0024-3205(96)00380-3; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; FAUCHERE JL, 1986, ADV DRUG RES, V15, P29; FAUCHERE JL, 1992, ADV DRUG RES, V23, P127; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; KHOSLA MC, 1981, P NATL ACAD SCI-BIOL, V78, P757, DOI 10.1073/pnas.78.2.757; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MATSAS R, 1989, NEUROSCIENCE, V31, P237, DOI 10.1016/0306-4522(89)90046-8; Murphey LJ, 2000, CIRCULATION, V102, P829; Murphey LJ, 2000, J PHARMACOL EXP THER, V294, P263; Mutter M, 1999, BIOPOLYMERS, V51, P121, DOI 10.1002/(SICI)1097-0282(1999)51:2<121::AID-BIP2>3.0.CO;2-O; MUTTER M, 1995, PEPTIDE RES, V8, P145; NAGARAJ R, 1978, FEBS LETT, V96, P273, DOI 10.1016/0014-5793(78)80416-5; Permanne B, 2002, FASEB J, V16, P860, DOI 10.1096/fj.01-0841fje; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POWELL MF, 1993, ANNU REP MED CHEM, V28, P285; Schaller A, 1998, PHYTOCHEMISTRY, V47, P605, DOI 10.1016/S0031-9422(97)00523-2; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Sigurdsson EM, 2000, J NEUROPATH EXP NEUR, V59, P11, DOI 10.1093/jnen/59.1.11; Sommer B, 2002, CURR OPIN PHARMACOL, V2, P87, DOI 10.1016/S1471-4892(01)00126-6; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Sugawara M, 2001, SPECTROCHIM ACTA A, V57, P1305, DOI 10.1016/S1386-1425(00)00493-5; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; WALTER R, 1980, MOL CELL BIOCHEM, V30, P111; Wen JJ, 1997, J PEPT RES, V49, P3; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205	38	168	183	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13905	13911		10.1074/jbc.M211976200	http://dx.doi.org/10.1074/jbc.M211976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578830	hybrid			2022-12-25	WOS:000182405000045
J	Caplan, MR; Erickson, HP				Caplan, MR; Erickson, HP			Apparent cooperative assembly of the bacterial cell division protein FtsZ demonstrated by isothermal titration calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GLUTAMATE-DEHYDROGENASE; INDUCED SELF-ASSOCIATION; CALF BRAIN TUBULIN; ESCHERICHIA-COLI; LIGHT-SCATTERING; POLYMERIZATION; SEDIMENTATION; EQUILIBRIUM; GTP	The assembly dynamics of FtsZ, a prokaryotic homolog of tubulin, are important for their role in bacterial cytokinesis. Here we used isothermal titration calorimetry (ITC) to measure the heat of FtsZ self-association under various conditions. The measurements were designed to test whether FtsZ protofilaments are assembled by an isodesmic (linear aggregates in which each bond has an identical equilibrium constant) or a cooperative (aggregates only become stable after forming a oligomeric nucleus) assembly process. The isodesmic model can fit the assembly in GDP closely but cannot fit the assembly in GTP. FtsZ-GTP without Mg2+ exhibits an apparent critical concentration, which is indicative of cooperative assembly, near 2.9 muM. With 2.5 mm Mg2+ (which allows FtsZ to hydrolyze GTP) the critical concentration is reduced 10-fold to similar to0.31 muM. Both with and without Mg2+ there is no evidence for assembly below the critical concentration, but there is an abrupt transition to full assembly above. The ITC data are highly suggestive of a cooperative assembly, although this is difficult to reconcile with the 1-subunit-thick protofilaments observed by electron microscopy.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Res Dr,POB 3709, Durham, NC 27710 USA.	h.erickson@cellbio.duke.edu			NIGMS NIH HHS [GM066014] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066014] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ET, 1968, BIOCHEMISTRY-US, V7, P1044, DOI 10.1021/bi00843a025; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; Erickson HP, 2000, J CELL BIOL, V148, P1103, DOI 10.1083/jcb.148.6.1103; ERICKSON HP, 1981, BIOPHYS J, V34, P293, DOI 10.1016/S0006-3495(81)84850-3; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4567, DOI 10.1021/bi00692a002; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; Levin PA, 1996, GENE DEV, V10, P478, DOI 10.1101/gad.10.4.478; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 1998, J STRUCT BIOL, V124, P235, DOI 10.1006/jsbi.1998.4041; Lu CL, 1997, PROTEIN EXPRES PURIF, V11, P179, DOI 10.1006/prep.1997.0775; Lutkenhaus J, 1998, CURR BIOL, V8, pR619, DOI 10.1016/S0960-9822(98)70391-4; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 2000, FEMS MICROBIOL REV, V24, P531, DOI 10.1016/S0168-6445(00)00038-3; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; REISLER E, 1970, BIOCHEMISTRY-US, V9, P3095, DOI 10.1021/bi00817a600; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; THUSIUS D, 1975, J MOL BIOL, V92, P413, DOI 10.1016/0022-2836(75)90289-2; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; WANG XD, 1993, MOL MICROBIOL, V9, P435, DOI 10.1111/j.1365-2958.1993.tb01705.x; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000	28	51	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13784	13788		10.1074/jbc.M300860200	http://dx.doi.org/10.1074/jbc.M300860200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566454	hybrid			2022-12-25	WOS:000182405000029
J	Salinas, M; Diaz, R; Abraham, NG; de Galarreta, CMR; Cuadrado, A				Salinas, M; Diaz, R; Abraham, NG; de Galarreta, CMR; Cuadrado, A			Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISMUTASE GENE-EXPRESSION; MEDIATED CELL-DEATH; PC12 CELLS; SUPEROXIDE-PRODUCTION; PARKINSONS-DISEASE; MESSENGER-RNA; RAT-BRAIN; KINASE-B; NEURONS; OVEREXPRESSION	The survival signal elicited by the phosphatidylinositol 3-kinase (PI3K)/Akt1 pathway has been correlated with inactivation of pro-apoptotic proteins and attenuation of the general stress-induced increase in reactive oxygen species (ROS). However, the mechanisms by which this pathway regulates intracellular ROS levels remain largely unexplored. In this study, we demonstrate that nerve growth factor (NGF) prevents the accumulation of ROS in dopaminergic PC12 cells challenged with the Parkinson's disease-related neurotoxin 6-hydroxydopamine (6-OHDA) by a mechanism that involves PI3K/Akt-dependent induction of the stress response protein heme oxygenase-1 (HO-1). The effect of NGF was mimicked by induction of HO-1 expression with CoCl2,; by treatment with bilirubin, an end product of heme catabolism; and by infection with a retroviral expression vector for human HO-1. The relevance of HO-1 in NGF-induced ROS reduction was further demonstrated by the evidence that cells treated with the HO-1 inhibitor tin-protoporphyrin or infected with a retroviral expression vector for antisense HO-1 exhibited enhanced ROS release in response to 6-OHDA, despite the presence of the neurotrophin. Inhibition of PI3K prevented NGF induction of HO-1 mRNA and protein and partially reversed its protective effect against 6-OHDA-induced ROS release. By contrast, cells transfected with a membrane-targeted active version of Akt1 exhibited increased HO-1 expression, even in the absence of NGF, and displayed a greatly attenuated production of ROS and apoptosis in response to 6-OHDA. These observations indicate that the PI3K/Akt pathway controls the intracellular levels of ROS by regulating the expression of the antioxidant enzyme HO-1.	Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Palmas Gran Canaria, Fac Med, Dept Bioquim, Gran Canaria 35016, Spain; New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Autonomous University of Madrid; Autonomous University of Madrid; Universidad de Las Palmas de Gran Canaria; New York Medical College	Cuadrado, A (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.	antonio.cuadrado@uam.es		Cuadrado, Antonio/0000-0002-4039-7140; Cuadrado, Antonio/0000-0002-3444-9012				Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dennery PA, 2000, CURR TOP CELL REGUL, V36, P181; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Goldshmit Y, 2001, J BIOL CHEM, V276, P46379, DOI 10.1074/jbc.M105637200; Gourley G R, 1997, Adv Pediatr, V44, P173; Hegyi T, 1994, J Perinatol, V14, P296; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Kirschner PB, 1996, BRAIN RES, V713, P178, DOI 10.1016/0006-8993(95)01513-2; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Lotharius J, 1999, J NEUROSCI, V19, P1284; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Martin D, 2001, J NEUROCHEM, V78, P1000, DOI 10.1046/j.1471-4159.2001.00472.x; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Ohashi T, 2002, FEBS LETT, V511, P21, DOI 10.1016/S0014-5793(01)03262-8; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Panahian N, 1999, J NEUROCHEM, V72, P1187; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Quan SO, 2001, P NATL ACAD SCI USA, V98, P12203, DOI 10.1073/pnas.211399398; Rubboli G, 1997, NEUROPEDIATRICS, V28, P281, DOI 10.1055/s-2007-973715; Ryter SW, 2000, METH MOL B, V99, P369; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sampath D, 1997, NEUROCHEM RES, V22, P351, DOI 10.1023/A:1027387105882; Satoh T, 1999, J BIOCHEM-TOKYO, V125, P952, DOI 10.1093/oxfordjournals.jbchem.a022374; Schipper HM, 1998, EXP NEUROL, V150, P60, DOI 10.1006/exnr.1997.6752; TABU J, 1999, NATURE, V399, P162; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; Takeda A, 2000, J BIOL CHEM, V275, P5395, DOI 10.1074/jbc.275.8.5395; Volti GL, 2002, BIOCHEM BIOPH RES CO, V296, P1077, DOI 10.1016/S0006-291X(02)02054-5; Wang W, 1999, NEUROSCI LETT, V259, P115, DOI 10.1016/S0304-3940(98)00929-X; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200	50	213	222	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13898	13904		10.1074/jbc.M209164200	http://dx.doi.org/10.1074/jbc.M209164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578834	Green Published, hybrid			2022-12-25	WOS:000182405000044
J	Vukmirica, J; Tran, K; Liang, XQ; Shan, J; Yuan, J; Miskie, BA; Hegele, RA; Resh, MD; Yao, ZM				Vukmirica, J; Tran, K; Liang, XQ; Shan, J; Yuan, J; Miskie, BA; Hegele, RA; Resh, MD; Yao, ZM			Assembly and secretion of very low density lipoproteins containing apolipoprotein B48 in transfected McA-RH7777 cells - Lack of evidence that palmitoylation of apolipoprotein B48 is required for lipoprotein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; NITRIC-OXIDE SYNTHASE; ACYLATION; PHOSPHORYLATION; IDENTIFICATION; CAVEOLAE; B100	We examined the role of S-linked palmitoylation of human apolipoprotein (apo) B in the assembly and secretion of very low density lipoproteins using recombinant human apoB48. There are four free cysteine residues (Cys(1085), Cys(1396), Cys(1478), and Cys(1635)) within apoB48 that potentially can be palmitoylated. All four cysteine residues were substituted with serine by site-specific mutagenesis. The mutant protein was expressed in transfected rat hepatoma McA-RH7777 cells. Metabolic labeling of the stably transfected cells with iodo-palmitic acid analog showed that the mutant apoB48 lacked palmitoylation. The lack of palmitoylation had little impact on the ability of apoB48 to assemble and secrete,very low density lipoproteins or high density lipoproteins. Immunocytochemistry experiments using confocal microscopy failed to reveal any major alterations in the intracellular distribution of the mutant apoB48 at steady state. Pulse-chase analysis combined with subcellular fractionation showed no apparent deficiency in the movement of the mutant apoB48 protein from the endoplasmic reticulum to cis/medial Golgi. However, the mutant apoB48 lacking palmitoylation showed retarded movement toward the distal Golgi and increased association (>2-fold) with the membranes of the secretory compartments. A marginal decrease (by 15-20%) in secretion efficiency as compared with that of wild type apoB48 was also observed. These results suggest that lack of palmitoylation may influence the partitioning of apoB48 between microsomal membranes and microsomal lumen, but it does not compromise the ability of apoB48 to assemble lipoproteins.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON K1H 8M5, Canada; Cornell Univ, Weill Grad Sch Med Sci, Cell Biol Program, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Biochem & Struct Biol, New York, NY 10021 USA; Robarts Res Inst, London, ON N6A 5K8, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Western University (University of Western Ontario)	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.		Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020	Hegele, Robert/0000-0003-2861-5325; Resh, Marilyn/0000-0001-6118-9466	NIGMS NIH HHS [GM 57966] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; GABEL B, 1994, FEBS LETT, V350, P77, DOI 10.1016/0014-5793(94)00737-3; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; HOEG JM, 1988, J LIPID RES, V29, P1215; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; Tran K, 2000, J BIOL CHEM, V275, P25023, DOI 10.1074/jbc.M908971199; Tran K, 2002, J BIOL CHEM, V277, P31187, DOI 10.1074/jbc.M200249200; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhao Y, 2000, MOL BIOL CELL, V11, P721, DOI 10.1091/mbc.11.2.721	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14153	14161		10.1074/jbc.M211995200	http://dx.doi.org/10.1074/jbc.M211995200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582154	hybrid			2022-12-25	WOS:000182405000076
J	Hilton, TL; Wang, EH				Hilton, TL; Wang, EH			Transcription factor IID recruitment and sp1 activation - Dual function of Taf1 in cyclin D1 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; RNA-POLYMERASE-II; PROMOTER SELECTIVITY; GENE; CELLS; EXPRESSION; UPSTREAM; REGION; TAF(II)250; ELEMENTS	Cyclin D1 is an oncogene that regulates progression through the G(1) phase of the cell cycle. A temperature-sensitive missense mutation in the transcription factor TAF1/TAF(II)250 induces the mutant ts13 cells to arrest in late G(1) by decreasing transcription of cell cycle regulators, including cyclin D1. Here we provide evidence that TAF1 serves two independent functions, one at the core promoter and one at the upstream activating Sp1 sites of the cyclin D1 gene. Using in vivo genomic footprinting, we have identified protein-DNA interactions within the cyclin D1 core promoter that are disrupted upon inactivation of TAF1 in ts13 cells. This 33-bp segment, which we termed the TAF1-dependent element 1 (TDE1), contains an initiation site that displays homology to the consensus motif and is sufficient to confer a requirement for TAF1 function. Electrophoretic mobility shift assays reveal that binding of ts13-TAF1-containing TFIID complexes to the cyclin D1 TDE1 occurs at 25 degreesC but not at 37 degreesC in vitro and involves the initiator element. Temperature-dependent DNA binding activity is also observed for TAF1-TAF2 heterodimers assembled with the ts13 mutant but not the wild-type TAF1 protein. These data suggest that a function of TAF is required for the interaction of TFIID with the cyclin D1 initiator. Our finding that recruitment of TFIID, by insertion of a TBP binding site upstream of the TDE1, restores basal but not activated transcription supports the model that TAF1 carries out two independent functions at the cyclin D1 promoter.	Univ Washington, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wang, EH (corresponding author), Univ Washington, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	ehwang@u.washington.edu			NIGMS NIH HHS [GM7750] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen JL, 1996, METHOD ENZYMOL, V273, P208; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Eto I, 2000, CELL PROLIFERAT, V33, P167, DOI 10.1046/j.1365-2184.2000.00176.x; HAYASHIDA T, 1994, GENE, V141, P267; HERBER B, 1994, ONCOGENE, V9, P1295; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; LIU HT, 1985, J BIOL CHEM, V260, P3269; MANTOVANI R, 1993, NUCLEIC ACIDS RES, V21, P4873, DOI 10.1093/nar/21.21.4873; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Mencia M, 2001, MOL CELL BIOL, V21, P1145, DOI 10.1128/MCB.21.4.1145-1154.2001; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MUELLER PR, 1992, CURRENT PROTOCOLS MO; MURRAY A, 1993, CELL CYCLE; Musgrove EA, 1996, J MAMMARY GLAND BIOL, V1, P153, DOI 10.1007/BF02013639; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nakamura S, 1997, PATHOL INT, V47, P421, DOI 10.1111/j.1440-1827.1997.tb04519.x; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Perry JE, 1998, PROSTATE, V35, P117; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Strauss EC, 1997, METHODS, V11, P164, DOI 10.1006/meth.1996.0402; Sutherland RL, 2002, BREAST CANCER RES, V4, P14, DOI 10.1186/bcr411; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Tsukihashi Y, 2001, J BIOL CHEM, V276, P25715, DOI 10.1074/jbc.M102416200; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zerby D, 1997, METHODS, V12, P217, DOI 10.1006/meth.1997.0474	49	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12992	13002		10.1074/jbc.M300412200	http://dx.doi.org/10.1074/jbc.M300412200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569092	hybrid			2022-12-25	WOS:000182189500052
J	Frese, KK; Lee, SS; Thomas, DL; Latorre, IJ; Weiss, RS; Glaunsinger, BA; Javier, RT				Frese, KK; Lee, SS; Thomas, DL; Latorre, IJ; Weiss, RS; Glaunsinger, BA; Javier, RT			Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein	ONCOGENE			English	Article						adenovirus; E4-ORF1; PDZ; PI3K; oncoprotein	TUMOR-SUPPRESSOR PROTEIN; PAPILLOMAVIRUS E6 ONCOPROTEINS; READING FRAME-1 ENCODES; GUANYLATE KINASE; S6 KINASE; ONCOGENIC TRANSFORMATION; MAMMARY TUMORIGENESIS; SIGNALING PATHWAY; DOMAIN PROTEIN; HUMAN HOMOLOG	While PDZ domain-containing proteins represent cellular targets for several different viral oncoproteins, including human papillomavirus E6, human T-cell leukemia virus type 1 Tax, and human adenovirus E4-ORF1, the functional consequences for such interactions have not been elucidated. Here we report that, at the plasma membrane of cells, the adenovirus E4-ORF1 oncoprotein selectively and potently stimulates phosphatidylinositol 3-kinase (PI3K), triggering a downstream cascade of events that includes activation of both protein kinase B and p70S6-kinase. This activity of E4-ORF1 could be abrogated by overexpression of its PDZ-protein targets or by disruption of its PDZ domain-binding motif, which was shown to mediate complex formation between E4-ORF1 and PDZ proteins at the plasma membrane of cells. Furthermore, E4-ORF1 mutants unable to activate the PI3K pathway failed to transform cells in culture or to promote tumors in animals, and drugs that block either PI3K or p70S6-kinase inhibited E4-ORF1-induced transformation of cells. From these results, we propose that the transforming and tumorigenic potentials of the adenovirus E4-ORF1 oncoprotein depend on its capacity to activate PI3K through a novel PDZ protein-dependent mechanism of action.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	rjavier@bcm.tmc.edu		Latorre, Isabel/0000-0003-0638-1783	NCI NIH HHS [R01 CA058541, T32 CA009197, R01 CA58541, T32 CA09197] Funding Source: Medline; NIAID NIH HHS [T32 AI07471, T32 AI007471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009197, R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; PELECH SL, 1987, J BIOL CHEM, V262, P11598; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SUSA M, 1992, J BIOL CHEM, V267, P22951; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Uthoff SMS, 2001, MOL CARCINOGEN, V31, P56, DOI 10.1002/mc.1039; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada KM, 2001, J CELL SCI, V114, P2375; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	51	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					710	721		10.1038/sj.onc.1206151	http://dx.doi.org/10.1038/sj.onc.1206151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569363	Green Accepted			2022-12-25	WOS:000180642100008
J	Lee, MS; Igawa, T; Yuan, TC; Zhang, XQ; Lin, FF; Lin, MF				Lee, MS; Igawa, T; Yuan, TC; Zhang, XQ; Lin, FF; Lin, MF			ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells	ONCOGENE			English	Article						prostate cancer; androgen independence; prostatic acid phosphatase; protein tyrosine phosphatase; ErbB-2; protein tvrosine kinase; PSA secretion; MAP kinases	IN-SITU HYBRIDIZATION; ANTIGEN MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; ACID-PHOSPHATASE; GROWTH-FACTOR; TYROSINE KINASE; RECEPTOR ACTIVATION; PROTEIN EXPRESSION; GENE-EXPRESSION; EGF RECEPTOR	The expression and secretion of prostate-specific antigen (PSA) are regulated by androgens in normal prostate secretory epithelial cells. In prostate cancer patients, the serum PSA level is usually elevated and cancer cells are initially responsive to androgens. However, those cancer cells become androgen-independent after androgen ablation therapy. In hormone-refractory, cancer patients, even in an androgen-deprived environment, the circulation level of PSA rebounds and is constitutively elevated through a yet unknown mechanism. Tyrosine phosphorylation of ErbB-2 is involved in regulating the androgen-responsive phenotype of prostate cancer cells, and it is at least partly regulated by the cellular form of prostatic acid phosphatase (PAc6) a prostate-unique protein tyrosine phosphatase. We investigated the ErbB-2 signal pathway in androgen-independent PSA secretion. LNCaP C-81 cells, which are androgen-independent LNCaP cells lacking endogenous PAcP expression with a hypertyrosine phosphorylated ErbB-2, secreted a higher level of PSA in conditioned media than did androgen-sensitive LNCaP C-33 parental cells. A restored expression of cellular PAcP in C-81 cells was concurrent with a decrease in tyrophosphorylation of ErbB-2 and reduction of PSA secretion. Moreover, transient transfection of C-33 cells with the wild-type ErbB-2 or a constitutively active mutant of MEK1 cDNA resulted in an increased level of secreted PSA. The elevation of secreted PSA level by the forced expression of ErbB-2 was inhibited by an MEK inhibitor, PD98059. In C-81 cells, the expression of a dominant negative mutant of ErbB-2 reduced the secreted level of PSA. The inhibition of ErbB-2 or mitogen-activated protein (MAP) kinases by specific inhibitors AG879, AG825, or PD98059 led to a decrease in PSA secretion. Taken together, our data clearly indicate that the ErbB-2 signal pathway via MAP kinases (ERK1/2) is involved in regulating the secretion of PSA by androgen-independent human prostate cancer LNCaP C-81 cells in an androgen-depleted environment.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sect Urol Surg, Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 9845255 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@.unmc.edu		LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auclerc G, 2000, Oncologist, V5, P36, DOI 10.1634/theoncologist.5-1-36; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BERCHUCK A, 1990, CANCER RES, V50, P4087; Bubendorf L, 1999, CANCER RES, V59, P803; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gioeli D, 1999, CANCER RES, V59, P279; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; Hobisch A, 1998, CANCER RES, V58, P4640; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Johannessen LE, 2001, BIOCHEM J, V356, P87, DOI 10.1042/0264-6021:3560087; Karan D, 2001, CLIN CANCER RES, V7, P3472; Kimmelman AC, 2002, MOL CELL BIOL, V22, P5946, DOI 10.1128/MCB.22.16.5946-5961.2002; KURIYAMA M, 1982, J NATL CANCER I, V68, P99; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LICHTENSTEIN A, 1990, CANCER RES, V50, P7364; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Lin MF, 2000, CELL BIOL INT, V24, P681, DOI 10.1006/cbir.2000.0433; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Mark HFL, 1999, EXP MOL PATHOL, V66, P170, DOI 10.1006/exmp.1999.2242; MAUCHER A, 1993, J CANCER RES CLIN, V119, P669, DOI 10.1007/BF01215986; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Osman I, 2001, CLIN CANCER RES, V7, P2643; PAPSIDERO LD, 1980, CANCER RES, V40, P2428; PIERCE JH, 1991, ONCOGENE, V6, P1189; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; PRESS MF, 1990, ONCOGENE, V5, P953; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; QIAN XL, 1994, ONCOGENE, V9, P1507; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ross JS, 1997, CANCER-AM CANCER SOC, V79, P2162, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; Stenman UH, 1999, SEMIN CANCER BIOL, V9, P83, DOI 10.1006/scbi.1998.0086; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VELDSCHOLTE J, 1994, J STEROID BIOCHEM, V49, P341, DOI 10.1016/0960-0760(94)90277-1; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; Wen Y, 2000, CANCER RES, V60, P6841; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOUNG CYF, 1991, CANCER RES, V51, P3748; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	74	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					781	796		10.1038/sj.onc.1206066	http://dx.doi.org/10.1038/sj.onc.1206066			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569372				2022-12-25	WOS:000180642100017
J	Carrillo-Vico, A; Garcia-Maurino, S; Calvo, JR; Guerrero, JM				Carrillo-Vico, A; Garcia-Maurino, S; Calvo, JR; Guerrero, JM			Melatonin counteracts the inhibitory effect of PGE(2) on IL-2 production in human lymphocytes via its mt1 membrane receptor	FASEB JOURNAL			English	Article						neuroimmunomodulation; cytokines; melatonin receptor; immune system	PROTEIN-KINASE-C; PINEAL-GLAND; NUCLEAR RECEPTOR; IMMUNE-SYSTEM; HUMAN INTERLEUKIN-2; HORMONE MELATONIN; ELEVATING AGENTS; GENE-EXPRESSION; HUMAN MONOCYTES; DOWN-REGULATION	It is well known that melatonin plays a fundamental role in human neuro-immunomodulation. Thus, melatonin regulates the production of a large number of cytokines, including interleukin-2 (IL-2) in the human system. Both membrane and nuclear receptors for melatonin are present in lymphoid cells. However, most of these effects have been shown to be mediated by the putative nuclear receptor for the neurohormone. In this paper, we show that prostaglandin E-2 (PGE(2)), a potent inflammatory mediator, inhibits IL-2 production in human lymphocytes by a cyclic AMP (cAMP)-dependent mechanism. In this model, melatonin counteracts the effects of PGE(2) on IL-2 and cAMP production. We propose that the effect of melatonin is mediated by a membrane receptor, since similar results were obtained when cells were cultured in the presence of S 20098, a specific melatonin membrane receptor agonist. No effect was observed by using CGP 52608, a nuclear receptor agonist. Moreover, when cells were stimulated with phorbol myristate acetate (PMA), which has been shown to inhibit mt1 melatonin membrane receptor expression, the neurohormone failed to counteract the effect of PGE(2). Therefore, we postulate, for the first time, a physiological role of the mt1 melatonin membrane receptor in the human immune system.	Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, E-41009 Seville, Spain; Virgen Macarena Hosp, Seville 41009, Spain	University of Sevilla; Hospital Universitario Virgen Macarena	Guerrero, JM (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Avda Sanchez Pizjuan 4, E-41009 Seville, Spain.	guerrero@us.es	García-Mauriño, Sofía/E-6707-2010; Guerrero, Josep M./D-5519-2014; Carrillo-Vico, Antonio/K-5265-2014; Guerrero, Josep M./Y-2929-2019; Calvo, Juan R./A-7338-2017; IBIS, NEUROINMUNO/O-9306-2015	García-Mauriño, Sofía/0000-0002-7698-5112; Guerrero, Josep M./0000-0001-5236-4592; Carrillo-Vico, Antonio/0000-0002-8516-0999; Calvo, Juan R./0000-0002-4854-2963; Guerrero, Juan Miguel/0000-0001-7553-0119				ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; Barjavel MJ, 1998, J IMMUNOL, V160, P1191; Barrett P, 1998, ENDOCRINOLOGY, V139, P163, DOI 10.1210/en.139.1.163; BENITEZKING G, 1993, LIFE SCI, V53, P201, DOI 10.1016/0024-3205(93)90670-X; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO LL, 1992, IMMUNOL LETT, V33, P123, DOI 10.1016/0165-2478(92)90035-M; Cos S, 1998, CANCER RES, V58, P4383; CSABA G, 1975, ENDOCRINOL EXP, V9, P59; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; DEPREUX P, 1994, J MED CHEM, V37, P3231, DOI 10.1021/jm00046a006; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Felli MP, 1996, CELL IMMUNOL, V172, P229, DOI 10.1006/cimm.1996.0237; Garcia-Maurino S, 2000, J PINEAL RES, V29, P129, DOI 10.1034/j.1600-079X.2000.290301.x; Garcia-Maurino S, 1998, J NEUROIMMUNOL, V92, P76, DOI 10.1016/S0165-5728(98)00179-9; Garcia-Maurino S, 1999, LIFE SCI, V65, P2143, DOI 10.1016/S0024-3205(99)00479-8; GarciaMaurino S, 1997, J IMMUNOL, V159, P574; GarciaPerganeda A, 1997, J IMMUNOL, V159, P3774; Gilad E, 1997, ENDOCRINOLOGY, V138, P4255, DOI 10.1210/en.138.10.4255; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; GOTO T, 1983, J IMMUNOL, V130, P1350; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; Guerrero Juan M., 2002, Current Topics in Medicinal Chemistry, V2, P167, DOI 10.2174/1568026023394335; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; LEWIS VM, 1978, J CLIN ENDOCR METAB, V47, P145, DOI 10.1210/jcem-47-1-145; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; MINAKUCHI R, 1990, J IMMUNOL, V145, P2616; MOCCHEGIANI E, 1994, J NEUROIMMUNOL, V53, P189, DOI 10.1016/0165-5728(94)90029-9; Molinero P, 2000, J NEUROIMMUNOL, V103, P180, DOI 10.1016/S0165-5728(99)00237-4; MORREY KM, 1994, J IMMUNOL, V153, P2671; Nelson RJ, 2000, ANN NY ACAD SCI, V917, P404; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Paliogianni F, 1996, CELL IMMUNOL, V171, P95, DOI 10.1006/cimm.1996.0178; PELUS LM, 1977, LIFE SCI, V20, P903, DOI 10.1016/0024-3205(77)90274-0; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; Reiter R J, 1997, Adv Pharmacol, V38, P103; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SkwarloSonta K, 1996, ACTA NEUROBIOL EXP, V56, P341; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Straub RH, 2000, J NEUROIMMUNOL, V109, P10, DOI 10.1016/S0165-5728(00)00296-4; WALDHAUSER F, 1988, J CLIN ENDOCR METAB, V66, P648, DOI 10.1210/jcem-66-3-648; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327	52	94	102	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					755	+		10.1096/fj.02-0501fje	http://dx.doi.org/10.1096/fj.02-0501fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594180				2022-12-25	WOS:000181456900002
J	Roehrich, ME; Mooser, V; Lenain, V; Herz, J; Nimpf, J; Azhar, S; Bideau, M; Capponi, A; Nicod, P; Haefliger, JA; Waeber, R				Roehrich, ME; Mooser, V; Lenain, V; Herz, J; Nimpf, J; Azhar, S; Bideau, M; Capponi, A; Nicod, P; Haefliger, JA; Waeber, R			Insulin-secreting beta-cell dysfunction induced by human lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E RECEPTOR-2; DIABETES-MELLITUS; CLASS-B; PROTEIN; CHOLESTEROL; APOPTOSIS; BINDING; PATHWAY; DEATH	Diabetes is associated with significant changes in plasma concentrations of lipoproteins. We tested the hypothesis that lipoproteins modulate the function and survival of insulin-secreting cells. We first detected the presence of several receptors that participate in the binding and processing of plasma lipoproteins and confirmed the internalization of fluorescent low density lipoprotein (LDL) and high density lipoprotein (HDL) particles in insulin-secreting beta-cells. Purified human very low density lipoprotein (VLDL) and LDL particles reduced insulin mRNA levels and beta-cell proliferation and induced a dose-dependent increase in the rate of apoptosis. In mice lacking the LDL receptor, islets showed a dramatic decrease in LDL uptake and were partially resistant to apoptosis caused by LDL. VLDL-induced apoptosis of beta-cells involved caspase-3 cleavage and reduction in the levels of the c-Jun N-terminal kinase-interacting protein-1. In contrast, the proapoptotic signaling of lipoproteins was antagonized by HDL particles or by a small peptide inhibitor of c-Jun N-terminal kinase. The protective effects of HDL were mediated, in part, by inhibition of caspase-3 cleavage and activation of Akt/protein kinase B. In conclusion, human lipoproteins are critical regulators of beta-cell survival and may therefore contribute to the beta-cell dysfunction observed during the development of type 2 diabetes.	Univ Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland; Univ Hosp, Inst Cellular Biol & Morphol, CH-1011 Lausanne, Switzerland; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Univ Hosp, Div Endocrinol & Diabet, CH-1211 Geneva, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Geneva	Waeber, R (corresponding author), CHU Vaudois, Univ Hosp, Dept Internal Med B, BH 10-640, CH-1011 Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch		Nimpf, Johannes/0000-0002-9273-3492; Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arya R, 2002, NAT GENET, V30, P102, DOI 10.1038/ng810; BANNISTER LH, 1995, GRAYS ANATOMY, P1793; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Cherradi N, 2001, ENDOCRINOLOGY, V142, P4540, DOI 10.1210/en.142.10.4540; Cnop M, 2000, AM J PATHOL, V156, P237, DOI 10.1016/S0002-9440(10)64724-4; Cnop M, 2002, ENDOCRINOLOGY, V143, P3449, DOI 10.1210/en.2002-220273; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175; Freeman DJ, 2001, CIRCULATION, V103, P357; Grupping AY, 1997, ENDOCRINOLOGY, V138, P4064, DOI 10.1210/en.138.10.4064; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Jeon H, 2000, J BIOL CHEM, V275, P30458, DOI 10.1074/jbc.M002583200; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; Ritz-Laser B, 1999, ENDOCRINOLOGY, V140, P4005, DOI 10.1210/en.140.9.4005; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Tacken PJ, 2000, BIOCHEM J, V347, P357, DOI 10.1042/0264-6021:3470357; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240	28	154	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18368	18375		10.1074/jbc.M300102200	http://dx.doi.org/10.1074/jbc.M300102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12594227	Green Published, hybrid			2022-12-25	WOS:000182838300102
J	Lee-Kwon, W; Kawano, K; Choi, JW; Kim, JH; Donowitz, M				Lee-Kwon, W; Kawano, K; Choi, JW; Kim, JH; Donowitz, M			Lysophosphatidic acid stimulates brush border Na+/H+ exchanger 3 (NHE3) activity by increasing its exocytosis by an NHE3 kinase A regulatory protein-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN INTERACTION CONTROLS; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR; ACTIVATION; ENDOCYTOSIS; INHIBITION; ISOFORM; CELLS; PROLIFERATION; TRAFFICKING	Na+/H+ exchanger 3 (NHE3) kinase A regulatory protein (E3KARP) has been implicated in cAMP- and Ca2+-dependent inhibition of NHE3. In the current study, a new role of E3KARP is demonstrated in the stimulation of NHE3 activity. Lysophosphatidic acid (LPA) is a mediator of the restitution phase of inflammation but has not been studied for effects on sodium absorption. LPA has no effect on NHE3 activity in opossum kidney (OK) proximal tubule cells, which lack expression of endogenous E3KARP. However, in OK cells exogenously expressing E3KARP, LPA stimulated NHE3 activity. Consistent with the stimulatory effect on NHE3 activity, LPA treatment increased the surface NHE3 amount, which occurred by accelerating exocytic trafficking (endocytic recycling) to the apical plasma membrane. These LPA effects only occurred in OK cells transfected with E3KARP. The LPA-induced increases of NHE3 activity, surface NHE3 amounts, and exocytosis were completely inhibited by pretreatment with the PI 3-kinase inhibitor, LY294002. LPA stimulation of the phosphorylation of Akt was used as an assay for PI 3-kinase activity. LY294002 completely prevented the LPA-induced increase in Akt phosphorylation, which is consistent with the inhibitory effect of LY294002 on the LPA stimulation of NHE3 activity. The LPA-induced phosphorylation of Akt was the same in OK cells with and without E3KARP. These results show that LPA stimulates NHE3 in the apical surface of OK cells by a mechanism that is dependent on both E3KARP and PI 3-kinase. This is the first demonstration that rapid stimulation of NHE3 activity is dependent on an apical membrane PDZ domain protein.	Johns Hopkins Univ, Sch Med, Dept Physiol, Div Gastroenterol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA; Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea	Johns Hopkins University; Johns Hopkins University; Pusan National University	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Div Gastroenterol, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484, R01DK026523] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK44484, R01 DK26523] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Akhter S, 2002, AM J PHYSIOL-CELL PH, V283, pC927, DOI 10.1152/ajpcell.00613.2001; Bianchini L, 1997, J BIOL CHEM, V272, P271; Brett CL, 2002, AM J PHYSIOL-CELL PH, V282, pC1031, DOI 10.1152/ajpcell.00420.2001; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Cavet ME, 1999, AM J PHYSIOL-CELL PH, V277, pC1111, DOI 10.1152/ajpcell.1999.277.6.C1111; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Czech MP, 2002, MOL CELL, V9, P695, DOI 10.1016/S1097-2765(02)00509-9; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Dixon RJ, 1999, AM J PHYSIOL-RENAL, V276, pF191, DOI 10.1152/ajprenal.1999.276.2.F191; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Donowitz M, 2000, ANN NY ACAD SCI, V915, P30; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gillis D, 2001, J MEMBRANE BIOL, V181, P205, DOI 10.1007/s00232-001-0023-3; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Hines OJ, 2000, J SURG RES, V92, P23, DOI 10.1006/jsre.2000.5941; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Laghmani K, 2001, J CLIN INVEST, V107, P1563, DOI 10.1172/JCI11234; Lee-Kwon W, 2001, J BIOL CHEM, V276, P31296, DOI 10.1074/jbc.M103900200; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; Matsuzaki T, 2002, J BIOL CHEM, V277, P19008, DOI 10.1074/jbc.M112472200; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Peng Y, 2001, AM J PHYSIOL-RENAL, V280, pF34, DOI 10.1152/ajprenal.2001.280.1.F34; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sturm A, 2002, DIGESTION, V66, P23, DOI 10.1159/000064418; Sturm A, 1998, ANN NY ACAD SCI, V859, P223, DOI 10.1111/j.1749-6632.1998.tb11134.x; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	52	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16494	16501		10.1074/jbc.M300580200	http://dx.doi.org/10.1074/jbc.M300580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12595524	hybrid			2022-12-25	WOS:000182818600009
J	Braccia, A; Villani, M; Immerdal, L; Niels-Christiansen, LL; Nystrom, BT; Hansen, GH; Danielsen, EM				Braccia, A; Villani, M; Immerdal, L; Niels-Christiansen, LL; Nystrom, BT; Hansen, GH; Danielsen, EM			Microvillar membrane Microdomains exist at physiological temperature - Role of galectin-4 as lipid raft stabilizer revealed by "superrafts"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER ENZYMES; CELL BIOLOGY; INTRACELLULAR-TRANSPORT; AMINOPEPTIDASE-N; PLASMA-MEMBRANE; ANIMAL LECTINS; CHOLESTEROL; CAVEOLAE; DOMAINS; PROTEINS	Lipid rafts (glycosphingolipid/cholesterol-enriched membrane microdomains) have been isolated as low temperature, detergent-resistant membranes from many cell types, but despite their presumed importance as lateral sorting and signaling platforms, fundamental questions persist concerning raft function and even existence in vivo. The nonionic detergent Brij 98 was used to isolate lipid rafts from microvillar membrane vesicles of intestinal brush borders at physiological temperature to compare with rafts, obtained by "conventional" extraction using Triton X-100 at low temperature. Microvillar rafts prepared by the two protocols were morphologically different but had essentially similar profiles of protein- and lipid components, showing that raft microdomains do exist at 37 degreesC and are not "low temperature artifacts." We also employed a novel method of sequential detergent extraction at increasing temperature to define a fraction of highly detergent-resistant "superrafts." These were enriched in galectin-4, a beta-galactoside-recognizing lectin residing on the extracellular side of the membrane. Superrafts also harbored the glycosylphosphatidylinositol-linked alkaline phosphatase and the transmembrane aminopeptidase N, whereas the peripheral lipid raft protein annexin 2 was essentially absent. In conclusion, in the microvillar membrane, galectin-4,, functions as a core raft stabilizer/ organizer for other, more loosely raft-associated proteins. The superraft analysis might be applicable to other membrane microdomain systems.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen, Denmark	University of Copenhagen	Danielsen, EM (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.							Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Booth A G, 1974, Biochem J, V142, P575; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; CHRISTIANSEN K, 1981, BIOCHIM BIOPHYS ACTA, V647, P188, DOI 10.1016/0005-2736(81)90245-5; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Edidin M, 2001, SCI STKE; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; HANSEN GH, 1987, EUR J CELL BIOL, V43, P253; HANSEN GH, 1992, HISTOCHEM J, V24, P132, DOI 10.1007/BF01047462; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Pace KE, 1999, J IMMUNOL, V163, P3801; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; Taylor CM, 2002, J NEUROCHEM, V81, P993, DOI 10.1046/j.1471-4159.2002.00884.x; TRIER JS, 1968, CODE CF HDB PHYSL AL, V6, P1125; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Werlen G, 2002, CURR OPIN IMMUNOL, V14, P299, DOI 10.1016/S0952-7915(02)00339-4	41	126	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15679	15684		10.1074/jbc.M211228200	http://dx.doi.org/10.1074/jbc.M211228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594212	hybrid			2022-12-25	WOS:000182680000029
J	Kang, DK; Jeong, J; Drake, SK; Wehr, NB; Rouault, TA; Levine, RL				Kang, DK; Jeong, J; Drake, SK; Wehr, NB; Rouault, TA; Levine, RL			Iron regulatory protein 2 as iron sensor - Iron-dependent oxidative modification of cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED OXIDATION; AMINOMALONIC ACID; ESCHERICHIA-COLI; BINDING PROTEIN; HIF-ALPHA; DEGRADATION; DESTRUCTION; METABOLISM; MECHANISM; CHAINS	Iron regulatory protein 2 coordinates cellular regulation of iron metabolism by binding to iron responsive elements in mRNA. The protein is synthesized constitutively but is rapidly degraded when iron stores are replete. This iron-dependent degradation requires the presence of a 73-residue degradation domain, but its functions have not yet been established. We now show that the domain can act as an iron sensor, mediating its own covalent modification. The domain forms an iron-binding site with three cysteine residues located in the middle of the domain. It then reacts with molecular oxygen to generate a reactive oxidizing species at the iron-binding site. One cysteine residue is oxidized to dehydrocysteine and other products. This covalent modification may thus mark the protein molecule for degradation by the proteasome system.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levine, RL (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 50,Rm 2351, Bethesda, MD 20892 USA.	rlevine@nih.gov	Levine, Rodney L/D-9885-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225, Z01HL000225] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allerson CR, 2003, RNA, V9, P364, DOI 10.1261/rna.2143303; BALDWIN JE, 1991, TETRAHEDRON, V47, P457, DOI 10.1016/S0040-4020(01)90503-4; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; COPLEY SD, 1992, ANAL BIOCHEM, V201, P152, DOI 10.1016/0003-2697(92)90188-D; de Montellano PRO, 2002, NAT PROD REP, V19, P477, DOI 10.1039/b101297p; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; LEVINE RL, 1982, J CHROMATOGR, V236, P499; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Okazaki R, 1995, ORGANOSULFUR CHEM, P225; PATCHORNIK A, 1964, J AM CHEM SOC, V86, P1206, DOI 10.1021/ja01060a049; REDDY VY, 1994, J BIOL CHEM, V269, P4683; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Stadtman Earl R., 1999, P657; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Taggart C, 2000, J BIOL CHEM, V275, P27258; VANBUSKIRK JJ, 1984, P NATL ACAD SCI-BIOL, V81, P722	26	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14857	14864		10.1074/jbc.M300616200	http://dx.doi.org/10.1074/jbc.M300616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591920	hybrid			2022-12-25	WOS:000182516100037
J	Yuan, LP; Yu, WM; Yuan, ZM; Haudenschild, CC; Qu, CK				Yuan, LP; Yu, WM; Yuan, ZM; Haudenschild, CC; Qu, CK			Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; ACTIVATED PROTEIN-KINASES; LARGE T-ANTIGEN; INDUCED APOPTOSIS; TRANSFORMING ACTIVITY; IONIZING-RADIATION; GENOTOXIC STRESS; GROWTH ARREST; P53; P73	SHP-2, a ubiquitously expressed Src hmology 2 (SH2) domain-containing tyrosine phosphatase, plays a critical role in the regulation of growth factor and cytokine signal transduction. Here we report a novel function of this phosphatase in DNA damage-induced cellular responses. Mutant embryonic fibroblast cells lacking functional SHP-2 showed significantly decreased apoptosis in response to DNA damage. Following cisplatin treatment, induction of p73 and its downstream effector P21(Cip1) was essentially blocked in SHP-2 mutant cells. Further investigation revealed that activation of the nuclear tyrosine kinase c-Abl, an essential mediator in DNA damage induction of p73, was impaired in the mutant cells, suggesting a functional requirement of SHP-2 in c-Abl activation. Consistent with this observation, the effect of overexpression of c-Abl kinase in SHP-2 mutant cells on sensitizing the cells to DNA damage-induced death was abolished. Additionally, we found that in embryonic fibroblast cells 30-40% of SHP-2 was localized in the nuclei, and that a fraction of nuclear SHP-2 was constitutively associated with c-Ahl via its SH3 domain. Phosphatase activity of nuclear but not cytoplasmic SHP-2 was significantly enhanced in response to DNA damage. These results together suggest a novel nuclear function for SHP-2 phosphatase in the regulation of DNA damage-induced apoptotic responses.	Amer Red Cross, Holland Lab, Dept Hematopoiesis, Rockville, MD 20855 USA; Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; American Red Cross; Harvard University; Harvard T.H. Chan School of Public Health; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Holland Lab, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Christian, Haudenschild C/D-1602-2009		NHLBI NIH HHS [R01HL68212-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agami R, 1999, NATURE, V399, P809; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DANIEL R, 1995, ONCOGENE, V10, P1607; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gong JG, 1999, NATURE, V399, P806; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	67	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15208	15216		10.1074/jbc.M211327200	http://dx.doi.org/10.1074/jbc.M211327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594211	hybrid			2022-12-25	WOS:000182516100081
J	Becker, L; Webb, BA; Chitayat, S; Nesheim, ME; Koschinsky, ML				Becker, L; Webb, BA; Chitayat, S; Nesheim, ME; Koschinsky, ML			A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE-BINDING-SITE; KRINGLE-IV REPEATS; RECOMBINANT APOLIPOPROTEIN(A); HUMAN PLASMINOGEN; LIPOPROTEIN(A); FORM; IDENTIFICATION; ASSOCIATION; EXPRESSION; CLEAVAGE	Lipoprotein(a) (Lp(a)) assembly proceeds via a twostep mechanism in which initial non-covalent interactions between apolipoprotein(a) (apo(a)) and low density lipoprotein precede disulfide bond formation. In this study, we used analytical ultracentrifugation, differential scanning calorimetry, and intrinsic fluorescence to demonstrate that in the presence of the lysine analog E-aminocaproic acid, apo(a) undergoes a substantial conformational change from a "closed" to an "open" structure that is characterized by an increase in the hydrodynamic radius (similar to10%), an alteration in domain stability, as well as a decrease in tryptophan fluorescence. Although E-aminocaproic acid is a well characterized inhibitor of the non-covalent interaction between apo(a) and low density lipoprotein, we report the novel observation that this ligand at low concentrations (100 pm-l mm) significantly enhances covalent Lp(a) assembly by altering the conformation of apo(a). We developed a model for the kinetics of Lp(a) assembly that incorporates the conformational change as a determinant of the efficiency of the process; this model quantitatively explains our experimental observations. Interestingly, an analogous conformational change has been previously described for plasminogen resulting in an increase in the hydrodynamic radius, an increase in tryptophan fluorescence, and an acceleration of the rate of plasminogen activation. Although the functions of apio(a) and plasminogen have diverged considerably, elements of structural and conformational homology have been retained leading to similar regulation of two unrelated biological processes.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca	Webb, Bradley/F-6946-2013; Webb, Bradley/HDO-7820-2022	Webb, Bradley/0000-0002-5299-2852; Koschinsky, Marlys/0000-0002-2643-2288				Becker L, 2001, J BIOL CHEM, V276, P36155, DOI 10.1074/jbc.M104789200; Brunner C, 1996, J BIOL CHEM, V271, P32403, DOI 10.1074/jbc.271.50.32403; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASTELLINO F J, 1988, Haemostasis, V18, P15; Cockell CS, 1998, BIOCHEM J, V333, P99, DOI 10.1042/bj3330099; Fless GM, 1996, BIOCHEMISTRY-US, V35, P2289, DOI 10.1021/bi951792q; GABEL BR, 1995, BIOCHEMISTRY-US, V34, P15777, DOI 10.1021/bi00048a023; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Hervio L, 1999, BBA-PROTEIN STRUCT M, V1434, P124, DOI 10.1016/S0167-4838(99)00179-X; Hrzenjak A, 2000, PROTEIN ENG, V13, P661, DOI 10.1093/protein/13.9.661; KEELSER GA, 1996, J BIOL CHEM, V271, P32096; Kornblatt JA, 2000, BBA-PROTEIN STRUCT M, V1481, P1, DOI 10.1016/S0167-4838(00)00119-9; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liaw PCY, 1998, J BIOL CHEM, V273, P8932, DOI 10.1074/jbc.273.15.8932; MALCOLM L, 2002, J BIOL CHEM, V277, P1040; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; Marcovina S M, 1999, Curr Cardiol Rep, V1, P105, DOI 10.1007/s11886-999-0067-z; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; OSTERBERG R, 1980, BIOCHEMISTRY-US, V19, P2283; Ozhogina OA, 2001, PROTEIN SCI, V10, P2114, DOI 10.1110/ps.15801; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Privalov P L, 1986, Methods Enzymol, V131, P4; Rahman MN, 2002, BIOCHEMISTRY-US, V41, P1149, DOI 10.1021/bi010964i; Sangrar W, 2000, BIOCHEM CELL BIOL, V78, P519, DOI 10.1139/bcb-78-4-519; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Watanabe K, 2002, J MOL BIOL, V319, P283, DOI 10.1016/S0022-2836(02)00199-7; Weisel JW, 2001, BIOCHEMISTRY-US, V40, P10424, DOI 10.1021/bi010556e; WHITE AL, 1994, J BIOL CHEM, V269, P28716	36	19	21	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14074	14081		10.1074/jbc.M212855200	http://dx.doi.org/10.1074/jbc.M212855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566443	hybrid			2022-12-25	WOS:000182405000067
J	Bes, C; Briant-Longuet, L; Cerutti, M; Heitz, F; Troadec, S; Pugniere, M; Roquet, F; Molina, F; Casset, F; Bresson, D; Peraldi-Roux, S; Devauchelle, G; Devaux, C; Granier, C; Chardes, T				Bes, C; Briant-Longuet, L; Cerutti, M; Heitz, F; Troadec, S; Pugniere, M; Roquet, F; Molina, F; Casset, F; Bresson, D; Peraldi-Roux, S; Devauchelle, G; Devaux, C; Granier, C; Chardes, T			Mapping the paratope of anti-CD4 recombinant fab 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; VARIABLE REGIONS; CDR3-LIKE REGION; ANTIGEN-BINDING; SPOT-SYNTHESIS; CD4 MOLECULE; T-CELLS; IDENTIFICATION; RECOGNITION; VACCINATION	We analyzed antigen-binding residues from the variable domains of anti-CD4 antibody 13B8.2 using the Spot method of parallel peptide synthesis. Sixteen amino acids, defined as Spot critical residues (SCR), were identified on the basis of a 50% decrease in CD4 binding to alanine analogs of reactive peptides. Recombinant Fab 13B8.2 mutants were constructed with alanine residues in place of each of the 16 SCR, expressed in the baculovirus cell system, and purified. CD measurements indicated that the mutated proteins were conformationally intact, with a beta-sheet secondary structure similar to that of wild-type Fab. Compared with the CD4-binding capacity of wildtype Fab 13B8.2, 11 light (Y32-L, W35-L, Y36-L, H91-L, and Y92-L) and heavy chain (H35-H, R38-H, W52-H, R53-H, F100K-H, and W103-H) Fab single mutants showed a decrease in CD4 recognition as demonstrated by enzymelinked immunosorbent assay, BIAcore, and flow cytometry analyses. The five remaining Fab mutants showed antigen-binding properties similar to those of wild-type Fab. Recombinant Fab mutants that showed decreased CD4 binding also lost their capacity to inhibit human immunodeficiency virus promoter activation and the antigen-presenting ability that wild-type Fab displays. Molecular modeling of the 13B8.2 antibody paratope indicated that most of these critical residues are appropriately positioned inside the putative CD4-binding pocket, whereas the five SCR that were not confirmed by mutagenesis show an unfavorable positioning. Taken together, these results indicate that most of the residues defined by the Spot method as critical matched with important residues defined by mutagenesis in the whole protein context. The identification of critical residues for CD4 binding in the paratope of anti-CD4 recombinant Fab 13B8.2 provides the opportunity for the generation of improved anti-CD4 molecules with more efficient pharmacological properties.	CNRS, UMR 5094, Inst Biotechnol & Pharmacol, Fac Pharm, Montpellier 5, France; CNRS, UMR 5121, Lab Infect Retrovirales & Signalisat Cellulaire, Inst Biol, F-34060 Montpellier 2, France; INRA, CNRS, UMR 5087, Lab Pathol Comparee, F-30380 St Christol Les Ales, France; CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France; Syntem, F-30035 Nimes 1, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); INRAE; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Chardes, T (corresponding author), CNRS, UMR 5094, Inst Biotechnol & Pharmacol, Fac Pharm, 15 Ave Charles Flahault, Montpellier 5, France.		Molina, Franck/E-8419-2011; Pugniere, Martine/T-1355-2017; Briant, Laurence/AAB-9281-2021; PUGNIERE, Martine/AAD-4315-2020; Chardès, Thierry/B-5420-2019	Pugniere, Martine/0000-0002-2049-2909; PUGNIERE, Martine/0000-0002-2049-2909; Chardès, Thierry/0000-0002-1836-7439				Anderson D, 1997, CLIN IMMUNOL IMMUNOP, V84, P73, DOI 10.1006/clin.1997.4363; BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; Bes C, 2001, FEBS LETT, V508, P67, DOI 10.1016/S0014-5793(01)03036-8; Bes Cedric, 2001, Human Antibodies, V10, P67; Bosshard HR, 2001, NEWS PHYSIOL SCI, V16, P171; Briant L, 1998, J VIROL, V72, P6207, DOI 10.1128/JVI.72.7.6207-6214.1998; Briant L, 2000, Adv Pharmacol, V48, P373; Chardes T, 1999, FEBS LETT, V452, P386, DOI 10.1016/S0014-5793(99)00649-3; Cohen GH, 1996, ACTA CRYSTALLOGR D, V52, P315, DOI 10.1107/S0907444995014855; CORBEAU P, 1993, J IMMUNOL, V150, P290; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Deckert PM, 1996, J IMMUNOL, V156, P826; DHIVER C, 1989, AIDS, V3, P835, DOI 10.1097/00002030-198912000-00009; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GORMAN SD, 1991, P NATL ACAD SCI USA, V88, P4181, DOI 10.1073/pnas.88.10.4181; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honegger A, 2001, J MOL BIOL, V309, P657, DOI 10.1006/jmbi.2001.4662; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; Laune D, 2002, J IMMUNOL METHODS, V267, P53, DOI 10.1016/S0022-1759(02)00140-0; Leder L, 1995, BIOCHEMISTRY-US, V34, P16509, DOI 10.1021/bi00050a035; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Manca F, 1996, EUR J IMMUNOL, V26, P2461, DOI 10.1002/eji.1830261029; Monnet C, 1999, J BIOL CHEM, V274, P3789, DOI 10.1074/jbc.274.6.3789; Pearlman R S, 1991, NIDA Res Monogr, V112, P62; Poul MA, 1995, IMMUNOTECHNOLOGY, V1, P189, DOI 10.1016/1380-2933(95)00019-4; POULIN L, 1991, J VIROL, V65, P4893, DOI 10.1128/JVI.65.9.4893-4901.1991; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; Pulito VL, 1996, J IMMUNOL, V156, P2840; REES AR, 1992, ABM COMPUTER PROGRAM; Reimann KA, 1997, AIDS RES HUM RETROV, V13, P933, DOI 10.1089/aid.1997.13.933; Reineke U, 1999, NAT BIOTECHNOL, V17, P271, DOI 10.1038/7018; Reineke U, 2002, J IMMUNOL METHODS, V267, P37, DOI 10.1016/S0022-1759(02)00139-4; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; Schedel I, 1999, VACCINE, V17, P1837, DOI 10.1016/S0264-410X(98)00483-6; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; TANIYAMA Y, 1990, J BIOL CHEM, V265, P16767; VRANA M, 1976, J IMMUNOL, V116, P1662; Welfle K, 2001, J MOL RECOGNIT, V14, P89, DOI 10.1002/jmr.523	46	21	43	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14265	14273		10.1074/jbc.M210694200	http://dx.doi.org/10.1074/jbc.M210694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566463	Green Published, hybrid			2022-12-25	WOS:000182405000089
J	Chu, CJ; Huang, SM; De Petrocellis, L; Bisogno, T; Ewing, SA; Miller, JD; Zipkin, RE; Daddario, N; Appendino, G; Di Marzo, V; Walker, JM				Chu, CJ; Huang, SM; De Petrocellis, L; Bisogno, T; Ewing, SA; Miller, JD; Zipkin, RE; Daddario, N; Appendino, G; Di Marzo, V; Walker, JM			N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLOID VR1 RECEPTORS; ACID AMIDE HYDROLASE; CANNABINOID-RECEPTOR; CB1 RECEPTOR; IN-VITRO; ANANDAMIDE; PALMITOYLETHANOLAMIDE; ACTIVATION; BRAIN; RATS	N-Arachidonoyldopamine (NADA) was recently identified as an endogenous ligand for the vanilloid type 1 receptor (VR1). Further analysis of the bovine striatal extract from which NADA was isolated indicated the existence of substances corresponding in molecular mass to N-oleoyldopamine (OLDA), N-palmitoyldopamine (PALDA), and N-stearoyldopamine (STEARDA). Quadrupole time-of-flight mass spectrometric analysis of bovine striatal extracts revealed the existence of OLDA, PALDA, and STEARDA as endogenous compounds in the mammalian brain. PALDA and STEARDA failed to affect calcium influx in VR1-transfected human embryonic kidney (HEK) 293 cells or paw withdrawal latencies from a radiant heat source, and there was no evidence of spontaneous pain behavior. By contrast, OLDA induced calcium influx (EC50 = 36 nM), reduced the latency of paw withdrawal from a radiant heat source in a dose-dependent manner (EC50 = 0.72 mug), and produced nocifensive behavior. These effects were blocked by co-administration of the VR1. antagonist iodo-resiniferatoxin (10 nm for HEK cells and 1 mug/50 mul for pain behavior). These findings demonstrate the existence of an endogenous compound in the brain that is similar to capsaicin and NADA in its chemical structure and activity on VR1. Unlike NADA, OLDA was only a weak ligand for rat CB1 receptors; but like NADA, it was recognized by the anandamide membrane transporter while being a poor substrate for fatty-acid amide hydrolase. Analysis of the activity of six additional synthetic and potentially endogenous N-acyldopamine indicated the requirement of a long unsaturated fatty acid chain for an optimal functional interaction with VR1 receptors.	Brown Univ, Dept Psychol, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA; CNR, Inst Biomol Chem & Cybernet, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy; Appl Biosyst Inc, Framingham, MA 01701 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA; Dipartimento Sci Chim, I-28100 Novara, Italy	Brown University; Brown University; Consiglio Nazionale delle Ricerche (CNR); Thermo Fisher Scientific; Applied Biosystems	Walker, JM (corresponding author), Brown Univ, Dept Psychol, 89 Waterman St,POB 1853, Providence, RI 02912 USA.		Bisogno, Tiziana/B-7891-2015; Appendino, Giovanni/O-4832-2015; Di Marzo, Vincenzo/AAD-7742-2019; Latyshev, Nikolay/D-1464-2014	Appendino, Giovanni/0000-0002-4170-9919; Di Marzo, Vincenzo/0000-0002-1490-3070; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000375, R01DA013012] Funding Source: NIH RePORTER; NIDA NIH HHS [DA13012, K02DA00375] Funding Source: Medline; NINDS NIH HHS [NS33247] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Appendino G, 2002, J MED CHEM, V45, P3739, DOI 10.1021/jm020844o; Bezuglov V, 2001, BIOORG MED CHEM LETT, V11, P447, DOI 10.1016/S0960-894X(00)00689-2; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 2002, CURR PHARM DESIGN, V8, P533, DOI 10.2174/1381612023395655; DAWBARN D, 1981, NEUROPHARMACOLOGY, V20, P341, DOI 10.1016/0028-3908(81)90006-X; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; De Petrocellis L, 2001, FEBS LETT, V506, P253, DOI 10.1016/S0014-5793(01)02934-9; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; De Petrocellis L, 2002, FUND CLIN PHARMACOL, V16, P297, DOI 10.1046/j.1472-8206.2002.00094.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Di Marzo V, 2001, BIOCHEM J, V358, P249, DOI 10.1042/0264-6021:3580249; Di Marzo V, 2001, EUR J PHARMACOL, V420, P123, DOI 10.1016/S0014-2999(01)01012-3; Fowler CJ, 2002, PROSTAG LEUKOTR ESS, V66, P193, DOI 10.1054/plef.2001.0357; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; HAJOS M, 1988, J NEURAL TRANSM, V74, P129, DOI 10.1007/BF01244779; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Hayes P, 2000, PAIN, V88, P205, DOI 10.1016/S0304-3959(00)00353-5; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; JANCSOGABOR A, 1970, J PHYSIOL-LONDON, V208, P449, DOI 10.1113/jphysiol.1970.sp009130; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 1999, J NEUROSCI, V19, P529; Marinelli S, 2002, J PHYSIOL-LONDON, V543, P531, DOI 10.1113/jphysiol.2002.022863; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Melzack R, 2001, ANN NY ACAD SCI, V933, P157; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Palazzo E, 2002, EUR J PHARMACOL, V439, P69, DOI 10.1016/S0014-2999(02)01367-5; Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2002, BRIT J PHARMACOL, V136, P452, DOI 10.1038/sj.bjp.0704732; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Szabo T, 2002, MOL BRAIN RES, V98, P51, DOI 10.1016/S0169-328X(01)00313-8; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 1999, PHARMACOL REV, V51, P159; TSENG CF, 1992, CHEM PHARM BULL, V40, P396, DOI 10.1248/cpb.40.396; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; WALPOLE CSJ, 1993, STRUCTURAL REQUIREME, P63	40	274	287	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13633	13639		10.1074/jbc.M211231200	http://dx.doi.org/10.1074/jbc.M211231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12569099	hybrid			2022-12-25	WOS:000182405000011
J	Heeren, J; Grewal, T; Laatsch, A; Rottke, D; Rinninger, F; Enrich, C; Beisiegel, U				Heeren, J; Grewal, T; Laatsch, A; Rottke, D; Rinninger, F; Enrich, C; Beisiegel, U			Recycling of apoprotein E is associated with cholesterol efflux and high density lipoprotein internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; MOUSE PERITONEAL-MACROPHAGES; B TYPE-I; TRIGLYCERIDE-RICH LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; SELECTIVE LIPID UPTAKE; HDL PARTICLE UPTAKE; PLASMA-MEMBRANE; INTRACELLULAR TRAFFICKING; ENDOCYTIC COMPARTMENT	After receptor-mediated endocytosis of triglyceride-rich lipoproteins (TRL) into the liver, TRL particles are immediately disintegrated in peripheral endosomal compartments. Whereas core lipids and apoprotein B are delivered for degradation into lysosomes, TRL-derived apoE is efficiently recycled back to the plasma membrane. This is followed by apoE re-secretion and association of apoE with high density lipoproteins (HDL). Because HDL and apoE can independently promote cholesterol efflux, we investigated whether recycling of TRL-derived apoE in human hepatoma cells and fibroblasts could be linked to intracellular cholesterol transport. In this study we demonstrate that HDL, does not only act as an extracellular acceptor for recycled apoE but also stimulates the recycling of internalized TRL-derived apoE. Furthermore, radioactive pulse-chase experiments indicate that apoE recycling is accompanied by cholesterol efflux. Confocal imaging reveals co-localization of apoE and cholesterol in early endosome antigen 1-positive endosomes. During apoE re-secretion, HDL3-derived apoA-I is found in these early endosome antigen 1, cholesterol-containing endosomes. As shown by time-lapse fluorescence microscopy, apoE recycling involves the intracellular trafficking of apoA-I to pre-existing and TRL-derived apoE/cholesterol-containing endosomes in the periphery. Thus, these studies provide evidence for a new intracellular link between TRL-derived apoE, cellular cholesterol transport, and HDL metabolism.	Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany; Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Cellular Biol, Barcelona 08036, Spain	University of Hamburg; University of Hamburg; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Heeren, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, Martinistr 52, D-20246 Hamburg, Germany.		Eckhardt, Erik/G-1567-2010	Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BASU SK, 1982, J BIOL CHEM, V257, P9788; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Bielicki JK, 1999, J LIPID RES, V40, P85; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Calvo M, 2000, ELECTROPHORESIS, V21, P3386, DOI 10.1002/1522-2683(20001001)21:16<3386::AID-ELPS3386>3.3.CO;2-C; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Enrich C, 1999, HEPATOLOGY, V30, P1115, DOI 10.1002/hep.510300505; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Garcia A, 1996, BIOCHEMISTRY-US, V35, P13064, DOI 10.1021/bi952223l; Goldschmidt HMJ, 2001, ACCREDIT QUAL ASSUR, V6, P388, DOI 10.1007/s007690100386; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; Heeren J, 1999, J CELL SCI, V112, P349; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; Heeren J, 2001, CURR OPIN LIPIDOL, V12, P255, DOI 10.1097/00041433-200106000-00003; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Klinger A, 1997, BBA-LIPID LIPID MET, V1345, P65, DOI 10.1016/S0005-2760(96)00164-6; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; Mahley RW, 1999, J LIPID RES, V40, P1; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Niemeier A, 1996, J LIPID RES, V37, P1733; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Ortega D, 1998, J CELL SCI, V111, P261; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; ROGLER G, 1991, BIOCHIM BIOPHYS ACTA, V1095, P30, DOI 10.1016/0167-4889(91)90041-U; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, CURR OPIN LIPIDOL, V12, P497, DOI 10.1097/00041433-200110000-00004; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	56	67	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14370	14378		10.1074/jbc.M209006200	http://dx.doi.org/10.1074/jbc.M209006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584196	hybrid			2022-12-25	WOS:000182405000102
J	Lidell, ME; Johansson, MEV; Hansson, GC				Lidell, ME; Johansson, MEV; Hansson, GC			An autocatalytic cleavage in the c terminus of the human MUC2 mucin occurs at the low pH of the late secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; PRE-ALPHA-INHIBITOR; MAMMARY ADENOCARCINOMA CELLS; DISULFIDE-BONDED DIMERS; VON-WILLEBRAND-FACTOR; MOLECULAR-CLONING; INTESTINAL MUCIN; HEAVY-CHAIN; SIALOMUCIN COMPLEX; EPITHELIAL MUCIN	During purification of a recombinant MUC2 C terminus expressed in CHO-K1 cells, the protein was partly cleaved when buffers with a pH of 6.0 were used. When buffers with higher pH values were used, less cleavage was found. Disulfide bonds held the two fragments generated together as these were only observed after reduction. Edman sequencing of the C-terminal 110-kDa fragment revealed that the cleavage had occurred at an Asp-Pro bond, a site described previously to generate the so-called "link peptide" after disulfide bond reduction. In vitro studies on the conditions for cleavage showed that it occurred in a time-dependent manner at a pH below 6.0. Furthermore, the reaction was not enzyme-mediated as it occurred in pure preparations of the MUC2 C terminus and was not inhibited by protease inhibitors. When expressed in the mucin producing cell line LS 174T, the C terminus was cleaved to a higher extent compared with the CHO-K1 cells. Neutralizing the secretory pathway with either N-H4Cl or bafilomycin A1 inhibited this cleavage. Altogether, our results suggest that the cleavage is an autocatalytic reaction that occurs in the acidic environment of the late secretory pathway. Furthermore, the cleavage produced a new, reactive C terminus that has the potential to attach the mucin to itself or other molecules. Because a pH below 6 can be reached in the late secretory pathway and on mucosal surfaces, the cleavage and possible cross-linking are likely to be of biological importance.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Gothenburg	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Medicinaregatan 9A, S-41390 Gothenburg, Sweden.		Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019; Johansson, Malin E. V./HCH-7451-2022	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869; Johansson, Malin E. V./0000-0002-4237-6677				Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; Axelsson MAB, 2001, GLYCOBIOLOGY, V11, P633, DOI 10.1093/glycob/11.8.633; Bell SL, 1998, EUR J BIOCHEM, V253, P123, DOI 10.1046/j.1432-1327.1998.2530123.x; Bell SL, 2001, BIOCHEM J, V357, P203, DOI 10.1042/0264-6021:3570203; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; Coakley R D, 2001, JOP, V2, P294; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Desseyn JL, 1998, J BIOL CHEM, V273, P30157, DOI 10.1074/jbc.273.46.30157; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FAHIM REF, 1987, BIOCHEM J, V243, P631, DOI 10.1042/bj2430631; FAHIM REF, 1983, BIOCHEM J, V209, P117, DOI 10.1042/bj2090117; Forstner G, 1989, Symp Soc Exp Biol, V43, P259; Forstner Janet F., 1995, P71; Forstner Janet F., 1994, P1255; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; GUM JR, 1994, J BIOL CHEM, V269, P2440; HELM RM, 1981, EXP CELL RES, V135, P418, DOI 10.1016/0014-4827(81)90181-6; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; MANTLE M, 1984, BIOCHEM J, V224, P345, DOI 10.1042/bj2240345; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Poschet JF, 2001, P NATL ACAD SCI USA, V98, P13972, DOI 10.1073/pnas.241182598; Pratt WS, 2000, BIOCHEM BIOPH RES CO, V275, P916, DOI 10.1006/bbrc.2000.3406; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Thuveson M, 2000, J BIOL CHEM, V275, P30996, DOI 10.1074/jbc.M002399200; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; XU GQ, 1992, J BIOL CHEM, V267, P5401; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200	56	73	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13944	13951		10.1074/jbc.M210069200	http://dx.doi.org/10.1074/jbc.M210069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582180	hybrid			2022-12-25	WOS:000182405000050
J	Coleman, KM; Dutertre, M; El-Gharbawy, A; Rowan, BG; Weigel, NL; Smith, CL				Coleman, KM; Dutertre, M; El-Gharbawy, A; Rowan, BG; Weigel, NL; Smith, CL			Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; CHICKEN PROGESTERONE-RECEPTOR; PROTEIN-KINASE-A; BREAST-CANCER CELLS; P68 RNA HELICASE; GROWTH FACTOR-I; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; GLUCOCORTICOID RECEPTOR	Although increases in intracellular cAMP can stimulate estrogen receptor-alpha (ERalpha) activity in the absence of exogenous hormone, no studies have addressed whether ERbeta can be similarly regulated. In transient transfections, forskolin plus 3-isobutyl-1-methylxanthine (IBMX), which increases intracellular cAMP, stimulated the transcriptional activities of both ERalpha and ERbeta. This effect was blocked by the protein kinase A inhibitor H89 (N-(2-(p-bromocinnamylamino)-ethyl)-5-isoquinolinesulfonamide) and was dependent on an estrogen response element. A 12-O-tetradecanoylphorbol-13-acetate response element (TRE) located 5' to the estrogen response element was necessary for cAMP-dependent activation of gene expression by ERbeta but not ERalpha, indicating that the former subtype requires a functional interaction with TRE-interacting factor(s) to stimulate transcription. Both p160 and CREB-binding protein coactivators stimulated cAMP-induced ERalpha and ERbeta transcriptional activity. However, mutation of the two cAMP-inducible SRC-1 phosphorylation sites important for cAMP activation of chicken progesterone receptor or all seven known SRC-1 phosphorylation sites did not specifically impair cAMP activation of ERalpha. The E/F domains of ERa are sufficient for activation by forskolin/IBMX, and this is accompanied by an increase in receptor phosphorylation. In contrast, cAMP signaling reduces the phosphorylation of the corresponding region of ERbeta, and this correlates with the lack of forskolin/IBMX stimulated transcriptional activity. Our data suggest that cAMP activation of ERalpha transcriptional activity is associated with receptor instead of SRC-1 phosphorylation. Moreover, differences in the cofactor requirements, domains of ERalpha and ERbeta sufficient for forskolin/IBMX activation, and the effect of cAMP on receptor phosphorylation indicate that this signaling pathway utilizes distinct mechanisms to stimulate ERalpha and ERbeta transcriptional activity.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA	Baylor College of Medicine	Smith, CL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Dutertre, Martin/N-7060-2017; DUTERTRE, Martin/Q-1815-2019	Dutertre, Martin/0000-0003-0278-4120; DUTERTRE, Martin/0000-0003-0278-4120	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053002] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07165] Funding Source: Medline; NIDDK NIH HHS [DK53002] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Bai WL, 1997, J BIOL CHEM, V272, P10457; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; BUELT MK, 1994, J BIOL CHEM, V269, P29367; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHO HS, 1994, ENDOCRINOLOGY, V134, P658, DOI 10.1210/en.134.2.658; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Dowhan DH, 1996, NUCLEIC ACIDS RES, V24, P264, DOI 10.1093/nar/24.2.264; Driggers PH, 2001, J BIOL CHEM, V276, P46792, DOI 10.1074/jbc.M106927200; ElTanani MKK, 1996, MOL CELL ENDOCRINOL, V124, P71, DOI 10.1016/S0303-7207(96)03930-5; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; Glass CK, 2000, GENE DEV, V14, P121; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; INCE BA, 1994, MOL ENDOCRINOL, V8, P1397, DOI 10.1210/me.8.10.1397; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Walters MR, 2002, J BIOL CHEM, V277, P1669, DOI 10.1074/jbc.M109320200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	78	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12834	12845		10.1074/jbc.M212312200	http://dx.doi.org/10.1074/jbc.M212312200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566449	hybrid			2022-12-25	WOS:000182189500033
J	Laneve, P; Altieri, F; Fiori, ME; Scaloni, A; Bozzoni, I; Caffarelli, E				Laneve, P; Altieri, F; Fiori, ME; Scaloni, A; Bozzoni, I; Caffarelli, E			Purification, cloning, and characterization of XendoU, a novel endoribonuclease involved in processing of intron-encoded small nucleolar RNAs in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING ENDONUCLEASE; RIBOSOMAL-RNA; ACTIVE-SITE; IN-VITRO; RIBONUCLEASE; YEAST; SNORNA; CLEAVAGE; GENE; ENZYME	Here we report the purification, from Xenopus laevis oocyte nuclear extracts, of a new endoribonuclease, XendoU, that is involved in the processing of the intron-encoded box C/D U16 small nucleolar RNA (snoRNA) from its host pre-mRNA. Such an activity has never been reported before and has several uncommon features that make it quite a novel enzyme: it is poly(U)-specific, it requires Mn2+ ions, and it produces molecules with 2'-3'-cyclic phosphate termini. Even if XendoU cleaves U-stretches, it displays some preferential cleavage on snoRNA precursor molecules. XendoU also participates in the biosynthesis of another intron-encoded snoRNA, U86, which is contained in the NOP56 gene of Xenopus laevis. A common feature of these snoRNAs is that their production is alternative to that of the mRNA, suggesting an important regulatory role for all the factors involved in the processing reaction.	Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Mol Biol & Pathol, Inst Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem, I-00185 Rome, Italy; CNR, Inst Anim Prod Syst Mediterranean Environm, Proteom & Mass Spectrometry Lab, I-80147 Naples, Italy; CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Caffarelli, E (corresponding author), Univ Roma La Sapienza, Dept Genet & Mol Biol, Inst Mol Biol & Pathol, Inst Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	elisa.caffarelli@uniroma1.it	Altieri, Fabio/D-2790-2009; Fiori, Micol Eleonora/J-7295-2016; Fiori, Micol E/J-4043-2014; laneve, pietro/ABD-1633-2020; laneve, pietro/M-3386-2014	Altieri, Fabio/0000-0002-6546-2738; Fiori, Micol Eleonora/0000-0002-1813-7035; Fiori, Micol E/0000-0002-1813-7035; Scaloni, Andrea/0000-0001-9362-8515; bozzoni, irene/0000-0002-3485-8537; laneve, pietro/0000-0002-8865-4038				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Ambros V, 2001, SCIENCE, V293, P811, DOI 10.1126/science.1064400; Bachellerie JP, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P191; BACHMANN M, 1984, BIOCHIM BIOPHYS ACTA, V783, P89, DOI 10.1016/0167-4781(84)90082-4; Bujnicki JM, 2000, FEBS LETT, V486, P328, DOI 10.1016/S0014-5793(00)02322-X; Caffarelli E, 1998, MOL CELL BIOL, V18, P1023, DOI 10.1128/MCB.18.2.1023; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; Caffarelli E, 1997, BIOCHEM BIOPH RES CO, V233, P514, DOI 10.1006/bbrc.1997.6487; Chanfreau G, 1997, GENE DEV, V11, P2741, DOI 10.1101/gad.11.20.2741; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; EDER PS, 1991, J BIOL CHEM, V266, P6472; Filippini D, 2001, BIOCHEM BIOPH RES CO, V288, P16, DOI 10.1006/bbrc.2001.5720; FORSTER AC, 1990, METHOD ENZYMOL, V181, P583; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; Giorgi C, 2001, EMBO J, V20, P6856, DOI 10.1093/emboj/20.23.6856; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; NASHIMOTO M, 1995, NUCLEIC ACIDS RES, V23, P3642, DOI 10.1093/nar/23.18.3642; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; Pan  T., 1993, RNA WORLD, P271; PRISLEI S, 1992, NUCLEIC ACIDS RES, V20, P4473, DOI 10.1093/nar/20.17.4473; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; SANTORO B, 1994, MOL CELL BIOL, V14, P6975, DOI 10.1128/MCB.14.10.6975; SCHOENBERG DR, 1997, MRNA METABOLISM POST, P217; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Zamore PD, 2001, MOL CELL, V8, P1158, DOI 10.1016/S1097-2765(01)00418-X	41	73	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13026	13032		10.1074/jbc.M211937200	http://dx.doi.org/10.1074/jbc.M211937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571235	hybrid			2022-12-25	WOS:000182189500056
J	Schmidt, P; Youhnovski, N; Daiber, A; Balan, A; Arsic, M; Bachschmid, M; Przybylski, M; Ullrich, V				Schmidt, P; Youhnovski, N; Daiber, A; Balan, A; Arsic, M; Bachschmid, M; Przybylski, M; Ullrich, V			Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE POLYACRYLAMIDE-GELS; NITRIC-OXIDE; SELECTIVE NITRATION; PEROXYNITRITE; PROTEINS; IDENTIFICATION; NITROTYROSINE; INACTIVATION; MACROPHAGES; SUPEROXIDE	Treatment of bovine aortic microsomes containing active prostacyclin synthase (PGI(2) synthase) with increasing concentrations of peroxynitrite (PN) up to 250 muM of PN yielded specific staining of this enzyme on Western blots with antibodies against 3-nitrotyrosine (3-NT), whereas above 500 muM PN staining of additional proteins was also observed. Following treatment of aortic microsomes with 25 muM PN, PGI(2) synthase was about half-maximally nitrated and about half-inhibited. It was then isolated by gel electrophoresis and subjected to proteolytic digestion with several proteases. Digestion with thermolysin for. 24 h provided a single specific peptide that was isolated by high performance liquid chromatography and identified as a tetrapeptide Leu-Lys-Asn-Tyr(3-nitro)-COOH corresponding to positions 427-430 of PGI(2) synthase. Its structure was established by precise mass determination using Fourier transform-ion cyclotron resonance-nanoelectrospray mass spectrometry and Edman microsequencing and ascertained by synthesis and mass spectrometric characterization of the authentic Tyr-nitrated peptide. Complete digestion by Pronase to 3-nitrotyrosine was obtained only after 72 h, suggesting that the nitrated Tyr-430 residue may be embedded in a tight fold around the heme binding site. These results provide evidence for the specific inhibition of PGI(2) synthase by nitration at Tyr-430 that may occur already at low levels of PN as a consequence of endothelial co-generation of nitric oxide and superoxide.	Univ Konstanz, Fak Biol, Dept Biol, Biol Chem Lab, D-78457 Constance, Germany; Univ Konstanz, Dept Chem, Analyt Chem Lab, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Dept Biol, Biol Chem Lab, Fach X910,Sonnenbuhl, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de	Petre, Brindusa/S-8307-2016; Petre, Brindusa-Alina/C-2793-2011	Bachschmid, Markus Michael/0000-0002-0748-5528				BACHSCHMID M, 2003, IN PRESS FASEB J; Bauer SHJ, 2001, ANAL BIOCHEM, V298, P25, DOI 10.1006/abio.2001.5330; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bian K, 2001, FREE RADICAL BIO MED, V31, P421, DOI 10.1016/S0891-5849(01)00600-1; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; Crow J P, 1995, Adv Pharmacol, V34, P17; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; Fligge TA, 2000, BIOCHEMISTRY-US, V39, P8491, DOI 10.1021/bi9922751; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; Hatae T, 1996, FEBS LETT, V389, P268, DOI 10.1016/0014-5793(96)00600-X; Heinz Kathrin, 2002, Nitric Oxide, V6, P400; HORIKAWA S, 1979, ANAL BIOCHEM, V97, P116, DOI 10.1016/0003-2697(79)90334-8; JACOBS E, 1986, ANAL BIOCHEM, V154, P583, DOI 10.1016/0003-2697(86)90033-3; Jiao KS, 2001, ANAL BIOCHEM, V293, P43, DOI 10.1006/abio.2001.5118; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Kroncke KD, 2002, J BIOL CHEM, V277, P13294, DOI 10.1074/jbc.M111216200; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Michels J, 2002, PROTEIN SCI, V11, P1565, DOI 10.1110/ps.2760102; MONCADA S, 1978, PHARMACOL REV, V30, P293; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 2001, J BIOL CHEM, V276, P34051, DOI 10.1074/jbc.M100585200; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Rossier JS, 2003, ANGEW CHEM INT EDIT, V42, P54; Sarver A, 2001, J AM SOC MASS SPECTR, V12, P439, DOI 10.1016/S1044-0305(01)00213-6; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shyue SK, 1997, J BIOL CHEM, V272, P3657, DOI 10.1074/jbc.272.6.3657; SIEGLE I, 1994, FEBS LETT, V347, P221, DOI 10.1016/0014-5793(94)00504-4; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Ullrich V, 2001, BBA-MOL CELL BIOL L, V1532, P1, DOI 10.1016/S1388-1981(01)00126-3; ULLRICH V, 1981, BIOCHEM PHARMACOL, V30, P2033, DOI 10.1016/0006-2952(81)90218-5; ULLRICH V, 1994, ANGEW CHEM INT EDIT, V33, P1911, DOI 10.1002/anie.199419111; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1999, DRUG METAB REV, V31, P343, DOI 10.1081/DMR-100101922; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	45	114	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12813	12819		10.1074/jbc.M208080200	http://dx.doi.org/10.1074/jbc.M208080200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562775	hybrid			2022-12-25	WOS:000182189500030
J	van Weelden, SWH; Fast, B; Vogt, A; van der Meer, P; Saas, J; van Hellemond, JJ; Tielens, AGM; Boshart, M				van Weelden, SWH; Fast, B; Vogt, A; van der Meer, P; Saas, J; van Hellemond, JJ; Tielens, AGM; Boshart, M			Procyclic Trypanosoma brucei do not use Krebs cycle activity for energy generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; ENZYME-ACTIVITIES; CIS-ACONITATE; DIFFERENTIATION; METABOLISM; TRANSFORMATION; COMPARTMENTATION; STRAINS; CULTURE; GLUCOSE	The importance of a functional Krebs cycle for energy generation in the procyclic stage of Trypanosoma brucei was investigated under physiological conditions during logarithmic phase growth of a pleomorphic parasite strain. Wild type procyclic cells and mutants with targeted deletion of the gene coding for aconitase were derived by synchronous in vitro differentiation from wild type and mutant (Deltaaco::NEO/Deltaaco::HYG) bloodstream stage parasites, respectively, where aconitase is not expressed and is dispensable. No differences in intracellular levels of glycolytic and Krebs cycle intermediates were found in procyclic wild type and mutant cells, except for citrate that accumulated up to 90-fold in the mutants, confirming the absence of aconitase activity. Surprisingly, deletion of aconitase did not change differentiation nor the growth rate or the intracellular ATP/ADP ratio in those cells. Metabolic studies using radioactively labeled substrates and NMR analysis demonstrated that glucose and proline were not degraded via the Krebs cycle to CO2. Instead, glucose was degraded to acetate, succinate, and alanine, whereas proline was degraded to succinate. Importantly, there was absolutely no difference in the metabolic products released by wild type and aconitase knockout parasites, and both were for survival strictly dependent on respiration via the mitochondrial electron transport chain. Hence, although the Krebs cycle enzymes are present, procyclic T. brucei do not use Krebs cycle activity for energy generation, but the mitochondrial respiratory chain is essential for survival and growth. We therefore propose a revised model of the energy metabolism of procyclic T. brucei.	Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Free Univ Berlin, Inst Mol Biol & Biochem, Mol Cell Biol Unit, D-12203 Berlin, Germany; Heidelberg Univ, Dept Internal Med 3, D-69115 Heidelberg, Germany; DLO, ATO, Agrotechnol Res Inst, NL-6700 AA Wageningen, Netherlands	Utrecht University; Free University of Berlin; Ruprecht Karls University Heidelberg	Boshart, M (corresponding author), Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	boshart@lmu.de	van Hellemond, Jaap/T-7555-2019; Boshart, Michael/A-2700-2011	van Hellemond, Jaap/0000-0003-4862-7796; Boshart, Michael/0000-0002-5070-2663; Tielens, Aloysius/0000-0002-5485-1105				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Bergmeyer H. U., 1970, METHODEN ENZYMATISCH, P1163; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUN R, 1981, Z PARASITENKD, V66, P17, DOI 10.1007/BF00941941; CARRUTHERS VB, 1993, NUCLEIC ACIDS RES, V21, P2537, DOI 10.1093/nar/21.10.2537; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; CRONIN CN, 1989, FEBS LETT, V244, P26, DOI 10.1016/0014-5793(89)81154-8; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; DURIEUX PO, 1991, MOL BIOCHEM PARASIT, V45, P19, DOI 10.1016/0166-6851(91)90023-Y; EVANS DA, 1972, J PROTOZOOL, V19, P686, DOI 10.1111/j.1550-7408.1972.tb03561.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; Fast B, 1999, BIOCHEM J, V342, P691, DOI 10.1042/0264-6021:3420691; HENSON CP, 1967, J BIOL CHEM, V242, P3833; HOREMANS AMC, 1991, PARASITOLOGY, V102, P259, DOI 10.1017/S0031182000062570; MATTHEWS KR, 1994, J CELL BIOL, V125, P1147, DOI 10.1083/jcb.125.5.1147; MRACEK J, 1991, J PROTOZOOL, V38, P554, DOI 10.1111/j.1550-7408.1991.tb06079.x; Mutomba MC, 1998, MOL BIOCHEM PARASIT, V93, P11, DOI 10.1016/S0166-6851(98)00012-7; MUTURINJOGU R, 1980, MOL BIOCHEM PARASIT, V1, P13, DOI 10.1016/0166-6851(80)90038-9; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; PANDE SV, 1976, ANAL BIOCHEM, V74, P25, DOI 10.1016/0003-2697(76)90306-7; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; terKuile BH, 1997, J BACTERIOL, V179, P4699, DOI 10.1128/jb.179.15.4699-4705.1997; TIELENS AGM, 1992, MOL BIOCHEM PARASIT, V56, P49, DOI 10.1016/0166-6851(92)90153-B; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; TIELENS AGM, 1981, MOL BIOCHEM PARASIT, V3, P205, DOI 10.1016/0166-6851(81)90052-9; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P91, DOI 10.1016/0166-6851(96)02727-2; Vassella E, 2001, MOL MICROBIOL, V41, P33, DOI 10.1046/j.1365-2958.2001.02471.x; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; Vogt AM, 1998, BIOCHEM BIOPH RES CO, V248, P527, DOI 10.1006/bbrc.1998.9005; ZIEGELBAUER K, 1990, EUR J BIOCHEM, V192, P373, DOI 10.1111/j.1432-1033.1990.tb19237.x	39	87	90	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12854	12863		10.1074/jbc.M213190200	http://dx.doi.org/10.1074/jbc.M213190200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562769	hybrid			2022-12-25	WOS:000182189500035
J	Hofmann, CS; Sonenshein, GE				Hofmann, CS; Sonenshein, GE			Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53	FASEB JOURNAL			English	Article						p21(CIP1); NF-kappa B; p50; p65; I kappa B	NF-KAPPA-B; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; SIGNALING TRANSDUCTION PATHWAY; NUCLEAR-FACTOR; BREAST-CANCER; TRANSCRIPTION FACTORS; NEOINTIMA FORMATION; EXPRESSION; PROMOTER	Green tea polyphenols (GTPs), which possess antioxidant properties, have been shown to inhibit the development of atherosclerotic lesions. Epigallocatechin-3-gallate (EGCG), the most abundant GTP, displays antiproliferative effects in a variety of cell types. Here, we examined the effects of GTPs on aortic smooth muscle cell (SMC) proliferation. Treatment with a GTP mixture or EGCG at a dose of 40 to 50 mug/ml slowed SMC growth, while at a higher dose of 80 mug/ml EGCG also induced cell death as judged by TUNEL assay. Apoptosis was mainly observed in proliferating SMCs in subconfluent cultures; whereas at higher confluency, cell viability was largely unaffected. Treatment with 80 mug/ml EGCG induced the tumor suppressor p53, which was functional as judged by activation of the target cyclin-dependent kinase inhibitor p21(CIP1). Inhibition of p53 activity with a dominant negative mutant reduced cell death. The increase in p53 protein was due to increased stability. EGCG also induced functional nuclear factor-kappaB (NF-kappaB) complexes, and inhibition of this activity reduced the extent of cell death. Thus, EGCG inhibits growth and induces death of SMCs in a p53- and NF-kappaB-dependent manner. These results provide evidence for a new molecular mechanism whereby green tea polyphenols inhibit SMC proliferation and function to prevent the development of atherosclerosis.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	gsonensh@bu.edu						Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; Aoki M, 1999, HYPERTENSION, V34, P192, DOI 10.1161/01.HYP.34.2.192; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Condorelli G, 2001, FASEB J, V15, P2162, DOI 10.1096/fj.01-0032com; Dreosti IE, 1997, CRIT REV FOOD SCI, V37, P761, DOI 10.1080/10408399709527801; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Dufresne CJ, 2001, J NUTR BIOCHEM, V12, P404, DOI 10.1016/S0955-2863(01)00155-3; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Hwang KC, 2002, J CARDIOVASC PHARM, V39, P271, DOI 10.1097/00005344-200202000-00014; IMAI K, 1995, BRIT MED J, V310, P693, DOI 10.1136/bmj.310.6981.693; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; KINDY MS, 1988, J BIOL CHEM, V263, P11426; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; Lee JS, 1998, EXP CELL RES, V239, P447, DOI 10.1006/excr.1997.3919; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lu LH, 1998, BRIT J PHARMACOL, V124, P1227, DOI 10.1038/sj.bjp.0701912; Matsushita H, 2000, CIRCULATION, V101, P1447, DOI 10.1161/01.CIR.101.12.1447; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P721, DOI 10.1006/bbrc.2001.5415; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pianetti S, 2002, CANCER RES, V62, P652; Pietta PG, 1998, BIOFACTORS, V8, P111, DOI 10.1002/biof.5520080119; Rodriguez-Campos A, 2001, ARTERIOSCL THROM VAS, V21, P214, DOI 10.1161/01.ATV.21.2.214; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Sriram V, 2001, CIRCULATION, V103, P2414; WAKSMAN R, 1995, CIRCULATION, V92, P3025, DOI 10.1161/01.CIR.92.10.3025; Wu M, 1999, J IMMUNOL, V163, P6530; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Yang TTC, 1997, PHARMACOL RES, V35, P505, DOI 10.1006/phrs.1997.0176; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200	48	88	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					702	+		10.1096/fj.02-0665fje	http://dx.doi.org/10.1096/fj.02-0665fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586742				2022-12-25	WOS:000181456900034
J	Campanella, GSV; Lee, EMJ; Sun, J; Luster, AD				Campanella, GSV; Lee, EMJ; Sun, J; Luster, AD			CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ALPHA-CHEMOATTRACTANT; INTERFERON-INDUCIBLE PROTEIN-10; MONOCYTE CHEMOTACTIC PROTEIN-1; ACUTE ALLOGRAFT-REJECTION; X-C CHEMOKINE; T-CELLS; DIFFERENTIAL EXPRESSION; RECEPTOR-BINDING; SULFATE PROTEOGLYCANS; MULTIPLE-SCLEROSIS	The chemokine IP-10 (interferon-inducible protein of 10 kDa, CXCL10) binds the G protein-coupled receptor CXCR3, which is found mainly on activated T cells and NK cells, and plays an important role in Th1-type inflammatory diseases. IP-10 also binds to glycosaminoglycans (GAGs), an interaction thought to be important for its sequestration on endothelial and other cells. In this study, we performed an extensive mutational analysis to identify the CXCR3 and heparin binding sites of murine IP-10. The mutants were characterized for heparin binding, CXCR3 binding, and the ability to induce chemotaxis, Ca2+ flux, and CXCR3 internalization. Double mutations neutralizing adjacent basic residues at the C terminus did not lead to a significant reduction in heparin binding, indicating that the main heparin binding site of IP-10 is not along the C-terminal alpha helix. Alanine exchange of Arg-22 had the largest effect on heparin binding, with residues Arg-20, Ile-24, Lys-26, Lys-46, and Lys-47 further contributing to heparin binding. A charge change mutation of Arg-22 resulted in further reduction in heparin binding. The N-terminal residue Arg-8, preceding the first cysteine, was critical for CXCR3 signaling. Mutations of charged and uncharged residues in the loop regions of residues 20-24 and 46-47, which caused reduced heparin binding, also resulted in reduced CXCR3 binding and signaling. CXCR3 expressing GAG-deficient Chinese hamster ovary cells revealed that GAG binding was not required for IP-10 binding and signaling through CXCR3, which suggests that the CXCR3 and heparin binding sites of IP-10 are partially overlapping.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Bldg 149,13th St, Charlestown, MA 02129 USA.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	NATIONAL CANCER INSTITUTE [R01CA069212] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA69212] Funding Source: Medline; NIDDK NIH HHS [R01-DK50305] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; Fleischer J, 2002, J IMMUNOL, V169, P770, DOI 10.4049/jimmunol.169.2.770; Flier J, 1999, J INVEST DERMATOL, V113, P574, DOI 10.1046/j.1523-1747.1999.00730.x; Flier J, 2001, J PATHOL, V194, P398, DOI 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oravecz T, 1997, J IMMUNOL, V159, P4587; Ottersbach K, 2001, BIOCHEM J, V354, P447, DOI 10.1042/0264-6021:3540447; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Sauty A, 2001, J IMMUNOL, V167, P7084, DOI 10.4049/jimmunol.167.12.7084; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205; Zhao DXM, 2002, J IMMUNOL, V169, P1556, DOI 10.4049/jimmunol.169.3.1556	50	84	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17066	17074		10.1074/jbc.M212077200	http://dx.doi.org/10.1074/jbc.M212077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12571234	hybrid			2022-12-25	WOS:000182818600084
J	Antonyak, MA; McNeill, CJ; Wakshlag, JJ; Boehm, JE; Cerione, RA				Antonyak, MA; McNeill, CJ; Wakshlag, JJ; Boehm, JE; Cerione, RA			Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN NEUROBLASTOMA-CELLS; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; APOPTOSIS; KINASE; DIFFERENTIATION; TRANSFORMATION; INDUCTION	Retinoic acid (RA) is a potent activator of tissue transglutaminase (TGase) expression, and it was recently shown that phosphoinositide 3-kinase (PI3K) activity was required for RA to increase TGase protein levels. To better understand how RA-mediated TGase expression is regulated, we considered whether co-stimulation of NIH3T3 cells with RA and epidermal growth factor (EGF), a known activator of PI3K, would facilitate the induction or increase the levels of TGase expression. Instead of enhancing these parameters, EGF inhibited RA-induced TGase expression. Activation of the Ras-ERK pathway by EGF was sufficient to elicit this effect, since continuous Ras signaling mimicked the actions of EGF and inhibited RA-induced TGase expression, whereas blocking ERK activity in these same cells restored the ability of RA to up-regulate TGase expression. However, TGase activity is not antagonistic to EGF signaling. The mitogenic and anti-apoptotic effects of EGF were not compromised by TGase overexpression, and in fact, exogenous TGase expression promoted basal cell growth and resistance to serum deprivation-induced apoptosis. Moreover, analysis of TGase expression and GTP binding activity in a number of cell lines revealed high basal TGase GTP binding activity in tumor cell lines U87 and MDAMB231, indicating that constitutively active TGase may be a characteristic of certain cancer cells. These findings demonstrate that TGase may serve as a survival factor and RA-induced TGase expression requires the activation of PI3K but is antagonized by the Ras-ERK pathway.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 208052, GM 61762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DADABAY CY, 1987, BIOCHEMISTRY-US, V26, P6587, DOI 10.1021/bi00395a004; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Katoh S, 1996, BIOCHEM J, V313, P305, DOI 10.1042/bj3130305; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOSA K, 1993, BIOCHEM BIOPH RES CO, V196, P1025, DOI 10.1006/bbrc.1993.2354; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MIRZA A, 1997, AM J PHYSIOL, V272, P281; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Paillaud E, 2002, J NEUROSCI RES, V67, P670, DOI 10.1002/jnr.10110; Piacentini M, 2002, J NEUROCHEM, V81, P1061; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SPORN MB, 1983, CANCER RES, V43, P3034; SUTO N, 1993, J BIOL CHEM, V268, P7469; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819	47	43	43	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15859	15866		10.1074/jbc.M300037200	http://dx.doi.org/10.1074/jbc.M300037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604597	hybrid			2022-12-25	WOS:000182680000052
J	Carr, BA; Wan, J; Hines, RN; Yost, GS				Carr, BA; Wan, J; Hines, RN; Yost, GS			Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-4; CYTOCHROMES P450; BRONCHOALVEOLAR MACROPHAGES; XENOBIOTIC METABOLISM; DNA-SEQUENCE; EXPRESSION; SUBFAMILY; PROTEIN; 3-METHYLINDOLE; PULMONARY	The CYP2F1 gene encodes a cytochrome P450 enzyme capable of bioactivating a number of pulmonary-selective toxicants. The expression of CYP2F1 is highly tissue-selective; the highest expression is observed in the lung with little or no hepatic expression. The objective of these studies was to elucidate the mechanisms that govern the unique tissue-specific regulation of CYP2F1. Cosmid and bacterial artificial chromosome clones were screened and sequenced to identify a gene that spanned 14 kbp containing 10 exons, including an untranslated exon 1. Primer extension analysis and 5'-rapid amplification of cDNA ends were used to identify the transcription start site. Several sequences homologous to known cis-elements were identified in the 5'-upstream region of the CYP2F1 promoter. Transient transfection studies with luciferase reporter constructs demonstrated a significant functional lung cell-specific CYP2F1 promoter region (from position -129 to + 115). DNase footprinting analysis of 1.6 kbp of the upstream sequence with nuclear extracts from human lung tissues revealed one strong DNA-protein complex at -152 to -182. This nuclear protein (called lung-specific factor, LSF) was present only in lung but not liver or heart tissues. Competitive electrophoretic mobility shift assays characterized a DNA consensus site, within the LSF-binding domain, that was highly similar to two E box motifs, but no known "E box" trans-factors were identified. These studies identified a novel LSF and its consensus sequence that may control tissue-specific expression of CYP2F1.	Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	Utah System of Higher Education; University of Utah; Medical College of Wisconsin	Yost, GS (corresponding author), Univ Utah, Dept Pharmacol & Toxicol, 30 S 2000 E,Rm 201, Salt Lake City, UT 84112 USA.	gyost@pharm.utah.edu		Hines, Ronald/0000-0002-3094-4200	NHLBI NIH HHS [HL 60143] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060143] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anttila S, 1997, AM J RESP CELL MOL, V16, P242, DOI 10.1165/ajrcmb.16.3.9070608; Aranburu A, 2001, BIOCHEM J, V354, P431, DOI 10.1042/0264-6021:3540431; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Cassel Tobias N., 2000, Molecular Cell Biology Research Communications, V3, P42, DOI 10.1006/mcbr.2000.0187; Chen N, 2002, MUTAT RES-FUND MOL M, V499, P155, DOI 10.1016/S0027-5107(01)00274-3; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; CZERWINSKI M, 1994, CANCER RES, V54, P1085; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; GUENGERICH FP, 1993, DRUG METAB DISPOS, V21, P1; Hoffman SMG, 1995, J MOL EVOL, V41, P894; Hoffman SMG, 2001, PHARMACOGENETICS, V11, P687, DOI 10.1097/00008571-200111000-00007; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Hukkanen J, 1997, MOL CARCINOGEN, V20, P224, DOI 10.1002/(SICI)1098-2744(199710)20:2<224::AID-MC9>3.0.CO;2-M; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kaczynski JA, 2002, BIOCHEM J, V366, P873, DOI 10.1042/BJ20020388; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lanza DL, 1999, DRUG METAB DISPOS, V27, P798; Lanza DL, 2001, DRUG METAB DISPOS, V29, P950; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maxam A M, 1980, Methods Enzymol, V65, P499; NAKAJIMA T, 1994, CHEM RES TOXICOL, V7, P891, DOI 10.1021/tx00042a026; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NHAMBURO PT, 1990, BIOCHEMISTRY-US, V29, P5491, DOI 10.1021/bi00475a012; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Piipari R, 2000, INT J CANCER, V86, P610, DOI 10.1002/(SICI)1097-0215(20000601)86:5<610::AID-IJC2>3.0.CO;2-M; Powley MW, 2000, J BIOCHEM MOL TOXIC, V14, P303, DOI 10.1002/1099-0461(2000)14:6<303::AID-JBT2>3.0.CO;2-8; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Skarin T, 1999, AM J RESP CELL MOL, V21, P177, DOI 10.1165/ajrcmb.21.2.3378; SMITH TJ, 1992, CANCER RES, V52, P1757; ThorntonManning J, 1996, J PHARMACOL EXP THER, V276, P21; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Willey JC, 1996, AM J RESP CELL MOL, V14, P262, DOI 10.1165/ajrcmb.14.3.8845177; Willey JC, 1997, AM J RESP CELL MOL, V17, P114, DOI 10.1165/ajrcmb.17.1.2783; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yost GS, 1996, ADV EXP MED BIOL, V387, P221; Yost GS, 2001, ADV EXP MED BIOL, V500, P53; Zhang JH, 1998, J BIOL CHEM, V273, P23454, DOI 10.1074/jbc.273.36.23454; Zhang JH, 2000, J BIOL CHEM, V275, P8895, DOI 10.1074/jbc.275.12.8895; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	50	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15473	15483		10.1074/jbc.M300319200	http://dx.doi.org/10.1074/jbc.M300319200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598524	hybrid			2022-12-25	WOS:000182680000005
J	Sung, YJ; Dolzhanskaya, N; Nolin, SL; Brown, T; Currie, JR; Denman, RB				Sung, YJ; Dolzhanskaya, N; Nolin, SL; Brown, T; Currie, JR; Denman, RB			The fragile X mental retardation protein FMRP binds elongation factor 1A mRNA and negatively regulates its translation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PEPTIDE PRECURSOR; DENDRITIC SPINES; HUMAN-BRAIN; KH DOMAINS; GENE; IDENTIFICATION; EXPRESSION; MUTATION; MRNP; RAT	Loss of the RNA-binding protein FMRP (fragile X mental retardation protein) leads to fragile X syndrome, the most common form of inherited mental retardation. Although some of the messenger RNA targets of this protein, including FMR1, have been ascertained, many have yet to be identified. We have found that Xenopus elongation factor 1A (EF-1A) mRNA binds tightly to recombinant human FMRP in vitro. Binding depended on protein determinants located primarily in the C-terminal end of hFMRP, but the hnRNP K homology domain influenced binding as well. When hFMRP was expressed in cultured cells, it dramatically reduced endogenous EF-1A protein expression but had no effect on EF-1A mRNA levels. In contrast, the translation of several other mRNAs, including those coding for dynamin and constitutive heat shock 70 protein, was not affected by the hFMRP expression. Most importantly, EF-1A mRNA and hFMR1 mRNA were coimmunoprecipitated with hFMRP. Finally, in fragile X lymphoblastoid cells in which hFMRP is absent, human EF-1A protein but not its corresponding mRNA is elevated compared with normal lymphoblastoid cells. These data suggest that hFMRP binds to EF-1A mRNA and also strongly argue that FAMP negatively regulates EF-1A expression in vivo.	New York State Inst Basic Res Dev Disabil, Biochem Mol Neurobiol Lab, Dept Mol Biol, Staten Isl, NY 10314 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; New York State Inst Basic Res Dev Disabil, Mol Genet Lab, Staten Isl, NY 10314 USA; New York State Inst Basic Res Dev Disabil, Dept Human Genet, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities; Columbia University; Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities	Denman, RB (corresponding author), New York State Inst Basic Res Dev Disabil, Biochem Mol Neurobiol Lab, Dept Mol Biol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	rbdenman@yahoo.com		Nolin, Sarah/0000-0001-5209-289X				Agulhon C, 1999, J NEUROPATH EXP NEUR, V58, P867, DOI 10.1097/00005072-199908000-00009; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Bakker CE, 2000, EXP CELL RES, V258, P162, DOI 10.1006/excr.2000.4932; Bardoni B, 1999, HUM MOL GENET, V8, P2557, DOI 10.1093/hmg/8.13.2557; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Ceman S, 2000, BIOCHEM BIOPH RES CO, V279, P904, DOI 10.1006/bbrc.2000.4035; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; Comery TA, 1996, NEUROBIOL LEARN MEM, V66, P93, DOI 10.1006/nlme.1996.0049; Corbin F, 1997, HUM MOL GENET, V6, P1465, DOI 10.1093/hmg/6.9.1465; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DENMAN R, 1991, ARCH BIOCHEM BIOPHYS, V288, P29, DOI 10.1016/0003-9861(91)90161-B; Denman RB, 1997, BIOCHEM BIOPH RES CO, V230, P226, DOI 10.1006/bbrc.1996.5926; Denman RB, 2002, BIOCHEM BIOPH RES CO, V292, P1063, DOI 10.1006/bbrc.2002.6768; DENMAN RB, 1995, ARCH BIOCHEM BIOPHYS, V323, P71, DOI 10.1006/abbi.1995.0011; Dolzhanskaya N, 2001, ARCH BIOCHEM BIOPHYS, V387, P223, DOI 10.1006/abbi.2000.2262; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; HAGERMAN RJ, 1996, FRAGILE X SYNDROME D, P3; Inoue Shunsuke B., 2000, Journal of Medical Investigation, V47, P101; Irwin SA, 2000, CEREB CORTEX, V10, P1038, DOI 10.1093/cercor/10.10.1038; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; Khandjian EW, 1999, BIOCHEM CELL BIOL, V77, P331, DOI 10.1139/bcb-77-4-331; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; LEE S, 1994, BIOCHEM BIOPH RES CO, V203, P1371, DOI 10.1006/bbrc.1994.2336; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Li JX, 2002, MOL CELL NEUROSCI, V19, P138, DOI 10.1006/mcne.2001.1085; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Moine H, 2001, SCIENCE, V294, P2487, DOI 10.1126/science.1068352; Munshi R, 2001, GENETICS, V157, P1425; O'Donnell WT, 2002, ANNU REV NEUROSCI, V25, P315, DOI 10.1146/annurev.neuro.25.112701.142909; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Setzer DA, 1999, METH MOL B, V118, P115; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; SLOBIN LI, 1993, EUR J BIOCHEM, V213, P919, DOI 10.1111/j.1432-1033.1993.tb17836.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Sung YJ, 2000, BIOCHEM BIOPH RES CO, V275, P973, DOI 10.1006/bbrc.2000.3405; SUNG YJ, 2001, RRD BIO BIO, V1, P109; Tamanini F, 1997, HUM MOL GENET, V6, P1315, DOI 10.1093/hmg/6.8.1315; TANAKA KJ, 1998, TECHNICAL TIPS ONLIN; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	56	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15669	15678		10.1074/jbc.M211117200	http://dx.doi.org/10.1074/jbc.M211117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594214	hybrid			2022-12-25	WOS:000182680000028
J	Ortega, AL; Carretero, J; Obrador, E; Gambini, J; Asensi, M; Rodilla, V; Estrela, JM				Ortega, AL; Carretero, J; Obrador, E; Gambini, J; Asensi, M; Rodilla, V; Estrela, JM			Tumor cytotoxicity by endothelial cells - Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; INTRACELLULAR-DISTRIBUTION; METASTATIC ACTIVITY; OXIDATIVE INJURY; REDOX REGULATION; COMPLEX-I; INHIBITION; DAMAGE	High GSH content associates with high metastatic activity in B16-F10 melanoma cells cultured to low density (LD B16M). GSH homeostasis was investigated in LD B16M cells that survive after adhesion to the hepatic sinusoidal endothelium (HSE). Invasive B16M (iB16M) cells were isolated using anti-Met-72 monoclonal antibodies and flow cytometry-coupled cell sorting. HSE-derived NO and H2O2 caused GSH depletion and a decrease in gamma-glutamyleysteine synthetase activity in iB16M cells. Overexpression of y-glutamyleysteine synthetase heavy and light subunits led to a rapid recovery of cytosolic GSH, whereas mitochondrial GSH (mtGSH) further decreased during the first 18 h of culture. NO and H2O2 damaged the mitochondrial system for GSH uptake (rates in iB16M were approximately 75% lower than in LD B16M cells). iB16M cells also showed a decreased activity of mitochondrial complexes II,III, and IV, less O-2 consumption, lower ATP levels, higher O-2(.-) and H2O2 production, and lower mitochondrial Membrane potential. In vitro growing iB16M cells maintained high viability (>98%) and repaired HSE-induced mitochondrial damages within 48 h. However, iB16M cells with low mtGSH levels were highly susceptible to TNF-alpha-induced oxidative stress and death. Therefore depletion of mtGSH levels may represent a critical target to challenge survival of invasive cancer cells.	Univ Valencia, Fac Med & Odontol, Dept Fisiol, E-46010 Valencia, Spain; Univ Cardenal Herrera CEU, Dept Fisiol Farmacol & Toxicol, E-46113 Moncada, Spain	University of Valencia; Universidad CEU Cardenal Herrera	Estrela, JM (corresponding author), Univ Valencia, Fac Med & Odontol, Dept Fisiol, Av Blasco Ibanez 17, E-46010 Valencia, Spain.	jose.m.estrela@uv.es	OBRADOR, ELENA/H-4069-2015; Ortega, Angel L./A-4113-2014; Carretero, Julian/N-5214-2014; Rodilla, Vicent/L-6977-2014; Miralles, Miguel A Asensi/I-2756-2015; Estrela, Jose/H-4449-2015	OBRADOR, ELENA/0000-0002-5934-5543; Ortega, Angel L./0000-0002-9901-3383; Carretero, Julian/0000-0001-7269-8506; Miralles, Miguel A Asensi/0000-0003-1922-7777; Estrela, Jose/0000-0002-2540-9190; Rodilla, Vicent/0000-0001-9460-7505; Ortega Granados, Ana Laura/0000-0002-5727-3371; Gambini, Juan/0000-0001-8979-2865				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Akerboom T P, 1981, Methods Enzymol, V77, P373; Anasagasti MJ, 1997, HEPATOLOGY, V25, P840, DOI 10.1002/hep.510250410; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; Bergmeyer H.U., 1985, METHODS ENZYMATIC AN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; ESTRELA JM, 1992, BIOCHEM J, V286, P257, DOI 10.1042/bj2860257; FIDLER IJ, 1990, CANCER RES, V50, P6130; Fukumura D, 1996, HEPATOLOGY, V24, P141, DOI 10.1053/jhep.1996.v24.pm0008707254; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; HAN J, 1995, BIOL NITRIC OXIDE, P84; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; KIMURA AK, 1986, JNCI-J NATL CANCER I, V76, P1247; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAFRENIE R, 1992, CANCER METAST REV, V11, P377, DOI 10.1007/BF01307188; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LASH LH, 1995, METHOD ENZYMOL, V252, P14; LI L, 1991, CANCER RES, V51, P245; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Pearce LL, 2001, NITRIC OXIDE-BIOL CH, V5, P128, DOI 10.1006/niox.2001.0338; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; Raha S, 2002, FREE RADICAL BIO MED, V32, P421, DOI 10.1016/S0891-5849(01)00816-4; REED DJ, 1980, BIOCHEM BIOPH RES CO, V94, P1273, DOI 10.1016/0006-291X(80)90557-4; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; SELLAK H, 1994, BLOOD, V83, P2669; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; Sies H, 1982, METABOLIC COMPARTMEN; Stevenson D, 2002, TOXICOL IN VITRO, V16, P609, DOI 10.1016/S0887-2333(02)00042-5; Stewart VC, 2000, J NEUROCHEM, V75, P694, DOI 10.1046/j.1471-4159.2000.0750694.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang HM, 2000, CANCER RES, V60, P5862; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	75	44	46	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13888	13897		10.1074/jbc.M207140200	http://dx.doi.org/10.1074/jbc.M207140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578841	hybrid			2022-12-25	WOS:000182405000043
J	Ruiz-Palacios, GM; Cervantes, LE; Ramos, P; Chavez-Munguia, B; Newburg, DS				Ruiz-Palacios, GM; Cervantes, LE; Ramos, P; Chavez-Munguia, B; Newburg, DS			Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; EPITHELIAL-CELLS; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; TOXIN PRODUCTION; SUCKLING MICE; ENTERO-TOXIN; OLIGOSACCHARIDES; EXPRESSION; RECOGNITION	The most common cause of infant mortality is diarrhea; the most common cause of bacterial diarrhea is Campylobacter jejuni, which is also the primary cause of motor neuron paralysis. The first step in campylobacter pathogenesis is adherence to intestinal mucosa. We found that such binding was inhibited in vitro by human milk and, with high avidity, by alpha1,2-fucosylated carbohydrate moieties containing the H(O) blood group epitope (Fucalpha1,2Galbeta1,4GlcNAc...). In studies on the mechanism of adherence, campylobacter, which normally does not bind to Chinese hamster ovary cells, bound avidly when the cells were transfected with a human alpha1,2-fucosyltransferase gene that caused overexpression of H-2 antigen; binding was specifically inhibited by H-2 ligands (lectins Ulex europaeus and Lotus tetragonolobus and H-2 monoclonal antibody), H-2 mimetics, and human milk oligosaccharides. Human milk oligosaccharides inhibited campylobacter colonization of mice in vivo and human intestinal mucosa ex vivo. Campylobacter colonization of nursing mouse pups was inhibited if their dams had been transfected with a human alpha1,2-fucosyltransferase gene that caused expression of H(O) antigen in milk. We conclude that campylobacter binding to intestinal H-2 antigen is essential for infection. Milk fucosyloligosaccharides and specific fucosyl alpha1,2-linked molecules inhibit this binding and may represent a novel class of antimicrobial agents.	Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City 14000, DF, Mexico; IPN, Ctr Invest & Estudios Avanzados, Dept Expt Pathol, Mexico City 07360, DF, Mexico; Univ Massachusetts, Sch Med, Shriver Ctr, Program Glyobiol, Waltham, MA 02452 USA	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of Massachusetts System	Ruiz-Palacios, GM (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Vasco Quiroga 15, Mexico City 14000, DF, Mexico.	gmrps@servidor.unam.mx	Ghorayeb, Imad/B-3473-2012; Duarte, Graziela Biude Silva/Q-7728-2016; Newburg, david/ABE-8139-2020; Ghorayeb, Imad/D-5073-2017; Ruiz-Palacios, Guillermo/GYQ-5462-2022	Ghorayeb, Imad/0000-0003-1996-8049; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD013021] Funding Source: NIH RePORTER; NICHD NIH HHS [HD13021] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLACKWELL CC, 1986, PROTEIN CARBOHYDRATE, P229; BLASER MJ, 1983, INFECT IMMUN, V39, P908, DOI 10.1128/IAI.39.2.908-916.1983; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; Carvalho ACT, 2001, J CLIN MICROBIOL, V39, P1353, DOI 10.1128/JCM.39.4.1353-1359.2001; CINCO M, 1984, FEMS MICROBIOL LETT, V21, P347, DOI 10.1111/j.1574-6968.1984.tb00334.x; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; CLEARY TG, 1983, J INFECT DIS, V148, P1114, DOI 10.1093/infdis/148.6.1114; COPPA GV, 1990, LANCET, V335, P569, DOI 10.1016/0140-6736(90)90350-E; CRANE JK, 1994, J NUTR, V124, P2358, DOI 10.1093/jn/124.12.2358; CRAVIOTO A, 1979, CURR MICROBIOL, V3, P95, DOI 10.1007/BF02602439; DU MH, 1994, GLYCOCONJUGATE J, V11, P443, DOI 10.1007/BF00731281; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FAUCHERE JL, 1986, INFECT IMMUN, V54, P283, DOI 10.1128/IAI.54.2.283-287.1986; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050; HAKOMORI S, 1985, CANCER RES, V45, P2405; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; Hutson AM, 2002, J INFECT DIS, V185, P1335, DOI 10.1086/339883; Ikehara Y, 2001, CANCER EPIDEM BIOMAR, V10, P971; JENNESS R, 1979, SEMIN PERINATOL, V3, P225; Jin SM, 2001, MOL MICROBIOL, V39, P1225, DOI 10.1046/j.1365-2958.2001.02294.x; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; Kelle K, 1998, RES MICROBIOL, V149, P723, DOI 10.1016/S0923-2508(99)80019-9; Konkel ME, 1999, MOL MICROBIOL, V32, P691, DOI 10.1046/j.1365-2958.1999.01376.x; KUNZ C, 1993, ACTA PAEDIATR, V82, P903, DOI 10.1111/j.1651-2227.1993.tb12597.x; LOMBERG H, 1986, PROTEIN CARBOHYDRATE, P235; Marchant J, 2002, TRENDS MICROBIOL, V10, P155, DOI 10.1016/S0966-842X(02)02323-5; Marionneau S, 2002, GASTROENTEROLOGY, V122, P1967, DOI 10.1053/gast.2002.33661; Mitchell E, 2002, NAT STRUCT BIOL, V9, P918, DOI 10.1038/nsb865; Mollicone R, 1996, GLYCOCONJUGATE J, V13, P263, DOI 10.1007/BF00731501; Newburg DS, 1996, J MAMMARY GLAND BIOL, V1, P271, DOI 10.1007/BF02018080; NEWBURG DS, 1993, J INFECT DIS, V168, P476, DOI 10.1093/infdis/168.2.476; NEWBURG DS, 1990, J INFECT DIS, V162, P1075, DOI 10.1093/infdis/162.5.1075; Pei ZH, 1998, INFECT IMMUN, V66, P938, DOI 10.1128/IAI.66.3.938-943.1998; PEI ZH, 1991, J BIOL CHEM, V266, P16363; Pickett CL, 1996, INFECT IMMUN, V64, P2070, DOI 10.1128/IAI.64.6.2070-2078.1996; PRIETO PA, 1995, J BIOL CHEM, V270, P29515, DOI 10.1074/jbc.270.49.29515; Prieto PA, 1997, J BIOL CHEM, V272, P2089; REGUIGNEARNOULD I, 1995, CYTOGENET CELL GENET, V71, P158, DOI 10.1159/000134098; RUIZPALACIOS GM, 1983, LANCET, V2, P250; RUIZPALACIOS GM, 1992, CAMPLYLOBACTER JEJUNI, P176; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; RUIZPALACIOS GM, 1997, PRINCIPLES PRACTICE, P987; RUSSELL RG, 1994, INFECT IMMUN, V62, P3773, DOI 10.1128/IAI.62.9.3773-3779.1994; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; van Vliet AHM, 2001, J APPL MICROBIOL, V90, p45S, DOI 10.1046/j.1365-2672.2001.01353.x; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WALKER RI, 1986, MICROBIOL REV, V50, P81, DOI 10.1128/MMBR.50.1.81-94.1986; Wassenaar TM, 1997, CLIN MICROBIOL REV, V10, P466, DOI 10.1128/CMR.10.3.466; Wassenaar TM, 1999, MICROBES INFECT, V1, P1023, DOI 10.1016/S1286-4579(99)80520-6	51	443	492	9	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14112	14120		10.1074/jbc.M207744200	http://dx.doi.org/10.1074/jbc.M207744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12562767	hybrid			2022-12-25	WOS:000182405000072
J	Satchell, DP; Sheynis, T; Shirafuji, Y; Kolusheva, S; Ouellette, AJ; Jelinek, R				Satchell, DP; Sheynis, T; Shirafuji, Y; Kolusheva, S; Ouellette, AJ; Jelinek, R			Interactions of mouse paneth cell alpha-defensins and alpha-defensin precursors with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT NEUTROPHIL DEFENSINS; NATURAL PEPTIDE ANTIBIOTICS; INTESTINAL HOST-DEFENSE; ANTIMICROBIAL PEPTIDES; PHOSPHOLIPID-VESICLES; COLORIMETRIC ASSAY; LUNG MACROPHAGES; LIPID VESICLES; MELITTIN; BILAYERS	The bactericidal activity of mouse alpha-defensins (cryptdins) requires proteolytic activation of inactive precursors by matrix metalloproteinase-7 (matrilysin, EC 3.4.24.23, NEAP-7(a)). To investigate mechanisms of cryptdin-4 (Crp4) peptide interactions with membrane bilayers and to determine whether NMP-7-mediated proteolysis activates the membrane disruptive activity of Crp4, associations of Crp4 and melittin with biomimetic lipid/polydiacetylene chromatic vesicles were characterized. The peptides differ in their sensitivity to vesicle lipid composition and their depth of bilayer penetration. Crp4 undergoes strong interfacial binding onto lipid bilayers with disruption of the bilayer head group region, unlike melittin, which inserts more deeply into the hydrophobic core of the bilayer. Colorimetric and tryptophan fluorescence studies showed that Crp4 insertion is favored by negatively charged phospholipids and that zwitterionic and Escherichia coli phospholipids promote stronger interfacial binding; melittin-membrane interactions were independent of either variable. In contrast to the membrane disruptive activity of Crp4, pro-Crp4 did not perturb vesicular membranes, consistent with the lack of bactericidal activity of the precursor, and incubation of Crp4 with prosegment in trans blocked Crp4 and G1W-Crp4 membrane interactions at concentrations that inhibit Crp4 bactericidal activity. CD measurements showed that Crp4 has an expected beta-sheet structure that is not evident in the pro-Crp4 CD trace or when Crp4 is incubated with prosegment, indicating that the beta-sheet signal is attenuated by proregion interactions or possibly disrupted by the prosegment. Collectively, the results suggest that the prosegment inhibits Crp4 bactericidal activity by blocking peptide-mediated perturbation of target cell membranes, a constraint that is relieved when NMP-7 cleaves the prosegment.	Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Ben Gurion University; University of California System; University of California Irvine; University of California System; University of California Irvine	Jelinek, R (corresponding author), Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel.		JELINEK, RAZ/F-2023-2012	jelinek, raz/0000-0002-0336-1384; Kolusheva, Sofiya/0000-0002-4406-2241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044632, R55DK044632, F32DK010184] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44632, DK10184] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P155, DOI 10.1016/0005-2736(87)90165-9; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BRAUNER JW, 1987, BIOCHEMISTRY-US, V26, P8151, DOI 10.1021/bi00399a020; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; Evrard D, 2001, PHARMACEUT RES, V18, P943, DOI 10.1023/A:1010980009823; FREY S, 1991, BIOPHYS J, V60, P922, DOI 10.1016/S0006-3495(91)82126-9; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; GAZIT E, 1995, BIOCHEMISTRY-US, V34, P11479, DOI 10.1021/bi00036a021; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Hristova K, 2001, BIOPHYS J, V80, P801, DOI 10.1016/S0006-3495(01)76059-6; Hristova K, 1997, J BIOL CHEM, V272, P24224, DOI 10.1074/jbc.272.39.24224; Kolusheva S, 2000, NAT BIOTECHNOL, V18, P225, DOI 10.1038/72697; Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b; Kolusheva S, 2001, J AM CHEM SOC, V123, P417, DOI 10.1021/ja0034139; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; Ladokhin AS, 2001, BBA-BIOMEMBRANES, V1514, P253, DOI 10.1016/S0005-2736(01)00382-0; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Ouellette AJ, 2001, INFLAMM BOWEL DIS, V7, P43, DOI 10.1097/00054725-200102000-00007; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1983, J BIOL CHEM, V258, P4485; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SMITH R, 1994, J MOL BIOL, V241, P456, DOI 10.1006/jmbi.1994.1520; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; White SH, 1998, METHOD ENZYMOL, V295, P62; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	41	95	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13838	13846		10.1074/jbc.M212115200	http://dx.doi.org/10.1074/jbc.M212115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574157	hybrid			2022-12-25	WOS:000182405000036
J	Hwang, HY; Olson, SK; Brown, JR; Esko, JD; Horvitz, HR				Hwang, HY; Olson, SK; Brown, JR; Esko, JD; Horvitz, HR			The Caenorhabditis elegans genes sqv-2 and sqv-6, which are required for vulval morphogenesis, encode glycosaminoglycan galactosyltransferase II and xylosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONIC ACID; HEPARAN-SULFATE; C-ELEGANS; EPITHELIAL INVAGINATION; BIOSYNTHESIS; PROTEOGLYCAN; EXPRESSION; MUTANTS; GALACTOSE; MUTATIONS	In mutants defective in any of eight Caenorhabditis elegans sqv (squashed vulva) genes, the vulval extracellular space fails to expand during vulval morphogenesis. Strong sqv mutations result in maternal-effect lethality, caused in part by the failure of the progeny of homozygous mutants to initiate cytokinesis and associated with the failure to form an extracellular space between the egg and the eggshell. Recent studies have implicated glycosaminoglycans in these processes. Here we report the cloning and characterization of sqv-2 and sqv-6. sqv-6 encodes a protein similar to human xylosyltransferases. Transfection of sqv-6 restored xylosyltransferase activity to and rescued the glycosaminoglycan biosynthesis defect of a xylosyltransferase mutant hamster cell line. sqv-2 encodes a protein similar to human galactosyltransferase II. A recombinant SQV-2 fusion protein had galactosyltransferase II activity with substrate specificity similar to that of human galactosyltransferase II. We conclude that C. elegans SQV-6 and SQV-2 likely act in concert with other SQV proteins to catalyze the stepwise formation of the proteoglycan core protein linkage tetrasaccharide GlcAbeta1,3Galbeta1 3Gabeta1,4Xylbeta-O-(Ser), which is common to the two major types of glycosaminoglycans in vertebrates, chondroitin and heparan sulfate. Our results strongly support a model in which C. elegans vulval morphogenesis and zygotic cytokinesis depend on the expression of glycosaminoglycans.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 77 Massachusetts Ave,Rm 68-425, Cambridge, MA 02139 USA.			Hwang, Ho-Yon/0000-0003-0204-8932	NIGMS NIH HHS [GM24663, GM33063] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R37GM024663, R01GM024663, R01GM033063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; BRENNER S, 1974, GENETICS, V77, P71; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Herman T, 1997, COLD SPRING HARB SYM, V62, P353, DOI 10.1101/SQB.1997.062.01.042; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14224, DOI 10.1073/pnas.172522499; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; Sambrook J., 2002, MOL CLONING LAB MANU; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	27	55	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11735	11738		10.1074/jbc.C200518200	http://dx.doi.org/10.1074/jbc.C200518200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12584198	hybrid			2022-12-25	WOS:000182015700003
J	Mcclain, MS; Iwamoto, H; Cao, P; Vinion-Dubiel, AD; Li, Y; Szabo, G; Shao, ZF; Cover, TL				Mcclain, MS; Iwamoto, H; Cao, P; Vinion-Dubiel, AD; Li, Y; Szabo, G; Shao, ZF; Cover, TL			Essential role of a GXXXG motif for membrane channel formation by Helicobacter pylori vacuolating toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; ANION-SELECTIVE CHANNELS; STAPHYLOCOCCUS-AUREUS; CELLULAR VACUOLATION; DIMERIZATION MOTIF; GASTRIC EPITHELIUM; ACID ACTIVATION; LIPID BILAYERS; VACA TOXIN; LOW PH	Helicobacter pylori secretes a toxin, VacA, that can form anion-selective membrane channels. Within a unique amino-terminal hydrophobic region of VacA, there are three tandem GXXXG motifs (defined by glycines at positions 14, 18, 22, and 26), which are characteristic of transmembrane dimerization sequences. The goals of the current study were to investigate whether these GXXXG motifs are required for membrane channel formation and cytotoxicity and to clarify the role of membrane channel formation in the biological activity of VacA. Six different alanine substitution mutations (P9A, G13A, G14A, G18A, G22A, and G26A) were introduced into the unique hydrophobic region located near the amino terminus of VacA. The effects of these mutations were first analyzed using the TOXCAT system, which permits the study of transmembrane oligomerization of proteins in a natural membrane environment. None of the mutations altered the capacity of ToxR-VacA-maltose-binding protein fusion proteins to insert into a membrane, but G14A and G18A mutations markedly diminished the capacity of the fusion proteins to oligomerize. We then introduced the six alanine substitution mutations into the vacA chromosomal gene of H. pylori and analyzed the properties of purified mutant VacA proteins. VacA-G13A, VacA-G22A, and VacA-G26A induced vacuolation of HeLa cells, whereas VacA-P9A, VacA-G14A, and VacA-G18A did not. Subsequent experiments examined the capacity of each mutant toxin to form membrane channels. In a planar lipid bilayer assay, VacA proteins containing G13A, G22A, and G26A mutations formed anion-selective membrane channels, whereas VacA proteins containing P9A, G14A, and G18A mutations did not. Similarly, VacA-G13A, VacA-G22A, and VacA-G26A induced depolarization of HeLa cells, whereas VacA-P9A, VacA-G14A, and VacA-G18A did not. These data indicate that an intact proline residue and an intact G(14)XXXG(18) motif within the amino-terminal hydrophobic region of VacA are essential for membrane channel formation, and they also provide strong evidence that membrane channel formation is essential for VacA cytotoxicity.	Vanderbilt Univ, Div Infect Dis, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Biophys Program, Charlottesville, VA 22908 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Virginia; University of Virginia	Cover, TL (corresponding author), Vanderbilt Univ, Div Infect Dis, Sch Med, Dept Med, A3310 Med Ctr N, Nashville, TN 37232 USA.	timothy.L.cover@vanderbilt.edu	Shao, Zhifeng/B-6075-2013; Cover, Timothy/I-3814-2015; McClain, Mark S/A-6942-2009	Cover, Timothy/0000-0001-8503-002X; McClain, Mark S/0000-0002-9857-4883	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39657] Funding Source: Medline; NIDDK NIH HHS [DK53623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; ATHERTON JC, 2001, HELICOBACTER PYLORI, P97; Breed J, 1996, BIOPHYS J, V70, P1643, DOI 10.1016/S0006-3495(96)79727-8; Brosig B, 1998, PROTEIN SCI, V7, P1052; Copass M, 1997, INFECT IMMUN, V65, P1949, DOI 10.1128/IAI.65.5.1949-1952.1997; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; COVER TL, 2001, PRINCIPLES BACTERIAL, P510; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; Fiocca R, 1999, J PATHOL, V188, P220, DOI 10.1002/(SICI)1096-9896(199906)188:2<220::AID-PATH307>3.0.CO;2-C; Forsyth MH, 1998, INFECT IMMUN, V66, P3088, DOI 10.1128/IAI.66.7.3088-3094.1998; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; HAWRYLIK SJ, 1994, J CLIN MICROBIOL, V32, P790, DOI 10.1128/JCM.32.3.790-792.1994; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MARSHALL BJ, 1991, J GASTROEN HEPATOL, V6, P121, DOI 10.1111/j.1440-1746.1991.tb01450.x; McClain MS, 2000, MOL MICROBIOL, V37, P433, DOI 10.1046/j.1365-2958.2000.02013.x; McClain MS, 2001, J BACTERIOL, V183, P6499, DOI 10.1128/JB.183.22.6499-6508.2001; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Molinari M, 1998, BIOCHEM BIOPH RES CO, V248, P334, DOI 10.1006/bbrc.1998.8808; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; Montecucco C, 2001, NAT REV MOL CELL BIO, V2, P457, DOI 10.1038/35073084; MONTECUCCO C, 1992, FEMS MICROBIOL IMMUN, V105, P101; Montecucco C, 1999, COMPREHENSIVE SOURCE, P264; Nguyen VQ, 2001, INFECT IMMUN, V69, P543, DOI 10.1128/IAI.69.1.543-546.2001; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OLSNES S, 1990, MICROB PATHOGENESIS, V8, P163, DOI 10.1016/0882-4010(90)90043-P; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; Papini E, 1998, FOLIA MICROBIOL, V43, P279, DOI 10.1007/BF02818613; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; Peek RM, 1999, CANCER RES, V59, P6124; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; Reyrat JM, 1999, J MOL BIOL, V290, P459, DOI 10.1006/jmbi.1999.2877; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Valeva A, 1997, P NATL ACAD SCI USA, V94, P11607, DOI 10.1073/pnas.94.21.11607; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Wang XM, 2000, FEBS LETT, V481, P96, DOI 10.1016/S0014-5793(00)01978-5; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WARREN JR, 1983, LANCET, V1, P1273; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; WILLIAMS KA, 1995, J MOL BIOL, V252, P6, DOI 10.1006/jmbi.1995.0469; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 2002, MOL MICROBIOL, V43, P1243, DOI 10.1046/j.1365-2958.2002.02818.x; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	80	120	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12101	12108		10.1074/jbc.M212595200	http://dx.doi.org/10.1074/jbc.M212595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12562777	hybrid			2022-12-25	WOS:000182015700051
J	Behzadian, MA; Windsor, LJ; Ghaly, N; Liou, G; Tsai, NT; Caldwell, RB				Behzadian, MA; Windsor, LJ; Ghaly, N; Liou, G; Tsai, NT; Caldwell, RB			VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor	FASEB JOURNAL			English	Article						vascular endothelial growth factor; endothelial cell junctions; occludin; beta-catenin signaling	PLASMINOGEN-ACTIVATOR RECEPTOR; CELLULAR-BINDING SITE; GROWTH-FACTOR; VASCULAR-PERMEABILITY; BETA-CATENIN; TGF-BETA; TIGHT JUNCTION; EXPRESSION; OCCLUDIN; BARRIER	Vascular endothelial growth factor/vascular permeability factor (VEGF) has been implicated in blood/tissue barrier dysfunctions associated with pathological angiogenesis, but the mechanisms of VEGF-induced permeability increase are poorly understood. Here, the role of VEGF-induced extracellular proteolytic activities on the endothelial cell permeability increase is evaluated. Confluent monolayers of bovine retinal microvascular endothelial (BRE) cells grown on porous membrane were treated with VEGF or urokinase plasminogen activator (uPA), and permeability changes were analyzed. uPA-induced permeability was rapid and sustained, but VEGF-induced permeability showed a biphasic pattern: a rapid and transient phase (1-2 h) followed by delayed and sustained phase (6-24 h). The delayed, but not the early phase of VEGF-induced permeability, was blocked by anti-uPA or anti-uPAR (uPA receptor) antibodies and was accompanied by reduced transendothelial electrical resistance, indicating the paracellular route of permeability. Confocal microscopy and Western blotting showed that VEGF treatment increased free cytosolic beta-catenin, which was followed by beta-catenin nuclear translocation, upregulation of uPAR, and downregulation of occludin. Membrane-bound occludin was released immediately after uPA treatment, but with a long delay after VEGF treatment, suggesting a requirement for uPAR gene expression. In conclusion, VEGF induces a sustained paracellular permeability in capillary endothelial cells that is mediated by activation of the uPA/uPAR system.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30809 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA; Indiana Univ, Dept Oral Biol, Indianapolis, IN 46204 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Indiana University System; Indiana University-Purdue University Indianapolis	Behzadian, MA (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30809 USA.	abehzadi@mail.mcg.edu		Caldwell, Ruth/0000-0003-0168-0354				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Balcerzak D, 2001, J ANIM SCI, V79, P94; Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054; Behzadian MA, 1995, GLIA, V15, P480, DOI 10.1002/glia.440150411; Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO;2-D; Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Cohen AW, 1999, AM J PHYSIOL-HEART C, V277, pH2038, DOI 10.1152/ajpheart.1999.277.5.H2038; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HADDOCK RC, 1991, J BIOL CHEM, V266, P21466; Hoyer-Hansen G, 2001, BIOCHEM J, V358, P673, DOI 10.1042/0264-6021:3580673; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kroon ME, 1999, AM J PATHOL, V154, P1731, DOI 10.1016/S0002-9440(10)65429-6; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; Makowski GS, 1998, INFLAMMATION, V22, P287, DOI 10.1023/A:1022300216202; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCarthy KM, 1996, J CELL SCI, V109, P2287; Mondino Anna, 1999, Thrombosis and Haemostasis, V82, P19; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NASDALA I, 2002, J BIOL CHEM, V14, P14; NELSON WJ, 1992, COLD SPRING HARB SYM, V57, P621, DOI 10.1101/SQB.1992.057.01.068; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; PALADE GE, 1961, CIRCULATION, V24, P368; Papadopoulos MC, 2001, NEUROPATH APPL NEURO, V27, P384, DOI 10.1046/j.0305-1846.2001.00341.x; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; SOLBERG H, 1994, INT J CANCER, V58, P877, DOI 10.1002/ijc.2910580622; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; Stewart PA, 2000, CELL MOL NEUROBIOL, V20, P149, DOI 10.1023/A:1007026504843; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; Tinsley JH, 1999, J BIOL CHEM, V274, P24930, DOI 10.1074/jbc.274.35.24930; TRAWEGER A, 2002, J BIOL CHEM, V8, P8; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; Vines DJ, 2000, J PEPT SCI, V6, P432, DOI 10.1002/1099-1387(200009)6:9<432::AID-PSC279>3.3.CO;2-H; Wang W, 1996, AM J PHYSIOL-CELL PH, V271, pC1973, DOI 10.1152/ajpcell.1996.271.6.C1973; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	66	101	113	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					752	+		10.1096/fj.02-0484fje	http://dx.doi.org/10.1096/fj.02-0484fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594181				2022-12-25	WOS:000181456900018
J	Grandjean, P; Budtz-Jorgensen, E; Steuerwald, U; Heinzow, B; Needham, LL; Jorgensen, PJ; Weihe, P				Grandjean, P; Budtz-Jorgensen, E; Steuerwald, U; Heinzow, B; Needham, LL; Jorgensen, PJ; Weihe, P			Attenuated growth of breast-fed children exposed to increased concentrations of methylmercury and polychlorinated biphenyls	FASEB JOURNAL			English	Article						body weight; eicosapentaenoic acid; diet; postnatal growth; prenatal exposure delayed effects	MATERNAL SEAFOOD DIET; HUMAN-MILK; BIRTH-WEIGHT; FATTY-ACIDS; IN-UTERO; MERCURY; PCBS; SIZE; INFANTS; FOOD	Breast-feeding has been linked to slowed postnatal growth. Although the basis for this "weanling's dilemma" is unclear, environmental contaminants in human milk may be of relevance. We studied a Faroese birth cohort of 182 singleton children, born at term in 1994-95. Concentrations of mercury in cord blood and of polychlorinated biphenyls in maternal milk were measured, and duration of breast-feeding was recorded. At 18 months, children who had been exclusively breast-fed for at least 6 months weighed 0.59 kg less [95% confidence interval (CI) = 0.03, 1.16 kg] and were 1.50 cm [95% CI = 0.52, 2.47 cm] shorter than those not breast-fed. However, calculated transfer of contaminants from human milk fully explained the attenuated growth. Irrespective of duration of breast-feeding, a doubling of the mercury concentration in cord blood was associated with a decrease in weight at 18 months by 0.19 kg (95% CI = 0.03, 0.35 kg) and in height by 0.26 cm (95% CI = 0.02, 0.55 cm). Weight and height at 42 months showed the same tendencies, but the main effect occurred before 18 months of age. Thus, in communities with increased contaminant exposures, risks associated with lactational transfer of toxicants to the infant must be considered when judging the benefits of prolonged breast-feeding.	Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Univ So Denmark, Inst Publ Hlth, Odense, Denmark; Univ Copenhagen, Panum Inst, Dept Biostat, DK-2200 Copenhagen, Denmark; Faroese Hosp Syst, Dept Occupat & Publ Hlth, Torshavn, Faroe Isl, Denmark; State Agcy Hlth & Occupat Safety Schleswig Holste, Flintbek, Germany; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA; Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense, Denmark	Boston University; Boston University; Boston University; Boston University; University of Southern Denmark; University of Copenhagen; Centers for Disease Control & Prevention - USA; University of Southern Denmark; Odense University Hospital	Grandjean, P (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	pgrandjean@health.sdu.dk	Needham, Larry/E-4930-2011; Grandjean, Philippe/I-2962-2014	Grandjean, Philippe/0000-0003-4046-9658; Budtz-Jorgensen, Esben/0000-0002-5551-0724				ALLEN JR, 1980, J TOXICOL ENV HEALTH, V6, P55, DOI 10.1080/15287398009529830; Armstrong J, 2002, LANCET, V359, P2003, DOI 10.1016/S0140-6736(02)08837-2; Boshuizen HC, 1998, AM J EPIDEMIOL, V147, P117; BREZNER E, 1984, COMP BIOCHEM PHYS C, V77, P65, DOI 10.1016/0742-8413(84)90131-2; Brock JW, 1996, J ANAL TOXICOL, V20, P528, DOI 10.1093/jat/20.7.528; CONTER V, 1995, BRIT MED J, V310, P768, DOI 10.1136/bmj.310.6982.768; Day NL, 1999, ALCOHOL CLIN EXP RES, V23, P863, DOI 10.1097/00000374-199905000-00015; DELEMARREVANDEWAAL HA, 1993, ENVIRON HEALTH PERSP, V101, P39, DOI 10.1289/ehp.93101s239; DEWEY KG, 1995, PEDIATRICS, V96, P495; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; FOLDSPANG A, 1990, AM J EPIDEMIOL, V132, P310, DOI 10.1093/oxfordjournals.aje.a115660; FREDRIKSSON A, 1993, PHARMACOL TOXICOL, V72, P377, DOI 10.1111/j.1600-0773.1993.tb01348.x; Grandjean P, 1995, ENVIRON RES, V71, P29, DOI 10.1006/enrs.1995.1064; GRANDJEAN P, 1993, ENVIRON RES, V61, P176, DOI 10.1006/enrs.1993.1062; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; Grandjean P, 2001, INT J EPIDEMIOL, V30, P1272, DOI 10.1093/ije/30.6.1272; GRANDJEAN P, 1994, ENVIRON HEALTH PERSP, V102, P74, DOI 10.1289/ehp.9410274; GRANDJEAN P, 1988, ENV HLTH, V29; Grandjean P, 2002, BIOMARKERS ENV ASS D, P235; GUO YLL, 1995, ENVIRON HEALTH PERSP, V103, P117, DOI 10.2307/3432359; Haschke F, 2000, J PEDIATR GASTR NUTR, V31, pS60, DOI 10.1097/00005176-200007001-00006; HOVINGA ME, 1992, ARCH ENVIRON CON TOX, V22, P362, DOI 10.1007/BF00212554; JACOBSON JL, 1990, NEUROTOXICOL TERATOL, V12, P319, DOI 10.1016/0892-0362(90)90050-M; Jensen A.A., 1991, CHEM CONTAMINANTS HU; Karlberg J, 2000, ACTA PAEDIATR, V89, P632, DOI 10.1080/080352500750043909; Kaya H, 2002, TOXICOL APPL PHARM, V178, P71, DOI 10.1006/taap.2001.9318; KRAMER MS, 2002, COCHRANE LIB; LAN SJ, 1989, B ENVIRON CONTAM TOX, V42, P931, DOI 10.1007/BF01701638; Lapillonne A, 2001, LIPIDS, V36, P901, DOI 10.1007/s11745-001-0800-y; Larroque B, 1998, ALCOHOL CLIN EXP RES, V22, P295, DOI 10.1111/j.1530-0277.1998.tb03652.x; LEWIS DS, 1986, J CLIN INVEST, V78, P899, DOI 10.1172/JCI112678; Martin RM, 2001, INT J EPIDEMIOL, V30, P481, DOI 10.1093/ije/30.3.481; National Research Council, 2000, TOX EFF METH; Nielsen GA, 1998, ACTA PAEDIATR, V87, P911, DOI 10.1080/080352598750031536; Patandin S, 1998, PEDIATR RES, V44, P538, DOI 10.1203/00006450-199810000-00012; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROWLAND IR, 1984, ARCH ENVIRON HEALTH, V39, P401, DOI 10.1080/00039896.1984.10545872; ROWLAND MGM, 1986, ACTA PAEDIATR SCAND, P33; SAUER PJJ, 1994, HUM EXP TOXICOL, V13, P900, DOI 10.1177/096032719401301213; Schade G, 1998, SCI TOTAL ENVIRON, V215, P31, DOI 10.1016/S0048-9697(98)00008-4; Smith JC, 1996, TOXICOL APPL PHARM, V137, P245, DOI 10.1006/taap.1996.0078; Steuerwald U, 2000, J PEDIATR-US, V136, P599, DOI 10.1067/mpd.2000.102774; Strauss RS, 1997, BRIT MED BULL, V53, P81; Turner W, 1997, ORGANOHALOGEN COMPD, V31, P26; VORHEES CV, 1985, NEUROBEH TOXICOL TER, V7, P717	45	64	64	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					699	+		10.1096/fj.02-0661fje	http://dx.doi.org/10.1096/fj.02-0661fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586743	Green Submitted			2022-12-25	WOS:000181456900023
J	Golemi-Kotra, D; Cha, JY; Meroueh, SO; Vakulenko, SB; Mobashery, S				Golemi-Kotra, D; Cha, JY; Meroueh, SO; Vakulenko, SB; Mobashery, S			Resistance to beta-lactam antibiotics and its mediation by the sensor domain of the transmembrane BlaR signaling pathway in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-LICHENIFORMIS; METHICILLIN RESISTANCE; PROTEIN; TRANSDUCER; ENZYME	Staphylococci, a leading cause of infections worldwide, have devised two mechanisms for resistance to beta-lactam antibiotics. One is production of beta-lactamases, hydrolytic resistance enzymes, and the other is the expression of penicillin-binding protein 2a (PBP 2a), which is not susceptible to inhibition by beta-lactam antibiotics. The beta-lactam sensor-transducer (BlaR), an integral membrane protein, binds beta-lactam antibiotics on the cell surface and transduces the information to the cytoplasm, where gene expression is derepressed for both beta-lactamase and penicillin-binding protein 2a. The gene for the sensor domain of the sensor-transducer protein (BlaR(S)) of Staphylococcus aureus was cloned, and the protein was purified to homogeneity. It is shown that beta-lactam antibiotics covalently modify the BlaR(S) protein. The protein was shown to contain the unusual carboxylated lysine that activates the active site serine residue for acylation by the beta-lactam antibiotics. The details of the kinetics of interactions of the BlaR(S) protein with a series of beta-lactam antibiotics were investigated. The protein undergoes acylation by beta-lactam antibiotics with microscopic rate constants (k(2)) of 1-26 s(-1), yet the deacylation process was essentially irreversible within one cell cycle. The protein undergoes a significant conformational change on binding with beta-lactam antibiotics, a process that commences at the preacylation complex and reaches its full effect after protein acylation has been accomplished. These conformational changes are likely to be central to the signal transduction events when the organism is exposed to the beta-lactam antibiotic.	Wayne State Univ, Inst Drug Design, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Inst Drug Design, Dept Pharmacol, Detroit, MI 48202 USA; Wayne State Univ, Inst Drug Design, Dept Biochem & Mol Biol, Detroit, MI 48202 USA	Wayne State University; Wayne State University; Wayne State University	Mobashery, S (corresponding author), Wayne State Univ, Inst Drug Design, Dept Chem, Detroit, MI 48202 USA.	som@chem.wayne.edu	/N-6611-2013	/0000-0003-1299-6987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061629] Funding Source: NIH RePORTER; NIAID NIH HHS [AI331790] Funding Source: Medline; NIGMS NIH HHS [GM61629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Archer GL, 2001, SCIENCE, V291, P1915, DOI 10.1126/science.1059671; Bernat BA, 2001, BIOCHEMISTRY-US, V40, P12712, DOI 10.1021/bi0114832; BOYCE JM, 1997, STAPHYLOCOCCI HUMAN, P309, DOI DOI 10.1002/9781444308464.CH15; Bush K, 1998, ADV EXP MED BIOL, V456, P71; Case D.A., 2002, AMBER, V7; Fung HB, 2001, CLIN THER, V23, P356, DOI 10.1016/S0149-2918(01)80043-6; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORIS B, 1990, FEMS MICROBIOL LETT, V70, P107, DOI 10.1016/0378-1097(90)90111-3; KOTRA LP, 2001, BACTERIAL RESISTANCE, P123; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; Lietz EJ, 2000, BIOCHEMISTRY-US, V39, P4971, DOI 10.1021/bi992681k; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Maveyraud L, 2002, J AM CHEM SOC, V124, P2461, DOI 10.1021/ja016736t; Maveyraud L, 2000, STRUCTURE, V8, P1289, DOI 10.1016/S0969-2126(00)00534-7; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; Novick RP, 2001, MICROBES INFECT, V3, P585, DOI 10.1016/S1286-4579(01)01414-9; OLSON ST, 1981, J BIOL CHEM, V256, P1065; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Tien M, 1999, P NATL ACAD SCI USA, V96, P7809, DOI 10.1073/pnas.96.14.7809; Tsiodras S, 2001, LANCET, V358, P207, DOI 10.1016/S0140-6736(01)05410-1; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Walsh TR, 2001, J CLIN MICROBIOL, V39, P2439, DOI 10.1128/JCM.39.7.2439-2444.2001; WANG PZ, 1991, NUCLEIC ACIDS RES, V19, P4000, DOI 10.1093/nar/19.14.4000; WOODWARDGRAVES K, 1998, BIOCHEM J, V332, P755; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144; Zhao GS, 1999, ANTIMICROB AGENTS CH, V43, P1124, DOI 10.1128/AAC.43.5.1124; ZHU YF, 1990, J BACTERIOL, V172, P1137, DOI 10.1128/jb.172.2.1137-1141.1990	30	68	71	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18419	18425		10.1074/jbc.M300611200	http://dx.doi.org/10.1074/jbc.M300611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12591921	hybrid			2022-12-25	WOS:000182838300108
J	Yatsuda, AP; Krijgsveld, J; Cornelissen, AWCA; Heck, AJR; de Vries, E				Yatsuda, AP; Krijgsveld, J; Cornelissen, AWCA; Heck, AJR; de Vries, E			Comprehensive analysis of the secreted proteins of the parasite Haemonchus contortus reveals extensive sequence variation and differential immune recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; C-TYPE LECTIN; PROTECTIVE ANTIGEN; CYSTEINE PROTEASES; MOLECULAR-CLONING; IMMUNOLOGICAL CHARACTERIZATION; ONCHOCERCA-VOLVULUS; NEMATODE PARASITES; INFECTIVE LARVAE; TOXOCARA-CANIS	Haemonchus contortus is a nematode that infects small ruminants. It releases a variety of molecules, designated excretory/secretory products (ESP), into the host. Although the composition of ESP is largely unknown, it is a source of potential vaccine components because ESP are able to induce up to 90% protection in sheep. We used proteomic tools to analyze ESP proteins and determined the recognition of these individual proteins by hyperimmune sera. Following two-dimensional electrophoresis of ESP, matrix-assisted laser desorption ionization time-of-flight and liquid chromatography-tandem mass spectrometry were used for protein identification. Few sequences of H. contortus have been determined. Therefore, the data base of expressed sequence tags (dbEST) and a data base consisting of contigs from Haemonchus ESTs were also consulted for identification. Approximately 200 individual spots were observed in the two-dimensional gel. Comprehensive proteomics analysis, combined with bioinformatic search tools, identified 107 proteins in 102 spots. The data include known as well as novel proteins such as serine, metallo- and aspartyl proteases, in addition to H. contortus ESP components like Hc24, Hc40, Hc15, and apical gut GA1 proteins. Novel proteins were identified from matches with H. contortus ESTs displaying high similarity with proteins like cyclophilins, nucleoside diphosphate kinase, OV39 antigen, and undescribed homologues of Caenorhabditis elegans. Of special note is the finding of microsomal peptidase H11, a vaccine candidate previously regarded as a "hidden antigen" because it was not found in ESP. Extensive sequence variation is present in the abundant Hc15 proteins. The Hc15 isoforms are differentially recognized by hyperimmune sera, pointing to a possible specific role of Hc15 in the infectious process and/or in immune evasion. This concept and the identification of multiple novel immune-recognized components in ESP should assist future vaccine development strategies.	Univ Utrecht, Dept Immunol & Infect Dis, Div Parasitol & Trop Vet Med, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	de Vries, E (corresponding author), Univ Utrecht, Dept Immunol & Infect Dis, Div Parasitol & Trop Vet Med, POB 80165, NL-3508 TD Utrecht, Netherlands.	e.vries@vet.uu.nl	Heck, Albert/D-7098-2011; Krijgsveld, Jeroen/F-5974-2011; AP, Yatsuda/D-2565-2012	Heck, Albert/0000-0002-2405-4404; AP, Yatsuda/0000-0001-7957-2279; Krijgsveld, Jeroen/0000-0001-7549-9326				Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bird AF, 1991, STRUCTURE NEMATODES, P167; BLAXTER ML, 1994, MOL BIOCHEM PARASIT, V68, P1, DOI 10.1016/0166-6851(94)00127-8; BRAUN G, 1995, J EXP MED, V182, P1121, DOI 10.1084/jem.182.4.1121; BRAUN G, 1991, J EXP MED, V174, P169, DOI 10.1084/jem.174.1.169; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; CHANDARSHEKAR R, 1995, PARASITOLOGY, V73, P231; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P271, DOI 10.1098/rspb.1949.0025; De Graaf DC, 1996, PARASITOLOGY, V113, P63, DOI 10.1017/S0031182000066282; Dornan J, 1999, J BIOL CHEM, V274, P34877, DOI 10.1074/jbc.274.49.34877; Fetterer RH, 1999, J PARASITOL, V85, P295, DOI 10.2307/3285637; Fluckiger S, 2002, EUR J IMMUNOL, V32, P10, DOI 10.1002/1521-4141(200201)32:1<10::AID-IMMU10>3.0.CO;2-I; FRENKEL MJ, 1992, MOL BIOCHEM PARASIT, V50, P27, DOI 10.1016/0166-6851(92)90241-B; GEMS D, 1995, J BIOL CHEM, V270, P18517, DOI 10.1074/jbc.270.31.18517; Gill JH, 1998, INT J PARASITOL, V28, P863, DOI 10.1016/S0020-7519(98)00068-X; Godovac-Zimmermann J, 2001, MASS SPECTROM REV, V20, P1, DOI 10.1002/1098-2787(2001)20:1<1::AID-MAS1001>3.0.CO;2-J; Gounaris K, 2001, INFECT IMMUN, V69, P3658, DOI 10.1128/IAI.69.6.3658-3662.2001; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; Hawdon JM, 1999, MOL BIOCHEM PARASIT, V99, P149, DOI 10.1016/S0166-6851(99)00011-0; HEALER J, 1991, PARASITOLOGY, V103, P305, DOI 10.1017/S0031182000059588; Henkle-Duhrsen K, 2001, MOL BIOCHEM PARASIT, V114, P129, DOI 10.1016/S0166-6851(01)00252-3; Holland MJ, 2000, EUR J IMMUNOL, V30, P1977, DOI 10.1002/1521-4141(200007)30:7&lt;1977::AID-IMMU1977&gt;3.0.CO;2-3; Hong HY, 2000, ELECTROPHORESIS, V21, P841, DOI 10.1002/(SICI)1522-2683(20000301)21:5<841::AID-ELPS841>3.3.CO;2-W; HONG XQ, 1993, EXP PARASITOL, V76, P127, DOI 10.1006/expr.1993.1015; Hotez PJ, 1999, IMMUNOL REV, V171, P163, DOI 10.1111/j.1600-065X.1999.tb01347.x; Jackson F, 2000, PARASITOLOGY, V120, pS95, DOI 10.1017/S0031182099005740; JASMER DP, 1993, J IMMUNOL, V151, P5450; Jasmer DP, 2001, MOL BIOCHEM PARASIT, V116, P159, DOI 10.1016/S0166-6851(01)00312-7; Jasmer DP, 1996, P NATL ACAD SCI USA, V93, P8642, DOI 10.1073/pnas.93.16.8642; Jefferies JR, 2001, PROTEOMICS, V1, P1128, DOI 10.1002/1615-9861(200109)1:9<1128::AID-PROT1128>3.0.CO;2-0; Jones BF, 2002, MOL BIOCHEM PARASIT, V119, P107, DOI 10.1016/S0166-6851(01)00409-1; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; Lazzaroni JC, 1999, FEMS MICROBIOL LETT, V177, P191, DOI 10.1016/S0378-1097(99)00293-1; Liddell S, 1998, PARASITOLOGY, V116, P383, DOI 10.1017/S0031182098002418; Longbottom D, 1997, MOL BIOCHEM PARASIT, V88, P63, DOI 10.1016/S0166-6851(97)00074-1; Loukas A, 1999, CURR BIOL, V9, P825, DOI 10.1016/S0960-9822(99)80366-2; Loukas A, 2000, PARASITOLOGY, V121, P545, DOI 10.1017/S0031182099006721; McKechnie NM, 2002, INVEST OPHTH VIS SCI, V43, P411; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Munn EA, 1997, PARASITE IMMUNOL, V19, P243, DOI 10.1046/j.1365-3024.1997.d01-205.x; Murray J, 2001, MOL BIOCHEM PARASIT, V118, P89, DOI 10.1016/S0166-6851(01)00374-7; Newton SE, 1999, PARASITOL TODAY, V15, P116, DOI 10.1016/S0169-4758(99)01399-X; ONDEK B, 1992, J BIOL CHEM, V267, P16460; Ortona E, 2002, CLIN EXP IMMUNOL, V128, P124, DOI 10.1046/j.1365-2249.2002.01807.x; Page Antony P., 2001, P167, DOI 10.1079/9780851994239.0167; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Prichard RK, 2001, TRENDS PARASITOL, V17, P445, DOI 10.1016/S1471-4922(01)01983-3; Punj V, 2000, INFECT IMMUN, V68, P4930, DOI 10.1128/IAI.68.9.4930-4937.2000; Redmond DL, 1997, MOL BIOCHEM PARASIT, V85, P77, DOI 10.1016/S0166-6851(96)02812-5; Rehman A, 1998, MOL BIOCHEM PARASIT, V97, P55, DOI 10.1016/S0166-6851(98)00132-7; RHOADS ML, 1995, J PARASITOL, V81, P505, DOI 10.2307/3283844; SCHALLIG HDFH, 1994, PARASITOLOGY, V108, P351, DOI 10.1017/S0031182000076198; Schallig HDFH, 1997, MOL BIOCHEM PARASIT, V88, P203, DOI 10.1016/S0166-6851(97)00093-5; Schallig HDFH, 1997, PARASITE IMMUNOL, V19, P447, DOI 10.1046/j.1365-3024.1997.d01-148.x; Selkirk ME, 1998, INT J PARASITOL, V28, P1315, DOI 10.1016/S0020-7519(98)00107-6; Shompole S, 2001, J BIOL CHEM, V276, P2928, DOI 10.1074/jbc.M007321200; SMITH MD, 1963, BIOCHIM BIOPHYS ACTA, V111, P503; SMITH TS, 1993, INT J PARASITOL, V23, P271, DOI 10.1016/0020-7519(93)90150-W; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TODOROVA VK, 1995, PARASITOLOGY, V111, P201, DOI 10.1017/S0031182000064957; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; Vervelde L, 2002, PARASITE IMMUNOL, V24, P189, DOI 10.1046/j.1365-3024.2002.00454.x; Yatsuda AP, 2002, RES VET SCI, V73, P297, DOI 10.1016/S0034-5288(02)00125-X; YATSUDA AP, 2001, PARASITOLOGY, V105, P131; Zaborina O, 2000, MICROBIOL-UK, V146, P2521, DOI 10.1099/00221287-146-10-2521; Zaborina O, 1999, MOL MICROBIOL, V31, P1333, DOI 10.1046/j.1365-2958.1999.01240.x; Zaborina O, 1999, INFECT IMMUN, V67, P5231, DOI 10.1128/IAI.67.10.5231-5242.1999	71	175	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16941	16951		10.1074/jbc.M212453200	http://dx.doi.org/10.1074/jbc.M212453200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12576473	hybrid			2022-12-25	WOS:000182818600068
J	Molinari, P; Ambrosio, C; Riitano, D; Sbraccia, M; Gro, MC; Costa, T				Molinari, P; Ambrosio, C; Riitano, D; Sbraccia, M; Gro, MC; Costa, T			Promiscuous coupling at receptor-G alpha fusion proteins - The receptor of one covalent complex interacts with the alpha-subunit of another	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; SIGNAL-TRANSDUCTION; GTPASE ACTIVITY; BETA(2)-ADRENERGIC RECEPTOR; GAMMA-SUBUNIT; ACTIVATION; G(I1)ALPHA; G(S)ALPHA; CELLS; ALPHA(2A)-ADRENOCEPTOR	Fusion proteins between heptahelical receptors (GPCR) and G protein alpha-subunits show enhanced signaling efficiency in transfected cells. This is believed to be the result of molecular proximity, because the interaction between linked modules of one protein chain, if not constrained by structure, should be strongly favored compared with the same in which partners react as free species. To test this assumption we made a series of fusion proteins (type 1 and 4 opioid receptors with G(o) and beta(2) adrenergic and dopamine I receptors with G(sL)) and some mutated analogs carrying different tags and defective GPCR or Galpha subunits. Using cotransfection experiments with readout protocols able to distinguish activation at fused and non-fused alpha-subunits, we found that both the GPCR and the Got limb of one fusion protein can freely interact with non-fused proteins and the tethered partners of a neighboring fusion complex. Moreover, a bulky polyanionic inhibitor can suppress with identical potency receptor-Galpha interaction, either when occurring between latched domains of a fused system or separate elements of distinct molecules, indicating that the binding surfaces are equally accessible in both cases. These data demonstrate that there is no entropy drive from the linked condition of fusion proteins and suggest that their signaling may result from the GPCR of one complex interacting with the alpha-subunit of another. Moreover, the enhanced coupling efficiency commonly observed for fusion proteins is not due to the receptor tether, but to the transmembrane helix that anchors Go to the membrane.	Ist Super Sanita, Dept Pharmacol, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Costa, T (corresponding author), Ist Super Sanita, Dept Pharmacol, Viale Regina Elena 299, I-00161 Rome, Italy.	tomcosta@iss.it	costa, tommaso/AAD-3714-2019; ambrosio, caterina/M-7952-2017	costa, tommaso/0000-0002-8729-3357; gro, maria cristina/0000-0001-9106-2191; ambrosio, caterina/0000-0002-0807-9003; molinari, paola/0000-0002-8454-0121				ABOOD ME, 1982, J BIOL CHEM, V257, P540; AKSAMIT RR, 1985, P NATL ACAD SCI USA, V82, P7475, DOI 10.1073/pnas.82.22.7475; Ambrosio C, 2000, MOL PHARMACOL, V57, P198; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; BUTLER SJ, 1988, BIOCHEM J, V251, P201, DOI 10.1042/bj2510201; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Fanelli F, 1999, PROTEINS, V37, P145, DOI 10.1002/(SICI)1097-0134(19991101)37:2<145::AID-PROT1>3.0.CO;2-R; Fong CW, 1999, BIOCHEM J, V342, P457, DOI 10.1042/0264-6021:3420457; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Guzzi F, 2001, BIOCHEM J, V355, P323, DOI 10.1042/0264-6021:3550323; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kellett E, 1999, MOL PHARMACOL, V56, P684; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; McAllister G, 2000, MOL PHARMACOL, V58, P407, DOI 10.1124/mol.58.2.407; Medici R, 1997, EMBO J, V16, P7241, DOI 10.1093/emboj/16.24.7241; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OGINO Y, 1992, MOL PHARMACOL, V42, P6; Pauwels PJ, 2001, N-S ARCH PHARMACOL, V363, P526, DOI 10.1007/s002100000395; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Rodbell M, 1997, ADV ENZYME REGUL, V37, P427, DOI 10.1016/S0065-2571(96)00020-9; Scheer A, 2000, MOL PHARMACOL, V57, P219; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SEIFERTWENZEL K, 2000, MOL PHARM, V58, P954; Small KM, 2000, BIOCHEMISTRY-US, V39, P2815, DOI 10.1021/bi992497z; Taylor JM, 1996, J BIOL CHEM, V271, P3336; VACHON L, 1987, MOL PHARMACOL, V31, P159; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; Ward RJ, 1999, FEBS LETT, V462, P459, DOI 10.1016/S0014-5793(99)01581-1; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Wenzel-Seifert K, 1998, BIOCHEM J, V334, P519, DOI 10.1042/bj3340519; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; Wurch T, 2001, J PHARMACOL TOX MET, V45, P3, DOI 10.1016/S1056-8719(01)00126-5; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183	55	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15778	15788		10.1074/jbc.M300731200	http://dx.doi.org/10.1074/jbc.M300731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598520	hybrid			2022-12-25	WOS:000182680000042
J	Olivares, C; Solano, F; Garcia-Borron, JC				Olivares, C; Solano, F; Garcia-Borron, JC			Conformation-dependent post-translational glycosylation of tyrosinase - Requirement of a specific interaction involving the cub metal binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULOCUTANEOUS ALBINISM TYPE-1; ENDOPLASMIC-RETICULUM; DOPACHROME TAUTOMERASE; MELANOMA-CELLS; MAMMALIAN TYROSINASE; MOUSE TYROSINASE; N-GLYCOSYLATION; BROWN LOCUS; PROTEIN; GENE	Tyrosinase, the rate-limiting enzyme in mammalian melanogenesis, is a copper-containing transmembrane glycoprotein. Tyrosinase undergoes a complex post-translational processing before reaching the melanosomal membrane. This processing involves N-glycosylation in several sites, including one located in the CuB copper binding site, movement from the endoplasmic reticulum (ER) to the Golgi, copper binding, and sorting to the melanosome. Aberrant processing is causally related to the depigmented phenotype of human melanomas. Moreover, some forms of albinism and several other pigmentary syndromes are considered ER retention diseases or trafficking defects. A critical step in tyrosinase maturation is the acquisition of an ER export-competent conformation recognized positively by the ER quality control system. However, the minimal structural requirements allowing exit from the ER to the Golgi have not yet been identified for tyrosinase or other melanosomal proteins. We addressed this question by analyzing the enzymatic activity and glycosylation pattern of mouse tyrosinase point mutants and chimeric constructs, where selected portions of tyrosinase were replaced by the homologous fragments of the highly similar tyrosinase-related protein 1. We show that a completely inactive tyrosinase point mutant lacking a critical histidine residue involved in copper binding is nevertheless able to exit from the ER and undergo further processing. Moreover, we demonstrate that tyrosinase displays at least two sites whose glycosylation is post-translational and most likely conformation-dependent and that a highly specific interaction involving the CuB site is essential not only for correct glycosylation but also for exit from the ER and enzymatic activity.	Univ Murcia, Sch Med, Dept Biochem & Mol Biol, E-30100 Murcia, Spain	University of Murcia	Garcia-Borron, JC (corresponding author), Univ Murcia, Sch Med, Dept Biochem & Mol Biol, Apto 4021,Campus Espinardo, E-30100 Murcia, Spain.	gborron@um.es	Solano, Francisco/G-5001-2013; Garcia-Borron, Jose Carlos/H-2247-2015; Olivares, Conchi/H-2794-2015	Solano, Francisco/0000-0001-9612-761X; Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Olivares, Conchi/0000-0001-7518-3858				AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BEERMANN F, 1995, EXP EYE RES, V61, P599, DOI 10.1016/S0014-4835(05)80053-3; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BINGHAM MJ, 1995, J PHYSIOL-LONDON, V482, P583, DOI 10.1113/jphysiol.1995.sp020542; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JARA JR, 1988, PIGM CELL RES, V1, P332, DOI 10.1111/j.1600-0749.1988.tb00128.x; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Jimenez-Cervantes C, 2001, FEBS LETT, V508, P44, DOI 10.1016/S0014-5793(01)03025-3; JIMENEZCERVANTES C, 1993, EUR J BIOCHEM, V217, P549, DOI 10.1111/j.1432-1033.1993.tb18276.x; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LEE ST, 1994, NEW ENGL J MED, V330, P529, DOI 10.1056/NEJM199402243300803; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Negroiu G, 1999, CELL MOL BIOL, V45, P1001; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/0264-6021:3540131; PALUMBO A, 1991, BIOCHIM BIOPHYS ACTA, V1115, P1, DOI 10.1016/0304-4165(91)90003-Y; PARK KC, 1993, AM J HUM GENET, V52, P406; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Prota G., 1992, MELANINS MELANOGENES; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; Spritz RA, 1997, J INVEST DERMATOL, V109, P207, DOI 10.1111/1523-1747.ep12319351; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Xu YQ, 2001, EXP CELL RES, V267, P115, DOI 10.1006/excr.2001.5232	52	33	34	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15735	15743		10.1074/jbc.M300658200	http://dx.doi.org/10.1074/jbc.M300658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595535	hybrid			2022-12-25	WOS:000182680000036
J	Pirola, L; Bonnafous, S; Johnston, AM; Chaussade, C; Portis, F; Van Obberghen, E				Pirola, L; Bonnafous, S; Johnston, AM; Chaussade, C; Portis, F; Van Obberghen, E			Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signalling pathways in L6 muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; HUMAN SKELETAL-MUSCLE; AMINO-ACID-TRANSPORT; SYNTHASE KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; IRS 1; DEGRADATION; ACTIVATION; RESISTANCE	Impaired glucose tolerance precedes type 2 diabetes and is characterized by hyperinsulinemia, which develops to balance peripheral insulin resistance. To gain insight into the deleterious effects of hyperinsulinemia on skeletal muscle, we studied the consequences of prolonged insulin treatment of L6 myoblasts on insulin-dependent signaling pathways. A 24-h long insulin treatment desensitized the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB) and p42/p44 MAPK pathways toward a second stimulation with insulin or insulin-like growth factor-1 and led to decreased insulin-induced glucose uptake. Desensitization was correlated to a reduction in insulin receptor substrate (IRS)-1 and IRS-2 protein levels, which was reversed by the PI3K inhibitor LY294002. Co-treatment of cells with insulin and LY294002, while reducing total IRS-1 phosphorylation, increased its phosphotyrosine content, enhancing IRS-1/PI3K association. PDK1, mTOR, and MAPK inhibitors did not block insulin-induced reduction of IRS-1, suggesting that the PI3K serine-kinase activity causes IRS-1 serine phosphorylation and its commitment to proteasomal degradation. Contrarily, insulin-induced IRS-2 down-regulation occurred via a PI3K/mTOR pathway. Suppression of IRS-1/2 down-regulation by LY294002 rescued the responsiveness of PKB and MAPK toward acute insulin stimulation. Conversely, adenovira-driven expression of constitutively active PI3K induced an insulin-independent reduction in IRS-1/2 protein levels. IRS-2 appears to be the chief molecule responsible for MAPK and PKB activation by insulin, as knockdown of IRS-2 (but not IRS-1) by RNA interference severely impaired activation of both kinases. In summary, (i) PI3K mediates insulin-induced reduction of IRS-1 by phosphorylating it while a PI3K/mTOR pathway controls insulin-induced reduction of IRS-2, (ii) in L6 cells, IRS-2 is the major adapter molecule linking the insulin receptor to activation of PKB and MAPK, (iii) the mechanism of IRS-1/2 down-regulation is different in L6 cells compared with 3T3-L1 adipocytes. In conclusion, the reduction in IRS proteins via different PI3K-mediated mechanisms contributes to the development of an insulin-resistant state in L6 myoblasts.	INSERM, U145, IFR50, Fac Med, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Van Obberghen, E (corresponding author), INSERM, U145, IFR50, Fac Med, F-06107 Nice 2, France.	vanobbeg@unice.fr	Pirola, Luciano/I-5250-2018	Pirola, Luciano/0000-0001-6539-5435				Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Janez A, 2000, ENDOCRINOLOGY, V141, P4657, DOI 10.1210/en.141.12.4657; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KLEIN HH, 1995, DIABETES, V44, P1310, DOI 10.2337/diabetes.44.11.1310; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; MAEGAWA H, 1991, DIABETES, V40, P815, DOI 10.2337/diabetes.40.7.815; NOLAN JJ, 1994, J CLIN ENDOCR METAB, V78, P471, DOI 10.1210/jc.78.2.471; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	60	97	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15641	15651		10.1074/jbc.M208984200	http://dx.doi.org/10.1074/jbc.M208984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594228	hybrid			2022-12-25	WOS:000182680000025
J	Rich, JN; Shi, Q; Hjelmeland, M; Cummings, TJ; Kuan, CT; Bigner, DD; Counter, CM; Wang, XF				Rich, JN; Shi, Q; Hjelmeland, M; Cummings, TJ; Kuan, CT; Bigner, DD; Counter, CM; Wang, XF			Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA; NEOPLASTIC PROGRESSION; SPARC EXPRESSION; CELL-LINES; PROTEIN; CYSTEINE; RICH; OSTEONECTIN/SPARC; ASTROCYTOMA; DATABASE	We employed a genetically defined human cancer model to investigate the contributions of two genes up-regulated in several cancers to phenotypic changes associated with late stages of tumorigenesis. Specifically, tumor cells expressing two structurally unrelated bone-related genes, osteonectin and osteoactivin, acquired a highly invasive phenotype when implanted intracranially in immunocompromised mice. Mimicking a subset of gliomas, tumor cells invaded brain along blood vessels and developed altered vasculature at the brain-tumor interface, suggesting that production of those two proteins by tumor cells may create a complex relationship between invading tumor and vasculature co-opted during tumor invasion. Interestingly, the same tumor cells formed massive spontaneous metastases when implanted subcutaneously. This dramatic alteration in tumor phenotype indicates that cellular microenvironment plays an important role in defining the specific effects of those gene products in tumor behavior. In vitro examination of tumor cells expressing either osteonectin or osteoactivin revealed that there was no impact on cellular growth or death but increased invasiveness and expression of MMP-9 and MMP-3. Specific pharmacologic inhibitors of MMP-2/9 and MMP-3 blocked the increased in vitro invasion associated with osteoactivin expression, but only MMP-3 inhibition altered the invasive in vitro phenotype mediated by osteonectin. Results from this genetically defined model system are supported by similar findings obtained from several established tumor cell lines derived originally from human patients. In sum, these results reveal that the expression of a single bone-related gene can dramatically alter or modify tumor cell behavior and may confer differential growth characteristics in different microenvironments. Genetically defined human cancer models offer useful tools in functional genomics to define the roles of specific genes in late stages of carcinogenesis.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu; wang0011@mc.duke.edu	Rich, Jeremy/AAM-1445-2021	Counter, Christopher M/0000-0003-0748-3079	NCI NIH HHS [CA 82481, R01 CA 94184, R01 CA 83770] Funding Source: Medline; NINDS NIH HHS [K08 NS 02055, NS 20023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082481, R01CA083770, R01CA094184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002055, P50NS020023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basu A, 1999, CELL GROWTH DIFFER, V10, P721; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gilles C, 1998, CANCER RES, V58, P5529; Golembieski WA, 1999, INT J DEV NEUROSCI, V17, P463, DOI 10.1016/S0736-5748(99)00009-X; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Lal A, 1999, CANCER RES, V59, P5403; LAWS ER, 1993, INT J DEV NEUROSCI, V11, P691, DOI 10.1016/0736-5748(93)90056-J; Le Bail B, 1999, J PATHOL, V189, P46; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Loging WT, 2000, GENOME RES, V10, P1393, DOI 10.1101/gr.138000; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rempel SA, 1999, CLIN CANCER RES, V5, P237; Rich JN, 2001, CANCER RES, V61, P3556; Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Sonoda Y, 2001, CANCER RES, V61, P4956; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Vajkoczy P, 2000, INT J CANCER, V87, P261, DOI 10.1002/1097-0215(20000715)87:2<261::AID-IJC18>3.0.CO;2-6; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	29	135	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15951	15957		10.1074/jbc.M211498200	http://dx.doi.org/10.1074/jbc.M211498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590137	hybrid			2022-12-25	WOS:000182680000064
J	Zhang, W; Chu, X; Tong, Q; Cheung, JY; Conrad, K; Masker, K; Miller, BA				Zhang, W; Chu, X; Tong, Q; Cheung, JY; Conrad, K; Masker, K; Miller, BA			A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNEL; ADP-RIBOSE; HUMAN ERYTHROBLASTS; HYDROGEN-PEROXIDE; ERYTHROPOIETIN; GENE; MELASTATIN; ACTIVATION; RECEPTOR; LTRPC2	TRPM2 is a Ca2+-permeable channel that is activated by oxidative stress and confers susceptibility to cell death. Here, an isoform of TRPM2 was identified in normal human bone marrow that consists of the TRPM2 N terminus and the first two predicted transmembrane domains. Because of alternative splicing, a stop codon (TAG) is located at the splice junction between exons 16 and 17, resulting in deletion of the four C-terminal transmembrane domains, the putative calcium-permeable pore region, and the entire C terminus. This splice variant was found in other hematopoietic cells including human burst forming unit-erythroid-derived erythroblasts and TF-1 erythroleukemia cells. Endogenous expression of both the short form of TRPM2 (TRPM2-S) and the full length (TRPM2-L) was determined by reverse transcriptase-PCR, and localization of endogenous TRPM2 to the plasma membrane was demonstrated by confocal microscopy. Heterologous expression of TRPM2-S in HEK 293T cells demonstrated similar membrane localization as TRPM2-L, and coexpression of TRPM2-S did not alter the subcellular localization of TRPM2-L. The direct interaction of TRPM2-S with TRPM2-L was demonstrated with immunoprecipitation. H2O2 induced calcium influx through TRPM2-L expressed in 293T cells. Coexpression of TRPM2-S suppressed H2O2-induced calcium influx through TRPM2-L. Furthermore, expression of TRPM2-S inhibited susceptibility to cell death and onset of apoptosis induced by H2O2 in cells expressing TRPM2-L. These data demonstrate that TRPM2-S is an important physiologic isoform of TRPM2 and modulates channel activity and induction of cell death by oxidative stress through TRPM2-L.	Geisinger Med Clin, Dept Med, Danville, PA 17822 USA; Geisinger Med Clin, Dept Pediat, Danville, PA 17822 USA	Geisinger Medical Center; Geisinger Medical Center	Miller, BA (corresponding author), Geisinger Med Clin, Sigfried & Janet Weis Ctr Res, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58672] Funding Source: Medline; NIDDK NIH HHS [DK 46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Duncan LM, 1998, CANCER RES, V58, P1515; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Herson PS, 1999, J BIOL CHEM, V274, P833, DOI 10.1074/jbc.274.2.833; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; KlonowskiStumpe H, 1997, AM J PHYSIOL-GASTR L, V272, pG1489, DOI 10.1152/ajpgi.1997.272.6.G1489; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Tsavaler L, 2001, CANCER RES, V61, P3760; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234	30	191	199	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16222	16229		10.1074/jbc.M300298200	http://dx.doi.org/10.1074/jbc.M300298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594222	hybrid			2022-12-25	WOS:000182680000097
J	Kramata, P; Zajc, B; Sayer, JM; Jerina, DM; Wei, CSJ				Kramata, P; Zajc, B; Sayer, JM; Jerina, DM; Wei, CSJ			A single site-specific trans-opened 7,8,9,10-tetrahydrobenzo[alpha]pyrene 7,8-diol 9,10-epoxide N-2-deoxyguanosine adduct induces mutations at multiple sites in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DIASTEREOMERIC BENZO<A>PYRENE 7,8-DIOL-9,10-EPOXIDES; GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; (+)-ANTI-BENZO<A>PYRENE DIOL EPOXIDE; DOSE-DEPENDENT DIFFERENCES; OPTICAL ENANTIOMERS; SEQUENCE CONTEXT; STRUCTURAL CHARACTERIZATION; DEOXYGUANOSINE ADDUCTS; ENERGY MINIMIZATION	Site-specific mutagenicity of trans-opened adducts at the exocyclic N-2-imino group of guanine by the (+)-(7R,8S,9S,10R)- and (-)-(7S,8R,9R,10S)-enantiomers of a benzo[a]pyrene 7,8-diol 9,10-epoxide (7-hydroxyl and epoxide oxygen are trans, BPDE-2) has been determined in Chinese hamster V79 cells and their repair-deficient counterpart, V-H1 cells. Four vectors containing single 10S-BPDE-dG or 10R-BPDE-dG adducts positioned at Go or G(-1) in the analyzed 5'-ACTG(0)G(-1)GA sequence of the non-transcribed strand were separately transfected into the cells. Mutations at each of the seven nucleotides were analyzed by a novel primer extension assay using a mixture of one dNTP complementary to the mutated nucleotide and three other ddNTPs and were optimized to quantify levels of a mutation as low as 1%. Only G --> T mutations were detected at the adducted sites; the 10S adduct derived from the highly carcinogenic (+)-diol epoxide was 40-50 and 75-140% more mutagenic than the 10R adduct in V79 and V-H1 cells, respectively. Importantly, the 10S adducts, but not the 10R adducts, induced separate non-targeted mutations at sites 5' to the G(-1) and G(0) lesions (G(0) --> T and C --> T, respectively) in both cell lines. Neither the T 5' to G(0) nor sites 3' to the lesions showed mutations. Non-targeted mutations may enhance overall mutagenicity of the 10S-BPDE-dG lesion and contribute to the much higher carcinogenicity and mutagenicity of (+)-BPDE-2 compared with its (-)enantiomer. Our study reports a definitive demonstration of mutations distal to a site-specific polycyclic aromatic hydrocarbon adduct.	Rutgers State Univ, Coll Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kramata, P (corresponding author), Rutgers State Univ, Coll Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	kramata@rci.rutgers.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bailey EA, 1996, P NATL ACAD SCI USA, V93, P1535, DOI 10.1073/pnas.93.4.1535; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Courtemanche C, 1999, MUTAT RES-FUND MOL M, V430, P23, DOI 10.1016/S0027-5107(99)00113-X; Custer L, 1999, BIOCHEMISTRY-US, V38, P569, DOI 10.1021/bi9813330; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Dipple A., 1984, ACS MONOGR SER, V182, P41, DOI DOI 10.1074/JBC.M409155200; FOUNTAIN MA, 1995, BIOCHEMISTRY-US, V34, P3152, DOI 10.1021/bi00010a004; Giri I, 2002, CHEM RES TOXICOL, V15, P638, DOI 10.1021/tx010187n; GOPALAKRISHNAN S, 1990, BIOCHEMISTRY-US, V29, P10438, DOI 10.1021/bi00498a002; Haff LA, 1997, GENOME RES, V7, P378, DOI 10.1101/gr.7.4.378; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; JELINSKY SA, 1995, BIOCHEMISTRY-US, V34, P13545, DOI 10.1021/bi00041a034; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kadkhodayan S, 1997, MUTAT RES-DNA REPAIR, V385, P47, DOI 10.1016/S0921-8777(97)00030-X; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; MOORE PD, 1977, ACS SYM SER, V44, P127; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Ponten I, 2001, CHEM RES TOXICOL, V14, P720, DOI 10.1021/tx0002684; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Sambrook J., 2001, MOL CLONING LAB MANU; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Shibutani S, 2001, BIOCHEMISTRY-US, V40, P3717, DOI 10.1021/bi0027581; Simhadri S, 2002, MUTAT RES-FUND MOL M, V508, P137, DOI 10.1016/S0027-5107(02)00211-7; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; SLAGA TJ, 1979, CANCER RES, V39, P67; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Syvanen AC, 1999, HUM MUTAT, V13, P1; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Vepachedu SR, 2000, CHEM RES TOXICOL, V13, P883, DOI 10.1021/tx000073w; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V77, P1389, DOI 10.1016/S0006-291X(77)80133-2; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; YAGI H, 1977, J AM CHEM SOC, V99, P2358, DOI 10.1021/ja00449a066; YAGI H, 1975, J AM CHEM SOC, V97, P6881, DOI 10.1021/ja00856a057; ZDZIENICKA MZ, 1987, MUTAT RES, V178, P235, DOI 10.1016/0027-5107(87)90274-0; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147	51	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14940	14948		10.1074/jbc.M211557200	http://dx.doi.org/10.1074/jbc.M211557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12595542	hybrid			2022-12-25	WOS:000182516100048
J	Saito, K; Sarai, A; Oda, M; Azuma, T; Kozono, H				Saito, K; Sarai, A; Oda, M; Azuma, T; Kozono, H			Thermodynamic analysis of the increased stability of major histocompatibility complex class II molecule I-E-k complexed with an antigenic peptide at an acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND SINGLE PEPTIDES; MHC MOLECULES; PROTEINS; BINDING; CALORIMETRY; KINETICS; EXCHANGE; EMPTY	The differential scanning calorimetry analysis of the murine major histocompatibility complex class II molecule, I-E-k, in complex with an antigenic peptide derived from mouse hemoglobin, showed that the thermal stability at the mildly acidic pH is higher than that at the neutral pH. Although the thermal unfolding of I-E-k-hemoglobin was irreversible, we extracted the equilibrium thermodynamic parameters from the kinetically controlled heat capacity curves. Both the denaturation temperatures and the enthalpy changes were almost independent of the heating rate over 1degreesC per min. The linear relation between the denaturation temperature and the calorimetric enthalpy change provided the heat capacity changes, which are classified into one for the mildly acidic pH region and another for the neutral pH region. The equilibrium thermodynamic parameters showed that the increased stability at the mildly acidic pH is because of the entropic effect. These thermodynamic data provided new insight into the current structural model of a transition to an open conformation at the mildly acidic pH, which is critical for the peptide exchange function of major histocompatibility complex class II in the endosome.	Sci Univ Tokyo, RIBS, Noda, Chiba 2780022, Japan; Tsukuba Inst, Inst Phys & Chem Res, RIKEN, Tsukuba, Ibaraki 3050077, Japan	Tokyo University of Science; RIKEN	Kozono, H (corresponding author), Sci Univ Tokyo, RIBS, 2669 Yamazaki, Noda, Chiba 2780022, Japan.			, Haruo/0000-0003-3352-0638; Oda, Masayuki/0000-0002-8568-4223				Baker BM, 1996, BIOPHYS J, V71, P2049, DOI 10.1016/S0006-3495(96)79403-1; Boniface JJ, 1996, J EXP MED, V183, P119, DOI 10.1084/jem.183.1.119; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.3.CO;2-F; Kasson PM, 2000, BIOCHEMISTRY-US, V39, P1048, DOI 10.1021/bi9921337; Kersh GJ, 2001, J IMMUNOL, V166, P3345, DOI 10.4049/jimmunol.166.5.3345; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KOZONO H, 1995, IMMUNITY, V3, P187, DOI 10.1016/1074-7613(95)90088-8; LEE JM, 1992, INT IMMUNOL, V4, P889, DOI 10.1093/intimm/4.8.889; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; McFarland BJ, 2001, P NATL ACAD SCI USA, V98, P9231, DOI 10.1073/pnas.151131498; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; Petrosian SA, 2000, PROTEIN SCI, V9, P387; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; Rotzschke O, 2002, P NATL ACAD SCI USA, V99, P16946, DOI 10.1073/pnas.212643999; Runnels HA, 1996, J EXP MED, V183, P127, DOI 10.1084/jem.183.1.127; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SETTE A, 1992, J IMMUNOL, V148, P844; Simon A, 2000, BIOPHYS J, V79, P2305, DOI 10.1016/S0006-3495(00)76476-9; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Tobita T, 2003, IMMUNOL LETT, V85, P47, DOI 10.1016/S0165-2478(02)00206-7; Villadangos JA, 2000, IMMUNITY, V12, P233, DOI 10.1016/S1074-7613(00)80176-4; Vogl T, 1997, BIOCHEMISTRY-US, V36, P1657, DOI 10.1021/bi962163z; Wilson N, 2001, IMMUNITY, V14, P513, DOI 10.1016/S1074-7613(01)00140-6	32	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14732	14738		10.1074/jbc.M301086200	http://dx.doi.org/10.1074/jbc.M301086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578842	hybrid			2022-12-25	WOS:000182516100020
J	Steenbergen, SM; Vimr, ER				Steenbergen, SM; Vimr, ER			Functional relationships of the sialyltransferases involved in expression if the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; OVERLAP EXTENSION; COLOMINIC ACID; SEROGROUP-B; ENDO-N; BIOSYNTHESIS; POLYSACCHARIDE; MECHANISM; POLYSIALYLTRANSFERASE; GLYCOSYLTRANSFERASE	Polysialic acid (PSA) capsules are cell-associated homopolymers of alpha2,8-, alpha2,9-, or alternating alpha2,8/2,9-linked sialic acid residues that function as essential virulence factors in neuroinvasive diseases caused by certain strains of Escherichia coli and Neisseria meningitidis. SA chains structurally identical to the bacterial alpha2,8-linked capsular polysaccharides are also synthesized by the mammalian central nervous system, where they regulate neuronal function in association with the neural cell adhesion molecule (NCAM). Despite the structural identity between bacterial and NCAM PSAs, the respective polysialyltransferases (polySTs) responsible for polymerizing sialyl residues from donor CMP-sialic acid are not homologous glycosyltransferases. To better define the mechanism of capsule biosynthesis, we established the functional interchangeability of bacterial polySTs by complementation of a polymerase-deficient E. coli K1 mutant with the polyST genes from groups B or C N. meningitidis and the control E. coli K92 polymerase gene. The biochemical and immunochemical results demonstrated that linkage specificity is dictated solely by the source of the polymerase structural gene. To determine the molecular basis for linkage specificity, we created chimeras of the K1 and K92 polySTs by overlap extension PCR. Exchanging the first 52 N-terminal amino acids of the K1 NeuS with the C terminus of the K92 homologue did not alter specificity of the resulting chimera, whereas exchanging the first 85 or reciprocally exchanging the first 100 residues did. These results demonstrated that linkage specificity is dependent on residues located between positions 53 and 85 from the N terminus. Site-directed mutagenesis of the K92 polyST N terminus indicated that no single residue alteration was sufficient to affect specificity, consistent with the proposed function of this domain in orienting the acceptor. The combined results provide the first evidence for residues critical to acceptor binding and elongation in polysialyltransferase.	Univ Illinois, Lab Sialobiol, Div Microbiol & Immunol, Dept Pathobiol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Vimr, ER (corresponding author), Univ Illinois, Lab Sialobiol, Div Microbiol & Immunol, Dept Pathobiol, 2001 S Lincoln Ave, Urbana, IL 61802 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042015] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI42015] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Arrecubieta C, 2001, J BIOL CHEM, V276, P4245, DOI 10.1074/jbc.M008183200; BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; Chao CF, 1999, J BIOL CHEM, V274, P18206, DOI 10.1074/jbc.274.26.18206; Charnock SJ, 2001, PLANT PHYSIOL, V125, P527, DOI 10.1104/pp.125.2.527; CHO JW, 1994, P NATL ACAD SCI USA, V91, P11427, DOI 10.1073/pnas.91.24.11427; Cieslewicz M, 1997, MOL MICROBIOL, V26, P237, DOI 10.1046/j.1365-2958.1997.5651942.x; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 2001, J BIOL CHEM, V276, P15200, DOI 10.1074/jbc.M010542200; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; EDWARDS U, 1994, MOL MICROBIOL, V14, P141, DOI 10.1111/j.1365-2958.1994.tb01274.x; EGAN W, 1977, BIOCHEMISTRY-US, V16, P3687, DOI 10.1021/bi00635a028; FERRERO MA, 1991, BIOCHEM J, V280, P575, DOI 10.1042/bj2800575; Gonzalez MD, 2002, J BACTERIOL, V184, P6050, DOI 10.1128/JB.184.21.6050-6055.2002; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodson N, 2000, J BIOL CHEM, V275, P27311; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Johnson JR, 2001, J INFECT DIS, V183, P1508, DOI 10.1086/320198; KWIATKOWSKI B, 1982, J VIROL, V43, P697, DOI 10.1128/JVI.43.2.697-704.1982; McGowen MM, 2001, GLYCOBIOLOGY, V11, P613, DOI 10.1093/glycob/11.8.613; ORTIZ AI, 1989, EUR J BIOCHEM, V178, P741, DOI 10.1111/j.1432-1033.1989.tb14505.x; PETTER JG, 1993, J BACTERIOL, V175, P4354, DOI 10.1128/JB.175.14.4354-4363.1993; PETTER JG, 1991, THESIS U ILLINOIS UR; Pogulis RJ, 2000, NUCLEIC ACID PROTOCOLS HANDBOOK, P857; Rappuoli R, 2001, VACCINE, V19, P2319, DOI 10.1016/S0264-410X(00)00552-1; Ringenberg M, 2001, GLYCOBIOLOGY, V11, P533, DOI 10.1093/glycob/11.7.533; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; Shen GJ, 1999, J BIOL CHEM, V274, P35139, DOI 10.1074/jbc.274.49.35139; Silver RP, 1990, BACTERIA, V11, P39; STEENBERGEN SM, 1990, MOL MICROBIOL, V4, P603, DOI 10.1111/j.1365-2958.1990.tb00629.x; STEENBERGEN SM, 1992, J BACTERIOL, V174, P1099, DOI 10.1128/jb.174.4.1099-1108.1992; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VIMR E, 1995, J IND MICROBIOL, V15, P352, DOI 10.1007/BF01569991; VIMR ER, 1992, J BACTERIOL, V174, P6191, DOI 10.1128/JB.174.19.6191-6197.1992; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; VIMR ER, 1993, POLYSIALIC ACID MICR, P73; VIMR ER, 1985, ANNU M AM SOC MICROB, V152, P154	45	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15349	15359		10.1074/jbc.M208837200	http://dx.doi.org/10.1074/jbc.M208837200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578835	hybrid			2022-12-25	WOS:000182516100100
J	Agazie, YM; Hayman, MJ				Agazie, YM; Hayman, MJ			Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; T-CELL; KINASE ACTIVATION; SH2 DOMAINS; CATALYTIC MECHANISM; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BINDING-SITE; MAP KINASE; SHP-2	Src homology containing phosphotyrosine phosphatase 2 (SHP2) is a positive effector of growth factor, cytokine, and integrin signaling. However, neither its physiological substrate nor its mechanism of action in tyrosine kinase signaling has been demonstrated. We reasoned that the identification of physiological substrates of SHP2 would be a stepping stone in elucidating its mechanism of action, and, thus, we constructed a potent trapping mutant of SHP2. Surprisingly, the frequently used Asp to Ala substitution did not give rise to a trapping mutant. However, we were able to develop an efficient trapping mutant of SHP2 by introducing Asp to Ala and Cys to Ser double mutations. The double mutant (DM) protein identified the epidermal growth factor receptor (EGFR), the Grb2 binder 1, and three other, as yet unidentified, phosphotyrosyl. proteins as candidate physiological substrates. Given that substrate trapping occurred in intact cells and that the interaction was very specific, it is highly likely that EGFR and Gab1 represent physiological SHP2 substrates. Therefore, the DM protein would serve as an important tool in future SHP2 studies, including identification of p190, p150, and P90.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1996, CELL, V85, P15; Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Buist A, 2000, J BIOL CHEM, V275, P20754, DOI 10.1074/jbc.M001626200; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; Elchebly M, 2000, J MOL MED-JMM, V78, P473, DOI 10.1007/s001090000141; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PALKA HL, 2002, J BIOL CHEM; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 1993, Harvey Lect, V89, P105; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	61	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13952	13958		10.1074/jbc.M210670200	http://dx.doi.org/10.1074/jbc.M210670200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582165	hybrid			2022-12-25	WOS:000182405000051
J	Beaudoin, J; Mercier, A; Langlois, R; Labbe, S				Beaudoin, J; Mercier, A; Langlois, R; Labbe, S			The Schizosaccharomyces pombe Cuf1 is composed of functional modules from two distinct classes of copper metalloregulatory transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER GENE-EXPRESSION; TRANSITION-METAL TRANSPORT; SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; YEAST COPPER; DNA-BINDING; FISSION YEAST; FACTOR MAC1; MOLECULAR CHARACTERIZATION; SUPEROXIDE-DISMUTASE	In fission yeast, the genes encoding proteins that are components of the copper transporter family are controlled at the transcriptional level by the Cuf1 transcription factor. Under low copper availability, Cuf1 induces expression of the copper transporter genes. In contrast, sufficient levels of copper inactivate Cuf1 and expression of its target genes. Our study reveals that Cuf1 harbors a putative copper-binding motif, Cys-X-Cys-X-3-Cys-X-Cys-X-2-Cys-X-2-His, within its carboxyl-terminal region to sense changing environmental copper levels. Binding studies reveal that the amino-terminal 174-residue segment of Cuf1 expressed as a fusion protein in Escherichia coli specifically interacts with the cis-acting copper transporter promoter element CuSE (copper-signaling element). Within this region, the first 61 amino acids of Cuf1 exhibit more overall homology to the Saccharomyces cerevisiae Ace1 copper-detoxifying factor (from residues 1 to 63) than to Mac1, its functional ortholog. Consistently, we demonstrate that a chimeric Cuf1 protein bearing the amino-terminal 63-residue segment of Ace1 complements cuf1Delta null phenotypes. Furthermore, we show that Schizosaccharomyces pombe cuf1Delta mutant cells expressing the full-length S. cerevisiae Ace1 protein are hypersensitive to copper ions, with a concomitant up-regulation of CuSE-mediated gene expression in fission yeast. Taken together, these studies reveal that S. cerevisiae Ace1 1-63 is functionally exchangeable with S. pombe Cuf1 1-61, and the nature of the amino acids located downstream of, this amino-terminal conserved region may be crucial in dictating the type of regulatory response required to establish and maintain copper homeostasis.	Univ Sherbrooke, Fac Med, Dept Biochem, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Med Nucl & Radiobiol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Sherbrooke Poistron Emiss Tomog Ctr, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochem, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.			Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Bellemare DR, 2002, J BIOL CHEM, V277, P46676, DOI 10.1074/jbc.M206444200; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Heredia J, 2001, J BIOL CHEM, V276, P8793, DOI 10.1074/jbc.M008179200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU S, 1990, New Biologist, V2, P544; Jensen LT, 1996, J BIOL CHEM, V271, P18514, DOI 10.1074/jbc.271.31.18514; Jensen LT, 1998, J BIOL CHEM, V273, P23805, DOI 10.1074/jbc.273.37.23805; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Keller G, 2000, J BIOL CHEM, V275, P29193, DOI 10.1074/jbc.M001552200; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1997, CHEM BIOL, V4, P549, DOI 10.1016/S1074-5521(97)90241-6; Koch KA, 1996, MOL CELL BIOL, V16, P724; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Labbe Simon, 2002, P571; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McDaniels CPJ, 1999, J BIOL CHEM, V274, P26962, DOI 10.1074/jbc.274.38.26962; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Serpe M, 1999, J BIOL CHEM, V274, P29211, DOI 10.1074/jbc.274.41.29211; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1993, J BIOL CHEM, V268, P12512; Turner RB, 1998, NAT STRUCT BIOL, V5, P551, DOI 10.1038/805; Van Ho A, 2002, ANNU REV MICROBIOL, V56, P237, DOI 10.1146/annurev.micro.56.012302.160847; Winge DR, 1998, PROG NUCLEIC ACID RE, V58, P165; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200; ZHOU PB, 1993, BIOFACTORS, V4, P105; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112; Zhu ZW, 1998, J BIOL CHEM, V273, P1277, DOI 10.1074/jbc.273.3.1277	61	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14565	14577		10.1074/jbc.M300861200	http://dx.doi.org/10.1074/jbc.M300861200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578838	hybrid			2022-12-25	WOS:000182405000125
J	Bland, CE; Kimberly, P; Rand, MD				Bland, CE; Kimberly, P; Rand, MD			Notch-induced proteolysis and nuclear localization of the delta ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING ENZYME; 4-AMINOPHENYLMERCURIC ACETATE; SIGNAL-TRANSDUCTION; CELL FATE; DROSOPHILA; PROTEIN; ACTIVATION; CLEAVAGE; TRANSCRIPTION; PATHWAYS	The Delta protein is a single-pass transmembrane ligand for the Notch family of receptors. Delta binding to Notch invokes regulated intramembrane proteolysis and nuclear translocation of the Notch intracellular domain. Delta is proteolytically processed at two sites, Ala(581) and Ala(593) in the juxtamembrane and transmembrane domains, respectively (Mishra-Gorur, K., Rand, M. D., Perez-Villamil, B., and Artavanis-Tsakonas, S. (2002) J. Cell Biol. 159, 313-324). Controversy over the role of Delta processing in propagating Notch signals has stemmed from conflicting reports on the activity or inactivity of soluble extracellular domain products of Delta. We have examined Delta proteolysis in greater detail and report that Delta undergoes three proteolytic cleavages in the region of the juxtamembrane and transmembrane domains. Only one of these cleavages, analogous to cleavage at Ala(581), is dependent on the Kuzbanian ADAM metalloprotease. The two additional cleavages correspond to the previously described cleavage at Ala593 and a novel unidentified site within or close to the transmembrane domain. Delta processing is up-regulated in co-cultures with Notch-expressing cells and is similarly induced by p-aminophenylmercuric acetate, a well documented activator of metalloproteases. Furthermore, expression of a truncated intracellular isoform of Delta shows prominent nuclear localization. Altogether, these data demonstrate a role for Notch in inducing Delta proteolysis and implicate a nuclear function for Delta, consistent with a model of bi-directional signaling through Notch-Delta interactions.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA	University of Vermont	Rand, MD (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, HSRF 426C, Burlington, VT 05405 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16435-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; deCelis JF, 1997, DEVELOPMENT, V124, P3241; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; HANCOCK ML, 2002, P SOC NEUR NOV 2 7 O, V28; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Heitzler P, 1996, DEVELOPMENT, V122, P161; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kopan R, 2002, J CELL SCI, V115, P1095; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Sun X, 1996, DEVELOPMENT, V122, P2465; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844	37	110	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13607	13610		10.1074/jbc.C300016200	http://dx.doi.org/10.1074/jbc.C300016200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12591935	hybrid			2022-12-25	WOS:000182405000005
J	Booth, JW; Telio, D; Liao, EH; McCaw, SE; Matsuo, T; Grinstein, S; Gray-Owen, SD				Booth, JW; Telio, D; Liao, EH; McCaw, SE; Matsuo, T; Grinstein, S; Gray-Owen, SD			Phosphatidylinositol 3-kinases in carcinoembryonic antigen-related cellular adhesion molecule-mediated internalization of Neisseria gonorrhoeae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; PHOSPHOINOSITIDE 3-KINASE; PHAGOSOME MATURATION; IGA1 PROTEASE; HOST-CELLS; INVASION; SALMONELLA; PROTEINS; PHAGOCYTOSIS; BIOGENESIS	Neisseria gonorrhoeae can be internalized by mammalian cells through interactions between bacterial opacity-associated (Opa) adhesins and members of the human carcinoembryonic antigen-related cellular adhesion molecule (CEACAM) family. We examined the role of phosphatidylinositol 3-kinases (PI3Ks) in gonococcal invasion of epithelial cell lines expressing either CEACAM1 or CEACAM3. CEACAM3-mediated internalization, but not that mediated by CEACAM1, was accompanied by localized and transient accumulation of the class I PI3K product phosphatidylinositol 3,4,5-trisphosphate at sites of bacterial engulfment. Inhibition of phosphatidylinositol 3-kinases reduced CEACAM3-mediated uptake but, paradoxically, led to an increase in intracellular survival of bacteria internalized via either CEACAM1 or CEACAM3, suggesting-additional roles for PI3K products. Consistent with this finding, the class III PI3K product phosphatidylinositol 3-phosphate accumulated and persisted in the membrane of gonococcal phagosomes after internalization. Inhibition of PI3K blocked phagosomal acquisition of the late endosomal marker lysosome-associated membrane protein 2 and reduced phagosomal acidification. Inhibiting phagosomal acidification with concanamycin A also increased survival of intracellular gonococci. These results suggest two modes of action of phosphatidylinositol 3-kinases during internalization of gonococci: synthesis of phosphatidylinositol 3,4,5-trisphosphate is important for CEACAM3-mediated uptake, while phosphatidylinositol 3-phosphate is needed for phagosomal maturation and acidification, which are required for optimal bacterial killing.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Takeda Chem Ind Ltd, Osaka 5408645, Japan	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Takeda Chemical Industries	Gray-Owen, SD (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 4381 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Gray-Owen, Scott/AAG-7337-2022; Gray-Owen, Scott/AFL-7380-2022	Liao, Edward/0000-0002-4955-6881; Gray-Owen, Scott D./0000-0002-1477-3616				Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Balla T., 2002, SCI STKE, V2002, p3pl; Billker O, 2002, EMBO J, V21, P560, DOI 10.1093/emboj/21.4.560; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen T, 2001, J BIOL CHEM, V276, P17413, DOI 10.1074/jbc.M010609200; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Dehio C, 1998, TRENDS MICROBIOL, V6, P489, DOI 10.1016/S0966-842X(98)01365-1; Demaurex N, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P380; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Gray-Owen SD, 1997, MOL MICROBIOL, V26, P971, DOI 10.1046/j.1365-2958.1997.6342006.x; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; Hauck CR, 1997, FEBS LETT, V405, P86, DOI 10.1016/S0014-5793(97)00163-4; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; Kwok T, 2002, INFECT IMMUN, V70, P2108, DOI 10.1128/IAI.70.4.2108-2120.2002; Lin L, 1997, MOL MICROBIOL, V24, P1083, DOI 10.1046/j.1365-2958.1997.4191776.x; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; MCGEE ZA, 1983, REV INFECT DIS, V5, P708; Mecsas J, 1998, MOL MICROBIOL, V28, P1269, DOI 10.1046/j.1365-2958.1998.00891.x; Mosleh IM, 1998, J BIOL CHEM, V273, P35332, DOI 10.1074/jbc.273.52.35332; Muenzner P, 2000, INFECT IMMUN, V68, P3601, DOI 10.1128/IAI.68.6.3601-3607.2000; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Scott CC, 2002, J BIOL CHEM, V277, P12770, DOI 10.1074/jbc.M110399200; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Steele-Mortimer O, 2002, CELL MICROBIOL, V4, P43, DOI 10.1046/j.1462-5822.2002.00170.x; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Wang J, 1998, MOL MICROBIOL, V30, P657, DOI 10.1046/j.1365-2958.1998.01102.x	33	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14037	14045		10.1074/jbc.M211879200	http://dx.doi.org/10.1074/jbc.M211879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571236	hybrid			2022-12-25	WOS:000182405000062
J	Yabe, U; Sato, C; Matsuda, T; Kitajima, K				Yabe, U; Sato, C; Matsuda, T; Kitajima, K			Polysialic acid in human milk - CD36 is a new member of mammalian polysialic acid-containing glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; N-ACETYLNEURAMINIC ACID; DIFFERENTIATION-DEPENDENT EXPRESSION; B SCAVENGER RECEPTOR; CARBOHYDRATE UNITS; OLIGOSIALIC ACIDS; ESCHERICHIA-COLI; POSSIBLE ROLES; SIALIC ACIDS; FAT GLOBULE	The neural cell adhesion molecule and the voltage-sensitive sodium channel a-subunit are the only two molecules in mammals known to be modified by alpha-2,8-linked polysialic acid (polySia). We found a new polySia-containing glycoprotein in human milk and identified it as CD36, a member of the B class of the scavenger receptor superfamily. The polySia-containing glycan chain(s) were removed by alkaline treatment but not by peptide: N-glycanase F digestion, indicating that milk CD36 contained polySia on O-linked glycan chain(s). Polysialylation of CD36 occurs not only in human milk but also in mouse milk. However, CD36 in human platelets is not polysialylated. PolySia CD36 is secreted in milk at any lactation stage and reaches peak level at 1 month after parturition. Thus, it is suggested that polySia of milk CD36 is significant for neonatal development in terms of protection and nutrition.	Nagoya Univ, Biosci Ctr, Div Organogenesis, Dept Anim Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University; Nagoya University	Kitajima, K (corresponding author), Nagoya Univ, Biosci Ctr, Div Organogenesis, Dept Anim Sci, Nagoya, Aichi 4648601, Japan.		SATO, Chihiro/B-7396-2014					AIKEN ML, 1990, BLOOD, V76, P2501; Angata K, 2002, J BIOL CHEM, V277, P36808, DOI 10.1074/jbc.M204632200; Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; ASAHINA S, 2001, GLYCOCONJUGATE J, V18, P148; BRUES JL, 2001, BIOCHIMIE PARIS, V83, P635; CARLSON SE, 1985, AM J CLIN NUTR, V41, P720, DOI 10.1093/ajcn/41.4.720; CARLSON SE, 1986, J NUTR, V116, P881, DOI 10.1093/jn/116.5.881; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FINNE J, 1982, J BIOL CHEM, V257, P1966; Fukuda M, 1996, CANCER RES, V56, P2237; GLASS JD, 1994, NEUROENDOCRINOLOGY, V60, P87; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; HOWARD LM, 2002, LEUKOCYTE TYPING, V7, P781; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; LI WX, 1993, J BIOL CHEM, V268, P16179; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; Mather IH, 2000, J DAIRY SCI, V83, P203, DOI 10.3168/jds.S0022-0302(00)74870-3; MICHALIDES R, 1994, INT J CANCER, P34; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; MORGAN BLG, 1980, J NUTR, V110, P416, DOI 10.1093/jn/110.3.416; Nadanaka S, 2001, J BIOL CHEM, V276, P33657, DOI 10.1074/jbc.M011100200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Peterson JA, 1998, BIOL NEONATE, V74, P143, DOI 10.1159/000014020; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROHR TE, 1980, J BIOL CHEM, V255, P2332; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Sato C, 2002, J BIOL CHEM, V277, P45299, DOI 10.1074/jbc.M206046200; Sato C, 1999, TRENDS GLYCOSCI GLYC, V11, P371, DOI 10.4052/tigg.11.371; SATO C, 1993, J BIOL CHEM, V268, P23675; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sato C, 1998, J BIOL CHEM, V273, P2575, DOI 10.1074/jbc.273.5.2575; Sato C, 2000, J BIOL CHEM, V275, P15422, DOI 10.1074/jbc.275.20.15422; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SATO C, 1999, GLYCOCONJUGATE J S, V16, P117; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Seki T, 1999, J COMP NEUROL, V410, P115, DOI 10.1002/(SICI)1096-9861(19990719)410:1<115::AID-CNE10>3.0.CO;2-C; Tanaka F, 2001, CANCER RES, V61, P1666; TANDON NN, 1989, J BIOL CHEM, V264, P7576; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; TROY FA, 1996, BIOL SIALIC ACIDS, P95; Tsuji S., 1999, SIALOBIOLOGY OTHER N, P145; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; ZUBER C, 1992, J BIOL CHEM, V267, P9965	55	113	115	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13875	13880		10.1074/jbc.M300458200	http://dx.doi.org/10.1074/jbc.M300458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576469	hybrid			2022-12-25	WOS:000182405000041
J	Chiu, PCN; Koistinen, R; Koistinen, H; Seppala, M; Lee, KF; Yeung, WSB				Chiu, PCN; Koistinen, R; Koistinen, H; Seppala, M; Lee, KF; Yeung, WSB			Binding of zona binding inhibitory factor-1 (ZIF-1) from human follicular fluid on spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG BINDING; PLACENTAL PROTEIN-14; IN-VITRO; PELLUCIDA BINDING; MAMMALIAN FERTILIZATION; ENDOMETRIAL PROTEIN; LIPOCALIN PROTEIN; GLYCODELIN; RECOGNITION; CAPACITY	Previous studies showed that zona binding inhibitory factor-1 (ZIF-1) was the glycoprotein mainly responsible for the spermatozoa zona binding inhibitory activity of human follicular fluid. ZIF-1 has a number of properties similar to glycodelin-A. A binding kinetics experiment in the present study demonstrated the presence of two binding sites of ZIF-1 on human spermatozoa. These binding sites were saturable, reversible, and bound to I-125-ZIF-1 in a time-, concentration-, and temperature-dependent manner. Glycodelin-A shared one common binding site with ZIF-1 on spermatozoa, and it could displace only 70% of the I-125-ZIF-1 bound on human spermatozoa. ZIF-1 and glycodelin-A formed complexes with the soluble extract of human spermatozoa. Coincubation of solubilized zona pellucida proteins reduced the binding of ZIF-1 to two complexes of the extract, suggesting that the ZIF-1 binding sites and zona pellucida protein receptors on human spermatozoa were closely related. ZIF-1, but not glycodelin-A, significantly suppressed progesterone-induced acrosome reaction of human spermatozoa. The carbohydrate moieties derived from ZIF-1 reduced the binding of native ZIF-1 on human spermatozoa as well as the zona binding inhibitory activity of the glycoprotein, although the intensity of the effects are lower when compared with the native protein. These effects are not due to the action of the molecules on the motility, viability, and acrosomal status of the treated spermatozoa. Deglycosylated ZIF-1 had no inhibitory effect on both ZIF-1 binding and zona binding capacity of spermatozoa. We concluded that the carbohydrate part of ZIF-1 was critical for the functioning of the glycoprotein.	Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland	University of Hong Kong	Yeung, WSB (corresponding author), Univ Hong Kong, Dept Obstet & Gynaecol, Queen Mary Hosp, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		/C-7476-2009; Seppala, Markku/AAT-6618-2021; Chiu, Chi Ngong/C-4245-2009; Koistinen, Hannu/AGU-1279-2022; Lee, Calvin Kai Fai/C-4328-2009	Chiu, Chi Ngong/0000-0001-6217-1970; Koistinen, Hannu/0000-0003-0926-3109; Lee, Calvin Kai Fai/0000-0001-5957-439X				Benoff S, 1997, MOL HUM REPROD, V3, P599, DOI 10.1093/molehr/3.7.599; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; Chapman NR, 1996, MOL HUM REPROD, V2, P767, DOI 10.1093/molehr/2.10.767; Chiu PCN, 2002, MOL REPROD DEV, V61, P205, DOI 10.1002/mrd.1149; Chryssikopoulos A, 1996, FERTIL STERIL, V66, P599, DOI 10.1016/S0015-0282(16)58574-4; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; FRANKEN DR, 1994, ANDROLOGIA, V26, P277; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; KADAM AL, 1995, J REPROD IMMUNOL, V29, P19, DOI 10.1016/0165-0378(95)00928-E; Koistinen H, 1999, FEBS LETT, V450, P158, DOI 10.1016/S0014-5793(99)00490-1; Koistinen H, 1997, LAB INVEST, V76, P683; Koistinen H, 1996, MOL HUM REPROD, V2, P759, DOI 10.1093/molehr/2.10.759; LIU DY, 1990, J REPROD FERTIL, V89, P127; MACEK MB, 1988, GAMETE RES, V20, P93, DOI 10.1002/mrd.1120200109; Mansouri A, 1998, BIOFACTORS, V7, P287, DOI 10.1002/biof.5520070401; MEIZEL S, 1990, SERONO S, V16, P205; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; Miranda PV, 2000, MOL HUM REPROD, V6, P699, DOI 10.1093/molehr/6.8.699; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; Oehninger S, 2001, CELLS TISSUES ORGANS, V168, P58, DOI 10.1159/000016806; Oehninger S, 1998, ANDROLOGIA, V30, P269; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; ORAND MG, 1988, GAMETE RES, V19, P315, DOI 10.1002/mrd.1120190402; Ozgur K, 1998, MOL HUM REPROD, V4, P318, DOI 10.1093/molehr/4.4.318; Qiao J, 1998, HUM REPROD, V13, P128, DOI 10.1093/humrep/13.1.128; RAM PA, 1989, GAMETE RES, V22, P321, DOI 10.1002/mrd.1120220309; RIITTINEN L, 1991, J IMMUNOL METHODS, V136, P85, DOI 10.1016/0022-1759(91)90253-C; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Seppala M, 2002, ENDOCR REV, V23, P401, DOI 10.1210/er.2001-0026; Shi YL, 1998, MOL REPROD DEV, V50, P354, DOI 10.1002/(SICI)1098-2795(199807)50:3<354::AID-MRD12>3.0.CO;2-4; Sinowatz F, 1998, ACTA ANAT, V161, P196; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; TOPFERPETERSEN E, 1985, HISTOCHEMISTRY, V83, P139; Tse JYM, 2002, MOL HUM REPROD, V8, P142, DOI 10.1093/molehr/8.2.142; TULSIANI DRP, 1990, BIOL REPROD, V42, P843, DOI 10.1095/biolreprod42.5.843; Tulsiani DRP, 1997, BIOL REPROD, V57, P487, DOI 10.1095/biolreprod57.3.487; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; Vigne JL, 2001, J BIOL CHEM, V276, P17101, DOI 10.1074/jbc.M010451200; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; *WHO, 1998, LAB MAN EX HUM SEM S; Yao YQ, 1996, HUM REPROD, V11, P1516; Yao YQ, 1998, HUM REPROD, V13, P2541, DOI 10.1093/humrep/13.9.2541; Yao YQ, 1996, HUM REPROD, V11, P2674; YEUNG WSB, 1994, HUM REPROD, V9, P656, DOI 10.1093/oxfordjournals.humrep.a138566; YOGEV L, 1995, HUM REPROD, V10, P851, DOI 10.1093/oxfordjournals.humrep.a136049	50	28	33	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13570	13577		10.1074/jbc.M212086200	http://dx.doi.org/10.1074/jbc.M212086200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12571233	hybrid			2022-12-25	WOS:000182189500122
J	Mauro, SA; Pawlowski, D; Koudelka, GB				Mauro, SA; Pawlowski, D; Koudelka, GB			The role of the minor groove substituents in indirect readout of DNA sequence by 434 repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-434 REPRESSOR; HIGH-RESOLUTION; OPERATOR; RECOGNITION; DIAMINOPURINE; AFFINITY; INOSINE; SPECIFICITY; CURVATURE; DODECAMER	The sequence of non-contacted bases at the center of the 434 repressor binding site affects the strength of the repressor-DNA complex by influencing the structure and flexibility of DNA (Koudelka, G. B., and Carlson, P. (1992) Nature 355, 89-91). We synthesized 434 repressor binding sites that differ in their central sequence base composition to test the importance of minor groove substituents and/or the number of base pair hydrogen bonds between these base pairs on DNA structure and strength of the repressor-DNA complex. We show here that the number of base pair H-bonds between the central bases apparently has no role in determining the relative affinity of a DNA site for repressor. Instead we find that the affinity of DNA for repressor depends on the absence or presence the N2-NH2 group on the purine bases at the binding site center. The N2-NH2 group on bases at the center of the 434 binding site appears to destabilize 434 repressor-DNA complexes by decreasing the intimacy of the specific repressor-DNA contacts, while increasing the reliance on protein contacts to the DNA phosphate backbone. Thus, the presence of an N2-NH2 group on the purines at the center of a binding site globally alters the precise conformation of the protein-DNA interface.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Koudelka, GB (corresponding author), SUNY Buffalo, Dept Biol Sci, Cooke Hall,N Campus, Buffalo, NY 14260 USA.		Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; Bailly C, 1998, NUCLEIC ACIDS RES, V26, P4309, DOI 10.1093/nar/26.19.4309; BAILLY C, 1995, EMBO J, V14, P2121, DOI 10.1002/j.1460-2075.1995.tb07204.x; BELL AC, 1993, J MOL BIOL, V234, P542, DOI 10.1006/jmbi.1993.1610; Duong TH, 1998, J MOL BIOL, V280, P31, DOI 10.1006/jmbi.1998.1846; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; JOACHIMIAK A, 1994, EMBO J, V13, P367, DOI 10.1002/j.1460-2075.1994.tb06270.x; JOHNSON BB, 1981, BIOCHEMISTRY-US, V20, P73, DOI 10.1021/bi00504a013; KILKUSKIE R, 1988, BIOCHEMISTRY-US, V27, P4377, DOI 10.1021/bi00412a026; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; Koudelka GB, 1998, NUCLEIC ACIDS RES, V26, P669, DOI 10.1093/nar/26.2.669; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; Lankas F, 2002, BIOPHYS J, V82, P2592, DOI 10.1016/S0006-3495(02)75601-4; MAIBENCO D, 1989, BIOPOLYMERS, V28, P549, DOI 10.1002/bip.360280203; Mollegaard NE, 1997, NUCLEIC ACIDS RES, V25, P3497, DOI 10.1093/nar/25.17.3497; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ShatzkySchwartz M, 1997, J MOL BIOL, V267, P595, DOI 10.1006/jmbi.1996.0878; SHIMON LJW, 1993, J MOL BIOL, V232, P826, DOI 10.1006/jmbi.1993.1434; Shui XQ, 1998, BIOCHEMISTRY-US, V37, P8341, DOI 10.1021/bi973073c; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457	24	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12955	12960		10.1074/jbc.M212667200	http://dx.doi.org/10.1074/jbc.M212667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569094	hybrid			2022-12-25	WOS:000182189500047
J	Zeigler, MM; Doseff, AI; Galloway, MF; Opalek, JM; Nowicki, PT; Zweier, JL; Sen, CK; Marsh, CB				Zeigler, MM; Doseff, AI; Galloway, MF; Opalek, JM; Nowicki, PT; Zweier, JL; Sen, CK; Marsh, CB			Presentation of nitric oxide regulates monocyte survival through effects on caspase-9 and caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE NITRATION; CELL-DEATH; APOPTOSIS; KINASE; INHIBITION; GENE; PEROXYNITRITE; MICE	In the absence of survival factors, blood monocytes undergo spontaneous apoptosis, which involves the activation of caspase-3. Although nitric oxide can block caspase-3 activation and promote cell survival, it can also induce apoptosis. We hypothesized that nitrosothiols that promote protein S-nitrosylation would reduce caspase-3 activation and cell survival, whereas nitric oxide donors (such as I-propamine 3-(2-hydroxy-2-nitroso-1-propylhydrazine (PAPA) NONOate and diethylamine (DEA) NONOate) that do not target thiol residues would not. Using human monocytes as a model, we observed that nitrosothiol donors S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine suppressed caspase-9 and caspase-3 activity and DNA fragmentation. In contrast, PAPA or DEA NONOate did not promote monocyte survival events and appeared to inhibit monocyte survival induced by macrophage colony-stimulating factor. The caspase-3-selective inhibitor DEVD-fluoromethyl ketone reversed DNA fragmentation events, and the caspase-9 inhibitor LEHD-fluoromethyl ketone reversed caspase-3 activity in monocytes treated with PAPA or DEA NONOate in the presence of macrophage colony-stimulating factor. These results were not caused by differences in glutathione levels or the kinetics of nitric oxide release. Moreover, S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine directly blocked the activity of recombinant caspase-3, which was reversed by the reducing agent dithiothreitol, whereas PAPA or DEA NONOate did not block the enzymatic activity of caspase-3. These data support the hypothesis that nitrosylation of protein thiol residues by nitric oxide is critical for promoting the survival of human monocytes.	Ohio State Univ, Dorothy M Davis Heart & Lung Res Int, Div Pulm & Crit Care Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; Ohio State Univ, Childrens Hosp, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital	Marsh, CB (corresponding author), Ohio State Univ, Dorothy M Davis Heart & Lung Res Int, Div Pulm & Crit Care Med, Rm 110 D HLRI,473 W 12th Ave, Columbus, OH 43210 USA.		Doseff, Andrea/E-2991-2011; Sen, Chandan K/A-8762-2013; Opalek, Judy/G-7755-2018	Opalek, Judy/0000-0001-5046-3562	NHLBI NIH HHS [HL67176, HL66108, HL63800] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063800, R01HL067176, R01HL066108] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Bosca L, 1999, CELL SIGNAL, V11, P239, DOI 10.1016/S0898-6568(98)00064-3; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Brune B, 1998, BIOCHEMISTRY-MOSCOW+, V63, P817; Deiana M, 1999, FREE RADICAL BIO MED, V26, P762, DOI 10.1016/S0891-5849(98)00231-7; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Estevez AG, 1999, METHOD ENZYMOL, V301, P393; Fahy RJ, 1999, J IMMUNOL, V163, P1755; FEELISCH M, 1995, METHODS NITRIC OXIDE; Guo Y, 1999, P NATL ACAD SCI USA, V96, P11507, DOI 10.1073/pnas.96.20.11507; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; LUKIC ML, 1991, BIOCHEM BIOPH RES CO, V178, P913, DOI 10.1016/0006-291X(91)90978-G; MANGAN DF, 1991, J IMMUNOL, V147, P3408; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MULLERQUERNHEIM J, 1986, J IMMUNOL, V137, P3475; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Sen CK, 1999, METHOD ENZYMOL, V299, P239; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Thornberry NA, 1997, BRIT MED BULL, V53, P478; TOCCI MJ, 1987, J IMMUNOL, V138, P1109; Xi L, 2000, TOXICOLOGY, V155, P37, DOI 10.1016/S0300-483X(00)00275-4; Zhao TC, 2000, CIRCULATION, V102, P902	29	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12894	12902		10.1074/jbc.M213125200	http://dx.doi.org/10.1074/jbc.M213125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566444	hybrid			2022-12-25	WOS:000182189500040
J	Kim, Y; Park, H; Lim, Y; Han, I; Kwon, HJ; Woods, A; Oh, ES				Kim, Y; Park, H; Lim, Y; Han, I; Kwon, HJ; Woods, A; Oh, ES			Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells	ONCOGENE			English	Article						colon carcinoma; historic deacetylase syndecan-2; tumorigenesis	HISTONE DEACETYLASES; INHIBITION; MODULATION; REVERSION; GROWTH	The inhibition of histone deacetylase activity is known to induce morphological changes of transformed cells. In this study, we investigated the effect of the specific HDAC inhibitor, trichostatin A (TSA), on colon carcinoma cell lines. Treatment of human colorectal carcinoma cells, KM1214 and KM12SM, with TSA induced distinct morphological changes. Both cell lines, which normally piled up in layers without clear boundary, became more flattened, and formed monolayers with evident boundaries between cells, with concomitant increased actin filament organization. Cell-cell interaction was not affected much, based on expression level, membrane localization, and interaction of E-cadherin with P-catenin. In contrast, syndecan-2 expression was dramatically reduced and it was correlated with the morphological changes of colon carcinoma cells. Consistently, downregulation of syndecan-2 expression by antisense cDNA clearly mimicked the morphological changes in KM12SM and reduced anchorage-independent growth of colon cancer cells. All these results indicate that reduced syndecan-2 expression correlates with TSA-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells.	Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Natl Caner Canc, Div Radiat & Nucl Med Radiat, Med Branch, Gyeonggi 411764, South Korea; Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Seoul 143747, South Korea; Univ Alabama Birmingham, Dept Cell Biol & Cell Adhes, Matrix Res Ctr, Birmingham, AL 35294 USA	Ewha Womans University; Ewha Womans University; National Cancer Center - Korea (NCC); Sejong University; University of Alabama System; University of Alabama Birmingham	Oh, ES (corresponding author), Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr	권, 호정/AAS-3642-2021					BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Couchman JR, 1999, J CELL SCI, V112, P3415; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; RACHEL BH, 2000, J CELL BIOL, V148, P779; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUGITA K, 1992, CANCER RES, V52, P168; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zimmermann P, 1999, FASEB J, V13, pS91	19	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					826	830		10.1038/sj.onc.1206068	http://dx.doi.org/10.1038/sj.onc.1206068			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584561				2022-12-25	WOS:000180864300004
J	Robbesyn, F; Garcia, V; Auge, N; Vieira, O; Frisach, MF; Salvayre, R; Negre-Salvayre, A				Robbesyn, F; Garcia, V; Auge, N; Vieira, O; Frisach, MF; Salvayre, R; Negre-Salvayre, A			HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappa B activation in smooth muscle cells	FASEB JOURNAL			English	Article						HDL; oxidized LDL; ROS	LOW-DENSITY-LIPOPROTEIN; CULTURED ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; SIGNALING PATHWAY; SPHINGOSINE KINASE; RECEPTOR PATHWAY; ALPHA-TOCOPHEROL; POTENTIAL ROLE; ATHEROSCLEROSIS	Oxidized low-density lipoproteins (oxLDL) exhibit proinflammatory properties and play a role in atherosclerosis plaque formation, rupture, and subsequent thrombosis. OxLDL alter the activity of the transcription factor NF-kappaB that is involved in the expression of immune and inflammatory genes. In contrast, high-density lipoproteins (HDL) are anti-atherogenic and exhibit anti-inflammatory properties. This work aimed to investigate how oxLDL activate NF-kappaB and whether and how HDL may prevent NF-kappaB activation. In cultured rabbit smooth muscle cells, mitogenic concentrations of mildly oxLDL trigger a rapid and transient NF-kappaB activation, which is strongly inhibited by HDL. Growth factors, phosphatidylinositol 3-kinase/Akt, and sphingosine kinase pathways are not implicated in the oxLDL-induced NF-kappaB activation and are not targets of HDL. OxLDL induce reactive oxygen species (ROS) generation and proteasome activation, which are implicated in NF-kappaB activation, as suggested by the inhibitory effect of the antioxidants N-acetyl-L-cysteine and pyrrolidinedithiocarbamate and the proteasome inhibitor PSI. HDL were able to prevent the intracellular ROS rise triggered by oxLDL or H2O2, thereby inhibiting the subsequent proteasome activation, IkappaB degradation, and NF-kappaB activation. In conclusion, the oxLDL-induced NF-kappaB activation involves ROS generation and proteasome activation, both events being inhibited by HDL. This 'antioxidant' and potentially anti-inflammatory effect of HDL may participate in their general anti-atherogenic properties.	CHU Rangueil, INSERM, U466, Inst Louis Bugnard, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Negre-Salvayre, A (corresponding author), CHU Rangueil, INSERM, U466, Inst Louis Bugnard, F-31403 Toulouse 4, France.	salvayre@toulouse.inserm.fr	Vieira, O V/C-4860-2013; Vieira, Otilia V/O-8660-2017; GARCIA, Virginie/W-8313-2019	Vieira, Otilia V/0000-0003-4924-1780; GARCIA, Virginie/0000-0002-9761-7036; Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDALIBI A, 1993, BIOCHEM SOC T, V21, P651, DOI 10.1042/bst0210651; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Auge N, 2000, PROG LIPID RES, V39, P207, DOI 10.1016/S0163-7827(00)00007-2; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; Caspar-Bauguil S, 1999, BIOCHEM J, V337, P269, DOI 10.1042/0264-6021:3370269; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1697, DOI 10.1016/S0891-5849(00)00227-6; Cockerill GW, 2001, CIRCULATION, V103, P108; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; FIELDING CJ, 1995, J LIPID RES, V36, P211; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; Han CY, 2000, BIOCHEM J, V350, P829, DOI 10.1042/0264-6021:3500829; Hundal RS, 2001, J LIPID RES, V42, P1483; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Libby P, 2001, AM J CARDIOL, V88, p3N; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MABILE L, 1995, FREE RADICAL BIO MED, V19, P177, DOI 10.1016/0891-5849(95)00006-J; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; MILLER GJ, 1980, ANNU REV MED, V31, P97, DOI 10.1146/annurev.me.31.020180.000525; NEGRESALVAYRE A, 1991, BIOCHIM BIOPHYS ACTA, V1096, P291, DOI 10.1016/0925-4439(91)90065-H; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Ozes ON, 1999, NATURE, V401, P82; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHMITT A, 1995, BBA-LIPID LIPID MET, V1256, P284, DOI 10.1016/0005-2760(95)00032-8; SCHMITT A, 1995, BRIT J PHARMACOL, V116, P1985, DOI 10.1111/j.1476-5381.1995.tb16402.x; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Shah PK, 2001, CIRCULATION, V104, P2376, DOI 10.1161/hc4401.098467; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Strack PR, 1996, BIOCHEMISTRY-US, V35, P7142, DOI 10.1021/bi9518048; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; Theilmeier G, 2000, FASEB J, V14, P2032, DOI 10.1096/fj.99-1029com; Vacaresse N, 1999, CIRC RES, V85, P892; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143	55	83	87	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					743	+		10.1096/fj.02-0240fje	http://dx.doi.org/10.1096/fj.02-0240fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586748				2022-12-25	WOS:000181456900028
J	Khabar, KSA; Siddiqui, YM; al-Zoghaibi, F; al-Haj, L; Dhalla, M; Zhou, AM; Dong, BH; Whitmore, M; Paranjape, J; Al-Ahdal, MN; Al-Mohanna, F; Williams, BRG; Silverman, RH				Khabar, KSA; Siddiqui, YM; al-Zoghaibi, F; al-Haj, L; Dhalla, M; Zhou, AM; Dong, BH; Whitmore, M; Paranjape, J; Al-Ahdal, MN; Al-Mohanna, F; Williams, BRG; Silverman, RH			RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ENCEPHALOMYOCARDITIS VIRUS; ANTIVIRAL ACTIVITY; VIRAL-INFECTION; TREATED CELLS; IN-VITRO; TRANSLATION; ACTIVATION; INITIATION; INHIBITOR	The transient control of diverse biological responses that occurs in response to varied forms of stress is often a highly regulated process. During the interferon (IFN) response, translational repression due to phosphorylation of eukaryotic initiation factor 2alpha, eIF2alpha, by the double-stranded RNA-dependent protein kinase, PKR, constitutes a means of inhibiting viral replication. Here we show that the transient nature of the IFN response against acute viral infections is regulated, at least in part, by RNase L. During the IFN antiviral response in RNase L-null cells, PKR mRNA stability was enhanced, PKR induction was increased, and the phosphorylated form of eIF2alpha appeared with extended kinetics compared with similarly treated wild type cells. An enhanced IFN response in RNase L-null cells was also demonstrated by monitoring inhibition of viral protein synthesis. Furthermore, ectopic expression of RNase L from a plasmid vector prevented the IFN induction of PKR. These results suggest a role for RNase L in the transient control of the IFN response and possibly of other cytokine and stress responses.	King Faisal Specialist Hosp & Res Ctr, Interferon & Cytokine Res Unit, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	King Faisal Specialist Hospital & Research Center; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Khabar, KSA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Interferon & Cytokine Res Unit, Dept Biol & Med Res, POB 3354,MBC-03, Riyadh 11211, Saudi Arabia.		Khabar, Khalid/AAG-3487-2019; Williams, Bryan R. G./A-5021-2009; Khabar, Khalid/A-4772-2011	Khabar, Khalid/0000-0003-1003-9788; Williams, Bryan R. G./0000-0002-4969-1151; Khabar, Khalid/0000-0003-1003-9788	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [CA44059] Funding Source: Medline; NIAID NIH HHS [AI343039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Biron C.A., 2001, FIELDS VIROLOGY, P321; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; EHRENFELD E, 1971, P NATL ACAD SCI USA, V68, P1075, DOI 10.1073/pnas.68.5.1075; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GANGEMI JD, 1989, J INTERFERON RES, V9, P227, DOI 10.1089/jir.1989.9.227; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hartmann R, 1998, J BIOL CHEM, V273, P3236, DOI 10.1074/jbc.273.6.3236; HOVANESSIAN AG, 1987, VIROLOGY, V159, P126, DOI 10.1016/0042-6822(87)90355-2; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Khabar KSA, 2000, J INTERF CYTOK RES, V20, P653, DOI 10.1089/107999000414835; Khabar KSA, 1997, J EXP MED, V186, P1077, DOI 10.1084/jem.186.7.1077; Kleijn M, 1996, VIROLOGY, V217, P486, DOI 10.1006/viro.1996.0143; Le Roy F, 2001, J BIOL CHEM, V276, P48473, DOI 10.1074/jbc.M107482200; LEWIS JA, 1987, LYMPHOKINES INTERFER, P73; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Li XL, 1998, J VIROL, V72, P2752, DOI 10.1128/JVI.72.4.2752-2759.1998; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5804; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Peery T, 1997, METHODS, V11, P371, DOI 10.1006/meth.1996.0435; Pitchford S, 1997, METHOD ENZYMOL, V288, P84; PRATT G, 1988, NUCLEIC ACIDS RES, V16, P3497, DOI 10.1093/nar/16.8.3497; Rajagopalan LE, 1996, J BIOL CHEM, V271, P19871, DOI 10.1074/jbc.271.33.19871; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhou AM, 2000, MAMM GENOME, V11, P989, DOI 10.1007/s003350010194; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	45	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20124	20132		10.1074/jbc.M208766200	http://dx.doi.org/10.1074/jbc.M208766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12582177	Green Published, hybrid			2022-12-25	WOS:000183078000071
J	Cham, CM; Xu, H; O'Keefe, JP; Rivas, FV; Zagouras, P; Gajewski, TF				Cham, CM; Xu, H; O'Keefe, JP; Rivas, FV; Zagouras, P; Gajewski, TF			Gene array and protein expression profiles suggest post-transcriptional regulation during CD8(+) T cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-STIMULATED CLONE-22; GROWTH-FACTOR-BETA; MAP KINASE PHOSPHATASE-1; BLOOD MONONUCLEAR-CELLS; IMMUNOLOGICAL SYNAPSE; CATALYTIC ACTIVATION; NEGATIVE REGULATION; IN-VIVO; RECEPTOR; PROLIFERATION	Peripheral CD8(+) T cells circulate in a quiescent naive state until they are primed by specific antigen and differentiate into effector cells. In the effector state, CD8(+) T cells acquire cytolytic activity and produce increased levels of cytokines such as interferon-gamma. They also exhibit increased T cell receptor sensitivity, decreased CD28 dependence, and become inhibitable by CTLA-4 and other negative regulatory pathways. We hypothesized that one mechanism by which these two states are regulated is via differential expression of specific genes. To this end, basal gene expression profiles of naive and effector 2C TCR transgenic x RAG2(-/-) CD8(+) T cells were analyzed using Affymetrix arrays representing 11,000 genes. Of the 177 differentially expressed known genes, 68 were expressed at higher levels in effector cells, but 109 were more abundant in naive cells, supporting the notion that the naive state is not passive. Expression of genes related to metabolism, actin cytoskeletal dynamics, and effector function increased with priming, whereas expression of putative anti-proliferative genes decreased. Semiquantitative reverse transcription-PCR was utilized as a secondary validation for selected transcripts, and Western blot analysis was used to examine protein expression for molecules of interest. Surprisingly, for 24 genes examined, 12 showed discordant protein versus mRNA expression. In summary, our study indicates that: 1) not only does the expression of some genes in naive CD8(+) T cells become up-regulated upon priming, but the expression of other genes is down-regulated as well and 2) the complexities of T cell differentiation include regulation at the post-transcriptional level.	Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Pfizer	Gajewski, TF (corresponding author), Univ Chicago, Comm Canc Biol, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA.	tgajewsk@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047919] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI47919] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Aulwurm UR, 2000, EUR J BIOCHEM, V267, P5693, DOI 10.1046/j.1432-1327.2000.01576.x; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Carroll RG, 1998, SEMIN IMMUNOL, V10, P195, DOI 10.1006/smim.1998.0131; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; CRONIN DC, 1994, IMMUNOL RES, V13, P215, DOI 10.1007/BF02935614; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; Davis SJ, 2001, CURR BIOL, V11, pR289, DOI 10.1016/S0960-9822(01)00165-8; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Fallarino F, 1998, J EXP MED, V188, P205, DOI 10.1084/jem.188.1.205; Fields PE, 1998, J IMMUNOL, V161, P5268; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gajewski TF, 2001, J IMMUNOL, V166, P3900, DOI 10.4049/jimmunol.166.6.3900; Glynne R, 2000, IMMUNOL REV, V176, P216; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; Grayson JM, 2001, J IMMUNOL, V166, P795, DOI 10.4049/jimmunol.166.2.795; GREINER EF, 1994, J BIOL CHEM, V269, P31484; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Hayashi RJ, 1998, J IMMUNOL, V160, P33; Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Huard B, 2000, NATURE, V403, P325, DOI 10.1038/35002105; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Kester HA, 1999, J BIOL CHEM, V274, P27439, DOI 10.1074/jbc.274.39.27439; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nakashiro K, 1998, CANCER RES, V58, P549; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Ohta S, 1997, BIOCHEM J, V324, P777, DOI 10.1042/bj3240777; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sprent J, 2000, PHILOS T R SOC B, V355, P317, DOI 10.1098/rstb.2000.0568; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Uchida D, 2000, LAB INVEST, V80, P955, DOI 10.1038/labinvest.3780098; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139	52	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17044	17052		10.1074/jbc.M212741200	http://dx.doi.org/10.1074/jbc.M212741200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12582156	hybrid			2022-12-25	WOS:000182818600081
J	Malakhov, MP; Kim, KI; Malakhova, OA; Jacobs, BS; Borden, EC; Zhang, DE				Malakhov, MP; Kim, KI; Malakhova, OA; Jacobs, BS; Borden, EC; Zhang, DE			High-throughput immunoblotting - Ubiquitin-like protein ISG15 modifies key regulators of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TARGETED DISRUPTION; INTERFERON; UBP43; HOMOLOG; MACROPHAGES; CONJUGATION; MECHANISMS; CLONING; KINASE	ISG15 is a ubiquitin-like protein that conjugates to numerous proteins in cells treated with interferon or lipopolysaccharide. Dysregulation of protein ISG15 modification (ISGylation) in mice leads to decreased life expectancy, brain cell injury, and hypersensitivity to interferon. Although ISG15 was identified more than two decades ago, the exact biochemical and physiological functions of ISG15-modification remain unknown, and the proteins targeted by ISG15 have not been identified. The major purpose of this work was to identify ISG15 targets among well characterized proteins that could be used as models for biological studies. We purified ISGylated proteins from human thymus by immunoaffinity chromatography and analyzed ISG15 conjugates by a high-throughput Western blot screen (PowerBlot(TM)). We found that three key regulators of signal transduction, phospholipase Cgamma1, Jak1, and ERK1 are modified by ISG15. In addition to that, we demonstrate that transcription factor Stat1, an immediate substrate of Jak1 kinase, is also ISGylated. Using whole cell protein extracts and phospholipase Cgamma1 as an example we demonstrate that ISG15 conjugates are not accumulated in cells treated with specific inhibitors of proteasomes. Our work suggests a role for ISG15 in the regulation of multiple signal transduction pathways and offers attractive models to further elucidate the biochemical function of ISGylation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Scripps Research Institute; Cleveland Clinic Foundation	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu	KIM, KEUN IL/D-2959-2011		NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NCI NIH HHS [CA79849] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Hansen TR, 1999, J REPROD FERTIL, P329; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; KNIGHT E, 1991, J IMMUNOL, V146, P2280; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ritchie KJ, 2002, GENE DEV, V16, P2207, DOI 10.1101/gad.1010202; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Schwer H, 2000, GENOMICS, V65, P44, DOI 10.1006/geno.2000.6148; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhang XX, 1999, VIROLOGY, V262, P152, DOI 10.1006/viro.1999.9914	39	205	217	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16608	16613		10.1074/jbc.M208435200	http://dx.doi.org/10.1074/jbc.M208435200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12582176	hybrid			2022-12-25	WOS:000182818600023
J	Eggler, AL; Lusetti, SL; Cox, MM				Eggler, AL; Lusetti, SL; Cox, MM			The C terminus of the Escherichia coli RecA protein modulates the DNA binding competition with single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ATPASE ACTIVITY; HOMOLOGOUS RECOMBINATION; PARTIAL SUPPRESSOR; BIOCHEMICAL BASIS; STABLE COMPLEXES; SSB PROTEIN; DUPLEX DNA; EXCHANGE; REPLICATION; FILAMENTS	The nucleation step of Escherichia coli RecA filament formation on single-stranded DNA (ssDNA) is strongly inhibited by prebound E. coli ssDNA-binding protein (SSB). The capacity of RecA protein to displace SSB is dramatically enhanced in RecA proteins with C-terminal deletions. The displacement of SSB by RecA protein is progressively improved when 6,13, and 17 C-terminal amino acids are removed from the RecA protein relative to the full-length protein. The C-terminal deletion mutants also more readily displace yeast replication protein A than does the full-length protein. Thus, the RecA protein has an inherent and robust capacity to displace SSB from ssDNA. However, the displacement function is suppressed by the RecA C terminus, providing another example of a RecA activity with C-terminal modulation. RecADeltaC17 also has an enhanced capacity relative to wild-type RecA protein to bind ssDNA containing secondary structure. Added Mg2+ enhances the ability of wild-type RecA and the RecA C-terminal deletion mutants to compete with SSB and replication protein A. The overall binding of RecADeltaC17 mutant protein to linear ssDNA is increased further by the mutation E38K, previously shown to enhance SSB displacement from ssDNA. The double mutant RecADeltaC17/E38K displaces SSB somewhat better than either individual mutant protein under some conditions and exhibits a higher steady-state level of binding to linear ssDNA under all conditions.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu		Eggler, Aimee/0000-0002-7286-2107	NIGMS NIH HHS [GM 32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; ASAI T, 1994, J BACTERIOL, V176, P7113, DOI 10.1128/JB.176.22.7113-7114.1994; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; CHOW SA, 1988, J BIOL CHEM, V263, P200; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; COX MM, 1982, J BIOL CHEM, V257, P8523; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; ENNIS DG, 1995, MUTAT RES-DNA REPAIR, V336, P39, DOI 10.1016/0921-8777(94)00045-8; Galitski T, 1997, GENETICS, V146, P751; KNIGHT KL, 1984, J BIOL CHEM, V259, P1279; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LAVERY PE, 1990, J BIOL CHEM, V265, P4004; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SMITH KC, 1987, MUTAT RES, V183, P1, DOI 10.1016/0167-8817(87)90039-3; Steiner WW, 1998, J BACTERIOL, V180, P6269; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; THOMAS A, 1983, J GEN MICROBIOL, V129, P681; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; VOLKERT MR, 1984, J BACTERIOL, V160, P702, DOI 10.1128/JB.160.2.702-705.1984; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; WANG TCV, 1986, J BACTERIOL, V168, P940, DOI 10.1128/jb.168.2.940-946.1986; WANG TCV, 1991, BIOCHIMIE, V73, P335, DOI 10.1016/0300-9084(91)90221-L; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	63	78	90	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16389	16396		10.1074/jbc.M212920200	http://dx.doi.org/10.1074/jbc.M212920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598538	hybrid			2022-12-25	WOS:000182680000118
J	Targett-Adams, P; Chambers, D; Gledhill, S; Hope, RG; Coy, JF; Girod, A; McLauchlan, J				Targett-Adams, P; Chambers, D; Gledhill, S; Hope, RG; Coy, JF; Girod, A; McLauchlan, J			Live cell analysis and targeting of the lipid droplet-binding adipocyte differentiation-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; LEYDIG TUMOR-CELLS; CORE PROTEIN; MESSENGER-RNA; LIVING CELLS; PERILIPIN-A; EXPRESSION; ADIPOPHILIN; ASSOCIATION; STORAGE	Neutral lipid is stored in spherical organelles called lipid droplets that are bounded by a coat of proteins. The protein that is most frequently found at the surface of lipid droplets is adipocyte differentiation-related protein (ADRP). In this study, we demonstrate that fusion of either the human or mouse ADRP coding sequences to green fluorescent protein (GFP) does not disrupt the ability of the protein to associate with lipid droplets. Using this system to identify targeting elements, discontinuous segments within the coding region were required for directing ADRP to lipid droplets. GFP-tagged protein was employed also to examine the behavior of lipid droplets in live cells. Time lapse microscopy demonstrated that in HuH-7 cells, which are derived from a human hepatoma, a small number of lipid droplets could move rapidly, indicating transient association with intracellular transport pathways. Most lipid droplets did not show such movement but oscillated within a confined area; these droplets were in close association with the endoplasmic reticulum. membrane and moved in concert with the endoplasmic reticulum. Fluorescence recovery analysis of GFP-tagged ADRP in live cells revealed that surface proteins do not rapidly diffuse between lipid droplets, even in conditions where they are closely packed. This system provides new insights into the properties of lipid droplets and their interaction with cellular processes.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; MRC Technol, Edinburgh EH4 2SP, Midlothian, Scotland; MTM Labs AG, D-69120 Heidelberg, Germany; European Mol Biol Lab, Cell Biol & Biophys Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	McLauchlan, J (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.			Targett-Adams, Paul/0000-0003-4967-1668				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; Burt AD, 1998, SEMIN DIAGN PATHOL, V15, P246; Charron AJ, 2002, J CELL SCI, V115, P3049; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Coy JF, 1996, CELL DEATH DIFFER, V3, P199; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; Gao J, 2000, J CELL PHYSIOL, V182, P297; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Litvak V, 2002, CURR BIOL, V12, P1513, DOI 10.1016/S0960-9822(02)01107-7; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Mather IH, 1998, J MAMMARY GLAND BIOL, V3, P259, DOI 10.1023/A:1018711410270; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; Schrader M, 2001, J HISTOCHEM CYTOCHEM, V49, P1421, DOI 10.1177/002215540104901110; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; VANROOIJEN GJH, 1995, PLANT PHYSIOL, V109, P1353, DOI 10.1104/pp.109.4.1353; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7	42	161	163	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15998	16007		10.1074/jbc.M211289200	http://dx.doi.org/10.1074/jbc.M211289200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591929	hybrid			2022-12-25	WOS:000182680000070
J	Yu, XW; Kennedy, RH; Liu, SJ				Yu, XW; Kennedy, RH; Liu, SJ			JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-STAT; SIGNAL-TRANSDUCTION; SERUM INTERLEUKIN-6; CARDIAC MYOCYTES; CYTOKINES; GP130; PATHWAY; JAK/STAT; RELEASE; FAMILY	Interleukin (IL)-6 decreases cardiac contractility via a nitric oxide (NO)-dependent pathway. However, mechanisms underlying IL-6-induced NO production remain unclear. JAK2/STAT3 and ERK1/2 are two well known signaling pathways activated by IL-6 in non-cardiac cells. However, these IL-6-activated pathways have not been identified in adult cardiac myocytes. In this study, we identified activation of these two pathways during IL-6 stimulation and examined their roles in IL-6-induced NO production and decrease in contractility of adult ventricular myocytes. IL-6 increased phosphorylation. of STAT3 (at Tyr(705)) and ERK1/2 (at Tyr(204)) within 5 min that peaked at 15-30 min and returned to basal levels at 2 h. Phosphorylation of STAT3 was blocked by genistein, a protein tyrosine kinase inhibitor, and AG490, a JAK2 inhibitor, but not PD98059, an ERK1/2 kinase inhibitor. The phosphorylation of ERK1/2 was blocked by PD98059 and genistein but not AG490. Furthermore, IL-6 enhanced de novo synthesis of iNOS protein, increased NO production, and decreased cardiac contractility after 2 h of incubation. These effects were blocked by genistein and AG490 but not PD98059. We conclude that IL-6 activated independently the JAK2/STAT3 and ERK1/2 pathways, but only JAK2/STAT3 signaling mediated the NO-associated decrease in contractility.	Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Liu, SJ (corresponding author), Univ Arkansas Med Sci, Dept Pharmaceut Sci, 4301 W Markham St,MS 522-3, Little Rock, AR 72205 USA.	sliu@uams.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062226] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 62226] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BASSANI JWM, 1993, AM J PHYSIOL, V265, pC533, DOI 10.1152/ajpcell.1993.265.2.C533; Bers DM, 1998, ANN NY ACAD SCI, V853, P157, DOI 10.1111/j.1749-6632.1998.tb08264.x; Debonera F, 2001, J SURG RES, V96, P289, DOI 10.1006/jsre.2001.6086; Decker T, 1999, CELL MOL LIFE SCI, V55, P1505, DOI 10.1007/s000180050390; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GUILLEN I, 1995, AM J PHYSIOL-REG I, V269, pR229, DOI 10.1152/ajpregu.1995.269.2.R229; HACK CE, 1989, BLOOD, V74, P1704; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; IKEDA U, 1992, J MOL CELL CARDIOL, V24, P579, DOI 10.1016/0022-2828(92)91042-4; JOURDAN M, 1990, ARTHRITIS RHEUM-US, V33, P398, DOI 10.1002/art.1780330313; Kammuller ME, 1995, TOXICOLOGY, V105, P91, DOI 10.1016/0300-483X(95)03128-3; KINUGAWA K, 1994, CIRC RES, V75, P285, DOI 10.1161/01.RES.75.2.285; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kodama H, 2000, AM J PHYSIOL-HEART C, V279, pH1635, DOI 10.1152/ajpheart.2000.279.4.H1635; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; LIU S, 1995, AM J PHYSIOL-CELL PH, V268, pC339, DOI 10.1152/ajpcell.1995.268.2.C339; Liu SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC826, DOI 10.1152/ajpcell.00465.2002; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; NEUMANN FJ, 1995, CIRCULATION, V92, P748, DOI 10.1161/01.CIR.92.4.748; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Omura T, 2001, J MOL CELL CARDIOL, V33, P307, DOI 10.1006/jmcc.2000.1303; Roig E, 1998, AM J CARDIOL, V82, P688, DOI 10.1016/S0002-9149(98)00388-9; Satoh M, 1996, VIRCHOWS ARCH, V427, P503; Sawa Y, 1998, J THORAC CARDIOV SUR, V116, P511, DOI 10.1016/S0022-5223(98)70018-2; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Schumann G, 1999, J NEUROCHEM, V73, P2009; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Steele IC, 1996, EUR J CLIN INVEST, V26, P1018, DOI 10.1046/j.1365-2362.1996.2560587.x; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5; Wollert K C, 2001, Heart Fail Rev, V6, P95; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yamauchi-Takihara K, 2000, INT J EXP PATHOL, V81, P1; YU XW, 2000, J MOL CELL CARDIOL, V32, pA72	44	104	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16304	16309		10.1074/jbc.M212321200	http://dx.doi.org/10.1074/jbc.M212321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595539	hybrid			2022-12-25	WOS:000182680000107
J	Braunwarth, A; Fromont-Racine, M; Legrain, P; Bischoff, FR; Gerstberger, T; Hurt, E; Kunzler, M				Braunwarth, A; Fromont-Racine, M; Legrain, P; Bischoff, FR; Gerstberger, T; Hurt, E; Kunzler, M			Identification and characterization of a novel RanGTP-binding protein in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT RECEPTOR; MESSENGER-RNA EXPORT; IMPORTIN-ALPHA; TRANSPORT FACTOR; EGG EXTRACTS; GTPASE RAN; IN-VIVO; BETA; XENOPUS; EXPRESSION	The small Ras-like GTPase Ran plays an essential role in the transport of macromolecules in and out of the nucleus and has been implicated in spindle (1, 2) and nuclear envelope formation (3, 4) during mitosis in higher eukaryotes. We identified Saccharomyces cerevisiae open reading frame YGL164c encoding a novel RanGTP-binding protein, termed Yrb30p. The protein competes with yeast RanBP1 (Yrb1p) for binding to the GTP-bound form of yeast Ran (Gsp1p) and is, like Yrb1p, able to form trimeric complexes with RanGTP and some of the karyopherins. In contrast to Yrb1p, Yrb30p does not coactivate but inhibits RanGAP1(Rna1p)-mediated GTP hydrolysis on Ran, like the karyopherins. At steady state, Yrb30p localizes exclusively to the cytoplasm, but the presence of a functional nuclear export signal and the localization of truncated forms of Yrb30p suggest that the protein shuttles between nucleus and cytoplasm and is exported via two alternative pathways, dependent on the nuclear export receptor Xpo1p/Crm1p and on RanGTP binding. Whereas overproduction of the full-length protein and complete deletion of the open reading frame reveal no obvious phenotype, overproduction of C-terminally truncated forms of the protein inhibits yeast vegetative growth. Based on these results and the exclusive conservation of the protein in the fungal kingdom, we hypothesize that Yrb30p represents a novel modulator of the Ran GTPase switch related to fungal lifestyle.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Inst Pasteur, Dept Biotechnol, F-75724 Paris 15, France; Hybrigen SA, F-75014 Paris, France; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Helmholtz Association; German Cancer Research Center (DKFZ)	Kunzler, M (corresponding author), ETH Zentrum, Inst Mikrobiol, LFV E23,Schelzbergstr 7, CH-8092 Zurich, Switzerland.		Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255; Kunzler, Markus/0000-0003-1275-0629; Fromont-Racine, Micheline/0000-0001-9906-0334				Bamba C, 2002, CURR BIOL, V12, P503, DOI 10.1016/S0960-9822(02)00741-8; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Kaiser C., 1994, METHODS YEAST GENETI; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Kunzler M, 2000, MOL CELL BIOL, V20, P4295, DOI 10.1128/MCB.20.12.4295-4308.2000; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kunzler M, 2001, J CELL SCI, V114, P3233; Lau D, 2000, J BIOL CHEM, V275, P467, DOI 10.1074/jbc.275.1.467; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; Nicolas FJ, 2001, J CELL SCI, V114, P3013; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sazer S, 2000, J CELL SCI, V113, P1111; Schroeder AJ, 1999, MOL GEN GENET, V261, P788, DOI 10.1007/s004380050022; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Steggerda SM, 2000, J BIOL CHEM, V275, P23175, DOI 10.1074/jbc.C000252200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 2002, CURR BIOL, V12, P498, DOI 10.1016/S0960-9822(02)00714-5	39	8	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15397	15405		10.1074/jbc.M210630200	http://dx.doi.org/10.1074/jbc.M210630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578832	hybrid, Green Published			2022-12-25	WOS:000182516100105
J	Buxton, DB; Golomb, E; Adelstein, RS				Buxton, DB; Golomb, E; Adelstein, RS			Induction of nonmuscle myosin heavy chain II-C by butyrate in RAW 264.7 mouse macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; SP1 BINDING; SODIUM-BUTYRATE; CELLULAR MYOSIN; MESSENGER-RNAS; CELLS; PROTEIN; LIPOPOLYSACCHARIDE; PROMOTER	RAW 264.7 macrophages express nonmuscle myosin heavy chain II-A as the only significant nonmuscle myosin heavy chain isoform,with expression of nonmuscle myosin heavy chain II-B and II-C low or absent. Treatment of the cells with sodium butyrate, an inhibitor of historic deacetylase, led to the dose-dependent induction of nonniuscle myosin heavy chain II-C. Trichostatin A, another inhibitor of histone deacetylase, also induced nonmuscle myosin heavy chain II-C. Induction of nonmuscle myosin heavy chain II-C in response to these histone deacetylase inhibitors was attenuated by mithramycin, an inhibitor of Spl binding to GC-rich DNA sequences. Bacterial lipopolysaccharide alone had no effect on basal nonmuscle myosin heavy chain II-C expression, but attenuated butyrate-mediated induction of nonmuscle myosin heavy chain II-C. The effects of lipopolysaccharide were mimicked by the nitric oxide donors sodium nitroprusside and spermine NONOate, suggesting a role for nitric oxide in the lipopolysaccharide-mediated down-regulation of nonmuscle myosin heavy chain II-C induction. This was supported by experiments with the inducible nitric-oxide synthase inhibitor 1400W, which partially blocked the lipopolysaccharide-mediated attenuation of nonmuscle myosin heavy chain induction. 8-Bromo-cGMP had no effect on nonmuscle myosin heavy chain induction, consistent with a cGMP-independent mechanism for nitric oxide-mediated inhibition of nonmuscle myosin heavy chain II-C induction.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Buxton, DB (corresponding author), Rockledge Ctr 2, Heart Res Program, 6701 Rockledge Dr,Suite 9044,MSC 7940, Bethesda, MD 20892 USA.			Buxton, Denis/0000-0003-3077-6435; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004230, Z01HL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beohar N, 1998, J BIOL CHEM, V273, P9168, DOI 10.1074/jbc.273.15.9168; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cesari M, 1998, BIOCHEM J, V336, P619, DOI 10.1042/bj3360619; Chakravortty D, 2000, J ENDOTOXIN RES, V6, P243, DOI 10.1179/096805100101532108; CHESNOKOV V N, 1990, Biokhimiya, V55, P1276; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; Collins SM, 2001, GUT, V49, P743, DOI 10.1136/gut.49.6.743; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Fukushima K, 1998, DIGESTION, V59, P683, DOI 10.1159/000007576; Fusunyan RD, 1998, PEDIATR RES, V43, P84, DOI 10.1203/00006450-199801000-00013; GOLD ME, 1990, P NATL ACAD SCI USA, V87, P4430, DOI 10.1073/pnas.87.12.4430; IKEDA K, 1990, J BIOL CHEM, V265, P5398; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KOYAMA H, 1976, J CELL PHYSIOL, V88, P49, DOI 10.1002/jcp.1040880107; Kroncke KD, 2000, FASEB J, V14, P166; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Penhoat A, 1996, MOL CELL ENDOCRINOL, V121, P57, DOI 10.1016/0303-7207(96)03851-8; Sekiguchi K, 2001, CIRC RES, V88, P52, DOI 10.1161/01.RES.88.1.52; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TOOTHAKER LE, 1991, BLOOD, V78, P1826; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; ZHANG JW, 1990, DEV GENET, V11, P168, DOI 10.1002/dvg.1020110207	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15449	15455		10.1074/jbc.M210145200	http://dx.doi.org/10.1074/jbc.M210145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12598534	hybrid			2022-12-25	WOS:000182516100112
J	Berenbaum, F; Humbert, L; Bereziat, G; Thirion, S				Berenbaum, F; Humbert, L; Bereziat, G; Thirion, S			Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phospholipase A(2) via ATP in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; PROTEIN-KINASE; INORGANIC PYROPHOSPHATE; PROSTAGLANDIN E-2; GENE-EXPRESSION; SYNOVIAL-FLUID; RECEPTORS; RELEASE; INDUCTION; INTERLEUKIN-1-BETA	Extracellular ATP is a pro-inflammatory mediator involved in the release of prostaglandin from articular chondrocytes, but little is known about its effects on intracellular signaling. ATP triggered the rapid release of prostaglandin E-2 (PGE(2)) by acting on P2Y(2) receptors in rabbit articular chondrocytes. We have explored the signaling events involved in this synthesis. ATP significantly increased arachidonic acid production, which involved the activation of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) but not a secreted form of PLA(2), as demonstrated by various PLA(2) inhibitors and translocation experiments. We also showed that ATP induced the phosphorylation of p38 and ERK1/2 mitogen-activated protein kinases (MAPKs). Both PD98059, an inhibitor of the ERK pathway, and SB203580, an inhibitor of p38 MAPK, completely inhibited the ATP-induced release of PGE(2). Finally, dominant-negative plasmids encoding p38 and ERK transfected alone into the cells impaired the ATP-induced release of PGE(2) to about the same extent as both plasmids transfected together. These results suggest that PGE(2) production induced by ATP requires the activation of both ERK1/2 and p38 MAPKs. Thus, ATP acts via P2Y(2)-purine receptors to recruit cPLA(2) by activating both ERK1/2 and p38 MAPKs and stimulates the release of PGE(2) from articular chondrocytes.	Univ Paris 06, UMR 7079, CNRS, Physiol & Physiopathol Lab, F-75252 Paris 5, France; Unite Format Rech St Antoine, Dept Rheumatol, F-75012 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Thirion, S (corresponding author), Univ Paris 06, UMR 7079, CNRS, Physiol & Physiopathol Lab, 7 Quai St Bernard,Bat A, F-75252 Paris 5, France.		Berenbaum, Francis/AAO-5690-2020	Berenbaum, Francis/0000-0001-8252-7815; Thirion, Sylvie/0000-0001-5361-8275				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; Aimond F, 2000, J BIOL CHEM, V275, P39110, DOI 10.1074/jbc.M008192200; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Bingham CO, 1999, P ASSOC AM PHYSICIAN, V111, P516, DOI 10.1046/j.1525-1381.1999.99321.x; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; BOWLER WB, 1995, J BONE MINER RES, V10, P1137; Burnstock G, 2000, J PHARMACOL EXP THER, V295, P862; CASWELL AM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P151, DOI 10.1016/0304-4165(91)90054-K; CASWELL AM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P52, DOI 10.1016/0167-4889(92)90099-W; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; Croucher LJ, 2000, BBA-MOL BASIS DIS, V1502, P297, DOI 10.1016/S0925-4439(00)00055-7; Dangelmaier C, 2000, EUR J BIOCHEM, V267, P2283, DOI 10.1046/j.1432-1327.2000.01235.x; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; Hedbom E, 2002, CELL MOL LIFE SCI, V59, P45, DOI 10.1007/s00018-002-8404-z; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hou MY, 2000, ARTERIOSCL THROM VAS, V20, P2064, DOI 10.1161/01.ATV.20.9.2064; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; John GR, 2001, J NEUROSCI, V21, P4134, DOI 10.1523/JNEUROSCI.21-12-04134.2001; John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613; Koolpe M, 1997, J ORTHOP RES, V15, P204, DOI 10.1002/jor.1100150208; Koolpe M, 1999, ARTHRITIS RHEUM, V42, P258, DOI 10.1002/1529-0131(199902)42:2<258::AID-ANR7>3.0.CO;2-O; Kumar Sanjay, 2001, Current Opinion in Pharmacology, V1, P307, DOI 10.1016/S1471-4892(01)00054-6; LEONG WS, 1994, BBA-GEN SUBJECTS, V1201, P298, DOI 10.1016/0304-4165(94)90054-X; LEONG WS, 1993, CLIN SCI, V85, P569, DOI 10.1042/cs0850569; Massaad C, 2000, J BIOL CHEM, V275, P22686, DOI 10.1074/jbc.M001250200; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Miwa M, 2000, OSTEOARTHR CARTILAGE, V8, P17, DOI 10.1053/joca.1999.0266; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Park W, 1996, J RHEUMATOL, V23, P665; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; PRUZANSKI W, 1995, J RHEUMATOL, V22, P2114; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; Ralevic V, 1998, PHARMACOL REV, V50, P413; RYAN LM, 1991, J RHEUMATOL, V18, P716; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; Troadec JD, 1998, J PHYSIOL-LONDON, V511, P89, DOI 10.1111/j.1469-7793.1998.089bi.x	45	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13680	13687		10.1074/jbc.M211570200	http://dx.doi.org/10.1074/jbc.M211570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12591927	hybrid			2022-12-25	WOS:000182405000017
J	Fujita, T; Maggio, A; Garcia-Rios, M; Stauffacher, C; Bressan, RA; Csonka, LN				Fujita, T; Maggio, A; Garcia-Rios, M; Stauffacher, C; Bressan, RA; Csonka, LN			Identification of regions of the tomato gamma-glutamyl kinase that are involved in allosteric regulation by proline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA(1)-PYRROLINE-5-CARBOXYLATE SYNTHETASE; ESCHERICHIA-COLI; OSMOTIC-STRESS; SALMONELLA-TYPHIMURIUM; ARABIDOPSIS-THALIANA; FEEDBACK INHIBITION; TRANSFERASE KINASE; PROB GENE; ENHANCED OSMOTOLERANCE; CARBAMOYL-PHOSPHATE	The first step of proline biosynthesis is catalyzed by gamma-glutamyl kinase (GK). To better understand the feedback inhibition properties of GK, we randomly mutagenized a plasmid carrying tomato tomPRO1 cDNA, which encodes proline-sensitive GK. A pool of mutagenized plasmids was transformed into an Escherichia coli GK mutant, and proline-overproducing derivatives were selected on minimal medium containing the toxic proline analog 3,4-dehydro-DL-proline. Thirty-two mutations that conferred 3,4-dehydro-DL-proline resistance were obtained. Thirteen different single amino acid substitutions were identified at nine different residues. The residues were distributed throughout the N-terminal two-thirds of the polypeptide, but 9 mutations affecting 6 residues were in a cluster of 16 residues. GK assays revealed that these amino acid substitutions caused varying degrees of diminished sensitivity to proline feedback inhibition and also resulted in a range of increased proline accumulation in vivo. GK belongs to a family of amino acid kinases, and a predicted three-dimensional model of this enzyme was constructed on the basis of the crystal structures of three related kinases. In the model, residues that were identified as important for allosteric control were located close to each other, suggesting that they may contribute to the structure of a proline binding site. The putative allosteric binding site partially overlaps the dimerization and substrate binding domains, suggesting that the allosteric regulation of GK may involve a direct structural interaction between the proline binding site and the dimerization and catalytic domains.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47906 USA; Purdue Univ, Dept Hort & Landscape Architecture, W Lafayette, IN 47906 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Csonka, LN (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47906 USA.	lcsonka@bilbo.bio.purdue.edu		Bressan, Ray/0000-0002-8754-606X				Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1988, GENE, V64, P199, DOI 10.1016/0378-1119(88)90335-6; CSONKA LN, 1988, J BACTERIOL, V170, P2374, DOI 10.1128/jb.170.5.2374-2378.1988; CSONKA LN, 1981, MOL GEN GENET, V182, P82, DOI 10.1007/BF00422771; CSONKA LN, 1983, AMINO ACIDS BIOSYNTH, P35; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; DANDEKAR AM, 1988, J BACTERIOL, V170, P5943, DOI 10.1128/jb.170.12.5943-5945.1988; Davis R., 1980, ADV BACTERIAL GENETI; DELAUNEY AJ, 1993, PLANT J, V4, P215, DOI 10.1046/j.1365-313X.1993.04020215.x; Fujita T, 1998, PLANT PHYSIOL, V118, P661, DOI 10.1104/pp.118.2.661; GarciaRios M, 1997, P NATL ACAD SCI USA, V94, P8249, DOI 10.1073/pnas.94.15.8249; Hong ZL, 2000, PLANT PHYSIOL, V122, P1129, DOI 10.1104/pp.122.4.1129; HU CAA, 1992, P NATL ACAD SCI USA, V89, P9354, DOI 10.1073/pnas.89.19.9354; Igarashi Y, 1997, PLANT MOL BIOL, V33, P857, DOI 10.1023/A:1005702408601; KISHOR PBK, 1995, PLANT PHYSIOL, V108, P1387, DOI 10.1104/pp.108.4.1387; Kosuge T, 1998, APPL ENVIRON MICROB, V64, P4328; KRISHNA RV, 1979, BIOCHEM J, V181, P215, DOI 10.1042/bj1810215; MAHAN MJ, 1983, J BACTERIOL, V156, P1249, DOI 10.1128/JB.156.3.1249-1262.1983; Marina A, 1999, PROTEIN SCI, V8, P934; Massarelli I, 2000, FEMS MICROBIOL LETT, V182, P143, DOI 10.1016/S0378-1097(99)00573-X; Nanjo T, 1999, PLANT J, V18, P185, DOI 10.1046/j.1365-313X.1999.00438.x; OMORI K, 1992, J GEN MICROBIOL, V138, P693, DOI 10.1099/00221287-138-4-693; OMORI K, 1991, J GEN MICROBIOL, V137, P507; Paleg L. G., 1981, PHYSL BIOCH DROUGHT; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Ramon-Maiques S, 2002, STRUCTURE, V10, P329, DOI 10.1016/S0969-2126(02)00721-9; RHODES D, 1986, PLANT PHYSIOL, V82, P890, DOI 10.1104/pp.82.4.890; Roosens NH, 1999, PLANT PHYSIOL, V121, P1281, DOI 10.1104/pp.121.4.1281; RUSHLOW KE, 1985, GENE, V39, P109, DOI 10.1016/0378-1119(85)90115-5; SAMARAS Y, 1995, ENV PLANT B, P161; Sambrook J., 2002, MOL CLONING LAB MANU; SAVOURE A, 1995, FEBS LETT, V372, P13, DOI 10.1016/0014-5793(95)00935-3; Sleator RD, 2001, APPL ENVIRON MICROB, V67, P4560, DOI 10.1128/AEM.67.10.4560-4565.2001; SMITH CJ, 1984, J BACTERIOL, V157, P545, DOI 10.1128/JB.157.2.545-551.1984; SMITH LT, 1985, J BACTERIOL, V164, P1088, DOI 10.1128/JB.164.3.1088-1093.1985; STEWART CR, 1981, BIOCH DROUG RESISTAN, P243; Stines AP, 1999, PLANT PHYSIOL, V120, P923, DOI 10.1104/pp.120.3.923; SZOKE A, 1992, PLANT PHYSIOL, V99, P1642, DOI 10.1104/pp.99.4.1642; TRISTRAM H, 1966, NATURE, V212, P74, DOI 10.1038/212074a0; YOSHIBA Y, 1995, PLANT J, V7, P751, DOI 10.1046/j.1365-313X.1995.07050751.x; ZHANG CS, 1995, J BIOL CHEM, V270, P20491, DOI 10.1074/jbc.270.35.20491; Zhou ZM, 2000, GENE, V243, P105, DOI 10.1016/S0378-1119(99)00552-1	45	35	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14203	14210		10.1074/jbc.M212177200	http://dx.doi.org/10.1074/jbc.M212177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566437	hybrid			2022-12-25	WOS:000182405000082
J	Sang, NL; Stiehl, DP; Bohensky, J; Leshchinsky, I; Srinivas, V; Caro, J				Sang, NL; Stiehl, DP; Bohensky, J; Leshchinsky, I; Srinivas, V; Caro, J			MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA HIF-1-ALPHA; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; HIF-ALPHA; DEGRADATION DOMAIN; STRUCTURAL BASIS; ACTIVATION; TRANSACTIVATION; VHL; COMPLEX	Hypoxia-inducible factors (HIF) are a family of heterodimeric transcriptional regulators that play pivotal roles in the regulation of cellular utilization of oxygen and glucose and are essential transcriptional regulators of angiogenesis in solid tumor and ischemic disorders. The transactivation activity of HIF complexes requires the recruitment of p300/CREB-binding protein (CBP) by HIF-1alpha and HIF-2alpha that undergo oxygen-dependent degradation. HIF activation in tumors is caused by several factors including mitogen-activated protein kinase (MAPK) signaling. Here we investigated the molecular basis for HIF activation by MAPK. We show that MAPK is required for the transactivation activity of HIF-1alpha. Furthermore, inhibition of MAPK disrupts the HIF-p300 interaction and suppresses the transactivation activity of p300. Overexpression of MEK1, an upstream MAPK activator, stimulates the transactivation of both p300 and HIF-1alpha. Interestingly, the C-terminal transactivation domain of HIF-1alpha is not a direct substrate of MAPK, and HIF-1alpha phosphorylation is not required for HIFCAD/p300 interaction. Taken together, our data suggest that MAPK signaling facilitates HIF activation through p300/CBP.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Physiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Caro, J (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Med, 1015 Walnut St,Curtis Bldg,Rm 809, Philadelphia, PA 19107 USA.	Jamie.caro@mail.tju.edu	Stiehl, Daniel/A-3622-2008	Stiehl, Daniel/0000-0002-0076-4874	NATIONAL CANCER INSTITUTE [R01CA089212, K01CA098809] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007821] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA098809, R01 CA089212, R01CA89212] Funding Source: Medline; NHLBI NIH HHS [T32-HL007821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fedele Anthony O, 2002, Mol Interv, V2, P229, DOI 10.1124/mi.2.4.229; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	55	271	289	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14013	14019		10.1074/jbc.M209702200	http://dx.doi.org/10.1074/jbc.M209702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12588875	Green Accepted, hybrid			2022-12-25	WOS:000182405000059
J	Shenoy, SK; Lefkowitz, RJ				Shenoy, SK; Lefkowitz, RJ			Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; UBIQUITIN; ENDOCYTOSIS; ACTIVATION; IDENTIFICATION; COMPLEXES; BINDING; PATHWAY; KINASES; SYSTEM	Agonist-dependent internalization of G protein-coupled receptors via clathrin-coated pits is dependent on the adaptor protein beta-arrestin, which interacts with elements of the endocytic machinery such as AP2 and clathrin. For the beta(2)-adrenergic receptor (beta(2)AR) this requires ubiquitination of beta-arrestin by E3 ubiquitin ligase, Mdm2. Based on trafficking patterns and affinity of beta-arrestin, G protein-coupled receptors are categorized into two classes. For class A receptors (e.g. beta(2)AR), which recycle rapidly, beta-arrestin directs the receptors to clathrin-coated pits but does not internalize with them. For class B receptors (e.g. V2 vasopressin receptors), which recycle slowly, beta-arrestin internalizes with the receptor into endosomes. In COS-7 and human embryonic kidney (HEK)-293 cells, stimulation of the beta(2)AR or V2 vasopressin receptor leads, respectively, to transient or stable beta-arrestin ubiquitination. The time course of ubiquitination and deubiquitination of beta-arrestin correlates with its association with and dissociation from each type of receptor. Chimeric receptors, constructed by switching the cytoplasmic tails of the two classes of receptors (beta(2)AR and V2 vasopressin receptors), demonstrate reversal of the patterns of both beta-arrestin trafficking and beta-arrestin ubiquitination. To explore the functional consequences of beta-arrestin ubiquitination we constructed a yellow fluorescent protein-tagged beta-arrestin2-ubiquitin chimera that cannot be deubiquitinated by cellular deubiquitinases. This "permanently ubiquitinated" beta-arrestin did not dissociate from the beta(2)AR but rather internalized with it into endosomes, thus transforming this class A receptor into a class B receptor with respect to its trafficking pattern. Overexpression of this beta-arrestin ubiquitin chimera in HEK-293 cells also results in enhancement of beta(2)AR internalization and degradation. In the presence of N-ethylmaleimide (an inhibitor of deubiquitinating enzymes), coimmunoprecipitation of the receptor and beta-arrestin was increased dramatically, suggesting that deubiquitination of beta-arrestin triggers its dissociation from the receptor. Thus the ubiquitination status of beta-arrestin determines the stability of the receptor-beta-arrestin complex as well as the trafficking pattern of beta-arrestin.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Box 3821,Rm 467,CARL Bldg, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	26	194	198	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14498	14506		10.1074/jbc.M209626200	http://dx.doi.org/10.1074/jbc.M209626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574160	hybrid			2022-12-25	WOS:000182405000117
J	Takagi, T; Walker, AK; Sawa, C; Diehn, F; Takase, Y; Blackwell, TK; Buratowski, S				Takagi, T; Walker, AK; Sawa, C; Diehn, F; Takase, Y; Blackwell, TK; Buratowski, S			The Caenorhabditis elegans mRNA 5 '-capping enzyme - In vitro and in vivo characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CAPPING ENZYME; CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSITION-STATE; P-TEFB; PROTEIN; GUANYLYLTRANSFERASE; TRANSCRIPTION; PHOSPHATASE	Eukaryotic mRNA capping enzymes are bifunctional, carrying both RNA triphosphatase (RTPase) and guanylyltransferase (GTase) activities. The Caenorhabditis elegans CEL-1 capping enzyme consists of an N-terminal region with RTPase activity and a C-terminal region that resembles known GTases, However, CEL-1 has not previously been shown to have GTase activity. Cloning of the cel-1 cDNA shows that the full-length protein has 623 amino acids, including an additional 38 residues at the C termini and 12 residues at the N termini not originally predicted from the genomic sequence. Full-length CEL-1 has RTPase and GTase activities, and the cDNA can functionally replace the capping enzyme genes in Saccharomyces cerevisiae. The CEL-1 RTPase domain is related by sequence to protein-tyrosine phosphatases; therefore, mutagenesis of residues predicted to be important for RTPase activity was carried out. CEL-1 uses a mechanism similar to protein-tyrosine phosphatases, except that there was not an absolute requirement for a conserved acidic residue that acts as a proton donor. CEL-1 shows a strong preference for RNA substrates of at least three nucleotides in length. RNA-mediated interference in C. elegans embryos shows that lack of CEL-1 causes development to arrest with a phenotype similar to that seen when RNA polymerase 11 elongation activity is disrupted. Therefore, capping is essential for gene expression in metazoans.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	steveb@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056663, R01GM062891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56663, GM62891, R01 GM062891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1991, Methods Enzymol, V194, P1; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bellier S, 1997, EMBO J, V16, P6250, DOI 10.1093/emboj/16.20.6250; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Deshpande T, 1999, J BIOL CHEM, V274, P16590, DOI 10.1074/jbc.274.23.16590; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hausmann S, 2001, J BIOL CHEM, V276, P36116, DOI 10.1074/jbc.M105856200; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ichetovkin IE, 1997, J BIOL CHEM, V272, P33009, DOI 10.1074/jbc.272.52.33009; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3930; JOVE R, 1984, J BIOL CHEM, V259, P8513; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kusakabe T, 1997, J BIOL CHEM, V272, P5943, DOI 10.1074/jbc.272.9.5943; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Martins A, 2000, J BIOL CHEM, V275, P35070, DOI 10.1074/jbc.M005748200; Matsuo H, 2000, J AM CHEM SOC, V122, P2417, DOI 10.1021/ja9926820; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P1693, DOI 10.1073/pnas.79.6.1693; Mukhopadhyay R, 2001, J BIOL CHEM, V276, P34738, DOI 10.1074/jbc.M103354200; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Seydoux G, 1997, DEVELOPMENT, V124, P2191; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; Shim EY, 2002, J BIOL CHEM, V277, P30413, DOI 10.1074/jbc.C200305200; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 2002, EUKARYOT CELL, V1, P448, DOI 10.1128/EC.1.3.448-457.2002; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Takase Y, 2000, MOL CELL BIOL, V20, P9307, DOI 10.1128/MCB.20.24.9307-9316.2000; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; VENKATESAN S, 1980, J BIOL CHEM, V255, P2835; Victor M, 2002, EMBO REP, V3, P50, DOI 10.1093/embo-reports/kvf006; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Walker AK, 2001, EMBO J, V20, P5269, DOI 10.1093/emboj/20.18.5269; WANG D, 1982, MOL CELL BIOL, V2, P993, DOI 10.1128/MCB.2.8.993; WANG DH, 1984, NUCLEIC ACIDS RES, V12, P2303, DOI 10.1093/nar/12.5.2303; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yokoska J, 2000, BIOCHEM BIOPH RES CO, V268, P617, DOI 10.1006/bbrc.2000.2188; Yuan Y, 1998, J BIOL CHEM, V273, P20347, DOI 10.1074/jbc.273.32.20347; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	84	19	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14174	14184		10.1074/jbc.M212101200	http://dx.doi.org/10.1074/jbc.M212101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576476	hybrid			2022-12-25	WOS:000182405000079
J	Yi, XW; Conesa, A; Punt, PJ; Hager, LP				Yi, XW; Conesa, A; Punt, PJ; Hager, LP			Examining the role of glutamic acid 183 in chloroperoxidase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALDARIOMYCES-FUMAGO CHLOROPEROXIDASE; ENANTIOSELECTIVE EPOXIDATION; BIOLOGICAL CHLORINATION; COMPOUND-I; OXIDATIONS; MECHANISM; BIOSYNTHESIS; PEROXIDASES; RESONANCE; ALKENES	Site-directed mutagenesis has been used to investigate the role of glutamic acid 183 in chloroperoxidase catalysis. Based on the x-ray crystallographic structure of chloroperoxidase, Glu-183 is postulated to function on distal side of the heme prosthetic group as an acid-base catalyst in facilitating the reaction between the peroxidase and hydrogen peroxide with the formation of Compound I. In contrast, the other members of the heme peroxidase family use a histidine residue in this role. Plasmids have now been constructed in which the codon for Glu-183 is replaced with a histidine codon. The mutant recombinant gene has been expressed in Aspergillus niger. An analysis of the produced mutant gene shows that the substitution of Glu-183 with a His residue is detrimental to the chlorination and dismutation activity of chloroperoxidase. The activity is reduced by 85 and 50% of wild type activity, respectively. However, quite unexpectedly, the epoxidation activity of the mutant enzyme is significantly enhanced similar to2.5-fold. These results show that Glu-183 is important but not essential for the chlorination activity of chloroperoxidase. It is possible that the increased epoxidation of the mutant enzyme is based on an increase in the hydrophobicity of the active site.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; TNO, Nutr & Food Res Inst, NL-3704 HE Zeist, Netherlands	University of Illinois System; University of Illinois Urbana-Champaign; Netherlands Organization Applied Science Research	Hager, LP (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	l-hager@uiuc.edu	punt, peter/AAI-8180-2020; Cegarra, Ana V Conesa/A-9559-2014; moreno manzano, Victoria/B-4175-2014	punt, peter/0000-0002-5689-9938; Cegarra, Ana V Conesa/0000-0001-9597-311X; moreno manzano, Victoria/0000-0002-6035-9491; , Xianwen/0000-0001-9320-2020	NIGMS NIH HHS [GM 07768] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADES IZ, 1987, ARCH BIOCHEM BIOPHYS, V253, P297, DOI 10.1016/0003-9861(87)90182-2; ALLAIN EJ, 1993, J AM CHEM SOC, V115, P4415, DOI 10.1021/ja00063a091; ALVAREZ JC, 1992, BIOCHEMISTRY-US, V31, P8315, DOI 10.1021/bi00150a027; ARAISO T, 1981, CAN J BIOCHEM CELL B, V59, P233, DOI 10.1139/o81-031; BECKWITH JR, 1963, J BIOL CHEM, V238, P3091; BECKWITH JR, 1963, J BIOL CHEM, V238, P3086; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; Clutterbuck PW, 1940, BIOCHEM J, V34, P664, DOI 10.1042/bj0340664; COLONNA S, 1990, BIOCHEMISTRY-US, V29, P10465, DOI 10.1021/bi00498a006; Conesa A, 2000, APPL ENVIRON MICROB, V66, P3016, DOI 10.1128/AEM.66.7.3016-3023.2000; Conesa A, 2001, J BIOL CHEM, V276, P17635, DOI 10.1074/jbc.M010571200; Conesa A, 2001, FEBS LETT, V503, P117, DOI 10.1016/S0014-5793(01)02698-9; CORBETT MD, 1970, BIOCHEM J, V183, P269; Debrunner PG, 1996, P NATL ACAD SCI USA, V93, P12791, DOI 10.1073/pnas.93.23.12791; DEEB SS, 1964, J BIOL CHEM, V239, P1024; DEXTER AF, 1995, J AM CHEM SOC, V117, P817, DOI 10.1021/ja00107a026; DOERGE DR, 1986, ARCH BIOCHEM BIOPHYS, V244, P678, DOI 10.1016/0003-9861(86)90636-3; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HAGER LP, 1973, OXIDASES RELATED RED, V1, P311; Herbaud ML, 2000, BBA-PROTEIN STRUCT M, V1481, P18, DOI 10.1016/S0167-4838(00)00117-5; HEWSON WD, 1980, J PHYCOL, V16, P340; HOLLENBERG PF, 1992, FASEB J, V6, P686, DOI 10.1096/fasebj.6.2.1537457; Hu SH, 1998, BIOCHEM BIOPH RES CO, V253, P544, DOI 10.1006/bbrc.1998.9721; Hu SH, 1999, J AM CHEM SOC, V121, P872, DOI 10.1021/ja983612g; HUTNER S. H., 1950, PROC AMER PHIL SOC, V94, P152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakner FJ, 1996, J ORG CHEM, V61, P3923, DOI 10.1021/jo960074m; Lakner FJ, 1997, J AM CHEM SOC, V119, P443, DOI 10.1021/ja962998x; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLER VP, 1995, ARCH BIOCHEM BIOPHYS, V319, P333, DOI 10.1006/abbi.1995.1302; MORRIS DR, 1966, J BIOL CHEM, V241, P1763; POULOS TL, 1980, J BIOL CHEM, V255, P322; Rai GP, 2001, ADV SYNTH CATAL, V343, P638, DOI 10.1002/1615-4169(200108)343:6/7<638::AID-ADSC638>3.0.CO;2-6; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER RJ, 1999, J BIOL CHEM, V257, P7958; SHAW PD, 1961, J BIOL CHEM, V236, P1626; SUNDARAMOORTHY M, 1995, ACTA CRYSTALLOGR D, V51, P842, DOI 10.1107/S0907444995001144; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Tanaka M, 1997, BIOCHEMISTRY-US, V36, P9889, DOI 10.1021/bi970906q; THOMAS JA, 1970, J BIOL CHEM, V245, P3135; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; THOMAS JA, 1969, BIOCHEM BIOPH RES CO, V35, P444, DOI 10.1016/0006-291X(69)90365-9; vanDeurzen MPJ, 1996, J MOL CATAL B-ENZYM, V2, P33, DOI 10.1016/1381-1177(96)00008-2; Yi XW, 1999, P NATL ACAD SCI USA, V96, P12412, DOI 10.1073/pnas.96.22.12412; ZAKS A, 1995, J AM CHEM SOC, V117, P10419, DOI 10.1021/ja00147a001; ZONG Q, 1995, BIOCHEMISTRY-US, V34, P12420, DOI 10.1021/bi00038a040; ZONG Q, 1997, THESIS U ILLINOIS	48	41	43	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13855	13859		10.1074/jbc.M210906200	http://dx.doi.org/10.1074/jbc.M210906200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576477	hybrid, Green Published			2022-12-25	WOS:000182405000038
J	Ochiai, Y; Tamura, Y; Saito, Y; Matsuki, A; Wakabayashi, Y; Aizawa, Y; Niwa, O; Kominami, R				Ochiai, Y; Tamura, Y; Saito, Y; Matsuki, A; Wakabayashi, Y; Aizawa, Y; Niwa, O; Kominami, R			Mapping of genetic modifiers of thymic lymphoma development in p53-knockout mice	ONCOGENE			English	Article						p53 modifier; genetic mapping; thymic lymphoma; skin cancer; consomic mouse	TUMOR-SUPPRESSOR GENE; INTESTINAL NEOPLASIA; P53-DEFICIENT MICE; P53 MUTATIONS; CANCER; TUMORIGENESIS; SUSCEPTIBILITY; RESISTANCE; CANDIDATE; HOMOLOG	The strain dependency of the spectrum and latency of tumors has been reported in p53-deficient (KO) mice, suggesting the presence of modifiers for the outcome of the p53 deficiency. The modifiers provide clues to the oncogenic pathway in cells lacking p53, the most frequently mutated gene in a wide variety of human cancers. To search the modifiers, we induced 160 lymphomas and 69 skin tumors by gamma-irradiation of p53(KO/+) backcross mice between BALB/c and MSM strains and performed genome scan. BALB/c-derived alleles at three loci on chromosome 19, Mp53D1 (modifier of p53-deficiency) at D19Mit5, Mp53D2 at D19Mit90 and Mp53D3 at D19MW23, extended the latency of thymic lymphoma development (P values in Mantel-Cox test were 0.0007, 0.0007 and 0.0003, respectively). Mp53D3 also increased the latency of skin tumors (P value, 0.0008). The linkage of Mp53D2 was confirmed by the experiment using 94 p53-KO mice consomic for chromosome 19, providing a significant linkage. However, the linkage was not confirmed for Mp53D1 or Mp53D3, suggesting epistasis of genes involved in the tumorigenesis.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Gene Regulat, Niigata 9518122, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Cardiovasc & Vital Control, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Gene Regulat, Asahimachi Doori 1-757, Niigata 9518122, Japan.							Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Demant P, 1992, Semin Cancer Biol, V3, P159; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Miyazawa T, 2002, JPN J CANCER RES, V93, P994, DOI 10.1111/j.1349-7006.2002.tb02475.x; Mori N, 1999, ONCOGENE, V18, P4282, DOI 10.1038/sj.onc.1202719; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	30	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1098	1102		10.1038/sj.onc.1206202	http://dx.doi.org/10.1038/sj.onc.1206202			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592396				2022-12-25	WOS:000180926100015
J	Bougeard, G; Brugieres, L; Chompret, A; Gesta, P; Charbonnier, F; Valent, A; Martin, C; Raux, G; Feunteun, J; Bressac-de Paillerets, B; Frebourg, T				Bougeard, G; Brugieres, L; Chompret, A; Gesta, P; Charbonnier, F; Valent, A; Martin, C; Raux, G; Feunteun, J; Bressac-de Paillerets, B; Frebourg, T			Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene	ONCOGENE			English	Article						TP53; Li-Fraumeni syndrome; deletion; PCR	GERMLINE MUTATION; HCHK2 MUTATIONS; P53; PTEN	The absence of detectable germline TP53 mutations in a fraction of families with Li-Fraumeni syndrome (LFS) has suggested the involvement of other genes, but this hypothesis remains controversial. The density of Alu repeats within the TP53 gene led us to search genomic rearrangements of TP53 in families without detectable TP53 mutation. To this aim, we adapted the quantitative multiplex PCR of short fluorescent fragments (QMPSF) method to the analysis of the 11 exons of TP53. We analysed 98 families, either fulfilling (six families) or partially meeting (92 families) the criteria for LFS, and in which classical methods had failed to reveal TP53 alterations. We identified, in a large family fulfilling the criteria for LITS, a complete heterozygous deletion of TP53. Additional QMPSF analyses indicated that this deletion, which partially removed the centromeric FLJ10385 locus, covered approximately 45 kb. This deletion was shown to result from a complex rearrangement involving two distinct Alu-mediated recombinations. We conclude that TP53 germline rearrangements occur as rare events, but must be considered in LFS families without detectable point TP53 mutation.	IFRMP, Fac Med, INSERM, EMI 9906, F-76183 Rouen, France; Inst Gustave Roussy, Dept Pediat, F-94805 Villejuif, France; Ctr Hosp, F-79021 Niort, France; CHU Rouen, Dept Genet, Rouen, France; Inst Gustave Roussy, Dept Cellular Genom Canc, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Dept Biol Clin, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; CHU de Rouen; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Frebourg, T (corresponding author), IFRMP, Fac Med, INSERM, EMI 9906, F-76183 Rouen, France.		Paillerets, Brigitte Bressac-de/D-8954-2018; Frebourg, Thierry/AAK-8390-2020; BOUGEARD, Gaëlle/ABI-6642-2020; Feunteun, Jean/AAZ-1267-2020	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; BOUGEARD, Gaëlle/0000-0002-1475-0254; CHARBONNIER, Francoise/0000-0002-4875-2506; Feunteun, Jean/0000-0003-1212-9189				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; BELL DW, 2000, SCIENCE, V289, P359; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1994, CANCER RES, V54, P1298; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Brown LTR, 2000, CANCER GENET CYTOGEN, V123, P65, DOI 10.1016/S0165-4608(00)00303-4; Burt EC, 1999, BRIT J CANCER, V80, P9, DOI 10.1038/sj.bjc.6690313; Charbonnier F, 2000, CANCER RES, V60, P2760; Charbonnier F, 2002, CANCER RES, V62, P848; Chompret A, 2002, BIOCHIMIE, V84, P75, DOI 10.1016/S0300-9084(01)01361-X; Chompret A, 2001, J MED GENET, V38, P43, DOI 10.1136/jmg.38.1.43; Eeles RA, 1995, CANCER SURV, V25, P101; LI FP, 1988, CANCER RES, V48, P5358; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; Portwine C, 2000, J Med Genet, V37, pE13, DOI 10.1136/jmg.37.8.e13; Slebos RJC, 1998, CANCER RES, V58, P5333; Sodha N, 2000, Science, V289, P359; Stone JG, 1999, CANCER LETT, V147, P181, DOI 10.1016/S0304-3835(99)00291-8; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328	23	47	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					840	846		10.1038/sj.onc.1206155	http://dx.doi.org/10.1038/sj.onc.1206155			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584563				2022-12-25	WOS:000180864300006
J	Miyake, S; Yanagisawa, Y; Yuasa, Y				Miyake, S; Yanagisawa, Y; Yuasa, Y			A novel EID-1 family member, EID-2, associates with histone deacetylases and inhibits muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSCRIPTIONAL ACTIVITY; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; CELL-GROWTH; BINDING; MYOD; REPRESSES; HDAC4; CYCLE	An EID-1 ((E) under bar 1A-like (i) under bar nhibitor of (d) under bar ifferentiation-(1) under bar) inhibits differentiation by blocking the histone acetyltransferase activity of p300. Here we report a novel inhibitor of differentiation exhibiting homology to EID-1, termed EID-2 ((E) under bar ID-1- like (i) under bar nhibitor of (d) under bar ifferentiation-(2) under bar). EID-2 inhibited MyoD-dependent transcription and muscle differentiation. Unlike EID-1, EID-2 did not block p300 activity. Interestingly, EID-2 associated with class I histone deacetylases (HDACs). The N-terminal portion of EID-2 was required for the binding to HDACs. This region was also involved in the transcriptional repression and nuclear localization, suggesting the importance of the involvement of HDACs in the EID-2 function. These results indicate a new family of differentiation inhibitors, although there are several differences in the biochemical mechanisms between EID-2 and EID-1.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miyake, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Bavner A, 2002, EMBO REP, V3, P478, DOI 10.1093/embo-reports/kvf087; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; MARUYAMA K, 1994, GENE, V138, P171; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Norton JD, 2000, J CELL SCI, V113, P3897; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Rescan PY, 2001, COMP BIOCHEM PHYS B, V130, P1, DOI 10.1016/S1096-4959(01)00412-2; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wen H, 2001, GENE, V263, P85, DOI 10.1016/S0378-1119(00)00585-0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	27	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17060	17065		10.1074/jbc.M212212200	http://dx.doi.org/10.1074/jbc.M212212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12586827	hybrid			2022-12-25	WOS:000182818600083
J	Choe, JY; Nelson, SW; Fromm, HJ; Honzatko, RB				Choe, JY; Nelson, SW; Fromm, HJ; Honzatko, RB			Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 2,6-BISPHOSPHATE; RECOMBINANT PORCINE; DYNAMIC LOOP; LIVER FRUCTOSE-1,6-BISPHOSPHATASE; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; NEUTRAL FORM; MECHANISM; AMP; CATALYSIS	Fructose-1,6-bisphosphatase requires divalent cations (Mg2+, Mn2+, or Zn2+) for catalysis, but a diverse set of monovalent cations (K+, Tl+, Rb+, or NH4+) will further enhance enzyme activity. Here, the interaction of Tl+ with fructose-1,6-bisphosphatase is explored under conditions that support catalysis. On the basis of initial velocity kinetics, TV enhances catalysis by 20% with a K-alpha of 1.3 mM and a Hill coefficient near unity. Crystal structures of enzyme complexes with Mg2+, Tl+, and reaction products, in which the concentration of Tl+ is 1 mm or less, reveal Mg2+ at metal sites 1, 2, and 3 of the active site, but little or no bound Tl+. Intermediate concentrations of Tl+ (5-20 mm) displace Mg2+ from site 3 and the 1-OH group of fructose 6-phosphate from in-line geometry with respect to bound orthophosphate. Loop 52-72 appears in a new conformational state, differing from its engaged conformation by disorder in residues 61-69. Tl+ does not bind to metal sites 1 or 2 in the presence of Mg2+, but does bind to four other sites with partial occupancy. Two of four Tl+ sites probably represent alternative binding sites for the site 3 catalytic Mg2+, whereas the other sites could play roles in monovalent cation activation.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS HA, 1963, ADV ENZYME REGUL, V1, P385; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LEE AG, 1971, CHEM THALLIUM; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MARCUS F, 1980, J BIOL CHEM, V255, P2481; MARCUS F, 1981, REGULATION CARBOHYDR, P269; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Nelson SW, 2000, J BIOL CHEM, V275, P29986, DOI 10.1074/jbc.M000473200; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; *RIG MOL STRUCT CO, 2001, CRYST RIG MOL STRUCT; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; SOLA MM, 1993, INT J BIOCHEM, V25, P1963, DOI 10.1016/0020-711X(88)90332-1; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	44	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16008	16014		10.1074/jbc.M212394200	http://dx.doi.org/10.1074/jbc.M212394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595529	Green Published, hybrid			2022-12-25	WOS:000182680000071
J	Esposti, MD; Ferry, G; Masdehors, P; Boutin, JA; Hickman, JA; Dive, C				Esposti, MD; Ferry, G; Masdehors, P; Boutin, JA; Hickman, JA; Dive, C			Post-translational modification of bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DRUG-INDUCED APOPTOSIS; KAPPA-B-ALPHA; PROTEIN-KINASE; DEATH RECEPTOR; IN-VITRO; MITOCHONDRIAL-MEMBRANE; INTERACTING PROTEIN; T-CELLS; PHOSPHORYLATION	Bid is instrumental in death receptor-mediated apoptosis where it is cleaved by caspase 8 at aspartate 60 and aspartate 75 to generate truncated Bid (tBID) forms that facilitate release of mitochondrial cytochrome c. Bid is also cleaved at these sites by caspase 3 that is activated downstream of cytochrome c release after diverse apoptotic stimuli. In this context, tBid may amplify the apoptotic process. Bid is phosphorylated in vitro by casein kinases that regulate its cleavage by caspase 8 (Desagher, S., Osen-Sand, A., Montessuit, S., Magnenat, E., Vilbois, F., Hochmann, A., Journot, L. Antonsson, A., and Martinou, J.-C. (2001) Mol. Cell 8, 601-611). Using a Bid decapeptide substrate, we observed that phosphorylation at threonine 59 inhibited cleavage by caspase 8. This was also seen when recombinant Bid (rBid) and Bid isolated from murine kidney were incubated with casein kinase II. However, there were differences in the susceptibility of rBid and isolated Bid to cleavage by caspases 3 and 8. Caspase 8 cleaved rBid to generate two C-terminal products, p15 and p13 tBid, but produced only p15 tBid from isolated Bid. Contrary to rBid, isolated Bid was resistant to cleavage by caspase 3, yet was readily cleaved within the cytosolic milieu. Our data suggest that one or more distinct cellular mechanisms regulate Bid cleavage by caspases 8 and 3 in situ.	Univ Manchester, Sch Biol Sci, Canc Res UK Cellular & Mol Pharmacol Grp, Manchester M13 9PT, Lancs, England; Inst Rech Servier, F-78290 Croissy sur Seine, France	University of Manchester; Servier; Institut de Recherches Internationales Servier	Dive, C (corresponding author), Univ Manchester, Sch Biol Sci, Canc Res UK Cellular & Mol Pharmacol Grp, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cdive@man.ac.uk	Degli Esposti, Mauro/C-3270-2012; Boutin, Jean Albert/W-9103-2019	Boutin, Jean Albert/0000-0003-0068-7204; Dive, Caroline/0000-0002-1726-8850; Degli Esposti, Mauro/0000-0002-0977-119X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; DEGLIESPOSTI M, 2001, MOL CELL BIOL, V21, P7268; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Ravi R, 2002, CANCER RES, V62, P4180; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Taylor JA, 1999, J MOL BIOL, V290, P839, DOI 10.1006/jmbi.1999.2912; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu K, 2001, BRIT J CANCER, V84, P670, DOI 10.1054/bjoc.2000.1636; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhuang SG, 2001, ONCOGENE, V20, P6764, DOI 10.1038/sj.onc.1204867	44	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15749	15757		10.1074/jbc.M209208200	http://dx.doi.org/10.1074/jbc.M209208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598529	hybrid			2022-12-25	WOS:000182680000038
J	Shah, OJ; Ghosh, S; Hunter, T				Shah, OJ; Ghosh, S; Hunter, T			Mitotic regulation of ribosomal S6 kinase 1 involves Ser/Thr, Pro phosphorylation of consensus and non-consensus sites by Cdc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; CELL-CYCLE; IN-VIVO; RAPAMYCIN; ACTIVATION; P70(S6K); INHIBITION; MITOSIS; CANCER; PDK1	During mitosis, the cyclin-dependent kinase, Cdc2, signals the inactivation of major anabolic processes such as transcription, mRNA processing, translation, and ribosome biogenesis, thereby providing energy needed for the radical and energetically costly structural reorganization of the cell. This is accomplished by phosphorylation and inactivation of several key anabolic elements, including TFIIIB, TFIID, RNA polymerase 11, poly(A) polymerase, and translation elongation factor 1gamma. We report here that ribosomal S6 kinase I (S6K1), a protein kinase linked to the translation of ribosomal protein mRNAs, is also subject to regulation by Cdc2 in mitosis. In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424). Concomitant with this, the phosphorylation of the hydrophobic motif site, Thr(389), is reduced resulting in a decrease in the specific activity of S6K1. The mitotic S/TP phosphorylation sites are readily phosphorylated by Cdc2-cyclin B in vitro. These proline-directed phosphorylations are sensitive to chemical inhibitors of Cdc2 but not to inhibitors of mammalian target of rapamycin, phosphatidylinositol 3-kinase, MEK1/2, or p38. In murine FT210 cells arrested in mitosis, conditional inactivation of Cdc2 reduces phosphorylation of S6K1 at S/TP sites while simultaneously increasing phosphorylation of Thr(389). and of the S6K1 substrate, RPS6. A physical interaction exists between Cdc2 and S6K1, and this interaction is enhanced in mitotic cells. These results suggest that Cdc2 provides a signal that triggers inactivation of S6K1 in mitosis, presumably serving to spare energy for costly mitotic processes at the expense of ribosomal protein synthesis.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu		Ghosh, Sourav/0000-0001-5990-8708	NATIONAL CANCER INSTITUTE [P30CA014195, R01CA082683, T32CA009523] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 82683, T32 CA 09523-18] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; CORMIER P, 1991, NUCLEIC ACIDS RES, V19, P6644, DOI 10.1093/nar/19.23.6644; Couch FJ, 1999, CANCER RES, V59, P1408; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Derenzini M, 2000, J PATHOL, V191, P181, DOI 10.1002/(SICI)1096-9896(200006)191:2<181::AID-PATH607>3.0.CO;2-V; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; EREMENKO T, 1975, EUR J BIOCHEM, V52, P203, DOI 10.1111/j.1432-1033.1975.tb03988.x; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nigg E A, 1991, Semin Cell Biol, V2, P261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2000, BIOCHEM J, V347, P389, DOI 10.1042/0264-6021:3470389; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STEWARD DL, 1968, SCIENCE, V161, P791, DOI 10.1126/science.161.3843.791; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sugiyama H, 1997, ONCOGENE, V15, P443, DOI 10.1038/sj.onc.1201207; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wong AST, 2001, GYNECOL ONCOL, V82, P305, DOI 10.1006/gyno.2001.6280; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	65	55	55	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16433	16442		10.1074/jbc.M300435200	http://dx.doi.org/10.1074/jbc.M300435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586835	hybrid			2022-12-25	WOS:000182680000123
J	Small, D; Kovalenko, D; Soldi, R; Mandinova, A; Kolev, V; Trifonova, R; Bagala, C; Kacer, D; Battelli, C; Liaw, L; Prudovsky, I; Maciag, T				Small, D; Kovalenko, D; Soldi, R; Mandinova, A; Kolev, V; Trifonova, R; Bagala, C; Kacer, D; Battelli, C; Liaw, L; Prudovsky, I; Maciag, T			Notch activation suppresses fibroblast growth factor-dependent cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; INTRACELLULAR DOMAIN; ALAGILLE-SYNDROME; DROSOPHILA NOTCH; MAMMALIAN NOTCH; SECRETED FORMS; CYCLE ARREST; CANCER CELLS; STEM-CELLS; DIFFERENTIATION	Aberrant activations of the Notch and fibroblast growth factor receptor (FGFR) signaling pathways have been correlated with neoplastic growth in humans and other mammals. Here we report that the suppression of Notch signaling in NIH 3T3 cells by the expression of either the extracellular domain of the Notch ligand Jagged1 or dominant-negative forms of Notch1 and Notch2 results in the appearance of an exaggerated fibroblast growth factor (FGF)-dependent transformed phenotype characterized by anchorage-independent growth in soft agar. Anchorage-independent growth exhibited by Notch-repressed NIH 3T3 cells may result from prolonged FGFR stimulation caused by both an increase in the expression of prototypic and oneogenic FGF gene family members and the nonclassical export of FGF1 into the extracellular compartment. Interestingly, FGF exerts a negative effect on Notch by suppressing CSL (CBF-1/RBP-Jk/KBF2 in mammals, Su(H) in Drosophila and Xenopus, and Lag-2 in Caenorhabditis elegans)-dependent transcription, and the ectopic expression of constitutively active forms of Notch1 or Notch2 abrogates FGF1 release and the phenotypic effects of FGFR stimulation. These data suggest that communication between the Notch and FGFR pathways may represent an important reciprocal autoregulatory mechanism for the regulation of normal cell growth.	Maine Med Ctr, Inst Res, Ctr Mol Med, Scarborough, ME 04074 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Inst Res, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	maciat@mmc.org	Bagalà, Cinzia/AAB-8981-2019; Prudovsky, Igor/GVU-1521-2022		NCI NIH HHS [CA 92255] Funding Source: Medline; NCRR NIH HHS [RR 15555] Funding Source: Medline; NHLBI NIH HHS [HL 32348, HL 35627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA092255] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbass SAA, 1997, J CLIN ENDOCR METAB, V82, P1160, DOI 10.1210/jc.82.4.1160; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bongarzone ER, 2000, J NEUROSCI RES, V62, P319, DOI 10.1002/1097-4547(20001101)62:3<319::AID-JNR1>3.0.CO;2-G; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Faux CH, 2001, J NEUROSCI, V21, P5587, DOI 10.1523/JNEUROSCI.21-15-05587.2001; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Harada H, 1999, J CELL BIOL, V147, P105, DOI 10.1083/jcb.147.1.105; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Ikeya T, 1999, DEVELOPMENT, V126, P4455; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAING R, 1998, GENE DEV, V12, P1046; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Krebs LT, 2000, GENE DEV, V14, P1343; Landriscina M, 2001, J BIOL CHEM, V276, P25549, DOI 10.1074/jbc.M102925200; Landriscina M, 2001, J BIOL CHEM, V276, P22544, DOI 10.1074/jbc.M100546200; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mustonen T, 2002, DEV BIOL, V248, P281, DOI 10.1006/dbio.2002.0734; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ozawa K, 1998, J BIOL CHEM, V273, P29262, DOI 10.1074/jbc.273.44.29262; Panek RL, 1998, J PHARMACOL EXP THER, V286, P569; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shawber C, 1996, DEVELOPMENT, V122, P3765; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Shutter JR, 2000, GENE DEV, V14, P1313; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Spinner NB, 2001, HUM MUTAT, V17, P18, DOI 10.1002/1098-1004(2001)17:1<18::AID-HUMU3>3.0.CO;2-T; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sun X, 1997, DEVELOPMENT, V124, P3439; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Wong MKK, 2000, BIOCHEM BIOPH RES CO, V268, P853, DOI 10.1006/bbrc.2000.2173; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	73	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16405	16413		10.1074/jbc.M300464200	http://dx.doi.org/10.1074/jbc.M300464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598523	hybrid			2022-12-25	WOS:000182680000120
J	Wissmann, R; Bildl, W; Oliver, D; Beyermann, M; Kalbitzer, HR; Bentrop, D; Fakler, B				Wissmann, R; Bildl, W; Oliver, D; Beyermann, M; Kalbitzer, HR; Bentrop, D; Fakler, B			Solution structure and function of the "Tandem inactivation domain" of the neuronal A-type potassium channel Kv1.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNELS; NMR STRUCTURE; COUPLING-CONSTANTS; BACKBONE DYNAMICS; BETA-SUBUNIT; MECHANISMS; PROTEIN; GATE; HIPPOCAMPUS; PORE	Cumulative inactivation of voltage-gated (Kv) K+ channels shapes the presynaptic action potential and determines timing and strength of synaptic transmission. Kv1.4 channels exhibit rapid "ball-and-chain"-type inactivation gating. Different from all other Kvalpha subunits, Kv1.4 harbors two inactivation domains at its N terminus. Here we report the solution structure and function of this "tandem inactivation domain" using NMR spectroscopy and patch clamp recordings. Inactivation domain I (ID1, residues 1-38) consists of a flexible N terminus anchored at a 5-turn helix, whereas ID2 (residues 40-50) is a 2.5-turn helix made up of small hydrophobic amino acids. Functional analysis suggests that only ID1 may work as a pore-occluding ball domain, whereas ID2 most likely acts as a "docking domain" that attaches ID1 to the cytoplasmic face of the channel. Deletion of ID2 slows inactivation considerably and largely impairs cumulative inactivation. Together, the concerted action of ID1 and ID2 may promote rapid inactivation of Kv1.4 that is crucial for the channel function in short term plasticity.	Univ Freiburg, Dept Physiol 2, D-79104 Freiburg, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Univ Regensburg, Dept Biophys & Phys Biochem, D-93053 Regensburg, Germany	University of Freiburg; University of Regensburg	Fakler, B (corresponding author), Univ Freiburg, Dept Physiol 2, Hermann Herder Str 7, D-79104 Freiburg, Germany.	bernd.fakler@physiologie.uni-freiburg.de	Oliver, Dominik/F-5845-2013	Oliver, Dominik/0000-0002-8368-0923; Kalbitzer, Hans Robert/0000-0002-6514-2355				Antz C, 1999, NAT STRUCT BIOL, V6, P146; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; Baukrowitz T, 1996, SCIENCE, V271, P653, DOI 10.1126/science.271.5249.653; Bentrop D, 2001, J BIOL CHEM, V276, P42116, DOI 10.1074/jbc.M107118200; Billeter M, 1995, J BIOMOL NMR, V5, P1; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; Cooper EC, 1998, J NEUROSCI, V18, P965; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hines ML, 2000, NEURAL COMPUT, V12, P995, DOI 10.1162/089976600300015475; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hollerer-Beitz G, 1999, PFLUG ARCH EUR J PHY, V438, P141, DOI 10.1007/s004240050891; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHIMA R, 1995, BIOCHEMISTRY-US, V34, P3162, DOI 10.1021/bi00010a005; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kondoh S, 1997, J BIOL CHEM, V272, P19333, DOI 10.1074/jbc.272.31.19333; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Ludwig J, 2001, P NATL ACAD SCI USA, V98, P4178, DOI 10.1073/pnas.071613498; MA MH, 1995, J NEUROSCI, V15, P6720; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; Schmitz D, 2001, P NATL ACAD SCI USA, V98, P11003, DOI 10.1073/pnas.191351498; Schott MK, 1998, EUR BIOPHYS J BIOPHY, V27, P99, DOI 10.1007/s002490050115; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wiebe SP, 1999, J NEUROSCI, V19, P10562; Wissmann R, 1999, J BIOL CHEM, V274, P35521, DOI 10.1074/jbc.274.50.35521; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	51	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16142	16150		10.1074/jbc.M210191200	http://dx.doi.org/10.1074/jbc.M210191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590144	hybrid			2022-12-25	WOS:000182680000087
J	Buensuceso, C; de Virgilio, M; Shattil, SJ				Buensuceso, C; de Virgilio, M; Shattil, SJ			Detection of integrin alpha(IIb)beta(3) clustering in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; BETA-GALACTOSIDASE COMPLEMENTATION; IIB-IIIA COMPLEX; LIGAND-BINDING; PLATELET RECEPTOR; TRANSFER BRET; PROTEIN INTERACTIONS; CYTOPLASMIC DOMAINS; HUMAN-FIBRINOGEN; ACTIN-FILAMENTS	In platelets, bidirectional signaling across integrin alpha(IIb)beta(3), regulates fibrinogen binding, cytoskeletal reorganization, cell aggregation, and spreading. Because these responses may be influenced by the clustering Of alpha(IIb)beta(3) heterodimers into larger oligomers, we established two independent methods to detect integrin clustering and evaluate factors that regulate this process. In the first, weakly complementing beta-galactosidase mutants were fused to the C terminus of individual alpha(IIb) subunits, and the chimeras were stably expressed with beta(3) in Chinese hamster ovary cells. Clustering of alpha(IIb)beta(3) should bring the mutants into proximity and reconstitute beta-galactosidase activity. In the second method, alpha(IIb) was fused to either a green fluorescent protein (GFP) or Renilla luciferase and transiently expressed with beta(3). Here, integrin clustering should stimulate bioluminescence resonance energy transfer between a cell-permeable luciferase substrate and GFP. These methods successfully detected integrin clustering induced by anti-alpha(IIb)beta(3), antibodies. Significantly, they also detected clustering upon soluble fibrinogen binding to alpha(IIb)beta(3). In contrast, no clustering was observed following direct activation of alpha(IIb)beta(3) by MnCl2 or an anti-alpha(IIb)beta(3)-activating antibody Fab in the absence of fibrinogen. Intracellular events also influenced alpha(IIb)beta(3) clustering. For example, a cell-permeable, bivalent FK506-binding protein (FKBP) ligand stimulated clustering when added to cells expressing an alpha(IIb)(FKBP)(2) chimera complexed with beta(3). Furthermore, alpha(IIb)beta(3) clustering occurred in the presence of latrunculin A or cytochalasin D, inhibitors of actin polymerization. These effects were enhanced by fibrinogen, suggesting that actin-regulated clustering modulates alpha(IIb)beta(3) interaction with ligands. These studies in living cells establish that alpha(IIb)beta(3) clustering is modulated by fibrinogen and actin dynamics. More broadly, they should facilitate investigations of the mechanisms and consequences of integrin clustering.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Shattil, SJ (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL-56595, HL-57900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595, P01HL057900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Ambo H, 1998, BIOCHEM BIOPH RES CO, V251, P763, DOI 10.1006/bbrc.1998.9526; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Boute N, 2002, TRENDS PHARMACOL SCI, V23, P351, DOI 10.1016/S0165-6147(02)02062-X; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Rossi FMV, 2000, TRENDS CELL BIOL, V10, P119, DOI 10.1016/S0962-8924(99)01707-9; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Simmons SR, 1997, ARTERIOSCL THROM VAS, V17, P3311, DOI 10.1161/01.ATV.17.11.3311; Simmons SR, 1996, J LAB CLIN MED, V128, P39, DOI 10.1016/S0022-2143(96)90112-2; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Zamir E, 2001, J CELL SCI, V114, P3583	61	62	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15217	15224		10.1074/jbc.M213234200	http://dx.doi.org/10.1074/jbc.M213234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12595537	hybrid			2022-12-25	WOS:000182516100082
J	Koutsoupakis, K; Stavrakis, S; Soulimane, T; Varotsis, C				Koutsoupakis, K; Stavrakis, S; Soulimane, T; Varotsis, C			Oxygen-linked Equilibrium CUB-CO species in cytochrome ba(3) oxidase from Thermus thermophilus - Implications for an oxygen channel at the Cu-B site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED FTIR; HEME-COPPER OXIDASES; TEMPERATURE; COMPLEX	We report the first study of O-2 migration in the putative O-2 channel of cytochrome ba(3) and its effect to the properties of the binuclear heme a(3)-Cu-B center of cytochrome ba(3) from Thermus thermophilus. The Fourier transform infrared spectra of the ba(3)-CO complex demonstrate that in the presence of 60-80 mum O-2 the nu(C-O) of Cu-B(1+)-C-O at 2053 cm(-1) (complex A) shifts to 2045 cm(-1) and remains unchanged in H2O/D2O exchanges and in the pH 6.5-9.0 range. The frequencies but not the intensities of the C-O stretching modes of heme a(3)-CO (complex B), however, remain unchanged. The change in the P(C-O) of complex A results in an increase of k(-2), and thus in a higher affinity Of CUB for exogenous ligands. The time-resolved step-scan Fourier transform infrared difference spectra indicate that the rate of decay of the transient Cu-B(1+)-CO complex at pH 6.5 is 30.4 s(-1) and 28.3 s(-1) in the presence of O-2. Similarly, the rebinding to heme a(3) is slightly affected and occurs with k(2) = 26.3 s(-1) and 24.6 s(-1) in the presence of O-2. These results provide solid evidence that in cytochrome ba(3), the ligand delivery channel is located at the Cu-B site, which is the ligand entry to the heme a(3) pocket. We suggest that the properties of the O-2 channel are not limited to facilitating ligand diffusion to the active site but are extended in controlling the dynamics and reactivity of the reactions of ba(3) with O-2 and NO.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Paul Scherrer Inst, OSRA 008, CH-5232 Villigen, Switzerland	University of Crete; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.		Stavrakis, Stavros/P-6267-2019	Stavrakis, Stavros/0000-0002-0888-5953; Varotsis, Constantinos/0000-0003-2771-8891				Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; Pinakoulaki E, 2002, J BIOL CHEM, V277, P32867, DOI 10.1074/jbc.M205568200; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; Than M. E., 2001, HDB METALLOPROTEINS, P363; Varotsis C, 1996, BIOSPECTROSCOPY, V2, P331; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	12	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14893	14896		10.1074/jbc.M210293200	http://dx.doi.org/10.1074/jbc.M210293200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594218	hybrid			2022-12-25	WOS:000182516100041
J	Ward, DG; Cavieres, JD				Ward, DG; Cavieres, JD			Inactivation of Na,K-ATPase following Co(NH3)(4)ATP binding at a low affinity site in the protomeric enzyme unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-TRANSPORTING ATPASE; ALPHA-BETA-UNITS; SARCOPLASMIC-RETICULUM; NUCLEOTIDE SITES; ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; AMINO-ACID; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; MAMMALIAN KIDNEY	The Na+-dependent or El stages of the Na,K-ATPase reaction require a few micromolar ATP, but submillimolar concentrations are needed to accelerate the K+-dependent or E2 half of the cycle. Here we use Co(NH3)(4)ATP as a tool to study ATP sites in Na,K-ATPase. The analogue inactivates the K+ phosphatase activity (an E2 partial reaction) and the Na,K-ATPase activity in parallel, whereas ATP-[H-3]ADP exchange (an El reaction) is affected less or not at all. Although the inactivation occurs as a consequence of low affinity Co(NH3)(4)ATP binding (K-m approximate to 0.4-0.6 mm), we can also measure high affinity equilibrium binding of Co(NH3)(4)[H-3]ATP (K-D = 0.1 mum) to the native enzyme. Crucially, we find that covalent enzyme modification with fluorescein isothiocyanate (which blocks El reactions) causes little or no effect on the affinity of the binding step preceding Co(NH3)(4)ATP inactivation and only a 20% decrease in maximal inactivation rate. This suggests that fluorescein isothiocyanate and Co(NH3)(4)ATP bind within different enzyme pockets. The Co(NH3)(4)ATP enzyme was solubilized with C12E8 to a homogeneous population of alphabeta protomers, as verified by analytical ultracentrifugation; the solubilization did not increase the Na,K-ATPase activity of the Co(NH3)(4)ATP enzyme with respect to parallel controls. This was contrary to the expectation for a hypothetical (alphabeta)(2) membrane dimer with a single ATP site per protomer, with or without fast dimer/protomer equilibrium in detergent solution. Besides, the solubilized alphabeta protomer could be directly inactivated by Co(NH3)(4)ATP, to less than 10% of the control Na,K-ATPase activity. This suggests that the inactivation must follow Co(NH3)(4)ATP binding at a low affinity site in every protomeric unit, thus still allowing ATP and ADP access to phosphorylation and high affinity ATP sites.	Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Fac Med & Biol Sci, Leicester LE1 9HN, Leics, England	University of Leicester	Cavieres, JD (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Fac Med & Biol Sci, Leicester LE1 9HN, Leics, England.	jdc7@le.ac.uk		Ward, Douglas/0000-0002-2328-1445				ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; Askari A, 2000, INT CONGR SER, V1207, P17; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Burden D, 2000, INT CONGR SER, V1207, P417; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CAVIERES JD, 1987, BIOCHIM BIOPHYS ACTA, V899, P83, DOI 10.1016/0005-2736(87)90242-2; Cavieres JD, 2000, INT CONGR SER, V1207, P115; CORNELIUS RD, 1977, INORG CHEM, V16, P2799, DOI 10.1021/ic50177a025; DAVIS RL, 1988, J BIOENERG BIOMEMBR, V20, P571, DOI 10.1007/BF00768920; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; ECKERT K, 1977, ACTA BIOL MED GER, V36, pK1; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; Faller LD, 2000, BIOPHYS J, V78, p77A; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; Faller LD, 2000, INT CONGR SER, V1207, P389; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; HAMER E, 1993, EUR J BIOCHEM, V213, P743, DOI 10.1111/j.1432-1033.1993.tb17815.x; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; Huang SH, 1998, BIOCHEMISTRY-US, V37, P6949, DOI 10.1021/bi980275f; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KANAZAWA T, 1967, J BIOCHEM-TOKYO, V61, P555, DOI 10.1093/oxfordjournals.jbchem.a128586; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KAPLAN JH, 1982, ANN NY ACAD SCI, V402, P292, DOI 10.1111/j.1749-6632.1982.tb25750.x; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P333, DOI 10.1113/jphysiol.1982.sp014267; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; LLEWELLYN DJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P483, DOI 10.1016/0003-9861(78)90302-8; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; Mildvan A S, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P103; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OHTA T, 1985, SODIUM PUMP, P237; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHACHMAN, 1959, ULTRACENTRIFUGATION, P82; SCHEINERBOBIS G, 1989, EUR J BIOCHEM, V183, P173, DOI 10.1111/j.1432-1033.1989.tb14910.x; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHLESSINGER G, 1960, INORG SYN, V6, P173, DOI 10.1002/9780470132371.ch55; SERPERSU EH, 1990, EUR J BIOCHEM, V191, P397, DOI 10.1111/j.1432-1033.1990.tb19135.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUSUKI H, 2000, BIOCHEMISTRY-US, V29, P7040; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Tran CM, 1996, BIOCHEMISTRY-US, V35, P47, DOI 10.1021/bi951238g; VILSEN B, 1987, J BIOL CHEM, V262, P10511; Ward DG, 1998, J PHYSIOL-LONDON, V511P, p29P; Ward DG, 1998, J BIOL CHEM, V273, P33759, DOI 10.1074/jbc.273.50.33759; Ward DG, 1998, J BIOL CHEM, V273, P14277, DOI 10.1074/jbc.273.23.14277; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; WEBB MR, 1981, J BIOL CHEM, V256, P4884	72	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14688	14697		10.1074/jbc.M211128200	http://dx.doi.org/10.1074/jbc.M211128200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591931	hybrid			2022-12-25	WOS:000182516100015
J	Cao, JS; Lockwood, J; Burn, P; Shi, YG				Cao, JS; Lockwood, J; Burn, P; Shi, YG			Cloning and functional characterization of a mouse intestinal Acyl-CoA : monoacylglycerol acyltransferase, MGAT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL SYNTHESIS; TRIGLYCERIDE SYNTHESIS; ENZYMES; OBESITY; BIOSYNTHESIS; MUCOSA; RATS; IDENTIFICATION; ABSORPTION	Acyl-CoA:monoacylglycerol transferase (MGAT) plays a predominant role in dietary fat absorption in the small intestine, where it catalyzes the first step of triacylglycerol resynthesis in enterocytes for chylomicron formation and secretion. Although the mouse small intestine exhibits the highest MGAT enzyme activity among all of the tissues studied, the gene encoding the enzyme has not been identified so far. In the present studies, we report the identification and characterization of a mouse intestinal MGAT, MGAT2. Transient expression of MGAT2 in AV-12, COS-7, and Caco-2 cells led to a more than 70-, 30-, and 35-fold increase in the synthesis of diacylglycerol, respectively. MGAT2 expressed in mammalian cells can catalyze the acylation of rac-1-, sn-2-, and sn-3-monoacylglycerols, and the enzyme prefers monoacylglycerols containing unsaturated fatty acyls as substrates. MGAT2 also demonstrates weak DGAT activity, which can be distinguished from its MGAT activity by detergent treatment that abolishes DGAT but not MGAT activity. We also analyzed the biochemical features of MGAT2 and demonstrated homogenate protein-, time-, and substrate concentration-dependent MGAT enzyme activity in transiently transfected COS-7 cells. Northern blot analysis indicates that the mouse MGAT2 is most abundantly expressed in the small intestine, suggesting that MGAT2 may play an important role in dietary fat absorption.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly	Shi, YG (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Endocrine Res, DK 0545, Indianapolis, IN 46285 USA.							BARACNIETO M, 1971, NEPHRON, V8, P488, DOI 10.1159/000179952; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRECKENRIDGE WC, 1975, CAN J BIOCHEM CELL B, V53, P1184, DOI 10.1139/o75-163; BRECKENRIDGE WC, 1975, CAN J BIOCHEM CELL B, V53, P1170, DOI 10.1139/o75-162; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2000, TRENDS CARDIOVAS MED, V10, P188, DOI 10.1016/S1050-1738(00)00066-9; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; JAMDAR SC, 1995, BBA-LIPID LIPID MET, V1255, P237, DOI 10.1016/0005-2760(94)00217-M; JOHNSTON JM, 1970, BIOCHIM BIOPHYS ACTA, V218, P124, DOI 10.1016/0005-2760(70)90099-8; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; Luan Y, 2002, DIABETES RES CLIN PR, V57, P75, DOI 10.1016/S0168-8227(02)00026-8; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; Mansbach CM, 1998, J LIPID RES, V39, P963; PALTAUF F, 1971, BIOCHIM BIOPHYS ACTA, V239, P47, DOI 10.1016/0005-2760(71)90191-3; Phan CT, 2001, FRONT BIOSCI-LANDMRK, V6, pD299, DOI 10.2741/Phan; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; RAO GA, 1966, BIOCHEM BIOPH RES CO, V22, P696; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Swanton EMS, 1997, BBA-LIPID LIPID MET, V1346, P93, DOI 10.1016/S0005-2760(97)00024-6; Trimble M E, 1977, Curr Probl Clin Biochem, V8, P362; TRIMBLE ME, 1978, LIFE SCI, V22, P883; TSO P, 2000, BIOCH PHYSL ASPECTS, P125; Tsujita T, 1996, J BIOL CHEM, V271, P2156, DOI 10.1074/jbc.271.4.2156; WESTERGAARD H, 1976, J CLIN INVEST, V58, P97, DOI 10.1172/JCI108465; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	33	103	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13860	13866		10.1074/jbc.M300139200	http://dx.doi.org/10.1074/jbc.M300139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12576479	hybrid			2022-12-25	WOS:000182405000039
J	Colombi, M; Zoppi, N; De Petro, G; Marchina, E; Gardella, R; Tavian, D; Ferraboli, S; Barlati, S				Colombi, M; Zoppi, N; De Petro, G; Marchina, E; Gardella, R; Tavian, D; Ferraboli, S; Barlati, S			Matrix assembly induction and cell migration and invasion inhibition by a 13-amino acid fibronectin peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATIN-BINDING FRAGMENTS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; TUMOR INVASION; MESSENGER-RNAS; IV COLLAGENASE; DOMAIN; TRANSFORMATION; FIBROBLASTS; EXPRESSION	Fibronectin (FN) is an extracellular matrix (ECM) protein involved in tumor growth and metastasis. Five human FN cDNA segments encoding for FN fragments, all starting with the Ill repeat and ending with different C-terminal extensions, have been stably expressed in chick embryo fibroblasts (CEF). These FN cDNAs induce the formation of an organized ECM in CEF as long as they retain a sequence coding for a 13-amino acid stretch (FN13), with collagen binding activity, localized between type 112 and 17 repeats. An FN13 synthetic peptide induces in control CEF the assembly of an FN-ECM comparable with that observed in CEF-expressing FN fragments. The activity of FN13 is specific for its amino acid sequence, although the cysteine present in the 6th position can be substituted with a polar serine without affecting the induction of a fibrillar FN-ECM. A less fibrillar matrix is induced by FN13-modified peptides in which the cysteine is methylated or substituted by a non-polar alanine. FN13 induces the assembly of an FN-ECM also in Rous sarcoma virus-transformed CEF lacking the ECM and in hepatoma (SK-Hepl) and fibrosarcoma (HT-1080) human cell lines. FN13 also promotes the adhesion of CEF and Rous sarcoma virus-CEF at levels comparable with those obtained with purified intact FN. Finally, FN13 inhibits the migratory and invasive properties of tumorigenic cells, whereas intact FN favors their migration. All FN13-modified peptides show similar effects, although with reduced efficiency. None of these activities is supported by a scrambled peptide. These data suggest a possible role of FN13 in tumor growth and metastasis inhibition and its possible use as anti-tumorigenic agent.	Univ Brescia, Div Biol & Genet, Dept Biomed Sci & Biotechnol, Fac Med, I-25123 Brescia, Italy	University of Brescia	Barlati, S (corresponding author), Univ Brescia, Div Biol & Genet, Dept Biomed Sci & Biotechnol, Fac Med, Viale Europa 11, I-25123 Brescia, Italy.	barlati@med.unibs.it	tavian, daniela/AAE-4584-2020; De Petro, Giuseppina/C-2719-2011; Barlati, Sergio/A-2666-2010	De Petro, Giuseppina/0000-0001-9306-0851; MARCHINA, Eleonora/0000-0002-1672-1908; ZOPPI, Nicoletta/0000-0003-0197-8927; Colombi, Marina/0000-0002-3105-5990				BARLATI S, 1994, B I PASTEUR, V92, P269; BARLATI S, 1988, CANCER J, V2, P95; BARLATI S, 1995, TUMOR MATRIX BIOL, P81; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; COLOMBI M, 1993, DNA CELL BIOL, V12, P629, DOI 10.1089/dna.1993.12.629; DARRIBERE T, 1992, DEV DYNAM, V194, P63, DOI 10.1002/aja.1001940108; De Petro G, 1998, CANCER RES, V58, P2234; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEPETRO G, 1981, P NATL ACAD SCI-BIOL, V78, P4965; Givol I, 1995, ONCOGENE, V11, P2609; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN LHE, 1979, P NATL ACAD SCI USA, V76, P1160, DOI 10.1073/pnas.76.3.1160; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1979, J SUPRAMOL STR CELL, V11, P95, DOI 10.1002/jss.400110110; INGHAM KC, 1992, PROTEINS, V12, P180, DOI 10.1002/prot.340120211; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRYCEVEMARTINERIE C, 1981, VIROLOGY, V112, P436, DOI 10.1016/0042-6822(81)90291-9; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; LESOT H, 1992, DIFFERENTIATION, V49, P109, DOI 10.1111/j.1432-0436.1992.tb00775.x; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; Mosher, 1989, FIBRONECTIN, P1; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; RUOSLAHTI E, 1979, J BIOL CHEM, V254, P6054; RUOSLAHTI E, 1994, B I PASTEUR, V92, P242; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SALONEN EM, 1984, J IMMUNOL METHODS, V72, P145, DOI 10.1016/0022-1759(84)90442-3; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; Schnepel J, 2000, J PROTEIN CHEM, V19, P685, DOI 10.1023/A:1007104420017; Schor SL, 1996, J CELL SCI, V109, P2581; SCHWARZBAUER JE, 1987, P NATL ACAD SCI USA, V84, P754, DOI 10.1073/pnas.84.3.754; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SKORSTENGAARD K, 1994, FEBS LETT, V343, P47, DOI 10.1016/0014-5793(94)80604-7; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TAKEUCHI J, 1995, TUMOR MATRIX BIOL, P1; Tremble P M, 1992, Matrix Suppl, V1, P212; VAHERI A, 1974, INT J CANCER, V13, P579, DOI 10.1002/ijc.2910130502; VAHERI A, 1989, FIBRONECTIN, P255; VARTIO T, 1983, INVAS METAST, V3, P125; VARTIO T, 1983, EUR J BIOCHEM, V135, P203, DOI 10.1111/j.1432-1033.1983.tb07638.x; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P79, DOI 10.1111/j.1432-1033.1991.tb16258.x; VIDMAR SL, 1991, EUR J BIOCHEM, V201, P71, DOI 10.1111/j.1432-1033.1991.tb16257.x; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; Yamada KM, 1989, FIBRONECTIN, P47; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620	58	22	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14346	14355		10.1074/jbc.M211997200	http://dx.doi.org/10.1074/jbc.M211997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582155	hybrid			2022-12-25	WOS:000182405000099
J	McCloskey, DE; Pegg, AE				McCloskey, DE; Pegg, AE			Properties of the spermidine/spermine N-1-acetyltransferase mutant L156F that decreases cellular sensitivity to the polyamine analogue N-1, N-11-bis(ethyl)norspermine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMINE N1-ACETYLTRANSFERASE; BIS(ETHYL)POLYAMINE ANALOGS; CANCER-CELLS; LUNG-CANCER; GROWTH; METABOLISM; CHEMOTHERAPY; DEGRADATION; RESIDUES; SEQUENCE	Properties of a mutant form of spermidine/spermine N-1-acetyltransferase, L156F (L156F-SSAT), that is present in Chinese hamster ovary cells selected for resistance to the polyamine analogue N-1, N-11-bis(ethyl)norspermine (BE 3-3-3) were investigated. Increased K. values, decreased V-max. values, and decreased k(cat) values with both polyamine substrates, spermidine and spermine, indicated that L156F-SSAT is an inferior and less efficient acetyltransferase than wild-type SSAT. Transfection of L156F-SSAT into C55.7Res cells indicated that cellular SSAT activity per nanogram of SSAT protein correlated well with the in vitro data and was also similar to20fold less for the mutant protein than for wild-type SSAT. Increased expression of L156F-SSAT was unable to restore cellular sensitivity to BE 3-3-3 despite providing measurable basal SSAT activity. Only a 4-fold induction of L156F-SSAT activity resulted from the exposure of cells to the polyamine analogue, whereas wild-type SSAT was induced similar to300-fold. Degradation studies indicated that BE 3-3-3 cannot prevent ubiquitination of L156F-SSAT and is therefore unable to protect the mutant protein from degradation. These studies indicate that the decreased cellular sensitivity to BE 3-3-3 is caused by the lack of SSAT activity induction in the presence of the analogue due to its inability to prevent the rapid degradation of the L156F-SSAT protein.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol H166, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	McCloskey, DE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol H166, Rm C4731B,500 Univ Dr, Hershey, PA 17033 USA.				NIGMS NIH HHS [GM-26290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Casero RA, 2001, J MED CHEM, V44, P1, DOI 10.1021/jm000084m; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; Coleman CS, 1997, J BIOL CHEM, V272, P12164, DOI 10.1074/jbc.272.18.12164; Coleman CS, 1996, BIOCHEM J, V316, P697, DOI 10.1042/bj3160697; Coleman CS, 2001, BIOCHEM J, V358, P137, DOI 10.1042/0264-6021:3580137; Fersht A., 1999, STRUCTURE MECH PROTE, P103; Frydman B, 1999, EXPERT OPIN THER PAT, V9, P1055, DOI 10.1517/13543776.9.8.1055; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Kanugula S, 2001, ENVIRON MOL MUTAGEN, V38, P235, DOI 10.1002/em.1077; Lu L, 1996, J BIOL CHEM, V271, P18920, DOI 10.1074/jbc.271.31.18920; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUI I, 1981, J BIOL CHEM, V256, P2454; McCloskey DE, 1999, J BIOL CHEM, V274, P6175, DOI 10.1074/jbc.274.10.6175; McCloskey DE, 2000, J BIOL CHEM, V275, P28708, DOI 10.1074/jbc.M004120200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; PILZ RB, 1990, J BIOL CHEM, V265, P8880; PORTER CW, 1991, CANCER RES, V51, P3715; Reddy VK, 2001, J MED CHEM, V44, P404, DOI 10.1021/jm000310s; SARHAN S, 1989, ANTICANCER RES, V9, P215; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Valasinas A, 2001, J MED CHEM, V44, P390, DOI 10.1021/jm000309t	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13881	13887		10.1074/jbc.M205689200	http://dx.doi.org/10.1074/jbc.M205689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12578836	hybrid			2022-12-25	WOS:000182405000042
J	Hsu, STD; Breukink, E; Bierbaum, G; Sahl, HG; de Kruijff, B; Kaptein, R; van Nuland, NAJ; Bonvin, AMJJ				Hsu, STD; Breukink, E; Bierbaum, G; Sahl, HG; de Kruijff, B; Kaptein, R; van Nuland, NAJ; Bonvin, AMJJ			NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles - Conformational changes are a key to antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; MOLECULAR-DYNAMICS SIMULATION; LANTIBIOTIC MERSACIDIN; STEREOSPECIFIC ASSIGNMENTS; COUPLING-CONSTANTS; PORE FORMATION; PROTEINS; BIOSYNTHESIS; MECHANISM; NISIN	Mersacidin belongs to the type B lantibiotics (lanthionine-containing antibiotics) that contain post-translationally modified amino acids and cyclic ring structures. It targets the cell wall precursor lipid 11 and thereby inhibits cell wall synthesis. In light of the emerging antibiotics resistance problem, the understanding of the antibacterial activity on a structural basis provides a key to circumvent this issue. Here we present solution NMR studies of mersacidin-lipid II interaction in dodecylphosphocholine (DPC) micelles. Distinct solution structures of mersacidin were determined in three different states: in water/methanol solution and in DPC micelles with and without lipid II. The structures in various sample conditions reveal remarkable conformational changes in which the junction between Ala-12 and Abu-13 (where Abu is aminobutyric acid) effectively serves as the hinge for the opening and closure of the ring structures. The DPC micelle-bound form resembles the previously determined NMR and x-ray crystal structures of mersacidin in pure methanol but substantially deviates from the other two states in our current report. The structural changes delineate the large chemical shift perturbations observed during the course of a two-step N-15-H-1 heteronuclear single quantum coherence titration. They also modulate the surface charge distribution of mersacidin suggesting that electrostatics play a central role in the mersacidin-lipid II interaction. The observed conformational adaptability of mersacidin might be a general feature of lipid II-interacting antibiotics/peptides.	Univ Utrecht, Ctr Biomembrane & Lipid Enzymol, NMR Dept, Bijovet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Bonn, Inst Med Microbiol & Immunol, D-53015 Bonn, Germany	Utrecht University; University of Bonn	Bonvin, AMJJ (corresponding author), Univ Utrecht, Ctr Biomembrane & Lipid Enzymol, NMR Dept, Bijovet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands.	abonvin@nmr.chem.uu.nl	Breukink, Eefjan/I-3039-2016; Bonvin, Alexandre M.J.J./A-5420-2009; Hsu, Shang-Te Danny/B-2324-2009; Hsu, Shang-Te Danny/L-2826-2014	Breukink, Eefjan/0000-0002-7311-0660; Bonvin, Alexandre M.J.J./0000-0001-7369-1322; Hsu, Shang-Te Danny/0000-0002-7231-0185; 				ANGLISTER J, 1993, J BIOMOL NMR, V3, P121; Bader R, 2001, J MOL BIOL, V305, P307, DOI 10.1006/jmbi.2000.4264; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; BIERBAUM G, 1995, FEMS MICROBIOL LETT, V127, P121, DOI 10.1016/0378-1097(95)00048-A; Bonvin AMJJ, 2001, J BIOMOL NMR, V21, P221, DOI 10.1023/A:1012935005256; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Brotz H, 2000, J ANTIMICROB CHEMOTH, V46, P1, DOI 10.1093/jac/46.1.1; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Brotz H, 1998, ANTIMICROB AGENTS CH, V42, P154, DOI 10.1128/AAC.42.1.154; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cudic P, 2002, P NATL ACAD SCI USA, V99, P7384, DOI 10.1073/pnas.102192099; Dayie KT, 1996, ANNU REV PHYS CHEM, V47, P243, DOI 10.1146/annurev.physchem.47.1.243; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feenstra KA, 1999, J COMPUT CHEM, V20, P786, DOI 10.1002/(SICI)1096-987X(199906)20:8<786::AID-JCC5>3.0.CO;2-B; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; Jack RW, 2000, CURR OPIN CHEM BIOL, V4, P310, DOI 10.1016/S1367-5931(00)00094-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KESSLER H, 1993, HELV CHIM ACTA, V76, P117, DOI 10.1002/hlca.19930760106; KESSLER H, 1992, BIOPOLYMERS, V32, P427, DOI 10.1002/bip.360320420; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LUDVIGSEN S, 1991, J MOL BIOL, V217, P731, DOI 10.1016/0022-2836(91)90529-F; Marrink SJ, 2000, J PHYS CHEM B, V104, P12165, DOI 10.1021/jp001898h; Mattos C, 2001, CURR OPIN STRUC BIOL, V11, P761, DOI 10.1016/S0959-440X(01)00278-0; NAGARJAN R, 1993, J ANTIBIOT, V46, P1181, DOI 10.7164/antibiotics.46.1181; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Opella SJ, 2001, METHOD ENZYMOL, V339, P285, DOI 10.1016/S0076-6879(01)39319-9; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; Prasch T, 1997, EUR J BIOCHEM, V244, P501, DOI 10.1111/j.1432-1033.1997.00501.x; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P705, DOI 10.1107/S0907444900003711; Vertesy L, 1999, J ANTIBIOT, V52, P730; Wand AJ, 1998, P NATL ACAD SCI USA, V95, P15299, DOI 10.1073/pnas.95.26.15299; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Williams KA, 1996, BIOCHEMISTRY-US, V35, P5145, DOI 10.1021/bi952897w; Wymore T, 1999, J MOL STRUCT, V485, P195, DOI 10.1016/S0022-2860(99)00090-3; XU RX, 1992, FEBS LETT, V305, P137, DOI 10.1016/0014-5793(92)80881-G; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zimmermann N, 1997, EUR J BIOCHEM, V246, P809, DOI 10.1111/j.1432-1033.1997.00809.x; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	50	110	114	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13110	13117		10.1074/jbc.M211144200	http://dx.doi.org/10.1074/jbc.M211144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562773	hybrid, Green Published			2022-12-25	WOS:000182189500067
J	McKenna, S; Moraes, T; Pastushok, L; Ptak, C; Xiao, W; Spyracopoulos, L; Ellison, MJ				McKenna, S; Moraes, T; Pastushok, L; Ptak, C; Xiao, W; Spyracopoulos, L; Ellison, MJ			An NMR-based model of the ubiquitin-bound human ubiquitin conjugation complex Mms2 center dot Ubc13 - The structural basis for lysine 63 chain catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; KAPPA-B-ALPHA; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN CHAIN; DNA-REPAIR; PROTEOLYTIC PATHWAY; ENZYME COMPLEX	A heterodimer composed of the catalytically active ubiquitin-conjugating enzyme hUbc13 and its catalytically inactive paralogue, hMms2, forms the catalytic core for the synthesis of an alternative type of multiubiquitin chain where ubiquitin molecules are tandemly linked to one another through a Lys-63 isopeptide bond. This type of linkage, as opposed to the more typical Lys-48-linked chains, serves as a non-proteolytic marker of protein targets involved in error-free post-replicative DNA repair and NF-kappaB signal transduction. Using a two-dimensional H-1-N-15 NMR approach, we have mapped: 1) the interaction between the subunits of the human Uhc13(.)Mms2 heterodimer and 2) the interactions between each of the subunits or heterodimer with a non-covalently bound acceptor ubiquitin or a thiolester-linked donor ubiquitin. Using these NMR-derived constraints and an unbiased docking approach, we have assembled the four components of this catalytic complex into a three-dimensional model that agrees well with its catalytic function.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Inst Biomol Design, Edmonton, AB T6G 2H7, Canada; Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada	University of Alberta; University of Alberta; University of Saskatchewan	Spyracopoulos, L (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	leo.spyracopoulos@ualberta.ca; mike.ellison@ualberta.ca		Xiao, Wei/0000-0001-7568-0782; McKenna, Sean/0000-0002-9407-7257				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jiang F, 1999, BIOCHEMISTRY-US, V38, P6471, DOI 10.1021/bi9901329; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Morelli XJ, 2001, PROTEIN SCI, V10, P2131, DOI 10.1110/ps.07501; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; PETERS JM, 1998, UBIQUITIN BIOL CELL, P345; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1999, J CELL SCI, V112, P1375; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; [No title captured]	49	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13151	13158		10.1074/jbc.M212353200	http://dx.doi.org/10.1074/jbc.M212353200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569095	hybrid			2022-12-25	WOS:000182189500072
J	Sadek, CM; Jimenez, A; Damdimopoulos, AE; Kieselbach, T; Nord, M; Gustafsson, JA; Spyrou, I; Davis, EC; Oko, R; van der Hoorn, FA; Miranda-Vizuete, A				Sadek, CM; Jimenez, A; Damdimopoulos, AE; Kieselbach, T; Nord, M; Gustafsson, JA; Spyrou, I; Davis, EC; Oko, R; van der Hoorn, FA; Miranda-Vizuete, A			Characterization of human thioredoxin-like 2 - A novel microtubule-binding thioredoxin expressed predominantly in the cilia of lung airway epithelium and spermatid manchette and axoneme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; OUTER ARM DYNEIN; CELL-DIFFERENTIATION; MOLECULAR-CLONING; IN-VITRO; PROTEIN; TESTIS; CENTROSOME; TRANSPORT; FAMILY	We describe here the cloning and characterization of a novel member of the thioredoxin family, thioredoxin-like protein 2 (Txl-2). The Txl-2 open reading frame codes for a protein of 330 amino acids consisting of two distinct domains: an N-terminal domain typical of thioredoxins and a C-terminal domain belonging to the nucleoside-diphosphate kinase family, separated by a small interface domain. The Txl-2 gene spans similar to28 kb, is organized into 11 exons, and maps at locus 3q22.3-q23. A splicing variant lacking exon 5 (Delta5Txl-2) has also been isolated. By quantitative real time PCR we demonstrate that Txl-2 mRNA is ubiquitously expressed, with testis and lung having the highest levels of expression. Unexpectedly, light and electron microscopy analyses show that the protein is associated with microtubular structures such as lung airway epithelium cilia and the manchette and axoneme of spermatids. Using in vitro translated proteins, we demonstrate that full-length Txl-2 weakly associates with microtubules. In contrast, Delta5Txl-2 specifically binds with very high affinity brain microtubule preparations containing microtubule-binding proteins. Importantly, Delta5Txl-2 also binds to pure microtubules, proving that it possesses intrinsic microtubule binding capability. Taken together, Delta5Txl-2 is the first thioredoxin reported to bind microtubules and might therefore be a novel regulator of microtubule physiology.	Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, Prot Anal Unit,Ctr Struct Biol, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Nutr, S-14157 Huddinge, Sweden; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; McGill University; University of Calgary; Queens University - Canada	Miranda-Vizuete, A (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, Dept Biosci, Halsovagen 7, S-14157 Huddinge, Sweden.		Davis, Elaine/F-3449-2012; IBIS, REDOX/J-7473-2017; Sadek, Christine/A-7356-2010; Kieselbach, Thomas/O-6023-2015; Jiménez, Alberto/A-6234-2009; Miranda-Vizuete, Antonio/D-6927-2012	Kieselbach, Thomas/0000-0001-5577-2938; Jiménez, Alberto/0000-0003-3685-6479; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189	Canadian Institutes of Health Research [11361] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9; Blouin JL, 2000, EUR J HUM GENET, V8, P109, DOI 10.1038/sj.ejhg.5200429; Chaudhuri AR, 2001, BIOCHEMISTRY-US, V40, P8834, DOI 10.1021/bi0101603; COUTAVAS EE, 1994, MAMM GENOME, V5, P623, DOI 10.1007/BF00411457; Cowan MJ, 2001, AM J MED SCI, V321, P3, DOI 10.1097/00000441-200101000-00002; DUTCHER SK, 1995, TRENDS GENET, V11, P398, DOI 10.1016/S0168-9525(00)89123-4; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GAN ZR, 1991, J BIOL CHEM, V266, P1692; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Junco A, 2001, BIOL REPROD, V64, P1320, DOI 10.1095/biolreprod64.5.1320; Kierszenbaum AL, 2002, MOL REPROD DEV, V63, P131, DOI 10.1002/mrd.10164; Kierszenbaum AL, 2002, MOL REPROD DEV, V63, P1, DOI 10.1002/mrd.10179; Kierszenbaum AL, 2001, MOL REPROD DEV, V59, P347, DOI 10.1002/mrd.1040; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; LECROISEY A, 1995, BIOCHEMISTRY-US, V34, P12445, DOI 10.1021/bi00038a043; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; LOMBARDI D, 1995, EXP CELL RES, V217, P267, DOI 10.1006/excr.1995.1086; Mehus JG, 1999, HUM GENET, V104, P454, DOI 10.1007/s004390050987; Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264; Miranda-Vizuete A, 1998, BIOCHEM BIOPH RES CO, V243, P284, DOI 10.1006/bbrc.1997.8003; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Miranda-Vizuete A, 2001, J BIOL CHEM, V276, P31567, DOI 10.1074/jbc.M101760200; Mochida K, 1998, DEV BIOL, V200, P46, DOI 10.1006/dbio.1998.8942; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Munier A, 1998, FEBS LETT, V434, P289, DOI 10.1016/S0014-5793(98)00996-X; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; Ogawa K, 1996, MOL BIOL CELL, V7, P1895, DOI 10.1091/mbc.7.12.1895; Oko R, 1998, ANDROLOGIA, V30, P193; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; Ostrowski LE, 2002, MOL CELL PROTEOMICS, V1, P451, DOI 10.1074/mcp.M200037-MCP200; Padma P, 2001, GENE, V275, P177, DOI 10.1016/S0378-1119(01)00661-8; Patel-King RS, 2002, J BIOL CHEM, V277, P34271, DOI 10.1074/jbc.M204137200; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; Roymans D, 2001, EXP CELL RES, V262, P145, DOI 10.1006/excr.2000.5087; Sadek CM, 2001, GENES CELLS, V6, P1077, DOI 10.1046/j.1365-2443.2001.00484.x; Sapiro R, 2002, MOL CELL BIOL, V22, P6298, DOI 10.1128/MCB.22.17.6298-6305.2002; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Valiron O, 2001, CELL MOL LIFE SCI, V58, P2069, DOI 10.1007/PL00000837; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Zou Y, 2002, BIOL REPROD, V66, P843, DOI 10.1095/biolreprod66.3.843	56	70	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13133	13142		10.1074/jbc.M300369200	http://dx.doi.org/10.1074/jbc.M300369200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12569107	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000182189500070
J	Zsembery, A; Boyce, AT; Liang, LH; Peti-Peterdi, J; Bell, PD; Schwiebert, EM				Zsembery, A; Boyce, AT; Liang, LH; Peti-Peterdi, J; Bell, PD; Schwiebert, EM			Sustained calcium entry through P2X nucleotide receptor channels in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; EXTRACELLULAR ATP; NA+ ABSORPTION; ION-TRANSPORT; PHARMACOLOGICAL MODULATION; PURINERGIC REGULATION; CL-SECRETION; RELEASE; EXPRESSION; MEMBRANE	Purinergic receptor stimulation has potential therapeutic effects for cystic fibrosis (CF). Thus, we explored roles for P2Y and P2X receptors in stably increasing [Ca2+](i) in human CF (IB3-1) and non-CF (16HBE14o(-)) airway epithelial cells. Cytosolic Ca2+ was measured by fluorospectrometry using the fluorescent dye Fura-2/AM. Expression of P2X receptor (P2XR) subtypes was assessed by immunoblotting and biotinylation. In IB3-1 cells, ATP and other P2Y agonists caused only a transient increase in [Ca2+](i) derived from intracellular stores in a Na+-rich environment. In contrast, ATP induced an increase in [Ca2+](i) that had transient and sustained components in a Na+-free medium; the sustained plateau was potentiated by zinc or increasing extracellular pH. Benzoyl-benzoyl-ATP, a P2XR-selective agonist, increased [Ca2+](i) only in Na+-free medium, suggesting competition between Na+ and Ca2+ through P2XRs. Biochemical evidence showed that the P2X(4) receptor is the major subtype shared by these airway epithelial cells. A role for store-operated Ca2+ channels, voltage-dependent Ca2+ channels, or Na+/Ca2+ exchanger in the ATP-induced sustained Ca2+ signal was ruled out. In conclusion, these data show that epithelial P2X(4) receptors serve as ATP-gated calcium entry channels that induce a sustained increase in [Ca2+](i) . In airway epithelia, a P2XR-mediated Ca2+ signal may have therapeutic benefit for CF.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming Jones Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA; Semmelweis Univ, Dept Pathophysiol, H-1085 Budapest, Hungary	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Semmelweis University	Zsembery, A (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 740,1918 Univ Blvd, Birmingham, AL 35294 USA.	zsembery@physiology.uab.edu; eschwiebert@physiology.uab.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNON A, 2002, AM J PHYSIOL, V278, pC163; Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Bennett BD, 2001, ENDOCRINOLOGY, V142, P1968, DOI 10.1210/en.142.5.1968; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Collo G, 1996, J NEUROSCI, V16, P2495; Communi D, 1999, BRIT J PHARMACOL, V127, P562, DOI 10.1038/sj.bjp.0702560; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Dhulipala PDK, 1998, GENE, V207, P259, DOI 10.1016/S0378-1119(97)00647-1; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Donaldson SH, 2000, MOL MED, V6, P969, DOI 10.1007/BF03401831; Furukawa M, 1997, AM J PHYSIOL-CELL PH, V272, pC827, DOI 10.1152/ajpcell.1997.272.3.C827; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRUENERT DC, 1990, IN VITRO CELL DEV B, V26, P411; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Homolya L, 1999, J BIOL CHEM, V274, P26454, DOI 10.1074/jbc.274.37.26454; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; Inglis SK, 1999, PFLUG ARCH EUR J PHY, V438, P621, DOI 10.1007/s004240051085; Iwase N, 1997, RESP PHYSIOL, V107, P173, DOI 10.1016/S0034-5687(96)02516-9; Jung S, 2000, J PHYSIOL-LONDON, V527, P549, DOI 10.1111/j.1469-7793.2000.00549.x; KNOWLES MR, 1995, AM J RESP CRIT CARE, V151, pS65, DOI 10.1164/ajrccm/151.3_Pt_2.S65; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2001, CLIN EXP PHARMACOL P, V28, P857, DOI 10.1046/j.1440-1681.2001.03541.x; Laubinger W, 1998, BIOCHEM PHARMACOL, V55, P687, DOI 10.1016/S0006-2952(97)00532-7; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406, DOI 10.1152/ajpcell.1994.266.2.C406; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Le KT, 1998, J NEUROSCI, V18, P7152; Lomri N, 1996, SEMIN LIVER DIS, V16, P201, DOI 10.1055/s-2007-1007232; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; Ralevic V, 1998, PHARMACOL REV, V50, P413; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; Sak K, 2002, ARCH BIOCHEM BIOPHYS, V397, P131, DOI 10.1006/abbi.2001.2616; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; Schwiebert EM, 2002, AM J PHYSIOL-RENAL, V282, pF763, DOI 10.1152/ajprenal.0337.2000; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; STUTTS MJ, 1995, AM J PHYSIOL-CELL PH, V268, pC425, DOI 10.1152/ajpcell.1995.268.2.C425; Taylor AL, 1999, J CLIN INVEST, V104, P875, DOI 10.1172/JCI7270; Uehara A, 2002, CELL CALCIUM, V31, P89, DOI 10.1054/ceca.2001.0257; VANSCOTT MR, 1995, AM J PHYSIOL-LUNG C, V269, pL30, DOI 10.1152/ajplung.1995.269.1.L30; Vennekens R, 2001, PFLUG ARCH EUR J PHY, V442, P237, DOI 10.1007/s004240100517; Wang X, 2000, CELL CALCIUM, V27, P205, DOI 10.1054/ceca.2000.0110; WARTH R, 1993, CELL PHYSIOL BIOCHEM, V3, P2, DOI 10.1159/000154663; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Wildman SS, 1999, BRIT J PHARMACOL, V126, P762, DOI 10.1038/sj.bjp.0702325; WILEY JS, 1989, BLOOD, V73, P1316; ZEITLIN PL, 1991, AM J PHYSIOL, V4, pL313; Zsembery A, 1998, HEPATOLOGY, V28, P914, DOI 10.1002/hep.510280403; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423	68	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13398	13408		10.1074/jbc.M212277200	http://dx.doi.org/10.1074/jbc.M212277200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566439	hybrid			2022-12-25	WOS:000182189500102
J	Fujino, H; Xu, W; Regan, JW				Fujino, H; Xu, W; Regan, JW			Prostaglandin E-2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED INTERNALIZATION; EGR-1 MESSENGER-RNA; PROTEIN-KINASE; COLON CARCINOGENESIS; CARCINOMA CELLS; EP(2) SUBTYPE; CYCLIN D1; C-FOS; ACTIVATION; PHOSPHORYLATION	Prostaglandin E-2 (PGE(2)) mediates its physiological effects by interactions with a subfamily of G-protein-coupled receptors known as EP receptors. These receptors consist of four primary subtypes named EP, EP2, EP3, and EP4. The EP2 and EP4 subtypes are known to couple to Galpha(s) and stimulate intracellular cyclic 3,5-adenosine monophosphate formation, whereas the EP1 and EP3 receptors are known to couple to Galpha(q) and Galpha(i), respectively. Recently we found that EP2 and EP4 receptors can activate T-cell factor signaling; however, EP2 receptors did this primarily through a cAMP-dependent protein kinase-dependent pathway, whereas EP4 receptors primarily utilized a phosphatidylinositol 3-kinase (PI3K)-dependent pathway (Fujino, H., West, K. A., and Regan, J. W. (2002) J. Biol. Chem. 277, 2614-2619). We now report that PGE(2) stimulation of EP4 receptors, but not EP2 receptors, leads to phosphorylation of the extracellular signal-regulated kinases (ERKs) through a PI3K-dependent mechanism. Furthermore, this activation of PI3K/ERK signaling by the EP4 receptors induces the functional expression of early growth response factor-1 (EGR-1). Under the same conditions induction of EGR-1 protein expression was not observed following PGE(2) stimulation of EP2 receptors. These findings point to important differences in the signaling potential of the EP2 and EP4 receptors, which could be significant with respect to the potential involvement of EP4 receptors in inflammation and cancer.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NEI NIH HHS [EY11291] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aeberli D, 2002, SWISS MED WKLY, V132, P414; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Chulada PC, 2000, CANCER RES, V60, P4705; DANESCH U, 1994, J BIOL CHEM, V269, P27258; Desai S, 2000, MOL PHARMACOL, V58, P1279, DOI 10.1124/mol.58.6.1279; Desai S, 2001, FEBS LETT, V501, P156, DOI 10.1016/S0014-5793(01)02640-0; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Fang MA, 1996, PROSTAG LEUKOTR ESS, V54, P109, DOI 10.1016/S0952-3278(96)90067-8; Fujino H, 2002, J BIOL CHEM, V277, P48786, DOI 10.1074/jbc.M209393200; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Mutoh M, 2002, CANCER RES, V62, P28; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; NISHIGAKI N, 1995, FEBS LETT, V364, P339, DOI 10.1016/0014-5793(95)00421-5; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Pierce KL, 1998, LIFE SCI, V62, P1479, DOI 10.1016/S0024-3205(98)00093-9; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; REGAN JW, 1994, MOL PHARMACOL, V46, P213; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shin SY, 2001, J BIOL CHEM, V276, P7797, DOI 10.1074/jbc.M009465200; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Watanabe K, 1999, CANCER RES, V59, P5093; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	30	250	262	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12151	12156		10.1074/jbc.M212665200	http://dx.doi.org/10.1074/jbc.M212665200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12566441	hybrid			2022-12-25	WOS:000182015700057
J	Logette, E; Wotawa, A; Solier, S; Desoche, L; Solary, E; Corcos, L				Logette, E; Wotawa, A; Solier, S; Desoche, L; Solary, E; Corcos, L			The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression	ONCOGENE			English	Article						caspase-2 gene; casp-2S; casp-2L; AUG; mRNA splicing; transcriptional regulation	PROGRAMMED CELL-DEATH; NEDD2 PRECURSOR; GRANZYME-B; BCL-X; APOPTOSIS; PROTEIN; IDENTIFICATION; ACTIVATION; PRODOMAIN; CASCADE	Caspases have been shown to play important roles in apoptotic cell death, cytokine maturation and cell differentiation. However, the transcriptional regulation of the corresponding CASP genes remains poorly known. We describe a 5.1 kb fragment located upstream of the first translated exon in the human CASP-2 gene, which is known to encode caspase-2L, and -2S protein isoforms. Transient transfection experiments, together with transcription start site mapping and transcript analysis, demonstrate that each caspase mRNA is initiated from separate promoter regions, and produced from alternative splicing events in these regions. The CASP-2L promoter is much stronger than the CASP-2S promoter, in good agreement with the respective transcript levels of the two caspases. In addition, several in-frame translational start sites can be identified for each isoform, one of which is common to both, present in the second common exon, and used efficiently. Surprisingly, the short isoform may also be initiated at a downstream AUG codon within the same exon. Thus, promoter strength, alternative transcriptional initiation and 5'-splicing events regulate the expression of the main caspase-2 isoforms that may be translated from alternative translation initiation codons.	INSERM, U517, Fac Med, F-21000 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Corcos, L (corresponding author), INSERM, U517, Fac Med, 7 Bd Jeanne Arc, F-21000 Dijon, France.		Corcos, Laurent/M-8915-2017; SOLIER, STEPHANIE/AAA-6851-2020; Corcos, Laurent/AAJ-2692-2020	Corcos, Laurent/0000-0001-8019-2505; Solary, Eric/0000-0002-8629-1341; SOLIER, Stephanie/0000-0003-3867-4644				Ahmad M, 1997, CANCER RES, V57, P615; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asahi M, 1997, J CEREBR BLOOD F MET, V17, P11, DOI 10.1097/00004647-199701000-00003; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bonfoco E, 2001, J BIOL CHEM, V276, P29242, DOI 10.1074/jbc.M100684200; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Droin N, 2000, CANCER RES, V60, P7039; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kojima M, 1998, NEUROSCI RES, V31, P211, DOI 10.1016/S0168-0102(98)00039-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; Kumar Sharad, 1997, Leukemia (Basingstoke), V11, P385; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morita Y, 2001, CELL DEATH DIFFER, V8, P614, DOI 10.1038/sj.cdd.4400845; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sato N, 1997, GENE, V202, P127, DOI 10.1016/S0378-1119(97)00463-0; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sordet O, 2002, LEUKEMIA, V16, P1569, DOI 10.1038/sj.leu.2402524; Stefanis L, 1998, J NEUROSCI, V18, P9204; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Swanton E, 1999, ONCOGENE, V18, P1781, DOI 10.1038/sj.onc.1202490; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 2000, J NEUROSCI, V20, P1386; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wotawa A, 2002, CANCER LETT, V185, P181, DOI 10.1016/S0304-3835(02)00287-2	53	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					935	946		10.1038/sj.onc.1206172	http://dx.doi.org/10.1038/sj.onc.1206172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584573				2022-12-25	WOS:000180864300016
J	Mateos, S; Calothy, G; Lamballe, F				Mateos, S; Calothy, G; Lamballe, F			The noncatalytic TrkCNC2 receptor is cleaved by metalloproteases upon neurotrophin-3 stimulation	ONCOGENE			English	Article						neurotrophin; Trk receptor; metalloendoproteases	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; EXTRACELLULAR DOMAIN; TRUNCATED RECEPTORS; ERBB-4 RECEPTOR; RAT TRKC; IDENTIFICATION; ENCODES; MEMBER; FAMILY	The trkC locus encodes catalytic and noneatalytic receptors, generated by alternative splicing. These primary high-affinity neurotrophin-3 (NT-3) receptors may act in concert to modulate responsiveness to NT-3. Signal modulation can also be achieved by receptors that are post-translationally processed. We report that the noncatalytic TrkC receptor, TrkCNC2, is cleaved at the membrane-proximal region of its extracellular domain. This generates a soluble ectodomain (gp90(TrkCNC2)) recovered in the cell culture medium and a membrane-bound fragment (p20(TrkCNC2)), which contains the transmembrane and intracellular regions including the juxtamembrane and the NC2-specific cytoplasmic domains. We also show that this processing, which does not occur in the TrkC catalytic counterpart, is upregulated by NT-3 and upon treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Moreover, cleavage inhibition after EDTA or 1.10 phenanthroline treatment suggests involvement of a metalloprotease(s). Finally, this post-translational processing was observed not only in TrkCNC2-overexpressing NIH3T3 cells but also in primary cultures of cortical neurons and brain extracts. This study shows that, in addition to alternative splicing, ectodomain shedding represents a novel means of regulating TrkC receptor signaling, and consequently NT-3 biological effects on target cells.	Ctr Univ Orsay, Inst Curie, CNRS UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Lamballe, F (corresponding author), IBDM, INSERM, U382, Campus Luminy,Case 907, F-13288 Marseille 09, France.	lamballe@ibdm.univ-mrs.fr	Lamballe, Fabienne/P-4293-2017; Lamballe, Fabienne/GLT-0820-2022	Lamballe, Fabienne/0000-0001-7631-942X				BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Benn B, 1998, J COMP NEUROL, V401, P47, DOI 10.1002/(SICI)1096-9861(19981109)401:1<47::AID-CNE4>3.0.CO;2-C; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Butowt R, 2001, J NEUROSCI, V21, P8915, DOI 10.1523/JNEUROSCI.21-22-08915.2001; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Eide FF, 1996, J NEUROSCI, V16, P3123; GARNER AS, 1994, NEURON, V13, P457, DOI 10.1016/0896-6273(94)90360-3; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Menn B, 2000, EUR J NEUROSCI, V12, P3211, DOI 10.1046/j.1460-9568.2000.00215.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Nilsson AS, 1998, FEBS LETT, V424, P285, DOI 10.1016/S0014-5793(98)00192-6; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	35	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					740	745		10.1038/sj.onc.1206213	http://dx.doi.org/10.1038/sj.onc.1206213			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569366				2022-12-25	WOS:000180642100011
J	van Wely, KHM; Molijn, AC; Buijs, A; Meester-Smoor, MA; Aarnoudse, AJ; Hellemons, A; den Besten, P; Grosveld, GC; Zwarthoff, EC				van Wely, KHM; Molijn, AC; Buijs, A; Meester-Smoor, MA; Aarnoudse, AJ; Hellemons, A; den Besten, P; Grosveld, GC; Zwarthoff, EC			The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription	ONCOGENE			English	Article						translocation; leukemia; retinoic acid; hormone receptor; coactivator	ACUTE PROMYELOCYTIC LEUKEMIA; FUSION PROTEIN; DNA-BINDING; PROGESTERONE-RECEPTOR; RESPONSE ELEMENTS; MYELOID-LEUKEMIA; CELL-GROWTH; GENE; TEL; DOMAINS	The t(12;22) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. The fusion partner TEL (ETV6) is a member of the ETS family of transcription factors. The nature of the other fusion partner, MAII, has not been investigated in detail until now. We recently described that MN1 activates the transcription activity of the moloney sarcoma virus long terminal repeat, indicating that this protein itself may act as a transcription factor. We show here that MN1 comprises multiple transcription activating domains. A search for a bound DNA sequence revealed that MN1 has affinity for retinoic acid responsive elements. A DR5 retinoic acid responsive element was observed in the LTR. The combination of MN1 and ligand-activated retinoic acid receptor leads to a synergistic induction of expression directed by the LTR. Cotransfection of MN1 with RAC3 or p300, known coactivators of retinoic acid receptors, leads to a further synergistic induction of transcription. In addition, the effect of MN1 can be inhibited by the wild-type adenovirus E1A protein that inhibits p300 function, but not by an E1A mutant lacking the p300-binding site. GAL4-MN1-mediated transcription can be enhanced directly by RAC3 and p300. Taken together, our results indicate that MN1 is a transcription coactivator rather than a sequence-specific transcription factor, and that it may stimulate RAR/RXR-mediated transcription through interaction with p160 and p300.	Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht Hosp, Dept Hematol, NL-3584 CX Utrecht, Netherlands; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38101 USA	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center; St Jude Children's Research Hospital	Zwarthoff, EC (corresponding author), Erasmus Univ, Dept Pathol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	zwarthoff@path.fgg.eur.nl		van Wely, Karel Hermanus Martinus/0000-0001-8431-8072	NATIONAL CANCER INSTITUTE [R01CA072996] Funding Source: NIH RePORTER; NCI NIH HHS [CA72996-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beverloo HB, 2001, CANCER RES, V61, P5374; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Goodman RH, 2000, GENE DEV, V14, P1553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Shao WL, 2000, BLOOD, V96, P2233; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	38	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					699	709		10.1038/sj.onc.1206124	http://dx.doi.org/10.1038/sj.onc.1206124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569362				2022-12-25	WOS:000180642100007
J	Hidaka, K; Lee, JK; Kim, HS; Ihm, CH; Iio, A; Ogawa, M; Nishikawa, SI; Kodama, I; Morisaki, T				Hidaka, K; Lee, JK; Kim, HS; Ihm, CH; Iio, A; Ogawa, M; Nishikawa, SI; Kodama, I; Morisaki, T			Chamber-specific differentiation of Nkx2.5-positive cardiac precursor cells from murine embryonic stem cells	FASEB JOURNAL			English	Article						cardiomyocyte; green fluorescent protein; embryoid body; diversification; retinoic acid	IN-VITRO; RETINOIC ACID; TRANSCRIPTION FACTORS; HEART DEVELOPMENT; FUNCTIONAL-PROPERTIES; IONIC CURRENTS; GENE NKX2-5; MOUSE HEART; ES CELLS; EXPRESSION	Embryonic stem (ES) cells are a useful system to study cardiac differentiation in vitro. It has been difficult, however, to track the fates of chamber-specific cardiac lineages, since differentiation is induced within the embryoid body. We have established an in vitro culture system to track Nkx2.5(+) cell lineages during mouse ES cell differentiation by using green fluorescent protein (GFP) as a reporter. Nkx2.5/GFP(+) cardiomyocytes purified from embryoid bodies express sarcomeric tropomyosin and myosin heavy chain and heterogeneously express cardiac troponin I (cTnI), myosin light chain 2v (MLC2v) and atrial natriuretic peptide (ANP). After 4-week culture, GFP(+) cells exhibited electrophysiological characteristics specific to sinoatrial (SA) node, atrial, or ventricular type. Furthermore, we found that administration of 10 7 M retinoic acid (RA) to embryoid bodies increased the percentage of MLC2v(-)ANP(+) cells; this also increased the expression of atrial-specific genes in the Nkx2.5/GFP(+) fraction, in a time- and dose-dependent fashion. These results suggest that Nkx2.5(+) lineage cells possess the potential to differentiate into various cardiomyocyte cell types and that RA can modify the differentiation potential of Nkx2.5(+) cardiomyocytes at an early stage.	Osaka Univ, Grad Sch Pharmaceut Sci, Dept Mol Pathophysiol, Suita, Osaka 5658565, Japan; Osaka Univ, Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5658565, Japan; Nagoya Univ, Environm Med Res Inst, Dept Circulat, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068507, Japan	Osaka University; National Cerebral & Cardiovascular Center - Japan; Osaka University; Nagoya University; Kyoto University	Morisaki, T (corresponding author), 5-7-1 Fujishiro Dai, Osaka 5658565, Japan.	morisaki@ri.ncvc.go.jp						ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Biben C, 2000, CIRC RES, V87, P888, DOI 10.1161/01.RES.87.10.888; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Chazaud C, 1999, DEVELOPMENT, V126, P2589; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Doevendans PA, 2000, J MOL CELL CARDIOL, V32, P839, DOI 10.1006/jmcc.2000.1128; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fujimoto T, 2001, GENES CELLS, V6, P1113, DOI 10.1046/j.1365-2443.2001.00490.x; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Huang XP, 1999, CIRC RES, V84, P1; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1995, AM J PHYSIOL-HEART C, V269, pH1913, DOI 10.1152/ajpheart.1995.269.6.H1913; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183, DOI 10.1007/BF01977348; METZGER JM, 1995, CIRC RES, V76, P710, DOI 10.1161/01.RES.76.5.710; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; Westfall MV, 1996, DEV DYNAM, V206, P24, DOI 10.1002/(SICI)1097-0177(199605)206:1<24::AID-AJA3>3.0.CO;2-2; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Xavier-Neto J, 1999, DEVELOPMENT, V126, P2677; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; Zammit PS, 2000, DEV DYNAM, V217, P75, DOI 10.1002/(SICI)1097-0177(200001)217:1<75::AID-DVDY7>3.0.CO;2-L; Zou YM, 1997, DEVELOPMENT, V124, P793	49	114	119	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					740	+		10.1096/fj.02-0104fje	http://dx.doi.org/10.1096/fj.02-0104fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594186				2022-12-25	WOS:000181456900006
J	Gupta, RA; Sarraf, P; Mueller, E; Brockman, JA; Prusakiewicz, JJ; Eng, C; Willson, TM; DuBois, RN				Gupta, RA; Sarraf, P; Mueller, E; Brockman, JA; Prusakiewicz, JJ; Eng, C; Willson, TM; DuBois, RN			Peroxisome proliferator-activated receptor gamma-mediated differentiation - A mutation in colon cancer cells reveals divergent and cell type-specific mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; ORPHAN RECEPTORS; CO-REPRESSOR; IN-VITRO; GENE; LIGAND; ADIPOGENESIS; EXPRESSION	Activation of the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma) inhibits cell growth and induces differentiation in both adipocyte and epithelial cell lineages, although it is unclear whether this occurs through common or cell-type specific mechanisms. We have identified four human colon cancer cell lines that do no undergo growth inhibition or induce markers of differentiation after exposure to PPARgamma agonists. Sequence analysis of the PPARgamma gene revealed that all four cell lines contain a previously unidentified point mutation in the ninth alpha-helix of the ligand binding domain at codon 422 (K422Q). The mutant receptor did not exhibit any defects in DNA binding or retinoid X receptor heterodimerization and was transcriptionally active in an artificial reporter assay. However, only retroviral transduction of the wild-type (WT), but not mutant, receptor could restore PPARgamma ligand-induced growth inhibition and differentiation in resistant colon cancer cell lines. In contrast, there was no difference in the ability of fibroblast cells expressing WT or K422Q mutant receptor to undergo growth inhibition, express adipocyte differentiation markers, or uptake lipid after treatment with a PPARgamma agonist. Finally, analysis of direct PPARgamma target genes in colon cancer cells expressing the WT or K422Q mutant allele suggests that the mutation may disrupt the ability of PPARgamma to repress the basal expression of a subset of genes in the absence of exogenous ligand. Collectively, these data argue that codon 422 may be a part of a co-factor(s) interaction domain necessary for PPARgamma to induce terminal differentiation in epithelial, but not adipocyte, cell lineages and argues that the receptor induces growth inhibition and differentiation via cell lineage-specific mechanisms.	Vanderbilt Univ, Med Ctr, Dept Cellular & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA 02115 USA; Psychiat Genom Inc, Gaithersburg, MD 20878 USA; Ohio State Univ, Ctr Comprehens Canc, Human Genet Program, Columbus, OH 43210 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; GlaxoSmithKline	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020; feinstein, doug/M-9414-2019	Eng, Charis/0000-0002-3693-5145	NCI NIH HHS [P01CA-77839] Funding Source: Medline; NIDDK NIH HHS [R01DK 47279] Funding Source: Medline; NIEHS NIH HHS [P030 ES-00267-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chang TH, 2000, CANCER RES, V60, P1129; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Glass CK, 2000, GENE DEV, V14, P121; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; GUPTA RA, 2001, J BIOL CHEM, V7, P7; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ikezoe T, 2001, CANCER RES, V61, P5307; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Komiya T, 1999, BBA-GENE STRUCT EXPR, V1444, P434, DOI 10.1016/S0167-4781(99)00010-X; Kubota T, 1998, CANCER RES, V58, P3344; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tanaka T, 2001, CANCER RES, V61, P2424; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Willson TM, 1996, ANN NY ACAD SCI, V804, P276, DOI 10.1111/j.1749-6632.1996.tb18622.x; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yen CJ, 1997, BIOCHEM BIOPH RES CO, V241, P270, DOI 10.1006/bbrc.1997.7798; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhou XP, 2000, J MED GENET, V37, P410, DOI 10.1136/jmg.37.6.410	47	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22669	22677		10.1074/jbc.M300637200	http://dx.doi.org/10.1074/jbc.M300637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12591919	hybrid			2022-12-25	WOS:000183503900067
J	Derebail, SS; Heath, MJ; DeStefano, JJ				Derebail, SS; Heath, MJ; DeStefano, JJ			Evidence for the differential effects of nucleocapsid protein on strand transfer in various regions of the HIV genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RNA SECONDARY STRUCTURE; ZINC-FINGER STRUCTURES; MURINE LEUKEMIA-VIRUS; REVERSE-TRANSCRIPTASE; INTERNAL REGIONS; VIRAL-RNA; RETROVIRAL RECOMBINATION; ESCHERICHIA-COLI; DNA-SYNTHESIS	An in vitro strand transfer assay that mimicked recombinational events occurring during reverse transcription in HIV-1 was used to assess the role of nucleocapsid protein (NC) in strand transfer. Strand transfer in highly structured nucleic acid species from the U3 3' long terminal repeats, gag-pol frameshift region, and Rev response element were strongly enhanced by NC. In contrast, weakly structured templates from the env and pol-vif regions transferred well without NC and showed lower enhancement. The lack of strong polymerase pause sites in the latter regions demonstrated that non-pause driven mechanisms could also promote transfer. Assays conducted using NC zinc finger mutants supported a differential role for the two fingers in strand transfer with finger 1 (N-terminal) being more important on highly structured RNAs. Overall this report suggests a role for structural intricacies of RNA templates in determining the extent of influence of NC on recombination and illustrates that strand transfer may occur by several different mechanisms depending on the structural nature of the RNA.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, JJ (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, Bldg 231, College Pk, MD 20742 USA.	jd146@umail.umd.edu			NIGMS NIH HHS [GM 51140, R01 GM051140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051140, R01GM051140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Berthoux L, 1999, J VIROL, V73, P10000, DOI 10.1128/JVI.73.12.10000-10009.1999; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; CASSAN M, 1994, J VIROL, V68, P1501, DOI 10.1128/JVI.68.3.1501-1508.1994; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Dinman JD, 2002, P NATL ACAD SCI USA, V99, P5331, DOI 10.1073/pnas.082102199; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; Gorelick RJ, 1999, VIROLOGY, V256, P92, DOI 10.1006/viro.1999.9629; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KHAN R, 1992, J BIOL CHEM, V267, P6689; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KOLLMUS H, 1994, J VIROL, V68, P6087, DOI 10.1128/JVI.68.9.6087-6091.1994; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LE SY, 1989, NUCLEIC ACIDS RES, V17, P6143, DOI 10.1093/nar/17.15.6143; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; PARKIN NT, 1992, J VIROL, V66, P5147, DOI 10.1128/JVI.66.8.5147-5151.1992; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; Poon DTK, 1998, J VIROL, V72, P1983, DOI 10.1128/JVI.72.3.1983-1993.1998; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; Raja A, 1999, BIOCHEMISTRY-US, V38, P5178, DOI 10.1021/bi9828019; Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RODA RH, 2002, J BIOL CHEM; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Sambrook J, 2001, MOL CLONING LAB MANU; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	83	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15702	15712		10.1074/jbc.M211701200	http://dx.doi.org/10.1074/jbc.M211701200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595541	hybrid			2022-12-25	WOS:000182680000032
J	Miyaso, H; Okumura, M; Kondo, S; Higashide, S; Miyajima, H; Imaizumi, K				Miyaso, H; Okumura, M; Kondo, S; Higashide, S; Miyajima, H; Imaizumi, K			An intronic splicing enhancer element in survival motor neuron (SMN) Pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; MOLECULAR ANALYSIS; GENE; BINDING; PROTEIN; IDENTIFICATION; DUPLICATION; EXPRESSION; INCLUSION; MUTATIONS	Spinal muscular atrophy is caused by the homozygous loss of survival motor neuron 1 (SMN1). SMN2, a nearly identical copy gene, differs from SMN1 only by a single nonpolymorphic C to T transition in exon 7, which leads to alteration of exon 7 splicing; SMN2 leads to exon 7 skipping and expression of a nonfunctional gene product and fails to compensate for the loss of SMN1. The exclusion of SMN exon 7 is critical for the onset of this disease. Regulation of SMN exon 7 splicing was determined by analyzing the roles of the cis-acting element in intron 7 (element 2), which we previously identified as a splicing enhancer element of SMN exon 7 containing the C to T transition. The minimum sequence essential for activation of the splicing was determined to be 24 nucleotides, and RNA structural analyses showed a stem-loop structure. Deletion of this element or disruption of the stem-loop structure resulted in a decrease in exon 7 inclusion. A gel shift assay using element 2 revealed formation of RNA-protein complexes, suggesting that the binding of the trans-acting proteins to element 2 plays a crucial role in the splicing of SMN exon 7 containing the C to T transition.	Nara Inst Sci & Technol, Div Struct Cellular Biol, Nara 6300101, Japan	Nara Institute of Science & Technology	Imaizumi, K (corresponding author), Nara Inst Sci & Technol, Div Struct Cellular Biol, 8916-5 Takayama, Nara 6300101, Japan.	imaizumi@bs.aist-nara.ac.jp		Miyaso, Hidenobu/0000-0003-2212-1500				Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brahe C, 1996, HUM MOL GENET, V5, P1971, DOI 10.1093/hmg/5.12.1971; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DiDonato CJ, 1997, ANN NEUROL, V41, P230, DOI 10.1002/ana.410410214; Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Lou H, 1999, MOL CELL BIOL, V19, P78; Miyajima H, 2002, J BIOL CHEM, V277, P23271, DOI 10.1074/jbc.M200851200; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; PEARN J, 1980, LANCET, V1, P919; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Rochette CF, 2001, HUM GENET, V108, P255, DOI 10.1007/s004390100473; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Simard LR, 1997, AM J MED GENET, V72, P51, DOI 10.1002/(SICI)1096-8628(19971003)72:1<51::AID-AJMG11>3.0.CO;2-T; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	31	63	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15825	15831		10.1074/jbc.M209271200	http://dx.doi.org/10.1074/jbc.M209271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604607	hybrid			2022-12-25	WOS:000182680000048
J	Bisaglia, M; Laalami, S; Uzan, M; Bontems, F				Bisaglia, M; Laalami, S; Uzan, M; Bontems, F			Activation of the RegB endoribonuclease by the S1 ribosomal protein is due to cooperation between the S1 four C-terminal modules in a substrate-dependant manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING PROPERTIES; ESCHERICHIA-COLI; MESSENGER-RNAS; IN-VITRO; BACTERIOPHAGE-T4; SITE; RIBONUCLEASE; SPECIFICITY	The RegB protein, encoded by the T4 bacteriophage genome, is a ribonuclease involved in the inactivation of the phage early messenger RNAs. Its in vitro activity is very low but can be enhanced up to 100-fold in the presence of the ribosomal protein S1. The latter is made of six repeats of a conserved module found in many other proteins of RNA metabolism. Considering the difference between its size (556 amino acids) and that of several RegB substrates (10 nucleotides), we wondered whether all six modules are necessary for RegB activation. We studied the influence of twelve S1 fragments on the cleavage efficiency of three short substrates. RegB activation requires the cooperation of different sets of modules depending on the substrates. Two RNAs are quite well cleaved in the presence of the fragment formed by the fourth and fifth modules, whereas the third requires the presence of the four C-terminal domains. However, NNR interaction experiments showed that, despite these differences, the interactions of the substrates with either the bi- or tetra-modules are similar, suggesting a common interaction surface. In the case of the tetra-module the interactions involve all four domains, raising the question of the spatial organization of this region.	Ecole Polytech, Grp ICSN RMN, F-91128 Palaiseau, France; Inst Jacques Monod, F-75005 Paris, France	Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Cite	Bontems, F (corresponding author), Ecole Polytech, Grp ICSN RMN, F-91128 Palaiseau, France.	Francois.Bontems@polytechnique.fr						BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Boni IV, 2000, J BACTERIOL, V182, P5872, DOI 10.1128/JB.182.20.5872-5879.2000; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DELSUC MA, 1989, FUND THEOR, V36, P285; DRAPER DE, 1977, P NATL ACAD SCI USA, V74, P4786, DOI 10.1073/pnas.74.11.4786; DRAPER DE, 1978, J MOL BIOL, V122, P321, DOI 10.1016/0022-2836(78)90193-6; DRAPER DE, 1978, J MOL BIOL, V122, P339; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; Jayasena VK, 1996, BIOCHEMISTRY-US, V35, P2349, DOI 10.1021/bi951879b; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Lebars I, 2001, J BIOL CHEM, V276, P13264, DOI 10.1074/jbc.M010680200; LEBARS I, 2001, THESIS U VERSAILLES; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUNIYAPPA K, 1993, BIOCHEM MOL BIOL INT, V31, P1; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; ROBERTS MW, 1989, J BIOL CHEM, V264, P2228; RUCKMAN J, 1989, New Biologist, V1, P54; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; Sanson B, 2000, J MOL BIOL, V297, P1063, DOI 10.1006/jmbi.2000.3626; SANSON B, 1993, J MOL BIOL, V233, P429, DOI 10.1006/jmbi.1993.1522; SEETHARA.A, 1973, J MOL BIOL, V76, P207, DOI 10.1016/0022-2836(73)90385-9; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; Snoussi K, 2001, J MOL BIOL, V309, P139, DOI 10.1006/jmbi.2001.4618; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; TZAREVA NV, 1994, FEBS LETT, V337, P189, DOI 10.1016/0014-5793(94)80271-8; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895; Uzan M, 2001, METHOD ENZYMOL, V342, P467, DOI 10.1016/S0076-6879(01)42567-5; VANDUIN J, 1988, VIRUSES, P116; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	35	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15261	15271		10.1074/jbc.M212731200	http://dx.doi.org/10.1074/jbc.M212731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576472	hybrid			2022-12-25	WOS:000182516100088
J	Cox, DM; Du, M; Marback, M; Yang, ECC; Chan, J; Siu, KWM; McDermott, JC				Cox, DM; Du, M; Marback, M; Yang, ECC; Chan, J; Siu, KWM; McDermott, JC			Phosphorylation motifs regulating the stability and function of myocyte enhancer factor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; NEUROFILAMENT PROTEINS; GENE-EXPRESSION; T-CELLS; MEF2; P38; DIFFERENTIATION; PURIFICATION; MYOGENESIS	The phosphorylation status of the myocyte enhancer factor 2 (MEF2) transcriptional regulator is a critical determinant of its tissue-specific functions. However, due to the complexity of its phosphorylation pattern in vivo, a systematic inventory of MEF2A phosphorylation sites in mammalian cells has been difficult to obtain. We employed modern affinity purification techniques, combined with mass spectrometry, to identify several novel MEF2 phosphoacceptor sites. These include an evolutionarily conserved KSP motif, which we show is important in regulating the stability and function of MEF2A. Also, an indirect pathway in which a protein kinase casein kinase 2 phosphoacceptor site is phosphorylated by activation of p38 MAPK signaling was documented. Together, these findings identify several novel aspects of MEF2 regulation that may prove important in the control of gene expression in neuronal and muscle cells.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; York Univ, Ctr Res Mass Spectrometry, Toronto, ON M3J 1P3, Canada; York Univ, Dept Chem, Toronto, ON M3J 1P3, Canada	York University - Canada; York University - Canada; York University - Canada	McDermott, JC (corresponding author), York Univ, Dept Biol, 4700 Keele St,247 Farquharson Bldg, Toronto, ON M3J 1P3, Canada.	jmcderm@yorku.ca						Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cox D M, 2000, Exerc Sport Sci Rev, V28, P33; Cox DM, 2002, BIOTECHNIQUES, V33, P267, DOI 10.2144/02332bm02; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Giasson BI, 1997, J NEUROSCI, V17, P9466; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Veeranna, 1998, J NEUROSCI, V18, P4008; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao M, 1999, MOL CELL BIOL, V19, P21	42	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15297	15303		10.1074/jbc.M211312200	http://dx.doi.org/10.1074/jbc.M211312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586839	hybrid			2022-12-25	WOS:000182516100093
J	Kroesen, BJ; Jacobs, S; Pettus, BJ; Sietsma, H; Kok, JW; Hannun, YA; de Leij, LFMH				Kroesen, BJ; Jacobs, S; Pettus, BJ; Sietsma, H; Kok, JW; Hannun, YA; de Leij, LFMH			BcR-induced apoptosis involves differential regulation of C-16 and C-24-ceramide formation and sphingolipid-dependent activation of the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE ACTIVITY; IGM-INDUCED APOPTOSIS; CERAMIDE GENERATION; ANTIGEN RECEPTOR; INHIBITION; UBIQUITIN; MITOCHONDRIA; SPHINGOMYELIN; DEGRADATION; MEMBRANE	In this study, we describe an ordered formation of long- and very long-chain ceramide species in relation to the progression of B-cell receptor (BcR) triggering induced apoptosis. An early and caspase-independent increase in long-chain ceramide species, in which C-24-ceramide predominated, was observed 6 h after Belt triggering. In contrast, very long-chain ceramide species were generated later, 12-24 h after BeR triggering. The formation of these very long-chain ceramide species, in which C-24-ceramide predominated, required the activation of effector caspases. BcR-induced formation of long-chain ceramide species resulted in proteasomal activation and degradation of XIAP and subsequent activation of effector caspases, demonstrating an important cell-biological mechanism through which longchain ceramides may be involved in the progression of BcR triggering induced apoptosis and subsequent formation of very long-chain ceramide species. BcR-induced activation of the proteasome was blocked with ISP-1/myriocin, a potent and selective inhibitor of serine palmitoyl transferase that catalyzes the first and rate-limiting step in the de novo formation of ceramide. Both ISP-1 and clasto-lactacystin beta-lactone, an irreversible inhibitor of the proteasome, prevented BcR cross-linking-induced XIAP degradation. Also, a mutant XIAP lacking the ubiquitin-ligating ring finger motif was completely resistant to proteasome-mediated degradation, and Ramos cells overexpressing XIAP became highly resistant to BcR cross-linking-induced activation of caspases. The formation of C-16-ceramide in response to BcR cross-linking was found unaltered in XIAP overexpressing Ramos cells, whereas C-24-ceramide formation was completely abolished. These results demonstrate how de novo generated long-chain ceramide species may be involved in the activation of downstream effector caspases and subsequent formation of very long-chain ceramide species. As such, these results provide novel and important insights into the significance of specific ceramide species in defined stages of apoptosis.	Univ Groningen Hosp, Dept Pathol & Lab Med, Med Biol Branch, NL-9713 GZ Groningen, Netherlands; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Groningen Hosp, Dept Pathol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; Medical University of South Carolina; University of Groningen; University of Groningen	Kroesen, BJ (corresponding author), Univ Groningen Hosp, Dept Pathol & Lab Med, Med Biol Branch, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	b.j.kroesen@thorax.azg.nl						Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Andjelic S, 1998, EUR J IMMUNOL, V28, P570, DOI 10.1002/(SICI)1521-4141(199802)28:02<570::AID-IMMU570>3.0.CO;2-M; ARIZTI P, 1993, ENZYME PROTEIN, V47, P285, DOI 10.1159/000468686; Berard R, 1999, J IMMUNOL, V163, P4655; Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dawson G, 1998, ACTA BIOCHIM POL, V45, P287, DOI 10.18388/abp.1998_4225; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; Dick LR, 1997, J BIOL CHEM, V272, P182; Donjerkovic D, 2000, CELL RES, V10, P179, DOI 10.1038/sj.cr.7290047; Doyle BT, 2002, J LEUKOCYTE BIOL, V71, P247; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gold MR, 2002, TRENDS PHARMACOL SCI, V23, P316, DOI 10.1016/S0165-6147(02)02045-X; Goldberg AL, 2000, NAT BIOTECHNOL, V18, P494, DOI 10.1038/75349; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hideshima T, 2001, CANCER RES, V61, P3071; Hirsch T, 1998, J IMMUNOL, V161, P35; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kong JY, 2002, AM J PHYSIOL-HEART C, V282, pH717, DOI 10.1152/ajpheart.00257.2001; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; PREISS J, 1986, J BIOL CHEM, V261, P8597; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Riley RT, 1999, ENVIRON TOXICOL PHAR, V7, P109, DOI 10.1016/S1382-6689(98)00047-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sauerwald TM, 2002, BIOTECHNOL BIOENG, V77, P704, DOI 10.1002/bit.10154; Shimeno H, 1998, LIPIDS, V33, P601, DOI 10.1007/s11745-998-0246-2; Shounan Y, 1998, J IMMUNOL METHODS, V217, P61, DOI 10.1016/S0022-1759(98)00090-8; Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zollner TM, 2002, J CLIN INVEST, V109, P671, DOI 10.1172/JCI200212736	51	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14723	14731		10.1074/jbc.M210756200	http://dx.doi.org/10.1074/jbc.M210756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12578840	hybrid			2022-12-25	WOS:000182516100019
J	Liang, FQ; Webb, P; Marimuthu, A; Zhang, SM; Gardner, DG				Liang, FQ; Webb, P; Marimuthu, A; Zhang, SM; Gardner, DG			Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; MYOSIN HEAVY-CHAIN; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONGESTIVE-HEART-FAILURE; CARDIAC-HYPERTROPHY; RESPONSE ELEMENTS; MESSENGER-RNA; NUCLEAR RECEPTORS; COACTIVATOR COMPLEXES; TRAP220 COMPONENT	Brain natriuretic peptide (BNP) gene expression is a well documented marker of hypertrophy in the cardiac myocyte. Triiodothyronine (T-3), the bioactive form of thyroid hormone, triggers a unique form of hypertrophy in cardiac myocytes that accompanies the selective activation or suppression of specific gene targets. In this study, we show that the BNP gene is a target of T-3 action. BNP secretion was increased 6-fold, BNP mRNA levels 3-fold, and BNP promoter activity 3-5-fold following T-3 treatment. This was accompanied by an increase in myocyte size, sarcomeric organization, and protein synthesis. Of note, several of the responses to T-3 synergized with those to the conventional hypertrophic agonist endothelin. The response to the liganded thyroid hormone receptor (TR) was mediated by an unusual thyroid hormone response element located between -1000 and -987 relative to the transcription start site. Both TR homodimers and TR-retinoid X receptor heterodimers associated with this element in an electrophoretic mobility shift assay. Protein fragments harboring the LXXLL motifs of the coactivators GRIP1 and SRC1 or TRAP220 interacted predominantly with the TR-retinoid X receptor heterodimeric pair in a ligand-dependent fashion. Both TR homodimers and heterodimers in the unliganded state selectively associated with glutathione S-transferase-nuclear receptor corepressor fragments harboring one of three receptor interaction domains containing the sequence (I/L)XX-(I/V)I. These interactions were dissociated following the addition of T-3. Collectively, these findings identify the BNP gene as a potential model for the investigation of TR-dependent gene regulation in the heart.	Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Ctr Diabet, Metab Res Unit, 1109 HSW,3rd & Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1991, CIRC RES, V69, P266, DOI 10.1161/01.RES.69.2.266; Basset A, 2001, J CARDIOVASC PHARM, V37, P163, DOI 10.1097/00005344-200102000-00004; BOERTH SR, 1996, CARDIOVASC RES, V31, P145; Chang KC, 1997, J CLIN INVEST, V100, P1742, DOI 10.1172/JCI119699; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; GARDNER DG, 1987, MOL ENDOCRINOL, V1, P260, DOI 10.1210/mend-1-3-260; GICK GG, 1990, J MEMBRANE BIOL, V115, P273, DOI 10.1007/BF01868642; HARTONG R, 1994, J BIOL CHEM, V269, P13021; Hoit BD, 1997, CIRCULATION, V96, P592, DOI 10.1161/01.cir.96.2.592; Hojo Y, 1997, J CARDIOVASC PHARM, V29, P75, DOI 10.1097/00005344-199701000-00012; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hystad ME, 2001, ACTA PHYSIOL SCAND, V171, P395, DOI 10.1046/j.1365-201X.2001.00805.x; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Kinugawa K, 2001, CIRC RES, V89, P591, DOI 10.1161/hh1901.096706; Kinugawa K, 2001, CIRCULATION, V103, P1089, DOI 10.1161/01.CIR.103.8.1089; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; KISS E, 1994, CIRC RES, V75, P245, DOI 10.1161/01.RES.75.2.245; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Kobori H, 1999, J ENDOCRINOL, V160, P43, DOI 10.1677/joe.0.1600043; KOHNO M, 1993, METABOLISM, V42, P1059, DOI 10.1016/0026-0495(93)90023-H; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Ojamaa K, 2000, METABOLISM, V49, P275, DOI 10.1016/S0026-0495(00)92262-5; Ojamaa K, 1999, ENDOCRINOLOGY, V140, P3170, DOI 10.1210/en.140.7.3170; Ojamaa K, 1996, ENDOCRINOLOGY, V137, P802, DOI 10.1210/en.137.3.802; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; RUPP H, 1990, J APPL PHYSIOL, V68, P973, DOI 10.1152/jappl.1990.68.3.973; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Treuter E, 1999, J BIOL CHEM, V274, P6667, DOI 10.1074/jbc.274.10.6667; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; WU JP, 1989, J BIOL CHEM, V264, P6472; YAO JL, 1992, CIRC RES, V71, P831, DOI 10.1161/01.RES.71.4.831; YEN PM, 1994, J BIOL CHEM, V269, P12704; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	62	65	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15073	15083		10.1074/jbc.M207593200	http://dx.doi.org/10.1074/jbc.M207593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12562779	hybrid			2022-12-25	WOS:000182516100065
J	Park, EJ; Park, SY; Joe, EH; Jou, I				Park, EJ; Park, SY; Joe, EH; Jou, I			15d-PGJ(2) and rosilglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; INHIBITION; RESPONSES; PROTEIN; GENE; TRANSCRIPTION; EXPRESSION	Peroxisome proliferator-activated receptor (PPAR)-gamma agonists are now emerging as therapeutic drugs for various inflammatory diseases. However, their molecular mechanism of action remains to be elucidated. Here we report a novel mechanism that underlies the PPAR-gamma agonist-mediated suppression of brain inflammation. We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ,) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia. The PPAR-gamma agonist-mediated reduction in phosphorylation leads to the suppression of JAK-STAT-dependent inflammatory responses. The effects of 15d-PGJ2 and rosiglitazone are not mediated by activation of PPAR-gamma. 15d-PGJ2 and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells. In addition, Src homology, 2, domain-containing protein phosphatase 2 (SHP2), another negative regulator of JAK activity, is also involved in their anti-inflammatory action. Our data suggest that 15d-PGJ, and rosiglitazone suppress the initiation of JAK-STAT inflammatory signaling independently of PPAR-gamma, thus attenuating brain inflammation.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea	Ajou University	Jou, I (corresponding author), Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea.	jouilo@madang.ajou.ac.kr						Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Balasingam V, 1996, J NEUROSCI, V16, P2945; Bousquet C, 2001, MOL ENDOCRINOL, V15, P1880, DOI 10.1210/me.15.11.1880; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jee Y, 2001, J NEUROIMMUNOL, V114, P40, DOI 10.1016/S0165-5728(00)00446-X; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MURPHY GJ, 2002, TRENDS PHARMACOL SCI, V21, P469; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; STROLL G, 1998, PROG NEUROBIOL, V56, P149; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Wesemann DR, 2002, J IMMUNOL, V169, P2354, DOI 10.4049/jimmunol.169.5.2354; Xiao BG, 1999, IMMUNOL TODAY, V20, P477, DOI 10.1016/S0167-5699(99)01501-7; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	45	193	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14747	14752		10.1074/jbc.M210819200	http://dx.doi.org/10.1074/jbc.M210819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584205	hybrid			2022-12-25	WOS:000182516100022
J	Yang, J; Jones, SP; Suhara, T; Greer, JJM; Ware, PD; Nguyen, NP; Perlman, H; Nelson, DP; Lefer, DJ; Walsh, K				Yang, J; Jones, SP; Suhara, T; Greer, JJM; Ware, PD; Nguyen, NP; Perlman, H; Nelson, DP; Lefer, DJ; Walsh, K			Endothelial cell overexpression of Fas ligand attenuates ischemia-reperfusion injury in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULAR IMMUNE PRIVILEGE; CD95 LIGAND; NEUTROPHIL DEPLETION; MEDIATED APOPTOSIS; GENE-TRANSFER; EXPRESSION; DEATH; SENSITIVITY; FLIP; AUTOIMMUNITY	Fas ligand (FasL) is a member of tumor necrosis factor family that induces apoptosis in target cells that express Fas. The function of FasL during inflammation remains controversial. In this study, we examined the role of vascular endothelial FasL during acute myocardial ischemia-reperfusion that is closely associated with inflammation. Transgenic mouse lines were established that overexpress human FasL on endothelium under the control of the vascular endothelial cadherin promoter. Expression of FasL transgene was detected at both mRNA and protein levels, and functional transgene-encoded FasL protein was specifically expressed on the surface of vascular endothelial cells. Transgenic mice developed normally and had normal hearts. When subjected to 30 min of myocardial ischemia and 72 h of reperfusion, myocardial infarct size was reduced by 42% in the transgenic mice compared with nontransgenic littermates (p < 0.05). Moreover, hemodynamic data demonstrated that transgenic hearts performed better following ischemia and reperfusion compared with nontransgenic hearts. Myocardial neutrophil infiltration was reduced by 54% after 6 h of reperfusion in transgenic hearts (p < 0.01). Neutrophil depletion prior to ischemia-reperfusion injury led to smaller infarcts that were not different between transgenic and nontransgenic mice, suggesting that endothelial FasL may attenuate ischemia-reperfusion injury by abating the inflammatory response. These results indicate that vascular endothelial FasL may exert potent anti-inflammatory actions in the setting of myocardial ischemia-reperfusion injury.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Tufts Univ, Sch Med, Program Cellular Mol & Dev Biol, Boston, MA 02111 USA; Louisiana State Univ, Ctr Hlth Sci, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Johns Hopkins Med Inst, Div Cardiol, Baltimore, MD 21205 USA; Osaka Univ, Sch Med, Dept Geriatr Med, Osaka 553, Japan; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Childrens Hosp, Med Ctr, Div Cardiol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	Boston University; Tufts University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Johns Hopkins University; Johns Hopkins Medicine; Osaka University; Saint Louis University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.		Lefer, David/A-6372-2012; Jones, Steven P./D-5092-2009	Jones, Steven P./0000-0001-5376-8089; Lefer, David/0000-0003-2293-7278	NHLBI NIH HHS [HL-66957, HL60849] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG-17241, AG-15052] Funding Source: Medline; NICHD NIH HHS [HD-23681] Funding Source: Medline; NIDDK NIH HHS [DK43785] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066957, R01HL060849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R37AG015052, R01AG017241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Bao JL, 2001, AM J PHYSIOL-HEART C, V281, pH2612, DOI 10.1152/ajpheart.2001.281.6.H2612; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bouchet D, 2002, MOL MED, V8, P612, DOI 10.1007/BF03402172; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Gregory MS, 2002, J IMMUNOL, V169, P2727, DOI 10.4049/jimmunol.169.5.2727; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hohlbaum AM, 2001, J IMMUNOL, V167, P6217, DOI 10.4049/jimmunol.167.11.6217; Jeremias I, 2000, CIRCULATION, V102, P915; Jones SP, 2001, AM J PHYSIOL-HEART C, V281, pH48, DOI 10.1152/ajpheart.2001.281.1.H48; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LITT MR, 1989, CIRCULATION, V80, P1816, DOI 10.1161/01.CIR.80.6.1816; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Luo ZY, 1999, CIRCULATION, V99, P1776, DOI 10.1161/01.CIR.99.14.1776; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; Muruve DA, 1997, HUM GENE THER, V8, P955, DOI 10.1089/hum.1997.8.8-955; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nelson DP, 2000, J CLIN INVEST, V105, P1199, DOI 10.1172/JCI8212; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Perlman H, 2000, CARDIOVASC RES, V45, P570, DOI 10.1016/S0008-6363(99)00346-6; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; Sano Y, 2002, EXP EYE RES, V75, P475, DOI 10.1006/exer.2002.2044; Sata M, 2001, FASEB J, V15, P2530, DOI 10.1096/fj.01-0415fje; Sata M, 2001, J IMMUNOL, V166, P6964, DOI 10.4049/jimmunol.166.11.6964; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Shiraishi H, 2002, LAB INVEST, V82, P1121, DOI 10.1097/01.LAB.0000029148.88524.CE; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Stassi G, 2000, NAT IMMUNOL, V1, P483, DOI 10.1038/82725; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Takeuchi T, 1999, J IMMUNOL, V162, P518; Tourneur U, 2001, J IMMUNOL, V167, P1338, DOI 10.4049/jimmunol.167.3.1338; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9	48	35	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15185	15191		10.1074/jbc.M211707200	http://dx.doi.org/10.1074/jbc.M211707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12576484	hybrid			2022-12-25	WOS:000182516100078
J	Jambrina, E; Alonso, R; Alcalde, M; Rodriguez, MD; Serrano, A; Martinez-A, C; Garcia-Sancho, J; Izquierdo, M				Jambrina, E; Alonso, R; Alcalde, M; Rodriguez, MD; Serrano, A; Martinez-A, C; Garcia-Sancho, J; Izquierdo, M			Calcium influx through receptor-operated channel induces mitochondria-triggered paraptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN RECEPTOR; APOPTOSIS; STIMULATION; ACTIVATION; EVENT; DNA	We address the specific role of cytoplasmic Ca2+ overload as a cell death trigger by expressing a receptor-operated specific Ca2+ channel, vanilloid receptor subtype 1 (VR1), in Jurkat cells. Ca2+ uptake through the VR1 channel, but not capacitative Ca2+ influx stimulated by the muscarinic type 1 receptor, induced sustained intracellular [Ca2+] rises, exposure of phosphatidylserine, and cell death. Ca2+ influx was necessary and sufficient to induce mitochondrial damage, as assessed by opening of the permeability transition pore and collapse of the mitochondrial membrane potential. Ca2+- induced cell death was inhibited by ruthenium red, protonophore carbonyl cyanide m-chlorophenylhydrazone, or cyclosporin A treatment, as well as by Bcl-2 expression, indicating that this process requires mitochondrial calcium uptake and permeability transition pore opening. Cell death occurred without caspase activation, oligonucleosomal/50-kilobase pair DNA cleavage, or release of cytochrome c or apoptosis inducer factor from mitochondria, but it required oxidative/nitrative stress. Thus, Ca2+ influx triggers a distinct program of mitochondrial dysfunction leading to paraptotic cell death, which does not fulfill the criteria for either apoptosis or necrosis.	Univ Valladolid, CSIC, Inst Biol & Genet Mol, Fac Med, E-47005 Valladolid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Izquierdo, M (corresponding author), Univ Valladolid, CSIC, Inst Biol & Genet Mol, Fac Med, Ramon & Cajal 7, E-47005 Valladolid, Spain.	mizdo@ibgm.uva.es	Izquierdo, Manuel/D-2971-2017; Izquierdo, Manuel/I-4812-2013; Garcia-Sancho, Javier/K-2975-2014; Izquierdo, Manuel/I-4812-2013	Izquierdo, Manuel/0000-0002-7701-1002; Izquierdo, Manuel/0000-0002-7701-1002; Serrano, Antonio/0000-0003-1993-640X; Garcia-Sancho, Javier/0000-0003-4573-7930; Izquierdo, Manuel/0000-0002-7261-404X				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; Alvarez J, 1999, NEWS PHYSIOL SCI, V14, P161; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Golstein P, 1998, SCIENCE, V281, P1283, DOI 10.1126/science.281.5381.1283; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Izquierdo M, 1996, J IMMUNOL, V157, P21; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2001, ARCH BIOCHEM BIOPHYS, V393, P321, DOI 10.1006/abbi.2001.2500; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; Montero M, 2001, MOL BIOL CELL, V12, P63, DOI 10.1091/mbc.12.1.63; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; PREMACK BA, 1994, J IMMUNOL, V152, P5226; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, FEBS LETT, V501, P79, DOI 10.1016/S0014-5793(01)02629-1; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Slagsvold HH, 2000, EXP BRAIN RES, V135, P173, DOI 10.1007/s002210000521; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Villalobos C, 1996, FASEB J, V10, P654, DOI 10.1096/fasebj.10.5.8621065	47	89	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14134	14145		10.1074/jbc.M211388200	http://dx.doi.org/10.1074/jbc.M211388200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12571238	Green Published, hybrid			2022-12-25	WOS:000182405000074
J	Joglekar, AP; Xu, DL; Rigotti, DJ; Fairman, R; Hay, JC				Joglekar, AP; Xu, DL; Rigotti, DJ; Fairman, R; Hay, JC			The SNARE motif contributes to rbet1 intracellular targeting and dynamics independently of SNARE interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; GOLGI NETWORK; BREFELDIN-A; COMPLEX; LOCALIZATION; ER; TRANSPORT; PROTEINS; FUSION	The endoplasmic reticulum/Golgi SNARE rbet1 cycles between the endoplasmic reticulum and Golgi and is essential for cargo transport in the secretory pathway. Although the quaternary SNARE complex containing rbet1 is known to function in membrane fusion, the structural role of rbet1 is unclear. Furthermore, the structural determinants for rbet1 targeting and its cyclical itinerary have not been investigated. We utilized protein interaction assays to demonstrate that the rbet1 SNARE motif plays a structural role similar to the carboxyl-terminal helix of SNAP-25 in the synaptic SNARE complex and demonstrated the importance to SNARE complex assembly of a conserved salt bridge between rbet1 and sec22b. We also examined the potential role of the rbet1 SNARE motif and SNARE interactions in rbet1 localization and dynamics. We found that, in contrast to what has been observed for syntaxin 5'. the rbet1 SNARE motif was essential for proper targeting. To test whether SNARE interaction's were important for the targeting function of the SNARE motif, we used charge repulsion mutations at the conserved salt bridge position that rendered rbet1 defective for binary, ternary, and quaternary SNARE interactions. We found that heteromeric SNARE interactions are not required at any step in rbet1 targeting-or dynamics. Furthermore, the heteromeric state of the SNARE motif does not influence its interaction with the COPI coat or efficient recruitment onto transport vesicles. We conclude that protein targeting is a completely independent function of the rbet1 SNARE motif, which is capable of distinct classes of protein interactions.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Haverford Coll, Dept Biol, Haverford, PA 19041 USA	University of Michigan System; University of Michigan; Haverford College	Hay, JC (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	jessehay@umich.edu			NIGMS NIH HHS [GM59378] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059378] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Hanson MA, 2000, NAT STRUCT BIOL, V7, P687, DOI 10.1038/77997; Hao JC, 1997, J NEUROSCI, V17, P1596; Hasegawa H, 2003, MOL BIOL CELL, V14, P698, DOI 10.1091/mbc.E02-09-0556; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 2001, EXP CELL RES, V271, P10, DOI 10.1006/excr.2001.5368; Kasai K, 2001, J CELL SCI, V114, P3115; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Matsuoka K, 1998, MOL CELL, V2, P703, DOI 10.1016/S1097-2765(00)80168-9; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Misura KMS, 2002, P NATL ACAD SCI USA, V99, P9184, DOI 10.1073/pnas.132274599; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Rein U, 2002, J CELL BIOL, V157, P395, DOI 10.1083/jcb.200112092; SARASTE J, 1991, J CELL SCI, V100, P415; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200	41	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14121	14133		10.1074/jbc.M300659200	http://dx.doi.org/10.1074/jbc.M300659200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12566453	hybrid			2022-12-25	WOS:000182405000073
J	Lin, P; Ye, RD				Lin, P; Ye, RD			The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COUPLED RECEPTOR; DEPENDENT ACTIVATION; LYSOPHOSPHATIDYLCHOLINE; CELLS; KINASE; RGS; SPHINGOSYLPHOSPHORYLCHOLINE; G-ALPHA(13); PATHWAY	G2A, a G protein-coupled receptor for which lysophosphatidylcholine (LPC) is a high affinity ligand, belongs to a newly defined lysophospholipid receptor subfamily. Expression of G2A is transcriptionally up-regulated by stress-inducing and cell-damaging agents, and ectopic expression of G2A leads to growth inhibition. However, the G proteins that functionally couple to G2A have not been elucidated in detail. We report here that G2A ligand independently stimulates the accumulation of both inositol phosphates and cAMP. LPC does not further enhance inositol phosphate accumulation but dose-dependently augments intracellular cAMP concentration. Expression of Galpha(q) and Galpha(13) with G2A potentiates G2A-mediated activation of a NF-kappaB-luciferase reporter. These results demonstrate that G2A differentially couples to multiple G proteins including Galpha(s), Galpha(q), and Galpha(13), depending on whether it is bound to ligand. G2A-transfected HeLa cells display apoptotic signs including membrane blebbing, nuclear condensation, and reduction of mitochondrial membrane potential. Furthermore, G2A-induced apoptosis can be rescued by the caspase inhibitors, z-vad-fmk and CrmA. Although apoptosis occurs without LPC stimulation, LPC further enhances G2A-mediated apoptosis and correlates with its ability to induce cAMP elevation in both HeLa cells and primary lymphocytes. Rescue from G2A-induced apoptosis was achieved by co-expression of a Galpha(12/13)-specific inhibitor, p115RGS (regulator of G protein signaling), in combination with 2',5'-dideoxyadenosine treatment. These results demonstrate the ability of G2A to activate a specific combination of G proteins, and that G2A/LPC-induced apoptosis involves both Galpha(13)- and Galpha(s)-mediated pathways.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NIAID NIH HHS [AI40176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040176, R56AI040176] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Goldman FD, 2002, CLIN IMMUNOL, V104, P31, DOI 10.1006/clim.2002.5249; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Le LQ, 2002, CANCER CELL, V1, P381, DOI 10.1016/S1535-6108(02)00058-2; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Shi CS, 2001, J BIOL CHEM, V276, P31845, DOI 10.1074/jbc.M101043200; Teitler Milt, 2002, Current Topics in Medicinal Chemistry, V2, P529, DOI 10.2174/1568026023393859; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	33	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14379	14386		10.1074/jbc.M209101200	http://dx.doi.org/10.1074/jbc.M209101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12586833	hybrid			2022-12-25	WOS:000182405000103
J	Meima, ME; Weening, KE; Schaap, P				Meima, ME; Weening, KE; Schaap, P			Characterization of a cAMP-stimulated cAMP phosphodiesterase in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP PHOSPHODIESTERASE; METALLO-BETA-LACTAMASE; CRYSTAL-STRUCTURE; BACILLUS-CEREUS; CGMP PHOSPHODIESTERASE; ADENYLYL-CYCLASE; GENE-EXPRESSION; GLYOXALASE-II; BINDING	A cyclic nucleotide phosphodiesterase, PdeE, that harbors two cyclic nucleotide binding motifs and a binuclear Zn2+-binding domain was characterized in Dictyostelium. In other eukaryotes, the Dictyostelium domain shows greatest homology to the 73-kDa subunit of the pre-mRNA cleavage and polyadenylation specificity factor. The Dictyostelium PdeE gene is expressed at its highest levels during aggregation, and its disruption causes the loss of a cAMP-phosphodiesterase activity. The pdeE null mutants show a normal cAMP-induced cGMP response and a 1.5-fold increase of cAMP-induced cAMP relay. Overexpression of a PdeE-yellow fluorescent protein (YFP) fusion construct causes inhibition of aggregation and loss of the cAMP relay response, but the cells can aggregate in synergy with wild-type cells. The PdeE-YFP fusion protein was partially purified by immunoprecipitation and biochemically characterized. PdeE and its Dictyostelium ortholog, PdeD, are both maximally active at pH 7.0. Both enzymes require bivalent cations for activity. The common cofactors Zn2+ and Mg2+ activated PdeE and PdeD maximally at 10 mm, whereas Mn2+ activated the enzymes to 4-fold higher levels, with half-maximal activation between 10 and 100 gm. PdeE is an allosteric enzyme, which is similar to4-fold activated by cAMP, with half-maximal activation occurring at about 10 muM and an apparent K-m of similar to1 mm. cGMP is degraded at a 6-fold lower rate than cAMP. Neither cGMP nor 8-Br-cAMP are efficient activators of PdeE activity.	Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Schaap, P (corresponding author), Univ Dundee, Sch Life Sci, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.		Schaap, Pauline/A-3682-2009; Schaap, Pauline/M-5355-2019	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bosgraaf L, 2002, EMBO J, V21, P4560, DOI 10.1093/emboj/cdf438; Bosgraaf L, 2002, MOL BIOL CELL, V13, P3878, DOI 10.1091/mbc.E02-05-0302; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; DELOZANNE A, 1987, METHOD CELL BIOL, V28, P489; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; Dunn O. J., 1987, APPL STAT ANAL VARIA; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; GILMAN AG, 1972, ADV CYCL NUCL RES<D>, V2, P9; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Goldberg JM, 2002, P NATL ACAD SCI USA, V99, P6749, DOI 10.1073/pnas.102167299; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KALPAXIS D, 1990, DEV GENET, V11, P396, DOI 10.1002/dvg.1020110512; KESBEKE F, 1985, EUR J BIOCHEM, V151, P179, DOI 10.1111/j.1432-1033.1985.tb09083.x; KESSIN RH, 1979, P NATL ACAD SCI USA, V76, P5450, DOI 10.1073/pnas.76.11.5450; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; Kuwayama H, 2001, BIOCHEM J, V353, P635, DOI 10.1042/0264-6021:3530635; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; Laub MT, 1998, MOL BIOL CELL, V9, P3521, DOI 10.1091/mbc.9.12.3521; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MARTIEL JL, 1987, BIOPHYS J, V52, P807, DOI 10.1016/S0006-3495(87)83275-7; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Meima ME, 2002, MOL BIOL CELL, V13, P3870, DOI 10.1091/mbc.E02-05-0285; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; PANNBACKER RG, 1972, SCIENCE, V175, P1014, DOI 10.1126/science.175.4025.1014; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHABB JB, 1991, J BIOL CHEM, V266, P24320; Shaulsky G, 1998, DEVELOPMENT, V125, P691; Shaulsky G, 1996, P NATL ACAD SCI USA, V93, P15260, DOI 10.1073/pnas.93.26.15260; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TANG YH, 1994, MATH BIOSCI, V120, P25, DOI 10.1016/0025-5564(94)90037-X; THEIBERT A, 1983, J CELL BIOL, V97, P173, DOI 10.1083/jcb.97.1.173; Thomason PA, 1998, EMBO J, V17, P2838, DOI 10.1093/emboj/17.10.2838; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X	54	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14356	14362		10.1074/jbc.M209648200	http://dx.doi.org/10.1074/jbc.M209648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12574165	hybrid			2022-12-25	WOS:000182405000100
J	Henderson, CJ; Otto, DME; Carrie, D; Magnuson, MA; McLaren, AW; Rosewell, I; Wolf, CR				Henderson, CJ; Otto, DME; Carrie, D; Magnuson, MA; McLaren, AW; Rosewell, I; Wolf, CR			Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7 ALPHA-HYDROXYLASE; BILE-ACID; CHOLESTEROL ABSORPTION; GENE; MICE; EXPRESSION; LIVER; HEPATOTOXICITY; GLUTATHIONE; DISRUPTION	Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of a large number of endogenous compounds and the majority of ingested environmental chemicals, leading to their elimination and often to their metabolic activation to toxic products. This enzyme system therefore provides our primary defense against xenobiotics and is a major determinant in the therapeutic efficacy of pharmacological agents. To evaluate the importance of hepatic P450s in normal homeostasis, drug pharmacology, and chemical toxicity, we have conditionally deleted the essential electron transfer protein, NADH:ferrihemoprotein reductase (EC 1.6.2.4, cytochrome P450 reductase, CPR) in the liver, resulting in essentially complete ablation of hepatic microsomal P450 activity. Hepatic CPR-null mice could no longer break down cholesterol because of their inability to produce bile acids, and whereas hepatic lipid levels were significantly increased, circulating levels of cholesterol and triglycerides were severely reduced. Loss of hepatic P450 activity resulted in a 5-fold increase in P450 protein, indicating the existence of a negative feedback pathway regulating P450 expression. Profound changes in the in vivo metabolism of pentobarbital and acetaminophen indicated that extrahepatic metabolism does not play a major role in the disposition of these compounds. Hepatic CPR-null mice developed normally and were able to breed, indicating that hepatic microsomal P450-mediated steroid hormone metabolism is not essential for fertility, demonstrating that a major evolutionary role for hepatic P450s is to protect mammals from their environment.	Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland	University of Dundee	Wolf, CR (corresponding author), Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Level 5, Dundee DD1 9SY, Scotland.	mark.magnuson@vanderbilt.edu; roland.wolf@cancer.org.uk	Magnuson, Mark A/B-1335-2009; Henderson, Colin J/A-6347-2009; Henderson, Colin/AAE-7141-2019; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Henderson, Colin/0000-0002-4764-639X; Magnuson, Mark/0000-0002-8824-6499; Wolf, Charles Roland/0000-0002-6969-0113; CARRIE, didier/0000-0003-2479-8144				Bosner MS, 1999, J LIPID RES, V40, P302; Brochet D, 1999, GEN PHARMACOL-VASC S, V33, P249, DOI 10.1016/S0306-3623(99)00018-X; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cairns W, 1996, J BIOL CHEM, V271, P25269, DOI 10.1074/jbc.271.41.25269; Carter CP, 1997, J NUTR, V127, P1344, DOI 10.1093/jn/127.7.1344; COLES B, 1988, ARCH BIOCHEM BIOPHYS, V264, P253, DOI 10.1016/0003-9861(88)90592-9; CONNEY AH, 1982, CANCER RES, V42, P4875; DIETSCHY JM, 1983, BIOCHEM SOC T, V11, P639, DOI 10.1042/bst0110639; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; GOEPTAR AR, 1995, CRIT REV TOXICOL, V25, P25, DOI 10.3109/10408449509089886; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; HENDERSON CJ, 1990, BIOCHEM J, V266, P675, DOI 10.1042/bj2660675; HENDERSON CJ, 1992, IMMUNOCHEMICAL PROTO, V10, P221; Hines RN, 2001, DRUG METAB DISPOS, V29, P623; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; Kang S, 2000, BBA-MOL CELL BIOL L, V1529, P223, DOI 10.1016/S1388-1981(00)00151-7; Kelly SL, 2001, BIOCHEM SOC T, V29, P122, DOI 10.1042/0300-5127:0290122; Lamb DC, 1999, FEBS LETT, V462, P283, DOI 10.1016/S0014-5793(99)01548-3; Le YZ, 2001, MOL BIOTECHNOL, V17, P269, DOI 10.1385/MB:17:3:269; Lee SST, 1996, J BIOL CHEM, V271, P12063, DOI 10.1074/jbc.271.20.12063; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEEHAN RR, 1988, BIOCHEM J, V254, P789, DOI 10.1042/bj2540789; MODI S, 1995, BIOCHEM SOC T, V23, pS476, DOI 10.1042/bst023476s; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Oinonen T, 1998, BIOCHEM J, V329, P17, DOI 10.1042/bj3290017; Omura T, 1999, BIOCHEM BIOPH RES CO, V266, P690, DOI 10.1006/bbrc.1999.1887; Pikuleva I, 1999, Mol Aspects Med, V20, P33; PIKULEVA L, 1999, MOL ASPECTS MED, V20, P43; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Raucy J. L., 2001, Pharmacogenomics Journal, V1, P178; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SEN CK, 1992, J APPL PHYSIOL, V73, P1265, DOI 10.1152/jappl.1992.73.4.1265; SHAPIRO BH, 1989, ENDOCRINOLOGY, V125, P2935, DOI 10.1210/endo-125-6-2935; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; SMITH G, 1993, BIOCHEM J, V289, P807, DOI 10.1042/bj2890807; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; SPADY DK, 1983, J LIPID RES, V24, P303; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; Tonge RP, 1998, TOXICOL APPL PHARM, V153, P102, DOI 10.1006/taap.1998.8543; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Voice MW, 1999, ARCH BIOCHEM BIOPHYS, V366, P116, DOI 10.1006/abbi.1999.1192; WOLF CR, 1984, CARCINOGENESIS, V5, P993, DOI 10.1093/carcin/5.8.993; WOLF CR, 1986, TRENDS GENET, V2, P209, DOI 10.1016/0168-9525(86)90232-5; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	53	213	219	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13480	13486		10.1074/jbc.M212087200	http://dx.doi.org/10.1074/jbc.M212087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566435	hybrid			2022-12-25	WOS:000182189500111
J	Wu, DH; Govindasamy, L; Lian, W; Gu, YR; Kukar, T; Agbandje-McKenna, M; McKenna, R				Wu, DH; Govindasamy, L; Lian, W; Gu, YR; Kukar, T; Agbandje-McKenna, M; McKenna, R			Structure of human carnitine acetyltransferase - Molecular basis for fatty acyl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MALONYL-COA SENSITIVITY; ELECTRON-DENSITY MAPS; PALMITOYLTRANSFERASE-I; CHLORAMPHENICOL ACETYLTRANSFERASE; CATALYTIC-ACTIVITY; HISTIDINE RESIDUE; ATOMIC-STRUCTURE; CDNA CLONING; PROTEIN	Carnitine acyltransferases are a family of ubiquitous enzymes that play a pivotal role in cellular energy metabolism. We report here the x-ray structure of human carnitine acetyltransferase to a 1.6-Angstrom resolution. This structure reveals a monomeric protein of two equally sized alpha/beta domains. Each domain is shown to have a partially similar fold to other known but oligomeric enzymes that are also involved in group-transfer reactions. The unique monomeric arrangement of the two domains constitutes a central narrow active site tunnel, indicating a likely universal feature for all members of the carnitine acyltransferase family. Superimposition of the substrate complex of a related protein, dihydrolipoyl trans-acetylase, reveals that both substrates localize to the active site tunnel of human carnitine acetyltransferase, suggesting the location of the ligand binding sites for carnitine and coenzyme A. Most significantly, this structure provides critical insights into the molecular basis for fatty acyl chain transfer and a possible common mechanism among a wide range of acyltransferases utilizing a catalytic dyad.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	McKenna, R (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, POB 100245, Gainesville, FL 32610 USA.	rmckenna@ufl.edu	Kukar, Thomas/AAW-2612-2021	Kukar, Thomas/0000-0002-3750-6262	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058197] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM58197] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BROWN NF, 1994, J BIOL CHEM, V269, P19157; BROWN NF, 1994, J BIOL CHEM, V269, P26438; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHASE JFA, 1970, BIOCHEM J, V116, P713, DOI 10.1042/bj1160713; CHASE JFA, 1966, BIOCHEM J, V99, P32, DOI 10.1042/bj0990032; CORTI O, 1994, GENOMICS, V23, P94, DOI 10.1006/geno.1994.1463; Cronin CN, 1997, BIOCHEM BIOPH RES CO, V238, P784, DOI 10.1006/bbrc.1997.7390; Cronin CN, 1997, EUR J BIOCHEM, V247, P1029, DOI 10.1111/j.1432-1033.1997.01029.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Lian W, 2002, ACTA CRYSTALLOGR D, V58, P1193, DOI 10.1107/S0907444902005498; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; Ramsay RR, 2000, BIOCHEM SOC T, V28, P182, DOI 10.1042/bst0280182; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; RAMSAY RR, 1993, ARCH BIOCHEM BIOPHYS, V302, P307, DOI 10.1006/abbi.1993.1216; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P131; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wagman AS, 2001, CURR PHARM DESIGN, V7, P417, DOI 10.2174/1381612013397915; WU DH, 1993, J NEUROCHEM, V61, P1416, DOI 10.1111/j.1471-4159.1993.tb13635.x; Zarain-Herzberg A, 2002, EXPERT OPIN INV DRUG, V11, P345	39	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13159	13165		10.1074/jbc.M212356200	http://dx.doi.org/10.1074/jbc.M212356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12562770	hybrid			2022-12-25	WOS:000182189500073
J	Chan, AOO; Kim, SG; Bedeir, A; Issa, JP; Hamilton, SR; Rashid, A				Chan, AOO; Kim, SG; Bedeir, A; Issa, JP; Hamilton, SR; Rashid, A			CpG island methylation in carcinoid and pancreatic endocrine tumors	ONCOGENE			English	Article						methylation; carcinoid tumors; pancreatic; endocrine tumors	ACID RECEPTOR-BETA; DNA METHYLATION; ABERRANT METHYLATION; NEUROENDOCRINE TUMORS; GENE-EXPRESSION; SUPPRESSOR GENE; UP-REGULATION; CYCLOOXYGENASE-2; INACTIVATION; HYPERMETHYLATION	Carcinoid tumors and pancreatic endocrine tumors (PETs) are uncommon neuroendocrine neoplasms and their genetic alterations are not well characterized. CpG island methylation is a mechanism of gene silencing, and concordant methylation of multiple CpG islands as CpG island methylator phenotype (CIMP) has been described in tumors. The aim of this study was to evaluate CIMP in carcinoid tumors and PETs. We studied 16 carcinoid tumors, 11 PETs, and 22 associated normal mucosa or pancreas. Methylation status of the p14, p16, cyclooxygenase 2 (COX2), O-6-methyl-guanine methyltransferase (MGMT), estrogen receptor (ER), thrombospondin 1 (THBS1), retinoic acid receptor beta 2 (RARbeta), T-type calcium channel (CACNA1G), and multiple endocrine neoplasia type-1 (MEN1) genes, and of MINT1, MINT2, MINT25, MINT27 and MINT31 loci was evaluated by methylation-specific-PCR (MSP) or combined bisultite restriction analysis (COBRA). Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. Other CpG islands were infrequently methylated or unmethylated. The adjoining normal mucosa was also methylated for ER, COX2, and RARbeta, but methylation at p14, p16, THBS1, and MGMT was tumor-specific. By contrast, PETs and normal pancreas were frequently methylated only at ER. Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, P = 0.03), THBS1 (44 versus 9%, P = 0.04), p14 (44 versus 9%, P = 0.04) and RARP (25 versus 0%, P = 0.03). Loss of p16 protein expression correlated with methylation of p16 gene in carcinoid tumors (P = 0.006). Our study indicates that methylation profile of carcinoid tumors differs from PETs, reflecting different molecular pathogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rashid, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Box 85, Houston, TX 77030 USA.			Issa, Jean-Pierre/0000-0003-2258-5030				Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Calender A, 1999, RECENT ADV PATHOPHYS, P155; CAPELLA C, 2000, WHO CLASSIFICATION T, P53; Eads CA, 2001, CANCER RES, V61, P3410; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Fujimori M, 2001, CANCER RES, V61, P6656; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; Gortz B, 1999, AM J PATHOL, V154, P429, DOI 10.1016/S0002-9440(10)65289-3; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jensen R.T., 1999, RECENT ADV PATHOPHYS, P192; Konishi N, 2002, AM J PATHOL, V160, P1207, DOI 10.1016/S0002-9440(10)62547-3; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Lim HY, 2000, CLIN CANCER RES, V6, P519; Lubomierski N, 2001, CANCER RES, V61, P5905; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Mignon M, 2000, DIGESTION, V62, P51, DOI 10.1159/000051856; Muscarella P, 1998, CANCER RES, V58, P237; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rashid A, 2001, CANCER RES, V61, P3406; Rindi G, 1999, ITAL J GASTROENTEROL, V31, pS135; Rindi G, 1999, RECENT ADV PATHOPHYS, P177; Ristimaki A, 1997, CANCER RES, V57, P1276; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; ROMAN SD, 1992, CANCER RES, V52, P2236; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Serrano J, 2000, J CLIN ENDOCR METAB, V85, P4146, DOI 10.1210/jc.85.11.4146; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SOLCIA E, 1997, ATLAS TUMOR PATHOL, P145; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Toyooka S, 2001, MOL CANCER THER, V1, P61; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Toyota M, 1999, CANCER RES, V59, P4535; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Ueki T, 2000, CANCER RES, V60, P1835; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WEBER HC, 1996, ADV PANCREATIC DIS M, P55; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	47	102	108	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					924	934		10.1038/sj.onc.1206123	http://dx.doi.org/10.1038/sj.onc.1206123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584572				2022-12-25	WOS:000180864300015
J	Bek, MJ; Wahle, S; Muller, B; Benzing, T; Huber, TB; Kretzler, M; Cohen, C; Busse-Grawitz, A; Pavenstadt, H				Bek, MJ; Wahle, S; Muller, B; Benzing, T; Huber, TB; Kretzler, M; Cohen, C; Busse-Grawitz, A; Pavenstadt, H			Stra13, a prostaglandin E-2-induced gene, regulates the cellular redox state of podocytes	FASEB JOURNAL			English	Article						retinoic acid; oxidative stress; heme oxygenase 1; cytoprotection	RETINOID-X-RECEPTORS; HEME OXYGENASE-1; PROSTANOID RECEPTORS; NAD(P)H OXIDASE; MESANGIAL CELLS; EXPRESSION; INDUCTION; ROLES; ACID; DIFFERENTIATION	Podocyte injury is a central mechanism in the pathogenesis of proteinuria. Prostaglandin E-2 (PGE(2)) has been suggested to protect podocytes from cellular injury. Here we investigated whether PGE(2)-induced gene expression accounts for the protective role of PGE(2) in podocytes. Using a suppressive-subtractive hybridization method, we isolated a differentially expressed clone that was identified as Stra13, a recently described retinoic acid-inducible gene. PGE(2), forskolin, and retinoic acid induced a time-dependent up-regulation of Stra13 mRNA and protein expression in podocytes. To test the function of Stra13 in podocytes, Stra13 was overexpressed by using retroviral gene transfer. Compared with control cells, cells overexpressing Stra13 showed markedly reduced NADPH-dependent superoxid anion generation. Furthermore, expression of heme oxygenase 1 (HO-1) was increased in podocytes overexpressing Stra13. HO-1 plays an important protective role in the defense against reactive oxygen species (ROS). After stimulation with exogenous ROS, Stra13-overexpressing podocytes were more resistant to oxidative stress than were control cells. Our data indicate that Stra13 may play an important protective role against oxidative stress in podocytes. ROS are involved in the pathogenesis of glomerular inflammation in several forms of glomerulonephritis. Therefore, knowledge about protective mechanisms may provide insight into new therapeutic strategies for glomerulopathies.	Freiburg Univ Hosp, Div Nephrol, Dept Med, Freiburg, Germany; Univ Munich, Med Poliklin, D-8000 Munich, Germany	University of Freiburg; University of Munich	Pavenstadt, H (corresponding author), Freiburg Univ Clin, Dept Internal Med, Div Nephrol, Hugstetter Str 55, D-79106 Freiburg, Germany.	paven@med1.ukl.uni-freiburg.de	Benzing, Thomas/X-5476-2019	Huber, Tobias B./0000-0001-7175-5062				Agarwal A, 2000, J AM SOC NEPHROL, V11, P965, DOI 10.1681/ASN.V115965; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Bek M, 1999, J AM SOC NEPHROL, V10, P2084; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Datta PK, 1999, J AM SOC NEPHROL, V10, P2540; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Greiber S, 1998, KIDNEY INT, V53, P654, DOI 10.1046/j.1523-1755.1998.00796.x; Greiber S, 2002, J AM SOC NEPHROL, V13, P86, DOI 10.1681/ASN.V13186; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gwinner W, 2000, NEPHROL DIAL TRANSPL, V15, P1127, DOI 10.1093/ndt/15.8.1127; HEIFETS M, 1987, KIDNEY INT, V32, P335, DOI 10.1038/ki.1987.214; Kanwar YS, 2001, KIDNEY INT, V59, P378, DOI 10.1046/j.1523-1755.2001.00505.x; KERJASCHKI D, 1994, KIDNEY INT, V45, P300, DOI 10.1038/ki.1994.39; Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200; Lucio-Cazana J, 2001, J AM SOC NEPHROL, V12, P688, DOI 10.1681/ASN.V124688; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Manzano VM, 2000, BRIT J PHARMACOL, V131, P1673, DOI 10.1038/sj.bjp.0703728; Morath R, 1999, J AM SOC NEPHROL, V10, P1851; Mosley K, 1998, KIDNEY INT, V53, P672, DOI 10.1046/j.1523-1755.1998.00798.x; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pavenstadt H, 2000, AM J PHYSIOL-RENAL, V278, pF173, DOI 10.1152/ajprenal.2000.278.2.F173; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; SRAER JD, 1982, KIDNEY INT, V21, pS63; STAHL RAK, 1987, KIDNEY INT, V31, P1126, DOI 10.1038/ki.1987.118; Sugawara A, 1997, ENDOCRINOLOGY, V138, P3175, DOI 10.1210/en.138.8.3175; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Wagner J, 2001, NEPHROL DIAL TRANSPL, V16, P441, DOI 10.1093/ndt/16.3.441; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966	35	25	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					682	+		10.1096/fj.02-0250fje	http://dx.doi.org/10.1096/fj.02-0250fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594185				2022-12-25	WOS:000181456900014
J	Banumathy, G; Singh, V; Pavithra, SR; Tatu, U				Banumathy, G; Singh, V; Pavithra, SR; Tatu, U			Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; HETEROPROTEIN COMPLEX; STRESS-PROTEINS; HSP90; PHOSPHORYLATION; CHAPERONE; CAPACITOR; LOCALIZATION; GELDANAMYCIN; SEQUENCE	Hsp90 is important for normal growth and development in eukaryotes. Together with Hsp70 and other accessory proteins, Hsp90 not only helps newly synthesized proteins to fold but also regulates activities of transcription factors and protein kinases. Although the gene coding for heat shock protein 90 from Plasmodium falciparum (PfHsp90) has been characterized previously, there is very little known regarding its function in the parasite. We have analyzed PfHsp90 complexes and addressed its role in parasite life cycle using Geldanamycin (GA), a drug known to interfere with Hsp90 function. Sedimentation analysis and size exclusion chromatography showed PfHsp90 to be in 11 s(20,w) complexes of similar to300 kDa in size. Similar to the hetero-oligomeric complexes of Hsp90 in mammals, PfHsp70 was found to be present in PfHsp90 complexes. Homology modeling revealed a putative GA-binding pocket at the amino terminus of PfHsp90. The addition of GA inhibited parasite growth with LD50 of 0.2 muM. GA inhibited parasite growth by arresting transition from Ring to trophozoite. Transition from trophozoite to schizonts and reinvasion of new erythrocytes were less significantly affected. While inducing the synthesis of PfHsp70 and PfHsp90, GA did not significantly alter the pattern of newly synthesized proteins. Pre-exposure to heat shock attenuated GA-mediated growth inhibition, suggesting the involvement of heat shock proteins. Specificity of GA action on PfHsp90 was evident from selective inhibition of PfHsp90 phosphorylation in GA-treated cultures. In addition to suggesting an essential role for PfHsp90 during parasite growth, our results highlight PfHsp90 as a potential drug target to control malaria.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Tatu, U (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	tatu@biochem.iisc.ernet.in	Viswanath, Pavithra/I-4318-2015	Viswanath, Pavithra/0000-0003-2980-3109; Tatu, Utpal/0000-0003-0404-8872				Bagatell R, 2001, CLIN CANCER RES, V7, P2076; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Banumathy G, 2002, J BIOL CHEM, V277, P3902, DOI 10.1074/jbc.M110513200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BONNEFOY S, 1994, MOL BIOCHEM PARASIT, V67, P157, DOI 10.1016/0166-6851(94)90105-8; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BUCHBERGER A, 1997, GUIDEBOOK MOL CHAPER, P147; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Das A, 1997, MOL BIOCHEM PARASIT, V88, P95, DOI 10.1016/S0166-6851(97)00081-9; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P400; JENDOUBI M, 1985, J IMMUNOL, V134, P1941; JENDOUBI M, 1988, NUCLEIC ACIDS RES, V16, P10928, DOI 10.1093/nar/16.22.10928; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Neckers L, 1999, HANDB EXP PHARM, V136, P9; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SCHLICHTHERLE M, 2000, METHODS MALARIA RES, P30; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SU Q, 1994, GENE, V151, P225; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200	34	169	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18336	18345		10.1074/jbc.M211309200	http://dx.doi.org/10.1074/jbc.M211309200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12584193	hybrid			2022-12-25	WOS:000182838300098
J	Bach, D; Pich, S; Soriano, FX; Vega, N; Baumgartner, B; Oriola, J; Daugaard, JR; Lloberas, J; Camps, M; Zierath, JR; Rabasa-Lhoret, R; Wallberg-Henriksson, H; Laville, M; Palacin, M; Vidal, H; Rivera, F; Brand, M; Zorzano, A				Bach, D; Pich, S; Soriano, FX; Vega, N; Baumgartner, B; Oriola, J; Daugaard, JR; Lloberas, J; Camps, M; Zierath, JR; Rabasa-Lhoret, R; Wallberg-Henriksson, H; Laville, M; Palacin, M; Vidal, H; Rivera, F; Brand, M; Zorzano, A			Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism - A novel regulatory mechanism altered in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE; OUTER-MEMBRANE; GENE-EXPRESSION; ADIPOSE-TISSUE; SOLEUS MUSCLE; PROTEIN; FUSION; MORPHOLOGY	In many cells and specially in muscle, mitochondria form elongated filaments or a branched reticulum. We show that Mfn2 (mitofusin 2), a mitochondrial membrane protein that participates in mitochondrial fusion in mammalian cells, is induced during myogenesis and contributes to the maintenance and operation of the mitochondrial network. Repression of Mfn2 caused morphological and functional fragmentation of the mitochondrial network into independent clusters. Concomitantly, repression of Mfn2 reduced glucose oxidation, mitochondrial membrane potential, cell respiration, and mitochondrial proton leak. We also show that the Mfn2-dependent mechanism of mitochondrial control is disturbed in obesity by reduced Mfn2 expression. In all, our data indicate that Mfn2 expression is crucial in mitochondrial metabolism through the maintenance of the mitochondrial network architecture, and reduced Mfn2 expression may explain some of the metabolic alterations associated with obesity.	Univ Barcelona, PArc Cient Barcelona, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Fac Med RTH Laennec, INSERM, U449, F-69372 Lyon, France; Fac Med RTH Laennec, Ctr Rech Nutr Humaine Lyon, F-69372 Lyon, France; Hosp Clin Barcelona, Serv Hormonal, Barcelona 08036, Spain; Univ Barcelona, Fac Biol, Dept Fisiol Biol Macrofago Immunol, E-08028 Barcelona, Spain; Karolinska Hosp, Dept Clin Physiol, SE-17177 Stockholm, Sweden; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	University of Barcelona; University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Karolinska Institutet; Karolinska University Hospital; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Zorzano, A (corresponding author), Univ Barcelona, PArc Cient Barcelona, E-08028 Barcelona, Spain.	azorzano@bio.ub.es	Camps, Marta/F-6557-2016; Brand, Martin D/A-9423-2012; Vidal, Hubert/M-6674-2017; Palacín, Manuel/G-9786-2015; Díaz, Nicanor Vega/R-4903-2019; Lloberas, Jorge/D-4303-2014; Soriano, Francesc X/U-7552-2017; Zorzano, Antonio/R-5479-2018	Camps, Marta/0000-0001-5392-1792; Brand, Martin D/0000-0003-4418-6153; Vidal, Hubert/0000-0002-9467-0317; Lloberas, Jorge/0000-0001-7075-4201; Soriano, Francesc X/0000-0003-1678-7162; Zierath, Juleen/0000-0001-6891-7497; Palacin, Manuel/0000-0002-8670-293X				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; AMCHENKOVA AA, 1988, J CELL BIOL, V107, P481, DOI 10.1083/jcb.107.2.481; Amessou M, 1998, MOL CELL ENDOCRINOL, V144, P139, DOI 10.1016/S0303-7207(98)00132-4; Andreelli F, 1999, DIABETOLOGIA, V42, P358, DOI 10.1007/s001250051163; ASTRUP A, 1987, INT J OBESITY, V11, P51; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; AUESTAD N, 1991, J NEUROCHEM, V56, P1376, DOI 10.1111/j.1471-4159.1991.tb11435.x; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAKEEVA LE, 1978, BIOCHIM BIOPHYS ACTA, V501, P349, DOI 10.1016/0005-2728(78)90104-4; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Buchberger P, 1996, AM J PHYSIOL-REG I, V271, pR472, DOI 10.1152/ajpregu.1996.271.2.R472; Canicio J, 1998, ENDOCRINOLOGY, V139, P5042, DOI 10.1210/en.139.12.5042; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; CRETTAZ M, 1980, BIOCHEM J, V186, P525, DOI 10.1042/bj1860525; CUENDET GS, 1976, J CLIN INVEST, V58, P1078, DOI 10.1172/JCI108559; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; KAPLAN ML, 1991, INT J OBESITY, V15, P809; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; KEMMER FW, 1979, BIOCHEM J, V178, P733, DOI 10.1042/bj1780733; KIRKWOOD SP, 1986, AM J PHYSIOL, V251, pC395, DOI 10.1152/ajpcell.1986.251.3.C395; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mora S, 1997, BIOCHEM J, V324, P455, DOI 10.1042/bj3240455; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rojo M, 2002, J CELL SCI, V115, P1663; Santalucia T, 1999, J BIOL CHEM, V274, P17626, DOI 10.1074/jbc.274.25.17626; Santel A, 2001, J CELL SCI, V114, P867; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Simoneau JA, 1998, FASEB J, V12, P1739, DOI 10.1096/fasebj.12.15.1739; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Suelmann R, 2000, CELL MOTIL CYTOSKEL, V45, P42, DOI 10.1002/(SICI)1097-0169(200001)45:1<42::AID-CM4>3.0.CO;2-C; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; TORGAN CE, 1989, J APPL PHYSIOL, V67, P1807, DOI 10.1152/jappl.1989.67.5.1807; Turcotte LP, 2001, DIABETES, V50, P1389, DOI 10.2337/diabetes.50.6.1389; WARDLAW GM, 1986, J NUTR, V116, P1841, DOI 10.1093/jn/116.9.1841; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; ZORZANO A, 2002, FRONT ANIM DIAB RES, V4, P297	52	613	659	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17190	17197		10.1074/jbc.M212754200	http://dx.doi.org/10.1074/jbc.M212754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598526	hybrid			2022-12-25	WOS:000182818600100
J	Blanca, G; Baldanti, F; Paolucci, S; Skoblov, AY; Victorova, L; Hubscher, U; Gerna, G; Spadari, S; Maga, G				Blanca, G; Baldanti, F; Paolucci, S; Skoblov, AY; Victorova, L; Hubscher, U; Gerna, G; Spadari, S; Maga, G			Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE-ANALOG; CONTAINING REGIMENS; ZIDOVUDINE-NAIVE; THERAPY; EMERGENCE; VIREMIA	Recombinant HIV-1 reverse transcriptase (RT) carrying non-nucleoside inhibitors (NNRTIs) resistance mutation at codon 181 showed reduced incorporation and high efficiency of phosphorolytic removal of stavudine, a nucleoside RT inhibitor. These results reveal a new mechanism for cross-resistance between different classes of HIV-1 RT inhibitors.	CNR, IGM, I-27100 Pavia, Italy; Policlin San Matteo, Serv Virol, Ist Ric & Cura Carattere Sci, I-27100 Pavia, Italy; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia; Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Consiglio Nazionale delle Ricerche (CNR); IRCCS Fondazione San Matteo; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Zurich	Maga, G (corresponding author), CNR, IGM, Via Abbiategrasso 207, I-27100 Pavia, Italy.		Paolucci, Stefania/J-4055-2018; Baldanti, Fausto/J-4924-2018; Maga, Giovanni/C-5409-2009	Paolucci, Stefania/0000-0001-8447-8586; Baldanti, Fausto/0000-0002-3358-8969; Maga, Giovanni/0000-0001-8092-1552; Gerna, Giuseppe/0000-0001-5956-2786				DYATKINA NB, 1987, BIOORG KHIM+, V13, P1366; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; Larder BA, 1999, ANTIMICROB AGENTS CH, V43, P1961, DOI 10.1128/AAC.43.8.1961; Loveday C, 2001, J ACQ IMMUN DEF SYND, V26, pS10, DOI 10.1097/00126334-200103011-00003; Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427; Maga G, 2002, CURR DRUG METAB, V3, P73, DOI 10.2174/1389200023337982; Mouroux M, 2001, ANTIVIR THER, V6, P179; Ross L, 2001, J HUMAN VIROL, V4, P217; Ross L, 2001, AIDS RES HUM RETROV, V17, P1107, DOI 10.1089/088922201316912718; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626	11	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15469	15472		10.1074/jbc.C300022200	http://dx.doi.org/10.1074/jbc.C300022200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601008	Green Accepted, hybrid			2022-12-25	WOS:000182680000004
J	Maniscalco, SJ; Tally, JF; Harris, SW; Fisher, HF				Maniscalco, SJ; Tally, JF; Harris, SW; Fisher, HF			The direct measurement of thermodynamic parameters of reactive transient intermediates of the L-glutamate dehydrogenase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; LOCATION; PATHWAY	In a previous report (Fisher, H. F., Maniscalco, S. J., and Tally, J. (2002) Biochem. Biophys. Res. Commun. 287, 343347) we demonstrated the capability of the "Le Chatelier forcing method" of producing stable solutions containing substantial amounts of transitory enzyme intermediate complexes that can otherwise be observed only fleetingly in the millisecond time range. The method requires nothing more than running an enzyme reaction using forcing concentrations of reactants against an equally forcing concentration of products until equilibrium is attained. Here we have applied this approach to the measurement of the thermodynamics of several such reactive (and normally transient) intermediate complexes of the bovine liver L-glutamate dehydrogenase-catalyzed reaction. At pH 9.5 and 20 degreesC, we observe both the enzyme-NADPH-alpha-iminoglutarate and enzyme-NADPH-a-carbinolamine complexes at concentrations whose sum accounts for 70% of the total enzyme. The pH dependence of these two complexes under equilibrium conditions provides thermodynamic parameters for both the protonated and the unprotonated forms of each of these two entities as well as those of the enzyme-NADP-L-glutamate complex. The equilibrium concentrations of each of these reactive complexes are compared with their corresponding transient steady-state values.	Vet Affairs Med Ctr, Res Serv, Lab Mol Biochem, Kansas City, MO 64128 USA; Univ Kansas, Med Ctr, Dept Biochem, Kansas City, MO 64128 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Kansas	Fisher, HF (corresponding author), Vet Affairs Med Ctr, Res Serv, Lab Mol Biochem, 4801 Linwood Blvd, Kansas City, MO 64128 USA.							ANDERSON KS, 1990, BIOCHEMISTRY-US, V29, P1460, DOI 10.1021/bi00458a017; BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; Fisher HF, 2002, BIOORG CHEM, V30, P199, DOI 10.1006/bioo.2002.1243; Fisher HF, 2001, BIOCHEM BIOPH RES CO, V287, P343, DOI 10.1006/bbrc.2001.5592; Maniscalco SJ, 1998, BIOCHEMISTRY-US, V37, P14585, DOI 10.1021/bi980923v; Maniscalco SJ, 1996, BIOCHEMISTRY-US, V35, P89, DOI 10.1021/bi9509098; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; PISZKIEW.D, 1970, J BIOL CHEM, V245, P2622; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; SAHA SK, 1994, J BIOL CHEM, V269, P29592; Saha SK, 1999, BBA-PROTEIN STRUCT M, V1431, P261, DOI 10.1016/S0167-4838(99)00040-0; SUBRAMANIAN S, 1978, BIOPHYS CHEM, V7, P375, DOI 10.1016/0301-4622(78)85013-3; Tally JF, 2002, BIOCHEMISTRY-US, V41, P11284, DOI 10.1021/bi0202068	13	3	3	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16129	16134		10.1074/jbc.M300692200	http://dx.doi.org/10.1074/jbc.M300692200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12578821	hybrid			2022-12-25	WOS:000182680000085
J	Zou, ZY; Tong, FM; Faergeman, NJ; Borsting, C; Black, PN; DiRusso, CC				Zou, ZY; Tong, FM; Faergeman, NJ; Borsting, C; Black, PN; DiRusso, CC			Vectorial acylation in Saccharomyces cerevisiae - Fat1p and fatty acyl-CoA synthetase are interacting components of a fatty acid import complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; TRANSPORT PROTEIN; PLASMA-MEMBRANE; YEAST; ACTIVATION; DISRUPTION; MECHANISM; COENZYME; CLONING; BINDING	In Saccharomyces cerevisiae Fat1p and fatty acyl-CoA synthetase (FACS) are hypothesized to couple import and activation of exogenous fatty acids by a process called vectorial acylation. Molecular genetic and biochemical studies were used to define further the functional and physical interactions between these proteins. Multicopy extragenic suppressors were selected in strains carrying deletions in FAA1 and FAA4 or FAA1 and FAT1. Each strain is unable to grow under synthetic lethal conditions when exogenous long-chain fatty acids are required, and neither strain accumulates the fluorescent long-chain fatty acid C-1-BODIPY-C-12 indicating a fatty acid transport defect. By using these phenotypes as selective screens, plasmids were identified encoding FAA1, FAT1, and FAA4 in the faa1Delta faa4Delta strain and encoding FAA1 and FAT1 in the faa1Delta fat1Delta strain. Multicopy FAA4 could not suppress the growth defect in the faa1Delta fat1Delta strain indicating some essential functions of Fat1p cannot be performed by Faa4p. Chromosomally encoded FAA1 and FAT1 are not able to suppress the growth deficiencies of the fat1Delta faa1Delta and faa1Delta faa4Delta strains, respectively, indicating Faa1p and Fat1p play distinct roles in the fatty acid import process. When expressed from a 2mu plasmid, Fat1p contributes significant oleoyl-CoA synthetase activity, which indicates vectorial esterification and metabolic trapping are the driving forces behind import. Evidence of a physical interaction between Fat1p and FACS was provided using three independent biochemical approaches. First, a C-terminal peptide of Fat1p deficient in fatty acid transport exerted a dominant negative effect against long-chain acyl-CoA synthetase activity. Second, protein fusions employing Faa1p as bait and portions of Fat1p as trap were active when tested using the yeast two-hybrid system. Third, co-expressed, differentially tagged Fat1p and Faa1p or Faa4p were co-immunoprecipitated. Collectively, these data support the hypothesis that fatty acid import by vectorial acylation in yeast requires a multiprotein complex, which consists of Fat1p and Faa1p or Faa4p.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College	DiRusso, CC (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, MC-8,47 New Scotland Ave, Albany, NY 12208 USA.		DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881; Borsting, Claus/0000-0003-0421-7429; Faergeman, Nils/0000-0002-9281-5287	NIGMS NIH HHS [GM 56840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Bartel P. L., 1997, YEAST 2 HYBRID SYSTE; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FRERMAN FE, 1973, ARCH BIOCHEM BIOPHYS, V159, P434, DOI 10.1016/0003-9861(73)90471-2; Gargiulo CE, 1999, J LIPID RES, V40, P881; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hamilton JA, 2001, J MOL NEUROSCI, V16, P99, DOI 10.1385/JMN:16:2-3:99; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kaiser C., 1994, METHODS YEAST GENETI; KLEIN K, 1971, EUR J BIOCHEM, V19, P422; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; RHINE J, 1991, METHOD ENZYMOL, V194, P239; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	30	93	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16414	16422		10.1074/jbc.M210557200	http://dx.doi.org/10.1074/jbc.M210557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601005	Green Published, hybrid			2022-12-25	WOS:000182680000121
J	Baron, GS; Caughey, B				Baron, GS; Caughey, B			Effect of glycosylphosphatidylinositol anchor-dependent and -independent prion protein association with model raft membranes on conversion to the protease-resistant isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL TRUNCATION; CELL-FREE FORMATION; SCRAPIE ISOFORM; BINDING-SITES; CULTURED-CELLS; COPPER-BINDING; NEUROBLASTOMA-CELLS; MASS-SPECTROMETRY; SULFATED GLYCANS; IN-VITRO	Prion protein (PrP) is usually bound to membranes by a glycosylphosphatidylinositol (GPI) anchor that associates with detergent-resistant membranes, or rafts. To examine the effect of membrane association on the interaction between the normal protease-sensitive PrP isoform (PrP-sen) and the protease-resistant isoform (PrP-res), a model system was employed using PrP-sen reconstituted into sphingolipid-cholesterol-rich raftlike liposomes (SCRLs). Both full-length (GPI(+)) and GPI anchor-deficient (GPI(-)) PrP-sen produced in fibroblasts stably associated with SCRLs. The latter, alternative mode of membrane association was not detectably altered by glycosylation and was markedly reduced by deletion of residues 34-94. The SCRL-associated PrP molecules were not removed by treatments with either high salt or carbonate buffer. However, only GPI(+) PrP-sen resisted extraction with cold Triton X-100. PrP-sen association with SCRLs was pH-independent. PrP-sen was also one of a small subset of phosphatidylinositol-specific phospholipase C (PI-PLC)-released proteins from fibroblast cells found to bind SCRLs. A cell-free conversion assay was used to measure the interaction of SCRL-bound PrP-sen with exogenous PrP-res as contained in microsomes. SCRL-bound GPI(+) PrP-sen was not converted to PrP-res until PI-PLC was added to the reaction or the combined membrane fractions were treated with the membrane-fusing agent polyethylene glycol (PEG). In contrast, SCRL-bound GPI(-) PrP-sen was converted to PrP-res without PI-PLC or PEG treatment. Thus, of the two forms of raft membrane association by PrP-sen, only the GPI anchor-directed form resists conversion induced by exogenous PrP-res.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Caughey, B (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000580, Z01AI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angrand M, 1997, EUR J BIOCHEM, V250, P168, DOI 10.1111/j.1432-1033.1997.t01-1-00168.x; Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1988, P NATL ACAD SCI USA, V85, P4657, DOI 10.1073/pnas.85.13.4657; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Chabry J, 1999, J VIROL, V73, P6245, DOI 10.1128/JVI.73.8.6245-6250.1999; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Mange A, 2000, J VIROL, V74, P3135, DOI 10.1128/JVI.74.7.3135-3140.2000; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nosjean O, 1999, EUR J BIOCHEM, V263, P865, DOI 10.1046/j.1432-1327.1999.00573.x; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; VIGUERA AR, 1993, BIOCHEMISTRY-US, V32, P3708, DOI 10.1021/bi00065a024; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Whittal RM, 2000, PROTEIN SCI, V9, P332; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zuegg J, 2000, GLYCOBIOLOGY, V10, P959, DOI 10.1093/glycob/10.10.959	57	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14883	14892		10.1074/jbc.M210840200	http://dx.doi.org/10.1074/jbc.M210840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594216	hybrid			2022-12-25	WOS:000182516100040
J	Bauer, PM; Fulton, D; Boo, YC; Sorescu, GP; Kemp, BE; Jo, H; Sessa, WC				Bauer, PM; Fulton, D; Boo, YC; Sorescu, GP; Kemp, BE; Jo, H; Sessa, WC			Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple-serine phosphorylation sites in endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT-DEPENDENT PHOSPHORYLATION; MOLECULAR-CLONING; SHEAR-STRESS; ACTIVATION; KINASE; CELLS; HSP90; ENOS; RECONSTITUTION; CAVEOLIN-1	We examined the influence of individual serine phosphorylation sites in endothelial nitric-oxide synthase (eNOS) on basal and stimulated NO release, cooperative phosphorylation, and co-association with hsp90 and Akt. Mutation of the serine phosphorylation sites 116, 617, and 1179 to alanines affected the phospho-state of at least one other site, demonstrating cooperation between multiple phosphorylation events, whereas mutation of serine 635 to alanine did not cause compensation. Mutation of serines 116 and 617 to alanine promoted a greater protein-protein interaction with hsp90 and Akt and greater phosphorylation on serine 1179, the major site for Akt phosphorylation. More importantly, using alanine substitutions, Ser-116 is important for agonist, but not basal NO release, Ser-635 is important for basal, but not stimulated, Ser-617 negatively regulates basal and stimulated NO release, and Ser-1179 phosphorylation is stimulatory for both basal and agonist-mediated NO release. Using putative "gain of function" mutants (serine to aspartate) serines 635 and 1179 are important positive regulators of basal and stimulated NO release. S635D eNOS is the most efficacious, yielding 5-fold increases in basal and 2-fold increases in stimulated NO release from cells. However, S617A and S617D eNOS both increased NO release with opposite actions in NOS activity assays. Thus, multiple serine phosphorylation events regulate basal and stimulate NO release with Ser-635 and Ser-1179 being important positive regulatory sites and Ser-116 as a negative regulatory. Ser-617 may not be important for directly regulating NO release but is important as a modulator of phosphorylation at other sites and protein-protein interactions.	Yale Univ, Sch Med, Vasc Cell Signaling & Therapeut Program, Boyer Ctr Mol Med,Dept Pharmacol, New Haven, CT 06536 USA; Georgia Tech, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Atlanta, GA 30322 USA; St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Yale University; University System of Georgia; Georgia Institute of Technology; Emory University; St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research	Sessa, WC (corresponding author), Yale Univ, Sch Med, Vasc Cell Signaling & Therapeut Program, Boyer Ctr Mol Med,Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Kemp, Bruce E/L-2633-2014; Jo, Hanjoong/L-6216-2019; Kemp, Bruce/G-9602-2019; Sessa, William C/B-6844-2011	Kemp, Bruce E/0000-0001-6735-5082; Jo, Hanjoong/0000-0003-1833-372X; Kemp, Bruce/0000-0001-6735-5082; Sessa, William C/0000-0001-5759-1938; Boo, Yong Chool/0000-0001-9895-2066	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007950, R01HL061371, R01HL064793, R01HL057665, R37HL061371] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61371, T32 HL07950-02, R01 HL57665, HL64793] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773	31	186	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14841	14849		10.1074/jbc.M211926200	http://dx.doi.org/10.1074/jbc.M211926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591925	hybrid			2022-12-25	WOS:000182516100035
J	Viswanathan, P; Chen, JJ; Chiang, YC; Denis, CL				Viswanathan, P; Chen, JJ; Chiang, YC; Denis, CL			Identification of multiple RNA features that influence CCR4 deadenylation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; DNA-REPAIR; EXONUCLEASE; YEAST; PROTEINS; ENDONUCLEASE; DEGRADATION	The CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA. Here we report the purification to homogeneity of the yeast CCR4 protein and the analysis of its substrate specificities. CCR4 deadenylated a 7N+23A substrate (seven nucleotides followed by 23 A residues) in a distributive manner. Only small differences in CCR4 activity for different A length substrates were observed until only 1 A residue remained. Correspondingly, the K-m for a 25N+2A substrate was found to be at least 20-fold lower than that for a 26N+1A substrate, although their V-max values differed by only 2-fold. In addition, the total length of the RNA was found to contribute to CCR4 activity: up to 17 nucleotides (not necessarily poly(A)) could be recognized by CCR4. Poly(U), poly(C), and poly(G) were also found to be 12-30-fold better inhibitors of CCR4 compared with poly(A), supporting the observation that CCR4 contains a non-poly(A)-specific binding site. Surprisingly, even longer substrates (greater than or equal to45 nucleotides) stimulated CCR4 to become a processive enzyme, suggesting that CCR4 undergoes an additional transition in the presence of such substrates. CCR4 also displayed no difference in its activity with capped or uncapped RNA substrates. These results indicate that CCR4 recognition of its RNA substrates involves several features of the RNA that could be sites in vivo for controlling the rate of specific mRNA deadenylation.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Denis, CL (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Rudman Hall,Rm 387,46 Coll Rd, Durham, NH 03824 USA.				NIGMS NIH HHS [GM41215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; Cao D, 2001, RNA, V7, P1192, DOI 10.1017/S1355838201010330; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	23	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14949	14955		10.1074/jbc.M211794200	http://dx.doi.org/10.1074/jbc.M211794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590136	hybrid			2022-12-25	WOS:000182516100049
J	Johnson, A; O'Donnell, M				Johnson, A; O'Donnell, M			Ordered ATP hydrolysis in the gamma complex clamp loader AAA plus machine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; REPLICATION FACTOR-C; ONE HOLOENZYME PARTICLE; BETA-SLIDING CLAMP; ESCHERICHIA-COLI; ACCESSORY PROTEINS; BIOCHEMICAL-CHARACTERIZATION; PYROCOCCUS-FURIOSUS; CRYSTAL-STRUCTURE; DEPENDENT ATPASE	The gamma complex couples ATP hydrolysis to the loading of beta sliding clamps onto DNA for processive replication. The gamma complex structure shows that the clamp loader subunits are arranged as a circular heteropentamer. The three gamma motor subunits bind ATP, the delta wrench opens the beta ring, and the delta' stator modulates the delta-beta interaction. Neither delta nor delta' bind ATP. This report demonstrates that the delta' stator contributes a catalytic arginine for hydrolysis of ATP bound to the adjacent gamma(1) subunit. Thus, the delta' stator contributes to the motor function of the gamma trimer. Mutation of arginine 169 of gamma, which removes the catalytic arginines from only the gamma(2) and gamma3 ATP sites, abolishes ATPase activity even though ATP site 1 is intact and all three sites are filled. This result implies that hydrolysis of the three ATP molecules occurs in a particular order, the reverse of ATP binding, where ATP in site 1 is not hydrolyzed until ATP in sites 2 and/or 3 is hydrolyzed. Implications of these results to clamp loaders of other systems are discussed.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY USA	Rockefeller University; Howard Hughes Medical Institute	Johnson, A (corresponding author), Rockefeller Univ, 1230 York Ave,Box 228, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Bruck I, 2002, J BIOL CHEM, V277, P17334, DOI 10.1074/jbc.M110198200; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, GENETICS, V152, P1249; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Davey MJ, 1997, J BIOL CHEM, V272, P15286, DOI 10.1074/jbc.272.24.15286; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; DONG ZM, 1993, J BIOL CHEM, V268, P11758; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; PODOBNIK M, 2003, IN PRESS STRUCTURE; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; Seybert A, 2002, NUCLEIC ACIDS RES, V30, P4329, DOI 10.1093/nar/gkf584; STEWART J, 2001, J BIOL CHEM, V6, P6; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Walker JR, 2000, J BACTERIOL, V182, P6106, DOI 10.1128/JB.182.21.6106-6113.2000; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	64	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14406	14413		10.1074/jbc.M212708200	http://dx.doi.org/10.1074/jbc.M212708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582167	hybrid			2022-12-25	WOS:000182405000107
J	Gonzalez, T; Seoane, M; Caamano, P; Vinuela, J; Dominguez, F; Zalvide, J				Gonzalez, T; Seoane, M; Caamano, P; Vinuela, J; Dominguez, F; Zalvide, J			Inhibition of Cdk4 activity enhances translation of p27(kip1) in quiescent Rb-negative cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; P27 MESSENGER-RNA; RETINOBLASTOMA PROTEIN; GENE FAMILY; GROWTH; P16(INK4A); CANCER; MICE; D1; TRANSFORMATION	We show in this work that the inhibition of Cdk4 (6) in Rb-l- 3T3 cells enhances the accumulation of the P27(kip1) cyclin-dependent kinase inhibitor when these cells are induced into quiescence. Two different forms of inhibition of Cdk4 (6), namely overexpression of the Cdk4 (6) inhibitor p16 and overexpression of a dominant negative mutant of Cdk4 (Cdk4(N158)), result in this effect. This suggests that the relevant activity of Cdk4 (6) that has to be inactivated in this setting is its kinase activity. The accumulation of p27(kip1) is due to enhanced translation of the protein, mediated by the 3'-untranslated region of the p27 mRNA. Moreover, the cells that overexpress p16(ink4alpha) or Cdk4(N158) show a delay in G(1) when made quiescent and restimulated to proliferate. This delay is overcome by transfection of a plasmid expressing antisense p27(kip1), which shows that the accumulation of P27(kip1) in these cells is related to their G(1) delay. In summary, we report a new functional link between two important cell cycle regulators, Cdk4 and p27(kip1), and provide a mechanistic explanation to the previously reported epistatic relations between these two proteins.	Univ Santiago de Compostela, Fac Med, Dept Fisiol, Santiago De Compostela 15705, A Coruna, Spain; Complejo Hosp Univ Santiago, Unidad Inmunol, Santiago De Compostela 15705, A Coruna, Spain; Complejo Hosp Univ Santiago, Unidad Biol Mol, Santiago De Compostela 15705, A Coruna, Spain	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Zalvide, J (corresponding author), Univ Santiago de Compostela, Fac Med, Dept Fisiol, Santiago De Compostela 15705, A Coruna, Spain.		Souto, Marcos Seoane/I-3380-2018; Zalvide, Juan/ABG-4050-2020	Vinuela, Juan Evaristo/0000-0001-7778-901X; Caamano Vara, Maria del Pilar/0000-0002-0853-3421; Zalvide, Juan/0000-0001-7645-156X				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Savatier P, 1996, ONCOGENE, V12, P309; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	42	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12688	12695		10.1074/jbc.M207530200	http://dx.doi.org/10.1074/jbc.M207530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12566456	hybrid			2022-12-25	WOS:000182189500014
J	Huber, TB; Schmidts, M; Gerke, P; Schermer, B; Zahn, A; Hartleben, B; Sellin, L; Walz, G; Benzing, T				Huber, TB; Schmidts, M; Gerke, P; Schermer, B; Zahn, A; Hartleben, B; Sellin, L; Walz, G; Benzing, T			The carboxyl terminus of Neph family members binds to the PDZ domain protein zonula occludens-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLIT DIAPHRAGM; TRANSMEMBRANE PROTEINS; NEPHROTIC SYNDROME; LOCALIZES; PODOCIN; COMPONENT; ZO-1; PHOSPHORYLATION; INTERACTS; MOTIFS	The PSD95/Dlg/(ZO-1 (PDZ) domain-containing protein zonula occludens-1 (ZO-1) selectively localizes to the cytoplasmic basis of the slit diaphragm, a specialized cell-cell contact in between glomerular podocytes necessary to prevent the loss of protein in the urine. However, the function of ZO-1 at the slit diaphragm has remained elusive. Deletion of Neph1, a slit diaphragm protein of the immunoglobulin superfamily with a cytoplasmic PDZ binding site, causes proteinuria in mice. We demonstrate now that Neph1 binds ZO-1. This interaction was mediated by the first PDZ domain of ZO-1 and involved the conserved PDZ domain binding motif present in the carboxyl terminus of the three known Neph family members. Furthermore, Neph1 co-immunoprecipitates with ZO-1 from lysates of mouse kidneys, demonstrating that this interaction occurs in vivo. Both deletion of the PDZ binding motif of Neph1 as well as threonine-to-glutamate mutation of the threonine within the binding motif abrogated binding of ZO-1, suggesting that phosphorylation may regulate this interaction. ZO-1 binding was associated with a strong increase in tyrosine phosphorylation of the cytoplasmic tail of Neph1 and dramatically accelerated the ability of Neph1 to induce signal transduction. Thus, our data suggest that ZO-1 may organize Neph proteins and recruit signal transduction.	Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany; Univ Hosp, D-44625 Herne, Germany	University of Freiburg; Ruhr University Bochum	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetter Str 55, D-79106 Freiburg, Germany.	walz@med1.ukl.uni-freiburg.de	Benzing, Thomas/X-5476-2019; Schermer, Bernhard/E-9972-2014; Schmidts, Miriam/A-3777-2012	Schermer, Bernhard/0000-0002-5194-9000; Schmidts, Miriam/0000-0002-1714-6749; Huber, Tobias B./0000-0001-7175-5062				Antignac C, 2002, J CLIN INVEST, V109, P447, DOI 10.1172/JC1200215094; Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Benzing T, 2000, J BIOL CHEM, V275, P28167; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Fanning AS, 2002, FASEB J, V16, P1835, DOI 10.1096/fj.02-0121fje; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; Harris BZ, 2001, J CELL SCI, V114, P3219; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kawachi H, 1997, AM J PHYSIOL-RENAL, V273, pF984, DOI 10.1152/ajprenal.1997.273.6.F984; Kerjaschki D, 2001, J CLIN INVEST, V108, P1583, DOI 10.1172/JCI200114629; KURIHARA H, 1992, AM J PATHOL, V141, P805; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Roselli S, 2002, AM J PATHOL, V160, P131, DOI 10.1016/S0002-9440(10)64357-X; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SCHNABEL E, 1990, J CELL BIOL, V111, P1255, DOI 10.1083/jcb.111.3.1255; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	37	91	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13417	13421		10.1074/jbc.C200678200	http://dx.doi.org/10.1074/jbc.C200678200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12578837	hybrid			2022-12-25	WOS:000182189500104
J	Lu, WC; Liu, YN; Kang, BB; Chen, JH				Lu, WC; Liu, YN; Kang, BB; Chen, JH			Trans-activation of heparanase promoter by ETS transcription factors	ONCOGENE			English	Article						ETS; heparanase promoter; tumor metastasis	MAMMALIAN HEPARANASE; PROTEIN; CLONING; CANCER; INVASION	The remodeling of extracellular matrix (ECM) is an important process required for cancer cells to turn into invasive and metastatic cancer cells. To dissolve the protein components of ECM, matrix metalloproteinases are some of the essential enzymes. Another ECM remodeling enzyme is the heparanase (Hpa) that digests the heparin sulfate component of the matrix. In metastatic cancer cells the Hpa gene is upregulated. To investigate the mechanism of why Hpa was upregulated in metastatic cancer cells, the regulatory sequence of heparanase gene was isolated and its function analysed in metastatic breast cancer cells. We found there are four ETS transcription factor binding sites. Two of them flanking the transcription initiation of the Hpa gene are nonfunctional, whereas two others are highly functional and responded to exogenously added ETS transcription factors. Mutation of these two ETS binding sites abolished the transcriptional activation of Hpa promoter by ETS transcription factors. Among four transcription factors tested (ETS1, ETS2, PEA3, and ER81), ETS1 and ETS2 are more potent in transactivating the human Hpa gene. Furthermore, dominant-negative ETS transcription factors failed to transactivate Hpa promoter and could abrogate the function of wild-type transcription factor in transactivation activity of ETS transcription factors on the Hpa promoter. These results suggest that ETS transcription factors play an important role in tumor invasion and metastasis by modulating the remodeling of ECM.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd,Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw	LU, Wei-Cheng/O-5577-2017					Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen JH, 1996, ONCOGENE, V13, P1667; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Eccles SA, 1999, NAT MED, V5, P735, DOI 10.1038/10455; FOLKMAN J, 1997, CANC MED, P181; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; KOHN EC, 1995, CANCER RES, V55, P1856; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8	19	55	57	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					919	923		10.1038/sj.onc.1206201	http://dx.doi.org/10.1038/sj.onc.1206201			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584571				2022-12-25	WOS:000180864300014
J	Ngan, ESW; Hashimoto, Y; Ma, ZQ; Tsai, MJ; Tsai, SY				Ngan, ESW; Hashimoto, Y; Ma, ZQ; Tsai, MJ; Tsai, SY			Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer	ONCOGENE			English	Article						coactivator; Cdc25B; prostate cancer; androgen receptor	TYROSINE PHOSPHATASES; EXPRESSION; MECHANISM; DOMAIN; ROLES	Cdc25B is a dual-specific phosphatase that mediates cell cycle progression by activating the cyclin-dependent kinases. It has been shown to possess oncogenic potential. To elucidate its potential contribution to human prostate cancer development, the expression profile of Cdc25B protein in human patients was analysed by immunohistocytochemistry. Cdc25B is frequently overexpressed in human prostate cancer tissues (29 of 30; 97%). In addition, the overexpression is more profound in the tumors of high combined Gleason scores and in late stages. Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP. This coactivator function, surprisingly, is independent of its cell cycle functions. Cdc25B, on the other hand, directly interacts with AR as evidenced in GST-pull down and mammalian two-hybrid assays. In addition, it is also able to enhance AR-mediated transcription in synergy with other coactivators, including CREB-binding protein (CBP) and p300/ CBP associated factor. Therefore, upregulation of Cdc25B in human prostate cancer and its interplay with AR may contribute to prostate cancer development.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Tsai, SY (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Ngan, Elly/N-1543-2019	Ngan, Elly/0000-0002-0022-7999				CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Gregory CW, 2001, CANCER RES, V61, P4315; Hernandez S, 1998, CANCER RES, V58, P1762; Lombardi DP, 1999, CANCER RES, V59, P5724; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; Ma ZQ, 1999, J STEROID BIOCHEM, V69, P155, DOI 10.1016/S0960-0760(98)00154-X; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; NAGATA A, 1991, NEW BIOL, V3, P959; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	17	99	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					734	739		10.1038/sj.onc.1206121	http://dx.doi.org/10.1038/sj.onc.1206121			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569365				2022-12-25	WOS:000180642100010
J	Plackett, TP; Schilling, EM; Douglas, DE; Choudhry, MA; Witte, PL; Kovacs, EJ				Plackett, TP; Schilling, EM; Douglas, DE; Choudhry, MA; Witte, PL; Kovacs, EJ			Aging enhances lymphocyte cytokine defects after injury	FASEB JOURNAL			English	Article						burns; trauma; IL-4; IL-10; IFN gamma	AGE-RELATED-CHANGES; FLOW CYTOMETRIC ANALYSIS; TRAUMA-HEMORRHAGE; THERMAL-INJURY; T-CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSES; INTERLEUKIN-6-DEFICIENT MICE; MEDIATED-IMMUNITY; ETHANOL EXPOSURE	Mortality and sepsis after a traumatic injury is greater in the elderly than in young individuals. The altered lymphocyte response observed to occur in healthy aged individuals is proposed to be a contributing factor to increased mortality. The immune response associated with the increased mortality was explored using a murine scald injury model. In the absence of injury, aged mice had depressed delayed-type hypersensitivity (DTH) and splenocyte proliferative responses relative to young mice. There was also an increase with age in the production of the TH2 cytokines interleukin (IL)-4 and IL-10 by splenocytes. There was no change in the TH1 cytokines IFNgamma or IL-12 with age. However, IL-2 production was significantly lower. Following injury, there was a further decrease in the DTH response of aged injured mice, compared with aged sham mice. In addition, there was a decrease in all of the cytokines examined, regardless of age. In contrast, IFNgamma and IL-2 were significantly lower in the aged injured animals compared with the young injured animals. These results suggest that the lack of an adequate amount of TH1 cytokines shortly after injury in the aged mice may parallel the increased incidence of sepsis and death that occurs in aged burn patients.	Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60513 USA; Loyola Univ, Stritch Sch Med, Dept Surg, Maywood, IL 60513 USA; Loyola Univ, Immunol & Aging Program, Maywood, IL 60153 USA; Loyola Univ, Burn & Shock Trauma Inst, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Kovacs, EJ (corresponding author), Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Bldg 110,Room 4237,2160 S 1st Ave, Maywood, IL 60513 USA.	ekovacs@lumc.edu		Plackett, Timothy/0000-0002-0580-6287				Adolfsson O, 2001, J IMMUNOL, V167, P3809, DOI 10.4049/jimmunol.167.7.3809; ALEXANDER JW, 1996, ARCH SURG-CHICAGO, V93, P75; Billiau A, 1998, ANN NY ACAD SCI, V856, P22, DOI 10.1111/j.1749-6632.1998.tb08309.x; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V119, P433, DOI 10.1046/j.1365-2249.2000.01146.x; Cumming J, 2001, J TRAUMA, V50, P510, DOI 10.1097/00005373-200103000-00016; DALRYMPLE SA, 1995, INFECT IMMUN, V63, P2262, DOI 10.1128/IAI.63.6.2262-2268.1995; De AK, 2000, CLIN IMMUNOL, V96, P52, DOI 10.1006/clim.2000.4879; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; Dhabhar FS, 2000, ANN NY ACAD SCI, V917, P876, DOI 10.1111/j.1749-6632.2000.tb05454.x; DORIA G, 1994, ANN NY ACAD SCI, V741, P299, DOI 10.1111/j.1749-6632.1994.tb23113.x; Durbin EA, 2000, CYTOKINE, V12, P1669, DOI 10.1006/cyto.2000.0768; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Ertel W, 1996, ARCH SURG-CHICAGO, V131, P51; Faunce DE, 1997, J LEUKOCYTE BIOL, V62, P733, DOI 10.1002/jlb.62.6.733; Ferrari E, 2001, EUR J ENDOCRINOL, V144, P319, DOI 10.1530/eje.0.1440319; FRANKLIN RA, 1993, MECH AGEING DEV, V67, P33, DOI 10.1016/0047-6374(93)90110-D; Ginaldi L, 2001, AM J HEMATOL, V67, P63, DOI 10.1002/ajh.1082; Glaser R, 2001, J GERONTOL A-BIOL, V56, pM477, DOI 10.1093/gerona/56.8.M477; Gregory MS, 2000, J LEUKOCYTE BIOL, V67, P319, DOI 10.1002/jlb.67.3.319; GRIFFITHS RW, 1981, BURNS, V7, P365, DOI 10.1016/0305-4179(81)90012-7; Han SN, 2000, J INFECT DIS, V182, pS74, DOI 10.1086/315915; Haynes L, 1999, J EXP MED, V190, P1013, DOI 10.1084/jem.190.7.1013; Hensler T, 1997, INFECT IMMUN, V65, P2283, DOI 10.1128/IAI.65.6.2283-2291.1997; Hobden JA, 1997, INFECT IMMUN, V65, P2754, DOI 10.1128/IAI.65.7.2754-2758.1997; Kahlke V, 2000, AM J PHYSIOL-CELL PH, V278, pC509, DOI 10.1152/ajpcell.2000.278.3.C509; Kahlke V, 2000, CYTOKINE, V12, P69, DOI 10.1006/cyto.1999.0511; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Kernacki KA, 2000, INVEST OPHTH VIS SCI, V41, P3019; Knoferl MW, 2001, AM J PHYSIOL-CELL PH, V281, pC1131, DOI 10.1152/ajpcell.2001.281.4.C1131; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kovacs EJ, 2002, J AM AGING ASSOC, V25, P3, DOI 10.1007/s11357-002-0001-4; KUBO M, 1990, EUR J IMMUNOL, V20, P1289, DOI 10.1002/eji.1830200614; LINN BS, 1980, J AM GERIATR SOC, V28, P118, DOI 10.1111/j.1532-5415.1980.tb00244.x; Mascarucci P, 2001, AGING-CLIN EXP RES, V13, P85, DOI 10.1007/BF03351530; MCIRVINE AJ, 1982, ANN SURG, V196, P297; Messingham KAN, 2002, ALCOHOL CLIN EXP RES, V26, P519, DOI 10.1097/00000374-200204000-00013; MEYERS BR, 1989, AM J MED, V86, P379, DOI 10.1016/0002-9343(89)90333-1; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; MILLER RA, 1991, INT REV CYTOL, V124, P187; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; Newton C, 2000, INFECT IMMUN, V68, P5234, DOI 10.1128/IAI.68.9.5234-5240.2000; O'Sullivan ST, 1997, BRIT J PLAST SURG, V50, P615, DOI 10.1016/S0007-1226(97)90507-5; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; PRUITT BA, 1990, BRIT J SURG, V77, P1081, DOI 10.1002/bjs.1800771002; PRUITT BA, 1964, ANN SURG, V159, P396; Puyana JC, 1998, J TRAUMA, V44, P1037, DOI 10.1097/00005373-199806000-00017; Ramzy PI, 1999, CRIT CARE CLIN, V15, P333, DOI 10.1016/S0749-0704(05)70058-0; Rittenbury M S, 1965, J Trauma, V5, P587; Schneider CP, 2000, SHOCK, V14, P347, DOI 10.1097/00024382-200014030-00019; Song C, 1999, PSYCHIAT RES, V85, P71, DOI 10.1016/S0165-1781(98)00130-9; SONG LJ, 1993, EXP GERONTOL, V28, P313, DOI 10.1016/0531-5565(93)90058-L; Spector WS, 1956, HDB BIOL DATA; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Straub RH, 2000, J NEUROIMMUNOL, V109, P10, DOI 10.1016/S0165-5728(00)00296-4; TEJERINA C, 1992, BURNS, V18, P149, DOI 10.1016/0305-4179(92)90015-M; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Wakikawa A, 1997, MECH AGEING DEV, V94, P113, DOI 10.1016/S0047-6374(97)01880-0; WEIGLE WO, 1989, HOSP PRACT, V24, P112; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3	60	46	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					688	+		10.1096/fj.02-0452fje	http://dx.doi.org/10.1096/fj.02-0452fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594182				2022-12-25	WOS:000181456900001
J	Mukai, K; Mitani, F; Nagasawa, H; Suzuki, R; Suzuki, T; Suematsu, M; Ishimura, Y				Mukai, K; Mitani, F; Nagasawa, H; Suzuki, R; Suzuki, T; Suematsu, M; Ishimura, Y			An inverse correlation between expression of a preprocathepsin B-related protein with cysteine-rich sequences and steroid 11 beta-hydroxylase in adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADRENAL-CORTEX; TUBULOINTERSTITIAL NEPHRITIS ANTIGEN; ALDOSTERONE SYNTHASE CYTOCHROME-P-450; ZONE-SPECIFIC EXPRESSION; FUNCTIONAL ZONATION; CYP11B1 GENE; CATHEPSIN-B; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION	A cDNA encoding a secretory protein hitherto unknown was cloned from mouse adrenocortical cells by subtractive hybridization between the cells without and with expressing steroid 11beta-hydroxylase (Cyp11b-1), a marker for the functional differentiation of cells in the zonae fasciculata reticularis (zFR). The deduced protein consisting of 466 amino acids contained a secretory signal, epidermal growth factor-like repeats, and a proteolytically inactive cathepsin B-related sequence. The amino acid sequence was 89% identical with that of human tubulointerstitial nephritis antigen-related protein. Among the mouse organs examined, adrenal glands prominently expressed its mRNA. The mRNA and its encoded protein were detected in the outer adrenocortical zones that do not express Cyp11b-1, i.e. the zona glomerulosa and the undifferentiated cell zone, while being undetectable in zFR that express Cyp11b-1. The new protein was designated as adrenocortical zonation factor 1 (AZ-1). Clonal lines with different levels of AZ-1 expression were established from Y-1 adrenocortical cells that originally express Cyp11b-1 but little AZ-1. Analyses of the clonal lines revealed that Cyp11b-1 is detected in the clonal lines maintaining little AZ-1 expression and becomes undetectable in those expressing AZ-1. On the other hand, irrespective of the AZ-1 expression, all clones expressed cholesterol side-chain cleavage enzyme, which occurs throughout the cortical zones. These results demonstrated that adrenocortical cells expressing AZ-1 do not express Cyp11b-1, whereas those with little AZ-1 express this zFR marker in vitro and in vivo, implying a putative role of AZ-1 in determining the zonal differentiation of adrenocortical cells.	Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan; Minophagen Pharmaceut Co, Kanagawa 2280002, Japan	Keio University	Mukai, K (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	mukaik@sc.itc.keio.ac.jp	Suematsu, Makoto/I-8135-2013; Suematsu, Makoto/O-5762-2018	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336; Mukai, Kuniaki/0000-0002-9590-5077				BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAIN AJ, 1950, J ANAT, V84, P196; CATER DB, 1954, J ANAT, V88, P437; DEANE HW, 1946, AM J ANAT, V79, P117, DOI 10.1002/aja.1000790104; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hall K, 1937, NATURE, V140, P318, DOI 10.1038/140318a0; HARTROFT PM, 1957, ENDOCRINOLOGY, V60, P641; IANNACCONE PM, 1987, J EXP ZOOL, V243, P217, DOI 10.1002/jez.1402430207; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V268, P225, DOI 10.1006/bbrc.2000.2103; KALFA TA, 1994, J BIOL CHEM, V269, P1654; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; Kanwar YS, 1999, P NATL ACAD SCI USA, V96, P11323, DOI 10.1073/pnas.96.20.11323; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAIRD SM, 1988, ACTA ENDOCRINOL-COP, V119, P420, DOI 10.1530/acta.0.1190420; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Mitani F, 1999, ENDOCRINOLOGY, V140, P3342, DOI 10.1210/en.140.7.3342; Mitani F, 2003, BBA-GEN SUBJECTS, V1619, P317, DOI 10.1016/S0304-4165(02)00490-7; Mitani F, 1996, ENDOCR RES, V22, P421, DOI 10.1080/07435809609043728; Mitani F, 1998, ENDOCR RES, V24, P983, DOI 10.3109/07435809809032721; Mitani F, 1997, STEROIDS, V62, P57, DOI 10.1016/S0039-128X(96)00160-2; MITANI F, 1995, ENDOCR RES, V21, P413, DOI 10.3109/07435809509030457; MITANI F, 1994, ENDOCRINOLOGY, V135, P431, DOI 10.1210/en.135.1.431; MITCHELL RM, 1948, ANAT REC, V101, P161, DOI 10.1002/ar.1091010204; Miyamoto H, 2000, ENDOCR RES, V26, P899, DOI 10.3109/07435800009048614; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; MOROHASHI K, 1994, MOL ENDOCRINOL, V8, P643, DOI 10.1210/me.8.5.643; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; MUKAI K, 1991, BIOCHEM BIOPH RES CO, V180, P1187, DOI 10.1016/S0006-291X(05)81321-X; MUKAI K, 1993, J BIOL CHEM, V268, P9130; Mukai K, 1998, EUR J BIOCHEM, V256, P190, DOI 10.1046/j.1432-1327.1998.2560190.x; MUKAI K, 1995, MOL CELL BIOL, V15, P6003; Mukai K, 2002, EUR J BIOCHEM, V269, P69, DOI 10.1046/j.0014-2956.2002.02624.x; NELSON TR, 1995, J BIOL CHEM, V270, P16265, DOI 10.1074/jbc.270.27.16265; NICANDER L, 1952, ACTA ANAT          S, V14, P16; Obinata M, 1997, GENES CELLS, V2, P235, DOI 10.1046/j.1365-2443.1997.1160314.x; Obinata M, 2001, BIOCHEM BIOPH RES CO, V286, P667, DOI 10.1006/bbrc.2001.5247; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; Okamoto M, 1998, ENDOCR RES, V24, P515, DOI 10.3109/07435809809032640; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Raza FS, 1998, ENDOCR RES, V24, P977, DOI 10.3109/07435809809032720; Raza FS, 2001, EUR J BIOCHEM, V268, P2141, DOI 10.1046/j.1432-1327.2001.02096.x; REISS M, 1936, ENDOKRINOLOGIE, V18, P1; Schimmer B P, 1979, Methods Enzymol, V58, P570; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; VERNET T, 1991, J BIOL CHEM, V266, P21451; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Wex T, 2001, BIOCHEMISTRY-US, V40, P1350, DOI 10.1021/bi002266o	51	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17084	17092		10.1074/jbc.M301477200	http://dx.doi.org/10.1074/jbc.M301477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600995	hybrid			2022-12-25	WOS:000182818600086
J	Alani, E; Lee, JY; Schofield, MJ; Kijas, AW; Hsieh, P; Yang, W				Alani, E; Lee, JY; Schofield, MJ; Kijas, AW; Hsieh, P; Yang, W			Crystal structure and biochemical analysis of the MutS center dot ADP center dot Beryllium fluoride complex suggests a conserved mechanism for ATP interactions in mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA HELICASE-II; RECOGNITION COMPLEX; MOLECULAR SWITCH; YEAST MSH2-MSH6; STRAND BREAK; PROTEIN MUTS; HMUTS-ALPHA; ABC-ATPASE; BINDING	During mismatch repair ATP binding and hydrolysis activities by the MutS family proteins are important for both mismatch recognition and for transducing mismatch recognition signals to downstream repair factors. Despite intensive. efforts, a MutS(.)ATP(.)DNA complex has eluded crystallographic analysis. Searching for ATP analogs that strongly bound to Thermus aquaticus (Taq) MutS, we found that ADP-beryllium fluoride (ABF), acted as a strong inhibitor of several MutS family ATPases. Furthermore, ABF promoted the formation of a ternary complex containing the Saccharomyces cerevisiae MSH2(.)MSH6 and MLH1(.)PMS1 proteins bound to mismatch DNA but did not promote dissociation of MSH2(.)MSH6 from mismatch DNA. Crystallographic analysis of the Taq MutS(.)DNA(.)ABF complex indicated that although this complex was very similar to that of MutS(.)DNA(.)ADP, both ADP(.)Mg(2+) moieties in the MutS(.)DNA(.)ADP structure were replaced by ABF. Furthermore, a disordered region near the ATP-binding pocket in the MutS B subunit became traceable, whereas the equivalent region in the A subunit that interacts with the mismatched nucleotide remained disordered. Finally, the DNA binding domains of MutS together with the mismatched DNA were shifted upon binding of ABF. We hypothesize that the presence of ABF is communicated between the two MutS subunits through the contact between the ordered loop and Domain III in addition to the intra-subunit helical lever arm that links the ATPase and DNA binding domains.	Cornell Univ, Dept Genet & Mol Biol, Ithaca, NY 14853 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet Biochem Branch, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Alani, E (corresponding author), 459 Biotechnol Bldg, Ithaca, NY 14853 USA.		Yang, Wei/ABB-4785-2020; Yang, Wei/D-4926-2011	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Kijas, Amanda/0000-0001-8538-7766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053085] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53085, R01 GM053085] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 2001, PROTEIN EXPRES PURIF, V21, P333, DOI 10.1006/prep.2000.1379; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petsko CA, 2000, P NATL ACAD SCI USA, V97, P538, DOI 10.1073/pnas.97.2.538; Pezza RJ, 2002, NUCLEIC ACIDS RES, V30, P4700, DOI 10.1093/nar/gkf606; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	45	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16088	16094		10.1074/jbc.M213193200	http://dx.doi.org/10.1074/jbc.M213193200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12582174	hybrid			2022-12-25	WOS:000182680000081
J	Boura-Halfon, S; Voliovitch, H; Feinstein, R; Paz, K; Zick, Y				Boura-Halfon, S; Voliovitch, H; Feinstein, R; Paz, K; Zick, Y			Extracellular matrix proteins modulate endocytosis of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN CYTOSKELETON; INTERNALIZATION; PHOSPHORYLATION; GALECTIN-8; ACTIVATION; ADIPOCYTES; RESISTANCE	Internalization of the insulin receptor (IR) is a highly regulated multi-step process whose underlying molecular basis is not fully understood. Here we undertook to study the role of extracellular matrix (ECM) proteins in the modulation of IR internalization. Employing Chinese hamster ovary cells that overexpress IR (CHO-T cells), our results indicate that IR internalization proceeds unaffected even when Tyr phosphorylation of IR substrates, such as IRS-1, is impaired (e.g. in CHO-T cells overexpressing IRS-1 whose pleckstrin-homology domain has been deleted or in CHO-T cells that overexpress the PH/PTB domain of IRS-1). In contrast, IR internalization is affected by the context of the ECM proteins to which the cells adhere. Hence, IR internalization was inhibited 40-60% in CHO-T cells adherent onto galectin-8 (an ECM protein and an integrin ligand of the galectin family) when compared with cells adherent onto fibronectin, collagen, or laminin. Cells adherent to galectin-8 manifested a unique cytoskeletal organization, which involved formation of cortical actin and generation of F-actin microspikes that contrasted with the prominent stress-fibers formed when cells adhered to fibronectin. To better establish a role for actin filament organization in IR endocytosis, this process was assayed in CHO-T cells (adherent onto fibronectin), whose actin filaments were disrupted upon treatment with latrunculin B. Latrunculin B did not affect insulin-induced Tyr phosphorylation of IR or its ability to phosphorylate its substrates; still, a 30-50% reduction in the rate of IR internalization was observed in cells treated with latrunculin B. Treatment of cells with nocodazole, which disrupts formation of microtubules, did not affect IR internalization. These results indicate that proper actin, but not microtubular, organization is a critical requirement for IR internalization and suggest that integrin-mediated signaling pathways emitted upon cell adhesion to different extracellular matrices and the altered cytoskeletal organizations generated thereof affect the itinerary of the insulin receptor.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Zick, Yehiel/K-1479-2012					BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CARPENTIER JL, 1993, J CELL BIOL, V118, P831; Fasching P, 1996, DIABETOLOGIA, V39, P1242, DOI 10.1007/BF02658518; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hadari YR, 2000, J CELL SCI, V113, P2385; HADARI YR, 1992, J BIOL CHEM, V267, P17483; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; Jager A, 2000, DIABETES, V49, P485, DOI 10.2337/diabetes.49.3.485; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; LEVY Y, 2003, J BIOL CHEM; LI CZS, 1997, AM J PHYSIOL, V273, pE801; Maggi D, 1998, ENDOCRINOLOGY, V139, P496, DOI 10.1210/en.139.2.496; Matsumoto K, 2000, ATHEROSCLEROSIS, V152, P415, DOI 10.1016/S0021-9150(99)00487-6; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Najjar SM, 2002, TRENDS ENDOCRIN MET, V13, P240, DOI 10.1016/S1043-2760(02)00608-2; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sasaoka T, 1999, ENDOCRINOLOGY, V140, P3826, DOI 10.1210/en.140.8.3826; Soni P, 1999, Mol Cell Biol Res Commun, V1, P102, DOI 10.1006/mcbr.1999.0116; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	44	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16397	16404		10.1074/jbc.M212385200	http://dx.doi.org/10.1074/jbc.M212385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594209	hybrid			2022-12-25	WOS:000182680000119
J	Butt, E; Gambaryan, S; Gottfert, N; Galler, A; Marcus, K; Meyer, HE				Butt, E; Gambaryan, S; Gottfert, N; Galler, A; Marcus, K; Meyer, HE			Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; INTACT HUMAN PLATELETS; VASP IN-VITRO; NITRIC-OXIDE; THROMBOXANE RECEPTOR; SUBSTRATE; ADHESION; MEMBRANE; LASP-1; PATHWAY	Various drugs that elevate cGMP levels and activate cGMP-dependent protein kinase (cGK) inhibit agonist-induced platelet activation. In the present study we identified the LIM and SH3 domain protein (LASP) that was recently cloned from human breast cancer cells (Tomasetto, C., Regnier, C., Moog-Lutz, C., Mattei, M. G., Chenard, M. P., Liderau, R., Basset, P., and Rio, M. C. (1995) Genomics 28, 367-376) as a novel substrate of cGK in human platelets. Recombinant human LASP was phosphorylated by cGMP- and cAMP-dependent protein kinase (cAK) in vitro. Cotransfection of PtK-2 cells with LASP and cGK confirmed phosphorylation of LASP in vivo. Studies with human LASP mutants identified serine 146 as a specific phosphorylation site for cGK and cAK in vivo. LASP is an actin-binding protein, and the phospho-LASP-mimicking mutant S146D showed reduced binding affinity for F-actin in cosedimentation experiments. Immunofluorescence of transfected PtK2 cells demonstrated the localization of LASP in the tips of cell membrane extensions and at cell-cell contacts. Expression of the human LASP mutant S146D resulted in nearly complete relocalization to the cytosol and reduced migration of the cells. Taken together, these data suggest that phosphorylation of LASP by cGK and cAK may be involved in cytoskeletal organization and cell motility.	Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Ruhr Univ Bochum, Med Proteome Ctr, D-44780 Bochum, Germany	University of Wurzburg; Ruhr University Bochum	Butt, E (corresponding author), Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	butt@klin-biochem.uni-wuerzburg.de	Gambaryan, Stepan/I-3940-2016	Gambaryan, Stepan/0000-0002-1470-0791				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Bieche I, 1996, CANCER RES, V56, P3886; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; BUTT E, 1994, J BIOL CHEM, V269, P14509; BUTT E, 1997, ADV MOL CEL, V18, P311; Chew CS, 2000, J CELL SCI, V113, P2035; Chew CS, 2002, J CELL SCI, V115, P4787, DOI 10.1242/jcs.00174; CHEW CS, 1998, J PHYSL, V275, pC56; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; Okamoto CT, 2002, J CONTROL RELEASE, V78, P35, DOI 10.1016/S0168-3659(01)00479-5; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Reep BR, 1996, BIOCHEM BIOPH RES CO, V219, P1, DOI 10.1006/bbrc.1996.0171; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; VONBRUCHHAUSEN F, 1997, HDB EXPT PHARM, V126; WALTER U, 1980, J BIOL CHEM, V255, P3757; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Yamamoto S, 2001, ARCH BIOCHEM BIOPHYS, V393, P97, DOI 10.1006/abbi.2001.2505; YOSHINORI S, 1999, BLOOD, V93, P3408	38	86	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15601	15607		10.1074/jbc.M209009200	http://dx.doi.org/10.1074/jbc.M209009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12571245				2022-12-25	WOS:000182680000020
J	Derrien, A; Zheng, B; Osterhout, JL; Ma, YC; Milligan, G; Farquhar, MG; Druey, KM				Derrien, A; Zheng, B; Osterhout, JL; Ma, YC; Milligan, G; Farquhar, MG; Druey, KM			Src-mediated RGS16 tyrosine phosphorylation promotes RGS16 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FUNCTIONAL-CHARACTERIZATION; PROTEIN-KINASE; UP-REGULATION; REGULATOR; MODULATION; TRANSLOCATION; ASSOCIATION; ACTIVATION; EXPRESSION	The amplitude of signaling evoked by stimulation of G protein-coupled receptors may be controlled in part by the GTPase accelerating activity of the regulator of G protein signaling (RGS) proteins. In turn, subcellular targeting, protein-protein interactions, or post-translational modifications such as phosphorylation may shape RGS activity and specificity. We found previously that RGS16 undergoes tyrosine phosphorylation on conserved tyrosine residues in the RGS box. Phosphorylation on Tyr(168) was mediated by the epidermal growth factor receptor (EGFR). We show here that endogenous RGS16 is phosphorylated after epidermal growth factor stimulation of MCF-7 cells. In addition, p60-Src or Lyn kinase phosphorylated recombinant RGS16 in vitro, and RGS16 underwent phosphorylation in the presence of constitutively active Src (Y529F) in EGFR- CHO-K1 cells. Blockade of endogenous Src activity by selective inhibitors attenuated RGS16 phosphorylation induced by pervanadate or receptor stimulation. Furthermore, the rate of RGS16 degradation was reduced in cells expressing active Src or treated with pervanadate or a G protein-coupled receptor ligand (CXCL12). Induction of RGS16 tyrosine phosphorylation was associated with increased RGS16 protein levels and enhanced GAP activity in cell membranes. These results suggest that Src mediates RGS16 tyrosine phosphorylation, which may promote RGS16 stability.	NIAID, Lab Allerg Dis, NIH, Rockville, MD 20852 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego; Cornell University; University of Glasgow	Druey, KM (corresponding author), NIAID, Lab Allerg Dis, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	kdruey@nih.gov	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Zheng, Bin/0000-0002-0998-7177; Ma, Yongchao/0000-0002-2469-4356	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Benzing T, 2002, J BIOL CHEM, V277, P32954, DOI 10.1074/jbc.M200859200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cavalli A, 2000, J BIOL CHEM, V275, P23693, DOI 10.1074/jbc.M910395199; Chausovsky A, 2000, ONCOGENE, V19, P878, DOI 10.1038/sj.onc.1203410; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Derrien A, 2001, J BIOL CHEM, V276, P48532, DOI 10.1074/jbc.M108862200; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hsieh HG, 2002, CYTOKINE, V19, P159, DOI 10.1006/cyto.2002.1952; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Johnson EN, 2002, J BIOL CHEM, V277, P16768, DOI 10.1074/jbc.M200751200; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; Kellett E, 1999, MOL PHARMACOL, V56, P684; Krug AW, 2002, J BIOL CHEM, V277, P45892, DOI 10.1074/jbc.M208851200; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Mittmann C, 2002, CARDIOVASC RES, V55, P778, DOI 10.1016/S0008-6363(02)00459-5; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1	46	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16107	16116		10.1074/jbc.M210371200	http://dx.doi.org/10.1074/jbc.M210371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12588871	hybrid			2022-12-25	WOS:000182680000083
J	Holtje, M; Winter, S; Walther, D; Pahner, I; Hortnagl, H; Ottersen, OP; Bader, M; Ahnert-Hilger, G				Holtje, M; Winter, S; Walther, D; Pahner, I; Hortnagl, H; Ottersen, OP; Bader, M; Ahnert-Hilger, G			The vesicular monoamine content regulates VMAT2 activity through G alpha(q) mouse platelets - Evidence for autoregulation of vesicular transmitter uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN HETEROTRIMERS; SMALL SYNAPTIC VESICLES; LARGE DENSE CORE; QUANTAL SIZE; DOPAMINE-RECEPTORS; TRANSPORTER VMAT2; ALPHA-SUBUNITS; CELLS; EXPRESSION; BINDING	Variations in the neurotransmitter content of secretory vesicles enable neurons to adapt to network changes. Vesicular content may be modulated by vesicle-associated Go(2), which down-regulates the activity of the vesicular monoamine transmitter transporters VMAT1 in neuroendocrine cells and VMAT2 in neurons. Blood platelets resemble serotonergic neurons with respect to transmitter storage and release. In streptolysin O-permeabilized platelets, VMAT2 activity is also down-regulated by the G protein activator guanosine 5'-(beta(i)gamma-imido)triphosphate (GMppNp). Using serotonin-depleted platelets from peripheral tryptophan hydroxylase knockout (Tph1-/-) mice, we show here that the vesicular filling initiates the G protein-mediated down-regulation of VMAT2 activity. GMppNp did not influence VMAT2 activity in naive platelets from Tph1-/-mice. GMppNp-mediated inhibition could be reconstituted, however, when preloading Tph1-/- platelets with serotonin or noradrenaline. Galpha(q) mediates the down-regulation of VMAT2 activity as revealed from uptake studies performed with platelets from Gaq deletion mutants. Serotonergic, noradrenergic, as well as thromboxane A(2) receptors are not directly involved in the down-regulation of VMAT2 activity. It is concluded that in platelets the vesicle itself regulates transmitter transporter activity via its content and vesicle-associated Galpha(q).	Humboldt Univ, Inst Anat, Charite, D-10115 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Oslo, Inst Basic Med Sci, Ctr Mol Biol & Neurosci, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; Humboldt Univ, Inst Pharmakol, Charite, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oslo; University of Oslo; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ahnert-Hilger, G (corresponding author), Humboldt Univ, Inst Anat, Charite, Philippstr 12, D-10115 Berlin, Germany.		Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164; Holtje, Markus/0000-0003-3193-4140				Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; Berk M, 2001, EUR NEUROPSYCHOPHARM, V11, P183, DOI 10.1016/S0924-977X(01)00074-8; Brouillet E, 1999, J NEUROSCI, V19, P1717; Brunk I, 1999, EUR J CELL BIOL, V78, P311, DOI 10.1016/S0171-9335(99)80065-X; Bruns D, 2000, NEURON, V28, P205, DOI 10.1016/S0896-6273(00)00097-0; CESURA AM, 1990, EUR J PHARMACOL, V186, P95, DOI 10.1016/0014-2999(90)94064-5; Colliver TL, 2000, J NEUROSCI, V20, P5276, DOI 10.1523/JNEUROSCI.20-14-05276.2000; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Engel D, 2001, J PHYSIOL-LONDON, V535, P473, DOI 10.1111/j.1469-7793.2001.00473.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Giesberts AN, 1997, BIOCHEM BIOPH RES CO, V234, P439, DOI 10.1006/bbrc.1997.6662; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; Holtje M, 2000, J NEUROSCI, V20, P2131; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Mendelson SD, 2000, J AFFECT DISORDERS, V57, P13, DOI 10.1016/S0165-0327(99)00177-9; Miller GW, 1999, EXP NEUROL, V156, P138, DOI 10.1006/exnr.1998.7008; MORGENSTERN E, 1995, EUR J CELL BIOL, V68, P183; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Pahner I, 2002, EUR J CELL BIOL, V81, P449, DOI 10.1078/0171-9335-00269; PETER D, 1994, J BIOL CHEM, V269, P7231; Pothos EN, 1998, J NEUROSCI, V18, P5575; Pothos EN, 1998, J NEUROSCI, V18, P4106; Pothos EN, 2000, J NEUROSCI, V20, P7297; Ricci A, 2001, N-S ARCH PHARMACOL, V363, P376, DOI 10.1007/s002100000339; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Van der Kloot W, 2000, J PHYSIOL-LONDON, V523, P247, DOI 10.1111/j.1469-7793.2000.00247.x; Walther DJ, 1999, MOL BRAIN RES, V68, P55, DOI 10.1016/S0169-328X(99)00046-7; WALTHER DJ, 2002, SCIENCE, V299, P5603; Watts VJ, 1998, J NEUROSCI, V18, P8692; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; Wenzel HJ, 1997, HIPPOCAMPUS, V7, P559; WURZINGER LJ, 1990, ADV ANAT EMBRYOL CEL, V120, P1; Youssefian T, 1997, BLOOD, V89, P4047, DOI 10.1182/blood.V89.11.4047; Zucker M, 2001, LIFE SCI, V69, P2311, DOI 10.1016/S0024-3205(01)01301-7	46	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15850	15858		10.1074/jbc.M212816200	http://dx.doi.org/10.1074/jbc.M212816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604601	hybrid			2022-12-25	WOS:000182680000051
J	Lin, DY; Lai, MZ; Ann, DK; Shih, HM				Lin, DY; Lai, MZ; Ann, DK; Shih, HM			Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor Co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; FAS-INDUCED APOPTOSIS; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVITY; MOLECULAR MECHANISMS; INTERACTING PROTEIN; NUCLEAR RECEPTORS; MODULATION; SEQUESTRATION; ONCOPROTEIN	Daxx has been reported to function as a transcriptional modulator in the nucleus. In the present study, we have explored the role of Daxx in regulating the transcriptional activity of the glucocorticoid receptor (GR). Overexpression of Daxx suppressed GR-mediated activation of the mouse mammary tumor virus promoter in COS-1, HeLa, and 293T cells. In vitro and in vivo studies revealed that Daxx could directly bind to GR. The mapping analysis further demonstrated that the C-terminal region of Daxx-(501-740) mediates the interaction and transcriptional repression of GR. The repressive effect of Daxx and Daxx-(501-740) on GR could be alleviated by co-expression of promyelocytic leukemia protein (PML). Furthermore, immunofluorescence analysis showed that overexpression of wild-type PML results in the translocation of Daxx and Daxx-(501-740) to the PML oncogenic domains (PODs). By contrast, a PML sumoylation-defective mutant failed to recruit Daxx to PODs and to reverse the Daxx repression effect on GR. Accordingly, As,03 treatment rendered the sequestration of endogenous Daxx to the PODs, leading to an enhancement of GR transactivation in COS-1 cells. Taken together, these findings suggest that recruitment of Daxx into the suhnuclear POD structures sequesters it from the GR/co-activators complex, thereby alleviating its repressive effects. Our present studies provide the important link between Daxx/PML interaction and GR transcriptional activation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11529, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; Academia Sinica - Taiwan; University of Southern California	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128 Sec2,Yen Chiu Yuan Rd, Taipei 11529, Taiwan.		Shih, Hsiu-Ming/S-7023-2018; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803	NIDCR NIH HHS [DE 14183, R01 DE 10742] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Almawi WY, 2002, J LEUKOCYTE BIOL, V71, P9; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HATTA M, 2001, SCI STKE; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Pluta AF, 1998, J CELL SCI, V111, P2029; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Singh P, 2001, J BIOL CHEM, V276, P13762, DOI 10.1074/jbc.M100137200; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	37	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15958	15965		10.1074/jbc.M300387200	http://dx.doi.org/10.1074/jbc.M300387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595526	hybrid			2022-12-25	WOS:000182680000065
J	Park, HJ; Wu, S; Dunker, AK; Kang, C				Park, HJ; Wu, S; Dunker, AK; Kang, C			Polymerization of calsequestrin - Implications for Ca2+ regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM VESICLES; CANINE CARDIAC CALSEQUESTRIN; RYANODINE RECEPTOR; CALCIUM-RELEASE; BINDING PROTEIN; CRYSTALLIZATION; SPECTROSCOPY; TRIADIN	Two distinct dimerization contacts in calsequestrin crystals suggested a mechanism for Ca2+ regulation resulting from the occurrence of coupled Ca2+ binding and protein polymerization. Ca2+-induced formation of one contact was proposed to lead to dimerization followed by Ca2+-induced formation of the second contact to bring about polymerization (1). To test this mechanism, we compared canine cardiac calsequestrin and four truncation mutants with regard to their folding properties, structures, and Ca2+-induced polymerization. The wild-type calsequestrin and truncation mutants exhibited similar K+-induced folding and end-point structures as indicated by intrinsic fluorescence and circular dichroism, respectively, whereas the polymerization tendencies of the wild-type calsequestrin differed markedly from the polymerization tendencies of the truncation mutants. Static laser light scattering and 3,3'-dithiobis sulfosuccinimidyl-propionate cross-linking indicated that wild-type protein exhibited an initial Ca2+-induced dimerization, followed by additional oligomerization as the Ca2+ concentration was raised or as the K+ concentration was lowered. None of the truncation mutants exhibited clear stepwise oligomerization that depended on increasing Ca2+ concentration. Comparison of the three-dimensional structure of rabbit skeletal calsequestrin with a homology, model of canine cardiac calsequestrin from the point of view of our coupled Ca2+ binding and polymerization mechanism leads to a possible explanation for the 2-fold reduced Ca2+ binding capacity of cardiac calsequestrin despite very similar overall net negative charge for the two proteins.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Kang, C (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	chkang@wsunix.wsu.edu		Park, HaJeung/0000-0003-4898-7919				AARON BMB, 1984, J BIOL CHEM, V259, P1876; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; FASMAN GD, 1996, CIRCULAR DICHROISM C, P109; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; Glover L, 2001, BBA-BIOMEMBRANES, V1515, P120, DOI 10.1016/S0005-2736(01)00406-0; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; HAYAKAWA K, 1994, J MOL BIOL, V235, P357, DOI 10.1016/S0022-2836(05)80039-7; HE ZP, 1993, J BIOL CHEM, V268, P24635; Hidalgo C, 1996, BIOPHYS J, V71, P2130, DOI 10.1016/S0006-3495(96)79413-4; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; IKEMOTO N, 1972, J BIOL CHEM, V247, P7835; Kang ChulHee, 2002, Methods Mol Biol, V172, P281; KRAUSE KH, 1991, J BIOL CHEM, V266, P9453; MacLennan DH, 1998, NAT STRUCT BIOL, V5, P409, DOI 10.1038/nsb0698-409; MACLENNAN DH, 1974, J BIOL CHEM, V249, P980; MacLennan DH, 2002, J MOL CELL CARDIOL, V34, P897, DOI 10.1006/jmcc.2002.2031; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; Maguire PB, 1997, BIOCHEM BIOPH RES CO, V240, P721, DOI 10.1006/bbrc.1997.7729; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; TANAKA M, 1986, ARCH BIOCHEM BIOPHYS, V251, P369, DOI 10.1016/0003-9861(86)90084-6; Wang SR, 1998, NAT STRUCT BIOL, V5, P476, DOI 10.1038/nsb0698-476; WILLIAMS RJP, 1978, BIOCHIM BIOPHYS ACTA, V505, P1, DOI 10.1016/0304-4173(78)90007-1; WILLIAMS RW, 1986, J BIOL CHEM, V261, P2408; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	29	97	97	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16176	16182		10.1074/jbc.M300120200	http://dx.doi.org/10.1074/jbc.M300120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594204	hybrid			2022-12-25	WOS:000182680000091
J	Schroder, NWJ; Morath, S; Alexander, C; Hamann, L; Hartung, T; Zahringer, U; Gobel, UB; Weber, JR; Schumann, RR				Schroder, NWJ; Morath, S; Alexander, C; Hamann, L; Hartung, T; Zahringer, U; Gobel, UB; Weber, JR; Schumann, RR			Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE DIFFERENTIATION ANTIGEN; GRAM-NEGATIVE BACTERIA; WALL COMPONENTS; BLOOD-STREAM; SEPTIC SHOCK; CUTTING EDGE; ANTIMICROBIAL SUSCEPTIBILITY; CYTOKINE INDUCTION; INNATE IMMUNITY; PEPTIDOGLYCAN	Lipoteichoic acid (LTA) derived from Streptococcus pneumoniae, purified employing a chloroform/methanol protocol, and from Staphylococcus aureus, prepared by the recently described butanol extraction procedure, was investigated regarding its interaction with lipopolysaccharide (LPS)-binding protein (LBP), CD14, Toll-like receptors (TLRs)-2 and -4, and MD-2. LTA from both organisms induced cytokine synthesis in human mononuclear phagocytes. Activation was LBP- and CD14-dependent, and formation of complexes of LTA with LBP and soluble CD14 as well as catalytic transfer of LTA to CD14 by LBP was verified by PhastGel(TM) native gel electrophoresis. Human embryonic kidney (HEK) 293/CD14 cells and Chinese hamster ovary (CHO) cells were responsive to LTA only after transfection with TLR-2. Additional transfection with MD-2 did not affect stimulation of these cells by LTA. Our data suggest that innate immune recognition of LTA via LBP, CD14, and TLR-2 represents an important mechanism in the pathogenesis of systemic, complications in the course of infectious diseases brought about by the clinically most important Gram-positive pathogens. However, the involvement of TLR-4 and AW-2 in this process was ruled out.	Humboldt Univ, Klinikum Charite, Inst Mikrobiol & Hyg, Fak Med, D-10117 Berlin, Germany; Univ Konstanz, D-78457 Constance, Germany; Forschungszentrum Borstel, Abt Immunchem & Med Mikrobiol, Zentrum Med & Biowissensch, D-23845 Borstel, Germany; Humboldt Univ, Fak Med, Klinikum Charite, Neurol Klin, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Konstanz; Forschungszentrum Borstel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schumann, RR (corresponding author), Humboldt Univ, Klinikum Charite, Inst Mikrobiol & Hyg, Fak Med, Dorotheenstr 96, D-10117 Berlin, Germany.			Hamann, Lutz/0000-0003-4719-2583				Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; BEHR T, 1992, EUR J BIOCHEM, V207, P1063, DOI 10.1111/j.1432-1033.1992.tb17143.x; Beutler B, 2001, J ENDOTOXIN RES, V7, P277, DOI 10.1177/09680519010070040901; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; COSENZA H, 1975, EUR J IMMUNOL, V5, P343, DOI 10.1002/eji.1830050510; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; Diekema DJ, 2000, INT J ANTIMICROB AG, V13, P257, DOI 10.1016/S0924-8579(99)00131-4; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Fan XL, 1999, INFECT IMMUN, V67, P2964, DOI 10.1128/IAI.67.6.2964-2968.1999; FISCHER W, 1990, BIOCHEM CELL BIOL, V68, P33, DOI 10.1139/o90-005; FISCHER W, 1994, MED MICROBIOL IMMUN, V183, P61, DOI 10.1007/BF00277157; Fluit AC, 2001, EUR J CLIN MICROBIOL, V20, P188, DOI 10.1007/s10096-001-8078-8; Gao JJ, 2001, INFECT IMMUN, V69, P751, DOI 10.1128/IAI.69.2.751-757.2001; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Ginsburg I, 2002, LANCET INFECT DIS, V2, P171, DOI 10.1016/S1473-3099(02)00226-8; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Greenberg JW, 1996, INFECT IMMUN, V64, P3318, DOI 10.1128/IAI.64.8.3318-3325.1996; Greenwood B, 1999, PHILOS T R SOC B, V354, P777, DOI 10.1098/rstb.1999.0430; Gupta D, 1999, J BIOL CHEM, V274, P14012, DOI 10.1074/jbc.274.20.14012; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hamann L, 2000, EUR J IMMUNOL, V30, P211, DOI 10.1002/1521-4141(200001)30:1<211::AID-IMMU211>3.3.CO;2-F; HAZIOT A, 1988, J IMMUNOL, V141, P547; Heer C, 2000, INFECTION, V28, P13, DOI 10.1007/s150100050004; Heine H, 1999, J IMMUNOL, V162, P6971; Hermann C, 2002, EUR J IMMUNOL, V32, P541, DOI 10.1002/1521-4141(200202)32:2<541::AID-IMMU541>3.0.CO;2-P; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; HOLTJE JV, 1975, P NATL ACAD SCI USA, V72, P1690, DOI 10.1073/pnas.72.5.1690; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; INGRAHAM JL, 1983, GROWTH BACTERIAL CEL, P3; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; KELLER R, 1992, INFECT IMMUN, V60, P3664, DOI 10.1128/IAI.60.9.3664-3672.1992; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kitchens RL, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; LEESON MC, 1994, INFECT IMMUN, V62, P4975, DOI 10.1128/IAI.62.11.4975-4980.1994; MANTHOUS CA, 1993, CHEST, V104, P1872, DOI 10.1378/chest.104.6.1872; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Metlay JP, 2002, CURR OPIN INFECT DIS, V15, P163, DOI 10.1097/00001432-200204000-00011; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Morath S, 2002, J EXP MED, V195, P1635, DOI 10.1084/jem.20020322; Morath S, 2002, INFECT IMMUN, V70, P938, DOI 10.1128/IAI.70.2.938-944.2002; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Munford RS, 2001, AM J RESP CRIT CARE, V163, P316, DOI 10.1164/ajrccm.163.2.2007102; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Pfaller MA, 1998, ANTIMICROB AGENTS CH, V42, P1762, DOI 10.1128/AAC.42.7.1762; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; Schneider O, 1999, NEUROLOGY, V53, P1584, DOI 10.1212/WNL.53.7.1584; Schroder NW, 2001, J BIOL CHEM, V276, P9713, DOI 10.1074/jbc.M008954200; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schumann RR, 2000, CHEM IMMUNOL, V74, P42; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; van Deventer SJH, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P379; van Langevelde P, 1998, ANTIMICROB AGENTS CH, V42, P3073, DOI 10.1128/AAC.42.12.3073; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	69	511	530	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15587	15594		10.1074/jbc.M212829200	http://dx.doi.org/10.1074/jbc.M212829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594207	hybrid			2022-12-25	WOS:000182680000018
J	Hiromura, M; Choi, CH; Sabourin, NA; Jones, H; Bachvarov, D; Usheva, A				Hiromura, M; Choi, CH; Sabourin, NA; Jones, H; Bachvarov, D; Usheva, A			YY1 is regulated by O-linked N-acetylglucosaminylation (O-GlcNAcylation)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TETRATRICOPEPTIDE REPEATS; CYTOSOLIC PROTEINS; GLCNAC TRANSFERASE; DYNAMIC INTERPLAY; CELL-DEATH; GLYCOSYLATION; NUCLEAR	YY1 is a zinc finger DNA-binding transcription factor that influences expression of a wide variety of cellular and viral genes. YY1 is essential for the development of mammalian embryos. It regulates the expression of genes with important functions in DNA replication, protein synthesis, and cellular response to external stimuli during cell growth and differentiation. How YY1 accomplishes such a variety of functions is unknown. Here, we show that a subset of the nuclear YY1 appears to be O-GleNAcylated regardless of the differentiation status of the cells. We found that glucose strongly stimulates O-linked N-acetylglucosaminylation (O-GlcNAcylation) on YY1. Glycosylated YY1 no longer binds the retinoblastoma protein (Rb). Upon dissociation from Rb, the glycosylated YY1 is free to bind DNA. The ability of the O-glycosylation on YY1 to disrupt the complex with Rb leads us to propose that O-glycosylation might have a profound effect on cell cycle transitions that regulate the YY1-Rb heterodimerization and promote the activity of YY1. Our observations provide strong evidence that YY1-regulated transcription is very likely connected to the pathway of glucose metabolism that culminates in the O-GlcNAcylation on YY1, changing its function in transcription.	Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; CHUQ, Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Quebec City, PQ G1R 2J6, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Laval University; Laval University	Usheva, A (corresponding author), Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	ausheva@bidmc.harvard.edu		Bachvarov, Dimcho/0000-0001-6509-9599	NHLBI NIH HHS [HL62458] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062458] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Fiordaliso F, 2001, DIABETES, V50, P2363, DOI 10.2337/diabetes.50.10.2363; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HOLT GD, 1986, J BIOL CHEM, V261, P8049; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lefebvre T, 2002, J CELL BIOCHEM, V85, P208, DOI 10.1002/jcb.10119; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001	37	92	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14046	14052		10.1074/jbc.M300789200	http://dx.doi.org/10.1074/jbc.M300789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12588874	hybrid			2022-12-25	WOS:000182405000063
J	Koopman, WJH; Bosch, RR; van Emst-de Vries, SE; Spaargaren, M; De Pont, JJHHM; Willems, PHGM				Koopman, WJH; Bosch, RR; van Emst-de Vries, SE; Spaargaren, M; De Pont, JJHHM; Willems, PHGM			R-Ras alters Ca2+ homeostasis by increasing the Ca2+ leak across the endoplasmic reticular membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DOWN-REGULATION; CALCIUM; BCL-2; CELLS; APOPTOSIS; STORES; PROLIFERATION; OSCILLATIONS; DEPRIVATION	Evidence in the literature implicating both Ras-like Ras (R-Ras) and intracellular Ca2+ in programmed cell death and integrin-mediated adhesion prompted us to investigate the possibility that R-Ras alters cellular Ca2+ handling. Chinese hamster ovary cells expressing the cholecystokinin (CCK)-A receptor were loaded with indo-1 to study the effects of constitutively active V38R-Ras and dominant negative N43R-Ras on the kinetics of the thapsigargin (Tg)- and CCK8-induced Ca2+ rises using high speed confocal microscopy. In the absence of extracellular Ca2+, both 1 pm Tg, a potent and selective inhibitor of the Ca2+ pump of the intracellular Ca2+ store, and 100 nm CCK8 evoked a transient rise in Ca2+, the size of which was decreased significantly after expression of V38R-Ras. At 0.1 nm, CCK, evoked periodic Ca2+ rises. The frequency of these Ca2+ oscillations was reduced significantly in V38R-Ras-expressing cells. In contrast to V38R-Ras, N43R-Ras did not alter the kinetics of the Tg- and CCK8-induced Ca2+ rises. The present findings are compatible with the idea that V38R-Ras expression increases the passive leak of Ca2+ of the store leading to a decrease in Ca2+ content of this store, which, in turn, leads to a decrease in frequency of the CCK8-induced cytosolic Ca2+ oscillations. The effect of V38R-Ras on the Ca2+ content of the intracellular Ca2+ store closely resembles that of the antiapoptotic protein Bcl-2 observed earlier. Together with reports on the role of dynamic Ca2+ changes in integrin-mediated adhesion, this leads us to propose that the reduction in endoplasmic reticulum Ca2+ content may underlie the antiapoptotic effect of R-Ras, whereas the decrease in frequency of stimulus-induced Ca2+ oscillations may play a role in the inhibitory effect of R-Ras on stimulus-induced cell detachment and migration.	Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam	Willems, PHGM (corresponding author), Univ Nijmegen, Ctr Med, Biochem NCMLS 160, POB 9101, NL-6500 HB Nijmegen, Netherlands.	P.Willems@ncmls.kun.nl	Spaargaren, Marcel/AAU-1298-2021; Koopman, Werner J.H./AAC-9668-2020; Willems, P.H.G.M./L-4759-2015; Koopman, Werner J.H./D-3592-2009	Spaargaren, Marcel/0000-0002-3135-5109; Koopman, Werner J.H./0000-0002-5340-6747; Willems, P.H.G.M./0000-0002-0915-1599; Koopman, Werner J.H./0000-0002-5340-6747				Bhatt A, 2002, J CELL SCI, V115, P3415; Bosch RR, 1999, BIOCHEM J, V337, P263, DOI 10.1042/0264-6021:3370263; Broadway NM, 1998, FEBS LETT, V437, P122, DOI 10.1016/S0014-5793(98)01155-7; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Hansen M, 2002, ONCOGENE, V21, P4448, DOI 10.1038/sj.onc.1205538; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; Kihara T, 2002, J NEUROSCI RES, V70, P274, DOI 10.1002/jnr.10426; Koopman WJH, 2001, BIOPHYS J, V81, P57, DOI 10.1016/S0006-3495(01)75679-2; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Osada M, 1999, MOL CELL BIOL, V19, P6333; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 2002, BIOCHIMIE, V84, P195, DOI 10.1016/S0300-9084(02)01373-1; Putney JW, 2001, J CELL SCI, V114, P2223; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Self AJ, 2001, J CELL SCI, V114, P1357; Smeets RLL, 1998, BRIT J PHARMACOL, V124, P935, DOI 10.1038/sj.bjp.0701913; Smeets RLL, 1996, CELL CALCIUM, V20, P1, DOI 10.1016/S0143-4160(96)90045-7; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Torres JJ, 2001, EUROPHYS LETT, V55, P746, DOI 10.1209/epl/i2001-00477-3; VANDEPUT FHMM, 1995, CELL CALCIUM, V17, P85, DOI 10.1016/0143-4160(95)90078-0; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J; WILLEMS PHGM, 1994, PFLUG ARCH EUR J PHY, V427, P233, DOI 10.1007/BF00374529; Yoo JK, 2002, J IMMUNOL, V169, P3637, DOI 10.4049/jimmunol.169.7.3637; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	41	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13672	13679		10.1074/jbc.M211256200	http://dx.doi.org/10.1074/jbc.M211256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12586830	hybrid, Green Published			2022-12-25	WOS:000182405000016
J	Takatsuna, H; Kato, H; Gohda, J; Akiyama, T; Moriya, A; Okamoto, Y; Yamagata, Y; Otsuka, M; Umezawa, K; Semba, K; Inoue, J				Takatsuna, H; Kato, H; Gohda, J; Akiyama, T; Moriya, A; Okamoto, Y; Yamagata, Y; Otsuka, M; Umezawa, K; Semba, K; Inoue, J			Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; FHA DOMAIN; DEFECTIVE INTERLEUKIN-1; TRAF6-DEFICIENT MICE; MOLECULAR-BASIS; ACTIVATION; CD40; PATHWAY; FAMILY; OLIGOMERIZATION	Tumor necrosis factor receptor-associated factor 6 (TRAF6) transduces signals from members of the Toll/interleukin-1 (IL-1) receptor family by interacting with IL-1 receptor-associated kinase-1 (IRAK-1) after IRAK-1 is released from the receptor-MyD88 complex upon IL-1 stimulation. However, the molecular mechanisms underlying regulation of the IRAK-1/TRAF6 interaction are largely unknown. We have identified TIFA, a TRAF-interacting protein with a forkhead-associated (FHA) domain. The FHA domain is a motif known to bind directly to phosphothreonine and phosphoserine. In transient transfection assays, TIFA activates NFkappaB and c-Jun amino-terminal kinase. However, TIFA carrying a mutation that abolishes TRAF6 binding or mutations in the FHA domain that are known to abolish FHA domain binding to phosphopeptide fails to activate NFkappaB and c-Jun amino-terminal kinase. TIFA, when overexpressed, binds both TRAF6 and IRAK-1 and significantly enhances the IRAK-1/TRAF6 interaction. Furthermore, analysis of endogenous proteins indicates that TIFA associates with TRAF6 constitutively, whereas it associates with IRAK-1 in an IL-1 stimulation-dependent manner in vivo. Thus, TIFA is likely to mediate IRAK-1/TRAF6 interaction upon IL-1 stimulation.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan; Keio Univ, Grad Sch Sci & Technol, Yokohama, Kanagawa 2238522, Japan; Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan	University of Tokyo; Keio University; Kumamoto University	Inoue, J (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan.		Yamagata, Yoshiki/T-6489-2019					Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fitzgerald KA, 2000, MICROBES INFECT, V2, P933, DOI 10.1016/S1286-4579(00)00396-8; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200; Kanamori M, 2002, BIOCHEM BIOPH RES CO, V290, P1108, DOI 10.1006/bbrc.2001.6315; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Li J, 2000, J CELL SCI, V113, P4143; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NINOMIYA TJ, 1999, NATURE, V398, P252; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yaffe MB, 1999, NATURE, V402, P30; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	39	68	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12144	12150		10.1074/jbc.M300720200	http://dx.doi.org/10.1074/jbc.M300720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12566447	hybrid			2022-12-25	WOS:000182015700056
J	Mac Partlin, M; Homer, E; Robinson, H; McCormick, CJ; Crouch, DH; Durant, ST; Matheson, EC; Hall, AG; Gillespie, DAF; Brown, R				Mac Partlin, M; Homer, E; Robinson, H; McCormick, CJ; Crouch, DH; Durant, ST; Matheson, EC; Hall, AG; Gillespie, DAF; Brown, R			Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX	ONCOGENE			English	Article						DNA mismatch repair; MYC; MAX; mutator phenotype; protein interactions	CELL-CYCLE; GENOMIC INSTABILITY; NUCLEAR EXTRACTS; APOPTOSIS; BINDING; DAMAGE; LINES; ALPHA; PCNA; DIFFERENTIATION	MSH2 and MLH1 have a central role in correcting mismatches in DNA occurring during DNA replication and have been implicated in the engagement of apoptosis induced by a number of cytotoxic anticancer agents. The function of MLH1 is not clearly defined, although it is required for mismatch repair (MMR) and engagement of apoptosis after certain types of DNA damage. In order to identify other partners of MLH1 that may be involved in signalling MMR or apoptosis, we used human MLH1 in yeast two-hybrid screens of normal human breast and ovarian cDNA libraries. As well as known partners of MLH1 such as PMS1, MLH3 and MBD4, we identified the carboxy terminus of the human c-MYC protooncogene as an interacting sequence. We demonstrate, both in vitro by yeast two-hybrid and GST-fusion pull-down experiments, as well as in vivo by coimmunoprecipitation from human tumour cell extracts, that MLH1 interacts with the c-MYC protein. We further demonstrate that the heterodimeric partner of c-MYC, MAX, interacts with a different MMR protein, MSH2, both in vitro and in vivo. Using an inducible c-MYC-ER(TM) fusion gene, we show that elevated c-MYC expression leads to an increased HGPRT mutation rate of Rat1 cells and an increase in the number of frameshift mutants at the HGPRT locus. The effect on HGPRT mutation rate is small (2-3-fold), but is consistent with deregulated c-MYC expression partially inhibiting MMR activity.	Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Newcastle Upon Tyne, Sch Med, Leukaemia Res Grp, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Beatson Institute; Cancer Research UK; University of Glasgow; Newcastle University - UK; University of Dundee	Brown, R (corresponding author), Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Garscube Estate,Swichback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019; Hall, Andy/AAD-8622-2020; Hall, Andrew G/B-3485-2009	Gillespie, David/0000-0002-6338-0544; Brown, Robert/0000-0001-7960-5755				Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; CROUCH DH, 1993, ONCOGENE, V8, P1849; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hardman RA, 2001, CANCER RES, V61, P1392; HAWN MT, 1995, CANCER RES, V55, P3721; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Karran P, 1996, CANCER SURV, V28, P69; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luria SE, 1943, GENETICS, V28, P491; Mai S, 1996, ONCOGENE, V12, P277; Matton N, 2000, J BIOL CHEM, V275, P17808, DOI 10.1074/jbc.M909794199; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moreland NJ, 1999, CANCER RES, V59, P2102; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; Rockwood LD, 2002, ONCOGENE, V21, P7235, DOI 10.1038/sj.onc.1205697; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	45	17	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					819	825		10.1038/sj.onc.1206252	http://dx.doi.org/10.1038/sj.onc.1206252			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584560				2022-12-25	WOS:000180864300003
J	Borrmann, L; Seebeck, B; Rogalla, P; Bullerdiek, J				Borrmann, L; Seebeck, B; Rogalla, P; Bullerdiek, J			Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat	ONCOGENE			English	Article						high-mobility group proteins; HMGA; promoter analysis; cancer; obesity; arteriosclerosis	I-C GENE; TRANSCRIPTION FACTORS; MESENCHYMAL TUMORS; H-DNA; EXPRESSION; ELEMENT; TRIPLEX; REARRANGEMENTS; LIPOMAS; VIVO	HMGA proteins are thought to be causally involved in the progression of different diseases, including benign and malignant tumors, obesity, arteriosclerosis, and restenosis. As HMGA proteins are architectural transcription factors, their binding to DNA leads to changes in DNA-conformation modulating the environment for the assembly and function of transcriptional complexes, thus influencing the expression of a huge variety of genes. Despite the emerging role of HMGA proteins for important diseases, only limited information is available about mechanisms regulating the expression of the HMGA2 gene. In this report, 2240bp of the 5' flanking region of the HMGA2 gene were functionally analyzed by luciferase assay experiments. Besides the identification of novel positive and negative regulatory elements, it was shown that transcription is initiated from two independent promoter regions within cell lines HeLa, MCF7, and L14(TSV40). Furthermore, a functional polymorphic dinucleotide repeat (TCTCT(TC)(n)) 500 bp upstream of the ATG translational start codon was found to regulate strongly the human HMGA2 promoter with an activation pattern that correlates to its TC-repeat length.	Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, Leobenerstr ZHG, D-28359 Bremen, Germany.							Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; ASHAR HR, 1995, CELL, V82, P57; Ashar HR, 1996, GENOMICS, V31, P207, DOI 10.1006/geno.1996.0033; Ayoubi TAY, 1999, ONCOGENE, V18, P5076, DOI 10.1038/sj.onc.1202881; Battista S, 1999, CANCER RES, V59, P4793; Borrmann L, 2001, ONCOGENE, V20, P4537, DOI 10.1038/sj.onc.1204577; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chau KY, 1999, FEBS LETT, V457, P429, DOI 10.1016/S0014-5793(99)01100-X; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; Ishwad CS, 1997, HUM GENET, V99, P103; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kim HG, 1998, BIOCHEMISTRY-US, V37, P2299, DOI 10.1021/bi9718191; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; Rogalla P, 1996, AM J PATHOL, V149, P775; Rustighi A, 2002, BIOCHEMISTRY-US, V41, P1229, DOI 10.1021/bi011666o; Rustighi A, 1999, BIOCHEM BIOPH RES CO, V265, P439, DOI 10.1006/bbrc.1999.1680; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Tamimi Y, 1996, BRIT J CANCER, V74, P573, DOI 10.1038/bjc.1996.403; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	31	24	26	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					756	760		10.1038/sj.onc.1206073	http://dx.doi.org/10.1038/sj.onc.1206073			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569368				2022-12-25	WOS:000180642100013
J	Mund, T; Gewies, A; Schoenfeld, N; Bauer, MKA; Grimm, S				Mund, T; Gewies, A; Schoenfeld, N; Bauer, MKA; Grimm, S			Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic reticulum	FASEB JOURNAL			English	Article						cell death; caspase-8; BH3 domain; tumors; Bap31	CYTOCHROME-C; CELL-DEATH; BH3 DOMAIN; INDUCE APOPTOSIS; MITOCHONDRIAL-MEMBRANE; BCL-2 FAMILY; ELEGANS; COMPLEX; ACTIVATION; RELEASE	We have isolated Spike, a novel and evolutionary conserved BH3-only protein. BH3-only proteins constitute a family of apoptosis inducers that mediate proapoptotic signals. In contrast to most proteins of this family, Spike was not found to be associated with mitochondria. Furthermore, unlike the known BH3-only proteins, Spike could not interact with all tested Bcl-2 family members, despite its BH3 domain being necessary for cell killing. Our findings indicate that Spike is localized to the endoplasmic reticulum. The endoplasmic reticulum is an organelle that has only recently been implicated in regulation of apoptosis. At this locale, Spike interacts with Bap31, an adaptor protein for pro-caspase-8 and Bcl-XL. In doing so, Spike is able to inhibit the formation of a complex between Bap31 and the antiapoptotic Bcl-XL protein. Furthermore, Spike transmits the signal of specific death receptors. Its down-regulation in certain tumors suggests that Spike may also play a role in tumorigenesis. Our findings add new insight for how BH3-only and antiapoptotic Bcl-2 proteins regulate cell death.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Grimm, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	sgrimm@biochem.mpg.de		Mund, Thomas/0000-0002-3957-1105; Gewies, Andreas/0000-0002-7606-6482				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Ghosh C, 2000, ANTISENSE NUCLEIC A, V10, P263, DOI 10.1089/108729000421448; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neudecker F, 2000, BIOTECHNIQUES, V28, P107; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	49	54	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					696	+		10.1096/fj.02-0657fje	http://dx.doi.org/10.1096/fj.02-0657fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594175				2022-12-25	WOS:000181456900016
